<SEC-DOCUMENT>0001564590-21-015518.txt : 20210325
<SEC-HEADER>0001564590-21-015518.hdr.sgml : 20210325
<ACCEPTANCE-DATETIME>20210325163103
ACCESSION NUMBER:		0001564590-21-015518
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		117
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210325
DATE AS OF CHANGE:		20210325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Relay Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001812364
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39385
		FILM NUMBER:		21772780

	BUSINESS ADDRESS:	
		STREET 1:		399 BINNEY STREET
		STREET 2:		2ND FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-370-8837

	MAIL ADDRESS:	
		STREET 1:		399 BINNEY STREET
		STREET 2:		2ND FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>rlay-10k_20201231.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
rlay-10k_20201231.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-K<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark&#160;One)</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:97%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended December 31, 2020</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:3%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:97%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number:&#160;<font style="Background-color:#FFFFFF;color:#000000;">001-39385</font></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">RELAY THERAPEUTICS, INC.</font><font style="font-size:10pt;color:#000000;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its Charter) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Delaware</font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">47-3923475</font></p></td>
</tr>
<tr>
<td valign="bottom"  style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:49.5%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">399 Binney Street, 2<sup style="font-size:85%;line-height:120%;vertical-align:top">nd</sup>&#160;Floor</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cambridge, MA</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">02139</font></p></td>
</tr>
<tr>
<td valign="bottom"  style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:7pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: <font style="Background-color:#FFFFFF;color:#000000;">(617)&#160;370-8837</font></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:20%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top"  style="width:39%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Common Stock, par value $0.001 per share</font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:20%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">RLAY</font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:39%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Nasdaq Global Market</font></p></td>
</tr>
</table></div>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act: <font style="font-weight:bold;">None </font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;<font style="text-transform:uppercase;">Yes</font> <font style="font-family:Segoe UI Symbol;">&#9744; </font><font style="text-transform:uppercase;">No</font>&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act. &#160;<font style="text-transform:uppercase;">Yes</font>&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> <font style="text-transform:uppercase;">No</font>&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;<font style="text-transform:uppercase;">Yes</font>&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> <font style="text-transform:uppercase;">No</font>&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files). &#160;<font style="text-transform:uppercase;">Yes</font>&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> <font style="text-transform:uppercase;">No</font>&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:10.8pt;">
<td valign="top"  style="width:16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:1.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:19%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;<font style="text-transform:uppercase;">Yes</font>&#160;<font style="font-family:Segoe UI Symbol;">&#9744; </font><font style="text-transform:uppercase;">No</font>&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate market value of the Registrant&#8217;s common stock held by non-affiliates of the Registrant was $2,543,277,454 as of the closing of the Registrant&#8217;s initial public offering on July 20, 2020 (based on a closing price of $42.87 per share as quoted by the Nasdaq Global Market as of such date). In determining the market value of non-affiliate common stock, shares of the Registrant&#8217;s common stock beneficially owned by officers, directors and affiliates have been excluded. This determination of affiliate status is not necessarily a conclusive determination for other purposes.<font style="font-size:10pt;">&#160;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of Registrant&#8217;s Common Stock outstanding as of March 23, 2021 was 90,399,972.<font style="font-size:10pt;">&#160;</font></p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2021 Annual Meeting of Stockholders within 120 days of the end of the registrant&#8217;s fiscal year ended December&#160;31, 2020. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><font style="text-decoration:underline;">Business</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><font style="text-decoration:underline;">Risk Factors</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><font style="text-decoration:underline;">Unresolved Staff Comments</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><font style="text-decoration:underline;">Properties</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><font style="text-decoration:underline;">Legal Proceedings</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><font style="text-decoration:underline;">Mine Safety Disclosures</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;II</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><font style="text-decoration:underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6"><font style="text-decoration:underline;">Reserved</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><font style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><font style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><font style="text-decoration:underline;">Financial Statements and Supplementary Data</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><font style="text-decoration:underline;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#N9A_CONTROLS_PROCEDURES"><font style="text-decoration:underline;">Controls and Procedures</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><font style="text-decoration:underline;">Other Information</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;III</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10"><font style="text-decoration:underline;">Directors, Executive Officers and Corporate Governance</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11"><font style="text-decoration:underline;">Executive Compensation</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12"><font style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13"><font style="text-decoration:underline;">Certain Relationships and Related Transactions, and Director Independence</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14"><font style="text-decoration:underline;">Principal Accounting Fees and Services</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;IV</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><font style="text-decoration:underline;">Exhibits, Financial Statement Schedules</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;16.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><font style="Background-color:#FFFFFF;text-decoration:underline;">Form 10-K Summary</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="Part_I"></a>Summary of the Material Risks Associated with Our Business </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We have never successfully completed any clinical trials, and we may be unable to do so for any product candidates we develop. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Positive results from early preclinical studies of our product candidates are not necessarily predictive of the results of later preclinical studies and any future clinical trials of our product candidates. If we cannot replicate the positive results from our earlier preclinical studies of our product candidates in our later preclinical studies and future clinical trials, we may be unable to successfully develop, obtain regulatory approval for and commercialize our product candidates. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Our current or future clinical trials may reveal significant adverse events not seen in our preclinical or nonclinical studies and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Although we intend to explore other therapeutic opportunities, in addition to the product candidates that we are currently developing, we may fail to identify viable new product candidates for clinical development for a number of reasons. If we fail to identify additional potential product candidates, our business could be materially harmed. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The incidence and prevalence for target patient populations of our product candidates have not been established with precision. If the market opportunities for our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability will be adversely affected, possibly materially. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Under our Amended and Restated Collaboration and License Agreement, or the DESRES Agreement, with D. E. Shaw Research, LLC, or D. E. Shaw Research, we collaborate with D. E. Shaw Research to rapidly develop various protein models, a process that depends on D. E. Shaw Research&#8217;s use of their proprietary supercomputer, Anton 2. A termination of the DESRES Agreement could have a material adverse effect on our business, financial condition, results of operations, and prospects. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We rely on third parties to conduct our ongoing clinical trials of RLY-1971 and RLY-4008 and expect to rely on third parties to conduct future clinical trials, as well as investigator-sponsored clinical trials of our product candidates. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We may enter into collaborations with third parties for the research, development, manufacture and commercialization of one or more of our programs or product candidates. If these collaborations are not successful, our business could be adversely affected.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We are a biopharmaceutical company with a limited operating history. We have incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable future. We have no products approved for commercial sale and have not generated any revenue from product sales. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We will need to raise substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate some of our product development programs or commercialization efforts. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A pandemic, epidemic, or outbreak of an infectious disease, such as&#160;COVID-19, may materially and adversely affect our business and our financial results and could cause a disruption to the development of our product candidates. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">If we are unable to adequately protect our proprietary technology or obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to post-market study requirements, marketing and labeling restrictions, and even recall or market withdrawal if unanticipated safety issues are discovered following approval. In addition, we may be subject to penalties or other enforcement action if we fail to comply with regulatory requirements. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act and a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act, and may avail ourselves of reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies, which could make our common stock less attractive to investors and adversely affect the market price of our common stock. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:6.67%;text-indent:-3.4%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K contains express or implied forward-looking statements that are based on our management&#8217;s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements contained in this Annual Report on Form 10-K include, but are not limited to, statements about: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical and clinical studies, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to identify research priorities and apply a risk-mitigated strategy to efficiently discover and develop product candidates, including by applying learnings from one program to other programs and from one modality to our other modalities; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability and the potential to successfully manufacture our drug substances, delivery vehicles, and product candidates for preclinical use, for clinical trials and on a larger scale for commercial use, if approved; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the ability and willingness of our third-party strategic collaborators to continue research and development activities relating to our development candidates and product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to obtain and maintain regulatory approval of our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to commercialize our products, if approved; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the pricing and reimbursement of our product candidates, if approved; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the implementation of our business model, and strategic plans for our business, product candidates, and technology; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">estimates of our future expenses, revenues, capital requirements, and our needs for additional financing; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the potential benefits of strategic collaboration agreements, our ability to enter into strategic collaborations or arrangements, and our ability to attract collaborators with development, regulatory and commercialization expertise; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">future agreements with third parties in connection with the commercialization of product candidates and any other approved product; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the size and growth potential of the markets for our product candidates, and our ability to serve those markets; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our financial performance; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the rate and degree of market acceptance of our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">regulatory developments in the United States and foreign countries; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to produce our products or product candidates with advantages in turnaround times or manufacturing cost; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the success of competing therapies that are or may become available; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to attract and retain key scientific or management personnel; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the impact of laws and regulations; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">developments relating to our competitors and our industry; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the effect of the&#160;COVID-19&#160;pandemic, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our preclinical studies and future clinical trials; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">other risks and uncertainties, including those listed under the caption &#8220;Risk Factors.&#8221; </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed above under &#8220;Summary of the Material Risks Associated with Our Business&#8221; and under the section titled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this Annual Report on Form 10-K and the documents that we reference in this Annual Report on Form 10-K and have filed with the Securities and Exchange Commission, or the SEC, as exhibits hereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The forward-looking statements in this Annual Report on Form 10-K represent our views as of the date of this Annual Report on Form 10-K. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report on Form 10-K. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K also contains estimates, projections and other information concerning our industry, our business and the markets for our product candidates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from our own internal estimates and research as well as from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we are not aware of any misstatements regarding any third-party information presented in this Annual Report on Form 10-K, their estimates, in particular as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties and are subject to change based on various factors, including those discussed under the section titled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K.</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:6.67%;text-indent:-3.4%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Except where the context otherwise requires or where otherwise indicated, the terms &#8220;Relay Therapeutics,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;our company,&#8221; the &#8220;Company,&#8221; and &#8220;our business&#8221; refer to Relay Therapeutics, Inc. and its consolidated subsidiary.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_BUSINESS"></a><a name="ITEM_1_BUSINESS"></a>Item 1. Business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Our company is built upon unparalleled insights into protein motion and how this dynamic behavior relates to protein function. These insights may enable us to more effectively drug protein targets that previously have been intractable (i.e., inadequately drugged or undruggable). We believe we have a differentiated approach to drug these protein targets based on their motion, which enables us to select and advance unique product candidates. We built our Dynamo<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> platform to integrate an array of leading edge experimental and computational approaches, which allows us to apply our understanding of protein structure and motion to drug discovery. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are advancing a pipeline of medicines to address targets in precision oncology, including our lead product candidates, RLY-1971 and RLY-4008, as well as our PI3K&#945; mutant selective program, or the RLY-PI3K1047 program. We initiated a Phase 1 clinical trial for RLY-1971, our inhibitor of Src homology region 2 domain-containing phosphatase-2, or SHP2, in patients with advanced solid tumors in the first quarter of 2020. In December 2020, we entered into a global collaboration and license agreement, or the Genentech Agreement, with Genentech, Inc., a member of the Roche Group, or Genentech, for the development and commercialization of RLY-1971. We initiated a first-in-human clinical trial of RLY-4008, our inhibitor of fibroblast growth factor receptor 2, or FGFR2, enriched for patients with advanced solid tumors having oncogenic FGFR2 alterations in the third quarter of 2020. We anticipate the RLY-PI3K1047 program, our program for molecules targeting cancer-associated mutant variants of phosphoinostide 3-kinase alpha, or PI3K&#945;, to be in Investigational New Drug, or IND, enabling studies in 2021. While our initial focus is on precision oncology, we believe our Dynamo platform may also be broadly applied to other areas of precision medicine, such as genetic disease. In addition to the three product candidates described above, we have five discovery stage programs across precision oncology and genetic disease. We are focused on using the novel insights derived from our approach to transform the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of our therapies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Precision medicine emerged as an approach for disease treatment as the understanding of the link between genetic alterations, protein dysfunction and diseases evolved. Precision medicine aims to specifically and potently drug genetically validated target proteins (i.e., genetic variants potentially implicated in biology of disease). However, some target proteins thus far have been intractable using conventional drug discovery tools, such as structure-based drug design, or SBDD. While SBDD is well-suited to solving some drug discovery problems such as orthosteric site kinase inhibitors, its reliance on static images of protein fragments limits its ability to gain accurate insights into the dynamic behavior of proteins in their natural state, which in turn limits its ability to discover medicines with exquisite specificity. Our approach pivots the understanding of protein targets from the industry-standard, static view, to a novel paradigm based on fundamental insights into protein motion. We then apply these novel insights into protein motion to drug discovery and design, which we term Motion Based Drug Design<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup>, or MBDD. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The confluence of three forces <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#8212;</font></font> the proliferation of readily available genomic data, the evolution of experimental techniques, and advancements in computational power and speed <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#8212;</font></font> led to the founding of Relay Therapeutics. We believe we are uniquely situated in our ability to consolidate these advances and, when combined with our world-class team of both experimental and computational experts, integrate these solutions into MBDD to create medicines that will make a transformative difference for patients. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Key Drug Discovery Steps of Our Dynamo Platform </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Dynamo platform puts protein motion at the center of drug discovery and design, integrating a broad and tailored array of leading-edge experimental and computational approaches, including deploying the Anton&#160;2 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">supercomputer, which was custom-built by D. E. Shaw Research, LLC, or D. E. Shaw Research, to perform molecular dynamic simulations of proteins. We have access to the Anton&#160;2 supercomputer, which we believe to be the only resource of computational power of its caliber, through our collaboration with D. E. Shaw Research, LLC, or D.E. Shaw Research, pursuant to which we collaborate with D.&#160;E.&#160;Shaw Research to rapidly develop various protein models. Our use of the Anton&#160;2 supercomputer and our collaboration with D.E.&#160;Shaw Research is subject to the terms and conditions of the Amended and Restated Collaboration and License Agreement with D. E. Shaw Research, or the DESRES Agreement. See &#8220;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;Our Collaborations</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;License Agreements and Strategic Collaborations</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;Collaboration and License Agreement with D.&#160;E.&#160;Shaw Research, LLC.&#8221; We deploy the power of the platform in three key phases of MBDD discovery: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Target Modulation Hypothesis. </font><font style="font-size:10pt;color:#000000;">By generating fundamental insights into the structure and conformational dynamics of full-length proteins, our Dynamo platform enables us to model a target protein&#8217;s function, to develop unique motion-based hypotheses for how to modulate the protein&#8217;s behavior, and to identify potential novel binding sites for new therapeutic agents. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Hit Finding and Lead Generation. </font><font style="font-size:10pt;color:#000000;">The integration of our computational and experimental platforms affords a deeper functional understanding of our targets and enables the design of physiologically relevant activity-based, ligand-centric and computational screens. These highly differentiated screens have the ability to yield a larger number of chemical series and potential therapies to proceed into lead optimization than conventional experimental techniques alone. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Lead Optimization. </font><font style="font-size:10pt;color:#000000;">Our Dynamo platform uses advanced computational models in tight integration with our medicinal chemistry, structural biology, enzymology and biophysics capabilities to predict, design and experimentally evaluate compounds that will achieve the most desirable characteristics, including potency, selectivity, bioavailability, and drug-like properties. We believe our approach enables us to converge on optimized compounds with much greater efficiency than conventional approaches, which are typically highly iterative over an extended timeframe. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Dynamo platform has the potential to address a diverse range of disease targets, including those proteins that have not been addressed selectively and potently with existing therapies. While we have initially focused our Dynamo platform on small molecule drug discovery in the area of precision oncology, we believe it could be readily deployed across broader precision and genetic medicine areas as well as other therapeutic modalities, such as protein therapeutics and antibody design. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Programs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have deployed our technology platform to build a pipeline of product candidates to address targets in precision oncology, where there is clear evidence linking target proteins to disease and where molecular diagnostics can unambiguously identify relevant patients for treatment. We believe this approach will increase the likelihood of successfully translating a specific pharmacological mechanism into clinical benefit. The targets associated with all of our current programs are Category 1 Targets under our DESRES Agreement. See &#8220;&#8212;Our Collaborations&#8212;License Agreements and Strategic Collaborations &#8212;Collaboration and License Agreement with D. E. Shaw Research, LLC.&#8221; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000001.jpg" title="" alt="" style="width:624px;height:283px;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">RLY-4008</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RLY-4008 is designed to be an oral, small molecule, selective inhibitor of fibroblast growth factor receptor 2, or FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. FGFR2 is one of four members of the FGFR family, a set of closely related proteins with highly similar protein sequences and properties. RLY-4008 demonstrates FGFR2-dependent killing in cancer cell lines, while showing minimal inhibition of other targets, including other members of the FGFR family. We initiated a first-in-human clinical trial of RLY-4008 enriched for patients with advanced solid tumors having oncogenic FGFR2 alterations in September 2020. We anticipate giving an initial clinical update on this trial in the second half of 2021. We believe FGFR2-mediated cancers affect approximately 8,000 late-line patients annually in the United States. In the future, if RLY-4008 advances to earlier lines of treatment, we believe it could potentially address approximately 20,000 patients annually in the United States.<font style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Mutant-PI3K<font style="font-style:normal;">&#945;</font> Inhibitor Program </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RLY-PI3K1047 is a lead compound in our franchise of programs targeting cancer-associated mutant variants of phosphoinositide 3-kinase alpha, or PI3K&#945;. RLY-PI3K1047 is a small molecule inhibitor of PI3K&#945; that we designed specifically to target PI3K&#945; H1047X mutants via a previously undescribed allosteric mechanism. Oral dosing of RLY-PI3K1047 resulted in tumor growth inhibition in mouse xenograft models of PI3K&#945; H1047R mutant carcinoma. We expect to begin IND-enabling studies for a differentiated PI3K&#945; H1047X mutant-selective inhibitor in 2021. We believe PI3K&#945; H1047X mutant cancers affect approximately 10,000 late-line patients annually in the United States. In the future, if RLY-PI3K1047 advances to earlier lines of treatment, we believe it could potentially be suitable for use in approximately 50,000 patients annually in the United States.<font style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Two additional mutations of interest for our PI3K&#945; franchise are E542X and E545X. We estimate there are approximately 15,000 late-line and 60,000 total patients annually in the United States who might benefit from a PI3K&#945; targeted inhibitor that targets the mutations at E542 and E545. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">RLY-1971 </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RLY-1971 binds and stabilizes SHP2 in its inactive conformation. SHP2 promotes cancer cell survival and growth through the RAS pathway by transducing signals downstream from receptor tyrosine kinases, or RTKs. Additionally, activating SHP2 mutations causes enhanced signaling in the absence of ligand stimulation and has been identified as an oncogenic driver in a range of tumors. As a critical signaling node and regulator, SHP2 drives cancer cell proliferation and plays a key role in the way cancer cells develop resistance to targeted therapies. We believe that inhibition of SHP2 could be effective as a monotherapy in cancers with specific alterations and could block a common path that cancer cells exploit to resist other antitumor agents, thus overcoming or delaying the onset of resistance to those therapies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently evaluating the safety and tolerability of RLY-1971 in a Phase 1 dose escalation study in patients with advanced or metastatic solid tumors. In December 2020, we entered into the Genentech Agreement, a global collaboration and license agreement with Genentech for the development and commercialization of RLY-1971. Future development for RLY-1971 will be governed by a joint development team between us and Genentech. We expect a combination trial of RLY-1971 and Genentech&#8217;s KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12C </sup>inhibitor, GDC-6036, to be initiated in 2021. Given the range of cancers that are related to SHP2 dependence, we believe RLY-1971 could serve as a backbone for compelling combination therapies. We believe SHP2-mediated cancers affect approximately 55,000 late-line patients annually in combination therapy settings in the United States. In the future, if RLY-1971 advances to earlier lines of treatment, we believe it could potentially have applicability to approximately 90,000 patients annually in the United States.<font style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup><sup style="font-size:85%;line-height:120%;vertical-align:top">&nbsp;&nbsp; </sup></font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Genentech Agreement, we have received $75 million in an upfront payment and are eligible to receive $25 million in near-term payments; and, if we do not opt into a U.S. profit/cost share, up to $695 million in additional development, commercialization and sales-based milestones for RLY-1971; and tiered royalties on annual global net sales (on a country-by-country basis), in the low-to-mid-teens, subject to reduction in certain circumstances. Additionally, we are eligible to receive additional royalties in the event of regulatory approval of RLY-1971 and Genentech&#8217;s <font style="color:#000000;">compound, GDC-6036, that directly binds to and inhibits KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup>, </font>in combination. We have the right to opt-in to a 50/50 U.S. profit/cost share and if we do opt into the U.S. profit/cost share, we are eligible to receive up to $410 million in additional commercialization and sales-based milestones for RLY-1971 outside of the U.S. and tiered royalties on annual net sales outside of the U.S. (on a country-by-country basis), in the low-to-mid-teens, subject to reduction in certain circumstances. We also retain the right to develop RLY-1971 in combination with our FGFR2 and PI3K&#945; programs. If we elect to opt-out of the profit/cost share, then the milestone and royalty payment obligations will revert to the financial terms that would be applicable if we had not opted into the profit/cost share, with certain adjustments. See &#8220;&#8212;Our Collaborations&#8212;License Agreements and Strategic Collaborations&#8212;Genentech Collaboration and License Agreement&#8221; for more details on the Genentech Agreement.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Discovery Programs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are deploying our Dynamo platform and MBDD approach to advance multiple discovery-stage precision oncology programs. As with our lead programs, these programs leverage insights into protein conformational dynamics to address high-value, genetically validated oncogenes that previously have been intractable to conventional drug-discovery approaches. Our Dynamo platform&#8217;s protein visualization capabilities can be applied to multiple therapeutic areas beyond precision oncology. To further diversify our pipeline, we are leveraging our Dynamo platform to address validated targets in monogenic diseases, where genetic alterations lead to disease-causing defects in protein motion. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Strategy </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our mission is to leverage unique insights into protein motion to transform the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of small molecule therapies. We believe that, by placing protein motion at the heart of MBDD discovery, our unique Dynamo platform has the potential to address previously intractable precision medicine targets. To accomplish this, we intend to continue building a team that shares our commitment to patients, to continue to enhance our platform, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and to rapidly advance our precision medicine pipeline of product candidates. The key elements of our strategy are to: </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rapidly advance our lead precision oncology programs, RLY-4008 and RLY-PI3K1047, through clinical development and regulatory approval. <font style="font-weight:normal;">We believe our lead precision oncology programs have the potential to treat a wide variety of cancers either as monotherapy or in combination regimens. In September 2020, we initiated a first-in-human clinical trial of RLY-4008. In 2021, we expect to have early safety and efficacy data for RLY-4008 and to be in IND-enabling studies for our RLY-PI3K1047 program. For our wholly-owned programs, we plan to conduct our clinical studies in genetically-defined patient populations. To potentially mitigate development risks, we will leverage learnings from recently approved precision oncology drugs to inform the clinical and regulatory pathways for our lead oncology programs. If we are successful in achieving clinically meaningful anti-tumor activity across solid tumor types, we plan to meet with regulatory authorities to discuss expedited regulatory approval strategies. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Continue to enhance our unique drug-discovery platform.<font style="font-weight:normal;"> Our Dynamo platform uniquely integrates a broad range of leading-edge experimental and computational technologies and tools, providing us with fundamental insights into the conformational dynamics of target proteins. We are committed to continuously integrating new computational and experimental tools, technologies and capabilities to enhance the power of our Dynamo platform. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Harness the insights and data generated from our platform against intractable targets in oncology and other therapeutic areas. <font style="font-weight:normal;">We have built a drug discovery process that leverages our collaboration with D. E.&#160;Shaw Research and their access to the Anton 2 supercomputer and our proprietary computational workflows. We are committed to deploying our Dynamo platform against targets in additional therapeutic areas beyond oncology. Our next focus, outside of oncology, is on rare genetic diseases where protein targets are genetically validated, where defects in protein conformational dynamics are abundant, and where we believe our approach is well-suited to identify therapies with the potential to have transformative impact for patients. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Selectively enter into strategic collaborations to maximize the value of our platform and pipeline.<font style="font-size:12pt;font-weight:normal;"> </font><font style="font-weight:normal;">We have initiated a Phase 1 clinical trial for RLY-1971 in patients with advanced solid tumors in the first quarter of 2020 and have continued to advance the clinical development of RLY-1971.</font>  <font style="font-weight:normal;">In December 2020, we entered into the Genentech Agreement, a global collaboration and license agreement with Genentech for the development and commercialization of RLY-1971. Other than our SHP2 program, we retain full development and commercialization rights to our current pipeline of precision medicine programs. We intend to build a fully integrated biopharmaceutical company and independently pursue the development and commercialization of our key product candidates. Given our potential to generate novel product candidates addressing a wide variety of therapeutic indications, we may enter into additional strategic partnerships around certain targets, product candidates, disease areas or geographies. If we believe these collaborations could accelerate the development and commercialization of our product candidates, and allow us to realize additional potential in our product candidates and our platform. </font></p>
<p style="margin-bottom:0pt;margin-top:24pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Dynamo Platform </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The continued and rapid development of new experimental techniques, such as room-temperature crystallography, and computational techniques, such as molecular dynamics and machine learning, is now enabling the deep understanding of protein motion to discover new therapeutic agents. Dynamo was built to capitalize on these recent advances to develop medicines against protein targets with greater specificity and potency. Using our Dynamo platform, we pivot from industry standard SBDD, which is based on static structures and often relies on incomplete protein fragments, to a novel drug-discovery paradigm based on fundamental insights into protein motion, which we term Motion Based Drug Design, or MBDD. We leverage insights from our platform to develop novel, motion-based hypotheses for how to drug target proteins. We can then more rapidly identify and optimize effective lead compounds by integrating powerful experimental and computational tools to sample a much broader range of chemical space than is possible using conventional approaches, which are labor intensive and require significant experimental effort. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2016, the confluence of three forces </font><font style="font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8212;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the proliferation of readily available genomic data, the evolution of experimental techniques, and advances in computational power and speed </font><font style="font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8212;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> led to the founding of Relay Therapeutics.&#160;We believe we are uniquely positioned to consolidate these advances and, when combined with our world-class team of experimental and computational experts, integrate these solutions in motion-based drug discovery. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000002.jpg" title="" alt="" style="width:624px;height:288px;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our platform integrates a broad and tailored array of leading-edge experimental and computational approaches to gain fundamental insights into protein function (<font style="font-weight:bold;">Figure 1</font>). </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 1: Dynamo drug-discovery platform integrates leading-edge experimental and computational tools. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000003.jpg" title="" alt="" style="width:618px;height:236px;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Key Drug Discovery Steps of our Dynamo Platform<font style="font-weight:normal;font-style:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We deploy the power of our Dynamo platform in three key phases of MBDD discovery (<font style="font-weight:bold;">Figure 2</font>). We first generate a target modulation hypothesis by developing a detailed mechanistic understanding of the dynamic behavior of the target protein and by identifying pockets where binding of a small molecule can impact protein function. Our platform then aids in the efficient generation of lead compounds through an integrated system of experimental and virtual screens. This enables rapid lead optimization by computationally prioritizing compounds </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for experimental evaluation. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> each cycle generates new learnings for both our team and our underlying machine learning models, our successful iteration of this process continuously improves our understanding of protein motion which leads to a more effective and efficient drug discovery process. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 2: Dynamo can be deployed across the various stages of drug discovery to provide novel insights and accelerate drug discovery. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000004.jpg" title="" alt="" style="width:616px;height:346px;"></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Target Modulation Hypothesis </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our first step is to establish a target modulation hypothesis for our protein target of interest. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For each target, the initial goal is to better understand the structure and conformational dynamics of all domains of a protein to generate the target modulation hypothesis. The process typically begins by expressing full-length proteins so we can fully understand the roles of specific domains and accurately capture the differences between the wild-type and mutant forms of the protein (or of different isoforms, etc.). We use a range of leading-edge structural biology techniques (e.g., room temperature X-ray crystallography, Cryo-EM) to visualize these protein conformations in the most physiologically representative context possible. The resulting data allow us to better visualize full-length proteins at atomic resolution. This comprehensive and dynamic visualization enables us to identify potential areas of interest in a protein target that can be exploited in the drug discovery process. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Using a range of protein visualization methods, we can generate a rich experimental understanding of the dynamic conformations of the target protein of interest. We can deploy these experimental data sets in an industry-leading computational platform to generate virtual simulations (molecular dynamics) of the full-length protein moving over long timescales. Long timescale molecular dynamics, or MD, simulations informed by the experimentally derived protein structural data help us better understand how proteins move and change shape over time. Our collaboration with D. E. Shaw Research provides us with access to Anton&#160;2, their proprietary supercomputer that was custom-built for performing molecular dynamics simulations &#8211; a technique that calculates the forces between each atom and every other atom in a given system at discrete time points in order to model behavior over time. We use MD simulations to predict the behavior of a given protein system, and with our collaborators we have simulated systems of up to 1&#160;million atoms at time slices of 2.5 x10<sup style="font-size:85%;line-height:120%;vertical-align:top">-15</sup> seconds. The individual time slices are then stitched together to create a high definition movie of the target protein over biologically relevant timescales, typically tens of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">microseconds. Other drug discovery approaches may use molecular dynamics, but they are limited to less than 1/100</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the timescale of our simulations. A 10 microsecond simulation of a 1&#160;million atom benchmark protein (satellite tobacco mosaic virus), which requires one day of processing on the Anton 2, would require 271 days on conventional hardware (Nvidia V100) (</font><font style="font-weight:bold;">Figure 3</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">). </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 3: The Anton 2 supercomputer enables Relay Therapeutics to simulate the motion of significantly larger biomolecules in far shorter periods of time compared to conventional forms of computation (e.g., GPUs and cloud computing). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000005.jpg" title="" alt="" style="width:539px;height:222px;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After understanding the dynamics of the target protein, we focus on identifying mechanisms to modulate the protein with a small molecule drug. There are multiple ways that a small molecule drug may bind to a target protein to impact its function. Molecules bind to a protein by interacting with amino acids which are often situated in a cavity on the protein&#8217;s surface, called a pocket. Most small molecule drugs modulate the function of the target protein by binding to the pocket that directly mediates the protein&#8217;s activity, which is called an &#8220;active&#8221; site. We leverage our platform to identify novel pockets that are not the active site but do impact protein function, so called &#8220;allosteric&#8221; sites. These binding sites are often part of an allosteric regulatory network that we can elucidate through a combination of computationally derived hypotheses and laboratory experiments on full-length proteins. Our ability to identify novel druggable pockets that have not previously been observed provides new handles for gaining isoform or mutant selectivity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our understanding of protein motion and modulation from our Dynamo platform informs the strategy and tools we employ for hit finding and lead generation phases. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Hit Finding and Lead Generation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once we have identified potential binding pockets and established a target modulation hypothesis, we then transition into hit finding and lead generation, where the goal is to identify a molecule that can serve as the starting point for a new drug. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Dynamo platform leverages our motion-based functional understanding of target proteins to enable the design of physiologically relevant activity-based and ligand-centric screens. These experimental measurements of biochemical or biophysical activity are then used to identify molecules to modulate our protein targets. Our Dynamo platform encompasses a variety of screening techniques to identify chemical starting points. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In parallel to our experimental screening efforts, we have made investments in our infrastructure that enables us to use cloud-computing to screen billions of molecules from a virtual compound library in days. The vast number of virtual molecules enables us to sample a much wider diversity of chemical space than would be possible through conventional methods. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the powerful hit finding approaches we utilize, we are able to generate a broad diversity of novel small molecules that act via our motion-based target modulation hypothesis and are ready to progress into lead optimization. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Lead Optimization </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once we have identified a chemical starting point and generated a lead compound, optimization is necessary to obtain a molecule that has the desired characteristics. Our Dynamo platform uses advanced computational models in tight integration with our medicinal chemistry, structural biology, enzymology and biophysics capabilities to predict and design the compounds that will achieve the most desirable characteristics, including potency, selectivity, bioavailability, and drug-like properties. Conventional optimization of small molecule lead compounds involves a highly iterative process that includes designing and synthesizing thousands of closely related compounds and experimentally testing them in the lab. This process is time consuming and requires significant experimental effort and expense. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During optimization, we leverage long timescale MD simulations to study binding pocket dynamics and to test analogs of our lead compound to prioritize which ones to synthesize and test experimentally. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once we have made and tested compounds in the lab, we can compare them to our computational predictions. Over time we can improve our computational predictions using the data that we generate experimentally. We believe that this integration of our long timescale molecular dynamics simulations with experimental data accelerates our lead optimization process. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Anton 2 supercomputer, that we access through our collaboration with D. E. Shaw Research, makes it possible to run thousands of simulations, which generate vast datasets. To take maximum advantage of this data, we use machine learning algorithms to establish relationships between molecular interactions observed in the simulations and biological activity observed in experiments. In <font style="font-weight:bold;">Figure 4</font>, we show how a machine learning model can be trained based on multiple parameters, including ligand motion, protein-ligand interactions and protein conformation, collected during long timescale MD simulations of molecules interacting with our target protein. This model can then be used to make predictions to prioritize the synthesis of new molecules. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 4: Data from long timescale molecular dynamics simulations are used to train machine learning models that can prioritize the next set of molecules to test. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000006.jpg" title="" alt="" style="width:618px;height:184px;"></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Benefits of Dynamo Platform </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Dynamo platform was built with the belief that integrating leading-edge computational and experimental approaches would unlock new insight about protein dynamics and ultimately the drug discovery process. We have shown multiple times that we can use this approach to develop novel target modulation hypotheses, generate a broad range of molecular starting points, and rapidly optimize potential drugs. <font style="font-weight:bold;">Figure 5</font> illustrates the timelines for our first two programs relative to conventional drug discovery. In general, it takes three to five or more years to advance from a validated hit to a development candidate, or DC. For our programs, however, we were able to advance from </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hit to DC in </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">two</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> years for RLY-1971 and 18 months for RLY-4008. In addition to the advantage of speed, as compared to conventional SBDD, our platform enables us to explore a greater diversity of chemical space, as illustrated by the number of chemical series. This breadth increases the intellectual property landscape that we cover and improves our ability to identify development candidates with optimal drug-like properties. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 5: The Relay Therapeutics Dynamo platform compared to conventional drug discovery approaches. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000007.jpg" title="" alt="" style="width:618px;height:278px;"></p>
<p style="margin-bottom:0pt;margin-top:24pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Therapeutic Opportunity </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our Dynamo platform could potentially be applied to a wide range of disease-associated protein targets, we currently focus on precision medicine targets, for which alterations in specific genes are known to cause disease. The genetic diseases we pursue include cancers with clear genetic driver alterations in the tumor genome, as well as monogenic diseases where the causal mutations are present at birth. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Precision Oncology </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our initial focus is in the area of precision oncology where we have seen initial proof of platform in our leading precision oncology pipeline. Over 125 genetic driver alterations across 10 canonical cellular signaling pathways have been identified in 89% of tumors. Targeting these genetic drivers could lead to clinically meaningful responses in patients. However, most of these targets have been intractable to conventional drug discovery approaches or are inadequately drugged by approved therapies. We believe our platform has the potential to address many of these targets by leveraging novel insights into protein dynamics. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Monogenic Diseases </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thousands of monogenic (change in a single gene) diseases exist and affect millions of individuals worldwide. Over 4,000 individual genetic drivers, and their associated protein defects, cause over 7,000 rare monogenic phenotypes. However, since 1996, the U.S. Food and Drug Administration, or FDA, has approved fewer than 70 therapies to specifically treat these conditions, presenting a vast unmet therapeutic need. We believe our Dynamo platform has the potential to address many of these targets. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Precision Medicines Opportunities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The decreasing cost and increasing resolution of genomic data have identified hundreds of additional actionable genetic targets beyond precision oncology and monogenic disease. These include genetically-defined subpopulations </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of more common diseases in neurology, immunology and other therapeutic areas. We believe that there are multiple genetically-validated targets in these disease areas that are unaddressed by approved therapies, representing an area of significant unmet need. We believe our Dynamo platform has the potential to address many of these targets. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our focus on addressing the genetic drivers of disease, also referred to as genetically validated targets, confers several advantages, including: </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Clear causal link to disease<font style="font-weight:normal;">: Genetic diseases offer an unambiguous causal link between the mutational alteration in a specific gene, disease biology, and a patient&#8217;s symptoms, such that the translational medicine hypothesis is well-validated at the beginning of a drug discovery program. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Precision medicine opportunity: <font style="font-weight:normal;">Because of the strong link between specific genetic alterations and disease symptoms, it is possible to precisely target therapy to genetically identifiable patients who are most likely to respond favorably to a precision medicine. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increased translational success:<font style="font-weight:normal;"> We believe that the ability to precisely target therapy to patients who are most likely to respond favorably to treatment will, in turn, increase the likelihood of successfully translating a specific pharmacological mechanism into clinical benefit. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we have initially focused our efforts on small molecule therapies, our Dynamo platform could also be readily deployed towards the discovery of other therapy types, such as large molecules including peptide or protein therapeutics. </p>
<p style="margin-bottom:0pt;margin-top:24pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Product Pipeline and Programs </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have deployed our Dynamo platform to initially focus on the area of precision oncology. To date, we have generated several promising precision oncology, orally available, small molecule product candidates that address previously intractable oncogenic targets. Our lead programs are targeting a range of driver alterations to treat various cancers that we believe can have a greater probability of translational success because they are genetically or clinically validated. The targets associated with all of our current programs are Category 1 Targets under our DESRES Agreement. See &#8220;&#8212;Our Collaborations&#8212;License Agreements and Strategic Collaborations &#8212;Collaboration and License Agreement with D. E. Shaw Research, LLC.&#8221; In addition, we are also advancing several early programs focused on other precision oncology and rare genetic disease targets. In December 2020, we entered into the Genentech Agreement, a global collaboration and license agreement with Genentech for the development and commercialization of RLY-1971. See &#8220;&#8212;Our Collaborations&#8212;License Agreements and Strategic Collaborations&#8212;Collaboration and License Agreement with Genentech.&#8221; Other than our SHP2 program, we retain full development and commercialization rights to our current pipeline of precision medicine programs.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our current portfolio of product candidates and programs. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000008.jpg" title="" alt="" style="width:624px;height:283px;"></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">RLY-4008, a selective inhibitor of FGFR2 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RLY-4008 is designed to be an oral, small molecule, selective inhibitor of fibroblast growth factor receptor 2, or FGFR2, a receptor tyrosine kinase that is frequently altered in cancer. FGFR2 is one of four members of the FGFR family, a set of closely related proteins with highly similar protein sequences and properties. RLY-4008 minimally inhibits targets other than FGFR2 and demonstrates FGFR2-dependent cell-killing in cancer cell lines. We initiated a first-in-human clinical trial of RLY-4008 enriched for patients with advanced solid tumors having oncogenic FGFR2 alterations in September 2020. We believe FGFR2-mediated cancers affect approximately 8,000 late-line patients annually in the United States, of which fusions represent approximately 2,700, amplifications approximately 1,600, and mutations approximately 3,800. In the future, if RLY-4008 advances to earlier lines of treatment, we believe it could potentially address approximately 20,000 patients annually in the United States across the different alterations.<font style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Role of FGFR in cellular proliferation and differentiation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of the FGFRs has an important role in normal physiology and the inhibition of FGFR2 is a well-validated pathway in disrupting cancer proliferation and growth. Two non-selective FGFR inhibitors have been approved (erdafitinib and pemigatinib) and several are in clinical development. However, these inhibitors as a class cause several dose-limiting, FGFR2-unrelated toxicities in patients leading to dose reductions and altered dosing schedules. One of the most common dose limiting toxicities of these agents is hyperphosphatemia (buildup of excess phosphate in the bloodstream), which causes soft tissue mineralization and requires active management. Hyperphosphatemia has been shown to be driven by inhibition of another member of the FGFR family known as FGFR1 (<font style="font-weight:bold;">Figure&#160;15</font>). </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;15: RLY-4008 is a selective inhibitor of FGFR2. FGFR1 is required for phosphate resorption in the kidney. Inhibition of FGFR1 by non-selective FGFR inhibitors results in increased serum phosphate and toxicity. This results in decreased efficacy by requiring dose reductions. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000009.jpg" title="" alt="" style="width:611px;height:363px;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that the toxicity attributable to inhibition of other FGFR family members, and other closely related kinases, limits the ability of the non-selective FGFR inhibitors to achieve optimal and durable inhibition of FGFR2, limiting the efficacy of these agents in patients with FGFR2-altered tumors. In addition to the lack of selectivity, these inhibitors are unable to overcome on-target resistance, which has been observed in patients treated with non-selective FGFR inhibitors. Our belief is that a selective inhibitor of FGFR2 that retains activity against resistance mutations will enable improved clinical efficacy. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Limitations of current FGFR inhibitors </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-selective FGFR inhibitors produced by other companies have demonstrated clinical proof-of-concept in patients with intrahepatic cholangiocarcinoma, or ICC, bearing FGFR2 gene fusions. These gene fusions result in a constitutively active FGFR2, which promotes oncogenic transformation. Genetic alterations in FGFR2, including gene fusions, amplifications, and point mutations, are also found in other solid tumor indications. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients with genetic alterations in FGFR2, primarily gene fusions in ICC, have been treated with FGFR inhibitors in investigational clinical trials. To date, these trials provide support for the critical role of FGFR2 for tumor survival with a response rate of up to 36% (<font style="font-weight:bold;">Figure&#160;16)</font>. A key limiting factor for existing FGFR therapies is that, as a class, they are associated with a dose-limiting side effect, hyperphosphatemia, which has been shown to be caused by FGFR1 inhibition. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;16: Hyperphosphatemia is a dose-limiting adverse event associated with non-selective FGFR inhibitors. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000010.jpg" title="" alt="" style="width:616px;height:188px;"></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Our solution, RLY-4008 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RLY-4008 is an oral, small molecule inhibitor of FGFR2 designed to inhibit FGFR2 with high potency while minimizing inhibition of other FGFR family members. In our initial assessment of the challenge of obtaining a highly selective inhibitor of FGFR2, we determined that there is a high degree of structural similarity between FGFR1 and FGFR2 when comparing static X-ray crystal structures. This similarity precluded the development of a structure-based selectivity hypothesis using conventional approaches. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We therefore set out to identify motion-based differences between FGFR2 and other FGFR family members by applying our expertise in computational modeling and experimental structural analyses. We discovered that there were segments of FGFR2 which displayed differential dynamics compared to the corresponding segments of FGFR1 (<font style="font-weight:bold;">Figure&#160;17</font>). We predicted these dynamic differences could be exploited to achieve selective inhibition of FGFR2. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;17: Using MD simulations, we predicted that a segment in FGFR1 was more dynamic than FGFR2, as represented by the schematic below where the segment opens &#8220;Up&#8221; more frequently in FGFR1 compared to FGFR2. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000011.jpg" title="" alt="" style="width:616px;height:220px;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We embarked on a process using computational methods such as long timescale molecular dynamics simulations, virtual docking and specialized experimental techniques to design, select, synthesize, and evaluate inhibitors. Our discovery process culminated with the selection of RLY-4008 as a product candidate based on its ability to meet our predetermined criteria for potency, selectivity and activity in animal models. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As described below, we have conducted a number of head-to-head preclinical experiments utilizing cellular </font><font style="font-style:italic;">in vitro</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> assays and mouse models using equivalent methods on all compounds tested. We compared RLY-4008 across a number of parameters against two approved molecules as well as three molecules in clinical development. We believe that the results of these preclinical experiments have demonstrated that RLY-4008 could potentially be a differentiated molecule warranting testing in clinical studies. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We initiated a first-in-human clinical trial of RLY-4008 enriched for patients with advanced solid tumors having oncogenic FGFR2 alterations in September 2020. Given RLY-4008&#8217;s strong preclinical activity against both primary oncogenic alterations and acquired pan-FGFR inhibitor resistance mutations, the trial will include patients that are na&#239;ve to pan-FGFR inhibitors, as well as those that have progressed on pan-FGFR inhibitors.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ultimately, extensive clinical studies of RLY-4008 will be required to determine if the differentiation we observed in the preclinical studies described below translates into clinical benefit for patients. The clinical data that we expect to generate in any such clinical studies will constitute the bulk of the data needed to support an application for marketing approval of RLY-4008. Unless we conduct head-to-head studies of RLY-4008 against other molecules as part of our future clinical trials, we would not expect to rely upon RLY-4008&#8217;s potential differentiation from any other molecules in connection with submissions to the FDA or other regulatory agencies, as applicable, for approval or otherwise. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in our head-to head preclinical experiments utilizing cellular <font style="font-style:italic;">in vitro</font> assays and mouse models, we selected dose levels for the other molecules to match human exposure of the approved dose or the dose being used in its clinical studies, as applicable, and we used the proportional dose levels of RLY-4008 that we believe are comparable to what we expect to utilize in our future clinical studies. The differences in these dose levels may have had an impact on the differentiation in the preclinical results we observed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We demonstrated in enzymatic and cellular assays that RLY-4008 was over 200-fold more potent at inhibiting FGFR2 compared to FGFR1 (<font style="font-weight:bold;">Figure&#160;18</font>). In addition to selectivity over FGFR1, RLY-4008 is also selective over the other members of the FGFR family, FGFR3 (&gt;80-fold) and FGFR4 (&gt;4,000 fold) in biochemical assays. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;18: RLY-4008 is selective for FGFR2 over FGFR1.<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000012.jpg" title="" alt="" style="width:233px;height:211px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The selectivity of RLY-4008 for FGFR2 over FGFR1 was determined by comparing the potency (IC50) of RLY-4008 and other clinical non-selective FGFR inhibitors in biochemical assays using Caliper technology (PerkinElmer). Human FGFR1 and FGFR2 (Carna Biosciences) were incubated with a peptide substrate (PerkinElmer) in the presence of varying concentrations of the indicated inhibitor for 30 minutes. Reactions were carried out in the presence of 100 mM ATP and 10 mM MgCl2 for 90 minutes. Non-selective FGFR inhibitors were obtained from vendors that provide compounds based on chemical structures published in the patent literature (Cayman Chemical, MedChemExpress, Selleckchem). Fold change in potency was calculated using the average IC50 obtained for each inhibitor in three independent experiments. RLY-4008 showed greater than 200-fold selectivity for FGFR2 over FGFR1. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RLY-4008 has minimal inhibition of targets other than FGFR2 and demonstrates FGFR2-dependent cell-killing in cancer cell lines. It has bioavailability suitable for oral dosing, is metabolically stable, and has demonstrated good </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pharmacokinetics in preclinical </font><font style="font-style:italic;">in vivo</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> models. Human pharmacokinetic projections are consistent with once or twice daily oral dosing. RLY-4008 is predicted to have low risk of drug-drug interactions based on weak inhibition of drug metabolizing enzymes. It is readily synthesized in bulk, can be formulated for oral delivery, and exposures at the highest non-severely toxic dose were several fold in excess of the predicted human efficacious exposures. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In a patient-derived xenograft, or PDX, mouse model of ICC harboring a FGFR2 fusion, treatment with RLY-4008 led to tumor regression at doses as low as 10 mg/kg delivered twice a day (<font style="font-weight:bold;">Figure 19</font>). Non-selective inhibitors, pemigatinib and futibatinib, also resulted in tumor volume reductions in this model when dosed at levels selected to match their human exposure in clinical studies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To preclinically validate our effort to engineer selectivity for FGFR2 as a means of reducing the risk of hyperphosphatemia, we examined the effect of RLY-4008 in an industry standard rat model of hyperphosphatemia. No evidence of hyperphosphatemia was seen with doses of RLY-4008 that resulted in exposures leading to tumor regression in our FGFR2 gene fusion ICC PDX mouse model (<font style="font-weight:bold;">Figure&#160;19</font>). By contrast, when dosed at levels selected to match human exposure in clinical studies, futibatinib led to increased hyperphosphatemia. Additionally, in 28-day GLP toxicology studies in rats and dogs, neither hyperphosphatemia nor tissue mineralization were observed with RLY-4008 at exposures in the animal corresponding to the predicted human efficacious exposures. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;19: RLY-4008 leads to tumor regression in an FGFR2 fusion positive ICC PDX model and does not cause hyperphosphatemia. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000013.jpg" title="" alt="" style="width:624px;height:293px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="font-style:italic;font-weight:normal;"> Anti-tumor activity of RLY-4008 dosed twice daily (BID) by oral administration in an FGFR2 fusion-positive ICC PDX model. RLY-4008 induced dose-dependent regression when administered at 10 or 30 mpk BID. TAS-120 at 2 mpk TID (red) and pemigatinib at 0.5 mpk BID (pink) were dosed at levels selected to match their clinical exposures. Data points indicate mean tumor volume (n=6 per group) and error bars represent standard error of the mean. All treatment groups are statistically significant when compared to vehicle with p&lt;0.001 as determined by two-sided t-test. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="font-style:italic;font-weight:normal;">Serum phosphate measurements in rats dosed twice daily with RLY-4008 (blue) or TAS-120 (red) by oral administration. Doses of RLY-4008 (100 and 200 mpk BID) resulting in exposures leading to tumor regression in our FGFR2 gene fusion ICC PDX model do not cause significant hyperphosphatemia. Doses of TAS-120 (3 mpk BID and 10 mpk QD) selected to match human exposures in clinical studies cause significant hyperphosphatemia. Data indicate the mean serum phosphate level (n=5 per group), and error bars represent standard deviation. TAS-120 treatment groups are statistically significant when compared to vehicle with p&lt;0.01 as determined by one-way ANOVA. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, RLY-4008 was able to achieve </font><font style="font-style:italic;">in vivo</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> efficacy in mouse models of FGFR2-fusion gastric cancer, FGFR2-amplified gastric cancer, and FGFR2-mutant endometrial cancer. Treatment with RLY-4008 led to tumor regression at 3 mg/kg delivered twice a day in a FGFR2 gene fusion gastric cancer model, and at 10 mg/kg delivered twice a day in a FGFR2-amplified gastric cancer or FGFR2-mutant endometrial cancer models (</font><font style="font-weight:bold;">Figure&#160;22</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">). All of these doses result in exposures that do not cause hyperphosphatemia in an industry standard rat model. Importantly, RLY-4008 achieved complete regression in an FGFR2-mutant endometrial cancer model (AN3CA) harboring the N550K mutation that reduced the potency of pemigatinib by 185-fold. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;22: RLY-4008 leads to tumor regression in an FGFR2-fusion gastric cancer PDX, the FGFR2-amplified gastric cancer SNU16 xenograft model, and the FGFR2 N550K-mutant endometrial cancer AN3CA xenograft model. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000014.jpg" title="" alt="" style="width:616px;height:204px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Anti-tumor activity of RLY-4008 dosed twice daily (BID) by oral administration in <font style="font-weight:bold;font-style:normal;">(a)&#160;</font>an FGFR2 fusion gastric cancer PDX model, <font style="font-weight:bold;font-style:normal;">(b)&#160;</font>the FGFR2-amplified SNU16 gastric cancer xenograft model, and <font style="font-weight:bold;font-style:normal;">(c)&#160;</font>the FGFR2 K310R; N550K mutant AN3CA endometrial cancer xenograft model. Data points indicate mean tumor volume and error bars represent standard error of the mean. Statistical analyses were performed using one-way ANOVA. (a)&#160;n=8&#160;per group; treatment groups are statistically significant when compared to vehicle with p&lt;0.001. (b)&#160;n=7&#160;per group; treatment groups are statistically significant when compared to vehicle with p=0.001 for 10&#160;mpk BID group and p&lt;0.001 for 30&#160;mpk BID group. (c) n=8&#160;per group; two high-dose groups are statistically significant when compared to vehicle with p=0.003 for 30&#160;mpk BID group and p=0.005 for 10&#160;mpk BID group. p=0.627 for 3&#160;mpk BID group.<font style="font-style:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Another predicted advantage of RLY-4008 concerns resistance mutations. These new mutations in FGFR2 arise during treatment, reducing the potency of non-selective FGFR inhibitors and making tumors resistant to treatment. In preclinical experiments, we have shown that RLY-4008 retains activity against a broad panel of mutations known to be associated with resistance to non-selective FGFR inhibitors (<font style="font-weight:bold;">Figure&#160;20)</font>. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;20: RLY-4008 retains potency against common FGFR2 resistance mutations. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000015.jpg" title="" alt="" style="width:516px;height:178px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Heatmap showing fold change in potency (IC50) on FGFR2 mutations compared to FGFR2 WT. Human FGFR2 cDNA (NCBI Reference Sequence: NM_022970.3) was cloned into pLenti-P2A-Puro vector, site-directed mutagenesis was performed for the indicated mutations, and plasmid purification was conducted at GenScript. Lentivirus for each vector was prepared using Lenti-vpak Lentiviral Packaging Kit, and FGFR2 WT or FGFR2 mutants were expressed in HEK-293 cells via lentiviral transduction. Cells were incubated with various concentrations of the indicated inhibitors for 2 hours and potency of FGFR2 was determined using a pFGFR2 (Tyr 653/654) HTRF assay (Cisbio) per the manufacturer&#8217;s protocol. Colors indicate the fold loss in potency for the mutant FGFR2 vs WT. Gatekeeper mutations block access to the binding site of non-selective inhibitors. Molecular brake mutations disrupt an autoinhibitory conformation of FGFR2, resulting in kinase activation. Other mutations listed have various reported mechanisms of kinase activation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the studies published to date describing resistance, multiple FGFR2 resistance mutations have been reported, with mutations at position V565 and N550 being most common. Mutations sterically block access to the binding site of non-selective FGFR inhibitors and/or disrupt an auto-inhibitory conformation of FGFR2. Among mutations, V565F and N550K are two of the most prevalent. To further evaluate the activity of RLY-4008 against FGFR2 resistance mutations, the <font style="font-style:italic;">in vivo </font>activity of RLY-4008 was compared to five different pan-FGFR inhibitors including pemigatinib, infigratinib, erdafitinib, zoligratinib, and futibatinib in an ICC FGFR2 fusion cancer PDX model with the V565F mutation and to pemigatinib in the AN3CA endometrial cancer CDX model with the N550K mutation. In both models, RLY-4008 was able to induce regression at doses resulting in exposures that do not cause hyperphosphatemia in an industry standard rat model. By contrast, when dosed at levels selected to approximate human exposure in clinical studies, the pan-FGFR inhibitors showed little to no anti-tumor activity in both models (<font style="font-weight:bold;">Figure&#160;23</font>). </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;23: RLY-4008 induces tumor regression in FGFR2 V565F and N550K-mutant xenograft models. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000016.jpg" title="" alt="" style="width:624px;height:162px;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Anti-tumor activity of RLY-4008 and pan-FGFR inhibitors in xenograft models harboring common on-target resistance mutations. (a) RLY-4008 and pan-FGFR inhibitors were dosed once daily (QD) by oral administration in an ICC FGFR2 fusion cancer PDX model with the V565F mutation. RLY-4008 induced regression whereas all pan </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">FGFR inhibitors grew in the presence of drug.</font><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> </font><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(b) RLY-4008 and pemigatinib dosed twice daily (BID) by oral administration in the FGFR2 K310R;N550K mutant AN3CA endometrial cancer xenograft model. RLY-4008 induced regression whereas pemigatinib was inactive. Data points indicate mean tumor volume and error bars represent standard error of the mean. RLY-4008 cohort is statistically significant when compared to vehicle or pan-FGFR inhibitors with p&lt;0.001 as determined by one-way ANOVA.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although RLY-4008 retains activity preclinically against common FGFR2 resistance mutations, tumors may develop bypass resistance by shifting growth factor signaling to an alternate receptor, rendering them less sensitive to the targeted therapy. SHP2, a protein tyrosine phosphatase, regulates the activity of multiple RTKs, and may be an effective way to overcome bypass resistance to RLY-4008. To demonstrate the potential for RLY-1971 as a combination partner for RLY-4008, we tested a population of four patient-derived FGFR2-fusion positive ICC cell lines. These cells were derived from patients that initially responded to non-selective FGFR inhibitors, but then acquired bypass resistance to FGFR inhibition during their treatment. While these cell lines were resistant to treatment with our FGFR2 inhibitor RLY-4008, all resistant cells were sensitive to RLY-1971 with IC50s of less than 100 nM (<font style="font-weight:bold;">Figure&#160;24</font>). Given the role of SHP2 in mediating bypass resistance to multiple targeted therapies, we intend to investigate the clinical potential of the combination of RLY-1971 with RLY-4008. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;24: RLY-1971 overcomes bypass resistance to FGFR2 inhibition in patient-derived FGFR2 fusion positive ICC cell lines. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000017.jpg" title="" alt="" style="width:618px;height:437px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Anti-proliferative effect of RLY-1971 in patient-derived FGFR2 fusion positive ICC cells tested in a 2D proliferation assay. These cell models were derived from patients that initially responded to non-selective FGFR inhibitors, but then progressed during their treatment (the specific FGFR2 fusion present in the cells is indicated). These cells are resistant to treatment with our FGFR2 inhibitor RLY-4008 (blue lines), whereas RLY-1971 demonstrates anti-</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">proliferative and cytotoxic activity (red lines), with IC50s as follows: </font><font style="font-weight:bold;">(a)</font><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> 13 nM, </font><font style="font-weight:bold;">(b)</font><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> 20 nM, </font><font style="font-weight:bold;">(c)</font><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> 39 nM, and</font><font style="font-weight:bold;"> (d)</font><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> 91 nM. The dotted line at 0 indicates complete growth suppression, with values below 0 indicating cytotoxicity. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Our clinical development plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The RLY-4008 clinical development plan seeks to leverage the unique potential for enhanced tolerability and broad FGFR2 mutational coverage to rapidly generate proof-of-concept in molecularly defined patient subsets. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We initiated a first-in-human clinical trial of RLY-4008 enriched for patients with advanced solid tumors having oncogenic FGFR2 alterations in September 2020. The primary objectives are to determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) and to define the overall safety profile of RLY-4008. Secondary objectives are to assess the pharmacokinetics, pharmacodynamics and to explore anti-tumor activity of RLY-4008. Patients will initially receive RLY-4008 administered orally, twice daily. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The first trial will employ a 2-part dose escalation/dose-expansion design. Given RLY-4008&#8217;s strong preclinical activity against both primary oncogenic alterations and acquired pan-FGFR inhibitor resistance mutations, the trial will include patients that are na&#239;ve to pan-FGFR inhibitors, as well as those that have progressed on pan-FGFR inhibitors. Observation of significant clinical activity in one or more patient populations in this exploratory first-in-human trial would support further trials to confirm the risk-benefit profile of RLY-4008 in patients with oncogenic FGFR2 alterations. These trials may include continued evaluation of RLY-4008 as a monotherapy in single arm trials in patient populations without an established standard-of-care therapy available, which could be used to support filings for marketing authorization for RLY-4008. The development program for RLY-4008 may also include randomized trials of RLY-4008 compared to a relevant standard-of-care therapy. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate giving an initial clinical update on this trial in the second half of 2021.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;25: First-in-human clinical trial for RLY-4008 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000018.jpg" title="" alt="" style="width:624px;height:222px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development of RLY-4008 will require identification of appropriate patients for treatment with FGFR2 alterations using molecular diagnostic tests. In early phase clinical trials, patients will be identified using local testing performed at clinical trial sites, with retrospective centralized testing to confirm the tumor genetic status. In later phase trials, we will likely collaborate with a diagnostic partner to identify patients for clinical trial enrollment using an analytically validated investigational molecular diagnostic. The tumor genetic contexts that we are considering for development of RLY-4008 (FGFR2 fusions, amplifications and mutations) can currently be detected using FDA-approved next generation sequencing based panel diagnostics (e.g. Foundation One, Guardant 360). </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Mutant-PI3K</font><font style="font-weight:normal;font-style:normal;">&#945;</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> Inhibitor Programs </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RLY-PI3K1047 is the lead compound in our franchise of programs targeting cancer-associated mutant variants of phosphoinositide 3-kinase alpha, or PI3K&#945;. RLY-PI3K1047 is a small molecule inhibitor of PI3K&#945; that we designed to specifically target PI3K&#945; H1047X mutant via a previously undescribed allosteric mechanism. Oral dosing of RLY-PI3K1047 resulted in tumor growth inhibition in a mouse xenograft model of PI3K&#945; H1047R mutant carcinoma. We expect to begin IND-enabling studies for a differentiated PI3K&#945; H1047X mutant-selective inhibitor in 2021. We believe PI3K&#945; H1047X mutant cancers affect approximately 10,000 late-line patients annually in the United States. In the future, if RLY-PI3K1047 advances to earlier lines of treatment, it could potentially address approximately 50,000 patients annually in the United States.<font style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Two additional mutations of interest for our PI3K&#945; franchise are E542X and E545X. We estimate there are approximately 15,000 late-line and 60,000 total patients annually in the United States who might benefit from a PI3K&#945; targeted inhibitor that targets the mutations at E542 and E545. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 26: PI3K<font style="font-weight:normal;">&#945;</font> addressable patient populations </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000019.jpg" title="" alt="" style="width:597px;height:169px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">1) Estimated frequency percentages are based on counts of known/likely functional alterations in the Foundation Medicine Insights database. 2) Based on projected cancer deaths in all solid tumors from the National Cancer Society&#8217;s SEER database as a proxy for late-line cancer patient incidence. 3) These data are based on projections from the National Cancer Society&#8217;s SEER program for estimated new cases of advanced solid tumors. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Role of PI3K<font style="font-style:normal;">&#945;</font> in cellular proliferation and differentiation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutations at amino acid H1047 of PI3K&#945; are among the most common kinase mutations in cancer and are believed to be a primary driver of carcinogenesis. There are no approved therapies that selectively target mutant versions of PI3K&#945;. Inhibitors that are not mutant-selective are associated with dose-limiting toxicities resulting in frequent discontinuations that restrict their therapeutic potential. Additionally, these inhibitors also can inhibit other isoforms of PI3K, including PI3K&#948;, which can further result in toxicity. Our belief is that selectively targeting mutant PI3K&#945; could result in improved target inhibition and increased clinical efficacy (<font style="font-weight:bold;">Figure 27</font>). </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 27: RLY-PI3K1047 is a selective inhibitor of H1047X mutant PI3K</font><font style="font-weight:normal;">&#945;.</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> WT PI3K</font><font style="font-weight:normal;">&#945;</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> plays a critical role in normal cellular signaling and function, including glucose uptake and insulin regulation. Inhibition of WT PI3K</font><font style="font-weight:normal;">&#945;</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> by non-mutant selective PI3K inhibitors results in hyperglycemia, hyperinsulinemia and other toxicities. This results in decreased efficacy by requiring dose reductions.</font><font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000020.jpg" title="" alt="" style="width:616px;height:446px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leveraging our structural biology capabilities, we solved what we believe to be the first full-length structure of PI3K&#945; using cyrogenic electron microscopy (Cryo-EM) and utilized a range of experimental techniques to understand both H1047R mutant and wild-type conformations. We used this rich experimental data set to power molecular dynamics simulations of H1047R mutant PI3K&#945; to identify a series of dynamic structural changes caused by the mutation, which were not elucidated by prior structural studies of either H1047R mutant or wild-type PI3K&#945;. The lead compound in this program, which we refer to as RLY-PI3K1047, was designed to exploit these dynamic differences and bind to a novel allosteric site to achieve heightened mutant selectivity. We intend to initiate IND-enabling studies for our first PI3K&#945; mutant selective inhibitor, which is focused on H1047X, in 2021. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">PI3K<font style="font-style:normal;">&#945;</font> mutations drive the development of cancer </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PI3K&#945; is the central regulator of a cellular signaling pathway that has been linked to a diverse group of cellular functions related to cancer including cell growth, proliferation and survival. Data collected as a part of Foundation Medicine Insights and other data sources identifies PI3K&#945; as the most frequently mutated kinase in cancer. (<font style="font-weight:bold;">Figure 28</font>). </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 28: PI3K</font><font style="font-weight:normal;">&#945;</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> is a common mutation in cancer. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000021.jpg" title="" alt="" style="width:618px;height:346px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approximately 80% of the mutations in PI3K&#945; cluster at three amino acids, or locations. These are E542 and E545 in the helical domain, and H1047 in the kinase domain. The most common mutation at amino acid H1047 is H1047R, but other H1047 mutations (such as H1047L, H1047Y, and others) are also observed across cancers. The abbreviation &#8220;H1047X&#8221; is used to refer to any H1047 mutation. Similarly, the most common mutations in the helical domain are E542K and E545K, but other mutations (such as E542Q, E545A, and others) are also observed across cancers. The abbreviation &#8220;E542/E545X&#8221; is used to refer to any helical domain mutation. The H1047R mutation has been shown to induce extensive and diverse cellular changes in pre-clinical models of breast cancer, demonstrating how a single mutation at amino acid H1047 can have large consequences and induce a cancer phenotype. The E5452K and E545K mutations have also been shown to increase PI3K&#945; activity, promote cell growth and invasion in vitro, and induce tumorigenesis in vivo. While H1047X and E542/E545X mutations have been shown to result in aberrant PI3K&#945; activity, they do so through distinct biological mechanisms. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Limitations of current PI3K<font style="font-style:normal;">&#945;</font> inhibitors </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the large number of patients with PI3K&#945; mutations, several small-molecule inhibitors of PI3K&#945; are in development for oncology indications. However, these inhibitors have to our knowledge been largely ineffective when used as monotherapy in cancer. All of these inhibitors target the catalytic (orthosteric) site of PI3K&#945;. One challenge faced by these inhibitors has been drug intolerance, especially at the high doses routinely used in cancer trials. Alpelisib, marketed as Piqray<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> by Novartis, is the only FDA-approved inhibitor for cancers with mutated PI3K&#945;. However, alpelisib is not a selective inhibitor for mutant forms of PI3K&#945;; it is a potent inhibitor of both the wild-type form of PI3K&#945; as well as the mutant form. Nonetheless, alpelisib is approved to be used in combination with fulvestrant, an estrogen receptor degrader, in PI3K&#945;-mutated breast cancer. When used in combination with fulvestrant, alpelisib was associated with significant adverse events, including severe hypersensitivity, diarrhea and severe pneumonitis. Hyperglycemia was reported in 64% of patients and over 36% of patients experienced Grade 3 or Grade 4 hyperglycemia. To manage hyperglycemia, insulin along with other anti-diabetic medication was used in 87% of patients. Gastrointestinal toxicity was reported in 93% of patients, with 9% experiencing Grade&#160;3 gastrointestinal toxicity. Additionally, 36% of patients experienced rash, with 10% experiencing Grade 3 rash. The combination of these adverse events resulted in 64% of patients requiring dose reductions and 25% of patients discontinuing treatment. Despite 11&#160;month progression-free survival (PFS) in the SOLAR-1 Phase 3 trial of alpelisib, the median duration of dosing in the alpelisib arm was 5.5&#160;months, indicating the majority of patients </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">discontinued dosing prior to disease progression. The observed hyperglycemia is believed to be caused by inhibition of wild-type PI3K&#945; and therefore is considered an on-target toxicity for alpelisib. In addition to causing dose-limiting toxicity, systemic glucose-insulin feedback caused by inhibiting wild-type PI3K results in elevated insulin that can activate PI3K signaling and subsequently limit the efficacy of PI3K inhibitors. While these factors limit the clinical utility of alpelisib, these data nonetheless establish mutant PI3K&#945; as a clinically validated target in breast cancer. Because these toxicities result in suboptimal doses and dosing schedules that result in incomplete PI3K&#945; inhibition, we believe that a H1047X or E542/E545K mutant selective inhibitor will enable improved target inhibition, and therefore improved clinical efficacy. Additionally, overcoming hyperinsulinemia and hyperglycemia could increase efficacy by preventing insulin feedback that activates PI3K signaling. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Our solution, mutant selective inhibition of PI3K&#945;<font style="font-style:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the existence of mutations in PI3K&#945; with different biological mechanisms underlying aberrant activity, we believe there are multiple opportunities to develop distinct mutant selective inhibitors of PI3K&#945;. Addressing the challenge of mutant selectivity required us to express and then solve the structure of the full-length PI3K&#945; protein. This structure, which to our knowledge had previously not been solved, represented a technical challenge because PI3K&#945; is a membrane-bound protein. This type of protein is typically difficult both to purify in large quantities and to crystallize. Nonetheless, we were able to obtain the structure of full-length PI3K&#945; using Cryo-EM. The three-dimensional structure of PI3K&#945; was determined by collecting data from two-dimensional electron microscopic projections of thin layers of protein. The resulting three-dimensional protein structure provided us with fundamental insights into the mechanism of activation of PI3K&#945; and the impact of mutations on its function. Through the integration of these structural insights with a combination of experimental and computational techniques, our aim is to develop a franchise of mutant selective PI3K&#945; inhibitors. The first lead molecule derived from these efforts, which is focused on H1047X, is described below. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Current lead molecules for PI3K-H1047X Mutations, RTX-1 and RTX-2 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RLY-PI3K1047 encompasses our lead small molecule inhibitors of PI3K&#945;, RTX-1 and RTX-2, that we designed to specifically target PI3K&#945; H1047X mutant via a previously undescribed allosteric mechanism.<font style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></font>As described above, adverse events such as hyperglycemia are common among PI3K inhibitors that have been tested in the clinic, leading us to focus on identifying an inhibitor that bound to a novel site on PI3K&#945;. Our intent was to obtain a molecule that could selectively bind to the mutant form of PI3K&#945;. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Structural analyses of PI3K&#945; showed that mutations at amino acid H1047 cause structural alterations that are located away from the catalytic site, the place where other PI3K inhibitors bind. We then performed long timescale molecular dynamics simulations of wild-type and H1047R mutant PI3K&#945; to identify a series of dynamic structural changes caused by the mutation that are not present in the wild-type protein. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilizing this structural information, we designed inhibitors to target a novel allosteric binding site on the PI3K&#945; H1047R mutant protein that our computational and experimental approaches exposed. This process led to the discovery of RTX-1 and RTX-2, which are approximately 5-10-fold selective for the H1047R mutant form of PI3K&#945; compared to the wild-type protein in biochemical assays (<font style="font-weight:bold;">Figure 29</font>). In contrast, alpelisib and GDC-0077 (an orthosteric PI3K&#945; inhibitor currently in development) biochemically inhibited the mutant and wild-type proteins with approximately equivalent potency. In addition, we found that RTX-1 and RTX-2 are selective for PI3K&#945; over other PI3K isoforms, including PI3K&#223; and PI3K&#948;, showing no measurable inhibition. In contrast, alpelisib and GDC-0077 inhibited the PI3K&#948; isoform with IC50 &lt; 1&#181;M. Given toxicities associated with inhibitors that target PI3K isoforms other than PI3K&#945; and GDC-0077, including gastrointestinal side effects and transaminitis, we believe that these molecules provide a dual advantage of isoform and mutant selectivity, which could result in increased clinical efficacy compared alpelisib or other orthosteric PI3K&#945; inhibitors. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 29: Compared to alpelisib and GDC-0077, </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RTX-1 and RTX-2</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">are</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">more selective for the PI3K</font><font style="font-weight:normal;">&#945;</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> mutant (H1047R) compared to wild-type (a)&#160;and more selective for the PI3K</font><font style="font-weight:normal;">&#945;</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> isoform compared to other PI3K isoforms PI3K&#223; and PI3K</font><font style="font-weight:normal;">&#948;</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (b). </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000022.jpg" title="" alt="" style="width:624px;height:223px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Biochemical potency for RLY-PI3K1047 compared to alpelisib and GDC-0077. IC50 values are shown for inhibition of the PI3K<font style="font-style:normal;">&#945;</font> mutant (H1047R) compared to wild-type <font style="font-weight:bold;">(a)</font>&#160;and for PI3K<font style="font-style:normal;">&#945;</font> compared to other PI3K isoforms <font style="font-weight:bold;">(b)</font>. Phosphotransfer activity (PtdIns(3,4,5)P3 production in liposomes using diC8-PtdIns(4,5)P2 as a substrate in the presence of 100uM ATP and titrated compounds after a 120min incubation) was measured by ADP-Glo. All samples were run in duplicate and data represent the mean. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This increased biochemical potency for PI3K&#945; H1047R mutant protein translates into an increased potency in cellular pharmacodynamic assays. RTX-1 was approximately 10-fold more potent for inhibition of phosphorylated AKT (pAKT), a key substrate of PI3K&#945;, in transformed breast epithelial cells expressing PI3K&#945; H1047R compared to the same cells expressing wild-type PI3K&#945;. RTX-2, an example of another lead compound generated in this program, also showed approximately 10-fold increased potency for inhibition of pAKT in transformed breast epithelial cells expressing PI3K&#945; H1047R (<font style="font-weight:bold;">Figure 30</font>). In contrast, alpelisib and GDC-0077 (an orthosteric PI3K&#945; inhibitor currently in development) showed approximately equal potencies in cells expressing either the mutant or wild-type forms. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 30: Compared to other clinical PI3K</font><font style="font-weight:normal;">&#945;</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> inhibitors (alpelisib and GDC-0077), Relay compounds more potently inhibits pAKT in cells expressing H1047R mutant PI3K</font><font style="font-weight:normal;">&#945;</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> compared to cells expressing wild-type PI3K</font><font style="font-weight:normal;">&#945;</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000023.jpg" title="" alt="" style="width:616px;height:382px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Inhibition of pAKT by Relay compounds RLY-PI3K1047 and RTX-2 in a pharmacodynamic assay. MCF10A immortalized breast epithelial cells endogenously expressing wild-type PI3K<font style="font-style:normal;">&#945;</font> <font style="font-weight:bold;">(a)</font>&#160;or engineered to express the PI3K<font style="font-style:normal;">&#945;</font> H1047R mutation <font style="font-weight:bold;">(b)</font>&#160;were treated with alpelisib, GDC-0077 or Relay compounds. After 2&#160;hours cell lysates were collected and the impact on pAKT levels was assessed using an HTRF assay (three fold dilution dose response was run in duplicate, data represented as mean +/- standard error of the mean). Half maximal effective concentrations (EC50) from the dose response curves (a, b) are plotted in <font style="font-weight:bold;">(c)</font><font style="font-weight:bold;font-style:normal;">.</font> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The selectivity of RTX-1 was then evaluated <font style="font-style:italic;">in vivo</font>. Oral dosing of RTX-1 resulted in tumor growth inhibition in a mouse xenograft model of PI3K&#945; H1047R carcinoma at doses of 100 mg/kg delivered once or twice daily or 50 mg/kg delivered twice daily. (<font style="font-weight:bold;">Figure 31</font>). An important validation of our efforts to avoid the dose-limiting toxicities associated with other PI3K inhibitors is the effect of RTX-1 on hyperinsulinemia. As discussed above, hyperinsulinemia and hyperglycemia can lead to decreased efficacy of PI3K inhibitors. In a study evaluating the effects of alpelisib or RTX-1 treatment on insulin levels, RTX-1 led to minimal changes in serum insulin (p=0.116 compared to vehicle by 2-way ANOVA) when administered orally at all doses tested for the duration of the study. In contrast, alpelisib treatment resulted in increases in serum insulin (p&lt;0.0001 compared to vehicle by 2-way ANOVA). Additionally, in an oral glucose tolerance test (OGTT) assessing insulin response after dosing of compounds, alpelisib treatment at 50 mg/kg once daily lead to larger increases in serum insulin compared to all doses of RLY-PI3K1047 tested (p&lt;0.0001 by 2-way ANOVA). </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 31: </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RTX-1</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> inhibits tumor growth in vivo with minimal increases in serum insulin levels. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000024.jpg" title="" alt="" style="width:624px;height:265px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Anti-tumor activity and impact on serum insulin levels in response to treatment with RTX-1.<font style="font-style:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(a)<font style="font-weight:normal;"> The CAL33 xenograft model was dosed once or twice daily (12 hour interval) with RTX-1 by oral administration or alpelisib once daily by oral administration, and tumor growth was evaluated. Data represent mean tumor volume over time, and error bars represent standard error of the mean. (n=8 per group). </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(b)<font style="font-weight:normal;"> Insulin levels in serum were measured one hour before and one hour after drug administration in non-tumor bearing animals throughout an 8 day dosing period (measurements were taken specifically on day 1, 3, 5 and 8, n=8 per group). Data presented as mean +/- standard error of the mean. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While RTX-1 is one lead molecule generated in this franchise, we are continuing lead optimization to identify mutant selective inhibitors of PI3K&#945; meeting our criteria to enter IND-enabling studies. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Our clinical development plan</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to begin IND-enabling studies for a differentiated PI3K&#945; H1047X mutant-selective inhibitor in 2021. With this profile, we will look to advance a precision medicine program that quickly establishes safety, tolerability, and preliminary efficacy, in patients with advanced solid tumors with H1047X mutations. Upon completion of dose escalation, the mutant PI3K&#945; inhibitor will be tested as a monotherapy in advanced cancer patients with PI3K&#945; H1047X mutations in a tumor-agnostic study. We will also pursue disease-specific development paths including combination with endocrine therapy +/- CDK4/6 inhibitors in hormone-receptor positive breast cancer and a PI3K&#945; H1047X mutation. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">RLY-1971, an inhibitor of SHP2 </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RLY-1971 is designed to be an oral, small molecule inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes SHP2 in its inactive conformation. SHP2 promotes cancer cell survival and growth through the RAS pathway by transducing signals downstream from RTKs. Additionally, activating SHP2 mutations result in enhanced signaling in the absence of ligand stimulation and has been identified as oncogenic drivers in a range of tumors. As a critical signaling node and regulator, SHP2 drives cancer cell proliferation and plays a key role in the way cancer cells develop resistance to targeted therapies. We believe that inhibition of SHP2 could block a common path that cancer cells exploit to avoid killing by other antitumor agents, thus overcoming or delaying the onset of resistance to those therapies. We are currently evaluating the safety and tolerability of RLY-1971 in a Phase 1 dose escalation study in patients with advanced or metastatic solid tumors. In December 2020, we entered into the Genentech Agreement, a global collaboration and license agreement with Genentech for the clinical development and commercialization of RLY-1971. Given the range of cancers that are related to SHP2 dependence, we believe RLY-1971 has the potential to serve as a combination backbone therapy. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate there are approximately 55,000 late-line patients annually in the United States with advanced lung cancer who might benefit from a combination of RLY-1971 with another targeted inhibitor. In the future, if RLY-1971 advances to earlier lines of combination treatment for lung cancer, we believe it could be applied in the treatment of approximately 90,000 patients annually in the United States. The subset of patients with KRAS <sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup> mutations in lung cancer that could potentially benefit from the combination of RLY-1971 with GDC-6036 is approximately 15,000-25,000 annually in the United States. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">SHP2: a central regulator of cell signaling </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SHP2 is a protein tyrosine phosphatase that plays a critical role in the transduction of intracellular signals downstream from RTKs, promoting cell survival and growth through the RAS pathway. SHP2 was the first phosphatase identified as a recurrently mutated oncogene, providing genetic support for the importance of SHP2 activation in promoting cancer. In addition to the central role of SHP2 in RTK signaling, some alterations in the RAS signaling pathway amplify signals transmitted by SHP2 and can therefore be suppressed by SHP2 inhibition. These include specific mutant forms of RAS (KRAS <sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup> and KRAS <sup style="font-size:85%;line-height:120%;vertical-align:top">G12A</sup>), genomic amplification of wild-type KRAS, loss-of-function mutations in NF1, and class 3 mutations in BRAF. Consequently, there are multiple cancer genetic contexts where SHP2 inhibition could be beneficial as a monotherapy. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A key feature of SHP2 as an oncology target is its ability to regulate cell signaling that arises from multiple RTKs (<font style="font-weight:bold;">Figure 7</font>). Therapies targeted to these RTKs, and therapies targeting downstream nodes such as PI3K, KRAS and MEK, are often unable to durably inhibit tumor growth because these tumors are able to bypass the targeted RTK and shift growth factor signaling to an alternate RTK, rendering them less sensitive to the targeted therapy. This is generally referred to as bypass resistance. Because SHP2 regulates the activity of multiple RTKs, inhibition of SHP2 is an effective way to overcome bypass resistance as confirmed by cellular and animal model experiments. Indeed, added benefit of SHP2 inhibition has been demonstrated pre-clinically in combination with multiple agents, such as those targeting MEK, KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup>, EGFR, and ALK. We believe our SHP2 inhibitor has the potential to become a commonly used combination partner with multiple targeted therapies including those in our own pipeline. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 7: SHP2 regulates the activity of multiple receptor tyrosine kinases (RTKs). </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000025.jpg" title="" alt="" style="width:616px;height:292px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Our solution, RLY-1971 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RLY-1971 is a small molecule inhibitor of SHP2 that binds and stabilizes SHP2 in its inactive conformation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We utilized a combination of experimental and computational techniques to identify unique inhibitors. For example, using long timescale MD simulations we were able to understand changes in the dynamics of the binding pocket over time that would not have been appreciated with shorter timescale simulations (<font style="font-weight:bold;">Figure 8</font>). Informed by high-resolution room-temperature X-ray crystallographic data, we created a virtual representation of our lead molecule bound to the SHP2 protein. We then simulated this system over long timescales. As shown in Figure 8, we observed that a loop (green) to the left of the small molecule (orange) moves down towards the molecule over the course of the simulation. Our medicinal chemists were then able to leverage this understanding in their designs to create an inhibitor of SHP2. Importantly, this loop cannot be resolved using conventional X-ray crystallography. Therefore, relying on standard techniques could deprive medicinal chemists of a critical insight as they attempt to design improved compounds. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;8: We depict a small molecule docked in a representation of the SHP2 protein where there is a green loop visible to the left of the small molecule (orange). A 500 ns MD simulation (0.5 &#181;s) shows that the green loop is far away from the small molecule (left). A longer simulation (10.0 &#181;s), reveals that the loop flips downwards, close to where the small molecule binds (right). </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000026.jpg" title="" alt="" style="width:616px;height:305px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We then prioritized compounds with the best predicted binding to SHP2 over a 10 &#181;s molecular dynamics simulation and tested the most stable compounds in our biochemical assay. This enabled filtering and prioritization of candidate molecules, resulting in the identification of RLY-1971, our clinical-stage compound. RLY-1971 inhibits SHP2 phosphatase activity (750 pM IC<sub style="font-size:85%; vertical-align:bottom">50</sub>) in a biochemical assay designed to monitor dephosphorylation of a probe substrate. RLY-1971 also inhibits SHP2 in cellular assays, as measured by inhibition of ERK1/2 phosphorylation at Thr202/Tyr204 (1.3 nM IC<sub style="font-size:85%; vertical-align:bottom">50</sub> in KYSE-520, an EGFR amplified gastric cancer cell line), and by inhibition of cancer cell proliferation (70 nM IC<sub style="font-size:85%; vertical-align:bottom">50</sub> in KYSE-520 and 11 nM IC50 in NCI-H358, a KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup> mutant NSCLC cell line) (<font style="font-weight:bold;">Figure&#160;9</font>). </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;9: RLY-1971 potently inhibits SHP2 in biochemical and cellular assays. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000027.jpg" title="" alt="" style="width:616px;height:76px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RLY-1971 shows minimal inhibition of targets other than SHP2. RLY-1971 has bioavailability suitable for oral dosing, is metabolically stable, and demonstrates favorable pharmacokinetic properties in preclinical <font style="font-style:italic;">in vivo</font> models. We do not predict that RLY-1971 will have significant drug-drug interactions based on weak inhibition of drug metabolizing enzymes. It is readily synthesized in bulk, can be formulated for oral delivery, and was well-tolerated in animal models. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe the key differentiating features of RLY-1971 from other SHP2 inhibitors in clinical development are: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Chemical distinctiveness: it is chemically distinct from other SHP2 inhibitors in clinical development </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Potency: demonstrated 750 pM IC<sub style="font-size:85%; vertical-align:bottom">50</sub> inhibition of SHP2 phosphatase in biochemical assays </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Dosing potential: projections of human pharmacokinetics suggest RLY-1971 will be amenable to continuous once daily dosing at relatively low active doses </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">RLY-1971 monotherapy pre-clinical experience </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SHP2 inhibition has been shown in third party studies to result in tumor stasis or regression in preclinical xenograft models of tumors harboring KRAS genomic amplification, KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup> mutations, NF1<sup style="font-size:85%;line-height:120%;vertical-align:top">LOF</sup> mutations, or BRAF<sup style="font-size:85%;line-height:120%;vertical-align:top">Class3</sup> mutations. Consistent with these findings, in our internal pre-clinical studies, RLY-1971 inhibited the proliferation of a panel of cancer cell lines driven by KRAS mutations that require signals transmitted by SHP2 (KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup> and KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12A</sup>) but was inactive in cancer cell lines driven by other KRAS mutations that do not require SHP2 signals (KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12D</sup>) (<font style="font-weight:bold;">Figure&#160;10</font>). </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;10: Inhibition of proliferation by RLY-1971 in cancer cell lines driven by KRAS mutations. Mutations that require SHP2 signals are potently inhibited by RLY-1971, whereas mutations that do not require SHP2 signals are insensitive to RLY-1971. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000028.jpg" title="" alt="" style="width:564px;height:407px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">A panel of KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12</sup> mutant cancer cell lines were grown in 3D spheroids and treated with RLY-1971 in a proliferation assay. KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup> and KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12A</sup> mutations retain intrinsic GTPase activity and therefore require SHP2 signaling, whereas the KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12D</sup> mutation does not. For cell lines indicated, cells were plated at a density of 2000 cells/well in round bottom ultra-low attachment 384-well plates (Corning) in growth media and cells are allowed to form three-dimensional structures at 37&#176;C, 5% CO2 incubator for 48 hours. After a 48&#160;hour incubation period, cells were then treated in triplicate with serial 3-fold dilutions of inhibitor in complete growth media and cells were returned to incubator for an additional 120 hours. CellTiter-Glo 3D reagent (Promega) was then added into each well and incubated are room temperature for 30 minutes followed by reading on an EnVision Reader (Perkin Elmer) using standard conditions. Assay data was normalized to DMSO control wells. Dose response curve fitting and IC50 values were determined using Genedata analyzer. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To demonstrate activity of RLY-1971 as a single agent </font><font style="font-style:italic;">in vivo</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, we tested it in multiple cancer xenograft mouse models. Consistent with our </font><font style="font-style:italic;">in vitro</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> data and the role of SHP2 as a critical mediator of RTK signaling, we observed that RLY-1971 induced regression in cancer xenograft models harboring a KRAS</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> mutation or genomic amplification of EGFR when administered on a continuous dosing schedule (</font><font style="font-weight:bold;">Figure&#160;11</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">). </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;11: RLY-1971 induces regression in KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top"> G12C</sup> mutant and EGFR amplified cancer xenograft models. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000029.jpg" title="" alt="" style="width:616px;height:157px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Anti-tumor activity of the SHP2 inhibitor RLY-1971 dosed twice daily by oral administration (PO BID) in <font style="font-weight:bold;">(a)</font><font style="font-weight:bold;font-style:normal;"> </font>the KRAS <sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup> mutant NSCLC xenograft model NCIH358 after 28 days on treatment and <font style="font-weight:bold;">(b)</font><font style="font-weight:bold;font-style:normal;"> </font>the EGFR amplified gastric cancer xenograft model KYSE-520 after 21 days on treatment. Treatment with RLY-1971 resulted in dose-dependent anti-tumor activity and regression in both models. Data represent waterfall plots of individual end of study tumors, with tumor volume expressed as percentage change relative to initial tumor volume. Each animal is represented as a separate bar (number of mice per group = 8). For each of the studies the statistical difference between the vehicle treated and RLY-1971 treated groups was assessed by one-way analysis of variance (ANOVA). In both studies the RLY-1971 treated groups were determined to be significantly different than the vehicle treated group with a P value &lt; 0.001. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, RLY-1971 inhibited the proliferation of cancer cell lines engineered to express known cancer mutations in SHP2 (<font style="font-weight:bold;">Figure&#160;12</font>). These mutations bias SHP2 towards an open, active conformation in direct opposition to the allosteric inhibition effected by RLY-1971. RLY-1971 retains nanomolar potency against activating mutations of SHP2. We hypothesize that the activity of RLY-1971 against activating mutations of SHP2 could result in more durable benefit by suppressing the emergence of resistant cell populations with SHP2 resistance mutations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;12: RLY-1971 inhibits the proliferation of cells expressing known SHP2 activating mutations. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000030.jpg" title="" alt="" style="width:616px;height:226px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Inhibition of proliferation by RLY-1971 in TF1 cancer cells expressing known cancer mutations in SHP2. TF1 cells were engineered to express the SHP2 mutations <font style="font-weight:bold;">(a)</font><font style="font-weight:bold;font-style:normal;"> </font>E69K (IC50 = 18.4 nM) or <font style="font-weight:bold;">(b)</font><font style="font-weight:bold;font-style:normal;"> </font>A461T (IC50 = 7 nM) and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">treated with RLY-1971 in a proliferation assay. 500 cells/well were seeded in round bottom ultra-low attachment 384-well plates (Corning) in growth media and incubated for 48 hours at 37&#176;C in 5% CO2. Cells were then treated in triplicate with serial 3-fold dilutions of inhibitor in growth media. Following incubation in the presence of compound for an additional 120 hours, cell viability was determined using the CellTiter-Glo 3D assay kit (Promega) following the manufacturer&#8217;s instructions. Luminescence was read in an EnVision Multimode Plate Reader (Perkin Elmer). Assay data was normalized to DMSO values, and dose response curve fitting was performed using Genedata analyzer. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">RLY-1971 as a combination therapy</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the role of SHP2 in mediating bypass resistance, we believe that SHP2 inhibitors have significant therapeutic potential when given in combination with other targeted therapies. Due to the increased potency and broader mutational coverage of next-generation targeted therapies, lower rates of on-target resistance have been observed in the clinic, with a greater number of patients progressing due to bypass resistance. An example of this is seen with EGFR inhibitors, where first-generation inhibitors (erlotinib and gefinitib) have greater on-target resistance compared to a third-generation inhibitor (osimertinib). As SHP2 is involved in signaling for numerous oncogenes, including EGFR, KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup>, ALK and MET, combination therapy with RLY-1971 represents a potential significant therapeutic opportunity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consistent with the role of SHP2 in RTK signaling in NSCLC, in our pre-clinical experiments, RLY-1971 demonstrated combination benefit in cell culture experiments when co-administered with inhibitors of MEK, ALK, or EGFR. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To demonstrate combination benefit with our SHP2 inhibitor <font style="font-style:italic;">in vivo</font>, we combined RLY-1971 with the ALK inhibitor alectinib in an ALK-translocated NSCLC xenograft mouse model (NCIH3122) that was derived <font style="font-style:italic;">in vitro</font> to have reduced sensitivity to ALK inhibition (<font style="font-weight:bold;">Figure&#160;13</font>). DNA sequencing did not reveal new ALK mutations in the cell line. Therefore, these cells likely have reduced sensitivity due to a bypass mechanism. The combination of RLY-1971 with alectinib resulted in tumor regressions in all treated animals. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;13: Anti-tumor activity of RLY-1971 and the ALK inhibitor alectinib as single agents or in combination in an ALK translocated NSCLC xenograft model (NCI-H3122) derived <font style="font-style:italic;">in vitro</font> to have reduced sensitivity to ALK inhibition. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gwpjrhodncoa000031.jpg" title="" alt="" style="width:510px;height:236px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Daily oral administration of RLY-1971 at 30mpk BID in combination with alectinib at 10mpk QD (green) resulted in increased efficacy compared to alectinib at 10mpk QD (red) or RLY-1971 at 30mpk BID (orange) alone in an ALK translocated NSCLC xenograft model (NCI-H3122) derived in vitro to be less sensitive to ALK inhibition. Data represent waterfall plots of individual tumors after 27 days of treatment with compounds, with tumor volume expressed as percentage change relative to initial tumor volume. Each animal is represented as a separate bar </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(number of mice per group = 9). The statistical difference between the combination treated group and the RLY-1971 or alectinib single agent groups was assessed using an unpaired t-test. The combination treated group with significant with P-value &lt;0.001 compared to either single agent group. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to RTK inhibitors, combination benefit for SHP2 inhibition has been demonstrated with other targeted agents including MEK inhibitors and KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup> inhibitors in cancer xenograft models harboring KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup> mutations or KRAS amplifications. The efficacy of direct KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12C </sup>inhibition may be limited by adaptive feedback reactivation of the RAS-MAPK pathway through upregulation of multiple RTKs. Activation of these RTKs leads to compensatory activation of wild-type RAS isoforms, which cannot be inhibited by KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup>-specific inhibitors, thus leading to resistance. SHP2 is unique in that it transmits signals from multiple RTKs and is therefore critical in mediating feedback reactivation of the RAS pathway during KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup> inhibition. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consistent with these observations, RLY-1971 demonstrated <font style="font-style:italic;">in vivo</font> combination benefit with the KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup> specific inhibitor AMG-510 in a KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup> lung cancer xenograft model (<font style="font-weight:bold;">Figure&#160;14</font>). Specifically, the combination resulted in regression in all animals, whereas each single agent resulted in more modest activity at the doses that were tested. These results suggest that SHP2 inhibition abrogates compensatory RAS-MAPK pathway activation during KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup> inhibition. Molecular characterization of phosphorylated-ERK, or Perk, a downstream marker of RAS-MAPK pathway activity, supports this conclusion. <font style="font-style:italic;">In vitro</font>, the combination of RLY-1971 and the KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup>-specific inhibitor ARS-1620 was able to fully suppress pERK in this model, while each inhibitor individually only partially suppressed pERK. Based on these data, we believe that the combination of RLY-1971 with KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup>-specific inhibitors warrants clinical studies in patients with tumors harboring KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12C </sup>mutations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure&#160;14: RLY-1971 and the KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup>-specific inhibitor AMG-510 demonstrate synergy when used in combination in the KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup> NCI-H358 lung cancer cell line. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <img src="gwpjrhodncoa000032.jpg" title="" alt="" style="width:360px;height:318px;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">In vivo combination benefit of RLY-1971 and the KRAS<sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup>-specific inhibitor AMG-510. Anti-tumor activity of the SHP2 inhibitor RLY-1971 dosed twice daily (BID) by oral administration at 30 mpk and the KRAS <sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup> inhibitor AMG-510 dosed once daily (QD) by oral administration at 10 mpk in the KRAS <sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup> mutant NSCLC xenograft model NCIH358. Treatment with the combination resulted in regression in all animals. Data represent waterfall plots of individual end of study tumors, with tumor volume expressed as percentage change relative to initial tumor volume. Each animal is represented as a separate bar (number of mice per group = 8)</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the therapeutic opportunity associated with combining with other targeted therapies, we believe RLY-1971 has the potential to be a combination partner with the product candidates in our own precision oncology portfolio</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RLY-4008 and RLY-PI3K1047. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Our clinical development plan</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the first quarter of 2020, we began evaluating the safety and tolerability of RLY-1971 in a first-in-human dose escalation study in patients with advanced or metastatic solid tumors. The primary objectives are to determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D), and to define the overall safety profile of RLY-1971. Secondary objectives are to assess the pharmacokinetics, pharmacodynamics, and to explore preliminary anti-tumor activity of RLY-1971. Patients will receive RLY-1971 administered orally, once daily. Once daily oral dosing was selected based on projected human pharmacokinetics and exposures calculated from multi-species pharmacokinetics and allometric scaling. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The first-in-human monotherapy data will facilitate subsequent clinical evaluation and development of RLY-1971 in combination with other targeted therapies in indications where SHP2 inhibition may exert synergistic antitumor effects. Future development for RLY-1971 will be governed by a joint development team between us and Genentech. We expect a combination trial of RLY-1971 and Genentech&#8217;s KRAC G12C inhibitor, GDC-6036, to be initiated in 2021.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Discovery Programs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are deploying our Dynamo platform to advance an additional three discovery-stage precision oncology programs. As with our lead programs, these programs leverage insights into protein conformational dynamics to address high-value, genetically validated oncogenes that previously have been intractable to conventional drug-discovery approaches. The capabilities for our Dynamo platform in protein visualization can be applied to multiple therapeutic areas beyond precision oncology. We are continuing to leverage the power of our Dynamo platform to further diversify our pipeline by extending our approach to address genetically validated targets in monogenic diseases with two discovery-stage programs, where genetic alterations lead to disease-causing defects in protein conformational dynamics. </p>
<p style="margin-bottom:0pt;margin-top:24pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Competition </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and pharmaceutical industries are characterized by rapid innovation of new technologies, fierce competition and strong defense of intellectual property. While we believe that our platform and our knowledge, experience and scientific resources provide us with competitive advantages, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We compete in the segments of the pharmaceutical, biotechnology, and other related markets that address experimentally and computationally driven structure-based drug design in cancer and genetic diseases. There are other companies focusing on structure-based drug design to develop therapies in the fields of cancer and other diseases. These companies include divisions of large pharmaceutical companies and biotechnology companies of various sizes. Any product candidates that we successfully develop and commercialize will compete with currently approved therapies and new therapies that may become available in the future from segments of the pharmaceutical, biotechnology and other related markets that pursue precision medicines. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe principal competitive factors to our business include, among other things, the rich protein structural data sets we are able to generate, the power and accuracy of our computations and predictions, ability to integrate experimental and computational capabilities, ability to successfully transition research programs into clinical development, ability to raise capital, and the scalability of the platform, pipeline, and business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While there are many pharmaceutical and biotechnology companies that use some of the same tools that we use in our platform, we believe we compete favorably on the basis of these factors. The effort and investment required to develop a highly integrated experimental and computational platform similar to ours will hinder new entrants that are unable to invest the necessary capital and time and lack the breadth and depth of technical expertise required to develop competing capabilities. Our ability to remain competitive will largely depend on our ability to continue to augment our integrated experimental and computational platform and demonstrate success in our drug discovery efforts. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our competitors may obtain regulatory approval of their products more rapidly than we may or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are more effective, more convenient, more widely used and less costly or have a better safety profile than our products and these competitors may also be more successful than us in manufacturing and marketing their products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we will need to develop our product candidates in collaboration with diagnostic companies, and we will face competition from other companies in establishing these collaborations. Our competitors will also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, we also face competition more broadly across the market for cost-effective and reimbursable cancer treatments. The most common methods of treating patients with cancer are surgery, radiation and drug therapy, including chemotherapy, hormone therapy and targeted drug therapy or a combination of such methods. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. While our product candidates, if any are approved, may compete with these existing drug and other therapies, to the extent they are ultimately used in combination with or as an adjunct to these therapies, our product candidates may not be competitive with them. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis. Insurers and other third-party payors may also encourage the use of generic products or specific branded products. We expect that if our product candidates are approved, they will be priced at a significant premium over competitive generic, including branded generic, products. As a result, obtaining market acceptance of, and gaining significant share of the market for, any of our product candidates that we successfully introduce to the market will pose challenges. In addition, many companies are developing new therapeutics, and we cannot predict what the standard of care will be as our product candidates progress through clinical development. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">RLY-4008 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While there are currently no approved products that selectively target FGFR2, we are aware of other companies developing therapeutics that selectively target FGFR2, including, but not limited to, Five Prime Therapeutics and Russian Pharmaceutical Technologies. Specifically, we expect RLY-4008 to compete with approved development stage non-selective inhibitors of the FGFR receptor family that are being tested in patients with FGFR2 alterations, including but not limited to, Incyte Corporation (pemigatinib), QED Therapeutics (infigratinib), Basilea Pharmaceutica AG (derazantinib), Janssen Pharmaceuticals, Inc. (erdafitinib), Otsuka Holdings Co., Ltd. through its subsidiary Taiho Pharmaceutical Co., Ltd. (TAS-120), Debiopharm Group (Debio1347), Eisai Co., Ltd. (E-7090), and InnoCare Pharma Limited (ICP-192). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development of RLY-4008 will focus on solid tumor patients with FGFR2 alterations, including intrahepatic cholangiocarcinoma (ICC) patients harboring FGFR2 gene fusions. While there are no approved systemic therapies for ICC, the current standard of care for unresectable or metastatic patients is first-line gemcitabine/cisplatin chemotherapy. In addition, there are other companies developing potentially competitive drug candidates in ICC including, but not limited to, Merck&#160;&amp; Co, Astrazeneca plc, Merck KGaA, and NuCana plc. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Mutant-PI3K<font style="font-style:normal;">&#945;</font> Inhibitor Program </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our mutant-selective PI3K&#945; inhibitor program will compete against an approved drug, Piqray (alpelisib), a non-selective PI3K&#945; inhibitor marketed by Novartis for the treatment of PI3K&#945; mutated breast cancer. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are aware of other companies developing therapeutics that target both wild-type and mutant PI3K&#945;, including, but not limited to, Roche Holding AG through its subsidiary Genentech, Petra Pharma Corporation, Menarini Group,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Luoxin Pharma</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and Shanghai HaiHe Pharma Co. Petra Pharma Corporation also has a preclinical development program for a mutant-selective PI3K&#945; inhibitor. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">RLY-1971 </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While there are currently no approved products targeting SHP2, we are aware of other companies in clinical trials developing therapeutics that target SHP2, including, but not limited to, Revolution Medicines in partnership with Sanofi S.A., Novartis International AG, Navire Pharma, Inc., Erasca, Inc. and Jacobio Pharmaceuticals, Inc. in partnership with AbbVie Inc. </p>
<p style="margin-bottom:0pt;margin-top:24pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Collaborations </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Key Scientific Collaborations</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we have invested extensively in our in-house capabilities and know-how, we selectively work with key collaborators and field experts on certain emerging technologies. Most of our experimental collaborations are focused on the technologies we use to visualize protein structure at the atomic level. For example, we work with Professor James Fraser from UCSF on performing and analyzing room temperature X-ray crystallography experiments and Professor Adam Frost from UCSF on Cryo-EM image analysis. Both are world leading experts on these technologies, and they provide important know-how and insights in collaboration with our scientists. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our key computational collaboration is with D. E. Shaw Research, LLC, or D. E. Shaw Research, a computational biochemistry research firm operating under the scientific leadership of Dr.&#160;David&#160;E. Shaw, which has developed proprietary software and hardware to perform long timescale molecular dynamics simulations. Through an affiliate, D.&#160;E.&#160;Shaw Research is also one of our investors. We collaborate with D.&#160;E. Shaw Research scientists to research certain protein targets on an exclusive basis, with a focus on the dynamic behavior of proteins, through the use of D.&#160;E. Shaw Research&#8217;s computational modeling capabilities, such as the Anton 2 supercomputer and proprietary algorithms and software developed specifically by D.&#160;E. Shaw Research for processing long timescale molecular dynamics simulations. Our scientists work closely with D.&#160;E. Shaw Research scientists on each of our programs, especially in the discovery stage as we develop motion-based hypotheses and identify lead compounds. See &#8220;&#8212;License Agreements and Strategic Collaborations &#8212;Collaboration and License Agreement with D.&#160;E. Shaw Research, LLC&#8221; for more detail on the terms of the DESRES Agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have other collaborations mostly focused on developing machine learning models. Specifically, we collaborate with Google on machine learning models to generate novel molecules with specific activity, and with Professor Tim Cernak from the University of Michigan on machine learning models focused on chemical synthesis and high throughput experimentation. </p>
<p style="margin-bottom:0pt;margin-top:24pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License Agreements and Strategic Collaborations</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Collaboration and License Agreement with D. E. Shaw Research, LLC </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 15, 2020, we entered into an Amended and Restated Collaboration and License Agreement with D.&#160;E.&#160;Shaw Research, extending the term and otherwise modifying the terms of a Collaboration and License Agreement originally entered into on August 17, 2016, as amended. We refer to this amended and restated agreement as the DESRES Agreement. Under the DESRES Agreement, we agreed to collaborate with D.&#160;E.&#160;Shaw Research to research certain biological targets through the use of D.&#160;E.&#160;Shaw Research computational modeling capabilities focused on analysis of protein motion, with an aim to develop and commercialize compounds and products directed to such targets. After completing the computational modeling with D.&#160;E. Shaw Research and naming a compound development candidate, we develop and commercialize such compounds and products. D.&#160;E. Shaw Research has no </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">involvement with the clinical development or potential commercialization of these compounds and products, regardless of any co-ownership rights pursuant to the terms of the DESRES Agreement, and instead receives solely milestone and royalty payments as described below. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the DESRES Agreement, there are three categories of targets: Category 1 Targets, Category 2 Targets and Category 3 Targets. We and D. E. Shaw Research agreed on a list of Category 1 Targets and Category 2 Targets as part of the DESRES Agreement. Category 1 Targets are targets that, among other things, we collaborate on with D.&#160;E. Shaw Research, D.&#160;E. Shaw Research has exclusivity obligations with respect to, and we may owe royalties on; Category 2 Targets are targets in connection with the potential re-categorization of which into a Category 1 Target, we may, among other things, perform in vitro non-clinical research and development (but not in vivo non-clinical development, clinical development or commercialization), and Category 3 Targets are all targets other than Category 1 Targets and Category 2 Targets. There are mechanisms for re-categorizing targets, and we and D. E. Shaw Research have re-categorized a number of targets during the first four years of our collaboration. Our rights and obligations, and D. E. Shaw Research&#8217;s rights and obligations, with respect to targets vary by the category of each target. However, the parties only conduct collaborative activities together for Category 1 Targets, and we are limited to a maximum of eleven Category 1 Targets in the current collaboration year (with such number potentially changing from year to year, with any increase in such number of targets subject to the collaboration in each collaboration year capped at four more than the highest number of such targets in the previous year). The sum of the number of Category 1 Targets and the number of Category 2 Targets is capped at twenty, in any event. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work product that is jointly developed with D. E. Shaw Research is initially co-owned with them. Specifically, intellectual property rights covering the composition of matter for RLY-1971 are currently co-owned by D. E. Shaw Research and us under this arrangement. We have the right to have patents claiming certain product candidates (including one claiming RLY-1971) assigned to us upon issuance of those patents. Although other compounds in our FGFR2 and PI3K&#945; programs were jointly conceived with D. E. Shaw Research, RLY-4008 and RLY-PI3K1047 were conceived solely by Relay Therapeutics inventors. For each Category 1 Target there is a limit of up to 10 core compounds and a total of 500 compounds including derivatives of those core compounds that can be designated as solely owned by us, provided that if D. E. Shaw Research provides us with notice that certain compounds cannot be designated as solely owned by us due to concerns in respect of a Category&#160;3 Target, then the limit on Category&#160;1 Target core compounds will increase by one and the limit on total compounds will increase by fifty, but subject to a maximum of 15 and 750, respectively, for each Category 1 Target. Each of we and D. E. Shaw Research grants to the other a perpetual, irrevocable, non-exclusive license for jointly held intellectual property, subject to certain exclusions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the initial research term, which is expected to last until August 2025, unless extended by mutual agreement, D. E. Shaw Research will not, and will cause its subsidiaries not to, research any Category 1 Target (or grant certain rights with respect to such target) with the aim of pursuing any compound designed to interact with or bind to such Category&#160;1 Target, subject to some exceptions. Following the end of the initial research term, D. E. Shaw Research will not, and will cause its subsidiaries not to, research a Category 1 Target (or grant certain rights with respect to such target) with the aim of pursuing any compound designed to interact with or bind to any target that was a Category 1 Target at the end of the initial research term, subject to some exceptions. D. E. Shaw Research will not be bound by such exclusivity provisions with respect to a particular Category 1 Target if we, and parties acting on our behalf, stop using commercially reasonable efforts to research, develop or commercialize any products against such Category 1 Target. Further, D. E. Shaw Research will be released from such exclusivity obligations with respect to a particular Category 1 Target if, at least 24 months after the end of the initial research term, D. E. Shaw Research informs us that D. E. Shaw Research will forgo all future payments with respect to such Category 1 Target. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the initial research term, neither D. E. Shaw Research nor we will, and we will each cause our subsidiaries not to, research a Category 2 Target (or grant certain rights with respect to such target) with the aim of pursuing any compound designed to interact with or bind to such Category 2 Target, subject to some exceptions. These exclusivity restrictions do not extend past the initial research term. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no exclusivity with respect to Category 3 Targets. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Through </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;31, 2020, we have made cash payments to D. E. Shaw Research totaling $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.4</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million in the aggregate. On a product-by-product basis, we have also agreed to pay D. E. Shaw Research milestone payments upon the achievement of certain development and regulatory milestone events for products we develop under the DESRES Agreement that are directed to a Category 1 Target or any target that was a Category 1 Target. Our SHP2, FGFR2 and PI3K programs are each directed to Category 1 Targets. Such payments for achievement of development and regulatory milestones total up to $7.25 million in the aggregate for each of the first three products we develop, and up to $6.25 million in the aggregate for each product we develop after the first three. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we have agreed to pay D. E. Shaw Research, on a product-by-product basis, with respect to products directed to Category 1 Targets or any target that was a Category 1 Target, royalties in the low single digits on worldwide net sales of products that we commercialize directed to the targets selected for development under the DESRES Agreement, subject to certain reductions. Royalties are payable on a product-by-product and country-by-country basis until the later of twelve years after first commercial sale in such country or the expiration of all applicable regulatory exclusivities in such country. On a product-by-product basis, we also agreed to pay D. E. Shaw Research sales milestone payments up to $36.0 million in the aggregate based on sales of each product directed to a Category 1 Target or any target that was a Category 1 Target. Further, if we enter into transactions granting third parties rights to a Category 1 Target or a compound or product directed to a Category 1 Target or any target that was a Category 1 Target.<font style="font-size:12pt;"> </font>such as our collaboration with Genentech for RLY-1971 discussed below, but subject to certain exclusions, we will share with D. E. Shaw Research a percentage of the proceeds of such transactions ranging from the low- to high-single digits, depending on the stage of development of compounds or products directed to such target at the time we enter into such transaction. We have also agreed to pay D. E. Shaw Research an annual collaboration fee in August of each year during the initial research term, such fee to be $7,900,000 for each year between 2020 and 2025. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless earlier terminated, the DESRES Agreement will continue at least until the end of the initial research term and thereafter on a target-by-target basis until all payment obligations have expired. D. E. Shaw Research has the right to terminate the DESRES Agreement due to non-payment. We and D. E. Shaw Research each have the right to terminate the DESRES Agreement due to an uncured material breach by the other party, or in the event the other party becomes insolvent or enters into bankruptcy or dissolution proceedings. Our payment obligations to D.&#160;E. Shaw Research survive termination of the DESRES Agreement. If D.&#160;E.&#160;Shaw Research terminates the DESRES Agreement, the exclusivity obligations will terminate. If we terminate the DESRES Agreement, D.&#160;E.&#160;Shaw Research remains bound by its exclusivity obligations with respect to certain targets until, on a target-by-target basis, there are no further payment obligations due to D.&#160;E.&#160;Shaw Research in respect of such targets. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Collaboration and License Agreement with Genentech  </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk60839968"></a>On December 11, 2020, we entered into a Collaboration and License Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd, collectively referred to as Genentech. <font style="color:#000000;">We refer to this agreement as the Genentech Agreement. </font>Pursuant to the Genentech Agreement, we and Genentech will collaborate on the development and commercialization of RLY-1971. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless Genentech elects to exercise its option to conduct the remainder of the ongoing Phase 1a clinical trial for RLY-1971, we will complete this trial. Genentech will be responsible for conducting all subsequent clinical development of RLY-1971, including in any combination trials with Genentech&#8217;s compound, GDC-6036, that directly binds to and inhibits KRAS <sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup>, or other compounds. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We retain the right to develop RLY-1971 or certain other small molecule inhibitors of SHP2 developed under the Genentech Agreement, or a Licensed Candidate, or pharmaceutical product containing a Licensed Candidate, or a Licensed Product, in combination with any of our compounds targeting FGFR2, including RLY-4008, or <font style="color:#000000;">PI3K&#945;,</font> including candidates in our RLY-PI3K1047 program, which we refer to as a Relay Combination Product. If we opt into the Profit/Cost Share described below, Genentech may share the development costs of any clinical trial for a Relay Combination Product. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genentech has the sole right and responsibility to commercialize Licensed Products, in any and all combinations, except that we have the right to co-promote a Licensed Product solely as part of our commercialization of Relay Combination Products. Genentech will be solely responsible for all regulatory matters for all Licensed Candidates </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Licensed Products after the assignment by us to Genentech of all related </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory materials, including the IND application for the Phase 1a Trial, other than with respect to Relay Combination Products. </font></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Genentech Agreement, we have received $75 million in an upfront payment and are eligible to receive $25 million in additional near-term payments.&nbsp;&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have the option, exercisable one time in our sole discretion, to fund half of the development costs of RLY-1971 in the United States and share half of the net profits or net loss of commercializing RLY-1971 in the United States, which we refer to as the Profit/Cost Share. If we opt into the Profit/Cost Share, we will also be eligible to receive up to an aggregate of an additional $410 million upon the achievement of specified commercialization and sales-based milestones for RLY-1971 outside of the United States and tiered royalties ranging from low-to-mid teens on annual net sales of RLY-1971 outside of the United States, on a country-by-country basis, subject to reduction in certain circumstances. At any time prior to the third anniversary of the first commercial sale of RLY-1971 in the United States, we may elect to opt-out of further participation in the Profit/Cost Share. If we elect to opt-out, then Genentech&#8217;s milestone and royalty payment obligations will revert to the financial terms that would be applicable if we had not opted into the Profit/Cost Share as described below as of the effective opt-out date, with certain adjustments. </p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we do not opt into the Profit/Cost Share, Genentech will be responsible for all development costs of RLY-1971 other than the costs incurred by us for the ongoing Phase 1a trial of RLY-1971, and we will be eligible to receive up to an aggregate of an additional $695 million upon the achievement of specified development, commercialization and sales-based milestones for RLY-1971 worldwide. We will also be eligible to receive tiered royalties ranging from low-to-mid teens on annual worldwide net sales of RLY-1971, on a country-by-country basis, subject to reduction in certain circumstances. </p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of regulatory approval of both RLY-1971 and GDC-6036 in combination, we are eligible to receive additional royalties.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Genentech Agreement, we granted an exclusive, worldwide, royalty-bearing license to Genentech, with the right to sublicense, to develop and commercialize RLY-1971. Between the parties, Genentech has the first right, but not the obligation, to file, prosecute and maintain any patents licensed to it pursuant to the Genentech Agreement, as well as to enforce infringement of or defend claims against such patents that relate to Licensed Candidates and Licensed Products. The parties will share any liabilities or damages arising from the enforcement of such patents or any third-party patent claims.<font style="font-size:8pt;color:#000000;"> </font></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other than with respect to Relay Combination Products and other activities in accordance with the Genentech Agreement, we may not, directly or indirectly, conduct any activities related to the research, development, manufacture or commercialization of any SHP2 inhibitor. During the first three years of the term of the Genentech Agreement, Genentech will cause its research and early development organization not to sponsor or conduct a registrational trial for a SHP2 inhibitor other than a Licensed Product. </p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless earlier terminated, the Genentech Agreement will remain in effect until the later of the date on which Genentech is no longer developing or commercializing RLY-1971 in the United States if we have opted into the Profit/Cost Share and have not subsequently opted-out, or the expiration of all Genentech&#8217;s royalty payment obligations to us. The parties may terminate the Genentech Agreement for the other party&#8217;s material breach or insolvency or, on a country-by-country basis, the failure to obtain merger control under applicable antitrust laws. Additionally, Genentech may terminate the Genentech Agreement for convenience, and we may terminate the Genentech Agreement for certain patent challenges by Genentech or if Genentech has not conducted any research, development, manufacturing or commercialization activities with respect to any Licensed Candidate or Licensed Product for a specified period.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:24pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We seek to protect the intellectual property and proprietary technology that we consider important to our business, including by pursuing patent applications that cover our product candidates and methods of using the same, as well as any other relevant inventions and improvements that we believe to be commercially important to the development of our business. We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position. Our commercial success depends, in part, on our ability </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to obtain, maintain, enforce and protect our intellectual property and other proprietary rights for the technology, inventions and improvements we consider important to our business, and to defend any patents we may own or in-license in the future, prevent others from infringing any patents we may own or in-license in the future, preserve the confidentiality of our trade secrets, and operate without infringing, misappropriating or otherwise violating the valid and enforceable patents and proprietary rights of third parties. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As with other biotechnology and pharmaceutical companies, our ability to maintain and solidify our proprietary and intellectual property position for our product candidates and technologies will depend on our success in obtaining effective patent claims and enforcing those claims if granted. However, our pending provisional and PCT patent applications, and any patent applications that we may in the future file or license from third parties, may not result in the issuance of patents and any issued patents we may obtain do not guarantee us the right to practice our technology or commercialize our product candidates. We also cannot predict the breadth of claims that may be allowed or enforced in any patents we may own or in-license in the future. Any issued patents that we currently own or may own or in-license in the future may be challenged, invalidated, circumvented or have the scope of their claims narrowed. In addition, because of the extensive time required for clinical development and regulatory review of a product candidate we may develop, it is possible that, before any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby limiting the protection such patent would afford the respective product and any competitive advantage such patent may provide. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of individual patents depends upon the date of filing of the patent application, the date of patent issuance and the legal term of patents in the countries in which they are obtained. In most countries, including the United States, the patent term is 20&#160;years from the earliest filing date of a non-provisional patent application. In the United States, a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier expiring patent. The term of a patent claiming a new drug product may also be eligible for a limited patent term extension when FDA approval is granted, provided statutory and regulatory requirements are met. The restoration period granted on a patent covering a product is typically one-half the time between the effective date of a clinical investigation involving human beings is begun and the submission date of an application, plus the time between the submission date of an application and the ultimate approval date. The restoration period cannot be longer than five years, and the restoration period may not extend the patent term beyond 14 years from the date of FDA approval. Only one patent applicable to an approved product is eligible for the extension, and only those claims covering the approved product, a method for using it, or a method for manufacturing it may be extended. Additionally, the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The United States Patent and Trademark Office reviews and approves the application for any patent term extension or restoration in consultation with the FDA. In the future, if our product candidates receive approval by the FDA, we expect to apply for patent term extensions on one issued patent covering each of those products, depending upon the length of the clinical studies for each product and other factors. There can be no assurance that patents will issue from our current or future pending patent applications, or that we will benefit from any patent term extension or favorable adjustments to the terms of any patents we may own or in-license in the future. In addition, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. The patent term may be inadequate to protect our competitive position on our products for an adequate amount of time. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">RLY-4008 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 28, 2021, we co-owned with D. E. Shaw Research pending PCT, Argentine, and Taiwanese applications which relate to our FGFR2 inhibitors. Any U.S. or foreign patent that may issue from these patent applications would be scheduled to expire in 2040, excluding any additional term for patent term adjustment or patent term extension, if applicable. As of February 28, 2021, we wholly-owned a pending U.S. provisional patent application relating to RLY-4008 composition of matter, methods of treatment, solid forms and methods of manufacture. Any U.S. or foreign patent that may issue from a non-provisional patent application claiming priority </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to th</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> application would be scheduled to expire in 204</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, excluding any additional term for patent term adjustment or patent term extension, if applicable.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Mutant-PI3K<font style="font-style:normal;">&#945;</font> Inhibitor Program </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 28, 2021, we co-owned with D.E. Shaw Research pending U.S. provisional patent applications that cover our PI3K program, which are directed to the composition of matter for the drug candidates of the program, analogs thereof, as well as methods of making and using these compounds. Any U.S. or foreign patent that may issue from a non-provisional patent application claiming priority to this applications would be scheduled to expire in 2041, excluding any additional term for patent term adjustment or patent term extension, if applicable. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">RLY-1971</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We wholly own a U.S. patent which relates to RLY-1971 composition of matter, which is scheduled to expire in 2039, excluding any additional term for patent term adjustment or patent term extension, if applicable. As of February 28, 2021, we co-owned with D. E. Shaw Research pending United States and foreign applications, which relate to SHP2 inhibitor compositions of matter and methods of treatment. Any U.S. or foreign patent that may issue from these patent applications would be scheduled to expire in 2039, excluding any additional term for patent term adjustment or patent term extension, if applicable. As of February 28, 2021, we wholly-owned pending U.S., PCT, Argentine and Taiwanese patent applications which relate to RLY-1971, solid forms and methods of manufacture. Any U.S. or foreign patent that may issue from a non-provisional patent application claiming priority to these patent applications would be scheduled to expire in 2040, excluding any additional term for patent term adjustment or patent term extension, if applicable.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Genentech Agreement, we have granted an exclusive, worldwide, royalty-bearing license to Genentech, with the right to sublicense, develop and commercialize RLY-1971 and any other SHP2 inhibitors developed under the Genentech Agreement. Genentech has the first right, but not the obligation, to file, prosecute and maintain any patents licensed to it, as well as to enforce infringement of or defend claims against such patents that relate to RLY-1971 or other SHP2 inhibitors. See &#8220;&#8212;Our Collaborations&#8212;License Agreements and Strategic Collaborations&#8212;Genentech Collaboration and License Agreement&#8221; for more information on the Genentech Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prosecution of the PCT patent application covering our FGFR2 inhibitors and the provisional patent application covering our PI3K program has not commenced, and will not commence unless and until they are timely converted into U.S. non-provisional or national stage applications. Prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the USPTO or other foreign jurisdiction are often significantly narrowed by the time they issue, if they issue at all. Any U.S. or foreign patent issuing from these provisional, PCT, or foreign patent applications (assuming they are timely converted into non-provisional applications, and such non-provisional applications are granted as issued patents) would be scheduled to expire in 2040 or 2041 (for our FGFR2 applications) or 2041 (for our PI3K application), excluding any additional term for patent term adjustment or patent term extension, and assuming national phase entries are timely made based upon the pending PCT application, and payment of all applicable maintenance or annuity fees. Any of our pending PCT patent applications are not eligible to become issued patents until, among other things, we file national stage patent applications within 30 months in the countries in which we seek patent protection. If we do not timely file any national stage patent applications, we may lose our priority date with respect to our PCT patent applications and any patent protection on the inventions disclosed in such PCT patent applications. Our provisional patent applications may never result in issued patents and are not eligible to become issued patents until, among other things, we file a non-provisional patent application and/or PCT patent application within 12 months of filing the related provisional patent application. If we do not timely file non-provisional patent applications, we may lose our priority date with respect to our provisional patent applications and any patent protection on the inventions disclosed in our provisional patent applications. While we intend to timely file non-provisional and national stage patent applications relating to our provisional and PCT patent applications, we cannot predict whether any of our current or future patent applications for any of our product candidates or technology, will issue as patents. If we do not successfully obtain patent protection, or, even if we do obtain patent protection, if the scope of the patent protection we, Genentech, or our potential licensors, obtain with respect to any of our product candidates or technology is not sufficiently broad, we will be unable to prevent others </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from using our technology or from developing or commercializing technology and products similar or identical to ours or other competing products and technologies. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to patent applications, we rely on unpatented trade secrets, know-how and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and confidential know-how are difficult to protect. In particular, we anticipate that with respect to the building of our compound library, our trade secrets and know-how will over time be disseminated within the industry through independent development and public presentations describing the methodology. We seek to protect our proprietary information, in part, by executing confidentiality agreements with our collaborators and scientific advisors and non-competition, non-solicitation, confidentiality and invention assignment agreements with our employees and consultants. We have also executed agreements requiring assignment of inventions with selected consultants, scientific advisors and collaborators. The confidentiality agreements we enter into are designed to protect our proprietary information and the agreements or clauses requiring assignment of inventions to us are designed to grant us ownership of technologies that are developed through our relationship with the respective counterparty. We cannot guarantee that we will have executed such agreements with all applicable employees and contractors, or that these agreements will afford us adequate protection of our intellectual property and proprietary information rights. In addition, our trade secrets and/or confidential know-how may become known or be independently developed by a third party or misused by any collaborator to whom we disclose such information. These agreements may also be breached, and we may not have an adequate remedy for any such breach. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our products or to obtain or use information that we regard as proprietary. Although we take steps to protect our proprietary information, third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our trade secrets and proprietary information. For more information regarding the risks related to our intellectual property, please see &#8220;Risk Factors&#8212;Risks Related to our Intellectual Property.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:24pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commercialization </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to receiving marketing approvals, we expect to commence commercialization activities by building a focused sales and marketing organization in the United States to sell our products. We believe that such an organization will be able to address the community of oncologists who are the key specialists in treating the patient populations for which our product candidates are being developed. Outside the United States, we expect to enter into distribution and other marketing arrangements with third parties for any of our product candidates that obtain marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also plan to build a marketing and sales management organization to create and implement marketing strategies for any products that we market through our own sales organization and to oversee and support our sales force. The responsibilities of the marketing organization would include developing educational initiatives with respect to approved products and establishing relationships with researchers and practitioners in relevant fields of medicine. </p>
<p style="margin-bottom:0pt;margin-top:24pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any manufacturing facilities or personnel. We currently rely, and expect to continue to rely, on third parties for the manufacture of our product candidates undergoing preclinical testing, as well as for clinical testing and commercial manufacture if our product candidates receive marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our drug candidates are small molecules and are manufactured in synthetic processes from available starting materials. The chemistry appears amenable to scale-up and does not currently require unusual equipment in the manufacturing process. We expect to continue to develop product candidates that can be produced cost-effectively at contract manufacturing facilities. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We generally expect to rely on third parties for the manufacture of companion diagnostics for our products, which are assays or tests to identify an appropriate patient population. Depending on the technology solutions we choose, we may rely on multiple third parties to manufacture and sell a single test. </font></p>
<p style="margin-bottom:0pt;margin-top:24pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Governmental Regulation</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, recordkeeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of drugs. We, along with our vendors, contract research organizations and contract manufacturers, will be required to navigate the various preclinical, clinical, manufacturing and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval of our product candidates. The process of obtaining regulatory approvals of drugs and ensuring subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, where we are initially focusing our drug development, the FDA regulates drug products under the Federal Food, Drug, and Cosmetic Act, or FD&amp;C Act, as amended, its implementing regulations and other laws. If we fail to comply with applicable FDA or other requirements at any time with respect to product development, clinical testing, approval or any other legal requirements relating to product manufacture, processing, handling, storage, quality control, safety, marketing, advertising, promotion, packaging, labeling, export, import, distribution, or sale, we may become subject to administrative or judicial sanctions or other legal consequences. These sanctions or consequences could include, among other things, the FDA&#8217;s refusal to approve pending applications, issuance of clinical holds for ongoing studies, suspension or revocation of approved applications, warning or untitled letters, product withdrawals or recalls, product seizures, relabeling or repackaging, total or partial suspensions of manufacturing or distribution, injunctions, fines, civil penalties or criminal prosecution. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process required by the FDA before our product candidates are approved as drugs for therapeutic indications and may be marketed in the United States generally involves the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with good laboratory practice, or GLP, requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">completion of the manufacture, under current Good Manufacturing Practices, or cGMP, conditions, of the drug substance and drug product that the sponsor intends to use in human clinical trials along with required analytical and stability testing; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">submission to the FDA of an investigational new drug application, or IND, which must become effective before clinical trials may begin; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">approval by an institutional review board, or IRB, or independent ethics committee at each clinical trial site before each trial may be initiated; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">performance of adequate and well-controlled clinical trials in accordance with applicable IND regulations, good clinical practice, or GCP, requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">submission to the FDA of a New Drug Application, or NDA; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a determination by the FDA within 60 days of its receipt of an NDA, to accept the filing for review; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">satisfactory completion of one or more FDA pre-approval inspections of the manufacturing facility or facilities where the drug will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">potentially, satisfactory completion of FDA audit of the clinical trial sites that generated the data in support of the NDA; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">payment of user fees for FDA review of the NDA; and </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">FDA review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the United States. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preclinical studies and clinical trials for drugs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before testing any drug in humans, the product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluations of drug chemistry, formulation and stability, as well as<font style="font-style:italic;">&#160;in vitro</font>&#160;and animal studies to assess safety and in some cases to establish the rationale for therapeutic use. The conduct of preclinical studies is subject to federal and state regulation, including GLP requirements for safety/toxicology studies. The results of the preclinical studies, together with manufacturing information and analytical data, must be submitted to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before clinical trials may begin. Some long-term preclinical testing may continue after the IND is submitted. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks, and imposes a full or partial clinical hold. FDA must notify the sponsor of the grounds for the hold and any identified deficiencies must be resolved before the clinical trial can begin. Submission of an IND may result in the FDA not allowing clinical trials to commence or not allowing clinical trials to commence on the terms originally specified in the IND. A clinical hold can also be imposed once a trial has already begun, thereby halting the trial until the deficiencies articulated by FDA are corrected. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical stage of development involves the administration of the product candidate to healthy volunteers or patients under the supervision of qualified investigators, who generally are physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCP requirements, which include the requirements that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters and criteria to be used in monitoring safety and evaluating effectiveness. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable compared to the anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. The FDA, the IRB, or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trials to public registries. Information about clinical trials, including results for clinical trials other than Phase 1 investigations, must be submitted within specific timeframes for publication on www.ClinicalTrials.gov, a clinical trials database maintained by the National Institutes of Health. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, FDA will nevertheless accept the results of the study in support of an NDA if the study was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials to evaluate therapeutic indications to support NDAs for marketing approval are typically conducted in three sequential phases, which may overlap. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Phase&#160;1</font><font style="font-size:10pt;color:#000000;">&#8212;Phase&#160;1 clinical trials involve initial introduction of the investigational product into healthy human volunteers or patients with the target disease or condition. These studies are typically designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, excretion the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Phase&#160;2</font><font style="font-size:10pt;color:#000000;">&#8212;Phase&#160;2 clinical trials typically involve administration of the investigational product to a limited patient population with a specified disease or condition to evaluate the drug&#8217;s potential efficacy, to determine the optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Phase&#160;3</font><font style="font-size:10pt;color:#000000;">&#8212;Phase&#160;3 clinical trials typically involve administration of the investigational product to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval and physician labeling. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FDA released a draft guidance entitled &#8220;Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics,&#8221; which outlines how drug developers can utilize an adaptive trial design commonly referred to as a seamless trial design in early stages of oncology drug development (i.e., the first-in-human clinical trial) to compress the traditional three phases of trials into one continuous trial called an expansion cohort trial. Information to support the design of individual expansion cohorts are included in IND applications and assessed by FDA. Expansion cohort trials can potentially bring efficiency to drug development and reduce development costs and time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Post-approval trials, sometimes referred to as Phase&#160;4 clinical trials or post-marketing studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and are commonly intended to generate additional safety data regarding use of the product in a clinical setting. In certain instances, the FDA may mandate the performance of Phase&#160;4 clinical trials as a condition of NDA approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA. Written IND safety reports must be submitted to the FDA and the investigators fifteen days after the trial sponsor determines the information qualifies for reporting for serious and unexpected suspected adverse events, findings from other studies or animal or<font style="font-style:italic;">&#160;in vitro</font>&#160;testing that suggest a significant risk for human volunteers and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must also notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible but in no case later than seven calendar days after the sponsor&#8217;s initial receipt of the information. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product candidate and finalize a process for manufacturing the drug product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and manufacturers must develop, among other things, methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. marketing approval for drugs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA package requesting approval to market the product for one or more indications. An NDA is a request for approval to market a new drug for one or more specified indications and must contain proof of the drug&#8217;s safety and efficacy for the requested indications. The marketing application is required to include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#8217;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA. FDA must approve an NDA before a drug may be marketed in the United States. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA reviews all submitted NDAs before it accepts them for filing and may request additional information rather than accepting the NDA for filing. The FDA must make a decision on accepting an NDA for filing within 60 days of receipt, and such decision could include a refusal to file by the FDA. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the NDA. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective for the indications sought and whether the facility in which it is </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity. Under the goals and polices agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, the FDA targets ten months, from the filing date, in which to complete its initial review of a new molecular entity NDA and respond to the applicant, and six months from the filing date of a new molecular entity NDA for priority review. The FDA does not always meet its PDUFA goal dates for standard or priority NDAs, and the review process is often extended by FDA requests for additional information or clarification. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, under PDUFA, as amended, each NDA must be accompanied by a substantial user fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA also may require submission of a Risk Evaluation and Mitigation Strategy, or REMS, if it believes that a risk evaluation and mitigation strategy is necessary to ensure that the benefits of the drug outweigh its risks. A REMS can include use of risk evaluation and mitigation strategies like medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk-minimization tools. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and are adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP and other requirements and the integrity of the clinical data submitted to the FDA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing in order for the FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if the FDA approves a product, depending on the specific risk(s) to be addressed it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase&#160;4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Orphan drug designation and exclusivity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or if it </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making the product available in the United States for the disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting an NDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process, though companies developing orphan products are eligible for certain incentives, including tax credits for qualified clinical testing and waiver of application fees. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to a seven-year period of marketing exclusivity during which the FDA may not approve any other applications to market the same therapeutic agent for the same indication, except in limited circumstances, such as a subsequent product&#8217;s showing of clinical superiority over the product with orphan exclusivity or where the original applicant cannot produce sufficient quantities of product. Competitors, however, may receive approval of different therapeutic agents for the indication for which the orphan product has exclusivity or obtain approval for the same therapeutic agent for a different indication than that for which the orphan product has exclusivity. Orphan product exclusivity could block the approval of one of our products for seven years if a competitor obtains approval for the same therapeutic agent for the same indication before we do, unless we are able to demonstrate that our product is clinically superior. If an orphan designated product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan exclusivity. Further, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Expedited development and review programs for drugs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA maintains several programs intended to facilitate and expedite development and review of new drugs to address unmet medical needs in the treatment of serious or life-threatening diseases or conditions. These programs include Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval, and the purpose of these programs is to either expedite the development or review of important new drugs to get them to patients more quickly than standard FDA review timelines typically permit. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A new drug is eligible for Fast Track designation if it is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address unmet medical needs for such disease or condition. Fast Track designation provides increased opportunities for sponsor interactions with the FDA during preclinical and clinical development, in addition to the potential for rolling review once a marketing application is filed. Rolling review means that the agency may review portions of the marketing application before the sponsor submits the complete application. In addition, a new drug may be eligible for Breakthrough Therapy designation if it is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough Therapy designation provides all the features of Fast Track designation in addition to intensive guidance on an efficient drug development program beginning as early as Phase&#160;1, and FDA organizational commitment to expedited development, including involvement of senior managers and experienced review staff in a cross-disciplinary review, where appropriate. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product submitted to the FDA for approval, including a product with Fast Track or Breakthrough Therapy designation, may also be eligible for additional FDA programs intended to expedite the review and approval process, including Priority Review designation and Accelerated Approval. A product is eligible for Priority Review, once an NDA or BLA is submitted, if the drug that is the subject of the marketing application has the potential to provide a significant improvement in safety or effectiveness in the treatment, diagnosis or prevention of a serious disease or condition. Under priority review, the FDA&#8217;s goal date to take action on the marketing application is six months compared to ten months for a standard review. Products are eligible for Accelerated Approval if they can be shown to have an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or an effect on a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, which is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated Approval is usually contingent on a sponsor&#8217;s agreement to conduct additional post-approval studies to verify and describe the product&#8217;s clinical benefit. The FDA may withdraw approval of a drug or an indication approved under Accelerated Approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, the FDA generally requires, as a condition for Accelerated Approval, that all advertising and promotional materials intended for dissemination or publication within 120&#160;days of marketing approval be submitted to the agency for review during the pre-approval review period. After the 120-day period has passed, all advertising and promotional materials must be submitted at least 30&#160;days prior to the intended time of initial dissemination or publication. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval do not change the scientific or medical standards for approval or the quality of evidence necessary to support approval, though they may expedite the development or review process. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Pediatric information and pediatric exclusivity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Pediatric Research Equity Act, or PREA, as amended, certain NDAs and NDA supplements must contain data that can be used to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers. The FD&amp;C Act requires that a sponsor who is planning to submit a marketing application for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan, or PSP, within 60 days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 study. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials and/or other clinical development programs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A drug can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. post-approval requirements for drugs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drugs manufactured or distributed pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, reporting of adverse experiences with the product, complying with promotion and advertising requirements, which include restrictions on promoting products for unapproved uses or patient populations (known as &#8220;off-label use&#8221;) and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available products for off-label uses, manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including investigation by federal and state authorities. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use or first publication. Further, if there are any modifications to the drug, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA or NDA supplement, which may require the development of additional data or preclinical studies and clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-market testing, including Phase 4 clinical trials, and surveillance to further assess and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">monitor the product&#8217;s safety and effectiveness after commercialization. In addition, drug manufacturers and their subcontractors involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMPs, which impose certain procedural and documentation requirements. Failure to comply with statutory and regulatory requirements may subject a manufacturer to legal or regulatory action, such as warning letters, suspension of manufacturing, product seizures, injunctions, civil penalties or criminal prosecution. There is also a continuing, annual prescription drug product program user fee. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, requirements for post-market studies or clinical trials to assess new safety risks, or imposition of distribution or other restrictions under a REMS. Other potential consequences include, among other things: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">fines, warning letters or holds on post-approval clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">refusal of the FDA to approve applications or supplements to approved applications, or suspension or revocation of product approvals; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">product seizure or detention, or refusal to permit the import or export of products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">injunctions or the imposition of civil or criminal penalties; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; or mandated modification of promotional materials and labeling and issuance of corrective information. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Regulation of companion diagnostics </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Companion diagnostics identify patients who are most likely to benefit from a particular therapeutic product; identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product; or monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness. Companion diagnostics are regulated as medical devices by the FDA. In the United States, the FD&amp;C Act, and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption or FDA exercise of enforcement discretion applies, diagnostic tests generally require marketing clearance or approval from the FDA prior to commercialization. The two primary types of FDA marketing authorization applicable to a medical device are clearance of a premarket notification, or 510(k), and approval of a premarket approval application, or PMA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To obtain 510(k) clearance for a medical device, or for certain modifications to devices that have received 510(k) clearance, a manufacturer must submit a premarket notification demonstrating that the proposed device is substantially equivalent to a previously cleared 510(k) device or to a pre-amendment device that was in commercial distribution before May&#160;28, 1976, or a predicate device, for which the FDA has not yet called for the submission of a PMA. In making a determination that the device is substantially equivalent to a predicate device, the FDA compares the proposed device to the predicate device and assesses whether the subject device is comparable to the predicate device with respect to intended use, technology, design and other features which could affect safety and effectiveness. If the FDA determines that the subject device is substantially equivalent to the predicate device, the subject device may be cleared for marketing. The 510(k) premarket notification pathway generally takes from three to twelve months from the date the application is completed, but can take significantly longer. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A PMA must be supported by valid scientific evidence, which typically requires extensive data, including technical, preclinical, clinical and manufacturing data, to demonstrate to the FDA&#8217;s satisfaction the safety and effectiveness of the device. For diagnostic tests, a PMA typically includes data regarding analytical and clinical validation studies. As part of its review of the PMA, the FDA will conduct a pre-approval inspection of the manufacturing facility or facilities to ensure compliance with the quality system regulation, or QSR, which requires manufacturers to follow design, testing, control, documentation and other quality assurance procedures. The FDA&#8217;s review of an initial PMA is required by statute to take between six to ten months, although the process typically takes longer, and may require several years to complete. If the FDA evaluations of both the PMA and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually contains a number of conditions that must be met in order to secure the final approval of the PMA. If the FDA&#8217;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny the approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. Once granted, PMA approval may be withdrawn by the FDA if compliance with post-approval requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July&#160;31, 2014, the FDA issued a final guidance document addressing the development and approval process for &#8220;In Vitro Companion Diagnostic Devices.&#8221; According to the guidance document, for novel therapeutic products that depend on the use of a diagnostic test and where the diagnostic device could be essential for the safe and effective use of the corresponding therapeutic product, the companion diagnostic device should be developed and approved or cleared contemporaneously with the therapeutic, although the FDA recognizes that there may be cases when contemporaneous development may not be possible. However, in cases where a drug cannot be used safely or effectively without the companion diagnostic, the FDA&#8217;s guidance indicates it will generally not approve the drug without the approval or clearance of the diagnostic device. The FDA also issued a draft guidance in July 2016 setting forth the principles for co-development of an in vitro companion diagnostic device with a therapeutic product. The draft guidance describes principles to guide the development and contemporaneous marketing authorization for the therapeutic product and its corresponding in vitro companion diagnostic. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once cleared or approved, the companion diagnostic device must adhere to post-marketing requirements including the requirements of the FDA&#8217;s QSR, adverse event reporting, recalls and corrections along with product marketing requirements and limitations. Like drug makers, companion diagnostic makers are subject to unannounced FDA inspections at any time during which the FDA will conduct an audit of the product(s) and the company&#8217;s facilities for compliance with its authorities. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other regulatory matters </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing, sales, promotion and other activities of product candidates following product approval, where applicable, or commercialization are also subject to regulation by numerous regulatory authorities in the United States in addition to the FDA, which may include the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services, the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&#160;&amp; Health Administration, the Environmental Protection Agency and state and local governments and governmental agencies. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other healthcare laws </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthcare providers, physicians, and third-party payors will play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Our business operations and any current or future arrangements with third-party payors, healthcare providers and physicians may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we develop, market, sell and distribute any drugs for which we obtain marketing approval. In the United States, these laws include, without limitation, state and federal anti-kickback, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">false claims, physician transparency, and patient data privacy and security laws and regulations, including but not limited to those described below. </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid; a person or entity need not have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. On November 20, 2020, the Office of Inspector General, or OIG, finalized further modifications to the federal Anti-Kickback Statute. Under the final rules, OIG added safe harbor protections under the Anti-Kickback Statute for certain coordinated care and value-based arrangements among clinicians, providers, and others. These rules (with exceptions) became effective January 19, 2021. We continue to evaluate what effect, if any, these rules will have on our business.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The federal civil and criminal false claims laws, including the civil False Claims Act, or FCA, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false, fictitious or fraudulent; knowingly making, using, or causing to be made or used, a false statement or record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. When an entity is determined to have violated the federal civil False Claims Act, the government may impose civil fines and penalties for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The federal civil monetary penalties laws impose civil fines for, among other things, the offering or transfer or remuneration to a Medicare or state healthcare program beneficiary, if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for knowingly and willfully executing a scheme, or attempting to execute a scheme, to defraud any healthcare benefit program, including private payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, or falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, impose, among other things, specified requirements on covered entities and their business associates relating to the privacy and security of individually identifiable health information including mandatory contractual terms and required implementation of technical safeguards of such information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates in some cases, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The Physician Payments Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, imposed new annual reporting requirements for certain manufacturers of drugs, devices, biologics, and </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;color:#000000;">medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, for certain payments and &#8220;transfers of value&#8221; provided to physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.&#160;In addition, many states also require reporting of payments or other transfers of value, many of which differ from each other in significant ways, are often not pre-empted, and may have a more prohibitive effect than the Sunshine Act, thus further complicating compliance efforts. Effective January&#160;1, 2022, these reporting obligations will extend to include transfers of value made in the previous year to certain non-physician providers such as physician assistants and nurse practitioners. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Federal consumer protection and unfair competition laws broadly regulate marketplace activities and activities that potentially harm consumers. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Analogous state and foreign laws and regulations may be broader in scope than the provisions described above and may apply regardless of payor. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and relevant federal government compliance guidance; require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers; restrict marketing practices or require disclosure of marketing expenditures and pricing information. State and foreign laws may govern the privacy and security of health information in some circumstances. These data privacy and security laws may differ from each other in significant ways and often are not pre-empted by HIPAA, which may complicate compliance efforts. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other related governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, disgorgement, exclusion from government funded healthcare programs, such as Medicare and Medicaid, reputational harm, additional oversight and reporting obligations if we become subject to a corporate integrity agreement or similar settlement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to similar actions, penalties and sanctions. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from its business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Insurance coverage and reimbursement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels for, the product. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. No uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, which will require additional expenditure above and beyond the costs required to obtain FDA or other comparable regulatory approvals. Additionally, companies may also need to provide discounts to purchasers, private health plans or government healthcare programs. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, our operations and financial condition. Additionally, a third-party payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of products have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved products. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Current and future healthcare reform legislation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and some foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system directed at broadening the availability of healthcare, improving the quality of healthcare, and containing or lowering the cost of healthcare. For example, in March 2010, the United States Congress enacted the Affordable Care Act, which, among other things, includes changes to the coverage and payment for products under government health care programs. The Affordable Care Act includes provisions of importance to our potential product candidates that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">created an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic products, apportioned among these entities according to their market share in certain government healthcare programs; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for both branded and generic drugs and revising the definition of &#8220;average manufacturer price,&#8221; or AMP, for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">expanded the types of entities eligible for the 340B drug discount program; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">established the Medicare Part D coverage gap discount program by requiring manufacturers to provide point-of-sale-discounts off the negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturers&#8217; outpatient drugs to be covered under Medicare Part D; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the Affordable Care Act, and we expect there will be additional challenges and amendments to the Affordable Care Act in the future. For example, various portions of the Affordable Care Act are currently facing legal and constitutional challenges in the Fifth Circuit Court of Appeals and the United States Supreme Court. Additionally, the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">previous</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> administration issued various Executive Orders which eliminated cost sharing subsidies and various provisions that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices, and Congress has introduced several pieces of legislation aimed at significantly revising or repealing the Affordable Care Act. It is unclear whether the Affordable Care Act will be overturned, repealed, replaced, or further amended. We cannot predict what effect further changes to the Affordable Care Act would have on our business</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, especially given the new administration</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. In August 2011, the Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030 unless additional Congressional action is taken. The Coronavirus Aid, Relief and Economic Security Act, or CARES Act, which was signed into law in March 2020, and subsequent legislation, suspended these reductions from May 1, 2020 through March 31, 2021. Proposed legislation, if passed, would extend this suspension until the end of the COVID-19 pandemic. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, including bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products, which has resulted in several Congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. For example, at the federal level, the previous administration&#8217;s budget proposal for fiscal year 2021 included a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March 10, 2020, the previous administration sent &#8220;principles&#8221; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. Additionally, the previous administration also released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. The U.S. Department of Health and Human Services, or HHS, has already started the process of soliciting feedback on some of these measures and, at the same time, is immediately implementing others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy, a type of prior authorization, for Part B drugs beginning January&#160;1, 2020. This final rule codified CMS&#8217;s policy change that was effective January&#160;1, 2019. It is unclear whether the current administration will challenge, reverse, revoke or otherwise modify these executive and administrative actions after January 20, 2021. Although a number of these and other measures may require additional authorization to become effective, Congress has indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there have been several changes to the 340B drug pricing program, which imposes ceilings on prices that drug manufacturers can charge for medications sold to certain health care facilities. On December 27, 2018, the District Court for the District of Columbia invalidated a reimbursement formula change under the 340B drug pricing program, and CMS subsequently altered the FYs 2019 and 2018 reimbursement formula on specified covered outpatient drugs, or SCODs. The court ruled this change was not an &#8220;adjustment&#8221; which was within the Secretary&#8217;s discretion to make but was instead a fundamental change in the reimbursement calculation. However, most recently, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on July 31, 2020, the U.S. Court of Appeals for the District of Columbia Circuit overturned the district court&#8217;s decision and found that the changes were within the Secretary&#8217;s authority. On September 14, 2020, the plaintiffs-appellees filed a Petition for Rehearing En Banc (i.e., before the full court), but was denied on October 16, 2020. It is unclear how these developments could affect covered hospitals who might purchase our future products and affect the rates we may charge such facilities for our approved products in the future, if any.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, on July 24, 2020 and September 13, 2020, the previous administration issued several executive orders related to prescription drug pricing that sought to implement several of the previous administration's proposals. In response, the FDA released a final rule on September 24, 2020, which went into effect on November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. On November 20, 2020 CMS issued an Interim Final Rule implementing the Most Favored Nation, or MFN, Model under which Medicare Part B reimbursement rates will be calculated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for Economic Cooperation and Development countries with a similar gross domestic product per capita. The MFN Model regulations mandate participation by identified Part B providers and will apply in all U.S. states and territories for a seven-year period beginning January 1, 2021, and ending December 31, 2027. The Interim Final Rule has not been finalized and is subject to revision and challenge. Additionally, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Implementation of the November 20, 2020 final Rule will be delayed until at least January 1, 2023. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the current administration may reverse or otherwise change these measures, Congress has indicated that it will continue to seek new legislative measures to control drug costs. Additionally, in the United States, the Medicare Modernization Act, or MMA, contains provisions that call for the promulgation of regulations that expand pharmacists&#8217; and wholesalers&#8217; ability to import cheaper versions of an approved drug and competing products from Canada, where there are government price controls. Further, the MMA provides that these changes to U.S. importation laws will not take effect,&#160;unless and until the Secretary of the HHS certifies that the changes will pose no additional risk to the public&#8217;s health and safety and will result in a significant reduction in the cost of products to consumers. On September 23, 2020, the Secretary of the HHS made such certification to Congress, and on October 1, 2020, FDA published a final rule that allows for the importation of certain prescription drugs from Canada. Under the final rule, states and Indian Tribes, and in certain future circumstances pharmacists and wholesalers, may submit importation program proposals to the FDA for review and authorization. Since the issuance of the final rule, several industry groups have filed federal lawsuits challenging multiple aspects of the final rule, and authorities in Canada have passed rules designed to safeguard the Canadian drug supply from shortages.&#160;On September 25, 2020, CMS stated drugs imported by states under this rule will not be eligible for federal rebates under Section 1927 of the Social Security Act and manufacturers would not report these drugs for &#8220;best price&#8221; or Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. Separately, the FDA also issued a final guidance document outlining a pathway for manufacturers to obtain an additional National Drug Code, or NDC, for an FDA-approved drug that was originally intended to be marketed in a foreign country and that was authorized for sale in that foreign country. The market implications of the final rule and guidance are unknown at this time. Proponents of drug reimportation may attempt to pass legislation that would directly allow reimportation under certain circumstances.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May&#160;30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside the United States, ensuring coverage and adequate payment for a product also involves challenges. Pricing of prescription pharmaceuticals is subject to government control in many countries. Pricing negotiations with government authorities can extend well beyond the receipt of regulatory approval for a product and may require a clinical trial that compares the cost-effectiveness of a product to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in commercialization. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed upon. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states, and parallel trade, i.e., arbitrage between low-priced and high-priced member states, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Compliance with other federal and state laws or requirements; changing legal requirements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any products that we may develop are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, labeling, packaging, distribution, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws, among other requirements to which we may be subject. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive recordkeeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The failure to comply with any of these laws or regulatory requirements may subject firms to legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, exclusion from federal healthcare programs, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, relabeling or repackaging, or refusal to allow a firm to enter into supply contracts, including government contracts. Any claim or action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Prohibitions or restrictions on marketing, sales or withdrawal of future products marketed by us could materially affect our business in an adverse way. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i)&#160;changes to our manufacturing arrangements; (ii)&#160;additions or modifications to product labeling or packaging; (iii)&#160;the recall or discontinuation of our products; or (iv)&#160;additional recordkeeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other U.S. environmental, health and safety laws and regulations </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Government regulation of drugs outside of the United States </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical trials, marketing authorization or identification of an alternate regulatory pathway, manufacturing, commercial sales and distribution of our products. For instance, in the United Kingdom and the European Economic Area, or the EEA (comprised of the 27 EU Member States plus Iceland, Liechtenstein and Norway), medicinal products must be authorized for marketing by using either the centralized authorization procedure or national authorization procedures. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">Centralized procedure</font><font style="font-size:10pt;color:#000000;">&#8212;If pursuing marketing authorization of a product candidate for a therapeutic indication under the centralized procedure, following the opining of the EMA&#8217;s Committee for Medicinal Products for Human Use, or, CHMP, the European Commission issues a single marketing authorization valid across the EEA. The centralized procedure is compulsory for human medicines derived from biotechnology processes or advanced therapy medicinal products (such as gene therapy, somatic cell therapy and tissue engineered products), products that contain a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, neurodegenerative disorders, diabetes, autoimmune diseases and other immune dysfunctions, viral diseases, and officially designated orphan medicines. For medicines that do not fall within these categories, an applicant has the option of submitting an application for a centralized marketing authorization to the EMA, as long as the medicine concerned contains a new active substance not yet authorized in the EEA, is a significant therapeutic, scientific or technical innovation, or if its authorization would be in the interest of public health in the EEA. Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the EMA is 210&#160;days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP. Accelerated assessment might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of major public health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of an MAA under the accelerated assessment procedure is 150&#160;days, excluding clock stops. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:10pt;color:#000000;">National authorization procedures</font><font style="font-size:10pt;color:#000000;">&#8212;There are also two other possible routes to authorize products for therapeutic indications in several countries, which are available for products that fall outside the scope of the centralized procedure: </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-style:italic;">Decentralized procedure</font>&#8212;Using the decentralized procedure, an applicant may apply for simultaneous authorization in more than one EU country of medicinal products that have not yet been authorized in any EU country and that do not fall within the mandatory scope of the centralized procedure. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-style:italic;">Mutual recognition procedure</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;In the mutual recognition procedure, a medicine is first authorized in one EU Member State, in accordance with the national procedures of that country. Following this, additional marketing authorizations can be sought from other EU countries in a procedure whereby the countries concerned recognize the validity of the original, national marketing authorization. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the EEA, new products for therapeutic indications that are authorized for marketing (i.e.,&#160;reference products) qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from relying on the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until ten years have elapsed from the initial authorization of the reference product in the EU. The ten-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The criteria for designating an &#8220;orphan medicinal product&#8221; in the EEA are similar in principle to those in the United States. In the EEA a medicinal product may be designated as orphan if (1)&#160;it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2)&#160;either (a)&#160;such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b)&#160;the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment; and (3)&#160;there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. During this ten-year orphan market exclusivity period, no marketing authorization application shall be accepted, and no marketing authorization shall be granted for a similar medicinal product for the same indication. An orphan product can also obtain an additional two years of market exclusivity in the EU for pediatric studies. The ten-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at any time if (i)&#160;the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior; (ii)&#160;the applicant consents to a second orphan medicinal product application; or (iii)&#160;the applicant cannot supply enough orphan medicinal product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar to the United States, the various phases of non-clinical and clinical research in the European Union are subject to significant regulatory controls. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Clinical Trials Directive 2001/20/EC, the Directive 2005/28/EC on GCP and the related national implementing provisions of the individual EU Member States govern the system for the approval of clinical trials in the European Union. Under this system, an applicant must obtain prior approval from the competent national authority of the EU Member States in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial at a specific study site after the competent ethics committee has issued a favorable opinion. The clinical trial application must be accompanied by, among other documents, an investigational medicinal product dossier (the Common Technical Document) with supporting information prescribed by Directive 2001/20/EC, Directive 2005/28/EC, where relevant the implementing national provisions of the individual EU Member States and further detailed in applicable guidance documents. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2014, the new Clinical Trials Regulation, (EU) No 536/2014 (Clinical Trials Regulation) was adopted. It is expected that the new Clinical Trials Regulation (EU) No 536/2014 will apply following confirmation of full functionality of the Clinical Trials Information System (CTIS), the centralized European Union portal and database for clinical trials foreseen by the regulation, through an independent audit. The regulation becomes applicable six months after the European Commission publishes notice of this confirmation. The Clinical Trials Regulation will be directly applicable in all the EU Member States, repealing the current Clinical Trials Directive 2001/20/EC. Conduct of all clinical trials performed in the European Union will continue to be bound by currently applicable provisions </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">until the new Clinical Trials Regulation becomes applicable. The extent to which ongoing clinical trials will be governed by the Clinical Trials Regulation will depend on when the Clinical Trials Regulation becomes applicable and on the duration of the individual clinical trial. If a clinical trial continues for more than three years from the day on which the Clinical Trials Regulation becomes applicable the Clinical Trials Regulation will at that time begin to apply to the clinical trial. The new Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the European Union. The main characteristics of the regulation include: a streamlined application procedure via a single-entry point, the &#8220;EU portal&#8221;; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part&#160;I is assessed by the competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted (Member States concerned). Part&#160;II is assessed separately by each Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned EU Member State. However, overall related timelines will be defined by the Clinical Trials Regulation. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Government regulation of data collection outside of the United States </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event we conduct clinical trials in the European Union, we will be subject to additional privacy restrictions. The collection and use of personal health data in the European Economic Area, or EEA (being the European Union plus Norway, Iceland, and Liechtenstein), is governed by the General Data Protection Regulation, or the GDPR, which became effective on May&#160;25, 2018. The GDPR applies to the processing of personal data by any company established in the EEA and to companies established outside the EEA to the extent they process personal data in connection with the offering of goods or services to data subjects in the EEA or the monitoring of the behavior of data subjects in the EEA. The GDPR enhances data protection obligations for data controllers of personal data, including stringent requirements relating to the consent of data subjects, expanded disclosures about how personal data is used, requirements to conduct privacy impact assessments for &#8220;high risk&#8221; processing, limitations on retention of personal data, mandatory data breach notification and &#8220;privacy by design&#8221; requirements, and creates direct obligations on service providers acting as processors. The GDPR also imposes strict rules on the transfer of personal data outside of the EEA to countries that do not ensure an adequate level of protection, like the United States (which, while deemed a third country, has the benefit of the Privacy Shield regime for transatlantic data transfers). Failure to comply with the requirements of the GDPR and the related national data protection laws of the European Union Member States and Norway, Iceland and Liechtenstein, which may deviate slightly from the GDPR, may result in fines of up to 4% of a company&#8217;s global revenues for the preceding financial year, or &#8364;20,000,000, whichever is greater. Moreover, the GDPR grants data subjects the right to claim material and non-material damages resulting from infringement of the GDPR. Given the breadth and depth of changes in data protection obligations, maintaining compliance with the GDPR will require significant time, resources and expense, and we may be required to put in place additional controls and processes ensuring compliance with the new data protection rules. There has been limited enforcement of the GDPR to date, particularly in biopharmaceutical development, so we face uncertainty as to the exact interpretation of the new requirements on any future trials and we may be unsuccessful in implementing all measures required by data protection authorities or courts in interpretation of the new law. Further, the United Kingdom&#8217;s decision to leave the European Union, often referred to as Brexit, has created uncertainty with regard to data protection regulation in the United Kingdom. In particular, it is unclear how data transfers to and from the United Kingdom will be regulated now that the United Kingdom has left the European Union. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty related to the manner in which data protection authorities will seek to enforce compliance with GDPR. For example, it is not clear if the authorities will conduct random audits of companies doing business in the EU, or if the authorities will wait for complaints to be filed by individuals who claim their rights have been violated. Enforcement uncertainty and the costs associated with ensuring GDPR compliance are onerous and may adversely affect our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should we utilize third party distributors, compliance with such foreign governmental regulations would generally be the responsibility of such distributors, who may be independent contractors over whom we have limited control. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Human Capital Resources</font></p>
<p style="margin-bottom:12pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 28, 2021, we had 159 full-time employees. Seventy-four of our employees have M.D. or Ph.D. degrees. Within our workforce, 114 employees are engaged in research and development and 45 are engaged in business development, finance, legal, and general management and administration. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our people are among our greatest assets. Accordingly, we are committed to building a dedicated and passionate team. We focus on recruiting talent that is additive to our existing teams and leverage a diversity of perspectives. We regularly review our compensation practices and analyze the equity of our compensation decisions for all employees. We provide what we consider to be a competitive mix of long and short-term incentives including competitive salaries, incentive compensation, participation in our equity programs, healthcare and insurance benefits, and various innovative health and wellness programs. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are committed to investing in the development of our employees and creating an environment where diverse perspectives and backgrounds are encouraged and supported. To empower our employees to continually develop and grow, we offer a wide range of learning and development opportunities and resources. These include formal leadership training, workshops, and access to specialized career coaching to foster continued growth. We also host regular company-wide sessions where our employees discuss ideas and feedback on corporate initiatives, share scientific breakthroughs and other corporate updates and recognize each other&#8217;s contributions and accomplishments. In addition, we regularly conduct an employee survey to gauge employee engagement and identify areas of focus. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also dedicated to providing an inclusive, collaborative and safe work environment for our employees. Our diversity and inclusion advisory group actively promotes engagement among our employees on a variety of topics related to diversity, equity and inclusion, including providing awareness workshops and supporting the growth of employee resource groups for under-represented populations as part of our efforts to create a more diverse and equitable workplace. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the COVID-19 pandemic, we undertook several initiatives to ensure the health and safety of our workforce and continuity of our operations. We developed and implemented safety protocols at our facilities taking into consideration national and local public health guidelines and input from our employees. We rapidly redesigned our facilities and introduced company-sponsored regular onsite COVID-19 testing as well as provided access to testing for family and household members of employees. Throughout the pandemic, much of our workforce has worked remotely, wherever possible. We also implemented remote hiring and onboarding programs to facilitate significant hiring during 2020 in a remote work environment.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Corporate Information</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated under the laws of the State of Delaware on May 4, 2015 under the name Allostery, Inc. In December 2015, we changed our name to Relay Therapeutics, Inc. Our principal corporate office is located at 399 Binney Street, 2<sup style="font-size:85%;line-height:120%;vertical-align:top">nd</sup> Floor, Cambridge, MA 02139, and our telephone number is (617) 370-8837. Our website address is www.relaytx.com. Our website and the information contained on, or that can be accessed through, the website will not be deemed to be incorporated by reference in, and are not considered part of, this Annual Report on Form 10-K.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, we completed our initial public offering, or IPO, pursuant to which we issued and sold 23,000,000 shares of common stock at a public offering price of $20.00 per share, resulting in net proceeds of $425 million, after deducting underwriting discounts and commissions and other offering expenses.  </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an "emerging growth company" as defined in the Jumpstart Our Business Startups Act of 2012. We will remain an emerging growth company until the earlier of: (i) the last day of the fiscal year (a) following the fifth anniversary of the completion of the IPO, (b) in which we have total annual gross revenue of at least $1.07 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that is held by non-affiliates exceeds $700.0 million as of the prior June 30th, and (ii) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available Information</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our website address is www.relaytx.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, proxy and information statements and amendments to those reports filed or furnished pursuant to Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, are available through the &#8220;Media &amp; Investors&#8221; portion of our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Information on our website is not part of this Annual Report on Form 10-K or any of our other securities filings unless specifically incorporated herein by reference. In addition, our filings with the SEC may be accessed through the SEC&#8217;s Interactive Data Electronic Applications system at www.sec.gov. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our code of conduct, corporate governance guidelines and the charters of our Audit Committee, Research and Development Committee, Compensation Committee and Nominating and Corporate Governance Committee are available through the &#8220;Media &amp; Investors&#8221; portion of our website.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1A_RISK_FACTORS"></a>Item&#160;1A. <a name="ITEM_1A_RISK_FACTORS"></a>Risk Factors. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding whether to invest in our common stock. We believe the risks described below include risks that are material to us as well as other risks that may adversely affect our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Product Candidates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Clinical Development </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have never successfully completed any clinical trials, and we may be unable to do so for any product candidates we develop. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not yet demonstrated our ability to successfully complete any clinical trials, including large-scale, pivotal clinical trials, obtain regulatory approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. We have two product candidates, RLY-1971 and RLY-4008, in first-in-human clinical development. We expect to be in IND-enabling studies for our RLY-PI3K1047 program by the end of 2021. We may not be able to file such IND or INDs for any of our other product candidates on the timelines we expect, if at all. For example, we may experience manufacturing delays with IND-enabling studies. Moreover, we cannot be sure that submission of an IND will result in the FDA allowing further clinical trials to begin, or that, once begun, issues will not arise that require us to suspend or terminate clinical trials. Commencing each of these clinical trials is subject to finalizing the trial design based on discussions with the FDA and other regulatory authorities. Any guidance we receive from the FDA or other regulatory authorities is subject to change. These regulatory authorities could change their position, including, on the acceptability of our trial designs or the clinical endpoints selected, which may require us to complete additional clinical trials or impose stricter approval conditions than we currently expect. Successful completion of our clinical trials is a prerequisite to submitting a new drug application, or NDA, to the FDA and a Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, for each product candidate and, consequently, the ultimate approval and commercial marketing of each product candidate. Our RLY-1971 and RLY-4008 first-in-human clinical trials are ongoing, but we do not know whether any of our future clinical trials will begin on time or ever be completed on schedule, if at all. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">be delayed in obtaining marketing approval for our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">not obtain marketing approval at all; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">obtain approval for indications or patient populations that are not as broad as intended or desired; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">be subject to post-marketing testing requirements; or </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">have the product removed from the market after obtaining marketing approval. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical product development involves a lengthy and expensive process, with an uncertain outcome. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is impossible to predict when or if any of our product candidates will prove effective and safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">can occur at any stage of testing. The outcome of preclinical development testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. Our preclinical studies and future clinical trials may not be successful. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may publish interim top-line or preliminary data from our clinical trials. Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may experience delays in completing our preclinical studies and initiating or completing clinical trials, and we may experience numerous unforeseen events during, or as a result of, any future clinical trials that we could conduct that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">regulators or institutional review boards, or IRBs, or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective contract research organizations, or CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials or we may decide to abandon product development programs; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our third party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may elect to, or regulators or IRBs or ethics committees may require us or our investigators to, suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the cost of clinical trials of our product candidates may be greater than we anticipate; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or IRBs or ethics committees to suspend or terminate the trials, or reports may arise from preclinical or clinical testing of other cancer therapies that raise safety or efficacy concerns about our product candidates. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions at which such trials are being conducted, by the Data Safety Monitoring Board, or DSMB, for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination or clinical hold due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Further, the FDA may disagree with our clinical trial design and our interpretation of data from clinical trials, or may change the requirements for approval even after it has reviewed and commented on the design for our clinical trials. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product development costs will also increase if we experience delays in testing or regulatory approvals. We do not know whether any of our future clinical trials will begin as planned, or whether any of our current or future clinical trials will need to be restructured or will be completed on schedule, if at all. Significant preclinical study or clinical trial delays, including those caused by the COVID-19 pandemic, also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. Any delays in our preclinical or future clinical development programs may harm our business, financial condition and prospects significantly. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. In particular, because we will be deploying our drug discovery platform across a broad target space, our ability to enroll eligible patients may be limited or may result in slower enrollment than we anticipate. In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. Furthermore, our ability to enroll patients may be significantly delayed by the evolving COVID-19 pandemic and we do not know the extent and scope of such delays at this point. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the competitive trial environment, the eligibility criteria of our planned clinical trials will further limit the pool of available study participants as we will require that patients have specific characteristics that we can measure to assure their cancer is either severe enough or not too advanced to include them in a study. Additionally, the process of finding patients may prove costly. We also may not be able to identify, recruit and enroll a sufficient number of patients to complete our clinical studies because of the perceived risks and benefits of the product candidates under study, the availability and efficacy of competing therapies and clinical trials, the proximity and availability of clinical trial sites for prospective patients, and the patient referral practices of physicians. If patients are unwilling to participate in our studies for any reason, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of potential products may be delayed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also engage third parties to develop companion diagnostics for use in our clinical trials, but such third parties may not be successful in developing such companion diagnostics, furthering the difficulty in identifying patients with the targeted genetic mutations for our clinical trials. Further, if we are required to develop companion diagnostics and are unable to include patients with the targeted genetic mutations, this could compromise our ability to seek participation in the FDA&#8217;s expedited review and development programs, including Breakthrough Therapy Designation and Fast Track Designation, or otherwise to seek to accelerate clinical development and regulatory timelines. The FDA has indicated that if we continue RLY-4008 in a specific biomarker-defined population, a companion diagnostic device will be required to ensure its safe and effective use. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patient enrollment may be affected by other factors including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the severity of the disease under investigation; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the eligibility criteria for the clinical trial in question; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the availability of an appropriate genomic screening test; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the perceived risks and benefits of the product candidate under study; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the efforts to facilitate timely enrollment in clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the patient referral practices of physicians; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the ability to monitor patients adequately during and after treatment; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the proximity and availability of clinical trial sites for prospective patients; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">factors we may not be able to control, such as current or potential pandemics that may limit patients, principal investigators or staff or clinical site availability (e.g., outbreak of COVID-19). </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Positive results from early preclinical studies of our product candidates are not necessarily predictive of the results of later preclinical studies and any future clinical trials of our product candidates. If we cannot replicate the positive results from our earlier preclinical studies of our product candidates in our later preclinical studies and future clinical trials, we may be unable to successfully develop, obtain regulatory for and commercialize our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any positive results from our preclinical studies of our product candidates may not necessarily be predictive of the results from required later preclinical studies and clinical trials. Similarly, even if we are able to complete our planned preclinical studies or any future clinical trials of our product candidates according to our current development timeline, the positive results from such preclinical studies and clinical trials of our product candidates may not be replicated in subsequent preclinical studies or clinical trial results. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical and other nonclinical findings made while clinical trials were underway, or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse events. Moreover, preclinical, nonclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or EMA approval. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our current or future clinical trials or those of our future collaborators may reveal significant adverse events not seen in our preclinical or nonclinical studies and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before obtaining regulatory approvals for the commercial sale of any products, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for use in each target indication. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials also may fail to show the desired safety and efficacy profile despite having progressed through nonclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved as products and there can be no assurance that any of our current or future clinical trials will ultimately be successful or support further clinical development of any of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may develop future product candidates, in combination with one or more cancer therapies. The uncertainty resulting from the use of our product candidates in combination with other cancer therapies may make it difficult to accurately predict side effects in future clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is the case with many treatments for cancer and rare diseases, it is likely that there may be side effects associated with the use of our product candidates. If significant adverse events or other side effects are observed in any of our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">current or future clinical trials, we may have difficulty recruiting patients to our clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of one or more product candidates altogether. We, the FDA or other applicable regulatory authorities, or an IRB may suspend or terminate clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and prospects. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Although we intend to explore other therapeutic opportunities, in addition to the product candidates that we are currently developing, we may fail to identify viable new product candidates for clinical development for a number of reasons. If we fail to identify additional potential product candidates, our business could be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research programs to pursue the development of our existing and planned product candidates for additional indications and to identify new product candidates and disease targets require substantial technical, financial and human resources whether or not they are ultimately successful. For example, pursuant to the DESRES Agreement, we collaborate with D.&#160;E. Shaw Research to develop various protein models and make predictions as to how molecules might move, with subsequent validation efforts in our and our CROs&#8217; labs. There can be no assurance that we will find potential additional targets using this approach, that any such targets will be tractable, or that such clinical validations will be successful. Our research programs may initially show promise in identifying potential indications and/or product candidates, yet fail to yield results for clinical development for a number of reasons, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the research methodology used may not be successful in identifying potential indications and/or product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">potential product candidates may, after further study, be shown to have harmful adverse effects or other characteristics that indicate they are unlikely to be effective products; or </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">it may take greater human and financial resources than we will possess to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, thereby limiting our ability to develop, diversify and expand our product portfolio. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited financial and human resources, we intend to initially focus on research programs and product candidates for a limited set of indications. As a result, we may forgo or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, there can be no assurance that we will ever be able to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, which could materially adversely affect our future growth and prospects. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We intend to develop our current product candidates and potentially future product candidates, in combination with other therapies, which exposes us to additional risks. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to develop our current product candidates, and may develop future product candidates, for use in combination with one or more currently approved cancer therapies. Even if any product candidate we develop was to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to bear the risks that the FDA or similar foreign regulatory authorities could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. Combination therapies are commonly used for the treatment of cancer, and we would be subject to similar risks if we develop any of our product candidates for use in combination with other drugs or for </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">indications other than cancer. This could result in our own products being removed from the market or being less successful commercially. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also evaluate our current product candidates or any other future product candidates in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA or similar foreign regulatory authorities. We will not be able to market and sell our SHP2 program, our FGFR2 program, or our PI3K program or any product candidate we develop in combination with any such unapproved cancer therapies that do not ultimately obtain marketing approval. Pursuant to the Genentech Agreement as further described above, Genentech will assume the development of RLY-1971, <font style="color:#000000;">including developing RLY-1971 in combination with Genentech&#8217;s KRAS <sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup> program.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA or similar foreign regulatory authorities do not approve these other drugs or revoke their approval of, or if safety, efficacy, manufacturing, or supply issues arise with, the drugs we choose to evaluate in combination with our current product candidates or any product candidate we develop, we may be unable to obtain approval of or market our SHP2 program, our FGFR2 program, or our PI3K program or any product candidate we develop. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our product candidates utilize a novel mechanism of action and novel binding locations, which may result in greater research and development expenses, regulatory issues that could delay or prevent approval, or discovery of unknown or unanticipated adverse effects. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates utilize novel mechanisms of action and novel binding locations, which may result in greater research and development expenses, regulatory issues that could delay or prevent approval, or discovery of unknown or unanticipated adverse effects. Our Dynamo platform uses advanced computational models in tight integration with our medicinal chemistry, structural biology, enzymology and biophysics capabilities to predict and design the compounds that will achieve the most desirable characteristics, including potency, selectivity, bioavailability, and drug-like properties. A disruption in any of these capabilities may have significant adverse effects in our abilities to expand our Dynamo platform, and we cannot predict whether we will continue to have access to these capabilities in the future to support our Dynamo platform. In addition, there can be no assurance that we will be able to rapidly identify, design and synthesize the necessary compounds or that these or other problems related to the development of this novel mechanism will not arise in the future, which may cause significant delays, or we raise problems we may not be able to resolve. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory approval of novel product candidates such as ours can be more expensive, riskier and take longer than for other, more well-known or extensively studied pharmaceutical or biopharmaceutical product candidates due to our and regulatory agencies&#8217; lack of experience with them. The novelty of our mechanism of action may lengthen the regulatory review process, require us to conduct additional studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. The novel mechanism of action also means that fewer people are trained in or experienced with product candidates of this type, which may make it more difficult to find, hire and retain personnel for research, development and manufacturing positions. Because our inhibitors utilize a novel mechanism of action that has not been the subject of extensive study compared to more well-known product candidates, there is also an increased risk that we may discover previously unknown or unanticipated adverse effects during our preclinical studies and clinical trials. Any such events could adversely impact our business prospects, financial condition and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may in the future conduct clinical trials for our product candidates outside the United States, and the FDA and similar foreign regulatory authorities may not accept data from such trials. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may in the future choose to conduct additional clinical trials outside the United States, including in Australia, Europe, Asia or other foreign jurisdictions. The acceptance of trial data from clinical trials conducted outside the United States by the FDA may be subject to certain conditions. In cases where data from clinical trials conducted outside the United States are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i)&#160;the data are applicable to the United States population and United States medical practice; (ii)&#160;the trials were performed by clinical investigators of recognized competence and (iii)&#160;the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on-site inspection or other appropriate means. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any similar foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any similar foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Obtaining Regulatory Approvals </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in other countries. Before we can commercialize any of our product candidates, we must obtain marketing approval. Currently, all of our product candidates are in development, and we have not received approval to market any of our product candidates from regulatory authorities in any jurisdiction. It is possible that our product candidates, including any product candidates we may seek to develop in the future, will never obtain regulatory approval. We have only limited experience in filing and supporting the applications necessary to gain regulatory approvals and expect to rely on third-party CROs and/or regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. In addition, regulatory authorities may find fault with our manufacturing process or facilities or that of third-party contract manufacturers. We may also face greater than expected difficulty in manufacturing our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process of obtaining regulatory approvals, both in the United States and abroad, is expensive and often takes many years. If the FDA or a comparable foreign regulatory authority requires that we perform additional preclinical or clinical trials, approval, if obtained at all, may be delayed. The length of such a delay varies substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted NDA, 510(k), premarket approval application, or PMA, or equivalent application types, may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. Our product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may not be able to enroll a sufficient number of patients in our clinical studies; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication or a related companion diagnostic is suitable to identify appropriate patient populations; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the FDA or comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change such that our clinical data are insufficient for approval. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, thereby narrowing the commercial potential of the product candidate. In addition, regulatory authorities may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Commercialization </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The incidence and prevalence for target patient populations of our product candidates have not been established with precision. If the market opportunities for our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability will be adversely affected, possibly materially. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently evaluating the safety and tolerability of RLY-1971 in a Phase 1 dose escalation study in patients with advanced or metastatic solid tumors and pursuant to the Genentech Agreement entered into in December 2020, future development for RLY-1971, including the potential to conduct multiple combination studies, will be governed by a joint development team between us and Genentech.<font style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></font>We estimate there are approximately 55,000 late-line patients annually in the United States with advanced lung cancer who might benefit from a combination of RLY-1971 with another targeted inhibitor. In the future, if RLY-1971 advances to earlier lines of combination treatment for lung cancer, we believe it could be applied in the treatment of approximately 90,000 patients annually in the United States. The subset of patients with KRAS <sup style="font-size:85%;line-height:120%;vertical-align:top">G12C</sup> mutations in lung cancer that could potentially benefit from the combination of RLY-1971 with GDC-6036 is approximately 15,000-25,000 annually in the United States. We are also evaluating the safety and tolerability of RLY-4008, our inhibitor of FGFR2 in patients with advanced solid tumors having oncogenic FGFR2 alterations, in a first-in-human trial initiated in September 2020. We believe FGFR2-mediated cancers affect approximately 8,000 late-line patients annually in the United States, of which fusions represent approximately 2,700, amplifications 1,600, and mutations 3,800. In the future, if RLY-4008 advances to earlier lines of treatment, it could potentially address approximately 20,000 patients annually in the United States. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to be in IND-enabling studies for our RLY-PI3K1047 program by the end of 2021. We believe PI3K&#945; H1047X mutant cancers affect approximately 10,000 late-line patients annually in the United States. In the future, if RLY-PI3K1047 advances to earlier lines of treatment, it could potentially address approximately 50,000 patients annually in the United States.<font style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></font>Two additional mutations of interest for our PI3K&#945; franchise are E542X and E545X. We estimate there are approximately 15,000 late-line and 60,000 total patients annually in the United States who might benefit from a PI3K&#945; targeted inhibitor that targets the mutations at E542 and E545. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potential to benefit from treatment with RLY-1971, RLY-4008</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or our RLY-PI3K1047 program</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> product candidates, are based on estimates. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total addressable market opportunity will ultimately depend upon, among other things, the diagnosis criteria included in the final label, if our product candidates are approved for sale for these indications, acceptance by the medical community and patient access, product pricing and reimbursement. The number of patients with cancers and solid tumors may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. We may not be successful in our efforts to identify additional product candidates. Due to our limited resources and access to capital, we must prioritize development of certain product candidates, which may prove to be the wrong choice and may adversely affect our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development and commercialization of new products in the biopharmaceutical and related industries is highly competitive. We compete in the segments of the pharmaceutical, biotechnology, and other related markets that address computationally focused structure-based drug design in cancer and genetic diseases. There are other companies focusing on structure-based drug design to develop therapies in the fields of cancer and other diseases. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach, and others are based on entirely different approaches. These companies include divisions of large pharmaceutical companies and biotechnology companies of various sizes. We face competition with respect to our current product candidates, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product candidates that we successfully develop and commercialize will compete with currently approved therapies and new therapies that may become available in the future from segments of the pharmaceutical, biotechnology and other related markets that pursue precision medicines. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our products. We believe principal competitive factors to our business include, among other things, the accuracy of our computations and predictions, ability to integrate experimental and computational capabilities, ability to successfully transition research programs into clinical development, ability to raise capital, and the scalability of the platform, pipeline, and business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of the companies that we compete against or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, we cannot predict whether our current competitive advantages, such as our ability to leverage our Dynamo platform and our relationship with D. E. Shaw Research, will remain in place in the future. If these or other barriers to entry do not remain in place, other companies may be able to more directly or effectively compete with us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we or our collaborators may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we or our collaborators are able to enter the market. The key competitive factors affecting the success of all of our product candidates, if approved, are likely to be their efficacy, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">safety, convenience, price, the level of generic competition and the availability of reimbursement from government and other third-party payors. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for any of our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Our ability to successfully commercialize our product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. The availability of coverage and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford treatments such as gene therapy products. Sales of these or other product candidates that we may identify will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If coverage and adequate reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is also significant uncertainty related to the insurance coverage and reimbursement of newly approved products and coverage may be more limited than the purposes for which the medicine is approved by the FDA or comparable foreign regulatory authorities. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Factors payors consider in determining reimbursement are based on whether the product is (i) a covered benefit under its health plan; (ii) safe, effective and medically necessary; (iii) appropriate for the specific patient; (iv) cost-effective; and (v) neither experimental nor investigational.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price, or ASP, and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the European Union do not follow price structures of the U.S. and generally prices tend to be significantly lower. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Reliance on Third Parties </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Under the DESRES Agreement, we collaborate with D. E. Shaw Research to rapidly develop various protein models, a process that depends on D. E. Shaw Research&#8217;s use of their proprietary supercomputer, Anton 2. A termination of the DESRES Agreement could have a material adverse effect on our business, financial condition, results of operations, and prospects. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the DESRES Agreement, we collaborate with D. E. Shaw Research to develop various protein models to make predictions as to how molecules might move in connection with identifying potential new biological targets and prospective drug compounds. There can be no assurance these protein models, or the technology used by D.&#160;E. Shaw Research to develop them (including the Anton 2 supercomputer), will provide reliable data or target information, or that the findings from these activities and our subsequent validation efforts will translate into the ability to develop therapeutically effective compounds. Our collaboration with D. E. Shaw Research is our key computational collaboration, and there can be no assurance that this collaboration will continue past the current term of the DESRES Agreement, on favorable terms or at all, or that at any time while the collaboration is in effect D. E. Shaw Research will provide a level of service that benefits our programs in a meaningfully positive manner. While we also have other computational collaborations, mostly focused on developing machine learning models, such collaborations do not provide a substitute for the technology made available through our collaboration with D. E. Shaw Research. The termination of the DESRES Agreement or any reduction in our collaboration with D. E. Shaw Research would require us to rely more heavily on these other collaborations and our own internal resources, and may delay or impair our development efforts. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, while the termination of the DESRES Agreement would not directly impact the development of our lead product candidates, we cannot predict the effects such termination could have on our preclinical studies and development efforts and our ability to discover and develop additional product candidates. In particular, the technologies accessed through D. E. Shaw Research, including the Anton 2 supercomputer, are important aspects of our Dynamo platform, and we do not currently have access to another source of computational power comparable to that provided by the Anton 2 supercomputer. Currently, not only is our collaboration with D.&#160;E.&#160;Shaw Research for a limited time period, but it is also limited in the current collaboration year to collaboration across a total of eleven target proteins (with such number subject to increases or decreases from year to year, with any increase in such number of targets in each collaboration year capped at four more than the highest number of such targets in the previous year, and with the number of targets capped at twenty, subject to some limitations), which could restrict our ability to broaden our platform across a larger number of targets and programs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the DESRES Agreement, D. E. Shaw Research controls the rights to its technology, we control the rights to certain compounds, and we jointly own with D. E. Shaw Research any other work product created by D.&#160;E.&#160;Shaw Research and us. Any work product we jointly own with D. E. Shaw Research and any other information that we or D. E. Shaw Research share is subject to a non-exclusive cross-license between us and D.&#160;E. Shaw Research, subject to certain exceptions. In some instances, D. E. Shaw Research is required to assign to us some of the work product created by D. E. Shaw Research. Disputes may arise between us and D. E. Shaw Research, as well as any future potential collaborators, regarding intellectual property subject to the DESRES Agreement. If disputes over intellectual property that we co-own or we own individually prevent or impair our ability to maintain our current collaboration arrangements on acceptable terms, or undermine our ability to successfully control the intellectual property necessary to protect our product candidates, we may be unable to successfully develop and commercialize the affected product candidates. Uncertainties or disagreements around our rights under any such intellectual property may undermine our ability to partner our programs with third parties. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the DESRES Agreement is complex and certain provisions may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could be adverse to us, for example by narrowing what we believe to be the scope of our rights to certain intellectual property, or increasing </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">what we believe to be our financial or other obligations under the DESRES Agreement, and any such outcome could have a material adverse effect on our business, financial condition, results of operations, and prospects. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are generally also subject to all of the same risks with respect to protection of intellectual property that we co-own, as we are for intellectual property that we own, which are described below. If we or D. E. Shaw Research fail to adequately protect this intellectual property, our ability to commercialize products could suffer. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, we are subject to certain payment obligations under the DESRES Agreement, including payments to D. E. Shaw Research in connection with certain transactions, including our collaboration with Genentech pursuant to the Genentech Agreement. These payment obligations may decrease the value to us of certain transactional opportunities or otherwise burden our ability to enter into such transactions. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We rely on third parties to conduct our ongoing clinical trials of RLY-1971 and RLY-4008 and expect to rely on third parties to conduct future clinical trials, as well as investigator-sponsored clinical trials of our product candidates. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have the ability to independently conduct clinical trials. We rely and expect to continue to rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct or otherwise support clinical trials for our product candidates, including our first-in-human clinical trials of RLY-1971 and RLY-4008, currently enrolling patients. We may also rely on academic and private non-academic institutions to conduct and sponsor clinical trials relating to our product candidates. We will not control the design or conduct of the investigator-sponsored trials, and it is possible that the FDA or non-U.S. regulatory authorities will not view these investigator-sponsored trials as providing adequate support for future clinical trials, whether controlled by us or third parties, for any one or more reasons, including elements of the design or execution of the trials or safety concerns or other trial results. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such arrangements will likely provide us certain information rights with respect to the investigator-sponsored trials, including access to and the ability to use and reference the data, including for our own regulatory filings, resulting from the investigator-sponsored trials. However, we would not have control over the timing and reporting of the data from investigator-sponsored trials, nor would we own the data from the investigator-sponsored trials. If we are unable to confirm or replicate the results from the investigator-sponsored trials or if negative results are obtained, we would likely be further delayed or prevented from advancing further clinical development of our product candidates. Further, if investigators or institutions breach their obligations with respect to the clinical development of our product candidates, or if the data proves to be inadequate compared to the first-hand knowledge we might have gained had the investigator-sponsored trials been sponsored and conducted by us, then our ability to design and conduct any future clinical trials ourselves may be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely and expect to continue to rely heavily on these parties for execution of clinical trials for our product candidates and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on CROs will not relieve us of our regulatory responsibilities. For any violations of laws and regulations during the conduct of our clinical trials, we could be subject to warning letters or enforcement action that may include civil penalties up to and including criminal prosecution. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We, our principal investigators and our CROs are required to comply with regulations, including Good Clinical Practices, or GCPs, for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial patients are adequately informed of the potential risks of participating in clinical trials and their rights are protected. These regulations are enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area and comparable foreign regulatory authorities for any products in clinical development. The FDA enforces GCP regulations through periodic inspections of clinical trial sponsors, principal investigators and trial sites. If we, our principal investigators or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, the FDA will </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determine that any of our future clinical trials will comply with GCPs. In addition, our clinical trials must be conducted with product candidates produced under current Good Manufacturing Practice, or cGMP, regulations. Our failure or the failure of our principal investigators or CROs to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process and could also subject us to enforcement action. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we designed our first-in-human clinical trials of RLY-1971 and RLY-4008 and intend to design the future clinical trials for the product candidates that we develop, we expect that CROs will conduct all of our clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, are outside of our direct control. Our reliance on third parties to conduct future clinical trials also results in less direct control over the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">have staffing difficulties; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">fail to comply with contractual obligations; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">experience regulatory compliance issues; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">undergo changes in priorities or become financially distressed; or </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">form relationships with other entities, some of which may be our competitors. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These factors may materially adversely affect the willingness or ability of third parties to conduct our clinical trials and may subject us to unexpected cost increases that are beyond our control. If the principal investigators or CROs do not perform clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development, regulatory approval and commercialization of our product candidates may be delayed, we may not be able to obtain regulatory approval and commercialize our product candidates, or our development program materially and irreversibly harmed. If we are unable to rely on clinical data collected by our principal investigators or CROs, we could be required to repeat, extend the duration of, or increase the size of any clinical trials we conduct and this could significantly delay commercialization and require significantly greater expenditures. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our relationships with these third-party principal investigators or CROs terminate, we may not be able to enter into arrangements with alternative CROs. If principal investigators or CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, any clinical trials such principal investigators or CROs are associated with may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, we believe that our financial results and the commercial prospects for our product candidates in the subject indication would be harmed, our costs could increase and our ability to generate revenue could be delayed. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We contract with third parties for the manufacture of our product candidates for preclinical development, clinical testing, and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently own or operate, nor do we have any plans to establish in the future, any manufacturing facilities or personnel. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical development and clinical testing, as well as for the commercial manufacture of our products if any of our product candidates receive marketing approval. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The facilities used by our contract manufacturers to manufacture our product candidates must be inspected by the FDA pursuant to pre-approval inspections that will be conducted after we submit our marketing applications to the FDA. We do not control the manufacturing process of, and will be completely dependent on, our contract manufacturers for compliance with cGMPs in connection with the manufacture of our product candidates. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to pass regulatory inspections and/or maintain regulatory compliance for their manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product candidates or if it finds deficiencies or withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Further, our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, if approved, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect our business and supplies of our product candidates. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">reliance on the third party for regulatory compliance and quality assurance; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the possible breach of the manufacturing agreement by the third party; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates and any products that we may develop may compete with other product candidates and approved products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We are also unable to predict how the COVID-19 pandemic may affect our third-party manufacturers, including any potential disruptions to our global supply chain. If our current contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers or manufacture the materials ourselves, for which we may not have the capabilities or resources. In either scenario, our clinical trials supply could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our products or product candidates may be unique or proprietary to the original contract manufacturing organization, or CMO, and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. Changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials. We may incur added costs and delays in identifying and qualifying any such replacement. Furthermore, a CMO may possess technology related to the manufacture of our product candidate that such CMO owns independently. This would increase our reliance on such CMO or require us to obtain a license from such CMO in order to have another CMO manufacture our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The third parties upon whom we rely for the supply of the active pharmaceutical ingredient used in our product candidates are our sole source of supply, and the loss of any of these suppliers could significantly harm our business. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The active pharmaceutical ingredients, or API, used in our product candidates are supplied to us from single-source suppliers. Our ability to successfully develop our product candidates, and to ultimately supply our commercial products in quantities sufficient to meet the market demand, depends in part on our ability to obtain the API for these products in accordance with regulatory requirements and in sufficient quantities for clinical testing and commercialization. We do not currently have arrangements in place for a redundant or second-source supply of any such API in the event any of our current suppliers of such API cease their operations for any reason. We are also unable to predict how changing global economic conditions or potential global health concerns such as the COVID-19 pandemic&#160;will affect our third-party suppliers and manufacturers. Any negative impact of such matters on our third-party suppliers and manufacturers may also have an adverse impact on our results of operations or financial condition. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For all of our product candidates, we intend to identify and qualify additional manufacturers to provide such API prior to submission of an NDA to the FDA and/or an MAA to the EMA. We are not certain, however, that our single-source suppliers will be able to meet our demand for their products, either because of the nature of our agreements with those suppliers, our limited experience with those suppliers or our relative importance as a customer to those suppliers. It may be difficult for us to assess their ability to timely meet our demand in the future based on past performance. While our suppliers have generally met our demand for their products on a timely basis in the past, they may subordinate our needs in the future to their other customers. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Establishing additional or replacement suppliers for the API used in our product candidates, if required, may not be accomplished quickly. If we are able to find a replacement supplier, such replacement supplier would need to be qualified and may require additional regulatory inspection or approval, which could result in further delay. While we seek to maintain adequate inventory of the API used in our product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain such API from alternate sources at acceptable prices in a timely manner could impede, delay, limit or prevent our development efforts, which could harm our business, results of operations, financial condition and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may enter into collaborations with third parties for the research, development, manufacture and commercialization of one or more of our programs or product candidates. If these collaborations are not successful, our business could be adversely affected.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may enter into collaborations with third parties for one or more of our programs or product candidates. For example, in December 2020, we entered into the Genentech Agreement, a global collaboration and license agreement with Genentech <font style="color:#000000;">to </font>develop and commercialize RLY-1971. If we enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that any future collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any collaborations we enter into, including our collaboration with Genentech, may pose several risks, including the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Collaborators may have significant discretion in determining the efforts and resources that they will apply to these collaborations;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Collaborators may not perform their obligations as expected;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The clinical trials conducted as part of these collaborations may not be successful;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Collaborators may not pursue development and/or commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">programs based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding or external factors, such as an acquisition, that divert resources or create competing priorities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Collaborators may delay clinical trials, provide insufficient funding for clinical trials, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We may not have access to, or may be restricted from disclosing, certain information regarding product candidates being developed or commercialized under a collaboration and, consequently, may have limited ability to inform our stockholders about the status of such product candidates;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Product candidates developed in collaboration with us may be viewed by any collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">A collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of any such product candidate;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development of any programs or product candidates, may cause delays or termination of the research, development, manufacture or commercialization of such programs or product candidates, may lead to additional responsibilities for us with respect to such programs or product candidates or may result in litigation or arbitration, any of which would be time-consuming and expensive;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation. For example, Genentech has the first right to enforce or defend certain of our intellectual property rights under our collaboration, and although we may have the right to assume the enforcement and defense of such intellectual property rights if Genentech does not, our ability to do so may be compromised by Genentech&#8217;s actions;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates. For example, Genentech may terminate its collaboration with us for convenience after a specified notice period.</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our collaborations do not result in the successful development and commercialization of products, or if one of any future collaborators terminates its agreement with us, we may not receive any milestone or royalty payments under the collaboration. If we do not receive the payments we expect under these agreements, our development of product candidates could be delayed and we may need additional resources to develop our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if any collaborator terminates its agreement with us, we may find it more difficult to attract new collaborators and our reputation among the business and financial communities could be adversely affected.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may seek to establish additional collaborations, and, if we are not able to establish them on commercially reasonable terms, or at all, we may have to alter our development and commercialization plans. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. For some of our product candidates, we may decide to collaborate with additional pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. The terms of any additional collaborations or other arrangements that we may establish may not be favorable to us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also be restricted under collaboration agreements from entering into future agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Financial Position and Ability to Raise Additional Capital </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Our Operating History </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are a biopharmaceutical company with a limited operating history. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a biopharmaceutical company with a limited operating history and have incurred net losses in each year since our inception. Our net losses were $52.4&#160;million and $75.3&#160;million for the years ended December&#160;31, 2020 and 2019, respectively. We had an accumulated deficit of $404.2&#160;million as of December&#160;31, 2020. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We commenced operations in May 2015. Since inception, we have focused substantially all of our efforts and financial resources on developing our drug discovery platform and initial product candidates. We have no products approved for commercial sale and therefore have never generated any revenue from product sales, and we do not expect to in the foreseeable future. We have not obtained regulatory approvals for any of our product candidates and there is no assurance that we will obtain approvals in the future. We expect to continue to incur significant expenses and operating losses over the next several years and for the foreseeable future. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; deficit and working capital. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable future. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of our operating losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect our research and development expenses to significantly increase in connection with the commencement and continuation of clinical trials of our product candidates. In addition, if we obtain marketing approval for our product candidates, we will incur significant sales, marketing and outsourced-manufacturing expenses. We will also continue to incur additional costs associated with operating as a public company. As a result, we expect to continue to incur significant and increasing operating losses for the foreseeable future. Because of the numerous risks and uncertainties associated with developing pharmaceutical products, we are unable to predict the extent of any future losses or when we will become profitable, if at all. Even if we do become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amount of our future losses is uncertain and our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline. Our quarterly and annual operating results may fluctuate significantly in the future due to a variety of factors, many of which are outside of our control and may be difficult to predict, including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.28%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the timing and success or failure of clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.28%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to successfully recruit and retain subjects for clinical trials, and any delays caused by difficulties in such efforts; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.28%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to obtain marketing approval for our product candidates, and the timing and scope of any such approvals we may receive; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.28%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the timing and cost of, and level of investment in, research and development activities relating to our product candidates, which may change from time to time; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.28%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the cost of manufacturing our product candidates, which may vary depending on the quantity of production and the terms of our agreements with manufacturers; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.28%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to attract, hire and retain qualified personnel; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.28%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">expenditures that we will or may incur to develop additional product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.28%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the level of demand for our product candidates should they receive approval, which may vary significantly; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.28%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential future therapeutics that compete with our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.28%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the changing and volatile U.S. and global economic environments, including as a result of the COVID-19 pandemic; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.28%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">future accounting pronouncements or changes in our accounting policies. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have no products approved for commercial sale and have not generated any revenue from product sales </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to become profitable depends upon our ability to generate revenue. To date, we have not generated any revenue from our product sales and we do not expect to generate any revenue from the sale of products in the near future. We do not expect to generate significant revenue unless and until we obtain marketing approval of, and begin to sell one or more of our product candidates. Our ability to generate revenue depends on a number of factors, including, but not limited to, our ability to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">successfully complete preclinical studies; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">successfully enroll subjects in, and complete, clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">have our IND applications go into effect for our planned clinical trials or future clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">receive regulatory approvals from applicable regulatory authorities; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">initiate and successfully complete all safety studies required to obtain U.S. and foreign marketing approval for our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">establish commercial manufacturing capabilities or make arrangements with third-party manufacturers for clinical supply and commercial manufacturing; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">obtain and maintain patent and trade secret protection or regulatory exclusivity for our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">launch commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">obtain and maintain acceptance of the product candidates, if and when approved, by patients, the medical community and third-party payors; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">effectively compete with other therapies; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">obtain and maintain healthcare coverage and adequate reimbursement; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">enforce and defend intellectual property rights and claims; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">take temporary precautionary measures to help minimize the risk of COVID-19 to our employees; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">maintain a continued acceptable safety profile of the product candidates following approval. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Raising Additional Capital </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will need to raise substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate some of our product development programs or commercialization efforts. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development of pharmaceutical products is capital-intensive. We initiated a Phase 1 clinical trial of RLY-1971 in patients with advanced solid tumors and a first-in-human clinical trial of RLY-4008 enriched for patients with advanced solid tumors having oncogenic FGFR2 alterations. We are currently advancing most of our product candidates, including RLY-PI3K1047, through preclinical development. We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, initiate clinical trials of, and seek marketing approval for, our product candidates. In addition, depending on the status of regulatory approval or, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. We may also need to raise additional funds sooner if we choose to pursue additional indications and/or geographies for our product candidates or otherwise expand more rapidly than we presently anticipate. Furthermore, we are incurring additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate certain of our research and development programs or future commercialization efforts. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our existing cash and cash equivalents and investments will be sufficient to fund our operations through at least the next 12 months. Our future capital requirements will depend on and could increase significantly as a result of many factors, including: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the impact of any business interruptions to our operations, including the timing and enrollment of patients in our planned clinical trials, or to those of our manufacturers, suppliers, or other vendors, resulting from the COVID-19 pandemic or similar public health crisis; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the scope, progress, results and costs of our current and future clinical trials of RLY-4008 and additional preclinical research of our RLY-PI3K1047 program;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the scope, progress, results and costs of drug discovery, preclinical research and clinical trials for our other product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the number of future product candidates that we pursue and their development requirements; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs, timing and outcome of regulatory review of our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to establish and maintain collaborations on favorable terms, if at all; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the success of any existing or future collaborations that we may enter into with third parties; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration arrangements for product candidates, such as our collaboration with Genentech;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the achievement of milestones or occurrence of other developments that trigger payments under any existing or future collaboration agreements, if any; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under any existing or future collaboration agreements, if any;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs and timing of future commercialization activities, including drug sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval, to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of any collaborator that we may have at such time; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our headcount growth and associated costs as we expand our business operations and our research and development activities; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs of operating as a public company. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identifying potential product candidates and conducting preclinical development testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. Disruptions in the financial markets may make equity and debt financing more difficult to obtain, and may have a material adverse effect on our ability to meet our fundraising needs. We cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities would dilute all of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborators or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product candidate or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of private and public equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, your ownership interest will be diluted, and the terms of those securities may include liquidation or other preferences that materially adversely affect your rights as a common stockholder. Debt financing, if available, would increase our fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to COVID-19 and the Global Economy </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">A pandemic, epidemic, or outbreak of an infectious disease, such as&#160;COVID-19, may materially and adversely affect our business and our financial results and could cause a disruption to the development of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Public health crises such as pandemics or similar outbreaks could adversely impact our business. The current COVID-19 pandemic has spread to most countries across the world, including all 50 states within the United States, including specifically Cambridge, Massachusetts where our primary office and laboratory space is located. The coronavirus pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed quarantines, travel restrictions and other public health safety measures. The extent to which the coronavirus impacts our operations or those of our third-party partners, including our preclinical studies or clinical trial operations, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, new information that will emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. The continued spread of COVID-19 globally could adversely impact our preclinical or clinical trial operations in the United States, including our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography. For example, similar to other biopharmaceutical companies, we may experience delays in initiating IND-enabling studies, protocol deviations, enrolling our clinical trials, or dosing of patients in our clinical trials as well as in activating new trial sites. COVID-19 may also affect employees of third-party CROs located in affected geographies that we rely upon to carry out our clinical trials. In addition, as a result of medical complications associated with SDC and mCPRC, the patient populations that our lead core and other core product candidates target may be particularly susceptible to COVID-19, which may make it more difficult for us to identify patients able to enroll in our current and future clinical trials and may impact the ability of enrolled patients to complete any such trials. Any negative impact COVID-19 has to patient enrollment or treatment or the execution of our product candidates could cause costly delays to clinical trial activities, which could adversely affect our ability to obtain regulatory approval for and to commercialize our product candidates, increase our operating expenses, and have a material adverse effect on our financial results. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, timely enrollment in planned clinical trials is dependent upon clinical trial sites which could be adversely affected by global health matters, such as pandemics. We plan to conduct clinical trials for our product candidates in geographies which are currently being affected by the coronavirus. Some factors from the coronavirus outbreak that will delay or otherwise adversely affect enrollment in the clinical trials of our product candidates, as well as our business generally, include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns, including the attention of physicians serving as our clinical trial investigators, hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our prospective clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">limitations on travel that could interrupt key trial and business activities, such as clinical trial site initiations and monitoring, domestic and international travel by employees, contractors or patients to clinical trial sites, including any government-imposed travel restrictions or quarantines that will impact the ability or willingness of patients, employees or contractors to travel to our clinical trial sites or secure visas or entry permissions, a loss of face-to-face meetings and other interactions with potential partners, any of which could delay or adversely impact the conduct or progress of our prospective clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the potential negative effect on the operations of our third-party manufacturers, suppliers or other collaboration partners; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">interruption in global shipping affecting the transport of clinical trial materials, such as patient samples, investigational drug product and conditioning drugs and other supplies used in our prospective clinical trials; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">business disruptions caused by potential workplace, laboratory and office closures and an increased reliance on employees working from home, disruptions to or delays in ongoing laboratory experiments and operations, staffing shortages, travel limitations or mass transit disruptions, any of which could adversely impact our business operations or delay necessary interactions with local regulators, ethics committees and other important agencies and contractors. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have taken temporary precautionary measures intended to help minimize the risk of the virus to our employees, including temporarily requiring many employees to work remotely, suspending all non-essential travel worldwide for our employees and discouraging employee attendance at industry events and in-person work-related meetings, which could negatively affect our business. We cannot presently predict the scope and severity of the planned and potential shutdowns or disruptions of businesses and government agencies, such as the SEC or FDA. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These and other factors arising from the coronavirus could worsen in countries that are already afflicted with the coronavirus or could continue to spread to additional countries. Any of these factors, and other factors related to any such disruptions that are unforeseen, could have a material adverse effect on our business and our results of operation and financial condition. Further, uncertainty around these and related issues could lead to adverse effects on the economy of the United States and other economies, which could impact our ability to raise the necessary capital needed to develop and commercialize our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, in 2008, the global financial crisis caused extreme volatility and disruptions in the capital and credit markets and the current COVID-19 pandemic has caused significant volatility and uncertainty in U.S. and international markets. See &#8220;<font style="font-style:italic;">&#8212;A pandemic, epidemic, or outbreak of an infectious disease, such as&#160;COVID-19, or coronavirus, may materially and adversely affect our business and our financial results and could cause a disruption to the development of our product candidates.</font>&#8221;<font style="font-style:italic;"> </font>A severe or prolonged economic downturn could result in a variety of risks to our business, including, weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Intellectual Property </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Protecting Our Intellectual Property </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to adequately protect our proprietary technology or obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success will depend in part on our ability to obtain and maintain proprietary or intellectual property protection in the United States and other countries for our product candidates, and our core technologies, including our novel target discovery technology and our proprietary compound library and other know-how. We seek to protect our proprietary and intellectual property position by, among other methods, filing patent applications in the United States and abroad related to our proprietary technology, inventions and improvements that are important to the development and implementation of our business. We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position. See &#8220;Business<font style="font-style:italic;">&#8212;</font>Intellectual Property&#8221; for more information regarding the patent application status for our product candidates. Other than our U.S. patent relating to RLY-1971 composition of matter, we do not own or in-license any issued patents relating to our platform, our SHP2 program, our FGFR2 program, or our PI3K program.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Genentech Agreement, we have granted an exclusive, worldwide, royalty-bearing license to Genentech, with the right to sublicense, develop and commercialize RLY-1971 and any other SHP2 inhibitors developed under the Genentech Agreement. Genentech has the first right, but not the obligation, to file, prosecute and maintain any patents licensed to it, as well as to enforce infringement of or defend claims against such patents that relate to RLY-1971 or other SHP2 inhibitors. See &#8220;Risks Related to Our Reliance on Third Parties<font style="font-style:italic;">&#8212;</font>&#8221; We may enter into collaborations with third parties for the research, development, manufacture and commercialization of one or more of our programs or product candidates. If these collaborations are not successful, our business could be adversely affected.&#8221; for a discussion of risks related to the protection of our intellectual property rights under our collaborations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most of the research and development for our programs has been performed under the DESRES Agreement. Under the DESRES Agreement, D. E. Shaw Research controls the rights to its technology (including its supercomputer and software, each of which are important aspects of our Dynamo platform), we control the rights to certain compounds, and we jointly own with D. E. Shaw Research any other work product created by D. E. Shaw Research and us. Subject to certain limits, we have the right to have the following work product assigned to us: the composition of matter, method of use, and method of manufacture of certain compounds directed to a Category&#160;1 Target, as set forth in the DESRES Agreement. For more information regarding the DESRES Agreement, see &#8220;Business&#8212;Collaboration and License Agreement with D. E. Shaw Research, LLC</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not yet designated all of the compounds for which we will have this right of assignment, and thus, we do not yet know the scope of exclusivity we will enjoy under our patent rights for our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After any work product is assigned to us, we will have the right to prepare, file, prosecute and maintain patents that cover such assigned work product. We also have the implicit right to defend patents that cover work product owned by us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, much of the work product created under our agreement with D. E. Shaw Research has been created by D.&#160;E. Shaw Research and us, together, and is thus co-owned. We have the first right to prepare, file, prosecute, maintain and defend patents that cover work product created by D. E. Shaw Research and us, together. If we choose not to exercise those rights with respect to patents and patent applications that cover joint work product, D. E. Shaw Research will have the right to take over such activities, unless such rights are waived, as is the case for our co-owned SHP2 patent applications. The party that is preparing, filing, prosecuting and maintaining a patent that covers joint work product also has the right to enforce such patent against infringers.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of patent protection we require to successfully commercialize our product candidates may be unavailable or severely limited in some cases and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances that any of our pending patent applications will issue, or that any of our pending patent applications that mature into issued patents will include claims with a scope sufficient to protect RLY-1971, RLY-4008 or our other product candidates. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Furthermore, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally twenty years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned patent portfolio and any patent portfolio we may license in the future may not provide us with adequate and continuing patent protection sufficient to exclude others from commercializing products similar or identical to our product candidates, including generic versions of such products. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We have licensed patent rights, and in the future may license additional patent rights, to or from third parties. For example, we have licensed our patent rights to our SHP2 program to Genentech. These licensed patent rights may be valuable to our business, and we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology or medicines underlying such licenses. We cannot be certain that these patents and applications will be prosecuted and enforced in a manner consistent with the best interests of our business. If any such licensors or licensees fail to maintain such patents, or lose rights to those patents, the rights we have licensed may be reduced or eliminated and our right to develop and commercialize any of our products that are the subject of such licensed rights could be adversely affected.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other parties have developed technologies that may be related or competitive to our own, and such parties may have filed or may file patent applications, or may have received or may receive patents, claiming inventions that may overlap or conflict with those claimed in our own patent applications, with respect to either the same methods or formulations or the same subject matter, in either case that we may rely upon to dominate our patent position in the market. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights cannot be predicted with any certainty. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Further, with respect to most of the pending patent applications covering our product candidates, prosecution has yet to commence. Patent prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the U.S. Patent and Trademark Office, or USPTO, have been significantly narrowed by the time they issue, if at all. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we acquire patent protection that we expect should enable us to maintain such competitive advantage, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. For example, we may be subject to a third-party submission of prior art to the USPTO challenging the priority of an invention claimed within one of our patents, which submissions may also be made prior to a patent&#8217;s issuance, precluding the granting of any of our pending patent applications. We may become involved in opposition, derivation, reexamination, inter parties review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others from whom we have obtained licenses to such rights. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may claim that they invented the inventions claimed in our issued patents or patent applications prior to us, or may file patent applications before we do. Competitors may also claim that we are infringing on their patents and that we therefore cannot practice our technology as claimed under our patents, if issued. Competitors may also contest our patents, if issued, by showing the patent examiner that the invention was not original, was not novel or was obvious. In litigation, a competitor could claim that our patents, if issued, are not valid for a number of reasons. If a court agrees, we would lose our rights to those challenged patents. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may in the future be subject to claims by our former employees or consultants asserting an ownership right in our patents or patent applications, as a result of the work they performed on our behalf. Although we generally require all of our employees, consultants and advisors and any other third parties who have access to our proprietary know-how, information or technology to assign or grant similar rights to their inventions to us, we cannot be certain that we have executed such agreements with all parties who may have contributed to our intellectual property, nor can we be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy. With respect to intellectual property arising in the course of our collaboration with D.&#160;E.&#160;Shaw Research, disagreements between us and D.&#160;E.&#160;Shaw Research may impact our exclusive control of intellectual property important for protecting our product candidates and proprietary position. A loss of exclusivity, in whole or in part, could allow others to compete with us and harm our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An adverse determination in any such submission or proceeding may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, without payment to us, or could limit the duration of the patent protection covering our technology and product candidates. Such challenges may also result in our inability to manufacture or commercialize our product candidates without infringing third party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if they are unchallenged, our owned patent portfolio and any patent portfolio we may license in the future may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. For example, a third party may develop a competitive product that provides benefits similar to one or more of our product candidates but that has a different composition that falls outside the scope of our patent protection. If the patent protection provided by the patents and patent applications we hold or pursue with respect to our product candidates is not sufficiently broad to impede such competition, our ability to successfully commercialize our product candidates could be negatively affected, which would harm our business. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees on issued patents often must be paid to the USPTO and foreign patent agencies over the lifetime of the patent. While an unintentional lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our products or procedures, we may not be able to stop a competitor from marketing products that are the same as or similar to our product candidates, which would have a material adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the protection afforded by patents, we rely upon unpatented trade secret protection, unpatented know-how and continuing technological innovation to develop and maintain our competitive position. With respect to the building of our proprietary compound library, we consider trade secrets and know-how to be our primary intellectual property. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our collaborators, scientific advisors, employees and consultants, and invention assignment agreements with our consultants and employees. We may not be able to prevent the unauthorized disclosure or use of our technical know-how or other trade secrets by the parties to these agreements, however, despite the existence generally of confidentiality agreements and other contractual restrictions. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the collaborators, scientific advisors, employees and consultants who are parties to these agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result. Enforcing a claim that a third party illegally obtained and is using our trade secrets, like patent litigation, is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our trade secrets could otherwise become known or be independently discovered by our competitors. Competitors could purchase our product candidates and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If our trade secrets are not adequately protected so as to protect our market against competitors&#8217; products, our competitive position could be adversely affected, as could our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Intellectual Property Litigation </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and frequent litigation regarding patents and other intellectual property rights. We may in the future become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our product candidates and technology, including interference proceedings before the USPTO. Our competitors or other third parties may assert infringement claims against us, alleging that our products or technologies are covered by their patents. Given the vast number of patents in our field of technology, we cannot be certain that we do not infringe existing patents or that we will not infringe patents that may be granted in the future. Many companies have filed, and continue to file, patent applications related to SHP2 inhibitors, FGFR2 inhibitors, and PI3K inhibitors. Some of these patent applications have already been allowed or issued, and others may issue in the future. Since these areas are competitive and of strong interest to pharmaceutical and biotechnology companies, there will likely be additional patent applications filed and additional patents granted in the future, as well as additional research and development programs expected in the future. Furthermore, because patent applications can take many years to issue and may be confidential for 18 months or more after filing, and because pending patent claims can be revised before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the manufacture, use or sale of our product candidates, or the practice of our technology. If a patent holder believes our product or product candidate infringes on its patent, the patent holder may sue us even if we have received patent protection for our technology. Moreover, we may face patent infringement claims from non-practicing entities that have no relevant product revenue and against whom our owned patent portfolio and any patent portfolio we may license in the future may thus have no deterrent effect. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are found to infringe a third party&#8217;s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our product candidates and technology. We may choose to obtain a license, even in the absence of an action or finding of infringement. In either case, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain such a license, it could be granted on non-exclusive terms, thereby providing our competitors and other third parties access to the same technologies licensed to us. Without such a license, we could be forced, including by court order, to cease developing and commercializing the infringing technology or product candidates. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed such third-party patent rights. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. If we lose a foreign patent lawsuit, alleging our infringement of a competitor&#8217;s patents, we could be prevented from marketing our products in one or more foreign countries, which would have a materially adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We could in the future be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged trade secrets or other proprietary information of former employers or competitors. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may in the future be subject to claims that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and could be a distraction to management. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our product candidates, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. An inability to incorporate such technologies or features would have a material adverse effect on our business, and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may prevent us from successfully commercializing our product candidates. In addition, we may lose valuable intellectual property rights or personnel as a result of such claims. Moreover, any such litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to commercialize our product candidates, which would have an adverse effect on our business, results of operations and financial condition. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming and unsuccessful. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors and other third parties may infringe, misappropriate or otherwise violate our patents and other intellectual property rights. To counter infringement or unauthorized use, we may be required to file infringement claims. A court may disagree with our allegations, however, and may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the third-party technology in question. Further, such third parties could counterclaim that we infringe their intellectual property or that a patent we have asserted against them is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims challenging the validity, enforceability or scope of asserted patents are commonplace. In addition, third parties may initiate legal proceedings against us to assert such challenges to our intellectual property rights. The outcome of any such proceeding is generally unpredictable. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Patents may be unenforceable if someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. It is possible that prior art of which we and the patent examiner were unaware during prosecution exists, which could render any patents that may issue invalid. Moreover, it is also possible that prior art may exist that we are aware of but do not believe is relevant to our future patents, should they issue, but that could nevertheless be determined to render our patents invalid. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. If a defendant were to prevail on a legal assertion of invalidity or unenforceability of our patents covering one of our product candidates, we would lose at least part, and perhaps all, of the patent protection covering such product candidate. Competing products may also be sold in other countries in which our patent coverage might not exist or be as strong. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming and is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Enforcement of Our Intellectual Property Rights </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be able to effectively enforce our intellectual property rights throughout the world. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive. The requirements for patentability may differ in certain countries, particularly in developing countries. Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. Additionally, the patent laws of some foreign countries do not afford intellectual property protection to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property rights. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, if our ability to enforce our patents to stop infringing activities is inadequate. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and resources from other aspects of our business. Furthermore, while we intend to protect our intellectual property rights in the major markets for our product candidates, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and prospects could be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Third Party Intellectual Property </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A third party may hold intellectual property, including patent rights, that are important or necessary to the development of our products. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially. Although we believe that licenses to these patents are available from these third parties on commercially reasonable terms, if we were not able to obtain a license, or were not able to obtain a license on commercially reasonable terms, our business could be harmed, possibly materially. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to comply with our obligations in the agreements under which we collaborate with or license intellectual property rights from third parties, or otherwise experience disruptions to our business relationships with our collaborators or licensors, we could lose rights that are important to our business. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our future license agreements will impose, various development, diligence, commercialization, and other obligations on us in order to maintain the licenses. In spite of our efforts, a future licensor might conclude that we have materially breached our obligations under such license agreements and seek to terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patent rights licensed thereunder fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization of certain of our product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the scope of rights granted under the license agreement and other interpretation-related issues; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the sublicensing of patent and other rights under our collaborative development relationships; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the priority of invention of patented technology. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreements under which we may license intellectual property or technology from third parties may be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These and similar issues may arise with respect to our collaboration agreements, such as our DESRES Agreement. Our collaboration with D. E. Shaw Research is our key computational collaboration, and there can be no assurance that this collaboration will continue past the current term of the DESRES Agreement, on favorable terms or at all, or that at any time while the collaboration is in effect D. E. Shaw Research will provide any particular level of services or that the parties will operate under the agreement without disputes. These disputes may involve ownership or control of intellectual property rights, exclusivity obligations, diligence and payment obligations, for example. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The DESRES Agreement imposes certain exclusivity obligations on us during the term of the agreement with respect to Category 2 targets, and certain exclusivity obligations on D. E. Shaw Research during and after the term of the agreement. While we have some degree of control over how we designate various targets under the DESRES Agreement, D. E. Shaw Research has some degree of control over such designations as well, and our exclusivity obligations limit or delay our ability to conduct research on selected targets with third parties. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the DESRES Agreement, D. E. Shaw Research controls the rights to its technology, we control the rights to certain compounds, and we jointly own with D. E. Shaw Research any other work product created by D.&#160;E.&#160;Shaw Research and us. Any work product we jointly own with D.&#160;E.&#160;Shaw Research and any other information that we or D. E. Shaw Research share is subject to a non-exclusive cross-license between us and D.&#160;E.&#160;Shaw Research, subject to certain exceptions. In some instances, D. E. Shaw Research is required to assign to us some of the work product </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">created by D. E. Shaw Research. Disputes may arise between us and D.&#160;E.&#160;Shaw Research, as well as any future potential collaborators, regarding intellectual property subject to the DESRES Agreement. If disputes over intellectual property that we co-own or we own individually prevent or impair our ability to maintain our current collaboration arrangements on acceptable terms, or undermine our ability to successfully control the intellectual property necessary to protect our product candidates, we may be unable to successfully develop and commercialize the affected product candidates. Uncertainties or disagreements around our rights under any such intellectual property may undermine our ability to partner our programs with third parties. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the DESRES Agreement is complex and certain provisions may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could be adverse to us, for example by narrowing what we believe to be the scope of our rights to certain intellectual property, or increasing what we believe to be our financial or other obligations under the DESRES Agreement, and any such outcome could have a material adverse effect on our business, financial condition, results of operations, and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Intellectual Property Laws </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes to the patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Recent patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act, or Leahy-Smith Act, signed into law on September&#160;16, 2011, could increase those uncertainties and costs. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. In addition, the Leahy-Smith Act has transformed the U.S. patent system into a &#8220;first to file&#8221; system. The first-to-file provisions, however, only became effective on March&#160;16, 2013. Accordingly, it is not yet clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could make it more difficult to obtain patent protection for our inventions and increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could harm our business, results of operations and financial condition. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Additionally, there have been recent proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact our ability to obtain patent protection for our proprietary technology or our ability to enforce rights in our proprietary technology. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce any patents that we may obtain in the future. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intellectual property rights do not necessarily address all potential threats. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">others may be able to make products that are similar to our product candidates or utilize similar technology but that are not covered by the claims of the patents that we license or may own; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we or our licensors or collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or own now or in the future; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we or our licensors or collaborators, might not have been the first to file patent applications covering certain of our or their inventions; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">it is possible that our present or future pending patent applications (whether owned or licensed) will not lead to issued patents; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may not develop additional proprietary technologies that are patentable; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the patents of others may harm our business; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Government Regulation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Regulatory Approval </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to post-market study requirements, marketing and labeling restrictions, and even recall or market withdrawal if unanticipated safety issues are discovered following approval. In addition, we may be subject to penalties or other enforcement action if we fail to comply with regulatory requirements. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and listing, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing studies, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">clinical trial holds </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">fines, warning letters or other regulatory enforcement action; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">product seizure or detention, or refusal to permit the import or export of products; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">injunctions or the imposition of civil or criminal penalties. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA&#8217;s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about approved prescription drug products. In particular, while the FDA permits the dissemination of truthful and non-misleading information about an approved product, a manufacturer may not promote a product for uses that are not approved by the FDA. If we are found to have promoted such off-label uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of regulated products for off-label uses and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees, corporate integrity agreements or permanent injunctions under which specified promotional conduct must be changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">European data collection is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event we decide to conduct clinical trials or continue to enroll subjects in our ongoing or future clinical trials, we may be subject to additional privacy restrictions. The collection, use, storage, disclosure, transfer, or other processing of personal data regarding individuals in the EU, including personal health data, is subject to the EU General Data Protection Regulation, or GDPR. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. Compliance with the GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional nonclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In short, the foreign regulatory approval process involves all of the risks associated with FDA approval. In many jurisdictions outside the United States, a product candidate must be approved for </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we may intend to charge for our products will also be subject to approval. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to successfully validate, develop and obtain regulatory approval for companion diagnostic tests for our product candidates that require or would commercially benefit from such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the clinical development of our product candidates for certain indications, we may engage third parties to develop or obtain access to <font style="font-style:italic;">in vitro</font> companion diagnostic tests to identify patient subsets within a disease category who may derive selective and meaningful benefit from our product candidates. Further, the FDA has indicated that if we continue RLY-4008 in a specific biomarker-defined population, a companion diagnostic device will be required to ensure its safe and effective use. Such companion diagnostics would be used during our clinical trials as well as in connection with the commercialization of our product candidates. To be successful, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. The FDA and comparable foreign regulatory authorities regulate <font style="font-style:italic;">in vitro</font> companion diagnostics as medical devices and, under that regulatory framework, will likely require the conduct of clinical trials to demonstrate the safety and effectiveness of any diagnostics we may develop, which we expect will require separate regulatory clearance or approval prior to commercialization. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to rely on third parties for the design, development and manufacture of companion diagnostic tests for our therapeutic product candidates that may require such tests. If we enter into such collaborative agreements, we will be dependent on the sustained cooperation and effort of our future collaborators in developing and obtaining approval for these companion diagnostics. It may be necessary to resolve issues such as selectivity/specificity, analytical validation, reproducibility, or clinical validation of companion diagnostics during the development and regulatory approval processes. Moreover, even if data from preclinical studies and early clinical trials appear to support development of a companion diagnostic for a product candidate, data generated in later clinical trials may fail to support the analytical and clinical validation of the companion diagnostic. We and our future collaborators may encounter difficulties in developing, obtaining regulatory approval for, manufacturing and commercializing companion diagnostics similar to those we face with respect to our therapeutic candidates themselves, including issues with achieving regulatory clearance or approval, production of sufficient quantities at commercial scale and with appropriate quality standards, and in gaining market acceptance. If we are unable to successfully develop companion diagnostics for these therapeutic product candidates, or experience delays in doing so, the development of these therapeutic product candidates may be adversely affected, these therapeutic product candidates may not obtain marketing approval, and we may not realize the full commercial potential of any of these therapeutics that obtain marketing approval. As a result, our business, results of operations and financial condition could be materially harmed. In addition, a diagnostic company with whom we contract may decide to discontinue selling or manufacturing the companion diagnostic test that we anticipate using in connection with development and commercialization of our product candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our therapeutic candidates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Anti-bribery, Anti-corruption and Other Government Regulations </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain products outside of the United States and require us to develop and implement costly compliance programs. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, which are collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase in time. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals and we can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm and diminished profits and future earnings. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we do not currently have any products on the market, once we begin commercializing our product candidates, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal government and the states and foreign governments in which we conduct our business. Healthcare providers, physicians and third-party payors play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our product candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">violate it in order to have committed a violation</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act or federal civil money penalties. On November 20, 2020, the Office of Inspector General, or OIG, finalized further modifications to the federal Anti-Kickback Statute. Under the final rules, OIG added safe harbor protections under the Anti-Kickback Statute for certain coordinated care and value-based arrangements among clinicians, providers, and others. These rule</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (with exceptions) became effective January 19, 2021. We continue to evaluate what effect, if any, these rules will have on our business;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the federal civil and criminal false claims and civil monetary penalties laws, including the federal False Claims Act, or FCA, imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government.<font style="font-size:12pt;"> </font>Manufacturers can be held liable under the federal False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The federal False Claims Act also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the federal False Claims Act and to share in any monetary recovery. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false of fraudulent claim for purposes of the False Claims Act; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the federal physician payment transparency requirements, sometimes referred to as the &#8220;Sunshine Act&#8221; under the Affordable Care Act, require manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report to the Department of Health and Human Services information related to transfers of value made to physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests of such physicians and their immediate family members. Effective January&#160;1, 2022, these reporting obligations will extend to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and its implementing regulations, impose obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">analogous state laws and regulations, such as state anti-kickback and false claims laws may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures. Further, many state laws governing the privacy and security of health information in certain circumstances, differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations, including anticipated activities to be conducted by our sales team, were to be found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Regulatory Review of Certain Drug Development Designations</font> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may seek priority review designation for one or more of our other product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster regulatory review or approval process. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA determines that a product candidate offers a treatment for a serious condition and, if approved, the product would provide a significant improvement in safety or effectiveness, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months. We may request priority review for our product candidates. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily result in an expedited regulatory review or approval process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or at all. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may seek orphan drug designation for certain of our product candidates, and we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of our business strategy, we may seek orphan drug designation for certain of our product candidates, and we may be unsuccessful. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population of 200,000 or more in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similarly, in Europe, the European Commission, upon the recommendation of the EMA&#8217;s Committee for Orphan Medicinal Products, grants orphan drug designation to promote the development of drugs that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than 5 in 10,000 persons in Europe and for which no satisfactory method of diagnosis, prevention, or treatment has been authorized (or the product would be a significant benefit to those affected). Additionally, designation is granted for drugs intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in Europe would be sufficient to justify the necessary investment in developing the drug. In Europe, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, if a drug with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same drug and indication for that time period, except in limited circumstances. The applicable period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain orphan drug exclusivity for a drug, that exclusivity may not effectively protect the drug from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition or if another drug with the same active moiety is determined to be safer, more effective, or represents a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. While we may seek orphan drug designation for our product candidates, we may never receive such designations. Even if we do receive such designations, there is no guarantee that we will enjoy the benefits of those designations. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Breakthrough therapy designation and fast track designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development, regulatory review or approval process, and each designation does not increase the likelihood that any of our product candidates will receive marketing approval in the United States. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek a breakthrough therapy designation for some of our product candidates. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that such product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek fast track designation for some of our product candidates. If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for fast track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive fast track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accelerated approval by the FDA, even if granted for our FGFR2 program or our PI3K program or any other future product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek accelerated approval of our FGFR2 program or our PI3K program and for future product candidates. A product may be eligible for accelerated approval if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug or biologic receiving </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">accelerated approval perform adequate and well-controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. Even if we do receive accelerated approval, we may not experience a faster development or regulatory review or approval process, and receiving accelerated approval does not provide assurance of ultimate FDA approval. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Healthcare Legislative Reform </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The FDA, the EMA and other regulatory authorities may implement additional regulations or restrictions on the development and commercialization of our product candidates, and such changes can be difficult to predict. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA, the EMA and regulatory authorities in other countries have each expressed interest in further regulating biotechnology products. Agencies at both the federal and state level in the United States, as well as the U.S. Congressional committees and other governments or governing agencies, have also expressed interest in further regulating the biotechnology industry. Such action may delay or prevent commercialization of some or all of our product candidates. Adverse developments in clinical trials of products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of any of our product candidates. These regulatory review agencies and committees and the new requirements or guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies or trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory agencies and comply with applicable requirements and guidelines. If we fail to do so, we may be required to delay or discontinue development of such product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Delays as a result of an increased or lengthier regulatory approval process or further restrictions on the development of our product candidates can be costly and could negatively impact our ability to complete clinical trials and commercialize our current and future product candidates in a timely manner, if at all. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our current or future product candidates or any future product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell a product for which we obtain marketing approval. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i)&#160;changes to our manufacturing arrangements, (ii)&#160;additions or modifications to product labeling, (iii)&#160;the recall or discontinuation of our products or (iv)&#160;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Affordable Care Act, or the ACA, was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the United States pharmaceutical industry. The ACA, among other things, subjects biological products to potential competition by lower-cost biosimilars, addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations, establishes annual fees and taxes on manufacturers of certain branded prescription drugs, and creates a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, effective as of 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D. Since then, the ACA risk adjustment program payment parameters have been updated annually.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, various portions of the ACA are currently undergoing legal and constitutional challenges in the United States Supreme Court. Additionally, the previous Administration issued various Executive Orders which </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eliminated cost sharing subsidies and various provisions that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices and Congress has introduced several pieces of legislation aimed at significantly revising or repealing the ACA. In December 2018, the Centers for Medicare &amp; Medicaid Services, or CMS, published a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of the federal district court litigation regarding the method CMS uses to determine this risk adjustment. Since then, the ACA risk adjustment program payment parameters have been updated annually. It is unclear whether the ACA will be overturned, repealed, replaced, or further amended. We cannot predict what affect further changes to the ACA would have on our business, especially given the new administration. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, on January&#160;22, 2018, a continuing resolution on appropriations for fiscal year 2018 was approved that delayed the implementation of certain ACA-mandated fees, including the so called &#8220;Cadillac&#8221; tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices; however on December&#160;20, 2019, the Further Consolidated Appropriations Act (H.R. 1865) was signed into law, which repeals the Cadillac tax, the health insurance provider tax, and the medical device excise tax. It is impossible to determine whether similar taxes could be instated in the future. The Bipartisan Budget Act of 2018, also amended the ACA, effective January&#160;1, 2019, by increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and closing the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; CMS published a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. In addition, CMS has recently published a final rule that would give states greater flexibility, starting in 2020, in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, and, due to subsequent legislative amendments, will remain in effect through 2030 unless additional Congressional action is taken; however, pursuant to the CARES Act and subsequent legislation, these reductions have been suspended from May 1, 2020 through March 31, 2021 due to the COVID-19 pandemic. The American Taxpayer Relief Act of 2012 among other things, reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the previous administration&#8217;s budget proposal for fiscal year 2021 includes a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March 10, 2020, the previous administration sent &#8220;principles&#8221; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. Additionally, the previous administration also released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of product candidates paid by consumers. The U.S. Department of Health and Human Services, or HHS, has already started the process of soliciting feedback on some of these measures and, at the same time, is immediately implementing others under its existing authority. For example, in May 2019, CMS issued a final rule to allow </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare Advantage Plans the option of using step therapy, a type of prior authorization, for Part B drugs beginning January 1, 2020. This final rule codified CMS&#8217;s policy change that was effective January 1, 2019. It is unclear whether the current administration will challenge, reverse, revoke or otherwise modify these executive and administrative actions after January 20, 2021.&nbsp;&nbsp;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there have been several changes to the 340B drug pricing program, which imposes ceilings on prices that drug manufacturers can charge for medications sold to certain health care facilities. On December 27, 2018, the District Court for the District of Columbia invalidated a reimbursement formula change under the 340B drug pricing program, and CMS subsequently altered the FYs 2019 and 2018 reimbursement formula on specified covered outpatient drugs, or SCODs. The court ruled this change was not an &#8220;adjustment&#8221; which was within the Secretary&#8217;s discretion to make but was instead a fundamental change in the reimbursement calculation. However, most recently, on July 31, 2020, the U.S. Court of Appeals for the District of Columbia Circuit overturned the district court&#8217;s decision and found that the changes were within the Secretary&#8217;s authority. On September 14, 2020, the plaintiffs-appellees filed a Petition for Rehearing En Banc (i.e., before the full court), but was denied on October 16, 2020. It is unclear how these developments could affect covered hospitals who might purchase our future products and affect the rates we may charge such facilities for our approved products in the future, if any.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 24, 2020 and September 13, 2020, the previous administration announced several executive orders related to prescription drug pricing that sought to implement several of the administration's proposals. In response, the FDA released a final rule on September 24, 2020, which went into effect on November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada, as further discussed below. Further, on November 20, 2020 CMS issued an Interim Final Rule implementing the Most Favored Nation, or MFN, Model under which Medicare Part B reimbursement rates will be calculated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for Economic Cooperation and Development countries with a similar gross domestic product per capita. The MFN Model regulations mandate participation by identified Part B providers and will apply in all U.S. states and territories for a seven-year period beginning January 1, 2021, and ending December 31, 2027. The Interim Final Rule has not been finalized and is subject to revision and challenge. Additionally, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Implementation of November 20, 2020 final Rule will be delayed until at least January 1, 2023. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the current administration may reverse or otherwise change these measures, Congress has indicated that it will continue to seek new legislative measures to control drug costs.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, on May 30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new product candidates that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its product candidates available to eligible patients as a result of the Right to Try Act.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our current or future product candidates or additional pricing pressures. In </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">particular any policy changes through CMS as well as local state Medicaid programs could have a significant impact on our business in light of the higher proportion of SCD patients that utilize Medicare and Medicaid programs to pay for treatments. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenue prospects could be affected by changes in healthcare spending and policy in the United States and abroad. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could negatively impact our business, operations and financial condition. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future, including repeal, replacement or significant revisions to the ACA. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the demand for our current or future product candidates, if we obtain regulatory approval; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to set a price that we believe is fair for our products; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to obtain coverage and reimbursement approval for a product; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to generate revenue and achieve or maintain profitability; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the level of taxes that we are required to pay; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the availability of capital. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent federal legislation and actions by federal, state and local governments may permit reimportation of drugs from foreign countries into the United States, including foreign countries where the drugs are sold at lower prices than in the United States, which could materially adversely affect our operating results. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may face competition in the United States for our development candidates and investigational medicines, if approved, from therapies sourced from foreign countries that have placed price controls on pharmaceutical products. In the United States, the Medicare Modernization Act, or MMA, contains provisions that call for the promulgation of regulations that expand pharmacists&#8217; and wholesalers&#8217; ability to import cheaper versions of an approved drug and competing products from Canada, where there are government price controls. Further, the MMA provides that these changes to U.S. importation laws will not take effect,&#160;unless and until the Secretary of the HHS certifies that the changes will pose no additional risk to the public&#8217;s health and safety and will result in a significant reduction in the cost of products to consumers. On September&#160;23, 2020, the Secretary of the HHS made such certification to Congress, and on October&#160;1, 2020, FDA published a final rule that allows for the importation of certain prescription drugs from Canada. Under the final rule, States and Indian Tribes, and in certain future circumstances pharmacists and wholesalers, may submit importation program proposals to the FDA for review and authorization. On September&#160;25, 2020, CMS stated drugs imported by States under this rule will not be eligible for federal rebates under Section&#160;1927 of the Social Security Act and manufacturers would not report these drugs for &#8220;best price&#8221; or Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. Separately, the FDA also issued a final guidance document outlining a pathway for manufacturers to obtain an additional National Drug Code, or NDC, for an FDA-approved drug that was originally intended to be marketed in a foreign country and that was authorized for sale in that foreign country. The market implications of the final rule and guidance are unknown at this time. Proponents of drug reimportation may attempt to pass legislation that would directly allow reimportation under certain circumstances. Legislation or regulations allowing the reimportation of drugs, if enacted, could decrease the price we receive for any products that we may develop and adversely affect our future revenues and prospects for profitability. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to the Regulatory Agency Review Process </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Disruptions at the FDA, the SEC and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, global health concerns, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical government employees and stop critical activities. Separately, in response to the COVID-19 pandemic since March 2020, foreign and domestic inspections by the FDA have largely been on hold with FDA announcing plans in July 2020 to resume prioritized domestic inspections. The FDA has developed a rating system to assist in determining when and where it is safest to conduct prioritized domestic inspections. Should the FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, the FDA has stated that it generally intends to issue a complete response letter. Further, if there is inadequate information to make a determination on the acceptability of a facility, the FDA may defer action on the application until an inspection can be completed. In 2020, several companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. Additionally, as of June 23, 2020, the FDA noted it is continuing to ensure timely reviews of applications for medical products during the COVID-19 pandemic in line with its user fee performance goals. On July 16, 2020, the FDA noted that it is continuing to expedite oncology product development with its staff teleworking full-time. However, the FDA may not be able to continue its current pace and approval timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required and due to the COVID-19 pandemic and travel restrictions, the FDA is unable to complete such required inspections during the review period. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Employee Matters and Managing Growth </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Employee Matters </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our future success depends on our ability to retain key executives and experienced scientists and to attract, retain and motivate qualified personnel. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are highly dependent on the research and development, clinical and business development expertise of the principal members of our management, scientific and clinical team. Although we have entered into employment letter agreements with our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. The loss of the services of our executive officers or other key employees, including temporary loss due to illness, could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. Failure to succeed in clinical trials may make it more challenging to recruit and retain qualified scientific personnel. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In particular, we have experienced a very competitive hiring environment in Cambridge, Massachusetts, where we are headquartered. Many of the other pharmaceutical companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success with which we can discover and develop product candidates and our business will be limited. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk that our employees, principal investigators, CROs and consultants may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate the regulations of the FDA and other regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities; healthcare fraud and abuse laws and regulations in the United States and abroad; or laws that require the reporting of financial information or data accurately. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Growth </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 28, 2021, we had 159 full-time employees. We expect to experience significant growth in the number of our employees and the scope of our operations, particularly as we function as a public company and in the areas of product development, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may acquire additional businesses or products, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the transaction.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Business Disruptions </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our or related parties&#8217; cyber security. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given our limited operating history, we are still in the process of implementing our internal security measures. Our internal computer systems and those of current and future third parties on which we rely may fail and are vulnerable to damage from computer viruses and unauthorized access. Our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection to the Internet, face the risk of systemic failure that could disrupt our operations. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of our product candidate or any future product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidate or any future product candidates could be hindered or delayed. In addition, in response to the ongoing COVID-19 pandemic, part of our workforce is currently working remotely. This could increase our cyber security risk, create data accessibility concerns, and make us more susceptible to communication disruptions. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our current operations are located in Massachusetts; and we or the third parties upon whom we depend may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current operations are located in Massachusetts. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, including any potential effects from the current global spread of&#160;COVID-19, power shortage, telecommunication failure or other natural or man-made accidents or incidents that result in us being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our product candidates or interruption of our business operations. Natural disasters or pandemics such as the&#160;COVID-19&#160;outbreak could further disrupt our operations and have a material and adverse effect on our business, financial condition, results of operations and prospects. For example, we have instituted a temporary work from home policy for non-essential office personnel and it is possible that this could have a negative impact on the execution of our business plans and operations. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure our investors that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities or the manufacturing facilities of our third-party contract manufacturers are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material and adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Common Stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Our Status as an &#8220;Emerging Growth Company&#8221; and &#8220;Smaller Reporting Company&#8221; </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act and a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act, and may avail ourselves of reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies, which could make our common stock less attractive to investors and adversely affect the market price of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We will remain an emerging growth company until the earlier of (i)&#160;the last day of the fiscal year in which we have total annual gross revenues of $1.07&#160;billion or more; (ii)&#160;the last day of the fiscal year following the fifth anniversary of the date of our IPO; (iii)&#160;the date on which we have issued more than $1&#160;billion in nonconvertible debt during the previous three years; or (iv)&#160;the date on which we are deemed to be a large accelerated filer under the rules of the SEC, which means the market value of our common stock that is held by non-affiliates exceeds $700&#160;million as of the prior June 30th. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, or Section&#160;404; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">providing only two years of audited financial statements in addition to any required unaudited interim financial statements and a correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reduced disclosure obligations regarding executive compensation; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may choose to take advantage of some, but not all, of the available exemptions. We have taken advantage of reduced reporting burdens. In particular, we have provided only two years of audited financial statements and have not included all of the executive compensation information that would be required if we were not an emerging growth company. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period for new or revised accounting standards during the period in which we remain an emerging growth company; however, we may adopt certain new or revised accounting standards early. Changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our financial position and results of operations. In addition, our independent registered public accounting firm will not be required to provide an attestation report on the effectiveness of our internal control over financial reporting so long as we qualify as an &#8220;emerging growth company,&#8221; which may increase the risk that material weaknesses or significant deficiencies in our internal control over financial reporting go undetected. Likewise, so long as we qualify as a &#8220;smaller reporting company&#8221; or an &#8220;emerging growth company,&#8221; we may elect not to provide you with certain information, including certain financial information and certain information regarding compensation of our executive officers, that we would otherwise have been required to provide in filings we make with the SEC, which may make it more difficult for investors and securities analysts to evaluate our company. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies until the fiscal year following the determination that our voting and non-voting common stock held by non-affiliates is more than $250&#160;million measured on the last business day of our second fiscal quarter, or our annual revenues are more than $100&#160;million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is more than $700&#160;million measured on the last business day of our second fiscal quarter. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our stock price may be more volatile and may decline. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Volatility in the Price of Our Common Stock </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The trading price of our common stock is likely to be highly volatile. Securities class action or other litigation involving our company or members of our management team could also substantially harm our business, financial condition and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our stock price is likely to be volatile. The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the success of competitive products or technologies; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">results of clinical trials of our product candidates or those of our competitors; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">regulatory or legal developments in the United States and other countries; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">developments or disputes concerning patent applications, issued patents or other proprietary rights; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the recruitment or departure of key personnel; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the level of expenses related to any of our product candidates or clinical development programs; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the results of our efforts to discover, develop, acquire or in-license additional product candidates or products; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">variations in our financial results or those of companies that are perceived to be similar to us; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">changes in the structure of healthcare payment systems; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">market conditions in the pharmaceutical and biotechnology sectors; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">general economic, industry and market conditions; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the other factors described in this &#8220;Risk Factors&#8221; section. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The market price of our common stock may be volatile. The stock market in general, and Nasdaq and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Insider Control </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our executive officers, directors, principal stockholders and their affiliates exercise significant control over our company, which will limit your ability to influence corporate matters and could delay or prevent a change in corporate control. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 15, 2021, the holdings of our executive officers, directors, principal stockholders and their affiliates, including entities affiliated with SoftBank Vision Fund, Third Rock Ventures and FMR LLC represented beneficial ownership, in the aggregate, of approximately 49.6% of our outstanding common stock. As a result, these stockholders, if they act together, will be able to influence our management and affairs and control the outcome of matters submitted to our stockholders for approval, including the election of directors and any sale, merger, consolidation, or sale of all or substantially all of our assets. These stockholders may have interests, with respect to their common stock, that are different from those of our public market investors and the concentration of voting power among these stockholders may have an adverse effect on the price of our common stock. In addition, this concentration of ownership might adversely affect the market price of our common stock by: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delaying, deferring or preventing a change of control of us; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">impeding a merger, consolidation, takeover or other business combination involving us; or </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Tax </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Section&#160;382 of the Internal Revenue Code of 1986, as amended, or the IRC, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50% change (by value) in the ownership of its equity over a three year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and certain other pre-change tax attributes to offset its post-change income may be limited. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As of December&#160;31, 2020, we had federal net operating loss carryforwards of approximately $174.0&#160;million, and our ability to utilize those net operating loss carryforwards could be limited by an &#8220;ownership change&#8221; as described above.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive tax reform legislation could adversely affect our business and financial condition. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service, or IRS, and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many changes have been made and changes are likely to continue to occur in the future. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, the Tax Cuts and Jobs Act, or Tax Act, was enacted in 2017 and made significant changes to corporate taxation, including the reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, the limitation of the tax deduction for net interest expense to 30% of adjusted taxable income (except for certain small businesses), the limitation of the deduction for net operating losses from taxable years beginning after December 31, 2017 to 80% of current year taxable income and the elimination of net operating loss carrybacks generated in taxable years ending after December 31, 2017 (though any such net operating losses may be carried forward indefinitely), and the modification or repeal of many business deductions and credits. In addition, on March 27, 2020, President Trump signed into law the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, which, among other things, suspends the 80% limitation on the deduction for net operating losses in taxable years beginning before January 1, 2021, permits a 5-year carryback of net operating losses arising in taxable years beginning after December 31, 2017 and before January 1, 2021, and generally caps the limitation on the deduction for net interest expense at 50% of adjusted taxable income for taxable years beginning in 2019 and 2020. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It cannot be predicted whether, when, in what form, or with what effective dates, new tax laws may be enacted, or regulations and rulings may be enacted, promulgated or issued under existing or new tax laws, which could result in an increase in our or our stockholders&#8217; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law or in the interpretation thereof.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Dividends </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Operating as a Public Company </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company, and particularly after we are no longer an &#8220;emerging growth company,&#8221; we will incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;404, we will be required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&#160;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section&#160;404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. In addition, if we are not able to continue to meet these requirements, we may not be able to remain listed on Nasdaq. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Our Charter and Bylaws </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our fourth amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a requirement that special meetings of the stockholders may be called only by the board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office, and special meetings of stockholders may not be called by any other person or persons; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">advance notice requirements for stockholder proposals and nominations for election to our board of directors; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds (2/3) of all outstanding shares of our voting stock then entitled to vote in the election of directors; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a requirement of approval of not less than a majority of all outstanding shares of our voting stock to amend any bylaws by stockholder action and not less than two-thirds (2/3) of all outstanding shares of our voting stock to amend specific provisions of our fourth amended and restated certificate of incorporation; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval, which preferred stock may include rights superior to the rights of the holders of common stock. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our fourth amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our amended and restated bylaws designate specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to our amended and restated bylaws, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for any state law claims for (1)&#160;any derivative action or proceeding brought on our behalf; (2)&#160;any action asserting a claim of or based on a breach of a fiduciary duty owed by any director, officer or other employee of ours to us or our stockholders; (3)&#160;any action asserting a claim pursuant to any provision of the Delaware General Corporation Law, our fourth amended and restated certificate of incorporation or our amended and restated bylaws; or (4)&#160;any action asserting a claim governed by the internal affairs doctrine, or the Delaware Forum Provision. The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our amended and restated bylaws further provide that unless we consent in writing to the selection of an alternative forum, the United States District Court for the District of Massachusetts shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or the Federal Forum Provision. In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to the Delaware Forum Provision and the Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize that the Delaware Forum Provision and the Federal Forum Provision in our amended and restated bylaws may impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or the Commonwealth of Massachusetts. Additionally, the forum selection clauses in our amended and restated bylaws may limit our stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of lawsuits against us and our directors, officers and employees, even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the United States District Court for the District of Massachusetts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risks Related to Market Analysts </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock will rely in part on the research and reports that industry or financial analysts publish about us or our business. If one or more of the analysts covering our stock downgrade their evaluations of our stock or publishes inaccurate or unfavorable research about our business, the trading price of our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stock may decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline. </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a>Item 1B. Unresolved Staff Comments. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2_PROPERTIES"></a><a name="ITEM_2_PROPERTIES"></a>Item 2. Properties. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our corporate headquarters is located in Cambridge, Massachusetts, where we lease and occupy approximately 46,631 square feet of office and laboratory space. The current term of our Cambridge lease expires April 30, 2029, with an option to extend the term five additional years with 12 &#8211; 15 months&#8217; notice at agreed upon market rate. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our existing facilities are sufficient for our needs for the foreseeable future. To meet the future needs of our business, we may lease additional or alternate space, and we believe suitable additional or alternative space will be available in the future on commercially reasonable terms. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_3_LEGAL_PROCEEDINGS"></a><a name="ITEM_3_LEGAL_PROCEEDINGS"></a>Item 3. Legal Proceedings. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a>Item 4. Mine Safety Disclosures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Part_II"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART II</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a>Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Certain Information Regarding the Trading of Our Common Stock</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock trades under the symbol &#8220;RLAY&#8221; on the NASDAQ Global Market and has been publicly traded since July 16, 2020. Prior to this time, there was no public market for our common stock.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holders of Our Common Stock</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 26, 2021, there were approximately 61 holders of record of shares of our common stock. This number does not include stockholders for whom shares are held in &#8220;nominee&#8221; or &#8220;street&#8221; name.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dividends</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any dividends on our common stock in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities Authorized for Issuance Under Equity Compensation Plans</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information about our equity compensation plans will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unregistered Sales of Equity Securities and Use of Proceeds</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk65142832"></a>Set forth below is information regarding stock options granted by us and exercised during the period covered by this Annual Report on Form 10-K that were not registered under the Securities Act of 1933, as amended, or the Securities Act. Included is the consideration, if any, we received for such shares and options and information relating to the section of the Securities Act under which exemption from registration was claimed.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk65138170"></a><a name="_Hlk65137843"></a>From January 1, 2020 to the closing of our IPO on July 20, 2020, we granted options to purchase an aggregate of 2,492,458 shares of common stock, with exercise prices ranging from $5.22 to $14.06 per share, to directors, employees and consultants pursuant to our 2016 Stock Option and Grant Plan, as amended, or the 2016 Plan. During such period, 280,548 shares of common stock were issued for gross proceeds of $1.1 million upon the exercise of stock options pursuant to the 2016 Plan.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No underwriters were involved in the foregoing issuances of securities. The issuances of the securities described above were deemed to be exempt from registration pursuant to Section 4(a)(2) of the Securities Act as transactions by an issuer not involving a public offering or Rule 701 promulgated under the Securities Act as transactions pursuant to compensatory benefit plans. All recipients either received adequate information about us or had access, through employment or other relationships, to such information.&nbsp;&nbsp;On July 17, 2020, we filed a registration statement on Form S-8 under the Securities Act to register all of the shares of our common stock subject to outstanding options and all shares of our common stock otherwise issuable pursuant to our equity compensation plans.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Sales of Unregistered Equity Securities</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not purchase any of our registered equity securities during the period covered by this Annual Report on Form 10-K.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_6"></a>Item 6. <a name="ITEM_6"></a>Reserved</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a>Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes included elsewhere in this Annual Report on Form&#160;10-K.&#160;This discussion and other parts of this Annual Report on Form&#160;10-K&#160;contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Annual Report on Form&#160;10-K,&#160;our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage, precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Our company is built upon unparalleled insights into protein motion and how this dynamic behavior relates to protein function. We built our Dynamo platform to integrate an array of leading edge experimental and computational approaches, which allows us to apply our understanding of protein structure and motion to drug discovery. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are advancing a pipeline of medicines to address targets in precision oncology, including our lead product candidates, RLY-1971 and RLY-4008, as well as our PI3K&#945; mutant selective program, or the RLY-PI3K1047 program. We initiated a Phase 1 clinical trial for RLY-1971, our inhibitor of Src homology region 2 domain-containing phosphatase-2, or SHP2, in patients with advanced solid tumors in the first quarter of 2020. In December 2020, we entered into a global collaboration and license agreement, or the Genentech Agreement, with Genentech, Inc., a member of the Roche Group, or Genentech, for the development and commercialization of RLY-1971. We initiated a first-in-human clinical trial for RLY-4008, our inhibitor of fibroblast growth factor receptor 2, or FGFR2, enriched for patients with advanced solid tumors having oncogenic FGFR2 alterations in the third quarter of 2020. We anticipate the RLY-PI3K1047 program, our program for molecules targeting cancer-associated mutant variants of phosphoinostide 3-kinase alpha, or PI3K&#945;, to be in Investigational New Drug, or IND, enabling studies in 2021. While our initial focus is on precision oncology, we believe our Dynamo platform may also be broadly applied to other areas of precision medicine, such as genetic disease. In addition to the three product candidates described above, we have five discovery stage programs across both precision oncology and genetic disease. We are focused on using the novel insights derived from our approach to transform the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of our therapies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated in May 2015. We have devoted substantially all of our resources to developing our lead product candidates, developing our innovative experimental and computational approaches on protein motion, building our intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. To date, we have principally financed our operations through private placements of preferred stock, convertible debt and proceeds from our initial public offering, or IPO, discussed below. Additionally, in January 2021, we received an upfront payment of $75.0 million in connection with the Genentech Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July&#160;20, 2020, we closed our IPO and issued 23,000,000 shares of our common stock at a price of $20.00 per share for net proceeds of $425.3&#160;million, after deducting underwriting discounts and commissions of $32.2&#160;million and expenses of $2.5 million. In connection with our IPO, all shares of Series A, Series B and Series C convertible preferred stock converted into 61,992,534 shares of common stock. Prior to our IPO, we had received gross proceeds of approximately $520.0&#160;million from sales of our preferred stock and our issuance of convertible debt. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, we entered into the Genentech Agreement with Genentech, for the development and commercialization of RLY-1971. Under the terms of the Genentech Agreement, we received $75.0 million in an upfront payment and are eligible to receive $25.0 million in near-term payments; and, if we do not opt into a U.S. profit/cost share, up to $695.0 million in additional development, commercialization and sales-based milestones for RLY-1971; and tiered royalties on annual global net sales (on a country-by-country basis), anticipated to be in the low-to-mid-teens, subject to reductions in certain circumstances. Additionally, we are eligible to receive additional royalties in the event of regulatory approval of RLY-1971 and Genentech&#8217;s <font style="color:#000000;">compound, GDC-6036, that directly </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">binds to and inhibits KRAS</font><font style="color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> G12C</sup></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, in combination. We have the right to opt-in to a 50/50 U.S. profit/cost share</font><font style="font-size:12pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and if we do opt into the U.S. profit/cost share, we are eligible to receive up to $410 million in additional commercialization and sales-based milestones for RLY-1971 outside of the U.S. and tiered royalties on annual net sales outside of the U.S. (on a country-by-country basis), anticipated to be in the low-to-mid-teens, subject to reduction in certain circumstances</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. We also retain the right to develop RLY-1971 in combination with our FGFR2 and PI3K&#945; programs.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting our employees, patients, communities and business operations, as well as contributing to significant volatility and negative pressure on the U.S. economy and in financial markets. Efforts to contain the spread of the COVID-19 pandemic have intensified and the United States, Europe and Asia have implemented severe travel restrictions, social distancing requirements, stay-at-home orders and have delayed the commencement of non-COVID-19-related clinical trials, among other restrictions.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we are currently continuing the clinical trials we have underway, we expect that COVID-19 precautions may directly or indirectly impact the timeline for some of our clinical trials. To date, we have been able to continue to enroll our patients in first-in-human clinical trials for RLY-1971 and RLY-4008, and we currently do not anticipate any interruptions in clinical enrollment. However, we are continuing to assess the potential impact of the COVID-19 pandemic on our current and future business and operations, including our expenses and clinical trials, as well as on our industry and the healthcare system. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have incurred significant operating losses on an aggregate basis. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our current or future product candidates. Our net losses were $52.4&#160;million and $75.3&#160;million for the years ended December&#160;31, 2020 and 2019, respectively. As of December&#160;31, 2020, we had an accumulated deficit of $404.2&#160;million. These losses have resulted primarily from costs incurred in connection with research and development activities, licensing and patent investment and general and administrative costs associated with our operations. We expect to continue to incur significant expenses<font style="color:#231F20;">, including the costs of operating as a public company,</font> and <font style="color:#231F20;">generate </font>increasing operating losses for at least the next several years.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that our expenses will increase substantially if and as we: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">conduct our current and future clinical trials of RLY-4008, additional preclinical research and development of our RLY-PI3K1047 program<font style="color:#231F20;">, and other early-stage programs</font>; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">initiate and continue research and preclinical and clinical development of our other product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">seek to identify additional product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">pursue marketing approvals for any of our product candidates that successfully complete clinical trials, if any; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">require the manufacture of larger quantities of our product candidates for clinical development and potentially commercialization; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">obtain, maintain, expand and protect our intellectual property portfolio; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">acquire or in-license other drugs and technologies; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">hire and retain additional clinical, regulatory, quality and scientific personnel;&nbsp;&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">build out new facilities or expand existing facilities to support our ongoing development activity; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"> add operational, financial and management information systems and personnel, including personnel to support our drug development, any future commercialization efforts and our operations as a public company. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if we obtain marketing approval for any of our lead product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, we will need additional financing to support our continuing operations. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity or debt financings or other sources, which may include collaborations with third parties. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed, on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates. </p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and may be forced to reduce or terminate our operations. </p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our cash, cash equivalents and investments of $678.1 million as of December 31, 2020<font style="color:#000000;">, together with the $75.0 million upfront payment received in January 2021 in connection with the Genentech Agreement,</font> will enable us to fund our operating expenses and capital expenditure requirements into 2024. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. We will need to raise additional capital in the future to continue developing the drugs in our pipeline and to commercialize any approved drug. We may seek to obtain additional financing in the future through the issuance of our common stock, through other equity or debt financings or through collaborations or partnerships with other companies. We may not be able to raise additional capital on terms acceptable to us, or at all, and any failure to raise capital as and when needed could compromise our ability to execute on our business plan.<font style="color:#000000;"> See &#8220;&#8212;Liquidity and Capital Resources.&#8221; </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Components of our Results of Operations </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:14pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2020, our revenue consists solely of amounts related to the Genentech Agreement. We recognize our revenue as the performance obligations are satisfied under the agreement. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operating expenses since inception have consisted solely of research and development costs and general and administrative costs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">salaries, benefits and other employee related costs, including stock-based compensation expense, for personnel engaged in research and development functions; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">costs of outside consultants, including their fees, stock-based compensation and related travel expenses; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">expenses incurred under agreements with contract research organizations, or CROs, contract manufacturing organizations, or CMOs, and other vendors that conduct our clinical trials and preclinical activities;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">costs of acquiring, developing and manufacturing clinical trial materials and lab supplies; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">costs related to compliance with regulatory requirements; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">facility costs, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expense research and development costs as the services are performed or the goods are received. We recognize costs for certain development activities, such as clinical trials, based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors and our clinical investigative sites. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our financial statements as prepaid </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expenses </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or accrued research and development expenses. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We began tracking external development costs by program on January&#160;1, 2020 for programs that have entered clinical trials.<font style="font-style:italic;">&#160;</font>We do not allocate internal costs, facilities costs or other overhead costs to specific programs.&#160;The following summarizes our costs based on their status in development: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">External costs for programs in clinical trials</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,447</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">External costs for programs in discovery and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; pre-clinical studies</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,431</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">External costs for platform research and other research</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and development activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,544</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee related expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,440</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,862</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our most advanced development programs, RLY-1971 and RLY-4008, are enrolling patients in first-in-human clinical trials. Programs in discovery and pre-clinical stages include our RLY-P13K1047 program as well as other earlier stage programs. Costs incurred for these programs include costs incurred to support our discovery research and translational science efforts up to the initiation of first-in-human clinical development. Platform research and other research and development activities include costs that are not specifically allocated to active product candidates, including facilities costs, depreciation expense and other costs. Employee related expenses includes salary, wages, stock-based compensation and other costs related to our personnel, which are not allocated to specific programs or activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot determine with certainty the duration and costs of future clinical trials and future development costs, if, when or to what extent we will generate revenue from the commercialization and sale of any our product candidates for which we obtain marketing approval or our other research and development costs. We may never succeed in obtaining marketing approval for any of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the scope, rate of progress, expense and results of our preclinical development activities, any future clinical trials of RLY-4008, our RLY-PI3K1047 program or other product candidates and other research and development activities that we may conduct; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">uncertainties in clinical trial design and patient enrollment or drop out or discontinuation rates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">establishing an appropriate safety and efficacy profile with IND-enabling studies; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the initiation and completion of future clinical trial results; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the timing, receipt and terms of any approvals from applicable regulatory authorities including the U.S. Food and Drug Administration, or FDA, and non-U.S. regulators; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">significant and changing government regulation and regulatory guidance; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">potential additional studies requested by regulatory agencies; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">establishing clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers in order to ensure that we or our third-party manufacturers are able to make product successfully; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the impact of any business interruptions to our operations, including the timing and enrollment of patients in our planned clinical trials, or to those of our manufacturers, suppliers or other vendors resulting from the COVID-19 pandemic or </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">similar public health crisis; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">maintaining a continued acceptable safety profile of our product candidates following approval, if any, of our product candidates. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will continue to increase for the foreseeable future as we continue clinical trials of RLY-4008, the development of our RLY-PI3K1047 program and to identify and develop additional product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant trial delays due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance, corporate and business development and administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our general and administrative expenses will increase in the future as we increase our general and administrative personnel headcount to support personnel in research and development and to support our operations generally as we increase our research and development activities and activities related to the potential commercialization of our product candidates. We also expect to incur increased expenses associated with operating as a public company, including costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and Securities and Exchange Commission, or SEC, requirements, director and officer insurance costs, and investor and public relations costs. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Income, Net </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net primarily consists of interest income related to interest earned on our cash, cash equivalents and investments. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception in 2015, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in any year or for our earned research and development tax credits, due to our uncertainty of realizing a benefit from those items. As of December&#160;31, 2020, we had federal NOL carryforwards of $174.0&#160;million available to reduce taxable income, of which $43.1&#160;million expire beginning in 2035 and $130.9&#160;million do not expire. We have state NOL carryforwards of $192.3&#160;million as of December&#160;31, 2020 available to reduce future state taxable income, which expire at various dates beginning in 2035. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we also had federal and state research and development tax credit carryforwards of $8.1&#160;million and $2.7&#160;million, respectively, which begin to expire in 2035 and 2030, respectively. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comparison of years ended December&#160;31, 2020 and 2019 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our results of operations for the years ended December&#160;31, 2020 and 2019: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,654</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,654</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,862</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,306</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,556</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,588</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,742</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,846</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138,450</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,048</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,402</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(55,796</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(84,048</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,252</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income and other expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,384</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,743</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,359</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,412</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,305</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,893</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognized revenue of $82.7 million for the year ended December 31, 2020 in connection with the Genentech Agreement related to the satisfaction of our performance obligation for the license transfer. We did not recognize any revenue for the year ended December 31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee related expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,440</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,914</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,526</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside and consulting services</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,009</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,585</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,424</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation of laboratory equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,889</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,410</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">479</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory supplies and other costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,754</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,289</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(535</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facilities and other allocated expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,770</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,108</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(338</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,862</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,306</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,556</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk65241340"></a>Research and development expenses were $99.9&#160;million for the year ended December&#160;31, 2020 compared to $70.3&#160;million for the year ended December&#160;31, 2019<a name="_Hlk65241340"></a>. The increase of $29.6&#160;million was primarily due to $18.5&#160;million of increased employee related costs, including $12.0&#160;million of additional share-based compensation expense, primarily due to increases in our stock price and increased headcount, and $11.4 million in increased outside and consulting expenses associated with our clinical and pre-clinical candidates.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and Administrative Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk65241317"></a>General and administrative expenses were $38.6&#160;million for the year ended December&#160;31, 2020 compared to $13.7&#160;million for the year ended December&#160;31, 2019<a name="_Hlk65241317"></a>. The increase of $24.8&#160;million was primarily due to $19.2&#160;million of increased employee related costs, including $15.5 million of additional share-based compensation expense, primarily due to increases in our stock price and increased general and administrative headcount to support the growth of our organization, and $5.2 million of other general and administrative expenses primarily attributed to increases in insurance, legal and other expenses.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Income (Expense), Net </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net, was $3.4&#160;million for the year ended December&#160;31, 2020 compared to $8.7&#160;million for the year ended December&#160;31, 2019 <font style="Background-color:#FFFFFF;color:#000000;">due primarily to decreases in interest rates and lower investment amounts.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have not generated any revenue from product sales and have incurred significant operating losses. We have not yet commercialized any products and we do not expect to generate revenue from sales of any product candidates for several years, if ever. On July 20, 2020, we closed our IPO and issued 23,000,000 shares of common stock <font style="color:#231F20;">for net proceeds of $425.3 million. Prior to our IPO</font>, we received gross proceeds of $520.0&#160;million from sales of our preferred stock and our issuance of convertible debt. As of December&#160;31, 2020, we had cash, cash equivalents and investments of $678.1 million. <font style="color:#231F20;">In January 2021, we received an upfront payment of $75.0 million from Genentech pursuant to the Genentech Agreement.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Flows </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our sources and uses of cash for each of the periods presented: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(102,489</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,133</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by (used in) investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,672</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(319,024</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">426,509</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,606</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash, cash equivalents</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">405,692</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(379,551</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Operating Activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, operating activities used $102.5&#160;million of cash, primarily resulting from our net loss of $52.4&#160;million and cash used by changes in our operating assets and liabilities of $85.2&#160;million, partially offset by non-cash charges of $35.1&#160;million. Net cash used by changes in our operating assets and liabilities of $85.2&#160;million during the year ended December&#160;31, 2020 consisted of increases of $75.0 million in accounts receivable, $7.7 million in contract assets, and $4.7 million in prepaid expenses and other current assets, offset by an increase of $2.0 million in accrued expenses and other liabilities. The increase in accounts receivable and contract assets was due to the upfront payment received and revenue recognized in connection with the Genentech Agreement. The increase in prepaid expenses was primarily due to increases in prepaid license fees and insurance. The increase in accrued expenses and other current liabilities was largely due to an increase in external research and development costs.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, operating activities used $66.1&#160;million of cash, primarily resulting from our net loss of $75.3&#160;million, partially offset by non-cash charges of $4.9&#160;million and cash provided by changes in our operating assets and liabilities of $4.3&#160;million. Net cash provided by changes in our operating assets and liabilities of $4.3&#160;million during the year ended December&#160;31, 2019 consisted of an increase of $5.2&#160;million in accounts payable, accrued expenses and other current liabilities as well as a decrease of $1.2&#160;million of operating lease assets, net, partially offset by an increase of $2.1&#160;million in prepaid expenses and other current assets. The increase in accounts payable, accrued expenses and other current liabilities was largely due to an increase in external research and development costs. The increase in prepaid expenses and other current assets was due to an increase in external research and development costs. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Investing Activities</font><font style="font-style:normal;">. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, investing activities provided $81.7&#160;million, consisting primarily of $83.6&#160;million of net investment proceeds from maturities offset by $1.9&#160;million for the purchase of property and equipment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, investing activities used $319.0&#160;million, consisting primarily of $311.0&#160;million of net investment purchases and $8.0&#160;million for the purchase of property and equipment. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Financing Activities<font style="font-style:normal;">. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, net cash provided by financing activities was $426.5&#160;million, consisting of net proceeds from the issuance of common stock upon the closing of our IPO of $425.3 million and proceeds from stock option exercises of $1.2 million.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, net cash provided by financing activities was $5.6&#160;million, consisting of net proceeds from our sales of Series C convertible preferred stock of $5.0&#160;million and proceeds from the exercise of stock options of $0.6&#160;million. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Funding Requirements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our expenses to increase substantially in connection with our ongoing clinical development activities related to the potential clinical development activities of RLY-4008 and the ongoing pre-clinical development activities of our RLY-PI3K1047 program. In addition, we are now incurring additional costs associated with operating as a public company. We expect that our expenses will increase substantially as discussed in more detail in &#8220;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#8212;</font></font> Overview&#8221; above.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we had cash, cash equivalents and investments of $678.1 million. We believe that our existing cash, cash equivalents and investments, together with the $75.0 million upfront payment received in January 2021 in connection with the Genentech Agreement, will enable us to fund our operating expenses and capital expenditure requirements into 2024. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with the development of RLY-4008, our RLY-PI3K1047 programs and other product candidates and programs, and because the extent to which we may enter into collaborations with third parties for the development of our product candidates is unknown, we are unable to estimate the timing and amounts of increased capital outlays and operating expenses associated with completing the research and development of our product candidates. Our future capital requirements will depend on many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the impact of any business interruptions to our operations, including the timing and enrollment of patients in our planned clinical trials, or to those of our manufacturers, suppliers or other vendors, resulting from the COVID-19 pandemic or similar public health crisis; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the scope, progress, results and costs of our current and future clinical trials of RLY-4008 and additional preclinical research of our RLY-PI3K1047 program;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the scope, progress, results and costs of drug discovery, preclinical research and clinical trials for our other product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the number of future product candidates that we pursue and their development requirements; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs, timing and outcome of regulatory review of our product candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to establish and maintain collaborations on favorable terms, if at all; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the success of any existing or future collaborations that we may enter into with third parties; </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration arrangements for product candidates, such as our collaboration with Genentech;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the achievement of milestones or occurrence of other developments that trigger payments under any existing or future collaboration agreements, if any; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under any existing or future collaboration agreements, if any;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs and timing of future commercialization activities, including drug sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval, to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of any collaborator that we may have at such time; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our headcount growth and associated costs as we expand our business operations and our research and development activities; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the costs of operating as a public company. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval for any product candidates or generate revenue from the sale of any product candidate for which we may obtain marketing approval. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to be commercially available for many years, if ever. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adequate additional funds may not be available to us on acceptable terms, or at all. We do not currently have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest may be diluted, and the terms of these securities may include liquidation or other preferences and anti-dilution protections that could adversely affect your rights as a common stockholder. Additional debt or preferred equity financing, if available, may involve agreements that include restrictive covenants that may limit our ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends, which could adversely impact our ability to conduct our business, and may require the issuance of warrants, which could potentially dilute your ownership interest. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technology, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or collaborations, strategic alliances or licensing arrangements with third parties when needed, we may be required to delay, limit, reduce and/or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Obligations and Commitments </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 15, 2020, we entered into an Amended and Restated Collaboration and License Agreement, or DESRES Agreement, with D.&#160;E.&#160;Shaw Research, LLC, or D. E. Shaw Research, extending the term and otherwise modifying the terms of the Collaboration and License Agreement originally entered into on August 17, 2016. The DESRES Agreement provides that the parties will jointly conduct research efforts with the goal of identifying and developing product candidates. On a product-by-product basis, we have agreed to pay D.&#160;E.&#160;Shaw Research milestone payments upon the achievement of certain development and regulatory milestone events for products we develop under the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DESRES Agreement that are directed to a Category&#160;1 Target or any target that was a Category 1 Target. Such payments for achievement of development and regulatory milestones total up to $7.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million in the aggregate for each of the first three products we develop, and up to $6.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million in the aggregate for each product we develop after the first three.&#160;In addition, we are obligated to pay D.&#160;E.&#160;Shaw Research royalty payments as defined in the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DESRES A</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">greement. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We assessed the milestone and royalty events under the DESRES Agreement as of December 31, 2020 and 2019, respectively, and concluded that $1.5 million was due related to the execution of the Genentech Agreement as of December 31, 2020 and no such payments were due as of December 31, 2019.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The DESRES Agreement extended the term of the original agreement to August&#160;16, 2025 and increased the annual fee from $1.0&#160;million to $7.9&#160;million, commencing on August&#160;16, 2020. The DESRES Agreement automatically renews for successive one year periods unless either party provides at least one year notice of non-renewal, and the annual fee during each of the one year renewal terms is subject to the mutual agreement of us and D. E. Shaw Research.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have certain research and license arrangements with other third parties, which provide us with research services with the goal of identifying and developing product candidates until all payment obligations by us to the third party have expired. We have the right to terminate these agreements with a reasonable period of notice. We are also obligated to pay development milestone payments for up to four targets, each in the range of $4.0&#160;million to $7.0&#160;million, upon the achievement of certain specified contingent events. We assessed the milestones as of December&#160;31, 2020 and 2019 and concluded no such milestone payments were due. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We enter into contracts in the normal course of business with CROs and CMOs for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts do not contain any minimum purchase commitments and are cancelable by us upon prior notice of 30&#160;days. Payments due upon cancelation consist only of payments for services provided and expenses incurred up to the date of cancelation. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2017, we entered into a facility lease agreement for approximately 44,336 square feet of office and laboratory space at 399 Binney Street, Cambridge, Massachusetts, which was increased to 44,807 square feet in January 2018. We gained control of the space in January 2019 and the lease expires in April 2029, subject to certain renewal options, which have not been included in our right of use asset and liability.<font style="color:#000000;"> In September 2020, we entered into an amendment to our existing facility lease agreement to expand the leased area by approximately 1,824 square feet of office space at 399 Binney Street, Cambridge, Massachusetts. The amendment commenced in October 2020 and expires in April 2029, subject to certain renewal options.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We provided a letter of credit in connection with our facility lease agreement in the amount of $878 with a financial institution, which expires September&#160;30, 2028.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For more information, see Note 13, <font style="font-style:italic;">Commitments and Contingencies,</font> and Note 14, <font style="font-style:italic;">Leases, </font>of the notes to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including expenses, clinical trials and research and development costs, will </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results could differ from our estimates. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements. </p>
<p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We account for revenue recognition in accordance with Accounting Standards Codification Topic 606, <font style="font-style:italic;">Revenue from Contracts with Customers</font>, or ASC 606. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. </p>
<p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within the contract and determine those that are performance obligations. We then determine the transaction price and allocate it to the performance obligations using the relative selling price model. As part of the accounting for these arrangements, we must use significant judgment to determine: (a) the number of performance obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above, including the determination of whether milestones or other variable consideration should be included in the transaction price; and (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of the transaction price in step (iv) above. </p>
<p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We utilize key assumptions and judgments to determine the stand-alone selling price for each performance obligation, which may include discounted cash flow models, evaluation of comparable transactions, pricing considered in negotiating the transaction and estimated costs,<font style="Background-color:#FFFFFF;"> to determine how the transaction price is allocated among the performance obligations</font>. We use judgment to determine whether milestones or other variable consideration should be included in the transaction price. For revenue-based royalties, including milestone payments based on the level of sales, we will include royalties in the transaction price at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty is allocated has been satisfied (or partially satisfied). As part of management&#8217;s evaluation of the transaction price, we consider numerous factors, including whether the achievement of the milestones is outside of our control, contingent upon the efforts of others or subject to the risks of success. If we conclude it is probable that a significant revenue reversal would not occur, the associated milestone payment is included in the transaction price. Milestone payments that are not within our control, such as regulatory approvals, are generally not considered probable until those milestones are achieved. We re-evaluate the transaction price, including estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</p>
<p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once the performance obligations are identified, the transaction price is allocated to each performance obligation based on the relative stand-alone selling price. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied, either at a point in time or over time. If the performance obligation is satisfied over time, we recognize revenue based on the use of either an output or input method. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had one collaboration and license agreement with Genentech, which we entered into on December 11, 2020.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accrued Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development and manufacturing expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. The majority of our service providers invoice us in arrears for services performed on a pre-determined schedule or when contractual milestones are met; however, some require advanced payments. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. Examples of estimated accrued research and development expenses include fees paid to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">CROs in connection with performing research activities on our behalf and conducting preclinical studies and clinical trials on our behalf; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">investigative sites or other service providers in connection with clinical trials; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">vendors in connection with preclinical and clinical development activities; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">vendors related to product manufacturing and development and distribution of preclinical and clinical supplies. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple CROs that conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation and vary from contract to contract, which may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing fees, we estimate the time period over which services will be performed, enrollment of patients, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or amount of prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low in any particular period. To date, we have not made any material adjustments to our prior estimates of accrued research and development expenses. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We measure stock options and other stock-based awards granted to employees, directors and non-employees based on their fair value on the date of grant and recognize compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. We recognize the impact of forfeitures on stock-based compensation expense as forfeitures occur. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We issued certain options with performance-based vesting conditions whereby the service inception date preceded the accounting grant date and therefore we applied variable accounting for the awards until the fair value of the awards was known on the accounting grant date. The board of directors approved the commencement of vesting for all such awards in 2020, therefore we no longer apply variable accounting as of December 11, 2020.<font style="font-size:12pt;">&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model, which uses as inputs the fair value of our common stock and assumptions we make for the volatility of our common stock, the expected term of our stock options, the risk-free interest rate for a period that approximates the expected term of our stock options and our expected dividend yield. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to our IPO, the estimated fair value of our common stock was determined by our board of directors, or compensation committee thereof</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as of the date of each option grant, with input from management, considering our most recently available third-party valuations of common stock and our board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. Historically, these independent third</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">party valuations of our equity instruments were performed contemporaneously with identified value inflection points.</font></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide,&#160;<font style="font-style:italic;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation, </font>or the Practice Aid. The Practice Aid identifies various available methods for allocating the enterprise value across classes of series of capital stock in determining the fair value of our common stock at each valuation date.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following our IPO, in connection with our accounting for granted stock options and other awards we may grant, the fair value of our common stock is determined based on the quoted market price of our common stock.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Emerging Growth Company and Smaller Reporting Company Status </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section&#160;107 of the JOBS Act provides that an &#8220;emerging growth company,&#8221; or an EGC, can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. Thus, an EGC can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period for new or revised accounting standards during the period in which we remain an emerging growth company; however, we may adopt certain new or revised accounting standards early. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will remain an emerging growth company until the earliest to occur of: (1)&#160;the last day of the fiscal year in which we have more than $1.07&#160;billion in annual revenue; (2)&#160;the date we qualify as a &#8220;large accelerated filer,&#8221; with at least $700.0&#160;million of equity securities held by&#160;non-affiliates;&#160;(3)&#160;the date on which we have issued more than $1.0&#160;billion in&#160;non-convertible&#160;debt securities during the prior three-year period; and (4)&#160;the last day of the fiscal year ending after the fifth anniversary of our initial public offering. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also a &#8220;smaller reporting company&#8221; meaning that the market value of our stock held by non-affiliates is less than $700&#160;million and our annual revenue was less than $100&#160;million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i)&#160;the market value of our stock held by non-affiliates is less than $250&#160;million or (ii)&#160;our annual revenue was less than $100&#160;million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700&#160;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form&#160;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued and Adopted Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note&#160;2 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a>Item 7A. Quantitative and Qualitati</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ve Disclosures About Market Risk.</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest rate risk</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to market risk related to changes in interest rates of our investment portfolio of cash equivalents and investments. As of December 31, 2020, our cash equivalents consisted of money market funds. As of December&#160;31, 2020, our investments consisted of investments in United States Treasury Bills, United States Treasury Bonds and agency bonds that have contractual maturities of less than two years. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates, including changes resulting from the impact of the COVID-19 pandemic. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of December 31, 2020 and 2019, we estimate that such hypothetical 100 basis point adverse movement would not result in a material impact to our consolidated results of operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had no debt outstanding and are therefore not exposed to interest rate risk with respect to debt.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign currency exchange risk</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our employees and our operations are currently located in the United States and our expenses are generally denominated in U.S. dollars. However, we have entered into a limited number of contracts with vendors for research and development services that permit us to satisfy our payment obligations in U.S. dollars (at prevailing exchange rates) but have underlying payment obligations denominated in foreign currencies, including the Euro. We are subject to foreign currency transaction gains or losses on our contracts denominated in foreign currencies. To date, foreign currency transaction gains and losses have not been material to our financial statements, and we do not have a formal hedging program with respect to foreign currency. A 10% increase or decrease in current exchange rates would not have a material effect on our financial results for the years ended December&#160;31, 2020 and 2019. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a>Item 8. Financial Statements and Supplementary Data.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statements required to be filed pursuant to this Item&#160;8 are appended to this Annual Report on Form 10-K. An index of those financial statements is found in Index to the Consolidated Financial Statements on page F-1 of this Annual Report on Form 10-K, as incorporated into Item 15, Exhibits and Financial Statement Schedules, of this Annual Report on Form 10-K, by reference.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a><a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a>Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="N9A_CONTROLS_PROCEDURES"></a>Item <a name="N9A_CONTROLS_PROCEDURES"></a>9A. Controls and Procedures.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have established disclosure controls and procedures (as defined in&#160;Rules&#160;13a-15(e)&#160;and&#160;15d-15(e)&#160;under the Securities Exchange Act of 1934, as amended, or the Exchange Act) designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and is accumulated and communicated to management, including the principal executive officer (our Chief Executive Officer) and principal financial officer (our Senior Vice President, Finance), to allow timely decisions regarding required disclosure. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</p>
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management has evaluated, with the participation of our Chief Executive Officer and Senior Vice President, Finance, the effectiveness of our disclosure controls and procedures&#160;(as defined in Rules&#160;13a-15(e)&#160;and&#160;15d-15(e)&#160;under the Exchange Act) as of the end of the period covered by this&#160;<font style="color:#000000;">Annual Report on Form 10-K. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives.&#160;Based on that evaluation, our Chief Executive Officer and Senior Vice President, Finance have concluded that, as of </font><font style="color:#000000;">December 31</font><font style="color:#000000;">, 2020, our disclosure controls and procedures were effective.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Internal Control over Financial Reporting</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Management&#8217;s Report on Internal Control over Financial Reporting<font style="font-style:normal;">&#160;</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K does not include a report of management&#8217;s assessment regarding internal control over financial reporting or an attestation report of our independent registered public accounting firm due to a transition period established by rules of the SEC for newly public companies.&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in Internal Control Over Financial Reporting</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There has been no change in our internal control over financial reporting (as defined in Rules&#160;13a-15(f)&#160;and&#160;15d-15(f)&#160;under the Exchange Act) that occurred during the fiscal quarter ended December 31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the&#160;COVID-19&#160;pandemic, many of our employees are working remotely. We have not identified any material changes in our internal control over financial reporting as a result of these changes to the working environment, in part because our internal control over financial reporting&#160;was designed to operate in a remote working environment. We are continually monitoring and assessing the&#160;COVID-19&#160;situation to determine any potential impacts on the design and operating effectiveness of our internal controls over financial reporting.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9B_OR_INFORMATION"></a><a name="ITEM_9B_OR_INFORMATION"></a>Item 9B. Other Information.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Part_III"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART III </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_10"></a><a name="ITEM_10"></a>Item 10. Directors, Executive Officers and Corporate Governance. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 10 will be included in our Definitive Proxy Statement to be filed with the Securities and Exchange Commission, or SEC, with respect to our 2021 Annual Meeting of Stockholders within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K and is incorporated herein by reference.<font style="color:#000000;"> </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_11"></a><a name="ITEM_11"></a>Item 11. Executive Compensation. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 11 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K and is incorporated herein by reference.<font style="color:#000000;"> </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_12"></a><a name="ITEM_12"></a>Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 12 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K and is incorporated herein by reference.<font style="color:#000000;"> </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_13"></a><a name="ITEM_13"></a>Item 13. Certain Relationships and Related Transactions, and Director Independence. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 13 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K and is incorporated herein by reference.<font style="color:#000000;"> </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_14"></a><a name="ITEM_14"></a>Item 14. Principal Accounting Fees and Services. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item 14 will be included in our Definitive Proxy Statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K and is incorporated herein by reference.<font style="color:#000000;"> </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Part_IV"></a>PART IV </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a>Item 15. Exhibits, Financial Statement Schedules. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">For a list of the financial statements included herein, see&#160;Index to the Consolidated Financial Statements&#160;on page F-1 of this Annual Report on Form&#160;10-K,&#160;incorporated into this Item by reference.</font> </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto.</font> </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">The exhibits filed as part of this Annual Report on Form 10-K are set forth on the Exhibit Index immediately preceding the signature page of this Annual Report on Form 10-K. The Exhibit Index is incorporated herein by reference.</font></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16_FORM_10K_SUMMARY"></a><a name="ITEM_16_FORM_10K_SUMMARY"></a>Item 16. Form 10-K Summary</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has elected not to include summary information.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Index to Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#OPINION"><font style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Financial Statements</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><font style="text-decoration:underline;">Consolidated Balance Sheets</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"><font style="text-decoration:underline;">Consolidated Statements of Operations and Comprehensive Loss</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CONVERTIBLE_PREF"><font style="text-decoration:underline;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</font></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><font style="text-decoration:underline;">Consolidated Statements of Cash Flows</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><font style="text-decoration:underline;">Notes to Consolidated Financial Statements</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="OPINION"></a><font style="Background-color:#FFFFFF;"><a name="OPINION"></a>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Stockholders and the Board of Directors of Relay Therapeutics, Inc. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Financial Statements</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of Relay Therapeutics, Inc. (the Company) as of December 31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and <font style="color:#000000;">stockholders&#8217; </font>equity (deficit), and cash flows for each of the two years in the period ended December 31, 2020, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles. </p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ <font style="font-size:10pt;">Ernst &amp; Young</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2017.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, Massachusetts</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Relay Therapeutics, Inc. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_BALANCE_SHEETS"></a><a name="CONSOLIDATED_BALANCE_SHEETS"></a>Consolidated Balance Sheets </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share amounts) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">447,646</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,954</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,415</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313,862</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract asset</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,654</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,385</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,720</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">770,100</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360,536</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,250</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,094</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,579</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,560</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">878</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">878</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">799,829</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">393,068</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities, Convertible Preferred Stock, and Stockholders&#8217; Equity</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; (Deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,351</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,991</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,760</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,746</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, current</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,521</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,249</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,632</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,986</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, net of current portion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,901</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,583</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,536</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,725</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 13)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock (Series A, B and C), $0.001 par value;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; no shares authorized as of December 31, 2020 and 337,272,859 shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; authorized as of December 31, 2019; no shares issued and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; outstanding as of December 31, 2020 and 212,642,857 shares issued</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and outstanding (aggregate liquidation preference of $519,825) as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">537,781</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity (deficit):</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Undesignated preferred stock, $0.001 par value, 10,000,000 shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; authorized as of December 31, 2020 and no shares authorized as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2019; no shares issued and outstanding at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2020 and December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $0.001 par value; 150,000,000 and 260,000,000 shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; authorized at December 31, 2020 and December 31, 2019, respectively;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; 89,991,324 and 4,716,634 shares issued at December 31, 2020 and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2019, respectively; 89,906,835 and 4,037,476 shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; outstanding at December 31, 2020 and December 31, 2019, respectively</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,167,367</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,715</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(404,228</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(189,482</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity (deficit)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">763,293</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(180,438</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities, convertible preferred stock, and stockholders&#8217; equity</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; (deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">799,829</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">393,068</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes. </p><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Relay Therapeutics, Inc. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"></a><a name="CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"></a>Consolidated Statements of Operations and Comprehensive Loss </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share data) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk65241540"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,654</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,654</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,862</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,306</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,588</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,742</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138,450</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,048</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(55,796</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(84,048</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,400</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,801</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income (expense), net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,384</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,743</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,412</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,305</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deemed dividend resulting from extinguishment upon modification</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; of Series&#160;C preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(177,789</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(230,201</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,305</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders per share, basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5.40</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21.82</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares of common stock, basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,619,582</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,450,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income (loss):</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized holding gain (loss)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(261</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other comprehensive income (loss)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(261</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,673</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74,980</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU12"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Relay Therapeutics, Inc. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_CONVERTIBLE_PREF"></a><a name="CONSOLIDATED_STATEMENTS_CONVERTIBLE_PREF"></a>Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share data) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.42%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Par</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-in</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">210,863,764</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">532,120</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,998,017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,247</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(114,177</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(110,927</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series C convertible preferred stock,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; net of issuance costs of $50</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,779,093</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,661</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178,969</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">613</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">613</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of restricted common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">860,490</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">399</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">400</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,456</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,456</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain on investments</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,305</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,305</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212,642,857</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">537,781</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,037,476</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,715</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(189,482</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(180,438</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Extinguishment upon modification of Series C preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">177,789</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,455</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(162,334</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(177,789</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible preferred stock into common stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; upon initial public offering</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(212,642,857</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(715,570</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,992,534</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">715,508</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">715,570</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock in public offering, net of discounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and issuance costs of $34,707</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,000,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">425,270</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">425,293</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">297,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,216</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,216</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of restricted common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">579,825</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">154</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,960</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,960</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(261</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(261</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.46%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,412</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,412</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.46%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,906,835</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,167,367</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(404,228</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">763,293</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU13"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Relay Therapeutics, Inc. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a>Consolidated Statements of Cash Flows </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,412</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,305</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,960</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,456</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,549</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,845</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net amortization of premiums and discounts on investments</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(416</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,495</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on sale of equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in assets and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,665</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,123</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease assets and liabilities, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">571</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,233</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(410</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,010</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,200</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract asset</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,654</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(102,489</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,133</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,931</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,002</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from sale of equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of investments</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(266,455</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(553,517</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from maturities of investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350,058</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242,475</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,672</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(319,024</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of convertible preferred stock, net of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,993</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock upon exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,216</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">613</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock upon initial public offering</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">427,800</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Offering costs paid</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,507</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">426,509</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,606</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash, cash equivalents and restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">405,692</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(379,551</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash at beginning of period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,832</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">422,383</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash at end of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">448,524</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,832</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of non-cash investing and financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment additions included in accounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; payable and accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">519</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">745</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of restricted stock liability to additional paid-in capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">400</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Extinguishment upon modification of Series C preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(177,789</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of preferred stock into common stock upon initial</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; public offering</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">715,508</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of use asset obtained in exchange for lease obligation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">819</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,936</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reconciliation of Cash, Cash Equivalents and Restricted Cash from Balance Sheets to Statements of Cash Flows</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63090921"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">447,646</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,954</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">878</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">878</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash as shown on consolidated</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; statements of cash flows</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">448,524</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,832</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes.</p><a name="_AEIOULastRenderedPageBreakAEIOU14"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Relay Therapeutics, Inc. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a>Notes to Consolidated Financial Statements </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share data) </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Business and Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Relay Therapeutics, Inc. (the &#8220;Company&#8221;) was incorporated in Delaware on May 4, 2015 and is headquartered in Cambridge, Massachusetts. The Company is a clinical-stage, precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The Company is built upon unparalleled insights into protein motion and how this dynamic behavior relates to protein function. The Company&#8217;s Dynamo platform integrates an array of leading edge experimental and computational approaches, which allows the Company to apply the understanding of protein structure and motion to drug discovery. The Company is advancing its pipeline of medicines to address targets in precision oncology, including its lead product candidates, RLY-4008 and RLY-1971, as well as its PI3K&#945; mutant selective program, known as the RLY-PI3K1047 program. The Company initiated a Phase 1 clinical trial for RLY-1971 in patients with advanced solid tumors in the first quarter of 2020 and a first-in-human clinical trial of RLY-4008 enriched for patients with advanced solid tumors having oncogenic FGFR2 alterations in the third quarter of 2020. <font style="color:#231F20;">In December 2020, the Company entered into the Collaboration and License Agreement (the &#8220;Genentech Agreement&#8221;) with Genentech, Inc. (&#8220;Genentech&#8221;), a member of the Roche Group, for the development and commercialization of RLY-1971, as further discussed in Note 5.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive pre-clinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s product candidates are in development. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has devoted substantially all of its resources to developing its product candidates, including RLY-1971 and RLY-4008, and the RLY-PI3K1047 program by developing its innovative, experimental and computational approaches on protein motion, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred net operating losses since inception and had an accumulated deficit of $404,228 as of December 31, 2020. The Company expects that its existing cash, cash equivalents and investments as of December 31, 2020, together with the upfront payment of $75,000 received in January 2021 from Genentech under the Genentech Agreement discussed in Note 5, will enable it to fund its planned operating expenses and capital expenditure requirements for at least one year from the date of the issuance of these consolidated financial statements. The future viability of the Company is dependent on its ability to generate cash from operating activities or to raise additional capital to finance its operations. The Company&#8217;s failure to raise capital as and when needed could have a material adverse effect on its financial condition and ability to pursue its business strategies. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into license or collaboration arrangements or obtain government grants. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. In the event </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company requires additional funding, there can be no assurance that it will be successful in obtaining sufficient funding on terms acceptable to the Company to fund its continuing operations, if at all. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Initial Public Offering </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 20, 2020, the Company closed its initial public offering (&#8220;IPO&#8221;) and issued 23,000,000 shares of its common stock at a price of $20.00 per share for net proceeds of $425,293, after deducting underwriting discounts and commissions of $32,200 and expenses of $2,507. In connection with the IPO, all shares of Series A, Series B and Series C convertible preferred stock converted into 61,992,534 shares of common stock. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reverse Stock Split </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 8, 2020, the Company&#8217;s stockholders approved a decrease in the number of authorized shares of common stock from 260,000,000 to 150,000,000. The Company also effected a one-for-3.55092 reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company&#8217;s preferred stock. Accordingly, all share and per share amounts for all periods presented in the accompanying financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse stock split and adjustment of the preferred stock conversion ratios.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. Significant Accounting Policies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis of presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) for reporting on Form 10-K. The Company&#8217;s consolidated financial statements include the accounts of Relay Therapeutics, Inc. and its wholly-owned subsidiary, Relay Therapeutics Securities Corporation. All intercompany balances and transactions have been eliminated. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development and manufacturing expenses, the valuation of equity instruments, the determination of the transaction price and standalone selling price of performance obligations under <font style="color:#000000;">Accounting Standards Codification Topic 606, </font><font style="font-style:italic;color:#000000;">Revenue from Contracts with Customers</font>, and the incremental borrowing rate for determining the operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has made estimates of the impact of COVID-19 within its financial statements and there may be changes to those estimates in future periods. Actual results could differ from the Company&#8217;s estimates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Segment Information </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company&#8217;s singular focus is on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets. The Company operates in the United States and all tangible assets are held in the United States.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash Equivalents </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all short-term, highly liquid investments with original maturities of 90&#160;days or less at acquisition date to be cash equivalents. Cash equivalents, which consist of money market funds, are stated at fair value. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Restricted Cash </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had restricted cash of $878 as of December&#160;31, 2020 and 2019 to secure a letter of credit in connection with the lease of the Company&#8217;s facilities (see Note 14). The Company classified the restricted cash as a noncurrent asset on its consolidated balance sheets. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Investments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments in marketable securities are classified as available-for-sale. Available-for-sale securities are measured and reported at fair value using quoted prices in active markets for similar securities. Unrealized gains and losses on available-for-sale securities are reported as a separate component of stockholders&#8217; equity (deficit). Premiums or discounts from par value are amortized to investment income over the life of the underlying investment. All of the Company&#8217;s available-for-sale securities are available to the Company for use in current operations. As a result, the Company classified all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) within the consolidated statements of operations and comprehensive loss. If any adjustment is required to reflect a decline in the value of the investment that the Company considers to be &#8220;other than temporary&#8221;, the Company recognizes a charge to the consolidated statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Significant Suppliers </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and investments. From time to time, the Company has maintained all of its cash, cash equivalents and investments at certain accredited financial institutions in amounts that exceed federally insured limits. The Company generally invests its excess capital in money market funds, U.S. treasury bonds, U.S. treasury bills and agency bonds are subject to minimal credit and market risk. Management has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. The investment portfolio is maintained in accordance with the Company&#8217;s investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is dependent on third-party suppliers for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a small number of these suppliers, including D. E. Shaw Research, LLC as discussed in Note 13, to meet its requirements for its programs. These programs could be adversely affected by a significant interruption in pre-clinical and clinical testing and the supply of active pharmaceutical ingredients and formulated drugs. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Level 2&#8212;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for revenue recognition in accordance with Accounting Standards Codification Topic (&#8220;ASC&#8221;) 606, <font style="font-style:italic;">Revenue from Contracts with Customers</font> (&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. </p>
<p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract and determines those that are performance obligations. The Company then determines the transaction price and allocates it to the performance obligations using the relative selling price model. As part of the accounting for these arrangements, the Company must use significant judgment to determine: (a) the number of performance obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above, including the determination of whether milestones or other variable consideration should be included in the transaction price; and (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of the transaction price in step (iv) above. </p>
<p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilizes key assumptions and judgments to determine the stand-alone selling price for each performance obligation, which may include discounted cash flow models, evaluation of comparable transactions, pricing considered in negotiating the transaction and estimated costs,<font style="Background-color:#FFFFFF;"> to determine how the transaction price is allocated among the performance obligations</font>. The Company uses judgment to determine whether milestones or other variable consideration should be included in the transaction price. For revenue-based royalties, including milestone payments based on the level of sales, the Company will include royalties in the transaction price at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty is allocated has been satisfied (or partially satisfied). As part of management&#8217;s evaluation of the transaction price, the Company considers numerous factors, including whether the achievement of the milestones is outside of our control, contingent upon the efforts of others or subject to scientific risks of success. If the Company concludes it is probable that a significant revenue reversal would not occur, the associated milestone payment is included in the transaction price. Milestone payments that are not within our control, such as regulatory approvals, are generally not considered probable until those milestones are achieved. The Company re-evaluates the transaction price, including estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</p>
<p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once the performance obligations are identified, the transaction price is allocated to each performance obligation based on the relative stand-alone selling price. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied, either at a point in time or over time. If the performance obligation is satisfied over time, the Company recognizes revenue based on the use of either an output or input method. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company ha</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> collaboration and license agreement</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with Genentech</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which the Company entered into on </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 11, 2020</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="letter-spacing:-0.1pt;">For a discussion of the accounting related to </font><font style="letter-spacing:-0.1pt;">the</font><font style="letter-spacing:-0.1pt;"> Genentech</font><font style="letter-spacing:-0.1pt;"> Agreement</font><font style="letter-spacing:-0.1pt;">, see Note 5,&#160;</font><font style="font-style:italic;letter-spacing:-0.1pt;">Collaboration and License A</font><font style="font-style:italic;letter-spacing:-0.1pt;">rrangement</font><font style="font-style:italic;letter-spacing:-0.1pt;"> with Genentech</font><font style="font-style:italic;letter-spacing:-0.1pt;">.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 842, <font style="font-style:italic;">Leases</font>, the Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does not recognize a right-of-use asset or lease liability. The Company&#8217;s operating leases are recognized on its consolidated balance sheets as other noncurrent assets, other current liabilities and other noncurrent liabilities. The Company does not have any finance leases. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Operating lease right-of-use assets also include the effect of any lease payments made prior to commencement and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has lease agreements with lease and non-lease components, which are accounted for as a combined element. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the useful life of the asset. Laboratory and computer equipment are depreciated over three years. Furniture and fixtures are depreciated over five years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the related asset. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured in an amount by which the book values of the assets exceed their fair value. The Company did not recognize any impairment losses for the years ended December&#160;31, 2020 and 2019.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Classification and Accretion of Convertible Preferred Stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s convertible preferred stock was classified outside of stockholders&#8217; equity (deficit) on the consolidated balance sheet because the holders of such shares had liquidation rights in the event of a deemed liquidation that, in certain situations, were not solely within the control of the Company and would require the redemption of the then-outstanding convertible preferred stock. The convertible preferred stock was not currently redeemable, except in the event of a deemed liquidation (see Note 8). Because the occurrence of a deemed liquidation event was not probable, the carrying value of the convertible preferred stock was not accreted to their redemption values. Subsequent adjustments to the carrying values of the convertible preferred stock would have been made only when a deemed liquidation event became probable. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the closing of the Company&#8217;s IPO in July 2020, all outstanding convertible preferred stock automatically converted into 61,992,534 shares of common stock. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures stock options and other stock-based awards granted to employees, directors and non-employees based on their fair value on the date of grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company recognizes the impact of forfeitures on stock-based compensation expense as forfeitures occur. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company issued certain options with performance-based vesting conditions whereby the service inception date preceded the accounting grant date and therefore applied variable accounting for the awards until the fair value of the awards was known on the accounting grant date. The board of directors approved the commencement of vesting for all such awards in 2020, therefore the Company no longer applies variable accounting as of December 11, 2020.<font style="font-size:12pt;">&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model, which uses as inputs the fair value of the Company&#8217;s common stock and assumptions the Company makes for the volatility of its common stock, the expected term of the stock options, the risk-free interest rate for a period that approximates the expected term of the stock options and the expected dividend yield. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Company&#8217;s IPO, the estimated fair value of its common stock was determined by the board of directors, or compensation committee thereof, as of the date of each option grant, with input from management, considering the most recently available third-party valuations of common stock and the board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. Historically, these independent third-party valuations of the Company&#8217;s equity instruments were performed contemporaneously with identified value inflection points.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide,&#160;<font style="font-style:italic;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation </font>(the &#8220;Practice Aid&#8221;). The Practice Aid identifies various available methods for allocating the enterprise value across classes of series of capital stock in determining the fair value of the Company&#8217;s common stock at each valuation date.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following the Company&#8217;s IPO, in connection with the accounting for granted stock options and other awards the Company may grant, the fair value of the Company&#8217;s common stock is determined based on the quoted market price of its common stock.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Costs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development expenses include salaries, stock-based compensation and benefits of employees, third-party license fees and other operational costs related to the Company&#8217;s research and development activities, including allocated facility-related expenses and external costs of outside vendors engaged to conduct both pre-clinical studies and clinical trials. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Research and Manufacturing Contracts </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development contracts with research institutions and other companies whose costs are included in research and development expense in the accompanying consolidated statements of operations and comprehensive loss. These agreements are generally cancelable and related payments are recorded as research and development expenses as the underlying services are performed. When evaluating the adequacy of the expense recognized, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the expense recognized and the related prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical estimates have not been materially different from the actual costs. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Patent Costs </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company&#8217;s financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive Loss </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. For the years ended December&#160;31, 2020 and 2019, other comprehensive income (loss) consisted of changes in unrealized gains and losses from available-for-sale investments.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Loss Per Common Share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed using the sum of the weighted average number of common shares outstanding during the period and the effect of dilutive securities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies the two-class method to calculate its basic and diluted net loss per share as the Company has issued shares that meet the definition of participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. The Company&#8217;s participating securities contractually entitle the holders of such shares to participate in dividends; but do not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, in periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. <font style="color:#000000;letter-spacing:-0.1pt;">For additional discussion of net loss per common share, please see Note 12, </font><font style="font-style:italic;color:#000000;letter-spacing:-0.1pt;">Net Loss Per Share. </font><font style="color:#000000;letter-spacing:-0.1pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2018-13, <font style="font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement</font> on January&#160;1, 2020. This standard modifies certain disclosure requirements on fair value measurements. The adoption of this standard did not have a material impact on the Company&#8217;s disclosures. </p>
<p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements Not Yet Adopted </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-13,<font style="font-style:italic;">&#160;Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</font>. This standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and it establishes additional disclosure requirements related to credit risks. For available-for-sale securities with expected credit losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This guidance was originally effective for fiscal years beginning after December&#160;15, 2019, including interim periods within those fiscal years, and early adoption was permitted. In November 2019, the FASB subsequently issued ASU 2019-10, <font style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging</font> <font style="font-style:italic;">(Topic 815), and Leases (Topic 842): Effective Dates </font>(&#8220;ASU 2019-10&#8221;), whereby the effective date of this standard for smaller reporting companies was deferred to fiscal years beginning after December&#160;15, 2022, including interim periods within those fiscal years, and early adoption is still permitted. The Company is assessing the impact of ASU 2019-10 on the consolidated financial statements and does not expect it to have a material impact.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the FASB issued ASU No.&#160;2020-06, <font style="font-style:italic;">Debt &#8211; Debt with Conversion and Other</font> <font style="font-style:italic;">Options</font> (Subtopic 470-20) <font style="font-style:italic;">and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity</font> (Subtopic 815-40)<font style="font-size:12pt;"> </font>(&#8220;ASU 2020-06&#8221;). This standard amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity&#8217;s own equity and amends the related earnings per share (&#8220;EPS&#8221;) guidance. The ASU will be effective for smaller reporting companies for fiscal years beginning after December&#160;15, 2023 and interim periods within those fiscal years. Early adoption is permitted in fiscal years beginning after December&#160;15, 2020, including interim periods within those fiscal years. The Company is assessing the impact of&#160;ASU 2020-06&#160;on the consolidated financial statements and does not expect it to have a material impact. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued&#160;ASU&#160;2019-12,<font style="font-style:italic;">&#160;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</font>&#160;(&#8220;ASU&#160;2019-12&#8221;), which is intended to simplify the accounting for income taxes.&#160;ASU&#160;2019-12&#160;removes certain exceptions to the general principles in Topic 740 and also clarifies and amends certain aspects of the existing guidance to improve consistent application. The new standard will be effective for public business entities for fiscal years beginning after December&#160;15, 2020. The Company is assessing the potential impact&#160;ASU&#160;2019-12&#160;may have on its financial statements upon adoption. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected to use the extended transition period related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different effective dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time that the Company either (i)&#160;irrevocably elects to &#8220;opt out&#8221; of such extended transition period or (ii)&#160;no longer qualifies as an emerging growth company. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3. Fair Value of Financial Assets </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63090922"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Assets</font></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">447,146</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">447,146</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US treasury bills</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,026</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,026</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US agency securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197,389</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197,389</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,415</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,415</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">447,146</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,415</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">677,561</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63090923"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Assets</font></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,658</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,658</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US treasury bills</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,604</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,604</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US agency securities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,258</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,258</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313,862</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313,862</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,658</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313,862</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">355,520</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In determining the fair value of its investments at each date presented above, the Company relied on quoted prices for similar securities in active markets or using other inputs that are observable or can be corroborated by observable market data. The Company did not have any financial assets or liabilities during any of the periods presented in the accompanying consolidated financial statements that required Level&#160;3 inputs. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4. Investments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of available-for-sale investments by type of security was as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:98.64%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S treasury bills</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,997</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S agency securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,996</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,001</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments with a maturity of one year or less</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,993</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S treasury bills</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,008</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,008</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S agency securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176,350</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176,388</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments with a maturity of one to two years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179,358</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179,396</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,351</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,415</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:93.84%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63090925"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S treasury bills</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,336</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">268</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,604</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S agency securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,201</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,258</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments with a maturity of one year or less</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313,537</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313,862</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. Collaboration and License Arrangement with Genentech</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 11, 2020, the Company entered into the Genentech Agreement, which granted Genentech a license to develop and commercialize RLY-1971. RLY-1971 is currently being developed in a Phase 1a clinical trial for patients with advanced solid tumors (the &#8220;Phase 1a Trial&#8221;). Unless Genentech elects to exercise its option to conduct the remainder of the ongoing Phase 1a Trial, the Company is responsible for the completion of this trial. Genentech is responsible for conducting all subsequent clinical development of RLY-1971. The Company is also responsible for the one-time transfer of the active pharmaceutical ingredient (&#8220;API&#8221;) and other materials related to RLY-1971 to Genentech. </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Genentech Agreement, the Company is entitled to a non-refundable upfront payment of $75,000, which is due upon completion of certain technology transfer activities and is reflected as accounts receivable on the consolidated balance sheet at December 31, 2020. The Company collected this amount in full in January 2021. The Company is eligible to receive up to $25,000 in near-term milestone payments. The Company is also eligible to receive up to an aggregate of an additional $695,000 upon the achievement of specified development, commercialization and sales-based milestones for RLY-1971 worldwide as well as tiered royalties ranging from low-to-mid teens on annual worldwide net sales of RLY-1971, on a country-by-country basis, subject to reduction in certain circumstances. </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has the option, exercisable one time at the Company&#8217;s sole discretion, to (a) fund half of the development costs of RLY-1971 in the U.S., (b) share half of the net profits or net loss of commercializing RLY-1971 in the U.S. (the &#8220;Profit/Cost Share&#8221;) and (c) be eligible to receive up to an aggregate of an additional $410,000 upon the achievement of specified commercialization and sales-based milestones for RLY-1971 outside of the U.S and tiered royalties ranging from low-to-mid teens on annual net sales of RLY-1971 outside of the U.S., on a country-by-country basis, subject to reduction in certain circumstances. The Company may elect to opt-out of further participation in the Profit/Cost Share at any time prior to the third anniversary of the first commercial sale of RLY-1971 in the U.S, in which case the financial terms would revert to the terms applicable as if Company had not opted into the Profit/Cost Share as of the effective opt-out date.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genentech may terminate the Genentech Agreement for convenience and the Company may terminate the Genentech Agreement under certain limited circumstances. Unless otherwise terminated, the Genentech Agreement will remain in effect until the expiration of all Genentech&#8217;s royalty payment obligations to the Company.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting Analysis </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Identification of the Contract </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company concluded that Genentech is a customer in this arrangement and as such, the arrangement falls within the scope of the revenue recognition guidance in ASC 606. </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Identification of Performance Obligations </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the commencement of the Genentech Agreement, the Company identified the following performance obligations in the agreement:</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.4%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;"></font><font style="color:#000000;"></font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License to develop and commercialize RLY-1971 and the related know-how; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.4%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Research and development services to complete the Phase 1a Trial for RLY-1971; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.4%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Transfer of API and other materials related to RLY-1971 </p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the performance obligations outlined above are both capable of being distinct and distinct within the context of the contract given such rights and activities are independent of each other. The license can be used by <font style="color:#000000;">Genentech without the research and development services or API outlined above,</font> and similarly those services and inventory provide distinct benefit to Genentech within the context of the contract, separate from the license.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Determination of Transaction Price </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined the transaction price for the Genentech Agreement to be $85,867, which includes both fixed and variable consideration amounts. The total transaction price of $85,867 is comprised of (i) the $75,000 fixed, non-refundable upfront payment, (ii) a $5,000 non-refundable milestone payment due upon the transfer of the  <font style="color:#000000;">Investigational New Drug (&#8220;IND&#8221;) application </font>to Genentech, (iii) a $5,000 non-refundable milestone payment due upon completion of the Phase 1a Trial for RLY-1971 and (iv) $867 of estimated variable consideration related to reimbursements due from Genentech for research and development services. No additional development milestone payments and no regulatory milestone payments are included in the transaction price as all such payments are fully constrained. As part of management&#8217;s evaluation of the constraint, the Company considered numerous factors, including the consideration that achievement of the milestones is outside of the Company&#8217;s control, contingent upon Genentech&#8217;s efforts and the receipt of regulatory approval and subject to scientific risks of success. </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Allocation of Transaction Price to Performance Obligations </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company allocated the transaction price of $85,867 based on the stand-alone selling prices (&#8220;SSP&#8221;) of each of the performance obligations as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.4%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>$82,654 million for the transfer of the license</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.4%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>$2,896 million for research and development services; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.4%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>$317 million for the transfer of API.</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SSP for the license was determined using an approach that considered discounted, probability-weighted cash flows related to the license transferred. The Company also reviewed comparable market transactions in determining the SSP of the license. The SSP for the research and development services as well as the transfer of API were based on estimates of the associated effort and cost of these services and cost to manufacture API, adjusted for a reasonable profit margin that would be expected to be realized under similar contracts. The Company performed sensitivity analyses supporting reasonable changes to the SSPs noting no material impact on revenue recognized for the year ended December 31, 2020.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Recognition of Revenue </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is recognizing revenue for each of the three performance obligations as follows: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.4%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>The Company recognized revenue related to the license at a point in time upon transfer of the license to Genentech. The Company recognized the full amount allocated to the license and related know-how in the fourth quarter of 2020 because the Company had transferred the license upon execution of the Genentech Agreement. Revenue recognized during the year ended December 31, 2020 related to the license amounted to $82,654.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.4%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>The Company will satisfy the research and development performance obligation for RLY-1971&#160;as the research and development services are performed.&#160;The research and development services performance obligation consists of the Company completing the Phase 1a clinical trial initiated in the first quarter of 2020. The Company recognizes revenue related to the research and development services over time using a cost-based input method by calculating actual costs incurred to date at each period end relative to total </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.4%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">estimated costs expected to be incurred to fulfill the performance obligation. There was </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> revenue recognized related to this performance obligation during the year </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ended December 31, </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as the services performed from contract inception to December 31, 2020 were immaterial.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.4%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>The Company will recognize revenue related to the transfer of API at a point in time upon transfer to Genentech. There was no revenue recognized related to this performance obligation during the year ended December 31, 2020.&nbsp;&nbsp;</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, the Company recognized an aggregate of $82,654 of revenue from the Genentech Agreement related entirely to the transfer of the license. At December 31, 2020, the Company recorded accounts receivable under the Genentech Agreement in the amount of $75,000 and a contract asset in the amount of $7,654, which is classified as a current asset, on the balance sheet. The contract asset relates to the amount of revenue recognized for which the right to payment is contingent upon conditions other than the passage of time, such as the completion of future milestone activities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6. Property and Equipment, Net </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63090926"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,534</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,003</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">886</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">860</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">888</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">827</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">895</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">895</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in process</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">577</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">490</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,780</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,075</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,530</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,981</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,250</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,094</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded $3,549 and $2,845 of depreciation expense for the years ended December&#160;31, 2020 and 2019, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7. Accrued Expenses and Other Current Liabilities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">External research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,099</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,077</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional services</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">464</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">336</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,760</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,746</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8. Convertible Preferred Stock </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company issued Series A, Series B and Series C convertible preferred stock (collectively, &#8220;Convertible Preferred Stock&#8221;). Upon issuance of each class of Convertible Preferred Stock, the Company assessed the embedded conversion and liquidity features of the shares and determined that such features did not require the Company to separately account for these features. The Company also concluded that no beneficial conversion feature existed on the issuance date of each class of Convertible Preferred Stock. The Company&#8217;s Convertible Preferred Stock was </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">classified outside of stockholders&#8217; equity (deficit) on the consolidated balance sheet prior to the Company&#8217;s IPO because the holders of such shares had liquidation rights in the event of a deemed liquidation that, in certain situations, were not solely within the control of the Company and would require the redemption of the then-outstanding Convertible Preferred Stock. The Convertible Preferred Stock was not </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">currently </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">redeemable</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Because the occurrence of a deemed liquidation event was not probable, the carrying values of the Convertible Preferred Stock were not accreted to their redemption values. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 8, 2020, the Company&#8217;s board of directors and its Series C preferred stockholders approved a reduction in the conversion price of the Series C preferred stock from $3.21 to $3.027603 and the Series C preferred stockholders relinquished their protective right with respect to the approval of an automatic conversion of preferred stock in a firm commitment underwritten public offering if the per share price is less than $22.80. As a result of the change in the conversion price, the outstanding shares of Series C preferred stock were convertible into 37,206,604 shares of common stock. The changes to the conversion feature were considered to be a significant change to the substantive contractual terms of the Series C preferred stock and, therefore, the Company accounted for the changes as an extinguishment and reissuance of the Series C preferred stock, which required the difference between the fair value of the modified Series C preferred stock and its carrying amount to be treated in a manner similar to the treatment of dividends paid on preferred stock.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the closing of the Company&#8217;s IPO in July 2020, all outstanding Convertible Preferred Stock automatically converted into 61,992,534 shares of common stock. No Convertible Preferred Stock was outstanding as of December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to January&#160;1, 2019, the Company issued a total of 56,824,740 shares of Series A convertible preferred stock (&#8220;Series A preferred stock&#8221;), 31,188,115 shares of Series B convertible preferred stock (&#8220;Series B preferred stock&#8221;) and 122,850,909 shares of Series C convertible preferred stock (&#8220;Series C preferred stock&#8221;) in exchange for net proceeds of $56,692, $62,876 and $393,587, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, the Company issued an additional 1,779,093 shares of Series C preferred stock at a per share price of $3.21 for proceeds of $5,661, net of issuance costs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible Preferred Stock consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63090928"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Authorized</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issued</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preference</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issuable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Upon</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Conversion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,824,740</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,824,740</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,657</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,825</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,002,820</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,188,115</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,188,115</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,876</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,783,102</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249,260,004</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124,630,002</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">399,248</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">400,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,097,955</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">337,272,859</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212,642,857</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">537,781</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">519,825</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,883,877</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no shares of Convertible Preferred Stock outstanding at December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of the Convertible Preferred Stock had the following rights and preferences: </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Voting </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of the Convertible Preferred Stock had voting rights equivalent to the number of shares of common stock into which their shares of preferred stock would convert. So long as any of the Convertible Preferred Stock was outstanding, a requisite vote of the Convertible Preferred Stockholders, which was defined as a majority of the Convertible Preferred Stockholders, was required to affirm certain corporate actions, which included, but was not </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">limited to</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the disposal of assets, the acquisition of assets or a business and the authorization of additional shares of the Company&#8217;s capital. In addition, such actions require</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a requisite vote of the Series C preferred stockholders and a majority vote of the Series B preferred stockholders, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> any of the respective preferred stock </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> outstanding. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Dividends </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of the Convertible Preferred Stock were entitled to receive noncumulative dividends when and if declared by the Company&#8217;s board of directors. If the Company declared, paid or set aside, on the same date, a dividend on shares of more than one class or series of capital stock of the Company, the holders of the Convertible Preferred Stock were entitled to the same dividend based on the number of common shares the Convertible Preferred Stock would convert into. No dividends were declared or paid during the years ended December&#160;31, 2020 or 2019.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidation Rights </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the corporation, holders of the Series C preferred stock then outstanding were entitled to be paid out of the assets of the Company available for distribution to its stockholders before any payment was made to the holders of Series A and B preferred stock or common stock by reason of their ownership thereof, an amount per share equal to the greater of (i)&#160;the Series C preferred stock original issue price ($3.21), plus any accrued but unpaid dividends declared, and (ii)&#160;an amount per share if the Series C preferred stock had been converted prior to the liquidation event. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Next, the holders of the Series A preferred stock then outstanding together with holders of Series B preferred stock were entitled to be paid out of the assets of the Company available for distribution to its stockholders before any payment would be made to the common stockholders by reason of their ownership thereof, an amount per share equal to the greater of (i)&#160;their original issue price, which was $1.00 and $2.02 for Series A and B preferred stock, respectively, plus any accrued but unpaid dividends declared, and (ii)&#160;an amount per share if the Series A and B preferred stock, respectively, had been converted prior to the liquidation event. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Conversion </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Convertible Preferred Stock was convertible into common stock at any time at the option of the holder, and was subject to automatic conversion upon the closing of a firm commitment underwritten public offering with either a price per share of at least $22.80 and proceeds of at least $100,000 or approval by a specified vote of the Convertible Preferred Stockholders. As of December 31, 2019, the Convertible Preferred Stock was convertible into 59,382,845 shares of common stock. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 8, 2020, the required Convertible Preferred Stockholders authorized the automatic conversion of all shares of Convertible Preferred Stock in an IPO, regardless of the price per share or total proceeds raised, as long as the IPO was completed on or before September 30, 2020.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Protective Rights </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For as long as any of the Series C preferred stock was outstanding, a requisite vote of the Convertible Preferred Stockholders was required to affirm a liquidation, dissolution, a merger or consolidation or any other deemed liquidation event if the per share proceeds to the holders of the Series C preferred stock would be equal to or greater than $22.80 per share. In addition, both a requisite vote of the Convertible Preferred Stockholders and a majority of the Series C preferred stockholders was required to affirm a liquidation, dissolution, a merger or consolidation or any other deemed liquidation event if the per share proceeds to the holders of the Series C preferred stock was less than $22.80 per share. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9. Common Stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Company&#8217;s board of directors, however, holders of convertible preferred stock were entitled to any dividend received by the common </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tock</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">holders if each preferred share </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">had been</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> converted into common stock. As of December&#160;31, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> dividends had been declared. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company issued restricted shares of common stock to its founders and non-employees. In addition, the Company issued restricted shares of common stock upon the early exercise of stock options under the Company&#8217;s 2016 Stock Option and Grant Plan (the &#8220;2016 Stock Plan&#8221;). The restrictions on the common shares generally lapse over four years. The Company included the proceeds from the sale of the restricted shares of common stock as a restricted stock liability on the accompanying consolidated balance sheets. Amounts are reclassified to additional paid-in capital as the restrictions lapse. The Company has the right to repurchase any unvested shares of restricted common stock at the original cost in the event of termination. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the restricted stock activity for the year ended December&#160;31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63090929"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchase</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">679,158</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.21</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(579,825</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.26</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,844</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.03</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,489</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.04</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of shares that vested during the year ended December&#160;31, 2020 was $9,619. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has reserved the following shares of common stock: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63090930"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Series A preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,002,820</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Series B preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,783,102</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Series C preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,097,955</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved under the compensation plan</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,026,772</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,407,169</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total shares of common stock reserved for</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issuance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,026,772</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,291,046</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July&#160;8, 2020, the Company&#8217;s stockholders approved the 2020 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP became effective on the date immediately prior to the effectiveness of Company&#8217;s registration statement on Form S-1 for its IPO. As of December 31, 2020, the ESPP provides for the issuance of up to 1,092,532 of share-based awards. As of December&#160;31, 2020, no shares have been issued under the ESPP. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. Share-Based Payments </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2016, the Company adopted the 2016 Stock Plan. On July&#160;8, 2020, the Company&#8217;s stockholders approved the 2020 Stock Option and Incentive Plan (the &#8220;2020 Stock Plan&#8221;), which became effective on the date immediately prior to the effectiveness of the Company&#8217;s registration statement on Form S-1 for its IPO. The 2020 Stock Plan provides for the issuance of up to 8,376,080 of share-based awards. Subsequent to July&#160;20, 2020, no further awards will be made under the 2016 Stock Plan and all future equity-based awards will be granted under the 2020 Stock Plan. To the extent outstanding options granted under the 2016 Plan are cancelled, forfeited or otherwise terminated without being exercised and would otherwise have been returned to the share reserve under the 2016 Plan, the number of shares underlying such awards will be available for future grant under the 2020 Stock Plan. All of the Company&#8217;s employees, officers, directors and consultants are eligible to be granted options, restricted stock units </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and other stock-based awards under the terms of the 2020 Stock Plan. There were </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">026</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,7</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> share-based awards available for grant at December&#160;31, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the stock option activity under the 2016 Stock Plan and the 2020 Stock Plan for the year ended December&#160;31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:89.88%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,306,176</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.62</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.99</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,214</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,898,663</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.90</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(297,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.09</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(210,781</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.91</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,697,058</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.99</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.50</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">266,050</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,148,119</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.49</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.90</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,625</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-vested at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,548,939</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.96</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.74</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,425</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the first quarter of 2020, the Company&#8217;s board of directors approved the issuance of options with performance-based vesting conditions to purchase 1,960,547 shares of common stock. The commencement of vesting was based on the achievement of certain scientific and operational milestones during a two-year period, for which the achievement was discretionary and subject to the approval of the Company&#8217;s board of directors. Accordingly, the Company applied variable accounting for these awards until the board of directors approved the commencement of vesting for the options. The service inception date preceded the grant date for these awards as the awards were authorized prior to the grant date, the recipients were providing service prior to the grant date and there were performance conditions that, if not met by the accounting grant date, would have resulted in the forfeiture of the award. The stock-based compensation expense for the options was determined based on the fair value of the awards on the accounting grant date. The Company&#8217;s board of directors, in its discretion, determined that a portion of the performance conditions were achieved during the second quarter of 2020 and that the remaining portion of the performance conditions were achieved during the fourth quarter of 2020. The grant dates for all performance-based awards was therefore known as of December 31, 2020, and all performance conditions have been resolved. The Company recognized stock-based compensation expense associated with the awards with performance-based vesting conditions in the amount of $25,527 in the statement of operations for the year ended December 31, 2020. Expense for these awards is recognized using an accelerated attribution model, over the four-year vesting term, commencing upon grant date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimated the fair value of its stock options using the following assumptions: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63090932"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.4 - 1.8%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5 &#8211; 2.5%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73.5 - 77.6%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.8 &#8211; 73.47%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average grant date fair value of stock options granted during the years ended December&#160;31, 2020 and 2019 was $30.14 per share and $3.34 per share, respectively. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-22</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense included in the Company&#8217;s consolidated statements of operations and comprehensive loss is as follows: </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63090933"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,691</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,687</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,269</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,769</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,960</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,456</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, total unrecognized compensation cost related to the unvested stock-based awards was $69,948, which is expected to be recognized over a weighted average period of 2.61 years. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11. Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2020 and 2019, the Company recorded no income tax benefits due to the losses incurred due to the uncertainty of future taxable income. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the expected income tax (benefit) computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows for the year ended December&#160;31, 2020 and 2019: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax computed at federal statutory rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes, net of federal benefit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27.3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D credit carryovers</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6.7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.9</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s deferred tax assets at December&#160;31, 2020 and 2019, consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,832</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,647</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credit carryforwards</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,270</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,309</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,430</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,542</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangibles</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,469</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,498</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,496</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">534</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross deferred tax asset</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,741</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,731</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,813</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,537</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax asset</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,928</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,194</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,928</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,194</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,928</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,194</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred net operating losses (&#8220;NOL&#8221;) since inception. As of December&#160;31, 2020, the Company had federal NOL carryforwards of $174,028 available to reduce taxable income, of which $43,127 expire beginning </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-23</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2035</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">901</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> do not expire. The Company has state NOL carryforwards of $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">346</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as of December&#160;31, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> available to reduce future state taxable income, which expire at various dates beginning in </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2035</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company also had available federal research and development tax credit carryforwards of $8,139 available to reduce future tax liabilities, which begin to expire beginning in 2035. The Company also has state research and development tax credit carryforwards of $2,699 available to reduce future state tax liabilities, which expire at various dates beginning in 2030.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilization of the NOL carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section&#160;382 of the Internal Revenue Code of 1986 (&#8220;Section 382&#8221;) due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section&#160;382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section&#160;382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section&#160;382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed and any limitation is known, no amounts are being presented as an uncertain tax position. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded a valuation allowance against its deferred tax assets for the years ended December&#160;31, 2020 and 2019 because the Company&#8217;s management believes that it is more likely than not that these assets will not be realized. The valuation allowance increased by approximately $14,276 and $23,307 for the years ended December&#160;31, 2020 and 2019, respectively, primarily as a result of operating losses generated with no corresponding financial statement benefit. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had no unrecognized tax benefits as of December&#160;31, 2020 and 2019.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company&#8217;s tax years are still open under statute from inception to the present. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law in March 2020. The CARES Act lifts certain deduction limitations originally imposed by the Tax Cuts and Jobs Act of 2017 (&#8220;2017 Tax Act&#8221;). Corporate taxpayers may carryback NOLs originating during 2018 through 2020 for up to five years, which was not previously allowed under the 2017 Tax Act. The CARES Act also eliminates the 80% of taxable income limitations by allowing corporate entities to fully utilize NOL carryforwards to offset taxable income in 2018, 2019 or 2020. Taxpayers may generally deduct interest up to the sum of 50% of adjusted taxable income plus business interest income (30% limit under the 2017 Tax Act) for tax years beginning January&#160;1, 2019 and 2020. The CARES Act allows taxpayers with alternative minimum tax credits to claim a refund in 2020 for the entire amount of the credits instead of recovering the credits through refunds over a period of years, as originally enacted by the 2017 Tax Act. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the CARES Act raises the corporate charitable deduction limit to 25% of taxable income and makes qualified improvement property generally eligible for 15-year cost-recovery and 100% bonus depreciation. The enactment of the CARES Act did not result in any adjustments to the Company&#8217;s income tax provision for the year ended December&#160;31, 2020, or to the Company&#8217;s net deferred tax assets as of December&#160;31, 2020, since the Company has not recorded any U.S. federal or state income tax benefits for the net losses incurred in any year due to the uncertainty of realizing a benefit from those items. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-24</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">. Net Loss Per Share </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the computation of basic and diluted net loss per share of the Company: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,412</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,305</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deemed dividend resulting from extinguishment upon modification of Series&#160;C preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(177,789</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(230,201</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,305</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders per share, basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5.40</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21.82</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares of common stock, basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,619,582</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,450,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As discussed in Note 8, on July&#160;8, 2020, the Company&#8217;s board of directors and its Series C preferred stockholders approved an amendment to the conversion preferences and rights of the Series C preferred stock which, among other changes, resulted in a reduction in the conversion price of the Series C preferred stock from $3.21 to $3.027603. The changes to the conversion feature were considered to be a significant change to the substantive contractual terms of the Series C preferred stock and, therefore, the Company accounted for the changes as an extinguishment and reissuance of the Series C preferred stock. In accordance with SEC staff guidance codified in ASC 260-10-S99-2, when equity classified preferred shares are extinguished, the difference between (1)&#160;the fair value of the consideration transferred to the holders of the preferred shares and (2)&#160;the carrying amount of the preferred shares, net of issuance costs, is subtracted from (or added back to) net income to arrive at income available to common stockholders in the calculation of earnings per share. This difference between the fair value of consideration transferred and carrying amount of the preferred shares, also referred to as a &#8220;deemed dividend&#8221;, was therefore added back to net loss above to derive net loss attributable to common stockholders. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s potentially dilutive securities, which include Convertible Preferred Stock (prior to the IPO), options to purchase common stock and unvested restricted stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,883,877</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,697,058</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,306,176</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,489</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">679,158</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,781,547</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,869,211</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13. Commitments and Contingencies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intellectual Property License </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a Collaboration and License Agreement with D. E. Shaw Research, LLC (&#8220;D. E. Shaw Research&#8221;), which held 9,999,999 shares of Series A preferred stock and 1,557,875 shares of Series C preferred stock at December 31, 2019. Upon the IPO these shares were converted into 3,281,253 shares of common stock, which are outstanding at December 31, 2020. The agreement provides that the parties will jointly conduct research efforts with the goal of identifying and developing product candidates. The original term of the agreement was three years and required the Company to pay an annual fee of $1,000. On June 15, 2020, the Company and D. E. Shaw Research agreed to amend the Collaboration and License Agreement (the &#8220;Amended and Restated Collaboration and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-25</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License Agreement&#8221;). The Amended and Restated Collaboration and License Agreement extended the term of the agreement to </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 16, 2025</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and increased the annual fee from $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,900</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The Amended and Restated Collaboration and License Agreement automatically renews for successive one year periods unless either party provides at least </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one year</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> notice of non-renewal, and the annual fee during each of the one year renewal terms is subject to the mutual agreement of the Company and D. E. Shaw Research.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is obligated to pay potential development milestone payments under the terms of the agreement up to $7,300 per target, plus sales milestones and royalties, upon the achievement of certain specified contingent events. Such payments for achievement of development and regulatory milestones total up to $7,250 in the aggregate for each of the first three products the Company develops, and up to $6,250 in the aggregate for each product the Company develops after the first three. The Company assessed the milestone and royalty events through December 31, 2020 and concluded $1,500 was due to D.E. Shaw related to the execution of the Genentech Agreement in December 2020. The Company concluded no such payments were due as of December 31, 2019. The Company recorded research and development expense of $6,376 and $1,500 under this agreement for the years ended December 31, 2020 and 2019, respectively. At December 31, 2020 and December 31, 2019, the Company had an accrued expense balance to D. E. Shaw Research of approximately $1,500 and $372, respectively, on its balance sheets. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Research Arrangements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has certain other research and license arrangements with third-parties, which provide the Company with research services with the goal of identifying and developing product candidates. The Company is obligated to pay development milestone payments for up to four targets, each in the range of $4,000 to $7,000 upon the achievement of certain specified contingent events. The Company assessed the milestones at December&#160;31, 2020 and 2019 and concluded no such milestone payments were due. The Company incurred approximately $2,704 and $3,493 of research and development expense under these agreements in the years ended December&#160;31, 2020 and 2019, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14. Leases </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">215 First Street </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leased office and laboratory space at 215 First Street in Cambridge, Massachusetts (&#8220;First Lease&#8221;) under an operating lease, which commenced in November 2015 and was originally set to expire in December 2020. As discussed below, the Company executed a lease at 399 Binney Street (&#8220;Binney Lease&#8221;) whereby the Company vacated the 215 First Street lease in January 2019 and the future lease commitments terminated at no cost once the Binney Lease commenced. The lease included certain tenant improvement allowances, which the Company amortized through January 2019, the termination of the lease. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">399 Binney Street </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2017, the Company entered into a facility lease agreement for approximately 44,336 square feet of office and laboratory space at 399 Binney Street, Cambridge, Massachusetts, which was increased to 44,807 square feet in January 2018. The Company gained control of the leased space in January 2019 and recorded a right of use asset and a lease liability, accordingly. The lease expires in April 2029, subject to certain renewal options, which have not been included in the Company&#8217;s right of use asset and liability, as the Company is not reasonably certain to exercise those options. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2020, the Company entered into an amendment to its facility lease agreement to expand the leased area by approximately 1,824 square feet of office space at 399 Binney Street, Cambridge, Massachusetts. The amended lease expires in April 2029, subject to certain renewal options. The amendment to the lease agreement met the criteria to be accounted for as a separate lease. The Company gained control of the leased space in October 2020 and recorded a right of use asset and a lease liability, accordingly. The right of use asset and lease liability recorded in connection with this amendment were not material.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-26</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As discussed in Note 2, the Company provided a letter of credit in the amount of $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">878</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with a financial institution, which expires </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30, 2028</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the presentation of the Company&#8217;s operating leases on its consolidated balance sheets: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63090938"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance sheet location</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,579</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,560</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current operating lease</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,521</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,249</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current operating lease</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, net of current portion</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,901</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,583</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,422</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,832</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the effect of lease costs in the Company&#8217;s consolidated statements of operations and comprehensive loss for the years ended December&#160;31, 2020 and 2019: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63090939"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Statement of operations location</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,273</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,216</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">748</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">581</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease cost</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,797</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company made cash payments of $4,878 and $2,602 under the lease agreements during the years ended December&#160;31, 2020 and 2019, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The minimum lease payments as of December&#160;31, 2020 for the next five years and thereafter is expected to be as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63090940"></a>Year Ending December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,985</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,134</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,254</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,377</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,503</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,959</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,212</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: interest</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,790</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of operating lease liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,422</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average remaining lease term and weighted average discount rate of the operating leases were 8.3 years and 10.4%, respectively, at December&#160;31, 2020. The weighted average remaining lease term and weighted average discount rate of the operating leases were 9.3 years and 10.4%, respectively, at December&#160;31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15. Employee Benefits </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2016, the Company established a defined-contribution plan under Section&#160;401(k) of the Internal Revenue Code (the &#8220;401(k) Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. The Company made </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-27</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">matching contributions to the 401(k) Plan of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">590</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for the year ended December&#160;31, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> not required to make and</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> did</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> not ma</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">k</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e any matching contributions to the 401(k) Plan for the year</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ended December&#160;31,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16. Related Party Transactions </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From inception to December&#160;31, 2020, the Company received consulting and management services from Third Rock Ventures LLP (&#8220;TRV&#8221;), an entity affiliated with certain of the Company&#8217;s investors. The Company did not incur expenses for such services during the year ended December 31, 2020<font style="font-size:12pt;">. </font>The Company incurred approximately $200 for these services during the year ended December&#160;31, 2019. No amounts were due to TRV at December&#160;31, 2020. At December&#160;31, 2019, $80 was due to TRV for these services.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17. Subsequent Events </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In preparing the consolidated financial statements as of December&#160;31, 2020, the Company evaluated subsequent events for recognition and measurement purposes through the filing date of this Annual Report on Form 10-K. The Company concluded that no events or transactions have occurred that require disclosure in the accompanying consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-28</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT INDEX</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">3.1</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000119312520196383/d29076dex31.htm"><font style="text-decoration:underline;">Fourth Amended and Restated Certificate of Incorporation of Relay Therapeutics, Inc. (Incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Form 8-K (File No. 001-39385) filed on July 21, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">3.2</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000119312520196383/d29076dex32.htm"><font style="text-decoration:underline;">Amended and Restated Bylaws of Relay Therapeutics, Inc. (Incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Form 8-K (File No. 001-39385) filed on July 21, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000119312520190069/d924757dex41.htm"><font style="text-decoration:underline;">Specimen stock certificate evidencing the shares of common stock (Incorporated by reference to Exhibit 4.1 to our Registration Statement on Form S-1/A (File No. 333-239412) filed on July 9, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:53.25pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000119312520190069/d924757dex42.htm"><font style="text-decoration:underline;">Second Amended and Restated</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Investors&#8217;</font><font style="letter-spacing:0.1pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Rights</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Agreement</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">among</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">the</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Registrant</font><font style="letter-spacing:0.1pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">and certain of its</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">stockholders,</font><font style="letter-spacing:0.1pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">effective</font><font style="letter-spacing:0.1pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">as of December</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">19, 2018 as amended</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">on June 26, 2020 (incorporated by reference to Exhibit 4.2 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-239412) filed on July 9, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3*</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="rlay-ex43_903.htm"><font style="text-decoration:underline;">Description of Securities</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1#</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000119312520177746/d924757dex101.htm"><font style="text-decoration:underline;">2016 Stock Option and Grant</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Plan, and form</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">of award agreements</font><font style="letter-spacing:0.1pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">thereunder (incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-239412) filed on June 24, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2#</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000119312520190069/d924757dex102.htm"><font style="text-decoration:underline;">2020 Stock Option and Incentive</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Plan, and form</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">of award agreements</font><font style="letter-spacing:0.1pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">thereunder (incorporated by reference to Exhibit 10.2 of the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-239412) filed on July 9, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3#</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000119312520190069/d924757dex103.htm"><font style="text-decoration:underline;">2020 Employee</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Stock Purchase</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Plan (incorporated by reference to Exhibit 10.3 of the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-239412) filed on July 9, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4#</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000119312520177746/d924757dex104.htm"><font style="text-decoration:underline;">Senior</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Executive</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Cash Bonus Plan (incorporated by reference to Exhibit 10.4 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-239412) filed on June 24, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5#</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000119312520190069/d924757dex105.htm"><font style="text-decoration:underline;">Non-Employee</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Director</font><font style="letter-spacing:0.1pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Compensation</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Policy (incorporated by reference to Exhibit 10.5 of the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-239412) filed on July 9, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6#</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000119312520177746/d924757dex106.htm"><font style="text-decoration:underline;">Form</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">of Indemnification</font><font style="letter-spacing:0.15pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Agreement</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">between</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">the</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Registrant</font><font style="letter-spacing:0.1pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">and each</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">of its</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">directors</font><font style="letter-spacing:0.1pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">and executive</font><font style="letter-spacing:0.1pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">officers (incorporated by reference to Exhibit 10.6 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-239412) filed on June 24, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7#</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000119312520190069/d924757dex108.htm"><font style="text-decoration:underline;">Form</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">of Amended and Restated</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Employment</font><font style="letter-spacing:0.1pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Agreement (incorporated by reference to Exhibit 10.8 of the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-239412) filed on July 9, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.8#</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000119312520177746/d924757dex109.htm"><font style="text-decoration:underline;">Amended and Restated Employment Agreement, by and between the Registrant and Sanjiv K. Patel dated March 25, 2020 (incorporated by reference to Exhibit 10.9 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-239412) filed on June 24, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.9</font><font style="color:#000000;">&#8224;</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000119312520177746/d924757dex1010.htm"><font style="text-decoration:underline;">Amended and Restated</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Collaboration</font><font style="letter-spacing:0.1pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">and License</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Agreement,</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">by and between</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">the</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Registrant and D. E. Shaw Research,</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">LLC, dated</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">June 15, 2020 (incorporated by reference to Exhibit 10.10 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-239412) filed on June 24, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.10</font><font style="color:#000000;">&#8224;</font><font style="Background-color:#FFFFFF;">*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="rlay-ex1010_1012.htm"><font style="text-decoration:underline;">Collaboration and License Agreement, by and between the Registrant and Genentech, Inc. and F. Hoffmann-La Roche Ltd, dated as of December 11, 2020.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.11</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000119312520177746/d924757dex107.htm"><font style="text-decoration:underline;">Lease</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Agreement</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">between</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">the</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">Registrant</font><font style="letter-spacing:0.1pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">and ARE-MA</font><font style="letter-spacing:-0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">REGION</font><font style="letter-spacing:-0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">NO.</font><font style="letter-spacing:-0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">58, LLC,</font><font style="letter-spacing:-0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">dated</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">as of January</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">10, 2018 (incorporated by reference to Exhibit 10.7 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-239412) filed on June 24, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.12</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001812364/000119312520291681/d24902dex107.htm"><font style="text-decoration:underline;">Second Amendment to Lease, dated as of September 23, 2020, between the Registrant and ARE-MA REGION NO. 58, LLC (incorporated by reference to Exhibit 10.7 of the Registrant&#8217;s Form 10-Q (File No. 001-39385) filed on November 12, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">21.1*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="rlay-ex211_904.htm"><font style="text-decoration:underline;">List</font><font style="letter-spacing:0.05pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">of Subsidiaries</font><font style="letter-spacing:0.1pt;text-decoration:underline;"> </font><font style="text-decoration:underline;">of Registrant.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">23.1*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="rlay-ex231_1123.htm"><font style="text-decoration:underline;">Consent of Ernst &amp; Young LLP, independent registered public accounting firm.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">24.1*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#POA"><font style="text-decoration:underline;">Power of Attorney (included on signature page).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">31.1*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="rlay-ex311_6.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">31.2*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="rlay-ex312_7.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">32.1**</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="rlay-ex321_8.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.INS*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Instance Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.SCH*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Schema Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.CAL*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.DEF*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Definition Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.LAB*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Label Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.PRE*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.93%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filed herewith.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Annual Report on Form 10-K and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Portions of this exhibit (indicated by asterisks) were omitted in accordance with the rules of the Securities and Exchange Commission.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"># </font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Indicates a management contract or any compensatory plan, contract or arrangement.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div><a name="_AEIOULastRenderedPageBreakAEIOU15"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a><a name="SIGNATURES"></a>SIGNATURES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized<font style="font-weight:bold;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Relay Therapeutics, Inc. </p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 25, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Sanjiv K. Patel</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sanjiv K. Patel, M.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="POA"></a>POWER OF<a name="POA"></a> ATTORNEY AND SIGNATURES</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each person whose individual signature appears below hereby authorizes and appoints <font style="Background-color:#FFFFFF;">Sanjiv K. Patel, M.D. and Brian Adams</font>, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue thereof.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Sanjiv K. Patel</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">President, Chief Executive Officer and Director</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sanjiv K. Patel, M.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">(Principal Executive Officer)</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;<font style="Background-color:#FFFFFF;">Thomas Catinazzo</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior <font style="Background-color:#FFFFFF;">Vice President, Finance</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Thomas Catinazzo</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="Background-color:#FFFFFF;">Principal Accounting Officer and </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Principal Financial Officer)</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;<font style="Background-color:#FFFFFF;">Alexis Borisy</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Alexis Borisy</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;<font style="Background-color:#FFFFFF;">Linda A. Hill</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Linda A. Hill, Ph.D.</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;<font style="Background-color:#FFFFFF;">Douglas S. Ingram</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Douglas S. Ingram</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;<font style="Background-color:#FFFFFF;">Mark Murcko</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Mark Murcko, Ph.D.</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;<font style="Background-color:#FFFFFF;">Dipchand (Deep) Nishar</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Dipchand (Deep) Nishar</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;<font style="Background-color:#FFFFFF;">Jami Rubin</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Jami Rubin</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;<font style="Background-color:#FFFFFF;">Laura Shawver</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:21.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p></td>
</tr>
<tr style="height:3pt;">
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Laura Shawver, Ph.D.</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>rlay-ex43_903.htm
<DESCRIPTION>EX-4.3
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
rlay-ex43_903.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;4.3</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Description of the Registrant&#8217;s Securities Registered Pursuant to</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Section 12 of the Securities Exchange Act of 1934, as amended</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The summary of the general terms and provisions of the registered securities of Relay Therapeutics, Inc. (&#8220;Relay,&#8221; &#8220;we,&#8221; or &#8220;our&#8221;) set forth below does not purport to be complete and is subject to and qualified in its entirety by reference to our Fourth Amended and Restated Certificate of Incorporation (our &#8220;certificate of incorporation&#8221;) and our Amended and Restated Bylaws (our &#8220;bylaws&#8221; and, together with our certificate of incorporation, our &#8220;Charter Documents&#8221;), each of which is incorporated by reference as an exhibit to our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. We encourage you to read our Charter Documents and the applicable provisions of the General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;) for additional information.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">General</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our authorized capital stock consists of One Hundred Fifty Million (150,000,000) shares of common stock, par value $0.001 per share and Ten Million (10,000,000) shares of undesignated preferred stock, par value $0.001 per share.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Common stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_2"></a>The holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is listed on the Nasdaq Global Select Market under the trading symbol &#8220;RLAY.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_3"></a>The transfer agent and registrar for our common stock is Computershare Trust Company, N.A.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:2.22%;text-indent:-2.22%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors will have the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. No shares of preferred stock are outstanding, and we have no present plan to issue any shares of preferred stock. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:2.22%;text-indent:-2.22%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Registration rights</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain holders of our common stock, including those issuable upon the conversion of convertible preferred stock are entitled to rights with respect to the registration of these securities under the Securities Act. These rights are provided under the terms of a second amended and restated investors&#8217; rights agreement between us and the holders of our preferred stock. The second amended and restated investors&#8217; rights agreement includes demand registration rights, short-form registration rights, and piggyback registration rights. All fees, costs and expenses of underwritten registrations under this agreement will be borne by us and all selling expenses, including underwriting discounts and selling commissions, will be borne by the holders of the shares being registered.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Demand registration rights</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain holders of our common stock, are entitled to demand registration rights. Under the terms of the second amended and restated investors&#8217; rights agreement, we will be required, upon the written request of a majority of holders of the registrable securities then outstanding that would result in an aggregate offering price of at least $7.5 million, to file a registration statement and to use commercially reasonable efforts to effect the registration of all or a portion of these shares for public resale. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Short-Form registration rights</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to our second amended and restated investors&#8217; rights agreement, if we are eligible to file a registration statement on Form S-3, upon the written request of at least 10% in interest of these holders to sell registrable securities at an aggregate price of at least $1.0 million, we will be required to use commercially reasonable efforts to effect a registration of such shares. We are required to effect only two registrations in any twelve-month period pursuant to this provision of the second amended and restated investors&#8217; rights agreement. The right to have such shares registered on Form S-3 is further subject to other specified conditions and limitations.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Piggyback registration rights</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to our second amended and restated investors&#8217; rights agreement, if we register any of our securities either for our own account or for the account of other security holders, the holders of these shares are entitled to include their shares in the registration. Subject to certain exceptions contained in the second amended and restated investors&#8217; rights agreement, we and the underwriters may limit the number of shares included in the underwritten offering to the number of shares which we and the underwriters determine in our sole discretion will not jeopardize the success of the offering. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Indemnification</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our second amended and restated investors&#8217; rights agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of registrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Expiration of registration rights</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The demand registration rights and short form registration rights granted under our second amended and restated investors&#8217; rights agreement will terminate on the fifth anniversary of the completion of our initial public offering.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:2.22%;text-indent:-2.22%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Anti-Takeover effects of our certificate of incorporation and bylaws and Delaware law</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our certificate of incorporation and bylaws include a number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue non-negotiated takeover attempts. These provisions include the items described below. </p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.85%;text-indent:-1.85%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Board composition and filling vacancies</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our certificate of incorporation provides for the division of our board of directors into three classes serving staggered three-year terms, with one class being elected each year. Our certificate of incorporation also provides that directors may be removed only for cause and then only by the affirmative vote of the holders of two-thirds or more of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum. The classification of directors, together with the limitations on removal of directors and treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition of our board of directors. </p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.85%;text-indent:-1.85%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">No written consent of stockholders</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our certificate of incorporation provides that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our bylaws or removal of directors by our stockholders without holding a meeting of stockholders. </p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.85%;text-indent:-1.85%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Meetings of stockholders</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our certificate of incorporation and bylaws provide that only a majority of the members of our board of directors then in office may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our bylaws limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting. </p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.85%;text-indent:-1.85%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Advance notice requirements</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for the preceding year. Our bylaws specify the requirements as to form and content of all stockholders&#8217; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting. </p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:1.85%;text-indent:-1.85%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Amendment to certificate of incorporation and bylaws</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any amendment of our certificate of incorporation must first be approved by a majority of our board of directors, and if required by law or our certificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the provisions relating to stockholder action, board composition, and limitation of liability must be approved by not less than two-thirds of the outstanding shares entitled to vote on the amendment, and not less than two-thirds of the outstanding shares of each class entitled to vote thereon as a class. Our bylaws may be amended by the affirmative vote of a majority of the directors then in office, subject to any limitations set forth in the bylaws; and may also be amended by the affirmative vote of a majority of the outstanding shares entitled to vote on the amendment, voting together as a single class, except that the amendment of the provisions relating to notice of stockholder business and nominations and special meetings must be approved by not less than two-thirds of the outstanding shares entitled to vote on the amendment, and not less than two-thirds of the outstanding shares of each class entitled to vote. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Undesignated preferred stock</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our certificate of incorporation provides for 10,000,000 authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares of </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our certificate of incorporation grants our board of </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">directors</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">deterring</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or preventing a change in control of us. </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Choice of forum</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our bylaws provide that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware (or, if the Chancery Court does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) will be the sole and exclusive forum for: (1) any derivative action or proceeding brought on our behalf; (2) any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (3) any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our certificate of incorporation or bylaws; (4) any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or (5) any action asserting a claim governed by the internal affairs doctrine. Our bylaws also provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. It is possible that a court of law could rule that the choice of forum provision contained in our restated certificate of incorporation is inapplicable or unenforceable if it is challenged in a proceeding or otherwise. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the United States District Court in the District of Massachusetts will be the exclusive forum for any private action asserting violations by us or any of our directors or officers of the Securities Act or the Exchange Act, or the rules and regulations promulgated thereunder, and of all suits in equity and actions at law brought to enforce any liability or duty created by those statutes or the rules and regulations under such statutes. If any action the subject matter of which is within the scope of the preceding sentence is filed in a court other than the United States District of Massachusetts, the plaintiff or plaintiffs shall be deemed by this provision of the bylaws (i) to have consented to removal of the action by us to the United States District Court in the District of Massachusetts, in the case of an action filed in a state court, and (ii) to have consented to transfer of the action to the United States District Court in the District of Massachusetts. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Section 203 of the Delaware general corporation law</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to the provisions of Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a "business combination" with an "interested stockholder" for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section 203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Arial;">before the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Arial;">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Arial;">at or after the time the stockholder became interested, the business combination was approved by our board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.</font></p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 203 defines a business combination to include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Arial;">any merger or consolidation involving the corporation and the interested stockholder;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Arial;">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;&nbsp;&nbsp; <br />subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Arial;">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Arial;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.</p>
<p style="margin-bottom:5pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:5pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>3
<FILENAME>rlay-ex1010_1012.htm
<DESCRIPTION>EX-10.10
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
rlay-ex1010_1012.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.10</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;"><a name="_Hlk41749046"></a><a name="_Hlk31946720"></a><a name="_Hlk39585428"></a>eXECUTION COPY</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">COnfidential</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark [***].</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COLLABORATION AND LICENSE AGREEMENT</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">between</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">GENENTECH, INC. and F. HOFFMANN-LA ROCHE LTD</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RELAY THERAPEUTICS, INC. </p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dated as of December 11, 2020</p>
<p style="margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Cambria;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Table of contents</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Times New Roman;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;"><a href="#_Toc51338578">Article 1. DEFINITIONS<font style="font-weight:bold;margin-left:36pt;"></font><font style="font-weight:bold;">1</font></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Times New Roman;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Article 2. COLLABORATION overview<font style="font-weight:bold;font-family:Cambria;margin-left:36pt;"></font><font style="font-weight:bold;font-family:Cambria;">33</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Times New Roman;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Article 3. Development<font style="font-weight:bold;font-family:Cambria;margin-left:36pt;"></font><font style="font-weight:bold;font-family:Cambria;">33</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Times New Roman;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;"><a href="#_Toc51338581">Article 4.</a>Opt-In Right; OPT-OUT RIGHT<font style="font-weight:bold;font-family:Cambria;margin-left:36pt;"></font><font style="font-weight:bold;font-family:Cambria;">50</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Times New Roman;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Article 5. Commercialization.<font style="font-weight:bold;font-family:Cambria;margin-left:36pt;"></font><font style="font-weight:bold;font-family:Cambria;">52</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Times New Roman;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Article 6. Regulatory Responsibilities<font style="font-weight:bold;font-family:Cambria;margin-left:36pt;"></font><font style="font-weight:bold;font-family:Cambria;">55</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Times New Roman;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Article 7. Manufacturing.<font style="font-weight:bold;font-family:Cambria;margin-left:36pt;"></font><font style="font-weight:bold;font-family:Cambria;">59</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Times New Roman;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Article 8. Compliance Provisions<font style="font-weight:bold;font-family:Cambria;margin-left:36pt;"></font><font style="font-weight:bold;font-family:Cambria;">60</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Times New Roman;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Article 9. Exclusivity.<font style="font-weight:bold;font-family:Cambria;margin-left:36pt;"></font><font style="font-weight:bold;font-family:Cambria;">61</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Times New Roman;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Article 10. GOVERNANCE; REPORTING<font style="font-weight:bold;font-family:Cambria;margin-left:36pt;"></font><font style="font-weight:bold;font-family:Cambria;">64</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Times New Roman;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Article 11. FINANCIAL TERMS<font style="font-weight:bold;font-family:Cambria;margin-left:36pt;"></font><font style="font-weight:bold;font-family:Cambria;">71</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Times New Roman;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;"><a href="#_Toc51338590">Article 12.</a>LICENSES; INTELLECTUAL PROPERTY<font style="font-weight:bold;font-family:Cambria;margin-left:36pt;"></font><font style="font-weight:bold;font-family:Cambria;">91</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Times New Roman;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Article 13. confidentiality<font style="font-weight:bold;font-family:Cambria;margin-left:36pt;"></font><font style="font-weight:bold;font-family:Cambria;">103</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Times New Roman;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Article 14. REPRESENTATIONS AND WARRANTIES<font style="font-weight:bold;font-family:Cambria;margin-left:36pt;"></font><font style="font-weight:bold;font-family:Cambria;">108</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Times New Roman;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Article 15. INDEMNIFICATION; INSURANCE<font style="font-weight:bold;font-family:Cambria;margin-left:36pt;"></font><font style="font-weight:bold;font-family:Cambria;">113</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Times New Roman;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Article 16. TERM AND TERMINATION<font style="font-weight:bold;font-family:Cambria;margin-left:36pt;"></font><font style="font-weight:bold;font-family:Cambria;">117</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Times New Roman;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Article 17. EFFECTIVE DATE; ANTITRUST AND COMPETITION LAW COMPLIANCE<font style="font-weight:bold;font-family:Cambria;margin-left:36pt;"></font><font style="font-weight:bold;font-family:Cambria;">125</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Times New Roman;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Article 18. MISCELLANEOUS<font style="font-weight:bold;font-family:Cambria;margin-left:36pt;"></font><font style="font-weight:bold;font-family:Cambria;">127</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:465pt;;">
<tr>
<td style="width:207.3pt;"></td>
<td style="width:50.4pt;"></td>
<td style="width:207.3pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-ii</a>-</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DocXTextRef2"></a><a name="DocXTextRef2"></a>LIST OF SCHEDULES</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 1.102 <font style="margin-left:36pt;">Global Development Plan</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 1.262<font style="margin-left:36pt;"></font>Technology Transfer Plan</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 3.2.3<font style="margin-left:36pt;">Transfer of Sponsor Obligations</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 3.3 <font style="margin-left:36pt;"></font><font style="margin-left:72pt;">Relay Phase Ia Plan</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 3.4.1<font style="margin-left:36pt;">Delegation of Authority</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 11.4.1<font style="margin-left:36pt;">Example Net Profits and Net Losses Calculations</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 13.5<font style="margin-left:36pt;">Press Release</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule  14.2<font style="margin-left:36pt;">Exceptions to Representations and Warranties of Relay</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:465pt;;">
<tr>
<td style="width:207.3pt;"></td>
<td style="width:50.4pt;"></td>
<td style="width:207.3pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-iii</a>-</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc41521285"></a><a name="_Toc41521501"></a><a name="_Toc50796649"></a><a name="_Toc51338576"></a><a name="_Toc53919193"></a><a name="_Toc53925677"></a>COLLABORATION AND LICENSE AGREEMENT</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This <font style="font-weight:bold;">LICENSE AGREEMENT</font> (this &#8220;<font style="font-weight:bold;">Agreement</font>&#8221;) is entered into as of December 11, 2020 (the &#8220;<font style="font-weight:bold;">Execution</font> <font style="font-weight:bold;">Date</font>&#8221;) by and between Genentech, Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal place of business at 1&#160;DNA&#160;Way, South San Francisco, CA 94080&nbsp;&nbsp;(&#8220;<font style="font-weight:bold;">Genentech</font>&#8221;)<font style="font-size:11pt;"> </font>and F. Hoffmann-La Roche Ltd, having a principal place of business at Grenzacherstrasse 124, CH 4070 Basel, Switzerland (&#8220;<font style="font-weight:bold;">Roche</font>&#8221;) (Genentech and Roche, together, &#8220;<font style="font-weight:bold;">Licensee</font>&#8221;), on the one hand, and<font style="font-weight:bold;"> </font>Relay Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal place of business at 399 Binney Street, 2nd Floor, Cambridge, Massachusetts 02139 (&#8220;<font style="font-weight:bold;">Relay</font>&#8221;), on the other hand.&nbsp;&nbsp;Licensee and Relay are each referred to herein by name or as a &#8220;<font style="font-weight:bold;">Party</font>&#8221;, or, collectively, as the &#8220;<font style="font-weight:bold;">Parties</font>&#8221;.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc41521286"></a><a name="_Toc41521502"></a><a name="_Toc50796650"></a><a name="_Toc51338577"></a><a name="_Toc53919194"></a><a name="_Toc53925678"></a>RECITALS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, Relay is a clinical-stage precision medicines company transforming the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, Licensee possesses expertise in the development and commercialization of pharmaceutical products; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, Licensee desires to obtain an exclusive license and other rights from Relay for the Research, Development, Manufacture and Commercialization of Licensed Candidates and Licensed Products, and Relay agrees to grant Licensee such an exclusive license, on the terms and conditions set forth herein; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-weight:normal;">, Licensee and Relay desire to conduct certain Development activities, to provide Relay with the option to share the costs of Development and profits and losses collaborate with respect to Lead Products, and to permit Relay to Develop and Commercialize certain compounds for Combination Use with Licensed Products in the Field in the Territory, in each case on the terms and conditions set forth herein.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE<font style="font-weight:normal;">, in consideration of the foregoing and the mutual agreements set forth below, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521644743"></a><a name="_Toc524107221"></a><a name="_Toc529816430"></a><a name="_Toc529966465"></a><a name="_Toc50796651"></a><a name="_Toc51338578"></a><a name="_Toc53919195"></a><a name="_Toc53925679"></a><font style="Background-color:#auto;text-decoration:none;">Article 1.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><br /><a name="_Ref521644743"></a><a name="_Toc524107221"></a><a name="_Toc529816430"></a><a name="_Toc529966465"></a><a name="_Toc50796651"></a><a name="_Toc51338578"></a><a name="_Toc53919195"></a><a name="_Toc53925679"></a>DEFINITIONS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless specifically set forth to the contrary herein, the following terms will have the respective meanings set forth below.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc524007724"></a><a name="_Toc524018178"></a><a name="_Toc524065360"></a><a name="_Toc524107223"></a><a name="_Toc524007723"></a><a name="_Toc524018177"></a><a name="_Toc524065359"></a><a name="_Toc524107222"></a><font style="Background-color:#auto;text-decoration:none;">1.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">1971 Patent</font><font style="color:#000000;">&#8221; means any Relay Patent that claims a Lead Candidate or Lead Product.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Accounting Standards</font><font style="color:#000000;">&#8221; means, with respect to either Party, generally accepted accounting principles as applicable in the United States or International Financial Reporting </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Standards of the International Accounting Standards Board (&#8220;</font><font style="font-weight:bold;color:#000000;">IFRS</font><font style="color:#000000;">&#8221;), in each case, as generally and consistently applied throughout such Party&#8217;s organization.&nbsp;&nbsp;Each Party will promptly notify the other Party in writing if such Party changes the Accounting Standards pursuant to which its records are maintained.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Acquired Program</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 9.2.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Acquirer</font><font style="color:#000000;">&#8221; means, collectively, the Third Party referenced in the definition of Change of Control and such Third Party&#8217;s Affiliates (as of the Change of Control or thereafter), other than the applicable Party in the definition of Change of Control and such Party&#8217;s Affiliates, determined as of immediately prior to the closing of such Change of Control.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Acquirer Program</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 9.3.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref58439229"></a><a name="_Toc523684257"></a><a name="_Toc523684617"></a><a name="_Toc524007725"></a><a name="_Toc524018179"></a><a name="_Toc524065361"></a><a name="_Toc524107224"></a><font style="Background-color:#auto;text-decoration:none;">1.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Action</font><font style="color:#000000;">&#8221; means any claim, action, suit, arbitration, inquiry, audit, proceeding or investigation by or before, or otherwise involving, any Governmental Authority.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646787"></a><a name="_Toc521651096"></a><a name="_Toc521845936"></a><a name="_Toc521842910"></a><a name="_Toc521850805"></a><a name="_Toc522061247"></a><a name="_Toc523684258"></a><a name="_Toc523684618"></a><a name="_Toc524007726"></a><a name="_Toc524018180"></a><a name="_Toc524065362"></a><a name="_Toc524107225"></a><a name="_Ref521644745"></a><a name="_Ref52009812"></a><a name="DocXTextRef6"></a><a name="DocXTextRef7"></a><font style="Background-color:#auto;text-decoration:none;">1.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Affiliate</font><font style="color:#000000;">&#8221; means, with respect to any Person, any other Person, as of the Execution <a name="DocXTextRef6"></a>Date or at any time during the Term, directly or indirectly controlling or controlled by, or under direct or indirect common control with, such first Person.&nbsp;&nbsp;For purposes of this definition, a Person will be deemed, in any event, to control another Person if it (a)<a name="DocXTextRef7"></a> owns or controls, directly or indirectly, or has the ability to direct or cause the direction or control of, more than fifty percent (50%) of the voting equity of such other Person, or (b) has the ability to direct, cause the direction of or control the management or policies of such other Person, whether through direct or indirect ownership of voting equity, by contract or otherwise.&nbsp;&nbsp;For purposes of this definition, the term &#8220;</font><font style="font-weight:bold;color:#000000;">control</font><font style="color:#000000;">&#8221;, &#8220;</font><font style="font-weight:bold;color:#000000;">controlled</font><font style="color:#000000;">&#8221; or &#8220;</font><font style="font-weight:bold;color:#000000;">controlling</font><font style="color:#000000;">&#8221; means (i) the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such entity, whether through the ownership of voting securities, by contract or otherwise, or (ii) when used with respect to any security, the possession, directly or indirectly, of the power to vote, or to direct the voting of, such security or the power to dispose of, or to direct the disposition of, such security.&nbsp;&nbsp;The Parties acknowledge that in the case of certain entities organized under the laws of certain countries outside the United States, the maximum percentage of ownership permitted by law for a foreign investor may be less than fifty percent (50%), and that in such case such lower percentage will be substituted in the preceding sentence; provided that such foreign investor has the power to direct the management and policies of such entity.&nbsp;&nbsp;Notwithstanding anything in the foregoing of this Section 1.7, for purposes of this Agreement, [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646788"></a><a name="_Toc521651097"></a><a name="_Toc521845937"></a><a name="_Toc521842911"></a><a name="_Toc521850806"></a><a name="_Toc522061248"></a><a name="_Toc523684259"></a><a name="_Toc523684619"></a><a name="_Toc524007727"></a><a name="_Toc524018181"></a><a name="_Toc524065363"></a><a name="_Toc524107226"></a><a name="_Ref521644746"></a><font style="Background-color:#auto;text-decoration:none;">1.8</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Agreement</font><font style="color:#000000;">&#8221;</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">has the meaning set forth in the preamble hereto.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646789"></a><a name="_Toc521651098"></a><a name="_Toc521845938"></a><a name="_Toc521842912"></a><a name="_Toc521850807"></a><a name="_Toc522286763"></a><a name="_Toc522450227"></a><a name="_Toc522636027"></a><a name="_Toc522731437"></a><a name="_Toc524007728"></a><a name="_Toc524018182"></a><a name="_Toc524065364"></a><a name="_Toc524107227"></a><a name="_Ref521644747"></a><a name="DocXTextRef8"></a><font style="Background-color:#auto;text-decoration:none;">1.9</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Alliance Manager</font><font style="color:#000000;">&#8221; has the meaning<a name="DocXTextRef8"></a> set forth in Section 10.13.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.10</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Allowable Expenses</font><font style="color:#000000;">&#8221; [***].</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref38879236"></a><a name="_Ref521646791"></a><a name="_Ref521648531"></a><a name="_Toc521651100"></a><a name="_Toc521845940"></a><a name="_Toc521842914"></a><a name="_Toc521850809"></a><a name="_Toc522061250"></a><a name="_Toc523684261"></a><a name="_Toc523684621"></a><a name="_Toc524007730"></a><a name="_Toc524018184"></a><a name="_Toc524065366"></a><a name="_Toc524107229"></a><a name="_Ref521644749"></a><font style="Background-color:#auto;text-decoration:none;">1.11</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">ANDA</font><font style="color:#000000;">&#8221; means an Abbreviated New Drug Application and all amendments and supplements thereto filed with the FDA under Section 505(j) of the FDCA (21 U.S.C. 355(j)), or the equivalent application filed with any equivalent Regulatory Authority outside the United States (including any supra national agency).</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1752"></a><a name="_BPDC_PR_INS_1753"></a><a name="_Ref39328922"></a><font style="text-decoration:none;Background-color:#auto;">1.12</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Antitrust Counsel Only Material</font><font style="color:#000000;">&#8221; has the meaning set forth in Section </font><font style="color:#000000;">17.2.4</font><font style="color:#000000;">.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1750"></a><a name="_BPDC_PR_INS_1751"></a><a name="_Ref57643883"></a><font style="Background-color:#auto;text-decoration:none;">1.13</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Antitrust Law</font><font style="color:#000000;">&#8221; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder (the &#8220;</font><font style="font-weight:bold;color:#000000;">HSR Act</font><font style="color:#000000;">&#8221;), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable Law of the United States, a state or territory thereof, or any foreign government or supranational body (including the European Commission) that are designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization, restraint of trade, or lessening of competition through merger or acquisition.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1748"></a><a name="_BPDC_PR_INS_1749"></a><a name="_Ref530914857"></a><a name="_Ref55481414"></a><a name="_Ref521646793"></a><a name="_Toc521651102"></a><a name="_Toc521845942"></a><a name="_Toc521842916"></a><a name="_Toc521850811"></a><a name="_Toc522061254"></a><a name="_Toc523684265"></a><a name="_Toc523684625"></a><a name="_Toc524007731"></a><a name="_Toc524018185"></a><a name="_Toc524065367"></a><a name="_Toc524107230"></a><a name="_Ref521644751"></a><font style="Background-color:#auto;text-decoration:none;">1.14</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Applicable Law</font><font style="color:#000000;">&#8221; means any applicable federal, state, local or foreign constitution, treaty, law, statute, ordinance, rule, regulation, standard, interpretation, guidance document, directive, policy, order, writ, award, decree, injunction, judgment, stay or restraining order of any Governmental Authority, the terms of any permit, certificate, or authorization, and any other ruling or decision of, agreement with or by, or any other requirement of, any Governmental Authority having proper jurisdiction over the matter, including, to the extent applicable, the Federal Food, Drug, and Cosmetic Act (&#8220;</font><font style="font-weight:bold;color:#000000;">FDCA</font><font style="color:#000000;">&#8221;), as amended, the Public Health Service Act (&#8220;</font><font style="font-weight:bold;color:#000000;">PHSA</font><font style="color:#000000;">&#8221;), as amended, United States Department of Health and Human Services (&#8220;</font><font style="font-weight:bold;color:#000000;">HHS</font><font style="color:#000000;">&#8221;)</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">privacy rules under the Health Insurance Portability and Accountability Act, as amended, and the General Data Protection Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1746"></a><a name="_BPDC_PR_INS_1747"></a><font style="Background-color:#auto;text-decoration:none;">1.15</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Back-Up Compound</font><font style="color:#000000;">&#8221; means any compound that is Directed to the Collaboration Target, other than the Lead Candidate, that is disclosed in a Relay Patent or a Joint Collaboration Patent.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1744"></a><a name="_BPDC_PR_INS_1745"></a><font style="Background-color:#auto;text-decoration:none;">1.16</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Back-Up Development/Commercial Milestone</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 11.5.3.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1742"></a><a name="_BPDC_PR_INS_1743"></a><a name="_Hlk56160924"></a><font style="Background-color:#auto;text-decoration:none;">1.17</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_Hlk56160924"></a>&#8220;</font><font style="font-weight:bold;color:#000000;">Back-Up Development/Commercial Milestone Payment</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 11.5.3.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.18</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Back-Up Product</font><font style="color:#000000;">&#8221; means any Licensed Product that constitutes, comprises or contains any Back-Up Compound, regardless of its finished form, formulation or dosage. For clarity, a Back-Up Product cannot be a Lead Product or a Shared Product.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.19</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Back-Up</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Sales Milestone</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 11.5.6.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.20</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Back-Up</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Sales Milestone Payment</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 11.5.6.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.21</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Bankruptcy Code</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 12.5.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1740"></a><a name="_BPDC_PR_INS_1741"></a><a name="_9kR3WTr8E84579AD"></a><a name="_Ref521646794"></a><a name="_Toc521651103"></a><a name="_Toc521845943"></a><a name="_Toc521842917"></a><a name="_Toc521850812"></a><a name="_Toc522061255"></a><a name="_Toc523684266"></a><a name="_Toc523684626"></a><a name="_Toc524007732"></a><a name="_Toc524018186"></a><a name="_Toc524065368"></a><a name="_Toc524107231"></a><a name="_Ref521644752"></a><font style="Background-color:#auto;text-decoration:none;">1.22</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Bulk Drug Product</font><font style="color:#000000;">&#8221; means formulated Bulk Drug Substance in bulk form prior to filling and finishing.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1738"></a><a name="_BPDC_PR_INS_1739"></a><font style="Background-color:#auto;text-decoration:none;">1.23</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Bulk Drug Substance</font><font style="color:#000000;">&#8221; means a Licensed Candidate bulk form manufactured for use as an active pharmaceutical ingredient in a Licensed Product.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1736"></a><a name="_BPDC_PR_INS_1737"></a><a name="DocXTextRef10"></a><a name="DocXTextRef11"></a><font style="text-decoration:none;Background-color:#auto;">1.24</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Business Day</font><font style="color:#000000;">&#8221;</font><font style="color:#000000;"><a name="DocXTextRef10"></a> means any day excluding </font><font style="color:#000000;">(a)</font><font style="color:#000000;"><a name="DocXTextRef11"></a> Saturdays and Sundays; </font><font style="color:#000000;">and (b)</font><font style="color:#000000;"> any day that is a legal holiday under the Applicable Law of the United States or Switzerland, or that is a day on which banking institutions located in San Francisco, California, Basel, Switzerland, or Boston, Massachusetts, are authorized or required by Applicable Law or other governmental action to close.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1734"></a><a name="_BPDC_PR_INS_1735"></a><a name="_Ref521646795"></a><a name="_Toc521651104"></a><a name="_Toc521845944"></a><a name="_Toc521842918"></a><a name="_Toc521850813"></a><a name="_Toc522061256"></a><a name="_Toc523684267"></a><a name="_Toc523684627"></a><a name="_Toc524007733"></a><a name="_Toc524018187"></a><a name="_Toc524065369"></a><a name="_Toc524107232"></a><a name="_Ref521644753"></a><font style="Background-color:#auto;text-decoration:none;">1.25</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Calendar Quarter</font><font style="color:#000000;">&#8221; means each successive period of three (3) calendar months commencing on January 1, April 1, July 1 and October 1, except that the first Calendar Quarter of the Term will commence on the Effective Date and end on the day immediately prior to the first to occur of January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar Quarter will end on the last day of the Term.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1732"></a><a name="_BPDC_PR_INS_1733"></a><a name="_Ref521646796"></a><a name="_Toc521651105"></a><a name="_Toc521845945"></a><a name="_Toc521842919"></a><a name="_Toc521850814"></a><a name="_Toc522061257"></a><a name="_Toc523684268"></a><a name="_Toc523684628"></a><a name="_Toc524007734"></a><a name="_Toc524018188"></a><a name="_Toc524065370"></a><a name="_Toc524107233"></a><a name="_Ref521644754"></a><font style="Background-color:#auto;text-decoration:none;">1.26</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Calendar Year</font><font style="color:#000000;">&#8221; means each successive period of twelve (12) calendar months commencing on January 1 and ending on December 31, except that the first Calendar Year of the Term will commence on the Effective Date and end on December 31 of the year in which the Effective Date occurs and the last Calendar Year of the Term will commence on January 1 of the year in which the Term ends and end on the last day of the Term.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1730"></a><a name="_BPDC_PR_INS_1731"></a><a name="_Ref521646797"></a><a name="_Toc521651106"></a><a name="_Toc521845946"></a><a name="_Toc521842920"></a><a name="_Toc521850815"></a><a name="_Toc522061258"></a><a name="_Toc523684269"></a><a name="_Toc523684629"></a><a name="_Toc524007735"></a><a name="_Toc524018189"></a><a name="_Toc524065371"></a><a name="_Toc524107234"></a><a name="_Ref521644755"></a><font style="Background-color:#auto;text-decoration:none;">1.27</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Change of Control</font><font style="color:#000000;">&#8221; means, with respect to a Party, (a) a merger or consolidation of such Party with a Third Party that results in the voting securities of such Party outstanding immediately prior thereto, or any securities into which such voting securities have been converted or exchanged, ceasing to represent at least fifty percent (50%) of the combined voting power of the surviving entity or the parent of the surviving entity immediately after such merger or consolidation, (b) a transaction or series of related transactions in which a Third Party, together with its Affiliates, becomes the direct or indirect beneficial owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of such Party, or (c) the sale or other transfer to a Third Party of all or substantially all of such Party&#8217;s and its controlled Affiliates&#8217; assets that relate to this Agreement; provided, however, that any public offering or any other bona fide capital raising event, public or private, a reorganization, spin-out, merger, consolidation or recapitalization, in each case, undertaken solely for tax planning purposes or solely to change a Party&#8217;s domicile will not constitute a &#8220;Change of Control&#8221;.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1728"></a><a name="_BPDC_PR_INS_1729"></a><font style="Background-color:#auto;text-decoration:none;">1.28</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;[***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1726"></a><a name="_BPDC_PR_INS_1727"></a><font style="Background-color:#auto;text-decoration:none;">1.29</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Clinical Transfer</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 3.2.4.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1724"></a><a name="_BPDC_PR_INS_1725"></a><a name="_Toc526370670"></a><font style="Background-color:#auto;text-decoration:none;">1.30</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Clinical Trial</font><font style="color:#000000;">&#8221; means a human clinical trial and any such other tests and studies in human subjects that are required by Applicable<a name="_Toc526370670"></a> Law, recommended by the Governmental Authorities, or are otherwise necessary to obtain or maintain Regulatory Approvals for a product.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1722"></a><a name="_BPDC_PR_INS_1723"></a><a name="_Hlk55280478"></a><a name="_Ref521646798"></a><a name="_Toc521651107"></a><a name="_Toc521845947"></a><a name="_Toc521842921"></a><a name="_Toc521850816"></a><a name="_Toc522061259"></a><a name="_Toc523684270"></a><a name="_Toc523684630"></a><a name="_Toc524007736"></a><a name="_Toc524018190"></a><a name="_Toc524065372"></a><a name="_Toc524107235"></a><a name="_Ref521644756"></a><font style="Background-color:#auto;text-decoration:none;">1.31</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">CMO</font><font style="color:#000000;">&#8221; means any Third Party contract manufacturer.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1720"></a><a name="_BPDC_PR_INS_1721"></a><font style="Background-color:#auto;text-decoration:none;">1.32</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Collaboration In-License</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 11.6.4(d).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1718"></a><a name="_BPDC_PR_INS_1719"></a><font style="Background-color:#auto;text-decoration:none;">1.33</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Collaboration Target</font><font style="color:#000000;">&#8221; [***] Src homology region 2 domain-containing phosphatase-2 (SHP2), [***]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1716"></a><a name="_BPDC_PR_INS_1717"></a><font style="Background-color:#auto;text-decoration:none;">1.34</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Combination Product</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 5.5.2(a).</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1714"></a><a name="_BPDC_PR_INS_1715"></a><a name="_9kR3WTr8E8458ABC"></a><a name="_Toc524007739"></a><a name="_Toc524018193"></a><a name="_Toc524065375"></a><a name="_Toc524107238"></a><a name="_Toc523684273"></a><a name="_Toc523684633"></a><font style="Background-color:#auto;text-decoration:none;">1.35</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Combination Use</font><font style="color:#000000;">&#8221; of a compound or product with one or more compounds or products means use of the first compound or product to be administered or dosed together, sequentially or concurrently, with one or more other compounds or products for the prevention or treatment of an Indication in patients.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1712"></a><a name="_BPDC_PR_INS_1713"></a><a name="_Ref521646805"></a><a name="_Ref521644763"></a><font style="Background-color:#auto;text-decoration:none;">1.36</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Commercialization</font><font style="color:#000000;">&#8221; means any and all activities directed to the commercial manufacturing (including Manufacturing) or commercial supply of a product, marketing, detailing, promoting, advertising and seeking of pricing and reimbursement of such products (if applicable), whether before or after Regulatory Approval has been obtained (including making, having made, using, importing, selling and offering for sale such product), and will include marketing, promoting, advertising, detailing, market research, distributing, order processing, handling returns and recalls, booking sales, customer service, administering and commercially selling such products, importing, exporting or transporting such products for commercial sale, and all regulatory compliance with respect to the foregoing.&nbsp;&nbsp;When used as a verb, &#8220;</font><font style="font-weight:bold;color:#000000;">Commercialize</font><font style="color:#000000;">&#8221; means to engage in Commercialization.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1710"></a><a name="_BPDC_PR_INS_1711"></a><a name="_Ref521646804"></a><a name="_Toc521651113"></a><a name="_Toc521845953"></a><a name="_Toc521842927"></a><a name="_Toc521850822"></a><a name="_Toc522061262"></a><a name="_Toc523684274"></a><a name="_Toc523684634"></a><a name="_Toc524007740"></a><a name="_Toc524018194"></a><a name="_Toc524065376"></a><a name="_Toc524107239"></a><a name="_Ref521644762"></a><font style="Background-color:#auto;text-decoration:none;">1.37</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Commercially Reasonable Efforts</font><font style="color:#000000;">&#8221; [***]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1708"></a><a name="_BPDC_PR_INS_1709"></a><a name="_Ref521646807"></a><a name="_Toc521651116"></a><a name="_Toc521845956"></a><a name="_Toc521842930"></a><a name="_Toc521850825"></a><a name="_Toc522061265"></a><a name="_Toc523684277"></a><a name="_Toc523684637"></a><a name="_Toc524007743"></a><a name="_Toc524018197"></a><a name="_Toc524065379"></a><a name="_Toc524107242"></a><a name="_Ref521644765"></a><font style="Background-color:#auto;text-decoration:none;">1.38</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Competing Program</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 13.8. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1706"></a><a name="_BPDC_PR_INS_1707"></a><a name="_Hlk55408386"></a><font style="Background-color:#auto;text-decoration:none;">1.39</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Competitive Infringement</font><font style="color:#000000;">&#8221; <a name="_Hlk55408386"></a>[***].&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1704"></a><a name="_BPDC_PR_INS_1705"></a><font style="Background-color:#auto;text-decoration:none;">1.40</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Competitive Product</font><font style="color:#000000;">&#8221; means any pharmaceutical product, other than a Relay Pipeline Combination, that is Directed to the Collaboration Target.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1702"></a><a name="_BPDC_PR_INS_1703"></a><a name="_Hlk55374417"></a><font style="Background-color:#auto;text-decoration:none;">1.41</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Composition of Matter Claim</font><font style="color:#000000;">&#8221; [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1700"></a><a name="_BPDC_PR_INS_1701"></a><a name="_Ref56094019"></a><font style="Background-color:#auto;text-decoration:none;">1.42</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Compulsory Sublicense</font><font style="color:#000000;">&#8221; means, with respect to a Licensed Product, in a country, a license or rights granted to a Third Party (a &#8220;</font><font style="font-weight:bold;color:#000000;">Compulsory Sublicensee</font><font style="color:#000000;">&#8221;) to sell or offer for sale such Licensed Product in such country under any Patent Controlled by Licensee (including any Patent licensed or sublicensed to Licensee under this Agreement)</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">by a Governmental Authority within such country, without direct or indirect authorization from Licensee or any of its Affiliates, for example a right granted pursuant to requests under 30 August 2003 WTO decision, or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">by Licensee or any of its Affiliates if such grant is required by a Governmental Authority within such country for the purpose of enabling the Compulsory Sublicensee to sell Licensed Product for free or for a significantly reduced price.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1698"></a><a name="_BPDC_PR_INS_1699"></a><a name="_Ref530145867"></a><font style="Background-color:#auto;text-decoration:none;">1.43</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Compulsory Sublicensee</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 1.42.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.44</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Confidential Information</font><font style="color:#000000;">&#8221; means, with respect to a Party, all confidential information and materials, including Know-How, marketing plans, strategies, and customer lists, in each case, that are disclosed by or on behalf of such Party to the other Party, regardless of whether any of the foregoing are marked &#8220;confidential&#8221; or &#8220;proprietary&#8221; or communicated to the other Party by or on behalf of the Disclosing Party in oral, written, visual, graphic or electronic form.&nbsp;&nbsp;The Joint Collaboration Know-How is the Confidential Information of each Party, with each </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Party treated as the Receiving Party. </font><font style="color:#000000;">The </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> </font><font style="color:#000000;">are the Confidential Information of</font><font style="color:#000000;"> each Party, with each Party treated as the Receiving Party</font><font style="color:#000000;">.</font><font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646808"></a><a name="_Toc521651117"></a><a name="_Toc521845957"></a><a name="_Toc521842931"></a><a name="_Toc521850826"></a><a name="_Toc522061266"></a><a name="_Toc523684278"></a><a name="_Toc523684638"></a><a name="_Toc524007744"></a><a name="_Toc524018198"></a><a name="_Toc524065380"></a><a name="_Toc524107243"></a><a name="_Ref521644766"></a><a name="_Ref526412591"></a><font style="Background-color:#auto;text-decoration:none;">1.45</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Control</font><font style="color:#000000;">&#8221;, &#8220;</font><font style="font-weight:bold;color:#000000;">Controls</font><font style="color:#000000;">&#8221; or &#8220;</font><font style="font-weight:bold;color:#000000;">Controlled</font><font style="color:#000000;">&#8221; means when used with respect to any item of Know-How, Regulatory Materials, Materials, Patent, or other intellectual property right, the possession (whether by ownership, license or sublicense, other than by a license, sublicense or other right granted (but not assignment) pursuant to this Agreement) by a Party of the ability (or the option to obtain the ability) to assign or grant to the other Party the licenses, sublicenses or rights to access and use such Know-How, Regulatory Materials, Materials, Patent, or other intellectual property right as provided for in this Agreement, without, other than with respect to any Existing Third Party Agreements and Collaboration In-Licenses, paying any consideration to any Third Party (now or in the future) or violating the terms of any agreement or other arrangement with any Third Party in existence as of the time such Party would be required hereunder to grant such license, sublicense or rights of access and use.&nbsp;&nbsp;Notwithstanding anything in this Agreement to the contrary, unless and until a Party (or its Affiliate) breaches Section 9.2.4, a Party will be deemed not to Control any Know-How, Regulatory Materials, Materials, Patent, or other intellectual property right that are owned or in-licensed by an Acquirer except (a)&#160;with respect to any such Know-How, Regulatory Materials, Materials, Patent, or other intellectual property right arising from active participation by employees or consultants of the Acquirer in connection with this Agreement after such Change of Control, (b)&#160;to the extent that any such Know-How, Regulatory Materials, Materials, Patent, or other intellectual property right is included in or used in furtherance of this Agreement by the Acquirer after such Change of Control, or (c)&#160;for Know-How, Regulatory Materials, Materials, Patent, or other intellectual property right constituting improvements (or direct improvements to such improvements) to the Relay IP or the </font><font style="Background-color:#FFFFFF;">Licensee </font><font style="color:#000000;">IP (as applicable) in existence prior to such Change of Control created, conceived or generated by any employees or consultants of the Acquirer.&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.46</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Coordinated Promotion Agreement</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 5.6.2.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.47</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Coordinated Promotion Right</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 5.6.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1696"></a><a name="_BPDC_PR_INS_1697"></a><font style="Background-color:#auto;text-decoration:none;">1.48</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Core Countries</font><font style="color:#000000;">&#8221; [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1693"></a><a name="_BPDC_PR_INS_1694"></a><a name="_Ref521646809"></a><a name="_Toc521651118"></a><a name="_Toc521845961"></a><a name="_Toc521842935"></a><a name="_Toc521850830"></a><a name="_Toc522061271"></a><a name="_Toc523684281"></a><a name="_Toc523684641"></a><a name="_Toc524007747"></a><a name="_Toc524018201"></a><a name="_Toc524065383"></a><a name="_Toc524107246"></a><a name="_Ref521644767"></a><font style="Background-color:#auto;text-decoration:none;">1.49</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Covered by</font><font style="color:#000000;">&#8221; or &#8220;</font><font style="font-weight:bold;color:#000000;">Cover</font><font style="color:#000000;">&#8221; or the like, means, with respect to a given Licensed Candidate or Licensed Product (as the case may be), that the sale, offer for sale or importation of such Licensed Candidate or Licensed Product, but for ownership of, or a license granted in this Agreement under, the relevant Patent would infringe a Valid Claim of such Patent (a) in the country of sale on the date of sale, in the case of royalty payments and (b) on the date a Development/Commercial Milestone, Opt-In Term Development/Commercial Milestone, or Back-Up Development/Commercial Milestone is achieved, in the case of a corresponding payments. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1691"></a><a name="_BPDC_PR_INS_1692"></a><font style="Background-color:#auto;text-decoration:none;">1.50</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">CRO</font><font style="color:#000000;">&#8221; means any Third Party contract research organization.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1689"></a><a name="_BPDC_PR_INS_1690"></a><font style="Background-color:#auto;text-decoration:none;">1.51</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Cure Period</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 16.3.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1687"></a><a name="_BPDC_PR_INS_1688"></a><font style="Background-color:#auto;text-decoration:none;">1.52</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Deductible Third Party IP Payments</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 11.6.4(g).</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1685"></a><a name="_BPDC_PR_INS_1686"></a><font style="text-decoration:none;Background-color:#auto;">1.53</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Deferred </font><font style="font-weight:bold;color:#000000;">Combination Agent</font><font style="font-weight:bold;color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Election&#8221;</font><font style="color:#000000;"> has the meaning set forth in </font><font style="color:#000000;">10.7.3(c)</font><font style="color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.54</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Delegation of Authority</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 3.4.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1683"></a><a name="_BPDC_PR_INS_1684"></a><a name="_Ref529284913"></a><a name="_Ref529285098"></a><font style="Background-color:#auto;text-decoration:none;">1.55</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&nbsp;&nbsp;&#8220;</font><font style="font-weight:bold;color:#000000;">DESRES Agreement</font><font style="color:#000000;">&#8221; shall mean the Amended and Restated Collaboration and License Agreement by and between D.E. Shaw Research, LLC (&#8220;</font><font style="font-weight:bold;color:#000000;">DESRES</font><font style="color:#000000;">&#8221;) and Relay Therapeutics, Inc., dated June 15, 2020.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1681"></a><a name="_BPDC_PR_INS_1682"></a><a name="_Ref521646810"></a><a name="_Toc521651119"></a><a name="_Toc521845962"></a><a name="_Toc521842936"></a><a name="_Toc521850831"></a><a name="_Toc522061272"></a><a name="_Toc523684282"></a><a name="_Toc523684642"></a><a name="_Toc524007748"></a><a name="_Toc524018202"></a><a name="_Toc524065384"></a><a name="_Toc524107247"></a><a name="_Ref521644768"></a><font style="Background-color:#auto;text-decoration:none;">1.56</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_Ref521646810"></a><a name="_Toc521651119"></a><a name="_Toc521845962"></a><a name="_Toc521842936"></a><a name="_Toc521850831"></a><a name="_Toc522061272"></a><a name="_Toc523684282"></a><a name="_Toc523684642"></a><a name="_Toc524007748"></a><a name="_Toc524018202"></a><a name="_Toc524065384"></a><a name="_Toc524107247"></a><a name="_Ref521644768"></a>&#8220;</font><font style="font-weight:bold;color:#000000;">Development</font><font style="color:#000000;">&#8221; means, for a compound or product, all activities, other than Research, necessary or reasonably useful or otherwise requested or required by a Governmental Authority as a condition or in support of obtaining or maintaining a Regulatory Approval, including pre-clinical and other non-clinical testing, test method development and stability testing, toxicology, formulation, process development, manufacturing scale-up, qualification and validation, quality assurance/quality control, Clinical Trials, Manufacturing in support of Clinical Trials and other development activities, statistical analysis and report writing, the preparation and submission of applications for Regulatory Approvals, development activities conducted after receipt of Regulatory Approval pursuant to a request or requirement of Regulatory Authorities, pharmacoeconomic studies relating to the Indication for which the compound or product is being developed, and regulatory affairs with respect to the foregoing.&nbsp;&nbsp;When used as a verb, &#8220;</font><font style="font-weight:bold;color:#000000;">Develop</font><font style="color:#000000;">&#8221; means to engage in Development.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1679"></a><a name="_BPDC_PR_INS_1680"></a><a name="_Ref55305062"></a><a name="_Ref_ContractCompanion_9kb9Ur017"></a><font style="Background-color:#auto;text-decoration:none;">1.57</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Development Costs</font><font style="color:#000000;">&#8221; [***]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1677"></a><a name="_BPDC_PR_INS_1678"></a><font style="Background-color:#auto;text-decoration:none;">1.58</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Development/Commercial</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Milestone</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 11.5.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1675"></a><a name="_BPDC_PR_INS_1676"></a><font style="Background-color:#auto;text-decoration:none;">1.59</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Development/Commercial</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Milestone Payment</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 11.5.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1673"></a><a name="_BPDC_PR_INS_1674"></a><a name="_Toc524007750"></a><a name="_Toc524018204"></a><a name="_Toc524065386"></a><a name="_Toc524107249"></a><font style="Background-color:#auto;text-decoration:none;">1.60</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Development Know-How and Materials</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 3.2.1</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1671"></a><a name="_BPDC_PR_INS_1672"></a><font style="Background-color:#auto;text-decoration:none;">1.61</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Development Milestone Composition of Matter Claim</font><font style="color:#000000;">&#8221; [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1669"></a><a name="_BPDC_PR_INS_1670"></a><font style="Background-color:#auto;text-decoration:none;">1.62</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Development Transfer</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 3.2.1(a).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1667"></a><a name="_BPDC_PR_INS_1668"></a><a name="_Ref521646812"></a><a name="_Toc521651121"></a><a name="_Toc521845964"></a><a name="_Toc521842938"></a><a name="_Toc521850833"></a><a name="_Toc522061274"></a><a name="_Toc523684284"></a><a name="_Toc523684644"></a><a name="_Toc524007751"></a><a name="_Toc524018205"></a><a name="_Toc524065387"></a><a name="_Toc524107250"></a><a name="_Ref521644770"></a><font style="Background-color:#auto;text-decoration:none;">1.63</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Directed</font><font style="color:#000000;">&#8221; means, with respect to a pharmaceutical product and a protein, that such pharmaceutical product directly binds to, or is designed to directly bind to, such protein, and directly inhibits, or is designed to directly inhibit, the function of such protein. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1665"></a><a name="_BPDC_PR_INS_1666"></a><a name="_Ref521646813"></a><a name="_Toc521651122"></a><a name="_Toc521845965"></a><a name="_Toc521842939"></a><a name="_Toc521850834"></a><a name="_Toc522061275"></a><a name="_Toc523684285"></a><a name="_Toc523684645"></a><a name="_Toc524007752"></a><a name="_Toc524018206"></a><a name="_Toc524065388"></a><a name="_Toc524107251"></a><a name="_Ref521644771"></a><a name="DocXTextRef31"></a><font style="Background-color:#auto;text-decoration:none;">1.64</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Disclosing Party</font><font style="color:#000000;">&#8221;<a name="DocXTextRef31"></a> has the meaning set forth in Section 13.1. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.65</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Discontinued Relay Pipeline</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Combination Eligible Licensed Product</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 16.9.1</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1663"></a><a name="_BPDC_PR_INS_1664"></a><a name="_Ref521646814"></a><a name="_Toc521651123"></a><a name="_Toc521845966"></a><a name="_Toc521842940"></a><a name="_Toc521850835"></a><a name="_Toc522061276"></a><a name="_Toc523684286"></a><a name="_Toc523684646"></a><a name="_Toc524007753"></a><a name="_Toc524018207"></a><a name="_Toc524065389"></a><a name="_Toc524107252"></a><a name="_Ref521644772"></a><a name="DocXTextRef32"></a><font style="Background-color:#auto;text-decoration:none;">1.66</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Dispute</font><font style="color:#000000;">&#8221;<a name="DocXTextRef32"></a> has the meaning set forth in Section 18.9.1.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1661"></a><a name="_BPDC_PR_INS_1662"></a><a name="_Toc523684287"></a><a name="_Toc523684647"></a><a name="_Toc524007754"></a><a name="_Toc524018208"></a><a name="_Toc524065390"></a><a name="_Toc524107253"></a><font style="Background-color:#auto;text-decoration:none;">1.67</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Distributor</font><font style="color:#000000;">&#8221; means any Person appointed by Licensee or any of its Affiliates or any Licensee Sublicensee to distribute, market and sell the Licensed Products in one or more countries in the Territory, in circumstances where the Person purchases its requirements of the Licensed Products from Licensee or its Affiliates or any Licensee Sublicensee but does not otherwise make any royalty or other payment to Licensee or its Affiliates or any Licensee Sublicensee with respect to its rights under the Relay IP or Licensee Collaboration IP.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1659"></a><a name="_BPDC_PR_INS_1660"></a><a name="_Ref521646816"></a><a name="_Toc521651125"></a><a name="_Toc521845967"></a><a name="_Toc521842941"></a><a name="_Toc521850836"></a><a name="_Toc522061278"></a><a name="_Toc523684289"></a><a name="_Toc523684649"></a><a name="_Toc524007756"></a><a name="_Toc524018210"></a><a name="_Toc524065392"></a><a name="_Toc524107255"></a><a name="_Ref521644774"></a><font style="Background-color:#auto;text-decoration:none;">1.68</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Dollars</font><font style="color:#000000;">&#8221; or &#8220;</font><font style="font-weight:bold;color:#000000;">$</font><font style="color:#000000;">&#8221; means the legal tender of the United States.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1657"></a><a name="_BPDC_PR_INS_1658"></a><font style="Background-color:#auto;text-decoration:none;">1.69</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">&#8220;Early Payment Election&#8221;</font><font style="color:#000000;"> has the meaning set forth in Section 3.8.3(b).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1655"></a><a name="_BPDC_PR_INS_1656"></a><a name="_Ref521646817"></a><a name="_Toc521651126"></a><a name="_Toc521845968"></a><a name="_Toc521842942"></a><a name="_Toc521850837"></a><a name="_Toc522061279"></a><a name="_Toc523684290"></a><a name="_Toc523684650"></a><a name="_Toc524007757"></a><a name="_Toc524018211"></a><a name="_Toc524065393"></a><a name="_Toc524107256"></a><a name="_Ref521644775"></a><font style="Background-color:#auto;text-decoration:none;">1.70</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Effective Date</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 17.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1653"></a><a name="_BPDC_PR_INS_1654"></a><a name="_Ref521646818"></a><a name="_Toc521651127"></a><a name="_Toc521845969"></a><a name="_Toc521842943"></a><a name="_Toc521850838"></a><a name="_Toc522061280"></a><a name="_Toc523684291"></a><a name="_Toc523684651"></a><a name="_Toc524007758"></a><a name="_Toc524018212"></a><a name="_Toc524065394"></a><a name="_Toc524107257"></a><a name="_Ref521644776"></a><a name="DocXTextRef34"></a><font style="Background-color:#auto;text-decoration:none;">1.71</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">EMA</font><font style="color:#000000;">&#8221;<a name="DocXTextRef34"></a> has the meaning set forth in Section 1.211.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.72</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Enforcing Party</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 12.9.4(a).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1651"></a><a name="_BPDC_PR_INS_1652"></a><a name="_Ref521646820"></a><a name="_Toc521651129"></a><a name="_Toc521845971"></a><a name="_Toc521842945"></a><a name="_Toc521850840"></a><a name="_Toc522061282"></a><a name="_Toc523684293"></a><a name="_Toc523684653"></a><a name="_Toc524007760"></a><a name="_Toc524018214"></a><a name="_Toc524065396"></a><a name="_Toc524107259"></a><a name="_Ref521644778"></a><font style="Background-color:#auto;text-decoration:none;">1.73</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">EU</font><font style="color:#000000;">&#8221; means the European Union and all its then-current member countries, but including in any case France, Germany, Italy, Spain and the United Kingdom regardless of whether they are then-current member countries.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1649"></a><a name="_BPDC_PR_INS_1650"></a><a name="_Toc522061283"></a><a name="_Toc523684294"></a><a name="_Toc523684654"></a><a name="_Toc524007762"></a><a name="_Toc524018216"></a><a name="_Toc524065398"></a><a name="_Toc524107262"></a><font style="Background-color:#auto;text-decoration:none;">1.74</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Exchange</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 13.3.1(a).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.75</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Execution Date</font><font style="color:#000000;">&#8221; has the meaning set forth in the preamble hereto.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1647"></a><a name="_BPDC_PR_INS_1648"></a><a name="_Ref521646823"></a><a name="_Toc521651132"></a><a name="_Toc521845974"></a><a name="_Toc521842948"></a><a name="_Toc521850843"></a><a name="_Toc522061284"></a><a name="_Toc523684295"></a><a name="_Toc523684655"></a><a name="_Toc524007763"></a><a name="_Toc524018217"></a><a name="_Toc524065399"></a><a name="_Toc524107263"></a><a name="_Ref39503563"></a><a name="_Ref521644781"></a><a name="DocXTextRef38"></a><a name="DocXTextRef39"></a><font style="Background-color:#auto;text-decoration:none;">1.76</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Executive Officers</font><font style="color:#000000;">&#8221; means<a name="DocXTextRef38"></a> (a)<a name="DocXTextRef39"></a> with respect to Relay, Relay&#8217;s Chief Executive Officer or his or her designee with appropriate decision-making authority and (b) with respect to Licensee, a Vice President of Genentech or his or her designee with appropriate decision-making authority. &nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.77</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Existing Sponsored Research Agreements</font><font style="color:#000000;">&#8221; [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.78</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Existing Third Party Agreement</font><font style="color:#000000;">&#8221; means any agreement with a Third Party in effect as of the Effective Date pursuant to which Relay Controls any Relay Patents or Relay Know-How. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1645"></a><a name="_BPDC_PR_INS_1646"></a><a name="_BPDC_LN_INS_1643"></a><a name="_BPDC_PR_INS_1644"></a><font style="Background-color:#auto;text-decoration:none;">1.79</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Expert</font><font style="color:#000000;">&#8221; means a Person with no less than ten (10) years of experience in the pharmaceutical and life sciences industries, but excluding any current or former employee or consultant of either Party. Such Person will be fluent in the English language.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1641"></a><a name="_BPDC_PR_INS_1642"></a><a name="_Ref521646825"></a><a name="_Toc521651134"></a><a name="_Toc521845976"></a><a name="_Toc521842950"></a><a name="_Toc521850845"></a><a name="_Toc522061285"></a><a name="_Toc523684296"></a><a name="_Toc523684656"></a><a name="_Toc524007764"></a><a name="_Toc524018218"></a><a name="_Toc524065400"></a><a name="_Toc524107264"></a><a name="_Ref521644783"></a><a name="DocXTextRef41"></a><font style="Background-color:#auto;text-decoration:none;">1.80</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">FDA</font><font style="color:#000000;">&#8221; has the meaning<a name="DocXTextRef41"></a> set forth in Section 1.211.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1639"></a><a name="_BPDC_PR_INS_1640"></a><font style="Background-color:#auto;text-decoration:none;">1.81</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">FDCA</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 1.14.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1637"></a><a name="_BPDC_PR_INS_1638"></a><font style="Background-color:#auto;text-decoration:none;">1.82</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">FGFR2</font><font style="color:#000000;">&#8221; [***].&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1635"></a><a name="_BPDC_PR_INS_1636"></a><a name="_Toc522061286"></a><a name="_Toc523684297"></a><a name="_Toc523684657"></a><a name="_Toc524007765"></a><a name="_Toc524018219"></a><a name="_Toc524065401"></a><a name="_Toc524107265"></a><a name="_Toc524007766"></a><a name="_Toc524018220"></a><a name="_Toc524065402"></a><a name="_Toc524107266"></a><a name="_Toc525806022"></a><font style="Background-color:#auto;text-decoration:none;">1.83</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Field</font><font style="color:#000000;">&#8221; [***]<a name="_Toc524007766"></a><a name="_Toc524018220"></a><a name="_Toc524065402"></a><a name="_Toc524107266"></a><a name="_Toc525806022"></a>. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1633"></a><a name="_BPDC_PR_INS_1634"></a><font style="Background-color:#auto;text-decoration:none;">1.84</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Financial Committee</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 18.9.4(a).</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1631"></a><a name="_BPDC_PR_INS_1632"></a><font style="Background-color:#auto;text-decoration:none;">1.85</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Financial Dispute</font><font style="color:#000000;">&#8221; means any Dispute related to determining the Relative Commercial Value pursuant to Section 5.5.2(e) in connection with a Combination Product.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1629"></a><a name="_BPDC_PR_INS_1630"></a><font style="Background-color:#auto;text-decoration:none;">1.86</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Financial</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Expert</font><font style="color:#000000;">&#8221; means a Person with no less than ten (10) years of experience in the pharmaceutical and life sciences industries, with expertise in the valuation of pharmaceutical products, but excluding any current or former employee or consultant of either Party. Such Person will be fluent in the English language.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.87</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Financial Liaison</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 10.12.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1627"></a><a name="_BPDC_PR_INS_1628"></a><font style="Background-color:#auto;text-decoration:none;">1.88</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Financial Report</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 18.9.4(b).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1625"></a><a name="_BPDC_PR_INS_1626"></a><font style="Background-color:#auto;text-decoration:none;">1.89</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Finished Product</font><font style="color:#000000;">&#8221; means the finished product formulation of a Licensed Product, containing Bulk Drug Product, filled into unit packages for final labeling and packaging.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1623"></a><a name="_BPDC_PR_INS_1624"></a><font style="Background-color:#auto;text-decoration:none;">1.90</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">First Commercial Sale</font><font style="color:#000000;">&#8221; [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1621"></a><a name="_BPDC_PR_INS_1622"></a><font style="Background-color:#auto;text-decoration:none;">1.91</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">First Tier GDP Overrun</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 3.8.5.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1619"></a><a name="_BPDC_PR_INS_1620"></a><font style="Background-color:#auto;text-decoration:none;">1.92</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Fixed SG&amp;A</font><font style="color:#000000;">&#8221; means the amount calculated by multiplying the Fixed SG&amp;A Percentage by the Net Sales amount.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1617"></a><a name="_BPDC_PR_INS_1618"></a><font style="Background-color:#auto;text-decoration:none;">1.93</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Fixed SG&amp;A Percentage</font><font style="color:#000000;">&#8221; [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.94</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Force Majeure Event</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 18.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1615"></a><a name="_BPDC_PR_INS_1616"></a><a name="_Ref521646831"></a><a name="_Toc521651140"></a><a name="_Toc521845981"></a><a name="_Toc521842955"></a><a name="_Toc521850850"></a><a name="_Toc522061288"></a><a name="_Toc523684299"></a><a name="_Toc523684659"></a><a name="_Toc524007768"></a><a name="_Toc524018222"></a><a name="_Toc524065404"></a><a name="_Toc524107268"></a><a name="_Ref521644789"></a><font style="Background-color:#auto;text-decoration:none;">1.95</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">FTE</font><font style="color:#000000;">&#8221; means a full time equivalent employee (i.e., one fully-committed or multiple partially-committed employees aggregating to one full-time employee) employed by a Party (or any of its Affiliates) and assigned to perform specific work, with such commitment of time and effort to constitute one employee performing such work on a full-time basis, which for purposes hereof will be [***] per year.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1613"></a><a name="_BPDC_PR_INS_1614"></a><font style="Background-color:#auto;text-decoration:none;">1.96</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">FTE Costs</font><font style="color:#000000;">&#8221; [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1611"></a><a name="_BPDC_PR_INS_1612"></a><a name="_Ref521646836"></a><a name="_Toc521651145"></a><a name="_Toc521845986"></a><a name="_Toc521842956"></a><a name="_Toc521850851"></a><a name="_Toc522061289"></a><a name="_Toc523684300"></a><a name="_Toc523684660"></a><a name="_Toc524007769"></a><a name="_Toc524018223"></a><a name="_Toc524065405"></a><a name="_Toc524107269"></a><a name="_Ref521644794"></a><font style="Background-color:#auto;text-decoration:none;">1.97</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">GCP</font><font style="color:#000000;">&#8221; means the applicable then-current ethical and scientific quality standards for designing, conducting, overseeing, monitoring, recording, and reporting trials that involve the participation of human subjects as are required by applicable Regulatory Authorities or Applicable Law in the relevant jurisdiction, including in the United States the regulations at 21 C.F.R. Parts 50, 54, 56, and 312 and FDA guidance documents (including Guideline for Good Clinical Practice &#8211; ICH Harmonized Tripartite Guideline (ICH E6)), and, outside the United States, Guidelines for Good Clinical Practice &#8211; ICH Harmonized Tripartite Guideline (ICH E6).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1609"></a><a name="_BPDC_PR_INS_1610"></a><a name="_BPDC_LN_INS_1607"></a><a name="_BPDC_PR_INS_1608"></a><font style="Background-color:#auto;text-decoration:none;">1.98</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Genentech</font><font style="color:#000000;">&#8221; has the meaning set forth in the preamble hereto. <a name="_BPDC_LN_INS_1607"></a><a name="_BPDC_PR_INS_1608"></a>&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1605"></a><a name="_BPDC_PR_INS_1606"></a><a name="_Ref56361041"></a><font style="Background-color:#auto;text-decoration:none;">1.99</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Generic Product</font><font style="color:#000000;">&#8221; [***]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1603"></a><a name="_BPDC_PR_INS_1604"></a><font style="Background-color:#auto;text-decoration:none;">1.100</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Generic Relay Combination Patent</font><font style="color:#000000;">&#8221; [***].</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1601"></a><a name="_BPDC_PR_INS_1602"></a><font style="Background-color:#auto;text-decoration:none;">1.101</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Global Development Budget</font><font style="color:#000000;">&#8221; means a budget for the Development Costs for the Lead Products covered by the GDP in the Field in the Territory.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1599"></a><a name="_BPDC_PR_INS_1600"></a><a name="_Ref52545333"></a><a name="_Ref51941441"></a><font style="Background-color:#auto;text-decoration:none;">1.102</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Global Development Plan</font><font style="color:#000000;">&#8221; or &#8220;</font><font style="font-weight:bold;color:#000000;">GDP</font><font style="color:#000000;">&#8221; means a written development plan that includes (a) a Global Development Budget, and (b) a description of Development activities (other than the Relay Phase Ia Trial) for Development of the Lead Products other than those [***] Combination Agents for which Relay issued a Deferred Combination Agent Election pursuant to Section 10.7.3(c), in the Field in the Territory designed, to the extent supported by scientific evidence, to obtain Regulatory Approval for the Lead Products to the extent such activities can be reasonably determined at the time.&nbsp;&nbsp;An initial draft of the Global Development Plan is attached as 1.102.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1597"></a><a name="_BPDC_PR_INS_1598"></a><a name="_Ref521646837"></a><a name="_Toc521651146"></a><a name="_Toc521845987"></a><a name="_Toc521842961"></a><a name="_Toc521850856"></a><a name="_Toc522061294"></a><a name="_Toc523684305"></a><a name="_Toc523684665"></a><a name="_Toc524007774"></a><a name="_Toc524018228"></a><a name="_Toc524065410"></a><a name="_Toc524107274"></a><a name="_Ref521644795"></a><font style="Background-color:#auto;text-decoration:none;">1.103</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Global Trial</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 3.8.2.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1595"></a><a name="_BPDC_PR_INS_1596"></a><a name="DocXTextRef49"></a><a name="DocXTextRef48"></a><font style="Background-color:#auto;text-decoration:none;">1.104</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">GLP</font><font style="color:#000000;">&#8221;<a name="DocXTextRef49"></a> means the applicable then-current good laboratory practice standards promulgated or endorsed by the FDA, as defined in the United States in 21<a name="DocXTextRef48"></a> C.F.R. Part 58 and relevant guidance documents, or such other comparable regulatory standards in jurisdictions outside the United States as promulgated or endorsed by the applicable Regulatory Authorities.<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1593"></a><a name="_BPDC_PR_INS_1594"></a><a name="_Ref521646838"></a><a name="_Toc521651147"></a><a name="_Toc521845988"></a><a name="_Toc521842962"></a><a name="_Toc521850857"></a><a name="_Toc522061295"></a><a name="_Toc523684306"></a><a name="_Toc523684666"></a><a name="_Toc524007775"></a><a name="_Toc524018229"></a><a name="_Toc524065411"></a><a name="_Toc524107275"></a><a name="_Ref521644796"></a><a name="DocXTextRef52"></a><a name="DocXTextRef51"></a><a name="DocXTextRef50"></a><a name="DocXTextRef53"></a><a name="DocXTextRef54"></a><font style="Background-color:#auto;text-decoration:none;">1.105</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">GMP</font><font style="color:#000000;">&#8221; means all applicable standards relating to current good manufacturing practices for fine chemicals, intermediates, bulk products, biologic components, raw materials or <a name="DocXTextRef52"></a>finished biological or pharmaceutical products, including (a)<a name="DocXTextRef51"></a> all applicable requirements under 21 U.S.C. &#167; 351(a)(2)(B) and in the FDA&#8217;s current Good Manufacturing Practices regulations at 21<a name="DocXTextRef50"></a> C.F.R. Parts 210, 211, 600, and 610 and relevant guidance documents<a name="DocXTextRef53"></a>, (b)<a name="DocXTextRef54"></a> all applicable requirements detailed in the EMA&#8217;s &#8220;The Rules Governing Medicinal Products in the European Community, Volume IV, Good Manufacturing Practice for Medicinal Products&#8221;, and (c) all analogous Applicable Law promulgated by any Governmental Authority having jurisdiction over the manufacture of the applicable biological or pharmaceutical compound or product.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1591"></a><a name="_BPDC_PR_INS_1592"></a><a name="_Ref521646839"></a><a name="_Toc521651148"></a><a name="_Toc521845989"></a><a name="_Toc521842963"></a><a name="_Toc521850858"></a><a name="_Toc522061296"></a><a name="_Toc523684307"></a><a name="_Toc523684667"></a><a name="_Toc524007776"></a><a name="_Toc524018230"></a><a name="_Toc524065412"></a><a name="_Toc524107276"></a><a name="_Ref521644797"></a><a name="DocXTextRef56"></a><a name="DocXTextRef57"></a><a name="DocXTextRef58"></a><a name="DocXTextRef59"></a><font style="Background-color:#auto;text-decoration:none;">1.106</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_Ref521646839"></a><a name="_Toc521651148"></a><a name="_Toc521845989"></a><a name="_Toc521842963"></a><a name="_Toc521850858"></a><a name="_Toc522061296"></a><a name="_Toc523684307"></a><a name="_Toc523684667"></a><a name="_Toc524007776"></a><a name="_Toc524018230"></a><a name="_Toc524065412"></a><a name="_Toc524107276"></a><a name="_Ref521644797"></a> &#8220;</font><font style="font-weight:bold;color:#000000;">Governmental Authority</font><font style="color:#000000;">&#8221;<a name="DocXTextRef56"></a> means any (a)<a name="DocXTextRef57"></a> federal, state, local, municipal, foreign or other government, (b) governmental or quasi-governmental authority of any nature (including any governmental division, subdivision<a name="DocXTextRef58"></a>, department, agency, bureau, branch, office, commission, council, board, instrumentality, licensing body, officer, official, representative, organization, unit, body or entity and any court or other tribunal of competent jurisdiction (including any arbitration or other alternative dispute forum)), (c)<a name="DocXTextRef59"></a> supra-national or multinational governmental organization or body or (d) entity or body exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature.&nbsp;&nbsp;The term &#8220;Governmental Authority&#8221; includes any Regulatory Authority.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1589"></a><a name="_BPDC_PR_INS_1590"></a><a name="_Ref521646841"></a><a name="_Toc521651150"></a><a name="_Toc521845990"></a><a name="_Toc521842964"></a><a name="_Toc521850859"></a><a name="_Toc522061297"></a><a name="_Toc523684308"></a><a name="_Toc523684668"></a><a name="_Toc524007777"></a><a name="_Toc524018231"></a><a name="_Toc524065413"></a><a name="_Toc524107277"></a><a name="_Ref521644799"></a><font style="Background-color:#auto;text-decoration:none;">1.107</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">gRED</font><font style="color:#000000;">&#8221; means the Research and Early Development organization of Genentech (or its equivalent, if reorganized).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1587"></a><a name="_BPDC_PR_INS_1588"></a><font style="Background-color:#auto;text-decoration:none;">1.108</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">HHS</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 1.14.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1585"></a><a name="_BPDC_PR_INS_1586"></a><a name="DocXTextRef61"></a><font style="Background-color:#auto;text-decoration:none;">1.109</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">HSR Act</font><font style="color:#000000;">&#8221; has the meaning<a name="DocXTextRef61"></a> set forth in Section 1.13.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1583"></a><a name="_BPDC_PR_INS_1584"></a><a name="_Toc522061298"></a><a name="_Toc523684309"></a><a name="_Toc523684669"></a><a name="_Toc524007778"></a><a name="_Toc524018232"></a><a name="_Toc524065414"></a><a name="_Toc524107278"></a><font style="Background-color:#auto;text-decoration:none;">1.110</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">HSR Clearance Date</font><font style="color:#000000;">&#8221; means the earliest date on which the Parties have actual knowledge that all applicable waiting periods and requests for information (and any extensions </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">thereof) under the HSR Act with respect to the transactions contemplated by this Agreement have expired or have been terminated.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1581"></a><a name="_BPDC_PR_INS_1582"></a><a name="_Ref521646844"></a><a name="_Toc521651153"></a><a name="_Toc521845991"></a><a name="_Toc521842965"></a><a name="_Toc521850860"></a><a name="_Toc522061300"></a><a name="_Toc523684311"></a><a name="_Toc523684671"></a><a name="_Toc524007780"></a><a name="_Toc524018234"></a><a name="_Toc524065416"></a><a name="_Toc524107280"></a><a name="_Ref521644802"></a><font style="Background-color:#auto;text-decoration:none;">1.111</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Immediate Tech Transfer Activities</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 11.1.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.112</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">In-License Payments</font><font style="color:#000000;">&#8221; [***]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1579"></a><a name="_BPDC_PR_INS_1580"></a><a name="DocXTextRef65"></a><a name="DocXTextRef64"></a><font style="Background-color:#auto;text-decoration:none;">1.113</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">IND</font><font style="color:#000000;">&#8221;<a name="DocXTextRef65"></a> means an investigational new drug application (including any amendment or supplement thereto) submitted to the FDA pursuant to U.S. 21<a name="DocXTextRef64"></a> C.F.R. Part 312.&nbsp;&nbsp;References herein to IND will include, to the extent applicable, any comparable filing(s) outside the U.S. for the investigation of any product in any other country or group of countries (such as a Clinical Trial Application in the EU).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.114</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">IND Transfer Milestone</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 11.1.2.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1577"></a><a name="_BPDC_PR_INS_1578"></a><a name="_Ref521646846"></a><a name="_Toc521651155"></a><a name="_Toc521845993"></a><a name="_Toc521842967"></a><a name="_Toc521850862"></a><a name="_Toc522061301"></a><a name="_Toc523684312"></a><a name="_Toc523684672"></a><a name="_Toc524007781"></a><a name="_Toc524018235"></a><a name="_Toc524065417"></a><a name="_Toc524107281"></a><a name="_Ref521644804"></a><a name="DocXTextRef66"></a><font style="Background-color:#auto;text-decoration:none;">1.115</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Indemnification Claim Notice</font><font style="color:#000000;">&#8221; has the<a name="DocXTextRef66"></a> meaning set forth in Section 15.3.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1575"></a><a name="_BPDC_PR_INS_1576"></a><a name="_Ref521646847"></a><a name="_Toc521651156"></a><a name="_Toc521845994"></a><a name="_Toc521842968"></a><a name="_Toc521850863"></a><a name="_Toc522061302"></a><a name="_Toc523684313"></a><a name="_Toc523684673"></a><a name="_Toc524007782"></a><a name="_Toc524018236"></a><a name="_Toc524065418"></a><a name="_Toc524107282"></a><a name="_Ref521644805"></a><font style="Background-color:#auto;text-decoration:none;">1.116</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Indemnified Party</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 15.3.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1573"></a><a name="_BPDC_PR_INS_1574"></a><a name="_Ref521646848"></a><a name="_Toc521651157"></a><a name="_Toc521845995"></a><a name="_Toc521842969"></a><a name="_Toc521850864"></a><a name="_Toc522061303"></a><a name="_Toc523684314"></a><a name="_Toc523684674"></a><a name="_Toc524007783"></a><a name="_Toc524018237"></a><a name="_Toc524065419"></a><a name="_Toc524107283"></a><a name="_Ref521644806"></a><font style="Background-color:#auto;text-decoration:none;">1.117</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Indemnifying Party</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 15.3.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1571"></a><a name="_BPDC_PR_INS_1572"></a><a name="_Toc495674964"></a><a name="_Toc496044694"></a><a name="_Toc502758306"></a><a name="_Toc504657943"></a><a name="_Toc506299968"></a><a name="_Toc498521741"></a><a name="_Toc499021761"></a><a name="_Toc527503443"></a><a name="_Toc527799955"></a><a name="_Toc527972263"></a><font style="Background-color:#auto;text-decoration:none;">1.118</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_Toc495674964"></a><a name="_Toc496044694"></a><a name="_Toc502758306"></a><a name="_Toc504657943"></a><a name="_Toc506299968"></a><a name="_Toc498521741"></a><a name="_Toc499021761"></a><a name="_Toc527503443"></a><a name="_Toc527799955"></a><a name="_Toc527972263"></a>&#8220;</font><font style="font-weight:bold;">Indication</font>&#8221; <font style="color:#000000;">[***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1569"></a><a name="_BPDC_PR_INS_1570"></a><a name="_9kR3WTr8E8459BGN"></a><a name="_Toc495674965"></a><a name="_Toc496044695"></a><a name="_Toc498521742"></a><a name="_Toc499021762"></a><a name="_Toc502758307"></a><a name="_Toc504657944"></a><a name="_Toc506299969"></a><a name="_Toc528767783"></a><a name="_Toc528768075"></a><a name="_Toc528914044"></a><a name="_Toc527503444"></a><a name="_Toc527799956"></a><a name="_Toc527972264"></a><font style="Background-color:#auto;text-decoration:none;">1.119</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Initiation</font><font style="color:#000000;">&#8221; means, with respect to a given Clinical Trial, the administration of the first dose of a Licensed Product to the first subject in such Clinical Trial in accordance with the protocol for such Clinical Trial.&nbsp;&nbsp;Cognates of the word &#8220;Initiation&#8221; will have correlative meanings.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1567"></a><a name="_BPDC_PR_INS_1568"></a><font style="Background-color:#auto;text-decoration:none;">1.120</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Inventory</font><font style="color:#000000;">&#8221; means the materials to be transferred by Relay or on its behalf to Licensee or its CMO as set forth on the Technology Transfer Plan, [***].&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1565"></a><a name="_BPDC_PR_INS_1566"></a><font style="Background-color:#auto;text-decoration:none;">1.121</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">JDT</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 10.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1563"></a><a name="_BPDC_PR_INS_1564"></a><a name="_Toc524007785"></a><a name="_Toc524018239"></a><a name="_Toc524065421"></a><a name="_Toc524107285"></a><font style="Background-color:#auto;text-decoration:none;">1.122</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> &#8220;</font><font style="font-weight:bold;color:#000000;">Joint Collaboration IP</font><font style="color:#000000;">&#8221; means collectively the Joint Collaboration Know-How and Joint Collaboration Patents.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1561"></a><a name="_BPDC_PR_INS_1562"></a><font style="Background-color:#auto;text-decoration:none;">1.123</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Joint Collaboration Know-How</font><font style="color:#000000;">&#8221; means any Know-How that is first created, conceived or generated jointly by or on behalf of Licensee or its Affiliates (or their respective Third Party Subcontractors), on the one hand, and Relay or its Affiliates (or their respective Third Party Subcontractors), on the other hand, as determined pursuant to Section 12.7.1 in the course of activities performed under this Agreement. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1559"></a><a name="_BPDC_PR_INS_1560"></a><font style="Background-color:#auto;text-decoration:none;">1.124</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Joint Collaboration Patents</font><font style="color:#000000;">&#8221; means any Patents that claim any Joint Collaboration Know-How.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1557"></a><a name="_BPDC_PR_INS_1558"></a><font style="Background-color:#auto;text-decoration:none;">1.125</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Joint Team</font><font style="color:#000000;">&#8221; means each of the (a) JDT and (b) JPT.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.126</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Joint Third Party Action</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 12.11.2.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1555"></a><a name="_BPDC_PR_INS_1556"></a><font style="Background-color:#auto;text-decoration:none;">1.127</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> &#8220;</font><font style="font-weight:bold;color:#000000;">JPT</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 10.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1553"></a><a name="_BPDC_PR_INS_1554"></a><a name="_Ref521646853"></a><a name="_Toc521651162"></a><a name="_Toc521846001"></a><a name="_Toc521842975"></a><a name="_Toc521850870"></a><a name="_Toc522061305"></a><a name="_Toc523684316"></a><a name="_Toc523684676"></a><a name="_Toc524007786"></a><a name="_Toc524018240"></a><a name="_Toc524065422"></a><a name="_Toc524107286"></a><a name="_Ref521644811"></a><font style="Background-color:#auto;text-decoration:none;">1.128</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Know-How</font><font style="color:#000000;">&#8221; [***].&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1551"></a><a name="_BPDC_PR_INS_1552"></a><a name="_Ref521646854"></a><a name="_Toc521651163"></a><a name="_Toc521846002"></a><a name="_Toc521842976"></a><a name="_Toc521850871"></a><a name="_Toc522061306"></a><a name="_Toc523684317"></a><a name="_Toc523684677"></a><a name="_Toc524007787"></a><a name="_Toc524018241"></a><a name="_Toc524065423"></a><a name="_Toc524107287"></a><a name="_Ref521644812"></a><a name="_Hlk52515793"></a><font style="Background-color:#auto;text-decoration:none;">1.129</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Knowledge</font><font style="color:#000000;">&#8221;<a name="_Hlk52515793"></a> means, with respect to a Party, the actual knowledge of any employees of such Party (including in such Party&#8217;s internal legal department and intellectual property group) who were directly involved in the negotiation of this Agreement with the other Party, without any duty to conduct any investigation.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1549"></a><a name="_BPDC_PR_INS_1550"></a><font style="Background-color:#auto;text-decoration:none;">1.130</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">[***]</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1547"></a><a name="_BPDC_PR_INS_1548"></a><a name="_Ref41749290"></a><a name="_Toc524007789"></a><a name="_Toc524018243"></a><a name="_Toc524065425"></a><a name="_Toc524107289"></a><a name="_Toc522061308"></a><a name="_Toc523684319"></a><a name="_Toc523684679"></a><a name="_Ref521646881"></a><a name="_Ref521644839"></a><a name="_Toc521651190"></a><a name="_Toc521846029"></a><a name="_Toc521843003"></a><a name="_Toc521850898"></a><font style="Background-color:#auto;text-decoration:none;">1.131</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Launch Costs</font><font style="color:#000000;">&#8221; [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1545"></a><a name="_BPDC_PR_INS_1546"></a><a name="_BPDC_LN_INS_1543"></a><a name="_BPDC_PR_INS_1544"></a><a name="_Hlk51926090"></a><font style="Background-color:#auto;text-decoration:none;">1.132</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Lead Candidate</font><font style="color:#000000;">&#8221; [***] Relay&#8217;s proprietary compound RLY-1971 [***]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1541"></a><a name="_BPDC_PR_INS_1542"></a><font style="Background-color:#auto;text-decoration:none;">1.133</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Lead Product</font><font style="color:#000000;">&#8221; [***]</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1539"></a><a name="_BPDC_PR_INS_1540"></a><a name="_BPDC_LN_INS_1535"></a><a name="_BPDC_PR_INS_1536"></a><font style="Background-color:#auto;text-decoration:none;">1.134</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Lead Royalty Product</font><font style="color:#000000;">&#8221; means, (a) during the Opt-In Term, each Lead Product but solely with respect to the Royalty Territory and (b) before or after the Opt-In Term, each Lead Product in the Territory.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1537"></a><a name="_BPDC_PR_INS_1538"></a><font style="Background-color:#auto;text-decoration:none;">1.135</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Licensed Candidate</font><font style="color:#000000;">&#8221; means the Lead Candidate and any Back-Up Compound. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.136</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Licensed Product</font><font style="color:#000000;">&#8221; [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1533"></a><a name="_BPDC_PR_INS_1534"></a><font style="Background-color:#auto;text-decoration:none;">1.137</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Licensee Collaboration IP</font><font style="color:#000000;">&#8221; means any (a) Know-How first created, conceived or generated by or on behalf of Licensee or its Affiliates (whether solely or jointly with any Third Party(ies)), in the course of activities performed under this Agreement, as determined pursuant to Section 12.7.1, and (b) Patents that claim such Know-How, but excluding, in each case of (a) and (b), Joint Collaboration IP. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1531"></a><a name="_BPDC_PR_INS_1532"></a><font style="Background-color:#auto;text-decoration:none;">1.138</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">[***] Combination</font><font style="color:#000000;">&#8221; means any Combination Use of a Licensed Candidate or Licensed Product with one or more other compounds or products, [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.139</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">[***]</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1529"></a><a name="_BPDC_PR_INS_1530"></a><a name="_BPDC_LN_INS_1527"></a><a name="_BPDC_PR_INS_1528"></a><font style="Background-color:#auto;text-decoration:none;">1.140</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Licensee IP</font><font style="color:#000000;">&#8221; means Licensee Collaboration IP and Licensee&#8217;s interest in Joint Collaboration IP. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1525"></a><a name="_BPDC_PR_INS_1526"></a><font style="Background-color:#auto;text-decoration:none;">1.141</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> &#8220;</font><font style="font-weight:bold;color:#000000;">[***] Agent</font><font style="color:#000000;">&#8221; [***]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.142</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">[***] Agent Product</font><font style="color:#000000;">&#8221; [***].&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1523"></a><a name="_BPDC_PR_INS_1524"></a><font style="Background-color:#auto;text-decoration:none;">1.143</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">[***] Back-Up Combination</font><font style="color:#000000;">&#8221; [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1521"></a><a name="_BPDC_PR_INS_1522"></a><font style="Background-color:#auto;text-decoration:none;">1.144</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">[***] Combination</font><font style="color:#000000;">&#8221; means the Combination Use of (a) one or more [***] Agents or [***] Agent Products with (b) the Lead Candidate or a Lead Product (and which may include Combination Use with one or more other compounds or products in addition).&nbsp;&nbsp;[***]. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1519"></a><a name="_BPDC_PR_INS_1520"></a><font style="text-decoration:none;Background-color:#auto;">1.145</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="color:#000000;">[***]</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1517"></a><a name="_BPDC_PR_INS_1518"></a><font style="Background-color:#auto;text-decoration:none;">1.146</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;[***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1515"></a><a name="_BPDC_PR_INS_1516"></a><font style="Background-color:#auto;text-decoration:none;">1.147</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;[***].&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1513"></a><a name="_BPDC_PR_INS_1514"></a><font style="Background-color:#auto;text-decoration:none;">1.148</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">[***] Other Back-Up Combination</font><font style="color:#000000;">&#8221; means the Combination Use of (a) one or more compounds or products [***] other than a [***] Agent or [***] Agent Product with (b) a Back-Up Compound or a Back-Up Product.&nbsp;&nbsp;For clarity, [***] Other Back-Up Combinations exclude use of the compounds or products described in clause (a) above as a monotherapy or in combination with one or more compounds or products without a Back-Up Compound or a Back-Up Product and further exclude [***] Back-Up Combinations.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1511"></a><a name="_BPDC_PR_INS_1512"></a><font style="Background-color:#auto;text-decoration:none;">1.149</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">[***] Other Combination</font><font style="color:#000000;">&#8221; means the Combination Use of (a) one or more compounds or products [***], other than a [***] Agent or [***] Agent Product, with (b) the Lead Candidate or a Lead Product.&nbsp;&nbsp;For clarity, [***] Other Combinations exclude use of the compounds or products described in clause (a) above as a monotherapy or in combination with one or more compounds or products without the Lead Candidate or a Lead Product and further exclude [***] Combinations.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1509"></a><a name="_BPDC_PR_INS_1510"></a><font style="Background-color:#auto;text-decoration:none;">1.150</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">[***] Pipeline Compound</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 11.6.4(b).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1507"></a><a name="_BPDC_PR_INS_1508"></a><font style="Background-color:#auto;text-decoration:none;">1.151</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Licensee Selection Data Package</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 3.8.3(a).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1505"></a><a name="_BPDC_PR_INS_1506"></a><font style="Background-color:#auto;text-decoration:none;">1.152</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Licensee Selection Data Package Review Period</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 3.8.3(b).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1503"></a><a name="_BPDC_PR_INS_1504"></a><font style="Background-color:#auto;text-decoration:none;">1.153</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Licensee</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Sublicensee</font><font style="color:#000000;">&#8221; means a Third Party to which Licensee (or its Affiliate) has, pursuant to Section  12.2, granted sublicense rights under any of the license rights granted under Section 12.1.1 or to any Licensed Candidate or Licensed Product, but excluding Distributors and Compulsory Sublicensees.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1501"></a><a name="_BPDC_PR_INS_1502"></a><a name="_Ref521646856"></a><a name="_Toc521651165"></a><a name="_Toc521846004"></a><a name="_Toc521842978"></a><a name="_Toc521850873"></a><a name="_Toc522061317"></a><a name="_Toc523684328"></a><a name="_Toc523684688"></a><a name="_Toc524007798"></a><a name="_Toc524018252"></a><a name="_Toc524065434"></a><a name="_Toc524107298"></a><a name="_Ref521644814"></a><font style="Background-color:#auto;text-decoration:none;">1.154</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Losses</font><font style="color:#000000;">&#8221; means all losses, costs, claims, damages, liabilities and expense (including reasonable attorneys&#8217; fees and other reasonable Out-of-Pocket Costs of litigation).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1499"></a><a name="_BPDC_PR_INS_1500"></a><a name="_Toc524007799"></a><a name="_Toc524018253"></a><a name="_Toc524065435"></a><a name="_Toc524107299"></a><a name="_Hlk53744283"></a><font style="Background-color:#auto;text-decoration:none;">1.155</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Major Market Countries</font><font style="color:#000000;">&#8221; [***].<a name="_Hlk53744283"></a> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1497"></a><a name="_BPDC_PR_INS_1498"></a><font style="Background-color:#auto;text-decoration:none;">1.156</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Major Market Country in the EU</font><font style="color:#000000;">&#8221; [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1495"></a><a name="_BPDC_PR_INS_1496"></a><a name="_Toc522061318"></a><a name="_Toc523684329"></a><a name="_Toc523684689"></a><a name="_Toc524007800"></a><a name="_Toc524018254"></a><a name="_Toc524065436"></a><a name="_Toc524107300"></a><font style="Background-color:#auto;text-decoration:none;">1.157</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Manufacture</font><font style="color:#000000;">&#8221; means all activities related to the manufacturing of a product or, in either case, any raw material, component or ingredient thereof, including test method development and stability testing, formulation, cell line development, process development and validation, manufacturing scale-up whether before or after Regulatory Approval, manufacturing any product in bulk or finished form for Development or Commercialization (as applicable), including filling and finishing, packaging, labeling, shipping and holding, in-process and Finished Product testing, release of a product or any component or ingredient thereof, quality assurance and quality control activities related to manufacturing and release of a product and regulatory activities </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">related to any of the foregoing.</font><font style="color:#000000;"> </font><font style="color:#000000;"> Cognates of the word &#8220;Manufacture&#8221; will have correlative meanings.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1493"></a><a name="_BPDC_PR_INS_1494"></a><a name="_Ref38623956"></a><a name="_Ref38624710"></a><a name="_Ref521646857"></a><a name="_Toc521651166"></a><a name="_Toc521846005"></a><a name="_Toc521842979"></a><a name="_Toc521850874"></a><a name="_Toc522061320"></a><a name="_Toc523684331"></a><a name="_Toc523684691"></a><a name="_Toc524007802"></a><a name="_Toc524018256"></a><a name="_Toc524065438"></a><a name="_Toc524107302"></a><a name="_Ref521644815"></a><font style="Background-color:#auto;text-decoration:none;">1.158</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Manufacturing Costs</font><font style="color:#000000;">&#8221; [***]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1491"></a><a name="_BPDC_PR_INS_1492"></a><font style="Background-color:#auto;text-decoration:none;">1.159</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Manufacturing Know-How and Materials</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 3.2.2</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1489"></a><a name="_BPDC_PR_INS_1490"></a><font style="Background-color:#auto;text-decoration:none;">1.160</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Manufacturing Transfer</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 3.2.2. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1487"></a><a name="_BPDC_PR_INS_1488"></a><font style="Background-color:#auto;text-decoration:none;">1.161</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Marketing Studies</font><font style="color:#000000;">&#8221; mean human clinical trials of a Licensed Candidate or Licensed Product conducted following Initiation of a Pivotal Trial for such Licensed Candidate or Licensed Product that is not required for receipt of Regulatory Approval (whether such human clinical trial is conducted prior to or after receipt of such Regulatory Approval) and is not a Post-Approval Study, but that may be useful in support of the post-Regulatory Approval exploitation of such Licensed Candidate or Licensed Product.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1485"></a><a name="_BPDC_PR_INS_1486"></a><font style="Background-color:#auto;text-decoration:none;">1.162</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> &#8220;</font><font style="font-weight:bold;color:#000000;">Material Communications</font><font style="color:#000000;">&#8221; means any material written, electronic, telephonic, or in person communications from or with any Regulatory Authority, including but not limited to any of the following:&nbsp;&nbsp;potential labeling changes, key product quality attributes (e.g., purity), product manufacturing, safety findings (e.g., serious adverse events, emerging safety signals, imposition of a clinical hold), clinical or non-clinical findings that may affect patient safety, lack of efficacy, receipt or denial of Regulatory Approval, the conduct or design of Clinical Trials, or the need for additional non clinical studies (e.g., additional toxicology or carcinogenicity studies) or Clinical Trials.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1483"></a><a name="_BPDC_PR_INS_1484"></a><font style="Background-color:#auto;text-decoration:none;">1.163</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Materials</font><font style="color:#000000;">&#8221; all tangible compositions of matter, devices, articles of manufacture, assays, biological, chemical, or physical materials, and other similar materials.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1481"></a><a name="_BPDC_PR_INS_1482"></a><a name="_Toc522061299"></a><a name="_Toc523684310"></a><a name="_Toc523684670"></a><a name="_Toc524007779"></a><a name="_Toc524018233"></a><a name="_Toc524065415"></a><a name="_Toc524107279"></a><font style="Background-color:#auto;text-decoration:none;">1.164</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Medical Affairs</font><font style="color:#000000;">&#8221; means the coordination of medical information requests and field based medical scientific liaisons with respect to a Shared Product (including any [***] Combinations), including activities of medical scientific liaisons, activities involving key opinion leaders, and the provision of medical information services with respect to such Shared Product.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1479"></a><a name="_BPDC_PR_INS_1480"></a><font style="Background-color:#auto;text-decoration:none;">1.165</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Merger Control Filing</font><font style="color:#000000;">&#8221; means any filing by Relay or Licensee with (a) the U.S. Federal Trade Commission&nbsp;&nbsp;and the Antitrust Division of the U.S. Department of Justice of a Notification and Report Form for Certain Mergers and Acquisitions (as that term is defined in the HSR Act) with respect to the matters set forth in this Agreement, or (b) with any other Governmental Authority of any merger control filing required under applicable Antitrust Law, in each case, together with all required documentary attachments thereto.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1477"></a><a name="_BPDC_PR_INS_1478"></a><font style="Background-color:#auto;text-decoration:none;">1.166</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_BPDC_LN_INS_1477"></a><a name="_BPDC_PR_INS_1478"></a> &#8220;</font><font style="font-weight:bold;color:#000000;">NDA</font><font style="color:#000000;">&#8221; means any (a) New Drug Application pursuant to the FDCA submitted to the FDA, or (b) a substantially similar application or submission submitted to a Regulatory Authority in a country or group of countries within the Territory to obtain Regulatory Approval (but not Pricing Approval) to Commercialize a Licensed Candidate or Licensed Product in that country or in that group of countries, including, with respect to the EU, a Marketing Authorization Application submitted to the EMA pursuant to the centralized approval procedure or to the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">applicable Regulatory Authority of a country in the EU with respect to the mutual recognition or any other national approval.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1475"></a><a name="_BPDC_PR_INS_1476"></a><a name="_Toc524007810"></a><a name="_Toc524018264"></a><a name="_Toc524065446"></a><a name="_Toc524107310"></a><a name="_Toc523684339"></a><a name="_Toc523684699"></a><a name="_Ref529019441"></a><font style="Background-color:#auto;text-decoration:none;">1.167</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_Toc524007810"></a><a name="_Toc524018264"></a><a name="_Toc524065446"></a><a name="_Toc524107310"></a><a name="_Toc523684339"></a><a name="_Toc523684699"></a><a name="_Ref529019441"></a> &#8220;</font><font style="font-weight:bold;color:#000000;">Net Profits and Net Losses</font><font style="color:#000000;">&#8221;, [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1473"></a><a name="_BPDC_PR_INS_1474"></a><font style="Background-color:#auto;text-decoration:none;">1.168</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Net Sales</font><font style="color:#000000;">&#8221; [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1471"></a><a name="_BPDC_PR_INS_1472"></a><a name="_Toc524007813"></a><a name="_Toc524018267"></a><a name="_Toc524065449"></a><a name="_Toc524107313"></a><font style="Background-color:#auto;text-decoration:none;">1.169</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Non-Publishing Party</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 13.5.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1469"></a><a name="_BPDC_PR_INS_1470"></a><font style="Background-color:#auto;text-decoration:none;">1.170</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Opt-In Data Package</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 4.1.2.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1467"></a><a name="_BPDC_PR_INS_1468"></a><font style="Background-color:#auto;text-decoration:none;">1.171</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">&#8220;Opt-In Deadline&#8221;</font><font style="color:#000000;"> has the meaning set forth in Section 4.1.2.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1465"></a><a name="_BPDC_PR_INS_1466"></a><font style="Background-color:#auto;text-decoration:none;">1.172</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Opt-In Effective Date</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 4.1.6.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1463"></a><a name="_BPDC_PR_INS_1464"></a><font style="Background-color:#auto;text-decoration:none;">1.173</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Opt-In Exercise Notice</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 4.1.6.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1461"></a><a name="_BPDC_PR_INS_1462"></a><font style="Background-color:#auto;text-decoration:none;">1.174</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Opt-In Right</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 4.1.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1459"></a><a name="_BPDC_PR_INS_1460"></a><font style="Background-color:#auto;text-decoration:none;">1.175</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Opt-In</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Sales Milestone</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 11.5.5.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1457"></a><a name="_BPDC_PR_INS_1458"></a><font style="Background-color:#auto;text-decoration:none;">1.176</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Opt-In</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Sales Milestone Payment</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 11.5.5.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1455"></a><a name="_BPDC_PR_INS_1456"></a><font style="Background-color:#auto;text-decoration:none;">1.177</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Opt-In Term</font><font style="color:#000000;">&#8221; means the period of time from the Opt-In Effective Date until the Opt-Out Date.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1453"></a><a name="_BPDC_PR_INS_1454"></a><font style="Background-color:#auto;text-decoration:none;">1.178</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Opt-In Term</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Development/Commercial Milestone</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 11.5.2.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1451"></a><a name="_BPDC_PR_INS_1452"></a><font style="Background-color:#auto;text-decoration:none;">1.179</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Opt-In Term</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Development/Commercial Milestone Payment</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 11.5.2.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1449"></a><a name="_BPDC_PR_INS_1450"></a><font style="Background-color:#auto;text-decoration:none;">1.180</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Opt-Out Date</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 4.2.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1447"></a><a name="_BPDC_PR_INS_1448"></a><font style="Background-color:#auto;text-decoration:none;">1.181</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Opt-Out Right</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 4.2.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1445"></a><a name="_BPDC_PR_INS_1446"></a><font style="Background-color:#auto;text-decoration:none;">1.182</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">"</font><font style="font-weight:bold;color:#000000;">Optional Additional Phase Ia Study&#8221;</font><font style="color:#000000;"> has the meaning set forth in Section 3.3.2.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1443"></a><a name="_BPDC_PR_INS_1444"></a><a name="_BPDC_LN_INS_1441"></a><a name="_BPDC_PR_INS_1442"></a><font style="Background-color:#auto;text-decoration:none;">1.183</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_BPDC_LN_INS_1441"></a><a name="_BPDC_PR_INS_1442"></a> &#8220;</font><font style="font-weight:bold;color:#000000;">Other Shared Expenses</font><font style="color:#000000;">&#8221; [***]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1439"></a><a name="_BPDC_PR_INS_1440"></a><font style="Background-color:#auto;text-decoration:none;">1.184</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Out-of-Pocket Costs</font><font style="color:#000000;">&#8221; [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1437"></a><a name="_BPDC_PR_INS_1438"></a><a name="_9kR3WTr8E845ACAAI"></a><a name="_Ref521646875"></a><a name="_Toc521651184"></a><a name="_Toc521846023"></a><a name="_Toc521842997"></a><a name="_Toc521850892"></a><a name="_Toc522061332"></a><a name="_Toc523684346"></a><a name="_Toc523684706"></a><a name="_Toc524007818"></a><a name="_Toc524018272"></a><a name="_Toc524065454"></a><a name="_Toc524107318"></a><a name="_Ref521644833"></a><font style="Background-color:#auto;text-decoration:none;">1.185</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Party</font><font style="color:#000000;">&#8221; or &#8220;</font><font style="font-weight:bold;color:#000000;">Parties</font><font style="color:#000000;">&#8221; has the meaning set forth in the preamble hereto. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.186</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Patent Challenge</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 16.5.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1435"></a><a name="_BPDC_PR_INS_1436"></a><a name="_Ref521646876"></a><a name="_Toc521651185"></a><a name="_Toc521846024"></a><a name="_Toc521842998"></a><a name="_Toc521850893"></a><a name="_Toc522061333"></a><a name="_Toc523684347"></a><a name="_Toc523684707"></a><a name="_Toc524007819"></a><a name="_Toc524018273"></a><a name="_Toc524065455"></a><a name="_Toc524107319"></a><a name="_Ref521644834"></a><font style="Background-color:#auto;text-decoration:none;">1.187</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Patents</font><font style="color:#000000;">&#8221; [***].&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1433"></a><a name="_BPDC_PR_INS_1434"></a><a name="_Ref521646878"></a><a name="_Toc521651187"></a><a name="_Toc521846026"></a><a name="_Toc521843000"></a><a name="_Toc521850895"></a><a name="_Toc522061334"></a><a name="_Toc523684348"></a><a name="_Toc523684708"></a><a name="_Toc524007821"></a><a name="_Toc524018275"></a><a name="_Toc524065457"></a><a name="_Toc524107321"></a><a name="_Ref521644836"></a><font style="Background-color:#auto;text-decoration:none;">1.188</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Pending Claim</font><font style="color:#000000;">&#8221; [***].</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1430"></a><a name="_BPDC_PR_INS_1431"></a><a name="_BPDC_PR_INS_1432"></a><a name="_Toc526448376"></a><a name="_Ref521646880"></a><a name="_Toc521651189"></a><a name="_Toc521846028"></a><a name="_Toc521843002"></a><a name="_Toc521850897"></a><a name="_Toc522061335"></a><a name="_Toc523684349"></a><a name="_Toc523684709"></a><a name="_Toc524007822"></a><a name="_Toc524018276"></a><a name="_Toc524065458"></a><a name="_Toc524107322"></a><a name="_Ref521644838"></a><font style="Background-color:#auto;text-decoration:none;">1.189</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Person</font><font style="color:#000000;">&#8221;<a name="_Toc526448376"></a><a name="_Ref521646880"></a><a name="_Toc521651189"></a><a name="_Toc521846028"></a><a name="_Toc521843002"></a><a name="_Toc521850897"></a><a name="_Toc522061335"></a><a name="_Toc523684349"></a><a name="_Toc523684709"></a><a name="_Toc524007822"></a><a name="_Toc524018276"></a><a name="_Toc524065458"></a><a name="_Toc524107322"></a><a name="_Ref521644838"></a> means an individual, corporation, partnership, limited liability company, joint venture, association, trust, unincorporated organization or other entity or any Governmental Authority.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1428"></a><a name="_BPDC_PR_INS_1429"></a><font style="Background-color:#auto;text-decoration:none;">1.190</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Pharmacovigilance Agreement</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 6.6.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.191</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Phase I Clinical Trial</font><font style="color:#000000;">&#8221; means a Clinical Trial conducted in healthy volunteers or patients to obtain initial information on a drug&#8217;s safety, tolerability, pharmacological activity or pharmacokinetics, as more fully defined in 21 C.F.R. &#167; 312.21(a) or its foreign equivalents.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.192</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Phase Ia Clinical Trial</font><font style="color:#000000;">&#8221; means a Clinical Trial, the principal purpose of which is a preliminary determination of safety, pharmacokinetic, and pharmacodynamic parameters in healthy individuals or patients, or a similar Clinical Trial. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.193</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Phase Ia Product</font><font style="color:#000000;">&#8221; means the pharmaceutical product that contains the Lead Candidate that is the subject of the Relay Phase Ia Trial and was manufactured for Relay for use in such trial.<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.194</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Phase Ib Clinical Trial</font><font style="color:#000000;">&#8221; means a Clinical Trial: (a) the principal purpose of which is to evaluate safety and tolerability following repeat dosing in patients and (b) the secondary purpose of which may be to evaluate biomarker-based or clinical endpoint-based trends of efficacy, conducted after the initiation of an initial Phase I Clinical Trial or Phase Ia Clinical Trial.&nbsp;&nbsp;A Phase Ib Clinical Trial may be prospectively designed to generate sufficient data (if successful) to commence a Phase II Clinical Trial or a Phase III Clinical Trial or, in some instances, to submit an application for Regulatory Approval, which may include accelerated approval under section 506(c) of the FDCA or conditional approval under analogous Applicable Law in other countries. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1426"></a><a name="_BPDC_PR_INS_1427"></a><a name="_Toc526448377"></a><font style="Background-color:#auto;text-decoration:none;">1.195</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Phase II Clinical Trial</font><font style="color:#000000;"><a name="_Toc526448377"></a>&#8221; means a controlled Clinical Trial conducted to evaluate the safety, dosing, and effectiveness of a drug for a particular Indication or Indications in patients with the disease or condition of interest as more fully defined in 21 C.F.R. &#167;312.21(b) or its foreign equivalents.&nbsp;&nbsp;A Phase II Clinical Trial may be prospectively designed to generate sufficient data (if successful) to commence a Phase III Clinical Trial or, in some instances, to submit an application for Regulatory Approval, which may include accelerated approval under section 506(c) of the FDCA or conditional approval under analogous Applicable Law in other countries. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1424"></a><a name="_BPDC_PR_INS_1425"></a><font style="Background-color:#auto;text-decoration:none;">1.196</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Phase III Clinical Trial</font><font style="color:#000000;">&#8221; means a controlled Clinical Trial with a patient population randomized to receive experimental or standard therapy to demonstrate the effects of the experimental therapy compared to standard therapy, performed after preliminary evidence suggesting effectiveness of a drug has been obtained, and is designed to gather additional information about the effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug, provide an adequate basis for physician labeling, and generate sufficient data to file for Regulatory Approval, as more fully defined in 21 C.F.R. &#167;312.21(c) or its foreign equivalents. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.197</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">PHSA</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 1.14.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1420"></a><a name="_BPDC_PR_INS_1421"></a><font style="Background-color:#auto;text-decoration:none;">1.198</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">PIK3CA</font><font style="color:#000000;">&#8221; [***]. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1418"></a><a name="_BPDC_PR_INS_1419"></a><font style="Background-color:#auto;text-decoration:none;">1.199</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Pivotal Trial</font><font style="color:#000000;">&#8221; means, with respect to any compound or product, a Clinical Trial that at the time of Initiation (or any later point, if applicable), is expected, based on guidance from the FDA or other applicable Regulatory Authority or otherwise, to provide the basis for submitting an application for Regulatory Approval for such compound or product.&nbsp;&nbsp;For avoidance of doubt, a Clinical Trial or portion thereof may be a Pivotal Trial regardless of whether the protocol for such Clinical Trial describes it as a Phase II Clinical Trial, Phase III Clinical Trial or any variation thereof, including but not limited to a Phase II/III Clinical Trial or Phase IIb Clinical Trial.&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1416"></a><a name="_BPDC_PR_INS_1417"></a><font style="Background-color:#auto;text-decoration:none;">1.200</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Post-Approval Study</font><font style="color:#000000;">&#8221; means a Clinical Trial or other nonclinical studies, whether required by a Regulatory Authority or not, of a Licensed Candidate or a Licensed Product initiated in a country after receipt of Regulatory Approval for such Licensed Candidate or Licensed Product in such country.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1414"></a><a name="_BPDC_PR_INS_1415"></a><font style="Background-color:#auto;text-decoration:none;">1.201</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Pricing Approval</font><font style="color:#000000;">&#8221; means any governmental approval, agreement, determination, or decision establishing the prices for a product that can be charged or reimbursed in regulatory jurisdictions where the applicable Governmental Authorities negotiate, approve, or determine the price or reimbursement of biological or pharmaceutical products. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.202</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Prior Agreement Third Party IP</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 11.6.4(e).  </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1412"></a><a name="_BPDC_PR_INS_1413"></a><font style="Background-color:#auto;text-decoration:none;">1.203</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> &#8220;</font><font style="font-weight:bold;color:#000000;">Profit Share</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Territory</font><font style="color:#000000;">&#8221; means the United States.</font><font style="font-weight:bold;color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.204</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Proposed Relay Pipeline Combination Development Plan</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 3.7.2.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1410"></a><a name="_BPDC_PR_INS_1411"></a><a name="_Ref521646884"></a><a name="_Toc521651193"></a><a name="_Toc521846032"></a><a name="_Toc521843006"></a><a name="_Toc521850901"></a><a name="_Toc522061337"></a><a name="_Toc523684351"></a><a name="_Toc523684711"></a><a name="_Toc524007824"></a><a name="_Toc524018278"></a><a name="_Toc524065460"></a><a name="_Toc524107324"></a><a name="_Ref521644842"></a><font style="Background-color:#auto;text-decoration:none;">1.205</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Prosecution and Maintenance</font><font style="color:#000000;">&#8221; or &#8220;</font><font style="font-weight:bold;color:#000000;">Prosecute and Maintain</font><font style="color:#000000;">&#8221; means, with regard to a Patent, the preparation, filing, prosecution and maintenance of such Patent, as well as reissues and appeals with respect to such Patent, together with the initiation or defense of interferences, derivation proceedings, post-grant proceedings, oppositions and other similar proceedings with respect to the particular Patent, and any appeals therefrom.&nbsp;&nbsp;For clarification, &#8220;Prosecution and Maintenance&#8221; or &#8220;Prosecute and Maintain&#8221; will not include any other enforcement or defense actions taken with respect to a Patent. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1408"></a><a name="_BPDC_PR_INS_1409"></a><font style="Background-color:#auto;text-decoration:none;">1.206</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Publications</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 13.6. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1406"></a><a name="_BPDC_PR_INS_1407"></a><a name="_Ref521646885"></a><a name="_Toc521651194"></a><a name="_Toc521846033"></a><a name="_Toc521843007"></a><a name="_Toc521850902"></a><a name="_Toc522061338"></a><a name="_Toc523684352"></a><a name="_Toc523684712"></a><a name="_Toc524007825"></a><a name="_Toc524018279"></a><a name="_Toc524065461"></a><a name="_Toc524107325"></a><a name="_Ref521644843"></a><font style="Background-color:#auto;text-decoration:none;">1.207</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Publishing Party</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 13.5.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1404"></a><a name="_BPDC_PR_INS_1405"></a><font style="Background-color:#auto;text-decoration:none;">1.208</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Quality Agreement</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 3.3.9.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1402"></a><a name="_BPDC_PR_INS_1403"></a><a name="DocXTextRef109"></a><font style="Background-color:#auto;text-decoration:none;">1.209</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Receiving Party</font><font style="color:#000000;">&#8221;<a name="DocXTextRef109"></a> has the meaning set forth in Section 13.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1400"></a><a name="_BPDC_PR_INS_1401"></a><a name="_BPDC_LN_INS_1398"></a><a name="_BPDC_PR_INS_1399"></a><a name="_Ref521644844"></a><font style="Background-color:#auto;text-decoration:none;">1.210</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Regulatory Approval</font><font style="color:#000000;">&#8221; means all approvals, licenses, permits, certifications, and authorizations of the applicable Regulatory Authority necessary for the development, manufacture, marketing and sale of a biological or pharmaceutical product in a country in the world, including Pricing Approvals.&nbsp;&nbsp;For avoidance of doubt, &#8220;Regulatory Approval&#8221; includes accelerated approval under section 506(c) of the FDCA or conditional approval under analogous Applicable Law in other countries.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1396"></a><a name="_BPDC_PR_INS_1397"></a><a name="_Ref521646887"></a><a name="_Ref521648396"></a><a name="_Ref521648427"></a><a name="_Ref521648552"></a><a name="_Toc521651196"></a><a name="_Toc521846035"></a><a name="_Toc521843009"></a><a name="_Toc521850904"></a><a name="_Toc522061340"></a><a name="_Toc523684354"></a><a name="_Toc523684714"></a><a name="_Toc524007827"></a><a name="_Toc524018281"></a><a name="_Toc524065463"></a><a name="_Toc524107327"></a><a name="_Ref521644845"></a><font style="text-decoration:none;Background-color:#auto;">1.211</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Regulatory Authority</font><font style="color:#000000;">&#8221;</font><font style="color:#000000;"> means any national or supranational Governmental Authority, including the UK Medicines and Healthcare products Regulatory Agency (and any successor entity thereto) in the UK, the U.S. </font><font style="color:#000000;">Food</font><font style="color:#000000;"> and Drug Administration (and any successor entity thereto) (the &#8220;</font><font style="font-weight:bold;color:#000000;">FDA</font><font style="color:#000000;">&#8221;) in the U.S., the European Medicines Agency (and any successor entity thereto) (the &#8220;</font><font style="font-weight:bold;color:#000000;">EMA</font><font style="color:#000000;">&#8221;) in EU and the Ministry of Health, Labour and Welfare of Japan, or the Pharmaceuticals and Medical Devices Agency of Japan (or any successor to either of them) as the case may be in Japan, or any health regulatory authority in any country or region in the Territory that is a counterpart to the foregoing agencies, in each case, that grants of Regulatory Approval for a biological, or pharmaceutical product, as applicable, in such country or region.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1394"></a><a name="_BPDC_PR_INS_1395"></a><font style="Background-color:#auto;text-decoration:none;">1.212</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Regulatory Expenses</font><font style="color:#000000;">&#8221; [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1392"></a><a name="_BPDC_PR_INS_1393"></a><a name="_Ref521644846"></a><font style="Background-color:#auto;text-decoration:none;">1.213</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Regulatory Lead</font><font style="color:#000000;">&#8221; means [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1390"></a><a name="_BPDC_PR_INS_1391"></a><font style="Background-color:#auto;text-decoration:none;">1.214</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Regulatory Materials</font><font style="color:#000000;">&#8221; means the regulatory registrations, listings, applications, licenses, certifications, authorizations, approvals and other submissions or filings made to or received from any Regulatory Authority for research, development (including the conduct of Clinical Trials), manufacture, distribution, or commercialization of a biological or pharmaceutical product in a regulatory jurisdiction, together with all related correspondence to or from any Regulatory Authority and all documents referenced in the complete regulatory chronology for each Regulatory Approval, including all drug master files (if any), INDs, supplements and amendments thereto, and foreign equivalents of any of the foregoing. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1388"></a><a name="_BPDC_PR_INS_1389"></a><font style="Background-color:#auto;text-decoration:none;">1.215</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Regulatory Transfer</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 3.2.3.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1386"></a><a name="_BPDC_PR_INS_1387"></a><font style="Background-color:#auto;text-decoration:none;">1.216</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Relative Commercial Value</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 5.5.2(e).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1384"></a><a name="_BPDC_PR_INS_1385"></a><font style="Background-color:#auto;text-decoration:none;">1.217</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> &#8220;</font><font style="font-weight:bold;color:#000000;">Relay</font><font style="color:#000000;">&#8221; has the meaning set forth in the preamble hereto.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1382"></a><a name="_BPDC_PR_INS_1383"></a><font style="Background-color:#auto;text-decoration:none;">1.218</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Relay Collaboration Know-How</font><font style="color:#000000;">&#8221; means any Know-How first created, conceived or generated by or on behalf of Relay or its Affiliates (whether solely or jointly with any Third Party(ies)) in the course of activities performed under this Agreement, as determined pursuant to Section 12.7.1, but excluding Joint Collaboration Know-How. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1380"></a><a name="_BPDC_PR_INS_1381"></a><font style="Background-color:#auto;text-decoration:none;">1.219</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Relay Collaboration Patents</font><font style="color:#000000;">&#8221; means any Patents that claim Relay Collaboration Know-How.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.220</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Relay Combination Collaborator</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 12.2.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1378"></a><a name="_BPDC_PR_INS_1379"></a><a name="_BPDC_LN_INS_1376"></a><a name="_BPDC_PR_INS_1377"></a><font style="Background-color:#auto;text-decoration:none;">1.221</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Relay Combination Patent</font><font style="color:#000000;">&#8221; [***]<a name="_BPDC_LN_INS_1376"></a><a name="_BPDC_PR_INS_1377"></a>.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.222</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Relay IND Transfer</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 3.2.3.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1374"></a><a name="_BPDC_PR_INS_1375"></a><font style="Background-color:#auto;text-decoration:none;">1.223</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Relay IND Transfer Date</font><font style="color:#000000;">&#8221; means the date on which the Relay IND Transfer is complete.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1372"></a><a name="_BPDC_PR_INS_1373"></a><a name="_Hlk50906341"></a><font style="Background-color:#auto;text-decoration:none;">1.224</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Relay IP</font><font style="color:#000000;">&#8221; means all Relay Patents, Relay Know-How, and Relay&#8217;s interest in Joint Collaboration IP.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1370"></a><a name="_BPDC_PR_INS_1371"></a><font style="text-decoration:none;Background-color:#auto;">1.225</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Relay Know-How</font><font style="color:#000000;">&#8221; </font><font style="color:#000000;">[***]</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1368"></a><a name="_BPDC_PR_INS_1369"></a><font style="Background-color:#auto;text-decoration:none;">1.226</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Relay Patents</font><font style="color:#000000;">&#8221; [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1366"></a><a name="_BPDC_PR_INS_1367"></a><font style="Background-color:#auto;text-decoration:none;">1.227</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Relay Phase Ia Plan</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 3.3.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1364"></a><a name="_BPDC_PR_INS_1365"></a><font style="Background-color:#auto;text-decoration:none;">1.228</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Relay</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Phase Ia Trial</font><font style="color:#000000;">&#8221; [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1362"></a><a name="_BPDC_PR_INS_1363"></a><font style="Background-color:#auto;text-decoration:none;">1.229</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Relay Phase Ia Trial CRO</font><font style="color:#000000;">&#8221; [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1360"></a><a name="_BPDC_PR_INS_1361"></a><font style="Background-color:#auto;text-decoration:none;">1.230</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Relay Phase Ia Trial CRO Costs</font><font style="color:#000000;">&#8221; [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1358"></a><a name="_BPDC_PR_INS_1359"></a><font style="Background-color:#auto;text-decoration:none;">1.231</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Relay Phase Ia Trial Data</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 3.2.4(c).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.232</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Relay Phase Ia Trial Milestone</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 11.1.3.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1356"></a><a name="_BPDC_PR_INS_1357"></a><font style="Background-color:#auto;text-decoration:none;">1.233</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Relay Pipeline Combination</font><font style="color:#000000;">&#8221; means the Combination Use of a Relay Pipeline Compound or Relay Pipeline Product with a Relay Pipeline Combination Eligible Licensed Product.&nbsp;&nbsp;[***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1354"></a><a name="_BPDC_PR_INS_1355"></a><font style="Background-color:#auto;text-decoration:none;">1.234</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Relay Pipeline Combination Eligible Licensed Product</font><font style="color:#000000;">&#8221; means, in connection with a Relay Pipeline Combination, a Licensed Candidate or Licensed Product [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.235</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Relay Pipeline</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Combination Eligible Licensed Product Cessation</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 16.9.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.236</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Relay Pipeline</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Combination Eligible Licensed Product Discontinuation Notice</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 16.9.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1352"></a><a name="_BPDC_PR_INS_1353"></a><font style="Background-color:#auto;text-decoration:none;">1.237</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Relay Pipeline Compound</font><font style="color:#000000;">&#8221; [***] RLY-4008 or RLY-PI3K1047, [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1350"></a><a name="_BPDC_PR_INS_1351"></a><font style="Background-color:#auto;text-decoration:none;">1.238</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Relay Pipeline Product</font><font style="color:#000000;">&#8221; means a product that constitutes, comprises or contains a Relay Pipeline Compound.&nbsp;&nbsp;[***]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1348"></a><a name="_BPDC_PR_INS_1349"></a><font style="Background-color:#auto;text-decoration:none;">1.239</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Relay Royalty Patent</font><font style="color:#000000;">&#8221; [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1346"></a><a name="_BPDC_PR_INS_1347"></a><font style="Background-color:#auto;text-decoration:none;">1.240</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> &#8220;</font><font style="font-weight:bold;color:#000000;">Relay</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Sublicensee</font><font style="color:#000000;">&#8221; means a Third Party to which Relay (or its Affiliate) has (a) pursuant to Section  12.2, granted sublicense rights under any of the license rights granted under Section 12.1.2 or (b) granted a license under any of the rights retained by Relay pursuant to Section 12.1.1. in each case ((a) and (b)), with respect to a Relay Pipeline Combination, but excluding Distributors.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.241</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Required Additional Phase Ia Study&#8221; </font><font style="color:#000000;">has the meaning set forth in Section 3.3.2.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1344"></a><a name="_BPDC_PR_INS_1345"></a><font style="Background-color:#auto;text-decoration:none;">1.242</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Research</font><font style="color:#000000;">&#8221; means with respect to a compound or product, any research activities with respect to such compound or product. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1342"></a><a name="_BPDC_PR_INS_1343"></a><font style="Background-color:#auto;text-decoration:none;">1.243</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Right of Reference</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 6.4.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1340"></a><a name="_BPDC_PR_INS_1341"></a><a name="_Toc524007833"></a><a name="_Toc524018287"></a><a name="_Toc524065469"></a><a name="_Toc524107331"></a><a name="_Hlk41708860"></a><a name="_Toc522061344"></a><a name="_Toc523684358"></a><a name="_Toc523684718"></a><font style="Background-color:#auto;text-decoration:none;">1.244</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_Toc524007833"></a><a name="_Toc524018287"></a><a name="_Toc524065469"></a><a name="_Toc524107331"></a><a name="_Hlk41708860"></a><a name="_Toc522061344"></a><a name="_Toc523684358"></a><a name="_Toc523684718"></a> &#8220;</font><font style="font-weight:bold;color:#000000;">Royalty Products</font><font style="color:#000000;">&#8221; means, (a) the Lead Royalty Products and (b) all Back-Up Products. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1338"></a><a name="_BPDC_PR_INS_1339"></a><font style="Background-color:#auto;text-decoration:none;">1.245</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Royalty Term</font><font style="color:#000000;">&#8221; [***].&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1336"></a><a name="_BPDC_PR_INS_1337"></a><font style="Background-color:#auto;text-decoration:none;">1.246</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Royalty Territory</font><font style="color:#000000;">&#8221; means the Territory, other than the Profit Share Territory.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1334"></a><a name="_BPDC_PR_INS_1335"></a><font style="Background-color:#auto;text-decoration:none;">1.247</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Rules</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 18.10.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1332"></a><a name="_BPDC_PR_INS_1333"></a><font style="Background-color:#auto;text-decoration:none;">1.248</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">SAE Management Plan</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 3.3.8.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1330"></a><a name="_BPDC_PR_INS_1331"></a><font style="Background-color:#auto;text-decoration:none;">1.249</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Sales</font><font style="color:#000000;">&#8221; [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.250</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Sales</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Milestone</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 11.5.4.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1326"></a><a name="_BPDC_PR_INS_1327"></a><font style="Background-color:#auto;text-decoration:none;">1.251</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Sales Milestone Payment</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 11.5.4.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1324"></a><a name="_BPDC_PR_INS_1325"></a><font style="Background-color:#auto;text-decoration:none;">1.252</font><font style="margin-left:36pt;color:#000000;"></font><font style="font-weight:bold;color:#000000;">&#8220;Second Tier GDP Overrun</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 3.8.5.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1322"></a><a name="_BPDC_PR_INS_1323"></a><a name="_Ref521646861"></a><a name="_Toc521651170"></a><a name="_Toc521846009"></a><a name="_Toc521842983"></a><a name="_Toc521850878"></a><a name="_Toc522061323"></a><a name="_Toc523684335"></a><a name="_Toc523684695"></a><a name="_Toc524007806"></a><a name="_Toc524018260"></a><a name="_Toc524065442"></a><a name="_Toc524107306"></a><a name="_Ref521644819"></a><font style="Background-color:#auto;text-decoration:none;">1.253</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Shared Collaboration In-License Payments</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 11.6.4(f).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1320"></a><a name="_BPDC_PR_INS_1321"></a><font style="Background-color:#auto;text-decoration:none;">1.254</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Shared Products</font><font style="color:#000000;">&#8221; means the Lead Products solely during the Opt-In Term.&nbsp;&nbsp;For clarity, if Relay exercises its Opt-In Right and later exercises its Opt-Out Right, all Shared Products will automatically become Royalty Products.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1318"></a><a name="_BPDC_PR_INS_1319"></a><a name="_Toc443395448"></a><a name="_Toc448470163"></a><a name="_Toc469309599"></a><font style="Background-color:#auto;text-decoration:none;">1.255</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> &#8220;</font><font style="font-weight:bold;color:#000000;">Sharing Percentages</font><font style="color:#000000;">&#8221; [***] Net Profits and Net Losses, fifty percent (50%) for Relay and fifty percent (50%) for Licensee for the Profit Share Territory. <a name="_Toc443395448"></a><a name="_Toc448470163"></a><a name="_Toc469309599"></a>[***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1316"></a><a name="_BPDC_PR_INS_1317"></a><font style="Background-color:#auto;text-decoration:none;">1.256</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Sponsor</font><font style="color:#000000;">&#8221; is defined in</font><font style="color:#000000;"> 21&#160;CFR&#160;&#167;&#160;312.3(b) and, with respect to a Clinical Trial </font><font style="color:#000000;">under this Agreement, means the entity that takes responsibility for the Clinical Trial </font><font style="color:#000000;">in any jurisdiction</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.257</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Subcontracting Party</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 8.1.4.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1314"></a><a name="_BPDC_PR_INS_1315"></a><a name="_Toc522061345"></a><a name="_Toc523684359"></a><a name="_Toc523684719"></a><a name="_Toc524007834"></a><a name="_Toc524018288"></a><a name="_Toc524065470"></a><a name="_Toc524107332"></a><font style="Background-color:#auto;text-decoration:none;">1.258</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Sublicensee</font><font style="color:#000000;">&#8221; means a Licensee Sublicensee or Relay Sublicensee.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1312"></a><a name="_BPDC_PR_INS_1313"></a><font style="Background-color:#auto;text-decoration:none;">1.259</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Subsequent Clinical Trial-Related Contracts</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 3.2.4(a).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.260</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Supply Agreement</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 7.2.4.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1310"></a><a name="_BPDC_PR_INS_1311"></a><a name="_BPDC_LN_INS_1308"></a><a name="_BPDC_PR_INS_1309"></a><font style="Background-color:#auto;text-decoration:none;">1.261</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_BPDC_LN_INS_1308"></a><a name="_BPDC_PR_INS_1309"></a> &#8220;</font><font style="font-weight:bold;color:#000000;">Technology Transfer</font><font style="color:#000000;">&#8221; means the Development Transfer, the Manufacturing Transfer, the Regulatory Transfer and the Clinical Transfer.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1306"></a><a name="_BPDC_PR_INS_1307"></a><a name="_Ref53744004"></a><font style="Background-color:#auto;text-decoration:none;">1.262</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Technology Transfer Plan</font><font style="color:#000000;">&#8221; means the technology transfer plan attached as Schedule 1.262.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1304"></a><a name="_BPDC_PR_INS_1305"></a><a name="_Ref521646899"></a><a name="_Toc521651208"></a><a name="_Toc521846047"></a><a name="_Toc521843021"></a><a name="_Toc521850916"></a><a name="_Toc522061347"></a><a name="_Toc523684362"></a><a name="_Toc523684722"></a><a name="_Toc524007837"></a><a name="_Toc524018291"></a><a name="_Toc524065473"></a><a name="_Toc524107335"></a><a name="_Ref521644857"></a><a name="DocXTextRef119"></a><font style="Background-color:#auto;text-decoration:none;">1.263</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Term</font><font style="color:#000000;">&#8221;<a name="DocXTextRef119"></a> has the meaning set forth in Section 16.1.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.264</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Terminated Other Licensed Product</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 16.8.2(c).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.265</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Terminated Relay Pipeline</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Combination Eligible Licensed Product</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 16.8.2(b).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.266</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Terminated Relay Pipeline</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Combination Eligible Licensed Product Terms</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 16.8.2(b).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1302"></a><a name="_BPDC_PR_INS_1303"></a><font style="Background-color:#auto;text-decoration:none;">1.267</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Termination Date</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 16.8.1(a).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1300"></a><a name="_BPDC_PR_INS_1301"></a><a name="_Ref521646900"></a><a name="_Toc521651209"></a><a name="_Toc521846048"></a><a name="_Toc521843022"></a><a name="_Toc521850917"></a><a name="_Toc522061348"></a><a name="_Toc523684363"></a><a name="_Toc523684723"></a><a name="_Toc524007838"></a><a name="_Toc524018292"></a><a name="_Toc524065474"></a><a name="_Toc524107336"></a><a name="_Ref521644858"></a><font style="Background-color:#auto;text-decoration:none;">1.268</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_Ref521646900"></a><a name="_Toc521651209"></a><a name="_Toc521846048"></a><a name="_Toc521843022"></a><a name="_Toc521850917"></a><a name="_Toc522061348"></a><a name="_Toc523684363"></a><a name="_Toc523684723"></a><a name="_Toc524007838"></a><a name="_Toc524018292"></a><a name="_Toc524065474"></a><a name="_Toc524107336"></a><a name="_Ref521644858"></a> &#8220;</font><font style="font-weight:bold;color:#000000;">Territory</font><font style="color:#000000;">&#8221; means worldwide.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1298"></a><a name="_BPDC_PR_INS_1299"></a><a name="_Ref521646901"></a><a name="_Toc521651210"></a><a name="_Toc521846049"></a><a name="_Toc521843023"></a><a name="_Toc521850918"></a><a name="_Toc522061349"></a><a name="_Toc523684364"></a><a name="_Toc523684724"></a><a name="_Toc524007839"></a><a name="_Toc524018293"></a><a name="_Toc524065475"></a><a name="_Toc524107337"></a><a name="_Ref521644859"></a><a name="_Ref56096174"></a><font style="Background-color:#auto;text-decoration:none;">1.269</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Third Party</font><font style="color:#000000;">&#8221; means any Person other than Relay or Licensee that is not an Affiliate of Relay or of Licensee. Notwithstanding anything in the foregoing of this Section 1.269, for purposes of this Agreement, [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1296"></a><a name="_BPDC_PR_INS_1297"></a><font style="Background-color:#auto;text-decoration:none;">1.270</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Third Party Action</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 12.11.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1294"></a><a name="_BPDC_PR_INS_1295"></a><a name="_Ref521646902"></a><a name="_Toc521651211"></a><a name="_Toc521846050"></a><a name="_Toc521843024"></a><a name="_Toc521850919"></a><a name="_Toc522061351"></a><a name="_Toc523684366"></a><a name="_Toc523684726"></a><a name="_Toc524007841"></a><a name="_Toc524018295"></a><a name="_Toc524065477"></a><a name="_Toc524107339"></a><a name="_Ref521644860"></a><font style="Background-color:#auto;text-decoration:none;">1.271</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Third Party Claim</font><font style="color:#000000;">&#8221; means any suits, claims, actions, proceedings or demands brought by a Third Party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1292"></a><a name="_BPDC_PR_INS_1293"></a><font style="Background-color:#auto;text-decoration:none;">1.272</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Third Party Lead Product Action</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 12.11.3.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1290"></a><a name="_BPDC_PR_INS_1291"></a><a name="_Ref521646903"></a><a name="_Toc521651212"></a><a name="_Toc521846051"></a><a name="_Toc521843025"></a><a name="_Toc521850920"></a><a name="_Toc522061352"></a><a name="_Toc523684368"></a><a name="_Toc523684728"></a><a name="_Toc524007843"></a><a name="_Toc524018297"></a><a name="_Toc524065479"></a><a name="_Toc524107341"></a><a name="_Ref521644861"></a><font style="Background-color:#auto;text-decoration:none;">1.273</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Third Party Subcontractor</font><font style="color:#000000;">&#8221; means any Third Party service provider, consultant, CRO, CMO or subcontractor used by or on behalf of a Party or its Affiliates in the performance of activities under this Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1288"></a><a name="_BPDC_PR_INS_1289"></a><a name="_Ref521646904"></a><a name="_Toc521651213"></a><a name="_Toc521846052"></a><a name="_Toc521843026"></a><a name="_Toc521850921"></a><a name="_Toc522061353"></a><a name="_Toc523684369"></a><a name="_Toc523684729"></a><a name="_Toc524007844"></a><a name="_Toc524018298"></a><a name="_Toc524065480"></a><a name="_Toc524107342"></a><a name="_Ref521644862"></a><font style="Background-color:#auto;text-decoration:none;">1.274</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Third Party Subcontractor Agreement</font><font style="color:#000000;">&#8221; means an agreement entered into by a Party with a Third Party Subcontractor.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1286"></a><a name="_BPDC_PR_INS_1287"></a><a name="_Ref521646905"></a><a name="_Toc521651214"></a><a name="_Toc521846053"></a><a name="_Toc521843027"></a><a name="_Toc521850922"></a><a name="_Toc522061354"></a><a name="_Toc523684370"></a><a name="_Toc523684730"></a><a name="_Toc524007845"></a><a name="_Toc524018299"></a><a name="_Toc524065481"></a><a name="_Toc524107343"></a><a name="_Ref521644863"></a><font style="Background-color:#auto;text-decoration:none;">1.275</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">TLF</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 4.1.2.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1284"></a><a name="_BPDC_PR_INS_1285"></a><font style="Background-color:#auto;text-decoration:none;">1.276</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Trademark</font><font style="color:#000000;">&#8221; means any word, name, symbol, color, designation or device or any combination thereof that functions as a source identifier, including any trademark, trade dress, brand mark, service mark, trade name, brand name, logo or business symbol, whether or not registered.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.277</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Transfer of Sponsor Obligations</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 3.2.3(b).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1282"></a><a name="_BPDC_PR_INS_1283"></a><font style="Background-color:#auto;text-decoration:none;">1.278</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Transition Period</font><font style="color:#000000;">&#8221; has the meaning set forth in Section 16.9.3.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.279</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">United States</font><font style="color:#000000;">&#8221; or &#8220;</font><font style="font-weight:bold;color:#000000;">U.S.</font><font style="color:#000000;">&#8221; means the United States of America and its territories and possessions (including the District of Columbia and Puerto Rico). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1280"></a><a name="_BPDC_PR_INS_1281"></a><a name="_Toc524007846"></a><a name="_Toc524018300"></a><a name="_Toc524065482"></a><a name="_Toc524107344"></a><a name="_Toc522061355"></a><a name="_Toc523684371"></a><a name="_Toc523684731"></a><a name="_Toc523684372"></a><a name="_Toc523684732"></a><font style="Background-color:#auto;text-decoration:none;">1.280</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Valid Claim</font><font style="color:#000000;">&#8221; [***].<a name="_Toc523684372"></a><a name="_Toc523684732"></a>  </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1278"></a><a name="_BPDC_PR_INS_1279"></a><a name="_Ref524066774"></a><a name="_Toc524107345"></a><a name="DocXTextRef121"></a><a name="DocXTextRef122"></a><a name="DocXTextRef123"></a><a name="DocXTextRef124"></a><a name="DocXTextRef125"></a><a name="_Toc524018301"></a><a name="_Toc524065483"></a><a name="_Toc524007847"></a><font style="Background-color:#auto;text-decoration:none;">1.281</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Violation</font><font style="color:#000000;">&#8221; with respect to a Person <a name="DocXTextRef121"></a>means that such Person is:&nbsp;&nbsp;(a)&#160;convicted of any of the felonies identified among the exclusion authorities listed on the U.S.&#160;Department of </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;"><a name="DocXTextRef122"></a>Health and Human Services, Office of Inspector General (OIG) website, including </font><font style="color:#000000;">42</font><font style="color:#000000;"><a name="DocXTextRef123"></a> U.S.C. 1320a-7(a) (http://oig.hhs.gov/exclusions/authorities.asp); </font><font style="color:#000000;">(b)</font><font style="color:#000000;"><a name="DocXTextRef124"></a>&#160;identified in the OIG List of Excluded Individuals/Entities (LEIE) database (http://exclusions.oig.hhs.gov/) or otherwise excluded from contracting with the federal government (see the System for Award Management (formerly known as the Excluded Parties Listing System) at http://sam.gov/portal/public/SAM/); or </font><font style="color:#000000;">(c)</font><font style="color:#000000;"><a name="DocXTextRef125"></a> listed by any U.S. federal agency as being suspended, debarred, disqualified, excluded or otherwise ineligible to participate in federal procurement or non-procurement programs, including under </font><font style="color:#000000;">21</font><font style="color:#000000;"> U.S.C. 335a</font><font style="color:#000000;"><a name="_Toc524018301"></a><a name="_Toc524065483"></a><a name="_Toc524007847"></a>.</font><font style="color:#000000;"> </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Toc524107347"></a><a name="_Toc529816431"></a><a name="_Toc529966466"></a><a name="_Toc50796652"></a><a name="_Toc51338579"></a><a name="_Toc53919196"></a><a name="_Toc53925680"></a><font style="Background-color:#auto;text-decoration:none;">Article 2.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><br /><a name="_Toc524107347"></a><a name="_Toc529816431"></a><a name="_Toc529966466"></a><a name="_Toc50796652"></a><a name="_Toc51338579"></a><a name="_Toc53919196"></a><a name="_Toc53925680"></a>COLLABORATION overview</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref53578407"></a><a name="_Toc529816432"></a><a name="_Toc529966467"></a><a name="_Ref209535774"></a><a name="_Ref482525982"></a><a name="_Toc338873022"></a><a name="_Toc524107348"></a><a name="_Ref521644867"></a><font style="Background-color:#auto;text-decoration:none;"> 2.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Collaboration Overview</font><font style="color:#000000;">.&nbsp;&nbsp;Prior to the Effective Date, Relay has been engaged in the Development of the Lead Candidate and Lead Products in the Field in the Territory.&nbsp;&nbsp;Under this Agreement, Relay and Licensee will collaborate in the further Development and Commercialization of the Lead Candidate and Lead Products in the Field in the Territory, and, subject to certain retained rights, to the extent set forth in Section  12.1, Relay grants Licensee an exclusive license for the Research, Development, Manufacture and Commercialization of Licensed Candidates and Licensed Products in the Field in the Territory.&nbsp;&nbsp;As part of the collaboration, (a) Relay will complete the Relay Phase Ia Trial in accordance with the Relay Phase Ia Plan and the applicable provisions of this Agreement, (b) Relay may share in the Development Costs and Net Profits and Net Losses for Shared Products with respect to the Profit Share Territory, and (c) Relay may Develop Relay Pipeline Combination Eligible Licensed Products solely in connection with the Development of Relay Pipeline Combinations and may co-promote the Relay Pipeline Combination Eligible Licensed Products solely for Combination Use in Relay Pipeline Combinations in coordination with Licensee and in accordance with this Agreement any applicable Coordinated Promotion Agreement.&nbsp;&nbsp;Except for the limited rights reserved to Relay hereunder, Licensee will have the sole right and responsibility to conduct Research and Development for the Licensed Candidates and Licensed Products and to Manufacture and Commercialize the Licensed Candidates and Licensed Products.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Ref38613525"></a><a name="_Ref38538855"></a><a name="_Ref530131931"></a><a name="_Ref530828104"></a><a name="_Ref209535989"></a><a name="_Ref338866754"></a><a name="_Toc338873025"></a><a name="_Toc50796653"></a><a name="_Toc51338580"></a><a name="_Ref51938926"></a><a name="_Toc53919197"></a><a name="_Toc53925681"></a><a name="_Ref57832303"></a><a name="_Ref57832310"></a><font style="Background-color:#auto;text-decoration:none;">Article 3.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><br /><a name="_Toc50796653"></a><a name="_Toc51338580"></a><a name="_Ref51938926"></a><a name="_Toc53919197"></a><a name="_Toc53925681"></a><a name="_Ref57832303"></a><a name="_Ref57832310"></a>Development </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref38562574"></a><font style="Background-color:#auto;text-decoration:none;"> 3.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Generally</font><font style="color:#000000;">.&nbsp;&nbsp;Except as otherwise expressly provided in this Article 3, Licensee shall have the sole right and responsibility to Develop the Licensed Candidates and Licensed Products in the Field in the Territory in its sole discretion.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57577229"></a><a name="_Ref53919453"></a><a name="_Ref53819047"></a><a name="_Ref54600346"></a><a name="_Ref38647527"></a><a name="_Hlk39351451"></a><a name="_Ref50582696"></a><a name="_Ref51938715"></a><a name="_Ref38648459"></a><a name="_Ref39503102"></a><a name="_Hlk38613008"></a><a name="_Hlk38652789"></a><a name="_Ref38566189"></a><font style="Background-color:#auto;text-decoration:none;"> 3.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Technology Transfer</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:13.46%;text-indent:1.92%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref55632804"></a><font style="Background-color:#auto;text-decoration:none;">3.2.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Development Transfer</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57180226"></a><a name="_Ref52337193"></a><a name="_Ref52337796"></a><a name="_Ref52338174"></a><a name="_Ref52548598"></a><a name="_Ref53663182"></a><a name="_Ref53743870"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Subject to clauses (b) and (c) of this Section 3.2.1, as promptly as possible and in any event in accordance with the timing set forth in the Technology Transfer Plan, Relay will, at its own cost and expense, initiate and complete a technology transfer to Licensee of the Relay Know-How, documentation and other Materials that relate to the Research, Development or Commercialization of the Lead Candidate or Lead Product (such Know-How, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">documentation and Materials, the &#8220;</font><font style="font-weight:bold;color:#000000;">Development Know-How and Materials</font><font style="color:#000000;">&#8221;</font><font style="color:#000000;">)</font><font style="color:#000000;"> and </font><font style="color:#000000;">that are listed on the Technology Transfer Plan (</font><font style="color:#000000;">such transfer, the &#8220;</font><font style="font-weight:bold;color:#000000;">Development Transfer</font><font style="color:#000000;">&#8221;)</font><font style="color:#000000;">.</font><font style="color:#000000;"><a name="_Ref52337193"></a><a name="_Ref52337796"></a><a name="_Ref52338174"></a><a name="_Ref52548598"></a><a name="_Ref53663182"></a><a name="_Ref53743870"></a> </font><font style="color:#000000;">To the extent any copies of documents or materials within the</font><font style="color:#000000;"> </font><font style="color:#000000;">Development</font><font style="color:#000000;"> Know-How and Materials </font><font style="color:#000000;">are </font><font style="color:#000000;">in possession of a Third Party, Relay is solely responsible, at its own cost and expense, to procure and provide to </font><font style="color:#000000;">Licensee</font><font style="color:#000000;"> </font><font style="color:#000000;">all such Development Know-How and Materials, together with all </font><font style="color:#000000;">right</font><font style="color:#000000;">s</font><font style="color:#000000;"> to access and use any such Development Know-How and Materials in accordance with this Agreement</font><font style="color:#000000;"> (which may be procured or provided by letters of authorization or comparable instruments where approved by Licensee)</font><font style="color:#000000;">. Relay will make available its personnel (and use </font><font style="color:#000000;">Commercially Reasonable E</font><font style="color:#000000;">fforts to cause its Third Party </font><font style="color:#000000;">Subcontractors</font><font style="color:#000000;"> with relevant subject matter expertise to be available) on a reasonable basis to consult with Licensee with respect to the </font><font style="color:#000000;">Development Know-How and Materials and </font><font style="color:#000000;">Development Transfer.</font><font style="color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57180228"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">It is understood and agreed that there may be additional Development Know-How and Materials that are not identified at the time of the Development Transfer but that are thereafter identified.&nbsp;&nbsp;If after the Development Transfer, either Party identifies any such additional Development Know-How and Materials that are in Relay&#8217;s Control, Relay shall transfer such additional Know-How and Materials to Licensee promptly after such identification and notification. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57180230"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">It is also understood and agreed that there are additional Development Know-How and Materials that are not yet existing at the time of the Development Transfer but are expected to be generated by Relay after the Effective Date. Relay shall provide such additional Development Know-How and Materials as such Know-How and Materials are generated, either in accordance with the timeline as set forth in the Technology Transfer Plan or in reasonable batches, as discussed by the Parties. [***].&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:13.46%;text-indent:1.92%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref55632819"></a><font style="Background-color:#auto;text-decoration:none;">3.2.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Manufacturing Transfer</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Subject to the remainder of this Section 3.2.2, as promptly as possible and in any event in accordance with the timing set forth in the Technology Transfer Plan, Relay will initiate and complete (and if applicable, use Commercially Reasonable Efforts to cause its CMO to initiate and complete) a technology transfer to Licensee, or to its CMO of the Phase Ia Product, such CMO to be selected by Licensee and reasonably acceptable to Relay, of Relay Know-How, documentation and other Materials that relate to the Manufacture of the Lead Candidate or Lead Product (such Know-How, documentation and Materials, the &#8220;</font><font style="font-weight:bold;color:#000000;">Manufacturing Know-How and Materials</font><font style="color:#000000;">&#8221;) and that are listed on the Technology Transfer Plan (such transfer, the &#8220;</font><font style="font-weight:bold;color:#000000;">Manufacturing Transfer</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;To the extent any copies of documents or materials within the Manufacturing Know-How and Materials are in possession of a Third Party, Relay is solely responsible, at its own cost and expense, to procure and provide to Licensee all such Manufacturing Know-How and Materials, together with all rights to access and use any such Development Know-How and Materials in accordance with this Agreement (which may be procured or provided by letters of authorization or comparable instruments where approved by Licensee). Relay will make available its personnel and use Commercially Reasonable Efforts to cause its CMO and other Third Party Subcontractors with relevant subject matter expertise to be available on a reasonable basis to consult with Licensee or Licensee&#8217;s CMO with respect to the Manufacturing Know-How and Materials and the Manufacturing Transfer.&nbsp;&nbsp;Relay will not be required to perform a Manufacturing Transfer to more than one CMO of Licensee.&nbsp;&nbsp;Subject to the completion of the Manufacturing </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Transfer, </font><font style="color:#000000;">Licensee will be solely responsible for contracting with </font><font style="color:#000000;">its </font><font style="color:#000000;">CMO for the supply of the </font><font style="color:#000000;">Licensed </font><font style="color:#000000;">Candidate</font><font style="color:#000000;">s</font><font style="color:#000000;"> or </font><font style="color:#000000;">Licensed </font><font style="color:#000000;">Product</font><font style="color:#000000;">s</font><font style="color:#000000;">, and Relay will have no obligations under such agreement between Licensee and such CMO. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">It is understood and agreed that there may be additional Manufacturing Know-How and Materials that are not identified at the time of the Manufacturing Transfer and are thereafter identified.&nbsp;&nbsp;If after the Manufacturing Transfer, either Party identifies any such additional Know-How and Materials such Party shall notify the other Party, and if such Manufacturing Know-How and Materials are in Relay&#8217;s Control, Relay shall transfer such additional Know-How and Materials to Licensee promptly after such identification and notification.  </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">To the extent any additional Manufacturing Know-How and Materials are generated by Relay after the Effective Date, Relay shall identify such Know-How and Materials and shall thereafter transfer such additional Know-How and Materials in reasonable batches as discussed by the Parties.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:13.46%;text-indent:1.92%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref58229290"></a><a name="_Ref55633106"></a><a name="_Ref55633534"></a><a name="_Ref55635988"></a><font style="Background-color:#auto;text-decoration:none;">3.2.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Regulatory Transfer</font><font style="color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref55633100"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay shall (i) as promptly as possible and in any event in accordance with the timing set forth in the Technology Transfer Plan, provide all Regulatory Materials that relate to the Lead Candidate and Lead Product and (ii) promptly after the Effective Date use Commercially Reasonable Efforts to expeditiously transfer and assign to Licensee Relay&#8217;s entire right, title, and interest in and to the IND for the Lead Product in the Relay Phase Ia Trial (the &#8220;</font><font style="font-weight:bold;color:#000000;">Relay IND</font><font style="color:#000000;">&#8221; and such transfer, the &#8220;</font><font style="font-weight:bold;color:#000000;">Relay IND Transfer</font><font style="color:#000000;">&#8221;) ((i) and (ii) collectively, the &#8220;</font><font style="font-weight:bold;color:#000000;">Regulatory Transfer</font><font style="color:#000000;"><a name="_Ref55633100"></a>&#8221;). The Regulatory Transfer will be conducted in accordance with the requirements of the Technology Transfer Plan, including the timing, method and format requirements set forth thereon.&nbsp;&nbsp;Relay will make available its personnel (and use Commercially Reasonable Efforts to cause its Third Party Subcontractors with relevant subject matter expertise to be available) on a reasonable basis to consult with Licensee with respect to the Regulatory Transfer. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57190966"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">As part of the Regulatory Transfer, Relay shall (i) duly execute and send to the FDA (with confirmed receipt) a letter transferring ownership of the Relay IND and designation as the sponsor for such Relay IND to Licensee, including an update to the Sponsor obligations as set forth in Schedule 3.2.3 attached hereto (the &#8220;</font><font style="font-weight:bold;color:#000000;">Transfer of Sponsor Obligations</font><font style="color:#000000;">&#8221;) executed by Relay, Licensee and the Relay Phase Ia Trial CRO, and deliver to Licensee copies thereof and (ii) execute or agree upon any necessary agreements (pursuant to Section 3.3.8 or 3.3.9) or amend any existing agreements (pursuant to Section 3.3.7), as necessary as part of such Relay IND Transfer.  All such activities are a condition to completion of the Relay IND Transfer.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">It is understood and agreed that there may be additional Regulatory Materials that are not identified at the time of the Regulatory Transfer but which are thereafter identified and are necessary or reasonably useful for the Regulatory Transfer.&nbsp;&nbsp;If, after the Regulatory Transfer, either Party identifies any additional Regulatory Materials with respect to the Lead Candidate or Lead Products in the Field in the Territory, such Party shall notify the other Party, and if such additional Regulatory Materials are in Relay&#8217;s Control and possession, then </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Relay shall transfer such additional Regulatory Materials to Licensee promptly after such identification and notification</font><font style="color:#000000;">.</font><font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">To the extent any additional Regulatory Materials are generated by Relay after the Effective Date, and to the extent providing such Regulatory Materials are not covered under the SAE Management Plan or elsewhere in this Agreement, Relay shall identify such Regulatory Materials and shall thereafter transfer such Regulatory Materials in reasonable batches as discussed by the Parties.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref55633481"></a><font style="Background-color:#auto;text-decoration:none;">3.2.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Clinical Transfer</font><font style="color:#000000;">.&nbsp;&nbsp;Promptly after the Effective Date and in accordance with the timing set forth in the Technology Transfer Plan, Relay shall conduct the following activities (the transfer pursuant to this Section 3.2.4, the &#8220;</font><font style="font-weight:bold;color:#000000;">Clinical Transfer</font><font style="color:#000000;">&#8221;):</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref55636705"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay shall cooperate with and assist Licensee by identifying key Third Party Subcontractors and any agreements entered into by Relay with such key Third Party Subcontractors to prepare for a subsequent Clinical Trial by Licensee for the Lead Candidate or Lead Products, including CRO agreements, clinical trial agreements, institutional review board agreements, manufacturing agreements, supply agreements, laboratory services agreements, and other service provider agreements (&#8220;</font><font style="font-weight:bold;color:#000000;">Subsequent Clinical Trial-Related Contracts</font><font style="color:#000000;">&#8221;). At Licensee's reasonable request, Relay shall use Commercially Reasonable Efforts to assign and transfer its rights and obligations under any Subsequent Clinical Trial-Related Contract with respect to the Lead Candidate or Lead Products to Licensee; provided, however, that Licensee shall inform Relay which Subsequent Clinical Trial-Related Contracts are to be assigned.&nbsp;&nbsp;To the extent such assignment and transfer is either not practicable, or not requested, Relay shall cooperate with and assist Licensee, at Licensee's reasonable request, in coordinating the transition of such rights and obligations (or proposed rights and obligations) from Relay to Licensee with such Third Parties (including providing relevant contact information and making introductions to key personnel of such Third Parties);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56243673"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Upon receipt of the Inventory at the location designated by Licensee, Relay hereby sells, conveys assigns and transfers to Licensee all right, title and interest in and to the Inventory.&nbsp;&nbsp;Relay shall enter into customary documents, including an appropriate bill of sale, if required, for shipment of Inventory to Licensee.&nbsp;&nbsp;[***].&nbsp;&nbsp;Relay shall deliver, or authorize Licensee to direct the relevant Third Party Subcontractor to deliver, to Licensee Inventory required to be shipped to Licensee pursuant to this Section 3.2.4(b) to the location designated by Licensee using a carrier selected by and paid for by Licensee, DAP(Incoterms 2020); and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref55636675"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay shall coordinate and cooperate with Licensee to transfer to Licensee the data and information relating to the Relay Phase Ia Trial&nbsp;&nbsp;(the &#8220;</font><font style="font-weight:bold;color:#000000;">Relay Phase Ia Trial Data</font><font style="color:#000000;">&#8221;). To the extent any Relay Phase Ia Trial Data is in the possession of a Third Party, Relay shall deliver any necessary instruments, including any letters of authorization and transfer of ownership, to such Third Party to grant Licensee the right to have transferred such Relay Phase Ia Trial Data from such Third Party and to document and to transfer any such Relay Phase Ia Trial Data from Relay to Licensee.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">For ongoing ancillary studies (chronic tox, stability, etc.) supporting the Relay Phase Ia Trial or necessary to maintain the IND for the Lead Product, upon Licensee&#8217;s </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">request </font><font style="color:#000000;">Relay will transfer </font><font style="color:#000000;">any such study to Licensee (or, as requested by Licensee, enter into an arrangement </font><font style="color:#000000;">that delegates the roles, rights, and responsibilities for such study between Licensee, Relay and the Third Party Subcontractor supporting </font><font style="color:#000000;">such study, including without limitation taking actions substantially similar to those described in Section </font><font style="color:#000000;">3.3.7</font><font style="color:#000000;"> for such study) and all data and information relating to such studies.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay will make available its personnel (and use Commercially Reasonable Efforts to cause its Third Party Subcontractors with relevant subject matter expertise to be available) on a reasonable basis to consult with Licensee with respect to the Clinical Transfer.&nbsp;&nbsp;It is understood and agreed that there may be additional data and information relevant to the Clinical Transfer that are not identified at the time of the Clinical Transfer but are necessary or reasonably useful for the Development of the Lead Candidate or Lead Product and are thereafter identified.&nbsp;&nbsp;If after the Clinical Transfer, either Party identifies any such additional data and information such Party shall notify the other Party, and if such data and information are in Relay&#8217;s Control, then Relay shall transfer such additional data and information to Licensee promptly after such identification and notification.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.2.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Technology Transfer Plan.</font><font style="color:#000000;">&nbsp;&nbsp;The Technology Transfer will be conducted in accordance with the Technology Transfer Plan, including the timing, method and format requirements set forth therein. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref39582994"></a><a name="_Ref54026660"></a><a name="_Ref55462593"></a><a name="_Ref55382738"></a><a name="_Ref53911560"></a><font style="Background-color:#auto;text-decoration:none;"> 3.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Relay Phase Ia Trial Prior to the Relay IND Transfer Date</font><font style="color:#000000;">.&nbsp;&nbsp;This Section 3.3 will apply from the Effective Date until the Relay IND Transfer Date and thereafter Section 3.4 shall apply. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref55498338"></a><a name="_Ref53919473"></a><a name="_Ref54748756"></a><font style="Background-color:#auto;text-decoration:none;">3.3.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Generally</font><font style="color:#000000;">.&nbsp;&nbsp;Until completion of the Relay IND Transfer, Relay will remain responsible as Sponsor for the Relay Phase Ia Trial and will conduct the Relay Phase Ia Trial in accordance with a written development plan that includes a description of Relay&#8217;s activities for the Relay Phase Ia Trial, which may be amended in accordance with this Section 3.3 or Section 3.4, as applicable (the &#8220;</font><font style="font-weight:bold;color:#000000;">Relay Phase Ia Plan</font><font style="color:#000000;">&#8221;) and in compliance with Applicable Laws, including maintaining a global safety database for safety and risk management activities as required by Applicable Laws.&nbsp;&nbsp;A copy of the initial Relay Phase Ia Plan is attached hereto as Schedule 3.3.&nbsp;&nbsp;In the event of any inconsistency between the Relay Phase Ia Plan and this Agreement, the terms of this Agreement will prevail.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref54196362"></a><a name="_Ref54710563"></a><a name="_Ref57190864"></a><a name="_Ref56089041"></a><a name="_Ref56672387"></a><a name="_Ref38654233"></a><a name="_Ref38964674"></a><a name="_Ref39402833"></a><a name="_Ref53912278"></a><a name="_Ref53915989"></a><a name="_Hlk57795475"></a><font style="Background-color:#auto;text-decoration:none;">3.3.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Amendments, Changes and Approvals</font><font style="color:#000000;"><a name="_Ref39402833"></a>.&nbsp;&nbsp;Either Party (through its representatives on the JDT after the JDT is formed), may propose amendments to the Relay Phase Ia Plan at any time until such time as no further Development activities are occurring or expected to occur under such Relay Phase Ia Plan.&nbsp;&nbsp;No amendment or material change to the Relay Phase Ia Plan, including any change to the protocol or investigator&#8217;s brochure, will be effective unless and until approved by the JDT<a name="_Ref53912278"></a><a name="_Ref53915989"></a>. Notwithstanding the foregoing, in the event Licensee desires to amend the Relay Phase Ia Plan to add an additional clinical or non-clinical study to the Relay Phase Ia Plan that is not required nor requested by a Regulatory Authority (each, an &#8220;</font><font style="font-weight:bold;color:#000000;">Optional Additional Phase Ia Study</font><font style="color:#000000;">&#8221;), then Licensee will submit the Optional Additional Phase Ia Study to Relay (through the JDT after the JDT is formed) for consideration.&nbsp;&nbsp;If Relay agrees to the addition of the Optional Additional Phase Ia Study to the Relay Phase Ia Plan, then the Relay Phase Ia Plan will be amended to add such Optional Additional Phase Ia Study at Licensee&#8217;s cost.&nbsp;&nbsp;If Relay does not </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">agree to the addition of the Optional Additional Phase Ia Study to the Relay Phase Ia Plan, then Licensee may conduct such Optional Additional Phase Ia Study at its own expense outside of the Relay Phase Ia Plan.&nbsp;&nbsp;</font><font style="color:#000000;">I</font><font style="color:#000000;">f </font><font style="color:#000000;">during the conduct of the Relay Phase Ia Trial </font><font style="color:#000000;">a Regulatory Authority</font><font style="color:#000000;"><a name="_Hlk57795475"></a> </font><font style="color:#000000;">requires that an additional clinical or non-clinical study be conducted </font><font style="color:#000000;">or otherwise requires an amend</font><font style="color:#000000;">ment to</font><font style="color:#000000;"> the protocol</font><font style="color:#000000;"> for </font><font style="color:#000000;">the </font><font style="color:#000000;">Relay Phase Ia Trial</font><font style="color:#000000;"> </font><font style="color:#000000;">(a &#8220;</font><font style="font-weight:bold;color:#000000;">Required Additional Phase Ia Study</font><font style="color:#000000;">&#8221;), then </font><font style="color:#000000;">the Parties will </font><font style="color:#000000;">amend the Relay Phase Ia Plan to add such Required Additional Phase Ia Stud</font><font style="color:#000000;">y </font><font style="color:#000000;">[***]</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">If </font><font style="color:#000000;">during the conduct of the Relay Phase Ia Trial </font><font style="color:#000000;">a Regulatory Authority requests but does not require</font><font style="color:#000000;"> </font><font style="color:#000000;">an additional clinical or non-clinical study be conducted or otherwise requests but does not require an amendment to the protocol</font><font style="color:#000000;"> for the Relay Phase Ia Trial</font><font style="color:#000000;"> (a &#8220;</font><font style="font-weight:bold;color:#000000;">Requested Additional Phase Ia Study</font><font style="color:#000000;">&#8221;), the Parties will, through the JDT, discuss in good faith whether the Requested Additional Phase Ia Study can and should be conducted as part of and with the same patient population as the existing or planned Relay Phase Ia Trial, or whether it should be conducted as a separate study</font><font style="color:#000000;"> by Licensee</font><font style="color:#000000;">, taking into consider</font><font style="color:#000000;">ation strategic factors and timing and resource considerations</font><font style="color:#000000;">. </font><font style="color:#000000;">[***]</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">It is understood that time is of the essence in Relay&#8217;s ability to conduct the Relay Phase Ia Plan, and that no decisions of the JDT shall be unreasonably withheld or delayed</font><font style="color:#000000;">.</font><font style="color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1276"></a><a name="_BPDC_PR_INS_1277"></a><a name="_Ref56337083"></a><font style="Background-color:#auto;text-decoration:none;">3.3.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Conflicting Activities</font><font style="color:#000000;">.&nbsp;&nbsp;Licensee shall have the right (through the JDT after the JDT is formed), to review and provide comments on Development activities with respect to the Relay Phase Ia Trial and to withhold approval of any Development activities that may, in Licensee&#8217;s good faith belief, conflict with, or have a negative impact on, Licensee&#8217;s Development activities with respect to Licensed Candidates or Licensed Products (including Licensee&#8217;s activities under the Global Development Plan during an Opt-In Term). Development activities that are conducted in accordance with the Relay Phase Ia Plan are hereby deemed by the Parties to not be in conflict with, and to not have a negative impact on, Licensee&#8217;s Development activities with respect to Licensed Candidates or Licensed Products. Notwithstanding the foregoing, if (a) prior to the transfer to Licensee of the safety database for the Relay Phase Ia Trial a (i) DLT or (ii) SAE, in each case ((i) and (ii)) that is related or could potentially be related to the Licensed Candidate or Licensed Product, or (b) following the transfer to Licensee of the safety database for the Relay Phase Ia Trial any DLT or SAE, is observed in the conduct of Development activities under this Agreement, then the Parties shall meet immediately to discuss next steps and, if Licensee then in good faith determines that any Development activities contemplated in the then-current Relay Phase Ia Plan would conflict with, or have a negative impact on, the safety of the Licensed Candidates or Licensed Product, Licensee shall have the right to prohibit Relay from conducting such activities and the Parties will modify the Relay Phase Ia Plan and such activities as reasonably directed by Licensee to address such safety concerns.&nbsp;&nbsp;To the extent Relay&#8217;s conduct then conforms to such modified activities in accordance with the modified Relay Phase Ia Plan, then such conduct will be deemed to not be in conflict with, and to not have a negative impact on, Licensee&#8217;s Development activities with respect to Licensed Candidates or Licensed Products.&nbsp;&nbsp;Further, notwithstanding anything herein to the contrary, nothing in this Section 3.3.3, shall limit Relay&#8217;s ability to comply with Applicable Laws or to act in the interest of the safety of subjects participating in any Clinical Trials. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1274"></a><a name="_BPDC_PR_INS_1275"></a><a name="_Ref54710623"></a><font style="Background-color:#auto;text-decoration:none;">3.3.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Information Sharing; Decision Making</font><font style="color:#000000;"><a name="_Ref54710623"></a>.&nbsp;&nbsp;Until completion of the Relay IND Transfer Date, Relay will provide updates regarding its Development activities with respect to the Relay Phase Ia Trial and comply with Section 3.9.1, and will provide such other information with respect to the Relay Phase Ia Trial as is reasonably requested by Licensee and is in Relay&#8217;s Control.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Relay will also provide notice to Licensee and the opportunity to review and approve any decision for which Licensee has final decision making rights with respect to the </font><font style="color:#000000;">Relay </font><font style="color:#000000;">Phase </font><font style="color:#000000;">I</font><font style="color:#000000;">a Trial under Section </font><font style="color:#000000;">10.7.3(b)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1272"></a><a name="_BPDC_PR_INS_1273"></a><font style="Background-color:#auto;text-decoration:none;">3.3.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Regulatory Rights and Responsibilities</font><font style="color:#000000;">.</font><font style="font-weight:bold;color:#000000;">&nbsp;&nbsp;</font><font style="color:#000000;">The Parties will have the rights and responsibilities set forth in Section 6.3.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1270"></a><a name="_BPDC_PR_INS_1271"></a><font style="Background-color:#auto;text-decoration:none;">3.3.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Subcontractor Meetings</font><font style="color:#000000;">. Relay will provide Licensee with reasonable advance notice of all meetings with the Relay Phase Ia Trial CRO, Relay&#8217;s CMO and Relay&#8217;s other Third Party Subcontractors (including investigators) pertaining to the Relay Phase Ia Trial, and use Commercially Reasonable Efforts to coordinate scheduling of such meetings to enable Licensee to participate in all such meetings, including any meetings relating to dose or safety, and Licensee shall have final say on any decisions as provided in Section 10.7.3(b), regardless of whether the JDT has yet been formed. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56088853"></a><a name="_Ref57182505"></a><a name="_BPDC_LN_INS_1268"></a><a name="_BPDC_PR_INS_1269"></a><font style="Background-color:#auto;text-decoration:none;">3.3.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Amendments to CRO and CMO Agreements</font><font style="color:#000000;">.&nbsp;&nbsp;As soon as practicable after the Effective Date, Relay will, as may be necessary or desirable, negotiate in good faith and enter into amendments to its existing agreements, letters of authorization, side letters, written confirmation or any other binding and written agreements with the Relay Phase Ia Trial CRO and its CMO and other Third Party Subcontractors for the Relay Phase Ia Trial to ensure that (a) Licensee will have the right to carry out the responsibilities assigned to it under the Delegation of Authority,&#160;SAE Management Plan and Quality Agreement and (b) such agreements are consistent with and enable Licensee to exercise its rights under such documents and this Agreement.&nbsp;&nbsp;Licensee will reasonably cooperate with such negotiations, including negotiating in good faith and entering into an acceptable three-party agreement with Relay and the Relay Phase Ia Trial CRO, CMO or other Third Party Subcontractor, as applicable, to the extent necessary or reasonably requested by Relay. Relay agrees to use Commercially Reasonable Efforts to complete the foregoing actions prior to the anticipated Relay IND Transfer Date, and acknowledges that they are conditions to completion of the Relay IND Transfer.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1266"></a><a name="_Ref55563065"></a><a name="_BPDC_PR_INS_1267"></a><font style="Background-color:#auto;text-decoration:none;">3.3.8</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Safety and Serious Adverse Event Management Plan</font><font style="color:#000000;">.&nbsp;&nbsp;Prior to the Relay IND Transfer Date, the Parties will, and will use Commercially Reasonable Efforts to cause the Relay Phase Ia Trial CRO and other Third Party Subcontractors, as applicable, to, negotiate in good faith and enter into a pharmacovigilance agreement or SAE management plan (the &#8220;</font><font style="font-weight:bold;color:#000000;">SAE Management Plan</font><font style="color:#000000;">&#8221;), that will govern the transfer of the safety database (which shall occur simultaneously or promptly upon execution of the SAE Management Plan), exchange of safety data information, adverse events reporting and Licensed Product complaints with respect to the Relay Phase Ia Trial to ensure timely communication to Regulatory Authorities and compliance with Applicable Law and to designate rights and responsibilities as between such parties to support the Relay IND after the Relay IND Transfer Date. Relay acknowledges that the transfer of the safety database and execution of the SAE Management Plan are conditions to completion of the Relay IND Transfer.&nbsp;&nbsp;Prior to the transfer of any activities by Relay to a Relay Combination Collaborator, the Parties will enter into a three (3) party pharmacovigilance agreement with such Relay Combination Collaborator.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1264"></a><a name="_BPDC_PR_INS_1265"></a><a name="_Ref55563106"></a><a name="_Ref57182489"></a><font style="Background-color:#auto;text-decoration:none;">3.3.9</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Quality Agreement</font><font style="color:#000000;">. Prior to the Relay IND Transfer Date, the Parties will, and will use Commercially Reasonable Efforts to cause Relay&#8217;s CMO for the Relay Phase Ia Trial </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">to</font><font style="color:#000000;">,</font><font style="color:#000000;"> negotiate in good faith and enter into a quality agreement (the &#8220;</font><font style="font-weight:bold;color:#000000;">Quality Agreement</font><font style="color:#000000;">&#8221;) with respect to the supply of Phase Ia Product for the Relay Phase Ia Trial and to designate rights and responsibilities as between such parties to support the IND for the Relay Phase Ia Trial after the Relay IND Transfer Date.</font><font style="color:#000000;"> Relay acknowledges that the foregoing is a condition to completion of the Relay IND Transfer.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref55383352"></a><a name="_Ref55454788"></a><a name="_Ref56008260"></a><a name="_Ref54602541"></a><a name="_Ref54715723"></a><font style="Background-color:#auto;text-decoration:none;"> 3.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Relay Phase Ia Trial after the Relay IND Transfer Date</font><font style="color:#000000;">.&nbsp;&nbsp;This Section 3.4 will apply after the Relay IND Transfer Date.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:16.35%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref55455244"></a><a name="_Ref55459598"></a><a name="_Ref55636256"></a><font style="Background-color:#auto;text-decoration:none;">3.4.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Generally.</font><font style="color:#000000;">&nbsp;&nbsp;Relay will continue to conduct the Relay Phase Ia Trial in accordance with the Relay Phase Ia Plan and in compliance with all Applicable Laws, provided that Licensee will be responsible as Sponsor for the Relay Phase Ia Trial and Relay will provide reasonable assistance and support to Licensee as Sponsor of the Relay Phase Ia Trial to maintain the Relay IND as described further in this Section 3.4.&nbsp;&nbsp;Without limiting any other provision herein, Licensee, Relay, the Relay Phase Ia Trial CRO and Relay&#8217;s CMO and other Third Party Subcontractors for the Relay Phase Ia Trial, as applicable, will have the respective rights and responsibilities with respect to the Relay Phase Ia Trial assigned to them in the Delegation of Authority attached as Schedule 3.4.1(&#8220;</font><font style="font-weight:bold;color:#000000;">Delegation of Authority</font><font style="color:#000000;">&#8221;), the SAE Management Plan and the Quality Agreement. The Parties agree to update the Delegation of Authority upon finalization of the SAE Management Plan if necessary in order to conform such Delegation of Authority to the SAE Management Plan. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:16.35%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref58227646"></a><a name="_Ref56090853"></a><a name="_Ref55584624"></a><font style="Background-color:#auto;text-decoration:none;">3.4.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Amendments, Changes and Approvals</font><font style="color:#000000;">.&nbsp;&nbsp;Either Party (through its representatives on the JDT after the JDT is formed) may propose amendments to the Relay Phase Ia Plan at any time until such time as no further Development activities are occurring or expected to occur under such Relay Phase Ia Plan.&nbsp;&nbsp;No amendment or material change to the Relay Phase Ia Plan, including any change to the protocol or investigator&#8217;s brochure, will be effective unless and until approved by Licensee. Notwithstanding the foregoing, in the event Licensee desires to amend the Relay Phase Ia Plan to add an Optional Additional Phase Ia Study, then Licensee will submit the Optional Additional Phase Ia Study to Relay (through the JDT after the JDT is formed) for consideration before making such amendment.&nbsp;&nbsp;If Relay agrees to the addition of the Optional Additional Phase Ia Study to the Relay Phase Ia Plan, then the Relay Phase Ia Plan will be amended to add such Optional Additional Phase Ia Study.&nbsp;&nbsp;If Relay does not agree to the addition of the Optional Additional Phase Ia Study to the Relay Phase Ia Plan, then Licensee may conduct such Optional Additional Phase Ia Study at its own expense outside of the Relay Phase Ia Plan.&nbsp;&nbsp;[***].&nbsp;&nbsp;With respect to a Requested Additional Phase Ia Study the Parties will, through the JDT, discuss in good faith whether the Requested Additional Phase Ia Study can and should be conducted as part of and with the same patient population as the existing or planned Relay Phase Ia Trial, or whether it should be conducted as a separate study by Licensee, taking into consideration strategic factors and timing and resource considerations.&nbsp;&nbsp;[***].&nbsp;&nbsp;It is understood that time is of the essence in Relay&#8217;s ability to conduct the Relay Phase Ia Plan, and that no decisions of the JDT shall be unreasonably withheld or delayed.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:16.35%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1262"></a><a name="_BPDC_PR_INS_1263"></a><a name="_Ref56345684"></a><font style="Background-color:#auto;text-decoration:none;">3.4.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Conflicting Activities</font><font style="color:#000000;">.&nbsp;&nbsp;Licensee shall have the right (through the JDT after the JDT is formed), to review and provide comments on Development activities with respect to the Relay Phase Ia Trial and to withhold approval of any Development activities that may, in Licensee&#8217;s good faith belief, conflict with, or have a negative impact on, Licensee&#8217;s Development </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">activities with respect to Licensed Candidates or Licensed Products (including Licensee&#8217;s activities under the Global Development Plan during an Opt-In Term). Development activities that are conducted in accordance with the Relay Phase Ia Plan </font><font style="color:#000000;">are hereby </font><font style="color:#000000;">deemed </font><font style="color:#000000;">by the Parties to </font><font style="color:#000000;">not </font><font style="color:#000000;">be in conflict with, and to not have a negative impact on, Licensee&#8217;s Development activities with respect to Licensed Candidates or Licensed Products</font><font style="color:#000000;">. </font><font style="color:#000000;">Notwithstanding the foregoing, if a </font><font style="color:#000000;">(a) DLT or (b) SAE</font><font style="color:#000000;"> </font><font style="color:#000000;">is observed</font><font style="color:#000000;"> in the </font><font style="color:#000000;">performance </font><font style="color:#000000;">of</font><font style="color:#000000;"> </font><font style="color:#000000;">Development </font><font style="color:#000000;">activities hereunder</font><font style="color:#000000;">, </font><font style="color:#000000;">the Parties shall meet immediately to discuss next steps</font><font style="color:#000000;"> and</font><font style="color:#000000;">, if Licensee </font><font style="color:#000000;">then </font><font style="color:#000000;">in good faith determines that any Development activities contemplated in the then-current Relay Phase Ia Plan would conflict with, or have a negative impact on, the safety of the Licensed Candidates or Licensed Product, Licensee shall have the right to prohibit Relay from such activities and the Parties will modify the Relay Phase Ia Plan and such activities as directed by Licensee to address such safety concerns</font><font style="color:#000000;">.&nbsp;&nbsp;To the extent</font><font style="color:#000000;"> Relay&#8217;s conduct </font><font style="color:#000000;">then conforms to </font><font style="color:#000000;">such modified activities in accordance with the modified Relay Phase Ia Plan</font><font style="color:#000000;">, then such conduct</font><font style="color:#000000;"> will be deemed to not be in conflict with, and to not have a negative impact on, Licensee&#8217;s Development activities with respect to Licensed Candidates or Licensed Products</font><font style="color:#000000;">.&nbsp;&nbsp;The approval rights set forth in this Section</font><font style="color:#000000;"> </font><font style="color:#000000;">3.4.2</font><font style="color:#000000;"> shall not limit Licensee&#8217;s approval rights pursuant to the Delegation of Authority</font><font style="color:#000000;">, SAE Management Plan or Quality Agreement</font><font style="color:#000000;">.</font><font style="color:#000000;">&nbsp;&nbsp;</font><font style="color:#000000;">Further, notwithstanding anything herein to the contrary, n</font><font style="color:#000000;">othing in this Section</font><font style="color:#000000;"> </font><font style="color:#000000;">3.4.2</font><font style="color:#000000;">, shall limit Relay&#8217;s ability to comply with Applicable Laws or to act in the interest of the safety of subjects participating in any </font><font style="color:#000000;">C</font><font style="color:#000000;">linical </font><font style="color:#000000;">T</font><font style="color:#000000;">rials</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:16.35%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1260"></a><a name="_BPDC_PR_INS_1261"></a><font style="Background-color:#auto;text-decoration:none;">3.4.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Information Sharing; Decision Making</font><font style="color:#000000;">.&nbsp;&nbsp;After the Relay IND Transfer Date, Relay will provide updates regarding its Development activities with respect to the Relay Phase Ia Trial and comply with Section 3.9.1, and will provide such other information with respect to the Relay Phase Ia Trial as is reasonably requested by Licensee and is in Relay&#8217;s Control. If Licensee is conducting Clinical Trials of the Lead Product during the time period that Relay is conducting the Relay Phase Ia Trial, Licensee will provide material updates to Relay regarding Licensee&#8217;s Development activities, and will provide such other material information as is reasonably requested by Relay, and notice of DLT and SAEs, as provided in Section 3.9.1, </font><font style="font-style:italic;color:#000000;">mutatis mutandis</font><font style="color:#000000;">.&nbsp;&nbsp;Relay will also provide notice to Licensee and the opportunity to review and approve any decision for which Licensee has final decision making rights with respect to the Relay Phase Ia Trial under Section 10.7.3(b).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:16.35%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1258"></a><a name="_BPDC_PR_INS_1259"></a><font style="Background-color:#auto;text-decoration:none;">3.4.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Regulatory Rights and Responsibilities</font><font style="color:#000000;">.</font><font style="font-weight:bold;color:#000000;">&nbsp;&nbsp;</font><font style="color:#000000;">The Parties will have the rights and responsibilities set forth in Section 6.3.2.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:16.35%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1256"></a><a name="_BPDC_PR_INS_1257"></a><font style="Background-color:#auto;text-decoration:none;">3.4.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Subcontractor Meetings</font><font style="color:#000000;">. Relay will provide Licensee with reasonable advance notice of all meetings with the Relay Phase Ia Trial CRO, Relay&#8217;s CMO and Relay&#8217;s other Third Party Subcontractors (including investigators) pertaining to the Relay Phase Ia Trial, and use Commercially Reasonable Efforts to coordinate the schedules of the Parties to enable Licensee to participate in all such meetings, and Licensee shall have final say on any decisions as provided in Section 10.7.3(b).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:16.35%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57574855"></a><font style="Background-color:#auto;text-decoration:none;">3.4.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Transfer of Phase Ia Trial</font><font style="color:#000000;">.&nbsp;&nbsp;Anytime after the Relay IND Transfer Date, notwithstanding anything in the foregoing, if Licensee may request by written notice to Relay that the conduct of the Relay Phase Ia Trial be transferred to Licensee, in whole or in part, such that Licensee has the sole right and responsibility for the conduct of such transferred Relay Phase Ia Trial. If Licensee request to transfer the Relay Phase Ia Trial in whole based upon a breach by </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Relay of </font><font style="color:#000000;">any of </font><font style="color:#000000;">its obligations </font><font style="color:#000000;">in </font><font style="color:#000000;">Sections</font><font style="color:#000000;"> 3.2</font><font style="color:#000000;">,</font><font style="color:#000000;"> 3.3</font><font style="color:#000000;">,</font><font style="color:#000000;"> 3.4</font><font style="color:#000000;">,&nbsp;&nbsp;</font><font style="color:#000000;">3.9.1</font><font style="color:#000000;">, </font><font style="color:#000000;"> 6.3</font><font style="color:#000000;"> and </font><font style="color:#000000;"> 6.4</font><font style="color:#000000;"> </font><font style="color:#000000;">that remains uncured </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> after written notice thereof from Licensee to</font><font style="color:#000000;"> Relay</font><font style="color:#000000;"> or multiple </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> breaches of </font><font style="color:#000000;">such </font><font style="color:#000000;">provisions </font><font style="color:#000000;">which were previously notified by Licensee to Relay, </font><font style="color:#000000;">whether or not cured or curable, then such notice will describe such uncured breach or multiple prior breaches in reasonable detail</font><font style="color:#000000;">, including identifying the provisions</font><font style="color:#000000;"> breached,</font><font style="color:#000000;"> and will state Licensee&#8217;s intention to transfer the Relay Phase Ia Trial pursuant to this Section </font><font style="color:#000000;">3.4.7</font><font style="color:#000000;">.&nbsp;&nbsp; Upon receipt of written notice pursuant to this Section </font><font style="color:#000000;">3.4.7</font><font style="color:#000000;">, </font><font style="color:#000000;">Relay shall transfer the conduct</font><font style="color:#000000;"> of the Relay Phase Ia Trial</font><font style="color:#000000;"> </font><font style="color:#000000;">(or the applicable part thereof) </font><font style="color:#000000;">to Licensee as reasonably directed in </font><font style="color:#000000;">an</font><font style="color:#000000;"> expeditious manner</font><font style="color:#000000;">. For avoidance of any doubt, the cost sharing provisions set forth in this Section 3.4 shall not be changed as a result of such transfer.</font><font style="color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56262573"></a><font style="Background-color:#auto;text-decoration:none;"> 3.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Global Development Plan</font><font style="color:#000000;">.&nbsp;&nbsp;In the event Relay exercises its Opt-In Right, then this Section 3.5 will apply during the Opt-In Term.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref38654763"></a><a name="_Ref39505402"></a><a name="_Hlk40968136"></a><a name="_Hlk38662025"></a><a name="_Ref38883020"></a><a name="_Ref38648114"></a><font style="Background-color:#auto;text-decoration:none;">3.5.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Global Development Plan</font><font style="color:#000000;">.&nbsp;&nbsp;Except with respect to Relay&#8217;s obligations under Section 3.3 and 3.4, Licensee will use Commercially Reasonable Efforts to Develop the Lead Products in the Field in the Territory in accordance with the Global Development Plan, subject to any amendments to the Global Development Plan, which<a name="_Hlk40968136"></a><a name="_Hlk38662025"></a><a name="_Ref38883020"></a><a name="_Ref38648114"></a> will be subject to JDT approval in accordance with Section 10.2.2(g).&nbsp;&nbsp;For clarity, Licensee may at its option Develop any such [***] Combination outside of the Global Development Plan, provided that the foregoing shall not limit the Parties rights and obligations with respect to sharing of Net Profits and Net Losses during the Opt-In Term as provided hereunder. In the event of any inconsistency between the Global Development Plan and this Agreement, the terms of this Agreement will prevail.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref39505409"></a><font style="Background-color:#auto;text-decoration:none;">3.5.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Global Development Budget</font><font style="color:#000000;">.&nbsp;&nbsp;The Global Development Plan will contain the Global Development Budget.&nbsp;&nbsp;The first full Calendar Year of the then-current Global Development Budget, will be binding for purposes of calculating First Tier GDP Overruns and Second Tier GDP Overruns as provided in Section 3.8.5, and will be non-binding for all other purposes.&nbsp;&nbsp;The Global Development Budget, and each update thereto, will be prepared by Licensee based on Licensee&#8217;s good faith estimation, consistent with its standard internal practices, of the probable Development activities to be conducted during the relevant Global Development Budget period, and based on and consistent with the documents and information related to the Licensed Products prepared by Licensee for its internal use and reference in the budgeting process.&nbsp;&nbsp;Upon request by Relay, the JDT will discuss the appropriate level of detail to include in the Global Development Budget for the applicable Development activities to be performed during the period covered by such Global Development Budget.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref39402887"></a><font style="Background-color:#auto;text-decoration:none;">3.5.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Reviews</font><font style="color:#000000;">.&nbsp;&nbsp;Beginning with the first [***] of the Opt-In Term and for each year thereafter during the Opt-In Term until such time as no further Development activities are occurring or expected to occur under such Global Development Plan, Licensee will provide to the JDT, [***], any updates to the Global Development Plan proposed for the following Calendar Year and thereafter, and thereupon, the JDT will review and discuss such updated GDP and endeavor to approve such updated GDP within [***] after receipt of such updated GDP.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref54196121"></a><font style="Background-color:#auto;text-decoration:none;">3.5.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Updates</font><font style="color:#000000;">.&nbsp;&nbsp;The Global Development Budget included in the updated GDP provided in accordance with Section 3.5.3 will contain&nbsp;&nbsp;[***], in accordance with the requirements set forth in Section 3.5.2.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref39331357"></a><font style="Background-color:#auto;text-decoration:none;">3.5.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Amendments</font><font style="color:#000000;">.&nbsp;&nbsp;In addition to the annual updates, either Party, through its representatives on the JDT, may propose amendments to the Global Development Plan at any time until such time as no further Development activities are occurring or expected to occur under such Global Development Plan, including amendments to add Development activities to such Global Development Plan.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref38654155"></a><a name="_Ref38654302"></a><a name="_Ref39040353"></a><a name="_Hlk38662779"></a><font style="Background-color:#auto;text-decoration:none;">3.5.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Approvals</font><font style="color:#000000;">.&nbsp;&nbsp;No annual update or amendment to the Global <a name="_Ref38654155"></a><a name="_Ref38654302"></a><a name="_Ref39040353"></a><a name="_Hlk38662779"></a>Development Plan will be effective unless and until approved by the JDT. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref55636735"></a><a name="_Ref50820076"></a><a name="_Ref50583857"></a><a name="_Ref52368400"></a><a name="_Ref51938723"></a><a name="_Ref39333009"></a><a name="_Ref41030366"></a><a name="_Ref38656882"></a><a name="_Hlk38884816"></a><a name="_Ref530174699"></a><a name="_Ref530838424"></a><font style="Background-color:#auto;text-decoration:none;"> 3.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Diligence</font><font style="color:#000000;">.&nbsp;&nbsp;Relay will use Commercially Reasonable Efforts to perform the Development activities set forth in the Relay Phase Ia Trial in accordance with the Relay Phase Ia Plan and in accordance with the estimated timetables set forth therein and to perform its obligations under Sections 6.3 and 6.4, including dedicating the appropriate amount of time and personnel in terms of knowledge and expertise to support the conduct of the Relay Phase Ia Trial and the Relay IND hereunder in the following functional areas: [***].&nbsp;&nbsp;Licensee will use Commercially Reasonable Efforts to Develop and obtain Regulatory Approval for and launch at least [***] Licensed Product in the Field in [***]. The GDP as of the Effective Date prioritizes a [***] Combination with the Lead Product [***], and for avoidance of any doubt, Licensee reserves the right to reprioritize based on the factors that are contemplated while using Commercially Reasonable Efforts. For the avoidance of doubt, (a) [***] and (b) the exercise of diligence by Licensee with respect to a Licensed Product is to be determined by judging Licensee&#8217;s Commercially Reasonable Efforts with respect to such Licensed Product taken as a whole. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;"> 3.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Relay Pipeline Combinations</font><font style="color:#000000;">.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk54189112"></a><a name="_Ref54179028"></a><font style="Background-color:#auto;text-decoration:none;">3.7.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notwithstanding anything herein to the contrary, Relay and its Affiliates retain the right to Develop all Relay Pipeline Combination Eligible Licensed Product<a name="_Hlk54189112"></a><a name="_Ref54179028"></a>s solely for Combination Use in Relay Pipeline Combinations.&nbsp;&nbsp;The Development of Relay Pipeline Combinations will occur separate from Licensee&#8217;s Development activities with respect to the Licensed Products and Licensed Candidates, subject to Section 3.7.2.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56002788"></a><a name="_Ref56327823"></a><a name="_Ref56246217"></a><a name="_Ref57799960"></a><a name="_Ref57833750"></a><a name="_Ref54723236"></a><a name="_Ref55635124"></a><a name="_Ref56004778"></a><font style="Background-color:#auto;text-decoration:none;">3.7.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Prior to conducting any Development activities with respect to a Relay Pipeline Combination, Relay will submit a proposed plan for such activities to the JDT, including if applicable a summary development plan for Regulatory Approval of such Relay Pipeline Combination (the &#8220;</font><font style="font-weight:bold;color:#000000;">Proposed Relay Pipeline Combination Development Plan</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;Within [***] days following the submission of such proposed plan to the JDT, Licensee will respond to Relay in writing indicating whether Licensee reasonably expects that the proposed Development activities with respect to a Relay Pipeline Combination in the Proposed Relay Pipeline Combination Development Plan will materially conflict with or negatively impact Licensee&#8217;s Development activities with respect to Licensed Products and Licensed Candidates (including Licensee&#8217;s activities under the Global Development Plan during an Opt-In Term), including a list of any expected conflicts or negative impacts (such as safety) and the reasons therefor.&nbsp;&nbsp;The Parties will discuss and attempt to resolve in good faith such issues, including considering whether Relay&#8217;s Development activities can be modified to avoid any conflicts or negative impacts.&nbsp;&nbsp;If the Parties do not agree on modifications to address Licensee&#8217;s concerns, Relay may proceed with such activities, subject to Licensee&#8217;s final say to stop such activities as provided in Section 10.7.3(b), Licensee&#8217;s approval rights in the Delegation of Authority, SAE Management Plan, and Quality </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Agreement</font><font style="color:#000000;">; </font><font style="color:#000000;">provided that Licensee&#8217;s approval shall be required </font><font style="color:#000000;">for Relay to proceed </font><font style="color:#000000;">with respect to such activities that would conflict with, or have a negative impact on, Licensee&#8217;s Development activities under the GDP.&nbsp;&nbsp;</font><font style="color:#000000;">In no event shall a delay in response by Licensee be taken to be deemed as an indication tha</font><font style="color:#000000;">t there is no such conflict or </font><font style="color:#000000;">negative impact</font><font style="color:#000000;">.</font><font style="color:#000000;">&nbsp;&nbsp;If after submission of the Proposed Relay Pipeline Combination Development Plan to the JDT, Relay propose</font><font style="color:#000000;">s</font><font style="color:#000000;"> to make any changes to the </font><font style="color:#000000;">Proposed </font><font style="color:#000000;"><a name="_Ref55635124"></a><a name="_Ref56004778"></a>Relay Pipeline Combination Development Plan that could reasonably be expected to materially conflict with or negatively impact Licensee&#8217;s Development </font><font style="color:#000000;">activities</font><font style="color:#000000;"> with respect to Licensed Products and </font><font style="color:#000000;">Licensed </font><font style="color:#000000;">C</font><font style="color:#000000;">a</font><font style="color:#000000;">ndidates, Relay will submit such changes to the JDT and this Section</font><font style="color:#000000;"> </font><font style="color:#000000;">3.7.2</font><font style="color:#000000;"> will apply to such </font><font style="color:#000000;">proposed changes (</font><font style="font-style:italic;color:#000000;">mutatis mutandis</font><font style="color:#000000;">)</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref50828671"></a><font style="Background-color:#auto;text-decoration:none;"> 3.8</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Development Costs and Launch Costs</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref53393028"></a><a name="_Ref55459242"></a><a name="_Ref40645523"></a><font style="Background-color:#auto;text-decoration:none;">3.8.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Relay Phase Ia Trial</font><font style="color:#000000;">. Except as set forth in Sections 3.3.2 and 3.4.2, (a) Relay will be responsible for [***] up to the Relay IND Transfer Date, (b) after the Relay IND Transfer Date, [***], and (c) otherwise each Party shall bear its own costs and expenses in performing its responsibilities and activities with respect to the Relay Phase Ia Trial.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref53393111"></a><a name="_Hlk56026413"></a><a name="_Hlk52311304"></a><a name="_Ref56024974"></a><font style="Background-color:#auto;text-decoration:none;">3.8.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Relay Pipeline Combinations</font><font style="color:#000000;">.&nbsp;&nbsp;Relay will be responsible for [***] for each Relay Pipeline Combination except that Licensee will provide the Relay Pipeline Combination Eligible Licensed Product therefor to Relay [***], Licensee will [***] for such Relay Pipeline Combinations in accordance with either (a) or (b) below (with such [***] being determined in the same manner as [***] pursuant to Section [***], </font><font style="font-style:italic;color:#000000;">mutatis mutandis</font><font style="color:#000000;">: <a name="_Hlk52311304"></a><a name="_Ref56024974"></a>[***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref52547495"></a><a name="_Ref57643787"></a><a name="_Ref56268796"></a>For avoidance of any doubt, if Licensee does not elect the [***] with respect to a Relay Pipeline Combination and such Relay Pipeline Combination does not receive Regulatory Approval in the Profit Share Territory, Licensee will not be required to [***] with respect to such Relay Pipeline Combination. As used in this Section 3.8.2, &#8220;<font style="font-weight:bold;">Global Trial</font>&#8221; shall mean, with respect to any Relay Pipeline Combination, [***]<a name="_Ref56268796"></a>&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.8.3</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Payment Elections</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57645505"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Promptly following preparation and compilation of the final approved tables, listings and figures for the Clinical Trial for a Relay Pipeline Combination immediately preceding [***] Pivotal Trial for such Relay Pipeline Combination, Relay will provide Licensee the same, together with the total development cost incurred or accrued for Global Trials of such Relay Pipeline Combination through such date, and a proposed clinical development plan and budget for the Pivotal Trial, including trial design, protocol, patient and site selection (the &#8220;</font><font style="font-weight:bold;color:#000000;">Licensee Selection Data Package</font><font style="color:#000000;">&#8221;) to Licensee.&nbsp;&nbsp;If the Licensee Selection Data Package provided by Relay is incomplete, then Licensee may notify Relay of the incomplete status of such Licensee Selection Data Package in writing including any items that, in Licensee&#8217;s reasonable determination made in good faith, should have been included therein but were not included therein within [***] after receipt thereof.&nbsp;&nbsp;Following receipt of such notice, to the extent such missing data is available, Relay will promptly deliver to Licensee the additional information to complete the Licensee Selection Data Package. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57642231"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licensee will have the right to [***] of the Relay Pipeline Combination in accordance with Section 3.8.2(a) by providing with written notice thereof within </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">[***]</font><font style="color:#000000;"> after receipt of the complete Licensee Selection Data Package (</font><font style="color:#000000;">such time period, the </font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Licensee Selection Data Package Review Period</font><font style="color:#000000;">&#8221;</font><font style="color:#000000;">, and election of such funding, the &#8220;</font><font style="font-weight:bold;color:#000000;">Early Payment Election</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;For the avoidance of doubt, the Licensee Se</font><font style="color:#000000;">le</font><font style="color:#000000;">ction Data Package Review Period will not commence until Licensee has been provided a complete Licensee Selection Data Package.</font><font style="color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If Licensee does not elect the [***] and the Relay Pipeline Combination receives Regulatory Approval in the Profit Share Territory, Relay will thereafter [***] pursuant to Section [***] in accordance with Section[***]&nbsp;&nbsp;If Licensee elects the [***], Relay will thereafter [***] pursuant to sub-clause (i) of Section [***] in accordance with Section [***] and will Relay will [***] Licensee [***] pursuant to sub-clause [***] of Section [***] in the same manner as Licensee [***] to Relay for [***] pursuant to Section [***] </font><font style="font-style:italic;color:#000000;">mutatis mutandis</font><font style="color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:13.46%;text-indent:1.92%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.8.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Shared Products; Royalty Products</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56116794"></a><a name="_Ref50895759"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">During the Opt-In Term, the Parties will share all Development Costs for Development activities conducted under the Global Development Plan for the Shared Products and all Launch Costs for the Shared Products, in each case in accordance with the applicable Sharing Percentages and in accordance with Section 11.3.1.<a name="_Ref50895759"></a>&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref41511649"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licensee will be responsible for all development costs for all Royalty Products (for the avoidance of doubt, however, excluding Relay&#8217;s development costs relating to Licensed Products or Licensed Candidates in connection with Development of Relay Pipeline Combinations).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk50883255"></a><font style="Background-color:#auto;text-decoration:none;">3.8.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">[***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref39115135"></a><a name="_Ref54717511"></a><font style="Background-color:#auto;text-decoration:none;"> 3.9</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Reports; Records</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref52309316"></a><a name="_Ref39333436"></a><a name="_Hlk58227104"></a><font style="Background-color:#auto;text-decoration:none;">3.9.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Commencing with the first meeting of the JDT and continuing until delivery of the TLF to Licensee pursuant to Section 4.1.2, Relay will prepare and deliver to the JDT, written reports summarizing its Development activities performed to date by Relay (or updating such report for activities performed since the last such report submitted hereunder, as applicable) with respect to the Relay Phase Ia Trial (including if (a) prior to the transfer to Licensee of the safety database for the Relay Phase Ia Trial, a (i) dose-limiting toxicity (&#8220;</font><font style="font-weight:bold;color:#000000;">DLT</font><font style="color:#000000;">&#8221;) or (ii) serious adverse event (&#8220;</font><font style="font-weight:bold;color:#000000;">SAE</font><font style="color:#000000;">&#8221;), in each case ((i) and (ii)) that is related to or could reasonably be related to the Licensed Candidate or Licensed Product, is observed or (b) following the transfer to Licensee of the safety database for the Relay Phase Ia Trial any DLT or SAE is observed in the Relay Phase Ia Trial) at least [***] prior to each scheduled JDT meeting.&nbsp;&nbsp;Relay will further report to the JDT (and for the period prior to the formation of the JDT, directly to Licensee) (A) prior to implementation, any contemplated amendments or material changes to the Relay Phase Ia Plan and any contemplated Development activities with respect to a Relay Pipeline Combination that could reasonably be expected to materially conflict with or negatively impact the design or conduct of any Development activities contemplated by Licensee, including pursuant to the GDP, (B) if <a name="_Hlk58227104"></a>a (1) DLT or (2) SAE is observed in accordance with the SAE Management Plan, or prior to execution of the SAE Management Plan, is observed and is related to or could reasonably be related to the Licensed Candidate or Licensed Product, then immediately, and in any event within </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">[***]</font><font style="color:#000000;"> after observation of or becoming aware of such DLT or SAE event</font><font style="color:#000000;">, </font><font style="color:#000000;">(</font><font style="color:#000000;">C</font><font style="color:#000000;">) </font><font style="color:#000000;">immediately (and in any event within </font><font style="color:#000000;">[***]</font><font style="color:#000000;">) </font><font style="color:#000000;">whenever Relay receives an inquiry/request for information or other Material Communication from a Regulatory Authority</font><font style="color:#000000;"> with respect to the Relay Phase Ia Trial</font><font style="color:#000000;">, (</font><font style="color:#000000;">D</font><font style="color:#000000;">) any contemplated dose or cohort decision </font><font style="color:#000000;">with respect to the Relay Phase Ia Trial </font><font style="color:#000000;">prior to any such decision, and (</font><font style="color:#000000;">E</font><font style="color:#000000;">) such other data and information and summaries thereof as are agreed by the JDT</font><font style="color:#000000;"> in </font><font style="color:#000000;">the</font><font style="color:#000000;"> data</font><font style="color:#000000;"> and information</font><font style="color:#000000;"> sharing plan</font><font style="color:#000000;"> contemplated in Section </font><font style="color:#000000;">10.2.2(k)</font><font style="color:#000000;">.</font><font style="color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref52373997"></a><a name="_Ref55206179"></a><a name="_Ref55564119"></a><a name="_Ref52308538"></a><font style="Background-color:#auto;text-decoration:none;">3.9.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">For such period during which Relay is conducting Development activities for Relay Pipeline Combinations, at least [***] prior to each Calendar Quarter JDT meeting, Relay will prepare and deliver to the JDT, written reports summarizing Development activities for Relay Pipeline Combinations performed to date by Relay (or updating such report for activities performed since the last such report submitted hereunder, as applicable), including copies of study designs, protocols and results for Clinical Trials for each Relay Pipeline Combination. Relay will further promptly report to the JDT any regulatory communications related to the Licensed Candidates or Licensed Products, including the Clinical Trials conducted by Licensee in the Global Development Plan. Relay will report to Licensee (a) the observation of a (i) DLT or (ii) SAE in accordance with the Pharmacovigilance Agreement, or prior to execution of such Pharmacovigilance Agreement, immediately, and in any event within [***] after becoming aware of any (A) DLT or (B) SAE in each case ((A) and (B)) that is observed and is related to or could reasonably be related to the Licensed Candidate or Licensed Product, and (b) such other data and information and summaries thereof as are agreed by the JDT in the data and information sharing plan contemplated in Section 10.2.2(k).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref52375403"></a><font style="Background-color:#auto;text-decoration:none;">3.9.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_Ref52375403"></a> For such period during the Opt-In Term as Licensee is conducting Development activities for Shared Products under the Global Development Plan, at least [***] prior to each Calendar Quarter JDT meeting, Licensee will prepare and deliver to the JDT, written reports summarizing Development activities for Shared Products performed to date by Licensee (or updating such report for activities performed since the last such report submitted hereunder, as applicable), including copies of study designs, protocols and results for Clinical Trials for each Shared Product.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref52315667"></a><a name="_Ref54717498"></a><font style="Background-color:#auto;text-decoration:none;">3.9.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">For such period as Licensee is conducting Development activities for any Back-Up Compound or any Back-Up Product (or outside of the Opt-In Term, the Lead Candidate or any Lead Product) and any Back-Up Development/Commercial Milestones pursuant to Section 11.5.3 (or Development/Commercial Milestones pursuant to Section 11.5.1 outside of the Opt-In Term), in each case that are tied to Development activities, remain to be achieved, on or about [***] of each Calendar Year, Licensee will provide Relay with an annual written report summarizing the material Development activities undertaken by Licensee with respect to&nbsp;&nbsp;the Back-Up Compounds and Back-Up Products (and outside of the Opt-In Term, the Lead Candidate and Lead Products) in the immediately preceding Calendar Year.&nbsp;&nbsp;Such reporting with respect to any Back-Up Compound or Back-Up Product (and outside of the Opt-In Term, the Lead Candidate and any Lead Product), shall commence following the initiation of the first IND-enabling study of such Back-Up Compound or Back-Up Product (or the Lead Candidate or Lead Product, as applicable), until Development activities are no longer being conducted with respect to such Back-Up Compound or Back-Up Product (or the Lead Candidate or Lead Product, as applicable).&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">3.9.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Each Party will provide the members of the JDT with written copies of all materials it intends to present at a JDT meeting.&nbsp;&nbsp;The JDT may also request at any time specific material data or information related to relevant Development activities or that a written report be prepared in advance of any meeting summarizing certain material data and information arising out of the conduct of relevant Development activities, and the Party or appropriate committee to whom such request is made will promptly provide to the other Party or JDT such report, data or information</font><font style="color:#000000;"> that was reasonably requested</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref52109565"></a><font style="Background-color:#auto;text-decoration:none;">3.9.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If during the Opt-In Term Licensee or its Affiliates makes a decision, including through a governance committee ([***] or their respective equivalent if such committees do not exist in the future), to permanently cease all Development and Commercialization activities with respect to a given Licensed Product, then Licensee will report such cessation and the date of such decision in the first report provided to Relay pursuant to Section 3.9.3 after such date.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.9.7</font><font style="margin-left:108pt;color:#000000;"></font><font style="color:#000000;">If Relay or its Affiliates makes a decision to cease all Development and Commercialization activities with respect to a given Relay Pipeline Combination, then Relay will report such cessation and the date of such decision in the first report provided to Licensee pursuant to Section 3.9.2 after such date.</font><font style="font-size:10pt;color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.9.8</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Each Party will maintain records with respect to the Lead Candidate, Back-Up Compounds, Lead Products and Back-Up Products (including Combination Use thereof), in sufficient detail and in sound scientific manner appropriate for Patent and regulatory purposes and in compliance with GLP, GMP and GCP, as applicable, with respect to activities intended to be submitted in regulatory filings (including INDs).&nbsp;&nbsp;All such records, and the information disclosed therein, are the Confidential Information of the Party maintaining such records and will be protected as Confidential Information by the recipient Party in accordance with Article 13.</font></p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;"><a name="_Toc51338581"></a><a name="_Toc53919198"></a><a name="_Toc53925682"></a><a name="_Ref50470707"></a>&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc51338582"></a><a name="_Toc53919199"></a><a name="_Toc53925683"></a>Opt-In Right; OPT-OUT RIGHT</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref50819240"></a><font style="Background-color:#auto;text-decoration:none;"> 4.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Opt-In Right</font><font style="color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref50828247"></a><font style="Background-color:#auto;text-decoration:none;">4.1.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Subject to the remainder of this Section 4.1, Licensee hereby grants to Relay an exclusive option, exercisable in Relay&#8217;s sole discretion one (1) time, to fund Development Costs for Lead Products in the Field and share in the Net Profits and Net Losses of Commercializing Lead Products in the Field in the Profit Share Territory, such funding and sharing of Net Profits and Net Losses to be in accordance with the Sharing Percentages (collectively, the &#8220;</font><font style="font-weight:bold;color:#000000;">Opt-In Right</font><font style="color:#000000;">&#8221;). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref52306998"></a><a name="_Ref54195770"></a><a name="_Ref50471241"></a><a name="_Ref57575024"></a><a name="_Ref57192527"></a><a name="_Hlk52524981"></a><font style="Background-color:#auto;text-decoration:none;">4.1.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_Hlk52524981"></a>Promptly following preparation and compilation of the final tables, listings and figures from the Relay Phase Ia Trial (the &#8220;</font><font style="font-weight:bold;color:#000000;">TLF</font><font style="color:#000000;">&#8221;), Relay will provide the same to Licensee.&nbsp;&nbsp;Within [***] after Licensee&#8217;s receipt of the TLF, Licensee will provide to Relay (a) a proposed, updated Global Development Plan, with the proposed updates thereto based in part on the TLF, other data and information created, conceived or generated in the conduct of the Relay Phase Ia Trial and on Licensee&#8217;s then good-faith plans with respect to Development of Lead Products (which Relay acknowledges may not be complete, with respect to all Licensee Combination Agents included in the initial Global Development Plan), (b) a good faith estimate of Development </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Costs incurred through such date for any Clinical Trials commenced by Licensee for Lead Products prior to such date (the &#8220;</font><font style="font-weight:bold;color:#000000;">Opt-In Data Package</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;Relay may exercise its Opt-In Right </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> </font><font style="color:#000000;">following receipt of the Opt-In Data Package in accordance with this Section </font><font style="color:#000000;">4.1.2</font><font style="color:#000000;"> (the &#8220;</font><font style="font-weight:bold;color:#000000;">Opt-In Deadline</font><font style="color:#000000;">&#8221;).</font><font style="color:#000000;">&nbsp;&nbsp;</font><font style="color:#000000;">For clarity, i</font><font style="color:#000000;">f Relay elects to exercise its Opt-In Right prior to receipt of the Opt-In Data Package </font><font style="color:#000000;">(including</font><font style="color:#000000;"> the amended Global Development Plan </font><font style="color:#000000;">contained therein)</font><font style="color:#000000;">, Relay shall have no right to revisit its election to exercise its Opt-In Right</font><font style="color:#000000;"> or object to the amended Global Development Plan</font><font style="color:#000000;">, provided that </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> and (b) Relay shall have the right to exercise its Opt-Out Right as provided in Section</font><font style="color:#000000;"> 4.2</font><font style="color:#000000;">.</font><font style="color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57192529"></a><font style="Background-color:#auto;text-decoration:none;">4.1.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If the TLF provided by Relay in accordance with Section 4.1.2 is incomplete, Licensee may notify Relay in writing of the incomplete status of such TLF in writing including any items that, in Licensee&#8217;s reasonable determination made in good faith, should have been included therein but were not included therein within [***] after receipt thereof.&nbsp;&nbsp;Following receipt of such notice, Relay will promptly deliver to Licensee the additional information requested by Licensee to complete the TLF. For clarity, delivery of such incomplete TLF will not trigger the [***] period for Licensee to provide to Relay the Opt-In Data Package, but such [***] period will thereafter be triggered on the date of Licensee&#8217;s receipt of the additional information requested by Licensee to complete the TLF.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.1.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If the Opt-In Data Package provided in accordance with Section 4.1.2 is incomplete, Relay may notify Licensee in writing of the incomplete status of such Opt-In Data Package in writing including any items that, in Relay&#8217;s reasonable determination made in good faith, should have been included therein but were not included therein within [***] after receipt thereof.&nbsp;&nbsp;Following receipt of such notice, Licensee will promptly deliver to Relay the additional information requested by Relay to complete the Opt-In Data Package. For clarity, delivery of such incomplete Opt-In Data Package will not trigger the [***] period after which the Opt-In Deadline would occur pursuant to Section 4.1.2, but such [***] period after which the Opt-In Deadline would occur pursuant to Section 4.1.2 will thereafter be triggered on the date of Relay&#8217;s receipt of the additional information requested by Relay to complete such Opt-In Data Package (such date of receipt in no event to exceed the [***] period described above). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.1.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Following delivery of the complete Opt-In Data Package, and prior to the Opt-In Deadline, Licensee will make its representatives reasonably available to Relay to discuss future Development of the Lead Products. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref52550841"></a><font style="Background-color:#auto;text-decoration:none;">4.1.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay will have the right, in its sole discretion, to exercise the Opt-In Right by delivering to Licensee by the Opt-In Deadline written notice of exercise (each such notice, the &#8220;</font><font style="font-weight:bold;color:#000000;">Opt-In Exercise Notice</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;If Relay provides an Opt-In Exercise Notice prior to the Opt-In Deadline, then (a) Relay will have exercised the Opt-In Right, and (b) the date of receipt of such Opt-In Exercise Notice will be the &#8220;</font><font style="font-weight:bold;color:#000000;">Opt-In Effective Date</font><font style="color:#000000;">&#8221;.&nbsp;&nbsp;If Relay fails to provide an Opt-In Exercise Notice prior to the Opt-In Deadline, the Opt-In Right will expire and be of no further force or effect.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.1.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">As of the Opt-In Effective Date, (a) Section 11.2 will apply with respect to the Shared Products and (b) notwithstanding anything to the contrary in Section 3.4, the proposed, updated Global Development Plan will be binding with respect to Shared Products in the Profit Share Territory until such plan is thereafter updated or amended in accordance with Section 3.4. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">If prior to the Opt-In Effective Date</font><font style="color:#000000;">,</font><font style="color:#000000;"> Licensee has paid to Relay </font><font style="color:#000000;">any </font><font style="color:#000000;">Development/Commercial Milestone, and Relay later exercises its Opt-In Right, then Relay will repay the corresponding</font><font style="color:#000000;"> </font><font style="color:#000000;">Development/Commercial Milestone Payment</font><font style="color:#000000;"> </font><font style="color:#000000;">to Licensee either (i) </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> following the Opt-In Effective Date or (ii) in equal installments due on or prior to the beginning of each of the next four (4) Calendar Quarters. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.1.8</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">As of the Opt-In Effective Date and prior to the Opt-Out Date, the Sections of this Agreement that apply to the Shared Products during the Opt-In Term shall apply. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57962701"></a><font style="Background-color:#auto;text-decoration:none;"> 4.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Opt-Out Right</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref50820323"></a><font style="Background-color:#auto;text-decoration:none;">4.2.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">At any time prior to the third (3<sup style="font-size:85%;line-height:120%;vertical-align:top">rd</sup>) anniversary of the First Commercial Sale of the first Shared Product in the Profit Share Territory, Relay has the right, at its sole discretion, to opt-out of further participation in co-funding Development and Commercialization activities for the Shared Products with respect to the Profit Share Territory by providing Licensee with written notice thereof, which election will become effective on the first day of the first Calendar Quarter that begins on or after the [***] anniversary of the date of such election (the &#8220;</font><font style="font-weight:bold;color:#000000;">Opt-Out Date</font><font style="color:#000000;">&#8221;) for the remainder of the Term (the &#8220;</font><font style="font-weight:bold;color:#000000;">Opt-Out Right</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;As of the Opt-Out Date and continuing for the remainder of the Term, (a) all Shared Products will automatically become Lead Royalty Products, (b) Licensee will be solely responsible for all Development Costs, Launch Costs and Commercialization costs for all Licensed Products in the Territory incurred thereafter, (c) Licensee will continue to comply with its diligence obligations in Section 3.6 and (d) Licensee will provide the reports in accordance with Sections 3.9.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref52217531"></a><a name="_Ref52535580"></a><font style="Background-color:#auto;text-decoration:none;">4.2.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In the event that Relay materially breaches its obligations to share Development Costs and Launch Costs with respect to the Shared Products in accordance with Section 11.3.1, and fails to cure such breach within [***] after written notice thereof is given by Licensee to Relay specifying the nature of the alleged breach, or Relay materially breaches its obligations under Article 9 (Exclusivity),  12.1 (Licenses), or  12.6 (Third Party Licenses), or its obligations under the SAE Management Plan, Quality Agreement, or the Pharmacovigilance Agreement, and fails to cure such breach within the applicable Cure Period set forth in Section 16.3 or such other agreement after written notice thereof is given by Licensee to Relay specifying the nature of the alleged breach, in lieu of exercising its termination right for such breach pursuant to Section 16.3.  Licensee will have the right to force the exercise by Relay of its Opt-Out Right upon written notice to Relay.&nbsp;&nbsp;In such case, (a) the consequences set forth in Section 4.2.1 will apply and (b) the date of such final written notice will be deemed to be the &#8220;Opt-Out Date.&#8221;&nbsp;&nbsp;Notwithstanding any such forced exercise of Relay&#8217;s Opt-Out Right, Relay shall remain responsible for its share of all Development Costs and Launch Costs for Shared Products incurred during the Opt-In Term, and shall not be entitled to any reimbursement for any such Development Costs or Launch Costs.&nbsp;&nbsp;Licensee may offset any amounts due from Relay pursuant to Section 11.3.2 and not paid as of the Opt-Out Date against any subsequent payments due from Licensee to Relay hereunder.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Toc529816434"></a><a name="_Toc529966468"></a><a name="_Toc50796654"></a><a name="_Toc51338583"></a><a name="_Toc53919200"></a><a name="_Toc53925684"></a><a name="_Ref38613567"></a><a name="_Ref530828777"></a><font style="Background-color:#auto;text-decoration:none;">Article 5.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><br /><a name="_Toc50796654"></a><a name="_Toc51338583"></a><a name="_Toc53919200"></a><a name="_Toc53925684"></a>Commercialization.<a name="_Ref38613567"></a><a name="_Ref530828777"></a>&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref50913126"></a><a name="_Ref53489213"></a><a name="_Ref54718308"></a><a name="_Ref52087142"></a><a name="_Ref530826011"></a><font style="Background-color:#auto;text-decoration:none;"> 5.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">General</font><font style="color:#000000;">.&nbsp;&nbsp;Subject to the terms and conditions set forth in this Agreement, Licensee will conduct Commercialization activities for the Licensed Products in the Field in the Territory as further set forth in this Article 5.&nbsp;&nbsp;Licensee shall have the sole right and responsibility for all Commercialization activities relating to the Licensed Products in the Field in the Territory, subject to Relay&#8217;s Coordinated Promotion Right<a name="_Ref50913126"></a><a name="_Ref53489213"></a><a name="_Ref54718308"></a><a name="_Ref52087142"></a><a name="_Ref530826011"></a>, including its retained rights in Section 12.1.1 and its rights in Section 16.9.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref38709658"></a><font style="Background-color:#auto;text-decoration:none;"> 5.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Commercialization Costs with Respect to Licensed Products</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:13.46%;text-indent:1.92%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref39113889"></a><a name="_Hlk38678733"></a><font style="Background-color:#auto;text-decoration:none;">5.2.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Profit Share Territory</font><font style="color:#000000;">.<a name="_Hlk38678733"></a> In the Profit Share Territory: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If Relay exercises its Opt-In Right, then during the Opt-In Term the Parties will share Net Profits and Net Losses in accordance with the Sharing Percentages pursuant to Section 11.3.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If Relay exercises its Opt-Out Right, then Licensee will be responsible for all costs and expenses incurred during the period from the Opt-Out Date for the remainder of the Term.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk38667561"></a><font style="Background-color:#auto;text-decoration:none;">5.2.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Royalty Territory</font><font style="color:#000000;">.&nbsp;&nbsp;As between the Parties, Licensee will be responsible for [***] costs and expenses incurred for [***] Commercialization activities for the Licensed Products in the Royalty Territory.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref54189412"></a><font style="Background-color:#auto;text-decoration:none;"> 5.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Sales and Distribution</font><font style="color:#000000;">.&nbsp;&nbsp;Notwithstanding anything to the contrary contained in this Agreement, Licensee and its Affiliates and Sublicensees will, as between the Parties, have the sole right to book sales, warehouse and distribute Licensed Products in the Field in the Territory, subject to Relay&#8217;s rights in Section 16.9. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref39114719"></a><a name="_Ref52279931"></a><font style="Background-color:#auto;text-decoration:none;"> 5.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Recalls, Market Withdrawals or Corrective Actions</font><font style="color:#000000;">.&nbsp;&nbsp;In the event that any Regulatory Authority issues or requests a recall or takes a similar action in connection with a Licensed Product in the Field in the Territory, Licensee will, as between the Parties, have the sole right to decide whether to conduct a recall, market withdrawal, or corrective action and the manner in which any such recall, market withdrawal, or corrective action will be conducted.&nbsp;&nbsp;Without limiting any indemnification obligation Relay may have under this Agreement, (a) if such recall, market withdrawal or corrective action occurs during the Opt-In Term, all such costs and expenses in the Profit Share Territory will be treated as Allowable Expenses (as applicable), (b) if such recall, market withdrawal or corrective action occurs outside the Opt-In Term, Licensee will bear the costs and expenses of any such recall, market withdrawal or corrective action in the former Profit Share Territory, and (c) Licensee will bear the costs and expenses of any such recall, market withdrawal or corrective action in the Royalty Territory.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc529816214"></a><a name="_Toc529816325"></a><a name="_Toc529816435"></a><a name="_Toc529816215"></a><a name="_Toc529816326"></a><a name="_Toc529816436"></a><a name="_Toc529816216"></a><a name="_Toc529816327"></a><a name="_Toc529816437"></a><a name="_Ref54189415"></a><a name="_Toc525806029"></a><a name="_Toc529816438"></a><a name="_Ref529960272"></a><a name="_Toc529966472"></a><a name="_Ref529614748"></a><a name="_Ref50814851"></a><font style="Background-color:#auto;text-decoration:none;"> 5.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Pricing; Combination Products</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.5.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Pricing</font><font style="color:#000000;">.&nbsp;&nbsp;Licensee shall have the sole right and responsibility to set the price of Licensed Products, including in Combination Use.&nbsp;&nbsp;[***].&nbsp;&nbsp;Relay acknowledges that pricing </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">takes into consideration multiple factors as mentioned above that in the totality may result in pricing the Licensed Candidate or Licensed Product higher or lower than other such pharmaceutical products Commercialized by or on behalf of a Third Party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:13.46%;text-indent:1.92%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref55635753"></a><a name="_Ref52551265"></a><a name="_Ref52296718"></a><font style="Background-color:#auto;text-decoration:none;">5.5.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Combination Products</font><font style="color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref55475440"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;color:#000000;">Combination Product</font><font style="color:#000000;">&#8221; [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If Licensee or its Affiliates or Sublicensees sell a Licensed Product in a Combination Product, then the Sales for such Licensed Product shall be calculated by [***]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref54196261"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In the event that such other active ingredient(s) are not sold separately (but such Licensed Product is), the Sales for such Licensed Product shall be calculated by [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In the event that such Licensed Product is not sold separately (but such other active ingredient(s) is), the Sales for such Licensed Product shall be calculated by [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref55212885"></a><a name="_Hlk56063505"></a><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In the event that Licensee or its Affiliates intend to sell a Combination Product, and do not intend to sell either the Licensed Product or the other active ingredient(s) included in the Combination Product separately, then [***]. In such event, or&nbsp;&nbsp;otherwise in the event that neither the Licensed Product nor the other active ingredient(s) include in a Combination Product are sold separately, the Parties will engage in good faith negotiations for up to [***] to determine the Relative Commercial Value, such negotiations to take into consideration: [***].&nbsp;&nbsp;If during such time Licensee and Relay cannot agree on the Relative Commercial Value, the Dispute will be referred to the Executive Officers in accordance with Section 18.9.2. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref50824262"></a><a name="_Ref38675935"></a><a name="_Toc529816439"></a><a name="_Toc529966473"></a><a name="_Ref521644881"></a><a name="_Toc524107352"></a><font style="Background-color:#auto;text-decoration:none;"> 5.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;"><a name="_Ref38675935"></a><a name="_Toc529816439"></a><a name="_Toc529966473"></a><a name="_Ref521644881"></a><a name="_Toc524107352"></a>Coordinated Promotion Right in Connection with Relay Pipeline Combinations</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref50883064"></a><a name="_Ref50587004"></a><a name="_Ref54195306"></a><a name="_Ref52375484"></a><a name="_Hlk50883392"></a><font style="Background-color:#auto;text-decoration:none;">5.6.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">During the Term, Relay will have the right to co-promote the Relay Pipeline Combination Eligible Licensed Products solely for Combination Use in Relay Pipeline Combinations, throughout the Territory in coordination with Licensee and in compliance with this Agreement and the applicable Coordinated Promotion Agreement (the &#8220;</font><font style="font-weight:bold;color:#000000;">Coordinated Promotion Right</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;At least [***] prior to the date of the anticipated submission of the first NDA for a Relay Pipeline Product that will be marketed as a Relay Pipeline Combination anywhere in the Territory (or such other time as may be mutually agreed by the Parties), the JDT will form a JPT pursuant to Section 10.3.&nbsp;&nbsp;Through the JPT, Licensee will have the right to review and provide comments on Relay&#8217;s Commercialization activities for such Relay Pipeline Combination (including choice of any contract sales organization, if any are proposed to be used by Relay), which comments Relay will consider in good faith, and if necessary or desirable by Relay, will modify Relay&#8217;s Commercialization activities in a manner to avoid negative impact on Licensee&#8217;s Commercialization activities for the relevant Licensed Product.&nbsp;&nbsp;Relay shall not co-package or co-formulate the Relay Pipeline Compound in a Relay Pipeline Combination with the Licensed Candidate without Licensee&#8217;s prior approval, such approval to be in Licensee&#8217;s discretion.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref50996674"></a><font style="Background-color:#auto;text-decoration:none;">5.6.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">At least [***] prior to the date of the anticipated submission of the first NDA for a Relay Pipeline Combination, the Parties will negotiate in good faith and enter into a </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">written agreement that sets forth the terms of the Parties&#8217; activities with respect to the promotion of the Relay </font><font style="color:#000000;">Pipeline Combination </font><font style="color:#000000;">throughout the Territory, such terms to be consistent with the high-level terms and principles set forth in this Section</font><font style="color:#000000;"> 5.6</font><font style="color:#000000;"> (each such agreement, a &#8220;</font><font style="font-weight:bold;color:#000000;">Coordinated Promotion Agreement</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;The Parties will coordinate the promotion of the Relay Pipeline Combinations in the Territory pursuant to the terms and conditions of this Agreement and the Coordinated Promotion Agreement</font><font style="color:#000000;">, </font><font style="color:#000000;">[***]</font><font style="color:#000000;">, subject to Section</font><font style="color:#000000;"> 16.9</font><font style="color:#000000;">.</font><font style="color:#000000;">&nbsp;&nbsp;Subject to Section </font><font style="color:#000000;">8.1.4</font><font style="color:#000000;">,</font><font style="color:#000000;"> Relay will be entitled to employ a contract sales organization to </font><font style="color:#000000;">perform </font><font style="color:#000000;">any of its obligations under a Coordinated Promotion Agreement.&nbsp;&nbsp;Costs and expenses incurred by or on behalf of a Party under any Coordinated Promotion Agreement will be borne as set forth in the Coordinated Promotion Agreement.</font><font style="color:#000000;"> </font><font style="color:#000000;"> In the event that the Parties cannot reach resolution on a definitive Coordinated Promotion Agreement within </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> </font><font style="color:#000000;">prior to the </font><font style="color:#000000;">date of the anticipated submission of the first NDA for a Relay Pipeline Combination, then </font><font style="color:#000000;">such </font><font style="color:#000000;">D</font><font style="color:#000000;">ispute in accordance with Section</font><font style="color:#000000;"> 16.10</font><font style="color:#000000;"> </font><font style="font-style:italic;color:#000000;">mutatis mutandis</font><font style="color:#000000;">. </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Ref38678696"></a><a name="_Ref39115608"></a><a name="_Toc50796655"></a><a name="_Toc51338584"></a><a name="_Toc53919201"></a><a name="_Toc53925685"></a><font style="Background-color:#auto;text-decoration:none;">Article 6.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><br /><a name="_Ref39115608"></a><a name="_Toc50796655"></a><a name="_Toc51338584"></a><a name="_Toc53919201"></a><a name="_Toc53925685"></a>Regulatory Responsibilities</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521644882"></a><font style="Background-color:#auto;text-decoration:none;"> 6.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Regulatory Lead Responsibilities</font><font style="color:#000000;">.&nbsp;&nbsp;Subject to Section 5.4, the Regulatory Lead will be solely responsible for all regulatory matters in the Field in the applicable Territory relating to the Licensed Candidates, Licensed Products, [***] Combinations, and Relay Pipeline Combinations for which such Party is the Regulatory Lead.&nbsp;&nbsp;The Regulatory Lead will own all INDs, NDAs, Regulatory Approvals, Regulatory Materials, and related regulatory documents in the Field in the Territory with respect to such Licensed Candidates, Licensed Products, [***] Pipeline Compounds, [***] Combinations, Relay Pipeline Products and Relay Pipeline Combinations including any drug master files maintained by such Regulatory Lead solely with respect thereto in the Territory.&nbsp;&nbsp;Notwithstanding anything herein to the contrary, the Regulatory Lead responsibilities with respect to Relay and Relay Pipeline Combinations apply only to the Relay Pipeline Products contained in a Relay Pipeline Combinations and the Relay Pipeline Combination taken as a whole but not with respect to the Relay Pipeline Combination Eligible Licensed Product contained therein on its own.&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;"> 6.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Drug Master Files</font><font style="color:#000000;">.&nbsp;&nbsp;If Licensee does not have access to or rights to cross reference any drug master files maintained by any Third Party (including any contract manufacturer) pursuant to Section 6.4 reasonably sufficient to permit Licensee to exercise its rights and comply with its regulatory obligations, in each case, in connection with the Development, Manufacture and Commercialization of Licensed Candidates or Licensed Products in the Field in the Territory under this Agreement, then, (a) with respect to any agreement between Relay and any such Third Party that exists as of the Effective Date, Relay will use Commercially Reasonable Efforts to secure for Licensee such reasonably sufficient access to or rights to cross reference any such drug master files maintained by such Third Party, and (b) with respect to any agreement between Relay and any such Third Party that is entered into on or after the Effective Date, Relay shall use Commercially Reasonable Efforts to secure for Licensee such reasonably sufficient access to or rights to cross reference any such drug master files maintained by such Third Party solely with respect to Licensed Candidates or Licensed Products.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref55456193"></a><a name="_Ref57838090"></a><a name="_Ref50885053"></a><a name="_Hlk50883408"></a><font style="Background-color:#auto;text-decoration:none;"> 6.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Relay Phase Ia Trial</font><font style="color:#000000;">.&nbsp;&nbsp;This Section 6.3 will apply to the conduct of the Relay Phase Ia Trial.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref55583823"></a><font style="Background-color:#auto;text-decoration:none;">6.3.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Prior to Relay IND Transfer Date</font><font style="color:#000000;">.&nbsp;&nbsp;While Relay is acting as Sponsor of the Relay Phase Ia Trial, the following shall apply:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay will immediately provide Licensee (through the JDT after it is formed) each Material Communication from or with Regulatory Authorities with respect to the Relay Phase Ia Trial.&nbsp;&nbsp;Relay will further provide descriptions of and copies of such Material Communications as part of the updates to the JDT regarding Development activities described in Section 3.9 after the JDT is formed.&nbsp;&nbsp;With respect to any Material Communication with a Regulatory Authority, Relay will allow Licensee a reasonable opportunity to review and comment on such proposed Material Communication or response thereto in advance of submission to the Regulatory Authority, and will reasonably consider all comments timely provided by Licensee in connection therewith. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay will provide Licensee with reasonable advance notice of all meetings with the Governmental Authorities pertaining to the Relay Phase Ia Trial, or with as much advance notice as practicable under the circumstances.&nbsp;&nbsp;If permitted by the relevant Governmental Authority, Licensee may have up to [***] representatives attend all such meetings; provided that Licensee will not select representatives to attend such meetings whose availability would unreasonably delay any such meeting.  Relay will also provide Licensee, in advance of such meetings, with any briefing documents or other materials associated with these meetings, will participate with Licensee in a pre-meeting to prepare for such meeting, and will reasonably consider all comments timely provided by Licensee in connection therewith.&nbsp;&nbsp;If a Governmental Authority contacts Licensee with respect to the Relay Phase Ia Trial, Licensee shall immediately inform Relay of the same and the Parties will coordinate on a response.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk50883422"></a><a name="_Ref50885106"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay will provide Licensee with a copy of all proposed material regulatory submissions with respect to the Relay Phase Ia Trial for the other Party&#8217;s review and comment sufficiently in advance of Relay&#8217;s filing or submission thereof, and Relay will reasonably consider all comments timely provided by Licensee in connection therewith (and Licensee&#8217;s approval will be required to the extent Licensee has final say on such submission or the matter to which such submission relates as provided in 10.7.3(b)). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref55585139"></a><font style="Background-color:#auto;text-decoration:none;">6.3.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">After Relay IND Transfer Date</font><font style="color:#000000;">.&nbsp;&nbsp;While Licensee is acting as Sponsor of the Relay Phase Ia Trial, the following shall apply:</font><font style="text-decoration:underline;color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licensee will immediately provide Relay any communication received by Licensee from Governmental Authorities with respect to the Relay Phase Ia Trial. Relay will reasonably assist in responding to queries of Governmental Authorities as requested by Licensee, including providing to Licensee immediately (within [***]) after request any data and information in Relay&#8217;s Control that was not previously transferred to Licensee and that Licensee reasonably determines is necessary or desirable to respond to any such query.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay will reasonably assist in preparing regulatory submissions and responding to queries from Governmental Authorities with respect to the Relay Phase Ia Trial as requested by Licensee, including the portions of any regulatory filing documentation relating to the Manufacture and supply of Phase Ia Product for the Relay Phase Ia Trial or other activities and responsibilities conducted by Relay in connection with the Relay Phase Ia Trial.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If </font><font style="color:#000000;">reasonably</font><font style="color:#000000;"> requested by Licensee, Relay will make appropriate Relay representatives available to participate in meetings with Government</font><font style="color:#000000;">al</font><font style="color:#000000;"> Authorities pertaining to the Relay Phase Ia Trial</font><font style="color:#000000;"> or in pre-meetings with Licensee to prepare for such meetings</font><font style="color:#000000;">.&nbsp;&nbsp;Licensee will make such request reasonably in advance of the meeting, or with as much advance notice as practicable under the circumstances.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay shall reasonably cooperate with Licensee and provide any other assistance reasonably requested by Licensee with respect to any such regulatory activities conducted by Licensee with respect to the Relay Phase Ia Trial. &nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57991385"></a><a name="_Ref56095881"></a><a name="_Ref39116479"></a><a name="_Ref57836953"></a><font style="Background-color:#auto;text-decoration:none;"> 6.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Ongoing Support for Development</font><font style="color:#000000;">.&nbsp;&nbsp;Relay will also use Commercially Reasonable Efforts to support Licensee as reasonably requested in support of preparation, submission and prosecution of&nbsp;&nbsp;regulatory submissions to, and responding to queries from, Governmental Authorities for Licensee Combinations, including preparation (data cleaning, tables and listings) of data to support dose decisions, Phase Ib Clinical Trial study design and preparation and summaries of data sets to support global filings and assistance with requests from Governmental Authorities related to new and existing data, dose justification and safety, preclinical experiments and assays conducted by Relay</font><font style="font-family:Calibri;color:#000000;">.</font><font style="color:#000000;">&#160; &#160;&#160;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref58510904"></a><font style="Background-color:#auto;text-decoration:none;"> 6.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Right of Reference</font><font style="color:#000000;">.&nbsp;&nbsp;Each Party hereby grants to the other Party, and at the request of the other Party will grant to the other Party&#8217;s Affiliates and Sublicensees, a </font><font style="font-weight:bold;color:#000000;">&#8220;Right of Reference,&#8221;</font><font style="color:#000000;"> as that term is defined in 21 C.F.R. &#167; 314.3(b) (or any successor rule or analogous Applicable Law recognized outside of the United States), to, and a right to copy, access, and otherwise use, all information and data (including all CMC information as well as data made, collected, or otherwise generated in the conduct of any Clinical Trials, or early access/named patient programs for any Licensed Candidates or Licensed Products included in or used in support of any regulatory filing, Regulatory Approval, drug master file) or other regulatory documentation (including orphan drug applications and designations) Controlled by such Party or its Affiliates or Sublicensees that relates to any Licensed Candidates or Licensed Products solely for the purpose of (a) in the case of Licensee, obtaining or maintaining any IND or Regulatory Approval of any Licensed Candidates or Licensed Products (including any Licensee Combination) or (b) in the case of Relay, obtaining or maintaining any IND or Regulatory Approval for any Relay Pipeline Combination or Relay Pipeline Product.&nbsp;&nbsp;Licensee will provide Relay with copies of Regulatory Materials related to any Relay Pipeline Combination Eligible Licensed Products that are reasonably requested by Relay for use by or on behalf of Relay, its Affiliates or Relay Sublicensees in connection with Developing, Manufacturing or Commercializing any Relay Pipeline Combination as permitted hereunder.&nbsp;&nbsp;In addition, upon the reasonable request of the other Party (on behalf of itself or a Sublicensee), each Party will provide a signed statement to this effect, if requested by the other Party, in accordance with 21 C.F.R. &#167; 314.50(g)(3) (or any successor or analogous Applicable Law outside of the United States) that the other Party may rely on, and the Regulatory Authority may access, in support of the other Party&#8217;s application for Regulatory Approval in its Territory, any underlying raw data or information submitted by such Party to the Regulatory Authority with respect to any regulatory submission, Regulatory Approval, drug master file, or other regulatory documentation (including orphan drug applications and designations) Controlled by such Party or its Affiliates or Sublicensees that relates to any Licensed Candidates or Licensed Products or Licensee Combinations or Relay Pipeline Combinations, as applicable.&nbsp;&nbsp;In addition, upon reasonable request of either Party (on behalf of itself or a </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Sublicensee), the other Party will obtain and provide to the requesting Party certificates or other formal or official attestations concerning the regulatory status of any Licensed Candidates or Licensed Products or Licensee Combinations or Relay Pipeline Combinations, as applicable, in the Territory (e.g., Certificates of Free Sale, Certificates for Export, Certificates to Foreign Governments), in each case, as is reasonably necessary for the requesting Party to exercise its rights under this Agreement.&nbsp;&nbsp;</font><font style="color:#000000;">Other than for safety concerns, notwithstanding anything in this Agreement to the contrary, neither Party will withdraw or inactivate any regulatory filing that the other Party references or otherwise uses pursuant to this Section </font><font style="color:#000000;"> 6.5</font><font style="color:#000000;"> unless otherwise mutually agreed by the Parties.</font><font style="color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref52307729"></a><a name="_Ref57184466"></a><font style="Background-color:#auto;text-decoration:none;"> 6.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Pharmacovigilance</font><font style="color:#000000;">.&nbsp;&nbsp;Upon the request of a Party, the Parties will negotiate in good faith and enter into a separate pharmacovigilance agreement at least [***] prior to filing the IND for the first Relay Pipeline Compound in a Relay Pipeline Combination (the &#8220;</font><font style="font-weight:bold;color:#000000;">Pharmacovigilance Agreement</font><font style="color:#000000;">&#8221;), which will govern the exchange of safety data information, adverse events reporting and Licensed Product complaints to ensure timely communication to Regulatory Authorities and compliance with Applicable Law.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;"> 6.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Costs of Regulatory Affairs</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.7.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">During the Opt-In Term, [***].&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.7.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Outside the Opt-In Term, [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.7.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">During the Opt-In Term, [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521644885"></a><a name="_Ref530773261"></a><a name="_Ref529708139"></a><a name="_Hlk38678417"></a><font style="Background-color:#auto;text-decoration:none;">6.7.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay will be responsible for [***]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;"> 6.8</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">NDA [***]</font><font style="color:#000000;">. It is understood and acknowledged that, for each Relay Pipeline Combination, Relay [***]. If, after using Commercially Reasonable Efforts [***], Relay anticipates, based upon reasonable inquiry with the applicable Regulatory Authority, that [***] may be required, then at least [***] prior to filing [***] for such Relay Pipeline Combination, Relay will provide written notice to Licensee of such potential requirement, and the Parties will cooperate to review and discuss potential alternatives [***], including [***].</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Toc529816440"></a><a name="_Toc529966474"></a><a name="_Ref39403221"></a><a name="_Toc50796656"></a><a name="_Toc51338585"></a><a name="_Toc53919202"></a><a name="_Toc53925686"></a><font style="Background-color:#auto;text-decoration:none;">Article 7.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><br /><a name="_Ref39403221"></a><a name="_Toc50796656"></a><a name="_Toc51338585"></a><a name="_Toc53919202"></a><a name="_Toc53925686"></a>Manufacturing.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref50902740"></a><a name="_Ref38881292"></a><font style="Background-color:#auto;text-decoration:none;"> 7.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Generally.</font><font style="color:#000000;">&nbsp;&nbsp;Except as otherwise expressly provided in Section 7.2, Licensee shall have the sole right and responsibility for the Manufacturing and supplying of Licensed Candidates and Licensed Products for clinical supply or commercial supply, except for the supplying of the Phase Ia Product as described below.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref55634434"></a><a name="_Ref56255907"></a><font style="Background-color:#auto;text-decoration:none;"> 7.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Responsibilities for Supply.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.2.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay will be responsible (itself or via a CMO), at its expense, for supplying the Phase Ia Product required for the Relay Phase Ia Trial conducted under the Relay Phase Ia Plan as such plan exists as of the Execution Date or as may be modified in accordance with Section 3.3.2 or 3.4.2, as applicable, except that if Relay runs out of such Phase Ia Product in its inventory </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">and is unable to supply thereafter, Licensee will supply, at its expense, by itself or via a CMO, the Phase Ia Product for the remainder of </font><font style="color:#000000;">the Phase Ia </font><font style="color:#000000;">Clinical </font><font style="color:#000000;">Trial</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref39116729"></a><font style="Background-color:#auto;text-decoration:none;">7.2.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">During the&nbsp;&nbsp;Term, Licensee will be responsible (itself or via a CMO), at its expense, for Manufacturing and supplying any Licensed Candidate or Licensed Product required for the Development or Commercialization of such Licensed Candidate or Licensed Product, except that for clinical supply of Shared Products under the Global Development Plan, Relay&#8217;s obligations with respect to reimbursement of its share of Development Costs for Shared Products pursuant to Section 11.2 shall apply.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56098299"></a><a name="_Ref50902784"></a><a name="_Ref56086626"></a><a name="_Hlk57216808"></a><font style="Background-color:#auto;text-decoration:none;">7.2.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_Hlk57216808"></a>Subject to Sections 7.2.4 and 16.9, Licensee will have the sole right and responsibility (itself or via a CMO), subject to Relay&#8217;s back-up rights in accordance with the Supply Agreement, for Manufacturing and supplying Finished Products that Licensee is then-currently Manufacturing for the Development of Licensee Combinations&nbsp;&nbsp;for clinical supply for the Development activities for Relay Pipeline Combinations.&nbsp;&nbsp;If Licensee supplies such Finished Products under this Section 7.2.3, then Licensee will provide such clinical supply at Licensee&#8217;s expense.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1254"></a><a name="_BPDC_PR_INS_1255"></a><a name="_Ref56332801"></a><a name="_Ref52318370"></a><a name="_Ref54196653"></a><font style="Background-color:#auto;text-decoration:none;">7.2.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Promptly after the Effective Date, and in any event within [***] following the Effective Date, the Parties will negotiate in good faith, and execute, a definitive supply agreement pursuant to which Licensee will supply such clinical supply of Finished Product to Relay (&#8220;</font><font style="font-weight:bold;color:#000000;">Supply Agreement</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;[***]. Notwithstanding anything in the foregoing, whether or not the Supply Agreement has been executed, Relay shall provide an initial forecast to Licensee at least [***] prior to anticipated <a name="_Ref52318370"></a><a name="_Ref54196653"></a>commencement of its Clinical Trial for which such supply is requested for Licensee&#8217;s planning purposes. </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Toc529816220"></a><a name="_Toc529816331"></a><a name="_Toc529816441"></a><a name="_Ref521646912"></a><a name="_Toc522731571"></a><a name="_Toc524107354"></a><a name="_Toc529816443"></a><a name="_Toc529966476"></a><a name="_Ref521644892"></a><a name="_Toc50796657"></a><a name="_Ref51335526"></a><a name="_Ref51335577"></a><a name="_Toc51338586"></a><a name="_Toc53919203"></a><a name="_Toc53925687"></a><font style="Background-color:#auto;text-decoration:none;">Article 8.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><br /><a name="_Toc50796657"></a><a name="_Ref51335526"></a><a name="_Ref51335577"></a><a name="_Toc51338586"></a><a name="_Toc53919203"></a><a name="_Toc53925687"></a>Compliance Provisions</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521644893"></a><font style="Background-color:#auto;text-decoration:none;"> 8.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">General</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref53489721"></a><font style="Background-color:#auto;text-decoration:none;">8.1.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Compliance with Laws</font><font style="color:#000000;">.&nbsp;&nbsp;Each Party shall use Commercially Reasonable Efforts to conduct, and to ensure its Affiliates and Third Party Subcontractors conduct, all activities hereunder in compliance with all Applicable Law.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57983189"></a><font style="Background-color:#auto;text-decoration:none;">8.1.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Debarment</font><font style="color:#000000;">.&nbsp;&nbsp;Each Party hereby certifies that it is not, and that to its Knowledge it has not employed or otherwise used, and will not knowingly employ or otherwise use, the services of any Person (including any employee, officer, director, Affiliate or Third Party contractor)&nbsp;&nbsp;that is (a) debarred under United States law (including 21 USC &#167;335a), disqualified under 21 C.F.R. Parts 56, 58 or 312, or any foreign equivalent thereof or (b) the subject of an HHS or FDA debarment or disqualification investigation or proceeding (or similar proceeding by any Regulatory Authority outside the United States), in each case, in the performance of Development or Commercialization activities under this Agreement.&nbsp;&nbsp;Each Party will notify the other Party in writing promptly if any such debarment or disqualification comes to its attention, and will, with respect to any Person or entity so debarred promptly remove such Person or entity from performing any such activities.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57983192"></a><a name="_Ref521644896"></a><font style="Background-color:#auto;text-decoration:none;">8.1.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Violations</font><font style="color:#000000;">.&nbsp;&nbsp;Each Party hereby certifies that it is not in Violation, and that to its Knowledge it has not employed or used, and will not employ or otherwise use, the services of any Person (including any employee, officer, director, Affiliate or Third Party contractor) who is in Violation in the performance of Development or Commercialization activities under this Agreement.&nbsp;&nbsp;Each Party will notify the other Party in writing promptly if any such Violation comes to its attention.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref55564711"></a><a name="_Ref57631438"></a><a name="_Ref58230365"></a><a name="_Ref50916415"></a><a name="_Ref54757409"></a><a name="_Hlk58229953"></a><font style="Background-color:#auto;text-decoration:none;">8.1.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Subcontractors</font><font style="color:#000000;">.&nbsp;&nbsp;Each Party will be entitled to utilize the services of Third Party Subcontractors to perform activities under this Agreement, provided that (a) the Party engaging a Third Party Subcontractor (the &#8220;</font><font style="font-weight:bold;color:#000000;">Subcontracting Party</font><font style="color:#000000;">&#8221;) will require that such Third Party Subcontractor satisfies its obligations in a manner consistent with the terms of this Agreement and (b) the Subcontracting Party will remain at all times fully liable for such Party&#8217;s responsibilities and for any actions or omissions by such Third Party Subcontractor that may be a breach of this Agreement, subject to the last sentence of Section 16.3<a name="_Hlk58229953"></a>.&nbsp;&nbsp;Each Third Party Subcontractor Agreement entered into by a Party after the Effective Date will (i) include confidentiality and non-use provisions that are substantially similar to those set forth in Article 13 (but of duration customary in confidentiality agreements entered into for a similar purpose); and (ii) assign ownership of, or grant a fully sublicensable license under and to, any Know-How and Patents that are created, conceived or generated by such Third Party Subcontractor in the performance of such agreement and are necessary or reasonably useful to Research, Develop, Manufacture or Commercialize Licensed Candidates or Licensed Products.&nbsp;&nbsp;For clarity, the foregoing requirement to obtain ownership of, or a fully sublicensable license will not apply to any improvements to the proprietary core or platform technology owned or in-licensed by any such Third Party Subcontractor or its Affiliates unless such improvements are necessary or reasonably useful to Research, Develop, Manufacture or Commercialize those Licensed Candidates or Licensed Products with respect to which a Party or its Affiliate conducted its activities under such Third Party Subcontractor Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Toc524107355"></a><a name="_Ref529025857"></a><a name="_Toc529816444"></a><a name="_Toc529966477"></a><a name="_Ref530175407"></a><a name="_Ref530773275"></a><a name="_Ref530777820"></a><a name="_Ref530823560"></a><a name="_Ref530831903"></a><a name="_Ref530837595"></a><a name="_Ref524016311"></a><a name="_Ref524017229"></a><a name="_Toc50796658"></a><a name="_Toc51338587"></a><a name="_Ref52534851"></a><a name="_Ref53060040"></a><a name="_Toc53919204"></a><a name="_Toc53925688"></a><a name="_Ref521644897"></a><a name="_Ref526450737"></a><font style="Background-color:#auto;text-decoration:none;">Article 9.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><br /><a name="_Toc50796658"></a><a name="_Toc51338587"></a><a name="_Ref52534851"></a><a name="_Ref53060040"></a><a name="_Toc53919204"></a><a name="_Toc53925688"></a>Exclusivity.<a name="_Ref521644897"></a><a name="_Ref526450737"></a>&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref528621488"></a><font style="Background-color:#auto;text-decoration:none;"> 9.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">General</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref528530463"></a><a name="_Ref531700329"></a><font style="Background-color:#auto;text-decoration:none;">9.1.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Commencing on the Effective Date and continuing until the third (3<sup style="font-size:85%;line-height:120%;vertical-align:top">rd</sup>) anniversary of the First Commercial Sale of the first Licensed Product (whether a Shared Product or a Royalty Product) in the Territory (or Profit Share Territory, as applicable), except for the performance of activities in accordance with this Agreement and the Supply Agreement, neither Relay nor its Affiliates will directly or indirectly, Research, Develop, Manufacture or Commercialize any molecule Directed to the Collaboration Target; provided that Relay and its Affiliates may directly or indirectly Develop the Relay Pipeline Combination Eligible Licensed Products and co-promote, in coordination with Licensee and in accordance with this Agreement and any applicable Coordinated Promotion Agreement, the Relay Pipeline Combination Eligible Licensed Products, in each case solely for Combination Use in Relay Pipeline Combinations.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref52513217"></a><a name="_Ref50554648"></a><a name="_Ref530752693"></a><a name="_Ref530822920"></a><font style="Background-color:#auto;text-decoration:none;">9.1.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Commencing on the Effective Date and continuing until the third (3<sup style="font-size:85%;line-height:120%;vertical-align:top">rd</sup>) anniversary thereof, Genentech will cause gRED not to conduct a Pivotal Trial for a molecule </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Directed to the Collaboration Target other than a Licensed Candidate or Licensed Product pursuant to this Agreement</font><font style="color:#000000;"> </font><font style="color:#000000;">[***]</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref532586314"></a><a name="_Ref532586655"></a><a name="_Ref532824873"></a><a name="_Ref532854298"></a><a name="_Ref532819734"></a><a name="_Ref55296256"></a><a name="_Hlk58229933"></a><font style="Background-color:#auto;text-decoration:none;">9.1.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notwithstanding anything herein to the contrary, Relay and its Affiliates will have the right to <a name="_Hlk58229933"></a>[***], (ii) as between Licensee and Relay, Relay will remain at all times fully liable for any actions or omissions by such Third Party that may be a breach of this Agreement, subject to the last sentence of Section  16.3, and (iii) Relay or its Affiliate obtain exclusive ownership in the Field of, or a fully sublicensable exclusive license in the Field (or, solely with respect to an academic institution, university or non-commercial Third Party, an option to obtain or negotiate such license limited to Patents) under and to, any Know-How and Patents specifically related to such Licensed Candidates that are created, conceived or generated by such Third Party in the exercise of such rights under such agreement and (iv) and the right to share data and reports with Licensee and for Licensee to use such data and reports in accordance with the rights granted hereunder; provided, further, that in each case of (a) and (b) above, [***].&nbsp;&nbsp;For the avoidance of doubt, notwithstanding anything to the contrary in Section 13.6, Relay and its Affiliates may not make any Publication with respect to activities conducted pursuant to this Section 9.1.3 without the prior written approval of Licensee in its sole and absolute discretion.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref38728538"></a><a name="_Ref524006536"></a><a name="_Ref524006929"></a><a name="_Ref522270926"></a><font style="Background-color:#auto;text-decoration:none;"> 9.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Acquired Programs</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref530752722"></a><a name="_Ref529619543"></a><a name="DocXTextRef2595"></a><font style="Background-color:#auto;text-decoration:none;">9.2.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Acquired Programs Generally</font><font style="color:#000000;">.&nbsp;&nbsp;Notwithstanding Section 9.1,<a name="_Ref530752722"></a> in the event<a name="_Ref529619543"></a> Relay or its Affiliate acquires a Third Party (by merger, sale, consolidation, reorganization, or other Change of Control) so that such Third Party becomes an Affiliate of Relay, or Relay or its Affiliate acquires all or substantially all of the assets of a Third Party (including any subsidiaries or divisions thereof), and as of the date of such acquisition, such Third Party has, or the acquired assets contain a program or product that existed prior to such acquisition that would otherwise violate Section 9.1 (an &#8220;</font><font style="font-weight:bold;color:#000000;">Acquired Program</font><font style="color:#000000;">&#8221;), then Relay will not be deemed to be in violation of Section 9.1 provided that <a name="DocXTextRef2595"></a>Relay either (a)&#160;divests its rights to such Acquired Program in accordance with Section 9.2.2, or (b)&#160;terminates such Acquired Program in accordance with Section 9.2.3, and, in each case ((a) or (b)), provides prompt written notice to Licensee within [***] after the closing of the acquisition of such Acquired Program and whether the acquiring Party is electing (i) or (ii).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref522271474"></a><font style="Background-color:#auto;text-decoration:none;">9.2.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Divestment of Acquired Program</font><font style="color:#000000;">.&nbsp;&nbsp;If Relay elects to divest its rights to an Acquired Program, then Relay (and its Affiliates, if applicable) will divest such Acquired Program within [***] following the closing of the applicable acquisition under Section 9.2.1 (provided that such period may be extended for up to an additional [***] after closing if Relay and its Affiliates are using diligent efforts to divest such Acquired Program); provided that for so long as Relay or its Affiliates retain such Acquired Program the Acquired Program is segregated in accordance with Section 9.2.4.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref524006513"></a><a name="_Ref522271483"></a><font style="Background-color:#auto;text-decoration:none;">9.2.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination of Acquired Program</font><font style="color:#000000;">.&nbsp;&nbsp;If Relay elects to terminate an Acquired Program, then Relay (and its Affiliates, if applicable) will cease any activities under such Acquired Program as soon as reasonably practicable and in any event within [***] of the closing of the applicable acquisition under Section 9.2.1, giving due consideration to ethical concerns and requirements under Applicable Law; provided that for so long as Relay or its Affiliates retain such Acquired Program,</font><font style="font-style:italic;color:#000000;"> </font><font style="color:#000000;">the Acquired Program is segregated in accordance with Section 9.2.4.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref522271675"></a><a name="_Ref524006519"></a><a name="_Ref38730177"></a><a name="_Ref531197337"></a><a name="_Ref52347978"></a><font style="text-decoration:none;Background-color:#auto;">9.2.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Segregation of Programs</font><font style="color:#000000;">.&nbsp;&nbsp;During any period prior to divestment or termination of an Acquired Program pursuant to Section </font><font style="color:#000000;">9.2.2</font><font style="color:#000000;"> or </font><font style="color:#000000;">9.2.3</font><font style="color:#000000;">,</font><font style="color:#000000;"> as applicable, Relay </font><font style="color:#000000;">may conduct such </font><font style="color:#000000;">Acquired Program to the extent permitted by this Section </font><font style="color:#000000;">9.2.4</font><font style="color:#000000;">;</font><font style="color:#000000;"> provided that, (a) none of the Relay Patents and Relay Know</font><font style="color:#000000;">-</font><font style="color:#000000;">How or Licensee IP will be used in the </font><font style="color:#000000;">Acquired Program, and (b) the activities required under this Agreement will be conducted separately from any research, development, manufacturing, and commercialization activities (as applicable) directed to such Acquired Program, including</font><font style="color:#000000;"> </font><font style="color:#000000;">establishing reasonable protections and safeguards, </font><font style="color:#000000;">[***]</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1252"></a><a name="_BPDC_PR_INS_1253"></a><a name="_Ref57631606"></a><a name="_BPDC_LN_INS_1250"></a><a name="_BPDC_PR_INS_1251"></a><a name="_BPDC_LN_INS_1248"></a><a name="_BPDC_PR_INS_1249"></a><a name="_BPDC_LN_INS_1246"></a><a name="_BPDC_PR_INS_1247"></a><font style="Background-color:#auto;text-decoration:none;"> 9.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Acquirer Programs</font><font style="color:#000000;">. Notwithstanding Section 9.1, in the event Relay is acquired by a Third Party (by merger, sale, consolidation, reorganization or other Change of Control) so that such Third Party becomes an Affiliate of Relay or is merged into Relay or Relay is merged into such Third Party, and, as of the date of such acquisition or later, such Third Party has a program or product that would otherwise violate Section 9.1 (an &#8220;</font><font style="font-weight:bold;color:#000000;">Acquirer Program</font><font style="color:#000000;">&#8221;), then such Party will not be deemed to be in violation of Section 9.1 and may continue such Acquirer Program subject to Section 18.3.&nbsp;&nbsp;In addition to the requirements of Section 18.3:<a name="_BPDC_LN_INS_1250"></a><a name="_BPDC_PR_INS_1251"></a><a name="_BPDC_LN_INS_1248"></a><a name="_BPDC_PR_INS_1249"></a> [***]<a name="_BPDC_LN_INS_1246"></a><a name="_BPDC_PR_INS_1247"></a>. </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Toc524107356"></a><a name="_Toc529816445"></a><a name="_Toc529966478"></a><a name="_Ref39331129"></a><a name="_Toc50796659"></a><a name="_Toc51338588"></a><a name="_Toc53919205"></a><a name="_Toc53925689"></a><font style="Background-color:#auto;text-decoration:none;">Article 10.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><br /><a name="_Toc529816445"></a><a name="_Toc529966478"></a><a name="_Ref39331129"></a><a name="_Toc50796659"></a><a name="_Toc51338588"></a><a name="_Toc53919205"></a><a name="_Toc53925689"></a>GOVERNANCE; REPORTING</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref50570023"></a><font style="Background-color:#auto;text-decoration:none;"> 10.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Joint Teams</font><font style="color:#000000;">. The Parties will establish a joint development team (&#8220;</font><font style="font-weight:bold;color:#000000;">JDT</font><font style="color:#000000;">&#8221;) to oversee the Development of Licensed Candidates and Licensed Products in the Field in the Territory and, a joint promotion team (&#8220;</font><font style="font-weight:bold;color:#000000;">JPT</font><font style="color:#000000;">&#8221;) to oversee the activities of the Parties with respect to the promotion of the Relay Pipeline Combination Eligible Licensed Product included&nbsp;&nbsp;in a Relay Pipeline Combination.&nbsp;&nbsp;Each Joint Team has the authority (a)&#160;for matters specifically delegated to it or expressly specified in this Agreement, (b)&#160;to resolve disputes within the jurisdiction of such Joint Team, and (c)&#160;with respect to any other matter agreed to by the Parties in writing.&nbsp;&nbsp;For clarity, neither Joint Team will have any power to amend, modify, or waive compliance with this Agreement.&nbsp;&nbsp;The Joint Teams have no other authority under this Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc522731579"></a><a name="_Toc524107357"></a><a name="_Toc529816446"></a><a name="_Ref529899508"></a><a name="_Toc529966479"></a><a name="_Ref50997579"></a><a name="_Ref521644913"></a><font style="Background-color:#auto;text-decoration:none;"> 10.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Joint Development Team</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref524002599"></a><a name="_Ref521644914"></a><a name="_Hlk38878168"></a><a name="DocXTextRef207"></a><a name="DocXTextRef209"></a><font style="Background-color:#auto;text-decoration:none;">10.2.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Establishment</font><font style="color:#000000;">.&nbsp;&nbsp;Within [***]<a name="DocXTextRef207"></a> after the Effective Date, the Parties will establish a JDT as more fully described in this Section 10.2.<a name="DocXTextRef209"></a>&nbsp;&nbsp;The JDT will oversee the Development of Licensed Candidates and Licensed Products in the Field in the Territory, to the extent expressly and as more specifically provided in Section 10.2.2.&nbsp;&nbsp;Each Party agrees to keep the JDT informed of its progress and activities under this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref529900720"></a><a name="_Ref530828242"></a><a name="_Ref521644916"></a><font style="Background-color:#auto;text-decoration:none;">10.2.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Responsibilities</font><font style="color:#000000;">.&nbsp;&nbsp;The JDT will have the following responsibilities with respect to the Development of Licensed Candidates and Licensed Products under this Agreement: [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc5582394"></a><a name="_Ref38878216"></a><a name="_Ref50822051"></a><font style="Background-color:#auto;text-decoration:none;"> 10.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Joint Promotion Team</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref39505928"></a><a name="_Hlk38881588"></a><font style="Background-color:#auto;text-decoration:none;">10.3.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Establishment</font><font style="color:#000000;">.&nbsp;&nbsp;In accordance with Sections 5.6.1, the Parties will establish a JPT with respect to Relay Pipeline Combinations at least [***] prior to the date of the anticipated submission of the first NDA for a Relay Pipeline Combination.&nbsp;&nbsp;The JPT will coordinate the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">activities of the Parties with respect to the promotion of the </font><font style="color:#000000;">Relay </font><font style="color:#000000;">Pipeline </font><font style="color:#000000;">Combination Eligible </font><font style="color:#000000;">Licensed</font><font style="color:#000000;"> Product</font><font style="color:#000000;">s</font><font style="color:#000000;"> that </font><font style="color:#000000;">are</font><font style="color:#000000;"> </font><font style="color:#000000;">contained in Relay Pipeline Combination</font><font style="color:#000000;">s</font><font style="color:#000000;"> and will serve as a forum for the coordination of such promotion activities to the extent expressly and as more specifically provided in Section </font><font style="color:#000000;">10.3.2</font><font style="color:#000000;">.</font><font style="color:#000000;">&nbsp;&nbsp;Each Party agrees to keep the JPT informed of its progress and activities with respect to coordinated promotion of such Relay Pipeline Combinations.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref38881700"></a><font style="Background-color:#auto;text-decoration:none;">10.3.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Specific Responsibilities</font><font style="color:#000000;">.&nbsp;&nbsp;The JPT will have the following responsibilities with respect to the coordinated promotion of the Relay Pipeline Combinations under this Agreement: [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;"> 10.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Membership</font><font style="color:#000000;">.&nbsp;&nbsp;Each Joint Team will be comprised of [***] representatives (or such other number of representatives as the Parties may mutually agree; provided that </font><font style="color:#000000;">such Joint Team will consist at all times of an equal number of representatives of each Party, unless otherwise agreed by the Parties in writing</font><font style="color:#000000;">) from each of Licensee and Relay.&nbsp;&nbsp;Unless otherwise agreed by Licensee, Relay&#8217;s representatives will include its [***].&nbsp;&nbsp;Each representative of a Party will have sufficient seniority and expertise to participate on the applicable Joint Team as determined in such Party&#8217;s reasonable judgment.&nbsp;&nbsp;Licensee will designate a chairperson for each Joint Team, which chairperson will be responsible for developing, in consultation with the representatives of Relay, and circulating the agenda for the applicable Joint Team meeting reasonably in advance thereof.&nbsp;&nbsp;No chairperson will have additional powers or rights beyond those held by the other representative for the applicable Joint Team.&nbsp;&nbsp;Each Party may replace any or all of its representatives on a Joint Team at any time upon written notice to the other Party in accordance with Section 18.10.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;"> 10.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Meetings</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.5.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The first scheduled meeting of the JDT will be held no later than [***] after establishment of the JDT unless otherwise agreed by the Parties.&nbsp;&nbsp;After the first scheduled meeting of the JDT and until delivery of the TLF to Licensee pursuant to Section 4.1.2, the JDT will meet at least [***], or more or less frequently as the Parties mutually deem appropriate, on such dates and at such places and times as provided herein or as the Parties otherwise agree.&nbsp;&nbsp;After delivery of the TLF to Licensee pursuant to Section 4.1.2 and until the JDT is disbanded in accordance with Section 10.8, the JDT will meet at least once [***], or more or less frequently as the Parties mutually deem appropriate, on such dates and at such places and times as provided herein or as the Parties otherwise agree.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="DocXTextRef213"></a><a name="_Hlk52304551"></a><a name="DocXTextRef214"></a><a name="DocXTextRef218"></a><font style="Background-color:#auto;text-decoration:none;">10.5.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="DocXTextRef213"></a>The first scheduled meeting of the JPT will be held no later than [***] after establishment thereof<a name="_Hlk52304551"></a> unless otherwise agreed by the Parties.&nbsp;&nbsp;<a name="DocXTextRef214"></a>After the first scheduled<a name="DocXTextRef218"></a> meeting of the JPT and until the JPT is disbanded in accordance with Section 10.8, the JPT will meet at least once [***], or more or less frequently as the Parties mutually deem appropriate, on such dates and at such places and times as provided herein or as the Parties otherwise agree. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.5.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The members of each Joint Team may meet by means of telecommunications, video conferences, electronic mail or correspondence, as deemed necessary or appropriate. Notwithstanding the foregoing, at least [***] meeting of each Joint Team per Calendar Year will be in-person, unless the Parties agree otherwise.&nbsp;&nbsp;The location of the in-person meetings will be mutually agreed by the Parties.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">10.5.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Each Party may invite </font><font style="color:#000000;">a reasonable number of </font><font style="color:#000000;">non-member representatives of such Party and any Third Party to attend meetings of any Joint Team as observers; provided, that any such representative or Third Party is bound by obligations of confidentiality, non-disclosure and non-use consistent with those set forth in </font><font style="color:#000000;">Article 13</font><font style="color:#000000;"> prior to attending such meeting.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.5.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">[***].&nbsp;&nbsp;Meetings of each Joint Team are only effective if at least [***] representative from each Party is present or participating in such meeting. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref38884788"></a><a name="_Ref510893380"></a><a name="_Ref529899602"></a><a name="_Ref521644918"></a><font style="Background-color:#auto;text-decoration:none;"> 10.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Procedural Rules</font><font style="color:#000000;">.&nbsp;&nbsp;Each Joint Team will have the right to adopt such standing rules as will be necessary for its work, to the extent that such rules are not inconsistent with this Agreement.&nbsp;&nbsp;A quorum of the Joint Team will exist whenever there is present at a meeting at least [***] representative appointed by each Party.&nbsp;&nbsp;Each Joint Team will take action or make decisions at a meeting at which a quorum exists, or by a written resolution signed by at least [***] appointed by each Party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref50885913"></a><a name="_Ref50911486"></a><a name="_Ref39600362"></a><a name="_Ref504655848"></a><font style="Background-color:#auto;text-decoration:none;"> 10.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Decision Making</font><font style="color:#000000;">. Subject to the remainder of this Section 10.7, each Joint Team will make decisions by unanimous agreement.&nbsp;&nbsp;The representatives from each Party on any Joint Team will have, collectively, [***] vote on behalf of that Party.&nbsp;&nbsp;Except as otherwise expressly set forth in this Agreement, the phrase &#8220;determine,&#8221; &#8220;designate,&#8221; &#8220;approve&#8221; or &#8220;determine whether to approve&#8221; by a Joint Team and similar phrases used in this Agreement will mean approval in accordance with this Section 10.7, including the tie breaking provisions herein<a name="_Ref504655848"></a>.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56671496"></a><a name="_Ref504655849"></a><font style="Background-color:#auto;text-decoration:none;">10.7.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Decisions of the JPT</font><font style="color:#000000;">.&nbsp;&nbsp;The JPT will use good faith efforts to promptly resolve any matter for which it has authority.&nbsp;&nbsp;Notwithstanding the foregoing, for any matter over which Party has final decision-making authority pursuant to Section 10.7.3, such Party may make the decision on such matter at any time, without waiting for the JPT to reach agreement on such matter<a name="_Ref504655849"></a>.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref50886153"></a><font style="Background-color:#auto;text-decoration:none;">10.7.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Decisions of the JDT</font><font style="color:#000000;">.&nbsp;&nbsp;</font>The <font style="color:#000000;">JDT</font> will use good faith efforts to promptly resolve any matter for which it has authority.<font style="color:#000000;"> </font>Notwithstanding the foregoing, for any matter over which Party has final decision-making authority pursuant to Section 10.7.3, such Party may make the decision on such matter at any time, without waiting for the JDT to reach agreement on such matter.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref52287943"></a><a name="_Ref52349135"></a><a name="_Ref38884424"></a><a name="_Ref38884682"></a><font style="Background-color:#auto;text-decoration:none;">10.7.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Final Decision Making Authority</font><font style="color:#000000;">.&nbsp;&nbsp;If the Joint Team is unable to reach unanimous agreement on any matter for which the Joint Team is responsible, then,</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref50886847"></a><a name="_Ref52348937"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Relay Decisions</font><font style="color:#000000;">.&nbsp;&nbsp;[***]</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref50886851"></a><a name="_Ref57218660"></a><a name="_Ref56006146"></a><a name="_Ref56004794"></a><a name="_Ref54718275"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Licensee Decisions</font><font style="color:#000000;">. <a name="_Ref54718275"></a>[***]</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1244"></a><a name="_BPDC_PR_INS_1245"></a><a name="_Ref57836171"></a><a name="_Ref56091517"></a><a name="_Ref56837801"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">[***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1242"></a><a name="_BPDC_PR_INS_1243"></a><a name="_Ref57836127"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notwithstanding clause (ii) of Section 10.7.3(b), in the event Licensee requests to amend or change the Relay Phase Ia Plan to add an Optional Additional Phase Ia Study or a Required Additional Phase Ia Study, such request will be subject to Relay&#8217;s rights in Section 3.3.2 or Section 3.4.2, as applicable. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">In any case, Licensee may move forward without delay on any activities for which it believes in good faith that it has final decision making authority regardless of any dispute, which would be escalated independently of the applicable Joint Team.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521644940"></a><a name="_Ref524002819"></a><a name="_Ref530145381"></a><a name="_Ref530827912"></a><font style="Background-color:#auto;text-decoration:none;"> 10.8</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Minutes</font><font style="color:#000000;">.&nbsp;&nbsp;The Parties will alternate responsibility (with Licensee having such responsibility first) for preparing and circulating minutes of each meeting of each Joint Team, setting forth, </font><font style="font-style:italic;color:#000000;">inter alia</font><font style="color:#000000;">, an overview of the discussions at the meeting.&nbsp;&nbsp;Such minutes will be effective only after such minutes have been approved by both Parties in writing or by e-mail, with any differences in the Parties&#8217; recollections noted in such finalized minutes.&nbsp;&nbsp;Definitive minutes of all Joint Team meetings will be finalized no later than [***]<a name="_Ref521644940"></a><a name="_Ref524002819"></a><a name="_Ref530145381"></a><a name="_Ref530827912"></a> after the meeting to which the minutes pertain.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;"> 10.9</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Disbandment</font><font style="color:#000000;">.&nbsp;&nbsp;The JDT will disband upon the earlier of [***].&nbsp;&nbsp;The JPT will disband upon the earlier of [***].&nbsp;&nbsp;Following the disbandment of all Joint Teams, all notices required to be delivered by a Party to the Joint Teams will thereafter be provided to the other Party in accordance with Section 18.12. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc5582400"></a><a name="_Ref56670262"></a><font style="Background-color:#auto;text-decoration:none;"> 10.10</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Sub-Committees and Working Groups</font><font style="color:#000000;">.&nbsp;&nbsp;Each Joint Team may establish sub-committees or working groups to interact on a more frequent basis on specific projects and tasks assigned to them by such Joint Team; provided, that the authority of such sub-committees or working groups will not expand beyond the authority of the applicable Joint Team.&nbsp;&nbsp;Any such sub-committees or working groups will have no decision-making authority but will make recommendations to the applicable Joint Team for its review and approval.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;"> 10.11</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Limitations on Authority</font><font style="color:#000000;">.&nbsp;&nbsp;Each Party will retain the rights, powers, and discretion granted to it under this Agreement and no such rights, powers, or discretion will be delegated to or vested in a Joint Team unless such delegation or vesting of rights is expressly provided for in this Agreement or the Parties expressly so agree in writing.&nbsp;&nbsp;No Joint Team will have the power to amend, modify, or waive compliance with this Agreement, which may only be amended or modified as provided in Section 18.15 or compliance with which may only be waived as provided in Section 18.15.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57631892"></a><font style="Background-color:#auto;text-decoration:none;"> 10.12</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Financial Liaisons</font><font style="color:#000000;">.&nbsp;&nbsp;[***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646920"></a><a name="_Ref521648204"></a><a name="_Toc522731581"></a><a name="_Toc524107358"></a><a name="_Toc529816447"></a><a name="_Toc529966480"></a><a name="_Ref521644943"></a><font style="Background-color:#auto;text-decoration:none;"> 10.13</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Alliance Managers</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk56670642"></a><a name="DocXTextRef233"></a><a name="_Hlk56670642"></a>.&nbsp;&nbsp;Promptly after the Effective Date, each Party will appoint an individual to act as alliance manager for such Party who possesses a general understanding of this Agreement and the conduct of activities hereunder and who will oversee contact between the Parties for all matters between meetings of each Joint Team and will have such other responsibilities as the Parties may agree in writing after the Effective Date (each, an &#8220;<font style="font-weight:bold;">Alliance Manager</font>&#8221;).&nbsp;&nbsp;<a name="DocXTextRef233"></a>The Alliance Managers may attend all meetings of the JDT as non-voting participants and will be responsible for assisting the JDT in performing its informational and review responsibilities.&nbsp;&nbsp;The name and contact information for each Party&#8217;s Alliance Manager, as well as any replacement(s) chosen by such Party, in its sole discretion, from time to time, will be promptly provided to the other Party in accordance with Section 18.10. Each Party may replace its Alliance Manager at any time by notice in writing to the other Party.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521644944"></a><a name="_Toc524107365"></a><a name="_Toc529816454"></a><a name="_Toc529966487"></a><a name="_Toc50796660"></a><a name="_Toc51338589"></a><a name="_Toc53919206"></a><a name="_Toc53925690"></a><font style="text-decoration:none;Background-color:#auto;">Article 11.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><br /><a name="_Ref521644944"></a><a name="_Toc524107365"></a><a name="_Toc529816454"></a><a name="_Toc529966487"></a><a name="_Toc50796660"></a><a name="_Toc51338589"></a><a name="_Toc53919206"></a><a name="_Toc53925690"></a></font><font style="color:#000000;">FINANCIAL TERMS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref50722640"></a><a name="_Ref38581362"></a><font style="Background-color:#auto;text-decoration:none;"> 11.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Upfront Payment and IND Transfer and Phase Ia Completion Payments</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57191734"></a><font style="Background-color:#auto;text-decoration:none;">11.1.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Upfront Payment</font><font style="color:#000000;">.&nbsp;&nbsp;As partial consideration for the licenses and other rights granted by Relay to Licensee under this Agreement, Licensee will pay Relay, in accordance with Section 11.1.4, a non-refundable, non-creditable initial payment of Seventy Five Million Dollars ($75,000,000) upon completion of all activities under the Technology Transfer Plan that are scheduled to be completed as of the Effective Date, including providing Licensee with complete access (including the ability to download) to all information and data in the data room to which Licensee was provided &#8220;read only&#8221; access as part of its due diligence activities conducted prior to the Execution Date (the &#8220;</font><font style="font-weight:bold;color:#000000;">Immediate Tech Transfer Activities</font><font style="color:#000000;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1240"></a><a name="_BPDC_PR_INS_1241"></a><a name="_Ref53754493"></a><font style="Background-color:#auto;text-decoration:none;">11.1.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">IND Transfer Payment</font><font style="color:#000000;">.&nbsp;&nbsp;As partial consideration for the licenses and other rights granted to Licensee hereunder, Licensee will pay to Relay, in accordance with Section 11.1.4, [***] upon completion of the Relay IND Transfer, including completion of all activities that are conditions to the Relay IND Transfer as described in Section 3.2.3(b), and completion of all activities under the Technology Transfer Plan that are scheduled to be completed within [***] after the Effective Date  (the &#8220;</font><font style="font-weight:bold;color:#000000;">IND Transfer Milestone</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57193230"></a><font style="Background-color:#auto;text-decoration:none;">11.1.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Relay Phase Ia Trial Payment</font><font style="color:#000000;">.&nbsp;&nbsp;As partial consideration for the licenses and other rights granted to Licensee hereunder, Licensee will pay to Relay, in accordance with Section 11.1.4, the non-refundable, [***] (the &#8220;</font><font style="font-weight:bold;color:#000000;">Relay Phase Ia Trial Milestone</font><font style="color:#000000;">&#8221;). Notwithstanding the foregoing, if the Relay Phase Ia Trial is transferred to Licensee pursuant to Section 3.4.7, then Licensee will pay Relay the Relay Phase Ia Trial Milestone upon the later of (i) Licensee&#8217;s confirmation of complete transfer of the Relay Phase Ia Trial as directed pursuant to Section 3.4.7 and (ii) Licensee&#8217;s receipt of the complete TLF, whichever occurs later; provided that if Licensee requested such transfer of the Relay Phase Ia Trial based upon breach by Relay as set forth in such Section 3.4.7, then no Relay Phase Ia Trial Milestone will be due or paid.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57801214"></a><font style="Background-color:#auto;text-decoration:none;">11.1.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Payment of Upfront, IND Transfer and Relay Phase Ia Trial </font><font style="color:#000000;">Payments.&nbsp;&nbsp;Licensee will provide Relay with written notice of completion of the Immediate Tech Transfer Activities or achievement of the IND Transfer Milestone or the Relay Phase Ia Trial Milestone, as applicable, promptly after Licensee&#8217;s confirmation of the achievement thereof and confirmation that Relay is in material compliance with all of its obligations with respect to the Technology Transfer and relevant obligations under Sections 3.2, 3.3, 3.4,&nbsp;&nbsp;3.9.1,  6.3 and  6.4 through such date.&nbsp;&nbsp;Relay shall invoice Licensee upon receipt of such notice from Licensee, and Licensee will make the corresponding payment within [***] after receipt of Relay&#8217;s invoice from Relay thereafter for the corresponding payment (or [***] in the case of the initial payment pursuant to Section 11.1.1).&nbsp;&nbsp;If Licensee is unable to confirm the foregoing, Licensee will promptly notify Relay in writing and the reasons Licensee is unable to confirm, including identifying any items that, in Licensee&#8217;s reasonable determination made in good faith, are still needed for achievement of the milestone or compliance with Relay&#8217;s obligations under Sections 3.2, 3.3, 3.4,&nbsp;&nbsp;3.9.1,  6.3 and  6.4.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1238"></a><a name="_BPDC_PR_INS_1239"></a><a name="_Ref55373564"></a><a name="_Ref56671851"></a><a name="_Ref39119446"></a><a name="_Ref54027971"></a><font style="text-decoration:none;Background-color:#auto;"> 11.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Relay </font><font style="text-decoration:underline;color:#000000;">Phase Ia Trial CRO Costs</font><font style="color:#000000;">.</font><font style="color:#000000;"> Relay</font><font style="color:#000000;"> Phase Ia Trial CRO Costs will be shared in accordance with Section </font><font style="color:#000000;">3.8.1</font><font style="color:#000000;">.</font><font style="color:#000000;">&nbsp;&nbsp;Relay will report to Licensee, within </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> after the end of each Calendar Quarter, the </font><font style="color:#000000;">Relay </font><font style="color:#000000;">Phase Ia Trial CRO Costs incurred by Relay during such Calendar Quarter.&nbsp;&nbsp;Such report will specify in reasonable detail (including supporting documentation, as appropriate) all amounts included in such </font><font style="color:#000000;">Relay </font><font style="color:#000000;">Phase Ia Trial CRO Costs during such Calendar Quarter. Concurrently with or after delivery of such report, Relay will deliver an invoice to Licensee for Licensee&#8217;s share of such </font><font style="color:#000000;">Relay </font><font style="color:#000000;">Phase Ia Trial CRO Costs.&nbsp;&nbsp;Payment by Licensee will be due </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> after receiving such an invoice from Relay pursuant to this Section</font><font style="color:#000000;"> 11.2</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1236"></a><a name="_BPDC_PR_INS_1237"></a><a name="_Ref56263304"></a><font style="Background-color:#auto;text-decoration:none;"> 11.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Development Costs During the Opt-In Term; Launch Costs</font><font style="color:#000000;">.&nbsp;&nbsp;During the Opt-In Term:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:13.46%;text-indent:1.92%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1234"></a><a name="_BPDC_PR_INS_1235"></a><a name="_Ref51831561"></a><a name="_Ref52087085"></a><a name="_Ref35233933"></a><font style="Background-color:#auto;text-decoration:none;">11.3.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Development Costs relating to the GDP; Launch Costs</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref53586555"></a><a name="_Ref50896285"></a><a name="_Ref56091208"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Development Costs incurred by Licensee for Shared Products pursuant to the GDP (including for the avoidance of doubt Development Costs incurred prior to the Opt-In Effective Date) and Launch Costs incurred by Licensee for Shared Products will be shared in accordance with the Sharing Percentages.&nbsp;&nbsp;[***].  Any Development for any such Licensee Combination after Regulatory Approval for the [***] Indication in the Profit Share Territory will be made under the GDP, and the GDP will be updated accordingly and Development Costs and Launch Costs will be shared in accordance with the applicable Sharing Percentages.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref51834638"></a><a name="_Ref53586568"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In addition, Relay will have the right, in its sole discretion, upon written notice to Licensee [***].&nbsp;&nbsp;If Relay exercises such right, the Second Tier GDP Overrun for such Calendar Year [***]&nbsp;&nbsp;Notwithstanding the foregoing, at its option [***] or any portion thereof against subsequent payments owed by Licensee to Relay under Section 11.5.1, 11.5.2, 11.5.4, 11.5.5, 11.6.1 or 11.6.2 until paid.&nbsp;&nbsp;For the avoidance of doubt, [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1232"></a><a name="_BPDC_PR_INS_1233"></a><a name="_Ref52217961"></a><font style="Background-color:#auto;text-decoration:none;">11.3.2</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Costs incurred by Licensee during such Calendar Quarter in accordance with the GDP with respect to Shared Products</font><font style="color:#000000;">.&nbsp;&nbsp;Licensee will provide Relay with a written report within [***] after the end of each Calendar Quarter indicating the Development Costs and Launch Costs incurred by Licensee, in each case, in accordance with the GDP in the just-ended Calendar Quarter.&nbsp;&nbsp;Each such report will specify in reasonable [***]. If Relay has not reported and issued an invoice to Licensee for reimbursement of Licensee&#8217;s share of development costs for a Relay Pipeline Combination during such just-ended Calendar Quarter calculated in accordance with Section 3.8.2, Licensee will thereafter deliver an invoice to Relay for any amounts due to Licensee.&nbsp;&nbsp;If Relay has also reported and issued an invoice to Licensee for reimbursement of Licensee&#8217;s share of development costs for a Relay Pipeline Combination during such just-ended Calendar Quarter as provided in Section 3.8.2, Licensee will prepare a reconciliation report for such Calendar Quarter and will deliver an invoice to Relay for any amounts due to Licensee after such reconciliation (or request an invoice from Relay for any amounts due to Relay after such reconciliation). If Relay has any questions related to the foregoing reports, Relay may raise such questions with Licensee (through the applicable financial sub-committee or working group under the JDT if one has been formed or otherwise through the JDT) and the Parties will seek to promptly resolve any such questions.&nbsp;&nbsp;Payment by a Party will be due [***] after receiving an invoice from the other Party pursuant to this Section 11.3.2.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1230"></a><a name="_BPDC_PR_INS_1231"></a><font style="Background-color:#auto;text-decoration:none;">11.3.3</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">FTE Records and Calculations</font><font style="color:#000000;">.&nbsp;&nbsp;Licensee will record and account for its FTE effort to the extent that such FTE efforts are included in Development Costs or Launch Costs in accordance with the GDP with respect to Shared Products for the Profit Share Territory.&nbsp;&nbsp;Licensee will allocate and maintain records of FTE effort incurred by it in the same manner as used for other products developed by Licensee.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref50913021"></a><a name="_Ref50890740"></a><font style="Background-color:#auto;text-decoration:none;"> 11.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Net Profits and Net Losses Share</font><font style="color:#000000;">.&nbsp;&nbsp;For so long as there is a sale of a Shared Product in the Profit Share Territory, the terms and conditions of this Section 11.4 will govern each Party&#8217;s rights and obligations with respect to Net Profits and Net Losses relating to Shared Products in the Profit Share Territory during the Opt-In Term.&nbsp;&nbsp;Subject to this Section 11.4, Net Profits and Net Losses with respect to each Shared Product will be shared equally by the Parties.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1226"></a><a name="_Ref58229325"></a><a name="_Ref50891338"></a><font style="Background-color:#auto;text-decoration:none;">11.4.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Net Profits and Net Losses Reports and Payments</font><font style="color:#000000;">.&nbsp;&nbsp;In the event that this Section 11.4 applies:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licensee will report to Relay within [***] after the end of each Calendar Quarter, a good faith, non-binding estimate of Net Profits and Net Losses that will be due for such Calendar Quarter;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">each Party will report to the other Party within [***] after the end of each Calendar Quarter commencing with the Calendar Quarter in which the First Commercial Sale in the Profit Share Territory of a Shared Product occurs, the elements of the Net Profits and Net Losses calculation, including Net Sales (and the calculation thereof showing deductions taken with respect thereto) and Allowable Expenses incurred by such Party during such Calendar Quarter.&nbsp;&nbsp;[***]. Within [***] after receipt of such reports, Licensee will provide to Relay a consolidated financial statement setting forth the Net Profits and Net Losses for the Calendar Quarter. The following remittances will be paid as set forth below after Licensee has provided the consolidated financial statement:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">if there is a Net Profit for a Shared Product in such Calendar Quarter, then Licensee will pay to Relay a reconciling payment amount equal to Relay&#8217;s portion of the Net Profit for such Calendar Quarter within [***] after providing the consolidated financial statement to Relay. An example of a Net Profit and corresponding reconciling payment calculation is set forth on Schedule 11.4.1; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">if there is a Net Loss for a Shared Product in such Calendar Quarter, then Licensee will invoice Relay for the amounts due to Licensee as a result of reconciliation.&nbsp;&nbsp;Payment by Relay will be due [***] after receiving such an invoice from Licensee.&nbsp;&nbsp;An example of a Net Loss and corresponding reconciling payment calculation is set forth on Schedule 11.4.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1224"></a><a name="_BPDC_PR_INS_1225"></a><font style="Background-color:#auto;text-decoration:none;">11.4.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">FTE Records and Calculations</font><font style="color:#000000;">.&nbsp;&nbsp;Licensee will record and account for its FTE effort to the extent that such FTE efforts are included in Allowable Expenses.&nbsp;&nbsp;Licensee will allocate and maintain records of FTE effort incurred by it in the same manner as used for other products developed by Licensee.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1222"></a><a name="_BPDC_PR_INS_1223"></a><a name="_Ref521646923"></a><a name="_Ref521649533"></a><a name="_Toc524107366"></a><a name="_Ref525743420"></a><a name="_Toc529816455"></a><a name="_Toc529966488"></a><a name="_Ref41451852"></a><a name="_Ref521644947"></a><font style="Background-color:#auto;text-decoration:none;"> 11.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Additional Milestone Payments</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1220"></a><a name="_BPDC_PR_INS_1221"></a><a name="_Ref522044569"></a><a name="_Ref50716407"></a><a name="_Ref41252645"></a><a name="_Ref528624005"></a><a name="_Ref530830891"></a><a name="_Ref41512967"></a><a name="_Ref52259734"></a><a name="_Ref52314791"></a><a name="_Hlk56160847"></a><font style="Background-color:#auto;text-decoration:none;">11.5.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Development/Commercial Milestones for Lead Royalty Products Outside the Opt-In Term</font><font style="color:#000000;">.&nbsp;&nbsp;Subject to Section 11.5.2, in partial consideration of the licenses and other rights granted to Licensee hereunder and subject to the terms and conditions set forth in this Agreement, Licensee will pay to Relay the non-refundable, non-creditable one-time milestone payments set forth in Table 11.5.1 (each, a &#8220;</font><font style="font-weight:bold;color:#000000;">Development/Commercial Milestone Payment</font><font style="color:#000000;">&#8221;) following the first achievement by or on behalf of Licensee (including by any of its Affiliates or any Licensee Sublicensee) <a name="_Hlk56160847"></a>of each of the milestone events by a Lead Royalty Product in the Territory (each, a &#8220;</font><font style="font-weight:bold;color:#000000;">Development/Commercial Milestone</font><font style="color:#000000;">&#8221;) which Lead Royalty Product is (a) Covered by a Development Milestone Composition of Matter Claim in the case of Development/Commercial Milestones 1 and 2 or (b) Covered by a Composition of Matter Claim in the case of Development/Commercial Milestones 3, 4 and 5.&nbsp;&nbsp;[***].&nbsp;&nbsp;Each of the Development/Commercial Milestone Payments set forth in this Section 11.5.1 is payable only upon the first achievement of the corresponding Development/Commercial Milestone [***] to achieve such Development/Commercial Milestone, and none of the Development/Commercial Milestone Payments will be payable more than once regardless of how many times the Development/Commercial Milestone is achieved.&nbsp;&nbsp;[***].</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Table 11.5.1:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:9.46%;"></td>
<td style="width:14.89%;"></td>
<td style="width:14.57%;"></td>
<td style="width:14.34%;"></td>
<td style="width:14.34%;"></td>
<td style="width:16.16%;"></td>
<td style="width:16.13%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">Number</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">Development/</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">Commercial Milestone</p></td>
<td colspan="3" valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref522044857"></a><a name="_Ref528624075"></a><a name="_Ref531700263"></a><a name="_Ref531202429"></a>[***].</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref50716327"></a><a name="_Ref50717700"></a><a name="_Ref50716545"></a><a name="_Ref52260655"></a><a name="_Ref52702453"></a><a name="_Ref41512981"></a><a name="_Ref39586556"></a><a name="_Hlk56160858"></a><font style="Background-color:#auto;text-decoration:none;">11.5.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Development/Commercial Milestones for Lead Royalty Products During the Opt-In Term</font><font style="color:#000000;">.&nbsp;&nbsp;During the Opt-In Term, the Development/Commercial Milestones and Development/Commercial Milestone Payments will not apply and in lieu thereof, in partial consideration of the licenses and other rights granted to Licensee hereunder and subject to the terms and conditions set forth in this Agreement, Licensee will pay to Relay the non-refundable, non-creditable one-time milestone payments set forth in Table 11.5.2 (each, an &#8220;</font><font style="font-weight:bold;color:#000000;">Opt-In Term</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Development/Commercial Milestone Payment</font><font style="color:#000000;">&#8221;) following the first achievement by or on behalf of Licensee (including by any of its Affiliates or any Licensee Sublicensee) <a name="_Hlk56160858"></a>of each of the milestone events by a Lead Royalty Product in the Royalty Territory (each, an &#8220;</font><font style="font-weight:bold;color:#000000;">Opt-In Term</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Development/Commercial Milestone</font><font style="color:#000000;">&#8221;) which Lead Royalty Product is Covered by a Composition of Matter Claim.&nbsp;&nbsp;[***].</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Table 11.5.2:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:9.32%;"></td>
<td style="width:14.42%;"></td>
<td style="width:14.67%;"></td>
<td style="width:14.42%;"></td>
<td style="width:14.42%;"></td>
<td style="width:16.35%;"></td>
<td style="width:16.29%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">Number</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">Opt-In Term<font style="font-family:Calibri;font-size:12pt;"> </font>Development/</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">Commercial Milestone</p></td>
<td colspan="3" valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***].</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1216"></a><a name="_BPDC_PR_INS_1217"></a><a name="_Ref52259095"></a><a name="_Ref52261583"></a><a name="_Ref50718802"></a><a name="_Ref52314797"></a><a name="_Ref57221454"></a><a name="_Ref58515197"></a><a name="_Hlk56160868"></a><a name="_Hlk52260893"></a><font style="Background-color:#auto;text-decoration:none;">11.5.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Development/Commercial Milestones for Back-Up Products at Anytime</font><font style="color:#000000;">.&nbsp;&nbsp;In partial consideration of the licenses and other rights granted to Licensee hereunder and subject to the terms and conditions set forth in this Agreement, Licensee will pay to Relay the non-refundable, non-creditable one-time milestone payments set forth in Table 11.5.3 (each, a &#8220;</font><font style="font-weight:bold;color:#000000;">Back-Up</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Development/Commercial Milestone Payment</font><font style="color:#000000;">&#8221;) following the first achievement by or on behalf of Licensee (including any of its Affiliates or any Licensee Sublicensee) of each of the milestone events by a Back-Up Product <a name="_Hlk56160868"></a>in the Territory (each, a &#8220;</font><font style="font-weight:bold;color:#000000;">Back-Up Development/Commercial Milestone</font><font style="color:#000000;">&#8221;) which Back-Up Product <a name="_Hlk52260893"></a>is (a) Covered by a Development Milestone Composition of Matter Claim in the case of Back-Up Development/Commercial Milestones 1 and 2 or (b) Covered by a Composition of Matter Claim in the case of Back-Up Development/Commercial Milestones 3, 4 and 5, but solely in the event that a Back-Up Product achieves the corresponding Back-Up Development/Commercial Milestone prior to achievement of the corresponding Development/Commercial Milestone by a Lead Royalty Product (for purposes of this Section 11.5.3 the Development/Commercial Milestone will be deemed to have been achieved by a Shared Product if the Development/Commercial Milestone would have been achieved and paid to Relay for the applicable Lead Product pursuant to Section 11.5.1 had the Lead Product been a Lead Royalty Product and not a Shared Product at the time of achievement) or achievement of the corresponding Opt-In Development/Commercial Milestone by a Lead Royalty Product. [***]. Each of the Back-Up Development/Commercial Milestone Payments set forth in this Section 11.5.3 are payable only upon the first achievement of the corresponding Back-Up Development/Commercial Milestone [***], to achieve such Back-Up Development/Commercial Milestone, and none of the Back-Up Development/Commercial Milestone Payments will be payable more than once regardless of how many times the Back-Up Development/Commercial Milestone is achieved. [***]</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Table 11.5.3:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:9.32%;"></td>
<td style="width:14.42%;"></td>
<td style="width:14.67%;"></td>
<td style="width:14.42%;"></td>
<td style="width:14.42%;"></td>
<td style="width:16.35%;"></td>
<td style="width:16.29%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">Number</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">Back-Up Development/</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">Commercial Milestone</p></td>
<td colspan="3" valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;text-transform:none;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***].</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1214"></a><a name="_BPDC_PR_INS_1215"></a><a name="_Ref50707901"></a><a name="_Ref52265292"></a><a name="_Ref56420298"></a><a name="_Ref38748743"></a><a name="_Ref39122719"></a><font style="Background-color:#auto;text-decoration:none;">11.5.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_Ref56420298"></a>&nbsp;&nbsp;</font><font style="text-decoration:underline;color:#000000;">Sales Milestones for Lead Royalty Products Outside the Opt-In Term</font><font style="color:#000000;">.<a name="_Ref38748743"></a><a name="_Ref39122719"></a>&nbsp;&nbsp;Subject to Section 11.5.5, in partial consideration of the licenses and other rights granted to Licensee hereunder and subject to the terms and conditions set forth in this Agreement, Licensee will pay to Relay the non-refundable, non-creditable one-time milestone payments set forth in Table 11.5.4 (each, a &#8220;</font><font style="font-weight:bold;color:#000000;">Sales Milestone Payment</font><font style="color:#000000;">&#8221;) upon the first achievement of the aggregated annual Net Sales thresholds set forth in Table 11.5.4 by a Lead Royalty Product (each, a &#8220;</font><font style="font-weight:bold;color:#000000;">Sales Milestone</font><font style="color:#000000;">&#8221;) which Lead Royalty Product is Covered by a Composition of Matter Claim.&nbsp;&nbsp;Multiple Sales Milestone Payments may be payable by Licensee within a given Calendar Year in the event that more than one Sales Milestone is achieved during such Calendar Year.&nbsp;&nbsp;By way of example, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">if in the first Calendar Year in which Net Sales for a given Lead Royalty Product first exceed the Net Sales threshold set forth as Sales Milestone 1, and the Net Sales for the same or another Lead Royalty Product also exceed the Net Sales threshold set forth as Sales Milestone 2, then Licensee will pay Sales Milestone 1 and Sales Milestone 2 simultaneously.</font><font style="color:#000000;"> </font><font style="color:#000000;">Notwithstanding the foregoing, any Sales Milestone Payments pursuant to this Section </font><font style="color:#000000;">11.5.4</font><font style="color:#000000;"> will be reduced by the amount of Opt-In Sales Milestone Payments made pursuant to Section </font><font style="color:#000000;">11.5.5</font><font style="color:#000000;">,</font><font style="color:#000000;"> and Relay will not be eligible for any Sales Milestone for which the equivalent amount of Opt-In Sales Milestone Payments have already been paid.&nbsp;&nbsp;</font><font style="color:#000000;">[***]</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Table 11.5.4</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:11.49%;"></td>
<td style="width:56.42%;"></td>
<td style="width:31.99%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Number</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Sales Milestone</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"><a name="_Ref532947167"></a><a name="_Ref522045906"></a><a name="_Ref522046542"></a>&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1212"></a><a name="_BPDC_PR_INS_1213"></a><a name="_Ref50716351"></a><a name="_Ref50717375"></a><a name="_Ref52265814"></a><font style="Background-color:#auto;text-decoration:none;">11.5.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Sales Milestones for Lead Royalty Products during the Opt-In Term</font><font style="color:#000000;">.&nbsp;&nbsp;During the Opt-In Term, the Sales Milestones and Sales Milestones Payments set forth in Section 11.5.4 will not apply and in lieu thereof, in partial consideration of the licenses and other rights granted to Licensee hereunder and subject to the terms and conditions set forth in this Agreement, Licensee will pay to Relay the non-refundable, non-creditable one-time milestone payments set forth in Table 11.5.5 (each, an &#8220;</font><font style="font-weight:bold;color:#000000;">Opt-In</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Sales Milestone Payment</font><font style="color:#000000;">&#8221;) upon the first achievement of the aggregated annual Net Sales thresholds set forth in Table 11.5.5 by a Lead Royalty Product in the Royalty Territory (each, an &#8220;</font><font style="font-weight:bold;color:#000000;">Opt-In</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Sales Milestone</font><font style="color:#000000;">&#8221;) which Lead Royalty Product is Covered by a Composition of Matter Claim.&nbsp;&nbsp;Multiple Opt-In Sales Milestone Payments may be payable by Licensee within a given Calendar Year in the event that more than one Opt-In Sales Milestone is achieved during such Calendar Year.&nbsp;&nbsp;By way of example, if in the first Calendar Year in which Net Sales for a given Lead Royalty Product first exceed the Net Sales threshold set forth as Opt-In Sales Milestone 1, and the Opt-In Net Sales for the same or another Lead Royalty Product also exceed the Net Sales threshold set forth as Opt-In Sales Milestone 2, then Licensee will pay Opt-In Sales Milestone 1 and Opt-In Sales Milestone 2 simultaneously. Each of the Opt-In Sales Milestone Payments set forth in this Section 11.5.5 is payable only upon the first achievement of the corresponding Opt-In Sales Milestone by the first Lead Royalty Product to achieve such Opt-In Sales Milestone, and none of the Opt-In Sales Milestone Payments will be payable more than once regardless of how many times the Opt-In Sales Milestone is achieved.&nbsp;&nbsp;[***].</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Table 11.5.5:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:11.49%;"></td>
<td style="width:56.42%;"></td>
<td style="width:31.99%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Number</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Opt-In Sales Milestone</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-weight:normal;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1210"></a><a name="_BPDC_PR_INS_1211"></a><a name="_Ref50900912"></a><a name="_Ref52266987"></a><font style="Background-color:#auto;text-decoration:none;">11.5.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Sales Milestones for Back-Up Products at Anytime</font><font style="color:#000000;">.&nbsp;&nbsp;In partial consideration of the licenses and other rights granted to Licensee hereunder and subject to the terms and conditions set forth in this Agreement, Licensee will pay to Relay the non-refundable, non-</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">creditable one-time milestone payments set forth in Table </font><font style="color:#000000;">11.5.6</font><font style="color:#000000;"> (each, a &#8220;</font><font style="font-weight:bold;color:#000000;">Back-Up</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Sales Milestone Payment</font><font style="color:#000000;">&#8221;) upon the first achievement of the aggregated annual Net Sales thresholds set forth in Table </font><font style="color:#000000;">11.5.6</font><font style="color:#000000;"> by a Back-Up Product (each, a &#8220;</font><font style="font-weight:bold;color:#000000;">Back-Up</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Sales Milestone</font><font style="color:#000000;">&#8221;), which Back-Up Product is Covered by a Composition of Matter Claim but solely in the event that a Back-Up Product achieves the corresponding Back-Up Sales Milestone prior to achievement or deemed achievement of the corresponding Sales Milestone by a Lead Royalty Product (for purposes of this Section </font><font style="color:#000000;">11.5.6</font><font style="color:#000000;"> the Sales Milestone will be deemed to have been achieved by a Shared Product if the Sales Milestone would have been achieved and paid to Relay for the applicable Lead Royalty Product pursuant to Section </font><font style="color:#000000;">11.5.4</font><font style="color:#000000;"> </font><font style="color:#000000;">had the Lead Product been a Lead Royalty Product and not a Shared Product at the time of achievement) or achievement of the corresponding Opt-In Sales Milestone by a Lead Royalty Product.&nbsp;&nbsp;</font><font style="color:#000000;">[***]</font><font style="color:#000000;">&nbsp;&nbsp;</font><font style="color:#000000;">[***]</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Table 11.5.6</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:11.49%;"></td>
<td style="width:56.42%;"></td>
<td style="width:31.99%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Number</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Back-Up Sales Milestone</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:13.46%;text-indent:1.92%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1208"></a><a name="_BPDC_PR_INS_1209"></a><font style="Background-color:#auto;text-decoration:none;">11.5.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Payment Terms for Milestone Payments</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref54688463"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licensee will provide Relay with written notice of achievement of any Development/Commercial Milestone, Opt-In Development/Commercial Milestone or Back-Up Development/Commercial Milestone within [***] after Licensee&#8217;s confirmation of the achievement thereof and will make the corresponding payment of the Development/Commercial Milestone Payment, Opt-In Development/Commercial Milestone Payment or Back-Up Development/Commercial Milestone Payment, as applicable, within [***] after receipt of an invoice from Relay for the corresponding payment. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">As part of the Calendar Quarter royalty reports delivered pursuant to Section 11.7, Licensee will provide Relay with written notice of achievement of any Sales Milestone, Opt-In Sales Milestone or Back-Up Sales Milestone and Licensee will pay to Relay the applicable Sales Milestone Payment(s), Opt-In Sales Milestone Payment(s) or Back-Up Sales Milestone Payment(s) within [***] after receipt of an invoice from Relay regarding the achievement of such Sales Milestone, Opt-In Sales Milestone or Back-Up Sales Milestone. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1206"></a><a name="_BPDC_PR_INS_1207"></a><a name="_Ref525743422"></a><a name="_Toc529816456"></a><a name="_Toc529966489"></a><a name="_Ref522029697"></a><a name="_Toc524107367"></a><font style="Background-color:#auto;text-decoration:none;"> 11.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Royalties</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref41584483"></a>.<a name="_Ref41584483"></a> </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1204"></a><a name="_BPDC_PR_INS_1205"></a><a name="_Ref528629944"></a><a name="_Ref508652775"></a><a name="_Ref39124337"></a><a name="_Ref522047132"></a><a name="_Ref41584613"></a><a name="_Ref509478208"></a><a name="_Ref509483709"></a><a name="_Ref416867049"></a><a name="_Ref508902421"></a><font style="Background-color:#auto;text-decoration:none;">11.6.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Royalties for Lead Royalty Products Outside the Opt-In Term</font><font style="color:#000000;">. Subject to Section 11.6.2, in partial consideration of the licenses and other rights granted to Licensee hereunder and subject to the terms and conditions set forth in this Agreement, during the applicable Royalty Term, on a Lead Royalty Product-by-Lead Royalty Product and country-by-country basis throughout the Territory, Licensee will pay to Relay royalties on the Net Sales in a given Calendar Year of each Lead Royalty Product that is Covered by a Valid Claim under a Relay Royalty Patent at the rates set forth in Table 11.6.1.&nbsp;&nbsp;Following the expiration of a particular Royalty Term with respect to a given country and Lead Royalty Product, the licenses to Licensee set forth in Article 12 will be perpetual, fully paid-up and royalty-free with respect to such Lead Royalty Product in </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">such country.&nbsp;&nbsp;The obligation to pay royalties will be imposed only once with respect to the same unit of Lead Royalty Product sold by Licensee, its Affiliate or </font><font style="color:#000000;">Licensee </font><font style="color:#000000;"><a name="_Ref41584613"></a><a name="_Ref509478208"></a><a name="_Ref509483709"></a><a name="_Ref416867049"></a><a name="_Ref508902421"></a>Sublicensees.</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Table 11.6.1</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:88.41%;">
<tr>
<td style="width:77.83%;"></td>
<td style="width:10.58%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Portion of Aggregate Net Sales </p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1202"></a><a name="_BPDC_PR_INS_1203"></a><a name="_Ref50718012"></a><a name="_Ref50718277"></a><a name="_Ref50890323"></a><a name="_Hlk55380490"></a><font style="Background-color:#auto;text-decoration:none;">11.6.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Royalties for Lead Royalty Products During the Opt-In Term</font><font style="color:#000000;">.&nbsp;&nbsp;During the Opt-In Term, the royalties set forth in Section 11.6.1 will not apply and in lieu thereof, in partial consideration of the licenses and other rights granted to Licensee hereunder and subject to the terms and conditions set forth in this Agreement, during the applicable Royalty Term, on a Lead Royalty Product-by-Lead Royalty Product and country-by-country basis throughout the Royalty Territory, Licensee will pay to Relay royalties on the Net Sales&nbsp;&nbsp;in a given Calendar Year in the Royalty Territory<a name="_Hlk55380490"></a> of each Lead Royalty Product that is Covered by a Valid Claim under a Relay Royalty Patent at the rates set forth in Table 11.6.2.&nbsp;&nbsp;Following the expiration of a particular Royalty Term with respect to a given country and Lead Royalty Product, the licenses to Licensee set forth in Article 12 will be perpetual, fully paid-up and royalty-free with respect to such Lead Royalty Product in such country.&nbsp;&nbsp;The obligation to pay royalties will be imposed only once with respect to the same unit of Lead Royalty Product sold by Licensee, its Affiliate or Licensee Sublicensees.</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Table 11.6.2</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:88.41%;">
<tr>
<td style="width:77.83%;"></td>
<td style="width:10.58%;"></td>
</tr>
<tr style="height:9.85pt;">
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Portion of Aggregate Net Sales in the Royalty Territory </p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">For the avoidance of doubt, (a) during the Opt-In Term, aggregate Net Sales and royalties will be calculated and payable solely with respect to Net Sales of Lead Royalty Products in the Royalty Territory pursuant to this Section 11.6.2; and (b) outside of the Opt-In Term, aggregate Net Sales and royalties will calculated and payable with respect to Net Sales and Lead Royalty Products throughout the Territory pursuant to Section 11.6.1.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1200"></a><a name="_BPDC_PR_INS_1201"></a><a name="_Ref50720161"></a><font style="Background-color:#auto;text-decoration:none;">11.6.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Royalties for Back-Up Products at Anytime</font><font style="color:#000000;">. In partial consideration of the licenses and other rights granted to Licensee hereunder and subject to the terms and conditions set forth in this Agreement, during the applicable Royalty Term, on a Back-Up Product-by-Back-Up Product and country-by-country basis throughout the Territory, Licensee will pay to Relay royalties on the Net Sales in a given Calendar Year of each Back-Up Product that is Covered by a Valid Claim under a Relay Royalty Patent&nbsp;&nbsp;at the rates set forth in Table 11.6.3.&nbsp;&nbsp;Following the expiration of a particular Royalty Term with respect to a given country and Back-Up Product, the licenses to Licensee set forth in Article 12 will be perpetual, fully paid-up and royalty-free with respect to such Back-Up Product in such country.&nbsp;&nbsp;The obligation to pay royalties will be imposed only once with respect to the same unit of Back-Up Product sold by Licensee, its Affiliate or Licensee Sublicensees.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Table 11.6.3</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:88.41%;">
<tr>
<td style="width:77.83%;"></td>
<td style="width:10.58%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Portion of Aggregate Net Sales </p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:13.46%;text-indent:1.92%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1198"></a><a name="_BPDC_PR_INS_1199"></a><a name="_Ref529814354"></a><a name="_Ref530167400"></a><a name="_Ref52535792"></a><a name="_Ref522046602"></a><a name="_Ref525229195"></a><a name="_Ref522061730"></a><font style="Background-color:#auto;text-decoration:none;">11.6.4</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Third Party Agreements; Anti-Stacking</font><font style="color:#000000;">.</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref53935392"></a><a name="_Ref57222242"></a><a name="_Ref530125391"></a><a name="_Ref530839229"></a><a name="_Ref528616889"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay will have the exclusive right to negotiate and enter into any agreement to obtain a license or otherwise acquire any intellectual property rights from a Third Party for Patents or Know-How [***].&nbsp;&nbsp;Relay will be responsible for all consideration due to a Third Party in connection with Relay or its Affiliates in-licensing or otherwise acquiring any intellectual property rights under this Section 11.6.4(a).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref53935394"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licensee will have the exclusive right to negotiate and enter into any agreement to obtain a license or otherwise acquire any intellectual property rights from a Third Party for Patents or Know-How [***] (such other compounds or products, &#8220;</font><font style="font-weight:bold;color:#000000;">Licensee Pipeline Compounds</font><font style="color:#000000;">&#8221;) [***].&nbsp;&nbsp;Licensee will be responsible for all consideration due to a Third Party in connection with Licensee or its Affiliates in-licensing or otherwise acquiring any intellectual property rights under this Section 11.6.4(b).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref529941212"></a><a name="_Ref530760443"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">After the Effective Date, if either Party identifies any Patents or Know-How of a Third Party that is not included in the Relay IP or Licensee IP [***], such Party shall promptly notify the other Party of the existence of such Third Party Patents or Know-How.  </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref55462163"></a><a name="_Ref53923034"></a><a name="_Ref52704341"></a><a name="_Ref41403627"></a><a name="_Ref528615626"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licensee will have the exclusive right to negotiate and enter into an agreement to obtain a license or otherwise acquire any intellectual property rights from a Third Party for Patents or Know-How [***] (a &#8220;</font><font style="font-weight:bold;color:#000000;">Collaboration In-License</font><font style="color:#000000;"><a name="_Ref52704341"></a><a name="_Ref41403627"></a><a name="_Ref528615626"></a>&#8221;), provided that Licensee will keep Relay reasonably informed regarding the progress of negotiating any such agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57575458"></a><a name="_Ref55635420"></a><a name="_Ref54767616"></a><a name="_Ref509479188"></a><a name="_Ref509953502"></a><a name="_Ref419825389"></a><a name="_Ref422303081"></a><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay will have the first right to negotiate and enter into an agreement to obtain a license or otherwise acquire any intellectual property rights from a Third Party for any Patents or Know-How Controlled by a Third Party arising out of any agreement between Relay and any Third Party existing as of or prior to the Effective Date and that is necessary or reasonably useful to Research, Develop, Manufacture or Commercialize any Licensed Candidate or Licensed Product, including in any Licensee Combination or any Relay Pipeline Combination (&#8220;</font><font style="font-weight:bold;color:#000000;">Prior Agreement Third Party IP</font><font style="color:#000000;">&#8221;), provided that [***].&nbsp;&nbsp;If Relay notifies Licensee that it declines to negotiate and enter into an agreement to obtain a license to or otherwise acquire such Prior Agreement Third Party IP, or fails to enter into such agreement or acquisition approved by Licensee within [***] after notice of the Prior Agreement Third Party IP pursuant to Section 11.6.4(c), Licensee will have the right to negotiate and enter into any such agreement.&nbsp;&nbsp;Regardless of the Party negotiating and entering into any such agreement to obtain a license or otherwise acquire any intellectual property rights from a Third Party for Prior Agreement Third Party IP, Relay shall be solely responsible for all payments under such agreement to obtain such license or acquire such intellectual property rights.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57647390"></a><a name="_Hlk54767457"></a><font style="text-decoration:none;Background-color:#auto;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">With respect to payments under a Collaboration In-License during the Term of this Agreement for a license under any Patents </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> (&#8220;</font><font style="font-weight:bold;color:#000000;">Shared Collaboration In-License Payments</font><font style="color:#000000;">&#8221;) (</font><font style="color:#000000;">i</font><font style="color:#000000;">) </font><font style="color:#000000;">such Shared Collaboration In-License Payments </font><font style="color:#000000;">will be</font><font style="color:#000000;"> included in</font><font style="color:#000000;"> Development Costs or Allowable Expenses, to the extent consistent with the definitions thereof and (</font><font style="color:#000000;">ii</font><font style="color:#000000;">) any Shared Collaboration In-License Payments that are not Development Costs or Allowable Expenses will be </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> in accordance with Section </font><font style="color:#000000;">11.5.1</font><font style="color:#000000;">,</font><font style="color:#000000;"> </font><font style="color:#000000;">11.5.2</font><font style="color:#000000;">, </font><font style="color:#000000;">11.5.4</font><font style="color:#000000;">, </font><font style="color:#000000;">11.5.5</font><font style="color:#000000;">, </font><font style="color:#000000;">11.6.1</font><font style="color:#000000;"> or </font><font style="color:#000000;">11.6.2</font><font style="color:#000000;"><a name="_Hlk54767457"></a>, </font><font style="color:#000000;">in accordance with Section</font><font style="color:#000000;"> </font><font style="color:#000000;">11.6.4</font><font style="color:#000000;">(g)</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref54767405"></a><a name="_BPDC_LN_INS_1196"></a><a name="_BPDC_PR_INS_1197"></a><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licensee may deduct [***] (collectively &#8220;</font><font style="font-weight:bold;color:#000000;">Deductible Third Party IP Payments</font><font style="color:#000000;">&#8221;) from any of the milestone payments otherwise payable to Relay under Sections 11.5.1, 11.5.2, 11.5.4 and 11.5.5 in an amount equal to up to [***] of such milestone payments and from any royalty payments under Sections 11.6.1 and 11.6.2&nbsp;&nbsp;in a given period in an amount equal to up to [***] of such royalty payments on a Lead Product-by-Lead Product basis in the applicable country, such [***] limit to be calculated after applying Sections 11.6.5 and 11.6.6.&nbsp;&nbsp;For clarity, Licensee may carry forward to subsequent periods any Deductible Third Party IP Payments amounts that are not fully repaid to Licensee pursuant to the foregoing deductions in any period<a name="_BPDC_LN_INS_1196"></a><a name="_BPDC_PR_INS_1197"></a>. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref529040739"></a><a name="_Ref524014396"></a><a name="_Toc524107368"></a><font style="Background-color:#auto;text-decoration:none;">11.6.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">No Valid Claim</font><font style="color:#000000;">.&nbsp;&nbsp;On a Licensed Product-by-Licensed Product and country-by-country basis, if during any portion of the Royalty Term for a given Licensed Product in a given country in the Royalty Territory or Territory, as applicable, no [***] Claim Covers the Licensed Product in the country of sale, then the royalty rate that would otherwise be owed and payable under Section 11.6, in each case, with respect to Net Sales of such Licensed Product in such country will be reduced by [***] for the remainder of such Royalty Term. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:16.35%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1194"></a><a name="_BPDC_PR_INS_1195"></a><a name="_Ref529040741"></a><a name="_Ref530831454"></a><a name="_Ref55378961"></a><a name="_Ref55379285"></a><a name="_Ref56416701"></a><a name="_Ref55934160"></a><a name="_Toc524107369"></a><a name="_Ref524014401"></a><a name="_Ref525229214"></a><font style="Background-color:#auto;text-decoration:none;">11.6.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Generic Entry</font><font style="color:#000000;">.&nbsp;&nbsp;On a Licensed Product-by-Licensed Product and country-by-country basis, if during any portion of the Royalty Term for a given Licensed Product in a given country in the Royalty Territory or Territory, as applicable, there is an entry of a Licensed Product sold by a Compulsory Sublicensee, a Competitive Product sold by Relay, its Affiliates or Relay Sublicensees or any Generic Product, in each case in a given country in the Territory when such Licensed Product is sold in such country by Licensee, its Affiliates or Licensee Sublicensees and (a) there has been a decline of the Sales of the applicable Licensed Product in such country greater than [***] of the average quarterly Sales of Licensed Product in such country [***] before the entry of such Licensed Product sold by a Compulsory Sublicensee, Generic Product or Competitive Product in such country, then the royalty rate that would otherwise be owed and payable under Section 11.6.1, 11.6.2 or 11.6.3 (as applicable), in each case, with respect to Net Sales of such Licensed Product in such country will be reduced [***] for [***] of the Royalty Term for such Licensed Product in such country or, if sooner, until further royalty reduction applies pursuant to clause (b) or (c) below, (b) there has been a decline of the Sales of the applicable Licensed Product in such country [***] of the average quarterly Sales of Licensed Product in such country [***] before the entry of such Licensed Product sold by a Compulsory Sublicensee, Generic Product or Competitive Product in such country, then the royalty rate that would otherwise be owed and payable under Section 11.6.1, 11.6.2 or 11.6.3 (as applicable), in each case, with respect to Net Sales of such Licensed Product in such country will be reduced by [***] for [***] of the Royalty Term for such Licensed Product in such country or, if sooner, until further royalty reduction applies pursuant to clause (c) below, or (c) there has been a decline of the Sales of the applicable Licensed Product in such country greater than [***] of the average quarterly Sales of Licensed Product in such country [***] before the entry of such Licensed Product sold by a Compulsory Sublicensee, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Generic Product or Competitive Product in such country, then the royalty rate that would otherwise be owed and payable under Section</font><font style="color:#000000;"> </font><font style="color:#000000;">11.6.1</font><font style="color:#000000;">, </font><font style="color:#000000;">11.6.2</font><font style="color:#000000;"> or </font><font style="color:#000000;">11.6.3</font><font style="color:#000000;">,</font><font style="color:#000000;"> in each case, with respect to Net Sales of such Licensed Product in such country will be reduced to </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> after which time the license for such Licensed Product in such country shall thereafter be fully paid-up and irrevocable for such Licensed Product in such country</font><font style="color:#000000;"> for so long as such Licensed Product is sold in such country</font><font style="color:#000000;">.</font><font style="color:#000000;"> </font><font style="font-weight:bold;font-size:11pt;color:#000000;"> </font><font style="color:#000000;">The royalty reductions in this Section</font><font style="color:#000000;"> </font><font style="color:#000000;">11.6.6</font><font style="color:#000000;"> and the royalty reductions in Section </font><font style="color:#000000;">11.6.5</font><font style="color:#000000;"> </font><font style="color:#000000;">taken </font><font style="color:#000000;">together shall not exceed </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> reduction for a Licensed Product in a country, except where clause (c) of this Section </font><font style="color:#000000;">11.6.6</font><font style="color:#000000;"> applies, in which case the royalty rate will be reduced to </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> and the license for such Licensed Product in such country shall thereafter be fully paid-up and irrevocable for such Licensed Product in such country</font><font style="color:#000000;"> </font><font style="color:#000000;">for so long as such Licensed Product is sold in such country</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">For the avoidance of </font><font style="color:#000000;">doubt</font><font style="color:#000000;">, royalty reductions pursuant to Section </font><font style="color:#000000;">11.6.4</font><font style="color:#000000;"> will be applied to the royalty as reduced pursuant to Section </font><font style="color:#000000;">11.6.5</font><font style="color:#000000;"> and </font><font style="color:#000000;">11.6.6</font><font style="font-size:11pt;color:#000000;">.</font><font style="color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1192"></a><a name="_BPDC_PR_INS_1193"></a><a name="_Toc529816457"></a><a name="_Ref529966000"></a><a name="_Toc529966490"></a><a name="_Ref530828382"></a><a name="_Ref531371619"></a><a name="_Ref532503399"></a><a name="_Ref532640050"></a><a name="_Ref532640448"></a><a name="_Ref532941571"></a><a name="_Ref41403574"></a><a name="_Ref50722884"></a><a name="_Ref529709495"></a><font style="Background-color:#auto;text-decoration:none;"> 11.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Royalty Payments and Reporting</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Licensee will calculate all amounts payable to Relay pursuant to Section 11.6 at the end of each Calendar Quarter and will pay to Relay the royalty amounts due with respect to a given Calendar Quarter within [***] after the end of such Calendar Quarter.&nbsp;&nbsp;Each payment of royalties due to Relay will be accompanied by a statement of the amount of Sales and Net Sales of each Licensed Product in each country in the Royalty Territory or Territory, as applicable, during the applicable Calendar Quarter (including such amounts expressed in local currency and as converted to Dollars) and a detailed calculation of the amount of royalty payment due on such Net Sales for such Calendar Quarter (including all deductions and reductions).&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1190"></a><a name="_BPDC_PR_INS_1191"></a><a name="_Ref50898274"></a><a name="_Ref41449775"></a><a name="_Toc529244647"></a><font style="Background-color:#auto;text-decoration:none;"> 11.8</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Opt-Out</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1188"></a><a name="_BPDC_PR_INS_1189"></a><font style="Background-color:#auto;text-decoration:none;">11.8.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In the event that Relay exercises its Opt-Out Right, all Shared Products will automatically become Lead Royalty Products as of the effective date of such exercise and, subject to the remainder of this Section 11.8, Section 11.5.1 will apply and Section 11.5.2 will not apply, Section 11.5.4 will apply and Section 11.5.5 will not apply, and Section 11.6.1 will apply and Section 11.6.2 will not apply.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1186"></a><a name="_BPDC_PR_INS_1187"></a><a name="_Ref54193050"></a><a name="_Ref57129155"></a><font style="Background-color:#auto;text-decoration:none;">11.8.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In addition to the foregoing in the case of an exercise by Relay of its Opt-Out Right pursuant to Section 4.2.1 (but expressly excluding any forced exercise of such Opt-Out Right by Licensee pursuant to Section 4.2.2), the royalty rates set forth in Table 11.6.1 will be increased by [***].&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1184"></a><a name="_BPDC_PR_INS_1185"></a><font style="Background-color:#auto;text-decoration:none;"> 11.9</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Relay Pipeline Compounds; Relay Pipeline Products</font><font style="color:#000000;">.&nbsp;&nbsp;Except as set forth in Section 7.2.3, in no event will Relay owe Licensee any milestones, royalties or other payments with respect to the  retained rights under the Relay IP or&nbsp;&nbsp;license under Licensee IP to Develop and co-promote, in accordance with this Agreement and any applicable Coordinated Promotion Agreement, the Relay Pipeline Combination Eligible Licensed Products for Combination Use in Relay Pipeline Combinations. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1182"></a><a name="_BPDC_PR_INS_1183"></a><a name="_Ref51077156"></a><a name="_Ref50722789"></a><font style="Background-color:#auto;text-decoration:none;"> 11.10</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">[***]</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1176"></a><a name="_BPDC_PR_INS_1177"></a><a name="_Ref50818704"></a><font style="Background-color:#auto;text-decoration:none;"> 11.11</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Other Amounts Payable</font><font style="color:#000000;">.&nbsp;&nbsp;With respect to any amounts owed under this Agreement by a Party to the other Party for which no other invoicing and payment procedure is specified in this Agreement, the Party owing such payment obligation will provide to the other Party an </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">invoice, together with reasonable supporting documentation, for such amounts owed and such other Party will pay any undisputed amounts within </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> after receipt of the invoice, and will pay any disputed amounts owed by such other Party within </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> of final resolution of the Dispute.</font><font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1174"></a><a name="_BPDC_PR_INS_1175"></a><a name="_Toc529816237"></a><a name="_Toc529816348"></a><a name="_Toc529816458"></a><a name="_Toc529816238"></a><a name="_Toc529816349"></a><a name="_Toc529816459"></a><a name="_Toc529816239"></a><a name="_Toc529816350"></a><a name="_Toc529816460"></a><a name="_Toc524107371"></a><a name="_Ref525806126"></a><a name="_Ref529040748"></a><a name="_Ref529814292"></a><a name="_Ref529814400"></a><a name="_Ref529814676"></a><a name="_Toc529816461"></a><a name="_Toc529966492"></a><a name="_Ref530142554"></a><a name="_Ref530831179"></a><a name="_Ref39503288"></a><a name="_Ref50722887"></a><font style="Background-color:#auto;text-decoration:none;"> 11.12</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Additional Payment Terms</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref521646925"></a><a name="_Ref521644949"></a><a name="_Ref521646925"></a><a name="_Ref521644949"></a>.  </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1172"></a><a name="_BPDC_PR_INS_1173"></a><a name="_Ref522054434"></a><font style="Background-color:#auto;text-decoration:none;">11.12.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">Method of Payment</font><font style="color:#000000;">.&nbsp;&nbsp;All payments to a Party under this Agreement will be made by deposit of Dollars in the requisite amount to such bank account as such Party&nbsp;&nbsp;may from time to time designate by notice to the other Party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1170"></a><a name="_BPDC_PR_INS_1171"></a><a name="_Ref522054440"></a><a name="_BPDC_LN_INS_1168"></a><a name="_BPDC_PR_INS_1169"></a><font style="Background-color:#auto;text-decoration:none;">11.12.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">Invoices.</font><font style="color:#000000;">&nbsp;&nbsp;All invoices that are required or permitted hereunder to be sent to Licensee shall be in writing and sent by Relay to Licensee&#8217;s Alliance Manager at [***] with a copy to [***]<a name="_BPDC_LN_INS_1168"></a><a name="_BPDC_PR_INS_1169"></a> or such other address as Licensee may later provide.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646926"></a><a name="_Ref521644952"></a><font style="Background-color:#auto;text-decoration:none;">11.12.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">Currency</font><font style="color:#000000;">.&nbsp;&nbsp;For the purpose of calculating any sums due under, or otherwise reimbursable pursuant to, this Agreement (including the calculation of Net Sales expressed in currencies other than Dollars), Licensee will convert any amount expressed in a foreign currency into Dollars equivalents using its, its Affiliate&#8217;s or the applicable Licensee Sublicensee&#8217;s standard conversion methodology consistent with Accounting Standards.<a name="_Ref521646926"></a><a name="_Ref521644952"></a>&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1166"></a><a name="_BPDC_PR_INS_1167"></a><a name="_Ref526507910"></a><font style="Background-color:#auto;text-decoration:none;">11.12.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">Blocked Currency</font><font style="color:#000000;">.&nbsp;&nbsp;Notwithstanding Section 11.12.1 or Section 11.12.2, in the event that Licensee (or its Affiliate or Sublicensee) is prohibited by Applicable Law from making any payment (or portion thereof) to Relay under this Agreement with respect to any given country, such payments shall continue to accrue in such country, but Licensee shall not be obligated to make such payments until such time as payment may be made through reasonable, lawful means or methods that may be available, as Licensee shall reasonably determine, and at the time of payment shall pay such accrued royalties in Dollars using the actual exchange rate which is used to remove such sales proceeds from such country.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1164"></a><a name="_BPDC_PR_INS_1165"></a><font style="Background-color:#auto;text-decoration:none;">11.12.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">Late Payments</font><font style="color:#000000;">.</font><font style="font-weight:bold;color:#000000;">&nbsp;&nbsp;</font><font style="color:#000000;">If any payment due to either Party under this Agreement is not paid when due, then the payor Party with respect thereto will pay simple interest thereon (before and after any judgment) at an annual rate (but with interest accruing on a daily basis) equal to [***].&nbsp;&nbsp;</font><font style="font-weight:bold;color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1162"></a><a name="_BPDC_PR_INS_1163"></a><font style="Background-color:#auto;text-decoration:none;">11.12.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">No Double Counting</font><font style="color:#000000;">.&nbsp;&nbsp;Notwithstanding anything to the contrary contained herein, no cost or expense will be included in calculations of amounts due under this Agreement </font><font style="color:#000000;">if inclusion therein would result in a duplication or double-counting of the same cost or expense hereunder.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1160"></a><a name="_BPDC_PR_INS_1161"></a><a name="_Ref529040753"></a><a name="_Toc529816462"></a><a name="_Toc529966493"></a><a name="_Toc524107372"></a><font style="Background-color:#auto;text-decoration:none;"> 11.13</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Taxes</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp; </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1158"></a><a name="_BPDC_PR_INS_1159"></a><a name="_Ref521644953"></a><a name="_Ref521644956"></a><a name="_Ref53991692"></a><font style="Background-color:#auto;text-decoration:none;">11.13.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_Ref53991692"></a> </font><font style="text-decoration:underline;color:#000000;">General</font><font style="color:#000000;">.&nbsp;&nbsp;Except as expressly set out in this Agreement, a Party making payments to the other Party under this Agreement will make such payments in full without set-off or counterclaim and without deduction or withholding for taxes except to the extent that any such deduction or withholding is required by Applicable Law in effect at the time of payment.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1156"></a><a name="_BPDC_PR_INS_1157"></a><font style="Background-color:#auto;text-decoration:none;">11.13.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">Taxes on Income</font><font style="color:#000000;">.&nbsp;&nbsp;Each Party will be solely responsible for the payment of all taxes imposed on its share of income arising directly or indirectly from the activities of the Parties under this Agreement. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1154"></a><a name="_BPDC_PR_INS_1155"></a><a name="_Ref521644954"></a><a name="_Ref531715614"></a><font style="text-decoration:none;Background-color:#auto;">11.13.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">Withholding</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">Licensee may withhold from payments due to Relay amounts for payment of any withholding tax that is required by Applicable Law to be paid to any taxing authority with respect to such payments.&nbsp;&nbsp;Licensee will give proper evidence, as may be reasonably requested by Relay, from time to time, as to the payment of any such tax.&nbsp;&nbsp;Notwithstanding the foregoing, if Licensee assigns its rights and obligations hereunder to an Affiliate or Third Party pursuant to Section</font><font style="color:#000000;"> 18.3</font><font style="color:#000000;"> or sublicenses any intellectual property licensed to Licensee hereunder, and if Licensee or such Affiliate or Third Party is required by Applicable Law to withhold any additional taxes from or in respect of any amount payable under this Agreement as a result of such assignment or sublicense, then any such amount payable under this Agreement will be increased to take into account the additional taxes withheld as may be necessary so that, after making all required withholdings (including withholdings on the withheld amounts), Relay receives an amount equal to the sum it would have received had no such withholding been made; provided, however, that Licensee will have no obligation to pay any additional amount to the extent that the withholding tax would not have been imposed but for (a) the failure by Relay to take advantage of an otherwise available exemption from or reduction in the rate of withholding tax under any applicable income tax convention between the United States and the jurisdiction in which such Affiliate or Third Party is domiciled, or (b) the assignment by Relay of its rights under this Agreement or any redomiciliation of Relay outside of the United States or any public offering or any other bona fide capital raising event, public or private, a reorganization, spin-out, merger, or consolidation.&nbsp;&nbsp;Notwithstanding the foregoing, if Licensee has an obligation to pay additional amounts to account for withholding taxes, it will be entitled to a full amount of any foreign tax credit attributable to Relay if and when realized in cash by Relay as a result of such payment</font><font style="color:#000000;">.</font><font style="color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1152"></a><a name="_BPDC_PR_INS_1153"></a><a name="_Ref521644955"></a><font style="Background-color:#auto;text-decoration:none;">11.13.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">Cooperation</font><font style="color:#000000;">.&nbsp;&nbsp;The Parties will cooperate with respect to all documentation required by any taxing authority, the preparation of any tax returns, or reasonably requested by either Party to secure a reduction in the rate of applicable withholding taxes. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1150"></a><a name="_BPDC_PR_INS_1151"></a><a name="_Ref528616841"></a><a name="_Ref57983371"></a><a name="DocXTextRef257"></a><a name="DocXTextRef258"></a><font style="Background-color:#auto;text-decoration:none;">11.13.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_Ref57983371"></a> </font><font style="text-decoration:underline;color:#000000;">Indemnification for Withholding</font><font style="color:#000000;">.&nbsp;&nbsp;Subject to Section 11.13.3,<a name="DocXTextRef257"></a> if the applicable paying Party had a duty to withhold taxes in connection with any payment it made to the other Party under this Agreement but such paying Party failed to withhold, and such taxes were assessed against and paid by such paying Party, then the other Party will indemnify and hold harmless such paying Party from and against such taxes (including interest, but not including any related penalties).&nbsp;&nbsp;If such paying Party makes a claim under this Section&#160;11.13.5,<a name="DocXTextRef258"></a> it will comply with the obligations imposed by Section 11.13.4 as if such paying Party had withheld taxes from a payment to the other Party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1148"></a><a name="_BPDC_PR_INS_1149"></a><font style="Background-color:#auto;text-decoration:none;">11.13.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">Tax Treatment</font><font style="color:#000000;">.&nbsp;&nbsp;Except as set forth in the following sentence, Relay and Licensee agree that, consistent with Section 18.19, this Agreement is not intended to constitute a partnership for any purpose, including U.S. federal income and other applicable tax purposes.&nbsp;&nbsp;Relay and Licensee agree to cooperate in good faith to determine the tax treatment of the exercise of the Opt-In Right in the Profit Share Territory, including determining treatment as a partnership for U.S. federal income and other applicable tax purposes, and Relay and Licensee will negotiate in good faith to enter into any agreements advisable or necessary to implement such tax treatment.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1146"></a><a name="_BPDC_PR_INS_1147"></a><a name="_Ref521646927"></a><a name="_Ref521649614"></a><a name="_Toc524107373"></a><a name="_Toc529816463"></a><a name="_Toc529966494"></a><a name="_Ref521644957"></a><font style="Background-color:#auto;text-decoration:none;"> 11.14</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Financial Records</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Each Party will, and will cause its Affiliates and Sublicensees to, keep complete and accurate books and records pertaining to amounts due under this Agreement in sufficient detail to calculate all amounts payable hereunder and to verify compliance with its </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obligations under this Agreement.&nbsp;&nbsp;Such books and records will be retained by each Party and its Affiliates and Sublicensees for </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> after the end of the period to which such books and records pertain</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1144"></a><a name="_BPDC_PR_INS_1145"></a><a name="_Ref50902856"></a><a name="_Ref521646928"></a><a name="_Toc524107374"></a><a name="_Ref521644958"></a><a name="_Toc529966496"></a><a name="_Ref530145650"></a><a name="_Ref530145656"></a><a name="_Ref532473200"></a><a name="_Ref532639714"></a><a name="_Ref532941582"></a><a name="_Ref39598975"></a><a name="_Ref41521456"></a><a name="_Ref41521484"></a><a name="_Toc529816465"></a><a name="_Toc529966497"></a><font style="Background-color:#auto;text-decoration:none;"> 11.15</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Audit Rights</font><font style="color:#000000;">.&nbsp;&nbsp;At the request of Relay, Licensee will, and will cause its Affiliates and Licensee Sublicensees to, permit a certified independent public accountant designated by Relay and reasonably acceptable to Licensee, at reasonable times and upon reasonable notice, to audit the books and records maintained by Licensee (or its Affiliate or Licensee Sublicensee, as applicable) pursuant to this Agreement to ensure the accuracy of all reports and payments made hereunder.&nbsp;&nbsp;Such books and records will be available to the auditor during regular business hours at such place or places where such books and records are customarily kept.&nbsp;&nbsp;Such examinations may not (a)&#160;be conducted for any Calendar Quarter more than [***] after the end of such Calendar Quarter, (b)&#160;be conducted more than once in any [***] period or (c)&#160;be repeated for any Calendar Quarter.&nbsp;&nbsp;Except as provided below, the cost of this audit will be borne by Relay, unless the audit reveals an underreporting of amounts due to, or an overreporting of amounts due from, Relay of at least [***].&nbsp;&nbsp;If such audit concludes that (A)&#160;the amount Licensee paid to Relay for a given Calendar Quarter exceeded the amount that was payable to Relay, then at Licensee&#8217;s option, (1) Relay will reimburse Licensee for such undisputed variance within [***] after the date on which such audit is completed or (2) Licensee will have the right to credit such excess amounts paid towards future payments owed to Relay under this Agreement, or (B)&#160;the amount Licensee paid to Relay for a given Calendar Quarter was less than the amount that was payable to Relay, Licensee will pay Relay for such undisputed variance within [***] after the date on which such audit is completed.&nbsp;&nbsp;Relay will treat all information subject to review under Section 11.14 and this Section 11.15 in accordance with the confidentiality provisions of Article 13.<a name="_Toc529816465"></a><a name="_Toc529966497"></a>&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Ref532653812"></a><a name="_Ref528632611"></a><a name="_Toc529816467"></a><a name="_Toc529966499"></a><a name="_Toc524107377"></a><a name="_Ref521644961"></a><a name="_Ref530175418"></a><a name="_Ref530837766"></a><a name="_Toc41521513"></a><a name="_Toc50796661"></a><a name="_Toc51338590"></a><a name="_Toc53919207"></a><a name="_Toc53925691"></a><font style="Background-color:#auto;text-decoration:none;">Article 12.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_Toc41521513"></a><a name="_Toc50796661"></a><a name="_Toc51338590"></a><a name="_Toc53919207"></a><a name="_Toc53925691"></a>&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Toc50796662"></a><a name="_Toc51338591"></a><a name="_Toc53919208"></a><a name="_Toc53925692"></a>LICENSES; INTELLECTUAL PROPERTY</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref41442371"></a><a name="_Toc529816468"></a><a name="_Ref526414361"></a><a name="_Toc528630578"></a><a name="_Toc529244655"></a><a name="_Ref529965863"></a><a name="_Toc529966500"></a><font style="Background-color:#auto;text-decoration:none;"> 12.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;"><a name="_Toc529816468"></a><a name="_Ref526414361"></a><a name="_Toc528630578"></a><a name="_Toc529244655"></a><a name="_Ref529965863"></a><a name="_Toc529966500"></a>Licenses</font><font style="color:#000000;">.</font><font style="font-weight:bold;color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:13.46%;text-indent:1.92%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56619310"></a><a name="_Ref39545924"></a><a name="_Ref52355327"></a><a name="_Ref41441228"></a><a name="_Ref51568843"></a><font style="Background-color:#auto;text-decoration:none;">12.1.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Relay</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1142"></a><a name="_BPDC_PR_INS_1143"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay hereby grants to Licensee and its Affiliates an exclusive, sublicensable (through multiple tiers, subject to the provisions of Section 12.2), non-transferrable (except as set forth in Section 18.3) license under the Relay IP to Research, Develop, Manufacture and Commercialize the Licensed Candidates and Licensed Products, including Combination Use of such Licensed Candidate and Licensed Products with other compounds or products, in the Field in the Territory; provided that Relay and its Affiliates retain rights under the Relay IP to perform its obligations hereunder or Develop, and co-promote in accordance with this Agreement and any applicable Coordinated Promotion Agreement, the Relay Pipeline Combination Eligible Licensed Products solely for Combination Use in Relay Pipeline Combinations and subject to Section 12.2, and the right to grant licenses (and further sublicenses) with respect thereto and to conduct the activities permitted under Section 9.1.3<a name="_BPDC_LN_INS_1142"></a><a name="_BPDC_PR_INS_1143"></a>.&nbsp;&nbsp;  For the avoidance of doubt the license granted to Licensee does not include the right to Research, Develop, Manufacture or Commercialize Relay Pipeline Compounds or Relay Pipeline Products.  </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:1.92%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">With respect to any Back-Up Compounds, upon determination by Licensee that it will commence Development of a Back-Up Compound, Licensee shall provide a written notice to </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Relay of such determination, and shall identify the Back-Up Compound, </font><font style="color:#000000;">[***]</font><font style="color:#000000;">, and the Relay Patent that </font><font style="color:#000000;">discloses or </font><font style="color:#000000;">claims </font><font style="color:#000000;">such Back-Up Compound.&nbsp;&nbsp;</font><font style="color:#000000;">[***]</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref52350930"></a><a name="_Ref57838989"></a><a name="_Ref51568846"></a><font style="Background-color:#auto;text-decoration:none;">12.1.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay hereby grants to Licensee a non-exclusive, royalty-free, fully paid-up, sublicensable (through multiple tiers, subject to the provisions of Section 12.2), non-transferrable (except as set forth in Section 18.3) license, under the Relay IP for Licensee&#8217;s internal research and pre-clinical development purposes in the Field and in the Territory.&nbsp;&nbsp;It is understood and agreed that no commercial license is granted by Relay under this Section 12.1.2.&nbsp;&nbsp;The license granted pursuant to this Section 12.1.2 will terminate on expiration or termination of this Agreement; provided that (a) [***] and (b) Licensee and its Affiliates shall be entitled to use for any purpose thereafter in the Field and in the Territory the residual information retained by personnel of Licensee and its Affiliates that had access to Relay Know-How or other Relay Confidential Information.&nbsp;&nbsp;As used herein, "residual information" means Know-How or other Confidential Information that are retained in the memories of individuals without the aid of any document or other recorded or stored information containing Relay Know-How or other Relay Confidential Information.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.1.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licensee hereby grants to Relay a non-exclusive, sublicensable (through multiple tiers, subject to the provisions of Section 12.2), non-transferable (except as set forth in Section 18.3), worldwide, royalty-free license under the Licensee IP to perform its obligations hereunder and Develop and co-promote in accordance with this Agreement any applicable Coordinated Promotion Agreement, the Relay Pipeline Combination Eligible Licensed Products solely for Combination Use in Relay Pipeline Combinations.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.1.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay shall further have such rights as are granted to it in the Supply Agreement or pursuant to Section 16.9.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref526414346"></a><a name="_Toc529816469"></a><a name="_Toc529966501"></a><a name="_Ref522042384"></a><a name="_Toc524107378"></a><a name="_Ref522043157"></a><font style="Background-color:#auto;text-decoration:none;"> 12.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Sublicensing</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_BPDC_LN_INS_1140"></a><a name="_BPDC_PR_INS_1141"></a><a name="_BPDC_LN_INS_1138"></a><a name="_BPDC_PR_INS_1139"></a><a name="_BPDC_LN_INS_1136"></a><a name="_BPDC_PR_INS_1137"></a><a name="_BPDC_LN_INS_1134"></a><a name="_BPDC_PR_INS_1135"></a><a name="_BPDC_LN_INS_1132"></a><a name="_BPDC_PR_INS_1133"></a>.&nbsp;&nbsp;Each Party will have the right to grant sublicenses, or in the case of Relay, licenses under the rights retained by Relay, under the rights granted to or retained by it, as applicable, under Section 12.1, through multiple tiers, to (a) any Affiliate and (b) in the case of Licensee, any Third Party and (c) in the case of Relay, (i) any Third Party that is a strategic collaborator (but not a CRO or CMO) with respect to a Relay Pipeline Combination (a &#8220;<font style="font-weight:bold;">Relay Combination Collaborator</font>&#8221;) and (ii) any other Third Party with Licensee&#8217;s prior written consent. As between the Parties, each Party will remain at all times fully liable for any actions or omissions by its Sublicensees that may be a breach of this Agreement, subject to the last sentence of Section  16.3.  Each sublicense granted under this Section 12.2 will be consistent with the terms and conditions of this Agreement, and with respect to sublicenses to Third Party Subcontractors, will be subject to Section 8.1.4.  Relay will give Licensee written notice of entering into an agreement <a name="_BPDC_LN_INS_1140"></a><a name="_BPDC_PR_INS_1141"></a><a name="_BPDC_LN_INS_1138"></a><a name="_BPDC_PR_INS_1139"></a><a name="_BPDC_LN_INS_1136"></a><a name="_BPDC_PR_INS_1137"></a><a name="_BPDC_LN_INS_1134"></a><a name="_BPDC_PR_INS_1135"></a><a name="_BPDC_LN_INS_1132"></a><a name="_BPDC_PR_INS_1133"></a>with a Relay Combination Collaborator.  </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646931"></a><a name="_Toc524107380"></a><a name="_Toc529816470"></a><a name="_Toc529966502"></a><a name="_Ref532472901"></a><a name="_Ref521644962"></a><font style="Background-color:#auto;text-decoration:none;"> 12.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Rights Retained by the Parties</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;For purposes of clarity, each Party retains all rights under Know-How, Patents and other intellectual property, controlled by such Party not expressly granted to the other Party pursuant to this Agreement.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1130"></a><a name="_BPDC_PR_INS_1131"></a><a name="_Toc529816471"></a><a name="_Toc529966503"></a><a name="_Ref57983385"></a><a name="_Ref521646932"></a><a name="_Toc524107381"></a><a name="_Ref521644963"></a><font style="Background-color:#auto;text-decoration:none;"> 12.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">No Implied Licenses</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Except as explicitly set forth in this Agreement, neither Party will be deemed by estoppel, implication or otherwise to have granted the other Party any license or other right to any Know-How, Patents or other intellectual property of such Party.&nbsp;&nbsp;Neither Party nor any of its Affiliates will use or practice any Know-How or Patents licensed or provided to such </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Party or any of its Affiliates outside the scope of or otherwise not in compliance with the rights and licenses granted to such Party and its Affiliates under this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1128"></a><a name="_BPDC_PR_INS_1129"></a><a name="_Ref521646933"></a><a name="_Ref521649659"></a><a name="_Ref521650632"></a><a name="_Toc524107382"></a><a name="_Toc529816472"></a><a name="_Toc529966504"></a><a name="_Ref521644964"></a><font style="Background-color:#auto;text-decoration:none;"> 12.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Bankruptcy</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;All licenses granted under this Agreement are deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to &#8220;intellectual property&#8221; as defined in Section 101 of such Code.&nbsp;&nbsp;Each Party, as licensee, may fully exercise all of its rights and elections under the Bankruptcy Code.&nbsp;&nbsp;The Parties further agree that, if a Party elects to retain its rights as a licensee under any Bankruptcy Code, such Party will be entitled to complete access to any technology licensed to it hereunder and all embodiments of such technology.&nbsp;&nbsp;Such embodiments of the technology will be delivered to the licensee Party not later than: (a) the commencement of bankruptcy proceedings against the licensor, upon written request, unless the licensor elects to perform its obligations under this Agreement; or (b) if not delivered under Section 12.5(a), upon the rejection of this Agreement by or on behalf of the licensor, upon written request.&nbsp;&nbsp;Any agreements supplemental hereto will be deemed to be &#8220;agreements supplementary to&#8221; this Agreement for purposes of Section 365(n) of the Bankruptcy Code.&nbsp;&nbsp;As used herein, &#8220;<font style="font-weight:bold;">Bankruptcy Code</font>&#8221; means the U.S. Bankruptcy Code and any foreign equivalent thereto in any country having jurisdiction over a Party or its assets. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1126"></a><a name="_BPDC_PR_INS_1127"></a><a name="_Ref52534898"></a><a name="_Ref56843319"></a><a name="_Toc529946759"></a><a name="_Ref532955165"></a><a name="_Ref39600613"></a><a name="_Toc524107383"></a><a name="_Toc529816473"></a><a name="_Toc529966505"></a><a name="_Ref521644965"></a><font style="Background-color:#auto;text-decoration:none;"> 12.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Third Party Agreements.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1124"></a><a name="_BPDC_PR_INS_1125"></a><a name="_Ref58527159"></a><a name="_Ref458434948"></a><font style="Background-color:#auto;text-decoration:none;">12.6.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay shall not provide the Lead Candidate to any Third Party, including any Third Party with whom Relay has an existing agreement, on or after the Effective Date.&nbsp;&nbsp; Promptly after the Effective Date, Relay will inform all Third Parties to whom Relay has previously provided the Lead Candidate pursuant to an existing agreement to discontinue use of the Lead Candidate [***].&nbsp;&nbsp;The foregoing sentences of this Section 12.6.1 will not apply to (a) use of the Lead Candidate as permitted under Relay&#8217;s agreement(s) with the Relay Phase Ia Trial CRO, (b) the use of the Lead Candidate by Relay, a Relay Combination Collaborator or Relay Subcontractor solely in connection with Relay&#8217;s pre-clinical Development activities to support Relay Pipeline Combinations, or (c) use of the Lead Candidate as permitted under the Supply Agreement or pursuant to Section 16.9.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.6.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Promptly after the Effective Date, to the extent Relay does not already have such right under the applicable Existing Sponsored Research Agreement, Relay will use Commercially Reasonable Efforts to obtain the right to share data and reports received by Relay under each of the Existing Sponsored Research Agreements with Licensee and for Licensee to use such data and reports for Licensee&#8217;s internal research purposes.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.6.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay shall be responsible for performing all obligations under each Existing Third Party Agreement (including any payment obligations), even if such obligations arise as a result of Licensee&#8217;s (or an Affiliate&#8217;s or Sublicensee&#8217;s) activities in compliance with this Agreement. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Except as could not reasonably be expected to have a materially adverse effect on the licenses or rights granted to Licensee hereunder or impose additional obligations on Licensee, during the Term, Relay shall maintain each Existing Third Party Agreement in full force and effect, in each case in accordance with its terms and conditions, and shall not (i)&#160;commit any acts or omissions that could cause a breach of or give rise to a right to terminate an Existing Third Party Agreement or (ii)&#160;amend or terminate an Existing Third Party </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Agreement</font><font style="color:#000000;"> or exercise or waive any rights it may have under </font><font style="color:#000000;">an</font><font style="color:#000000;"> </font><font style="color:#000000;">Existing Third Party Agreement</font><font style="color:#000000;">, in all cases, without the prior consent of Licensee.</font><font style="color:#000000;">&nbsp;&nbsp;</font><font style="color:#000000;">[***]</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In the event of any notice of breach by Relay given to Relay under any Existing Third Party Agreement, Relay shall immediately notify Licensee in writing and if Relay fails to cure such breach, Licensee shall have the right, but not the obligation, to cure such breach on behalf of Relay solely if the termination of such Existing Third Party Agreement could be reasonably expected to have a materially adverse effect on the licenses or rights granted to Licensee hereunder, and to offset any amounts incurred or paid by Licensee in connection with the cure of such breach against any amounts otherwise payable by Licensee to Relay under this Agreement until fully offset.&nbsp;&nbsp;In the event Relay receives notice of any breach by the other party of the applicable Existing Third Party Agreement in a manner that could be reasonably expected to have a material adverse effect Licensee&#8217;s rights or obligations under this Agreement, Relay shall promptly notify Licensee in writing, and Relay shall take such actions as are reasonably requested by Licensee to enforce such Existing Third Party Agreement. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1122"></a><a name="_BPDC_PR_INS_1123"></a><a name="_Ref58242941"></a><font style="Background-color:#auto;text-decoration:none;"> 12.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Intellectual Property</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1120"></a><a name="_BPDC_PR_INS_1121"></a><a name="_Ref532941616"></a><font style="Background-color:#auto;text-decoration:none;">12.7.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Inventorship</font><font style="color:#000000;">.&nbsp;&nbsp;Notwithstanding the provisions of Section 18.6, inventorship of any inventions (whether patentable or not), and associated Know-How created, conceived or generated by or on behalf of a Party or its Affiliates, whether solely or jointly with any Third Party (or with the other Party or its Affiliates), in the course of activities performed under this Agreement, will be determined by application of U.S. patent law pertaining to inventorship. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1118"></a><a name="_BPDC_PR_INS_1119"></a><a name="_Ref521644967"></a><a name="_Ref530774073"></a><font style="Background-color:#auto;text-decoration:none;">12.7.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Relay</font><font style="color:#000000;">.&nbsp;&nbsp;As between the Parties and subject to Section 12.7.4, Relay will retain all right, title and interest in and to all Relay IP, and no rights or licenses are granted to Licensee hereunder with respect to any Relay IP other than the licenses and rights granted to Licensee pursuant to this Article 12.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1116"></a><a name="_BPDC_PR_INS_1117"></a><a name="_Ref530169335"></a><font style="Background-color:#auto;text-decoration:none;">12.7.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Licensee IP</font><font style="color:#000000;">.&nbsp;&nbsp;As between the Parties and subject to Section 12.7.4, Licensee will retain all right, title and interest in and to all Licensee IP, and no rights or licenses are granted to Relay hereunder with respect to any Licensee IP other than the licenses and rights granted to Relay pursuant to this Article 12.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1114"></a><a name="_BPDC_PR_INS_1115"></a><a name="_Ref532968163"></a><a name="_Hlk39419454"></a><font style="Background-color:#auto;text-decoration:none;">12.7.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Joint Collaboration IP</font><font style="color:#000000;">.&nbsp;&nbsp;As between the Parties, the Parties will each own an equal, undivided interest in all Joint Collaboration IP.&nbsp;&nbsp;Each Party will have the right to exploit the Joint Collaboration IP without a duty of seeking consent or accounting to the other Party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1112"></a><a name="_BPDC_PR_INS_1113"></a><a name="_Ref521644973"></a><a name="_Ref532941629"></a><a name="_Ref521644974"></a><font style="Background-color:#auto;text-decoration:none;">12.7.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Cooperation</font><font style="color:#000000;">.<a name="_Ref521644974"></a>&nbsp;&nbsp;Subject to Section 8.1.4, each Party will cause all Persons who perform activities for such Party under this Agreement to be under an obligation to assign their rights in any Know-How or Patents resulting therefrom to such Party, except where Applicable Law requires otherwise, and except in the case of governmental, not-for-profit and public institutions which have standard policies against such an assignment (in which case a suitable license, or right to obtain such a license, will be obtained).&nbsp;&nbsp;Without limiting (but subject to) the foregoing, each Party will cause its employees, consultants, sublicensees, agents and contractors to assign to such Party, such Person&#8217;s right, title and interest in and to all Know-How or Patents resulting from activities under this Agreement, and intellectual property rights therein.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1110"></a><a name="_BPDC_PR_INS_1111"></a><a name="_Ref532957115"></a><font style="Background-color:#auto;text-decoration:none;">12.7.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Disclosure of Joint IP</font><font style="color:#000000;">.&nbsp;&nbsp;Each Party will promptly disclose to the other any Joint Collaboration Know-How created, conceived or generated during the Term, but no later than [***] after Licensee&#8217;s or its Affiliate&#8217;s intellectual property department receives written notice of such creation, conception or generation.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1108"></a><a name="_BPDC_PR_INS_1109"></a><font style="Background-color:#auto;text-decoration:none;">12.7.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Trademarks</font><font style="color:#000000;">. Licensee will have the sole right to determine and own the Trademarks used in connection with the Development, Manufacture and Commercialization of the Licensed Products on a worldwide basis. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1106"></a><a name="_BPDC_PR_INS_1107"></a><a name="_Toc529946760"></a><a name="_Ref530174979"></a><a name="_Ref530835988"></a><a name="_Ref532476130"></a><a name="_Ref39504270"></a><a name="_Ref39600670"></a><a name="_Ref41760652"></a><a name="_Ref41763205"></a><a name="_Ref50904242"></a><a name="_Ref55368008"></a><a name="_Ref58243009"></a><a name="_Ref530838518"></a><font style="Background-color:#auto;text-decoration:none;"> 12.8</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Prosecution and Maintenance</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:13.46%;text-indent:1.92%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1104"></a><a name="_BPDC_PR_INS_1105"></a><a name="_Ref531355301"></a><a name="_Ref50903661"></a><font style="Background-color:#auto;text-decoration:none;">12.8.1</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Relay Patents and Joint Collaboration Patents</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref39419369"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licensee will have the first right (but not the obligation), in its sole discretion and with counsel of Licensee&#8217;s choice, to Prosecute and Maintain the Relay Patents&nbsp;&nbsp;and Joint Collaboration Patents (other than Relay Combination Patents).&nbsp;&nbsp;[***].&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1102"></a><a name="_BPDC_PR_INS_1103"></a><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licensee shall have the right to allow any Relay Patent to lapse or become abandoned in any Core Country in which such Relay Patent is pending, so long as [***] Relay Patent in the same family has been granted and remains in force in such Core Country; provided that if Licensee intends to allow to lapse or abandon in any Core Country a Relay Patent that includes [***] the Lead Candidate, Relay shall have the rights set forth in Section 12.8.1(b);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1100"></a><a name="_BPDC_PR_INS_1101"></a><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licensee shall have the right to allow any Relay Patent to lapse or become abandoned in all other countries other than the Core Countries even if no related Relay Patent in the same family has been granted in such country; and </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56422686"></a><a name="_Ref41760548"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If Licensee intends to allow a Relay Patent to lapse or become abandoned, and only in such case where such lapse or abandonment is (A) in a Core Country in which [***] other Relay Patent in the same family has been granted and remains in force, (B)&nbsp;&nbsp;worldwide for the entire patent family to which such Relay Patent relates, or (C) such lapse or abandonment is in a Core Country and such Relay Patent includes [***] the Lead Candidate, then in any of the foregoing (A), (B) or (C), Licensee will provide reasonable prior written notice to Relay of such intention (which notice will, in any event, be given no less than [***] prior to the date for which lapse or abandonment will occur), and Relay will thereupon have the right (but not the obligation) to assume the Prosecution and Maintenance thereof, at Relay&#8217;s cost and expense with counsel of Relay&#8217;s choice, after prior written notice to Licensee.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay will have the first right (but not the obligation), in its sole discretion and at its cost and expense with counsel of Relay&#8217;s choice, to Prosecute and Maintain the Relay Combination Patents.&nbsp;&nbsp;Notwithstanding the foregoing, if Relay&#8217;s strategy with respect to the Prosecution and Maintenance of any Relay Combination Patent could reasonably be expected to materially conflict with or negatively impact Licensee&#8217;s strategy with respect to the Prosecution and Maintenance of Licensed Candidates and Licensed Products, including Licensee Combinations, Relay will notify Licensee and meet with Licensee a reasonable time prior to Relay&#8217;s filing a patent application with respect to such Relay Combination Patent to discuss such strategy and attempt to resolve in good faith any such material conflict or negative impact, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">including considering whether Relay&#8217;s strategy can be modified to avoid any conflicts or negative impacts. </font><font style="color:#000000;"> </font><font style="color:#000000;">[***]</font><font style="color:#000000;">.</font><font style="color:#000000;"> </font><font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref58519621"></a><a name="_Hlk58410215"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay will keep Licensee&#8217;s outside patent counsel informed as to material developments with respect to the Prosecution and Maintenance of&nbsp;&nbsp;Generic Relay Combination Patents<a name="_Hlk58410215"></a> and other Relay Combination Patents [***]with compounds or products Directed to the Collaboration Target, including by providing Licensee&#8217;s outside patent counsel with a copy of material communications to and from any patent authority regarding such Generic Relay Combination Patent or such other Relay Combination Patent, and by providing the drafts to Licensee&#8217;s outside patent counsel of any material filings or responses to be made to such patent authorities sufficiently in advance of submitting such filings or responses so as to allow for a reasonable opportunity for Licensee&#8217;s outside patent counsel to review and comment thereon.&nbsp;&nbsp;Relay will consider in good faith the requests and suggestions of Licensee&#8217;s outside patent counsel with respect to such drafts of Relay and with respect to strategies for filing and prosecuting the applicable Generic Relay Combination Patent or applicable other Relay Combination Patent.&nbsp;&nbsp;Notwithstanding the foregoing, Relay will promptly inform Licensee&#8217;s outside patent counsel of any adversarial patent office proceeding or sua sponte filing, including a request for, or filing or declaration of, any interference, derivation proceeding, post-grant proceeding, opposition, post-grant proceeding or reexamination relating to the applicable Generic Relay Combination Patent or applicable other Relay Combination Patent.&nbsp;&nbsp;Relay  will consult with Licensee&#8217;s outside patent counsel and Relay will consider in good faith all comments, requests and suggestions provided by Licensee&#8217;s outside patent counsel. Licensee will cause its outside counsel to not share with Licensee the foregoing information provided by Relay to Licensee&#8217;s outside patent counsel under this Section (d), except if Licensee exercises its back-up rights as provided below. If Relay intends to allow a Generic Relay Combination Patent or another Relay Combination Patent [***] with compounds or products Directed to the Collaboration Target to lapse or become abandoned, then Relay will provide reasonable prior written notice to Licensee of such intention (which notice will, in any event, be given no later than [***] prior to the next deadline for any action that may be taken with respect to such Patent in such country), and (i) in the case of Generic Relay Combination Patents, Licensee will thereupon have the right (but not the obligation) to assume the Prosecution and Maintenance thereof, at Licensee&#8217;s cost and expense with counsel of Licensee&#8217;s choice and (ii) in the case of&nbsp;&nbsp;Relay Combination Patents other than Generic Relay Combination Patents [***] with compounds or products Directed to the Collaboration Target, to the extent it is possible, Licensee may file a continuing applications [***], which application would then constitute a Generic Relay Combination Patent for all purposes under this Agreement, except that with respect to Prosecution and Maintenance, Licensee will have the sole right (but not the obligation) to Prosecute and Maintain such Generic Relay Combination Patent at Licensee&#8217;s cost and expense with counsel of Licensee&#8217;s choice.&nbsp;&nbsp;<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1098"></a><a name="_BPDC_PR_INS_1099"></a><a name="_Ref52704534"></a><a name="_Ref54196143"></a><a name="_Ref41760555"></a><a name="_Ref521644981"></a><font style="Background-color:#auto;text-decoration:none;">12.8.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Cooperation</font><font style="color:#000000;">.&nbsp;&nbsp;&nbsp;&nbsp;Each Party will provide the other Party all reasonable assistance and cooperation in the Prosecution and Maintenance efforts with respect to any Relay Patent or Joint Collaboration Patent, including providing any necessary powers of attorney and executing any other required documents or instruments for such prosecution&nbsp;&nbsp;and taking all actions necessary to correct any error or mistake in inventorship. When a Party assumes the responsibilities for the Prosecution and Maintenance of a Patent under Section 12.8.1, the other Party will promptly transfer to such Party the patent prosecution files for such Patent and provide reasonable assistance </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">in the transfer of the prosecution responsibilities. The Party assuming such Prosecution and Maintenance responsibilities will have the right to engage its own counsel to do so.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1096"></a><a name="_BPDC_PR_INS_1097"></a><a name="_Ref55574715"></a><a name="DocXTextRef289"></a><font style="Background-color:#auto;text-decoration:none;">12.8.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">CREATE Act/AIA</font><font style="color:#000000;"><a name="DocXTextRef289"></a>.&nbsp;&nbsp;It is the intention of the Parties that this Agreement is a &#8220;joint research agreement&#8221; as that phrase is defined in the Cooperative Research and Technology Enhancement Act of 2004, 35 U.S.C. 103(c)(2)-(c)(3) (the &#8220;</font><font style="font-weight:bold;color:#000000;">CREATE Act</font><font style="color:#000000;">&#8221;) or the Leahy-Smith America Invents Act of 2011, 35 U.S.C. 100(h) and 102(c)(1)(3) (the &#8220;</font><font style="font-weight:bold;color:#000000;">AIA</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;&nbsp;&nbsp;In the event that a Party intends to overcome a rejection of a claimed invention within the Relay Patents or Joint Collaboration Patents under this Agreement pursuant to the provisions of 35 USC &#167; 102(c) or 35 USC &#167; 103(c), such Party shall first obtain the prior written consent of the other Party.&nbsp;&nbsp;Following receipt of such written consent, such Party shall limit any amendment to the specification or statement to the patent office with respect to this Agreement to that which is strictly required by 35 USC &#167; 102(c) or 35 USC &#167; 103(c) and the rules and regulations promulgated thereunder and which is consistent with the terms and conditions of this Agreement.&nbsp;&nbsp;If the Parties agree that, in order to overcome a rejection of a claimed invention within the Relay Patents or Joint Collaboration Patents pursuant to the provisions of the CREATE Act or AIA, the filing of a terminal disclaimer is required or advisable, the Parties shall first agree on terms and conditions under which the patent application subject to such terminal disclaimer and the patent or application over which such application is disclaimed shall be jointly enforced, if and to the extent that the Parties have not previously agreed to such terms and conditions. To the extent applicable or necessary, Relay shall use Commercially Reasonable Efforts to obtain the prompt cooperation of DESRES in effectuating the objectives of this Section 12.8.3.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1094"></a><a name="_BPDC_PR_INS_1095"></a><a name="_Toc529946761"></a><a name="_Ref530139851"></a><a name="_Ref530175045"></a><a name="_Ref530754336"></a><a name="_Ref531371241"></a><a name="_Ref532476132"></a><a name="_Ref39600680"></a><a name="_Ref39606170"></a><a name="_Ref52354267"></a><a name="_Ref56159813"></a><a name="_Ref56259075"></a><a name="_Ref56333633"></a><a name="_Ref56333686"></a><a name="_Ref58243012"></a><a name="_Ref522276537"></a><font style="Background-color:#auto;text-decoration:none;"> 12.9</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Enforcement</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;"> of Relay Patents and Joint Collaboration Patents</font>.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1092"></a><a name="_BPDC_PR_INS_1093"></a><a name="_Ref530175023"></a><font style="Background-color:#auto;text-decoration:none;">12.9.1</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Notice</font><font style="color:#000000;">.&nbsp;&nbsp;If either Party learns of any actual or suspected infringement of any Relay Patent or Joint Collaboration Patent in the Field, in each case, such Party will promptly notify the other Party in writing and will provide such other Party with available evidence of such infringement, and following such notification, the Parties will confer.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:13.46%;text-indent:1.92%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1090"></a><a name="_BPDC_PR_INS_1091"></a><a name="_Ref52354522"></a><a name="_Ref522729634"></a><font style="Background-color:#auto;text-decoration:none;">12.9.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Enforcement</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref50904469"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Infringement</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref530208332"></a><a name="_Ref532495849"></a><a name="_Ref50904454"></a><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_Ref530208332"></a><a name="_Ref532495849"></a><a name="_Ref50904454"></a>Licensee will have the first right (but not the obligation) in its discretion to enforce any Patent within the Relay Patents or Joint Collaboration Patents against any infringement in the Field, including without limitation Competitive Infringement (which may include settlement or otherwise seeking to secure the abatement of such infringement) by counsel of its choice, in its own name, including the right to control the defense of any challenges to any such Relay Patent or Joint Collaboration Patent as a counterclaim in such infringement proceeding as well as the defense of declaratory judgment actions.&nbsp;&nbsp;Relay shall reasonably cooperate with Licensee in any infringement action pursuant to this Section 12.9.&nbsp;&nbsp;If Licensee finds it necessary or desirable for Relay to join Licensee as a party to any such claim, suit, or proceeding with respect to any such infringement, the Parties will cooperate to execute all papers and perform such acts as will be reasonably required for Relay to join such claim, suit, or proceeding.&nbsp;&nbsp; </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref55575182"></a><a name="_Ref532495850"></a><font style="text-decoration:none;Background-color:#auto;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If Licensee notifies Relay that Licensee declines to enforce any </font><font style="color:#000000;">of the Relay Patents or Joint Collaboration </font><font style="color:#000000;">Patent</font><font style="color:#000000;">s</font><font style="color:#000000;"> against any </font><font style="color:#000000;">i</font><font style="color:#000000;">nfringement </font><font style="color:#000000;">in the Field</font><font style="color:#000000;"> or fails to commence an enforcement action with respect to any </font><font style="color:#000000;">i</font><font style="color:#000000;">nfringement of any </font><font style="color:#000000;">of the Relay Patents or Joint Collaboration </font><font style="color:#000000;">Patent</font><font style="color:#000000;">s</font><font style="color:#000000;"> </font><font style="color:#000000;">under Section </font><font style="color:#000000;">12.9.2(a)(i)</font><font style="color:#000000;"> within </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> following delivery of notice pursuant to Section </font><font style="color:#000000;">12.9.1</font><font style="color:#000000;">,</font><font style="color:#000000;"> Relay will thereupon have the right (but not the obligation) to enforce </font><font style="color:#000000;">applicable Relay Patents or Joint Collaboration Paten</font><font style="color:#000000;">t</font><font style="color:#000000;">s</font><font style="color:#000000;"> </font><font style="color:#000000;">against such </font><font style="color:#000000;">i</font><font style="color:#000000;">nfringement, at its own cost and expense (which may include settlement or otherwise seeking to secure the abatement of such infringement), by counsel of its choice, in </font><font style="color:#000000;">its </font><font style="color:#000000;">own name, including the right to control the defense of any challenges to </font><font style="color:#000000;">any</font><font style="color:#000000;"> such </font><font style="color:#000000;">Relay Patent or Joint Collaboration Patent </font><font style="color:#000000;">as a counterclaim in such infringement proceeding as well as the defense of declaratory judgment actions, in each case</font><font style="color:#000000;"> </font><font style="color:#000000;">after prior written notice to Licensee.&nbsp;&nbsp;</font><font style="color:#000000;">For the avoidance of doubt</font><font style="color:#000000;">, </font><font style="color:#000000;">Relay shall have no right to take over enforcement of any Relay Patent or Joint Collaboration Patent against an infringement pursuant to this subclause (a)</font><font style="color:#000000;">(ii)</font><font style="color:#000000;"> if Licensee is enforcing </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> Relay Patent or Joint Collaboration Patent </font><font style="color:#000000;">or other Patent in the Licensee IP </font><font style="color:#000000;">against such infringement.&nbsp;&nbsp;</font><font style="color:#000000;">Relay shall </font><font style="color:#000000;">further </font><font style="color:#000000;">have no right to take over enforcement of any </font><font style="color:#000000;">Relay </font><font style="color:#000000;">Patent </font><font style="color:#000000;">or Joint Collaboration Patent </font><font style="color:#000000;">against </font><font style="color:#000000;">an infringement </font><font style="color:#000000;">pursuant to this subclause (a)</font><font style="color:#000000;">(ii)</font><font style="color:#000000;"> if</font><font style="color:#000000;">&nbsp;&nbsp;</font><font style="color:#000000;">such </font><font style="color:#000000;">i</font><font style="color:#000000;">nfringement is a deemed </font><font style="color:#000000;">i</font><font style="color:#000000;">nfringement as a result of the filing of an ANDA by a Third Party with respect to a Licensed Product in the Field in the Territory with the Licensed Product as the reference product by any such Third Party.&nbsp;&nbsp;Licensee shall reasonably cooperate with Relay in any infringement action pursuant to this Section </font><font style="color:#000000;">12.9.2</font><font style="color:#000000;">(a)</font><font style="color:#000000;">(ii)</font><font style="color:#000000;">.</font><font style="color:#000000;">&nbsp;&nbsp;If Relay finds it necessary or desirable for Licensee to join Relay as a party to any such claim, suit, or proceeding with respect to any such infringement, the Parties will cooperate to execute all papers and perform such acts as will be reasonably required for Licensee to join such claim, suit, or proceeding.&nbsp;&nbsp;During any such claim, suit, or proceeding with respect to any </font><font style="color:#000000;">i</font><font style="color:#000000;">nfringement of any 1971 </font><font style="color:#000000;">Patent </font><font style="color:#000000;">or</font><font style="color:#000000;"> Relay </font><font style="color:#000000;">Combination Patent, Relay will keep Licensee regularly informed of the status and progress of such enforcement efforts and will reasonably consult with Licensee, including using reasonable efforts to take License</font><font style="color:#000000;">e</font><font style="color:#000000;">&#8217;s comments into good faith consideration with respect to such </font><font style="color:#000000;">i</font><font style="color:#000000;">nfringement or the claim construction of any </font><font style="color:#000000;">i</font><font style="color:#000000;">nfringement claim in any such Patent.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notwithstanding anything herein the contrary, Licensee&#8217;s rights under this Section 12.9 with respect to Relay Combination Patents are limited to Generic Relay Combination Patents and Licensee has no rights under this Section 12.9 with respect to other Relay Combination Patents. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1088"></a><a name="_BPDC_PR_INS_1089"></a><a name="_Ref54781684"></a><a name="_Ref530175233"></a><a name="_Ref531700592"></a><font style="Background-color:#auto;text-decoration:none;">12.9.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Cooperation</font><font style="color:#000000;">.&nbsp;&nbsp;The Party not controlling any infringement action pursuant to Section 12.9.2(a) will reasonably cooperate with the controlling Party. A settlement or consent judgment or other voluntary final disposition of a suit with respect to any Relay Patents or Joint Collaboration Patent under Section 12.9.2(a) may be entered into without the consent of the non-controlling Party; provided, however, that any such settlement, consent judgment or other disposition of any action or proceeding by the controlling Party under Section 12.9.2(a)<a name="_Ref530175233"></a><a name="_Ref531700592"></a> will not, without the prior written consent of the non-controlling Party (a) impose any liability or obligation on the non-controlling Party or any of its Affiliates or (b) conflict with or reduce the scope of the subject matter claimed in the applicable Relay Patent or Joint Collaboration Patent.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:13.46%;text-indent:1.92%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1086"></a><a name="_BPDC_PR_INS_1087"></a><a name="_Ref39606277"></a><font style="Background-color:#auto;text-decoration:none;">12.9.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Costs and Recoveries</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:13.46%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref532653682"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Party enforcing any Patent under this Section 12.9 (the &#8220;</font><font style="font-weight:bold;color:#000000;">Enforcing Party</font><font style="color:#000000;">&#8221;) will pay all costs and expenses incurred in connection with any action, suit or proceeding brought under Section 12.9.2(a).&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref52354617"></a><a name="_Ref50905688"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">To the extent the enforcement of a Patent against any infringement pursuant to this Section 12.9 involves a Shared Product in the Profit Share Territory, then all costs and recoveries incurred or obtained pursuant to this Section 12.9.4 will be deemed to be Other Shared Expenses and included in the calculation of Net Profits and Net Losses in accordance with the Sharing Percentages pursuant to Section 11.3.1.<a name="_Ref50905688"></a> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref532629876"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Except as set forth in Section 12.9.4(b), all damages or other monetary awards recovered in any action, suit or proceeding brought under Section 12.9.2(a) to the extent related to any Relay Patent or Joint Collaboration Patent will be shared as follows:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521644989"></a><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the amount of such recovery actually received will first be applied to Out-of-Pocket Costs incurred by each Party in connection with such action (including, for this purpose, a reasonable allocation of expenses of internal counsel); and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521644990"></a><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any remaining proceeds constituting direct or actual damages for acts of infringement will be paid to, or retained by, the Enforcing Party; provided that, if the Enforcing Party is Licensee, such amounts will be included in Net Sales for the Calendar Quarter in which such amounts are received by Licensee; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any remaining proceeds constituting punitive or treble damages will be allocated between the Parties as follows: [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay will retain all recoveries obtained by Relay with respect to Relay Combination Patents that are not Generic Relay Combination Patents. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1084"></a><a name="_BPDC_PR_INS_1085"></a><a name="_Toc529946763"></a><a name="_Ref530175089"></a><a name="_Ref531371468"></a><a name="_Ref39600714"></a><a name="_Ref55297768"></a><a name="_Ref55297774"></a><a name="_Ref55411978"></a><a name="_Ref58348004"></a><font style="Background-color:#auto;text-decoration:none;"> 12.10</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Invalidity or Unenforceability Defenses or Actions</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1082"></a><a name="_BPDC_PR_INS_1083"></a><a name="_Ref530175096"></a><font style="Background-color:#auto;text-decoration:none;">12.10.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&nbsp;&nbsp;</font><font style="text-decoration:underline;color:#000000;">Notice</font><font style="color:#000000;">.&nbsp;&nbsp;During the Term of this Agreement, each Party will promptly notify the other Party in writing of any written assertion of invalidity or unenforceability of any Relay Patents or Joint Collaboration Patents by a Third Party, including any inter partes review, re-examinations, post-grant proceedings or other similar proceedings with respect to any Relay Patent or Joint Collaboration Patent, in each case, of which such Party becomes aware.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1080"></a><a name="_BPDC_PR_INS_1081"></a><a name="_Ref53924338"></a><font style="Background-color:#auto;text-decoration:none;">12.10.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_Ref53924338"></a>&nbsp;&nbsp;</font><font style="text-decoration:underline;color:#000000;">Defense</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref53924749"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">During the Term of this Agreement, Licensee will have the first right (but not the obligation) to defend and control the defense of the validity and enforceability of any Relay Patent or Joint Collaboration Patent (other than Relay Combination Patents), at its own cost and expense, subject to the remainder of this Section 12.10.2.&nbsp;&nbsp;With respect to any such action involving the validity or enforceability of any such Relay Patent or Joint Collaboration Patent, if Licensee finds it necessary or desirable for Relay to join Licensee as a party to any such action, Relay will, at Licensee&#8217;s request and expense, join Licensee as a party to such suit; provided that, Relay will pay for counsel of its choosing if Relay chooses not to participate with Licensee&#8217;s counsel; provided further that Licensee will retain control of the defense in such claim, suit, or </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">proceeding.&nbsp;&nbsp;With respect to 1971 Patents, Licensee will initially pay its costs and expense and all liabilities, damages, recoveries or settlement payments with respect to the defense of the relevant 1971 Patent and the Parties will thereafter will share any Licensee costs and expenses and liabilities, damages, recoveries, or settlement payments arising out of Licensee&#8217;s defense of such 1971 Patent (i) as an Other Shared Expense to the extent the defense of such 1971 Patent involved a Shared Product in the Profit Share Territory and included in the calculation of Net Profits and Net Losses in accordance with the Sharing Percentages pursuant to Section </font><font style="color:#000000;">11.13.1</font><font style="color:#000000;"> and (ii) Licensee </font><font style="color:#000000;">may deduct </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> of the remaining costs, expenses, </font><font style="color:#000000;">liabilities, damages, recoveries, or settlement payments paid by Licensee pursuant to this Section </font><font style="color:#000000;">12.10.2</font><font style="color:#000000;"> </font><font style="color:#000000;">from the </font><font style="color:#000000;">subsequent payments due from Licensee to Relay in accordance with Section </font><font style="color:#000000;">11.5.1</font><font style="color:#000000;">,</font><font style="color:#000000;"> </font><font style="color:#000000;">11.5.2</font><font style="color:#000000;">, </font><font style="color:#000000;">11.5.4</font><font style="color:#000000;">, </font><font style="color:#000000;">11.5.5</font><font style="color:#000000;">, </font><font style="color:#000000;">11.6.1</font><font style="color:#000000;"> or </font><font style="color:#000000;">11.6.2</font><font style="color:#000000;"> </font><font style="color:#000000;">in accordance with Section </font><font style="color:#000000;">11.6.4(g)</font><font style="color:#000000;">.</font><font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If Licensee notifies Relay that Licensee declines to defend and control the defense of any such action with respect to any Relay Patent or Joint Collaboration Patent under Section 12.10.2 or fails to commence defending any such action Section (a) within [***] following delivery of notice pursuant to Section 12.10.1, Relay will thereupon have the right (but not the obligation) to assume control of such defense, at its own cost and expense (which may include settlement), by counsel of its choice after prior written notice to Licensee.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref55575665"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">During the Term of this Agreement, Relay will have the first right (but not the obligation) to defend and control the defense of the validity and enforceability of any Relay Combination Patent.&nbsp;&nbsp;With respect to any such action involving the validity or enforceability of any such Relay Combination Patent, if Relay finds it necessary or desirable for Licensee to join Relay as a party to any such action, Licensee will, at Relay&#8217;s request and expense, join Relay as a party to such suit and participate with its own counsel at its own cost and expense; provided that Licensee will pay for counsel of its choosing if Licensee chooses not to participate with Relay&#8217;s counsel; provided further that Relay will retain control of the defense in such claim, suit, or proceeding.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If Relay notifies Licensee that Relay declines to defend and control the defense of any such action with respect to any Generic Relay Combination Patent under Section 12.10.2(c) within [***] following delivery of notice pursuant to Section 12.10.1, Licensee will thereupon have the right (but not the obligation) to assume control of such defense, at its own cost and expense (which may include settlement), by counsel of its choice after prior written notice to Licensee. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1078"></a><a name="_BPDC_PR_INS_1079"></a><font style="Background-color:#auto;text-decoration:none;">12.10.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&nbsp;&nbsp;</font><font style="text-decoration:underline;color:#000000;">Cooperation</font><font style="color:#000000;">.&nbsp;&nbsp;Each Party will assist and cooperate with the other Party as such other Party may reasonably request from time to time in connection with its activities set forth in this Section 12.10, including by being joined as a party plaintiff in such action or proceeding, as applicable, providing access to relevant documents and other evidence, and making its employees available at reasonable business hours.&nbsp;&nbsp;In connection with any such defense or claim or counterclaim, the controlling Party will consider in good faith any comments from the other Party and will keep the other Party reasonably informed of any material developments, and will provide copies of all documents filed, in connection with such defense, claim, or counterclaim.&nbsp;&nbsp;During the Term of this Agreement, in connection with the activities set forth in this Section 12.10, each Party will consult with the other as to the strategy for the defense of any Relay Patent or Joint </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Collaboration Patent, as applicable</font><font style="color:#000000;">;</font><font style="color:#000000;"> provided that Licensee will have no such consultation right with respect to Relay Combination Patents that are not Generic Relay Combination Patents</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1076"></a><a name="_BPDC_PR_INS_1077"></a><a name="_Ref521646935"></a><a name="_Ref521649974"></a><a name="_Toc524107386"></a><a name="_Toc529244663"></a><a name="_Ref521644992"></a><font style="Background-color:#auto;text-decoration:none;"> 12.11</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Defense of Claims Brought by Third Parties</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1074"></a><a name="_BPDC_PR_INS_1075"></a><a name="_Ref522058678"></a><a name="_Ref52704768"></a><font style="Background-color:#auto;text-decoration:none;">12.11.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_Ref52704768"></a> </font><font style="text-decoration:underline;color:#000000;">Notice</font><font style="color:#000000;">.&nbsp;&nbsp;If a Party becomes aware of any actual or potential claim that the Development, Manufacture or Commercialization of any Licensed Candidate or Licensed Product (including any Licensee Combination or Relay Pipeline Combination) under this Agreement infringes the intellectual property rights of any Third Party (a &#8220;</font><font style="font-weight:bold;color:#000000;">Third Party Action</font><font style="color:#000000;">&#8221;), such Party will promptly notify the other Party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1072"></a><a name="_BPDC_PR_INS_1073"></a><a name="_Ref522058725"></a><a name="_Ref57633137"></a><a name="_Ref54196720"></a><a name="_DV_C1012"></a><a name="_Ref88643671"></a><a name="_DV_C1014"></a><a name="_Ref522059053"></a><a name="_Ref55630764"></a><a name="_DV_C1018"></a><font style="Background-color:#auto;text-decoration:none;">12.11.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_Ref57633137"></a> </font><font style="text-decoration:underline;color:#000000;">Defense</font><font style="color:#000000;"><a name="_Ref54196720"></a>.&nbsp;&nbsp;If a Third Party Action is commenced against either Party, its Affiliates or its Sublicensees then the Party (or its Affiliate or Sublicensee, as applicable) who is named as the defendant shall have the right (but not the obligation) to defend such Third Party Action at its own expense using counsel of its choice.&nbsp;&nbsp;Notwithstanding the foregoing, if a Third Party Action is commenced against both&nbsp;&nbsp;Relay (or any of its Affiliates or Sublicensees), on the one hand, and Licensee (or any of its Affiliates or Sublicensees), on the other hand (a &#8220;</font><font style="font-weight:bold;color:#000000;">Joint Third Party Action</font><font style="color:#000000;">&#8221;), then Licensee will have the right (but not the obligation) to conduct and control defense of the Joint Third Party Action and to compromise or settle the same.<a name="_DV_C1012"></a><a name="_Ref88643671"></a> Subject to Licensee&#8217;s right to conduct and control such defense, Relay will be entitled to be represented by independent counsel of its choice at its own expense. If Licensee declines or fails to assert its intention to conduct and control the defense of such Joint Third Party Action within [***] following receipt of notice under Section&#160;12.11.1, then Relay (or its Affiliates or Sublicensees) will have the right (but not the obligation) to defend itself in such Third Party Action<a name="_DV_C1014"></a><a name="_Ref522059053"></a><a name="_Ref55630764"></a> with counsel of its choice.&nbsp;&nbsp;The Parties will reasonably cooperate with each other in all Third Party Actions.<a name="_DV_C1018"></a>&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1070"></a><a name="_BPDC_PR_INS_1071"></a><a name="_Ref53926085"></a><a name="_Ref50906030"></a><a name="_Ref57647767"></a><a name="_Ref53925255"></a><a name="_DV_C1020"></a><font style="Background-color:#auto;text-decoration:none;">12.11.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_Ref53926085"></a><a name="_Ref50906030"></a><a name="_Ref57647767"></a> </font><font style="text-decoration:underline;color:#000000;">Costs of a Third Party Action</font><font style="color:#000000;"><a name="_Ref53925255"></a>.&nbsp;&nbsp;Subject to the remainder of this Section 12.11.3, the controlling Party will pay all costs and expenses of defending such Third Party Actions and all liabilities, damages, recoveries or settlement payments associated with such Third Party Action (other than, in the case of a Joint Third Party Action controlled by Licensee as provided in Section 12.11.2, the costs and expenses of Relay if Relay elects to be represented by independent counsel of its choice in such Joint Third Party Action)<a name="_DV_C1020"></a>.&nbsp;&nbsp;Notwithstanding the foregoing, with respect to a Third Party Action that alleges the manufacture, use or sale of the Lead Candidate or a Lead Product (including any Licensee Combination or Relay Pipeline Combination including the Lead Candidate or a Lead Product) infringes a Patent Controlled by such Third Party (a &#8220;</font><font style="font-weight:bold;color:#000000;">Third Party Lead Product Action</font><font style="color:#000000;">&#8221;), (a) to the extent the Third Party Lead Product Action involves a Shared Product in the Profit Share Territory, then the controlling Party&#8217;s costs and expenses and liabilities, damages, recoveries or settlement payments for such Third Party Lead Product Action will be deemed to be Other Shared Expenses and included in the calculation of Net Profits and Net Losses in accordance with the Sharing Percentages pursuant to Section 11.3.1; and (b) Licensee may deduct [***] of the remaining costs and expenses and liabilities, damages, recoveries or settlement payments paid by Licensee under this Section 12.11.3 from any subsequent payments due from Licensee to Relay in accordance with Section 11.5.1, 11.5.2, 11.5.4, 11.5.5, 11.6.1 or 11.6.2 in accordance with Section 11.6.4(g).&nbsp;&nbsp;In addition, with respect to a Third Party Action that alleges the Research, Development, Manufacture or Commercialization of a Licensed Candidate or Licensed Product (including any Licensee Combination or Relay Pipeline Combination including a Licensed Candidate or Licensed Product), infringes Prior Agreement Third Party IP, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Relay shall be solely responsible for the costs and expenses and any liabilities, damages, recoveries or settlement payments for such Third Party Action and will promptly reimburse Licensee for any of the foregoing incurred by Licensee.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1068"></a><a name="_BPDC_PR_INS_1069"></a><a name="_Ref528669410"></a><font style="Background-color:#auto;text-decoration:none;">12.11.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">No Settlement Without Consent</font><font style="color:#000000;">.&nbsp;&nbsp;Neither Party will settle or otherwise compromise any Third Party Action by admitting that any Patent within the Relay Patents or Joint Collaboration Patents is invalid or unenforceable without the other Party&#8217;s prior written consent; provided that Relay may make such admissions with respect to Relay Combination Patents that are not Generic Relay Combination Patents.&nbsp;&nbsp;Without limiting the foregoing, in the event that Relay is the controlling Party, Relay may not, without the prior written consent of Licensee, (a) settle or otherwise compromise a Third Party Action which would require the grant of any license, covenant or other rights to any Third Party that would conflict with or reduce the scope of the rights or licenses granted to Licensee under this Agreement or otherwise adversely affect the interest of Licensee in any respect and (b) enter into any license with such Third Party in connection with any such settlement unless any license or rights granted to Relay are fully sublicensable to Licensee in accordance with the terms of this Agreement. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1066"></a><a name="_BPDC_PR_INS_1067"></a><font style="Background-color:#auto;text-decoration:none;"> 12.12</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Common Interest Disclosures</font><font style="color:#000000;">.&nbsp;&nbsp;The Parties have a common legal interest in determining whether, and to what extent, Third Party intellectual property rights may affect the conduct of the activities under this Agreement or Licensed Candidates or Licensed Products, and have a further common legal interest in defending against any actual or prospective Third Party claims based on allegations of misuse or infringement of intellectual property rights relating to the conduct of the activities under this Agreement or Licensed Candidates or Licensed Products. Accordingly, any information or opinions disclosed pursuant to this Agreement by one Party to each other regarding intellectual property or technology owned by Third Parties will be used solely for purposes of the Parties&#8217; common legal interests with respect to the conduct of this Agreement. All information and materials will be treated as protected by the attorney-client privilege, the work product privilege, and any other privilege or immunity that may otherwise be applicable. By sharing any such information and materials, neither Party intends to waive or limit any privilege or immunity that may apply to the shared information and materials. Neither Party shall have the authority to waive any privilege or immunity on behalf of the other Party without such other Party&#8217;s prior written consent, nor shall the waiver of privilege or immunity resulting from the conduct of one Party be deemed to apply against any other Party. Notwithstanding the foregoing, neither Party&#8217;s attorney represents the other Party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1064"></a><a name="_BPDC_PR_INS_1065"></a><a name="_Toc524107388"></a><a name="_Toc529244665"></a><font style="Background-color:#auto;text-decoration:none;"> 12.13</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Patent Term Extension</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Relay will reasonably cooperate with Licensee, upon Licensee&#8217;s reasonable request, in obtaining at Licensee&#8217;s expense patent term extension or supplemental protection certificates and the like with respect to any Patents within the Relay Patents or Joint Collaboration Patents that claim a Licensed Product, in each country and region where it is possible to do so.&nbsp;&nbsp;Licensee will make the election in accordance with the preceding sentence and Relay agrees to abide by such election; provided that in no event may Licensee make any such election with respect to a Relay Combination Patent that is not a Generic Relay Combination Patent.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521644998"></a><a name="_Toc524107390"></a><a name="_Toc529816480"></a><a name="_Toc529966512"></a><a name="_Toc50796663"></a><a name="_Toc51338592"></a><a name="_Toc53919209"></a><a name="_Toc53925693"></a><font style="Background-color:#auto;text-decoration:none;">Article 13.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><br /><a name="_Ref521644998"></a><a name="_Toc524107390"></a><a name="_Toc529816480"></a><a name="_Toc529966512"></a><a name="_Toc50796663"></a><a name="_Toc51338592"></a><a name="_Toc53919209"></a><a name="_Toc53925693"></a>confidentiality</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646937"></a><a name="_Ref521647262"></a><a name="_Ref521648347"></a><a name="_Ref521650001"></a><a name="_Toc524107391"></a><a name="_Toc529816481"></a><a name="_Toc529966513"></a><a name="_Ref521644999"></a><font style="Background-color:#auto;text-decoration:none;"> 13.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Nondisclosure</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DocXTextRef312"></a><a name="DocXTextRef313"></a><a name="DocXTextRef314"></a><a name="DocXTextRef316"></a><a name="DocXTextRef311"></a>.&nbsp;&nbsp;Except to the extent expressly authorized by this Agreement or otherwise agreed by the Parties in writing, each Party agrees that a Party (the &#8220;<font style="font-weight:bold;">Receiving Party</font>&#8221;) receiving Confidential Information of the other Party (the &#8220;<font style="font-weight:bold;">Disclosing Party</font><a name="DocXTextRef312"></a>&#8221;) will (a)<a name="DocXTextRef313"></a>&#160;maintain in confidence such Confidential Information using not less than the efforts such Receiving Party uses to maintain in confidence its own proprietary or confidential information of similar kind and nature, but in no event less than a reasonable degree of care, (b) not disclose such Confidential Information to any Third Party without the prior written consent of the Disclosing Party, except for disclosures expressly permitted pursuant to this Article 13,<a name="DocXTextRef314"></a> and (c) not use, directly or indirectly, such Confidential Information for any purpose except to exercise its rights or perform <a name="DocXTextRef316"></a>its obligations as permitted by this Agreement (it being understood that this clause (c) will not create or imply any rights or licenses to a Party that are not expressly granted under this Agreement).&nbsp;&nbsp;The obligations of confidentiality, non-disclosure and non-use under this Section 13.1 will be in full force and effect during the Term and for a period of [***] thereafter.&nbsp;&nbsp;The Receiving Party will, at the Receiving Party&#8217;s election, return all copies of or destroy (and certify such destruction in writing) the Confidential Information of the Disclosing Party disclosed or transferred to it by the other Party pursuant to this Agreement, within [***]<a name="DocXTextRef311"></a> of the termination of this Agreement; provided, however, that a Party may retain one (1) copy of all other Confidential Information in archives solely for the purpose of establishing the contents thereof; provided, further, that such retained copy will remain subject to the terms of confidentiality and non-use set forth herein.&nbsp;&nbsp;Further, upon the termination of this Agreement, the Development Know-How and Materials, the Manufacturing Know-How and Materials, the Relay Phase Ia Trial Data and the Regulatory Materials, in each case as transferred to Licensee hereunder, shall be the Confidential Information of Relay only and without regard to Section 13.2(a).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646939"></a><a name="_Toc524107393"></a><a name="_Toc529816483"></a><a name="_Toc529966515"></a><a name="_Ref521645001"></a><font style="Background-color:#auto;text-decoration:none;"> 13.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Exceptions</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DocXTextRef320"></a><a name="DocXTextRef320"></a>.&nbsp;&nbsp;The obligations in Section 13.1 will not apply with respect to any portion of the Confidential Information of the Disclosing Party that the Receiving Party can show by competent written proof:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645002"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">was known to the Receiving Party or any of its Affiliates, without any obligation to keep it confidential or any restriction on its use, prior to disclosure by the Disclosing Party;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645003"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">is subsequently disclosed to the Receiving Party or any of its Affiliates by a Third Party lawfully in possession thereof and without any obligation to keep it confidential or any restriction on its use;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645004"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">is published by a Third Party or otherwise becomes publicly available or enters the public domain, either before or after it is disclosed to the Receiving Party, without any breach by the Receiving Party or its Affiliates of its obligations hereunder;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645005"></a><a name="DocXTextRef321"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="DocXTextRef321"></a>is published by a Party in accordance with Section 13.6 without any breach by such Party of its obligations hereunder; or</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645006"></a><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">is independently developed by or for the Receiving Party or its Affiliates without reference to, use of or reliance upon the Disclosing Party&#8217;s Confidential Information.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">The exceptions set forth in the foregoing clauses (a) and (e) will not apply to Joint Collaboration IP.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any combination of features or disclosures will not be deemed to fall within the foregoing exclusions merely because individual features are published or available to the general public or in the rightful possession of the Receiving Party unless the combination itself and principle of operation are published or available to the general public or in the rightful possession of the Receiving Party.&nbsp;&nbsp;In addition, Confidential Information will not be deemed to be within the exceptions set forth above merely because such information is embraced by more general information in the public domain or in the possession of the Receiving Party.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc524107394"></a><a name="_Toc529816484"></a><a name="_Toc529966516"></a><a name="_Ref532955381"></a><a name="_Ref52363457"></a><a name="_Ref56271913"></a><a name="_Ref521645007"></a><font style="Background-color:#auto;text-decoration:none;"> 13.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Authorized Disclosure</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645008"></a><a name="DocXTextRef322"></a><font style="Background-color:#auto;text-decoration:none;">13.3.1</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Disclosure</font><font style="color:#000000;"><a name="DocXTextRef322"></a>.&nbsp;&nbsp;Notwithstanding Section 13.1, the Receiving Party may disclose Confidential Information belonging to the Disclosing Party in the following instances:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645009"></a><a name="_Ref58350100"></a><a name="DocXTextRef323"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="DocXTextRef323"></a>subject to Section 13.5, to comply with Applicable Law (including the rules and regulations of the U.S. Securities and Exchange Commission or any national securities exchange, any other similar regulatory agencies in a country other than the United States or of any stock exchange or other securities trading institution (for purposes of this Section 13.3.1(a), each an &#8220;</font><font style="font-weight:bold;color:#000000;">Exchange</font><font style="color:#000000;">&#8221;) or any tax authority), if such disclosure is necessary for such compliance or for such judicial process (including prosecution or defense of litigation);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645010"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">to a Governmental Authority or Regulatory Authority, provided that reasonable steps are taken to ensure confidential treatment of such Confidential Information (if available);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref58520257"></a><a name="_Ref521645011"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">to prosecute or defend litigation as contemplated by this Agreement;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">to any licensor under any Third Party agreement under which a Party receives a (sub)license, to the extent required provided that each such licensor is bound by written confidentiality obligations no less restrictive than those set forth in this Article 13;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref58411193"></a><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">to any (i) of its officers, directors, employees, agents or Affiliates solely on a &#8220;need to know basis&#8221; in the course of conducting activities in accordance with this Agreement in order to carry out its responsibilities or exercise its rights under this Agreement or (ii) bona fide actual or prospective acquirers, underwriters, investors, lenders or other financing sources or permitted Third Party Subcontractors, licensees or Sublicensees, and to employees, officers, directors, agents, consultants and advisers of any such Third Party set forth in clause (ii), in each case on a &#8220;need to know basis&#8221;, provided that each such disclosee set forth in (i) or (ii) is bound by written confidentiality obligations and non-use obligations no less restrictive than those set forth in this Article 13 (with a duration of confidentiality and non-use obligations as is customary in such agreements); provided that with respect to disclosures by a Party to a potential licensee or Sublicensee pursuant to the foregoing clause (ii), such Party (A) will require that all </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">such disclosure </font><font style="color:#000000;">by such Party of the other Party&#8217;s </font><font style="color:#000000;">Confidential Information</font><font style="color:#000000;"> containing chemical structures, CMC information, patent prosecution matters, financial information, clinical trial strategy or design, or assay protocols</font><font style="color:#000000;"> prior to execution of a definitive license or sublicense agreement with such licensee or Sublicensee be made only to </font><font style="color:#000000;">Third Party subject </font><font style="color:#000000;">matter</font><font style="color:#000000;"> experts who may advise</font><font style="color:#000000;"> such potential licensee or Sublicensee </font><font style="color:#000000;">and (B) </font><font style="color:#000000;">may only disclose the structure of the Lead Candidate following execution of a definitive agreement with such licensee or Sublicensee</font><font style="color:#000000;">; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645012"></a><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">disclosure, solely on a &#8220;need to know basis&#8221; to its advisors (including attorneys and accountants); provided that, prior to any such disclosure, each disclosee must be bound by written obligations of confidentiality, non-disclosure and non-use no less restrictive than the obligations set forth in this Article 13 (provided, however, that in the case of legal advisors, no written agreement will be required), which for the avoidance of doubt, will not permit use of such Confidential Information for any purpose except those permitted by this Agreement (with a duration of confidentiality and non-use obligations as is customary in such agreements).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645013"></a><a name="_Ref58350106"></a><a name="DocXTextRef325"></a><a name="DocXTextRef326"></a><a name="DocXTextRef327"></a><a name="DocXTextRef328"></a><font style="Background-color:#auto;text-decoration:none;">13.3.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Terms of Disclosure</font><font style="color:#000000;"><a name="DocXTextRef325"></a>.&nbsp;&nbsp;If and whenever any Confidential Information is disclosed in accordance with this Section 13.3,<a name="DocXTextRef326"></a> such disclosure will not cause any such information to cease to be Confidential Information except to the extent that such disclosure results in a public disclosure of such information (other than by breach of this Agreement).&nbsp;&nbsp;Where reasonably possible and subject to Section 13.5,<a name="DocXTextRef327"></a> the Receiving Party will notify the Disclosing Party of the Receiving Party&#8217;s intent to make any disclosures pursuant to Section&#160;13.3.1(a)<a name="DocXTextRef328"></a> sufficiently prior to making such disclosure so as to allow the Disclosing Party adequate time to take whatever action it may deem appropriate to protect the confidentiality of the information, and the Receiving Party will provide reasonable assistance to the Disclosing Party with respect thereto; provided that, in such event, the Receiving Party will use reasonable measures to ensure confidential treatment of such information and will only disclose such Confidential Information of the Disclosing Party as is necessary for the purposes of Section 13.3.1(a), as applicable; provided, further, that i</font><font style="color:#000000;">f either Party concludes that a copy of this Agreement must be filed with an Exchange, then such Party will seek confidential treatment for portions of this Agreement from such Exchange will, a reasonable time prior to any such filing, provide the other Party with a copy of such Agreement showing any provisions hereof as to which the Party proposes to request confidential treatment, will provide the other Party with an opportunity to comment on any such proposed redactions and to suggest additional redactions within [***], and will take such Party&#8217;s reasonable comments into consideration before filing such agreement and use Commercially Reasonable Efforts to have terms identified by such other Party afforded confidential treatment by the applicable Exchange and shall thereafter provide reasonable advance notice ([***]) and opportunity for comment on any subsequent changes to such filing including opportunity to participate in any meetings with the Exchange related thereto; provided, further, that notwithstanding the foregoing, no such notice will be required for any disclosure made in connection with any submission by either Party or any of its Affiliates to any tax authority</font><font style="color:#000000;">.  In filing the Agreement with an Exchange Relay shall, whether or not requested by Licensee, (i) redact all Exhibits and any references to scientific Confidential Information of Licensee, and (ii) with respect to any financial terms, to the extent not allowed to redact, request confidential treatment for such financial terms, including the basis for the royalties under Section  11.10.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646940"></a><a name="_Toc524107395"></a><a name="_Toc529816485"></a><a name="_Toc529966517"></a><a name="_Ref521645015"></a><font style="Background-color:#auto;text-decoration:none;"> 13.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Terms of this Agreement</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DocXTextRef336"></a>.&nbsp;&nbsp;The Parties agree that this Agreement and all of the respective terms hereof will be deemed to be Confidential Information of both Relay and Licensee with each Party treated as the Receiving Party, and each Party agrees not to disclose any of them without the prior written consent of the other Party, not to be unreasonably withheld, conditioned or delayed<a name="DocXTextRef336"></a>, except that each Party may disclose any of them in accordance with the provisions of Section 13.3.1(a), 13.3.1(c), 13.3.1(e)(i), 13.3.1(f), 13.3.2 and 13.5.1.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref522061501"></a><a name="_Ref522061524"></a><a name="_Ref522061543"></a><a name="_Ref522061551"></a><a name="_Toc524107397"></a><a name="_Toc529816488"></a><a name="_Toc529966520"></a><a name="_Ref521645016"></a><font style="Background-color:#auto;text-decoration:none;"> 13.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Publicity</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Notwithstanding Section 13.3 </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref54026907"></a><font style="Background-color:#auto;text-decoration:none;">13.5.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Parties will jointly issue a press release, in the form attached hereto as Schedule 13.5, regarding the signing of this Agreement on a date to be determined by the Parties following the Effective Date.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57645889"></a><a name="_Ref52704983"></a><a name="_Ref51076764"></a><font style="Background-color:#auto;text-decoration:none;">13.5.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Except as set forth herein, Relay may not make any press release or public announcements regarding this Agreement or any matter covered by this Agreement, including the Development, Manufacture or Commercialization of Licensed Candidates or Licensed Products, without the prior written consent of Licensee. Except as set forth herein, Licensee may not make any press release or public announcements regarding this Agreement or the Development of Shared Products during the Opt-In Term or the Commercialization of Relay Pipeline Combinations without the prior written consent of Relay.&nbsp;&nbsp;In the event that a Party (the &#8220;</font><font style="font-weight:bold;color:#000000;">Publishing Party</font><font style="color:#000000;">&#8221;) reasonably believes it is required to issue a press release or make another public announcement to comply with Applicable Law, the Publishing Party may only issue such press release or other public announcement if the Publishing Party provides the text of such planned disclosure to the other Party (the &#8220;</font><font style="font-weight:bold;color:#000000;">Non-Publishing Party</font><font style="color:#000000;">&#8221;) in no less than [***] prior to disclosure, and incorporates all reasonable comments of the regarding such disclosure.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.5.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">For the avoidance of doubt, this Section 13.5 does not apply to press releases and public announcements by [***].&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646942"></a><a name="_Toc524107398"></a><a name="_Toc529816489"></a><a name="_Toc529966521"></a><a name="_Ref530142770"></a><a name="_Ref52364624"></a><a name="_Ref521645017"></a><font style="Background-color:#auto;text-decoration:none;"> 13.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Publications</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.Notwithstanding the other provisions of this Article 13, both Parties recognize that the publication or disclosure of papers, presentations, abstracts or any other written or oral presentations regarding results of and other information regarding the Development, Manufacture or Commercialization activities under this Agreement may be beneficial to both Parties, and the Parties agree that the JDT will develop a publication strategy in accordance with Section 10.2.2(d) in pursuance thereof; provided that such publications or presentations are subject to reasonable controls to protect Confidential Information, the patentability of inventions and other commercial considerations.&nbsp;&nbsp;Accordingly, except for disclosures permitted in accordance with the other provisions of this Article 13, the following shall apply with respect to papers, posters, publications, presentations and any other public disclosures regarding the Development, Manufacture or Commercialization activities under this Agreement proposed for disclosure by either Party (each, and collectively, as used in this Section 13.6 &#8220;<font style="font-weight:bold;">Publications</font>&#8221;):</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56274528"></a><a name="_Ref51077043"></a><font style="Background-color:#auto;text-decoration:none;">13.6.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">With respect to any Publications proposed for disclosure by Licensee, except as provided in Section 13.6.2, Licensee shall be free to make, publish and disclose such Publications at its discretion.&nbsp;&nbsp;With respect to any such Publication that discloses Licensee&#8217;s use of the Licensed Candidates or Licensed Products, including the results of any Clinical Trials with respect thereto, Licensee shall (i) acknowledge Relay in such Publication and (ii) provide a courtesy copy of the draft Publication prior to its public disclosure.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57579898"></a><font style="Background-color:#auto;text-decoration:none;">13.6.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">With respect to any Publication proposed for disclosure by Licensee which (a) includes Confidential Information of Relay other than the Development Know-How and Materials, the Manufacturing Know-How and Materials, the Relay Phase Ia Trial Data and the Regulatory Materials transferred to Licensee hereunder, (b) that relates to a Relay Pipeline Combination or (c) that is proposed prior to launch of a Shared Product during the Opt-In Term and relates to such Shared Product, Licensee will deliver to Relay a copy of the proposed Publication at least [***] prior to submission for publication or presentation.&nbsp;&nbsp;Relay shall review such submitted materials and respond to Licensee as soon as reasonably practicable, but in any case within [***] of receipt thereof.&nbsp;&nbsp;Relay will have the right to (i) propose modifications to the publication or presentation for patent reasons or trade secret reasons or to remove Confidential Information of the Relay or its Affiliates or Sublicensees, and Licensee will remove all Confidential Information of Relay or its Affiliates or Sublicensees if requested by Relay and otherwise use good faith efforts to reflect Relay&#8217;s reasonable comments, or (ii) request a reasonable delay in publication or presentation in order to protect patentable information.&nbsp;&nbsp;If Relay requests a delay to enable Relay to file patent applications protecting Relay&#8217;s right in such information, then Licensee will delay such submission or presentation for a period of [***] (or such shorter period as may be mutually agreed by the Parties).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref52365934"></a><a name="_Ref57839917"></a><font style="Background-color:#auto;text-decoration:none;">13.6.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">With respect to any Publication proposed for disclosure by Relay (or its Affiliates or Sublicensees or Third Party Subcontractors or any other Third Party under Existing Third Party Agreements or future agreements as permitted in accordance with Section 9.1.3, including any investigators or academic or non-profit collaborators) which (a) includes Confidential Information of Licensee or (b) relates to a Licensed Candidate or Licensed Product (including any Relay Phase Ia Trial Data), Relay will deliver to Licensee a copy of the proposed Publication at least [***] prior to submission for publication or presentation.&nbsp;&nbsp; Licensee shall review such submitted materials and respond to Licensee as soon as reasonably practicable, but in any case within [***] of receipt thereof.&nbsp;&nbsp;Licensee will have the right to (i) propose modifications to the publication or presentation for patent reasons or trade secret reasons or to remove Confidential Information of the Licensee or its Affiliates or Sublicensees, and Relay will remove all Confidential Information of Licensee if requested by Licensee and otherwise use good faith efforts to reflect Licensee&#8217;s reasonable comments, or (ii) request a reasonable delay in publication or presentation in order to protect patentable information.&nbsp;&nbsp;If Licensee requests a delay to enable Licensee to file patent applications protecting Licensee &#8217;s right in such information, then Relay will delay such submission or presentation for a period of [***]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.6.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notwithstanding the foregoing in Section 13.6.3 above, (a) with respect to any Publication that relates to the Relay Phase Ia Trial Data or any other data (clinical and pre-clinical) regarding a Licensed Candidate or Licensed Product, but not for any proposed Publication that relates solely to a Relay Pipeline Combination, in the event that Licensee in its reasonable and good faith belief determines that any foregoing Publication may negatively impact the Development or Commercialization of any Licensed Candidate or Licensed Product, Licensee shall notify Relay of such belief and the Parties shall discuss and negotiate in good faith for an alternative solution, and Relay acknowledges and agrees that Licensee may require Relay to delay the disclosure of any such Publication or may require Relay not to publish such Publication indefinitely and (b) with respect to any Publication that discloses Relay&#8217;s use of the Licensed Candidates or Licensed Products only in a Relay Pipeline Combination that is not subject to the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">foregoing subclause (a), Relay shall provide a courtesy copy of the draft Publication prior to its public disclosure.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.6.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">With respect to any proposed Publications by investigators or academic or non-profit collaborators or any other&nbsp;&nbsp;Third Party in accordance with Section 13.6.3 above, such materials will be subject to review under this Section 13.6, and as between the Parties, it shall be Relay&#8217;s sole responsibility to ensure its compliance under this Agreement, as well as its compliance under any other agreement it entered into with any Third Party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646943"></a><a name="_Toc524107399"></a><a name="_Toc529816490"></a><a name="_Toc529966522"></a><a name="_Ref521645018"></a><font style="Background-color:#auto;text-decoration:none;"> 13.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Use of Names</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DocXTextRef341"></a><a name="_Ref521646944"></a><a name="_Ref521648473"></a><a name="_Toc522731612"></a><a name="_Ref521645019"></a><a name="DocXTextRef341"></a>. Except as expressly provided herein, neither Party will mention or otherwise use the name, logo, or Trademark of the other Party or any of its Affiliates (or any abbreviation or adaptation thereof) in any publication, press release, marketing and promotional material, or other form of publicity without the prior written approval of such other Party in each instance.&nbsp;&nbsp;The restrictions imposed by this Section 13.7<a name="_Ref521646944"></a><a name="_Ref521648473"></a><a name="_Toc522731612"></a><a name="_Ref521645019"></a> will not prohibit either Party from making any disclosure identifying the other Party that is required by Applicable Law.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57098920"></a><font style="Background-color:#auto;text-decoration:none;"> 13.8</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Safeguards</font><font style="color:#000000;">.&nbsp;&nbsp;If Relay is conducting Development activities for a Relay Pipeline Combination, and Licensee is conducting Development activities for a [***] Combination that includes a compound or product that is Directed to the same target as the Relay Pipeline Compound included in such Relay Pipeline Combination ([***])&nbsp;&nbsp;(such Licensee Combination Development activities and such Relay Pipeline Combination Development activities, a &#8220;</font><font style="font-weight:bold;color:#000000;">Competing Program</font><font style="color:#000000;">&#8221; of the Party conducting such activities), then each Party will establish reasonable protections and safeguards to protect against the other Party&#8217;s Confidential Information regarding such other Party&#8217;s Confidential Information of the Competing Program [***].</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645021"></a><a name="_Toc524107401"></a><a name="_Toc529816492"></a><a name="_Toc529966524"></a><a name="_Toc50796664"></a><a name="_Toc51338593"></a><a name="_Toc53919210"></a><a name="_Toc53925694"></a><font style="Background-color:#auto;text-decoration:none;">Article 14.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><br /><a name="_Ref521645021"></a><a name="_Toc524107401"></a><a name="_Toc529816492"></a><a name="_Toc529966524"></a><a name="_Toc50796664"></a><a name="_Toc51338593"></a><a name="_Toc53919210"></a><a name="_Toc53925694"></a>REPRESENTATIONS AND WARRANTIES</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646946"></a><a name="_Toc524107402"></a><a name="_Toc529816493"></a><a name="_Toc529966525"></a><a name="_Ref521645022"></a><font style="Background-color:#auto;text-decoration:none;"> 14.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Representations and Warranties of Both Parties</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Each Party hereby represents and warrants to the other Party, as of the Effective Date, that:&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645023"></a><a name="_Ref521645028"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">such Party is duly organized, validly existing and in good standing under the laws of the jurisdiction of its formation and has full corporate power and authority to enter into this Agreement, and to carry out the provisions hereof;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645024"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">such Party has taken all necessary corporate action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645025"></a><a name="DocXTextRef343"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, binding obligation, enforceable against it in accordance with its terms, except to the extent that enforcement of the rights and remedies created hereby is <a name="DocXTextRef343"></a>subject to (i) bankruptcy, insolvency, reorganization, moratorium and other similar laws of general application affecting the rights and remedies of creditors, or (ii) laws governing specific performance, injunctive relief and other equitable remedies; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645026"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the execution, delivery and performance of this Agreement by such Party does not conflict with any agreement or any provision thereof, or any instrument or </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">understanding, oral or written, to which it is a party or by which it is bound, nor violate any Applicable Law of any Governmental Authority having jurisdiction over such Party;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645027"></a><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">no government authorization, consent, approval, license, exemption of or filing or registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any Applicable Law currently in effect, is or will be necessary for the consummation of the transactions contemplated by this Agreement or for the performance by it of its obligations under this Agreement (including, in the case of Relay, the grant of the rights to Licensee hereunder), except for any filing required under Antitrust Laws; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">that no consideration received by such Party under this Agreement is intended by such Party to be a prohibited payment for the recommending or arranging for the referral of business or ordering of products or services, nor is any such consideration intended by such Party to induce illegal referrals of business under Applicable Law; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref52705241"></a><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">it has obtained all necessary authorizations, consents and approvals of any other Person that is required to be obtained by it as of the Effective Date in connection with, the transaction contemplated by this Agreement (including, in the case of Relay, the grant of the rights to Licensee hereunder).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646947"></a><a name="_Toc524107403"></a><a name="_Toc529816494"></a><a name="_Toc529966526"></a><a name="_Ref52468882"></a><a name="_Ref521645029"></a><font style="Background-color:#auto;text-decoration:none;"> 14.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Representations and Warranties of Relay</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Relay hereby represents and warrants to Licensee, as of the Effective Date, that:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref55446333"></a><a name="_Ref521645030"></a><a name="_Ref531371859"></a><a name="_Hlk56412074"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Schedule 14.2(a)<a name="_Hlk56412074"></a> contains a complete and accurate list of all Patents Controlled by Relay or its Affiliates that are necessary or reasonably useful to Research, Develop, Manufacture or Commercialize any compound that is Directed to the Collaboration Target.&nbsp;&nbsp;Except for the Patents set forth on Schedule 14.2(a), Relay and its Affiliates do not Control any Patent that is necessary or reasonably useful to Research, Develop, Manufacture or Commercialize any compound that is Directed to the Collaboration Target; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref532825398"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">all issued Patents set forth on Schedule 14.2(a) (i) are in full force and effect, (ii) have been Prosecuted and Maintained in good faith, and (iii) exist and, to the Knowledge of Relay, are not invalid or unenforceable, in whole or in part;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645031"></a><a name="_Ref532500896"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">all current and former officers, employees, contractors, consultants and sublicensees of Relay who are inventors of or have otherwise contributed in a material manner to the creation or development of any Relay Patents or Relay Know-How have executed and delivered to Relay or such Affiliate an assignment or other agreement regarding the protection of proprietary information and the assignment to Relay of any such Relay Patents or Relay Know-How, and with respect to any such Relay Patents (i) all inventors of such Relay Patents are correctly identified, (ii) they have been timely and duly filed in such a manner as to perfect title and preserve priority entitlement, including by virtue of assignment documents associated with each priority filing, (iii) all filing and renewal fees payable with respect thereto have been timely paid, and (iv), to the Knowledge of Relay, no current officer, employee, agent, or consultant of Relay or any of its Affiliates is in violation of any term of any assignment or other agreement regarding the protection of Patents or other intellectual property or proprietary information of Relay or such Affiliate or of any employment contract or any other contractual obligation relating to the relationship of any such Person with Relay;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref522443829"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">except as set forth on Schedule 14.2(d), all Relay Patents that claim the Lead Candidate are exclusively owned by Relay or its Affiliates;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Relay IND and all Know-How contained or incorporated by reference therein and all Relay Phase Ia Trial Data is exclusively owned by Relay or its Affiliates; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645033"></a><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay&#8217;s interest in the Relay Patents and Relay Know-How is free and clear of all liens, claims, security interests or other encumbrances of any kind that would interfere, or the exercise of which would interfere, with Licensee exercising any of the licenses or rights granted to it hereunder;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref52469090"></a><a name="_Ref52705291"></a><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:238pt;color:#000000;"></font><font style="color:#000000;">Schedule 14.2(g) contains a complete and accurate list of all agreements with a Third Party pursuant to which Relay Controls any Relay Patents that claim the Lead Candidate or Relay Know-How that relates to the Lead Candidate Controlled as of the Effective Date and Licensee has been provided with complete and accurate copies of each such agreement (in redacted form to the extent necessary to comply with confidentiality restrictions);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="margin-left:238pt;color:#000000;"></font><font style="color:#000000;">(i) to the Knowledge of Relay, each Existing Third Party Agreement is in full force and effect and is valid and enforceable in accordance with its terms, (ii) no written notice of default or termination has been received or given by Relay under any Existing Third Party Agreement, and (iii) to the Knowledge of Relay, no event has occurred or circumstance exists that (with or without notice or lapse of time) that would give a party the right to declare a default or terminate any Existing Third Party Agreement;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645034"></a><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:238pt;color:#000000;"></font><font style="color:#000000;"><a name="_Ref521645034"></a>no claim has been issued and served against Relay or any of its Affiliates that alleges that any Relay Patent is invalid or unenforceable;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645036"></a><font style="Background-color:#auto;text-decoration:none;">(j)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Except as set forth on Schedule 14.2(j), Relay is not subject to any payment obligations to Third Parties as a result of the execution or performance of this Agreement in order to maintain any rights of Relay with respect to any Relay Patents or Relay Know-How in the Field licensed hereunder or any other Patent or Know-How that would be included as Relay Patents or Relay Know-How in the Field licensed hereunder but for non-compliance with such payment obligations;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645037"></a><font style="Background-color:#auto;text-decoration:none;">(k)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Except as set forth on Schedule 14.2(k), Relay has not granted any right or license to any Third Party under the Relay Patents or Relay Know-How for any Licensed Candidate in the Field that would conflict with or limit the scope of any of the rights or licenses granted to Licensee hereunder;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56259027"></a><font style="Background-color:#auto;text-decoration:none;">(l)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No funding provided by a Governmental Authority was used in</font><font style="text-decoration:underline;color:#000000;"> </font><font style="color:#000000;">activities related to the Research, Development or Manufacture of the Lead Candidate that resulted in any grant to such Governmental Authority of ownership in, or license under, any Relay Patents or any Relay Know-How that is incorporated in any Relay Patents;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(m)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay and, to the Knowledge of Relay, its former and current employees, consultants, and agents have complied with all Applicable Laws in the development or creation of the Relay Patents and Relay Know-How, including any duties of candor to applicable patent offices, in connection with the filing, Prosecution and Maintenance of the Relay Patents, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">including conducting due inquiry to determine the correct inventorship of the inventors listed in the </font><font style="color:#000000;">1971 </font><font style="color:#000000;">Patents;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645039"></a><font style="Background-color:#auto;text-decoration:none;">(n)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay has not received any written notice of any claim that any Patent or Know-How owned or controlled by a Third Party would be infringed or misappropriated by the Research, Development, Manufacture, or Commercialization of any Licensed Candidate or Licensed Product in the Field;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56258988"></a><a name="_Ref521645040"></a><font style="Background-color:#auto;text-decoration:none;">(o)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> Relay owns all right, title and interest in and to the Lead Candidate;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56258954"></a><font style="Background-color:#auto;text-decoration:none;">(p)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Except as set forth on Schedule 14.2(p), to the Knowledge of Relay, the Research, Development, Manufacture, and Commercialization of any Licensed Candidate or Licensed Product in the Field as contemplated hereunder does not violate, infringe, misappropriate or otherwise conflict or interfere with any Patent or any potential Patent claim based on disclosures in any Patent or any other intellectual property or proprietary right of any Person;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref55577917"></a><font style="Background-color:#auto;text-decoration:none;">(q)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The [***] (&#8220;</font><font style="font-weight:bold;color:#000000;">DSUR</font><font style="color:#000000;">&#8221;) that Relay has disclosed to Licensee prior to the Effective Date sets forth a true and complete list of all information in Relay&#8217;s Control concerning side effects, injury, toxicity or sensitivity reaction and incidents or severity thereof with respect to the Lead Candidate or Phase Ia Product that would be required to be included in a DSUR with respect to the Phase Ia Clinical Trial if a DSUR were to be submitted to the FDA on the Effective Date</font><font style="color:#000000;">;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645041"></a><font style="Background-color:#auto;text-decoration:none;">(r)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">there are no claims, judgments, settlements, litigations, suits, actions, disputes, arbitration, judicial or legal, administrative or other proceedings or governmental investigations pending or, to the Knowledge of Relay, threatened against Relay or any of its Affiliates which would be reasonably expected to adversely affect or restrict the ability of Relay to consummate or perform the transactions contemplated under this Agreement; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(s)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Phase Ia Product, including the Inventory transferred to Licensee by Relay pursuant to the Technology Transfer, has been manufactured (including the facilities and equipment used in its manufacture), stored, and handled in material compliance with, and conform to, then-current specifications, cGMPs (if applicable) and other Applicable Laws.&nbsp;&nbsp;Title to Inventory shall pass to Licensee free and clear of any liens or encumbrances.&nbsp;&nbsp;Neither Relay, any of its Affiliates, nor, to the Knowledge of Relay, their respective CMOs has received: (i) any FDA Form 483 Notice of Observation, or similar notice from any Governmental Authority, relating to the Phase Ia Product or the facilities in which the Phase Ia Product are manufactured; (ii) any FDA Notices of Adverse Findings, or similar notice from any Governmental Authority, with respect to the Phase Ia Product; or (iii) any &#8220;warning letters,&#8221; or &#8220;untitled letters,&#8221; or other similar Governmental Authority notice of inspectional observations or deficiencies or other material written correspondence from any other Regulatory Authority concerning the Phase Ia Product or, to the Knowledge of Relay, the facilities in which the Phase Ia Product is manufactured;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(t)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the Relay Phase Ia Trial and all other preclinical and clinical studies conducted by Relay and its Affiliates for the Lead Candidate and the Phase Ia Product have been conducted in accordance with all applicable Regulatory Materials and all Applicable Laws, including as applicable GCP, GLP, GMP, &#8220;Informed Consent&#8221; and &#8220;Institutional Review Board&#8221; </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">regulations, patient privacy and security regulations and all applicable requirements relating to the protection of human subjects for its </font><font style="color:#000000;">C</font><font style="color:#000000;">linical </font><font style="color:#000000;">T</font><font style="color:#000000;">rials as required by the FDA or their equivalents in the country in which the clinical study is conducted. Relay and its Affiliates are, and at all times have been, in compliance with all adverse event reporting requirements applicable to the Phase Ia Product.&nbsp;&nbsp;Neither Relay nor any of its Affiliates have received any written notice for any Regulatory Authority relating to any violation of any Regulatory Materials or Applicable Laws in conducting any such preclinical or clinical studies.&nbsp;&nbsp;Neither Relay</font><font style="color:#000000;">, </font><font style="color:#000000;">any of its Affiliates</font><font style="color:#000000;">,</font><font style="color:#000000;"> </font><font style="color:#000000;">n</font><font style="color:#000000;">or any of their respective officers</font><font style="color:#000000;"> or</font><font style="color:#000000;"> employees or</font><font style="color:#000000;">, to the Knowledge of Relay, </font><font style="color:#000000;">agents have made an untrue statement of material fact to any Regulatory Authority (whether in a submission to such Regulatory Authority or otherwise) or failed to disclose a material fact required to be disclosed to any Regulatory Authority with respect to the Lead Candidate or the Phase Ia Product; and&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(u)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">neither Relay nor any of its Affiliates has knowingly withheld any material information in its possession from Licensee in response to Licensee&#8217;s reasonable inquiries in connection with its due diligence relating to Licensed Candidates or Licensed Products, this Agreement and the underlying transaction, and to the Knowledge of Relay, the information that Relay and its Affiliates have provided to Licensee is up-to-date and accurate in all material respects.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1062"></a><a name="_BPDC_PR_INS_1063"></a><a name="_Toc529816275"></a><a name="_Toc529816386"></a><a name="_Toc529816496"></a><a name="_Toc529966528"></a><a name="_Ref531357005"></a><font style="Background-color:#auto;text-decoration:none;"> 14.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Representations and Warranties of Licensee</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Licensee hereby represents and warrants to Relay, as of the Effective Date:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.3.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">[***]</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.3.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">there are no claims, judgments, settlements, litigations, suits, actions, disputes, arbitration, judicial or legal, administrative or other proceedings or governmental investigations pending or, to the Knowledge of Licensee, threatened against Licensee or any of its Affiliates which would be reasonably expected to adversely affect or restrict the ability of Licensee to consummate or perform the transactions contemplated under this Agreement. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1060"></a><a name="_BPDC_PR_INS_1061"></a><a name="_BPDC_LN_INS_1058"></a><a name="_BPDC_PR_INS_1059"></a><font style="Background-color:#auto;text-decoration:none;"> 14.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Acknowledgement</font><font style="color:#000000;">.<a name="_BPDC_LN_INS_1058"></a><a name="_BPDC_PR_INS_1059"></a>&nbsp;&nbsp;Licensee hereby acknowledges that the transfer of certain technical data, computer software, laboratory prototypes or other commodities as contemplated under this Agreement (including in connection with the Development, Manufacture or Commercialization of Licensed Candidates or Licensed Products) may be subject to Applicable Laws controlling their export, some of which prohibit or require a license for the export of certain types of technical data, to certain specified countries and that Relay does not represent that a license will not be required in connection with such transfer under this Agreement, nor that if required, it will be issued.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1056"></a><a name="_BPDC_PR_INS_1057"></a><a name="_BPDC_LN_INS_1054"></a><a name="_BPDC_PR_INS_1055"></a><a name="_Ref521646949"></a><a name="_Toc524107405"></a><a name="_Toc529816497"></a><a name="_Toc529966529"></a><a name="_Ref521645050"></a><font style="Background-color:#auto;text-decoration:none;"> 14.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Disclaimer</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED (AND EACH PARTY HEREBY EXPRESSLY DISCLAIMS ANY AND ALL REPRESENTATIONS AND WARRANTIES NOT EXPRESSLY PROVIDED IN THIS AGREEMENT), INCLUDING WITH RESPECT TO ANY PATENTS OR KNOW-HOW, OR MATERIALS, INCLUDING WARRANTIES OF VALIDITY OR ENFORCEABILITY OF ANY PATENTS, TITLE, QUALITY, COMPLETENESS, ACCURACY, MERCHANTABILITY, FITNESS FOR A </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PARTICULAR USE OR PURPOSE, PERFORMANCE, AND NONINFRINGEMENT OF ANY THIRD PARTY PATENTS OR </font><font style="text-transform:uppercase;">OTHER INTELLECTUAL PROPERTY RIGHTS.</font><font style="text-transform:uppercase;">&nbsp;&nbsp;Without limiting the generality of the foregoing, and except as otherwise expressly provided in this Agreement, each Party disclaims any warranties with regards to: (a) the success of any LICENSED CANDIDATES OR Licensed ProductS; or (b) the safety or usefulness for any purpose of the LICENSED CANDIDATES, or LICENSED PRODUCTS.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645051"></a><a name="_Toc524107406"></a><a name="_Ref529816025"></a><a name="_Toc529816498"></a><a name="_Toc529966530"></a><a name="_Toc50796665"></a><a name="_Toc51338594"></a><a name="_Toc53919211"></a><a name="_Toc53925695"></a><font style="Background-color:#auto;text-decoration:none;">Article 15.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><br /><a name="_Ref521645051"></a><a name="_Toc524107406"></a><a name="_Ref529816025"></a><a name="_Toc529816498"></a><a name="_Toc529966530"></a><a name="_Toc50796665"></a><a name="_Toc51338594"></a><a name="_Toc53919211"></a><a name="_Toc53925695"></a>INDEMNIFICATION; INSURANCE</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646950"></a><a name="_Ref521646981"></a><a name="_Ref521650338"></a><a name="_Toc524107407"></a><a name="_Toc529816499"></a><a name="_Toc529966531"></a><a name="_Ref38754232"></a><a name="_Ref521645052"></a><font style="Background-color:#auto;text-decoration:none;"> 15.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">General Indemnification by Licensee</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Licensee will indemnify, defend and hold harmless Relay, its Affiliates, and its and their respective directors, officers, employees, agents, [***], Relay Sublicensees, Third Party Subcontractors, successors and assigns, from and against any and all Losses to the extent arising out of or attributable to any Third Party Claim based upon: </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645054"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any material breach by Licensee of any of its representations, warranties, covenants, agreements or obligations under this Agreement; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645055"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any Research, Development, Manufacturing or Commercialization of a Licensed Candidate or Licensed Product (including as part of [***] Combinations or [***] Other Combinations) by or on behalf of Licensee or any of its Affiliates or any Licensee Sublicensees;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DocXTextRef354"></a><a name="DocXTextRef355"></a><a name="_Ref521645057"></a>provided<a name="DocXTextRef354"></a>, however, in each case ((a) through (b<a name="DocXTextRef355"></a>)), that such indemnity will not apply to the extent that (i) Relay has an indemnification obligation pursuant to Section 15.2<a name="_Ref521645057"></a> for such Losses or (ii) such Losses arise out of the negligence, gross negligence or willful misconduct of Relay or its Affiliates or Relay Sublicensees or its or their respective directors, officers, employees or agents, including any of its Third Party Subcontractors [***], in connection with this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646951"></a><a name="_Ref521648492"></a><a name="_Ref521650323"></a><a name="_Ref521650363"></a><a name="_Toc524107408"></a><a name="_Toc529816500"></a><a name="_Toc529966532"></a><a name="_Ref521645056"></a><font style="Background-color:#auto;text-decoration:none;"> 15.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">General Indemnification by Relay</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Relay will indemnify, defend and hold harmless Licensee, its Affiliates and its and their respective directors, officers, employees, agents, Licensee Sublicensees, Third Party Subcontractors, successors and assigns, from and against any and all Losses to the extent arising out of or attributable to any Third Party Claim based upon:&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645058"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any material breach by Relay of any of its representations, warranties, covenants, agreements or obligations under this Agreement; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any Research, Development, Manufacturing or Commercialization of a Licensed Candidate or Licensed Product (including as part of Relay Pipeline Combinations) by or on behalf of Relay or any of its Affiliates.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DocXTextRef356"></a><a name="DocXTextRef357"></a>provided<a name="DocXTextRef356"></a>, however, in each case ((a) through (b<a name="DocXTextRef357"></a>)), that such indemnity will not apply to the extent that (i) Licensee has an indemnification obligation pursuant to Section 15.1 for such Losses or (ii) such Losses arise out of the negligence, gross negligence or willful misconduct&nbsp;&nbsp;of Licensee, its Affiliates or Licensee Sublicensees or its or their respective directors, officers, employees or agents, including any of its Third Party Subcontractors, in connection with this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;"> 15.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Indemnification Procedure</font><font style="color:#000000;">.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref526506956"></a><a name="_Ref521645061"></a><a name="DocXTextRef358"></a><a name="DocXTextRef359"></a><a name="DocXTextRef360"></a><a name="DocXTextRef361"></a><font style="Background-color:#auto;text-decoration:none;">15.3.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Notice of Claim</font><font style="color:#000000;">.&nbsp;&nbsp;All indemnification claims in respect of a Party, its Affiliates, or their respective directors, officers, employees, agents, Sublicensees and Third Party Subcontractors will be made solely by such Party to this Agreement (the &#8220;</font><font style="font-weight:bold;color:#000000;">Indemnified</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Party</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;The Indemnified Party will give the indemnifying Party (the &#8220;</font><font style="font-weight:bold;color:#000000;">Indemnifying Party</font><font style="color:#000000;">&#8221;) written notice (an &#8220;</font><font style="font-weight:bold;color:#000000;">Indemnification</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Claim</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Notice</font><font style="color:#000000;"><a name="DocXTextRef358"></a>&#8221;) of any Losses or learning of the Third Party Claim upon which such Indemnified Party intends to base a request for indemnification under Section 15.1<a name="DocXTextRef359"></a> or Section 15.2,<a name="DocXTextRef360"></a> as applicable, promptly after receipt by such Indemnified Party of actual notice of the Third Party Claim.&nbsp;&nbsp;A delay or failure to provide such notice will not affect the indemnification provided under Section 15.1<a name="DocXTextRef361"></a> or Section 15.2, as applicable, except to the extent the Indemnifying Party has been actually prejudiced as a result of such delay or failure.&nbsp;&nbsp;Each Indemnification Claim Notice must contain a description of the claim and the nature and amount of such Loss (to the extent that the nature and amount of such Loss is known at such time).&nbsp;&nbsp;The Indemnified Party will furnish promptly to the Indemnifying Party copies of all papers and official documents received in respect of any Losses and Third Party Claims.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645062"></a><a name="DocXTextRef362"></a><font style="Background-color:#auto;text-decoration:none;">15.3.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Control of Defense</font><font style="color:#000000;">.&nbsp;&nbsp;Subject to Sections 12.10 and  12.11, at its option, the Indemnifying Party may assume the defense of any Third Party Claim by giving written notice to the Indemnified Party within [***]<a name="DocXTextRef362"></a> after the Indemnifying Party&#8217;s receipt of an Indemnification Claim Notice.&nbsp;&nbsp;The assumption of the defense of a Third Party Claim by the Indemnifying Party will not be construed as an acknowledgment that the Indemnifying Party is liable to indemnify the Indemnified Party in respect of the Third Party Claim, nor will it constitute a waiver by the Indemnifying Party of any defenses it may assert against the Indemnified Party&#8217;s claim for indemnification.&nbsp;&nbsp;Upon assuming the defense of a Third Party Claim, the Indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel selected by the Indemnifying Party.&nbsp;&nbsp;In the event the Indemnifying Party assumes the defense of a Third Party Claim, the Indemnified Party will immediately deliver to the Indemnifying Party all original notices and documents (including court papers) received by the Indemnified Party in connection with the Third Party Claim.&nbsp;&nbsp;Should the Indemnifying Party assume the defense of a Third Party Claim, except as provided in Section 15.3.3, the Indemnifying Party will not be liable to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party in connection with the analysis, defense or settlement of the Third Party Claim unless specifically requested in writing by the Indemnifying Party.&nbsp;&nbsp;In the event that it is ultimately determined that the Indemnifying Party is not obligated to indemnify, defend or hold harmless the Indemnified Party from and against the Third Party Claim, the Indemnified Party will reimburse the Indemnifying Party for any and all costs and expenses (including attorneys&#8217; fees and costs of suit) and any Losses incurred by the Indemnifying Party in its defense of the Third Party Claim.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645063"></a><a name="DocXTextRef366"></a><a name="DocXTextRef363"></a><a name="DocXTextRef364"></a><a name="DocXTextRef367"></a><a name="DocXTextRef365"></a><font style="Background-color:#auto;text-decoration:none;">15.3.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Right to Participate in Defense</font><font style="color:#000000;"><a name="DocXTextRef366"></a>.&nbsp;&nbsp;Without limiting Section 15.3.2, any Indemnified Party will be entitled to participate in, but not control (unless the Indemnifying Party has failed to assume the defense and employ counsel in accordance with Section 15.3.2),<a name="DocXTextRef363"></a> the defense of such Third Party Claim and to employ counsel of its choice for such purpose; provided, however, that such employment will be at the Indemnified Party&#8217;s own cost and expense unless (a)<a name="DocXTextRef364"></a>&#160;the employment thereof has been specifically authorized by the Indemnifying Party in writing, (b)<a name="DocXTextRef367"></a> the Indemnifying Party has failed to assume the defense and employ counsel in accordance with Section 15.3.2<a name="DocXTextRef365"></a> (in which case the Indemnified Party will control the defense), or (c)&#160;the interests of the indemnitee and the Indemnifying Party with respect to such Third Party Claim are </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">sufficiently adverse to prohibit the representation by the same counsel of both Parties under Applicable Law, ethical rules or equitable principles.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645064"></a><a name="DocXTextRef368"></a><font style="Background-color:#auto;text-decoration:none;">15.3.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Settlement</font><font style="color:#000000;">.&nbsp;&nbsp;With respect to any Losses relating solely to the payment of money damages in connection with a Third Party Claim that are subject to indemnification by the Indemnifying Party under this Article 15, and (a) that will not result in the Indemnified Party&#8217;s becoming subject to injunctive or other relief or otherwise adversely affect the business of the Indemnified Party in any manner, (b) which includes as an unconditional term thereof, the giving by each claimant or plaintiff to the Indemnified Party of a release from all liability in respect of such claim<a name="DocXTextRef368"></a> and (c) as to which the Indemnifying Party will have acknowledged in writing the obligation to indemnify the Indemnified Party hereunder, the Indemnifying Party will have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the Indemnifying Party, in its sole discretion, will deem appropriate.&nbsp;&nbsp;With respect to all other Losses in connection with Third Party Claims, where the Indemnifying Party has assumed the defense of the Third Party Claim in accordance with Section&#160;15.3.2, the Indemnifying Party will have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss; provided that it obtains the prior written consent of the Indemnified Party (which consent will not be unreasonably withheld or delayed).&nbsp;&nbsp;If the Indemnifying Party does not assume and conduct the defense of a Third Party Claim as provided above, the Indemnified Party may defend against such Third Party Claim; provided that the Indemnified Party will not settle any Third Party Claim without the prior written consent of the Indemnifying Party, not to be unreasonably withheld or delayed.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645065"></a><font style="Background-color:#auto;text-decoration:none;">15.3.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Cooperation</font><font style="color:#000000;">.&nbsp;&nbsp;Regardless of whether the Indemnifying Party chooses to defend or prosecute any Third Party Claim, the Indemnified Party will, and will cause each indemnitee to, reasonably cooperate in the defense or prosecution thereof and will furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith.&nbsp;&nbsp;Such cooperation will include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Third Party Claim, and making the Indemnified Party and other employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder; provided, however, that the Indemnified Party will be given the opportunity to redact any Confidential Information not relevant to the Third Party Claim; provided, further, that the Indemnifying Party will keep confidential any Confidential Information disclosed or made available during such visits.&nbsp;&nbsp;The Indemnifying Party will reimburse the Indemnified Party for all its reasonable Out-of-Pocket Costs in connection therewith.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646953"></a><a name="_Toc524107410"></a><a name="_Toc529816502"></a><a name="_Toc529966534"></a><a name="_Ref521645067"></a><font style="Background-color:#auto;text-decoration:none;"> 15.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Insurance</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:13.46%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref531343183"></a><a name="_Ref508817449"></a><a name="_Ref530142991"></a><a name="_Ref424031440"></a><font style="Background-color:#auto;text-decoration:none;">15.4.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_Ref508817449"></a><a name="_Ref530142991"></a>.&nbsp;&nbsp;During the Term and for a period of [***] after the expiration or termination of this Agreement (provided that the time periods set forth in Section 15.4.1(a) or 15.4.1(b) will control in the event of a conflict with the foregoing)<a name="_Ref424031440"></a>, each Party will have and maintain in full force and effect, at its own expense, insurance coverage to include: [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref522283364"></a><font style="Background-color:#auto;text-decoration:none;">15.4.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">All insurance maintained pursuant to this Section 15.4 will be underwritten by companies with an AM best rating of at least A-VII.&nbsp;&nbsp;Each Party will provide the other Party with written evidence of such insurance upon request.&nbsp;&nbsp;Each Party will provide the other Party written notice at least [***] prior to the cancellation, non-renewal or material change in such </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;"><a name="_Ref522283364"></a>insurance. Each Party shall name the other Party as additional insured under its commercial general liability and products liability insurance policies. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">15.4.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notwithstanding the foregoing, Licensee may satisfy the insurance requirements of this Section 15.4 through a program of self-insurance.&nbsp;&nbsp;The minimum amounts of insurance coverage required under this Section 15.4 will not be construed to create a limit of liability with respect to indemnification under Section 15.1. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646954"></a><a name="_Toc524107411"></a><a name="_Toc529816503"></a><a name="_Toc529966535"></a><a name="_Ref521645068"></a><font style="Background-color:#auto;text-decoration:none;"> 15.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">LIMITATION OF LIABILITY</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DocXTextRef369"></a><a name="DocXTextRef370"></a><a name="DocXTextRef371"></a>.&nbsp;&nbsp;EXCEPT IN THE EVENT OF (A) A PARTY&#8217;S BREACH OF ITS OBLIGATIONS <font style="text-transform:uppercase;">UNDER Article 9</font>,<a name="DocXTextRef369"></a> (B) A PARTY&#8217;S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, (C) A BREACH BY A PARTY OF ITS OBLIGATIONS UNDER ARTICLE 12<a name="DocXTextRef370"></a> OR ARTICLE 13,<a name="DocXTextRef371"></a> OR (D) ANY DAMAGES REQUIRED TO BE PAID TO A THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION UNDER THIS ARTICLE 15, NEITHER RELAY NOR LICENSEE, NOR ANY OF THEIR RESPECTIVE AFFILIATES, WILL BE LIABLE TO THE OTHER PARTY OR ITS AFFILIATES UNDER OR IN CONNECTION WITH THIS AGREEMENT FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL OR PUNITIVE OR EXEMPLARY DAMAGES (INCLUDING LOST PROFITS OR LOST REVENUES), WHETHER LIABILITY IS ASSERTED IN CONTRACT, TORT (INCLUDING NEGLIGENCE AND STRICT PRODUCT LIABILITY), CONTRIBUTION OR OTHERWISE, AND IRRESPECTIVE OF WHETHER THAT PARTY OR ANY REPRESENTATIVE OF THAT PARTY HAS BEEN ADVISED OF, OR OTHERWISE MIGHT HAVE ANTICIPATED THE POSSIBILITY OF, ANY SUCH LOSS OR DAMAGE. <font style="font-weight:bold;"> </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645069"></a><a name="_Toc524107412"></a><a name="_Toc529816505"></a><a name="_Toc529966537"></a><a name="_Toc50796666"></a><a name="_Toc51338595"></a><a name="_Toc53919212"></a><a name="_Toc53925696"></a><font style="Background-color:#auto;text-decoration:none;">Article 16.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><br /><a name="_Ref521645069"></a><a name="_Toc524107412"></a><a name="_Toc529816505"></a><a name="_Toc529966537"></a><a name="_Toc50796666"></a><a name="_Toc51338595"></a><a name="_Toc53919212"></a><a name="_Toc53925696"></a>TERM AND TERMINATION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646955"></a><a name="_Ref521648671"></a><a name="_Toc524107413"></a><a name="_Toc529816506"></a><a name="_Toc529966538"></a><a name="_Ref521645070"></a><font style="Background-color:#auto;text-decoration:none;"> 16.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Term</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Except as set forth in Article 17, this Agreement will become effective on the Effective Date and, unless earlier terminated in accordance with this Article 16, will remain in effect (a) on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration of the Royalty Term for such Licensed Product in such country; provided that the term of this Agreement for any Shared Product will expire on the date on which Licensee is no longer Commercializing such Shared Product in the Profit Share Territory and (b) for any [***] until the expiration of the [***] (the &#8220;<font style="font-weight:bold;">Term</font>&#8221;).&nbsp;&nbsp;Following expiration of the Royalty Term for any Licensed Product in a given country or the [***], no further royalties will be payable in respect of sales of such Licensed Product in such country or the [***], as applicable, and, thereafter the license granted to Licensee under Section 12.1.1 with respect to such Licensed Product in such country will automatically become fully paid-up, perpetual, irrevocable and royalty-free. Upon expiration of the Royalty Term for all Licensed Products in all countries in the Territory (or the Royalty Territory if Opt-In Term is continuing), all licenses granted to Licensee under Section 12.1.1 will automatically become fully paid-up, perpetual, irrevocable and royalty-free in the Territory or the Royalty Territory, as applicable.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref50644601"></a><font style="Background-color:#auto;text-decoration:none;"> 16.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination for Convenience</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;At any time during the Term, Licensee may terminate this Agreement in its entirety immediately following [***] written notice to Relay. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc524107414"></a><a name="_Toc529816507"></a><a name="_Ref529965881"></a><a name="_Ref529966019"></a><a name="_Ref529966049"></a><a name="_Toc529966539"></a><a name="_Ref51331733"></a><a name="_Ref51338606"></a><a name="_Ref52356459"></a><a name="_Ref52534978"></a><a name="_Ref55445118"></a><a name="_Ref56618930"></a><a name="_Ref57128869"></a><a name="_Ref58516779"></a><a name="_Ref58521936"></a><a name="_Ref58526690"></a><a name="_Ref521645071"></a><font style="Background-color:#auto;text-decoration:none;"> 16.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination for Breach</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref528630469"></a><a name="_Ref521645072"></a><a name="DocXTextRef375"></a><a name="DocXTextRef377"></a>.<a name="_Ref528630469"></a><a name="_Ref521645072"></a>&nbsp;&nbsp;This Agreement may be terminated by either Party for the material breach by the other Party of its obligations under this Agreement; provided that the breaching Party has not cured such breach within [***] after the date of written notice to the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">breaching Party of such breach (the &#8220;</font><font style="font-weight:bold;">Cure Period</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DocXTextRef375"></a>&#8221;), which notice will describe such breach in reasonable detail and will state the non-breaching Party&#8217;s intention to terminate this Agreement pursuant to this </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 16.3</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> provided, however, if such breach is not capable of being cured within such Cure Period, the Cure Period shall be extended for such amount of time that the Parties agree to in writing is reasonably necessary to cure such breach, so long as the breaching Party is using diligent efforts to do so</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">; provided further than in all cases in which the breach is a failure to pay any amount due hereunder, the Cure Period will be limited </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DocXTextRef377"></a>.&nbsp;&nbsp;Any such termination of this Agreement under this </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 16.3</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> will become effective at the end of the Cure Period, unless the breaching Party has cured such material breach prior to the expiration of such Cure Period.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any Dispute as to whether a notice of termination pursuant to this Section</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 16.3</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> is proper, or whether a breach has occurred, is material or has been cured, shall be resolved under Section</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 18.9</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;In such event, if the allegedly breaching Party is found to be in material breach, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the remaining Cure Period (meaning, any portion of the Cure Period that did not elapse between the notice of breach and the notification of a Dispute with respect thereto) will be counted from the date of </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">resolution of such Dispute.&nbsp;&nbsp;If Relay has the right to terminate this Agreement due to a material breach by Licensee, and if such breach relates solely to a given </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lead Candidate or</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lead </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product or solely to </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Back-Up </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compound or </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Back-Up Product</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, then Relay may only </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">terminate this Agreement with </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">respect</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to all Lead Candidates and </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lead </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Products or all Back-Up Compound</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and Back-Up Products, respectively. </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event a Sublicensee or Third Party Subcontractor of a Party </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">breaches its sublicense agreement or subcontractor agreement with such Party, as applicable, such that the sublicensing or subcontracting Party would be in breach of this Agreement, and such Sublicensee or Third Party Subcontractor is unable or unwilling to cure such breach, then </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">without limiting any other right of the non-breaching Party to pursue any and all remedies against the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sublicensing or subcontracting</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Party or its Sublicensee or Third Party Subcontractor, the non-breaching Party may not exercise its right to terminate this Agreement pursuant to this Section </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 16.3</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> if the </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sublicensing or subcontracting Party terminates the applicable sublicense agreement or subcontracting agreement with the breaching Sublicensee or Third Party Subcontractor.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646957"></a><a name="_Ref521648251"></a><a name="_Ref521650656"></a><a name="_Ref521650698"></a><a name="_Toc524107416"></a><a name="_Toc529816509"></a><a name="_Toc529966541"></a><a name="_Ref521645075"></a><font style="Background-color:#auto;text-decoration:none;"> 16.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination for Bankruptcy</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DocXTextRef387"></a>.&nbsp;&nbsp;If either Party makes a general assignment for the benefit of creditors, appoints or suffers appointment of a receiver or trustee over all or substantially all of its property, files a petition under any bankruptcy or insolvency act or has any such petition filed against it which is not dismissed, discharged, bonded or stayed within [***]<a name="DocXTextRef387"></a> after the filing thereof, the other Party may terminate this Agreement in its entirety effective immediately upon written notice to such Party; provided that, in connection therewith, the provisions of Section 12.5 will apply.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1052"></a><a name="_BPDC_PR_INS_1053"></a><a name="_Ref56120334"></a><a name="_Ref532459111"></a><a name="_Ref532389014"></a><a name="_BPDC_LN_INS_1050"></a><a name="_BPDC_PR_INS_1051"></a><a name="_Ref56120402"></a><a name="_Ref56068718"></a><font style="Background-color:#auto;text-decoration:none;"> 16.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination for Patent Challenge</font><font style="color:#000000;">.&nbsp;&nbsp;Relay may terminate this Agreement upon written notice to Licensee if Licensee or any of its Affiliates or any Licensee Sublicensee directly or indirectly challenges in a legal or administrative proceeding the patentability, enforceability or validity of any Patent within the Relay Patents (each, a &#8220;</font><font style="font-weight:bold;color:#000000;">Patent Challenge</font><font style="color:#000000;">&#8221;); provided, however, that Relay shall first notify Licensee in writing that it believes Licensee or any of its Affiliates or any Licensee Sublicensee has initiated a Patent Challenge and shall give Licensee no less than [***] to withdraw, or have its Affiliate or Licensee Sublicensee withdraw, such Patent Challenge (or in the case of a Licensee Sublicensee, for Licensee to terminate the applicable sublicense of such Licensee Sublicensee if such Licensee Sublicensee is unwilling to withdraw the Patent Challenge).&nbsp;&nbsp;In any event, (a) this Section 16.5 will not apply to any such Patent Challenge that is first made by Licensee or any of its Affiliates or Licensee Sublicensees in defense of a claim of patent infringement brought by Relay, (b) with respect to any Third Party that becomes an Affiliate </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">of Licensee during the Term as a result of a Change of Control of Licensee or acquisition of such Third Party by Licensee, this Section 16.5 will not apply to any Patent Challenge involving such Third Party if such Patent Challenge was initiated before the signing of the definitive document(s) whereby such Third Party becomes such an Affiliate and such Third Party promptly terminates the Patent Challenge within </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> after the closing of the applicable Change of Control.</font><font style="color:#000000;">&nbsp;&nbsp;</font><font style="color:#000000;"><a name="_BPDC_LN_INS_1050"></a><a name="_BPDC_PR_INS_1051"></a><a name="_Ref56120402"></a><a name="_Ref56068718"></a>&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref532392128"></a><font style="Background-color:#auto;text-decoration:none;"> 16.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination for Cessation</font><font style="color:#000000;">.<a name="_Ref532392128"></a>&nbsp;&nbsp;Relay may, at its election, terminate this Agreement upon [***] prior written notice to Licensee in the event that Licensee, its Affiliates and Licensee Sublicensees have not conducted any Research, Development, Manufacturing or Commercialization activities with respect to any Licensed Candidate or Licensed Product for a continuous period of [***]; provided that (a) if such cessation is a result of a Third Party Action, safety concern, force majeure, injunction or other operation of law, any action by any Regulatory Authority that prevents, limits or otherwise adversely affects any such Research, Development, or Commercialization activity, including for safety or Manufacturing issues, or any material breach by Relay or any of its Affiliates of its obligations under this Agreement or under the SAE Management Plan, the Quality Agreement, the Pharmacovigilance Agreement, the Supply Agreement or any Coordinated Promotion Agreement, such [***] period will be extended for each day any of the foregoing listed in this clause (a) caused such cessation and (b) if such cessation of activity is due to a Manufacturing issue other than as described in clause (a) and Licensee is using Commercially Reasonable Efforts to seek to remedy such issue, such [***] period will be extended for a reasonable period of time as is reasonably necessary to resolve the Manufacturing issue.&nbsp;&nbsp; &nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1048"></a><a name="_BPDC_PR_INS_1049"></a><a name="_Toc529816289"></a><a name="_Toc529816400"></a><a name="_Toc529816510"></a><a name="_Toc529816290"></a><a name="_Toc529816401"></a><a name="_Toc529816511"></a><a name="_Ref526410289"></a><a name="_Toc529816512"></a><a name="_Toc529966544"></a><a name="_Ref522032610"></a><a name="_Ref522041326"></a><a name="_Ref524018090"></a><a name="_Toc524107418"></a><font style="Background-color:#auto;text-decoration:none;"> 16.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination for Failure to Obtain Merger Control</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Each of Relay and Licensee will have the right to terminate this Agreement on a country-by-country basis (with respect to any affected country), effective immediately upon written notice to the other Party, in the event that (a) a Governmental Authority obtains a preliminary injunction under any applicable Antitrust Law to enjoin the transactions contemplated by this Agreement or (b) the Parties have not secured the clearance, approval, expiration, or termination of all applicable merger control waiting periods under applicable Antitrust Law on or prior to <font style="text-decoration:none;color:#auto;letter-spacing:0pt;">[***]</font> after the effective date of all applicable Merger Control Filings in such country.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1046"></a><a name="_BPDC_PR_INS_1047"></a><a name="_BPDC_LN_INS_1043"></a><a name="_BPDC_PR_INS_1044"></a><a name="_Ref521646958"></a><a name="_Toc524107419"></a><a name="_Toc529816513"></a><a name="_Toc529966546"></a><a name="_Ref521645076"></a><font style="Background-color:#auto;text-decoration:none;"> 16.8</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Effects of Termination</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1041"></a><a name="_BPDC_PR_INS_1042"></a><a name="_Ref530142011"></a><a name="_Ref521645077"></a><font style="Background-color:#auto;text-decoration:none;">16.8.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Generally</font><font style="color:#000000;">.&nbsp;&nbsp;Upon termination of this Agreement in its entirety pursuant to this Article 16:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref55498832"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_Ref55498832"></a> the Parties&#8217; rights, licenses and obligations under this Agreement will terminate and neither Party will have any further rights or obligations under this Agreement from and after the effective date of termination (&#8220;</font><font style="font-weight:bold;color:#000000;">Termination Date</font><font style="color:#000000;">&#8221;), except as set forth in this Section 16.8 or Section 16.11;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licensee and its Affiliates and Sublicensees may complete and sell any work-in-progress, committed supply or inventory of the applicable Licensed Products that exist as of the Termination Date, provided that Licensee pays Relay the applicable royalty or other amounts due on such sales of Licensed Products in accordance with the terms and conditions of this Agreement;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any Compulsory Sublicense shall remain in full force and effect </font><font style="color:#000000;">to the extent </font><font style="color:#000000;">required by Applicable Law, and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any existing, permitted sublicense granted by Licensee to a Licensee Sublicensee hereunder (and any further sublicenses thereunder) shall, upon the written request of Licensee, remain in full force and effect, provided that (i) such Licensee Sublicensee is not then in breach of its sublicense agreement (and, in the case of termination by Relay for breach by Licensee pursuant to Section 16.3, that such Licensee Sublicensee and any further Sublicensees did not cause the breach that gave rise to the termination by Relay); and (ii) and such Licensee Sublicensee agrees to be bound to Relay under the terms and conditions of such sublicense agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1039"></a><a name="_BPDC_PR_INS_1040"></a><a name="_Ref530132876"></a><font style="Background-color:#auto;text-decoration:none;">16.8.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination by Relay Pursuant to Section 16.3, Section 16.4, Section 16.5, Section 16.5 or Termination by Licensee Pursuant to Section 16.2</font><font style="color:#000000;">.&nbsp;&nbsp;In the event of termination of this Agreement by Relay pursuant to Section 16.3, Section 16.4, Section 16.5 or Section 16.5 or by Licensee pursuant to Section 16.2, in each case, effective upon the Termination Date: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645078"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">except as set forth in Section  16.11, all rights and licenses granted by Relay to Licensee herein with respect to the Licensed Candidates, Licensed Products and Relay IP will terminate; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1037"></a><a name="_BPDC_PR_INS_1038"></a><a name="_Ref56265158"></a><a name="_Ref57633931"></a><a name="_Ref530151499"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">if Licensee or any of its Affiliates or Licensee Sublicensees have any ongoing Development or Commercialization activities at termination or expiration of this Agreement with respect to a Relay Pipeline Combination Eligible Licensed Product and at such time Relay or any of its Affiliates or any Relay Sublicensee has ongoing Development or Commercialization activities with respect to the Combination Use of such Relay Pipeline Combination Eligible Licensed Product in a Relay Pipeline Combination (such Relay Pipeline Combination Eligible Licensed Product a &#8220;</font><font style="font-weight:bold;color:#000000;">Terminated Relay Pipeline</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Combination Eligible Licensed Product</font><font style="color:#000000;">&#8221;), then Relay may notify Licensee in writing that it (through itself, an Affiliate or a Relay Sublicensee) wishes to continue Development or Commercialization activities with respect to such Terminated Relay Pipeline Combination Eligible Licensed Product.&nbsp;&nbsp;If Relay delivers such notice to Licensee within [***] after the Termination Date, then Licensee and Relay shall meet and negotiate in good faith the appropriate license, financial and other terms and conditions for Relay to receive (i) a transition of ongoing Development or Commercialization activities with respect to such Terminated Relay Pipeline Combination Eligible Licensed Product to Relay, which transition may include a transfer of Regulatory Materials, assignment of clinical trial agreements, transfer of biological materials, transitional distributor or supply arrangement, or a transfer or assignment of certain trademarks, as applicable, or (ii) a non-exclusive, sublicensable (through multiple tiers, subject to the provisions of Section 12.2 (mutatis mutandis)), non-transferable (except as set forth in Section 18.3 (mutatis mutandis)), worldwide, royalty-bearing license under Licensee IP and other Patents or Know-How Controlled by Licensee and then used by or on behalf of Licensee or its Affiliate in connection with the Development or Commercialization of a Terminated Relay Pipeline Combination Eligible Licensed Product, in each case, to Research, Develop, Manufacture or Commercialize the Terminated Relay Pipeline Combination Eligible Licensed Product solely for Combination Use in the applicable Relay Pipeline Combination (including any improvements, modifications, or enhancements to any such product or combination) (the license, financial and other terms and conditions described in this </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">sentence, the &#8220;</font><font style="font-weight:bold;color:#000000;">Terminated Relay </font><font style="font-weight:bold;color:#000000;">Pipeline</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Combination Eligible Licensed Product Terms</font><font style="color:#000000;">&#8221;)</font><font style="color:#000000;">; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref52530814"></a><a name="_Ref57128105"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">if Licensee or any of its Affiliates or Licensee Sublicensees have any ongoing Development or Commercialization activities at termination or expiration of this Agreement with respect to a Licensed Candidate or Licensed Product other than a Terminated Relay Pipeline Combination Eligible Licensed Product (such Licensed Candidate or Licensed Product, a &#8220;</font><font style="font-weight:bold;color:#000000;">Terminated Other Licensed Product</font><font style="color:#000000;">&#8221;), then Relay may notify Licensee in writing that it (through itself, an Affiliate or a Relay Sublicensee) wishes to continue Development or Commercialization with respect to such Licensed Candidate or Licensed Product and to receive a transition of ongoing Development or Commercialization activities with respect to such Licensed Candidate or Licensed Product, which transition may include a transfer of Regulatory Materials, assignment of clinical trial agreements, transfer of biological materials, transitional distributor or supply arrangement, transfer or assignment of certain Trademarks, or a non-exclusive, royalty-bearing license under Licensee IP and other Patents or Know-How then used by or on behalf of Licensee or its Affiliate in connection with the Development or Commercialization of a Licensed Candidate or Licensed Product, in each case, as applicable and mutually agreed, to Research, Develop, Manufacture, or Commercialize such Licensed Candidate or a Licensed Product (including any improvements, modifications, or enhancements to any such candidate or product). If Relay delivers such notice to Licensee within [***] after the Termination Date, then Licensee and Relay shall meet and negotiate in good faith for the appropriate license,&nbsp;&nbsp;financial and other terms and conditions for Relay to receive (i) a transition of ongoing Development or Commercialization activities with respect to such Licensed Candidate or Licensed Product to Relay, which transition may include a transfer of Regulatory Materials, assignment of clinical trial agreements, transfer of biological materials, transitional distributor or supply arrangement, or a transfer or assignment of certain Trademarks, as applicable, or (ii) a non-exclusive, sublicensable (through multiple tiers, subject to the provisions of Section 12.2 (mutatis mutandis)), non-transferable (except as set forth in Section 18.3 (mutatis mutandis)), worldwide, royalty-bearing license under Licensee IP and other Patents or Know-How then used by or on behalf of Licensee or its Affiliate in connection with the Development or Commercialization of the Terminated Other Licensed Product, in each case, to Research, Develop, Manufacture or Commercialize such Licensed Candidate or Licensed Product (and all improvements, modifications and enhancements to such candidates and products). Notwithstanding the foregoing, neither Party shall be obligated to enter into an agreement for any such transition or license if the Parties are unable in good faith to agree on mutually acceptable terms and conditions.&nbsp;&nbsp;  </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_PR_INS_1036"></a><a name="_BPDC_LN_INS_1033"></a><a name="_BPDC_PR_INS_1034"></a><font style="Background-color:#auto;text-decoration:none;">16.8.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination Pursuant to Section 16.7</font><font style="color:#000000;">.&nbsp;&nbsp;In the event of termination of this Agreement with respect to a particular country pursuant to Section 16.7, then, notwithstanding any provision in this Agreement to the contrary, neither Party will have any obligation to the other Party with respect to the subject matter of this Agreement with respect to the terminated country; provided that Article 13 will survive. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1031"></a><a name="_BPDC_PR_INS_1032"></a><a name="_Ref56098488"></a><a name="_Ref54729468"></a><a name="_Toc524107421"></a><a name="_Toc529816515"></a><a name="_Ref529965975"></a><a name="_Ref529966067"></a><a name="_Toc529966548"></a><a name="_Ref530143221"></a><a name="_Ref521645085"></a><a name="_Ref532941728"></a><a name="_Ref50913192"></a><font style="Background-color:#auto;text-decoration:none;"> 16.9</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Discontinuation by Licensee of Development/Commercialization of a Relay Pipeline Combination Eligible Licensed Product included in a Relay Pipeline Combination</font><font style="color:#000000;">.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1029"></a><a name="_BPDC_PR_INS_1030"></a><a name="_Ref56264184"></a><font style="Background-color:#auto;text-decoration:none;">16.9.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If during the Term, Licensee or its Affiliates makes a decision through a governance committee ([***] or their respective equivalent if such committees do not exist in the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">future)</font><font style="color:#000000;">,</font><font style="color:#000000;"> to permanently cease all Development and Commercialization activities </font><font style="color:#000000;">and</font><font style="color:#000000;"> </font><font style="color:#000000;">Manufacturing</font><font style="color:#000000;"> activities </font><font style="color:#000000;">with respect to a Relay </font><font style="color:#000000;">Pipeline</font><font style="color:#000000;"> Combination Eligible Licensed Product</font><font style="color:#000000;">, and </font><font style="color:#000000;">at such time Relay has ongoing Development or Commercialization activities with respect to the Combination Use of such Relay </font><font style="color:#000000;">Pipeline </font><font style="color:#000000;">Combination Eligible Licensed Product</font><font style="color:#000000;"> </font><font style="color:#000000;">then Licensee will notify Relay in writing of such cessation and the date of such decision (a &#8220;</font><font style="font-weight:bold;color:#000000;">Relay </font><font style="font-weight:bold;color:#000000;">Pipeline</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Combination Eligible Licensed Product Discontinuation Notice</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;In the event that </font><font style="color:#000000;">(a)</font><font style="color:#000000;"> Licensee sends Relay a Relay </font><font style="color:#000000;">Pipeline </font><font style="color:#000000;">Combination Eligible Licensed Product Discontinuation Notice with respect to a Relay </font><font style="color:#000000;">Pipeline </font><font style="color:#000000;">Combination Eligible Licensed Product </font><font style="color:#000000;">and </font><font style="color:#000000;">at such time Relay or any of its Affiliates or any Relay </font><font style="color:#000000;">Sublicensee</font><font style="color:#000000;"> has ongoing Development or Commercialization activities with respect to the Combination Use of such Relay </font><font style="color:#000000;">Pipeline </font><font style="color:#000000;">Combination Eligible Licensed Product in a Relay Pipeline Combination </font><font style="color:#000000;">or (b) a Relay</font><font style="color:#000000;"> Pipeline</font><font style="color:#000000;"> Combination Eligible Licensed Product Cessation occurs with respect to a Relay </font><font style="color:#000000;">Pipeline </font><font style="color:#000000;">Combination Eligible Licensed Product, and at such time Relay </font><font style="color:#000000;">or any of its Affiliates or any Relay Sublicensee </font><font style="color:#000000;">has ongoing Development or Commercialization activities with respect to the Combination Use of such Relay </font><font style="color:#000000;">Pipeline </font><font style="color:#000000;">Combination Eligible Licensed Product in a Relay Pipeline Combination (such Relay </font><font style="color:#000000;">Pipeline </font><font style="color:#000000;">Combination Eligible Licensed Product </font><font style="color:#000000;">in the case of (a) or (b),</font><font style="color:#000000;"> a &#8220;</font><font style="font-weight:bold;color:#000000;">Discontinued Relay </font><font style="font-weight:bold;color:#000000;">Pipeline</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Combination Eligible Licensed Product</font><font style="color:#000000;">&#8221;), then</font><font style="color:#000000;">, in each case ((a) and (b)),</font><font style="color:#000000;"> Relay may notify Licensee in writing that it</font><font style="color:#000000;"> (through itself, an Affiliate or a </font><font style="color:#000000;">Relay</font><font style="color:#000000;"> Sublicensee)</font><font style="color:#000000;"> wishes to continue Development or Commercialization activities with respect to such Discontinued Relay </font><font style="color:#000000;">Pipeline </font><font style="color:#000000;">Combination Eligible Licensed Product.&nbsp;&nbsp;A &#8220;</font><font style="font-weight:bold;color:#000000;">Relay </font><font style="font-weight:bold;color:#000000;">Pipeline</font><font style="color:#000000;"> </font><font style="font-weight:bold;color:#000000;">Combination Eligible Licensed Product Cessation</font><font style="color:#000000;">&#8221; means that Licensee, its Affiliates and Licensee Sublicensees have not conducted any Research, Development, Manufacturing or Commercialization activities with respect to such Relay </font><font style="color:#000000;">Pipeline </font><font style="color:#000000;">Combination Eligible Licensed Product for a continuous period of </font><font style="color:#000000;">[***]</font><font style="color:#000000;">; provided that (</font><font style="color:#000000;">i</font><font style="color:#000000;">) if such cessation is a result of a Third Party Action, safety concern, force majeure, injunction or other operation of law, any action by any Regulatory Authority that prevents, limits or otherwise adversely affects any such Research, Development, Manufacturing, or Commercialization activity, including for safety or Manufacturing issues, or any material breach by Relay or any of its Affiliates of its obligations under this Agreement</font><font style="color:#000000;"> or the SAE Management Plan, the Quality Agreement, the Pharmacovigilance Agreement, the Supply Agreement or any Coordinated Promotion Agreement</font><font style="color:#000000;">, such </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> period will be extended for each day any of the foregoing listed in this clause (</font><font style="color:#000000;">i</font><font style="color:#000000;">) caused such cessation and (</font><font style="color:#000000;">ii</font><font style="color:#000000;">) if such cessation of activity is due to a Manufacturing issue other than as described in clause (</font><font style="color:#000000;">i</font><font style="color:#000000;">) and Licensee is using Commercially Reasonable Efforts to seek to remedy such issue, such </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> period will be extended for a reasonable period of time as is reasonably necessary to resolve the Manufacturing issue.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1027"></a><a name="_BPDC_PR_INS_1028"></a><a name="_Ref56264899"></a><a name="_Hlk57107772"></a><font style="Background-color:#auto;text-decoration:none;">16.9.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If Relay delivers such written notice under Section 16.9.1 to Licensee within [***] after receipt of the Relay Pipeline Combination Eligible Licensed Product Discontinuation Notice or Relay becoming aware of the occurrence of the Relay Pipeline Combination Eligible Licensed Product Cessation, as applicable, Licensee and Relay shall meet and negotiate in good faith the appropriate license, financial and other terms and conditions for Relay to receive (a) a transition of ongoing Development or Commercialization activities with respect to such Discontinued Relay Pipeline Combination Eligible Licensed Product to Relay, [***], or (b) a non-exclusive, sublicensable (through multiple tiers, subject to the provisions of Section 12.2 (mutatis mutandis)), non-transferable (except as set forth in Section 18.3 (mutatis mutandis)), worldwide, royalty-bearing license under the Relay IP and Licensee IP and other Patents or Know-How then used by or on behalf of Licensee or its Affiliate in connection with the Development, Manufacture </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">or Commercialization of the Discontinued Relay </font><font style="color:#000000;">Pipeline </font><font style="color:#000000;">Combination Eligible Licensed Product</font><font style="color:#000000;">, in each case, to Research, Develop, Manufacture or </font><font style="color:#000000;">Commercialize</font><font style="color:#000000;"> such Discontinued Relay </font><font style="color:#000000;">Pipeline </font><font style="color:#000000;">Combination </font><font style="color:#000000;">Eligible</font><font style="color:#000000;"> Lic</font><font style="color:#000000;">ensed Product</font><font style="color:#000000;"> for Combination Use in Relay Pipeline Combination</font><font style="color:#000000;">s</font><font style="color:#000000;"> (the license, financial and other terms and conditions described in this sentence, the &#8220;</font><font style="font-weight:bold;color:#000000;">Discontinued </font><font style="font-weight:bold;color:#000000;">Relay Pipeline Combination Eligible Licensed </font><font style="font-weight:bold;color:#000000;">Product Terms</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;For clarity, the licenses under this Section shall not include any licenses that Licensee has with a Third Party under which Licensee or its Affiliates would incur financial obligations to such Third Party (unless Relay agrees to bear such financial obligations)</font><font style="color:#000000;"> or </font><font style="color:#000000;">for which such grant would be prohibited or unduly burdensome to Licensee</font><font style="color:#000000;"><a name="_Hlk57107772"></a> (unless the Parties are able to negotiate a mutually acceptable solution </font><font style="color:#000000;">to address such burden on Licensee</font><font style="color:#000000;">)</font><font style="color:#000000;">. In negotiating the Discontinued Relay </font><font style="color:#000000;">Pipeline </font><font style="color:#000000;">Combination Eligible Licensed Product Terms, the Parties shall take into account the value of the applicable Licensee IP and contribution made by Licensee to the Development and Commercialization of the Discontinued Relay </font><font style="color:#000000;">Pipeline </font><font style="color:#000000;">Combination Eligible Licensed Product</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57613111"></a><a name="_Ref57132015"></a><font style="Background-color:#auto;text-decoration:none;">16.9.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If the Relay Pipeline Combination that includes the Discontinued Relay Pipeline Combination Eligible Licensed Product is in Development at the time of Relay&#8217;s timely delivery of written notice of desire to continue Development or Commercialization activities with respect to such Discontinued Relay Pipeline Combination Eligible Licensed Product under Section 16.9.1, then from such date until agreement by the Parties to Discontinued Relay Pipeline Combination Eligible Licensed Product Terms or final resolution of baseball-style binding arbitration with respect to such Discontinued Relay Pipeline Combination Eligible Licensed Product Terms pursuant to Section 16.10 (the &#8220;</font><font style="font-weight:bold;color:#000000;">Transition Period</font><font style="color:#000000;">&#8221;) Licensee will continue to Manufacture and supply the clinical supply of such Discontinued Relay Pipeline Combination Eligible Licensed Product to Relay pursuant to the Supply Agreement, or if Licensee fails to do so Relay shall have the remedies set forth in the Supply Agreement.&nbsp;&nbsp; If Commercialization activities have commenced with respect to the Relay Pipeline Combination that includes the Discontinued Relay Pipeline Combination Eligible Licensed Product at the time of Relay&#8217;s timely delivery of written notice of desire to continue Development or Commercialization activities with respect to such Discontinued Relay Pipeline Combination Eligible Licensed Product under Section 16.9.1, then during the Transition Period Licensee will have the option to continue to Manufacture and book sales for the commercial supply of such Discontinued Relay Pipeline Combination Eligible Licensed Product and to continue to conduct coordinated promotional activities with respect thereto in accordance with the applicable Coordinated Promotion Agreement.&nbsp;&nbsp;&nbsp;&nbsp;If Licensee notifies Relay that it will not continue to Manufacture and book sales for the commercial supply of such Discontinued Relay Pipeline Combination Eligible Licensed Product and to continue to conduct coordinated promotional activities with respect thereto in accordance with the applicable Coordinated Promotion Agreement, or if Licensee materially fails to do so, Licensee hereby grants to Relay and its Affiliates, solely for the Transition Period, a non-exclusive, sublicensable (through multiple tiers), non-transferrable (except as set forth in Section  18.3), royalty-free license under the Relay IP and the Licensee IP to Manufacture and Commercialize the Discontinued Relay Pipeline Combination Eligible Licensed Products in the Field in the Territory, at its sole cost and expense; provided that such license is exercisable beginning on such notice from Licensee or Licensee&#8217;s material failure to Manufacture and book sales for the commercial supply of such Discontinued Relay Pipeline Combination Eligible Licensed Product and to continue to conduct coordinated promotional activities with respect thereto in accordance with the applicable Coordinated Promotion Agreement.&nbsp;&nbsp; </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1025"></a><a name="_BPDC_PR_INS_1026"></a><a name="_Ref56078095"></a><a name="_Ref41135486"></a><font style="Background-color:#auto;text-decoration:none;"> 16.10</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Baseball Arbitration</font><font style="color:#000000;"><a name="_Ref41135486"></a>.&nbsp;&nbsp;If the Parties are unable to agree on (a) terms and conditions for a Supply Agreement pursuant to Section 7.2.4 (&#8220;</font><font style="font-weight:bold;color:#000000;">Supply Agreement Terms</font><font style="color:#000000;">&#8221;) within one hundred and [***] after the Effective Date, (b) Terminated Relay Pipeline Combination Eligible Licensed Product Terms within [***] following timely notice from Relay pursuant to Section 16.8.2(b) indicating that Relay wants to negotiate the Terminated Relay Pipeline Combination Eligible Licensed Product Terms, or (c) Discontinued Relay Pipeline Combination Eligible Licensed Product Terms within [***] following timely notice from Relay pursuant to Section 16.9.2 indicating that Relay wants to negotiate the Discontinued Relay Pipeline Combination Eligible Licensed Product Terms (each such period in (a), (b) or (c), the applicable &#8220;</font><font style="font-weight:bold;color:#000000;">Negotiation Period</font><font style="color:#000000;">&#8221;), then such Dispute will be subject to final resolution by baseball-style binding arbitration in accordance with the following procedures: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1023"></a><a name="_BPDC_PR_INS_1024"></a><a name="_Ref56078264"></a><font style="Background-color:#auto;text-decoration:none;">16.10.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay shall notify Licensee of its decision to initiate the arbitration pursuant to this Section 16.10 through written notice to Licensee within [***] following expiration of the applicable Negotiation Period.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1021"></a><a name="_BPDC_PR_INS_1022"></a><font style="Background-color:#auto;text-decoration:none;">16.10.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Within [***] following Licensee&#8217;s receipt of such notice, each Party shall appoint one Expert, and the two Experts so selected shall appoint a third Expert within [***] of their nomination, and such final Expert shall act as the chair of the three Expert panel.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1019"></a><a name="_BPDC_PR_INS_1020"></a><font style="Background-color:#auto;text-decoration:none;">16.10.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Within [***] after the appointment of the final Expert, such Expert shall set a date for the arbitration, which date shall be no more than [***] after the date Relay notified Licensee of its decision to initiate the arbitration under Section 16.10.1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1017"></a><a name="_BPDC_PR_INS_1018"></a><font style="Background-color:#auto;text-decoration:none;">16.10.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The arbitration shall be &#8220;baseball-style&#8221; arbitration; accordingly, at least [***] prior to the arbitration, each Party shall provide the Experts and the other Party with the Terminated Relay Pipeline Combination Eligible Licensed Product Terms, Discontinued Relay Pipeline Combination Eligible Licensed Product Terms or Supply Agreement Terms, as applicable, proposed by it (its &#8220;</font><font style="font-weight:bold;color:#000000;">Proposed Terms</font><font style="color:#000000;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1015"></a><a name="_BPDC_PR_INS_1016"></a><font style="Background-color:#auto;text-decoration:none;">16.10.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In addition, at least [***] in advance of the arbitration, each Party may submit to the Experts and the other Party a revised version of its Proposed Terms (together with a redline showing the changes from the prior draft of its Proposed Terms). The Parties&#8217; briefs may include or attach relevant exhibits in the form of documentary evidence, any other material voluntarily disclosed to the submitting Party in advance, or publicly available information. Neither Party may have any other communications (either written or oral) with the Experts other than for the sole purpose of engaging the Experts or as expressly permitted in this Section  16.10.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1013"></a><a name="_BPDC_PR_INS_1014"></a><font style="Background-color:#auto;text-decoration:none;">16.10.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The arbitration shall consist of [***] hearing of no longer than eight (8) hours, such time to be split equally between the Parties, in the form of presentations by counsel or employees and officers of the Parties. No live witnesses shall be permitted.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1011"></a><a name="_BPDC_PR_INS_1012"></a><font style="Background-color:#auto;text-decoration:none;">16.10.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No later than [***] following the arbitration, the Experts shall issue their written decision. The Experts shall select one Party&#8217;s revised Proposed Terms as their decision and shall not have the authority to render any substantive decision other than to select the Proposed Terms submitted by either Licensee or Relay. The Experts shall have no discretion or authority with respect to modifying the positions of the Parties. The Experts&#8217; decision shall by a majority </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">vote of the Experts and such decision shall be final and binding on the Parties and the written agreement selected by the Experts shall constitute a binding agreement between the Parties that may be enforced in accordance with its terms. Each Party shall bear its own costs and expenses in connection with such arbitration and shall share equally the fees and expenses of the Experts.</font><font style="color:#000000;">&nbsp;&nbsp;Within </font><font style="color:#000000;">[***]</font><font style="color:#000000;"> following the decision of the Experts, the Parties will execute the winning Proposed Terms.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1009"></a><a name="_BPDC_PR_INS_1010"></a><font style="Background-color:#auto;text-decoration:none;">16.10.8</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The violation of one of the time limits specified in this Section 16.10 by the Experts shall not affect the Experts&#8217; competence to decide on the subject matter and shall not affect the final and binding decision rendered by the Experts, unless otherwise agreed by the Parties.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1007"></a><a name="_BPDC_PR_INS_1008"></a><font style="Background-color:#auto;text-decoration:none;">16.10.9</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The &#8220;baseball-style&#8221; arbitration in this Section 16.10 shall be the exclusive remedy of either Party if the Parties cannot agree on the Terminated Relay Pipeline Combination Eligible Licensed Product Terms, Discontinued Relay Pipeline Combination Eligible Licensed Product Terms or Supply Agreement Terms, as applicable</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1005"></a><a name="_BPDC_PR_INS_1006"></a><a name="_Ref56261789"></a><font style="Background-color:#auto;text-decoration:none;"> 16.11</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Surviving Provisions</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1003"></a><a name="_BPDC_PR_INS_1004"></a><a name="_Ref521645086"></a><font style="Background-color:#auto;text-decoration:none;">16.11.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">Accrued Rights; Remedies</font><font style="color:#000000;">.&nbsp;&nbsp;Termination or expiration of this Agreement for any reason will be without prejudice to any rights that will have accrued to the benefit of any Party prior to such termination or expiration, and any and all damages or remedies (whether in law or in equity) arising from any breach hereunder, each of which will survive termination or expiration of this Agreement, including any payments that are payable prior to the effective date of termination.&nbsp;&nbsp;Except as otherwise expressly set forth in this Agreement, the termination provisions of this Article 16 are in addition to any other relief and remedies available to either Party under this Agreement and at law or in equity.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_BPDC_LN_INS_1001"></a><a name="_BPDC_PR_INS_1002"></a><a name="_Ref521645087"></a><a name="DocXTextRef409"></a><font style="Background-color:#auto;text-decoration:none;">16.11.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">Survival</font><font style="color:#000000;"><a name="DocXTextRef409"></a>.&nbsp;&nbsp;Without limiting the provisions of Section 16.11.1, the rights and obligations of the Parties set forth in the following Sections and Articles of this Agreement will survive the expiration or termination of this Agreement, for the time period specified therein and, if no such time period is specified, indefinitely: Sections 11.13.5,  11.15, 12.1.2 (solely to the extent set forth therein), 12.4, 12.7, 12.8 (with respect to Joint Collaboration Patents), 12.9 (with respect to Joint Collaboration Patents),  12.10 (with respect to Joint Collaboration Patents), Article 11 (Financial Terms) (with respect to amounts earned but not paid), Article 13 (Confidentiality) (other than Section 13.8), Article 14 (Representations and Warranties; Covenants), Article 15 (Indemnification; Insurance), Article 16 (Term and Termination), and Article 18 (Miscellaneous).</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Ref39127264"></a><a name="_Toc50796667"></a><a name="_Toc51338596"></a><a name="_Toc53919213"></a><a name="_Toc53925697"></a><font style="Background-color:#auto;text-decoration:none;">Article 17.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><br /><a name="_Ref39127264"></a><a name="_Toc50796667"></a><a name="_Toc51338596"></a><a name="_Toc53919213"></a><a name="_Toc53925697"></a>EFFECTIVE DATE; ANTITRUST AND COMPETITION LAW COMPLIANCE</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref58259965"></a><a name="_Ref39127179"></a><font style="Background-color:#auto;text-decoration:none;"> 17.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Effective Date</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Notwithstanding anything to the contrary contained herein, none of the terms and conditions contained in this Agreement (including the obligation for Licensee to make any payments hereunder) will be effective until the HSR Clearance Date or clearance, approval, or expiration or termination of the waiting period under any other applicable Antitrust Law (the later of such date or the Execution Date, the &#8220;<font style="font-weight:bold;">Effective Date</font>&#8221;).&nbsp;&nbsp; The Parties acknowledge </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that the HSR waiting period for this Agreement expired November 2</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2020 with no requests from the FTC.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;"> 17.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Antitrust and Competition Law Compliance</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">17.2.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Efforts</font><font style="color:#000000;">.&nbsp;&nbsp;Each of Relay and Licensee will use its good faith efforts to eliminate any concern on the part of any Governmental Authority regarding the legality of this Agreement under any Antitrust Law, including, promptly taking all steps to secure government antitrust clearance, subject to Section 16.7, including cooperating in good faith with any government investigation including the prompt production of documents and information demanded by any request for documents and of witnesses if requested.&nbsp;&nbsp;Notwithstanding the foregoing, this Article 17 and the term &#8220;good faith efforts&#8221; do not require that either Party (a) offer, negotiate, commit to or effect, by consent decree, hold separate order, trust or otherwise, the sale, divestiture, license or other disposition of any capital stock, assets, rights, products or businesses of Relay, Licensee or their respective Affiliates, (b) agree to any restrictions on the businesses of Relay, Licensee or their respective Affiliates, or (c) pay any amount or take any other action to prevent, effect the dissolution of, vacate, or lift any decree, order, judgment, injunction, temporary restraining order, or other order in any suit or proceeding that would otherwise have the effect of preventing or delaying the transactions contemplated by this Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref39328709"></a><font style="Background-color:#auto;text-decoration:none;">17.2.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Merger Control Filings</font><font style="color:#000000;">.&nbsp;&nbsp;At the written request of Licensee, each of Relay and Licensee, as appropriate, will, within [***] after receipt of Licensee&#8217;s written request under this Article 17 (or such later time as may be agreed to in writing by the Parties), file any Merger Control Filing required under any other applicable Antitrust Law in the reasonable opinion of Licensee with respect to the transactions contemplated by this Agreement.&nbsp;&nbsp;The Parties will cooperate with one another to the extent necessary in the preparation of any such Merger Control Filing.&nbsp;&nbsp;Each Party will pay: [***]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">17.2.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination for Failure to Obtain Merger Control Clearance</font><font style="color:#000000;">.&nbsp;&nbsp;Each of Relay and Licensee will have the right to terminate this Agreement in accordance with Section 16.7.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref58271587"></a><a name="_Ref56093512"></a><font style="Background-color:#auto;text-decoration:none;">17.2.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Information Exchange</font><font style="color:#000000;">.&nbsp;&nbsp;Each of Relay and Licensee will, in connection with any Merger Control Filing, (a) reasonably cooperate with each other in connection with any communication, filing or submission and in connection with any investigation or other inquiry, including any proceeding initiated by a private party; (b) keep the other Party or its counsel informed of any communication (and if in writing, provide a copy to the other Party or its counsel) received by such Party from, or given by such Party any Governmental Authority and of any communication received or given in connection with any proceeding by a private party, in each case regarding the transactions contemplated by this Agreement; (c) consult with each other in advance of any meeting or conference with such Governmental Authority or, in connection with any proceeding by a private party, with such private party, and to the extent permitted by the Governmental Authority or such private party, give the Parties or their counsel the opportunity to attend and participate in such meetings and conferences; and (d) permit the other Party or its counsel to review in advance any submission, filing or communication (and documents submitted therewith) intended to be given by any Governmental Authority, or, in connection with any proceeding by a private party, to such private party; provided that materials may be redacted to remove references concerning the valuation of the business of either Party.&nbsp;&nbsp;Relay and Licensee, as each deems advisable and necessary, may reasonably designate any competitively sensitive </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">material to be provided to the other under this </font><font style="color:#000000;">Article 17</font><font style="color:#000000;"> as &#8220;</font><font style="font-weight:bold;color:#000000;">Antitrust Counsel Only Material</font><font style="color:#000000;">&#8221;.&nbsp;&nbsp;Such materials and the information contained therein will be given only to the outside antitrust counsel of the recipient and will not be disclosed by such outside counsel to employees, officers or directors of the recipient unless express permission is obtained in advance from the source of the materials (Relay or Licensee, as the case may be) or the applicable Party&#8217;s legal counsel</font><font style="color:#000000;">.</font><font style="color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">17.2.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Assistance</font><font style="color:#000000;">.&nbsp;&nbsp;Subject to this Article 17, at the reasonable request of either Party, Relay and Licensee will cooperate and use respectively all reasonable efforts to make all other registrations, filings and applications, to give all notices and to obtain as soon as practicable all governmental or other consents, transfers, approvals, orders, qualifications, authorizations, permits and waivers, if any, and to do all other things necessary or desirable for the consummation of the transactions as contemplated by this Agreement in accordance with applicable Antitrust Laws.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;"> 17.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Obligations Prior to Effective Date</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Subject to Applicable Law, during the period between the Execution Date and the Effective Date:&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">17.3.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Conduct of Business Prior to Effective Date</font><font style="color:#000000;">.&nbsp;&nbsp;Relay will conduct its business relating to the Licensed Candidates and Licensed Products in, and will not take any action except in, the ordinary course of business and in a manner consistent with past practices. Relay will continue to conduct the Relay Phase Ia Trial in accordance with accepted pharmaceutical industry norms and ethical practices and in accordance with the Relay Phase Ia Plan as disclosed to Licensee prior to the Execution Date.&nbsp;&nbsp;Relay will not (and Relay will ensure that its Affiliates do not) take any action that would conflict with any or limit the scope of any rights or licenses granted to Licensee hereunder, including that it will not (a) assign, transfer, convey, encumber (including any liens or charges) or dispose of, or enter into any agreement with any Third Party to assign, transfer, convey, encumber (including any liens or charges) or dispose of, any Relay IP related to the Licensed Candidates or Licensed Products, or (b) disclose any material information related thereto to any Third Party, in each case ((a) through (b)), if such activity would conflict with any or limit the scope of any rights or licenses granted to Licensee hereunder.&nbsp;&nbsp;For the avoidance of doubt, an assignment of this Agreement in accordance with Section 18.3 will not be a breach of this Article 17; provided that any such assignment does not, or would not reasonably be expect to, have the effect of delaying, impairing, or impeding, the early termination or expiration of any applicable waiting period under Antitrust Law for the transactions contemplated by this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645089"></a><a name="_Toc524107422"></a><a name="_Toc529816516"></a><a name="_Toc529966549"></a><a name="_Toc50796668"></a><a name="_Toc51338597"></a><a name="_Toc53919214"></a><a name="_Toc53925698"></a><font style="Background-color:#auto;text-decoration:none;">Article 18.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><br /><a name="_Ref521645089"></a><a name="_Toc524107422"></a><a name="_Toc529816516"></a><a name="_Toc529966549"></a><a name="_Toc50796668"></a><a name="_Toc51338597"></a><a name="_Toc53919214"></a><a name="_Toc53925698"></a>MISCELLANEOUS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646960"></a><a name="_Toc529284553"></a><a name="_Toc529966550"></a><a name="_Ref521645090"></a><a name="_Toc522731635"></a><a name="_Toc524107426"></a><font style="Background-color:#auto;text-decoration:none;"> 18.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Force Majeure</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Neither Party will be held liable or responsible to the other Party or be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement (other than an obligation to make payments) when such failure or delay is caused by or results from events beyond the reasonable control of the non-performing Party, including fires, floods, earthquakes, hurricanes, embargoes, shortages, epidemics, pandemics, quarantines, war, acts of war (whether war be declared or not), terrorist acts, insurrections, riots, civil commotion, strikes, lockouts, or other labor disturbances (whether involving the workforce of the non-performing Party or of any other Person), acts of God or acts, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">omissions or delays in acting by any Governmental Authority (each a &#8220;</font><font style="font-weight:bold;">Force Majeure Event</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">&#8221;).&nbsp;&nbsp;The non-performing Party will notify the other Party of such Force Majeure Event within </font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">[***]</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"> after such occurrence by giving written notice to the other Party stating the nature of the event, its anticipated duration, and any action being taken to avoid or minimize its effect.&nbsp;&nbsp;The suspension of performance will be of no greater scope and no longer duration than is necessary and the non-performing Party will use Commercially Reasonable Efforts to remedy its inability to perform.</font><font style="font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646961"></a><a name="_Toc529284554"></a><a name="_Toc529966551"></a><a name="_Ref521645091"></a><font style="Background-color:#auto;text-decoration:none;"> 18.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Export Control</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Each Party agrees that it will not export, directly or indirectly, any technical information acquired from the other Party under this Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export license or other governmental approval, without first obtaining such license or other governmental approval from the appropriate agency or other Governmental Authority in accordance with Applicable Law.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646962"></a><a name="_Toc529284555"></a><a name="_Toc529966552"></a><a name="_Ref50828772"></a><a name="_Ref57576970"></a><a name="_Ref521645092"></a><font style="Background-color:#auto;text-decoration:none;"> 18.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Assignment; Change of Control</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">18.3.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Except as provided in this Section 18.3, this Agreement may not be assigned otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the consent of the other Party, which consent will not be unreasonably withheld.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">18.3.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licensee may, without consent of Relay, assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate of Licensee or in its entirety in connection with a Change of Control.&nbsp;&nbsp;Relay may, without the consent of Licensee, but upon written notice to Licensee, assign this Agreement in whole or in part to an Affiliate of Relay or in its entirety in connection with a Change of Control of Relay, subject to Section 18.3.4.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">18.3.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Any attempted assignment not in accordance with this Section 18.3 will be void.&nbsp;&nbsp;Any permitted assignee will assume all assigned obligations of its assignor under this Agreement.&nbsp;&nbsp;Except as provided under Section 18.3.4, the terms and conditions of this Agreement will be binding upon, and will inure to the benefit of, the Parties and their respected successors and permitted assigns.&nbsp;&nbsp;This Agreement is for the sole benefit of the Parties and not for the benefit of any other Person.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref_ContractCompanion_9kb9Ur013"></a><a name="_Hlk56063208"></a><font style="Background-color:#auto;text-decoration:none;">18.3.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In the event that there is a Change of Control of Relay, then the following provisions will apply and be in full force and effect:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relay will provide written notice to Licensee on or prior to such Change of Control becoming effective.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> If the Acquirer of Relay is Developing or Commercializing a Competitive Product or any other compound or product that is competitive with a [***] Combination, upon Licensee&#8217;s request, Relay will establish reasonable protections and safeguards to protect against Licensee&#8217;s Confidential Information regarding Development or Commercialization of Licensed Candidates or Licensed Products (including [***] Combinations) being shared with the personnel of Relay&#8217;s Acquirer who are materially participating the Development or Commercialization of such Competitive Product or other competitive compound </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">or product</font><font style="color:#000000;"> (such protections and safeguards will not extend to personnel at or above supervisory level)</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">For the avoidance of doubt, upon a Change of Control of Relay:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If Relay&#8217;s Opt-In Right has not been previously exercised or expired, Relay&#8217;s Opt-In Right shall not survive a Change of Control of Relay and shall expire upon completion of the Change of Control; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">if Relay&#8217;s Opt-In Right has been previously exercised, but Relay&#8217;s Opt-Out Right has not been previously exercised or expired, the Opt-Out Right shall expire upon the [***] anniversary of the completion of the Change of Control [***]</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">In the event of any sale, transfer or license by Relay of all or substantially all of its assets or rights relating to one or more of the Relay Pipeline Compounds that are included in a Relay Pipeline Combination, this Section 18.3.4 shall apply to such sale or transfer in the same manner as a Change of Control to the extent applicable, <font style="font-style:italic;">mutatis mutandis</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc529284556"></a><a name="_Toc529966553"></a><font style="Background-color:#auto;text-decoration:none;"> 18.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Performance by Affiliates</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Either Party may discharge any obligations and exercise any right hereunder through any of its Affiliates; provided that such Party will cause its Affiliates to comply with the applicable provisions of this Agreement in connection with such performance and the Party will remain fully responsible and obligated for its obligations hereunder.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646963"></a><a name="_Toc524107427"></a><a name="_Toc529816521"></a><a name="_Toc529966554"></a><a name="_Ref521645093"></a><font style="Background-color:#auto;text-decoration:none;"> 18.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Severability</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DocXTextRef411"></a><a name="DocXTextRef412"></a><a name="DocXTextRef413"></a><a name="DocXTextRef414"></a><a name="DocXTextRef411"></a>.&nbsp;&nbsp;If any provision of this Agreement is held to be illegal, invalid, or unenforceable under any present or future Applicable Law, and if the rights or obligations of either Party under this Agreement will not be materially and adversely affected thereby, (a)<a name="DocXTextRef412"></a>&#160;such provision will be fully severable, (b)<a name="DocXTextRef413"></a>&#160;this Agreement will be construed and enforced as if such illegal, invalid, or unenforceable provision had never comprised a part hereof, (c)<a name="DocXTextRef414"></a>&#160;the remaining provisions of this Agreement will remain in full force and effect and will not be affected by the illegal, invalid, or unenforceable provision or by its severance herefrom, and (d)&#160;in lieu of such illegal, invalid, or unenforceable provision, <font style="color:#000000;">the Parties will make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering into this Agreement may be realized</font>.&nbsp;&nbsp;To the fullest extent permitted by Applicable Law, each Party hereby waives any provision of law that would render any provision hereof illegal, invalid, or unenforceable in any respect. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646964"></a><a name="_Ref521649673"></a><a name="_Toc524107428"></a><a name="_Toc529816522"></a><a name="_Toc529966555"></a><a name="_Ref521645094"></a><font style="Background-color:#auto;text-decoration:none;"> 18.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Governing Law</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;This Agreement will be governed by, and construed in accordance with, the laws of the State of New York, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws thereof.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646966"></a><a name="_Ref521650940"></a><a name="_Toc524107430"></a><a name="_Toc529816524"></a><a name="_Toc529966557"></a><a name="_Ref521645096"></a><font style="Background-color:#auto;text-decoration:none;"> 18.7</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Waiver of Right to Trial by Jury</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DocXTextRef421"></a><a name="DocXTextRef422"></a><a name="DocXTextRef423"></a><a name="_Ref521646967"></a><a name="_Ref521650970"></a><a name="_Ref521650982"></a><a name="_Toc524107431"></a><a name="_Toc529816525"></a><a name="_Toc529966558"></a><a name="_Ref521645097"></a>.&nbsp;&nbsp;<font style="text-transform:uppercase;">Each party hereto, </font>TO THE EXTENT PERMITTED BY APPLICABLE LAWS, KNOWINGLY, VOLUNTARILY, AND INTENTIONALLY<font style="text-transform:uppercase;"> waives its right to trial of any issue by jury </font><a name="DocXTextRef421"></a>IN ANY ACTION OR OTHER LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE TRANSACTIONS IT CONTEMPLATES.&nbsp;&nbsp;THIS WAIVER APPLIES TO ANY ACTION OR LEGAL PROCEEDING, WHETHER SOUNDING IN CONTRACT, TORT, OR OTHERWISE.&nbsp;&nbsp;Each Party hereto (a)&#160;certifies that no representative or attorney of any other Party has represented, expressly or otherwise, that such Party would not, in the event of any action or other proceeding arising out of or relating to this Agreement and the transactions it </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DocXTextRef422"></a>contemplates, seek to enforce the foregoing waiver and </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DocXTextRef423"></a>&#160;acknowledges that it and the other Party have been induced to enter into this Agreement, by, among other things, the mutual waiver and certifications in this </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref521646967"></a><a name="_Ref521650970"></a><a name="_Ref521650982"></a><a name="_Toc524107431"></a><a name="_Toc529816525"></a><a name="_Toc529966558"></a><a name="_Ref521645097"></a> 18.7</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref57999130"></a><font style="Background-color:#auto;text-decoration:none;"> 18.8</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Equitable Relief</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DocXTextRef426"></a><a name="DocXTextRef427"></a><a name="DocXTextRef426"></a>&nbsp;&nbsp;Each Party acknowledges and agrees that the restrictions set forth in Article 8, Article 12 and Article 13 are reasonable and necessary to protect the legitimate interests of the other Party and that such other Party would not have entered into this Agreement in the absence of such restrictions, and that any breach or threatened breach of any provision of such Section or Articles may result in irreparable injury to such other Party for which there will be no adequate remedy at law.&nbsp;&nbsp;In the event of a breach or threatened breach of any provision of such Section or Articles, the non-breaching Party will be authorized and entitled to seek to obtain injunctive relief, whether preliminary or permanent, specific performance, and an equitable accounting of all earnings, profits, and other benefits arising from such breach, which rights will be cumulative and in addition to any other rights or remedies to which such non-breaching Party may be entitled in law or equity to prevent such breach or threatened breach of this Agreement and to enforce specifically the terms and provisions of such Section or Articles of this Agreement in a court of competent jurisdiction.&nbsp;&nbsp;Both parties agree to waive any requirement that the other (a) post a bond or other security as a condition for obtaining any such relief, and (b) showing irreparable harm, balancing of harms, consideration of the public interest, or inadequacy of monetary damages as a remedy.&nbsp;&nbsp;<a name="DocXTextRef427"></a>Nothing in this Section  18.8 is intended, or should be construed, to limit either Party&#8217;s right to equitable relief or any other remedy for a breach of any other provision of this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc524107432"></a><a name="_Toc529816526"></a><a name="_Toc529966559"></a><a name="_Ref38581470"></a><a name="_Ref38581502"></a><a name="_Ref41760172"></a><a name="_Ref50911518"></a><a name="_Ref52356498"></a><a name="_Ref53496219"></a><a name="_Ref53496249"></a><a name="_Ref53496330"></a><a name="_Ref56276988"></a><a name="_Ref521645098"></a><font style="Background-color:#auto;text-decoration:none;"> 18.9</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Informal Dispute Resolution</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref41714279"></a><a name="_Ref521645099"></a><a name="_Ref56672105"></a><font style="Background-color:#auto;text-decoration:none;">18.9.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">General</font><font style="color:#000000;">.&nbsp;&nbsp;The Parties recognize that disputes as to certain matters may from time to time arise that relate to either Party&#8217;s rights or obligations hereunder, including the interpretation, alleged breach, enforcement, termination or validity of this Agreement (a &#8220;</font><font style="font-weight:bold;color:#000000;">Dispute</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;Matters subject to decision-making pursuant to Section 10.7 or resolution in accordance with Section 16.10 are not subject to this Section 18.9.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645100"></a><a name="_Ref56672113"></a><font style="Background-color:#auto;text-decoration:none;">18.9.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;"><a name="_Ref56672113"></a> Alliance Managers; Escalation to Executive Officers</font><font style="color:#000000;">.&nbsp;&nbsp;In the event of the occurrence of such a Dispute, the Parties shall first refer such Dispute to the Alliance Managers for attempted resolution by such Alliance Managers within [***] after such referral.&nbsp;&nbsp;If such Dispute is not resolved within such [***] period, either Party may, by written notice to the other, have such Dispute referred to the Executive Officers, who will confer in good faith on the resolution of the issue.&nbsp;&nbsp;Any final decision mutually agreed to by the Executive Officers will be conclusive and binding on the Parties.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521645101"></a><a name="_Ref50992741"></a><a name="DocXTextRef431"></a><a name="_Ref519444324"></a><font style="Background-color:#auto;text-decoration:none;">18.9.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Jurisdiction; Equitable Relief</font><font style="color:#000000;">.&nbsp;&nbsp;If the Executive Officers are not able to agree on the resolution of any Dispute within [***] after such Dispute was first referred to them, then, subject to this Section 18.9.3, either Party may initiate arbitration in accordance with Section 18.10 or with respect to any Disputes that involve the validity, infringement or validity of any Patents, such Dispute will be resolved as provided in Section 18.11.<a name="DocXTextRef431"></a>&nbsp;&nbsp;Notwithstanding anything herein to the contrary, nothing in this Section 18.9 will preclude either Party from seeking interim equitable relief concerning a Dispute as provided in Section  18.8 or 18.10.5.<a name="_Ref519444324"></a>&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">18.9.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">[***]</font><font style="color:#000000;">. [***].</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref53495307"></a><a name="_Ref521646968"></a><a name="_Ref521649280"></a><a name="_Ref521649507"></a><a name="_Ref521650909"></a><a name="_Ref521651021"></a><a name="_Toc524107433"></a><a name="_Toc529816527"></a><a name="_Toc529966560"></a><a name="_Ref521645102"></a><font style="Background-color:#auto;text-decoration:none;"> 18.10</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Arbitration</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56095964"></a><font style="Background-color:#auto;text-decoration:none;">18.10.1</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_Ref56095964"></a>&nbsp;&nbsp;Except as otherwise expressly provided in this Agreement, any Dispute not resolved by the Parties pursuant to Section  18.9 shall be resolved through binding arbitration conducted by the International Chamber of Commerce in accordance with the then prevailing Rules of Arbitration of the International Chamber of Commerce (for purposes of this Section  18.10, the &#8220;</font><font style="font-weight:bold;color:#000000;">Rules</font><font style="color:#000000;">&#8221;), except as modified in this Agreement, applying the substantive law specified in Section 18.6.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">18.10.2</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&nbsp;&nbsp;Each Party shall, within [***] of the initiation of the arbitration, select one (1) arbitrator, and the two (2) arbitrators so selected shall choose a third (3<sup style="font-size:85%;line-height:120%;vertical-align:top">rd</sup>)  arbitrator within [***] of their election.&nbsp;&nbsp;All three (3) arbitrators shall serve as neutrals and have at least [***] of (a) dispute resolution experience (including judicial experience) and (b) legal or business experience in the biotech or pharmaceutical industry.&nbsp;&nbsp;If a Party fails to nominate its arbitrator, or if the Parties&#8217; arbitrators cannot agree on the third (3<sup style="font-size:85%;line-height:120%;vertical-align:top">rd</sup>) arbitrator, the necessary appointments shall be made in accordance with the Rules.&nbsp;&nbsp;Once appointed by a Party, such Party shall have no ex parte communication with its appointed arbitrator.&nbsp;&nbsp;The arbitration proceedings shall be conducted [***].&nbsp;&nbsp; The arbitration proceedings and all pleadings and written evidence shall be in the English language.&nbsp;&nbsp;Any written evidence originally in another language shall be submitted in English translation accompanied by the original or a true copy thereof.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">18.10.3</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&nbsp;&nbsp;Each Party agrees to use reasonable efforts to make all of its current employees reasonably available, if reasonably needed, and agrees that the arbitrators may determine any person as necessary.&nbsp;&nbsp;The arbitrators shall be instructed and required to render a written, binding, non-appealable resolution and award on each issue that clearly states the basis upon which such resolution and award is made.&nbsp;&nbsp;The written resolution and award shall be delivered to the Parties as expeditiously as possible, but in no event more than [***] after conclusion of the hearing, unless otherwise agreed by the Parties.&nbsp;&nbsp;Judgment upon such award may be entered in any competent court or application may be made to any competent court for judicial acceptance of such an award and order for enforcement.&nbsp;&nbsp;Each Party agrees that, notwithstanding any provision of Applicable Law or of this Agreement, it will not request, and the arbitrators shall have no authority to award, damages that are specifically prohibited pursuant to Section 15.5.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">18.10.4</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&nbsp;&nbsp;The Parties will share equally the fees and expenses of the arbitrators and bear their own attorneys&#8217; fees and associated costs and expenses.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref53495344"></a><a name="_Ref56265588"></a><font style="Background-color:#auto;text-decoration:none;">18.10.5</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_Ref56265588"></a>&nbsp;&nbsp;Notwithstanding anything to the contrary in this Section 18.10 or Section 18.9, in the event that a Party reasonably requires relief on a more expedited basis than would be possible pursuant to the procedure set forth in this Section 18.10 or Section 18.9, such Party may seek a temporary injunction or other interim equitable relief in a court of competent jurisdiction pending the ability of the arbitrators to review the decision under this Section 18.10.&nbsp;&nbsp;Such court shall have no jurisdiction or ability to resolve Disputes beyond the specific issue of temporary injunction or other interim equitable relief.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">18.10.6</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&nbsp;&nbsp;At the request of either Party, the arbitrators shall enter an appropriate protective order to maintain the confidentiality of information produced or exchanged in the course of the arbitration proceedings.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref53496096"></a><font style="text-decoration:none;Background-color:#auto;"> 18.11</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Subject Matter Exclusions</font><font style="color:#000000;">.&nbsp;&nbsp;Notwithstanding the provisions of Section</font><font style="color:#000000;"> 18.10</font><font style="color:#000000;">,</font><font style="color:#000000;"> any Dispute not resolved internally by the Parties pursuant to Section</font><font style="color:#000000;"> 18.9</font><font style="color:#000000;"> that involves the validity, infringement or enforceability of a Patent included in a license granted in this Agreement (a) that is issued in the United States shall be subject to actions before the United States Patent and Trademark Office </font><font style="color:#000000;">or</font><font style="color:#000000;"> </font><font style="color:#000000;">submitted exclusively to the federal court located in the jurisdiction of the district where any of the defendants reside and (b) that is issued in any other country (or region) shall be brought before an appropriate regulatory or administrative body or court in that country (or region), and in all cases, the Parties hereby consent to the jurisdiction and venue of such courts and bodies.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref56265982"></a><font style="Background-color:#auto;text-decoration:none;"> 18.12</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Notices</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref111895968"></a><a name="DocXTextRef432"></a><a name="DocXTextRef433"></a><a name="DocXTextRef434"></a><a name="_Ref111895968"></a>.&nbsp;&nbsp;<a name="DocXTextRef432"></a>Any notice, request, demand, waiver, consent, approval, or other communication permitted or required under this Agreement will be in writing, will refer specifically to this Agreement and will be deemed given only if delivered by hand or sent by internationally recognized overnight delivery service that maintains records of delivery, addressed to the Parties at their respective addresses specified in this Section 18.10<a name="DocXTextRef433"></a> or to such other address as the Party to whom notice is to be given may have provided to the other Party in accordance with this Section 18.10.&nbsp;&nbsp;Such notice will be deemed to have been given as of the date delivered by hand or on the [***]<a name="DocXTextRef434"></a> (at the place of delivery) after deposit with an internationally recognized overnight delivery service.&nbsp;&nbsp;This Section 18.10 is not intended to govern the day-to-day business communications necessary between the Parties in performing their obligations under the terms of this Agreement.&nbsp;&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to Licensee, to:&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:36.54%;text-indent:-13.46%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:36.54%;text-indent:-13.46%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to Relay, to:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:36.54%;text-indent:-13.46%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Relay Therapeutics, Inc.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:36.54%;text-indent:-13.46%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">399 Binney Street</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:36.54%;text-indent:-13.46%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2nd Floor</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:36.54%;text-indent:-13.46%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cambridge, MA 02139</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:36.54%;text-indent:-13.46%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Chief Executive Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with a copy (which will not constitute notice) to:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:36.54%;text-indent:-13.46%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwin Procter, LLP</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:36.54%;text-indent:-13.46%;font-family:Raleway;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100 Northern Avenue </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:36.54%;text-indent:-13.46%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, MA 02210</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:36.54%;text-indent:-13.46%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Kingsley L. Taft, Ph.D., Esq. </p>
<p style="margin-top:0pt;margin-bottom:6pt;margin-left:23.08%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646969"></a><a name="_Toc524107434"></a><a name="_Toc529816528"></a><a name="_Toc529966561"></a><a name="_Ref521645103"></a><font style="Background-color:#auto;text-decoration:none;"> 18.13</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Entire Agreement</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="DocXTextRef435"></a><a name="_Ref521645117"></a>.&nbsp;&nbsp;<a name="DocXTextRef435"></a>This Agreement, together with the Schedules<a name="_Ref521645117"></a> expressly contemplated hereby and attached hereto, contains the entire agreement between the Parties with respect to the subject matter hereof and supersedes all prior agreements or understandings between the Parties with respect to the subject matter hereof.&nbsp;&nbsp;Each Party confirms that it is not relying on any representations or warranties of the other Party except as specifically set forth in this Agreement.&nbsp;&nbsp;The Parties agree that they have been represented by counsel during the negotiation, drafting, preparation and execution of this Agreement and, therefore, waive the application of any </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Applicable Law or rule of construction providing that ambiguities in an agreement or other document </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> be construed against the party drafting such agreement or document.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646970"></a><a name="_Toc524107435"></a><a name="_Toc529816529"></a><a name="_Toc529966562"></a><a name="_Ref521645104"></a><font style="Background-color:#auto;text-decoration:none;"> 18.14</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">English Language</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;This Agreement will be written and executed in, and all other communications under or in connection with this Agreement will be in, the English language.&nbsp;&nbsp;Any translation into any other language will not be an official version thereof, and in the event of any conflict in interpretation between the English version and such translation, the English version will control.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc529816530"></a><a name="_Toc529966563"></a><a name="_Ref38883989"></a><a name="_Ref38883996"></a><a name="_Ref521645105"></a><a name="_Toc524107436"></a><font style="Background-color:#auto;text-decoration:none;"> 18.15</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Amendments and Waivers</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref521645106"></a><a name="_Ref521645111"></a><a name="_Ref521645107"></a><a name="_Ref521645106"></a>.<a name="_Ref521645111"></a>&nbsp;&nbsp;No modification, amendment or waiver of any provision of, or consent or approval required by, this Agreement will be effective unless it is in writing and signed by an authorized representative of both Parties.&nbsp;&nbsp;Such modification, amendment, waiver, consent or approval will<a name="_Ref521645107"></a> be effective only in the specific instance and for the purpose for which given.&nbsp;&nbsp;Neither the failure of either Party to enforce, nor the delay of either Party in enforcing, any condition or part of this Agreement at any time will be construed as a waiver of that condition or part or forfeit any rights to future enforcement thereof.&nbsp;&nbsp;No action taken pursuant to this Agreement, including any investigation by or on behalf of either Party, will be deemed to constitute a waiver by the Party taking action of compliance by the other Party with any representation, warranty, covenant, agreement or obligation contained herein.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646971"></a><a name="_Toc529284567"></a><a name="_Toc529966564"></a><a name="_Ref521645108"></a><font style="Background-color:#auto;text-decoration:none;"> 18.16</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Cumulative Rights</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Except as expressly provided herein, the various rights under this Agreement will be construed as cumulative, and no one of them is exclusive of any other or exclusive of any rights allowed by Applicable Law.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646972"></a><a name="_Toc529284568"></a><a name="_Toc529966565"></a><a name="_Ref521645109"></a><font style="Background-color:#auto;text-decoration:none;"> 18.17</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Benefits of Agreement</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;All of the terms and provisions of this Agreement will be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns.&nbsp;&nbsp;Except as set forth in Article 15, this Agreement is for the sole benefit of the Parties and not for the benefit of any other Person.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646973"></a><a name="_Toc529284569"></a><a name="_Toc529966566"></a><a name="_Ref521645110"></a><font style="Background-color:#auto;text-decoration:none;"> 18.18</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Further Assurance</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">.&nbsp;&nbsp;Each Party will duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents, and instruments, as may be necessary or as the other Party may reasonably request in connection with this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref521646974"></a><a name="_Toc529284570"></a><a name="_Toc529966567"></a><font style="Background-color:#auto;text-decoration:none;"> 18.19</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Relationship of the Parties</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;It is expressly agreed that Licensee, on the one hand, and Relay, on the other hand, will be independent contractors and that the relationship between the two Parties will not constitute a partnership, joint venture, or agency.&nbsp;&nbsp;Neither Licensee, on the one hand, nor Relay, on the other hand, will have the authority to make any statements, representations, or commitments of any kind, or to take any action, which will be binding on the other, without the prior written consent of the other Party to do so.&nbsp;&nbsp;All Persons employed by a Party will be employees of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment will be for the account and expense of such Party.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc529816535"></a><a name="_Toc529966568"></a><a name="_Ref521646975"></a><a name="_Toc524107441"></a><a name="_Ref521645112"></a><font style="Background-color:#auto;text-decoration:none;"> 18.20</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Counterparts</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;This Agreement may be executed in two counterparts, and each such counterpart hereof will be deemed to be an original instrument, but both such counterparts together will constitute but one agreement.&nbsp;&nbsp;Delivery of an executed counterpart of a signature page of this Agreement by email or other electronic transmission will be effective as delivery of a manually executed original counterpart of this Agreement.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc529816536"></a><a name="_Toc529966569"></a><font style="text-decoration:none;Background-color:#auto;"> 18.21</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Schedules</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;In the event of any inconsistencies between this Agreement and any Schedules or other attachments hereto, the terms of this Agreement will control.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc529816537"></a><a name="_Toc529966570"></a><a name="_Ref521645114"></a><a name="_Toc524107443"></a><font style="Background-color:#auto;text-decoration:none;"> 18.22</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Descriptive Headings</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref521645115"></a><a name="_Ref521645115"></a>.&nbsp;&nbsp;Descriptive headings are for convenience only and will not control or affect the meaning or construction of any provision of this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc529816538"></a><a name="_Toc529966571"></a><a name="_Toc524107444"></a><font style="Background-color:#auto;text-decoration:none;"> 18.23</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Certain Interpretations</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref521645116"></a><a name="DocXTextRef438"></a><a name="DocXTextRef439"></a><a name="DocXTextRef440"></a><a name="DocXTextRef441"></a><a name="DocXTextRef442"></a><a name="DocXTextRef443"></a><a name="DocXTextRef444"></a><a name="DocXTextRef445"></a><a name="DocXTextRef446"></a><a name="_Ref521645116"></a>.<a name="DocXTextRef438"></a>&nbsp;&nbsp;Except as otherwise expressly provided in this Agreement or as the context otherwise requires, the following rules of interpretation apply to this Agreement:&nbsp;&nbsp;(a)<a name="DocXTextRef439"></a>&#160;the singular includes the plural and the plural includes the singular; (b)&#160;&#8220;or&#8221; and &#8220;any&#8221; are not exclusive, &#8220;or&#8221; means &#8220;and/or&#8221; and the words &#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, will not be deemed to be terms of limitation, but rather will<a name="DocXTextRef440"></a> be deemed to be followed by the words &#8220;without limitation;&#8221; (c) the terms &#8220;will&#8221; and &#8220;shall&#8221; will<a name="DocXTextRef441"></a> be deemed to have the same meaning; (d) a reference to any contract includes permitted supplements and amendments; (e)<a name="DocXTextRef442"></a> a reference to Applicable Law includes any amendment or modification to such Applicable Law; (f)<a name="DocXTextRef443"></a> a reference to a Person includes its successors, heirs and permitted assigns; (g) a reference to one gender will<a name="DocXTextRef444"></a> include any other gender; (h)<a name="DocXTextRef445"></a> a reference in this Agreement to an Article, Section or Schedule is to the referenced Article, Section or Schedule of this Agreement, unless expressly specified otherwise; (i) &#8220;hereunder,&#8221; &#8220;hereof,&#8221; and words of similar import will<a name="DocXTextRef446"></a> be deemed references to this Agreement as a whole and not to any particular Article, Section&#160;or other provision; (j) unless otherwise provided herein, any reference to &#8220;days&#8221; means calendar days; (k) &#8220;extent&#8221; in the phrase &#8220;to the extent&#8221; means the degree to which a subject or other thing extends, and such phrase does not necessarily mean simply &#8220;if&#8221;; (l) the phrase &#8220;non-refundable and non-creditable&#8221; will in no way limit either Party&#8217;s right to pursue or receive damages in connection with any breach of this Agreement; and (m) a list or phrases with an oxford comma shall be read in the same way as a list without an oxford comma.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:24pt;margin-top:0pt;text-indent:38.01%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[Signature Page Follows]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have caused this COLLABORATION AND LICENSE AGREEMENT to be executed by their respective duly authorized representatives as of the Execution Date.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:-0.05%;width:468pt;;">
<tr>
<td style="width:233.45pt;"></td>
<td style="width:234.55pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman Bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;">Genentech, Inc.</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Relay Therapeutics, Inc.</p></td>
</tr>
<tr style="height:90.4pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">By:/s/ Edward Harrington</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Name: Edward Harrington</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Title:CFO, Genentech</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">By:/s/ Sanjiv Patel</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Name: Sanjiv Patel</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Title:CEO</font></p></td>
</tr>
<tr style="height:99.9pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman Bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;">F. Hoffmann-La Roche Ltd</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">By:/s/ Stefan Arnold</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Name: Stefan Arnold</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Title:Head Legal Pharma</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman Bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;">F. Hoffmann-La Roche Ltd</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">By:/s/ Vikas Kabra</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Name:Vikas Kabra</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Title:Head Transaction Excellence</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:99.9pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:72pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Signature Page to Collaboration and License Agreement</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;"><font style="text-decoration:underline;">Schedule 1.102</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;"><font style="text-decoration:underline;">Global Development Plan</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;">Global Development Plan</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Schedule 1.102</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Tahoma;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/106477415.6&nbsp;&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc41521311"></a><a name="_Toc41521527"></a><a name="_Toc50796672"></a><a name="_Toc51338598"></a><a name="_Hlk53664029"></a><font style="text-decoration:underline;">Schedule 1.262</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc53919216"></a><a name="_Toc53925700"></a><font style="text-decoration:underline;">Technology Transfer Plan </font></p>
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Exhibit A</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_heading=h.30j0zll"></a><a name="_heading=h.1fob9te"></a>[***]</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Exhibit B</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Know-How and Materials (Manufacture Transfer)</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 1.262</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Tahoma;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACTIVE/106477415.6&nbsp;&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc53919217"></a><a name="_Toc53925701"></a><font style="text-decoration:underline;">Schedule 3.2.3</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Transfer of Sponsor Obligations</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 3.2.3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc53919215"></a><a name="_Toc53925699"></a><font style="text-decoration:underline;">Schedule 3.3</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman Bold;font-variant: small-caps;font-weight:bold;font-size:12pt;font-style:normal;text-transform:none;"><a name="_Toc41521312"></a><a name="_Toc41521528"></a><a name="_Toc50796673"></a><a name="_Toc51338599"></a><a name="_Toc53919218"></a><a name="_Toc53925702"></a><a name="_Toc51338600"></a><font style="text-decoration:underline;">Relay Phase Ia Plan</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-top:0pt;margin-bottom:8pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 3.3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc51338604"></a><a name="_Toc53919223"></a><a name="_Toc53925707"></a><a name="_Toc41521529"></a><a name="_Toc41521313"></a><a name="_Toc50796674"></a><font style="text-decoration:underline;">Schedule 3.4.1</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Delegation of Authority</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 3.4.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Schedule 11.4.1</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc51338605"></a><a name="_Toc53919224"></a><a name="_Toc53925708"></a><font style="text-decoration:underline;"><a name="_Toc53919224"></a><a name="_Toc53925708"></a>Example Net Profits and Net Losses Calculations</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 11.4.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Schedule  13.5</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;"><font style="text-decoration:underline;">Press Release</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Relay Therapeutics Announces a Worldwide License and Collaboration Agreement </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">with Genentech for RLY-1971</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;text-transform:none;font-variant: normal;">Collaboration brings together clinical stage SHP2 and KRAS G12C inhibitors</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;text-transform:none;font-variant: normal;">Relay Therapeutics will receive $75 million upfront and is eligible to receive an additional $25 million in near-term payments and $695 million in additional potential milestones, </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;text-transform:none;font-variant: normal;">plus royalties on global net product sales </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;text-transform:none;font-variant: normal;">Relay Therapeutics to host conference call at 8:00 a.m. ET</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cambridge, MA &#8211; December 14, 2020 &#8211; Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today announced it has entered into a worldwide license and collaboration agreement with Genentech, a member of the Roche Group, for the development and commercialization of RLY-1971, a potent inhibitor of SHP2. Under the collaboration, Genentech will assume development of RLY-1971 with the potential to expand into multiple combination studies including with Genentech&#8217;s investigational inhibitor of KRAS G12C, GDC-6036. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk54683793"></a>&#8220;RLY-1971 has the potential to serve as a backbone for combination therapy across numerous solid tumors and therefore represents an encouraging approach for cancer patients,&#8221; said Sanjiv Patel, M.D., president and chief executive officer of Relay Therapeutics. &#8220;Roche and Genentech&#8217;s global footprint and deep expertise in oncology makes them the perfect partner for us to execute the broad development and commercialization of RLY-1971.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Genentech has a longstanding commitment to understanding the underlying biology of KRAS, the most commonly mutated oncogene and an important driver of cancer growth,&#8221; said James Sabry, M.D., Ph.D., global head of pharma partnering, Roche. &#8220;We are excited to partner with Relay Therapeutics, and we believe that the combination of KRAS G12C and SHP2 inhibitors together represents a promising approach that we hope could become a new treatment option for patients with KRAS G12C mutant tumors.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the agreement, Relay Therapeutics will receive $75 million in an upfront payment and is eligible to receive $25 million in additional near-term payments. Relay Therapeutics also has the right to opt in to a 50/50 U.S. profit/cost share on RLY-1971. If Relay elects to opt in, then Relay will be eligible to receive 50 percent of profits from U.S. sales and up to $410 million in additional ex-U.S. commercialization and sales-based milestone payments, as well as royalties on ex-U.S. net sales. If Relay Therapeutics elects not to opt in, then Relay will be eligible to receive up to $695 million in additional development, commercialization and sales-based milestones, as well as royalties on global net sales, anticipated to be in the low-to-mid-teens. In the event of regulatory approval of both RLY-1971 and GDC-6036 in combination, Relay Therapeutics is eligible to receive additional royalties. Relay Therapeutics retains the right to combine RLY-1971 with its selective FGFR2 and mutant-selective PI3K&#945; programs.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 13.5</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With the execution of this collaboration, Relay Therapeutics anticipates it will have cash and investments to sustain its operations through 2024.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Conference Call Information</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Relay Therapeutics will host a live webcast today beginning at 8:00 a.m. ET to discuss the collaboration. To access the live call, please dial 1 (833) 540-1168<font style="color:#FF2D21;"> </font>(domestic) or 1 (929) 517-0359 (international) and refer to conference ID 8792127. A webcast of the conference call will be available under "News and Presentations" in the Investors &amp; Media section of Relay Therapeutics&#8217; website at http://ir.relaytx.com. The archived webcast will be available on Relay Therapeutics&#8217; website approximately two hours after the conference call and will be available for 30 days following the call.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">About RLY-1971</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">RLY-1971 is a potent small molecule inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2). SHP2 is a critical signaling node and regulator that promotes cancer cell survival and growth through the RAS pathway, playing a key role in the way cancer cells develop resistance to targeted therapies. Preclinically, RLY-1971 demonstrated significant anti-tumor activity as a monotherapy in cancers with specific alterations as well as in combination with other anti-tumor agents, potentially overcoming or delaying the onset of resistance to those therapies. RLY-1971 is currently being evaluated in a first-in-human trial designed to treat patients with advanced or metastatic solid tumors. To learn more about the first-in-human clinical trial of RLY-1971, please visit&#160;</font><font style="Background-color:#FFFFFF;color:#008BDB;">here</font><font style="Background-color:#FFFFFF;color:#666666;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">About Relay Therapeutics</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicines company transforming the drug discovery process with the goal of bringing life-changing therapies to patients. Built on unparalleled insights into protein motion and how this dynamic behavior relates to protein function, Relay Therapeutics aims to effectively drug protein targets that have previously been intractable, with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The Company&#8217;s Dynamo platform integrates an array of leading-edge experimental and computational approaches to provide a differentiated understanding of protein structure and motion to drug these targets. For more information, please visit www.relaytx.com or follow us on Twitter. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Cautionary Note Regarding Forward-Looking Statements</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk48278549"></a>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the expected strategic benefits of the collaboration; the receipt of upfront and near-term payments and potential milestone and royalty payments under the collaboration; the potential of RLY-1971, including in combination with Genentech&#8217;s GDC-6036; the potential therapeutic benefits of inhibiting KRAS G12C and SHP2 in combination; the&nbsp;&nbsp;Company&#8217;s strategy, business plans and focus; and expectations regarding our cash runway. The words "may," &#8220;might,&#8221; "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," &#8220;expect,&#8221; "estimate," &#8220;seek,&#8221; "predict," &#8220;future,&#8221; "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of COVID-19 on countries or regions in which we have operations or do business, as well as on the timing and anticipated results of our clinical trials, strategy and future operations; the delay of any current or planned clinical trials or the development of&#160;the Company&#8217;s&#160;drug candidates, including, but not limited to, RLY-1971 and RLY-4008;&#160;the risk that the results of our clinical trials may not be predictive of future results in connection with future clinical trials;&#160;the Company&#8217;s ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of the Company&#8217;s planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property.&#160; These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in&nbsp;&nbsp;Relay Therapeutics&#8217; Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Relay Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Relay Therapeutics explicitly disclaims any obligation to update any forward-looking statements.</font><font style="Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;"> </font><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Contact<font style="font-weight:normal;">:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pete Rahmer, Head of Investor Relations and Communications</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">617-322-0715</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prahmer@relaytx.com</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Media<font style="font-weight:normal;">:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dan Budwick</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1AB</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">973-271-6085</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dan@1abmedia.com </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Schedule 14.2</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;text-indent:7.69%;"><font style="text-decoration:underline;">Exceptions to Representations and Warranties of Relay</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:86.54%;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 14.2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>rlay-ex211_904.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
rlay-ex211_904.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 21.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SUBSIDIARIES</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:51%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subsidiary</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Jurisdiction of Incorporation</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Relay Securities Corporation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Massachusetts</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>rlay-ex231_1123.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
rlay-ex231_1123.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-239912) pertaining to the 2020 Stock Option and Incentive Plan, and 2020 Employee Stock Purchase Plan of Relay Therapeutics, Inc. of our report dated March 25, 2021, with respect to the consolidated financial statements of Relay Therapeutics, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Ernst&#160;&amp; Young LLP</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, Massachusetts </p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 25, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>rlay-ex311_6.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
rlay-ex311_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Sanjiv K. Patel, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have reviewed this Annual Report on Form 10-K of Relay Therapeutics, Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#FFFFFF;color:#000000;">(Paragraph omitted pursuant to SEC Release Nos.&#160;33-8238/34-47986&#160;and&#160;33-8392/34-49313);</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 25, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Sanjiv K. Patel</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sanjiv K. Patel</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>rlay-ex312_7.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
rlay-ex312_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Thomas Catinazzo, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have reviewed this Annual Report on Form 10-K of Relay Therapeutics, Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#FFFFFF;color:#000000;">(Paragraph omitted pursuant to SEC Release Nos.&#160;33-8238/34-47986&#160;and&#160;33-8392/34-49313);</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 25, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Thomas Catinazzo</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thomas Catinazzo</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior Vice President, Finance</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Accounting Officer and </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>rlay-ex321_8.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
rlay-ex321_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of Relay Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of their knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 25, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Sanjiv K. Patel</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sanjiv K. Patel</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 25, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Thomas Catinazzo</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thomas Catinazzo</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior Vice President, Finance</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Accounting Officer and </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gwpjrhodncoa000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000012.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #0 .4# 1$  A$! Q$!_\0
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MHU52J74I54+BTUBECAB\<N&_C3<]\O\ 0!US_4)O5R5SCI/U/378AM6JWE<
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MA*1:I;;"JI)).F8;:QB)C/#%8?ZFJ#[X,JU)A:[PD2O$H!!P_P";.,:#JE1
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M(>2BU$F_KO60W^[A4TW,1@EG.227L1U7P9& , 8 P!@# & , 8 P!@# & ,
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MU7%L^9#Q7BXO%1GDNL_C>J_H6ETWE+K$/5IGS+:%ND5Q6("0L;8*XI8<:/\
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M.JHI=,+&)>,X9;XP["S,&1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M[U=5*X*9<+$J#-''& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8!-UY?K/XV_B1*/^(/5>"K*KL]Z*1P08 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@$E=/EXP!E_(I693<>.#D7TE/>2$S*+>-V+/U
M]R=U%'-/MUO?/?-/O#YVV:I?3Y_W++IZ?_O;,5UT6=+KM*E313$U/)2TE/:V
MEYSNNA="Z6UATC8:'T)<+SI/2E[5MR:XW2CPEXM^3V-I>K;P=$K:\%=[&UMJ
M^%%G4]Q0P2?AED0OI$"$D450?CQ>/]E(=QXZ9^/6NJ6[AM]KYYYY]JCHNCMO
MK]'^WBFO_OBSM;.UIV[.M5TRU-+E2LU[3JZ>U<T[JO?_ .3-8=%WO1&D'86=
MYY)?;)V5MX"U==-G:[#;\2MV=:I>]TO@9?FSLHP!@# & , 8 P!@# & , 8
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MX6IV]>V_#;+2IV:*6FWNC.N>## & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & 3=>7ZS^-OXD2C_B#U7@JRJ[/>BD<$& , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8!+?1#[>/L;B]9/313U7J218[:[_3Y
MYYI)<K=/L%-_/J^^>_73T<[*:?3]/GN^OGFWGOGON1N%YZ5WM+WG+N=A3>;2
MULZJG2J+I?;=.F)=5UNMK>*:7.ZJJR5-6_9;C&"I,IQ!@# & , 8 P!@# &
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M]71VZ7$3AP*+P08 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP";KR_6?QM_$B4?\0>J\%6579[T4C@@P!@# & , 8 P!@# & , 8 P!@# &
(, 8 P!@'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gwpjrhodncoa000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000009.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %I E\# 1$  A$! Q$!_\0
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M45E=5=&#(ZAD92"K*P!5E(V(((((V(-\8H<=?&AC/@*X<[=Q!9,36E$HM5M
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M\B<WYFRW='5OM<C*T]Q7+>YHF8GU7O2ERC6M;;R#_P 4L)$V^)$XUY'DKU$
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M?M@"$C(''_G_ "E3(.JWUIARRSL%&T"#2S!(8*Q.KGF0@<7O85Y1X:6S)[U
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M**P47A KI)***>!)SF5<*JHIZES)44U94B?IZJ"9R2\4KE0+HFF,E#U%G%;
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M!EU'34%*I2FI((Z>!69G98HE"("[$LQ"@ LQ)/,XKZB>2IGFJ)B&EGD>61@
MH+NQ9B%4  7.P L,1YJ5AG!HP8-&#!HP8-&#!HP8-&#!HP8E+"N%LF\0^4*=
MAO#U3D[KD.]2[>&K\%%HF.<ZJH\SA_(.!#Q>+A8EJ5:2FYI^HA&P\6V=2,@X
M0:-U52P\PS"CRNCGKZ^=*>EID,DLCGD!L%4<WD=K)'&H+R.5506(&'Z:FGJY
MXZ>GC:6:5@J(HW)ZR3R55%RS$A54%F( )Q]2O@IX:8C@]X5L(\-T.\1DRXOI
M;:+FIANF9%M.6^5=O+'>)YJBH4JJ#2:N,S.2;-NMS+-FCI!NJ=0Z1CF^.\_S
M:3/<YS#-9%*>&5!>.,D$QP(JQ4\;$7!:.".-&(V+*2-CCW/+*)<NH*6B4AN@
MB"NP%@\K$O*X!W >5G8 [@$ \L8?^&)\'BX\(;PLJ5"EJQ['.&+9E:_X>>2:
MZ;-A+RGB"K"P4.2D%OJ4?'W2,%%)!\J9)LRLD56WL@X1BFS_ )[S@7B@<+YR
M)Z@.V7UD8IJY4!9D34&BJ44;NU.]R5%V:)Y54%V7%;Q'DYS>AT1:154[&6G+
M;!C:SPEON1*MK'8!U0L0H)Q\W_)N+<CX8NT[C?+%(LN/+W67:C*<JMLB7<-,
M,%B&$"G,U>)IBLT<E %V,@V%9A(-3I.V+EPU526/]5T=925]/'5T51%54TRA
MHYH761&'9=2;,.3*;,INK $$8\<G@FII7AJ(GAEC-GCD4JRGN/,'F"+AA8@D
M$'#"U)PU@T8,&C!@T8,&C!@T8,&C!@T8,273\PY+H%+RACNGVQ]!4O-$17X'
M*$ V08*-;?$56P-K57V3Y5TT7=MB1D^T;R*)XUPR644(**ZBK8ZB)XD]!255
M11U4\"R5&7O+)1RDN&@>:(PRLH5@K:XB4(<,+;@ [X>CJ)HHIX8Y"L52J).@
M (D6-Q(@:X)&EP&%B.PW&V)?MW&]Q6WN-L\7;,UVJ71ND=AN,MCQ1&%:S=A1
MX?7$FZPVZE;&QBFM@=S-%<3#]6-L"LF,ZZ,HC[K2,@#)D#>!!P[DM,\+PY?"
MAIWKW@4&0QQ',PJUZI$SF(1U(10T6CHUWZ-$U->1)F=?*LBR5,C"5:99#Y(=
MQ1EC3%G"ART18Z7+:SMJ9K"T@W[PF7'7E ];/?.(RWV(*C?\?Y5KJ+B+J#5K
M&Y)Q>Y>NZ5>",X^N-&CBS1KE^LJ_EW:+AW9#), LZDP6+C0:1J;A+ARC$HIL
MJ@BZ>FJJ.4AYRSTE8%6HIRS2LPA=5 5%(6&[="(];ZGI<ZS2?1TM9(_1S0U"
M K'99X"3%* $ UJ6)+$$OMKU:5M$2'%WQ*,T5D6&7[5%]OQ!*<51G,2=A$R"
M7$&LS=QZF4&LG&L6LBRGC,W[MN"#-TA$E(N?EC@-L8)QR/*6(+4,+VRL9+9]
M3J<K#*W@;*[%6BU*INP+W'M\1QF%: 0*B1;U?A]ULI%98CIPR@$/8D;$+ORQ
M,T/X0;-]EXC.'//'$!8I7*B'#UE:'RC%5^L-:1B1_)OFMCKECL"835(I#-LG
M*VY>JP[6=L4E#S$L[:M^4ZXJ""@0).&,NARK-<MRR)*(YI124;RS-45JHK12
MQ1'HZBH8E(!-(T<2.B!CRQ)7-JEZRCJJMVG%'4+.J((J<L1(COY<40\J3HU#
M.RLQ YWWQCYQ$YWM?$9Q!Y9XAK-SL;-E+(UAOZC--V9X2 )*RJKR&@63PZ*!
MUV58C CX.,5.@B864:V$R1!W*%GE>6P95EE%E<-FAHZ6*F#%0O2Z$"R2,H)
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MBG='< (BFS*A<L/+ 'JCUXWC=X-&#!HP8-&#$=96Q%C#.=&FL:9BH56R30K
MD5.7JMPAV<U$.C)")F[HC=VF<6DBR5$'$=*,SMY&-=%([8.FSE--4LJBKJS+
MJB.KH:F:DJ8C=)H)&C<7YK=2-2L-F1KJXV8$&V&:BG@JHF@J8HYHG]M'(H93
MV&QY,.:L+,IW!!WQI4M__)M_!H6::=2L3!9HH+1RJ=4E?J&57#B%:<YA-V;4
MUUA+C-%2)OL0BTPOREV* [ &V_@]E;BV&-4>6@J6  Z6>B42-;K;P>2".YZ[
M1C&:DX,R61BRK4P@_<1U!*CNZ5)7]]CAK?G9?P<?[<\2/\IU8_JXT]_A;XJ^
M\RK]3E_K6&_J)R?[^M_GX_F,'YV7\''^W/$C_*=6/ZN-'^%OBK[S*OU.7^M8
M/J)R?[^M_GX_F,'YV7\''^W/$C_*=6/ZN-'^%OBK[S*OU.7^M8/J)R?[^M_G
MX_F,'YV7\''^W/$C_*=6/ZN-'^%OBK[S*OU.7^M8/J)R?[^M_GX_F,'YV7\'
M'^W/$C_*=6/ZN-'^%OBK[S*OU.7^M8/J)R?[^M_GX_F,'YV7\''^W/$C_*=6
M/ZN-'^%OBK[S*OU.7^M8/J)R?[^M_GX_F,'YV7\''^W/$C_*=6/ZN-'^%OBK
M[S*OU.7^M8/J)R?[^M_GX_F,'YV7\''^W/$C_*=6/ZN-'^%OBK[S*OU.7^M8
M/J)R?[^M_GX_F,'YV7\''^W/$C_*=6/ZN-'^%OBK[S*OU.7^M8/J)R?[^M_G
MX_F,'YV7\''^W/$C_*=6/ZN-'^%OBK[S*OU.7^M8/J)R?[^M_GX_F,'YV7\'
M'^W/$C_*=6/ZN-'^%OBK[S*OU.7^M8/J)R?[^M_GX_F,'YV7\''^W/$C_*=6
M/ZN-'^%OBK[S*OU.7^M8/J)R?[^M_GX_F,'YV7\''^W/$C_*=6/ZN-'^%OBK
M[S*OU.7^M8/J)R?[^M_GX_F,'YV7\''^W/$C_*=6/ZN-'^%OBK[S*OU.7^M8
M/J)R?[^M_GX_F,'YV7\''^W/$C_*=6/ZN-'^%OBK[S*OU.7^M8/J)R?[^M_G
MX_F,'YV7\''^W/$C_*=6/ZN-'^%OBK[S*OU.7^M8/J)R?[^M_GX_F,'YV7\'
M'^W/$C_*=6/ZN-'^%OBK[S*OU.7^M8/J)R?[^M_GX_F,'YV7\''^W/$C_*=6
M/ZN-'^%OBK[S*OU.7^M8/J)R?[^M_GX_F,'YV7\''^W/$C_*=6/ZN-'^%OBK
M[S*OU.7^M8/J)R?[^M_GX_F,'YV7\''^W/$C_*=6/ZN-'^%OBK[S*OU.7^M8
M/J)R?[^M_GX_F,'YV7\''^W/$C_*=6/ZN-'^%OBK[S*OU.7^M8/J)R?[^M_G
MX_F,'YV7\''^W/$C_*=6/ZN-'^%OBK[S*OU.7^M8/J)R?[^M_GX_F,'YV7\'
M'^W/$C_*=6/ZN-'^%OBK[S*OU.7^M8/J)R?[^M_GX_F,'YV7\''^W/$C_*=6
M/ZN-'^%OBK[S*OU.7^M8/J)R?[^M_GX_F,'YV7\''^W/$C_*=6/ZN-'^%OBK
M[S*OU.7^M8/J)R?[^M_GX_F,'YV7\''^W/$C_*=6/ZN-'^%OBK[S*OU.7^M8
M/J)R?[^M_GX_F,'YV7\''^W/$C_*=6/ZN-'^%OBK[S*OU.7^M8/J)R?[^M_G
MX_F,'YV7\''^W/$C_*=6/ZN-'^%OBK[S*OU.7^M8/J)R?[^M_GX_F,'YV7\'
M'^W/$C_*=6/ZN-'^%OBK[S*OU.7^M8/J)R?[^M_GX_F,'YV7\''^W/$C_*=6
M/ZN-'^%OBK[S*OU.7^M8/J)R?[^M_GX_F,'YV7\''^W/$C_*=6/ZN-'^%OBK
M[S*OU.7^M8/J)R?[^M_GX_F,5F__ "9OP<"*R2JDCQ%NTTSE,=LXR?7RHK%
M=Q35,UQ^V< 0W<847"2FWP3E'KI#[+7%9! 7*P2.8HY+CSB]21?O!'FP#@K)
M@;ZJT^8SI8^]"#[Q&-J'"AP#<)7!+$O8[APPY7Z-(R[9-I/W%PK(66^V%N0Y
M%O%9>ZV1W*6!2-%RF5V6#:OFD"W<@"S2+;F -L;G7$F=\02*^:U\M2J$M%
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M/O?#BN\=/O:E3S?7S\/UG%4+KD'E+S5>G 83!S@%OFA*!-QW$IO>8 F, ;"
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MX72^;^56*CMR_K;9,#Y>_0.M/+Y.WZ[J._ZW2>+(/PF7]73^L8/&TGX.A_\
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ME/U5,UO/3IS_ %CX?@P>-I/P>/N$S?+ ,<J72_@8.RK%/,38>83VZ:(;?KL
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M+5JDJX623/W'&\KK'&I=V-E51<G:Y\P  )8FP4 DD $XY=TC1GD8(BB[,38
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MT^'[(_?@\;R 7-,FPO[LWS.+0E]OZW.=&K4T4P,JF437";*85$5#)' P!2C
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M<@B6KU#M/, VZ: G?YS!3!-\'K\#OZ=W70,H@OO52V\U.E_^8P>.GM]K)?\
M/FWO]#\F*87C(?,7>JTP"\OE"%QG!,!MAZ% :2 "7?8-Q, ["([;@ "OBB#\
M*F_5D_K.#QU)^"I_/M\SBK[][YL;]#%1YO*Y/T6S.PAMY/,/O-W+N/P@ #;!
MW".D\407^VI;=?V.E_\ F,+XZ?\ !E\WUX_,_OQ1]_&1/)_0K2^\>?\ 1E.=
M WZ<OZ".H[=1 >7KTW$.NE\44^_V5-YOL9/A^R<)XZD_!4_GV^9Q6+=[YUYJ
MQ40#8-N6VS(]=O*WWIH;  ]P]=PZB #TTGBB'\*E_5T_K'9^[SX7QT_X,O\
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MY(.VH*>8%C5IBCP:,&+C4?$C!HP8-&#!HP8X$P![?1HP=^+<ZY2_", >SO\
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MMP%5G&&46= JL5R_.U50(@I4\7Y]0U,3950#IE293/.1:)#"6M%3BPOI;9W
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M$]Q,51DJH._7RSF4/U]F^V_> !T[M<3#ZXUK7+#F;=O9OMR':;"^-;P7,TG
M?L?RN3J2@@C!O<E8G:);7MMH1;=@&+6AD$UB'8!Z,U@\KS;)E*&PCUV -O8
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M/"4NS@U$325-G8V_IH+*D2*Z9UUO)DED4U5! A%DXJ0>/" <P=J+44"""BI
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MQS4]53-("T8J*2HCBGC$H#=&[1]'+9Q&[%&"TN;SR--'/+8WU&*5'$D;FX+
M.A8%@=.H'R@#N +8E-E%LS"J*"B(B@)R.5"JI\C82$ ZH.#@(@B*9! Z@'Y1
M*40,(;&+K1B1 K'6IT$AK$>25 )#;V!"D$@D$"U\44U:Y!9VV%R+W)[@+\^K
M;X,(EQH4-E+&-IB*C.0$JXL#!Y$L99"13>0:;YJ\!!VBN\BB/S&,U<-G#5VF
MD155!PF=%5$JA#E#,<343<3\,YOE>755&SYA324L50TI>E$BRJ'$LD"S$:&C
M97"(S*P*E=L53YO,LBW!$2GR@!>1E\UR%!%[V'7<WWMB$TN$6Q14O:#1"M(M
M-+-<Z1,U3']N=2K")D*7!-LC+R-!MCUM7[ "47%SE];/JP8L98FYV=8AV<DQ
M3!(IB>7-[%^;4E3FB4D^39GD9SC(ZO*^'\VEJH*.HR7+4XCEEX?S62.@KU6C
MI*_B%)\JM2YA%T.6T<,].H565ELY8QJKM/&YB>.62+2UI+Q]'(B,Z V6-@P+
M(09&*G?"_7.#V?8.:S(R4O6I.:K2F"1BI;QJ;!U#,Z/=K/.Y(BXDZS)8Q&<S
M59J/JL&98_/*LXTK>:)%M]A.Y0^QCFM+/E=745]#45V4MP/X%5F6M,M%%D><
M9E6Y_34;20N5AJ\KK8,JHBY)J:>G$58*>(B\*7B C5I$R@BJ !",#TD,:4I.
M_P#DY0TDBCEJ\G7?9ZW3A;MLW;J]+U^Y X48U.QUN1O=S<P4A:V2<S'VA%K[
MW:U 8VA(V)DHZ1E8IRC:82UUE\XCT'D5.15@13CE$+?.>"<\K<XR^OH\ZZ>6
M#*<RRR;/<Y:@FS6!*ZGS-(_%U!0</45/1U5/45=-(F:T&9Y;424\<E+74N8(
MM.8V(N)&2-S-'=M:,D42LL=E9-3-(]0[6*AQT9B=2VE@Z6(Q%S3@OR,QJ3*+
M0FH" DT#7([IU"3ZLFT;O)S$<GC^/L$%'QF-L=H1C]26>-)27:^+O'RY&QY!
M>RRLRJ90^?H_8QSR'+8*1*^CRJKC\=AYZ2N,\,51F/!]7P[!F-#!1<.\/1T=
M0U7-%55D?1RU#K$:B3,ZNL9G:;%Q+2/*3:47T!3+&JDCI=94L)Y@;+<*24W(
M 55%\,N/X8[97VL*X<1=(DTH>4L;^5J,O8UW=:07E(FHQ\=;:V2$Q;5(]C8(
M%6NR:S2'][#9-5>=D) ;2C*O'3LTO+O8XS:B\2R24N0UD-%F.95-7D=;F;RY
M/'-64>2TU+G.5IE_">3TM-F&7ME=3)#1#*8@\U?451SA*R>:=M)3YDDLU-9F
M*&52NP !#>U($A\EA:[ G<"PMB1,8\*%BF\=L(V)<4>LI,(G/Z4/*P3V5!^Y
MM-TNM$N.+K)-,DZZT0:/:7(TIM%R;1)]*=C%0T&,:\=%>+,HN33>Q-F,>7-E
MU.V1Y7'3Q\?&@J<OEJEEEK<_SK(\[X6S*LIQET*12Y-)E$5'40)-5B.EHJ+P
M:>42/#2^,<;9]!D_&.<15$5=4!LRR*4P2PQ)3IEM/19A!74U(QJ7+0UM+F(E
MB;1$IGEJ5D1>B$DLH,N$C(PW/']RL%C@9QXW<L;+=QCK": 7@[ZXRO-9*L<_
M1'LKBZYR[F.D6DM'U$T7'2^,7LI6JM%0LU,NHAVJQ9/Q>Q?GYS?(LVKZ^BK)
M8Y(<QSDP5[44E'GDG$]9Q#F%=DLU3PYFU5)3U$=33Y4::"JX<FJ<ORVFI*RK
MDI96@AR;\7Y8*+,**FIIX$9)*6@Z2F$ZSY>N4P9734]?'%FE%"DD;0RUG2R0
MYHD535RSP0I-&'DV(Z]WQYSC@W</L'YM*O,=X]>$;D>X^K$'ROQG(?9KK[\?
M6J@]PA_-1_$7&-G]WG_/S?TKXI,G M'C9R'^8734';SE*<!,'_6+N'RZZE3I
M(W3[Y6 OVD;'T&QPD3]'+')]XZL?. 02/2+@^8XFT! 0 0$! 0 0$.X0'J A
MZA#6:QK.?+& ?']Q^8WX&<:^ZTKXI:,M6EH[2QGC1-UV;F7=)@*)K#83(F\8
MBJ;$N!+X^^V(XDG!0B(GF=G7<,<EQ9Q;1<+41DDTSYA.K"BH0UFD8;=+,1O'
M31GV[\W/UN.[$E?>O8%]@7B/V;^(Q2TO2Y7PGE<L3<2\2-%JCI(FLXR_+PXZ
M.JSBKCOT$.\=-&35U=HECCG\/F1>(_-.4<U/.(6V7Z>5RTO/M+%'VR.>KQCR
MN/(Q<JT(VJX-%"! QL 5-)"&8,!319()%* '.9513Y@K<YS.OS-LXJ*N4Y@9
M5F2=&*-"R&\2P:2.B2&P$2)8*!UDDG]L>'O8ZX,X8X,A]C_*<AH4X42@ER^?
M*JB%*F',8:E"E;)F9E5C7U->6>2LGGU/,[DD@!57UZ>"\\*'7N,"O,\497>1
ME<XDJY&"*R( A'Q66(J/0YG%FK+<O9H-K"V03,YM-6;%*5(I5IV"1&%%^PKW
MT+P-QS#Q%"N7Y@R0YU"FXV2/,(T&\\ V"S*!JG@7EO+$.CUI#^2?\)O^#)F'
ML1YA-Q5PK#4YC['.8U-E8ZZBJX5JJA[1Y;F4AU/)E\CL(\LS.0DL2E#7/X9T
M$]?N,UZ/CY QYV>/R/;X]\(3C_-F'*TMG/B L9>''%=KX6,K<)EXR=3+KCZ-
MR:O.QN6L%<19:DM4\*6K$X6"?M=EDSV@]=92=:1EK,P;R<=&(2U=466H5T&N
M0]&IB:(LK -?4DFDA"H-R;V%M][8N*2[TCQR'HHATTBSQSJC*^BQCEBU!I%>
MP"BU[,;;<H,I.</"%S.0>*21M.6[S4<BU:F^$*3G\#N8/-TJ[2CZO5[^OPN2
MN'JVEPUL,.49.MKPE$EZG?(C/%I?Y=CIUV1\:6M,BVA&3:R3EI;NP<+47C(?
MJ5NC* 1A%MY-FZ0Z_.<.O%2!( L:-&S4EI;QBY9DZ<2$S&1KW<,IB 2PM9=\
M25.Y=XJ^%ZJ\+\_>\K<7^54^(;P?W$)9Y=XXQ[8\C2C/C:O%.PK9,9T5I7,6
M8W ] + /%+DVQ[&V=@U9PA%+"25GEB-9%PT[+RQ"(L\S])!(3Y+-]>95*K95
M\FQOI!Y;[VO9L1P3M,JQTZ=#5PJ &" TR-(LCDN_E:O)U:22=K"Y%X6R+?\
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MB1^U#+(ZC:Y()4*3?<\SSQLDU)Q"P:,&(NS ;EI3D>P\8_N^/^I;;[_5AZ[
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MO?;JV[^5\9K,XGZ/R-[$7 O?G?;M\_HZL1,SBY-5 Q@36Y.40V.)PW]>P^T
M[O9OJ[DFB#>V4&]R!Y[=_?OZ!;G1".5A>QMOSO?TCZ'OVQCYF-MXI"RA3M-U
MP;+&((D 1 Q4SB.VX#WB'G]/IU:4S:PC!MKB]C;:_9V]8\][##*#3(0PWW(]
M._;;;N/7B?O!W8]A:GAYO;6BB;N=R9+2%AL#THE.*7N;)OX2+AB"7J1**;-%
M3J)F\HLB^?B(@7D OG'&-=-59N].X*Q4*)#"I!\KI$2627<"YD=K [_6U3T^
MG<-TT=/ET<JV:2IM)(UMP58HJ7[$&]B!Y3-C9>EW?('\W?K&-S/><:+%728,
M0U8_CN0_?2?>4]::B^U8?R3\9L9/,/MR?\I?B+A$U*Q#Q+%9<^,1#<!'<S<3
MMS>H$QW3#Y$CIA\FJ&M314/86#V<?I>V/I8-C1T$G24R;W*$QG]$W4?R"O\
M=AP:BXFX-&#!HP8-&#!HP8-&#!HP8-&#!HP8-&#"IC#?M\B[G WZ.F^Q0  %
M,/H>T+R!$.HB([J;FV'8X!\$"B-)F_NT'^S#_F*C&CRC[6?\^W]'%A!M(!]%
M$P[&YO>#'AOTY-O?%+] 'OYMQ'?S;;:EY7?P23E;P@]]^C7X,0\Y]VA_--\<
M83K--I5FMV"QKH*.D:_"2TVLV2,4BKA**8.'ZB"9S[D(HL1 4R&, E*8P";H
M ZMZ6 U533TRL%:HGA@5B"0IFD6,,0-R 6N0-[#%#4SBFIJBI92RT\$LY4$
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MI:*HD45<N6SP0K3QPAB)9A12Q31F,:VIEDA50L)"IE91)V7S'E"1LL?(.(Q
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MTR02:;=)&UP+KN05*E6Y@D$@V( V?5M!LSC4E#%*0B*/:F-R_ 3(7<X] W$
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M[HSEZO"4]A(P+]-9DZ>V<BRGCB!P,D<Z,6S6;F0*8!$4S.7JAC%, +-4S")
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MN@0(<QCD;BLL8Z!#F,<J1B 81$!'7BN8TZ4M;5T\1U1P54\*,2"62.5E4D@
M$V&Y&QM<8]0I9&FIX)7!#2PQ2,-P SHK,.O8,3ML?,,23J#A_$-6/X[D/WTG
MWE/6FHOM6'\D_&;&3S#[<G_*7XBX1-2L0\/JEN=CO6@C\(I') _<CV:H_+S)
M?:U69BFT<ENLH3W^4H^!L6^52;RQ$\PLBCLL=+'TW3WL6>6,OXYP=3G-_P I
MV0E5J+1\PCG$NI&34N5-[)K"@Q0%G QTK(F%=4.0%"-#))]ZIR%ZZKHH9)W$
M<2ZG() NJ[#<[L0/AQ&XIXLX?X+RB3/>)LP&695#-!3R5;4U95A9JE^CA3H:
M&GJJ@ZWVU+$57FQ4;XQ7_--^!S_QZ-?_ +@Y3_(?4KQ;6_Q/_B1?.8\Q_P#2
M0]A;_36/]A<3_P#\EQEQC3)=(S#2(/(V.)PMDI=D*_/"S1&$I&%>EBY1]"OA
M!C-,8V30["3C7K40=,D!4% 54@40425/%EB>%VCD72ZVNMP;7 8;J2#<$'8]
M>/5>'.(\FXMR:BXAX>K1F.3YB)S1U@@J:83"FJ9J.<]!60T]2FBIIYHOKL*:
MM&I=2,K-IHL?'MQD8.X@N*N X@7'"_(8"X-L/X_X@\HO<38IRU]%FV8YR2XR
M&WB:[1@M>=/>FVND.:DHFD7LZW"$?@]4!L@TY"F+6&HG2242=%T<*K(Y1'UE
M6O8+>2VH6WOMC7BDIY8H##TPEJ9'BC$CQZ%=--RY6/45.K[G<6QF#ECPF6 L
M/3>5:Y/U?,4[,XCM?"[2IR.IE+C+'(3UBXNV\HOB2.IT:C9T9.=<&4BE64^V
M\2:/&K]TR;1#:<%8QDGWJ8T+@JY*&($*H))EOI"B]SRWY>:^(\=%+($(:(!U
MG8%F*@+3D"0L=-@-[C>U@;VQ'^*/"XX!RCD.F8Y>8GXF,4N[;D?*N%7UJRWC
M6 K%&I&;\-05BM5WQ#;[)&WN?1+;V=6K+^?0>5I"RTXS51!DYM32:3?Q;'E:
MN-F"E)4NS)=U "N@)9&(8[V%]KC?F+''3Y?*B.XD@DTHDFF-RS-%(559%!0>
M26:WE%6VN 1OA'C_  R/#.XJMAO4SCGB-IU+2P'DCB9Q;9K?CNN1$;Q#8=Q4
MYCT+?8\-$+?7+Y=VV0F(:59061F>.9I]!R\=-)L@CEQ<$05L=BQ611H:1"5
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MSW_87^.F/HC^#1_V\^QA_O+#_P K58^?[KY)Q^]N/9IX 7_(@L?_ -("^?\
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M)FGC/1R"SPAV!ELR%+2$D.(T%]B FJXU:AAE33)32#I86O%4%$(AU)*)&:(
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M#83?WM;=1#S"/>(>O6QE]UDZOKC[=GE'&(7VJ]P\W5V8<6F\+BXU'Q(Q25$
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MF89E)6%BTAD.FQ+(!J%K FR@LQ',L;G<]N-+0T I1'Y(7RB05<FQO?R1J(4
M[V&W9M;$]2D6TF8$T7)B8Z2OBZI%2" *H.&JR;AJX2$0Z*HN$B*%WW VPIF
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MR"--]<D3_<%]FT BQ6]B;7N,9SB/+D@K#,^F0$DKJ/UM&'M6"\M1# EC<WN
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MA_--\<8NM6&*C!HP8N-1\2,&C!BDKW?(;Y@TJ\QWCUX,0Q>A^HJA_P!&8?\
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M]G("]N_?%VGVJ(\Q!$0WZ@/4!V^0/D]8AT\PKU]0/HO:_J-C]!AM]+K9K $
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M:B,AN\LMO3L?1?$BJI)+IG1723624#E425(51,Y1[RG(<!*8/48!#5,0&!#
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MOK4B4B03.BV(9A=5NT8Q\D.0RI)#!*AJI$E$82IE:**=:2D=(XB5M-&]:]1
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M.\,C0,B8[Q#CJ>L^*,RX9XB%I"8;7VY5V+CF%JR73;0V<)MUWKID6EQ#6'?
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M )1Z"4W0-A$/2'?OU#KZ V#8-*;"X!Y'<;WY\QU[6!V/O=9%-K)4[^8\CW[
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MRE1%4PE[$Z'D"$WM?!YA14V6P@-)T\DT(>&6&.707:HJ:81D.JNK&:CG"!E
M=4+  7 E#*$B[3J2JCHH(/C1J9W:13%$$G1VX"X3\@1*/9JB<@"0PE';H(@&
MXZ.CC7I"$W0.^@]94$Z#ON-@#8]MSVXSKN0RAAY05=0%C9MBPN-MCO<;;'GR
MQC+@3',3EC"F2ZI+MVPDN%EMT2L_4;D66:/R,8H(>3YQ**IE8=Z#=XW$IRF+
MV)B%$"JG <IQ1F%3EG%67U43N%I:>ED$8:RF/I)1,EA8:9!K4WVN1U@''H7#
MU)%69#/ RK>:29=1 +!]*F-[G<%6LP&Q&^^^+GP=N!,XXTXATI2V4.<JE>K]
M1M$%.3SPH)0\^=VHU3BD(MT50R$P15XW0D4CM3+$11;=LH9,W(!K+B_.,IK\
MFZ.EK(:J6:HIYHHXV!DB #EVE0V,95&,9!YEK#4!<1L@R^OILS+2T\D4212H
M[L+(Q)4 (W*345+"UP +D@BV/0,B.Y0]@=/YOZ->2L+,>^_O[XW8Y=6W4#_=
MV;[8B"Q_'<A^^D^\IZTE%]JP_DGXS8R>8?;D_P"4OQ%PB:E8AXERN-O%HAJ
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M@W/,<]@;;$;\^K^W?*N+7N;6%[]GG'+Z;8BW*>;ZIBB.2<RYE'TL]*?W)@&
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M0S*0I)5E-T'M@58CRV-B+@:@#C8KC:]Y6K;LB\=E&2LK=,P"I!7E,DJT<D*
M<R02',#YJ<P ($.BJF &$.8>7?51445)*I!@6,_?PV4KZ!Y)Y\B".LV.*NM%
M,X*S9>D/4)J,E&0]ICMI8"_*^^^W;FC0,T5[)J,G'H(&A+? %+[X*PY5*=9!
M-0P$+(QZNQ1>Q:JFQ2K%(4Z)C)IK%*"J"BU!5T+TC;G7$Y(20#G_ *K <GOR
ML2#:XN+VAQT4E,\;EQ+3R[PU"<F//0XWTR6'(VO8D#8V<+MV!#;E$ Z;"/<
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M(8X>A13ZJH'R'.8-9V=^DFD>]P7(!_U1Y*_\(&-32Q]'3PI:Q" D=C-Y;?\
M$QQ '&1_DA\5/_T;\X_^S&T:H.(_\7L^_P#<V:?\C/CTWV'O^USV+?\ _(W!
M'_S-EF/G/Z^.,?T-8]:W_)W/^83/_P#\[T/_ /DR.U] ^P]_^B<V_P#>,?\
MRT>/RC__ %@_^/7 /^Z=;_UB;'H:UZ_C\^\:].(3PBE.X?LW6'!(</?$UF>Q
MTK!T)Q$7Z:PC4L<V>$I>+YNT6^II2LBPL>5*A<YE^RD*5+N7L34*G8WWB!VB
MK))ZX.LU0CR5(CD,?1R.502,4"D*I)%[%@3:QO8$]E\2X:-I8A+TL,8:4PH)
M&92S@*U@0C 7#"Q) OSMB9&G&_P@+UK#-KD.)3"U7B^(6MP5MPNA>,BU:C3>
M0H.R)-SQ+BNUVVR</./%U5W2,:NQ"/!XSF3##.T$90IF@=]/#9"9$'2 %-3
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MQ9V*PQ1@D*MR;*HN0NYWOV\^J&*>HF6FIXIJFH<L$2)7EED(!8A0 S,P +6
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M5V#T-(CK[';S;_CJ=26U.!U#?SW(/P7/O[8P_P#"$6V0<);_ .?YE_RM/_\
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M -F%OUBHQH\H^UG_ #[7_D1_);"-:3J?1.%/E#L@H; X'Z<PJ#8)8IB[;[[
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MPC6E( R8*W.',-%8I"GMU "V"5.!]]]]A$PEVY>\!ZCW!+RL_8D@_P#:"?\
MPT&(F<>[0]O1M\??Y,5M6&*?!HP8N-1\2,&C!BDKW?(;Y@TJ\QWCUX,0Q>@^
MI*C_ -&8/_5T^>7Z0^$C]V&Q[<>;4/A8XUZY!'D<O!\X%3'[;EN'L]([>D #
MU:AU'M'[S[V_P6^#'J_L+C_]I'#U^OQB1^S*T?(3[V,6,F<+M4XG589.U31X
MLE8H>;:A$*-X1C)2T/+9@JK&HH7NMR3Y;: M=&39'DZ](-VB[DK]P51)RS,A
MSJ5I0.NYY!AW%@-P;[$6OU WM<;X^MN.LBCS-Z6:5^C$5+7TZ$1AG1ZZ!(UG
MB=C:*: *SQL 6)M8H!?$,!X)Q&0:T!BAE&L1,72I!]-NHJM8JM2"<C.2#M\,
MC)0DE:\Y72P0*,Y%OS,)ZOOIBR5<SE)28J\#4Y"6L*DSU$BHZ$L%"L#R-K[G
M>[;7N;VN.H;X\IJ>'A D+I51*:5NE5(J:4%G+DNR-)62R1AU-GC9Y(K@O%'"
M[R%XDH_@F5Z6M7HX,FQD1+U*?.X=2U)Q8>INUJH&/<=8\[&JL27^5K$+8+9'
MXZCIV]WF6KUKEWMD5;RE1;4&1AT'"EIX*AC1ED4$<RD82RB...P4.0&98KNY
M#,S$,NBPQ"CRVG2.G,=9'&0;AX*7H&4"EI:1X53PEHHYY5I5DFJ)(YGDD*R0
M"F95&'HP\%G'P5(N3HECHMJNRF%<X42D5]GBV.H%!CK=D'#.(L35*Y1T<-BN
M*E8M3)CB%!S;+6T5>/+%(W"5=LVU>81K6)7B-2@7((9M#J (PBAF1$!L6:Q\
MCRFWN23Y/+#0R>-4E D@DE\$K((8UIU@A$M124M)',%,DG1RA:53)*"QD:5B
M- 4*6"\\&9$Q<0Y</;Y0XVSV.IY@J=D/6\*QT97X9IE2I89KC0^-8UM>.TIC
MRLGPTB^DGZKV9:W!SD'*"Y(RLJ6[FCW8:$M>[*NI9%8]&-(#K';1=@05Z,7)
M)U:WV743BVH>&%E74:BG22:"M@D*4*B-161448\&45 Z%HO E+&\@F-15^3%
MTWD0Q-\ ]5&V24]8+?$6")/=)&SC"NL=1Y3V-D^M.3K>9/);]S8I%O?[(RE<
MD+-X>UJQ<,$?$1*;08-P^DGDD$Z.@4O<N'7I-17HU(<:I&^N'4W2$=)8,0+!
M;6N2<7R<'P&4RS5$4T9J&GZ)J*/Z\C35M1:M=IG%5.KUI"5!CC"1QZ1$6=GP
MF.< W2PXGC<"S%MAY,L._P 0P&.9%.O.94DI&8T;8X.R;9 @'4DS3L*5UMU3
MF'5D@4)1LW][5B+7DYAPNU/++6 IF\$:&21=,?0]&^C6O1TPB:TJ%EUK))&Y
MD0,!T;Z0Q(U&<<GJ#DS9=4U<)BICEPI9C"TBM!EBT4GV="TJ"H6JGI9GGA61
M!X/-T E9@9#GM3O!74*JKU-*4M-/MD.PA<*M;K$3V'89\>SR>(<SY$R_[GQ4
M@O9UFL#CF?#(RU+4H<E#VCW/K]&QJ5*?=)5,&,ADWA'2,;K8FYLEA[<O8"Y"
MKY6G2;Z0JBYMC+TO#4!*S.\#I(:5YHFHDLQIJZIK D>J5A%32>$=":=EE"1P
M4UI"(K,R"^";JL9%OH^3RFC94'F)\?XQ]T)RF6E2;C6E&QUCK&;EG$(M<OM:
M+[Q;%"8Y9R;JF3M#GWS"Q3$I)L[<!"L6C5OH!R+$[!;V)M8 6MJY&P-K&W:!
MRF47!L+DI)5"16I:>EU203,RK!3TU*RHJUJTY@ECI@[0R4\A$DC.LUM*C<GP
MI1\9$2]GAH9@QB8>(AJY&145%M$&$9&1L>==JPCH]BU32:LF+-LDDV:-&R2:
M#=NFFB@F1,A2A94=KN!U6 ]-MNX6Y=6_5MBB_A#Q1P\.\&Q1HL21UF8I''&H
M2-(THZ0(B*H"JB@*J*H 4#2H &VPE#X)?W/XPU(?VQ]'J&/E8<F[OE&+C7.$
MQP;N'V#\VE7F.\>O"-R/<?5B#Y7XSD/LUU]^/K50>X0_FH_B+C&S^[S_ )^;
M^E?#\I[;LHY5P(>4Z7-L/I31#D+]I05=5>8/JF" [(@!'8S>4?\ ATXN<LCT
MP,]MY'-CVJFP]YM>';J!BRP:,&.IDR',0QR$,9(PG2,8H&,F<2'3$Y!$!$AA
M34.F)B[")#G*(\IA 2P-K@&QN/,;$7'8;$CN)'7A0S , 2 PTL 2 RZ@UF Y
MC4JM8[:E!Y@8[:,)@T8,&C!@T8,&C!@T8,&C!@T8,&C!B-,LF,6G.!(8"F\>
M8AN/+M^FCO\ #$"Z[2US??;LOUCJP]3^[)^E\5L>,J6^-9/^$'OX2KK&8U;<
MSWGUXVJ\*> V4WPYM\CU?AGR-Q&V>[6V[4"^-(/-LKAB'A*I#)U24B(OQ:*(
M3WZ0]@>G.[DBO%'+:/EX%NFX;)G"/4,8Z N-@3?GO;K\XWO\%L:V\L0PUW)M
M]@AI+G&PQ%KG(\<?O)Q2S.J;XJ_71][;BPK%*K-*Q'+XF>34*!G@I=N/4^C'
M!YG'M&PN/+PUXG-MS;8.H@[=^^U"BAVV\^_=KI/;IU>4N_I&'3[0VYZ/DPD5
M(W/5:R;EY.:OPQN7NY>:-;#R[=-N7?;N\VMC+[K)^6_QCC$K[5>X>K#@UQA<
M7&H^)&#1@Q15(!@'?N$-A_IZ^KI_8=*#8WP$7'81[_?O[W=Z3B/+'#=N100
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M,2B['(G'2X7I4VC99)X]9TYC'+Q$;3ZT9Y;W+JSS*"ID(/+8*0+1FUB5/-R
M23?:VPWQG9I,U"2$2E7D*F2-%@Z/R:,$NFM&-VK+K<W(0+8(NIBQK/ >$]J<
M_CF&58W.X0##.\*YN-\2>\,";*9PG(V'!*]QC;C3XRNP\\DI#5^9SNWJ$OC]
MQ%6%(]8BF<S"V-X\A+ O.C>9VC%R5Z1=3$PB\>J/4&! Y*9-.@@V47!V.)%#
M5YHU13QI*Y454?2&8TB@T_24XE5V95)"QM/H:(B0!1=6)4G#"\8$XL&V%^#A
MI4(FYL\H</W"Q9XB1KIVE FXR/SRTP_3*O4DWKBT1\\QE9<)Q&S1K.QQ,J,2
MS-VJCN6;0TL^/)3! XAIBCVDBII+K>,@5 B41[M=22=5F!ML;L 2<;*&BS),
MOR9Z>5$J\MRJK'1FHR]T&8BCACIM?A'2*\G2"5%='$:D$/(L;-JMD,8^$@NU
MJ//,:Q9*96??K"NXFFVU7!31JM49G,L@SEF5Q<L'$Y/)^]G#CMK+J%JL^:25
MDV"2;5Y8)4%F#YX33(^L.RJKJ5C(IR60SD,'TZB"M/9@%>Y>WE-N#;MF.>-,
M9UFEBB%5$\5$1E<@>FDS-TECJ6@Z>53#EC(XZ"I#&5!:25]2M4JG"IQLJDJM
MMM<9ER:MSK$EBAYVJ6*5X7"42$RXSMN,Y(DNM%0LNJVDZM)Q)[\E0)MKVULC
M%X*.1L"<2PDE3SD&IK*F557I)MX0LJLT!5I 48D")5LEPP2^I[;-L26K)UXE
MS". ,<S97H'BJX:B3*4IWK!+2R,XB@6,"G-IUIGN\ZHBI*41VZ3)\(WPH%@E
M7L<K9;C2XEW:G1;!/)M>%5V>+30@>)ETA]!Q)6&L2BF+7S]#AJCB*91BGN44
MY)X_6.#1@G<7+>L+3,;"X)-S[2_W=P+@@#VO.Y^'#ZP<3N_1!Y8$,C*[@946
M4"+,R/ P4D^QF=<L4>%(:K4[$JJ"<B>.'^6XL!L>1R\1S26+".JKBR1J;AY]
M">-AXFUKUA1#)-3KT/C]Y8)^191MA;A)GN5NLZ:4L66:Q<%5X=*'>.7_ &FN
MY+WL0"-UL#]T+#?8\R>L^:^-APO!G+551XS1^C:*B:%F-&J+,8R*J**.G:65
ME20!S//+Y8<)'#&(V9]C?"FQ446NLX/1!T^B8I =NAS,TWKIYL;N$4P<L@$-
MNXX#YPU8T8N'?M-MQU#E;M\_[[X\O_A*5\2_4ADRE3+##F68S*#NJ5+4U+ ;
M<Q<TU2 >1L;[XST0^"7]S^,-/O[8^CU#'R\IV/GO[VJX]6+C7.%QP;N'V#\V
ME7F.\>O"-R/<?5B#Y3XSD/LUS]^/K50>X0_FH_B+C&S^[S_GYOZ5\2W&-O%(
M]FWVV,D@F!P_Z0P<ZOVU#&'5!,_22R/U,Q(_)O9?^$ 8TM/'T4,4=K%474/]
M8B[?\1.+[3>'L&C!@T8,&C!@T8,&C!@T8,&C!@T8,&C!@T8,&C!B+LP)$6I3
MDAS"4HOX\1$._HL(A^M-\P_)WZ<C-FOYCV^;LL<.P"\J#\KL^]/;?'C0EOC6
M3_A![^$JZQ>-8W,]Y]>-I/";B:-M6$("<QYPXXYXE;K)Y M$1F,EZR&:KO\
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MT$:@B$D]6S$#<>?S';Y+8[IIMT_@ 0/8 =WH$=MQ^WIIGE?8WY#K[.S?$I8
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M 8P=>ODF#K\G\^^VVNM1'-2//S'IQP<@E'4O;U\O-MBDM=TN4>4P^H '?V=
M](_+OZ@VTFK>QO?GRM;S'MV[!Y_..X\A<$Z@!RYJ1RYBY ML;]WFQ8(J62TK
M WB(]=0AAY3NE@\7:I;CMNHNKRD#N'8-^81#8H".VG$CED(TJ0#N2>5O-<?)
M;GYCBJSGB+A#@^!I\]SBC@D4%EHXY!45\S >UBHXF>8DW&[A4%]V WQE!B/%
M+>OK!*NS!(SC@G(H^,F8$FB1P^J-V*9P Y /\%9R<"K*%W3(5),RI5;"&G6(
M7YM:Q/[K_(.W'R5[)OLN9AQL?%>71OE?#D4BNE(6!JJ^1"=$]>R$KI7G'2QE
MHT;RW>:0(R9E0; &R!-R[#L'>'4 \P#TV'[>_IZ[Z=8V'G/+]^/&U'+M._5R
M\^W7WCMYWPYRAL >G;K_ &]6^F<=X[:,&.#=P^P?FTJ\QWCUX1N1[CZL1_!-
MNTL,PY$-P;K.BEZ=RB[@X (#ZDR* /[K5U5/:DIDONZ1D^=507O^D5([L4%$
MFJMJI#R228?I/*UO^%6P^=5F+C!HP8-&#!HP8-&#!HP8-&#!HP8-&#!HP8-&
M#!HP8-&#$6YA(92E.2E.*8B_C_* =A#981[^8O?W=^G(]F]![/-V@CX,.P;R
MI^EV_>GL(]>/&C+?&LG_  @]_"5=8O&L;F>\^O$J-^(KB":H(M6N=<R-FS9)
M-NW;M\G79%!!!$A4T4444YPJ:22292D33(4I"$*4I2@4 #1A,17*RTK/2;^:
MG).0F9B4=KOY.6E7CF1DY%\Y4,JY>/W[Q19T\=N%3&47<.%5%E5#&.H<QA$=
M&#'N(X?RE/@+"1#E Q#X?QN4Y3  E,4U+A0,4P#T$! 1 0'H(#HP^.0[AZL,
MRKD4A4/>1)GY)NHMT(L2+&*5>6@VI0:P=G;)B83+L9EDBF*[A$%&S6;1EX45
MC/(IT0FP65:A%J4L5FNS <HY3O)$>QD8[ V+1E)+!77&-G@:FE:%A[7VA/W<
M=_(<=MQLUM@X9>K#KT8:Q<;AZ0U'Q(.W/:W.^..8O^D'VPT8,',4>H"&WIW#
M1@Y[#GV8ZF #><-]NG4.N_S^K1A;=1!WY"W/Z;X2W#!%81$P &_0=]OM>@?3
M_P!W5P2;;C?S<O[,<:#<@=W:>H6MRM\MK<L4DHILD(#RE'<-^X.OK !#;S=_
MI#VZ#(+<O?Y#T_W8--NS<'>P'6.0Y=1YWW]["B""8%Y0 G<( &X;]-]^G=T_
MFUR7/;8>]\//X<=$6V_=MYNS;T^?>^$*5AF[M,X<A-^N_P 'UCM\OI^T/7HX
MK@]^UNSJ[[_3J&_#+YKV/5R-R3:]]NO?WNP1++4=NJJ)NQ(.X^?J/4=_-_1O
MZQVW'K;MY=W9??NYX-1%A8V\_/J^G+<["]KFS3K)6B1RD(!0$-C  \H&V[M_
M2'>.W=_/N6OMOZ.K;S>_O^[!K%^NP-]NWO![>9'/N&^(_%'PV-N(:C!0WEHF
M:BT"<CYI9Y$-V[PSP(]-VFFP?-'"S8CAF91R5T!?&"<CILV5$I^S NKSA_.S
MD%<:Y*6&J<P20*LK%.C#E27C902& 72;@@HS+MJ)Q79IEZYI2BF:H>G7I%D)
M55;5I! 5E)7R=]0L?;!3N0"(OX;_  =6(L+3[6W$-,7:W,Q$8R9M!F?BL*H?
M<OC4-#LFZ;9L^,F82>.O%I%RA\)D=JH)CFM,[XUS7.8#2$0T5*^TL5/K+SC?
MR)978L4Y71 BM8ZPPL!!R[AZ@RZ03 O4SK[1YM.B-C]TD:V :QL#=RHY6)-]
MBRE(;^*\O8AU)W 4.G\W]([=^L=J'6PW[2-\7^JVY\U]O:\N?P$#G8[]6(GF
M\<LG9G#5TR;.F3Q)=L[9N4$7+9VU<D.BX;N$%2'2<-UT3F1615(=-5,YB'(8
MIA*/2,8W62-BDB,K*ZL59'4@JRD$%6! ((L00"-P,*=+J58 JX*LI&I64[,+
M<F!%]CS'5;$*T_P?/#U%76"O,+#6JL2<!/,+%&1U=M\DQ@49./=D>H'*R<%>
M.V[<RZ1 .U8R+-N"(B@B1%+8H:E^,\[FI9*2HDIJA9HG@DDGIHVF9)%*L"RE
M59]R0[*[!M[G%".'\M2H6>%98F1Q*JQS,L:NAU+Y+ D $  !E 7:UL;-F@ 5
M,H;@/*7<1W#IOMOO_/\ )K'N=[=@MS[/[]_/C0*-F/I%O1?Z=FYWWQ=[AZ0^
MV&N<%CV?0<\<[AZ0T86Q[#[V.-P](?;#1A,',7_2+]L-&#"%%MP+(SCL=OJS
MM%$H]/@HMTS"(#Z#&5V]8D]6I=1)>"ECOLL;.>]G8#W@OPXA4T5JBLFM[:1$
M![ L:L?02P_DX6CB [;#OW_BTQ'U_3MQ)D!%K@]?R8IZ<PW@T8,&C!@T8,&C
M!@T8,&C!@T8,&C!@T8,6$G)L8=BXD9%<&[1L4#*'Y%%5#F.<J:+=NW0(HX=N
MW2QTV[-DU26=O'2J+5JBLX533,H!8V'/SD  #<DDV"JHN69B%5068@ G!S(
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MJ[6.NJFS:EE3$:MBJ*&!%NF/9()\J212IE*4,QC2Z5[/7A._,F^"G_Y!V?\
ME"MW_P#)Z,&A>SX3^_'8G@G>"@AR&-0+*H!3%,*9\A7$"*  @(D.*<J0X%,
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M;']UMNNZ>+H-O*DN-[WCW(-P3];/P#K\PM5^AB<3<WO^N^PE .4"TH $0$!
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MM[NA0.)A#9*C_4S',8QCD_05L)C'.)Q[0#EWV\G;<!4YM.;?6J?:PY3;@
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M@GV+B"!PY(I((##.L]N"1S&K,BMQS%P1?F"-L*/9T]D\$$\11L 02IR;(K$
M\CIRT-8\C8@VY$'?'MQPM<9+(F',39 FDFJ$Q><9T2XRR#$BB3%&2LU6BII^
MDS354653:INGJI&Y%%55"(@0IU#F 3#\%9]0Q99GF<Y; SM!E^:YC0PM(09&
MBI*R:GC9R H+E(P6(4 M<@ ;8^\,CK9<RR7)\QG"+/7Y7E];,L8(C66JI(9Y
M @)8A \A"@DD+8$D[X1)VYV&:E)&&IZ[2'B8EXK&REN612E'KN2:B"<E&5>.
M5*:+*:+<'.Q?S\L:20934?(P8UEZHBN^9O4>71F-)ZK4QD4/' IT#0?:O,_M
M[.!J6- A9&202J"%9FMS-HW:&G"ZD)625AJ"L.:HNRDK>Q=B55@4*,;D(96%
ME\HRV1;LNH<H@90QJLWZB !S%18U=HV3-TWV30(3<1'EZZG^"T?51P@7O[:<
M^B[3$D=YQ6>'UM[^$O\ R(;>\(K?3LQ<A'SP%(7W^W(>0P&YA<07,?81'E.(
M0  )1WV$  !V .NF>@I=_L6'<6YR^^/KO/#WAM7^$/\ R(O>]S_M\^ 8^>%3
MG]_MR /V,'$%V?=MW>X F]?PN_U=-'04MK>"P^_-?^E^G7?!X95_A#_R8OF_
MIU8X".G@()/?]=!$1WYQ<P0G#;;H ^X   =.ODB([CU[MCH*6]_!8??FM[W2
MX/#:O\(?^1%\W].K')X^>.8I@OMR)R[>21Q! 4VP[^4 P B._<.PAT[MM @I
M1MX+">\S?.X#659_SAQW+%\W].O'!8^>#G_1]<QY]]N9S!#R;[_ _O &VV_3
M?FVV#1T%+M]BP[>>7?O^NX/#:S\(?^1#\W@/'SQBE*%^N9.4-N8CB" QN[J8
M1@! 1Z>8 #J/3T'04OX+#[\W;?\ C?H/3<\-J_PA_P"1%\WCDL?/ <3^_P!N
M0@(;<AG$$) Z &X![@ ._3?J80W$>FCH*7\%AZ^N:^__ ,7>W5>^#PVL_"'_
M )$/S>.183PD GO\N0" B/.#B"YQ[^@B,"(;=?1Y@T=!2_@L/OS?._3WK'AM
M7^$/_(B^;^GOWZ%CI\IBF]_]T-RAL)3.8$2FZ#U, 5\!WZ[]! -P#IMI>@I?
MP2#WYOG<'AE7^$OM_JQ?-[^G%06,\)3![^[B',._,#B#YB^HO]X=@#U" ^W2
M>#TOX+#[\WSN#PVK_"'_ )$7S>*01L^ E'Z(%U'E'?87,#L;J [&_0_U#IMT
MV';?KOUTO04OX)![\WSN#PRK_"7[?:Q?-_!RQ6\2GMCA[^K?Y8  ?5X/<FP;
M;D_O%T$>\=]^ND\'I?P6'WYOG<'AM7^$/_(B^;]=\4!C)\0V^B#=@\K?<',#
MOW;<O^+PAR^?NWW\^W32]!2C_-(/?F^=PGAE7^$R?R8OF\5P93P#O[^K>/D\
MNPKP8AW[\WQ$'E>;?NVZ;:3P>E_!8??F^=POAM7^$/\ R(OF\431D^(&#Z(%
MU+S;=2N8'<NW^CO7Q[_/OOZMM*(*46^Q(#;M,WP_7M\'AE7^$O\ R8OF\52,
M9XG)^CNXGY $!YW$&//N&VY]H$-Q#O#;E#?S:0P4IO\ 8L(OV&;;N^NX!6U8
MM]D.>]8M^_ZWBF>.GS&,/O\ KH3F P<I',$!2[CON7> $0$O<7<1#;O = @I
M1_FD)Z]S-\/UWX.6#PRK_"'_ ),7S?\ ;CL2/GB%* WVY'Y3 ;F.X@A,;81'
ME-M %#E'?80  '8 Z[]=!@I2;^"0CS S6[_=?[/-@%95C_.'.]]UB/H]SY?3
MMP'83QS\P7VY$_U".(("=VW<, 8?7W]^_FZ:.@I?P6$]YFO_ $OJP>&U?X0X
M_0B^;QU)&SY"F*-_NA]QWYCN8$3%[NA1"OE  Z><![QTI@I2;^"0#S S6/\
MXV 5E6/\X?TK$?\ R\=C,YU;RB7RX$ !$@@DX@P 3)G,4P#S0)NO, E-L(=
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M)@'NWZ%#?V#I!!2C_-8?29C_ .;@\,J_PA_Y,7S=O>MV\\=2L9PJ@G]_US,
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M)6GL-8-&#'TC>&AR9GPJ</[LI2G,UX?,4N2D,(E*8R&.(%4"F,&X@4PEV$0
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M$DR1MITAB-V  ) /TV'P<K^Q<&^Q'6\4Y'%GM7G5)D=)6S34^5+/3254E=)
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M/:&OR[XLVXOXF_WDSG_JE3C]/^%/\5.&O]WLG_Z;38J50"A5JT! $"! 0P$
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M&,R>J%666\3<)22!%.<A$B^LY/GD9R2!^)ZNEI:BL9Y*224)#))%$5,$QCC
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M?%O45JR+GRZK&FX@IO0LF3Y1*+7/7J]^XOMA,1:+(/&/3<S2:7)TWYB%,+8
M*4 \D"[@H81'80Y^@B'73C &)";&S'MW'FMYNT\K#>P&*>@K#'[(7%M&Y(BS
M7A+(<Q3>ZEZ-ZBC=@;<_KMC:Y(4 WM8."X,E&\LJ7D#DD"-S]0ZF/V?+MO\
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M/\<.)>O_ /,F<_\ 5*G'Z>\*?XJ<-?[O9/\ ]-IL=ZF7EJM:+S<W+7X8O-N
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M"=5E.Q)6W(VM8X4(IK&M#22Q&Q"+2BZR[E4R)%%3G74$YC&4,41';F O?T
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MIZ9ZC_(K43!(C(+$:K*0Q!Q1\35N89?DE;5Y9$9:N((5TQ=.\49D19IUAO\
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M]- A?)#<0#KN'3;;Y._H'<'V^L2]K[\B+[&UB>0\]MSSW\PV:GG:1C<GOO\
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MK& #+-DW:2X-E3@!U&X)',',(Z\BS2C\!KZND#&1:>9X@_6R@W0D=1*E=0
M#7 QZ+15'A--3SD!#/&KE>PD '>^X!%P3S !MB5M5^).(4G/CB2^RUO]H=:B
MD^UH/S:^K&0K/MJH_.OZ\)6I&(V)5JSGQB)2(([G:J*-S>GE 043^0"*%*'F
M\GU:HJU-%0QZG <>:^Q]]E)].-%ETFNF4=<;-&?1Y2^\K "VVW;?&N[PM_\
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M7-IK*_MM?R)/BX\-_A4?]D.9?^^<C_YS'E#UI\?EYCU^^#'_ ,AO!?V-?_\
MVJWG66S/[>F[H?Z"/'ZP?P;_ /L6X*_-Y[_\SYWBX\)-@#(?$_P?W["^*V\2
MZN]BN^ IZ-0FY1.&C31^/.(3%N1[(9:0535(DJE6:G,*M$A((NWA$&A!*=<I
M@J:F-I861+%BT9%S8661&._<#CWFDE2&H21[A0LH-A<W>)T&WY3"_FQKOXF.
M"'C%NG$OQ(.\<T'&=@PSQ#\3_@]^(];(LQE4:[8ZC&\*PXMK]ZI:>/S5-^K.
M3\BG1CV6)D!L,3"C!F=-?&G%A,SB%HTL$S2RZ54I))3R:B]B!$%#+IMN3:X-
MP+>?;$VGJJ=(80[N)(8:R+0([AC/K*MKU !1<*18G5S 7?#0H7@?U'&;\*9"
MR[@C ]PBF?'#X0?-.<W4_'U:SO[KA_-["_N^'V-L",C$+GN",+:WE*G25&3.
MX8U&4:#+H($?(N%E.11DNC,B$&:=Y+V-T>_1@W&]C8VWM:_/';YBO1RHDLH^
MQ:6.(#4NF6,J)2+'R25#+JVU VO;$!CX*CBYB,)XLHUEP;@OB+F%_!N67@E1
MBLD9,C6L=PO97E,FWVQL,VU)U,4^S)RT8%9M-31<NZ*2/O[1SCR'C8UPDQ*S
M4;<>"3!$4HDA\':&S-M$Y<GI!L;[$;KY6UN6'/#J<R2,LLL(%6M22B$F=!&J
MF-@"+'4K'R[J0Y-KWQM&X,. >6P7Q3<0^=\MP=)R!:9K'?"-CS$&:I%NPFLB
M'0Q-PU0&)LP2C=S(-W$S237>SP_C$LFS?)KV=@5J,JJZ0:-TTY4,!261W"L=
M$*HYW;R(PCD7N5U$"^]R!OB#4U0E@ABC9D4/4-)$+A?KD[21@@;-I4[<])Y8
MVP:EX@8-&#%_BS]59,\H3?X0&NP"&P$_P;8[#E+Z0$=S[A^N,8.\-4N;^[4_
M^RC_ )BIQH\G^UI/S[?T<6$NTB3Z)>VX\_O&8B)>NW)[ORG*/=MN(\P=XCT[
M@[QDY7]JR?GS_1KB)G-NFA[>C;WM0\WR^C#-K6-Z13[)>[=6J^UB;'DV6BYR
M]RJ"KQ1:Q2L-#-:_&/'2;ARLW04:0[-LR(1DBU2.1+M%4SKG45-?U69UU939
M?1U50\U-E<,L%!$P0+30SSO4RHA50S!YG:0EV<@FP(4 #,TV6T-'4U]934Z0
MU.9RQ3U\JERU3+!"E/$[AF*J4A14 15! N06))@MEP0<*<;D9IE>-PM68Z[L
M+4G>F+U@ZGF<,SNB*P.4K4TI[:72IK>P$<@#H)9& (^\:_NCMNV^J:OWX[XM
MERU\HESRJDH9*0T$B2)3O.]$RZ&I'K6A-:U,4\CH6J#'H\G3IVQ1)P/PI'F2
MYM'DM-'7)5BN1T>H2%*U6UBK2C6842U ?RQ,*<2:O*U7).)6CL$XEC,:6O$#
M"E1[;&]Z&ZC;*J1U*"RF1R(ZD7ES[=P9^:01]W7,K(*K^*/&_BXN#%9>*D(D
M4E)-G^<29K29R]=(V9Y?X#X'5E8M<'BU(DHM*]'T;>#K%&%UHVK3>3622;J'
M(<HCRNJR=**-<MK_  [PND#RZ)O&+RO6ZF,AD'3M+(6T.NG59-(  2)?AHP=
M./"R,C06)I F*$\&@^:2E@C'AL4(/VLFVI:CF,EF:RL<UD&;=VS<*G/)-%BJ
M';/4NW7[5V'BC/J=#'%F,@C.;G/^C>*FE09NT;1-7!987597C=D=0!$ZV#1G
M2MFYN&<CG?I),OC,@RD9%TB2U$3G*5D65:(O%,C&-9$5T8DR(URKC4U^</<.
MN&>'B-G(K#=);TB-L+AL]EV327L,HW=.FAWIT5RISTO*@U.*DB]56%GXN#E5
MP=5R"R@$,4SKB7.^))J>;.Z]J^6F1TAD>&FB9$<(&4FGAAUBT:!=>K0% 32"
M05R?AS)>'HIX<FH5H8JEXVF1)JB569&<A@)YI0AO+(6T:=98E]1L13OIA*BX
M'S !_D_MN/V]5&+@"[7["WR<_?/]V,![8L))@YP,("54@#N(AL!@4*(@(#Z!
M'IMYM0YMT8^<$>__ &]>/8?8077Q[2J>O+<S^"GO\G=V[8?$368:=3;R#R(B
M74PT:JIQLH\C63E^P*N4><C1XL@=TV36$=E2MU4P.!C<P" B&FHJRH@C>G6H
MJ$I9R#44Z32)#-R Z6)66.2P!L74D!1N-L?0O$&74$];'634=))64P=:6KDI
MH9*FG!8ZE@G9&EA#7NP2103L>T8]L.)R.X>;0EC'B.=J5:EO7R;#&^;Y4Q_>
MB"+A4B;"D90F3D[*I3[,YR,:Y;9<R5;MT<FT3?RK"UD=M)!NHIVA"SI=Z=C9
M91<A&.W1R$7TL"=B;!CUW.G&,\9^ 2FEK[QQ,0(*IMXUN=HIS_DR#LDC'1(+
M;A[KC/Y@Z9R+1F]CW39\R>HI.FCUFNDY:.VRI 41<-G*)CHKH+$$#IJI'.10
MH@8AA 0$8EN1[QZC]._$YI ZEE*L&'D,#<$$7&X.^QYC:UAA=1W P<H\HAL&
M^_3R@ =Q .@[;" ;[[;;^C2=1)ZR3MS%MN?<+['U8BOOL1< V'FOOU6\]NXW
MO?"LF<P>;</3TW';S>H>[T>GKH%[V(]/G[+?!Z//B*RV8]0[SUCLZP.X^_A2
M;NP\DIQ$H^83=P^CKZ=NO7OZAWAH&W7U[>;KL.T=G9RZL19X;@LMC;LY^:U^
MKJM;Y,*Y5C  CU[N\.O?MY]_6 [?S!I"J\^7=;^[$!DOY+#?LZ\5!<AMU'I[
M=OQ>C7.CS_!_;ZL<K$-K FW=U^CKZ_APS[@J5:"DR"(;>)K*!N'G3+VA1 /4
M)/7W;Z[4 &PYFU_/?8=@'7R^#%UE Z.NI2 =IT'DBQLYLVV]]F].(]X=%#*/
M+B<-M@?Q)!V']<=!^;?Y (;U#W:MJ3VKV[0/@_<>7,=8&*#^$ A'U'$[7I\V
M!'?+0C8]A QF4E\'Y"_,.G#N2>TG'SL!MW6'K_=BKI,&.#=P^P?FTJ\QWCUX
M1N1[CZL04^_5KS[*<??CZU</N47YM/BC&,F]UE_./\8XM=.8;P]JB=%P22BW
M*::[=RCSG;K$*HDLD<HMW*:J9P,11-4ATR'(<!*8NY3 ("(:J\RC!$;VN#JC
M;S@BZCX_OXN,IE(:2,$@C3*MCR((5CW[IOYN[&+6-.&&K4[,>16$[486S467
MA8^;I)I^)9S"$;VLFN23ATQ?H. 2=Q1U$D.<HBJXC58Y990RJBI4\Q#1I'4R
MJT:O$R!X]2A@MV(*[CFOJ()-\:Z>NDDIH621TE5RDNABI)T@JVUMFW/F(/9C
M)/Z!F%__ !48[_\ N= ?_L-3/!:?^(B_D+^[$'PNJ_")OYQ_WXQTSQPT5FX2
MV+ZW1*=7JDV>V"3<VZ:KT%&Q:C2ML63<[@ZZK-JEVRJBBI&L:BKSIFD'2!CE
M*B590D.JHTD>!(HUC!9C(R*!90!N;#T*#UG$VDKI(TJ))9'D(11&KN6N[$VL
M"?-=K;V!QF7!PL76X>,@(1FE'Q$.Q;1T<R0#9-NT:)%113 1$3&,!"@)U#B9
M14XF44,90YC#8JJHJHHLJ@ #L Q6.[2,SN;LQ)8GK)QA'FOP?^&^(CBRQCQ+
MYI@:%E. Q?A2XXKB,/9(QA7;W7#62S7JIW*-R6V?V5R^91\W6V]=D8-DT)6'
M#A5"P.G*<TR*DHS>LO3I),LKA6"H4T,H87+!@UR=B-Q:QY\^V1%5R0T[P1%X
MR\JR&1'*-I",I0A;$AK@DZN8&QYB*<T>#0CLO3W%U-$R\K5TN*J_\$5X&/;T
M!"01Q^3@RG:K,M(9J<+=&EGTK^2L R,Z%&""IE> JFSL -@07Y>FUF8Z[=*T
M#6TWT]"1M[87U6\VGSX<BK3&*<='JZ!:E;E[:_"0P)/DFVB]^O5VC#&BO!83
ML?DJ*77XDSO^'BF\6F3>-W'.%%L.0XVJ SUDAA=P(6PY;6NKA.W8VJD_D.T3
M\/3E<>Q$K( [;1%@MDHR9)F/R*4AA]=^MB5IE30+B1@UKOJW52Q(73OR)..S
M7@H?K'UYJ>.F>7I38Q(5O:,*-+LJ*I8.;;D 7MC%.\^"DXBL60F"XS .5:TZ
MG \(KA[B*D4<?XEC\?</_#13Z1@W--*FK;2.'N[YOMY'+.RVFT03W(M8I=\B
M5+$[EDO>A7Z@WC1?LVFI9%""-Q?PA)#I4+'$JHXU+&SGF2"RJUCR4"U\/)7P
MN93*AMX')"-;EY9F>6)PK2I$MM*J0C,NUKL3?&5^*O!1H8[E<:6N7SX_M]WK
ME>XZAR78%,;,8-KDG(W'7.UBP7*ZQD*SM[AK1(BG/*V5"&IR*MC"2:.$R+V!
M@LV46>.K2:2K=(2P$^HZ;:GGM=@-7DA;;+O?MPS)7ZPZB$*I-+H <G0E*&"J
M25\HL&W;:W8<0?,^!,FYAA@RM.^+1S*TW"N..$"DQ<19\02LZ]B)3A.GXR;5
MF,6'3S;&5G&D9F4\<B.0XMU4;M/"];1R[&Y>Y[5>)><&B)T#IKA%B !0FQB(
M-T^N ('L-0LQOUX<&9@&5O![-(]0Q*R  ].--G^M%G,8]J=2CGY-]\2)D[P0
M[_(S#+<,MQ"09X"S<;SGCOQ%7[3@E"TQ-!R9:(JTPN2Z=DA%#*=?5R_CNW1E
MH5;Q+",5Q;8:DHR0=(V&77.<0Z>D+:QT@L9NG0%+V<@A@UG&I2#M;21VD[XX
MCS (8ST)N*84LA66Q9%*E&0E#T;J5N;ZPW8,9GX_P.TX;N%ROXD;*4 ',-.S
M,M+/\5XT'$E+D)>U7":L[UW$8_&V7MS"[C*D;.U'UPL4A)NFZTL_D5'+U4B<
MVEC$0">2;:CLNA=S?8%FMZ22>?/#!E,]2)/+%Q8:W,K@*A&[!4ORZE  V L,
M>$6=^/)G^%9'\+6U^F5/]KP?F8OB+C\T9_=YOSLGQVQL?X3^++*=4H>;J9;\
MCTMU#8PX=\EOL.P&:H:-LTK#6FTK5_%4Q2<03TM,P5NJ$I,4>^6YV:M5J7=Q
M#I&'=NGM/D$V[IPW\PXQX.RBLS+(*^BRNO2?->)LJCSNHR*>6DAGHZ-:G.(*
M_.Z>&"HHJV&#,,NHD%550I.K3HD==$616]/X/XPS>DR[/Z&LS2A>#*N&LTDR
M6FSV".KF@JJLTV43T.2U$T]/644L]!F-8_@M+,\+K"[R44H1V767KU7'E>/I
M"<.@"/"1@D  !$>'/&   ]PC]#.#V ?4.OR\XL_QPXEZO_S+G._9_P"M*G'Z
M?\*?XJ<-_P"[V3_]-I\=ZD A5*P @!1"O0H"4.X!"-; (!MTV >@;:GR^ZR?
MG'^,<4Z^U7N'JPX=-X7%QJ/B1B@L [#MYPVW#V]?YAUTOMA]-[;?#A#R_MY>
M?T<\1!<2K=FMR@(=#;=X#^NY>OH_%OZM/']W+S6OMZ/?W&.![8BP O?K';8#
MJZ^76+XTR<7G"=5LM3:]XC73VFY'1; @G9HL ,C)D;$Y6R$_'G$J<BFB0 23
M7(HV>I) 1/QHZ*1$ UW#O&==D0%'+&E;EA;4::0D/'J/E&GD%S&Q-SI8/&S;
ME%)UBCS;AZFS-C,K&"ITVZ11=7(MI,BW&H[:=6S@?=$;8UOT*]VO#F1"8^RY
M%$1>&V\2FVAC.8J:8&/V O&IE2%$Q1\H'#=5,BR)AY%4RE,4Q_;\JJ:#B&A\
M.RF8D+Y,L$@"3TLM@>CD4$V/,JREE8"ZMU+Y!GE!4Y3,8ZR,V8'2XW25#UK<
M#;>S"P(.V^^-KU')3Y-O'R<(6+;*&!)=)9@5)KN?8H[*)(\A!Y]^4W,03AS=
M^X=:S,8ZK2\4W2L""I#W;:W:=R+]8.]AUWQ3T;1!P\>D%7# J+';<7O[]B.1
M)M;&5C5!M/0+Z%D"*"QE(YY&ORHK'1.+9^U4:N 2<)"51!0R*IP(J0Q5$S;&
M()3  AA:FE5 Z7-F!4W.Y!N-CL3MRL;CU;6FJF;HGW\A@P.S#4#M<;[7 )OS
MZ[XUY4WP<3R/?XY8Y+SLCE3&^*'6"6M0QC*XYDT:LZK^ :?D2D55>SP,[E6W
MT92^R<+<JVG/VVC47'T!(K4&,?JT,TO)OI-/,1Y&P,9FJ!-# 8.CB,+!-%-'
M-&FM6F>+I&61-3QQQ(>B4F+421KY>(T99.@I#3SU(JC+4+..D#UDL,LG1NM-
M'*(5>.31'-+,ZB5@)M( .M3)W@TX6)E)#'\CE(JR<,ZQS4Y.8JN/4:>ZN^.:
MQ0[14+1&WI,EOF!G<EY>K]W='RAE4CEBO89R$@9I"KL31P-3UD>0:UTM,U@\
M43O'$$,D2QR(\<OUQM4E0DC&:>]V**PC!7&LCSX]"DJP@,\<TJI)-K$<C3*4
M:/ZV-,,#(!# 00J,4+&^K%&#\'G"&09&L-V@+?)2\=3$,F6&PXN8/IV_RM8X
MC&W$!(NCNC6CLHR)M>\A1)J >MK"V+!)UQ1!R#>O>Y<G90\.!K!Y5D9DBZ9V
MI07F:.N%8YU=(%59!JA9") %T6)$>EJRHXB9&;3$\:H9C J5)$<*R4)HP-HR
M6:/R9D8&/RBX(NX=7QDK@+G<@8SPSAJLS-34J%##,T=-V&R4)"P(04#D> L\
M;$!4Z4-BC&C><JB4^BSJ4JG-@A6WT3%S18MZV:#"*.U>0,\%)2HT0CB\*5Y)
M(0^A)TD5!'$94!>(N%B<.1&RJQ5A=#"I>)%BJ*JJ>.4R3"E*1Q3%"TD#QNW2
MS:&\B0(3(FC4X9D++<.+BS>#RKLINK&W*)92$A:LS3%HFIK&K*?L#]++F1ZS
M?V\W"2Y+/%.Z[EC'S6JM*O4,HNPG3Q\9)3*B571%\F@VC5/#R\TE4%I:IW9X
M0SD5$Z2W5M:E:B+0(XYO+LI8B/RA:12\2LQL\36$=,L:K4%$'@\+PE7!C97I
MY3(99(!HNRH#(;$FNZX!ZJ^>(.9Z_*.5FDZYGF+Y&D,B2D4NK$<4[-NK"RKB
M;>J0\C&RW$C&V:-E$6ZZC.<Q=!/DV_C,@W<0%<<HC$@,DIL'8A^C&I;BK46)
M9K,K52N'L;-"I&[ K:IFTCQDQ("= 729#9P#1$@J$ 8,M(T;+?VL[#>Q#MZ"
MX!JU3:A+&1MU&4GFN.+O6(.:+B5Q-PT+*6TU$2D;3%U_(&2KZ6*D9*N4ES5I
M=M6IBNI.F=GF'T.K 22[MQ(.G)8TADM-$6$$RJX@U(&<17D42S3:"5C*%49;
MB1BFAKWX3.I7J8U,,H5JF!G1I@'94,H",8H(2ZAI!(I=6(,:ABRV"KG"9P%1
M@+3D>RR)%PXI#A=63L<3C8K"\I+8VRID'(<>G5K@:[NG5=AWT;96E:>1KUE8
M7)7-.I,\G*"G E@G$7*LF^RX;S >U!T1D.3'(TJA6U^3JN%!L2"JMN%TX>XE
MSGH:;4(=9(F4!I3T0$B+$2Z"/ZY8W(L5N&=3L^I<E4_!%5%_1Y"L364J6[>G
MI-NJT(I5L&1E:K-;G);#N/\ $55RC$5%?(4_XME.")06]OL=P:S;1[:[&\14
MCR5!*+:%/=CAX=&4DD128I(U*TG1QQN]/%!'.L?2L!.G1"1I RF1R+=&%&,J
MW%+"59(H)"O31RL'K#)))&M5-52T[R= A-,XF,21%"(HQ9C+J-MEU=<WR/JS
M]3)KRM.;*I9+JZ;$JJ+U*)CZFZMTXYH40JM( 1Q(34/2#U^.L<N5NP;2E@;2
M;YDQ:LED$2ZVBCF(O/H+=)*1T8;2(VD8PH;D%G$/1J[  %PS  $ 8RL>'7]C
MB18Q'$IZ4@LTPA19WLA(5'FZ1HUNQ6,HK,6!.-:/%)<(:4\<C#N$^T'G  $V
MQP$-]A#8=P'<>8/D[M;&AC9%#6/( ;V!)/4/,.L7W/FMB NH6M8V()[0.9OZ
M?5[VT7P:_$X&;L6JTNS/RN,C8M(SA)8ZQ]W4[6A)V%=L6PF$RRW8HC%2RH\Q
MC/6B;M<W:2!0'RGC3(AE==X13K:BKR\B6%EAJ-FF@OR"W/21#[QBH]H;>H<.
MYF:VD$4IU5%.%1NV2,;1R><V#*Y/W2WY$7V;D'</9TUAL:/$+3GQQ)?9:W^T
M.M12?:T'YM?5C(5GVU4?G7]>$K4C$;#AJZ:AYEN*8B )$645'_H^R,00'U&.
M<A?4(@/FU$KB!3N#S8J%[]0/P $^C$W+U8U49&VD.S<_:Z2N_>2.>P-CS QA
M%X6__(TLG_EQ0_\ M<VH>5_;:_D2?%QXK_"H_P"R',O_ 'SD?_.8\H>M/C\O
M,>OWP8_^0W@O[&O_ /[5;SK+9G]O3=T/]!'C]8/X-_\ V+<%?F\]_P#F?.\/
M#BGXQJWPPS^$:"GC3(N9LL\1-FM-8Q-C'&SC'T3+SZ]&K)[?<'KJQ94O..J1
M%-HB#*F9NU=V4)>;DGC*-A8QZJHX.UJI9A$472SM(Q5572"; L3=BJ[#JO<D
MV&/>(*<SB5M:11PJK2.X<@:FTJ-,:NQN>9"V !)(Q'=9\(]@I;B-N_#;E63@
M>'NYU^J<-LW4(_-&0*34;/D*R\1<%;9EKCF$JCF4$5;I1EZRU@[$QA)JR(.)
MJ<8-&*X]JS/(<BICZ1HWM&0(R-;*"QD!.D"_MEM8V)%SSY7[:CEZ)9HP9E+3
M!C&K,J+"RKK+6]J]R5N%-A>W.T@98XX\"X^)8H>JY#Q3E')-.MU*JUQQ7!YS
MPU5[=4D[7E>NX@?2=E+>+K ,80U=M-B1C5862<MIN9GTT:E"LG=BD&;(ZO41
MJ"%9'=2 R"1%(NX0DZB +$VL=R; ;G',=+*Y4LDB(RLRN8I&5M*&2RZ5)-U'
M,; ;D@ G#]9\6_#',WF5Q56.('"UKRY$M+JY7Q37LHTJ5R%VV.WDO%W1@:IL
M9EQ.(OJS+0,U%SS51@#B'>Q$JD_11-&O00[$T1)59$+@$Z PU>3<':]]B"#M
MM8XX-/.%#M%(L9*#I"C!/+L5.JUK,""#>QN+<QB%\&>$5X:<J\.E X@;YD[%
MV"26W#]1S79:1D;*]+CYK'5,NTNO7:[*6=>0>PQF\1,6)NK PDTYCV#.;F0]
MS(X%GW]SZ;CJ8GC5V9([H'*LXNH)L"2;;$[ V%SL,.34<T<SQ*CRZ9#&'1&(
M=E )"@7W -R+FPW.)6G.-;@\K./J3EBQ\4_#S 8PR2XD&N/\A3.8L?QE,NCF
M(5,WF4*Q8WD^C$S2L(X(=O-IL'2YH9P0Z$F#54HD#LSPA58RQA6OI8L #;G8
MWL;8X%-4%VC$$I=+:T$;%EORU "XOU7YX7&'%APNRMXI.,XOB+P?)9#R56X:
MXX\I##*=(>6J\52QQ(S]<L53@VTVI(V"'L,"!YR!D(MNZ;34.DM*1BCIBBJN
M11-$651(A9@&5=0NP(N"!>Y!&X[1OCDT\X5G,,@1&*NQ1M*LILP8VL"#L;\C
ML=\9*XQ'=?(@<G)RWEN'-L =I_@^H1N?H4-]M^SW$3C]3VY@  *6HS;W:#_9
MA_3SXOLH^U7V_P NWI\B/?Y/1A!M(&^B@)N0O*-"CP ^P<PF"PRPB3???E !
M 0#;;<1ZZEY7]J2;G[8.W5[FN_?B'G'NT/9T3?'V^7%SJPQ48-&#%8GP0^7Y
MQTR_MCZ/4,/)[4>GUG';7..L6Z_P3?N?QCKI/;#T^HX0\O2OK&(.R#^IUO8I
M^/3V.>M>]_6<8"7#XS4_?D_M;J;_ ,VHLWM7ORO\.K;'L?L'?X_48[<KS7_E
MVQ+].'^Y4Q]"1=OG ?E =5_.X[;_    _#CZ/SKW5[\R3;^4/D /OXJY$Q92
M\K5R1K5QA6$M'231RQ=HO6C=XBNU<$,FNV<MW*2J#MJL0>59LX3405+Y)R&#
MH+M+634KG3I:.0$20R -%(K#VKH;J002=QU=1QDZRCAJXFBF174I;<7VZQV=
MGOGNQI2R#PK\:? <[>7K@(R:YF,:-W"LC(\,.257=LQ,[1,<5G+:F)/WJ<KC
MQRL4# FV@9F'8JJF /=&/:)E:FG> TF8!GRV1:2JYF@J7M!(>L4\K'5$2?:Q
MNQ2]@'4"QPE7EN:Y*QERN9GIAN:235)"1JW5%N6BOM[1E V( !PZ,:>'HPE(
M8_R2RSO1+!P]\1V-:Q-2J^++*#MY 76:AH]5PG%TRS"R:JIO918B16T+8&4<
MZ.FY3&(?6!(@NAJ-)BF:GJT:FDB60R1R@JPLK,H ;GTA%DV(:XTZA:_,/%5.
M\,WA434U7$C'H6N4E=1[6-K @M;97TFU]-QN-F/@Y>)A[Q=<'F&LWSJK-6WS
M\*\B;X1DDF@V2NM9E'L%/]DV2Y2-DW3EB60;H$*4J;=XCR!R[::1M:@]O9R[
MO1\//NL<KK&KZ""H<CI&4K)IL!K1BK6 V%R+V/4>0O;&=!6W, >;?J&W7IMO
MZQ]'LV'T]5!)Y#;S[=?+K^G9RQ,>0(;<SV>;X/I\%9,YT/)-N9/V;\N_^COY
M@]'7T@(#WI<@$$6WMORL3Z.0ZO[;-%4EY !N8MM<]A\^YL?7M;E940#<![PW
M#J/=ZOQ]/9Z-*"#L!MOYO>^7E:^!$(/(W.W=UVZMQ;MPT["H)HQ\3<=C-7!1
M]ADS 'I\PB/=OT]6NUYCO&+;+D'A4#<B)8]QVAA].KKPR^&L-E[KW_&D-MZ_
M[EE Z_:'T:LZ,65[$GRAS]-_AQF_X0HM]1O9X/FFD]9/2T(/HV\V,T$N[Y"_
M,.G,?.'4>\>IL5=&$QP;N'V#\VE7F.\>O"-R/<?5B"GWZM>?93C[\?6KA]RB
M_-I\48QDWNLOYQ_C'%KIS#>'=3D#'D%E^H$0;B [=PG6,!2@/7J'*10WGZE
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M:9BKA9RA%."VA617XC9S)M0G<<6QQ'L6=%R;B"XXOK-IFXFR595:?4EHXJ,
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M,-4@]LU-()67SE+!R.5K*?/UVR'D$4TDP$!*8IR <IR"!BG*(<Q3)B B!RF
M0,4P"(#TV$=5@-P;[$$6!%K6)!!'F[+;>_B'22-(Q[.1!^YO<[]8-]M_/AJ*
MN ()BB/0 \GN[M^[KZ.H^;N'U[. \AUVWW[#OVWW)W[;@G%TJ$@$<KF]_P"P
M#T_)AI6!V ,G(=.J*O>/40Y3=-PZ><?7Z>G=VHN1;J]/]OIOSZ[VQ;9=$3/&
M;'9TL!SO<<_?/5U[G"%PTB KW?TA*PH_;;2G_'NV_GU:4GM7/:PL=MQI'R]N
M,=_"&%CP=_L^:'WY:/WL9I)=WR%^8==X^<.H]X]38JZ,)C@W</L'YM*O,=X]
M>$;D>X^K$%/OU:\^RG'WX^M7#[E%^;3XHQC)O=9?SC_&.+73F&\2;4&W91IU
MQ#8SI<Q@'TII?4RA_P"F"HA[=4N8/JF"CE&H!_*;RC\!4=XQ?Y9'I@+GG(Y(
M/^JOD@>AM?9S\V'4(@4!,80*4H")C"(    ;B(B/0  .HB/0 U!Q8D@ DFP&
MY)Y =IQJ7OWA:L,T[B&C,8,& V+%C)5S!W?+$8X.Y;QMC47110=UY@W(H$]5
MH0Y%T)V10,9>0%<[RO)O&T4B%AM(\KF>G,I.F4V9(B+$K_K$GR6;F!U<FL20
MORUGG\*;@_*>/J;AJ"$YAPS"TE%G/%--(98Z;,6D1(Y:""-6\.RNB*R1UU1&
M2\Y<S9>LT5*@S#:S$RT7/1<=-PDBREX:79-I**E8URB]CY&/>HD<-'K)VW.H
M@Y:N4%"+(+HG.FJF<IR&$H@.JP@@D$$$$@@BQ!&Q!!W!!V(/+'T]2U5-74U/
M64=1#54E5#'44U33R)-!403()(IH98RR212(RNCHQ5E(8$@X4-)A_!HP8-&#
M!HP8-&#!HP8-&#!HP8BO,AE2TAR**A$E/="/V.<0 H *P[@(B4W>'0.FG(K:
MC<$['ESYC#L'NJ\ONN?+VIQ\\"=^/)G^%9'\+6U^EU/]KP?F8OB+C\UY_=YO
MSLGQVQZ88J$SK7(*+>.9_P $I6U,90>/Y+B!6M6"*S$2W#VE<ZVVL-%]\KY6
M$ ;=8YY$I(MHUJ1G#I:XG0C$S=@J>40^5YJCA^IJ98UI_9EJAFM1F47#8H^(
MJN>'B5J&J:FS#P6,5%J*EIF)F=ZW0BT(:8C4!"WU+#39_34\4C5'L.4K95!E
MTO$;5?#M'#/PV*ZE6JR_PJ0T]ZRJJ% A1:,LYKBL0.DF9?/OQ*VTM]X@LT74
MEVC<D%M62[C/A?H:L/Z7$7#W4FWCL;#%U.47=25=CI051=,HA^Y7>,FZB:+E
M4ZQ3F'Z/X5HSEW#>14!H)<K-'E5%3>+9ZN.OGHNA@1/!IJV%4BJ98K:))HE6
M.1@60!2!CYSXIK!F'$F>UPKXLT%9FM=4C,8*22AAK>FJ'?PF*CF9I::.;5K2
M&1F>-2%8D@G'T%N'3_)(P3T$?_@YXPZ!ON/^#.#Z!MUW'U==?FWQ7_CAQ+_O
M+G/_ %2IQ^D/"G^*G#?^[V3_ /3:;'>H_P"*E8W 2C[WH7<H]X?WM;=!WZ[A
MW#Z]3Y?=9.OZX^_;Y1Q3K[5>X>K#ATWA<7&H^)&#1@PAS"@$:JCW]#"&_0.N
M_P"+KIR,'?S[>>_T..7Y$?W'?LY]5^75WC&%V7I!-%!RHH/*@B15941[BI)%
M,HH8?/L4A#"/J#H("&NRI<K&!=G8(!:]R386[;D@>>^ , NH^U4$FYZ@"3OL
M!;>U]N5]KX\VF(LL6,]VGUJY$/YV5G)B?L"C"-;+.7(-UW[A^Y6,FF!C@FF"
M@=3;")S$2+N<Y -])U,5'09?3+6SQ4T$$5-3=+*X1=8C$2KJ.VIBNRVVM?:V
M/%6CK*VMG-+#)/),\TW1Q+J.EF+L0+W(!.VY)N!:YMC/ZD7 V86:<>H9U'JL
MEB'66 G(Z9/6BQ3E(*2Y/)6172Y%TE2@(E[1(>4QA$KD70TD0D4QRI(A"BX*
M/&P%V#+<,'4^2RDC<$7M<Y>M@F>5E<-&R/Y1((975K%2K6*LI%B#;K%P=L3_
M ",HO1JK9;7)NGMD=5JN2\TJ5=4K8SE"$C'#_P 2;[%73:BN1L"0+&(N8AC
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M8XY75%D619'&H@*6BTK87-B5=F OY+=6Z]OT*4/.!=OEZ#KSAA8GSDGX3C7
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M#&M3.6;9[(LF]JU:?N(ZDLECM5C-%5$5;,LB<2+.GJI#%4-%"<!!FR P(KD
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M!B\H@ 9/,^(LWS8,M75-T)-S3P*L$'/[J.,#78VL9"Y%N=S?%Y1Y304+ T\
M$ES]=E+2R^;2SWZ,>:,1[7!-CC.)N78I0\X%W]'7N[M9UN9WO;^^WPXMQ;?S
M^CS=?F'FQ#LY\<27V6M_M#K34GVM!^;7U8R%9]M5'YU_7BR:("Z=-VQ>]=9-
M+?T <X%$?^J B(^H-.R.(T=S]RI:W;87MZ>6&8T,DB1C[MU7NU$"_7RO<XFX
MI2D*4A0V*0H%* =P%*&P!\@!MK-$W))YG<XU@    L   .P#8#&L#P@?@_(;
MB6AG62<;-6$)G2$8!L.Z+*.R1',D>5&#G%C<B+>?;HD*A7[ N8I0*5*&F5?<
MSQ)["6-#7-3-H>[0,=QS,9/W2^;[Y1SYC>X;YL]GCV!Z3V1:27B+AV*"CXVH
MX/\ 4AI^(J>%+)15KG2D=?&BB/+Z^0@6"T=8W@W03T/F)B\9Y FL@(8KC:A/
M.<C.)X]8)3O<]=&=3G45SMW,>Y9+E349J,SI*F?*.NQ08H(KN7:J+9%54FD,
MD8CZ4NHC"Z]=_)TGD;CG>XL!<DD  D@8_-VFX<SVLSV/ABGRFNDX@DKFRU<H
M\'=*X5R.R24\D$@5H6A*N9VET) B/+,R1H[CU4<"' ?6.%.L$LME)'V/-]CC
MRIV*QID!=G5V2X$54JE444(!TVA#@0)>7 J;F<<I (@C'HM&J>9KJYJIM*W6
M!3Y*\BQ^_>W6>I=PHV%R2Q_3GV$/81RWV+\M&8YB(,PXSS& +F&8*-<.6POI
M9LKRMF *Q*P'A=799*V502$ITBB78?J!CWW!HP8-&#!HP8-&#!HP8-&#"ABT
MZAG.2BG  *G?FQ$A#O,F..,>J"(]1Z]J=0O<'0 Z><:3-_=J?_9A?]8J/DMC
M1Y1]K/YIV^)&?EPEVD!^B3S;ARC1V0 'GW">DQ$>[N$!#S^;N[MY65_:LGY_
M_P M<1,Y'UZ$]71L/^(>C%35CBGP:,&*Q/@A\OSCIE_;'T>H8>3VH]/K..VN
M<=8MU_@F_<_C'72>V'I]1PAY>E?6,0=D']3K>Q3\>GL<]:][^LXU^W@>5\L/
MF[5/?[:OX]1)S9)#W_"<>S^P3O[(-%_[LS,^]"3\F)#HBP'C6P[AT*( (_NN
M_P!O=W;].G?J!R (Y7'H !VO?MY7-KG'U!Q!&/"I3RW)]\WL>ZUN>$3.LZYA
M,;V-PS4,DZ78A'(*%$2F3-*N&\8=0@AN)3%1=*G*(;& VQ@$! !U89:@DG46
M&Q!M<$7%V O<>:W5U8R@A$M9216N#(7*GD>C&L#M]L!Z+WQHNR'@;)N3,]8Q
MF*]:).DT.J5ME)2TW'2$L+IS/0V2ZA9!KT9$Q=N@FY'=IK45+UN5E;#!6F")
M69.69*1JCUPU*%A5)-+41L)&2-5YJ6]LLJ-HTAUL9%4HQ9&&DL+&XQWF&5UU
M9FE%-%/)2TD$"O),CR:NFBKJ:?H42.HB6\\,<L+R313Q"%Y%*%R!B**5B/PA
MV.\,T>CP8722/"8WH31H>.-PZ/K;7;DEA1RS)3%W=I*WKLEC6NY481;"U3;L
MTO?G<>Y\9A;)+1IG[UK 7PV*.-+R$K&@%N@9E<0D:/*&DQB55UDWDL;ZCN10
M4T?%-#E]+2(U2YAHZ105\4M415"Y:5\&+3*(GHXJU46>1C)5,&+1SNNHK=Y9
M=\>U9EI6M1[:_C*6.\Y!;X_EJI$\/A6D@T8T"YSE5C&<?;$91G!42"M+&JM9
M>SW.SGNESK;MTXCX*J6%-U#)=23UI) ,A9GD$958 +!&*"S@@(K! 69BSJ38
M(;C'=94\3+))3+X2SS5%6M))3QY2595I:F6GC5:A76.FBG2!99JB<U-1"S%8
MH)M482&<'QNXSC;VA"FM+Y*X6[*EB:QT#+832&D2M@X@I.6BI:I.[E!2Z\E$
M3]!FWD\^@K:O(*-&R;6.CW=0DD#-#O(M:@D":VZ1I6 4P QDU)(92X:X:-M1
M5R1;8:#88;;*N(((ZHQI-)X1/72JD<N6CP9Y,V=HG@:='9XY:.4S/%.6*J%5
M# X*EG24[X0BMF1L[&PWM.WO;+BBX^-";!UBAJC*MN'VM-;)'4JORC^-19Q+
M+.$5-)W2$!^SCY"-+7)6KR)W$W=[&[[,>8LDJ$R'IE02#['=5U4H5U16(  G
M#:U!%P4:-KM*V(<66\3H*A46HU524IG &63+%KRM!,L,<KHNA,Q$BU$8==2=
M"\$AZ2IEQZR&LT::BHF4YB",K%1TD/9%$B8B^9HN3 F03G,4@"IY)1.<0+L!
MCF$!$:0IT;R(W)7*WY@Z687[MNOOON,:*DB*II:Q:-BA(Y'22"1U[V/._?;"
M+.NS P62';82"&_<(!_HB'3S]-]P[]NX0VXO<VVZCMROR)'HWM\H(-UE\0-0
MC;>2;]F]MCV#>W/J&'7PQ& ZMW'?_P *PFW_ -5EAV#U=?YM6-)[5Q:UGM\
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M^;EBI8CNG\:J5!505"CS@4#CN< '<=A =^[?;T^O13*D<GE!=Q;=0+$\N?\
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M!MR()-R1?<;#;EO](<;YFV65YC%(:A? ):Z63INCT)'-%3JH3HG+:IIH];7
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MPM;7Z84_VO!^9B^(N/S6G]WF_.R?';"5I[#6#1@Q](;AR 1X2L#@'>/#KB\
M]OT-(/;OZ:_+OBS_ !OXF_WDSG_JE3C]/^%/\5.&_P#=[)_^FTV.]4 0JU:
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M,U-4:0!TE13+),5%O)=U9-=Q8%F!>P/E7L13CA'):B368IHRQMIAFTH";@%
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MFY4D&[= #K+JG,)2D32*8YAV  W[W3"D2-)*Z1(BEG=B%554$L69K *+;L2
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M'S7Q+IQ<@CKMU\CV&W]AY]F(Y@H$C( 9/4S@V4 HE-W'14 1$JJ9AZ 8@CN
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M_M>#\S%\1<?FO/[O-^=D^.V$K3V&L&C!CZ0_#B50W"7@8J*9UEC<.V+BI(I
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MW*W;M?<[;<NK#?7QC7W:C5Q*UZ&E7$<?M6#B3BF$@X8*@('!1BLZ;K*-% ,
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M7;;NV*(CW#Z1D] Q',KYN6_9VVW[NS'JV6^S_D].BBOX;KM8%B::NIJF._\
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MF?L='\%6TJ\D[T]8P=;]P]1PBH?!@_LA7\,2UW)R?T?%.!^0[_D.'+_X4#[
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M:;A]HWH]28)/;+].IL)4#^I'?M>_[:>G)O;I].O',?)OR?\ Z5Q?R/Z0P_\
M-??4-<Q^V?T^IL=2>U3T>M<64/\ J]U^^G_V%]=2^U7\D^M,<Q^W]_UOC)+A
BQ_YP(#]]<?.&J?-_M:3T>H8LLO\ =5]/RXV>ZQ^+['__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gwpjrhodncoa000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000011.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #9 ET# 1$  A$! Q$!_\0
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MC+R,T\J1E%RXMPOS;1;N/N:U4K6[2PW&I0&>S!$ D225G;A#.]@M&4,2RMA
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M@L0,E^3ER2Q.O<&T4J[UY464RUIK-A99)7DDEGMQ&*>6=F),CNG;O@+@<0
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M 6;]=^FFGTF'+SY>-[_ +-^N_333Z3#EY\O&]_@%F_7?III])AR\^7C>_P
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M:(?\*5X*?>3Y:?DEI[_];.I'_<=\1_XPV3_Q[_\ _7:U?[N=J_ZMN'_AUO\
M^5I_PI7@I]Y/EI^26GO_ -;.G]QWQ'_C#9/_ ![_ /\ UVG[N=J_ZMN'_AUO
M_P"5I_PI7@I]Y/EI^26GO_ULZ?W'?$?^,-D_\>__ /UVG[N=J_ZMN'_AUO\
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M>+]'Y+([<4!5F;KI^!MI.NC5A;Q; Z)U:]X\58AW3&D^VF<?\7N=T9&/5?\
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M&B3G(#%';G8RRC4[DB-'-O50_)G-,S</1E;+N;0J3 :'Z^11Y@=NVDY VV$
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MQ]15"&1>DC!G5?+S+%BQ0(A)PL: 8UWNXOW._P [_P!5]:+6ZUEK?_HM;_R
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M?$E7=_[.?]F>J8(]?O\ _P#?[#IJUH#BD3M>K:KL8'>H,=TH'38[9"L@(H-
MU.O/R]]HCD8E@!OV@K9Y$:!Q\M) P'AU&"78P7"("0[$PT<EAZG(^7P]5 ^
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M%VR[3:QR-&6T)]P"GT9MOJ+8NJISV8P!3\"=9Y,XH\A(#"I+VNR+S:,9RM$
MQ7"C^.['?E.(HTU+E*5]K"4LY5G/Q83G/Q=9+;)N8!/NC, ._!H7/?[(RS?E
MWU$*O_I%>Q>W,L$?CNA"[G"M>H;SMT)^&38O[;6KJH^+-*%';)[ZA0F%+@9[
MPHZ,(AR<97ADP"D.3!F,9[\X[G(\IMMY'?W?%E2,8S]G&<XSW]:R2-HG99(V
MC*9RKJRMGMCD",X]<?K]>_7=NW/;=XIP[AM-^EN="PO."[M]J&Y5F4_&.>N\
MD3CY\6.#V/?7#4C&?CQ\6?\ 5_;^W\/5L$>A'SP?E^7KK.UX>%7[W]O[?^?3
M 'J1^'<_=C./V]=-9SK&D1=AW--<(')E<%QJCL6Y%2P\,U8"# S7&O;5L,BP
M/"R#->CSR!"%5WQT)J0;&1TRI;+K\I#+:^\!D#'SP3^6/Z=-6=SV?N[R%D17
M:P8I)N1+,P84%N<<D5B>R%*V&[A(-EL,8Y CP*[ @0]8;.LETBR2\B;KRO:X
MN!.YM!XT,:X68]<G'X9S^O[1@^ASIJ&=H<:]E:@J[%ENL@##?23"AC568GSG
M+552AV1L,;%'66 \,CPH!*(>U/L6MF1;)*64!G*K,BEX<-F8)DD'E'S/?'R!
M_+)_HS^>FH!1ESO_ +M6<?;[\_ZL=5&,=E'<$ $Y)(QW].V._P 1G\M-<I.,
M]WQYSWY_?^UU0X'8?#U./C^P_ITU_<X[_MYQ_%GNZIW'JOS]0?[1IK^]W^K^
MWQ]"#ZXP#Z?MG_CZ_;IJQ^IN,]JW&&K1&LF(+$ZV6>_5(4/G1WFHJ3%,;TVW
M"1-*X=]/$8L)+<P49'>6UGT3\%:EIDJG1VD,'Y?#/?MGU/\ 4?RTU@9O2FP1
M=T>HPH2_<RB M3LD>73X9@B.F@+Q5 MUK)5"IHP:0@QR%=L R8MDR/%S83CS
MD6=%C26'6DWH:T]AN$$3S/\ S8U+G[S@$ ?:2!]N,:T>_>)O#OA:I[_XDWS:
MMCIY(6QNEZO221ACR1=>1#-(<C$<0=R2 %)(UEJ>*7(14?U.-<$L-]W?X%%J
M\F1W?9_P51C$GO\ _F^5XOM=W?UL1L6Z<2WN<OIG&8\_;Y2^2?AVUR\_^D9[
M%1-T#X^VWGRX\A3WAH<YQ_?"[<:_'/\ +ZG#'FY8[ZBNS46XTB4B%;ZR;KLA
M??AE)8=)AHD]V/C5&?<;PQ)1CNSWKCNN(Q_[7V>L">K/6)6>"6%B?*)$9<CY
M@D8;/V$C[?372_#WBWPQXMK&YX9W_:=]KKCJ/MEZO;,)/HL\<3M+7?\ ]R9(
MV^S6.9:QW8SW?']O'?G_ #?%_M_]_5LH,=AW^_\ I^'_ !U(=>O*,?PX_M]O
M_P N[JWZ>H^/?X'[OV&=->M:<IQGX_M9[L_O?%T\O;&?M]/3[--6FIW%@I>]
M?C+6!N<:.;=UN8W&=&G0<J!5@6M*]L"\4 X13;8$TP2+VD4Y0S%L>ID"G9(D
M:A%)3:[(.%Q4@(NO8XP#ZX'?N3V]<CM^&FLJF\!-_#1)&R$54J'4Q)"VC2%J
M=L^5B(S]*)9%&LJ:CC7C"O%,@VI(UA I4TFF@WOT<5U5<E(4[?+)..Q/S_ ?
MTZ:J==JF6H-RM=&-N173-.L9JL%'1[[DB \0!$9(R6]!D.,QW'X;K\9;D5UR
M.PXXPIM;C+2\J;2QGT4??W[?K.FL?0G.>['?G/[^?WO]/^__ -U2H![XP!V]
M?,<??^OT&FO;E&/M?%_KZ\C'Q]/U_AIKP\*OC^+['52,8(/8^A_X>O;YXTUF
M&NJ:]L/85#U\R18#OWJZ5:FM%Y32GXPMVT'( 1LC(90XTIYB$J=B2\TEUI3C
M;2D)<1G.%8H<9['/V^FFI7(<8;Y"TZ)W,DJ$]C3JB4MDT!-R2@66"R%V*]KX
MG$;C*@/CW%Q,R*\?RLB1#NS!QY#0J*1D0G<.B,=OL_JSZ?M]N--0S4Z%>[T^
MN/3JL?L:VL]SRQ0V3*CQ\]V,_MJ6AOTL;OPI/=F0\WC/?CN^SCJ_!4LVCBO!
M+,1Z\$+ ?>0,#\3J->(O&7A3PC"MCQ/XBV?8HW!,0W._7JRS8SGW>"203V#V
M/EACD/;TU*#W%WD&PQF2O6AM3>$Y5X690:2_W8^UB+').R<J_>3AGQ9^UC/6
M:=DW4+R]RE^X<"W_ ,H8G]6N?1?^D+[&)I_=T\?[.LF>/*:/<:\&<X_OF>E'
M6QD_6ZO''?. 3J(#->/UF>X+L88J"(M8[W()B#*'RTX[\I\66);33F49RG.,
M+2GPYSCXLY^/K EADA8I)&\;YQPD5E8?>& /W9^'KKJFT[SM&_4X]QV3=-OW
M>A+_  =S;+E>]6?L#A9ZTDD9(!&5Y9&>X&NMRG.,8S_I_@_M_M_S=>" >P&&
M'KW]?F!D_#6RUX=WQ]_?G^+[7^CKS]F,G\<_EGX?=IK]!GZ$V_Q?6\?Y9%W_
M *$]!=4TU]!G)USR]*6A?C0W_P :T)/B6]&83CQ[#JB.[+DJ<.9QE7B\*49E
MI<<5G#3#,M];<1_<;#_&U3MGO-Z G_H\W?LK'MZYQ@>I*@%AJ]Z_BNY_W0^(
M'_.)\R/Z>_I@GL83/V$!4P\^Q6DX'K5?%,XD$SI\G"#!QS"G$,I?GDR+\:%#
M94ZXVUAR0^VC+CB$85XEIQF7DA02Q"@>I8A0/O)( _$ZYZJL[!45G8]@J@LQ
M/R  )/X#72#-CZ\-EU5\-?*87/(*V4&L(,M .>72;I>1R;B'4-BSG9B2M348
M$)LH_+.)8+)4=@HS%S.C>:#*3@.A.2,!E)RN.0P#G*Y'(>JY&<9U4Q2*O)HW
M"X1N11@O%\\&R1C#X/ ^C8.,X.LSZKKQITTU@]/V9KS8,4E-H]VK%KB!EH;+
MO@34 DV+6XEY;:2.8S[GHLN-QWW&\2<-^-MIQQ/>A.58\JZ/DJRMCL>+ X^_
M![?9\_AKV\4D9 D1DY?5Y C/W'T/J/3YC6709T(G"ADALR*0'$(L>= GP9#4
MN%.A2VD2(LR'*CK<8DQ9+#C;T>0RXMIYI:'&UJ0I*L^@01D'(/<$>A'SUY((
M)!!!!(((P01V((/<$'U&L!D[BU5#IC^Q)>Q*=&HT<%:+.[:GSXYH,FO4E,A5
MO-)F+?PVX-K*8LA1R6WE;(W#2LRU-?%W^>:<2_-> #,6Y#CQ7)8YSC"X.3\-
M>Q#*7$8C<R%E3AQ/+D_U%QCU;/E'Q^&L]GSX(J#-*%)L0:,&Q),\B1GR68<&
M!!ALKD2YLV7(6W'BQ(L=MQ^3)?<;989;6ZZM*$J5CT2 "2< =R3Z ?,Z\ $D
M  DD@  9))[  #N23V 'KKDI4E:4K0I*T+3A2%ISA25)5C&4J2K&<X4E6,XS
MC.,YQG&<9QGNZ:IKRZ::=--97Q[2K%QW5G.'<)45HWARM#J6E=U5QA7DK7&:
M:<[L]V'/)DRO KNPYY"L^7F/>)/_ ,.]/X"?Y9_OA_7N3Z?,#[,]\3'PQ_>]
MO_*%^'_P4^/Q]/O'W8UG.XOW._SO_5?48U)]9:W_ .BUO_(!/_=W'5R'^%B_
M[Q/]8:\2?P<G_8;_ %3K\A[K[DU\]:=--.FFG333IIKZ.?H7W_&%;%_DG;%_
MI1TGUROVO_\ )>K_ )ZJ_P"Y[AJ8^"/XWF_R";_;UM:8^U2L=AJ?:E\XCE6/
M&:T:C<E-NM1RX I.#%&&I=A)Q93;) <_&EM-R8KST:0A#R4O,.N,N84VXI.?
MFO)],]OEKJ^M?2+O=&XPJ$W;[0W# M%8X.(@^63&#,'GO4G&13"9>&AS1F1^
MSE6X:&4$7OV68EY?UW5<GX$_#]7I_P --=5,-&2+>6"!<G/94]F1EF9/E2FE
M2%/SI67\MONK1E[,DH3D9=SCQY?(SGLJ\R7(4Y49)P<GOW_#Y_=_PTUQ$HQW
MXQ_K^W]CJH/KG& .P^&>WK\^_P _OTURD)QG/\&,?^[JF3@L?4]@?Z<?J&=-
M>WNQ^]C_ $8Z!F^!)[??^WWZ:\5X[D_%CNQW_O?%]OJAY>ISCX9^WY?E^W;3
M5G.+LP['LDLY*N=H :^U*AW<)@4&,SXD:580+2(81^&/0_B"D_(=<;C,E,L)
MG(@L/18TR,XXRXC9;76BGFEDLD^ZU(7L3@$@NJD!8@1W'4=@#CX9[@D$<D]L
M'B[>_#>Q[1M/A-8SXO\ &^_4O"?AV>=!)7VV>\LDMS>+","KQ;;2AFE4%7 G
M:&1X9H4EC;9QP5N]KWM:]@[7MX@L5HU4)*"$ZK(I^LKEJH4//#BMIB$;8S>;
M*.L!BTS9U<?CO&V!3S"ES,CLS&)5KC06L/>-TW.XBPU9VH5\Y1*C*BQ*IPL;
M0\0LZ,#F0ET;MY"F01;\'>QOP+X0XWMPV^'Q?XMM$3[GXJ\4QMNF\[A?=5$U
MJO8LBU^C '7->*L,QQA5EDL.K2/8;F"GCF[QOV3D+IS4-&W)*KH>^"2&F@ S
M7=X!EQLX\4=GQ3D-\W72X)SU1@G:@5=,,M>ZRXH@)/ER!-8:A:VM'NL,L;RS
MEDX@LWG0]P1R4AY P)56&6!4YPS Y/09(MIO 4Y*5:>F[/#[M<KU[,!0@*(Y
M(988^!XDQC,3+)@%XXR6 TJ:QW3*N<@;JK=KCEXI5EF,B81HNKU5IIQ2?E,0
M>9%'7L.3?+:E+93+1*<D9Q&4O*5*82]#E2JIN)L,E'<R;5:5A&LLF6FK.YPD
MD<AR^!Y>:Y.5SZ@8/$/'WLI@\*P7_:+[)(H_"/B[8JLNY6MIVM?=O#GBS;Z2
MM:N;1NNS1%*9DF@6;W2:ND#+:*%BLIBM5X!OE1F4.Y6:GSG,2)%=,31F924>
M6B6S'>SB-,2WE2LMIF1LLR4MJ4K*,.X1E6<XSGK4VJSU;$T#>8PR/&2!C(5B
M V/DPPP^_P#'7:?!WB6KXQ\*^'_%-.,PU]^VJGN2P,P=ZSV(5::J[@ .]6?J
M5W8 !FC)  .L0[L?V_M]C^#['5CS8^./Q[_+O^7V>FI)KU._;_ZN?]_5.XQ\
M#ZC362P-A7X6U7&!EXN YBG.$'JBS LIJ&U57BRGEE7:XW'FMH!N$UR9"R"Q
MF(JIJGWE2<N9=7E0DGU_;&FNM5:;.N&T.58CRQ[#3S#$%1<@J&RS(07;?9:B
MYD99;;?;L!Y#S:&\(=0:+I7C."4S#[N3\3G]OZM-<0DT6]<^^:01P0FO2)<I
MXHF3B;*?<DO)E27W)>//?><F(D)D/.96XJ2E[#JLNI7C'K##ZP.!WP01DY/V
M?/.?R/V4!!]"#]QSKCHQ]CXN_&.['\6<?;_M^_TR0"?BQ_+&<_TCO]_Q&JZ]
MW7C37CX4_O8Z]<C]F?GC)_7GX]\#X^FFO2F5)@RXLR&^_$EQ)"),65&=<8DQ
MI##B'6)$=]I2'67V7$H=9=;6E;;B4K0K"DXSBJ_'/J3C[B0W_P#FFK@ZELYL
MS1]A7G;MHM%WUW0;$W<T4,R<GSAMZV[<(PP#"+63U3SZR[K$$ (:F226)CC,
M-M&6L*C*)19NUVV&!8[5^TG4BI! D!])K$I(B5S_ (-2O)Q\1\^ZMP_VM^(?
M$<VZ>#_9CX.O-L^^^/9MR:_XA0%I_#WAG9H(Y]WNTAE>.Y64D%;;Y.2E)0X1
MX)GALPWFXJ:,F<I!9[9'+^Y;]U)IDDR-AZ=BZG$0 -/N#R'R\0[A"YT(X^W6
MJSD<+@/$X54LDEY920\W)<6'?AR=+O7B/< T" 2S":7HB"MD0UAQ)3E#$>8C
MP./()(PP,Y)[R?P7['O9_P"#H6&T;'MEC=8D:Q<W[?5@W'Q!?G=BT]B?=;D;
MRBQ.[M(T,+5J[,QX1(!JM^Y>$]\XNZ0C[ILNYX$:\3=@XJ@VCZZ>*V>+ &K9
M>D1R%@V@!GQ@P:PS&8[TZ'7TP)+3D".ZB68@'\.5YGS!?D,S)7,HZ?/J6%9X
MUCD0A3$"<,S9SGCD#N&.3WFMW:]FW:N:>Z;9MU^O+&/WEN-*K:CEA89+&M8C
MEC,8PH(9?4C (&=1KK38"M]YCZ:V^MDP3*Q)C&O=B26$9LM<L#<=Z3$A3Y[:
M</%1)%3.&7F9&<O.N^6V\ZXIUB3!D]2W^E2-NOD2/("*EQN\T4O'*([ <GC=
MA@@]\D9^8^</'?@L>QE9_:G[,(Y=JV_;;%:QXY\"UI67P_OVQO-'!<N4:+MT
M-MW;;XI.O#-7$<*1)(5B $L%NI1(;)%$)PR8G#<P=,DP);>,^+"),-]R.^C"
ML8QWX2ZVI.,]V._&._K1O$49D(XLC%6'K@J2"/O!'SQV_'7TU2N0;A3J7ZK]
M2K>K07*TF,<X+,230O@]QRC=6P?3.-<'P9QC/V,=W?\ P_VQ_GQUXX=B2?0?
M#[!V]=9.O(4>.5@O#.UHR6KQL?YBX!D&1F"2L);S3T9Y<0A >CRXRG8[SS#B
MF7D96RZXTK.4.*3GQ_)'WG_]NFN6N[7-R'''N6ZSN0(CA]V)!6?*JAQ7;7%>
MA6AR/&5+RRRY9(4B1$/K;0E1B*^]'(YDM.K0JFFN$0L!\TJ1DN<,%?5RE3Y>
M21.;.S*G*EE9ZIDC,E]WSI:IQPW-5(=\3V91@K(ROSB$M;WH#L3CY8SZ?$'[
M_P!??377MIQ^]]CN_P!/[_\ JZKR.,GU/8?9\\?T9]?7OIKEHQ\6<_O_ !?Y
MNA\N .Q_E??ZC]A^.FO+PX_>Q_HZH"V>W<^OIG'SQ\OPTT4G/@SGN^+XOX/B
M[\="&QR/X_/UQ^WV::G3CI[\G-E5:GU6Z6&I#G[,'N!98LH^Q 8>HCV;) /2
M!CBUB9I0,[!\T*^2A2VXA!QA?@RVIQ*LRA4-VU# 69$8EI7_ )D2*7D89['R
M \?49(!^V ^T_P :K[/? ^^^*EKK<MT8(8-LI-RXW-VW"S#0VVNP0B1HC;L1
M/.(R)/=XYBA# $; ..MOF\A=Q%A0QS:@G5]%(UDJS&H5$,[$(["-2+.-'PL[
MLM*3PHP/KUFA0R*CA.8<B> *S+S-(QV1DTHW<W/>+*QFMM2-6J*Q1! ZPRE>
M)!GED)S([$9X _$##8)U ?!_L5VA3%XK]J)@\=>/]PC2Q?N>(%%_:-ID?,J[
M1L6U2))0JTZ1?I1RBNS/*K31&NDBPK?'9O%7BC?ST[8US$W_ %TZW7IDB+"T
M?:!^O9Q.,%,'YLZZN:YLU6M!DH5(-$P@= JGCPV'VA;;=9K1)1 ;.(QN&?>X
M88^3&[*9&Y3.YB?I# CD*D+R<G)DP%((^H>Q/8&I>'@LE6#;-M@I@+"M7W"M
M)54D$/6^CC,4<8"\4#@H5;#.I5E71C3^0QX3-D56]2I.U-53YKD2>%M^5E2*
M127G$,$PY&;G$^ 5C,93)C-Y>0RES'@0W#>RW)CRNIN]A?H+>;=1L"2"<]1E
M&,%HG8ED=<DI@XS\!G(Y3XO]AWAW<&/B#P)'%[/?'E%'GVG?O#<:;96GL@<Q
M4WK;JJ+2O[?;=5CM\ZYF9#EFFC#UY<)W7KZ+K78!*OBY3DZORHL ]6)SN?$[
M*KYJ.F7 4XKPH\QR/G+L)QWP(\Y<93V$(PYA.+>X514M/$C<XB$EA<^K12H'
M0G '< \3V[D9'8C4J]E'C6SX]\%;=O>XUDH[W!/>V;Q#2C!$=7?-GM24KZ1@
MLW&*9HTM1)S<Q1V%B9V9"QB7*,9^/['\76"0#ZC72-<9].$XQW=_QX5]G^+'
M5MP!C ^?]6FN]@WJ[C(84<-N5J'#ZV6R?KL&#82\2& .JRK*C06+'F-L"BV<
MJ5G)*"AB9G*E9R]WYSUXR?GIKT/7&W2&78\BTV-^.^^])>8>.$W67I,E9AR1
M(=:7*4AQ]]RQ6!;SJTY<=6=,*6I2B<W+]0"<8^.?C^?]7ZM-=9*=F27W)A!R
M3(F3E*F/RIBW79,Q<E:G%RG7W\J=D*?7E2U/K4O+J_$K*U9[\]>CG( )P< =
M_L ]/^'?5 0?0@X.#CX'Y??KQ3CXL8^WG_7G/3U;'<@=ON_+T[_JU77(RG&<
M?8[OX?[?9_S]7,#N,#OZZ:\/!G]_'^O_ ,.O/ 9]3C]?[?M][7&>RIO.5)5E
M*DX2I*DYSC*58SC.,ISCNSC.,XQG&<?'C/QX[NK;#!(TU9W3Y>X[:(V<;M#8
M]V(ZLKT(CM+9L2;8BTU^SY"P@8Z''(OOR791>:\D* A0<3WG\CX0Q7LK,.5A
MMS.QVRK'9FD:P2M6K"]FP5^L43TC4X]9'(7U! +$=QKE/M>\9[OX2\/;?4\,
M0PV/&'B_?*'A/PLE@!JU?<MR,C2;C:4]C6V^K#/.2RM'U_=UF5HF<:N_PJOU
M9WIMJ+7+53MIPM?UHM#57]<ZA$X;UJFL*$V5\K!V>3#K!G$E'HD')H3.]Z@
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M"/.?G,C6\9>V-4F4MYEOVBG-I4^IS##;.3S2I;CB(C8T^X^BOE-SX?&=WI@
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M1<W&,X26^D:P"N;\MJF6#<; O/=Z:\>63,>/!GSBO,<\5K6SVQDGHD*!R,D
M!GCUF\G&UW.^/HP,\N/JZ#&3+#ZYQCGEL\0DA/3>K^YQE],ZFV()U:<F5K8I
M*HFX5+L(^($(3@MBD0G6AI*) LDB&"FR(DA27FHA2>-B25IPRX4%^/!"-+9
MY1PAXN58*V <,0<'#=C@_ X'VCU'/X#&LT;2J'C#J74E@&4'N"5RP!'Q )'\
MUO0Z?]FB^UAI53N%HFWN1*>G5_3%?!5O5=2@[+0 ?E2=!1=A&5Y&AY>R2)D3
M("[WR3>#T^<U,%WN$7:M$A06OCJGKY!?57;F.XB"K&@< DPB0GL9"01,?*IR
MK@YRJA=S$=HD=%Z8&&G9FE<P\NU@QKW(B (:#&7&&CX\?,[/)=-U9VDY9V@W
MCX=KN,&26M?G9M!V''TX/GH&P;;Q:?G M@! % )RH1TIKQ_E?B_C*W>7\(N;
ME-AU^PLPH 5Z+[6.Z2C&9@"4)1Q$"%#5^SA8R02GO/,*Y\W *V N+4DVV*)(
MQ7C8CJ*)(S,1DI; :-FD XK(*AC+1_4YEER6!]=%T]VI:A5 <OO(3.3H0@X5
MN\81#U:,$'RR;QQ18("F7\UFT32NOR5*$<K3(93:*'8H)6SUT=D. @1J^(!U
M6.]]&7G&0<N L8!/*OD?48LA46"OU"&8#B%X@))MIY2<*WD8 )DS%E'3MX.
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MO%T\(,-6/=8*K-M[V0T45R&>:,S1)'9: 3BO/6;I.\CS)%&["^[&VMFMS+
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M_5KM6NNZ\8)]!G36U'A4; 533&PC3=]@3+/*."(ZJJ7CDVA](@Q6CBHF691
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MD_[#?ZIU^0]U]R:^>M.FFG333IIITTU]'/T+[_C"MB_R3MB_THZ3ZY7[7_\
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M<)MQQ*CK\)+ <N4:ALNHD]3VW;8=JKQ;6MR62"E#8+F2P$DC%HR*@B:N'4O
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M=79%8*0Q&OH<U3Q,XR\;C-2WYI_8!\]DQD-71,:W7:LRJ_)AGRP:7"*'T@!
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M75.U6S* %A8,&NI18XJJB* -L^9LMO$HH8! #Q%@H$+MXAD"L9]ICUKC2YI
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M'C14N+>5+?>?;;PIQ*$=3;PMX0;Q%6LV/?EIB&<0(&A$QE;I-*V!UHB,#CC
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MW/?6BJ;?=AE>.]#"9(I;<T"M[N#+&Z<X6ST@/FK5GET<:7I!B%:=@0:9*AQ
MTX67%.S;V'K3]42HRVMA/DF24^R (C\IEM<:30+&B8EA,=E*_1K'#'F,*6'<
M$?5)Y=OF!Q)],\@?0ZP:7MEVQSLE>ULER+<]_AV:6&*G-6MU6FWVGMLFU@VU
M9!PN6)MRH0O*BM')L.X+,$$: \F#S7JA4:0*"*6?*PA,"\&",R*1$QH+(2G
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MR!@92Y%6CR7?#YSM-5P/D/R&M?'9=[G[.W3FT-H&>T2TG:=W:\,4J(/UT%K
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MZ$I[9449<(7JTDJBJ//5N:JY?]F4V;7!;^<U^%Y3\%UKNE8;]7(KD_,Z8 ]
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MT]E^-(C0UCE/MN+C/MRE>+"(RLR%-XS&9>GTY.J0(^#=0L<+PP>63\!C/?\
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M.WL%>)'-G9)7=,8Y<]$[7LSV)5T-:^9"SZQ=R.4X0Z?L-/,Q,M(LTA*&L3#
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M%2Y\^:\[#,2ITV7)==DRI+T28\\\XX^[GQ94\GZ;W=$BV7<4C58XX]OL(B*
MB(BP,JHH!5550 JJ" !@#Y:X]$2]B-F)9FF0LS$L68N"22<DDGN2<DGOW.OT
M2MZ:ZJ&W]*[<U1L$D^%HNRM:WBB6\U%F#A\P+6[96R0,R8A$"\6:*'SA4"<^
M0A3R,.7!ARH[,F5&>9:6VKYQE19(I(W[))&Z,>V0K*58@D$ @$D$@@$9((U+
MX)7AGAFC'*2*6.1%()#,CAE4@$$AB " 02#@:U[VGL_N+=TGC3DG>]D@7:QR
MK1=QMMK-NU97BMG)2+7IJY%[''B@:K @%!8.=H@7$9C#8R!%?%'+4U!P-EM
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M5QUU:&FFJV'<<=<4E#;;:!D=2UK6K.$H0A.,J4I6<)2G&<YSC&.@!)P!DGL
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M+<%S]';11W,E8L6( )>%I8P"S(5C_B+9EW>D1&H%RORDK/V!8X\\#$XPDH
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M(^OK8FF.VV9<KS>[:5H6)D:LG[7L*R3K?930T)("@(M5@RCA:>T)J8@=@37
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M2CI=<PP[Q[AO.,X6K#3CS&QZLAAU:._PJ<:1)D(;7G&5(2\[A.<86KOX][9
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MW!$J3.*O)VOKW*XX2E1CH6=C-Q,^*=.CJS%(]WM&,TU_.T!VWV=NT=SZSL/
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M?3&N%G&,_%GKSW4]_P ?M!_;\]5U[X:<X<7C/_L?YL_78ZK@C./B1@@_#O\
MM]^FNRQC/VL?%_!CJA#'U!/;/?\ ;U^SUTUR(D.7/E1X,*+(F39C[,6)$BLN
M/RI4F0XEF/'C,-)6Z^^^ZM+3++2%..N*2A"5*SC'51&Q( [DD #ODD]@ ,=R
M2< ?/MH2 "2< =R3Z ?,ZY1D$: 2LCSP@F%GX;P]Z(O EC9>&E+6WAST\QIE
M[P*6TXC"O!X<K;6GO\2<XQZ:-XVXR*5)_DL"",Y .& ^((SCMWU0$$9!!'S!
M!'ZM8\XC&?L?%^]_!^__ )L_ZO\ ;0GL0W?!P2/N)&/3N/3\_GJNN,I/V<9_
MM_#CJG=3D9*_#Y'_ (_V>FFO2I/=G^#[75,8\P],_B/O_;[_ %TU^A1]"6X[
MNSTW=C_Z9%Y_H5T)GKR>_P#PTU]"/)Z.F3I2TLJ8Q)3DM0G/*S%8F=^6=B5-
M[#GD20%F:5Y.6\/8<R(<6QEOU#,X,\TV9@;C8#C=Z9SCO-WR5]:\P]5DC/?T
MQS[YP5<$HVKWH9VNYVS]$.V ?1T/\I7';U^KV]05.&%8MQ[5K&CM5W_;]S;+
M/5;7%5+VTW&!04DC<N$(BKDJA"(+DB(Q()35I1$A(E3(,+$AYM4V="B)>E-2
MV218HWD;/%%+' R< 9P 2 2?09(&?4@=]0"&%YY8X4QSE<(O(X4$GU) ) 'J
M< GY GMJC$OM2],###E6,ZDY#U^[MTL9?U4>S5&B5>R8K);></CI"FJ:LFS!
M(YCU&SB$&-&]418;FU>=!O4%R33Y\,T_BF]$&X-'.K\0_!D16XF;H X:0#^$
M( [_ %2'SQ()SQM,[+S6:LR<VCYJ\C+S6 V2,K$2<1 DX!(<&,X<%1AH7M8=
M8R"5ODE];['Q7!,%ZP08HB'2G;76ZG31-<1N$_>VY^PXE:G(H-KLXP+'&:R.
M7L[;(S_M"EB+1"9?FMT%Z/+$I)@!FP G)50#J%P7 \C$*1&SEO5 P&=>VVB7
M" 2Q<R0I)+\&=V;HK&1&6'41"Q,JHJG"N4) UFE0[0V38J)RIN7P'VF:QQAU
M&=VPJ;$LE,&#=C,"2&V8N:\)B2[#/.5M]I.K"+3Q<M EQY"FRDF/";4T$'G_
M $MO*6&Z3D01F3.5 DQU.PRQ*]XR,D?,X[ 'Q)MH22HG70&U,L."KEHLB$\B
M0H5Q],/*I&.PR?,RXY![2K"++9:?:M-7.H&VMH:VK%-D2<TP^&,5NT;%X5:V
MN@F?(K&Q2LYO85&.\RZAB8J+ 51R4).)M5L-L=%EA^?(NCDRO&ZGG&J_4(*M
M)4C8'#D\U:VH[#@?56;# >CMGD61)XW!BE9Q](K!DCO2(PY1 =-UI/@$]0'L
MRIE2<FV[VDE.I/%5'(2IZQV&4L]D![O]T]6V=JC5^S5FTZ2U]?[W:HFWHLO8
M<2'3X]<C4*9BTUB";*;,BYD-BQU+F'D21T3U)<5*_66-RS++QC/!65HDD=A*
M"XX<1&>2@F09 "9R!XAVQY+9KM+&$1H.<J]1E=)Y(XT,.(B7+&0<&*B(X),G
M'#'A6GM5-'U./<LO:TWF?G:T7>(VR8-> Z[2[3)NLAFZ[/L"*278=G@&9,FO
MZ^T8=V>U"%/$9YVAW+6)&NQ2Y.YQA$6C7X5#DI,3&9 X"IY3&)6<'E(O<)"7
MP,DH\97)<#7I-IF<H!-742B,Q%FE\XE,"H1QB8X:2=8LD "1) Q4(6UYWWM4
M]%T SM0%)USNJRS=1SCV3SM1@ZG+#3%6JM<Y$6JT7JLEY&W8 HB KPKBUN1H
MJ*DS(%ZCFP$>L9I^;+*<$13WX4,@*2L8B>7$1L"JK.Q=6ZN"![O*".SAEX\2
MW;5(]IGD$1$L"B8+QY]8$.[556-EZ)(9C;A*G!0AN7,+WUV KM(Z43V$BAXU
M3M1FQ$"PZC"]?RF=7P+NSL=BQ\EX5K&%ST[;C&JHH4-5N-%NMS)!%ZRW+@*A
M0(,@C92L6MQZBXA?@(Y.18($/3#<^5@,"QDZ8 6N[9YX(P 2QXZH=L=8^H9H
MN 4R-(.J4Z7&J58*(NJ2SVD3' $')("@L=DW69K6:=--95Q[?4Y<=U,YDNNI
M8*T7PQUS'7FHWFU3"U9:B+L9-J'E_.,+<RS7JSZG*<..9-*3B8U'_$@Q^C3@
M=Z\_?B 3BP_JW20MCX9EEQGL(\X,Q\,'][VQG_I*G&?3,,?PY'&<?S%S\V_D
MYUN+]SO\[_U7U%]2?6.[J_Z(NV?Y.-\_HR*];#:?XUVS_.%+_>8M8M[^\KG^
M2V/]B^ORK]1UT9<-KZQJ1MMUX-:-A4NNEVF'EQWG1ANR#1D]MF0WW.,.KB2G
M4MO(SXVEYPM/UR<=?9U^5Z]&Y/&0)(:EB6,D @/'"[J2#V(#*,@]CZ:X-719
M)X(VSQDFC1L'!XLZJ<'X'!]=;X-Q\(N(5'WIR]FL:SJQ#57"NF7PZK5>I>49
M:]6[:A?X>:SI6EHW49F1C!G2$*HM''[1LX*&90:@Q(K\5N=#RRN2CF]'Q#OE
MC;MC4VYEN[_8K1>^7=G2O!2C_1TM^P=O12D>XM.8Q#4DD/39B"4.0#*;.V;?
M%:W$B!#!ML<K="O>,LD[>]QU8_>6/)JPBYF2PJCDH!&?CKD5/@GQ[Q)Y!WG8
M.B=,UH15.,G'/=&K0+_-JQHX_'&-M[TL.MIEVQO)^) +@Q1@(,S%!U8_/LCR
M[0-:].94Q9H< 6F\1[IQVRO6W&_-)-N^Z[?<D'A^$[G&:.W16UK_ *.#/'(\
M<C\I)HQ$!"YY1\H69ZIM53-N66K6C6.E3LP(=S;W1Q8M/"9?>B%9%95PD;LY
MZB]FQ( O6/\ !#B=*X%2=ZS*3$%6_/$W=>^566E;OL5NOT#8->Y(6W4VKQ8S
M4'L\U"L>B'FXE>!73:;C :*$C+>-S3D><ZVF3Z'B3>AXD7;5L,\'Z:V_;>E8
MVZ*"L]67:H+MQWNEHVAW(<I9:]/,C2$=-8RH.*?HJ@=I-HQA9/<+-OG%9>28
M3)=DKP*M;BX>H<(DMC"A!EBX;UICR\U'QGIW$+C/LJK:=LW'7D)M6UV8K#UB
M=VN7V:4N?&J& ',U7>%QAF08%VE%+G=O:D&GQ!@<"#M-<'$K&('21SD-V)O]
MCO;M8WS=ZDUZ'=-KI0PHUR*G'42#=FD8S;? T<DGO"5Z_!IV=Y)(966)V#\N
M6MW"O2CV^E,E=Z=RP[L('L-.TM((!':E#(AB:64,(@JHDJ*TB*5(QL_^A7O^
MEER/_D[L?TE5#J'^V3^)MI_SFW^ZS:WG@7^,+G^1_P#UXM:#^UD_QF7.K^4Y
MM?\ [S3.OGU/0_?_ %#74-46JU5LUXL0:H4RNF;;:[$0C"J_6JZ+FFCIHI+<
MPU$'B1(YF1/(39#BDH:C16'77%9QA*,YZ]$@>NA( ))P!W)/H!\SKZ5ZGPQ?
MY <,9D7E-JYNE;'XZ5K7C88O0&M=5#8<.J3X+LI-/L(D@.B&AA2IU0<N98Z+
M:HK)$M9CA&=6<$#2'H(V7T)-KW:.AMVY1="<$5H+5=(XGZ<2^2($"3DTA9^J
M98BB,W->_P#!ZF42P2&:L^8YD:4AQ))"5!8=0,K8!,A(=QDJJH&'$CEJ/V[Q
MMT%KK86(0NZ'Y0 H6U]+K0*QJ>7-B5HFG$NT3+LY !@2^1\U+2X050&%#(06
M'EDR3R8N!TDA,YO9E3A5[/Z4$:2V]I@VVC8!:>5[4P6X;K5HU=*L4:R%;%6.
M0QAHWGZ:DLNH7?[,C=*.NLO3BNM8L0E3&KPC$,<)9VCZY)Y/'*Q!*&-<MD+<
MG8W""F<@,:81IJBZZT]J9B018QL$?+L3UYME1=?RUYUE"EXTB&^9]N(CQ09>
MU7"(0<188L=E1 8PS%';/?/9W5NS;?!L<%>I2K82_N*VS/(Z.CRL@IF".:>>
M$JWTPG?,;)R"\66/#J[])5]Z-J6>S9D(,=9E3IQOG *2!O*A4^9$BXAD/U2P
M+0!VEW'K56FA>O3U9U:9UM9;2_[('(KQ,'.UB4J]7&I:=E26&6/;"+M*;GUZ
M1(*JF+CFNXQ*G,.D<KEYC?M(\.;#LB;=-M8L1SV 8714"U0M:-%D>3E](MEW
M=#A04=>;-Q<$MF^&]QLWFM)).)HX68L)0XLI+)(PX@GRF!>$@ QE#Q53Q'%=
M2+*,><WG'_M=_=]K[&?L=<I)!S\_F/0_;CX?MZ:EFL@3G.<XQ_H[L8[_ /9^
M_P#9_P!?5[37U3\'2>F../#VG2=4CR1+9_)%E96=M10D-'-52$/#U*K7QNQF
M25,F%D:LJFS_ &U6Q(>&/5 )D,.2&BA4K-&D\^:=3<[N\58ML%F0(B2VND[I
M7KJ)"H-DQQ,S!F*JH;C&'*><DDCRYKI#+)8>OA2%2%U9IIY#YEA@'7B0,%"N
M\F255@"I')3X\C.> ?:=Q,V-\=0]@:48#A:Q;J9L\2(ED!C8^>ZV&-*A&!BX
M-F=FRH\0V/J #+^1Q264*10\#(Z6=A=A\"^'XX('BW>C!8FW6Z7W))IJ\D5&
M'OT&^FD*2!2G/A"K,7DD*AE1P(MO,BHB1PO-$]=&%.>LLBO,0O4D5RAS'@LT
M8DEX\T2-2YR$-).%'&K2$J/<+]FB MR24'RJZNQL.JW C" 5$FRX,@#R5> M
M%Z@>LTD;+>*I@NQLSP^,QR[3@[$6 ^[O_#/L_P!D06;5MX=UCDM3+M[2<JW&
MJ#)%BW!:18TD9 DR-P=LO'P"AE8:_=-YMLJ1<Y*12.,S&"6-LS <F"2C$G$.
M @\P5L$')Y 8W9^S+J^O:!M:]W*KWVS.#QQ:V@!6N[K7(0^K"F/4%&*E#(VT
M0@A<3HR$AN 8FX"Y]3G"V 0J>0]#(+:>3V;[73VG==RNRWI;4*V+-3;-ODBD
MF@K1$O%')/)7$<\O3!,\H15$:L88I)%7-]/$DL]FI7A:&-7*QR2V(9&ZCX53
M(R1.1 C,3P5I!@C+N$#<-'*L8QGNQC/[_P!G_P O]_7%#QQR /RP,8S^WX?/
M&IIKWP\8\_&?M^%7^[HI)(SC[_CZ'XZ:[A.._./CQC^'/V.KNFMH&FM9V*PA
M=:[NWGN 7=J$X?'5B#3#MA'WH:.@9IYH>&G6&+8#*@0EREF) 25*I9& J7-&
MM3,,8434/'$^B^&?!%S<Z:[W(]:7;XYX!/ +%8<H75H5EL.\RQ0M6F> /7GX
MS-&6X N41]#N.\+#+[@J3+(Z%D8B0 A)%9UC6,<RK(&XR@A S#.5#E<KL>S-
MRAC8PO1',Q3ZSD,0FU 8,"+"&8L5?A"HC)R9#!8E/IS!RZ]*24E3@H]I6&&X
M+LF*VJ+TF&KN%:2O%6IMN(M(:U>.'@]*9[,,,%=9><+03&%'ZC]5^A%'YV#8
M1UU,\M26.5))A%$F99$<OU2L4CNYC^E!4.P"1B,"1F/8@$@VIX>U(/9-5V5-
MJKL@4)I!MRES:G&C3!KGIR$=F):R*AU:V,,/391;$NP./1H 7$00MIDJ(<<)
M/K?:D&QT =F7:+.WV]H@XW(#5,EJFLY>.6K;G#B2:)*\UH3ND:RK"CY>/F.#
MMI]PLL;/6@G2SD1S&7*NJGD'B4L\0 :->EZ\G<$A^*A@.EWEJC1U,XQ;6BZ3
MI%<F5Z&!)6NL+MNI#Q:>ZH:W/KUDM:;T0>FFL$Q<8H7Q7)1-Q,$1.8'.,Y2.
MA3UL1SQ%X8V+9O!VY+2VJ@UF"&6869W>Q.)!*D<K\@BRF:&&8BOYQ&&P[*T:
MG.91W"]8W2J;5B0<WZ;K'.B %@'CBZ:@(RLRCJ8 8KD <B-?/.M/=\>,?%_O
M_M^]_P"'7S>3R_DX(]?GC]OZOMUT#79Q?[C_ .JC_9GJL?Q_#^O37?!#)6O%
M8)L&1E"2PV0B3!(PGEL28SR._&%MN(SC/<I.<H<1GO0ZVI;;B5MK4G-^.1XG
M62-F21#R1D.&4CX@C&/Z_0]M8&Z;5MN][?<VG=Z-;<MLOP/7N4;D*3UK$+CS
M))&X*D9 93V9'"NA5U5AL[XP[.K]T*'=Q['9U\%NFE?=T^/L@F(>@7JUR9LI
MZ$YZT('AY!V "T-CD&;;DH3B1U#Y; [ .?#(2EQ>D>#*$OB2U<MR"K7EV6M^
MD)[JK(+/319"9)((O+8BPK).1W'-5,3JYQ\Y[C[*?$O@<P5_9=[2-]\/[7<F
M:.#PKX@JUO%7AZH78,(-L:_+'=VN(.0P5&L.26=IPP ,^[4W35+)/&D\QFK:
M[;!IQIN>U96:HT7%6"3-?DJL M,QN8Y!80!E1BI*4-=?&#TL"LS"#,QF+GJ2
M[7O,K0/%/!-#N-:Y2JGW/J4YY'1SPEK61QB$HAE5KS08J@>H>8 Z-_#WMQN+
M-5N>T[PYMD,4\3SS[1X02Q?B"\<F VYEKK-](K+$LI)D8L,<,ZS?C<38NP3:
M]!*5_6;[->#B0=0I8X@T8$&*Y,D.QI$&"R4I=B%O.N/Y#J]I$'Q4>+@O'C38
M+<A^:AC*VOPI'3$E+=Z-6U&D<D$$:VH;T#5XLHR]*189*Z+R66(!.L5EC9UC
M)XC;^'?9OLWA[=U\66MVW[Q1XOEB;WCQ1XI9I;U1FC?*;7"CK7H5BCS1=.LS
MR(@:*.TT)P]D;U?Z5/X\V.FA1);65<"::N=,S6)]9%%]6+P+#E'YJSHH*2R^
M,%#)32!,JX0>])2;A9MG*RW?B3E;GM-.IX:W>K'5I15(Z%HQ16HGACKXINZE
MR O+'!G):5"CD 2,Q373(&E_25:5F2>1K<3.ZNW79FD5>44CJ0793DQ8R%/$
MD+DGY4LXQXD9QW=_C3^_W_9_?[L=?)>05/KV'Q]<D$?G\#KJFNS8_N,_];/^
MS'1/0_?_ %#37NZ]Z:O1KWDOOW8U2U?Q*KQ!R!2)4NM51F"$E+@DY"X]M.F6
M#ZR)^Q#P40D-C6DQ"2\0FBJ\@:EA!#TS49$MC,IUY+]JI2@KK)8EE6*$JN9>
M<CX++R=5Y '&&(7 ]03D>))UK0R2NP5$5RS%<G#8)7LI8CDH( !.2< YQJ>=
MYY$'*H7U\^18KL)AH:%F6&TEHQF$U.JS$E_,H57JY7T/.6FW3@K+3)D<_ K4
M94T@F?@4(EQ$H[)9\-6+^W1[,/<ZHE>M$UZ_*(Q%*DJDR"*)2YLS 2>J)%TE
MF:21,1J\>>^U=C.1)9(#.(H4 8HV?K.\G$1Q!NZC+GRA%=O3O>SNJE.3<-A/
M5<<?9MP1"C8:^8KK%@+UFG1!SXFP 5%'WAM8K[MRR1GMHL4[,""D4.DP7G"R
M"#@EW*\%^'-EJ6]X6!X+\\=MZ>W6;]4R=.O'BO9GZ4<K12"S*9DK&(2=2->?
M4(#(NMWNW9DBJ"8<(Y$0RPQNX5I6/43"!#*QA C+J2,,?1,<C/BN$O&@+QNV
MSF"!4:V 3E3@6-BS984\:%SX*Q%P]'K6OQC8BM9D07)D2KSIM?1(5/@PC+#<
M[#9-J'&NS>S/9X-NW.))+,]X5)YQ;]V+M"R2-8CCBJ1DHK&%5BX]57;E\!E3
M87?-PDNU&8JD(9>5=255ED#1!YY&4O@D%N+@\'(.!QSKYZ6L=SS>,X^/#J,9
MQG[6<+Q_LSU\^+@-COG'X>F?OU/==YU<TU;'A2=TB"Y"416_14^;1RAD(%:-
MP"948NA&B5G LQ=A/N!2@<C)8J4#!,BF/'F96F3B/*Q%F*BIC.^6 .<J7\K
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M85CB,$+(4,,*S.GP1\$?.Q(D/1K,MZ;;V@L013O(LJF-X0!TW7!#-(V(T/Q
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M%< '!6BB=5@Y],L39R&"A\2+PS:CCM35WBZ;SJ%BD; +-#R9T5>/("0%G!+
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MWNP*\F(,B(S*.G)D*2.05>? /QQW99^V[7.2UKK]UV)NV#:JX(U>(K<,7/L
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MF2)'C@A)BEA +&1ITJ$R012JJK&)>F)5#$R-A(PM!-:BKO#&"L,THC>6%?I
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MN_5&E639-@KU:MXXL+KDJ*"F; Q[RU6 TTZ/<68&27QD(J5E29;9&'%#RRS
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MV[&4;=;:%N#K'RY ,2$5E,A 7S$],-@#!/S'KK?=81.A],F+L!KM<^#0C9"
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MQ)CCWS[UWKC8]G*<(.1U1U^2I)LC;KO:=.;,9KU7JCE7>A'K"D_.JL$>$!X
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MG3M[1=VD3C-#'(W6-@R\^$O5( 9E=(U*AAD.HRK<B2O+OK+&TUU8LGE''@%
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MSWUZ7PX3''#+;YQQX8@1 %F7D%&>79%4@!?7(SG6%[WHW-77H!_:?(+B+O\
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ME]QI<GZYEK./"RGZQ/Q=--5TX]]DEV[O&+E%?>8&J8G&6#NG9#VPG[02,W4
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M.[4GQ52V8SUU0(==;QKE_P!(HHP)HKTIKQR/9:[D89PN?BG)=LE!O6T]LRW
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M&>>9JZI[3:O@V:]2B$\1MC++OA9]8BLC'<MQO>938,=ZVG+8FN$ MQ/N<8Y
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M%TY8'IRSCX:QK%.I;XBU5KV>.>/7ACEXY]>/45N.?CC&=09]3<[/;Y#O$O\
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M###2$-LLM(2VVVE*$)2E.,8T9)8EF)9F)+,2222<DDGN23W)/<G6P
M   P !V  '8 #T&O?U35=.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.
MFFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG
M333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333
MIIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFH3W%^YW
M^=_ZKZ::JH*_^*QO_P#00_\ _7;Z::Y_333IIITTTZ::=--.FFG333IIITTT
MZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::
M=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--
M.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FF
DG333IIITTTZ::=--.FFG333IIK"[?_\ N[_^[_\ ^;IIK__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gwpjrhodncoa000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000007.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $1 ET# 1$  A$! Q$!_\0
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MI9YG $MCB;J3H"YQW6,#GN:TX61OU\94EN67$1Q#@T:%\CW<&11@Z:O>> Z
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M2%T\XEDWMV/<8TCWQUW]&Z J_%3L2Q3RLC);7;"^0$$/+9Y!'&6,TU?O..O
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M7!]Y<@EC<WCIO0M,[':=&K1&]H)Z ]W:O?\ 6*::UJOSMC?%.9E 0\G-/"I
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M%9).IXGI/6>U2EGI<0[[];P_Q/L?Q,*-YPZSY>/K4A9R6$0 7RW]#T/^;E0
MW2>L'V*=]W;Z![%)VZE?3JWWR^YRIK01Q'7X? F^[M] ]BG[<RGIQ7^A[G#6
M@CB.OP^!1J>T^<J0LO)"'?>*^'^+]C^+E6XWL])]JG><.OZ?6KNVTEZ;5_H^
MYQN-[/2?:F^[M] ]BD)+2(@/-VH/?_B_8_BXW&]GI/M4;SCUGU>I7]M9#TTI
M]XON<;C>STGVIJ>T^<J4LF_$ $7*G]'T?^;C<;V>D^U3O.[?4J]LG_IE3^C[
MG&XWL])]J;[NWT#V*4LB^Z(?M@_S?F%]$?XN-QO9Z3[5&\[M/G5W;%[Z8/\
M>+[G&XWL])]J:GM/G*E*_>" "*Y_Z/H^+&XWL])]JG>=V^I5[.=_1S_T?:QN
M-[/2?:F^[M] ]BE!XZ$ _9C^ /FA[66CP)\93?=V^@>Q5[,=?1C_ 'P]K(3?
M=V^@>Q3 [<<@_93> /0]K";[NWT#V*O9;CZ*;^;VL)ON[?0/8I0<+B ?LAO
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MVGH9;7%BU_":_NY=DV5U.:V;JRX=BV1_5DG#5%:91.J^6;+I"\76 4A)*'0
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MR3@:]?A]?#S#S^L[30Z?&X>;CY-=/$NR+)5"81,(M6P*^.^9DC <FD3.4 8
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M5VUM?VO:?M]JN$KE?JX*QYE&(QU72<(QI9-MV2!GBQDW*H.E"*H==Y@)2I"
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M5NS^%DQ-V-SC$][&V72"Q!HQP)AB;,UI]\SLVI%H6J5@:291.9H8>QI) O\
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M/H]BD[@&?J@Y]:2]O&^>P>GVJ.3\/H_BI UZS$ 'MBY[X<_\2E[>3RG@]/\
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M]H9PK+\3N<)XCR'<G$-W_P#C76W_ (<Y>Y])\1G][VKV3^GWW4>/_P TM@>
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MP]B*OF/U'U2V7^6K<GP]QJ?!YA[$4P:>J'(/W2V9X _UU[F^'N-3X/,/8I/
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MV)WQE^)'YG?O)W3._2[?^L]WCO='^$?YF^Q.^,OQ(_,[]Y7ELCH0YB@AX?\
M:?8_CY2ZA&TZ;[SPU^]]B=\9?B1^9W[RN[HG/T!#^L]WE/,8_CO_ +OL3OC+
M\2/S._>5>Z-Q\UNC]]0/_J')YC'IKOOZ2/O>K3P>%5MOR.UU8SA_WO:G=&X]
M+H_A']O(YC'\=_\ =]BJY])\1G][VJ\+ X$ 'K"/?^R?W6.8Q_'?_=]BH.0D
M!(Y-G#PN]JKV_<?0$?OG]UEMU1@)&\[T=GB50OR$ [C/[W;XT[?N/H"/WS^Z
MRIM)CAKON''3H"JY\_\ !M\Y5Y9U<0Y]82\/+PG]O(=38TZ;[CPUZ HY])\1
MG][VJ4LRN8.?64@[_+_/]UE/-6?&=Z/8G/I/B,_O>U5[<+_0DOZ?NL<U9\9W
MH]B<^?UL9YR/I*J$PN(@'6DN^/+_ #_=8YJSXSO1[%(O/) W&\3ITE7]M%_H
M:7WC^[QS5GQG>CV*YSI_Q6^GVJO;57Z&G_2]O+;J[02-X^8)SI_Q6^GVIVU5
M^A)_TO;R.0'QCY@G.G_%;Z?:I DE1 !Z"??#G_G>ZR>09VN\X]B<Z?\ %;Z?
M:G;%7YQ/[QO=8Y!G:[SCV)SI_P 5OI]JD!\H( /0)WP#Y[V\MF-H)&IX$]GL
M3G3_ (K?3[57LY3YPG]+V\C<':?1[%4VR]VOO6C3Q^U.SE/G"?TO;QN#M/H]
MBJY=W8WT^U5[./\ 0R_?'&X.T^CV*>7/Q1YRI =G$ 'HE[X<_F^WDF, D:G@
M=.KV)RY^*/.4[*/\Z7^?V\C<':?1[$Y<_%'G*DZ^?T"_>'V\;@[3Z/8KF^>P
M>GVIU\_H%^\/MXW!VGT>Q-\]@]/M5>OC\Z'WQRTF^>P>GVIU\?G0^^.$WSV#
MT^U2=,?0#^?V\)OGL'I]J=,?0#^?V\)OGL'I]J=,?0#^?V\*>4\'I_@G3'T
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M*0R-MR#'N._8R,CCZ1<H7SA52^$/&'EPI;TCQCUJ?"OIEE_PCY/4$3*44Y?
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MZ1BI]<4$RISG-MIB,76PV.JXZHT-BK1AN]H Z60\99I-.F260N>X] )W1HT
M#3;,Y:UG,G;REQVL]J4OW0260QCWL4$>O1'#&&QLUXD-WG$N<XG:.<BN,3")
MA$PB81,(N?O!/M9PTEGFJ9=R8["33=2]5ZZ<1[$DFZ9G$K&H](1Z*#YH1613
M3*)2).6;HY2F5?'-GC_=1V?9)7BV@K1@2P&.MD-T:<I"\[E>=VG2Z*0MA+CJ
M7,DC!(;$ O;>Y#M*^*U+LS:D)@LMEM8S>.O)6(VF2S79KQ#)X@ZPUHT:V2&4
M@;\Y)[*\\/6P:81,(OR]\^L"^3Z81,(F$3")A$PB]3O#_P#Y/AMK[3;:_P!Z
M>:D[1_VD,-^>P_\ E!6V^S?]F_,_F,S_ )LO+%FVRU(3"+OAKW'OPYIO-+-^
MSW--+K2\=3?M=TLL76KC*O-LPW#[KV/JFQJ]8(^27E&D'(ZIG#NI.IR%.85I
MA=8A-\T?MY^43B7[C7ZSW/-IG,SK^39>[ZX_NH4Z%2:U2A9AY]I,E+<Q=FM+
M$V%]B+,5PR*Y%>DM24)C$^-U>(SQLV$K=T39@/P;>4?1[U7^YC<O6H:MV9^9
MK[.8V*GDZMF.5TK*\N'L%\U.2E'5CO0B1DC;$PAD=Q:GN)6AT+ALW9H6H[,:
M[2/:ML5Z3I<ZSIEKJ<DWT_L%RO:]^T&+G+$P0DZU&SMLUOID95BFF5O+F&87
M:-WB#R7'.V5]EK^1VIP6T5S%OQ(J8>U%>KOO4[D3LUC6MI[.Y":O6D=%:EKT
MLKG>1D)+H/N#7N8Z.!=1L;4X_'[+YW9ZEE&98V\Q6EHV&4;E.9F%R;G6]H\=
M#8LL;)5BL7,7@^5C#=V;6=S&/;)-IUXWF6J,Y9G\E1J@YHE:7(S*PK#NRN;<
MNP.BS01>'///(^+</ >/$UWI2'9) U*N#4@J$1*H;TFA#<@JQQ7[C+]II?RE
MIE5M-L@<]SF 5V2S-9N,+8R1(=\MWSH7$#S6_-3L6I):%)V/JN#.3J/M/N.C
M+6-:\FQ)'$Y^^\.> 6#<#MP:ANIVCF8L->C[XGK_ (8XKOM;I;^U;2S6O[(G
M^JV2_.9S_#B5LA]CU_6[6?F\)_BRJ],6:QK9A;;M]JC:36Y:SRQ^3.):'7ZT
M4P%4=.#<DFC)#I=[K[QR=)NES^1*90#G$"%,8*7Z;IU\'EX] \)ZES^R^S][
M:G/8W!8YNMG(6&Q;Y:7,KP@%]BU-N\1#6@;)-)IQ+6%K07N:#TD;"W/$/=C/
M6EKD7'=98:S;-CBBFS=+-B5JI.X1A+"DN0ATDPC1G8EHQ8B<7"K<!ZR4X(''
M,8O:UVZ===TOX#AHWI_]%]&,5'@]DJF,V5J;T+*.&M7*\?).<9*F-?69>M2R
M,;N&S-8NLGE'!TTLLKVMX$+%$?Q&:F>I0#IU8P@F%L)1QJLA/H&C&M@4V%65
M;;7D&/7#'704&&2$\@:308(,')T6BRW7ET2J4B:,Z<=-[=#=1TEP+@/!P!UU
MT&O7Q"N0[78*5M21]SFT5\8PT9;;# RV<M3=?J-BWB7-<:[29>6;$V)Y;&YV
M\YH/8GK6S]O88&3I7I2<24B"HF'Y-PTY=%JY[_?,8"EZPN;F8W7$RJJ" KE#
M/0L'?YW6Y*0ZSU@&.UZ7Q]$;_"0!N.Z>(#C\,!?.C[)'N9^X?;%V;QE?D]F]
MJY)[U41MTAH97>Y3)XX!HW8HW/D%VFS1C.0GDKPM+:3R,CYS:US3"+IMT;J?
M>=FD>%.N[PBW4SJI>M<3K66K8TO8]8L-<[*L<2]@T-M69_;WK1^ZEUVR#JF"
MG!T]0&J#A-L63(<RA.J4ZUR1^,CN-+ZQCR0='R4\;X]9&%@LR.E<'%Q ,)#(
MN .F]JN\Y&[CXFYB7'O#+@FQ)9*)ZLT4ND+VR&G$V!KFA@)$^LDXWB"=PA5T
MC7Y71,/P)6ZP47<4<DYJ^\%=S!$T#;U]FF]NG(>J1576NM;KL)9IR+6<E9G1
MCU'\4T:(E077 4@!=7(J,-)F%FDAM-!CN&WNP6IGB5[(V1F:-C)'M)TT;O-
M&A/#BF0D;D9-HH(K%)Y$] 4-^S2K1F".2=\HKR2R0QO W@7!KW.)(!UX!=R.
M=L71DPB81,(L8;2>P24&9G(D*O)K<SQ*9! '#=8! IG0F#OIM@ .BJ4WR+@0
M!,I1,4#I<W@X[3K0DA)9"WA8<?@.;TB/3H+STM(XL^$3H='<)G):K:ICF =,
M_C7:--]KAPY37[U@Z'?'^" 3Q;QFSNJZ4F$7&+>\P_K&QN'6V'C;H_JL!<+Z
M>W*4VHW&ZJ,VDGJZT1,.I*0E*AYR45:JSKQ@B@H>/511<G(N8R94CJDZUG)G
MULAL_;,=Q]6O;O&V:E6U;+62XRS%$9(:D4TCFF=\8!+"UKM'$C34=JV?@CMX
MW:6F):,=NQ1QXIB[<I40]\66IS3"*>]-7B:\5V2.<!('.:"T D@'C!582SNK
MI25@K6U6W$(CQ'6"9V);Y&%V RJ2VDS6>U+E;A9I%!&@NJ8]UVI78>NU=D[.
M_:V!-$J40UD&CQ8O7*T-EURD>;Y-N>&T$\U^VZ&^VH[#&Q9('.9&BB^H^@:\
M5>LQW*,G#=(FR->5VJW/591OM-K$.V;.S%:#&THY\>^X,Z*E1I=S6)YR++S,
MF+4]FW(P1OK%V]*^-[&KL\STA>5IA$PB81,(M5QE\6=[X,^#)S KS:C';.[!
M?5;3$4=0Q;#2:J=F4MPNZYA$JS-.)9/VS>LH&,#B.L$Q$NBD4;-WC5KX!MQ;
MQ%O,..+:WE6!S+]B/3D+%AKFC6,#@Y[&ZMDF'O9':?"W"Y_TZ^P*[AF;[IFU
M5:UM;7?+L/LA+3S=ZM:C+N7)>]^)P$Q<#K'E+4+K4]1X/)XJG=B<Z%]JNQOF
MN-P:[T5U@PVRTC:C*0TCK-YNDE;C]B4ISLI/4T?-R]?D]BGUN:;)<G%5C)6"
MEDI648Q#PD8@Q=/I K9DV<N$>D\LS>+.(.]N:EIW2[0'=WNC70CITUZE]LAW
M6]BV[23[+RSY6M;K[10[('(3X#,1[/':B>G5OUL -H!3=B(\G9JW:KZM::U$
MZP^:*&#E)I(V.^HYUGOS@MLVL]UN)BDT_8E8L51L<;46>Q:7,;+J+V7B#VRN
M([ UK%3J]K@8RR5Q%7MFRF(Y%$D=()PMB+'.YAFQ=RV1LA+0'$#[[=<&G0\=
M'$:$@^?I&H6'W_V%[L>+VEV+%/,9?9[*8[*XZUE)L!EZFSN5@JVFXO(/P.T5
MJDS&7;6.R#V&M/4G>_G-<W,>;$=.6:+W0\+?$/4.*?15 W=3#II,K=$D-,0W
M7RKN:O:F ]AV:L/C !#]?AY9)P@BLHDCVPCQ92J"8-'[<QJ"-"0OA?W4>Y[E
M^Y9MUG]B<R'/GQ%MPIW-PLBR>*G'+8S)P ZCD[E1\<CV-<_F]CEJKW<K!(!R
M#+X0\8>7(70&](\8]:GPKZ99?\(^3U!$RE%.7P!X@\F$5<(IR^ /$'DRP[I/
MC/K15R%<CZ_)]*85Q,(IR^ /$'DR7=)\9]:*N0BU&%D)A$S'1,(M1A$PB81,
M(F$52^$/&'EPI'3Y'>HKB/QK6)6(U&WAT#B0]HLT;'.2@/+I,&"3J86 1#OB
M'9C"/*)? )3" CR[P^D=R^DVSM&^R]H(H49YV$\=)I71UF^#7DIIB#U$<./1
MY=W6KSZNS#*K':'(Y"O7D'1K!"V6V[__ +00 CK!/5P74MFQ"UG3"*-55)!)
M5==0B***9U5E5# 1-)),HG444.80*0A"%$QS&$ *4!$1  R"0T%SB &@DD]
M &I)\ '%2 7$-:"7.(  &I))T  ZR3P 7'^E\5G#[L)]98ZI[*BI!W4:\]ML
M\F[C;!")MJM'% [^Q-'$]$1C>7A6B9B*+R4.J_:)I*)J&5 BJ9C<%3VGP-]]
MEE7(Q2.J5WVYPZ.>$-JQC5]ACIXHVS0L&A=)"9&@$$G0C7L=[9':/&QU9;F+
MFC9=LLIURR6M8+K<ITCK/;7FE?#.\@AL4[8WEP< W5I ^YJSB&TYNI].Q>M+
MJVL<G6DVJ\U&J1-@@9%HV>B(-7I&-DB8AT\CUQ H$D&*3EES40 5P%='KE[&
M9_$YA\\6.N-GEKAIFC,4\$C6O^"\,L11.?&[J>P.;Q&I&\-<?+[-YO!1UYLI
M1=6AM%[8)1-6L1/>SX<9DJS3L9(WCK'(6OX.][[UVF:,YA<&F$6[J#8EJE=J
MG9D#BF:$L$5('$!Y=-N@\2,[1-X.:;AKUY!0.8=)-0P<PYYQV7I-R.*R-%P!
M%JG8A;KU/?$X1N'A9)NO;V%H*Y3"7W8O,8S(M=NFG>JV''70&..9AE8?^%\>
M^QPZVN(7?UFH"W<3")A%^7OGU@7R?3")A$PB81,(F$7J=X?_ /)\-M?:;;7^
M]/-2=H_[2&&_/8?_ "@K;?9O^S?F?S&9_P V7EBS;9:D+61R#5S(,6SY\6,9
M.'C9!Y)';K.RQ[55<B;A\9JV SAR5HB8ZYFZ!166!,4T@$YBAE$CGLCD=''R
MLC6/<R(.:PR/#26Q[[O>LWW -WG>];KJ> 5<36/DC;)((HW/8U\I:YXC8YP#
MI"QOOGAC27;K??.TT'$A=JE2ZG=0[1N2W4.+V?L2T5> U1PV[*A>Y374"MLZ
MR,.(6(I<H><&D/;N1C&5;6S*UGFKLX;S\TX81Z#-N*H%=K2K7R.[W2LA4PE+
M(2XG&U+=G+[4XNQSS)V&XJK)LU/?A%?G\>/,DUO*/IB"@QU:!LDKGO#26"%_
MKM/N:8^WG+F.ARN3MU*^(V7RD',\97=EK4>TL-&4S\P??$<53%LN<O?<VS.Z
M.)K&ZZ/=,S%<]PEZ;K&K.(N>GMH['B;[PX;29:9GUWNOZV&KK?L"1V18*NVB
M:7-M+R]MTF=M2:K9+_+)+U=JLP8Q"S4 7.[C3/>7K[8YNWE]F:]?$XR;&[3X
MF3.5Q'D;1RU+'18NM;=->@?CV4X@^_<JXZ$MMO;)).UVK=R7D^)L;'8.IB=I
MK%C+Y.'([,99F#L.DQU48F[DI<G9J,AHSLOONREM"G:R,S75&NBCA<WWY=&7
M\?N)_2]:T7L*OU:H6^5O-;LNIM1;1B+%-5YO59)TRVGKZ!O+=%S MI>>2C3M
M4IHB'8P2\@9/H= [I8Q15/V/93.6L_C;-N[2AQ]JKF,UB9ZL%EUR)DF(R5G'
MO<RRZ"L90]U<NWN0B!UU#&@Z#K>U>#J[/Y.O3I79K]6SB,-E8;-BLVI*^/+8
MVO?:U]=D]AL18)PW=Y>0C30O<1J>.F=E765Z/OB>O^&.*[[6Z6_M6TLUK^R)
M_JMDOSF<_P .)6R'V/7];M9^;PG^+*KTQ9K&MF%UW\4>R^Z"P)T6*<=*(K*X
MJ2IDS?L;RP= R9TC<A$#DB$3G;!X!!ZL^(<H]92/EESM3PZ!J/&>OS:<./;J
MMU_L?]A.\N%?M;D8=W)YZ(,Q[7MT?5PV\'LD (!:_)2-;.3QUJQ5',(Y61IZ
MO-O<.L)N&]P5ILHQ[V)@M:[ IS6'=I/P53G[;(U5Y&6!-PR>-0%*)1@GJ*S1
M3I@X%\F8.0)CF/)#RCPXZ:!CFZ'7I)!!X=FB]9S^R-7:#)U;MTQ205</E<?'
M7D;+J+5^:A)#;#XY(_>UVU96NC(.^90>&ZL/1_!].13&H'1LM0E):G/>'IXS
M+.UMV]B7@:<UH^UU.-G*17I'*2-@+(&F&'6E![&78LT'950YKI6A7< .+"08
MS[YI(]XTM</!KJ#KX.(77H>Y]9@BQY;=H3SXZ79*2/G-.22"3W.X:7$66/:)
M0]K;8F-B+==[QT<;)-[X0[$ZS/+UR9:2:/2,1,W6W:(#R[(9J" +I#WP 3<@
M!1(3?(E632.("!>6<O1MOI68[#=2&G=D:/OXG$;[>S4CBW7@'!IZERG=+V%H
M]T78_*[,W-R.:>,6<5<>W>[WY>L'.I6QH"X,#G.@LAGOY*<]F)I!DU',)JZ0
M>MD'C50JK=RBFN@J7P'25*!R&#GWPYE$.8" " \P$ $!#/28Y&2L9)&X.8]H
M>UPZ"UPU!\Q\8ZU\@LGC;V&R-[$Y.O)4R&-MST;M:4:/@LUI7131NTU!W7L(
M#FDM<-'-):03/E:P4PB81,(F$3"+9]PN#*JLNF?HN))P4P,F0&[YQ\'7U^7?
M3;)C\L;O&4,'6T^_TC$Y#'X^6_+H-60L(Y673@!\5NO O(Z!T >^=PT!X_(9
M"*A%J='S/!Y*+7B3\9VG$,!Z3TD^];QU(XK2<F]EWJ\A(+F<.G!ND<YO 4/\
MU-,O@323#Y%-,H 4I0Y!\T1[W!!%7B;#"T,8P: #I)ZW./27$\23Q)71)YY;
M$KIIG%[WG4D] '4UHZ T#@ . "T&75:3")A$PB81,(F$3"+F_IC2\)2J^^W1
MN15G"PE:B'MI2:38@@Q@X:(9JR;RT6,%0Y)$9,FZKUNT5*/8R2?9;D@K@DBC
MY!MIMIOF7#X>71G&.[=C=IO]3J]=X^\Z1+,T^^XL8=W><[W?N9=S2[E,ABYK
M-"6[E,E<J5,#A&1E\\]VY,R"F9(3Q=8FGDC95K.'O7.:^0;^ZUGCWX[N*^;X
MQ>(RX[6=G=MJBW4[E]8P+H1*,#0(9PY"'350Z1RHR<RJN[L<X4IU2DF)=XW1
M5,S;M2)^6M&@T\Z_2]W".Y11[CO<YP^RD(AER\C>^FT]^( \_P!H+D<9N.:_
M0%]6DUD6.HDM:33J0R/8)I)7.RNQXTM;0>NZ(I$:RNCC>-'X2KCPD1-BD+G"
MI:UCZ[?)?9JU@O!:LVJRMBE[,2 VC/0\5'NK*QA6;H&DJZ0D#- :N+'(N+G
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M&A.HX:]!U6YB]0IX$!#F+';?A^J*/V/^),C?=V^@>Q1_3I[NWX?9+_\ #O\
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MNTXQMJC:]OG%59"<A4::Q=&M6H',"T;,)T$'*B,^PAFRPN)V:V7VCOY3"W+
MN8J/#X'N:VK%VYWWAR#W4,1*_,8>G7 BKSF](WF>;99>^2OOM#JTD[FAL;3;
M4;.4,9F*E<T\I)F,[W2:L%*IWHFQ[!>R\3</F+M@F2Q VC&_GF%=78V.QNN+
M;$<#"7;IM4F_>7C4-!N=RTOMR(J?!_QN,MX[LU=>M$3K:VH631]JNZ573K&H
MIMU,UV@:?L<92876TE=*]65Y>V!+.JY$1[(L>W)B5(8XZ&:R-&CG<--<VUV#
MDP."R^/V@KOI.K9^GCW6S;S4#(+61S=6:_/E8J-FVV"GR++4TLG*/.7<FDDO
M87'7KV"S,-+8O;R//YW$7]GK#;C;6 N7Q4%7"S23UL;A;,5"#&2WJU5\USEG
MU88XQ$U>>?-D%K8O1]\3U_PQQ7?:W2W]JVEFM?V1/]5LE^<SG^'$K9#['K^M
MVL_-X3_%E5Z8LUC6S"N)\L'W?(.4O^"?)ZPJF?"'E]14V65>6QI;6U+FY)S+
MOH82R;WK79SR.DI:&5?G02(@@J_&'?L"OET6Z:;=-P[*LN1NDDW*H"*29"TE
MC2=2.)Z2"1KX]"-?*KC97M&@=P'0" [37B=-X'34\=!U\5\_S)*)ZFROXVV_
M]?9')M[#\YWM4\M)\8?,9^ZGF240/!'2H?\ S;</U]CDV]A^<[VIRTAZ2#_R
M,_=5?,EHOJ?+?C=</U]CDV]A^<[VJ.5?_P /S&?NIYDM%]3Y;\;KA^OL<FWL
M/SG>U.5?_P /S&?NIYDM%]3Y;\;KA^OL<FWL/SG>U.5?_P /S&?NIYDE$'PQ
MTL/_ ,VW#]?8Y-O8?G.]JK9*\D\6]'Q&#K'8U4\R2B>ILK^-MO\ U]CDV]A^
M<[VJYRCNT?-;[$\R2B>ILK^-MO\ U]CDV]A^<[VIRCNT?-;[$\R2B>ILK^-M
MO_7V.3;V'YSO:G*.[1\UOL6VK-K&2CF\>OJZ5G:[).)B+C+!RL4I)-G%1E':
M;&PO$&5BDWL>A.P;!=2;@I-ND600>L0:D!VV>.6#JE[" .3+FG4 ^^/P3P)X
MZ\1T@](\6H537@Z[X#AH2W@!HX#5NN@!+2>#AT$'J(!&ZRZAHH% #,IQ8P
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M8!(.H.A'$$=(/:HZ>E=.G$SI!UJVV+S$0T.-%LKM9Q$+I$$R,.^5$R[F <&
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M\K+RLKT??$]?\,<5WVMTM_:MI9K7]D3_ %6R7YS.?X<2MD/L>OZW:S\WA/\
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MD)/-G'B7,F/)CANS$G=;KQM3W+LIC'R6L&V3*X\ESN;M =D:S>G=,3=.=M'
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M?.*>N&R1;F T!;\T*>9P]COG%5"&9!X"J>N#@VI3T[OS?XIS.'L=\XJ\(EF
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M;T?Y@]K"G?=V^@>Q.F;T?Y@]K";[NWT#V)TS>C_,'M83?=V^@>Q5 QA$._\
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MV8_\3K_HF^Q>8=^<K^/V?TA3NPM(?^WY7V8L/E-CO9C_ ,3K_HF^Q._.5/\
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M@8YLDH!<7Q,+7NZI[ML6Z;$D3R=PL#^86$YC(-U513CF(&$?V./C4>MLF28
M/(000(8_RRIE#B8P[!8K"XO"P"#&TX:S= 'O:W>GE(^^FG=K+*>S?<0.AH
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MO KFO =O0A(GNH&(&R=KFG;T8 KPL(,MU@G9XQ)9$QGY8X7/7.Q >&,Y!#H
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ML :S5W#G+G=%T%2H(*N5T6S=,RJ[A5-!%(@<SJ*JG!--,@!WQ,<YBE*'S1$
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M@KUXWS3S2O.C(XHHPY[WN/ -:TD]B]M] X&]ATWJ1,]PC]!L?<5BU'=I1[&
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K15+X0\8>7"AW0?$?4I\*PF$3")A5,^$/+ZBF%>3")A$PB81,(F$3"+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gwpjrhodncoa000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )R!3,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDML_1?WA_0U[G7CG@#3;SQ#\4M;\77MK/#!"[);>?&5)+?*N,^D8Y_WA7L=
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M/B#37.0HC?'H5+*?YC\J]OKQ#X!V\L][K^I2=&$<>?5B68_R'YU[?0 4444
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MPH%FQD@,2H8-@'(;J#GCIV-7?B+XOUF/QQ8>%].U6/1K:14:6]<#JV>I/0#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !17(?$>_N;7PU#:V5U-:W>H7L%G%+"Q5UW.,X(Z
M< UD>(O#FJ>%M$NM=T;Q5K<D]DGG-!J%S]HBE1>64@C@X[C_ .O0!Z-17,WG
MC;3]/TC2KJ>&ZFN]3B62WL;2+S)I,J&.%]!GJ33-&\>:;K>J2:;!9ZE#>06[
M3W$5S;>6T(! VL"?O'((QD>] '4T5AV'BO3=0\(GQ-'YL=@(9)F$B@.H0D$$
M D9^4]ZT=+U!-5TJUU"**:*.YB65$F4!U!&1D GG\: +=%>?_$Z]\16.@WUU
M8W\>GV$,: /""UQ/(S!0H/ C49'(R>.U=IIT366CVL5Q.\C0P(LDTSY9B%&6
M9CU/<F@"Y17DWB76]8\1ZAH\^DW]S8Z/<:I':6I@D:-[P<F24D<^6-N%'?DG
MM7K- !17(7_Q%TRTO+FWM=.U?5%M&*W,^GVGFQ0L.JLV1R.IQFE\2^-(+#P,
M^O:9'<7<5Q Q@F@C!6,D':S[B, -@'OGC% '745PWPZT6RM].CU)M'O[35VB
M$=U<WQ/F7+$!F8?,<@MT)P:K_$G2WL]"U3Q!#KVNVUQ'&HBM[6^:.(.2%7Y
M/4Y/K0!Z#17 #3K?P/I,'B+5]>\1WAMT02P37YDC9WPA^1B!P6SR>,5T&F>+
MK'4X+V[%M>VNGVL8E^W7</E0S(<_-&2<L.,]!U'K0!OT5R$'Q%TN6XM=^GZM
M;V-W(L5OJ$]H4MY6;[N#G< >Q*@5=UWQE8:%?QZ?]EO]1U"2/S?LFGP>;(L?
M3<1D #/O0!T5%<QI/CK3M<CU)].L]1F;3D4S1_9]KESG]VJD@[QM.0<#WK(\
M">,=1UUKV2_L-1-O+=3/;7#6\:P0PKP$+!LEL@YX//>@#OJ*X,?%K07T^._A
ML=7GM,_Z1-#:;DM><#S&!P.H. 2<>_%7)?B5H:7D$<<6H3V4TP@&I16I-J')
MP!YG?GT!H ["BL;7?$UAX?\ L\=PMQ<7=R2+>SM8C)-,0,G:H[#U) ]ZCT/Q
M98ZY+>6XM[RRO+,!I[6]A\N1%/1N"00<'H: -VBN#'Q9T)].2_@L-8N+4?\
M'Q+#:;TM><?O&#8''. 2<5+\0O%EYHOA^ Z-#=/=7[1I;744*NB%F& 0QY8C
M.!@_A0!V]%4-'U%]3L%N)+"]LFW%?*O8U20X[X4D8-7Z "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'?\ )/-/_P"PK'_Z*EKV"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!VXK->36$1G,5CA1DXD?_P")K2J.X_X]I?\ </\ *DT:4Y)/57,NRO=5OK2.
MYBAL@D@R TC9ZX]*U8O-\I?.""3'S!"2,^V:S_#O_( M/]T_S-:=*&R9>(:5
M244K6;"BBBJ, HHHH **** "BBB@"&Z_X\Y_^N;?RKF_AO\ \D_TK_=D_P#1
MC5TEU_QYS_\ 7-OY5S?PW_Y)_I7^[)_Z,:LG_%7H_P!#OA_N$_\ ''\IG544
M45J< 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 444A( )/04 >8Z[\5KY=:O-&\,^&KO4[NTD,4LI5BJ,#C[J DC@
M\DK5#^W_ (QS#S$\.6**W(7"C'X&7/YU8;XL7J6\MQ:^%9A:7,[0:?<>9A;B
M;=CYA@8SR?P(KJO!GB?4M;?4=/UO3DL-5T]U$T2/N4JXRI')_F: .,_X61XZ
MT EO$W@YGMEQOGM590@[DMEU/TR*],\/:[:>)=#MM7L1(+>X!*B5<,""001S
MW!K3IJ1I$NV-%1<DX48&3R: '4444 %%%% !1110!X_^T=_R3S3_ /L*Q_\
MHJ6O8*\?_:._Y)YI_P#V%8__ $5+7L% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7,^(['P;I=I<:UKNDZ5MSF2>:R1W=CT
M_A)8FNFK@OC%817WP]NGENH[?[-*DZ;R<2$9&SCN=W'OZ=0 <>WQ&^%H8@>#
M0P'<:5;<_P#CU>B^ ]<T#7M#EN?#NF_V?:)<-&\/V=(?GPI)PA(Z$<UPFF?$
M[X=II=LDVA+;2K& \*6*.%/?#=Q[UZ%X/U_1/$6DR76@P^3:I,8V3R1%\^ 3
MP/8CF@#H:*** "BBB@ HHHH **** / /BG_R<+X*_P"W'_TK>O?Z\ ^*?_)P
MO@K_ +<?_2MZ]_H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.X_X]I?]P_RJ
M2H[C_CVE_P!P_P J&..Z*'AW_D 6G^Z?YFM.LSP[_P @"T_W3_,UIU,/A1KB
M/XT_5_F%%%%48A1110 4444 %%4]6N)+31KZYA.)8K>21"1G!"DBO"O^%I>+
M/^?Z+_P'3_"L*V(A1:4NIZV6Y-B,QC*5%I<O>_\ DSWNZ_X\Y_\ KFW\JYOX
M;_\ )/\ 2O\ =D_]&-7D[_%#Q4Z,C7L15A@C[.G^%5M,^('B'2-/BL+&YBBM
MH00B>2K8R23R1GJ37*\;3YU+79_H>Y'A?&K#2HWC=R3W?127;S/HNBOG[_A:
M7BS_ )_HO_ =/\*]5^'FN7_B#PTU[J,JR3BX>/<J!> %QP/K712Q4*LN6)Y&
M/R#%8&C[:JU:]M&_\CK****Z3Q HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "CJ,444 <_;^#='MK"*S=));:WO3?6Z22'$
M,F2>,8X!).#GK7-P^,O ?AW7=6N'U[SKZ]E#3N$:0+M&%12BXP!7;ZO:R7VC
M7UI$_ER3P/&KG^$E2 :\.\#Q_#FWT:2T\31VZZO!,Z3M,S,KX)P4*G&,<4 >
MN:#XY\.>)KU[/2-1%Q<(GF,GE.GRY S\P'J*Z*N(\'GP!_:LO_"+?8_MOE'?
MY.[=LR,]>V<5V] !1110 4444 %%%% 'C_[1W_)/-/\ ^PK'_P"BI:]@KQ_]
MH[_DGFG_ /85C_\ 14M>P4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?]N/_I6]>_UX!\4_^3A?!7_;C_Z5O7O] !1110 4444 %%%% !1110 4444
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MWTY+=HD9U*^>S$=,]0,'GUQ7T=0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7.ZSX$\+Z_(TNHZ+;23,=S2Q@Q.Q]2R$$
M_C715R7Q&\53^$/"<E_:1J]W+*L$.\956()R1WP ?QQ0!G#X->"LY_LZ8^WV
MJ3_&NCT7P?X>\.D-I6D6UO( 0)=NZ3![;VRV/QKSOP9J_C.7QOJWA_7-9\RX
M33&F39&A6*1@A4CY0,C?TZ?6NI^%OB:_\4>$FN=4E$MY!<O!)($"[L $'  '
M1L<#M0!VU%%% !5+5KJYL=(N[JSLGO;J*)GAMD;:97 X7/;)[U=K+\1:[;^&
MM O-9NX+B:WM$WR);(&?&0,@$@<9R>>@- 'C-U>?&*71=0\1:AKEAH$=MO=+
M":)$+!1D[<JV0>@W,<GVKM?A!X[U/QUX>NI]5MHTN+281&>)=J39&>G9AWQZ
MCI6/?IX'^->AIJUUJ5U8#3A+&$DFCB:#.#O=3D8(5>^.HZUE?L_>*-3O_P"T
MO#\SI<:;I\2M;3"((4RQ&TX'.>3SSP: /<J*X/QKX$U[Q1K,-[I?CC4M"@CM
MUB:VM0^UV#,=YVR*,D,!T_A'-<W_ ,*@\8?]%9US\IO_ (_0!@?%/_DX7P5_
MVX_^E;U[_7RYKWAO4O"_QL\(66J>(;O79Y+BRE6YN@VY%-R1L&YV. 5)Z_Q'
MBOJ.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *JZE_R"KS_K@__H)JU574O^05>?\
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M-BLEP.S2'K^)Y] ,Y/K-AI]GI5A#8V%M%;6L*[8XHEVJHJS10 4444 %%%%
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M>&='\*Z;]@T6QCM+?=N8*26=O5F.23]36M10 4444 > ?%/_ ).%\%?]N/\
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M^IWM%%%>T?F84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_HJ6O8*\?_:._P"2>:?_ -A6/_T5+7L% !1110 4444 %%%% !1110 4444
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MVK?TK=KT*?P(^/QG^\3]0HHHJSF"BBB@#.U__D7-4_Z])?\ T U\NU]1:_\
M\BYJG_7I+_Z :^7:\K,?BB??<&_PJOJOR"BBBO./LPKW;X0_\B6__7W)_):\
M)KW;X0_\B6__ %]R?R6NS ?Q?D?-<5_\B_\ [>7ZG>T445[1^9A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $<\\=K
M;R7$SA(HE+NQ[ #)->56WQFEOO$%C:VN@R#3KRZ%O%=RR$;_ )@"0,8XR.,U
MZ9J]C_:>C7MANV_:8'BW>FY2/ZU\VW]]JWAL^'=*U319HI-#O'F#<@7 +AL
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M?%35["6QU#7].N+648>-VX/.1_RR]: )K;P'\2KBW2:;QNT3N-Q1;F5@,^^
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MEV1+DENS7NKWQ[:6DUS)8^&RD,;2,%NY\D 9./W=4]!U_P ;^(=#M-6M-/\
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M5_\ (O\ ^WE^IWM%%%>T?F85E>)M0N]*\,ZEJ-BD3W-K;O,BR@E3M&3D @]
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MWUTUT\%HI6"#( VIGG&!UP/I734 %%%% !1110 4444 %%%% !1110 4444
M5[Z\CT_3[B]FSY5O$TKXZX49->/0_$WQWKN^[T+PI%+8;B(V>)Y#Q_M!@#^
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M[ 9 _$UY3_PL#XE_]"5_Y+R_XT =-X,\:Z[XCU>2TU+PQ<:9 D)D$\BN 6!
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M=6;0/"I)674I5Q/=#H1&.P^A]<M_#5W1_AMJGB;4HO$'Q(NEO+A3NM](C/\
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M6/\ ]%2U[!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0L1@F.,*2/PJQ10 4444 > ?%/\ Y.%\%?\ ;C_Z5O7O]> ?%/\ Y.%\%?\
M;C_Z5O7O] &7XD_Y%K4O^O=_Y5XI7M?B3_D6M2_Z]W_E7BE !1110 5ZSX#_
M .15A_ZZ/_.O)J]9\!_\BK#_ -='_G0!TU%%% !1110 50UO_D!7_P#U[O\
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M .ON3^2UV8#^+\CYKBO_ )%__;R_4[VBBBO:/S,**** "BBB@ HHHH ****
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M_P!%2U[!7C_[1W_)/-/_ .PK'_Z*EKV"@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBD=UC1G=@JJ,LQ. !ZT +17C]_^T1X9M-::SAL+VYL
MT8JUW'M //55/)'U(^E37?Q(U[QK=/I?PWTYFB!VS:U>H4AB_P!T$<GZ@G_9
M[T =SXK\;:#X,L?M.L7JQNPS%;I\TLO^ZO\ 4X'O7 >7X[^*G,IE\*>%G_@'
M_'W=)[], CZ#G^*NA\*?"K2]$O?[8UFXDUW7W.][V\^8(W^PISC'8G)],=*[
M^@#!\+>#="\'6/V71K%(=P'F3-\TLO\ O-U/TZ#L!6]110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!!>WD.GV%Q>W#%8+>-I9&
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MSX#_ .15A_ZZ/_.@#IJ*** "BBB@ JAK?_("O_\ KW?_ -!-7ZH:W_R K_\
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M<5_\B_\ [>7ZG>T445[1^9A1110 4444 %%%% !1110 4444 %%%% !1110
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M%>/_ +1W_)/-/_["L?\ Z*EKV"@ HHHH **** "BBB@ HHHH **** "BBB@
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MJSRJIR$9V+;?PS@^X-=710 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7SU9^/8O WQ"\72SZ8]Y)=7KJK"784"NWJ
M#D'(_*OH6B@#YKT_XGP6'Q%U+Q2FD/Y5[ (C;"< @_)\Q.WG[A[=Z]N\#^,$
M\:Z++J4=D]H(YS#L9]^< '(.!_>_2NFHH **** "BBB@ HHHH **** / /BG
M_P G"^"O^W'_ -*WKW^O /BG_P G"^"O^W'_ -*WKW^@#+\2?\BUJ7_7N_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY+79@/XOR/FN*_\ D7_]O+]3O:***]H_,PHHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC7XLZ#X$UF'2]4M-2FGEMUN%:UC1E"EF7!W.ISE#V]*YO_AH[P?_ - W7/\
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MBFKXYK] X._@5?5?D<N(W04445]B<P5],? S_DG8_P"OR7_V6OF>OICX&?\
M).Q_U^2_^RU\SQ9_R+_^WE^IO0^,]*HHHK\T.P**** "JNI?\@J\_P"N#_\
MH)JU574O^05>?]<'_P#032>Q=/XUZGF%%%%>:?;!1110!WGA+_D"?]M6_I6[
M6%X2_P"0)_VU;^E;M>A3^!'Q^,_WB?J%%%%6<P4444 9VO\ _(N:I_UZ2_\
MH!KY=KZBU_\ Y%S5/^O27_T U\NUY68_%$^^X-_A5?5?D%%%%><?9A7NWPA_
MY$M_^ON3^2UX37NWPA_Y$M_^ON3^2UV8#^+\CYKBO_D7_P#;R_4[VBBBO:/S
M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7H7@WQA:>--)FU"SMYX(XIS"5FQDD*#G@G^]0!T5%%% !1110 4444 %%%%
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MXK_Y%_\ V\OU.]HHHKVC\S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** *FJB<Z1>"VMTN)S"_EPN?ED;!PI]CTKQ;P
M_;?%7PS:266G:)$+-I#)'#*Z.(LG)"G?G'UKVG4_MG]E7?\ 9^W[;Y+>1NZ;
M\?+G\<5Y3_Q>G_IT_P#(- '3>#-0\?7>KR)XHTRWMK$0DJ\>W)?(P.&/;-=W
M7F'PW\0>+=6\1ZG8^(KN &Q3;):&,)(KDC## P5QGOZ5Z?0 4444 %%%% !1
M110!X_\ M'?\D\T__L*Q_P#HJ6O8*\?_ &CO^2>:?_V%8_\ T5+7L% !1110
M 4444 %>9_$GX4+XTO(]4L+N.TU%4$<@E4E)0.A)'((^A[5Z916^'Q-3#5%4
MI.S$TFK,\4T?X+:[X;MEU/1_$J0Z_&3@"/\ <.O]PD\G/J1CV[UT>C_%!K*_
M31?'.GMH>I]%G(_T:;W#<X_,CW'2O2*S]8T33-?L'L=5LHKJW;^&1>A]0>H/
MN.:ZY8_ZP_\ :US>:T:_S7DR>2WPCKG3-+U6,/=65I=HZ@AI(E?([$$US]Y\
M-/"UV=RV#6TG]ZWE9<?ADC]*YA_"OBWX>R-<^#[IM6T8'=)H]VV70=_+;_#!
M]FKIO"?Q%T3Q4YM%9['54XDT^Z^20,.H&?O?ASZ@5S5\OBXNI3M./>VJ]5NO
MR\SJH8[$4-*<W'T;.8\0_#]M L)M5T[4+NY\D#S(K@!R$[D$8Z=>G3-<;'J%
MW+(D<8#N[!555R6)Z "OHBL^VT+2+*[-U:Z9:0W'/[R.%0PSUP<<5O@\?]6I
MNFX*7:_3_@>6AO+'5IOFE-I^5E?\M?/7\#BD\;ZOX>M8+76/#LRB)!'YRR8#
M8&..""?^!5=MOBKX=D(%RMY9^IEAW#\T)KMV574JZAE(P01D&N;U+P)H.I$N
M+7[+*?\ EI;'9^G3]*QDZ%75W@_+5?<[/\3"G5II_O8<WH[/]5^!9L_&/AR_
MQY&M69)Z*\@0G\&P:VHY(Y4#QNKH>C*<@UYA>_#2ZM26M([#4X>28KB/RI#_
M ,#4@GZ[A6/_ &/HVG3[;^SUSP].3@2V\Q>(_B1D_@36?U3$/6ERS]'9_<]3
MIY<NGM.4/5)K[TU^1[35>^MS=Z?<VRL%,T31ACVR"*\_T_2M=F3S/#_C\7BC
MGR[I Y ]\EC^@JQ<:C\1=%M99[FRTG4(88V=Y(F*L !DG!*YX[ 5RRJ3IOWX
M--&D,!&4DZ%:#]6XO_R9)?B+_P *_NO^?Z'_ +Y-=!IOA:QM]-CM[RVM[B92
M<R!,$\^O6OGVZ\0:O>:D=0FU&Y-UNW"02$%?ICH/85Z]X9^*.CS:/;1ZW>F'
M4%7;*QA8JQ!X.5!Y(P3TYS2CFSK/ED['NYIE694J,9*7/W45JONW1TLO@W1)
M.EJT9]4D;^IJ'_A#XHO^/35-0@^DO _+%7[3Q-H5_@6NKV4C'HHG7=^6<UJ
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MH **** "BBB@ HHHH \ ^*?_ "<+X*_[<?\ TK>O?Z\ ^*?_ "<+X*_[<?\
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M@HHHK[$Y@KZ8^!G_ "3L?]?DO_LM?,]?3'P,_P"2=C_K\E_]EKYGBS_D7_\
M;R_4WH?&>E4445^:'8%%%% !574O^05>?]<'_P#035JJNI?\@J\_ZX/_ .@F
MD]BZ?QKU/,****\T^V"BBB@#O/"7_($_[:M_2MVL+PE_R!/^VK?TK=KT*?P(
M^/QG^\3]0HHHJSF"BBB@#.U__D7-4_Z])?\ T U\NU]1:_\ \BYJG_7I+_Z
M:^7:\K,?BB??<&_PJOJOR"BBBO./LPKW;X0_\B6__7W)_):\)KW;X0_\B6__
M %]R?R6NS ?Q?D?-<5_\B_\ [>7ZG>T445[1^9A1110 4444 %%%% !1110
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M@Z_4_,:\[\>7GBBXU2/3=<:+=!&&5;;(C?.?FYZGJ/PKT[_A!9X/^/'Q+JT
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M1YAC\6!%6H?#/AO.=,\<7UJ<Y ^W*/R'!K*5#&0^*D_Q_5#]CE\OAK->L?\
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M*36^K0>1=SW;SF+>K;00H'*DC^'UH [JBBB@ HHHH **** "BBB@#P#XI_\
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M4\WQ#;]L_:)ZVE=I/RUT^1T0^)'B01JQL]%D]0MQM)_-^*L#XDZZK@2:/IC
M_P!W4H_Y[C62WQ7^&+C!T)_PT^(?R:C_ (6/\*YE#/IDL9_N_8\'_P =->/_
M &0^D:G_ )*_T-?[3IO>A3_\F7_MQMQ_$W5-S(WAVWD8?\\]3C_P-<CXN\5Z
MGXHE2"2*33[2-?FMEEW;V]2<#/;%:/\ PG7PFDD^:SG7/4^1( /P!KD/$/BC
MPE+K8303+'8^2I+R*^"^3D#=STQU]ZZ<)DD9U4JRFX]FDE]ZU#^U8TO?H4HP
MGT:<G;T4FT=S\+-4OX-9;2'G>:QDB9T1SGRF&.GL<FO7:^=_!'CWPUH7B5[C
M5;QH;<6[!9Q$[J')'&%!/3/.*](_X7;\//\ H8?_ "2N/_C=<698.GA*[ITU
M9;V.:KBIXJ7M*GQ=7M?S?F>@45Y__P +M^'G_0P_^25Q_P#&Z/\ A=OP\_Z&
M'_R2N/\ XW7 9'H%%>?_ /"[?AY_T,/_ ))7'_QNC_A=OP\_Z&'_ ,DKC_XW
M0!Z!17G_ /PNWX>?]##_ .25Q_\ &Z/^%V_#S_H8?_)*X_\ C= 'H%%>?_\
M"[?AY_T,/_DE<?\ QNC_ (7;\//^AA_\DKC_ .-T >@45Y__ ,+M^'G_ $,/
M_DE<?_&Z] H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***I:OJMIH>CW>J7SE+6UB:60@9.!V [D]!0!=HKP^S^*WQ$\3Q76J>%O!UI
M-H]NY5C,Q:0XY('SKDX[*IQGO7<?#7XCVOQ"TNXD%M]DO[1@MQ;[]PP<[64X
M&0<'Z$?0D [BBBB@#P#XI_\ )PO@K_MQ_P#2MZ]_KP#XI_\ )PO@K_MQ_P#2
MMZ]_H R_$G_(M:E_U[O_ "KQ2O:_$G_(M:E_U[O_ "KQ2@ HHHH *]9\!_\
M(JP_]='_ )UY-7K/@/\ Y%6'_KH_\Z .FHHHH **** "J&M_\@*__P"O=_\
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MY=KRLQ^*)]]P;_"J^J_(****\X^S"O=OA#_R);_]?<G\EKPFO=OA#_R);_\
M7W)_):[,!_%^1\UQ7_R+_P#MY?J=[1117M'YF%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% 'G&M>'?$NC?$6X\6^&;&SU%=0LA;75K//Y)5UQM<-CD84#'U]L:W@'P:_A
MSPA<:;JYM[NZU&>6YOU"[HG:0 ,N#P5V@ \8/-=C10!XO\:_ EG_ ,(;9_\
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M_P %T/\ \37044 <_P#\()X/_P"A4T/_ ,%T/_Q-'_"">#_^A4T/_P %T/\
M\37044 <_P#\()X/_P"A4T/_ ,%T/_Q-'_"">#_^A4T/_P %T/\ \37044 >
M7^/O FC_ /%+_P!D>%+'_D8+3[9]DTY/^/?YM_F;5_U?3.>.F:[#_A!/!_\
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M]<]?_P ()X/_ .A4T/\ \%T/_P 37044L1B*F(J.I5=VP225D<__ ,()X/\
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M]^5_^1Z/^$>^.?\ T.>A_P#?E?\ Y'KV"B@#Q_\ X1[XY_\ 0YZ'_P!^5_\
MD>F3^%_C?<P202^,=#:.12K+Y2C(/7_EWKV.BA-K5!N>"_\ "L/BO_T,NA_D
M?_C%8_BGPI\2_"/AR[UR_P#$&E26MKLWI N7.YU08!A ZL.]?25>?_&W_DD.
MN_\ ;O\ ^CXZV^LUOYW][,O84OY5]QY#X*T7XB^.]&FU32]>TV&"*X:W9;I
MK%@JMD;8F&,.._K72?\ "L/BO_T,NA_D?_C%;7[./_)/-0_["LG_ **BKV"C
MZS6_G?WL/84OY5]QXO9>#_C5IUN+>U\7:''$"3M\L'D_6WJQ_P (]\<_^AST
M/_ORO_R/7L%%9-N3NS1))61X_P#\(]\<_P#H<]#_ ._*_P#R/1_PCWQS_P"A
MST/_ +\K_P#(]>P44AGC_P#PCWQS_P"AST/_ +\K_P#(]'_"/?'/_H<]#_[\
MK_\ (]>P44 >,7OA+XUZC87%C=>+]#DM[F)H94\L#<C @C(M\C@]JX[_ (9]
M\;_]!70_^_TO_P :KZ8HKHHXO$4$U1FXW[-K\A.*>Z/D_P 4_"'Q7X1\.7>N
M7^HZ5):VNS>D$CESN=4& 8P.K#O5/P5\,_$OCO1IM4TN_P!-A@BN&MV6Z=U8
ML%5LC:C#&''?UKWSXV_\DAUW_MW_ /1\=<_^SC_R3S4/^PK)_P"BHJV_M3'?
M\_I_^!/_ #%R1['#_P##/OC?_H*Z'_W^E_\ C5=-H7P^^+_AK3O[/TCQ3H=M
M:[R^S;O^8]3EH">U>Y45E5QN)K1Y*M24EV;;_,%&*V1X_P#\(]\<_P#H<]#_
M ._*_P#R/1_PCWQS_P"AST/_ +\K_P#(]>P45S%'C_\ PCWQS_Z'/0_^_*__
M "/1_P (]\<_^AST/_ORO_R/7L%% 'C_ /PCWQS_ .AST/\ [\K_ /(]-D\,
M_'":)XI/&.AE'4JP\I>0?^W>O8J* 3L>$_\ "N/BW_T,^A_E_P#:*IZMX)^*
MNC:-?:I<>)=&:"RMY+B18URQ5%+$#,(&<#U%?05<_P"._P#DGGB;_L%77_HI
MJGDCV-_K5?\ G?WL\%\%:;\2O'>C3:II?B#388(KAK=ENHU5BP56R-L3#&''
M?UKI/^%<?%O_ *&?0_R_^T5K?LX_\D\U#_L*R?\ HJ*O8*.2/8/K5?\ G?WL
M\8M/"/QKL8/)MO%^AI'G./+!Y_&WJ?\ X1[XY_\ 0YZ'_P!^5_\ D>O8**I*
MQC*3D[O5GC__  CWQS_Z'/0_^_*__(]'_"/?'/\ Z'/0_P#ORO\ \CU[!10(
M\?\ ^$>^.?\ T.>A_P#?E?\ Y'H_X1[XY_\ 0YZ'_P!^5_\ D>O8** /&[CP
MM\;KJVEMYO&&AM%*A1U\I1E2,$<6]<O_ ,*1^(G_ $'-#_[[?_XS7T9142IP
ME\2N=%'%XB@FJ,W&_9M?D?,^K?"/Q]HVC7VJ7&LZ,T%E;R7$BQLY8JBEB!F(
M#.!ZBL?P5X'\9>.]&FU32]5TV&"*X:W9;HE6+!5;(VQL,8<=_6OI#QW_ ,D\
M\3?]@JZ_]%-7G_[./_)/-0_["LG_ **BJ?84OY5]QM_:F._Y_3_\"?\ F<G_
M ,*1^(G_ $'-#_[[?_XS6[I'@/XQZ#9&STSQ7H<%N7+E-F[YCC)RT!/85[?1
M51IPB[Q21E5QN)K1Y*M24EV;;_,\?_X1[XY_]#GH?_?E?_D>MCPMHWQ6M/$=
MI/XE\3:5>Z0N_P"T001J'?*,%P1"O1MIZCI^%>D459S!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 >*#1K3XD^/?'*:[)<R0Z*([?3HUF9%MV*OEP%/+;DSSGK]
M,=E\(-6O=9^&.DW5_.\]P!)$97.68)(RKD]S@ 9]JS]4\$>*K#Q3K>J^$=2T
MN&'78T6]2_1RT+*"N^/;U."3AN,FNL\'>&H?"'A2PT."4RBV0[Y2,>8[$LS8
M[9)/'84 ;M%%% !1110 4444 %%%% !1110 4444 %%%% !6=K>CQ:[I_P!A
MGNKRWA9PTGV28Q-(!_ 6'(4]\$'WK1K*\0_\)!_9G_%-?V9]O\P?\A+S/*V<
MY^YSGI0!Y'X$UBXT']F[4-3M'*7,/VCRG !*.S;0W/H3G\*H_P!B0>$M/^'?
MBO2KB[35=7NK5-2EDN'?[4)T#,'!)'J!]<]1FNI\&_#OQ/IOA"_\'Z_<:,VB
M7-M,J2V32M<+*Y&"=P"[1\QZ9R![TNF?#SQ5<S^'+'Q)JFE2Z)X=D26U2SCD
M\VX,8Q'YF[@8P.F<\CWH ]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*R/$?AZP\2Z<EEJ<ERMFDHEDCAN&B$H"D;7*D$KSG&1R!Z5KUQWQ+\/>(?%/
MA1M(\/7UM9O<2 733NR!X<'*@JI/)QGU&1WP0#RGPQJ$_AO1/B1J?AN>Y7P[
M:CRM+=G+HLI8KNCSG.-P.>XVYS5C^Q(/"6G_  [\5Z5<7::KJ]U:IJ4LEP[_
M &H3H&8."2/4#ZYZC-=QHG@_Q,_AJ[\*:[#X;M- DL7MX1HXG\U)"1ACYG!_
MB)/4G'O5'3/AYXJN9_#ECXDU32I=$\.R)+:I9QR>;<&,8C\S=P,8'3.>1[T
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M_H5PEQ;BUC<3W!CR$$F[Y5 !QQGCWYH ]8HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO<V-Q?6_FRV,WGV[;V78_KP1GIWS44_AG1[G6)-6ELP;Z6W-K)*)'7=$>JD
MX/UQGIZ5K5PGB7X@ZAX:EDN9_"MVVC13B![YKA$8G.,K'R2OH20#0!IZ/\._
M"N@:G'J.F:5Y%W$"$D^T2MC(P>&8CH?2M>UT/3K/6+W5K>VV7UZ%6XEWL=X4
M8'!.!^ %8>N>-FLM0L=+T729=8U.\@^TI LRPJL7]YF;I[#']*I)\3K'_A%9
M=5FT^XCOHKO["VFA@9/M'9 >X]\>O':@#NJH7&BZ?=:Q::M-;[KZT5D@EWL-
M@88;@'!S[BN?T/QM+>:S=:/KVD-H>H0V_P!J"27*RH\7=MX  Q_CZ5O1Z_HT
MTZP1:M823-'YRQK<H6*8SN S]W'.>E &9J?@#PKK&J_VG?Z-!-=D@L^YE#D?
MWE! ;\0:LZ[X1T#Q+%#%JVFQ7"P#$1!9&0>@*D''MTJY'K>DRZ?)J$>J63V,
M9P]RMPAC4^[9P.HI]OJVFW=W-:6NH6D]U",R0Q3*SI]5!R/QH H2>#_#TV@)
MH3Z5;G34.Y8,$;6_O YSNY/.<\TW0/!WA_PP\CZ/ID=M)*-KR;F=B/3<Q)Q[
M5G>$/&(U?PZNHZU/8V4CWDEK'\_EJY!PH&YCECZ9KKJ *FIZ;::QIL^GW\7G
M6LZ[9(]Q7</J""*DM[.WM;"*QAB MHHQ$D9)8! , <]>/6IZ* .6L_AQX1T^
MZCN;718HIXYUN$D$CY5QTP=W Y^[T]N*T)?">AS>)(_$+V"_VK&,+<!V!Z;>
M5!VDX.,D5LUSOB+7M8TN=8=(\,W&K,(_-D<7"P1H.> S9W-QT ]* 'GP3X=.
ME_V8VFJ]D;K[887D=@9?4Y/(]NGM2:5X(\-:)'>1Z?I$$2WBE)PQ9]ZGJOS$
MX7V'%,\-^,M-\0>'+76&9;%)Y?(\NYD5<2YQL!/WB>W<^E:'_"1Z&;>:X&M:
M=Y$#A)9/M2;8V/0,<X!]C0!EZ3\/?"NAW\%]INDK!=0,S1RB:1B"R[3U8Y&.
MQX':K47@WP_!J][JL6G*E[>QO'<2+(XWJWWOES@$XZ@9K2EU33X! 9K^UC%P
MI:$O,H\P 9)7GD <\=JP_$OBN*Q\$ZAKVB7-E?&V4;&602QEMP!!*GW]: +D
M/A'0X(M*BBL=J:4Q>R'FN?*)Z_Q?-^.:6?PEH=RVK-+8[CJP07O[UQYH7A>_
MRX_V<59L-7M;E+2"6ZMEU">V6X-L) 'VD<L%SG;GO6C0!SVI>!O#6KB$:AI:
M7'D6PM8MTC_)&#D <\'C[W7WJQ%X3T.#PY)X?AT](]+D!#P*[#=GJ2V=Q/ Y
MSFMFB@""WL[>UL(K&&("VBC$21DE@$ P!SUX]:YVS^''A'3[J.YM=%BBGCG6
MX202/E7'3!W<#G[O3VXKJ::[!(V<AB%!.%&2?H* ,B7PGH<WB2/Q"]@O]JQC
M"W =@>FWE0=I.#C)%0GP3X=.E_V8VFJ]D;K[887D=@9?4Y/(]NGM5'0/&SZY
MXJOM%DT:YL#;6ZW :Y<"1@2,90?=ZYY.?:L[5/B1<V]YJG]E>'+C4]/TE]E_
M>+<K&(R/O;5()? ZXQ^7- &]I7@CPUHD=Y'I^D01+>*4G#%GWJ>J_,3A?8<5
M!I/P]\*Z'?P7VFZ2L%U S-'*)I&(++M/5CD8['@=JT8/$VBSV%O>'4K6&*>V
M%THGF5&$1Q\Q!/ !."?6IEU[1V:U5=6L2;O_ (]@+A/WW;Y.?F_"@"E%X-\/
MP:O>ZK%IRI>WL;QW$BR.-ZM][Y<X!..H&:=#X1T."+2HHK':FE,7LAYKGRB>
MO\7S?CFKEUKFD6+3+=ZK8V[0[?-$UPB&/=]W=D\9QQGK6-K_ (FN--USPS:6
M0MIK;5KAHY)&RQVA004(.._O0!>G\):'<MJS2V.XZL$%[^]<>:%X7O\ +C_9
MQ4&I>!O#6KB$:AI:7'D6PM8MTC_)&#D <\'C[W7WK9M;^SOFF6TNX+AH',<H
MBD#^6XZJV.A]C5B@"AH^BZ=H&G)8:7:);6J$D(N3DGJ23R3[DU?HHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *PO%WBNP\&:!)K.HQ7$MO&ZH5MU5G)8X'#$#]:W:\R^/?_)++K_KYA_\
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M[JWS9X^]F@#VZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@,886D >0+C=M'4XR,XZ9H:]M4O8[)KF%;J1#(D!D =E'!8+U(&1S[T 3T5
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M1+JZ2(L/4!B,BK=I>6M_;+<6=S#<P/\ =EAD#J?H1Q0!/1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -DC26-HY$
M5T8896&01Z$4V""&UMX[>WACAAC4*D<:A54#H !P!4E% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW<*H)."Q)).30!F77_(]?#C_ +!][_Z)AJQKD::1\5/"US81K%)JXN;:^"#
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M5E1IN-[_ -+H>AF.,C7Y53T5KM?WG\3_ $]-@HHHK8\T**** "BBB@ HHHH
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M-U"\N;%8GN#;QH502 E?O,"<@'H.U9?CG_D.^"O^PT/_ $3+3?#O_)5?&_\
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MH PE\'Z.D6I0)%<+;:DDR7-L+J3RCYO^L*INVJ3SR .IQC)JPOAW3%N])N1
MWG:3"\%FV]OD1E56!YYX5>OI6K10!GPZ)86^J:CJ4<)%UJ*1I<MO.'$8(7C.
M!@,>E9TG@CP_-HVF:3-8^;9:8VZUC>1CL.UE!SG)(#'!/0X(Y%=#10!DZ;X?
ML-'GN;NUCFEO)U"O/<W#S2,J_=7>Y)"CT]23UJ#PCHEQH6BM%>S^=?7-Q)=W
M+*Q9%DD;<53/.T=!],]ZW:* ,"_\'Z5J.O#6Y3>1Z@(?LZS07<D>V/.=H"D
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MT#S0N^0ENJ2 DECDX+#WYKO** ,C2O#6FZ/>37END\EY-&L3W%U<23R>6O1
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MTZXU"_G6"UMT,DLC=%4?3D_0<FO-=.^/W@^_UE+!EOK6*1]B7<\:B//JV&)
M/KCZXH ]3HHZC(HH ***Q/#?B./Q##J&+=[:XL+V6RN(7.2KH>"#W!!!!]Z
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX+66Z>;S[B2X12_VSS226+<^8'Z=QP!VKDM1>9/!_C8(ZI;OXOV7;/G8("8
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
,B@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gwpjrhodncoa000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000014.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #* ET# 1$  A$! Q$!_\0
M'@ !  (# 0 # 0            <(!08)! $" PK_Q !2$  !! (" 0($ 00-
M"00'"0 % P0&!P$"  @)$1(3%!4A%A<B,4$8&3(X.5%7879XF;?8(R0T-D)Q
MM;:Y)7*7UPHF)S52@:$H*3-#8G.(E-/_Q  < 0$! 0 # 0$!
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M\\U8SI[W:FW8VYNT/7RUNNA#K[:W5S>GW4H'-[2C%Q1DL*NR,&I9%$DY9%1
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M'1:/6'B%=5(E##D-[&I!K%AO=TKW09'1E*CD87HZE_701UOG=8,(&1L(L[:
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M@U022QMOMMC7UVSG)%FN$3A$X1.$3A$X1.$6H2ZOH%8"0A&>0B(39&/EV\@
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M)PB<(G")PB<(N<L?[H]62'DFGG5)E=4/<]@]*.@@_P#)HFH1R44+QLM9<\/
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MTUUQC77777&,:ZXQC&,8QC&,8QSX$DDDDDDDDDW))S)).9).I7V
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M!40RP3QFTD,S'QRL) < ]CP'-)!! (&1!&1"L51%51MGAFCGBD%V2Q/;)&X
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M;?VJ_$G?_=;G_*CCMX6ZKX_8=UXO_P"]+,[6%L9SZ[:J=PNS8=/?^;9*+6D
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MA,8BZA_$>XA4 W(X@.^!SSX*YO[9QTI_E6D7_@A?W_E=RK*?MG'2G^5:1?\
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ME+/7$>^6YV7 Q88@,/JOJP--?V?]&WMPC>#VA^Z)/LR_L]\QA]V;^[OC=N%
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MEYC<TN&=P#H<Q8YKL<.Q?%<(?-)A6)5V'/J(C!.^AJIZ5TT+M8Y'0O87MOF
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M%Z^$3A%6"].H-+]CY*&DEM-)>?3#U_9-7?AAE/)6!AI:#V\!<1>QPQV-!";
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5PB<(G")PB<(G")PB<(G")PB<(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gwpjrhodncoa000017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000017.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &L ET# 1$  A$! Q$!_\0
M'@ !  (!!0$!              @)!P,$!08* @'_Q !4$   !@,  0$% @@)
M" 8)! ," P0%!@<  0@)$1(3%!4A%AD8,5%769>8U1<B.5-8D[C1UB-!5'5V
MM]?8"B0R87%W)2A"58&4EM+3)S4W<GBFL?_$ !T! 0 " @,! 0
M   ! @,&! 4'" G_Q !8$0 " 0,# P," P4%! ,- !,! @, !!$%$B$&$S$'
M(D$443)A<0@5(X'P0I&AL<$6)%+1%S-B)31#4U56<H*2DY3A\7,F*#5$16-T
M=7:#AI6UML/2T]7_V@ , P$  A$#$0 _ +Y/'9=5E$<F=:=Y1FNVNX+4Z0[!
MG\DTSRFT8S4,98:VCSFU06'I9#84TTH;F*'UJT)W71  (W)S.2G$-Z%"<</W
M@%2<C /P./Y\_P!?\L5O)/U</R3\?>3#G&=UW#8/:7/54%R33E5=OL]V5E)'
M7<5=K3K*0PZPV)J8TXSF^3P5&G>$A0#C6\S6TYJHM<!P;4*F/&>/S(_K-6D\
M 7&^] <5<QW!*3QJY7-*?B"J6+C-^HW*5MC>!BDSKOZB]G3J^-:]QT'>][ %
M3H&_J'>*CQ4O\4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4JE&9.:FY/-)]F792L%%N-^%I1/
M(>U^_,"C36U=#^FC3U) DZ&$L9QM=.B-J)&( QISV[1Q1A8]Z]%3_9_4_P"7
MW^^<\?;''DU79XU/(]='-'&'&A5L\X2%_P"99[=4IHY1U"X6RW.$C%-IY:T_
M=F]>DK<UL<7Y5#HYO:Q@6NCF]MPE*V//93< .TC4F>E,?G_7S_=^?QS5E/&"
M]PJ7R@^2SFI&H$*OIINJNMX>U;,WLMEE-BQ]M:[94E%^WL(/M)*%+<IV6$(
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MW+DLQ9I&9F>1F+,Y8@Y8GDMG)9B26)R:ZA/_  >O'0$.Z@5]7=M6#?O0G1=
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M9\<<\#_3SX_//YU.5W%B@VG<0BLP"Y!V@%BS84D8W%B0,$DDFNYOW+E9SOE
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M<8S@\=@Z0\1EH]3.TIC5J^0Z_'3F^[T-*&=1\V#B<;=(C9$@ILUE<3%5./\
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M222UD9Y+=W50S0.[/$Q*,Q*DUVD3,\4;NH1W1&9%<2*C,H)59 %#A2<!P &
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M0MB(L0MZ#H:E44'8MZUK?KOTQ2NAU-T;SU?8'$VB[WIFZ"VCV?FQE36A"+&
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M=*";>2Q*@1)UG/?*;FK(2IB52\WIB?)E"U062 !RLXA)SF2B(-4&Z$:84E+
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MH?.P0Z$+\6O:&$/KO^,(.O7>J?N[TY_\Y^IQ_P#NQ9?Z:_4]_7?_ "?IO_\
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MG1]:Y37D,L_GR^K5=+KJ!+$C6K2MXL]LJE<X.HQ(7RK J1J44>D[<9'_ !'
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M%Q+]0"T(A0"1(NP8YQ+*3&)K:1,L\T0B]7:8@"5.0F+$<,M.240 :@\Y4H&
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M-N[W>,'/P3P< '8^"3@ [?YKY'(MA"91WV"Q;)"V69"V$8JB.MK>%'=L*K&
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MS@R-';NKQ;LO3TYC5F5@;6%>29M4*GJ<MSY%9&H9[<>DQY*EH)EP8M)F%,G
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M?)VG_P!UMW_R2;_\66[TO_C9/_;;_G3 ^P_N%/D[3_[K;O\ Y)-_^+'>E_\
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M\=.@W>P+D=[68ZOM>;5"U-#S0L'K!(FW'75"8S2)4YL;.UN1DI7,^SM/D3,
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M8(69I"$(=MK>/80ZUL8D*3VA;UKTV(7LDA#[0OQ[]D(0^N_H'6O36:CWI?\
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M'F5D$8Y+E() H2LI#NX%I@1!^.)7G^RL0:3X P'SP0,8*DG=N7@'^RV 3D_
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M^W:]Z]K=KKE5.;3LQ56U*(Z\@<020"M8Y,;%?9$S%N[O,5"[4K&A;')&B:3
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MXPACDCMI$[Q>?M']4/6KU:]+O73I#I#TZU_K+TV74;F.VBTWJ7IU^JD;I/U
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M,4IBE,4K#E\/+^SURY%,52K[H)D"UMB4HAZ"61*&;30>4*0LLRE"YXFCHSM
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M3[] 4)]4;2I$^R$?PUMS<\_B4*?'*J5('\BB_GQS\UG^IG_B_P 0CO01VTN
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MB[.WMB,  !0H P, 8%<.VZ@UVSUN/J6UUG5+?J*&_.JQZ[%?W2:NNIF4SMJ
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M"VB5-BN0.;0WNC>K4R%RI;<O S@D[CRHP!CDC=G''"L1D"LXM@899OJ;8&-
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M6\]T4+E8CRFU*C3!+/,3DD%)]Z*U%8JZ[]REXP/Z*4?_ %@W%_Q$Q2GW*7C
M_HI1_P#6#<7_ !$Q2GW*7C _HI1_]8-Q?\1,4J-U$>"'CZ+3;IYSNBD(5,XA
M-KVW*>=VANL:Y#%%>4S_  6UJQ!ACL 4G9PDN&K&99_(]E@5OX=I9 F,V[^V
M8) ADXXP3XYR,8.3P.3D8QSQSD8XR;,$ 78S,2N7W(%"ODY52'?>NW:=Y"$D
ME=@"AFDC]REXP/Z*4?\ U@W%_P 1,BJT^Y2\8']%*/\ ZP;B_P"(F*4^Y2\8
M']%*/_K!N+_B)BE/N4O&!_12C_ZP;B_XB8I3[E+Q@?T4H_\ K!N+_B)BE/N4
MO&!_12C_ .L&XO\ B)BE1QL+P1<=N_2'.,Q@M'PMBH*'1V]4=^0)38UR!=9Z
M^RAH@R>FES65J3K0&%0YT;)@K<!B?6,10'=/H*=WT8(M'/&#R<\8&.#]\G/'
MY<'/Y58!-KEF8.-NQ0@*MD^[>Y=2F!RN$?<>#M'-2.^Y2\8']%*/_K!N+_B)
MD56GW*7C _HI1_\ 6#<7_$3%*?<I>,#^BE'_ -8-Q?\ $3%*?<I>,#^BE'_U
M@W%_Q$Q2GW*7C _HI1_]8-Q?\1,4I]REXP/Z*4?_ %@W%_Q$Q2HX]=^"/CR?
M<UW##N7*,A-:= R")'-]5SQ]LFY4C1&),-:C,+<UZDJ22DPDD",M65[8(\ZB
MT,T'HFW_ -L"E2(3^%'QBA(("HY5CPSPDEA/&&P;A]D9V@!T8(/_ .H0?H(?
MM;U_%#]-_P#9U^+2E:WW*7C _HI1_P#6#<7_ !$Q2GW*7C _HI1_]8-Q?\1,
M4I]REXP/Z*4?_6#<7_$3%*?<I>,#^BE'_P!8-Q?\1,4I]REXP/Z*4?\ U@W%
M_P 1,4I]REXP/Z*4?_6#<7_$3%*R9XZN0'CBBK[FJA4H8=1*1=57Q:=1LD>?
M)(_I8?3<[D*157,-5K)226Y%.L>849*-Q1EJ'-&G/UO2=V<=B,5#DXXP2>.<
M@#!^0,$Y'YG!/V%7?9[-C.WL&_>BIM?)RJXD?>@&,.VQCD@QJ "; ,BJ4Q2F
M*4Q2F*4Q2F*56]W5Q).NGX]8BJ+7'(G0I_J<R!I>4;7=S"^,[&="G0]T YVN
MU0!D9KL+<%X#@(@O,3LU&A:U+:PN2R)R1$WN3"^6! &"H/YY(8<J>#G;G"D#
M*L &8D$[2N:.2-5*/ D@)YD#2),%+PL>VVYHE8+$\:,\$BA;B8LCL(3%3X9X
M<NU(]7K')ZT.YJBT[#87D 2Q_F ^S+,44!SW2'>-#P*FCHK5]BBJ]5('955D
MD@!=JFQHFMH?%I*MF,J8&<<:'[#LY5K#5GKYX:./K0IZAZMOQ';%E"I*@*8H
M0!['T+T)5L2DS52[*V(F)[<ZZKBT8W#3W8QX;]/A;DM:5KPG5 0:VYFC:T)A
M,YX ^ 2? SSC//D^!P3@<X\G-B[%%C]NU6=QA$#9<(&W2!0[+B-=JLQ5#N*!
M2[EM?[E?A7_1^JOV^^Y?^87(JM/N5^%?]'ZJ_;[[E_YA<4I]ROPK_H_57[??
M<O\ S"XI4<1^$:H_PN4SN!WZ-UR+KG%<VJHMOO+LK[3;Z.W9K<J0OX5>[NW)
M/D0:R"XMPTX7X+)\P$ P;0-?L"P$\8SGG/C'&,><Y^_&,?GFKX3M[MY[N\CM
M[/;LV@A^YN\ELKLV>!NW<XJ1WW*_"O\ H_57[??<O_,+D52GW*_"O^C]5?M]
M]R_\PN*4^Y7X5_T?JK]OON7_ )A<4I]ROPK_ */U5^WWW+_S"XI3[E?A7_1^
MJOV^^Y?^87%*?<K\*_Z/U5^WWW+_ ,PN*5&SJCPCU0YUQ'$_*SIT7'K'+N>B
MUDC723O;LHY ?3"*V8DJO1K3@?[L?46G9WJ<J6MK.,E&2YEN2E,-I<FMQ"F<
M$ZE23^Y7X5_T?JK]OON7_F%Q2GW*_"O^C]5?M]]R_P#,+BE/N5^%?]'ZJ_;[
M[E_YA<4I]ROPK_H_57[??<O_ #"XI3[E?A7_ $?JK]OON7_F%Q2GW*_"O^C]
M5?M]]R_\PN*5^;\*_"WIOV4_5/M>F_3U[Z[E]/7_ #>O_K"_B]?QXI4=.1_"
M-4+1S=4;;UP[]&RGI%'%]%6Y((UWGV4D8G23_,5XMJ6U/&[N86,I/\N$@+]E
MM:$"?9A8]^XT/8Q"DX!.#D?!(QG^63C^^KR"-798G,D8/M=D[988\E-S[><C
M&X_>I&?<K\*_Z/U5^WWW+_S"Y%4I]ROPK_H_57[??<O_ #"XI3[E?A7_ $?J
MK]OON7_F%Q2GW*_"O^C]5?M]]R_\PN*4^Y7X5_T?JK]OON7_ )A<4I]ROPK_
M */U5^WWW+_S"XI7-<7\*O?'G5?4KU"7F<G<NV35G.:&K8]8-^6W=S^U69$'
M.YC;=<=[MV5S-[8$3J@DE>%I=I'K:-PVWGA B3"1B&>SQC]3_?C_ )5;<2H7
MC:&9AP,Y8*#EL;B,(N 20O)4 LV;1L56F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4
MQ2F*4Q2F*5&2Z+6LENEJ"C:KK2RBIO95?31;#>C#Z]99MS=4,Q0,CZ..?PQ!
M!9$/F:G9CJWH1D1Z/M9FGS3@WH=OS3\4I6-]E \G&!@D9P6&5! _/!SSC@$C
MQBLT2*<R.4[<>&:,R!9)5$D*/'&HRV\K+N!("E$E92QC9:\W\.OFY77B#B-B
MZ:[,MF UK9/DG[EJGK7K]'9*FGI8"+U7+^NE54QLVSTR].33D2FUCP."QI"V
M,+JT-+0SIFV!,8D[";I 9*AO<P4-L 9LC("[E&2,C()(4^>&/ZB]NDN99$@2
M46\:3RB495(Q<0('*EEW!Y)(XF7#925O:/QK?%XM+/M>Z/'?R!:5X+W-XM*:
MTE%'B4O[TDTB>)0(11R=GESJG"F1A"XRY@3M4E6F!2D@/4NIAX0>R;K>Z>/-
M<=E96*L"K*2K*P(96!P00>00>"#R#P:GSBHIBE,4IBE,4KRS^9_L^YW-KIF(
M5Z?T=QCI!,>L0.CC;UJ-_%\+MU34M&KW6 RJ*]!P1_L5S>PHYDXM[Y65)+V=
MO*OM42Y-4H2QY&PI59MPI R"K'<H 'N.3N(&TC!'&"#P3@8(-<U;=TC$D9AG
M?OVP18\3MND69EC:(HRMN9 &C=6W$!-K D5Z,.<)JMLCGNC+!<QR@URF]0UQ
M*W$^;14<%F*A>_P]G<UJF40L9I^XF_J5*DT]UCNCSP,ZTPY  \X! 3!5/D\8
MY\?;\JXCC#,-I3#$;#G*\GVG/.5\<\\<\UFC(JM,4IBE,4IBE55^5+KB\N=>
M<N@&_GND;R?[/1<WSVQHI?48B,3=Z9J]:R)'G;F9*'IUD^GPF:L+$TN$E869
M/ 9"U+UQL=(6*@$+%VD5E7/.5_1FQGE1CDCSN^XX#'/%<B&'> X>W]I)[4TP
MB+[7@7:26C #][(/<0E(IR&4H,XN\)EWNEJTQ?\ $7.:V1: :?Z#7QEKLF5=
M#I>NH"^M$AKV"2Y,SU'TR&%P1VLQ@CZAV5CD221M"QVALJ=W&/)WI8P$LB1O
M-Y! X(R.,9&2,XR<<C'DDXR3DTN=I9&1=L;H3&=BQ;T61T#&-9)2,;>V2TCN
MY0L[NQ9C=+E:X],4IBE,4IBE8FNVTUE,UV[3]!5%LW4I:E+4F!7M),+#);$=
MM.;BG;QJ6EHDLHAS0H3-85&W!U&>_)1D-R=0<06I-  @R0,G&0/S.<?X UDC
M3N-MWQQ\$[I&VKP"<9P>3X QR>*H.H#N'IZW_."3 K)A?3E*T(\<^])PJIZ$
MG%06;$(JM#4E@4YMLZ0E[PY,Z:'2);/U*Z>MC5)&-P>XO"(TMJZ)C?\ 4OGZ
MU"?;!PP&W"X+'*<G.T;">3G=DJA)(!<C:A*YC$XCG1>R5@$<D[F6V8NPE,,8
MMI#MD<,+@%[:W>5G6-[J5#%;%K?TE92N+3%*8I3%*8I3%*8I3%*8I3%*8I3%
M*P#T5T"@YQAK1,W&I[]N$IWE+=%2XWSM4<CN29(#G%&XK /CM&XR$2UMBZ33
M<),X/ZCV42)8L;DYPM#6%9(7.>0, 'D@9RP7 S@$\Y/V4$G@&LL41EW@/$A1
M58"65(MY:6.$*A<JI8&4.V64+$DDC$*C&O/CU1U3W3SU(/-VO<.@PO[S4/.'
M&D[H1+%H26P0[G>,W=:UU0Y\=(_''ARE.WF7Q> ($$FET\D1QH'R2L.W#;*S
M1AK:H^WOZ^,YXS_+[?\ S-5+ A5& J\Y*KNW,JA\LJAF7*Y16)"@G&"S$V6>
M)RT;"G$3[%KZ86O++WB/./<%JT335P3I[:I7+Y;6+'!ZNEJ-)(9FT(&]/-'*
M,R:9R5A%)3BAJU"9(F;5)HS6L7I']?U^O_TJI.3G ' &!G'  SR3RV,GXR3@
M 8 M@Q44Q2F*4Q2F*52=Y<^VIE4%*VU4E4L?3%9V?I9SRD8+]8ZX/B=-/ +0
MORJH*Y5G&.FY.G55]7\\EC%*W.-&S%:B<AUB!2X3 :%2I8"2#;;3C=E<<<;A
MD9+#\.<_V23QP"I.-PSF,+"(3!X2I"DJ)H^ZI=YD53"6$I/\%G8HC+&CPM(R
M]Z,-F_Q!V[8EO<>C46S.I%/[%K>_.D::DKC*WAFF3^QZK*YI='F"&.-JQQ(W
M1V[%,0BQ+$Q'7&S-;4EGQR0QW4-R5R$N+RI_7/C[_;QR!X\'XSX)'-8B #@,
M&X4Y&[&2H)7W!3E22K<;=P.TLN&-H6*BF*4Q2F*4Q2H_7]T(@Y^10=:NJ2_[
M9^W4P1PU,DH.HI';2V,GK2AF!D,X(CH=[BD/3^S[M9)7(0$"4P00FBUZ^NI
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MC<IP<$8(!$+K6\SUAU!)9O9+SSU%'?D"NNW'#Q^/C^WV.^;Z4<+A:8R6YJ[
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M9*T>TD@@"4)+.M;D99T07HB"6%Q+3@<D#/M1'"5@8\L6-9X.X!4,P5@ RAB
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M\)+V'2EC<V[[1KE(Y0>)W]ZZ/+BF3_"& 1P#XY/ &>?S_D.#P.<>34*R^U9
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MBC8=(G49*#7MZ  ^6 \^=WP,CPI_$>!^?G YJZ1HPRTT49_B>UQ,2-D9=?\
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MR+CW-'$<C9S!JC>*>HZ#0^$2W.C5/7W57),?;J1<9=R\Z1EY$^\%=.I*_P!
MJVSEU9U]!$,LD%1UFK5.4;<4,W;37FN"R%2B125\$\$LCFP<D<<?F,><<'.#
M_(^.?%!$Q=HP8]RD@DS0JF0P3VR,XC<9.048@KEP2@+"0=17=,NQ?)A!':VN
M1^P^>:.YHLNQ6W@.JT_%-GQ*E%ML2EE?6EQZ\Z>LY5'H^QLY;AIP=CX=#4"<
M*1B5.H'5T>#GDUR/DTX]WN.>23SYQDG!Y!)Q@'Y)%6 WSMWG!.Z1Y7,@8R%
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M.8KJ?HR\F2'R>*2.0P'H&>PNLX8H:$+H LQV9IG8[$^U^USQF6*$2V&E3(3
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M,:5(HY&%[WVL(1%'O8+'IZ PQ]\O"J@-OZ'I^X^F>^^LNK,)=7$EU%(-6@N
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M$DFC7857NEDR=W,?]R=_ Z_P/U,W%_!N)T?0,38T^\0-UBV3Y*HP"G: "53
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M'/X9DD!\$&HGCNOO3DJXG!CN6(2[J_D9E1-R57T#"Z]:FVTX:E&C4.RQWE<
MB9FEEB:CR(YM2222Q"/M;2)&4XKTJ9PDR%PCH=J&B]"=5Z1'/H]Y:=*]63/(
MR:!>:A+)I=X^]8DAM;Z[&S3_ *AQ(]M;7=Q+,',<;-';/'<'K_JM9TVY9+N*
M34],4#-[#"B74(()+2V\1S<=L;>X\,2*5#,JM(.W5K< L&$6K#F"P*XE++-(
M7*$!3FPR2/KBG!L<4AOKKVBCBM[V6>29H:=8C4!*6(591R-:0G5$'$@\MO\
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M5D_ZX@#-H[5,9M>(O$4)&T,\OEP:;?WA1HB(/9+Q7.0 ? SC &>><'QQGY^
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M@WL@Y^3-=<6 6C,*+"4+TEQZHL0C#PJ!"&(&^H'5/3=X,:QT)I)<\&YZ?O\
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MN"2'P4?.!@C:?PG/)) !'+#F6WLAEF$L",>Y"%:1DN=LEI=!]B]MT:&5289
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MCTLR55P9!HG*4#W+UH?L,\L+PFEC>PI5RJ(+E3@%B0O@$JE\(4MI9Y W]?\
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MN79VMN[O=MNQNW\=ON[.[CW=O=L]V*\Z/BAYW;I[TI5?4T+;/%/+(#5-</\
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M;5$:41]4C5%]9HNM7/U3:#KRI!K<"%X)D&RUUNS3@7UE_964#_ORS!+P.&=
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M.?,*9T(A1MRR:&$Q"%O,=7HW$$.G+Y/FQH5,[--W=?M A=4BU8VL*V1IE#$
MUL3F"<M>2P]0]9:)U;;Z=KUQW-!29;)M1NK1;6SFMG#BVOI+Y(C&EW(VP.&E
M6-IE:!NV-T@^[=2])_V</4KT"U3K'TJL+FS]6Y;-]?7H72M>?6]>L-4MY[5M
M<Z>T_IR[O8;V_P"G[*V%S<6<]O#=ZC;Z7+%J+)=RH+0WYEF%G%@-*& THT 3
M"S"Q!&686,.A & 8=[", P[T((@[V$0=ZWK>];SVP$$ @@@@$$'((/(((X((
MY!'FOSA961F1U9'1BKHP*LK*2&5E(!5E((((!!!!&:^\FJTQ2F*5 5=K=6>1
MYD6[WI)'>LN<7!A," 7\1=:_-DD^=MXS2_Q:5KZPLM[  W?H,U)#_=^HPI]:
M*WQ#^]/3N9.7N.E.HHYP2/\ J]*ZDM^Q( ?.R/4]-@)'@/=YX+<].V;?7$/
MCU*P9",^;G3Y-ZG'W>WNG&1Y6'GP*GUFAUW%,4IBE,4IBE,4IBE,4IBE83Z
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MCQ_/.0<Y_+\ZJ^%01$2+)'++O1P $XB7&,!Q(&1Q(&X "8 ;?7IFR*Q4Q2J
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M=_"OL6H<$H0?>.(#/:+#4C'^!\@^1GX_Q'D'@\UA92IP<'(5O:RL,,H8<J2
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M*9D,IZ576:=J;U!M@H&'YV65,%<<"L+BQ[:]%N_P_P K4[U7& #QSGY!/'W
MY'Y9QGSXK"4*JCDH0^[ #HS#:=IWHK%H\G\(<*6'N4%2"=647&VQ8FT3CH';
MKUJJF^..#@7&*QE+^=,]25,-40CJ\M"C'NPW!I #1<C21OXL;$I, F7[*/\
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MW$E$$3RY0K?+)TL;B_L#%9'J'GDPB12/:-OEZA_B13*8HW(V_8ZD8X_R(/\
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M':N6')VKSP*^3JCJI0I6+%%:0 ]8XUZ"I%ZHV'Q\Q0MJHL:HTNM%9PV_9BB
M@,7+3 0\T0X^$:M2+3?H1YFQ15:UT]6UFD.1J4M>0=,H;H'NK4!Z>*,1)J*L
M]C3&;KQ(86A"-/!_;1I!_90G8&+VDJ<7P/J27L-M[@ !F #;P-QP'\;@,X#8
M ]WGCS6<75R%""XG"+/]4J"60*MS@#Z@*&P)\*!W0.Y@ ;L 5I-]3U:TJ&%6
MUUO VY5%8$?5<94H8BP)3X]6*H30-37;(:0W@,:X,H''V(1T41"(8C1,S6(:
M 6T"794$DDDDDDY)))))\DD\DG)R3R<U22665Y))9))7ED:65Y'9WDE<EFDD
M9B2\C%F+.Q+$L22237PQ5'5,8^QOV;K2 L'\'4&55C7_ ,EB$?;/L16RT,?"
ML@$2^";R?L["U88G%PJ8NT?",I^HXQZ-1"TU(?<15,G!7)VD@D9."0" 2/!(
M#, ?(!./)K[CU35;$BX*5%:W@<;*J^,KH76I;#$F%H!7T/<RF<ARBL*"@0)P
MQ>.N!,>82EK,R:0MRHME:@'IS MZ714[FP1N.&(+#)PQ&<$CP2,G!/(R<>36
M3O3;)(N]+VYG22:/N/LEDBWB-Y$SM=XQ+($9@63N/M(WMG;L-.5'%@P ,9JZ
MNX\&J6IY8JO"QPN.-6JX99&2D3R%H@ND+:1]DFU](0(27E"P_ )G,I(F+6EG
M@(+T&"2223DGDD^2?N:QLS,Q9B69B69F)+,Q.223R23R2>2>37ZR4Y4<9!!"
MXY5U>,!=7!?P5H!EAD<:P5Z"5DG)Y0&$!1-Q&HJ&1D*%!#Z%CTAT[%'G%K]*
M &#UM_\ 3_(\_P P*!F 8 D!AM8 D!EW!L,!Y&Y5;!XW*#Y K5;*CJID##0,
MU:0%I!73I(GNOP-L0CZ$,'>)>6[DRMUB(4S>5J-N,F*?WTI_6,^D:AW+>70#
M@8H"O5:-MN8YRS'< &Y/(&, _<# P#XP,>!61KB=NYNFE;NHD<NZ1SW(XMG;
M23+'>D?;CV*V53MIM V+C3;Z>J5I#%0M=7UZVA@LME,]A(4$,CJ,,0G,XU)M
M328Q@*=N+TPRF6ZFLPU)7]KTE='S4JD7S-4I^=./Q-:Q@D @$@'&0"<'&<9'
M@XR<9\9.*U$M254ATQZ15I 4FHS-Y!9D<TFB$?(TP6-+-R$4HGK-HIO#\LF4
MCW+93M]DR+W+RZ[DC[M<M/\ FJ[W]MS<^YN5"GD\J  %//*@*H \  8' K*;
MBX)<F>8F2&.WD)E<E[>(1+% _N]T,:PPK'$V4011!5 C7'P"H*G+TVA+K&OP
M!9[$=K>:0AAT>#IKM=^->SWRS6_6F[6D=@/!TED1KG,4_NY"O,?G@:IP-$Y+
M-G023C))P !DDX \ 9\ ? ' JKRRR[.Y)))VXUBCWNS]N)<[8TW$[8UR=J+A
M1DX R:$U!4Z<&RT]95^07NQ5%O[ 3#H\4#=L*SS5*JS=A W!UNP%"D\X\^8[
MUN0FG&F&C<1#&(6P)&<$C(P<'&1]C]QP./RJ$DDC#A'=!(ACD",RAXR58H^"
M-R%E5BK94E5.,@5]BJ2JQ 6%BK6!"+<; 26RX %$6#8%UI(#&\U#9"L.V_>E
M$[1FM+68EEINAOQ VU"(I>':4C8)W-YW-G;MSD_AQC;_ .CCC'C''BK?43YW
M=Z7=VC;[NX^>P4,9ASNSVC&3&8_P%"5V[3BM)53M2+BG=.MJ^O59#_8#';#X
M2JAD=/*>;2C*A@51RR'0LUN&!?.V%5%(PI9I:JT:_MI\=9#D:\DQK1"(@DG&
M23@8&3X&2<#[#))Q]R:HSNX0.[,(UV1AF+!$W,^Q 20J[W=MJX&YF;&6).HM
MJ.JG(J1D.-:0%>1,)A'["EA*R(,"HJ3SV*;C@HO-9 6<WC \2N."A\3VQR%P
MTH=FK<98-H59&VA![B=[\>YN%*#W'A&!!4<\*0S J."&.1R:RBYN04(N)P8H
M9+>,B60&.WE$JRP(=V4AD6>821+A'$TH92)'S\.E/5*^$R].]5A7KN18,@C4
MLGI+G#8ZO*FLIAGV?U#Y)+"U3<:"1/L5U$HM]G79WTL7LOV;8OEQZ;Y2A]Q&
M3]SXQ_(YR/T.3_>:Q;WX]S>U61?<>$;=N4<\*V]]RC@[FR/<<_CQ3M22($T*
M?ZOKU[+LA=&W2PP.\,CKB"=N4-"V!B#A,0K&X[4F6Q8+*SACJIYTM.90M3=I
MM&FTB3^[BH!*D,I(8$$$$@@@Y!!'((/((Y!K4?ZBJF5$S=/)ZS@,C(LQ&RM]
MCDOL/C[L5/D$; ,N/(IF6O;SP2=*PEF& 9D[UI:4V &(*(!.A;UN=S8 W'"Y
MVC)P-WXL#P,_.//S63OS%(XS-*4B$@B3N/LB$O\ UHC7.$$O_A H&_\ M9K3
MD-.U)+=3S4JJ^O9+JTX^TQ.S=/\ #8Z\:L2+,&G0+%&YQIP;E'VJ8F8+X]::
MFE\^.0-^G9RTD()TM4^\BL9)( )) S@$G SYP/ S\X\UKO-3U;(E$T5O];P1
M[561%&V"6$I=HDPN*B=0AG^>?*(?+SE: XR21AKW)I'MN8G@2QL1;?GG:9*7
M\R6>^E692K*Q5E(92I(*L""&4CD$$ @CD$#[5DBGG@DBE@FEAEMY5G@DBD>.
M2&=61EFB="&CE5HT99$*N&1"""HQWPHHI.4400462026 HDDH 2RBBBPZ 64
M46#00%EE@#H   UH(0ZT$.M:UK616*M3%*8I3%*8I3%*8I3%*8I51/EHCTY9
M:O8KBBG5?7%-FMCQ#ZBBU)\MDT5\??%KW-8$>@M:1]Q<+OAD@8F54KD[XW-A
MCXX/;''V1E,<'5STH$E 69(/&.!SG<<YX!]O&>#^GG&2!FL@93'VRL:G<9.Z
M0^_A#B+V[AM8CCV#WD%G5 2,/>$FRS)C'[O:I%:'2<^G[PQ\^7J^MW0Y5%*S
MFMIO&#/CJA=HQ):,@T#02!6ND4>ET2F"B6-8WLQT@*-T0#$QO" X]\#Q\G/.
M>>,'/'&,C'WY.> 8CMQJ-A.7=F4.'&XA!'(6 4[1'W$[>X 3'<Y;*)>OD5CI
MBE0ZF7 _*<_Z7B_74KK$3E>,34Q5T;WL$OFZ&*N,E@39(V6OIK**T02-+7$O
MGE?L\ODK7!IM)XJZR>*H74Q.RNB0"5!I(S_CQX!_S\?J.:D$C.,<C!R >,@\
M9!VGCR,'&1G!(,<.KOY43Q*_ZE\@?^Y6NL5%6J8I3%*8I3%*8I3%*8I3%*8I
M3%*8I3%*8I3%*8I3%*XA_86B4L3S&G]$6Y,4@:U[*\MQPC0$KVMT2FHEZ,T9
M)A1P2U*4XTD8BC"S-!'O8!A%K0M8;BWANH)K:X0207$3PS1DL \4BE'0E2K
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M.#@A2:9WEK+V2J6$%*#-G -'H8->R,(?76U*['RSPWR=Q,W3%HY6I&)TLVV
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M/4UN^>UM7;"RM[9&!HA'O$K0F+'AV9FIO+5.#BE3'/OS_GSSX''\^<# /.<
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MTH/^_<4I^$ASO^?JE_UI0?\ ?N*4_"0YW_/U2_ZTH/\ OW%*?A(<[_GZI?\
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+I3%*8I3%*8I7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gwpjrhodncoa000023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000023.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %W ET# 1$  A$! Q$!_\0
M'P !  (" P$! 0$           <(!@D$!0H#"P(!_\0 5!   00# 0   @0(
M"0D% PL%!0,$!@<  0(("101$A,5%A<85UB7F-89(3E6=7>6U=<D-3<XM+:W
MN-@B(W-X>0H:U"4Q,C,V455AE*'3)T1VM?#_Q  = 0$  00# 0
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M$ID,M&+E6P]DZ,I-6#HDBJK]E._AV[@\^\C??Y45JXS47Q"Y92A'SS9+'SI
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MTHMM-'6D=\[4UWTGSTVW_)S4$@=O>=ORKM,*4PB81,(F$6NCTE_*"_#2_P#
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M'_.51_ULB?\ =2994W[;\$_,J7?:_A#YU+.4JI,(F$3")A%KH])?R@OPTO\
MP/9W_!N,850^Q=_J_*MB#ERV9-G#QXX0:-&B"KETZ<JIH-FS9!/I5=PX75ZX
M21012XZ4554ZY333YZ[[ZYYUO>H<YK6N<YP:UH+G.<0&M:!N7.)V   )))V
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M*M3-1,:+\#K=">-MAD=JH'\+9@RS!7FA<[<%]:>..S7<>"Q%%)[U?*(4+2<
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M-@NSTV'@6$FGY!R5A!7H;V],D40O_#UF[ET8E8J8P](HU:QV?&B;S?#K33T
MPLJ6VI+I<U9D*^+2DP'G;]_"*_<O =DU>9"UG#4HRHVD(%=".-"+$4_!-OK@
MBJ+B25\/D2AV02B-FF)5'9N+2%U1S:L1IUC)@M*0Y):7OC!BQ7A>P58GJ7<)
M2*)25\\E4A@#1J8?3Z;HK*>?/)ZU82UO,)BK'2G8445<P6."^!JH2N95,BY!
M&=/(NR"P:N(FRT1B(6!#^#8"!Q5^_+O+)?N!K'F7$OO0BL+*/]+54?T-9?\
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M6#&&;:L'8P[+GK^1Q=[&1]GR]-T'(-FU31NT"/#7EP'8.D"; G8;]@/;X\_
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MOU[L4PH36:<-XQO@:_R.6W5BL\/4R68&/,K=4WB#QA,/ANL[(D*W#.:PJ?E
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MUK53?MOP3\RI=]K^$/G4R92JEIA^)G[!\O>>[3K*&7IY2J"_3)2K+*L).5W
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M/8<M\I+PV9.)K9>HI-I?/T ;*>C5&;"J6L;6:R>,+,Y!H<W-]D(  [CW[^<
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M6<I52\YOQ9KPKDC>=1@(EZ8\L5-/JM=&V163^HKEHYY3<$EHY:+R(@$-><;
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MKQOLX;D!P[#L2-P=B1S4FY;%V$PB81,(F$3")A$PB81,(HHE'^EJJ/Z&LO\
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M\[P%+N]LDR;=G>3Z-O7OV\QV@*,/+_HBG/2WQ.?1DXI*9<3>+"/!_E**$2O
M.3 --C[/T%["+N1^V<J# R"NTAQL6Y^91:*,^].M))N.ET7":15$$-:#\)Q^
M)JV]X5"81,(F$3")A$PB811M; 8^3A)I["TM=6#'F#\W 5M*((]IR=JP<\,V
MO7;K6VBC0JFJL)(-'GU6CQD]6164;[WPZ;]+(1S/JRNK#^ZX6NEJ'< B=K7!
MK?? M+9 3&]KO>N:X@EO)PRC1U['5,]1@SKR--Y*Q6H:C9PR/#L3+9B=/*&P
MD3-FIN8R[6F@WFAL01R,9+LZ&2$/)$QNZ21J5#K\X[;3$.<1[&M2@L>!D2D?
M?L^%$GCL2-:L6W0GI^D\:BB:;3G3I9J1:]K*]L-_5M>G[.4FAL,RWO;,<H+&
MR1LBF,3V[ASHV-8WJ^,.;&\-'$6O;N>#EG_3/A- XO*X>ST<N;+A+N/>VU-4
MMV<CC&Y&O.6O@ANVIK$PN-KO@EN5'S$PLEJS!C!8YV5F,7'3>)R:&F/\T2P
M7C97GY(.2UV--L' U^ET/D PT"?<*M'*J?;0P()C7/'72+UBZ;]J(]WNS RU
M7GK2?WNQ#)#)[V-_O)6%CQP3,EB<"UQ!;)&]C@=G,<"0=68/+VL!FL3G:/\
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M#!1!D4[D;^<;'T;@_* L(J_RE2M/V9-K=A863ZG<Z:%!;XE)[%L*<,H\!.S
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MJ/UB1#^^,)L? ^HI^/FC?SS51^L2(?WQA-CX'U%/Q\T;^>:J/UB1#^^,)L?
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MIZ?CX..D4[SG*=1M0)6-F&:E+?9".H=UR^CND5G?":^RR2#V4#PLO>H\\+G
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MC 1T"X'FH60B!^IHET5<R4.1YE\U9B'S5VBWU)39%GO7M^3B90VKHE5 PI,
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MDBSF\P>&2,>;1R.:<:27)%5C(DFPY:H([[^V8N=]?0FEUWHB^S7T31#VWG=
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MH7*YWG$0DZS:,O+'\/GY_@[_ ';^B)Z%_57+O[LRQ^Y&1_>__P"V#]:O;/\
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MM'"[9;ZGVB"RJ77'?7A7,6(K66REJ!W'!9R-VQ"_A<WCBFLRR1NX7AKV\3'
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M]BPB6>?K3C*,9K7T=94#,R!]%ASJQ0_F5EIU,'[J'<$74TKZ*2[KI+JL9G+
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M9CCS@428-WO0WY[A)H]Y=\3M\WQ_3V<D4P"OB+LWDB\ZM"7GVTPL(]$:HL.
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M>(]O?MMOW]N_/Q\/0BY''PS;A&B(*/">N>524 JZZ/,@J3S*G>9B>>>5+9?
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M?H@KZ!LB]*TLLC*J5AE*R8/':-(P%=J#K#C["$.HN96M.5=#U2G2SDO/42#
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MB*V^%2Q KRG'0,K'QM=NVDK7HV-!<(J.&+9W\JVG<GO18SKX=-GNS?F(2?\
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M&FM*U[3X,<FU4YTC)7*ZZ_&PO7:_2\[^;O!])&_;Z247=OOAF7A+H;;:$_\
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M])?KSL_]Z,>[69^ZV3_A]K]:G[%O1E_FZT)_NCI_^KT_++]?_I6>DOUYV?\
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M)A$PB81,(OSX/C*?REGJ+^G8!_PBK[//&M?W3Y7\.M_(JR^U/U+?^07H^_\
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5 (IQ?^CJ7\FB4SY9%<4PB81,(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gwpjrhodncoa000031.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000031.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #H ?4# 1$  A$! Q$!_\0
M'P !  (!!0$! 0            @)!P(#!08*! $+_\0 6!    4$ 0 $!PL)
M! 8'" ,  P0%!@<  0(("1$2$Q0*%1DX.7BW%B%9=G>8M+6VUM<7&"(Q-UAU
ME[@V.GFQ(U%Q<W2R&B0R-4)7U24F05-459.4E=+3_\0 '@$!  (" P$! 0
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M6'&UCD?AH"J846ZC.,,=-P5G(24<00RRT 7SL:*@Y]N"+?'&X=\,LBY6PG.
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M%AUNJ2[(D9S)AC2YL"#"ABS1ZUC>750I\IAOI^]#)_\ _($/_3JQ?]N<7?\
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M]?#A.?\ GN0_]'8._P#\-31URU@AC4]E*T?0:V#34:BVZ#CR4D\VX7 Y!!W
M>2D9%,G,3KC4E0Z#@(G("6!8J"8P*X9%\AL <1AQ\Q,GHM"IF'I6))4J Z7E
MXL=TR]CHT:.3&?#A0G.SQWQ'@%D&&,H(:+7 N23H?:CM;QWMEK\GB;:%5X-9
MK,A2(%"E9F#3*92FPZ9+3L_4(, R]+E).7>YLU4YR(8SX;HSA%#'/+(<-K9
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M3/D38-[VRPSQO? 8$2P9DH8#&*&P0#0 P.!=A@(,,'0AK_K%1/XH_07<W_\
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MD7NT+",>8%K6SO$$3#=??(Q*A#E9:<<ZG1XLQ+<5-M<Z$!$BP)9Y> TYV\4
M#:SBLMUFBPQ*(E$2B)1$HB41*(E$74WN_6-&;;//*1WHTX_:"7F4#4W4]W$C
MM1MIPB@< 3R 9Y<7CA!+*9G3YHL1*8F#0>1DX8 + VS&%#PR(NCLW8O7R14]
MR*T?3M#;[2F:F#+3O4V;)[)<Z>U$8N",9,*SD.HBX>+(:8 7+F!QCZH(5*A
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MA#Z(I%QR*F7*F@A L26/,?$N_,Y[,R0V^1=C =S8?+54["W37,SE]*<S?4+
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M5?%"''EH]K6^0I-@/5J&8DD !*440%WL=F)R&NAI"MB%BIIV!XMAB+B5/8@
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M1D07#L;*9M984;M)I*I],'1CJ@AI!<B:,I1DP5-#D!A0L;99E13)(H-F%?\
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M-=JE8FZE5W0&RIGZ@YDY',NP960B9AD1I:P$AMVW;?0A=D1&ZCMT(<!'*9%
MC F(HV.1HX:ZXF./4QRMD<,&,L.C'WNC#+'&_P"N]KW]^OJR%,D:8R)#D8)@
MLBN#W@QH\;,X#*#>/%BEMAR-('*1=?+GZG.U-\.)/1A&?"86,(@P(-FDYB+0
M(4)IUUNX$\E[+FZ[ZZ"41*(E$2B+RZ[QF!\-K9FQP'&QQLX$WHQQ$SQQM_[M
M(=_>M;*UK>__ *J_(WA Q'C;'CH![P!4I2P#B /^R:?R77ZU[ (4,['L#$PV
M$FFS5R6-)/\ VK4-Y(NHH=Z,_P#U _\ ^83_ /M6G.,B?]X_^IWYK</$PO\
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M._2.G1QAD7CI<CM<I!R4JM/<,VLRI#]HL:(JZO*QM=3W6B)&3[P<>Q#<1B"
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M9\+.]TJYS<KR+.;<@WMSFPN]["UUD"T>.-EN]>4;H2:O=^1!$;$EW=3$.!!
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M=1(THM1LI;F+@K#L)D2.:J=%:I-1Q)".2Y1*#&5C(2)8^, E #J0@>)$ 8?
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MG>:GMM3 \R."86P:5#V#+:)N6VT3E^[?26VM&FH*3CF0RS!/G&MB%CD5SN(
MU]8;;R!8BQY=Y'/>XW<O2(.2Y,=<;JK8(39/T21BT-!=I]I89:<42(Y8J+]1
MP[F[-./6Y\#B(&2:K&4E*A4PQL4AJ&AK-!?0!4<DZ4!<3DM,*%R$V%R 3F%[
M@?PBX\?-\UE],W2]-<*12@NJVV^P"-G.O']KCL;*T@N!^&7"(QI(5-N=46D]
M)&C%OJ!(RUHP3C#%E][)BG'[&;Z1'A]++IA8RTQ\RPXAL@ YAHXC=S \YU^?
M=SKD]B7\\LG:XHXU"F/':&+V9LQQ8.N(W5,DVNF96(U=J7U.$E .Z.#\X7-O
MIYJK-&:3=A.2G6U4]77S+$">(F#:)(Q-VI:45* -UQ8V=?2UQETL.FXON\15
MLVE$@*$B:7.=2>CO?SGG-&$E9L[-I<E*@!IRQ]L4C ' I,CTBBIM@F^TF$WS
M^982*$5K$B;>/Q<>9[L)75!7*:7E8JG?INY.Z.0]//W;C>J,-79:%58+X5D,
M7=;7#9W-F/+3$JEZ018V&DD3RPSBE$OY.3#J=+J;$L2 \,\-74!U+CTD<NM,
M!@H[@)-54)NA0;_;AH9]^MWZ_6O1R.T<_0MN7:F]B+WYMSB-.Z5G2$Y1C.'I
M4T0?$MR(Q8M91+=WG>)'7A(SN0&0URAQ1V,EHJGE#3@<R@F))<R>,YX%R8 I
MO 4T/EB"!AF)E;&Y003H 2;0] +_ +BFM""P8G_=K="<=,'RTS<)KT=:H,%R
MRPV!2J[&4MSW'P^PQI_J#,="0&H-]X*+0CEXPHT78Y4,T=+7-)R8VS"B.<;(
MY1/*IT !O<$G7F(%OQ/SWY5P_/>E!K>H4-)*=$>,\2"H[P:JDHAAY;R1\8TD
MF3#CT-E4EB319>.IB0)%KT1AE]J+ :@III/);6F[WL\7*V'SL4L-G;[:&YY;
M6Y.[S+JW'Q'&P[8V&3%.2^#[3+0YNX-!S@&-A(.>VM*V]R)\4L6Q+-8LF1>@
M$7;9*<XELP%#,,]D2!# #[]87'J7HI=;+I$+MWK2'#RDC17QT7&E$2B)1$HB
M\.O,/YOO.WZ_VBW]/L1T78A[X?P7_6*@UQ1^@NYO_P"",+ZD4**S_98:U>#/
M?KY2O4.=_P#FM441]S>D^18M\%C]*T@_(),GT5 HIC]8/A#R%1_XF_3L:_\
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M'+QHCVPFOB0V.B$!@<]C2;N .,M I]@E!VLC=579JB5%3"Q5[V,**M([.3B
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M$HB41*(E$2B)1$HB41*(E$2B*%^]VY[?T9A9*E14C209F<STDUBPQ%T2Q>1
M.O*1)0D4V;+-ALI?><K EKF@TY1'R'[(V/G<M@3)$3IXT6+"%+1F-K@<I)W
M!8%U,WTVAV$EXG'4K\96QVK#1,H"VKBRQ)KE:ZHURA]+!!%(H0I-*3RQRYY:
MS$S!)YV$M@'F%G<3&]KVM120 .N![@#OQ: K2J*J41*(J[^3;4V1-N=?&JWX
M<5FFES+"T^0OLO% #],*1%D.!Z0PZL%PNUG2IHY%44TI,<"295T[!2*)I_(H
MH"D1!P+%>W&"*S2 =;V((-M^H(_5UB'2_0)6*M';]Q[Y1G TBN_=K90Y/3Y@
M^Z<3FB'V0@HB6WD:-&88,2"TD\B]EYLXH-ULZXQ&LGD\5<R5R2BH.:=B;&*7
M.ZW*39HL#N)O>YTW#6P%]RB7I%H1HN[-R^5]K.K2_4]RMF.=CH20X];J_KM$
M*PA,1$5M88S<"HCLU(46>83VPEJ2\?/+:@GHA<B4.*YTVI& A#AD8;,K.<[*
MSUSM0Z^IU]<=^JM!\F/QM_!\Z1?-2@G[AT5,[_XG?U'\T\F/QM_!\Z1?-2@G
M[AT3._\ B=_4?S3R8_&W\'SI%\U*"?N'1,[_ .)W]1_-/)C\;?P?.D7S4H)^
MX=$SO_B=_4?S3R8_&W\'SI%\U*"?N'1,[_XG?U'\T\F/QM_!\Z1?-2@G[AT3
M._\ B=_4?S3R8_&W\'SI%\U*"?N'1,[_ .)W]1_-/)C\;?P?.D7S4H)^X=$S
MO_B=_4?S3R8_&W\'SI%\U*"?N'1,[_XG?U'\T\F/QM_!\Z1?-2@G[AT3._\
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MP>&.-M&4BOUV+CR7DHE9JL23.((T RKZA-OES!;-16B$8+HQAF&&@-#"TML
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M&UT.,7!ACO>6!Q +@VP) )W!9YP9<18@Q!3,6OKU=K%;?+3U*9+OJ]3G:DZ
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M1*(E$2B)1$HB41*(E$2B)1%B::)1AF"(Z=DP3F[&9'<;-(F7/NQZ/0<D11R
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M#KO;4_9<,=X8/U@L4X 7M=MW^5VI?8.3D)]&IQ=_%!P?9QKU&,NP? 7Q:/\
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M9&G:7"F8K(38CXCQ":^*YL,/B/>& !SW&[CU/D)]&IQ=_%!P?9QKUUL9=@^
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M/0*='J$5\G!D9B%%BB=D)V3:&Q7QG,:8;IIKW$M-PP@6)!%4IOTIV7K[@_U
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G$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gwpjrhodncoa000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000010.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "Y ET# 1$  A$! Q$!_\0
M'@ !  (" P$! 0            <(!08!! D# @K_Q !6$  !! (! 0,&"@4&
M"P4'!0 % @,$!@$'  @1$A,4%1=6EI<)%A@A55C4U=;7(R0Q-W<B)C.&ML8E
M,C4V.$%'47:UN#1&876W0W%SD;*T\#E4='C!_\0 '0$!  $% 0$!
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M:AO!H\BH=%>Y!L8-'.551C&-1=UJ(D)>D._^O-P]IC7VWD]U5TQ[.4/P>O\
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M>T5[\7L/F,>D._\ KS</:8U]MXZJZ8]G*'X/7_+XZT:F]HKWXO8?,8](=_\
M7FX>TQK[;QU5TQ[.4/P>O^7QUHU-[17OQ>P^8QZ0[_Z\W#VF-?;>.JNF/9RA
M^#U_R^.M&IO:*]^+V'S&/2'?_7FX>TQK[;QU5TQ[.4/P>O\ E\=:-3>T5[\7
ML/F,>D._^O-P]IC7VWCJKICV<H?@]?\ +XZT:F]HKWXO8?,8](=_]>;A[3&O
MMO'573'LY0_!Z_Y?'6C4WM%>_%[#YC'I#O\ Z\W#VF-?;>.JNF/9RA^#U_R^
M.M&IO:*]^+V'S&39JJZW*71NI1^7;;-*?&:3"3AKT@\5>='S5]1&A!JYD%QR
M6I<24L<0GP%2(ZFWE0ILN+E>6)+S:X*WTSIMEAI9K-/TC&EO9 RM;50&H4::
M9U&5&$1(Z(]B%&,B-=M:A!L?LWF-5)ZGU)J)\#5+GW]T]PJ$!!.=:SG*(BZE
MTZ)7C53JK'J(A!JYNQRL(]FW=>Y%A/TAW_UYN'M,:^V\G>JNF/9RA^#U_P O
MD#UHU-[17OQ>P^8SM0+KLLI.AC1UONTT@1EQX,&''L1QV1+F2WD1XT9AM,W*
MG'GWW$--(3C*EK6E.,=N>6$TSI40WE+I[3XQC8XA'OJ*YK6,8U7/>Y5C[$:U
MJ*JJO!$15R\>I-4E(P0M07[R%>T8V-MK!7/>]R-8QJ)(VJYSE1$1/2J[,E/9
MM,ZD-.OOL;#+V8+AF8/@MRH>S1MD&D9)",1E)0#+5>U&A=@0.\U3(E@?!S"#
M%9*ICAK$X++384*1$5,;0-VUKJREI#[S"D5C].CBE$T3Q,59 9=> L92],-\
M9LA@G2PJX\9"A&0C9:UD:\I'.;9W-T#=>,:.9J$DH17E:5Z)'-$L#ADH+H7L
MDNCO*V*;=!)41B#8[X:\I_4YM4W1P%"C;7/3-DVAFFTF8@G88($]9'<N>(-C
M68E,AUYI<%IB3+*/22;$83 B3)Y)Z+#B2'V[K.+Y/J>/82;&NTM'95Q%G3V+
M6UI)$>*FS85\04=\E4(YS6!:P3G&(]@Q->][6K2MDZ_MY%?&K[#5$A]I+;!@
M/^TK(<>1*<J[1-E%.R,BC:USS.>5K0C8\A7,8QSDD/6VANK+;3MK9HYU<MRG
M[!#ZH().[XI-+P4V18OC!\7:34U76^U]-RLE@^*QW(055E%I93R!S$-IW*VL
M+C;25Y.*9(;I]'6L;-K3W UCZ1-.Z&KB^;>=3YB0:F2L&+&\\C^<&F(%@>D3
M?5-B[)*KB>46Y68V!=V+UA60:@B2-6A@]+:2?.?-H$-9UK'2=*D^:2.@##Z9
MY>C7<1VU-NC Z!U76-4W @%NN1B!4[7>GW7UVN PY4J.VARV&X4@B_$8)1 ?
MBLM3$CG)3_E3\>&TRY*?997OR!>3F*C.GB:0;TDR'7M1L&J(Y)M@JI#CD:(+
MW"?(V.</I48W<:YZN1C7.2/CE\HDE2(&7JUW1PYE@Y5FV@VK#@(BS) W$,QI
M61]K4?T2O=ON:QJ*]S6KC;#7.HVM$2XZ:]LJ?@'88%3(%:Z;.VBNILQ5J(\-
M Q[+7II(#-+3T3HF(<"(0>E2''T---+<SW.9HT'04H02CJM-#\XC$F##)JJZ
M))6*%SVED.BRHXI PC4;]\CQ-8U&JJJB<<Q29NNXI3"?:ZD)T$D<,AHMI82X
MWG1FL<*.R5&D%CD,1",W!L(Y[E<C415X9W6J/U4/5^RVCS-N=D'3U4_%CES'
M;5!<'8O\N3!ICF8,U^.0E,V.7$?8&OP8LEEYS#>,N)P_'R[C='\G;9,6)YEI
M)TB;Y[YJQD"J(A?LUC23DZ08'#8Z*Q[7%:1['-3;P7==LR(?RANC2Y?GFK&@
MA>9>=/?.M!N$ED]PX*]&0[2O;*>QS1.&Q[7+LXIO-VQZ?L&WZF6E@;2;V36C
ML#+>)P4^2LX8M#R\TA]G$L<1>C3(^76'6WF\/,HRMIQ#B>U"TJS)1M/Z/F!9
M)B4FFI4<FU1GC5M6<)$15:JL*(+F.V.16KNN78J*B\47(V3?ZOAF?'EW6I(L
M@>SI 2;*S 9F\B.;OB*9KV[6JCDWFIM145."IF&](=_]>;A[3&OMO,_573'L
MY0_!Z_Y?,'6C4WM%>_%[#YC+6=,=LM13X[^<[-8"/@?%KP/+S)&7X/B^?_%\
M+RB2YX?B>&WW^YV=_N([W;W4]GBOE@HZ6%U=\SIZN)TGVOTGFU?$!TFY]F;F
M_P!$%F_N;[MW>V[N\[9LVKM]J\C]U<S>L7GEM9R^C^R.C\YGRC]'O_:>_N=*
M5^YO[C=[=V;VZW;MV)LJKL7]X-[_ .,K/_SN=SVG2G^%M-?Y!3_[=&SQ;57^
M)]1_Y]<?[A(S3>3^0..,8XQCC&.,8XQGU8_IV?\ XK?_ -:>4=Z%_!?TRYG]
MMO\ ^3?U3)LZG?\ 24ZA?XX[9_MZ?Y :2_PKIG_3]-_MT;)W5?\ BG4O^?W'
M^XR<@[G09 8XQCC&.,8XQD[ZA_=]U2_P(KW_ %.=.?.>NO[RTC_J&3_Q34^=
M!3?W=JW_ $_&_P"5:9R".=#G/XXQCC&.,8XQCC&3O7O]&/;W\=^G/_T^ZI><
M])_Q72_Z>U/_ +EI'.@C?X5N?]0:9_V[5N01SH<Y_/5VP_![ZWKS]:CS=K7%
MIF-I^#OC8Y5@9IXRN!0XV@F-V6(74J0'W-)V:JTXDD@]3!+O].HU9FX?FV-9
MS(MD=@MX_&\I-I);*<RFA*YUV33U6%Q;L"%L'ZC=0QC3)YZ-E4D/=$>9(2MG
M6$H:M'%2/TKBJ'U^3Y-ZN,Z*TEQ-1K*5FH+,S!4AU'7LTZV^DBAP 7CK7SM'
ME!#CK8P:^*1'$E+(Z%H^F^]=^#RH!D?<KA,N^T@E,'4C2EWJ8^PAM)4NSDHF
MVC.UJ_*9FF]A[MI^M)L0"3U9,Q#)!;D_*-((*C>9(!(24@QK9/E*L0$@PF0*
MB1.+/OJ^:2,>_G1!$I@4\EBC!6T$VU8^0&W&I!'@M8!1;WG!!&"1]T7R:UQQ
M3ISY]O'@B@T4Z&.2"A@RBLN37$=Z/D65]!JB,CEJ'HPH)RO.A5;YN,H2L;U3
MOP>NMQ>F0>VI6X[I5P\J@:"V4<L=@U]6CU6& -VW.I5:0.:$478A_:*SM4'V
ME^Q(R]K]L#8< )@$>;:*%!"I%P/*59FO)%,.C@RSMLM1U4>+'LY4>6630P9L
MQA5-85<:H\WF$AMC+NV7G$7SD<DH%"$^[CD>3>L%1Q[E]W.B ?6Z=M)$J36Q
M9$04>]G0X;A("OLI%LLB(.8LI-M<D>2D=\89T,4*NI=U-:2$:&OP>HA[*</-
M&*/6[E*&7&L0:5L&D2[#B:O%.V'4!UFM\:N6N)#BQ##@S)U^6V&.!G2,481=
ME#8G=Z5OC:AKCS318\=06$J"PT&62?6SV1NC3SZLFEB072H;WO>!#)':Q3QS
MM$\PFL*_A]54(=/6 (8)4B0AZ^+.>*;$9 L8#Y/2?]%90ARIK8LMC&,.HED.
M>@) %*P15>)F-Z:OWOAO^&-G?^EMSYDU3_<I_P#U=3_N\',>EO[Z!_Z2V_VB
M=D$<Z'.>QQC'&,<8QQC'&,<8QQC'&,<8R=]L?NUZ8?X06S_J%W;SGJ;^]-6?
MYW#_ .,T&=!<?W7I3_)9G_)+[((YT.<_CC&.,8XQCC&.,8XQCC&.,8XQCC&.
M,8XQD[=1O[QQ?\&^F_\ Z==6<Y_3/]V&_P \U1_R:WSH-3?WH+_)=,_\;J<@
MGG09S^7>OO1_%'4-N^Z=O)3>XR/3!Y\\FB4]!1-;),(\YW!\Y(KEAM#(6K5*
MN9A$2S]C4!N8>58JW%LM( L37YD?@J[6KRV#JZ[KQ:>*Z<6-'6PFN$LH;E0,
M%H&RHL-QY<V3T@P-BI)@F9%E/BV$APVL?WECHMHJ]MA23RZ@$V".3(^SX2&2
M,5J=--<=T:3*2/$AQ>C*9TI8\\+Y,5DJOCM(Y[,%J7HNV+MBJ52Y1;5KVM#+
M?DF6$B#Q@IFW2]>U>XC*1>MF0@8T+.B2:Q2BY"3DI#>,1+.1CA3<@  +,#GG
M<9[G7593S)D%\2RE%A=$ QXX ^9#LY<$L^OJB2"R!O;+G@&SH7M"^()TB.V3
M) XK4S7I]#6=Q$B3F2ZV**9TI@AD'+YX^MB30P+"U& 0",=$@&*[I1N.R65H
M#NC1S-$Y<G37O0I1+MN;JOUVSL*\FJYTV6$37H1:FU6IOV"V.3=A-:^)3I$"
M\72B 0\8)+S*)$$O6#*?)X3[41^7^A??@++R@V$"DT=9.K*\$K5,8TD@9TR8
MV-"0=8MD(;25\"PD'>=FX(>[&1=Y[7/:S[S6]!6^3^OGWFL*UME8'BZ7DAC#
M-!APWR9JOLDK2D<.?/KXX& ?OE)O25^ZQS6.>NZKN]6O@O+S9[*V]!W%KAS4
M4W95QH(G:\$?;2L0F- $=FBZY;X4.$&S6"X^XRM8D<,"ZW?#Q<#'+A9YV-$'
MD8$N9CE>5FOB15:2DLTNAU4&Q-3D)""\19(JHLJ$1Y#^=@)!9:BWC2JZ,"0X
M!QQWO*(C&7Q?)1/ERD4=U6+3$M)M<&X&*89A11R6HHLT;& \T.*<^J*C11+&
M2:,TP"R6#$49'Z1-^#EW(2H4S9](>%&*6+UA5K\_-)+*L/FYI#38;=-H%U]T
M:$("8#02J&H4P:Y>BE-?/N3QH(,V1M4KS&G?'Y3J,5BRIGH4$\MM,K6C'T+F
MQV"O#T,0TE"G$8BR)@'L*E>&<V,@RR#J*&SSA= GDSNRUQ+: H300U,2Q<0J
ME:X[R4@+V6*,H@$"-L>&<9!K8%A.D*04<"%EOZ#,B3^#9V%6(VTG;AMG40]_
M6]<VH_AH"2L!Z,2V#J"YZIJ%MUJ3(2P0"+6R#6=P4Z<U89"IX)"C V))>82F
MQ3*SB%Y4:R6ZH2%3W)&VDFH;MD"C1GBK;N#<385H(3)$A\H;OL2<-8S.CD*@
M"O8URK%9+RE\F%E%9;.FW-,-U7%MW;L<LF0TME2SJB',JRD?'CLC$1;J$]LE
MRDCHIAC>YNR4^)%5^Z'-RZYWKK_IY.RJFJ^;-;3BHOH>M@L$1GO$2X:$-:D6
M>HU\I*67,"%#Z^7'!YU8LN2(DA7SQ,//;(XF*W7]'::>LM2QV3$KJI56:U6P
MS2!#:()R%<V)-DB8@0'0LD)3#EQ>B,.3'$8:BR(L= W=9J"MTW(?#6PM43S)
MR+,%'*1Q3 &)KI<*,5ZF.%11C""2)*4@21I!0$0N2>#^#BVA&?DXV38ZO3H$
M@!@D&)P9[QI*9$=S1[MAE$X*(,>6L32&=X Q%N0,Q*+1+<.* (4*;Y"_+Q$G
M\I]2]K%JXLN<1LE1'$0;8Z[CDOTC-"12.9TT]: YX2F5@20BADO(SI&LR6!Y
M,K9CG_:DJ)"&^-TH"C(XZ(YJT"R7&&@VOZ& V_ &8@M\PY@BQV#)T;G9\-Y]
M !/5-)LEOJ^VZ7?UT)K:I&Y ? +UVQ.UK6?40_T^2K56Q4N#+B2QK9Z56UG8
MA$U!GPIQ>7% MV<<)E%^5T_Y1PW$^)"ETT^M2Q6G%!D;P945)5KIENI60Y1F
M/8]A5CLE)'>,!!D&%CY"Q"F8'+;_ ,G1:B#*F1+F!8K7-MRSH^Z:-)6+5ZD?
MIQ\R*%XWL>))#XOG#"G&093O9'26,+S9YW\],SS7)VU#_F#U1?P)!?\ 4KT\
M<Y^Y_O'27^H)/_%=39T-+_=VK?\ 3T?_ )3IK()YT&<]GZ0M;2T.-K4VXVI*
MVW$*RA:%HSA2%H4G.%)4E6,*2I.<93G&,XSC..45$5%14145%145-J*B\%14
M7@J*GI3*HJHJ*BJBHJ*BHNQ45.**BIQ147T+ET375ZFXZIM]"V3K]>T;>< A
M!U?VQL&TQ[==P1II$==CL<LY9JH;M;\R8[&APP":C;:&Y"K8.K56YR=A :_$
MA*X8&BO,;>#8U5BE1"C2)!)%/6PW0X$B.Y7)&BLCQ9D>&UC&O>^2LV%9(25(
MES(#*R3)>1.Y/K1)U/-KK2N6VFR(\<<>XLI;9L^.=NZLJ421*AGF.>16#'&2
M%,KE9%CQ(D]]G'C,'DVZH^$DDZKKNIX435A8H?UW$TY72CBMJR(%%,5+3%[)
M7L.JLT-NDR54J^VB004'N-U59+)$)BWC6(U7A/V,JXY 7/DN;<2;A[[<(8UF
M^\DA:E.PE@"9>UPJX_G=BL]GG]=$:/IX4!(L5XBI'WY9&Q0HD[3^5!]1&IV,
MJ#%DUC*2*9?M9PJ\\*CL#6 ?-:](+U@V,MY5#-GK)E,*%QT;$&Z495KCJ'J_
MV1H[5%WH.NU(#VZY[8U_M%.S'V@)LP">HM;V&$Q$#C[)6S61QZ?/O,8W#O(@
MJ*L8%\$J/ <7@O)?C]1=:*J[^X@6-GM-"@TUE4K5-63'#(;82JR1OG+%E Z6
M,,=>Z.^O,$T60V1O$1.A8UW,4NM+.@IY]=6; S9MQ76R6KDCR#1UKXME'1@1
M2HI^BD$)8-.RP"8,F.Z/NC5>F<YMIYOPF3$S6H_6N=06-F#Z.35 -E6]OQ%%
MY23NA8>E9I 46?U4]8<,)F"QMUB0KJ>OTH>XTY51A:"!C 4@N19Y*G#M"VJ7
M45Q/M0%D +J4B 9YOJ(E\P10MN$C;RC,6 \D"-6L*BI,, DATA9'7$\J;7U8
MJO[%DM']F'KCF;=,Z9_G&G64+R",ZH=)W=\0IS1SY%B\:M\T$8<=D= ;4]\+
M0;<:BJ9T_B [!V,)MZ(,*W4UT.7KT3:&O=J$*_8WB^ERUSD''S%!CP15FKMU
MJXX;%>%/SJD;F5Z*[+TF^1N.BN1UWTC7U9H2D)"G(<,I]194XI,5H+T,!L=H
M+%Q#1)4"84SVF8.;'9)>C-M?+"=6LW:7HU'9@FH-DR"X)HS+:MMR1I3C41IS
MCN/6L8&5%GQ!"8H7$AG?%8KX] ?"76$<%K4 Q1[.7,U<E1SD.T,;9>C%Y1JA
M]3>U.H81)GK+46PHF1&86TI-)C0)7CMQGZ\'L;CDH>J34').3Y*XI3RR GQ
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MT4>%E3AD6B-;ETY*MUJ#(WYJ74E5W",M S6Y0,.HNPZUL*RW0!6EULH0BMT
MFI%N, YS1B/=$U[K.>T 8L6G>4[!E?8NH[MD*&==.W-S,I"Q"V@3EL*R5618
M$F4DH0WK9"VPP2!K'=;+T'HZ XYI<FX8,#WA97MO*1\R6!-0TU/$NA2Q590#
MK[*+92IT:+YL8C$KB[)IHY&G;E@GP=W3)/'TU9#<YH;F3MJZT>Q'BE_I@R%9
MX=?/;D%UP%K\; U_90Z#MH30:<.40?OUBM $E;ED"FGDA7P;LW#(\IFJQDG(
M.B 7<I8-A%CAKIQ21"28U&65(LBDLHIUCPW64XB#;6Q8<D4)!BN_.&R&CS1_
M)KI4@X*EO#BWKF= E2"V$(0Y;(\B[%%CUPAUTH*2)?V="$I'6,F7'+,4A:1
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MZ+$_@JI>D7=^]MW_ +V:;[FS(ENCY;W)>E::VVL%_P!:5LOSYKR;&)N*DO\
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M_P!_/ZK_ -XN>'^6G_RU_P"\_P#Q6>X>1;_S+_[-_P#*Y778O[P;W_QE9_\
MG<[GJNE/\+::_P @I_\ ;HV>4ZJ_Q/J/_/KC_<)&:;R?R!QQC,^!M-CJWGKX
MNFB(7XQ@"-6.^;I+D;SM7"_@^<PL[P\X\H'3O)V/*8R^UMWPD=[&>[CFO(B1
M9?0>=1Q'\UDBEQ^E8C^AE!WNBD#VHNZ4>\[<>G%N\NQ>.;$>7*B=/YL<H/.8
MY8DCHGJSIHIMWI0$V?VA$W6[[%X.V)M]&8#FQFOCC&.,9]6/Z=G_ .*W_P#6
MGE'>A?P7],N9_;;_ /DW]4R;.IW_ $E.H7^..V?[>G^0&DO\*Z9_T_3?[=&R
M=U7_ (IU+_G]Q_N,G(.YT&0&.,9GG;38WJO!I3IHBY4AIXK:1]=7*<4)AV,V
M/#B2YJ/#SGP6R)$97PD&7*2G#CT85":7G*6$8QKI$BMEDGM ))A8X8A)*,3I
MGQ8Y3F"!Q/[2B$63((QBKL:\Q')Q<N;"RY3H@X#CE6$*2:6.*KUZ%DJ0( 3'
M:S^RA2BC &]^S:Y@1HO!J9@>;&:^;08NUNL%?JE4-V(L3K-%8+1J<!ES'715
M;:/$,E3?FF#E7D\1PL0[DDB^VC#\Q;,9+[BVXL9#6H"!"C29DP$4(I=@X+IT
MAC$0TI8PNAC],3^T] BVL$U5W6(YZM1%>]5VSSYLF-#AGDF+%KVF9"CO>JAB
MMD%Z8_0C_LL4Q=CRN1-YZM;O*J-:B2?J']WW5+_ BO?]3G3GR)NO[RTC_J&3
M_P 4U/DK3?W=JW_3\;_E6F<@CG0YS^.,8XQDG57=.VJ-4;'0:=L6WUJF6[$]
M-DK08Y.@B2N"PO((QY1$8=0A&30+/F,VICPE&0N$B2>98]*8V(F914UA-BV,
MZKA2IT)1K%EGCC(</0F\X!NO<U55 2/^H CMJ /M,)&%579*P[VYKX4JNA6<
MV+!F])YU%!((,)NF%YN?>8U41%/'_P"G.K=BG!_!+OC^[D8\ELBL<8R=Z]_H
MQ[>_COTY_P#I]U2\YZ3_ (KI?]/:G_W+2.=!&_PK<_Z@TS_MVK<F;H9VQH?4
MM_MQ3?@$6;KAFK01(Y1#6==V1+@/-VL"3,.@D6MLV! F9@& 1',2B='MD Q'
ME2J\077H!248:@_*!3ZAN:Z$+3DDT>4"60Y$%:R:MA46'($!LE8:QY,@#))!
M%<P-A#(%S&21I)(%@%G- W&GZ:QF&U%'">*>(,(NDJHUH\;FS(QC+'26AX\<
M[XXRC:\T"8,S7NC$\W&9YVV\9ZO>C&OTN@P*/KU=?+!]7;,ILUUG5-6$WB";
MMG2MN_4!R>7V#7I\%ZP#]E[)O54LQ ;/:LC(>#'\4>Y5FJO'#6/BW:*UU)G6
M)+"S22$]M53AHZXEF@/!#U?078!AK)(R-C%JJNNF1!E$Z,XY7;"I+66X\7LV
M:ST/&@UPX%:L8P*BU@D5*>(&P8>9I&_I9!3648C'2!VMG80Y1!$;*: ;-HEB
M)$:&7L5LZM>A S:,RZ30*IKS*JN8B4VU3.E76UV:UX(G; U:<C:^L=')DF:S
ML0LS0:WL&GP[K.%O&ADFUO=^YE8ECDSZAK0M&^4($1&6%E,LT\[ ^=$'J^T@
M+9F'6V\=]E%L!"676!=8RJV:2 ,K8YF0V[( 7Q6BF[,S6/D^-+5\"NAUFV(=
MD&8_2-7/2M$^QJ3MKI4 I&Q;,R5T6QA#G$$IPOF.VSC,DN)"TJ3UK].<RL:L
M8/4P?<FZH/Z>:@8I173U*&Q&:'KV][XQLH1&G1U3H[CQ[7VQ*LY7G'),YV#9
M8"R;LK):(LC+WFZ#U..5;NC3R073":EF@GANYY7K8V5=IY:HSQN0;D;&LZR6
MDIJ,&TD4B":SH7H(>B_7>F21*ALB .:D,>FH1X1:6 )B5];/U%]JA81JD15D
M5UG#\V57$<.4)2J_IF=*_!VKJ9Z*Y.D=P:ZJ6J0@\TF*=I6O3!;350EV.[5T
M1KG6U'U;?)=LBRXAZC76%9:G;]D7#,8VMN28N<U4IB[)(S1$+8B:5UVV^I+.
M9<2"1]\$^S &\FLBP)1K.UL+>O9#>PD:P@$BS(-7!1X$<P$$:,= 40SDUI>J
M=#/H;FLAU !G1DB#6G-1PGRIT8-95P*FP?,81DBOG#E0YMI.5AU1YIQ-]D]"
MD .AG35^]\-_PQL[_P!+;GST/5/]RG_]74_[O!SS_2W]] _]);?[1.R".=#G
M/8XQCC&9Z=:;&2KX&J$#1&96ZO*-S:Z$D27'!H679%CUGI(Z*K.6XSQ=8D:J
M>MO&,R%08V7.WPD]FN.)%%)D3!@$R5+8 <J0UB(4[(J%2.TKT3:] H8J#1=N
MZA'(GIS8)+DEC1X9#E?%B/.2,!SE40'RE&LAPV>AKC*$2D5/[71MV^A,P/-C
M-?'&,<8QQC'&,<8R=]L?NUZ8?X06S_J%W;SGJ;^]-6?YW#_XS09T%Q_=>E/\
MEF?\DOL@CG0YS^.,8XQCC&<XSG&<9QG.,XSC.,XSV9QG'SXSC./GQG&?GQG'
M[.,>CT9)>Q]S[8W X'=VEL2W7YP U-;#*M)N:7\@437&<*RF<2G7,><"[D.&
MX8)KPLB6<AQ%D94E49C+<55T5-2(=M160JY)*C4Z1(XP=(@D<@6.5C47H@(]
MZ $FP04>]!,8CW;96SO+BZ4"VUE,L5C(] >=G(;H^E5BF<W?5?XAE&Q3%7:0
MRL8I7O5C=D9\E<BL<8QQC'&,<8QQC'&,G;J-_>.+_@WTW_\ 3KJSG/Z9_NPW
M^>:H_P"36^=!J;^]!?Y+IG_C=3DD].N_JAIO4_4563]0K]Z.[,8U(Q5Z[<0A
M S3Y.:?<YIHW(,X%'0$Z-(AP)"'PZVI:D.3D82ZWE"<X5%:FTY-O+C3,N--D
MU\>J=<NERH,@0)S//8(P :!31Y(WM>1JM,CF(J#7:B[?1)Z:U%"I*C4L63"C
M6$BU;3-B1IH"GA.\RG/.=Q^AD1B,<P;D<%4>J*3@J;,]2,;WZ2=K[/J>VC]:
MU,HAN#K^^*2)NQ1>M/*5=+A7=U-W38-@;-%D94^96"\ JW,UM(/7)F,T4UF=
M+5\<9DUT44A)\DZO:SIJF931I=R@Z7R<>>*RL-:[J:M#03Z&-6U)A,&.6$@7
M#M&QH+G.#:QP22@9),$B^M=8-&W%K#N)$6G4EWY1/,T?9AJM_JF:_@WLFRM0
ME>5\4PS-?5ND3FM:6KD'C",^,$HTB>+U7="X^M&Q!C7=2M]]^((8)8MBXZ8]
M<UT#LSR25NM;E7"T #/B0M<E!@BW:H!_':M%*V3/S:*H[*L#3E?"IL,R_1_E
M ++CG!9S(5;]HGD1:SK7:2I%4CV4.R6>QDC>^T"4\*XD>82Q2A1AV'F[(KDD
MR/-H<>L- CC'#(K8<RQ2N "39]5*N/'M=Q]ZKH@*Z.1C*PP0S:B/Y_%+%+))
M7K())18P/.LG4.I+I%?$W>_66K:B&42N[*T340NNXW3CI<I?[[J^#I'9+^TJ
ME$COQ1YZNN7/9+GBD-QHFS#86=(K,19F!!0%&1\,W2VM&FKZZ+,NC6,FJU#,
M/:.U1>BKJZV)?53:B:]R/+&E-@5:;HZ-1LCG&V4] $(IS.RPM4:-<&?8RHE,
M*OC6FGX8*QNF*,UC8U0Z&T=;0V-<,<B*LZT7:6[1[S@(Z*SIQC0 FZ,_UE=,
M5MF L7FG"IA"J5[458U[=I^C=>V0I39E?Z))&G3MFML*;'8?VR+J^_1U-M F
ML7>>=CN5^NQ)8F,P@=%K\F0;H;5<-DA8$XS!S)5S+LH ]06<44YDG7K+R/%A
M$$YS:8TO3A9T,TNO''>DF2]AG.4CY+=!VM]*3'@2P@A>2)&IHE;.)05LHL)\
M?0CZ21+F,(C77 HFHAP98(L\DABQHS7A8WHV1G;,,ZD.A*QC[/47J17()2RW
M;72H]C3H/6-1Q9K%! :1 V6XD)9#XRA*+K>RW&I;$N,VFUG&O7Z4)M95F'(L
M35H*A@NJ72_E"BEB36V$H@8L"S1T9=16TWS2*23?R8L$;!^:GL+2)!F5D$<Z
M5]I-GFAA<1L58@3R-H6I_)])'*AN@1AEE3ZS=E=7:J%YU)''H8\J<5Y?.H]?
M5RIL.RFE@Q$K'00RRM&Z2V68$?.W?K'Z7];V#8%>I >C68E(.IKA,^ Z<]1"
M-<'Z&(ZIZQ=1=-73(<8K2[=FGZI!V,>)V%,%S")V0;$I@%7'A0\ZSKP-$:MM
M(U;)L#V$0; >="C2-3W1K2-8FTC,@&G).(X,Z%Y]<28Q#5@S,%': RE"C3%C
MNV9^MM)U<FQC0 0)17R/-2R8^F*8-9(K@ZMB3A05@,::!-6%4 E"#9D"0LAQ
MP]&97!%(;]:5UE]#NN6J2[1ZMYF)@KW.*0S+V@]</GJK6[,!Z@*Y:H'G9@<R
M0L8IU5ZUG*B"C9(_,="UG#2R$64.@@V:3M#Z_LUGI82T.*17#$\#=1VC8\R5
M$DZ;E0R= XCA13-2OMF/-'%&&T\O>03VE)(=6!K?0-8D!8$10ECV!#,.[3M6
MZ1#C2H^HXLL?3-$TLH+OM"K>P,@LE[@1$1Q6/$,#8^N75WT<,5@8[KW5-)CV
MP/J8Z*I^"O3KK>7FIWMVGZ_%PTGY9*/,#7=$FY!+-:(9>QUVR3X"ISY+SM"?
MLI:MQ)&#HO6[I9FV=Q/="/<QS3>AU/:C\\KDG61B+'8%PSP%;!D1(CPQ9449
M$&T2A(V*&4^.FZTT2R*):VG@-EAISAA=+IJK(L.P="K0L22\S7@GM=-CRY;#
M28TH@^D<7IF.E&BLRISJXZ'K):;4N;K6" JI:YF18QNFZ(UF$>8U%&ZO- [5
MIXR2#CP8X H6'ZCJ&T \IRP0BTB<LPW6S,DL-*/-MXH^C-?Q8<-&6I),P, )
M2NG:AMI#773]%:CIYQ6R'$?)" MU-J3L2,\+1H!90&!*%JKD/K+0<J7+4E8.
M/$+.D"&V#I^JCJE,W6>G+B")T=@V1BF%2PK:.]9(S.>IDBF<8)51*)=9NRM.
M[6V=6K/ID*/#"FM;5L+;\BZ2&H$$O>A1(^P4-L  ,(8,4F>(4!["3(D0Z1PS
MA^8)&S,OPV?0=#55W3U4J)>R"R#+:2CPNFGGL2!KS"C.#'=(DD*9%&9)'\)Q
MC-$J[K#%9NO=Y_KBUI+BUBRZ, P!2KC F]% !6C-8!+):4[8\9@@JA K'V%0
M('%1$<0(G[S&Q[J'_,'JB_@2"_ZE>GCDG<_WCI+_ %!)_P"*ZFR.I?[NU;_I
MZ/\ \ITUD$\Z#.>R;M'Z.);PGWYB+>*'KL-K37<[9UOM>Q';B@% K4&U5&G+
M2TS1*;>[%,(O&KJ%0Q&C '&LQ_*WWI+.&$I=@;^_%0#KG/K["S/:V8ZF%#K$
M@K()*)$FS45SK&=7Q6":" =7/=)1=[<:C7;RJV>H: M\2Q:R?7UH*JL):S9E
MDLWS<<4<N%!7=;7P;"2\KCSP(UC(RIN[[G.:C>.ZWCHUZAJ3(O3N* 2N%7U_
M!&F2VP*.S*/4<C7"],![&'V6OEU18<DL&50;, N!%QH>W-K@ K%G6>$%2I:4
M:$#7&FI[:]%L10I=D0H UM@YD>P'*#/D59(LD&^]H3I8Q),$2*1629(7CBO.
MJ)MWI^B-2076"I7%FQ*X8CFL8".D0"QC08]F*5&-N,>8"UTJ/.*J#0D:,9A)
M8P(JHG51T:=4ZS[571HG8BS[PITPD:D(YEY$9@O&K[T1]>%^!&.-6"9" .5J
M0ZU8DG9D,/D7@E*8BN7KKG2"1G2UU#6)&:9 *7SA-U7."^2U[4V;SHZQADDI
M*:BQECL>?INB8YZ6)HC5JR$B)I^R60H5/T70+O(QIFQG,<NW=9(;)>R,L5RI
M)20]@%#TKFL78= =&]]ZA 1,\$NFO:.U!V;4=/PX%[:V8HH:V#=X)N?7PD.-
M0]:WMH8TZW7R+,PO:9%="CI"66YQ!C#N%XU=1ZXKM-R!1CP+*P<2IFW;R5RU
M71 K8!(XY,A[K&UKE,YJR1.8"&V2<K5<HQ.5-F;.G=$V&I(Y9()U; :RUATC
M!V"6BE/93QG)& QM?5V"":Y(Q4>>6Z, 3D1"$:B[<UEWH]ZFFY5?C-:8NTW%
MK,D@5;ECQGEH\Q-%P3I:0]&GL.+BM"W@=8L5B'&9CL844K0(O8ATR2&'3)K.
MVW6VE%9)>M[ 'YF$1Y3"&Z,H&&)'"UKA.1'N*V1+C1B 8UYA2I 8Q6,.48W:
MJZ*U4CXS6T<\GGARQXKQ"Z01R"&<SG,(U58@71XLF2,[W-"6+'-)&]P!/(WZ
M;)Z1-]:OLKU7-TB>2FQ:^@_,E@8\Z4/AIAZ.I_4/;1$IV="&R&C6O=978.5O
M,3,7+(EY$Q,:40AML39-*K6FG;>*DN//&(;I*QF,D.&PI.DOYNF81V-&0K5!
M9VT X:]^]O'16;S!O5PVUM-&:AJ93HDB 0I&1DDO?':1XQ[E#"U),"]Q&"<A
MZVJG@-/9N*T*H_<>5B-([]-]&756Z6&@TZ$V3@J6"+L,"&Y7I+*W1S<X2+6A
MQQ[N,QBJ2IX"*R E.,GO.IP*-\V^7%1[$@NN=(($LCK%5J$,A(Q'I)8Y&E49
MBHJ(W:YP5#'D&\Y8CH_0QSEZ7HPD<VJ:'U>XPHZ:>M.F-'62,:QG-51(0(51
M5=L:TR&D1P^;/5LCII !=%TAAM=T"'2KNT%I@UOFTU";4*"*F4Z)"=L\8B**
MV3%VG6,<+F (#D!:783$BKD<RWB<@5EYA<:0);*,YD+CY!ZOH9%Z#3L2:.;8
MF'.(1L1XC!B^8#BE,R21"HK2.;,%N-$PVZY'M,H7(U'8B:1O8]&?4,N$^%7!
M?"8Q9;"A-*\_)*$%\8:C5%&U\,N^XK@[S=UP4*W>5M=.=-G-9;SI5_[^?U7_
M +Q<\+\M/_EK_P!Y_P#BL]T\BW_F7_V;_P"5SJW3I-ZJ#%QMA<1TT=0)044L
MQXB,)CM-;&G#R(^<4E284^!-C5MV-,A3(SK4B+*CNN,2&'$.M.+;6E6>RTSK
M'2(--Z?";56FPF#1U(BB+>5@RB*.!'809!OE(]A&/16O8Y$<UR*UR(J*F<9J
M71^K3ZCOS!TMJ,P37=J4114EF091DG'>,@R,BJU['M5',>U5:YJHY%5%1<UK
MY'?5Q]5GJ-]R&S/PQR;Z[:,]KM,?'ZKYO(3J5K+V2U-\!M?E,?([ZN/JL]1O
MN0V9^&..NVC/:[3'Q^J^;QU*UE[):F^ VORF/D=]7'U6>HWW(;,_#''7;1GM
M=ICX_5?-XZE:R]DM3? ;7Y3'R.^KCZK/4;[D-F?ACCKMHSVNTQ\?JOF\=2M9
M>R6IO@-K\ICY'?5Q]5GJ-]R&S/PQQUVT9[7:8^/U7S>.I6LO9+4WP&U^4Q\C
MOJX^JSU&^Y#9GX8XZ[:,]KM,?'ZKYO'4K67LEJ;X#:_*9]&>CSJXP\UG/2UU
M&XQAUO.<YTCLS&,8PO';G.?BQ\V,<HNMM&;%_P#W=ICT+_\ 7ZKYO+FZ+UBC
MF[=)ZF_M)_\ 0;3G_P"ER8>HSI-ZJ#'4)O<N)Z:.H$H**;EV>1&$QVFMC3AY
M$?.NYR3"GP)L:MNQID.7&=:D194=UQB0PXAUI:VUI5F$TOK'2(--:=";56FP
MF#15 BB+>5@RB*.!'809!OE(]A&/16O8Y$<UR*UR(J*F36IM'ZM/J34)@Z6U
M&8)KRV*(HJ2S(,HR3Y#V$&1D56O8]JHYCVJK7-5%15147(:^1WU<?59ZC?<A
MLS\,<G.NVC/:[3'Q^J^;R#ZE:R]DM3? ;7Y3'R.^KCZK/4;[D-F?ACCKMHSV
MNTQ\?JOF\=2M9>R6IO@-K\ICY'?5Q]5GJ-]R&S/PQQUVT9[7:8^/U7S>.I6L
MO9+4WP&U^4Q\COJX^JSU&^Y#9GX8XZ[:,]KM,?'ZKYO'4K67LEJ;X#:_*8^1
MWU<?59ZC?<ALS\,<==M&>UVF/C]5\WCJ5K+V2U-\!M?E,FK5G2;U3P:-U)Q9
MO31U 0Y)G2H(:'CRM-;%COE2+747H(P[ &LO5Q#DZ:V)%%"CD6*EU] X;/FJ
M;Q&AR'6X*WUCI$EAI9X]5:<>P%[(*=S+RL<T(ETSJ,"$*YLI4&-3&"%'O5&J
M4HQHN^]J+.5&C]6C@:H832VHV//11Q!:^DLVN,5-2Z=,HQ-=%12$0(2E5C$5
MR"$0BIN,<J0K\COJX^JSU&^Y#9GX8Y.]=M&>UVF/C]5\WD'U*UE[):F^ VOR
MF/D=]7'U6>HWW(;,_#''7;1GM=ICX_5?-XZE:R]DM3? ;7Y3'R.^KCZK/4;[
MD-F?ACCKMHSVNTQ\?JOF\=2M9>R6IO@-K\ICY'?5Q]5GJ-]R&S/PQQUVT9[7
M:8^/U7S>.I6LO9+4WP&U^4Q\COJX^JSU&^Y#9GX8XZ[:,]KM,?'ZKYO'4K67
MLEJ;X#:_*8^1WU<?59ZC?<ALS\,<==M&>UVF/C]5\WCJ5K+V2U-\!M?E,FH%
MTF]4[73IM,.[TT=0#9:=NK01*$+<TUL5!&8.%4;J3BE)\6$JN8DR(0V29#QY
M\IEI;$-\J-9D.-N3HJ78*1K'2*ZFJ#IJK3BA'1:C$0R7E8HF%-8:6>$;R)*W
M&D*P!W#8Y4<]H2N:BH-ZI.1]'ZM335N%=+:C0Q+W3I1B6DLT*\08&J&%(P:Q
M=]PQ/.%I'M16L<837*BD8BPK\COJX^JSU&^Y#9GX8Y.]=M&>UVF/C]5\WD'U
M*UE[):F^ VORF/D=]7'U6>HWW(;,_#''7;1GM=ICX_5?-XZE:R]DM3? ;7Y3
M'R.^KCZK/4;[D-F?ACCKMHSVNTQ\?JOF\=2M9>R6IO@-K\ICY'?5Q]5GJ-]R
M&S/PQQUVT9[7:8^/U7S>.I6LO9+4WP&U^4Q\COJX^JSU&^Y#9GX8XZ[:,]KM
M,?'ZKYO'4K67LEJ;X#:_*9-73WTF]4XC:HB<5Z:.H 9!;KFQF7)A#36Q845#
MTS6UNAQ&ER)-<:92Y*F2&(D9"EX4_)?98:PIUQ"%06I=8Z1-3F&'56FRD656
M.1@[RL(]6LM(1'N1K92N5&,:Y[EV;&L:YR[$15R=TUH_5H;@)#:6U&(:1;-J
MO)268V(Y]7-&QJN=%1J*][FL:FW:Y[FM3:JHF0K\COJX^JSU&^Y#9GX8Y.]=
MM&>UVF/C]5\WD%U*UE[):F^ VORF/D=]7'U6>HWW(;,_#''7;1GM=ICX_5?-
MXZE:R]DM3? ;7Y3'R.^KCZK/4;[D-F?ACCKMHSVNTQ\?JOF\=2M9>R6IO@-K
M\ICY'?5Q]5GJ-]R&S/PQQUVT9[7:8^/U7S>.I6LO9+4WP&U^4Q\COJX^JSU&
M^Y#9GX8XZ[:,]KM,?'ZKYO'4K67LEJ;X#:_*8^1WU<?59ZC?<ALS\,<==M&>
MUVF/C]5\WCJ5K+V2U-\!M?E,?([ZN/JL]1ON0V9^&..NVC/:[3'Q^J^;QU*U
ME[):F^ VORF/D=]7'U6>HWW(;,_#''7;1GM=ICX_5?-XZE:R]DM3? ;7Y3'R
M.^KCZK/4;[D-F?ACCKMHSVNTQ\?JOF\=2M9>R6IO@-K\ICY'?5Q]5GJ-]R&S
M/PQQUVT9[7:8^/U7S>.I6LO9+4WP&U^4R:MG=)W5/-U]TYQ(733U 2Y8?55G
M@EXL736Q9$@7.?WON$HS#(LM5Q;D&4\,(CR+4>2EIYR!.AS$(S'DL.+@JG6.
MD1V6IWDU5IQC#W$4@7OO*QK3#;IVC"YXG+*1",:41!*YBJU"#>Q5WF.1)VUT
M?JTE;IEC-+:C>\-1*&9K*2S<X1':@NS-85J154;U$494:]$<HR,>B;KVJL*_
M([ZN/JL]1ON0V9^&.3O7;1GM=ICX_5?-Y!=2M9>R6IO@-K\ICY'?5Q]5GJ-]
MR&S/PQQUVT9[7:8^/U7S>.I6LO9+4WP&U^4Q\COJX^JSU&^Y#9GX8XZ[:,]K
MM,?'ZKYO'4K67LEJ;X#:_*8^1WU<?59ZC?<ALS\,<==M&>UVF/C]5\WCJ5K+
MV2U-\!M?E,?([ZN/JL]1ON0V9^&..NVC/:[3'Q^J^;QU*UE[):F^ VORF/D=
M]7'U6>HWW(;,_#''7;1GM=ICX_5?-XZE:R]DM3? ;7Y3'R.^KCZK/4;[D-F?
MACCKMHSVNTQ\?JOF\=2M9>R6IO@-K\ICY'?5Q]5GJ-]R&S/PQQUVT9[7:8^/
MU7S>.I6LO9+4WP&U^4Q\COJX^JSU&^Y#9GX8XZ[:,]KM,?'ZKYO'4K67LEJ;
MX#:_*8^1WU<?59ZC?<ALS\,<==M&>UVF/C]5\WCJ5K+V2U-\!M?E,?([ZN/J
ML]1ON0V9^&..NVC/:[3'Q^J^;QU*UE[):F^ VORF/D=]7'U6>HWW(;,_#''7
M;1GM=ICX_5?-XZE:R]DM3? ;7Y3'R.^KCZK/4;[D-F?ACCKMHSVNTQ\?JOF\
M=2M9>R6IO@-K\IDT[]Z3>J<K?QTL7TT=0!**C4W3_ 7)@::V+,CHG"=":U%%
M82GH]<<;3+&E(4P:0C95AZ'/B28<E#<AAUM$'IW6.D0UQ6%U5IL3UN=2$1I+
MRL8Y1FU%:F"1&NE(JL*)["C=LW7C>Q[55KD59W46C]6FLAO%I;496)4:=&KA
MTEF]J$#I^K"5BN;%5$>(K'B(W;O,(QS'(CFJB0M\COJX^JSU&^Y#9GX8Y.==
MM&>UVF/C]5\WD%U*UE[):F^ VORF/D=]7'U6>HWW(;,_#''7;1GM=ICX_5?-
MXZE:R]DM3? ;7Y3'R.^KCZK/4;[D-F?ACCKMHSVNTQ\?JOF\=2M9>R6IO@-K
M\ICY'?5Q]5GJ-]R&S/PQQUVT9[7:8^/U7S>.I6LO9+4WP&U^4Q\COJX^JSU&
M^Y#9GX8XZ[:,]KM,?'ZKYO'4K67LEJ;X#:_*8^1WU<?59ZC?<ALS\,<==M&>
MUVF/C]5\WCJ5K+V2U-\!M?E,?([ZN/JL]1ON0V9^&..NVC/:[3'Q^J^;QU*U
ME[):F^ VORF/D=]7'U6>HWW(;,_#''7;1GM=ICX_5?-XZE:R]DM3? ;7Y3'R
M.^KCZK/4;[D-F?ACCKMHSVNTQ\?JOF\=2M9>R6IO@-K\ICY'?5Q]5GJ-]R&S
M/PQQUVT9[7:8^/U7S>.I6LO9+4WP&U^4Q\COJX^JSU&^Y#9GX8XZ[:,]KM,?
M'ZKYO'4K67LEJ;X#:_*9-.K.DWJG@TCJ0C3>FCJ AR3&E@HT1'E::V+'?*D6
M^H70Y=R -:>KB')TUL4+)DUQ8J77T#QT^:IO$:'(=;@[?6.D23]+O'JK3;V
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M.9]+8PZ>7,-?T\.K-;V4F3#JJROLY<P$*PF6LB'+97,B&*.4.,>0PGFPW&2
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MJ_B(Z.YXR&0ZA>8SP->A2&5&!<]1L8XA7N<Q&[%VHW9N,8UK_OG\H3?,WAN
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M/*1H^+HRXK8$;[5CNL:&!<RJ74 0Q]0:<E2SS /IKL06B:R:T<05B/>C1"K
ML8:EBB(KD6T/)3//L<8QQC'&,<8QQC/.DAT.7NT$.I>;?>H-JUN=1T'XI23/
MHQF#KA2-3+N,0L[IRNG%[/(B8>OUTIRPTQX?7ZS5Y10I8I-^L<H]9&G/*W[_
M '^^[&2GOCI# ;<D+.5 T+U!=&! . /N5.JL@19),@"7#YAM6:U4>TZ^V 4K
M;%(AV#7$&O5^[U!\;6;W<$1#279H_ QM_?IQEGJ6 FU6G5.KDK$7N!&MUD"
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M]P=1[<O6.:>*@DQ%9UIJG4$BJ4LB7<&.$$J'E]G.%RLE$U$\C9AI#Q9WF=N
M'BZD&=;R+<;#'W(CYEDCHR@8US!1HD)0A5^ZKONOE*]Z[V\XK'_>W$:QO1ZM
MTEY-J7R:3Y-;3.EZCBZ7T(X6H$M))8\JPO\ 4>IV6=J&(DAH-AHVGVQ8PU$H
M05YP; ^=N-*)['<[+/EW'&,<8QQC'&,<8SR_ZTNH[<&G^H+0E4JQU==UZ>@B
M2A,8.F4J+9]L6,AN76U%F4*JB[CKR[2;T1#56S3#TZD4L[J^SK"3R=L3?&&J
MLR)(\M=V4R'8UX1$4<<C6/<QK@(665TV+'6.)IHYW'>P15(X 'Q2=&YYO.$0
M*,=]!>2K0NF-4:*UG8V,1)UW"+(CQSG#;$K]-P0:6OK<5S92:J\J!4\>78UX
MH0;:VAZAKTEA!6K3/?8NE KUJ_J%ZE=P MIVS3W5M3-DT[65^H#DN<7KFJJY
M>;(W)5? ]I#U;6]5HMT+!M<W6VL5 %I:A[#D -R[ D"[!V[GK4 F"+$(^+8V
M4P<LT*W#*#%D1]YSQ1!'>B^<,,P48,<[V1C%0+(4>2HYLA6$VS1->-[NVU%H
MG0>EYFG*W5'DTM:"TU!2W2"#&G:DG5$%1_8TFNE6-]96]3&E7M36$M)FK+BD
M'-TK2LDP532L\P)D8'H]TJ]0,7>U:N$=]@^BW:WN)6I7ITK$K; S%E5-FS98
MJNYK1<HN*(KREJ!#PUTCU[9T$- #D+W6X)(RS-)=)4V#9XC(J$Z:,9X9"O02
M-Z7><YS!]$]VQ@__  VL.@Y36-8XXFN>CG>%>4319-'SZQ['PUK;VKC65.V.
M2>^0L!!"$*3.2?&CM))G(B3#RJE\[3Y91I0*>>8$5XH]I^2N>>8XQCC&.,8X
MQCC&.,8XQCC&>+<'JAZFCNVNLVC1+Z.KYNB4OJ5.:Z!J"TN]B=5B]+W6H"J,
M9N=#@U2C7NLF]MT<P_9==DK?M?85<O+LDU88-2%@Z6FO6#BF6EH27= 20P9(
MX;-\8>X&0R(R$<3([SQVA <1)@'J6,XTN0,^UY$"T84&3ZL-Y/= 0]->2NW+
M32)L2YM=!Q+R8DJVII.HY&JJFSD7$2JN365Q3SXFFK>*R!>!J]-TDZH:.)"-
M9R)ELLV#)%SW3U*ZZ&ZXV]8]B02>I[AH2B'CE7""Z6U<PD_ S7\G8>Q7H5AI
M]>KP/R4@;>&-W>R;;C:SKL^]U5NT:S#5NMV&\YV3S;*,V-+)(1\0\ #WB&P/
M3#=NQUD250@1C'NN)N].66D8;I NEC,$(A\@*K2F@KR1>Z8@TAH^I*S65Q#A
MV$N3:NJI8%D70Z.C:6%:3ILSI0Q&2%J(&F2:@G!I[)U=J"5/G0J=/276M]$;
M2U]2MD (A2 $O59#6H5#-QX\4M&@&X+)",S/:ARR$#,AMI]*5O#2)$9)QC$D
M81GP'8\Q[I8TADJ."2-'-&<3"L1Z(CT:1J.1'(U7-V[%]+7.8OI8YS51R^$7
MU-)T[=VU%,+&-+I["7722Q"/)&(:(9X"/"XH@&Z-SF*J-. $@?\ 8. )FO$S
M=^9\B<<8QQC*%];O^S'^NG]T^9!^O\OYYC)ZOS_EEM-3?NKUI_#^F_V<&\L=
MZ5_%?UR]OH3\$_3) Y3*XSC&<9QG';C/S9QG]F<?[L\8R(=7:%U)IB58YVM*
M;%K4ZV($1ST[!$V8FRQU>66<KP-B6>)E) VM5YP\<<K]8%N0Z\$68*+%C(BI
M\K+K&2]QC'&,<8QQC'&,<8R#K#T\:I/RY):34(;QF29R=<EJ)G(6'B#I>49D
MN2/-T^/E]ER<1)3$Q'4N1D2Y:W4-MKPA;=BL;ZD3T^]/7M7T+^/NRCE(C?X:
MM1W#9O[=W9MX[43BO!5V>_9ZLC4ATKUB1)=7&KM:1%>'2(.8:SMY8BMIFCQ8
M.6AE$4JF2RA($5$@0VV9;<5AJ.VSF(IG*,,6]&O%=C>/J7>V>K;[_0G/9D>]
MUQM1!K6JFQ%VO;)V[V^U7)L:OH5N\K5V\'-1%14=]W:&NG&F1ULY8K(5*(SY
M.9&[YZY/.1I)N+B*40TJ04>QY"XTPQAH:XE<##LB9(5%PXI6'Z[G'U>OGMX^
MKBJ_OU*B(F9E6PV[46'P:U$X&V[?O;>.WT)]U&^M=JJJINHCIFI%1%4:O,UT
M-";'CV)QB:U$9F$)K#:RI:83>4RX2D29+3;SLI;V(F'5,1,N*CQ^UIM*E7HF
MQ-GX]Z[?W^J^G-EBD5NTNYO[7;=S;NJF\NZJ;>**K=BN3CL<JHBN1-J[;RN7
M8XQCC&.S'S_-^W]O_C_[^,8XQG&<8SG&<XQG*<]J<YQC.4YSC*<YQG_5G.,Y
MQVX_U9SC]F<\8QC&$_,G&,8SG.<XQC&.W*LYRK/S?Z\YSG.<_MSG.<Y^?C&<
M\8QQC'&,<8Q^S]G&,<8QQC'&,<8QQC'&,I/?M$;*N>QYEJRNMG*P+MEFG/T&
MYFR$&J;-KQVOZ&9#!S218:TH&"*R3H=CGYCS0)+!"Q!Q;CXEX39RTR,QF&D]
M/NS!T.WR1P+6N;(6K[3%.N >R7'XUZ]EMZD!4.OT"KX+Q(JT:\J&P1B=F1RI
M.US8ZUIESX>K6[JL>=AU]7Z\E]/'^7HQE\>4QCC&.,8XQCC&,XQG&<9QVXS\
MV<9_9G'^[/&,8QC&.S&.S&/FQC'[,8_W<8QQC'&,?_G_ .?_ #SQC'_^_MXQ
MF/CB1D0@1*QH$1@F7Q"04(-L-IF3VQS3C(]J5)PGQ76(3;S^(C"EY9CJDRG&
MD(<DR%.6HQC7.>C41[]W?<B)O.1J;&HJ^E4:BKL3T)M54XJNW.^3(($$8AB/
MCQE*L<+GN407'<CS.&/;NM>5S6=(]$WGH,;7*K1L1N0Y=F#'&,<8Q_\ G_R_
M9QC'&,<8QQC'&,<8QQC'&,XSC&<XSG&,Y3GM3G.,9SC/9E/;C_=GNYSCMQ\_
M9G./V9SQC^?IQG&,_-G&,X[<9^?';\^,XSC/_OQG&,XS_JSC&<?/QC]]OISG
MC&.,8XQCC&.,8XQCC&.,8XQCC&<=F,9SG&,8SGLQG/9CMSC';V8SG]N>SMSV
M=O[.W/9^WC'[_?8F.S';V]F.WLSCM[/G[,]F<X[?V]F<XQVX_P##'&,YXQCC
M&.,8XQE"^MW_ &8_UT_NGS(/U_E_/,9/5^?\LLQJF/9<ZNUKE!8&EOT?TWL2
MJO3UKQ_@: O':O%G0G/ZEE$?/8WCME)7,^9E>(*+7;-KN"^E?7],N3;L3BGH
M3U?7-]S&M/9GL,@,9\/.$YS6B.<8>\J[^%YQBV8SEO$/]7RUA259E?K?C8:_
M4N4X<E[?IE>/-.SZYRN/:,X<\,P 3G.'/"RNMD7,(SEY*F<N83:F\N81'PMI
MS"<M>*\I+Z<LH1F,MPY+V_3GX>_''FG8OCA4>SY\3N%P*<95)RUWJX07W$*R
MCR1+G9:4>(IC&'/*5IPUB5E2,M(A^&K#CAR7M^F./-.Q?'"H]GSE7=, <)RJ
M5E&%5P@K*4+:3B&E2L6I.%*CO86Y*7A*,2VE)9:1"6G+ZW#DO;V^K^GOQQYI
MV?7&8]G^?L, <?TO9VUPAGY\Q\)8[>RU8[?#E=YYW'S>-'SB,C+#F,RU.')>
MWZ8X\T[/KC$>S_-VF /[$=O97"&/Y6(V4N9Q_.K/9A4OL?0GY\MQNV*I3CN?
M+,.')>U/#''FG8OCA,>S]N.\8 YQWHV<X37""<Y2EE29F,9S:E8PI^1E#L96
M<9Q%92IAU,Q:\24.')>WZ8X\T[%\<)CV?&4=\P!5C"XV7>[7""<K;1A?EB49
MS:E^&M]66\QEJPZF)A"\.MS<N)4VX<E[>SU?U]V./-.SZX1'L^/#\0P!5V>#
MXO<KA!'?[KJ\O^'WK4YX7BLY;;9[WC> ZE;R_*$+2PVX<E[?ICCS3L7QSJRG
M#PZ%(GDK'5X<.#$<E3YTD!-B0XS,9U<B5+?>?MWAQHC0].4.9>=REEU"YKC^
M6?U1-'.8U%<Y=UK45SG.<B(UJ)M5554V(B>E57@B>GGES6O>YK&(KGN5&M:U
MJN<YSEV(C6HJJJJJHB(FU55>'+-.'7Y!6;#'1['$@R2N%M!7CNM;M7X!J5A2
MIJ6PI Z5%P#+F1+;SJ((Z8_*D(9?+L95 CO,)UV2P/<UJ*1JO548I!%$TBHB
MKL&\HVL>JHBN1&N55:BN1%:BNS.^'(8U[U0;D'Q(@RA,X2;R-VE8(KWL1'*C
M55[6HCE1JJCE1,WM<>T9\3PS %.<^+X7?K9!SN=KR5,>)A-J;\7PV,+;=[N6
MO&>4E]'@(1F.O9X<E[?IFMQYIV?7"H]GSESN& *<97)RUA5<(+RA"NYY(ES.
M+4CQ5L=CGE*TX:Q*[Z/";A^&KQ'#DO;],<>:=GUQF/9^W/=, <8[TG*<9KA!
M6<)6RE,/&<XM2<94P_A;DE6,)Q+94EAI,):,R%N')>WM]7]/?CCS3L^N,Q[/
MVY["X'&.QSL[:X0SG&<Q\):SG/QIQVX1+[7W,=F,NQ\XBIRR[CRS+AR7M^F.
M/-.Q?'&(]G^;M, <_,WV]E<(8[<XCY2[G';:L]F%R^Q]O'SY:CXS%5EYW/EF
M'#DO;],<>:=GUQB/9^W'>, <X[T;*L8KA!.<I0RI,S&,YM2L84^_E#D96<*Q
M$92IAU,U:\2$.')>WL]7]?=CCS3L[?7_ $]^$Q[/C+??, 58PN-EW":X01E;
M:<+\K2WG-J7X2W\Y;\F<5AU,7"%X=;F>(G+3AR7M3PQQYIV+XX1'M&,-^(8
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M-<(9SCO1TIC]N<6E/;X4KO//?-CRB/E,9OR9Q.9:G#DO;],<>:=B^./)[/\
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MG,2%*6I"<VMS+:%1,I80A2G%(D85*RXMI6(:7#DO:GACCS3L7QQF-:>S/89
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M%PV97ABH#X.+(D5DJ#(,+)#'9XJOJ]/Y=OAWXS/:>ZF]J7C:M9KY^A.A*S>
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MU6K/6C$%F26+%&XKP6##ES5@IP]4$F/+REH@L9#=_P!P=0%'NUDK .!:+!0
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M(@3AC.TYUK;/8C2ENZ.[[S8.#,C.Q+!#DQ,M2MF@*.N\S9/E;0^%0&JX9E;
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M_7&9.W]4W4)#UI8R@C5)",8CZ_66K))F.5+V%ZS#JIHLU*P=!8H;8MYB>4W
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).,8XQCC&?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gwpjrhodncoa000030.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000030.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #? ET# 1$  A$! Q$!_\0
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MO,)VH<ULF.=US<TQ,==F-K0N>WLQ7(0+FK8!%N2M4W(9RF_8FM^KSGP77?\
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M<>,_H2D*[\=Y-86C3+E:G#LOZB.7'SB/S85>S2(]-O\ *!.QR-&Q+$TC1O\
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M6M&'2QB"]3!W>7)<U%29O6NK(F)8F9"D9TC.E<%![V].AA(A&UOMU\^G1O\
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M<6V-H%JM.E$X.1Q1Z@EO0A/,+VK7&D)E)Q:1/HQ0,I.>8$O8"C!! YV , 8
MP!@# & 0$Z2J&X+DLV";BE90V&N5<SV!2& ]6([5<$,YB4'3OD4?K9BAD$:X
M>D<GC\.4#0^04^ .DD=ZXD;8M:)3(W%(XH2V)#/Z_/\ +N!I63>/5/.(!+7*
M4PV(K+PM/K7=GS64F2!W,):J<.Z;;I&-G1;+&4@<GE/S:P-<-+1G-H23'U0:
M2(_:8@)VX_7X>>?UTP#>->\>,_X<W!<MNMCK+9Y+>AY'<$4B K0G8ZQ+*A:2
M/0VCGMVKLIZ3UNMF;3$(!$'5*]O<2>7**O041R%9[]'VU4FG+QCW=-_CU[P?
MOFR"7\NM>47#U#6T:;K&<8VYQ^*R&/66EED5KB&J7YM6DU=7<4#&6I:WD/($
MB1\L&P79R4/\ZD+$UA4I&J-ML4BT4CV=/U^O(&G.A>,[ZOI+U'8.[870RP9C
M$G&N:,KAJ3U^Z0<B$5RL,E%8D2R226!/DJC[I8EHIQ3B=KX2\L:A$T'0YA4&
MN"R!(5NY6-LK;O\ UD&2S_C.WY+?<&M-NN@X]@>;\B]NV>TO<3B*QRCD;K""
MRTBL:\A[P-%M:X1J/S1U1&H6LW2-"B6O4MGQI2R6NBE4M?I>WS_7AW P"E>-
M[,KZT87,E5:5Q'GVJ[4Z7M637'')H8?8/3>K:66R?#*_>2MQQ(?'H@(ZRD$L
MF*24NSHA99O"F ,8:W1,>ID25GKWY2_#'^0)1<RQ*ZX]+.H)O;-<L,6>K>M)
MOL&-Z:;"1RW1C(SUA!JSCT/4C3L+4%L^#HJ^*=%*S?MDZEQE+@:03K99XS(!
ML/ERL9-2G-M55Y)M-[A8$?A1*Z=;;E>QM;C9LB,52N?&H7 PDL9J!?.7I\-2
MKSDX##DYP%)Q(1C$#0$$*XX/MAH?Z5;):\Q;58.E#56GZXC[:L4J%]GW/4T^
ML.V6R--VQIRDQT"E-EW)*7B;.2W7MI)&HD@AKB@,:9.Y:(G;\\>/=U!PBN9.
MNZ\AE>FUTPUK(;/(X^O&N7!Y>Y^M8V>O.@K_ )\RVW9\I( 3%W)9+&EXE;6A
M)9CT8FHY2XLA/QD]H;'0US1O'KC/S[_$&82SD6Y$##T17%=-\9)89=PQ3O,U
M/3,V8'LA[,&IVBQ&A9"W!M2,:ET8-2\5AN9@IFU*%8&Q"0UCVC-6MQ) &?'Q
M;^.,[=.X'"?>1[8MU\L5RG]:55 X=9#IQ;6X:V8) 2_)V3FSG"Q7^UIA%7M:
MFCC*W.3I,G1W'$%C(UHOA!,7&C94KBM1LX'1=&?U_,&<.G-=N(INWSANC,1?
M4SIWV=T%+HJ"3E,(15A&.=%'/M5G(E(V58AVLCJN.U_/W6/!3EGB&W*4R%6:
MN!HLY^OQ[_UX LJP!@# & , 8 P!@# & , 8 P#'I=^2DG_P\]?[:IP"NCPP
M_FJ^$?U>87_I*<%ZGVY>TLXP4& , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , JK\G7Y;>*W_-4I7_CYU+@M'I/
M^%?WXEJF"HP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , ZU<],[6<C3N;LV-RAQ-]@WD+EZ5(<N/UZOI)1E*#2QJC?ZP?[,@(Q_P!8
M/]7Z]8!V6 , 8!CTN_)23_X>>O\ ;5. 5T>&'\U7PC^KS"_])3@O4^W+VEG&
M"@P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@%5?DZ_+;Q6_YJE*_\?.I<%H])_P *_OQ+5,%1@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , X+F+06UP%LQ<3H*%6+9K8
M3M0Y%:T09O9C>G"0J$>N!Z/62$A3*-FGZ+!H@[8O9B \J?3U:>*YJJ6-797%
M"U[W=/9W9)M>7#=/8EM=02J55*]$QB1248.@@-5?7-==1R]\6LH8O&($;3U>
M-#>\N1!8BH\04@0.8RQE+..9Q6,I14=_9NEYMYWPR\7QSU1"J^YL@,MK^)7%
M44:N&%0>PRN>+4M&Q;.;:+<79@ K<HI C;5&;-(NPJ3UNE!T>5@9$)8R$RLB
M%P]>I=6K!23;>^'C*RDEGX=?;O[3!(]Y:^,I6R]K3&.S-\>:WX/8XF^6]9[:
MRIUL&E(9<V2I8A0U(X)G0UPG:E.Y1!QC(UI;6VL3K(5+>GC3P^H#S'$@.5KE
M\9=%W]<;]RR_/VX,>)\N%";KMVDJZI.EF:V6F_X3S']%%WKZ)).E%]Q61#2;
M(@K AC>K%-K_ $W22N!J9TDDBZRD3 F8&QTTY."%T1B;!!R/.,I[9RGMC+6?
MBL$NZ6Z)KCK#F1JO^ISGH<(G\2EQJ%')6H3')V-VCRQ^B<JB\G9A'*M-DCBD
MK8GJ-OJ,E6M2E.C6JTB7+D>R%9PAK#Q^O=Y>!%WPP_FJ^$?U>87_ *2G!:I]
MN7M+.,%!@&+3*<PJN6!5++"F$6@D60F)25TEF4@:8NP(SER@M&B*5/+VK0MR
M<Q8K.*2I2SE(!*%!I9!6AFC"'?U6=C>ZC<0M-/L[J^NJBDX6UG;U;FXFH1<Y
MN%&A"=22A"+E)J+48IR>$FS%6K4;>#JUZM*A2BTG4K5(TX)R>$G.;C%-MI++
MW;PMSH:]N*H[; ZF53:=<6:6PB1 ?#*]G$9F@&8;EI4)N ZBC;HY!;A+PH5H
MD05FR=JM(U6R-&:3F^IGU#2-6TETEJNEZCICKJ;H+4+*YLW65/E51TE<TJ;J
M*FYPYW#/+SQYL<RS2A=6MTI.VN;>X4&E-T*U.LH.6>52=.4N5O#QG&</'0V/
MFN/H& , 8 P!@&/RV4,T(BLEFDB.5IX_$6!XD[ZH0-;H]KB&=A;U#HY'(V5C
M1N+T[JBT24X:=L:&]<YKSM 2H$:E4:42/Z+2UK7MU;65NH2N+NXHVM"-2K2H
MPE6N*D:5)3K5ITZ-*#G.*E5JU(4J:S.I.,$Y+'5J0HTJE:HVH4J<ZDW&,IR4
M(1<I.,(*4YO">(PC*4GM%-M(C50W<7-?3$M>8134PD\ED<>0N:]Z3.E2V]"4
M+:%F6-*!S1*GN=06-L@'E(I?&S1C#\1V][)4"5 0"3)U)Q/1Z[P5Q%PW:T;W
M6+2UM[>XG2A1E2U72;V=3MH5:E*<:-C>W%9T9QH5<5^S['FBHNHI2BG\%EK&
MGZA5G1M*M6I4IQE*:G:W5&,>1PC*+G6HTX<Z<X^AS<^'GEPFU+7.4-F, 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P")'8;;'I-"8+ )+UO*N/T%CV8U1
M F7P&4P2!S^QURF.2ES35'"9W.F=[U$WZ1B;!/9;C#TJ>>*4496M<<<6\Q>I
M4@$KOVSL_/'F_9Y[9P4)AAG*L [R!R55EI^1.K[=!9#55JF^V;R+LTOFKG9C
MM5:.X4+@_P#*5Q6E/YQ/ZHVQ+DI#O83Q0[E7YCP!<$PH;&@4OI#P_7Z_P+O/
M*FU'#R_L)=,K&4E^?AWO!Z/)W:<'YJI);970MK,K/%JSAB1985J2P#5%TKLK
M9VLHMS>Q-#:$I"2\25>0:<VQ6.I33E3HN(8X^WJ3S$:48HEEX2Z]$1ML_P F
M_&-.UG15MV!:+LV0SHVMB+DJ\YHK.T)@]*JC_!N.RYTLV41J&P^0/\%@L98)
M9'ETKDTR;F1JCVW(I,Y*250#B2Q/+)MK&Z>'NNN^RWW>SPEG/<9')_(AQ_$;
MXA_-[S;A.[/FY]=(&<+5$IP_05(]W"C<7&H(U)+59(VX5E$Y3:[>TN*ZNHY)
M98UO$M2D%',Z-2!P:]K@46TWCIGO2>W79[O'?A;&@?)U^6WBM_S5*5_X^=2X
M$>D_X5_?B3<Z(Z9I+E&"H[*OR:;@D*<)(@B*1ZU&Y9*-&2%T0.KFA0";X:Q2
M%T*T>B9',[WPY"6A+$GT2:I+//3%G;WA_AO6N*;Z>FZ#9_7KVG;5+N='ZQ:6
MV+>E4I4IU.TO*]O2?+.M27)&;J/FYE%QC)Q^"_U&STRBKB]J]C1E4C24^SJU
M,U)1E*,>6E"<EF,)/+2BL8;RTGP><.JZ%ZVB3U.N?9UN?Q6.R(V)O#K^#$QB
MVDD@);6YX-;](YI'XZO4[ W.S>HVI2I3T?\ U.BM*-G%FEEWXBX6UWA2[HV.
MOV/U"ZN+=7=&E]9M+KGMY5:E%5.>SN+B$<U*-2/+*49^CGEPTW73]3LM4I3K
M6-9UJ=.HZ4Y.G5I8FHQGRXJPIR?HRB\I-;XSDD-G/GWD%>M?(CSQQ1(XA&[U
MW8#:HG;.M>(NY1V%+)"RN0&Q<% Z-Y;@F4E!"[-@SV\]:AV7ZY*5V:S]"%I5
MK0>XX4^C[B#C.WN[C0_J%2-C6A1N:=Q>PMZU-U8.I2J.G*+?955&I&$\X<Z5
M6.%R[Z;5-=L=(J4J=[V\77A*=.5.BZD)<LN6<>9->E',7)8V4XOO)J,+L!_8
MV9]+0N;66]-+<[ ;'I)MO>&X#BC)6!0NR#8S-HG-($[2=>DV89M,J+-)V,6P
M>MOC*])T*]:@ZE*JZ-6I2=6C/M*-1TYN':4JF%STIXYJ<\+FBT\+)MX2YX0G
MRRCSQC+EFN6<>9)\LH[XDLXDNYIH[;,18Z(J41D]6% 3(F(Y<,[W<",IW;S%
M8U&A;!L@*<"C9PCM#UL/LM V/UM;#ZOIUZ,SNUN8P=25O74$N9S=*HH*.,\S
MDXXQC?.<8**I3;Y54@WG&%..<^&,YSY'>Y@+C & , 8 P!@# & , 8 P!@#
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M H:6@:%I7KD2D0I-QDNY17<O6CWXSW^)?S@H, 8 P!@# & , 8 P!@# & ,
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MJG *Z/##^:KX1_5YA?\ I*<%ZGVY>TLXP4& , 8 P!@# & , 8 P!@# & ,
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MYRLKIT>.BQG;&_?[3O\ PP_FJ^$?U>87_I*<$U/MR]I9Q@H, 8 P!@# & ,
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M8LE^_P"J'[@Y\FT1CDYBUD5?:D1<8VKD$*>VY[TVC=$FQ(7 DQ(>8-KDD><
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M:<6EE0PFDY/S>-EX+/AW[=,(]@F#$, 8!57Y.ORV\5O^:I2O_'SJ7!:/2?\
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MEQA*O4J.$6]VHM)O=K)6C;V]NI*A0HT%)IR5&E"DI-;)R4(Q3:6R;,S,+ :
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M3;?TBA_:T_\ $P!\3;?TBA_:T_\ $P!\3;?TBA_:T_\ $P!\3;?TBA_:T_\
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M4RUQ5%M[6B5*QIT"-4L."5LM,G..$ L0=2FOI_N*X9G(?'%;_'5IUHJXJO\
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M;8TH4Z-O(2"LDESX7V9\J]GI=?@CT)X*# & , 8 P!@# & , 8 P!@# & ,
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<,]V/-]_N+/\ !48 P!@# & , 8 P!@# & ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gwpjrhodncoa000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000003.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #H EX# 1$  A$! Q$!_\0
M'@   00" P$               8'" D$!0(#"@'_Q !J$  !!0 ! P(" PD*
M!PH) A<$ 0(#!08'  @1$A,4(0D5,188(D%15Y?4U1<9(S)66&&5EM8U57%W
M@92R)#-"4E21DK'1TR4W4V)R>).8H=<T-EECM"<X0W:SM<'P1$B#A**VPL/&
MTN'_Q  = 0$   <! 0               0,$!08'" ()_\0 91$  @(! @,#
M!0<,#0D%!@,) 0(#! 4 $082(0<3,10B05%A%1=6<8&1E18C,E)5DZ&QTM/4
M\ @80E-45Y*4EL'1U>$D,S0U8F-R=H)#=++C\7-WHK.TPR5$1W6%Q(.$AJ7"
MXO_:  P# 0 "$0,1 #\ ]_'331TTT=--1Q[KNX2I[8N$-;RO8"16MC7M&J,I
M1RRNACO-;</</3@32,5LC0H5;/:VKHG-G;45Q[AO42D3'9;P/PK/QEQ'1P<4
MA@BEYY[UE5#&M1K@//(H.X,C;K! &'(9YHN?9.8C#>/N+Z_ _"^0S\T:SS0A
M*]"JS%1:R%@E*T+,.HC79YYRIYQ7AE*;N%!\B/*?.O.?<?K9[3>Z_5;6UL2)
MYJ_."2G24M9$ULA"A9S*5ZK7UP@@\;WJT,/WGQQ2%&SD$+.2_N["<-<-<(T4
MAQ="CCH8419;DBQ"S,Q(426[TNTLTCN0 9).4$B.)40(@^>>=XJXJXSR#3Y7
M(W\G8F=FAI1-*:T  9^[I4(28H8XU!.T4?,0IDD9WYG+*$Q&!D3"%QDBE#2O
M@(&)9+ 1!-$Y620S0RHV2*6-Z*U\;VM>QR*UR(J*G61HZ2*KHRNC@,KHP964
MC<,K D,".H()!'4:QEQ-$[1R"2.1&*NC\R.C*=BK*VS*P/0@@$'H1K@BSN<Q
MK5F5TBHD;4]:N>KG>EJ,1/FY7._!3THOEWR3Y]1W'4[C8>/7PZ;]?5TZ_%J&
M\A( +DMMRC=MVW.PV'IW/0;>)Z:Y3L+%GF&):0.2/+) 0/.V2&>">%ZQRPS1
M2(V2*6*1KF21O:U['M5KD1R*G165U5T971E#*RD,K*PW5E8;@J00002"#N.F
MHOWL;LC]XCHS(Z/S*Z.I(964[%64@AE(!!!!&^MC:TNAHGPLO*FYIGDM>\=E
MJ =7/G9&K4D?"TN*%96L5S4>YB.1JN:BJBJGF3!:K60QK6(+ 0@.8)8Y0I.Y
M 8QLP4D [ [;[';4ZQ6NU"HM06JQ<$H+$4T)<#8$J)%4L 2-R-P-QOXZP(HC
M9V$RP1E31AP(29)$R61@@SB(!&D$O8CFP0.+*%&26561J03!"CO<FC:Z:SHI
M1695,C%(PS %W"-(50$[LP1'<JNY"(S;;*2)*B9P[()&6->>0KS,(T+I&'<C
M<(IDD1.9MASNB[\S 'H]R3_RC_\ I._[>O6O/._VS?RC_;KO@B,*=(P:,HA\
M4$Y,K8&2S.C&&B=,21(V-'*R >%CY9Y7(D<43'22.:QJJGEG1 "[*H+*@+,%
M!=V"HH)(W9F(55'5F( !)UZ032$B,2N51Y&"<S%412SN0N^R(H+.QZ*H)) &
M^NIL\S'->R:5CV.1S'MD>US7-7RCFN145KD5$5%145%^:=1(!!! ((V((W!'
MJ(/0C7D2.""'<$'<$,001X$'?H1JSOL2^D%Y*X3Y!S&&Y)UUOKN%='9@T5F+
MI; BU)P:6$\8@VBSUB=),8#65<TC)[BC9+)6$5OQLP@45HD)"Z;[2^RS#\1X
MJYDL10KT.(JD,EF&2G$D"9/NE+O4MPQ*L<LTR@I7LE1,DW=*\A@YDUO#LJ[7
M<UPSEZ.+S60L9#AF[/%5G2[,\[XKOF$<=RI-*S2100.P:S5#&!X.]:.-9PCZ
M]*_.O+V?X%XCW?+FGC>158JDDL4!BD;#/;69$\%;1TH\SVO9#/=79M?5Q3O8
M^,=Y:3R-6.-R=<@<-8&UQ/G<9@J9"SY&R(N]8%E@A16FLV&4$%EKUHY9V4$%
MA&5!!(UVOQ3Q#3X4X?RO$-X%Z^,JM-W2D*]B9W6&K61B"%>S9EA@5B"$,@9A
ML#KQZ<^=U?-W<?I;"]Y&VMM-6$$RR5>*K#C*_%9\17N6 *KS\4_P:N@B]$,E
MF<TNX.2-DE@>3(B.3OCAC@GASA&I%6Q..@6=$"S9&:..7(VGVV:2:TR]X QW
M80Q&.O'N1%$@)!^='%G'O$_&=V:UF<G8:!W9H,9!+)%C*<9/FQ05%?NR54*K
M3RB2Q+RAII78 Z8SZET"J2B5-RJALFD+3X WR+&,,AI$A*>UY@9 &YI<SI?2
MV(9R3O5L2H_K)O*:WF'RB#:0J(SWL?GEW[M GG><6D\Q0NY9_-&[=-8OY-=W
M<=Q:WC#F0=U-O&(T$KE_-\T)$1(Y;8*A#G93OKO7-ZI!23EH= @0<,))9BU=
MB@HHY$$94$Y)'L>S!#.++$3#+*]K)()(YF.=&]KE\>6T^=(_*ZW>2,R1Q]_%
MSNZN4943GYF975D90"0X*D @C7OR/(B-Y35NB*)5>23N)^[C1T$B.[\G*BM&
MRNK,0&1@P)!!T_G;QW=<W=M6FK;G";"U(ST!,3KGC^XL3#L9H 4D:I A-1-+
M(. 5+$CF#W-9&+:@N<JP$K$Z:";%^*^!.'.+Z<U?)T($M,C"OE*\4<>0JR['
MDD2=5#2H&V+UYB\$HZ,G,%9<KX/[0^*."KT%G%Y&Q)31U-G$69I9<;<BW'/&
M]=F9(9&7<)9@"3Q$[JY4LC>G3EKO:Q>%[/Z_NGH!&VD>RHZAF"SA\OI<5M;]
MA$$6?M9!WL14S9@5Q+HD$F8^07/VD8$WO.'>O&^#[.LAD^/9>"K4AA./LV#D
M[<2[\F.JE6:U KAMC<CDKK4,BD"2U"95Y0XUW#Q!VFXS%=G</'=2,3KD:M<8
MFG*Q!DR=L,JU)V7;I3DCL-<Y"I:.I.(FYBA/EBY<YHYWYY.L.0.3]3L=57R6
M;AFS3.L(\71ES)[\5-35PR,SM(C(7(^( .*&>5ODF;WYY)9Y.U<%P]PUPQ'%
MB\-2Q]&40A^51$<C9C4\C6+$S[V[.[;AI9&95/F+RJ%4<'\0\2\5\5RRY?.7
M\E>A:<H&8S+C*LC;NM:M"FU.L IW6*-5=AY[<S%G+'^Y)_Y1_P#TG?\ ;UDF
ML8YW^V;^4?[=;:LI=#=-*?35-S;,!:QYKZP X]H;)4E6-Y3A8I4';(D$RL=*
MK$>D,JM54C?XD36JU<H+%B" R$B,32QQ&0KR@A [*7(++N%WVYEW\1JH@K7;
M0D-:"U8$0!E,$4TPC#<Q4R&-6" A6V+; \K;>!V?+AGG[N"[;[^#3\=Z369\
M6K)KIKC/6*6D^+MH+"/XH0'29XIS*R>&W#9(X(A6#6;8'/,ICQ2&,*CQOB'A
M?A;BZJU/+5*-IYTF6"W$85R,#1'DDDIVT!F5H)".\3=X>8".Q$Z$H<HX:XMX
MOX,MI>P]S(5(X)('LTYA8?&6$F!DCBNU)"(&6Q'S&)]DGY29:TJ.!(/6KPKW
M+8OESMRJ>XR5[<_G69.ZT&R%ED4E<J7D(3?NQ"DD1C)2(*R>L.E"(=##(?6*
M&:D$2%-C3ACB+@_(X+BV?A-0;5LWJ]7'N $\MCOM'[GR ;E4:9)HED4,RQ3=
MY&6/=DZ^@?#/&N,XAX-K\8DBI3&/LV\DC'F\@DQZR^Z43'8%D@>"5HW*J98.
M[EY5[P >7/NJ[Y.9>YK6W$Q6EO,IQFAA$68XWIK,BOJ!:ADCFARZ*,&6)FCO
MIH4;,<?9*3# 3+/#4P@ *P9.S^">S;A_@ZC75*=:]F.[1KF7L0I+8><CZXM0
MRJQIU58E8XH>1F14:=I9=WUPMQ[VI<2<;Y"RSW;6/P@D=:.%K3O#7CK@D1M<
M$3*+EMEV:668NJ.SK76*(A-0_#K+NR'L#*^NM#Q*F!I5J4&(64/6#/<K&$V$
M\$<D04#WHK6S$NCC<Y%:CE5%3K/I)X(6BCEFAB>=C' DDB(TS@;E(E9@9& Z
ME4!('7;6NXH;<R32PQ6)8ZZA[$D4<LB0(3L'F=05B4GH&<J">F^N/U=<>ALG
MP-E[;@%M6R?"E>AU8A#A%LFN]'I4!"F.&4Q%4="&NA63W&JU'?P[E>^BW$O<
M$=XFXFY!)W)&^_>\A#]W]GR$-MMUT[JUL&[NQRF$V W))L8 YC,X.VQA$@*&
M3[ ."O-S=-9)E%I*X-UC84UV#7M/FJG'&5QXP;;0=KG3UKB9H60(?"UCG3!J
M_P"(C:UROC:C55/$=NK+((HK->64Q+.(XYHWD,#D!9@BL6[IB0%DVY"2 "=]
M>Y:MZ&,S35[<40E:N998IHXQ.@):$NRA1*H!+1[\Z@$E1MIYN"NZ'FSMUT@%
M_P :;BX $&)CEL<D<:6?C- ,U[5F"N<Y*0@$[9XO7"TX=@ML"DKY:RP")\3)
MCW$O!G#O%E26KF,=!+(Z%8KT<:19"JY!Y9*]M5[U2K$,8W+P2$!9HI$W4Y)P
MKQUQ/P==AMX7*68HT<--CYI9)L;;3?SXK--G[I@Z[J)4"6(N8M#+&^S:]<G%
MW<KA>1^VZM[EI'NI<BW$W.MU KY$*(SL^4A/;KJE7(D+C):NPJ;$4.3VH'V<
M3!28H8VF1,3A3-<(9+$<73<'@"S?]T:]&DX'(EM;S1&A/MNPC6>*>%Y!S,(6
M+HS$QL=?0?!<:XK,\%P<;$FMCO<RSD+R$B1Z;8]91D:_[DR-!-7FCC/*AG41
MNJ@2*->6#NB[V^:>YO5VY=OIKG-<>J7.S-<:TEH4%GZVJ;(J!_7,(<D#-)=N
MA1)#K:U9.[XF4B.LAKJY80(>U>#.SKA[@ZC!'7IU[F5Y$-S,684DM33[?7/)
MVD#&G6#$B." J.14,S32AI6X0XZ[3^)N-\A8DL7K-'#]XPI86K/)%4A@!(C\
MI6,H+EHKYTMB</Y[.(%AAY8EB)# <2V5X\)9#($B6=\,<TK84GF8/"LKHT<D
M:33R1P1*]4]R:1D;/+W-:N>M(B%0[HA;FY0S!2W*I=N4$C?E12S;>"@L>@)U
MKU!/(&*"5PG+SE [!>=@B\Q&_+S.RHN^V[,%&Y(&ML_-:N)@LDE!H8XSBI @
MI'U5DQAAD3I62B"O= C2"HWP3LD'B5\K'0RM<Q%C>B2!=IDNHMUB8T$D@$\1
M,<;!2KN ^ZH0RD,VRD,I!ZC50:6158V:I="RN8HF,$X6212P:.,E-G=2C@HN
M[ JP(\T[8,=;<RR,AB LY)9 GV<<48I3Y)*V.*2:2P8QL:N>%'#%+*\MJ+ V
M*.21TB-8Y4F&>%06::)5$@A),B "4L%$1).PD+$*$^R+$ #<C4I8;;,%6*PS
M-$9U54D+&$*6,P !)B"JS&0#D"@DG8$ZRFY_3/'++927KQ  1+0XIM;8.'"K
M+!OJ L2YDA6,8$UOX0A<SF#DM^<,CTZ\&Y4#I&;5<22RR0QH9X@\DT7^=B1>
M;F>6+_M(U!9/W0&I@J9 I)(*UPQQ11SRR"&8I%!,-XII&Y>5(I1UCD8A''V)
M.N[,['6XNV&OL?J-#E;L.1DHMOG;FQI;(>1B^IKH3:X@<B-47Y_@R(GVHOE%
M7KQ<H4<C ];(4ZMZO("KP6Z\5F%P1L0T<R.A!'K&HTLED<;82WCK]RC:C(:.
MQ3LS5ID(.X*R0NCC8^W7IV^C([VM%W)YO0\:\I%0G\I\>UXEK#H&0P"R[/'S
MD1U[K(X49D8[+JBL90P;8F"$: ^&TJ24A4U;&:3C?MC[.JG"%NIF,*C187*R
MO U4LSC'WU0R]S&[DL:]J)9)($9G>)H)TYA'W*CN'L0[3KG&M*YA<[(LN=P\
M,<ZVPJQMDL<SB$SRQH @LU9FCBL.BHDJSUWY>],K-:OUI+6^M1QYLY/L<]-%
MELZ0X2PF&839V42HA D$_J2 01WVPDRL:LTLZ(DD4+X?8<V21SXZJO"'\]NJ
M[[ >LCQ)Z>'H\?'?6R^!N%JV11\MDHQ-624Q5:SCZW,Z;&2:8?NXD8\B1GS7
M=9.\!50K0^=:+:3E3.L5L2(2'CF2N+^+GB+:UDDD!3UDDD80UDL<CXY521&R
M,>YOA[56M  Z  #U#I^+6X8HX8D$<"11QIYH2)51$V \T*@ 78$=-AL".FCR
MOY5_YUZCJ9K36^ES^?0=;^_IZ-"UE05;>U"K4)6#VUF0=39X$F6%)8O=2/U>
MW[L?K\>MOD2!XD#X]2Y)HHMN]ECCYM^7O'5.;;;?;F(WVW&^WAN-_'6Q%-%.
M@:2$7 8,Y\T;2!9XR('2#S2#D1MEA>^-7P$12P3-1WJBFCDB>C7L<U&O:LK#
MF5@P.^Q4@@[$@]1TZ$$'U$$:R/*_E7_G7IJ.CROY5_YUZ::Z1RH"X8R1"8BA
MYF^J(@>9DT,K?*IZHY8W.C>WRBIY:Y4\HJ>?ETU $, 5(8'P(((/Q$=#K22:
M_*PC-,FU&?B$<(X]I4EW7,&<"PZ*L>:V=Q*1*(RRG@KW$H[V6G31"*])Y&1K
M#<>L?/J69X0.8S1!>7FW,B <O,$YMR=N7G(7?PYB%WW(&G7P7*%UF9@;&GME
MMJ$A(IW@H9\956 4J-<DH<C7RPQ/DC5'CF"+\U1BN]Z%71/ER1)(#T 8^##Q
M^7UCU_V[:L>9X<Q>=K.)(88[#(6KWH403(Q&Z,SIMW\1/V4;DJRDE"C\KK-?
M5<@5]#AV[$5$*98"B.IH)/P4)*L8O<&CF1KO+$A8DDQ3$<CT8/-&UR2>GJ@2
M,M)R'IL3S>P#Q_PUI/$\.V<AG3A9B86KRS"[(OG=U%6?EE:/F YB[<L<+%2I
M:1'(*;Z@C?ZK0:<N0R[M2S9)'JYL3Y7-$@15\I&,(Q6CCQM_$V*-OE?PG*YZ
MJY;DJ(@V50/;Z?E/CK?F/Q..Q4*PT*D,"J "ZH#-(=MN:68[R2,?278[#H-E
M  @AR]W,:;C?F*?#!!X@ZDK0NWJ2:EL3[ ;D'4D<[<I;GC<R;&P1E_!&1\?C
M94?6W(4M=,I=.MG[UE3QCQF)!GY3MTV\WIZ3S$CIZ]MM]4%_,34[YK*M9HT7
M%$QNS+:F.3NVJ;&N W*WD@@6Q(I0\T?/N\84-IO*3O\ :>^AQ-2%D+--'IXN
M&TD*FGST8$AG(-QV["7@[,RW82:BF$@$[A:%**VLT(KYB*^T(CEN1:\5MYY$
MN^W3J=OG/+OTWZ?9=.I\/3JDCXHBE%9%@?OIAC]R3"%+6Y<0D@$(L&:,!<M%
MW;ONI*.=Y%11+@4GTA -_68X&# E ;+3YWCB\)C6W#N,M6D[#2\7 6]&^SKI
MXRTL:S.<G5EP- 3 -8L(]EEG5" D@&6#O>@Z=2 ?'IU(Z?,=_6/2->(N*DF2
MNHJLEB:&G*P[Q)($-B:DDD?.C!N=(KL<B@@/OMSQJI5G>S@'NG&YE-RN4-R=
MI2[2TXQI>3KOV'P29P.@N\[@K2MLP2)"Y+!X%W>;"YS%)&5 PLBQX^VCY&M%
MKQR#/2OS; C8[;^L;$#;Y]^GQ'5RQ>:7(-! T#QV'I1W9-MC"L4D55T=26+E
M9)+$D,?, S/4L_N4!9AN.._:[.XGI.3-]@V6+]!ER-JE+Q^5FX9,_FJ+!OY
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MWD:%;E;O9()',M:)$ W)OQUN> #<2):C;P?7FUZZZUQ;I_.#^9 >(A]XA>:
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M0ZRO]L5@/@_F/OU+\[K#OVL?$?PDPGWB_P#FM'[R7S'^>7C/^K=3^H=/VQ6
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MO*BB>Z0=I8SI6L2>)7^!PWPJ9'B& X?,J*CO&,5CC(B2%Q&[H(.95D,<@1B
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M[#S^IV!.P] )\ ==W[J7(7\K+;_VK/\ N^G<1?:#\/\ ;J/U)\.?<BI_)?\
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MHAU55^^$#3ROV)S-3>$_H3S5*OA/Z55?RJO6S_JT[=_@JY__ +?L?U3ZU/\
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M&54C&SOF":O\>0=7$!O7Y^5E!D1ZM\_C='[K_/\ %1O4AZ^X\WK[#T/LV/\
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M\]C\[H^]OS/^/[W_ *-?^J]/*G^U7\/]NGOF93[GT/GL?G='WM^9_P ?WO\
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MGYWP2+$3'G18()K34$PO9-$KZP=M1"9#('87 ,R>.J'B+M!Q6$9H(2;=L?\
M91$,RD[[=XQV2('<$[DN5V94.JCACLXRV>5;#IY)2;_\Q8#*K@'8]R@!>4C8
MC=0$!!5I%.IZYGZ+_$,'CDY!YBY,TUEZ4]UN69GL52.>OS?Z02:W56GA%^3'
M?7K5\?-6^5\-U=<[4,_88]Q'6KH? ,))W ]7-S1K\T>_MUMNEV2\.UT7RJ:W
M;D'V14Q01D]-_,*3.!N-]N]_!TUM+SZ,#B0@2;[EN3>8<U:>VY!22KG-Z*M9
M,K51DAE89F12BHVN5'.B'MZ]ST3T^ZWRBI(K=I?$4#@R&M-'N"R<DD;$ ]0L
M@D;E)'3<JP'0[';;51:[*N&9XV6$6Z\FQY7$D4B@[; LC1 L!ZA(A\>HZ$5W
M\Z=EO>]PC&9?9"RXXYRX^"8^<JSJ<[I*/<U(<?J=(39X>*SOE-%@9Z?<(S=S
M=$^ELQ15: )$^5NU>&^U+AF^8J^:K9"A.Q"ADFKS5V)('FV&2%E)Z])(T'4*
M'8[#6H>*NR7BO'+)9P=C&Y.L@+E7@LP6T4;D\T"R3AU V&\4DC'JQC4 [1.J
M+7G.[$C-KS>)IX9&HY%;]TRJGG\2I[?E%3[%1?FB_)>MN0S<+SQB6/W49#Z0
M:QVW]>S'6F9J_%%=S'*,2K D$$6QX?&NL'697G+99^PS=J3QG&!9?"_$/"?H
MX2F_!FC'Q>U)*(1&WS,+&C_5"_S&KVIZ7*CFUM.WP_2L1VH5R9DBY^4.(&7S
MXVC.X#J3YKG;J.NQ]FK?=IY^]6EJS-BQ'*%YBALJPY'61=B48#SD&_FGIN/'
MKK?10=P,,4<39N*E;%&R-JN33*Y6L:C4\JD2(J^$3RJ(B>?Q)U3EN&V)8C*[
MDDG_ $?Q)W]>JD+Q&H !Q&P  _TKP'0>C6K/M>?A"@:T:/C:VNK4J$"HHZ@+
M765Q:GD.]L<*OK@QY2S"IY%1D4$$3Y'N5$1O5%?O\)8Z![%I\G%&BEF9FJJ%
M &^Y+, !JX4,9Q?DIXZ]6/%RR2,%1$2X[,2=@%55))/78 $]-3[X4^CS[N>0
MX1[SG/>\?\+T9",FARF4H#]GNYQW(B^W9E$WE9F\S.]BI)'[<NH)B\+"=7B$
M(]C-*\0]K&(C9X.'J5ZQMS+Y3;FBKQ CH&1$BEDE!&^^YA!W!#,-;VX:['<W
M(B3<1WZ%0$!C5I02V+!W'A)(\T<4)Z[CE[\CJ&4'PFN#]&%P= ,R.QWG-5N9
MZ$24Z;5YP)72>/PGQ#5V.%'B9Y5?1&]L[FM\-=)(J*YVO)>TCB21RPDK1KN2
M%6*0@?&6F)/M]!]6MDP]EO"T:!7CN3-MU=YHP2?3T2!0 ?5L=M('8_1ACC#R
MD\3\UZJO/C:Z2&JY(KZK2UA4J(OI&6USP>9.JX'JJ>25KKN6-$\_#3*ORNF/
M[5,Q X%VO#8C)V8PEXG Z=>5VE1F&WANF^YZCQU:<EV0X:=&./MV*TFQY5L!
M)HR?0"T2PNJ^TK(?6#JO_D/"\H<'Z ;,<R95U#)8RO@H=36S.M,9IW1HKG?4
MMZR&%BE(QKI9*BS@K;R"#T3D5D,,L3W[<X?XPQ/$";02B.PJ@O X"2IN=MF0
MG8C<[=XA*;] W0ZTQQ+P3E^')/\ *8.:!B1'9B//!(!X[. -B!U*.J2 =2FW
MG:UC7->U'-5'-<B*BHOE%1?L5%ZRLC;^H^@CUCV:PL@@['H1KA+#$1%)!/%'
M-#*QT<L,K&R12QO14<R2-Z.8]CD54<UR*U4545%3H"5(9200=P0=B#[#J()!
M!!((.X(.Q!]8(Z@Z8VQXOTF*THO)? 6KM.-.0*F1Y0;J<Z8 (ISE19A6NC5S
M!QRVHL15<3$72'1.^%+"C'?*Y:YYJ61J28W.4X,C0G 21)XPY '@W78AD.S)
M(A26,@,CA@-7K&9Z_C;$=FO9F@GC^PL0N4D4>E7 Z2QMX.C@AUW#!AT-J?9W
M]*95[B[!X6[IP@N+^6VR05M7KR&QU.,V93_$8\1WOO:/F+P]WH05S)I<Y=$/
M7ZN)K99@ZN71''/9#8Q<4N:X5:7*8@!I9J(#2WJ* <S-$0"URM&-^8\HLPJ-
MY%E4/,.A^$.TNIEC#0S+14[S[+#<!"4[;'8!7WV%:PQ( 0GNI&W"F-F2(VWZ
MO7YS$4A6AT]H-558C55TT[_+YY5:YT8H<#?,Q9<WI5(1AV22R*BJC?2USDTB
MB,[!5!)/J]'M/J'K)Z:W3B,/DL[>AQV*J2V[<Q\V.,>:B[@-+-(=DAA3<%Y9
M&5%W )W(!KRY"YYW'+DQ-1D%*Q^%5SX9BD>L5M;P_-CT,)A=ZF1RM\HM8#(D
M*-<L9Q9#7-1MQBKQQ %P)'^=5V/H!]/M(^0:Z0X<[/\  <'1Q7<T(<WQ!RB1
M(2 ].D_V2F&&1=BRG;:W80ONH:M#$0VZ#I\[64K$^&B]PCQX>9.B/(<OCPOI
M=X1(F+\_P(T:BI_'5Z_A+.))Z>CU>CKJ^WLG:OL>]?ECWW6&/=8QUZ;C?=R/
M6Q.QWY0N^VM[U#5OTG-+J:?* /L+<ID$;4\1Q^?,L\BJC61Q1IY>][W*C6-:
MUSG.5&M155$Z@Q"@DG8#4J:9(4+NP4 $DD@  >).^PV'M(^/2NQ?!O._*L45
MJ<\/AS)%(D@<E]7SVNV/&=X<R9F7817,IXY6>6M6\L@K*!RI(^FEB5JOI7L[
M$A=CMZ?$']?E^/6NLOV@5*KM#00W)5W!D5@D /@0)-F+[; _6U*'[<'?3W"=
MCV(6)'7G)?+=P8Y/,LL=Y050B/7[?AA \RLD,?GYM9.86Y/L65W4@SR'T[>/
MAOZ?E^3\6QZZP^7CW.2,2@J1+OT CD8@>HLTQW^, ?%X[Z:_[(W#C2R\<\S[
M:BLT3U01[0&GVE)ZF?-(GBUT&1LV1R_Q'RK:D.C\^XV*3T^T[TMAP?.ZCP\=
MCZ/2=_[>OCJMH=H>0@E4WZD-N#?STKR/5E(/I$CBRFX]1BZCS=QXB)&TJNXS
MAH^(3E"GQDF>*)8)6\A4/UR;E2IY7HP<>QD=%$;0'S^IC6"W H\1,ZOAK#+%
M(GR)5)/$_0EE/_3[=^IW&W3Q^?6WL!Q?P1F%6-O=J"UR[M6<T@XV\>[)(651
M]LAY@-BR*3UW$$W(9,,<\$^+EAE:CV2,6W<US53RBHJ-5.I^R^M__A_LUEP?
MA8C<+G"#U'6CX>O[+6OM:7?V_P!7_%391GU;9#6@_L.M6^HD7U^TV7UP2>J)
M?6[UM;Z'+\O#TZB"HWZL=QMUY?ZMM5M2_P .4O*>ZCS)\JJRU).<4SM%-R\Y
M3ED79QRCE)Y@.NZG6QE?R+#&^66;%QQQM5SWN6W:UK4^:JJJWPG4-E];_P#P
M_P!FJ(OPL!N5S@'QT?RM)O+M[@>6K@NBXFHL?:#UY""76SM'W%?CZ.?PCG0D
M6CH9I3SXVOC>^JIA;*RCCEBFG&A%D^(24\T4?3=F/CMYO7V;C;;X^NL8SO%7
M ^&0ASFWL%28ZZ&F97]1V!(13L0'D*KN.AWVU+;-=DUP9!'/RAS9I[4]S4?*
M#Q[4U>0J()'(BN']^[9KK$Z*+YL:2Q:J2;Q[BC#^KVFTCV6)\WS1Z-SN=ODV
M'X#\>M09+M%M32-[F44J1$D VYVM2E?03W2541CXD;2;>',WB503V.X'VG+5
M\C<O51:?A1D)HJ ^+W$_BK.,=EIDDC\_QV0RC/<GR;*S[>O'?R_;?K_A_P"N
MK5'QYG$8%O))!ZC%(/CV*S#8GV[_ !:9O8=O'.O&T4MIFK('F3.C(LA%:.%]
MS^Y&';^$]1:R4HVLOUAC1SGH%8A69+_1$!2DRO2-)R6OMQ\H_4;?+\XUEN*[
M0JT[K%D(339B!WJMWD&^_P"Z;8/&/:RNH&_,X'72/Q._ALVN-HC" 3A99!K&
MNG9(,8&4-(Z(D&Q (:R2.8>9CXB!BH6R0RL<R1C'M7Q4D)(OH(]!](/L/H.W
MS@^D'6P&6EDX%YUCGC=0R,"#MN.C1NIW7<'H5/7P._IE1@^7)(9HA#)&!S/<
MB.BD<[ZM,>OA%5OJ<JAD.\)X57>ERHB>X[RD2TTD!&Y&Y'SL/P>'Z]-8'Q!P
M>KH\T*-,B@D,NWE,*C<['8;31C<]-B?3R@^=J5%/=AW,/N0.]$S4_AAI%3W8
MU^Q51$7\.-5^39&_+[$<C7?@I2$$>(^7T:U-<HSTGVD',C$A)5^P?U _:MMX
MH>OCL6'G'<=0U1Z.FFCIIHZ::C;V^_X;Y^_SX:S_ &!.JJS]C6_[NGXSK9_:
M-_H/9W_R%AO_ +NFVY:Y1NKB]L:*H/(KZ*K)F 5H4SX)+(@9[HB2"9HE;)(.
MLS7L'@1_L+$QDSV.E?Y;.@A55#, 6(WZ^@'P&WK]9\=9)PAPK1I4*N0N5X[.
M0M1)8#3H)%JQRJ'BCB1P560(5,DA7O Y9%8(.L=;O95F<EHH;R\=7RZ:]&S-
M$V>4IRV5\8(<>-6PK$V1$GF$K3IVNE6.+TC/1TB.5K73B%&VX'4[#IZ=9I)Y
M+"8A(L2&:00Q HOGRLK.J#9?$JC$;[#H>OAKLEUM3 06)-IJZ$H"0:(\:6Z&
MC("E-B?.'&7"\E)!I"X(Y)AF3-8Z>*-\D2/8USD;+ZE_!J/^2@LI\G#(0'7Z
MWNI8;J&'BI8=0#MN.HZ:X,V5+(Z-D>JJY'S6/U1$UEX(YTMMZYX_JR-K2E5]
MC[@I,?P344GUCSM]KU0R(V.R^I?';T>/J^/0>2$[#R<DMR #NR2_7S/^+S6\
MWQZ'IT.DA)S9@(=R3QO-LVP[ -4B*KYHK>($<Y:0;2_4\NAD$;G&:'[FC!-&
MN<6V^ODH"8+I:Y*R6,IWG=-^7IO\7LW\=MO#KMOX:D&SCA9:H6A$Z]&4Q$*&
M[L3=V92G=";N66;N>?O>Z(EY.0\VM[?<E9++ V%EHMQ24H-4&1861%C?B#,"
M!$/^JBRR4D)1\0XUG_X.(E<U&0G>1)%;.BQ]1\T>A?F'Q?CZ?'J9+)1@5GF:
MM&J*7=G,2A55N1F._@%?S"? -YIZ]-;&39TD23++JZJ-!C8JTA9+T1B06,[8
MGP@3*XI/:-F9/"^(5_IGD;-$YD:I(Q5>;_L_@U[)J#?<UQRL$;?NALYV(0^I
MB""%/4[C8:TE_P JXW+Q8V>]V8((_(.JKL1BR?CI21=%J[<6R-K*6O*#^('>
M4:/463X'221P/<*^+WDF='&]YO3H.IV'0=3J5+-0A%<RM75;4Z5J[<JLLT\B
MNR1HRJ0681N1N0/-(WWV&NG&<O87D+/U&IQNZJKVBOP[6QICQ[-T"6-?26)5
M1;GC#&.&+<%7V010A12CI!%)$JK)Z',<X.0C<<I'CX#P\-]0KV,?;BCGKO6E
MBE5WC=0@YTC=HY&4, Q5'4JS;; CQVVUCIS1QZZ@N]0SD"HDH<[#K";>QCLW
M21P#86.:;6E01,5Q%@-10CRRF$5T)</MHU\3Y6R1J]NFQ/F[#?T#T>/S:AY3
MCNZDF[RMW40G9W 0@+6W,[ ;;NL04EB@8>HG<:WE1R%G;UL:UFH'EDF,N08!
MIRY@#B",_9VM1;?#@6'PII XI]';1M,A'>&5"!.8'.0$C2'/-]0]/H&_0D'\
M6IL;TY=N3N26:1%4HJLS1/)')LCJK$*T4@Y@"K!2RDKUUO:W006P[#JB[BLQ
M'*U8S*VR88.YRL9*U6$"S21*JQR1R-]+_/H>QZ?)S56.RGP /R#4Q4K2+NB0
M2(1XJL;*01OX@$$$$'V@^W4D^&.3[F.\#RMZ=/8UMHY1Z^<R5TY(!WI<Z")I
M$BNED%)5OPR02.>D,KX70K$Q)FR4L\*\I=1L1U( Z$>O;T$>/MZ[]=:ZXVX5
MI-0FRU"O'6LU )+$<"K'%8@Y@)&,2@(LT0/>F10I=!(LG.W=E9A=46M-:.FF
MCIIHZ::ASWW=NECW.=NNFX_SSX&[.JL*[:XAA<K(!"])01F0MJYYY',B'^NJ
M>QMZ8<J:2(<0P\8HJ1!89D7/^S/BR'@WBRGE+88X^>*;'9$HI:2.I:,;=\J@
M$MY/8AKV'10SR1Q/&@YV4C7/:KP=-QOP=>Q%,J,E!+#DL8)&"1R7:@D40.[;
M*GE->:Q71V*I')*DDC!%;7D62/D;@[D4.<JNN,'R/@+X.R&%O*=D-G27=22P
MH(B:JN@YAIVQSQ1S1-+$)"+B]+O1./(GJ[LWQ/$F)D5):^3Q&4JR0N]:P6AL
MUIT*2*L]>174E6*DQR))&VXW5QT^>G+F>%LS$\D-G%9G$VXYXTM5@LU:S7</
M&[068VC<!U#+SQO%(NQV=#U4+^>^4$5Z!6]%1P2?6_K R^"X^R=2YU_G",E<
MRK3YG+5-5[]CG2IZPDCX/WWQN;,DB%1Q3LI1PSANG>06;+#R?:6[D\I>G JV
MUO5U%BY=GGY8K:+,B]YR@@KL4+*:T\6YW<]W9JU4;RC>&CB<1CZY-NF^/LMY
M-2H5Z_/-3D>%W[KF((;?O%5PJ;'NQY^M6S,/W<4\4CJEX\"9#"PC5+Z2;WP7
MYX8?,Q09ESY/E9.ST=8MU$B#W*GP(D:44/ _"\'+W6,92!.&;R_)L\XLKRRB
MT[W&>X /\R+33"NV[5^Z8DZKINT#BZQS";*JX8P%5&.Q2I7-9N:,TT2BJTB3
M_GC3$!LKYMGO5Z:TX?<GS0$DK&:X<L<B!!2@+?*8R\JS1$&T83@["INLZ?6V
M D@NMT,$PIHDX\\=D])HY/8$]BHDX1X>DV)H,CJW.DL%[(5IHY.>I()(IZ]N
M*:*0/1J,KQNKJ805(YGYJ>/C7B:+F R*R(Z]W)%8H8VU!+'R7(S'-7LTY8)H
MS'?MJT<L;HPF/,IY(^3G;]R_-]_6:&GO-S-<5^H%L [F&SHLN:^2.UM]=>6,
MH!)-)(52FFV.\UCB+*EFK["0.XDJW%?58H(8L(.#^'*LU6Q6QJP2TGBDKM#9
MNQA3!!0K0K*B60EB..+&40L-A98A)7$W)WSRR/&QQOQ1;@N5K65:Q#>2:.RL
M]2C*2)[.0MS-$[U3)6EEFRN0+SUGAF,=EH#)W"11IJ,USURWD'5KLYL2:WZH
MHJ?,@-9649$<5!0Z0_6UE5+$96$1EB17MI8DD,,9.M@*<556+BZB>0%T^YPQ
M@KXF%O'I-W]FQ<E)FLH3:M5(J,TZM',C1R-6AA1#&5[IXHYX>[G19134N+.(
M<<8#2R3P>3U:U*(""JZK4J79<A! RR0.LD:VYYI'$@?ODED@G,E=VB.T'[E.
M:PS_ *R"VGP126"6<:!9W)AB0%MT..U,:BUXU%%7B#PWO'^/-@"%%A"';20A
MP#Q@$&BDR7X0X=DB[F3']XG==R>\MWGD>,U,A1/>2O9,LCM5RE^-Y7=I7-EI
M&<RK&Z5"<;<3QS=_%D^ZD$O?+W5/'QQI(+F-OCNX4J+%&BV\1CI5BC18D%5(
MU01/(C]M5W,\WTE;1U-=MW1!YFPREIG?>SN3,+HS,4/DQ<Z^JL3:$BQ A&@P
MN2C.$&*C$O$HQ%OH+)SIW3>9^#N'+$UF>;'<TER*]#;Y;=Z-+,>1:\]L3Q1V
MDBE9VR5XQR.ADK>4OY,T("\L:_&_%%:&K7ARA6*C-0GI<U/'RO5EQB8^.F:\
MTM1YHE1,7CUEC1Q':\EC-M9R7+<*/N6YLSL4(U7M$8'#5U]*@!V;R5O72UE3
M0X;-58I==;T)P)J5U1QKA8PI3!YYQC<V#;PRLMW$G3QL\(<.VRS3X[=VGEL]
M[';O03+-/9R5N=TF@LQ2Q][/F,F9%C=5>.W) RF )$L*O&_$])52OD]HUKPU
M1%+2Q]B%H*]7%TH(Y(;%26*7N:^%Q0C:1'=):45A6%CGE;42\\\L$5UG4DZQ
MQ5;<9\;+60A=+G2HBZ,+&YS !"/^(J)',F#RN1S=>)81.99#$U MS 7'>>Y9
M25"\,X-)89THA)J]I[L,B6+:-'9DR%S*2..2< K)>OW)9(B#"Z6'KM&:W+"*
M=N+.('AGKOD#)!9II0GCDK4Y%DJQ8VGB8HSSUV(:*ACZ<,<RD3H]=+*2"US3
M%U>T3M.W_=-R91T--2V<''X-J'+R%N%&FAIJ"BAECGL!(;%[$'(T=@(CAJ6H
M@?(7*3/&7/'!5C''#6/COCC%\%8>S:L6(6RDL$BXK&AU:Q:LLK+$[0@\Z4XI
M-GL6&"QJBF-6:=XHWOW9YP!E^.\W6JUJTR8B&>)LOE"C+6J5596EC68CD>Y-
M'NE:NI,C.PD<+ DLB>B_O3AB&Y/["QX(V0P#]T&=AABC1&LBBBIR(XXV-3Y-
M8QC6M:B?)$1$ZY.[/&9\+VG.Q+,W!EIF8]26:PI))]9)).NR.TM53.]E"( J
MIQQ455 V"JM9P !Z    /5JP[K5.MP:.FFN$DC(F/DD<UD;&JY[W+X:UJ)Y5
M57\B)U$ L0 -R3L /23J!( ))V ZDG41^X'N)H^-JMT+G(;;&1R?4V?BE]LB
MQ<U?0AUB]J.<%51/\KZG-]9#V.B@;)*URCY]PEP?:S<X;K%6C(\IN,O,D0.Q
M[J$$@2V"/4=D!#,54CGP'C/C2CPW4\\B:[,K>1T5;9Y=MU,TY&YBK*WBQ&\A
M!2,,W,4IXV^ZT?(%X1H=.>XPN1%9#$B>V'7B-<Y\88 Z*K!QHO4YWA/+Y9'/
MGGDEGDDE=T5C,73Q-5*=&$1QKU9OLI)7V :69]MW<[>/@J@*@5%51RWF,SD,
M]=>]D9S-*WFQH/-B@BW)6&"/?:.-23TZLQ)=V9V9BX/:CVYIW.[VQN=9&0SA
M7CJP@&O!XI)H/N\U?MPFP9&,F%S'Q5( DHUCJI8)&D/&,K:H96+:3FU^N.T/
MC!\9'[E8^3EM3J2\BG<PQ;E3(1O_ )QR"L6XVZ,QW"A6VCV:<%1Y64Y7(QEJ
M-9@$C;H+,^P81]/^S12&E(.Y#)&/LF*WZU]>!4 !554")65E:*.#75U>-"&"
M $)$R 4,,0=D8XHHT#&0P#P1LBAB8V.-C6-1$Y_9F=F=V9G8EF9B69F)W+,Q
MW))/4DDDGJ==((B1JJ(JHB*%1$4*JJHV554 !5       V UF=>=>M'331TT
MU4+WX=K@F3CLNY#BNK8!$.0A?,63KHDC!-!(E1DW(58'$WT"V(,TK9-A%"QH
MU@ ^723(.:!;DVNU>S[C&>C:AQ%Z4R59B(ZKN=S&W@(&)/5&\(M]RC;1C<,@
M33O:3P3!<J39O'0K'9A#278D7994\6LA5'213UF('GJ3*=F1B\ 1"8C!H2H7
M(^*:-LC'(J*BHY//VI_^?X^N@]P0K+U5@&4^P^CXQZ=<UNI1F4C8@D==:S07
M,-%63G2(Y[FIZ((8V.DEFF?^#%%%&Q'/DDD>K61QL17/>YK4157QU*L6(ZL,
MEB4@+&I;J0HW'7J2>@'C\A]6I]6L]J:.&,%F=@H !)))VZ =?$CPZ]1MXZN3
M[+.TL3AZA&Y,Y#KH3N;M:"A)LA;6D)QY3GL]R+(4GJ];!K%H[VMU-F/_  II
MZS5L)$M4' \GE_C#BJSQ!=D1)&7'0N1#&"0)BI_ST@].Y&\:GHHV;8,2!UKP
M3P?6X<H12RQ*V4GC#3R, QKAE'^3Q'KL0-A*PZNVZ@E%7>?'6&:SK1TTT=--
M(W?\?8_E')7&'WE$%HLS>#J.=7FL7\%R?A#FA$1JPFOL@9D:37604L!P!4<9
M(D\4T;7I45;=BE8CM597AGB8,DB'8@CQ!]#*PZ,K JP)!!!U37*=:_6EJ7(4
MGKS*4DC<;@@^!!\5=3U1U(9& 92" =>>CEGB?0]NW*EEQ7?ED6]$4-]?<=:D
MEC6R:#*S3O@CA-=$UD"7U(0QU7=Q1-B:^6,:TB&'"M F+TYP3Q.G$..42$+<
MK[1S1[^#A>A7?J8Y!YR=3L?-))4ZY/X\X3;AK),L09Z=C>:M*1]E&3U5B !S
MQ$%7 V&^S@!9%728ZS36 :.FFF_W_#F>Y?K5J;4=![&&-_U;H1XVH=4R.1?2
MY'_@_$BN?\Y:^9_M3^%5BPS-81%37.*8>%*S7K$G-&20E/<<]R4#I%&#ORL-
MP6EVY8E/,^X(5MC=F'9OQ/VH<2P</<-P';S)LKDYE?W/P]#G"R7+DBC;<#F6
MM74B>W,!#"-^9T;7AGNYN<3R&!V\]R7)#]MB\*2W*9/8MO5M0LLOEJ@U=\1[
MTL\-1Z)81"""WNL\VD458;,M.%&^LQ#BG@2EQ?AUXTX/H24;]J(V\C@VA[E[
M6^YDFJ1A57R@[,Z]V.YOK]=A"V&*S=9]G?:??["^)\KV5<;RXNS2DO\ DV+X
M[J,LRPE=DCKW[#<[/23=$,<[][@K32Q65DKL98+HQ?AOAH%"]A1'0QN&496*
M.Z![4=$Z%8_,;HG,5',<Q5:YJHYJJB^>N>&5E9E92K*2K*P(96!V*L#L0000
M01N#T.NKS+W_ ->[SON] D$O/WG>!AN'#[GF# @A@2"""#MKOZAIK76UF-3U
MQ=F8]L8X<#YI'.5$3PQJN\>5\)\_'Y>AZ GU:\NP12Q.VP/X![=/+VM\(IH7
MU_/?) *%6=FC3N,,V?'[@F:HI/P@=80+*BQR:&[A5AE3(]CEIJF0:>%8[(Z=
MH5OFE+$J#YH_7T?AZG<CU:TAQEQ-+=L2XVI(RU86*6'5B#/(-PT6X/\ FHSN
MK?OC;@CE4<T_.J?6 :.FFCIIK7VU35WU8?2W=>%;5%H+,#8UEB-$8"<&0Q8Y
MQBA9V/AGAE8Y6OCD8YKD7YIT\/#7M'>)UDC=HY$8,CH2K*RG<,K#8@@]00=Q
MJJ_D/CPSM_Y!"SD$Q1G%^V>7/AC3)9"9Z"Q&1LI^-/,E<^2?X2*1I=&42]23
MJI9897EF5-@9-75Y2WFL>H'0GYO[/EW]8&MX<&<2'*P&M9(\LKA0_3;O4V(6
M8 #IN1M*J] _G  .H&PZJM9[OTW]'CI-YO&6O/'(J<;59I57D* <>WY*T #U
MC*&K)Y98@<]6S(US8;K12P$PC3/3T@@"6=DC9I@X!"J>>7D7E!\X_B_L]?Q^
M/CK#.+>(AAJG+$5:W/S)70[$*0!SRN!XI&""0#YSLJ] 2PM7S.8S^,H:S,9:
MI"HZ"F%8'6U@$20C#0L57*OCRKY9YI'/G**G?*263)*25-,1+)*^@)).YZDZ
MT/--+8EDGGD:6:5B\DCG=F8^DGU ;  ;!0 H   UO>H:E:.FFCIIJ%?=!P3)
M9#F<R<; (/R%GAE,TE2#'Z&<@YT&)%+'G&B3Q/J:P*)TM(:UCBK&&'ZA)2=)
M*J6LFQ2%&\>A\?UW'^'CK-.$^)9<59CIV)"U"9PHYR=JLC'HZG?I$[':53YJ
M[]X-B&YHSYN^"TM,!<@2-E'-@CF:YBHY$5[454\IY3\?GJY@[C?UZWQ%()$#
M [@@>G?T>.GPP_(QM%.,+8$3.$C<UHYJ.<X@'[41K_DKB!5\^E\;O4Z./RUJ
M/C3VNI$L08$J.OI'H/Q>H_C^/6+YWAJ"_')+7C02L"9(" (Y_#<KU CE'BK#
M8,WB5;SA-7-Z0:\&C_#B0I8FR)[;D=$3$YJ*DX[D54<U45%<U%7T^?**K%14
MH&4J?9^O0^W6D,GC):$K=&,7,5\X$/$P.QCD'B&!Z D#?U [C2GZ\ZM6CIIH
MZ::C;V^_X;Y^_P ^&L_V!.JJS]C6_P"[I^,ZV?VC?Z#V=_\ (6&_^[J//(N;
M.S&ON0BXGMA(.*/KYW(OH* +GDF'EC?]CW,:[V9T15]LB.6-?FWYU43!XU(/
M4  CU$#8_P"'LUL3AO)P93#TIX74O'!%7LQ@CFBL0QJDB,/$!B.>,G[*-D;T
MZCERQQE-R97Y.$'5V.,N,7MJO=4=W6UU5;216E76W-5' 17W(Y() LPUV5[C
M7Q^M'LB<QR>%\^F7FVZ[;'<>GUC^O5?>IFXL 6=Z\E:REJ*1$239T22/9DD!
M4J5E;?T[[$'4>P>R7).Y2;ROJ-G>:^[DU%7K3Z^VI\_'2V5M5-)E&E(K( TK
MQ_:L#9S('5X@;XE@KGR.GLABK0_SW8YN8DG?8D$#;IU_'^N_75K3AV#RWRZ:
MQ+/(9DG9'2(1/(@)5B@7D&S,6'(JD;(26<,[LCQQ]',."?56>_U,8SLC9YP+
M*U>/+A('.R>7 R0@L^IL8,EA'V.Q.EQE)/+>%UEL<+*VS)+M;PVTB(J_(B/I
M/@1L!Z0 /'H.O0?%Z=]]6VGPDJ.DEJ8#R=X4@2!@P>"!(%5IW%>J7L.:\1,K
M)(RGG9GE:0%)"<K]I=3R'L-UOVWY*V.LQVFH9LK%#3Y*OT!-OQC9<<@5&OVN
M?SY6GM<F'\9!I0(;H'4VF:UH=?>T9'P=17YUGID!)/I(/3V\NPW.WAZ?3L>O
MLU=;V"CMSVK7>MSSUYXC !'768R4GIK'/9BA:9X%YA,@D2>2&PJ2Q'EC2'3=
MD?1_Y6Z#I9]#OM$_1)QA+C->?7@U*A:K66T6D/T>V/ -%E!))M=AK[_7^D@!
MUN/9SL%"O :2>SISX=T.FY.^VQ]IZ[D[^/4D]?GVZ:I3PO!(L1EM2F84FKV'
M54Y9YY!,TUET8%2SV+$MCJID#D*LJQEXV^F?1U\66+=NVPT^E.^[4S:%SJ;!
M6'?5[MG3\L5[WP1V$!D#BZ,[F'2VE*7'".X>0.I26.8WZXLK=W0Z]3UW]7I#
M?A'-^ :@W"=%_*>>:9O*6LLQ8(Q4V8[Z$CG#*6B;(SO$W*"I5 =V[QY'-V?:
M!C==QQG.-Q]/HLN!D.7>3.9LO:9V"G$.H=1R$9RU9A15<+P9 ! \1:<L$GYI
MD8R.9+FZ5A7NQJ6V7T4! &^VS%AX>)YOQ;_@U6V,#7GIPTQ-+"M>_<R,#Q"-
M6BGMM?=>0%2@6L]]GA'+XPQ!MQS MF=]';Q>6&33PZ[5U]"57ZT/X$,'+J<&
M[2,Y?%$AK+PJF)LP:*IK^9]$//EV2R4E]+65$UN--#-H!;WSW0\-SMU] ]._
ML\/.\-4;<)T64QB>=(BLZ\JK#S)WWEX41R&,ND2)D9E,()BE*1F12#,)<<OZ
M.SCRQ/L[2PV^G<==T.XIK-M974=%503[5W)TTA]!15 PM12_5\W+.F:@[A#_
M (T(>H"GG8D=K+;NZ!]/COZ /'?J -O#<^O?4&X3J.[.]F<M)%9C?D6*) ;!
MNL7BBC58XN4WYQR\K\ZB,,=P[2;_ $78=Q_<AZ]ZW]V3;Z(71QB&SMJ@3*Q=
M'K^XW:'AUUV/4EV-0*>?W&7=:80'%--\!F<],Z DF,I"(F,'?KU._P FY8]#
MZ/LOP:FR\,U)%L?79#),)@K'D5D[ZQE[+JD@C9XU=LO*C%03R0Q$AB&W>#MA
MX?TG#.#O*/6EYLF^T>XO-D9!DAQ8*&N^LPJBNB!"^!S&+#E\14["YI!LK31I
M.7)"Z$J2)]@9Z0%1L=M]R>GM^0?BU7X:A-CZLD4[0M++9EL,(%58DYPBA5Y8
M:ZGHG,2((QNQ&S$%VG#P]G#K[<4Y$$3_ (*C+AMK KTK[4#1'+,-$Y_\7W2B
M61Q1QHOK5GNRHU60R*DN=PL;#TL-@/C\3\@W^75JXSR<&/P5V.1U[^_#)3KQ
M;CGD,R\DK@>/)%$S.S;;!N1"0SKO/WJVZYZT=---9S!S7QCP+CR=URMK*_)Y
MZ"5!1Y2DF(/M;!\;Y(JNDJ@XR+&WLI61R2-$!&F?'!',41[(D$\\5[P'#N9X
MGOIC<)1EO6F7G94Y4B@B! ::Q/(4A@A4D#GE=0S%43FD95:P\1<38/A3'/E<
M_D(<?31N16DYGEGE()6"M7C5YK$S $B.)&*J&D?EC1W6L"U^FJ[?13IX*GC+
MERU!B>YD1\X^1K%)1JJGNQB.TQ<D<+_'JB]Y\<RL5/=@A?Y8FY8/V/'%+Q*T
M^8P4$C %HE>_-R;_ +DN*<8+#P;E!7??E9AL3HVQ^R8X1CE=*^#X@L1*2%F9
M,?!S[';F$9NR,%/BO,5;;[)5/36N_?L>$/S0\J_^WR/[;ZF_M=>(_N]A/Y-_
M]&U)_;-\,?!W/?R\?^DZ3E]],!VQ:E87:?MXV6C<,BM'=?57'UNL#7+Y<V%;
M"Q(6)%7YJC/2BK\U^?576[!>,J7,*?%>/J!SNXK3Y6#F(Z MW4*<Q Z==]45
MK]D5P/>*F]P?DKA0$(;4&(L% ?$*9IGY0?3MMI._OJ79M_-0L/[(<6?K'57[
MRG:!\.(OY_F_R-4GO]=G'P!F^C\%^7H_?4NS;^:A8?V0XL_6.GO*=H'PXB_G
M^;_(T]_KLX^ ,WT?@OR]'[ZEV;?S4+#^R'%GZQT]Y3M ^'$7\_S?Y&GO]=G'
MP!F^C\%^7H_?4NS;^:A8?V0XL_6.GO*=H'PXB_G^;_(T]_KLX^ ,WT?@OR]'
M[ZEV;?S4+#^R'%GZQT]Y3M ^'$7\_P W^1I[_79Q\ 9OH_!?EZ/WU+LV_FH6
M']D.+/UCI[RG:!\.(OY_F_R-/?Z[./@#-]'X+\O1^^I=FW\U"P_LAQ9^L=/>
M4[0/AQ%_/\W^1I[_ %V<? &;Z/P7Y>C]]2[-OYJ%A_9#BS]8Z>\IV@?#B+^?
MYO\ (T]_KLX^ ,WT?@OR]=L/TJ/9@LL:3]JEK%"KT262'%\4SRL9Y_"='"\X
M=DCT3YHQT\2*OR5[?MZ\MV*=H7*>7C:!FV.RMD<VJD^HL(G('K(5OB.O2=O/
M9L64/P'85"1S,N-P+L!Z2$,J!C["Z[^O5H?;/W2=O_<7GI6\+70@TU$/'):8
M$RL@S6CS8\ST:R6>@B<X66O=+(V-;.C(LJ="9$&4Y"E="FF>,."^*>$[2GB&
ML[K98B')QS-<J6V4$E5M'9UEY03W-E(;'("_=<GG:WGP3QUPEQE3;ZFK4:-5
M13/B98%I7:2,=@SU%)C:(L0._JO-7YR$,O>;J&6[VO\ QJ]B'_K2T/\ ^*B>
MLA[.O]1]IG_)=G_YZ:QKM-_U_P!E7_/57_Z:35A/6J];>T?9]O3346^X?G2I
MXPS,Q2NC,LBUE%S]1[B-=;6#$3U$S^AWN-J:_P!3)296^/7ZHHF*DY$"MS?A
M#A:QG;RQ]8X(PLERQL=H(23M&G0@V)MBJ*?#9F/F(^^#\9\6U>&L<T[<LMF7
MFCHU>;8V)P-R[['F6O#N&E<=3NJ AY%U2EI]/=[&\L-%H3I;&ULIEF(GE7Y-
M3[(AX(T_ @%'C1L0X\:-CBB:UC43Q\^EZ5&KCJL5.G$L->%>5$7Q]99F\7=S
MNSN>K,23KDS(Y&YE;D]^_.UBU8<O)(W@!X*B+X)'&NRQQJ J* H&PTWNLM$I
M\]:6"KZ5'$F>B^?'A48JI_\ 'PG^GJ;8D$->:4_N$)'QGTCU$:EU(N^L11^A
MG ]'I^/;T;^G7H5[7.+A^'N!.,\0@[8;0;-A7&HD]/B4K7Z)GUYIYYGJGN2^
MFX/*%%697/A &#%14B'C8WD'-WWR>5O7'8L);$G=[G<"%&*1*/4!&JD@="Q)
M\2==KX#&QXG#T***%,->,R[#;FGD423,?#QD9@-^H4 >C3_=6K5XT=--'331
MTTUA6=:!<UMA3VHD%A5VH)=;9 %1I*,: =!(*8(1$[\&2 D>62&:-WR?&]S5
M^2]>D=HW5T8JZ,KHRG9E92"K CP((!!]!&O+HLB/&ZAT=61U8;JRL"K*1Z00
M2"/2#KS)%96?CG:\B\7$2S3IQYMM#F@""'^N<JE"L)OJ$V9?"+[IU))7%O3Y
MHCIE1%7QY7K3A7(^ZF#HVCU=X(R_J#[<LBCXG!'3U>C7&/&&+&(SV0IJ-DBL
M2+'ZS&6+1'VDQE6/CU/CZGC[6\$-RIW4<=4=E TNBP(5GRK<B/;ZHIY,O* +
MG&R>I%8K8=?<9\U\3D>TB 2:%S?0]SFXSVFY1Z6#\FB<J]QEK[@['EDYFE'0
MCH8D==_06]>LL[*<0F0X@2>5 T=&-[9##<%XRJ1'PVZ321/U\0IV\=QZ%^N;
M]=2:.FFCIIHZ::.FFJ]?I)N/A]#P0-R,- BZ#B#44U\*1&W_ '3)G=%8@Y?4
M5J/\+Z1'LL*R]*;\E<[.#JB_@JQ^;\ 9.3'\0UXPVT5T&"0$^:64&2)C[059
M!_[0CP.L [2,3'DN&[$Q4&;'LMB-M@2$8B*9>O[GE99#[8E]6JDQI4G'AF3Y
MI+&Q_P#TFHJ__'KJ(G?9O0P##Y?F_7PZ:Y(<<K,/43[/P:S1AI2YF00M\O>O
M]/AK4^USE_$UJ?:O^1/M5.J'(Y"KBJ4]^Y((X($YF\"SL>B11J2.:21B$1=Q
MU.Y(4%ADW!G!^<X]XEQ?"O#M4V<GE9Q%'S;K!6A4%[-VW( >ZJ5(5>>>38D(
MA5%>1D1H&=[7=LG%P)/#7%EBUFY/%5FPTHDC72Y4,J)O_@X&5J.1FBL('*LD
MR.;)2!OC?"C; B&4'#N&,#:XRR/U3\01D8N%RN*QS$F*81MN"5/+O6C<!G8C
M_*YPP?:%"C_13+6,#V%<)1]F/ 4JR<0V8EEXMXE152Z]J6(*[<ZES%;FC9DJ
MP*Y&(I,G=%KD[6%I8KKDZM-4Z.:2225ZN*25[G_%H]RND]]SE5SWO57.]QRJ
M]'KZ_*KY\[RKRM6='BV7D  0;!2@_<$ ;!=O#8>;XKMKF7-X:GGJ4M.\G-S\
MSQ3>,L$Y!Y9HV/7F!/G ])%+(^X8ZOP^C?[VF3R4W W)-NLE<>Y@/&6ALB&H
M^N.<KO1A[,B9WJ6 IZ^WF999%6(CVZ6/UPE5D0^G^UGL^BN59^-.'X LB;R9
MZA$NY*@#GR,<:;@21>-U54*\6]SH5F9\X["NU*_P]EXNRKC:R61BL7".8G?9
M&5BQAQ,LTA'/#./,QC,Q:&=3C-VYJL<=X?7->NSM(F\H4WVUXSXM>KU$W&N#
M&NXHW.9)-FJF$B]TT+7M\*QTU!5V,4<B+_!R/:_PJM]*RIFY8SZST'Z_-_AX
MZQSBB^<=B+EA3RNL16,_[V0B.+I[)'4D;=0#X#KJX****"*.""..&&&-D4,,
M3&QQ111M1D<<<;$1C(V,1&L8U$:UJ(UJ(B(G5LUSF2222223N2>I)/B2?23K
MLZ:AHZ::.FFCIIJ/W=%BF;?A';P0Q(^YS%;+N<W*U$]^&[R44MO%$,Y45&26
MH,)]%([_ )+:D-\M]7K;[1BKJ1X[_C]>KUP]>;'YBC."0C3+!*-]@8IB(VYO
M6$)60#[9!J 5?H&$8V'0*Y/2M2A:N1?EZD@]7GYHOX^KH#N ?#<;ZZ063ZR'
M_P!G?;YR?'U_J-M30[-<>S/\+5>F(C1;SDZQL-];$N3R^46TF4?,PL>[R]!H
M<N)4RQP^?;:42;/&UJDR*ZV2MS.3X==MNOR^/M]GAL-<]<67VO9NV2Q,=9O)
M8QN=AW1/>'U;F8ON>FX"@^ VE=U+UC6CIIHZ::.FFCIIJH^TSD?'?-'*_'PD
M:0TD=S#K<U U/3$/4:T2"Z>&-&B(V$2LM";.I$B9Y:P8&)$5$_!2XUVYDV](
M_7U>PGT]== \&9%K^&JM(W-)$IKR$G=BT)**Q/B2Z!&)^V8^O2@ZGZR_3G<?
M;HC/&0!&$/;7.E:H\_GRZMG5WRD:J^?]RO<O\/&OEK/*R(BI[C9*>:+G',OV
M0\1Z&]FWK_#\NL6XCP$>2ADGA0&RJ$21^BS&!U4@>$H \QAU.P4]>4K.6@NH
M;D1LB*Q"(VL2=C7(K5]2?@31JGVQ2HBN;X\HU?+?*^$<Z@(V/X.OH(\1\GZ[
M>&M#WZ3TIBA!,;$]VQ\1L?.1AZ'0]#ZQL>FY WO4-4&CIIJ-O;[_ (;Y^_SX
M:S_8$ZJK/V-;_NZ?C.MG]HW^@]G?_(6&_P#NZ>[3T^7MZYS=6+635T"J_P!^
MS?&.P5SO#5?&:Z2&05S_  C5?%/$KD\-553Y=4Z,ZGS"P)]"[]=O9Z=8'BKN
M5IV0<1+:2S( O=U5:0S!=R%> *ZS!=R0KQN >H /730+D.WI%7R;FOM_%M#/
M'_PO/'4_O+7J?[V/R=9D,SVC$?YC*?+@X0?F\@'XM?/N1[>?^6YO^VAG[<Z=
MY:]3_>Q^3I[L=HW[QD_H.'] T?<CV\_\MS?]M#/VYT[RUZG^]C\G3W8[1OWC
M)_0</Z!H^Y'MY_Y;F_[:&?MSIWEKU/\ >Q^3I[L=HW[QD_H.'] T?<CV\_\
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M&D1J3ZO/R]/LH_SY^7CSY^7GJVY@.<9<Y/LNY?;U_8MT'Z^K5WP?(,G4,GV
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MI1F*BPJD99W[U0/-0R=YO=9P2-"Z8#;1Z3T&<?!R,RU3<W_H?R=<XNERKEG
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M)_\ Q7HO7ENT'MQ92HX0N(2-@Z\(Y<LOM <NF_\ Q*P]FO2]FO8"K*QXRHN
M02C<9X<*P'H8IR/L?3RLI]1&IU\,[GZ/;M]S\N:XBY9[<L?7EOBELR!>6,<;
M<W,\+7I#-=7UGI#;FU?#[DOPS#3IH TFEC"B'B>Z/K6G$&.[5.*;2W,]@^+;
M\J!A"CX+(1UZZMMS+6JPTXZ\ ;9><QQJTA53(SL-];3X;R79%PC3:EP]G^#<
M=#(5:=X^(,;+9LLH(5K-N>[)9L%=VY!+*RQAF$:H"1ID>Z#FKA[E#F/L>K>-
MN5..]_8UO<WGSK$'&;//:8P )]?..PLP:FL#)AAGSO9"V>9C(W2N;&CE<J)U
MD?!G#V?PW#_:1-E\)EL7%-P=:CBER&.MTXY9!*K&.-[$,:NX4%BJDL%!.VPU
MC''/$G#N;XD[+X<-G</EIH>-ZLLT6-R5.])%&8'022)6FE9$+$*&8!2Q WW.
MK)MQ<C4=":<9*D 8@I5@=,JHB1 5T#BRI%553PC6,1RJJHGI:Y%^2]:DQE:2
MU:BBC4M)))'#$H_=2S,(T4>TEMA[2-;JR%J.G6EL3,$A@BFL3,?!8H(VD=B?
M0 %W^37GEV>G-VFKT&JL'.4J]M"[!S'+ZO8AFE7X41J_^3#%2$6)$^38H6(B
MKXZZZQM*/&T*E"$#NZL$<((&W,RK]<D(^VED+2-ZV8G7$V7R,V7R=[)3DF2Y
M9EG())Y%9CW<8W)\V*,+&HW.RJ!I,]5NK=HZ::%3RBHOV+\EZ:>&G;[9^X$S
MM=Y"L"K6,P_AS?3BIN  HI2B<Q;P-0<'<58,37R$N''7X+1A",^+LZE@T\+"
MSJ:M!FUEQ_P><S![HT4'EU=3LNX'?1^+0L?0=]VB9N@8E3RAV;6VNSGC9<'8
M-"^[>YUIU#'JQKR]%6=5Z[C;S957SG0*5#/&J-?[GM#1:RDJ]+F+>NO\_=!Q
M6%3<U)<)U=8!SM]41 I0[WQ31N^:*K7*K7M<QZ->US4YXEBDAD>*9'BEC8J\
M;J5=&'B&4[$$>W734,T5B*.>"1)895#QRQL'1T8;AE9200?8=;CJ7J9HZ::%
M5$15541$3RJK\D1$^U57\2)TTU2_WO\ =2%RO*3P%Q+:,L<8,?"[E/:ULZ/K
MKZ:N(;/#A\^="JQG5D)D,9.ELQ7N&-E'@I1IYQ/KB(C</9]P7-+8CS&1B:)(
MMFJ0R+LVY_[>12/-(&XB5MB#NY (4KI'M)XZ@2O+@\7,)&D/+>L1MNNP/6O&
MPW##FV,SCS3L(U)!?>%(\$8T,4$34;'$QK&-1/"(UJ>$^76]]@  HV50%4>H
M#PUSLS%F+'J2=R?63Z3[?7K77M.+>UA5:6Q'1D1.9\T_BJJ?)47\2HOA45/L
M5$7\77B6))XGAD *2 C8^&Y&W7Y"0>FIM>=Z\J2HQ5E(.X\>A]FK:NR?NZ'W
M=96<+<L6S N7,^(T"AM[.9(HN4*0"/T#&BDS*B2;((2-K+^K>]Q5HD3]#7^_
M'+:BT_,W&G"%C!7);->)FQTTA8%1OY,S'?D;;_LB?\V^P5=Q&VQ"E^K.!.-:
MW$%.*E;E5,K!&$(=@/+$0;"1"=N:8#_.I]DVQE4$%Q'8[U@>MC:.FFCIIIMN
M5^6L'PIC++=<A7<-/2@)[<$2>F:TNK*1CW"4E#7(YL]K<'+&YHP<"?@L;*45
M(,",45!64*%O)6HZE.%III2  H/*J[@%Y&VV1%WZL?8!NQ -#D<E3Q526[>G
M2""(;EF(YG;]S'&N^[R-X*H]I.RAF'GPY"Y)U7//)MSR]LAG5BF01U&-S"S>
M_#D<B'+/+7522(C6SV$TA!%E='(UJ%VQA+H(X HPQ!NG^#^&H>'<:D9V>S+M
M)-*1U>1@ QV/55  1%.^R@;[DECR7QKQ5-Q+DY)^J5XMXJL.^XBA4GE&_3=V
M)+NVPW=CML@11%_O'Y(?Q9VYZ:4*=![[=N9C*IS7^)F,NXITM"(T3\)%@H(+
M!&2L5%@)('?ZD>K6K:4B^J7M#JU&\^AP^GE$B[;HTT/=RN#XC=KC5X74_9)
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M9Z>3R_PB'[__ (:?4'Q5\.N&?Z7S_FM'[N/&?YE.2/T4!_K/3R>7^$0_?_\
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MKO2J>IR+BG916:>+.YV8?7LC>[L$]=E0O8E(/J:6P >O4Q#U#7TV[?)8,.O
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M'\9/9[]-_P#E:>^KD?XK>TKZ!'Y[1]_=L?YC/>=^BQG[2Z>]E0_C)[/?IO\
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M021+YW?D=R8P&YB7"+U/GAE>4,.9G&D_@N/^>,IQ_P ;YWC?.\FYC5T67[S
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MS]Q9C*2@[!MR%;U;^T^@CH?CUJ>1I.421MS(?$>E?F/H]/J^+PQ\SI#[P2P
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MT 'V,A&PV9MF6KCH+,(8\9Z/@*A9-&YJHJ*U[4<GS3_+U<-;N1@RAAZ1^O\
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M[P^;&'R4'OU&IWC]+S );65W9F4-1 RMCM:.JJ2JN.IN8&/?;<[GPW('V(#
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M>8.[@/,J?NF)(!!(4E5)?Z+B+FN"-D,7<E:1Q1M1C&-XVS*(UK4\(B?^$/\
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MM>3N(U4]0L\KLD.S;$B.1CS\IY48C3%K>=N?E?\ P)+]OX@[I$_T)\4GA/\
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MRN'E*)X[U-9HB!1T12#:B&;V;X"!55/3+8TD]@#&Y5]+7$(YR*U%194R\Z$
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MJ84+$J35PH$_J(?I3M,[2>-<K$V!R.#L<(T+ YIJ4J6?++\2L#R2W9X:RS5
MX4E:L$:2'S9GE391OCLJ[+>!,/,O$6,S];C/(UCRP7X7J^1XZ1U(YHZ->>TT
M%PH6 >W/))&OG0QQ."Y=SZ0/_P#4P_\ 7NX!_P#\JZL79;_^H7_NSXI__@=9
M#VN?_IK_ .];A'_^/U85UJO6WM'330J(J*BHBHJ>%1?FBHOVHJ?C1>FFH[\T
M\'YSDFA(!L0U?&U))PRQFM^LZ,MR)_NRND5%5\#E:Q"@W^8IHF^F1JM:R2#+
MN&^)[N%MK-!( 3RI+$Y/<6HP?\W,H(V8>,<@\Y6)((/1\3XGX6Q_$5%JMN+?
MEYG@G0 6*DA ^N0.0?-;8=Y$?,D4!6!(4K33RCQ'J>++9P=S!\75$2/2KOQ8
MWK7V$?EWI8Y51?A#FL:JS@S.61BHKH7D0>B=_1V#X@HYVN):S]W.@'?U)".^
MA;U@?]I$3]C*HY3N P1]T'+/$G"N3X9M=W;3O:LC'R6]$K=Q.NY(4G_LIPHW
M>%CNIW*-)'RNVKX(YPO^V#D>?9 !F7O'>L8(!R5DPE:I<HXLDGP&GHHY'QP?
M=%0H00L4$LD0]S73F59$H\T@-C78WQSPBN?J^4U@J7JX+1-ML&W&[1/L-^[?
M;H1N48!NH#*<F[/^-'X=N=Q9+/C[)5;$8ZLA&_)-&"=C)&2>AVYT)0D'D8>@
M# \@XSE'*U>UP.AKM/F;>+W [.NE5[4>U$]X,P>1L95=9!O7V3ZP^ :P (:\
M<P:&9CF)S=9JV*<\E>U"\$T9*O'(-B-O2/0RGQ5E)5AU4D===1U+E6_7CM4Y
MX[%>50R21L&4[^(/I5U\&1@&1MU8 @C2RZD:J='336,::'7!E6%@6,  "/,6
M:<;/$*&&(-&Z8@HHF=\<(X\$3'RS32O9'%&USWN:UJJD55F8*JEF8@*J@EF)
M.P  W))/0 =2=>6945G=E5%!9F8A550-RS,=@ !U))  ZG5''>)W4Q=PMBWB
MCC R63AVCLX#-7J8T?%#R/=59#9P0*IKO0Z7&4QL49K3)6HW16\ I@C&U=<$
M9;;N[/\ @F6&5<OE(N20+O6A<=858=7<>B5U/*JCK&I/-YS%5T%VC\>0V8WP
MN)FYZ_,/*K*'S;#*=UCC(ZF!&',6Z=ZX5E\Q%9XMQ1LAC9%&B-9&U&-:GV(B
M)X3K=/3H -@  !Z@/#6AV)8DGQ)WUJ;RJ6T%8D!$X5@'/ ?5V(DKQS:^Q#F8
M2$:&3$YDPQ0I,44X\\3VR131LD8YKFHY*>W5AO5Y:LZATE1DV8 CJ"""#XAM
M]B/;X=3JJHW)J-F*S [))$ZNK*2K*RD$,I'@00"".H(!'4:N4[0>\:IYAK@.
M-^2C0Z#F^G$0:8<E8@0.1A@XU1='E_/MCOLY8(U(OLY C209VE&UXSZ=%<'S
M%Q;PA;X>M22)&\F-=MXI0"W<<QZ13'Q !Z1R'HP*@GG/G=9<&<:T^):D44TL
M<65C0+-"2%\H*J-YH1T!)\9(EZH=V4&/;:>W6&:SO1TTT=--12[H.ZW&=NF>
M<,CAM-RE=AR?<9Q\*0CC"II/7%#=:%87+)2Y82=KG$GS^W-8+#,#4,),;)[&
M0\/<.7N(;:PUXV6NK#RBR5\R-?$JA/1Y2/L4&^VX+; C?&>)N**'#5-YK#I)
M:9&\FJ!O/D;8A6<#JD(;[)S]EL53=O"BF"2_NKB_VFSLY+S:[&T(O-);S-1K
MB3BU3S'#&W\ 8$.%L05<#"C1@*\<8(5D8\$4;>I,/BJ^&H0T:Z!%CC53L?4.
MI/K9CNS$DEB23U.^N1LYF+.:R%B]9<O)-(SL3[3T &Y"JH 55&P5551L!MK9
M]7/5FT=--,[R1SF!QI+!44(\FHY M'PATV4KFR%SRF&/9""VQA%20AOQ$TL3
M1 (&.L+"1[(A6,;(I,<;'#%7B&E+#E%6+'*#)):<B-X.[!8SP2-YJ-&H):1C
MW87F$@9"4;.NSWC3BKL_XEI<1\*6I*V0B80O79'FJ96M(ZB3&W:JLOE5>P0J
M\BE98Y1'-6DBLQQ2HO>'>R_>X':4O<'W8XR1-!KIF:;-9YP(S:_.6A*,F&.T
MH(S$';J0(8X704!RJ;410#$EJ39BL@K]4\8=H6/@QIX-X&D,.)K1^27<HDC-
M-?1=U>&M,3S&M)NW?600+',R0A*[%INW>QWLOD[0\UD>U#M"RM7*<:^6M?Q_
M"LD*0UL2&(>.]/6 $1F#,HI0Q)+#3>-)+DTE]AY+9\,2.9!&2+-'/!*WU1RQ
M.1S')]B^%3[%145'-7PYKD5KD145.M*:Z5EBDAD:*5&CD0[,C@A@?B/H/B".
MA&Q!((.N_IJ7K'+%A-&F%(8V2&>-T4C'(BHK7HJ*GA?E]B]-090P(/I'Z[^S
M2FX"YK;P<8SC#D8QT/&AQT\N'V)+E43'$'3NGGSF@G=Y^&SA!<LA%7:2JD-'
M/-,(=(RF>--4T,\)!++X>D > V_7X_C!UJ7C+A.5Y'R>/B+R$<UJN@ZR #_/
M1#TN%'UQ!U<#F7SPP>RZ*6*>*.>"2.:&:-DL,T3VR12Q2-1\<D<C%5DD<C%1
MS'M56N:J.:JHJ+U2ZU6002"""#L0>A!'B"/01KLZ:AHZ::1F]Y!R'&6;,U>U
MNAJ6G#\,:^55D+/+>URCUM4#$CR[.T+5CFB@!13$S*USD8D<<CV1 ).P&YU4
MU*=F_.E:I"\TSGHJCP&^Q9V\$0;]68@#U[D#57]SI]%S3O'\G:L*:HJ:\>>K
MX]R9#V2/H*2:6.68T[VW/@??W<D,)5O+"KXXFPA5D,Q U; 1+<(8@@W.Y)]F
MWK]'C\_Q^GIOGA;AZ/"U &Y7LS<KV9=MN9@#M&I/G=W&">0;C<DN0"VQ4?V_
M;U/UEVM'CMM=< [LO<5(1=SA-,T8;D/, HUY:-&<] ]/20O<R-;JI;-.V0=7
MQQ6]?+*#.]A$=<6%33Q<_4; ]?E^,_$/Z_#?6$\6\,KF*XEAY4N0!C!(>@<'
MJT,I^U?8$-L2C#< @LK6CY#8YC>Y^OU./N@;^ALX_<$L )?7&KFKZ9AR(W(R
M<,T61'0&@&10&A$,D'+@AGC?&VA((.QZ$:T78K3U)GKV8GAFC/*\;C9E/XB#
MXA@2K#J"1UTI>H:DZ.FFL8TT.M$*L+$L8  (>4HTTV>(4004=CI9R2B9WQPC
MCPQM=)+-*]D<;&N>]S6HJHUZ56=E1%9G8A55069F)V"JHW))/0  DGH-5A<V
M<P/[A+L;'X]\[.'<[9P'VUT]DD#>0[RNG;*$T.*1&2+E*@EB%"23,;]<V<<%
MC'$P2OKB#*R"']VVX]0^/V^G?V>'AK;O!G"DE1ADKZ<MEEV@A8 FNC#J['J!
M,PZ;#K&A(WYF*C"BB9#''#$U&LC:UC&-3Y(U$\(B(G59K:  4>@ ?(-/-A.,
MS+8D<JT&>K'JUXU:J*CY41?/O'>?'L#M^3EC=X<]%\2>AOALE/+, "%/QM_4
M/6?;\WK&&9_BB&G'+%5E *[K):!\U#M]A7VZR2'J.8=%(\WF.Y69M!0#T@[6
MM1CRG,:R25K4:QC&HGB&!OA/1"WPGV(BO5$<Y$1&,90LQ8^S]>I]NM*9#(RW
MY"266(,2B$[DDD[O(?W3MXGJ0NY )ZDJ#KSJW:.FFCIIJ-G;5_@_F/\ S^\B
M_P"Q1]5=OQ@_[M%^-M;/[4/])X*_]WG#7_BOZ;SF;A>PG/NSJ^D;I<QI&F_6
MU0@;+)&-LV2,M 3:MT<J&U9J33^IJ030(/+(*5&V-K7S>X9U*A'(! VW/0$#
MPZGIOMX[^.KUPGQ;CK..@Q>4GBKV:\(K!K15:]NNJB./>20]V)>[VCECE([T
MCG4MSLB0M$[2.(P ZNO&X+I(QJ:W?> ,?EB9Y8[*2*E@?).1/%*2:,H^;S8W
MU<=*37(-F\\,@B04=5&).^M=!NG3J.H]GM]@^8>H:RA8>&E5%4XGECD[U/KU
M<[.1&NY)D)9>6&$<C$IM#".7:*/E5-?V_P"0J;N@T=9Q6,!>9>N6IH;(3/%0
M$5M=[MS/$)$L<+621BS:/12 >^R5]<Z_NU!</];6'Q$=X]P=TW'@=Q[?;[3\
MY]>IZ/@HY(I4GQJR0IW<3K8K@HF\A"C:3;93-,5WWY.]DY=N\??&L^W3#W(K
M@[3B0(T=7:^1K)LX2KH9]]N*CDS8%C2MA;**;>\A4%)M"SAGQ%LTM376X\T)
MHD$K&\?K3T^D>D[GT^L;_'KRYP$B\KRXQE_R@[&Q7Z&U9CNV&![S=6EMQ166
M8;,)HTD4AE!#66'8MQ ?'L(_W,#P_NP%J*Z10:A($SU33T&9S4=5EX754@]6
M&;598*&Q?)"685\=<L^+C@LYX>O.T77SEZ_[0Z#8#8?,-_EU1/1X:<6!W]%?
M*%C0\EJJ.ZCCBAAY(02517CA4.2&9N:3S@'(TX(_:WQD*%)70<+53 YZRRIR
M(5S)+_BJZY"UM?<0%R/A=*6ZV$WNT9:$$R2DV#]1=SES3$6!$KX_6O6GJ\1[
M1Z_3N=_7OJK"<.JA0/BN4H\;#OZYYDD6PL@8ER6[Q;5D.6)+F>4L27)/5Q5V
MFUW'_(>^W>0SVM*TG)1"K9PDU%4%5U8\NAO]1.'6QTN;HO Y-[I;2P+L=(9=
M6DLTON36OEY#IX;Q(2W.O7VCIU)V '7QZ^DZIXI>'\5+=R!R51&M$M)S6:@5
M1WLLY2&.!4=RTDTC'F$TS$]&))WM*XEP$N$HIV6#HWW5O+$39)"Y'Q#,A8Y@
MH+)4^4RCI+,^65OX#IIY&QJ^)C)'T4TO>,-OL5W ]N_B?9OL/FUJ#B_B%,_D
M(S7#+1IH\58N.5Y2[ S3E3U02%$5$/G!(U+!79E5U>I.L2T=--'331TTT=--
M'331TTT=--'331TTT=--'331TTT=--'331TTT=-->)SNH[AM;W+<QZKD+169
MD].ZS/ PU')-(H&8QT!<C*:L %5WLP32B,A+MR(HXWV5M,4=,B.E:QGT3X*X
M4H<'X"EBJD,:6!#%+DK*J.]NWV0&Q-+)L&=5D+)71B1# J1+T7<_,KCSC#(<
M:\1Y#+W)Y'K&Q-%BZI=C#1QR2$5H84)Y59HPLEAU53-.TDK#=@!ES=K.]&R.
M.V)-GGX0-AQWR%R+&(LMBXZE#X_R8F]=374;:]8AK;3XJVH-+FO9FG!,KKL9
M9BQYA3XA?"\:XM[^0QZ0VFEQ^6Q6)+\L(CL292])C!8KDS<SP4\C!:IW.95D
MCFK/RQNKQ%YC\!Y:/'8W)23U%BR6'S&96/FF,M6/$8^/+&M97N>5+%[&6*EV
MERL\4D-I.:1&258]CC>U#6;/#A;8'49V-EIA%WM;G1@-5?:::M35\KY*1Q--
MFZ"V.%KA+#B2V6RT"03TU7]?YEIY,#"K&:LE9#C>AC\C)CI:=LF#)C%S6WEH
MU::S&EA+PY+%NU!&\KQ9V#N:O,MB;R6X8D8QQ+-/QO9_D,EBXLG%?I*)\3[K
M04TBOV[S0^7Y_'GGK4ZEB6.&.7A^QW]SE>M!Y72$KJKS/ B>W3GO:=N'*V9Y
M,QM@9!]6'BQ:2EB(?&#J\Q(1$MQG;6#U>P0.<*U_PLDS'OKK%@EF(L1@<$S+
MCQ9PQCN+L)<P^0BC;OHG-2PR RT;H1A7MP-MS(\3D<X4@2Q&2%^:.1E-JX-X
MLR?!F?HYO&S2+W$L:W:RN1%?HEU\IISIORNDL>_=E@3#,(YXRLD:,/37W[EP
M'B=DQPK_ '!C.^;MZ+'D\*WUP$1:>:)_A414]4;VN\*B*GGPJ>>N.NS%&B?M
M%C<;/'V;<5HX]3(:2L/D((UV]VL2++'V92H=TD[4^#Y$/ANKK?93M[00=6)=
M:HUN'1TTT=--'333:[CC6BV-<:&6 $5";&K#*XV%LH!J?:BN8J+\.0UWA\9$
M2(YDJ-D;Z)4]U+QC,S;QT\4L4TL;Q'>.:-RLL?K&XZNA&ZLC'8J2O5?--KR6
M*J9*O+7L00SQ3*5EAF0/%(-O2I'FN#LRNNS*P#*RL PJOYA[1K:@)++Q$<Q0
MJJ]\F8LI&_&PQ_:OU982N2&R'^U(XIW,(1C6M:09*[K>G#W:%6N(D66Y(W(Y
M?+85/<OOT_RB%1S0,1U9D!CW)/)$JZT!Q/V5VJKR6N'RTT8)8XZ=P)XQU)\F
MG8A;"#P5'*R@  23L=]0VS)_)O">H-NN,-5H>-=%)*Q+RH6%KZ:W=%\FQZ'+
M6X\]58/9&KXX""@/C@V32.!*&>_W$R7*\-8/B2%9)8X)0ZDQ686!VW],4T1W
MY=P-P&Y6V (.VL*Q'%/$'"]EXXI;%5T8+/4L(P4E?W,M>9=N;8[ LG.H^Q<;
M[ZF'F?I(^;Z6",?:\/8?;S,1(W667TUOA7RHWPU)Y0;&MV\+IG)^%*V"<6%T
MBK[<4#%:QNN+G9&W.32R+JA/19HDFVW] 9'A) Z^@G8==SOK:%+MF\P"]BXI
M' ',]>=X ?'J5=+ !Z GS@#N=@/#6XN?I,N3C1WPY?M_S]*6YJ^W8Z3D4Z_$
MC>J*B>NJJ\EG9I6M5/*HVXA5Z?)%8OS21!V1VRX\HR0Y/2(JX1MO3YTDS#_X
M#L=5%GMFKA#Y-B=G]#2VV=0?]I$KQ$^CIW@^/4/N4>6^<.>G+!RUNG2YGWHR
M&<?9,5<[BFR1O26/XROA()L+Y(96LE'=IK6Y>)*U)!5A=\^L^P7 6$PK+,(S
M8L+U$\Q$D@(/[DD!(]^H/=JNX\=^FM<<0]HF<SJM"\X@JD_Z-6!BB8>(YQNS
MR;>@2R2;$ KMI("BCA0L'&B9#%&U&M8Q$:B(B>$^2(B?9UFX  "J JCP   ^
M,[>)]NL =V<EF))/I))_'K(Z:\Z.FFM+;4(%PD3IVOB*&FB)#.&D>.:$4/(V
M4<H0F%S)AR!YFLEAGA>R6*1K7L<CFM5)%FK7N1-#9B65&4J0P!\TC8@[@@CK
MML>FQ.JJK<L4Y%EKR-&Z$,I5BI# [@@C8@@]0001Z"-26X\[S>Z#B\8>J)N:
M+E[/BM;%!#R".7]U, T:)Z(8=?4$B'&R+\_<,T@6A,=Y\>]Z6M1-:9;LLQ5M
MVEQ\LE)FW/)$5,6Y/[RX\T >"QL@^<:VOANUO,4D2&^D60C4 <TX99P!Z._0
M@N?6TJRL?7IS]']+1K<NN8%-[7X2SM)?A9Z%X_,GPXD1!GE&E*DG&$\WMHJ>
M?A_PG>/"?$?/U=6.MV,9"UY6R9:)5JUY+!WI,S.J;>;TM  GU]=MCT]&L@M]
MN6/I^1J^$E=[=F.J.6^%5&DWV8[TCN!M]B#U^VTC-WWW]SV]&GK<T+CN':PE
MKF/-I!Y]3KHXW_@R1P7=^UM./ZHU5J$#9:$Z%ZI,,5!(UBMN.,[)Z4++)D;,
MMK;8]V"L43;=?L4)D;K^Y,O*1T((.K7E>V'(SH\>.JP4@=QWNYGF4'<=&D C
M'QB$,#U5@=1,%IO%B??6]A9:+2V\[B[C1WQQ-M=6A;T:CR#K(Z6<PJ54:UJ/
MFE=Z6-8QJ-:QJ)M"ACJ6,A6"E!'"B#E7D14 'J55  W^?J=:DR.5NY2=[%R>
M2:61BS/([.S';;<LQ))]I)(]!UN^JW5MUK;6XJZ(*:QN#Q:X&!%60DN5L4:?
M)51C?4OJDD=X\,BC1\LCO#6,<Y43KW'&\K!(U+,?0!^$^H>T]->XXY)6"1HS
ML? *-S_@/63L!Z=-/FB>:NYC42\<=LF.LK.1'LAO=X="H-+GA)W.8IQUD3&X
M&D&5C)7CR%K+<G>V^*IJGFL8QTS)7\%PM4]T>([T4(()KTT/>6++@=8X(%/>
M3L"5YBH$,>X:614)(RO \(Y3-V17J5FG<;&1OL:M8$_969SYB[;$A!N[[$1K
M(>FKM^S/Z-_C+MB>-OM;/#RCSJ3&Z8W<6L$DM;FR26HI4&,KSEED'F\^J&;3
M'(Z^-8LJPK4BED5R\X<<]I^6XLY\?45L5@ 0%HQ,!-;5>BO>E38,-@&%6,^3
MHVW-WSHLHZ.X4X"QG#@CM3!+V5"[>5.FT5;<#=*<3;A-NH[]AWS#?;NU8QZL
M,OJ"FU%2;1Z"M%MJFPB="6$9$DD4C5^QS?L?%-&[Q) 1"Z.>"5K989(Y&->F
ML59D(925(\"/U\/6/ ^G6R,?D+N*N07\=:FIW*[AX9X6Y70CQ!\5=&&ZR1N&
MCD0E)%9"0:_>1^W#7<=3E:#C%Q6DRZN<09G)44BWKHF^7.2*)OAUI QOE&3B
MM98QL]+)1RF,D(=7Q65DV6796\ _[D^H'?P^4[>T;ZZ*X9[2\-Q-%#C>*A%B
M\L (X,HA$=.RYZ+WC'I4=CMS1S$UG;=DDA9EC5HZ?45UMXA<JA'HJMD!)5&2
M)(B^'-B>Y&I*J.\IZ41LJ>%]4343JH((^+U^CQV_7\&LNO8FS2W?I/ >JSQ>
M<I7Q#.HW* CKN24]3G2EZAJUZP;*L!MA)0; :(H:9BLDBE8U[5:J>%^3D7\O
M0@'H1N/4=>717'*PW&M5D;3EOB%$@XKVC5SD;E?'@]@*^_RL/E?4L5;'\2';
M44/E7N^&HK:M$?+(Z:<::3\))$E=7ZCS3^/]?;OK$<OP;BLH6E:(PSMXSUSW
M<A.WBXY6CD/0#=T+;=.8>ATI^]?E3/OJ ;_@JDN2;,Z.O;84?(9-0,LST3Q(
ME:=D;F6)BK\_2ZTE5$7QZE5/*R148\VS> W&X\?EW'XOG\=8]!V3SW%O2U\K
MW:4ZSV2LM/O&=4)W7G2P@!]O)_TC7*W[J.?+^-X^:X[Q&#21%8I]W=66V+A:
MY/"S#0#B9(1A#4\NB0F$X=K_ ![D,S?+%"J=^K=/F/XB/'V^O4BKV;QJP-N]
M+,OCRPQI"#L>H+,\QV]!VY3X[$';3,2YN[T]Y%K>3=3:[[2PMD:&1;NA975$
M<KFOD@I*82(>HIX'N8Q98ZT(9"',9(2LLJ*]:F.)(_ ;GTD_/^O76?8O!8_%
M1]W4KI%X<S#<NY'7=Y&+.^W4#F8[> V&EJUK6HC6HC6M3PC41$1$3[$1$^2)
MU,U>@-N@U]Z::XO8R1CF2-:]CD5KFN1%:J+\E147IJ! ((/@=(RMHM-AKDG2
M\3ZZRPML8]LMD&(D!>>NW,\(WZYSYT1%4?(C$6&,N45#Q8WO^"+&>[UI*>)'
M'4 'T$#]?EV(WU8LKP[C<LA%JNCL >20;I*G_!(FS@$C<KU4[ %3I[:GNNYT
MIHV0:;B[%[)[$1BV&=T=IC72(WPB2O!/K]@QTKD_"D;&0/$KU56,B9X8VG-4
M^AOU^/IM^'U'T;X'9[-E+$U;\D:_:SPI+L"?MD>#XANOR^K+L.[SF ]CH,_P
MKFZ.=R+Z+"_W1MZ,QWY75E=F\]+(UJ_-4;;1J[[$5OVI 56])'Z_%O\ B&VI
M4/9M)S SY$LNXW6*N$;^4\LFV_H\P_+X:9+4R<F\LSQR<N;22TIXYXR8</GQ
MDHL;#-$])8G3UL,LQ-PZ&5J2#2Z ^WG%>B/&EB7SYGQP*AW/4^C]?3Z_ #V:
MS3$<)8O%%9(H.\G _P _,>\E]NQ(Y8R1T(B5 ?3OI=9S*%&,C!I0&Q"PHC%D
M1B0B0-3Y?AR>$:KD3_@,]4BI_%8O4QG5!U/Q >/^&K[:O4\>F\TBJ=O-C7SI
M7]6R#KL?MCLH)ZD:DU@N(TC=$;,QLTB*BK8E1>(8_FBK\ ,Y55[V_B(<OGRB
MHV2+RYG5)).6! V ]0Z_.?ZA\77QUK3B'C L'@1BB]=JT3^>WJ\HE'V(/[V-
M^AW*OT.I)U=0%40)")'X543W9G^%FF<GXWN\?9Y55:QOAC?*^E/FJK3$D^)U
MK*U;GN2<\S=!OR(.B(/4J^OUL=V/3<D  ;/J&J71TTT=--'334;.VK_!_,?^
M?WD7_8H^JNWXP?\ =HOQMK9_:A_I/!7_ +O.&O\ Q7]*OD7F2LQ1;J<$/ZYO
M&,8\B%9_8#KTD:CXVDRM9))(0]CFR(-$UOB-[723QJYK72XH#(.8GE7T'Q)V
M]0^/T_'JS\-\%6LY"+MB;R*BS,L3]WWD]@J2K&)"558PP*F5B=W4A8V )#1?
M?(:;_$%%_P!*P_6NI_DJ?;-^#^S68>]GB_NA?^:O^:T??(:;_$%%_P!*P_6N
MGDJ?;-^#^S3WL\7]T+_S5_S6G5X\YJK=B='2V@24UQ,B_!^B=9P3WL:KW112
M/9'(.2K4<Z."7W&R(U480LJMB=)EKF,<P/,OIZ;$?CW'M_!Z=8EQ'P/:PL#7
MJLYNTD([[>/DL5U) #NJEEDB!(#2)R%-P6C"!G#X=4^L%T=--'331TTT=--'
M331TTT=--'331TTT=--'331TTT=--'331TTT=--'331TTT=--'337CN[V^SW
M>=L?*&EE^Y^Q+XCOKLZQP6S$$F(I65=D3(2'F[8V)CH:V_IF2_5LHIJC263!
M$LZ^*02=$C[Y[.>/L9QEA::^51)G:M:*+*8^1U2P9X4"26X(V(::K8*]\KQ\
MXA,G<RL)$._SG[3^SG+<$9VZWDDTG#UNU+/B<E%&SUE@FD+QTK$B@K!;K!NY
M:.7D,XC[^%6C;S6<&[H>>ATBC?R-9V(8T40P=1>5]#H:  &+*G8A:NMSU]56
M-'6T\^5L2J8RG!KQZL\=1Y#1""0@IQ\@?@SAA^8C$PQ2.Q>2Q6ELU;4LIO19
M+OIK=:>*S+86["EB.Q)*T\3<ZQR*DDBOCB<=<6)R@YF>:.-52*O:AJ7*D,2T
M)<7W$%.W7FJP5WH325I:T4*02KR-+&\D4;IBB]R/,@36L$U0(T0X;P:N&''8
M>.#.1NNMAH6DY&!N;2+&V@]OOM>4'<Y5E/;@LO"1 CH HA1Q_;\(\/R$F2E(
MY:023,V0R1:V16H5.2^QN;Y"%J^+H))7O&Q!*:R221M*SNWB/C7B6+;N[\2!
M(S% JXW%A:8-K(W.?'J*7+C9UL9;(/'9H"M8B6T\4<J1+&B.?V?=H?(7=+R/
M15E=1V@G&=?;"3;_ '<HTX]+5T@T\<MC6@V+V-@-TMB.C@ZNK$?,2PB=AQC!
MZP8LN&S<>\>8K@K$69I;,$F8E@=<7C%=&LSV74K%-)""6CIPN1)/,X5"JF.,
MO,\<;7OLY[.\OQWFJL,-6>/"0V(WR^59&2M!51@TT$4Q 66[.@,4$$99P[B6
M0) DDB^B;OX"<D/9>."*]80^^7@!?:&A<Y@P@[=0Q'*V-JI%!"ST-5R^&,3T
MHJI\NN4.S"0<W:$TCCFD[-N*?.=@"[N:1VW)\YF.YVZD]==C=K$1Y>S58HR5
MB[4^$3RHI(2-!?&Y"CS44;#<[ #;KJPGK5>MNZ.FFCIIHZ::.FFM?8U=?;0*
M-8BQ$Q?:U'HJ/C=]GJBD:K9(G?B]4;FJJ?)?**J=38II8&YXG9&\#MX$>I@>
MC#V$$:\/&D@Y74,/1ZQ[0?$?)J-O)W;=FMN.Y9ZX6V='%(P=2%^#N!$7RK6A
M6L'MJ]&N57)"0L<"JG\(V;U.1<OPG&%[%/\ 6YY( Q!=5'>UI".A,E=N8 D=
M"Z O]J5Z;8IGN$,5G8^6[4BL,JE4E/UJU$#OMW=A.5]@3OR,>[)^R1O#5>.^
M[2M#03RNSQSY6HLCFU>AB< =Z6K^"@Y\42A&>KYHDCXPH_EY]QWGRFWL3VAT
M[2*+T/(V^QGIMWT/HW+Q,W>Q;>H-*Q^U&VM*9OLGNUF9\1;6= "16O 03@;[
M!4G13#,3ZV2!1ZSOJ,M]C-5F)',OJ&RKFM<K$GF&>X-[D7QXB-A]P27Y_9[4
M[_Q=9Q4R>/O@&G<KSDC?D21>] _VHFVE3_J0:UKD,'E\4Q&0QUJLH8J)7B8P
M,0=O,G3FA?V<KG?29ZKM6K1TTT=--'331TTT=--,ORW_ (6XF_SF47_]SJ^X
M7_,YG_\ 95C\6K'F?\[AO_VM7_\ #)IZ.K%J^:3]MJ:"D8]UC9C1/8BK\.Q_
MOE+^1$'A]<J>5^2*YK6^?FKD1%5/:QNQV ^?]=_P:KJV,OV]C!6E9#_VC*4B
MV])[Q^53M["3[-:?+NY=YCL7T/!?%^BUA/N-'GNW N2HK))5]+)+ ^1\-)5,
M\>7LFM[:!CO'A8'>%:M'D,IA<&G?9G(UZ:;%EC>0=]* -R(8%#3SD>!$4;'K
MZ!K+L3P+D<BX"Q2V&YE!2LA$2@[?YVU(%CC'78[[>!V;IJ>G#GT3I=]8 Z_N
MLWL^D(BE80SCG'&SPU+8_P &3X2YTRQ"3I&]56(L#- UZ-5GJ'T$[7_+5>?[
M9BB25.%*(@!!49.^BF4$[CFKTPSH"/%)+3R;[^?6!&MPX'LOJUE1\K(I (8T
MJ995;;T6+1VE???9EB";$>;,P.KA<+Q_B>,<U7X[C[+TV0S%6Q6!4U&%$$)&
MYR)[D\J1I[A1DZHCRC2Y)S"I/,I,\LBJY=(Y#)7\K:DNY*W/=MRG>2>=R[GU
M*N_FHB^"QH%1!T50.FMI5*=6A E:G7BK01C98H4"*/63L-V8^+.Q+,>K$GKI
M7]46JG1TTT=--,CR3P#@>25E.+"=2:)_X3=#3MCA*E>UJHSZP&5/A;%GGT^I
MTS&%^AJ,B,A;U/BL21= >9=P>5O8=^A\1^+V'6<\,=H7$'#(2"&87L:O0XZZ
M6>)5/B*\H/>UCX[*C&'<DM"YU#_3\)\N<>R.D&%;NLZQSD874QS3V$$#?FUY
M-=X?80.]*>7^Q]9"0HB^9T3PJUB6(I ?W#=.A/0GT['P^(=#[#K<V+XXX/XC
M"K)+]3^18#FAN,D=9Y#ON(K.ZUI 6(VY_)9G)&T9ZZ;X71@3/6$CW02&JK'Q
M%,5J-D1?#F>O[&JU45%]U(G>?EZ47J;MZ?$>OT=?U\?#IX^&^1RXNS&O>1\E
MB(C=7B8'=2-PW+Z=QX<A<>HG?6]9(R1J/C>R1B_8]CD>U?\ (YJJB_Z%Z:MS
M*RDJRE6'B&!!'Q@[$:1&P_PCC/\ [Y1O_P &[KTO@_\ P_\ ^RZO^$_T7.__
M ++D_P#$-+GKSK']'331TTT=--'331TTU]1%541$557Y(B)Y55_(B)]O30D#
MJ3L/6=;X#,W-@K5C$?!&[Q_#%>8(_"_8J(Y/<>B_ECC>G]/V=>"ZCT[^.^W7
M;;Q]GR>/LU;K&4I5@>:82-X<D7UQM_42#RK_ -3#\>G@R?#I-@Z.8B"4QGVK
M+-ZQ*QJ_/_AJGO$HU?'E(_/GY^J'QU3O8/4#8?A/]@UAN6XTBK\Z(ZPD= L9
M6:TW0]"/L(M_6VVWH?4DZ#C^JJ(HD(:PM\36I' V-(@8/'A?3' WPLJ(OXY?
MP'?:L2*J]4K.23Z/Q_K\7Q:UGD>(K=UG[HM"C,27+%YWWW&[2'['<'?9.H/3
MG(TO41$1$1$1$1$1$3PB(GR1$1/DB(GV)UXUCWCXZ^]--'331TTT=--'334;
M.VK_  ?S'_G]Y%_V*/JKM^,'_=HOQMK9_:A_I/!7_N\X:_\ %?U&/7.,?JM(
MX_U_&K>6J$^OSZDE0V='-^?V-;X]+$3Y(Q&HW\%$ZJH]N1-O#E'XM;0PXA7$
MXP5P!#Y!4[KEVV*&",@]/$G?<GQ)))ZDZK<YQN^[(/6\_P!QQK8:D7&8/C*O
M.P%54U.<-EOMI8Y"^ED91YL[@'>7W() =ZRMFGBJN2*1*<N,<>?,:."::H.@
MW/NQ7?8#H.GCMZ!RDGK_ +0_JU:,E)G%GRDE-YUKU:0:K'&D+&:R]>4[1PMB
M[4MHK+R$B.Y%W;!5,$P)1M!D[[N[UVPXW!SNFU@^=$JZZ\WEKOLR%1TIJC\J
MM&T-*9-I>TWAS47AY/&L)$%!59S.\83"VI05F5HKNO&(.*@.<D;$[>G<=/'V
MHI.X_P"'X_3J3!)GIYZ:Q36%A5$DM/;A6*-^6]M+&QFP./GD=J898DAAHE7*
M.TLB!G:S6C<6RZJ'@>OXYMH X+T>?7\6A42C^CQ\_4LWH\>/GY\=>WVY6W\.
M4[_%L=]9)>$+4;BV-O)S5L"?FVY>Y,3]YS;]-N3FWWZ;:L\ZM.N6='331TTT
M=--'331TTT=--'331TTT=--'331TTT=--'331TTT=--'331TTT=--'331TTU
MU3CP%0RC%00DCSL=%-!/&R:&:-Z>'QRQ2-<R1CD^3F/:K7)\E14Z]*S(RNC,
MCJ0592592/ JP(((]!!W&O+HDBLCJKHP*LCJ&5E/B&4@@@^D$$'217CGCU55
M5P>,55^:JN7I/*K^5?\ </5=[K97[IY#^>V?SFK?[C8C[E8W^8U?S6C]SCCS
M^0>,_LO1_J/3W6ROW3R'\]L_G-/<;#_<K&_S&K^:TK!A1@AXA QX!!8&)' ,
M-#' /#&W^+'%#$UD<;$_$UC6M3\2=4+N\CL\CM(['=G=BSL3XEF8DDGUDDZK
MTC2)%CC1(XT&RHBA$4#P"JH"J/8 !KOZ\Z]Z.FFCIIHZ::.FFCIIHZ::.FFL
M8L(,^%PYPHYD#_/JA)ACFC7RGCSZ)&N;Y\+\E1/*?B5.O:221,'C=HV'@R,5
M/S@CYM>657&S*&'J(!'X=-??<-9"Y9*D$954^5KT<T61)Q7^OSY204MLS59\
M_P#>X9(&^/E\DZNU;.7JY4EEFY2""X*N-O JZ%2"/60Q^75#-C*LP8<O*&!!
M V9#OZ"C @CU@; ZC9K>S:IM722B"9LY5\N]:0EY\V1555_C5WN1/?\ /YNE
MG:UR_-?'V=9?0[0K];E!L7(QX<K-';B4=-MA/U"]/!5W'HWUAV2[/<%?+-)C
M:3,=]WB1Z4A/K+5F3<^'V1(W\=1RT79?H W2/#HM$Q$5?2E>;66\+D^7A611
M^Z9Z5^:HDBH_\J?-.LPJ=IB, LLU*3UF6*>N_I\6W6+K_LKM^'6%W.R*@Q8U
MSD:_4\HCF@LQ@>C97C,I Z=#)O[?3IF+KMLV=1ZEEKM,.UOJ_P#GF4LHF^$_
M'[J.1JM_\Y$5%_R=9#7X^HS;#DK,3^]7XF/\@Q[[]/MM8]8[);*'ZUDIAUVV
MFQK[#XW2QL?C"_)IO#.++\-RM>V=53\3JXV-W^3PL:KY^?5S3BZD_P#V+^GJ
MLL3#IZ=]QXZM+]F625B!?K';[:"=3\VS?CUJG8#0>4;$">2Y5\(T>L-E<J^?
M'R1L2JO4X\44@>J\OK+S1*!OMZ=SZ^N@[,\AZ;\'_16G<_-NNMJ%PURK:-\U
M''&ZLD7Y-D'RMTL"KX^7F=0_9:GGQY<Z1K?G]J=4TO&6)B_SENA$?2)+\!;^
M0-F^3KOZ-5L/9;;?8M8N2>L18YT&WL=Y7 ^5?\6EYJ[?.;*V^X$#N<9/FW[/
MFG+93,D79=>,R?06?NH&.3 TL@T:%$9))*1,"V&-K%17*]6,??.'.,L1;J<4
MR06XISC>'+U^PM:.5RL$'+S.&=1$Y\X (K;D^C;<ZQWBSL_]R[O!$31VB,KQ
M?C<<QLRPHKB<2[J%B598R0.KDGE'J.VITY[Z,_D>\DB?R'RU2T8:^ETX.2!L
M;PB1JJBNA6<YN<$'?X_!]U!SF-<GE(Y$^W5ESM;JH"*&-M6&Z@-;EBJQ@[ <
MW)#Y0SCIOL3&=CMN-;JH=F-.OREQ2KE? PPM:F^_6.1E.WI'/U]'0:E;QY]'
M=VT866 ZSS)_(EM J/0W=V"V(:2?)7>*"OBK:&:)7(KFLL*\][//CW7?;UAF
M2[2N*<@&CBMQXR%NG=X^/NWVZ[;V93+85NO4QR1@^H#IK,*G".%JD,\#6W'7
MFM/SJ#L!_FD"1$';P='^/4UJFGJ:&O&J:.KKJ:K#8D0E;5!#5X L:?9&.&)'
M"/"S\?ICC:GGY^.L%FFFL2/-8EEGF<[O+-(TLCGUN[EF8^TDG62)&D2+'&B1
MHHV5$4(BCU*J@ #V :V/4K7O1TTT=--'331TTT=--'332&U7&F%VB.71YNN.
M(<GA#V1N$LF^$\)XL0W0&*C?">&.F='\O"L5/*+[261/L6('J\1Z_L3N/P:O
MV)XHS^#(&,REFO&/_P N6$U4]23O6G$D WW.[",-UW# [$,#=]J%/ZY2,CJK
M2HD=ZG-$LXH[ ;RJ^6QM)&<"1#&GV>J5AC_'V^I>J@6V)W=0?:.A^/KN/9TV
MUL.CVN72%CS.)J75VV,U5VK2#P\\Q2BQ$[=!N$:!2?#;PU&OE#A[?9&WX]&,
MFJ[I]SL!:VG^KB5]9![XGNBAF:; "L2R-1?#G2.B1?DLJ+\^JJ&>-UE\1RIS
M'?U!AUW&_IVUL_A3C/A[,4N))8([=$4L+-9N^4Q#EC@5PK2(8); 8*3N5"AM
MO!" =;\G"<A >?CL7?,:W^-(/7DE0M1//E5E$83%X_I]SQ_3U 2QGP=?G /S
M$C5LBS_#M@J(,WCR6Z!9+$43DGPV29HF]0VV].M1+6V,#O20 8.[RB*V<6>)
M6JO_ !D?&U4_TIU$.IWZ^'M'7Q\.OL^?5:MFM(-X[$$@V)!CEC<$>L<K'<:Y
M-KYW?D3Y^/FUZ?\ ]/\ 3T[P>D'\?]FAG4#?I\C#6P&SIQ+D;&BN5?/CT0S/
M\JB>?^"SKR90/0?G'K_7YCJEER,$0)8J /7(B^GVGP]6E2!QGH3E3VZVXE8O
M_#BJB4C_ "?[Z]OMI_E5?"?CZ\]^OL'QD?-L.O\ 9T/IU:K'%&-@^RMTD(_<
MO;BYMAX^8K<Q]70:7M5P;=D.:I%:^%B^%5]@=#"U/Z%B%5Q"?-4\HL?V)X^:
M^?,MK Z[-U]&P^+IUW]O]>L>M\>48PPCLAR/!:U=W8CV/,!%U_XQ\G33J4O"
M@@2L<86+ K?'J96B^J1W]'QA*->GA?E\X'>?FOR5>I!F8^DGXSX?)X>CY>NL
M4O<<RS<P@@E<'P:U,=AZ.L,1(^:4;>W3G5F,SU5Z70@,(F;X_P!T&K\3)Y3[
M'-:]/9C=_3%$Q>I9=CON3L=]P.@Z^S^W6*VLWDK>XDL-&A_[. =TGQ$KY[#V
M.[:5*(B)X1/")\D1/L1/R=>=6K1TTT=--'331TTT=--'331TTU'OMYJ[.J!Y
M9;9UQ]:X[G'?6(33PR W&5Y3*;X8\5"(XU(#(]N3V"HD?!+Z'^V]WI=XJK3*
MQ@Y2#M7C!V(.Q!;<';P(](\=;'[2+=2W8X/-2S7M"#@/AZM.:\T<PALQ->[V
MO*8V81SQ\R]Y$_+(G,O,HW&L[DGA8;8'27E*9#57,S6H;$3&]U?8/8U&,G>Z
M%'S"DHQK62RQQ3LF:QJNA;+ZY9/,4YC'*PYE]'K'K^,:IN&>-Y<- M"]"]ND
MA)@:)E%BN&)9HU#E4EBYB2BL\;(6(#E.5%9[[W;=?\NS2_\ [_8__EJ>I_E4
M?VK_ #+^5K,O?(P/\'RG\WJ_INC[W;=?\NS7^OV'[)Z>51_:O\R_E:>^1@?X
M/E/YO5_3=.QQSPA!E;&&]T!H]I:BKZP11&2?5X4_A40I9)V1S%D,1?X!7001
MP/\ ,J-DE2)\4F6P7'*H*J?$GQ/LZ= /7X[^O;QQ'B7CJ3+5GH8Z"2I4F'+8
MEF9?*9TW![H+&62&-MOKFTDC2#S-U3G5W_ZIM:]T=--'331TTT=--'331TTT
M=--'331TTT=--'331TTT=--'331TTT=--'331TTT=--'331TTT=--'331TTT
M=--'331TTT=--'331TTT=--'331TTT=--'331TTT=--'331TTT=--5Y=]G_T
M<=B__KC\:_\ X(_K:W9G_J[M*_\ =_F?QQZU!VI_ZT[+?_>/A?\ P3ZL-ZU3
MK;^CIIHZ::.FFCIIHZ::.FFCIIHZ::.FFCIIHZ::C9SW_P#17V^?YWZC_P"M
MY.JFO]A9_P#8-_XEUL_L]_U1VC?\F7/_ )BZDGU3:UAH^W[>FFN/H9_Q6_\
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M)_QH<;'_ />_$']6&&A3/HT'?QN^'N6=_EY Y97_ *^..H=WVPCP[..#Q_\
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M4<U?IX?)U>8]S/#>G6M#,Z;[&6G/,EB&0#O%"R1 ]W-*CS0^F5YTU5ERCF.
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/HZ::.FFCIIHZ::.FFO_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gwpjrhodncoa000016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'W!XP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X'P=X\O?%WB_6;."
MUMQHUCD1W"[O,<[L+GG&" QZ=JZ+QE?OI?@O6;R(E9([23RV'9B, _F17#?
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MUZ!XI^)FB^&-1&F-'=7VI$9-M:(&*9&1N)(ZCG R: .SK$D\7:'#XE3P[)?
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M]F/S?^.[JR?A_I\=C\$Y'5</=6US/(?4G<H_\=5: .F\&>-K#QM97-S8VUS
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M$VI:/KMEJ,GC&[N4MI1(T!@91(!_"3YAX/T-<I=W*>'/VC/M6H,4MY9N)7'
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M=6DN;IXMK7UP"Q=M^_)Y)]NIXJWX'\-R^$_"MMI$UPEQ)$SL9$4@'<Q/?ZT
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M@E3_ 'AC[OO0!2\?^/;GPYK>FZ+H^FP7FLWBCRFG/RH';:HX(/)'J!P*\O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;VWCG2&6XFC609 <. #COC)I_CN"*S^/'AQ[>-8FFDLWD*#&XF8J2?P 'X4
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M"VJQRP6C(JAXI<, 6.[@ KU&3[5RWPK^)B+%#H.LS:I?:E>7N()Y&$JJC*H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>A!7ID@Y&*])^"WAN[\,_#NWBOH'@NKR9[N2)QADW *H([':JG';//->A44
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MC]* />J*\D\.?'O1]3U&+3-:TN\TB^D<1C/[U-Q. #P&&<C^'\:];H ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#S_ .-O_)(==_[=_P#T?'70>!/^2>>&?^P5:_\ HI:Y_P"-O_)(
M==_[=_\ T?'70>!/^2>>&?\ L%6O_HI: .@HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHJ*YG2UM9KB3.R)"[8'. ,F@#S3Q?_R7/P%_URNO_1;5ZA7QQXA^*?B+6O&=
MOXBCFCM9K%F%C&D:L(4/!!R/F)'4G]*^HO 'BA_&/@NPUJ6%89YE99D7[H=2
M5)'L<9]LXH Z6BBB@ HHHH **** "HKBZ@M(O-N)DBCSC<YP,U+45Q:P7<7E
M7$*2QYSM<9&:<;7][83O;0RM0\3Z;:63S0W,5Q*.%C1\DG_"N<L?'-W]L47L
M<1MV.&V*04'J/6NCO_#&FW=G)#%;16\A^[(B $'_  KGK'P+<B\4WLT/V=3E
MA&22WMT&*]3#_4O9RY]_/?Y'!6^M<ZY?P_4ZK^WM)/\ S$;;_OX*T:SO[!TD
M?\PZV_[]BM&O.J>S^Q?YG;#G^W8BN69+69U.&5&(/OBOG2R\5^)8OAF?&#^/
MI5U**XV)IUPL3+, X&T#&[.,GZ ].H^B[E6>UF11EF1@![XKP#3?A/J47PN@
MO[?2WLO&=A=FY@;(WR*&X4\D'CD ]P!T)K,L[6[\3ZT?BQX)TXSR6UIJ.FO/
M=V8'RF3RY&YR,\$#\JM>.M<U;P?XPT'6VO)#X:N7^Q:A V-D+-G;+GM[_P"[
M[UB>((O$LGQ \'^+X_#%]<BUTYQ=VT)0-'*ZNI7).."WY5T?B^/4_&/PHU:%
M=!N;;4)T CL9RADRKJ0>#CMD4 1?#C5]7\6:AK7B>XNYAHD\YM]+M" %\M.#
M)TSDD?@=WM6]XX\3_P#"*^')+J&,3ZC<.MM86_>:=^$&/0=3["JND>%(KOX:
MZ)H.I)<6C165N)DMY3$ZR*@W#<O^UG/K6=J7PLM;G^R#8:YJEB^E/+)!(9!,
M^Z3&3E\^G% '%^&O&WB70-+^(4FO:I_:5UH0@2 RJ @E<R+T&,C=M[]NU32:
MQXQ\)VG@_P 0ZEXEEU*+6;B&*^L98(U1!*-PV%1P5&>G4CTXJGI_PL\1W<_C
M^TO;V[\N^"BUEN-FR^<,SJ[XY&"%Z8^^:OC1_%WBZT\(:!JOAN73(-%GBFOK
MV6=&63RAM 0*>2PS]"?2@"R=4\5^--7\7W&E>(I-(L="D>WLX884832H&W-(
M2"<$@?@>G'.5<_$;Q!JWACP;=SZB^AZ?J#S1:IJT%N)-CQL54=,(&(!_$]E.
M=--,\6>#-9\86FF>&Y-7LM=E>YLIX9D18I'#960$@X&X>GW??C-D^'^O>']/
M\'PSZ.?$6E:?'*]_ID4RA?/=F8-M;AP-P Z_=/3- '7?"K6=<U9]>6^U*35M
M'M[E8],U*2$1FX'S;^F-P!"\XZD\]A!XB)UOXZ>&=)D^:UTNRDU)D/0R$E5/
MU!"D&CX6^&]7TC6_$>HSZ2VAZ1?RH]II33!]A&=SX!PN?3\.BBDU%SIW[1>D
MRRJ1%J.C/;Q/CC>K,Y'Y*/S% %+XGGQ;X9T&^\30>-9(6CN@+:P2TC$?ELV%
M3)!+,!\Q)]#Q7I?A^\NM0\-Z7>WT0AO+BTBEGC"D;'9 6&#TP2:\CUN+Q/K?
MQ":_U_P?J=_HNERL-,LK9H_+=@<>;(2?FS@''3MZY]BTR[FOM-M[J>SELI94
MW-;RD%XSZ''&: /.3\;-/_LNXU*+P[K,]G9S&*\GCC79 =V!\Q(!)X.!TR,G
MFM.R^*VG7FNZ58G2-5M[/5F*V%_/"$CG([@$[@#Q@X[CC!S7'Z/X.\06_P &
M?&&D3:7,FH7NH22V\!*[I$/E8(Y_V6_*M#6O"NN7&F?"N&'3I7DTB:T:_ (_
M<!!%NSSVVMT]* -27XQ68.K"U\.ZQ>?V3/+'>-!&I2)$./,+$XY^; ZX4DX%
M9/B;Q9!J/C3X<ZO8:A+#I5XMQ-)F0HNT*,[QG''(.>F#7->&=0\10#X@V&C>
M')-56^U*Y@66.94\F1BR_."1E<'.1Z8.,U<O?A/J,UEX T&\M)+BSM([D:C-
M"X @:0[^OL3QZXH ]6\(>+H?&5G<W]E8W,.G),8K>YF  N0"064=0,CO_0UR
MNLZ[K_B;XF3^#=!U7^R+/3K99[^\CB625RVTA$W<#AEY]C]#J?#*#Q!I&CS^
M'->LY!_9<GDV=[QLN8.=N,'(( []B.^:Q=6T/Q'X6^*=WXPT723K&GZG;+#=
MVL4JI+$P"C<H;J/D!_$YQP: %T_6/$GA'XG:?X6UC5VUK2]6@=[6XFA5)874
M$D$KU''?U&,8-9'@^+Q?XS3Q!=P^-KZQFLM2EMK>/R8Y(L#!&01TYQ4%UK-Y
M<_&/0=:\7Z5=^']/@A:'31(/-669\KAW3(4G=G'^R,\<U/X/D\7^#%\06D/@
MJ^OIKW4I;FWD\Z..+!P!DD^V: ([[6;[QW\%O$D>L1QQZWH4[+))#\H\R$AM
MZ^A(W#CWQCI7JOA356USPCI&J/@275I%*X!Z,5&?US7FCZ!=>"/@GXJN-=DB
M;5-4\V>Z\MLJLDN$50>_4'ZD\XYKT#P!8R:;\/M M)E*2I8Q;U/56*@D?@30
M!T=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>5:W\6Y++
M6]4@3PS<WOAO39C9ZCJ"'.R3HPVXP0"<'GOVXSZK7):)X(30_%FNZI#?22:?
MJY\V33W7,:3$Y=_0Y^GY\8 .3\+_ !#O;/5],TO5? Q\.:7JCB*PFC 5 Y^X
MC+M !/0=#[=<>LUP?BSPY9-XITWQ3KVOBTT'1U22.QD.V+[2&.V0G..ZX&,Y
M'O@S?\+=\!?]#);?]\2?_$T =9>Z;8ZBBK?65O<JC!E$T0?:0<@C/0@\YJU6
M?HNN:9XBTY=0TF[2ZM&8J)4! )'7J!6A0 5AZ]XQ\.^&)(H]:U>VLY)1E(W;
M+$>NT9./?I6Y7FOC'P;X8L-1U/QCK&F:CKUQ<QK +%4$P3@ >6H *\+UR<9)
MH ]"L+^SU2RBO;"YBN;64;HY87#*P]B*P[;X@>$KS6/[)M_$%C)?%]BQK)]Y
MO0-T)]@:\C\&27&A?LX>(;RWU*.:64R%%@ER;7>$3:<?=;!W8_VA6;K/@W0[
M+]GC3M>M[)(]67R;@WB\2,SR8()] #P/84 ?0NJZMI^B:?)?ZI>0VEK'C=+,
MVT9/0>Y]JJ:#XJT+Q/%))HNJ6]Z(L>8(V^9,YQE3R,X...U>.^.+Q_%NJ?"S
M3]2W-9ZG'#=W40;B1G$><_@6&?\ :-6WTVQ\'?M):+::):QV=IJ>G'[1!$,(
M<B7H.W,2'CN/>@#T[6/'7A?P_J"V&JZW:6MTP!\IWY4'INQ]W\<5O0S17,$<
M\$B2PR*'1T;*LIY!!'45X'\.?#6D^.8_'&KZ]:+>7D]W)&DDIR800QRGH1D<
M]@H%=7^S]J4]_P##3R9F)%E>RV\9)S\N%?\ FYH ]4KQ_P 0_P#)T/A/_L%/
M_P"@W5=!_P +M^'G_0P_^25Q_P#&ZXA?%.C>+?VD/"]_H=Y]KM8]/EA9_*>/
M#B.X)&' /1A^= 'N]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !12,RHI9B H&22>!7/W_B^PMI/(M ][
M<$X"0],_7_#-7"G*;M%&M*A4JNU-7+/B+6QHE@)%4//(=L:GI[D^PKS_ $K7
M[C3-6FOMBR&=B9E/&<G)QZ<U3^(/BF[TIM+F\00&V@NGD6$(H/EX"Y+#.[G(
M_+H*P-3\0Z;I6FK?3W"F*1=T(0Y,O&1M]>WYUZ5"G2C3:DUYGT6!H8:%"4:C
M3?VM?Z_X<]_MYTNK:*XB.8Y4#J3Z$9J2L7PA=/?>#=%NY(?*:>RBD*9SC*@_
MKUK:KRW:^A\U*W,^78****1(4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<+<6<X)CE4$!L$@]0#U!H NT444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !61K'AK3-<O]+OKV)S=:9/Y]K*CE2IXR#CJIP,C
MVK7HH **** "BBB@#&T+PQI?AR349-.B=&U"Y:ZN"\A;+MUQGH*V:** "BBB
M@!KQI*FR1%=?1AD4ZBB@#)\1>&].\4Z:NGZK&\EJ)5F,:N5#E>@;'4>U:H
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M6[$$QGD[2=IR,_Q$]ZZ^\L+#X<?%C08/#]N;:RO],GCNK=6)64Q(S(QR?O9
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M0!C_ /")^&_^A?TK_P  H_\ "M*UM;>RMTM[2WBMX$^[%$@55YSP!P.:FHH
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MW^5N#DL?I69XD\$^.-23P\4UW2=8ETRYDNI3J=NUO'-)QY9,<0.=HW=QU[T
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M.7]I:4R1*_EZ('4LN=IW 9'IU(_&@#HY?BQX$BMK6X?Q):[+G_5A5=F';YE
MRG_ @*T-5\>>%]#NQ:ZEK$%O*UH+U=P8AH2VT,K 8))Z ')]*\<T"QMA\*/B
M61:Q K?SH#Y8X"[2H_ \CTJI;ZO8:-XY^'NIZQ#)):6_A>!G=8#+Y0'F@.5
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MV33K$SRA;>2<RD'/)W'UKN:YKP'XJ@\9>%XM8MK$V4;R.@A+!L;3C.0!72T
M%%%% !1110 4444 %%%% !7C_B'_ ).A\)_]@I__ $&ZKV"O'_$/_)T/A/\
M[!3_ /H-U0![!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M67GT.15NBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2(&(4AF.W/3ELY'H/05O_L\WDMS\-9(9#E;74)88QZ*51_YNU 'K%>/^(?\
MDZ'PG_V"G_\ 0;JC_AH[P?\ ] W7/^_$/_QVN<TOQKIOCO\ :(\,ZII<%W#!
M%92V[+=(JL6$=PV1M9AC#COZT ?0=%%% !1110 4444 %%%% !1110 4444
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MK&ZN(!(;6/,CEMH+!5 R0,\G&!WQ7,?''$GA;1+>0_N;C7+:*93T9"KD@^W
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M6+#U4;>O0D\=*^@: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX/O0!VE%>:CXQV'F_;&T74%\.&\-D-:)7RB^<;MN<[/]K],\5Z50!Y_\;?\
MDD.N_P#;O_Z/CKH/ G_)//#/_8*M?_12US_QM_Y)#KO_ &[_ /H^.N@\"?\
M)//#/_8*M?\ T4M '04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG]GH6I7_ ,:M0\17MHT.GV&GI96,CX_?,QW,P]@2X_$5Z!110 4444 %%%%
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M'_+2;YC^70?E67)3A\3OZ?YG-['#TOXD^9]H_P"?^1E?V[KNL_+I&G^1"?\
MEXF_F,\?SJ2'P>UU*)]:OY;N3^XK$*/;/7'TQ7544>W:T@K?G]X/&RBK48J"
M\M_O*UGI]I81[+2WCA7OM')^IZFK-4]2U;3M'MC<:G?VUG"/X[B54!_/K7G.
ML_'CPM93?9='BO-;NV.$2UB*H3Z;FY/X UBVV[LXY2<G>3NSU*H+N]M-/MFN
M;VZAMH%^]+-($4?4GBO(/[8^,7C+C3=)M?#%D_2:Z'[T#WW M^2"I[3X%1:C
M<+>^,?$NI:U<]2@D*H/;));'TVTA&KKGQR\&Z2YAM+B?5KG.T1V4>5)[?.<
M_AFL/_A+OBQXPX\/^&8=!LWZ75_RX'8C>!D?1#7I6A>#?#GAI0-'T:TM6 QY
MJIF0_5SEC^=;E 'CL/P3O]=F2Y\<>+[_ %1P<_9X&*QJ?0%L\?15KO= ^'_A
M3PSM;2]$M8YEZ3NOF2_]]MDC\*Z6B@ KYQ^*GBW6_'&BIHD'@K6+;[-?";SS
M$[APJNG "#KNSU[5]'44 <)X%\>WWBJ^FL;KPKJ.D+!!Y@FN@VUSD#:,J.><
M_A7=T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X1\4= U_3-6\0RZ0^
MF3V/B:&!;J*YN4BFB:+@%-[*"#^/4\< UT_PTAU/5/$^L>*M?N],74[R%((K
M"QN$E\B%3U;:S=3CN>_3H.5\5:;X,'Q>UT_$"\)BN;>WDTW;,^V-0I#JP3E3
ME<C. <D]378_#BR^&UKJUVW@JX62\,&)P)96Q'N']_CKB@#TFBBB@ KQ3QGH
M\6L?M":+8ZC/<PV-WI13]S,T7FA3*WE[ACC(!(^GK7M=8?B3PAH7BV""/6K%
M;@V[;H9 [))&>,[64@C.!Q[#TH ^?]>N=2F^%/BO23=3WFGZ+XA%O;3RR;V,
M(9E"ENX!VG_@7TKT'QJ'U#XS>$X]/D#S+IEW*2ASA&B<*<CL3P#7H-EX1T#3
MO#C>'[;2X%TIU(>W8%@^>I8GDGIR3G@>E5/#?@'PUX2N9KG1M-$%Q,HC:9Y7
MD<(,84%B2!P.!Z#T% 'B@FB;]E180ZM*UYY00')W_:-VW'KMY^E>D^/T^(\6
MGZ%'X(.95B=;\_Z/U CV?ZW_ ('T_'M6T/AEX/'B$:X-&C^VB7SQ^\?RQ+_?
M\O.W/X=>>O-=;0!\P>-O^%R_\(A??\)7_P @3]W]I_X\_P#GHNW_ %?S??V]
M/Y5[_P"!/^2>>&?^P5:_^BEKG_C;_P DAUW_ +=__1\==!X$_P"2>>&?^P5:
M_P#HI: .@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJ6J:QINB6ANM4O[:S@
M'\<\@0'V&>I]A0!=KR'XZ2>#[;3;6?7K.:\U9HI(["*&9DVYQEVP<;0<=0<]
M/7&A<_&"/5+A[+P1H&H>(;D':9E0Q6Z'U+L,_F!]:\]^(_@'XB>)+/\ X2?6
MDTYYK:(J;"R8Y@B&6)R>&(.<X)H R/AGXJ\*^'H+>XMO#>IWOC!-\4*V\A9+
MG=GMGY<#@_*>F?7'J$7@7Q1X]F2\\?Z@;33L[X]"L'VK[>8PZG\2?0KTK@_@
M/X!U2;7[7Q?<IY&FP))]F)(S.Y#1G [*,MR>X YYQ])T 4M*TC3M#T^.PTNS
MAM+6/[L<2X'U/J?<\FKM%% !1110 4444 %%%% !1110 4444 %%%% !112'
M[IXSQTH I?VUI7_03L_^_P"O^-6X9HKB)989$DC;HZ,"#^(KS.]O-.36+<G1
MUACBW":W+_>/;/IBO0M(*'2H#%:_94()6'/W>3_/K^--SI-1Y+ZJ^J:TV/0Q
M>#5"$9*^O>WZ/_@%VBBBD>>%%%% !1110 4454U'4[+2;7[3?W"6\.X+O?ID
M]!32;=D-)R=D6Z*X[6OB/H6GZ5-<6-[#>W0&(H4)^8GU]A7#Z1\6]6354.J)
M!)92/AQ''M:-?5?7'H:ZZ> KU(N26W<[Z668FK!S4;6[Z?<>TT5SP\<^&"0!
MK5KD^Y_PKH:YI4YP^)6.*=*</C37J%%17+%+29E.&5&(/IQ7COA'XEW&A?";
M2]=UXW>J27.J-9M(7RZ@[CGWP%/%00>ST5PFF?$B2\\1OH-[X:U'3M0DM&N[
M.*X=,W"C.!P?D8X/!Z8.<5Y;X?O;O6+KQWK>MZ=JI:!+M&N(M0"_9%VL/("\
M@D#HV"!B@#Z-HKS/2_'%MH7@OPC9Z9IFHZI?:I;8L[1I5\QE1<L7<X' ]OY4
MR+XP-_PC.N:W=>&;JVCTBY2UDB:Y0LTI8*R],@KD=L'- 'I]%<9;>.KVYT27
M54\):PT;R(MC$JJTERK@D.1G]VO');H"*K:7\1;J_P!2U+19_"][::]9VGVN
M.P>>,^>F0/E<< Y8=?Z4 =Y17C'AGQUKGBCX8:[=>(--N3:I8W+'4K66.+?C
MCRU4#*L 3\Q!'%:MC\0K#PKX2\%6\6FZG?1ZM;,D"[Q)."@7"G@;BQ8#M0!Z
ME17 67CZ/78O$NCZCI%]I.HZ;9/+-;O*I8QE"<HZY ."/S'6O,M1UN.R\&?#
M'4=-.K2VJ:I(YA>3S;B4+.,I\N Q."%'H0* /HRHKBY@M('GN9HX(4Y:25PJ
MK]2>*Y'PUX_&M>)KOPYJ.BWFCZK!"+A8;AE<21\<AEXSR./KZ'&+\8V>_@\,
M>' 6\K5]7BCN /XHE(W#]0?^ T >F*RNH92&4C((/!%+7G7Q(N[72WMY-1\<
M7OAZS>W9;>VL8,O+(I^9MP!)&&0;>/KSQR</CKQ9:_!?3;VXNU;6M5OULK2[
M8*66-LX<@<9&".1GD$T >XT5Y1:W.O>#/BEH>@W7B&]UG3=9MY"PO-I>*503
MN4@<#@#&>YZX%=?XV\:V_@BST^ZNK.>ZCN[Q;7$'WER"<@?Q'CIWH ZBBO-D
M^+$W]M2Z'-X.UB/66C$MK9[HR9D/\1;.$ '7.>F.O%/'Q=L!X(N_$<FEW436
M5Z+*ZLY& >)\C/..0,^E 'HU%<%IWQ.CN?$VGZ1J/A_4=+CU12VGW-UMQ. ,
M\J#E#TX//(SC-<1X;\<0^%-:\>RWGVB]N)M?:WL;&-B7F<R.-JCL.G/T'4@4
M >Z452%\\.C?;[^#[,R6_G3P[P_EX7++D<''/->6^$8/%/Q)TB;Q+=^++[2(
M9YW6QL]."A(E4X^<D9?D'CVZ\X !Z_17B</C?Q%-\,/&EM?WA&N>'YS:_;H
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MY(G^VSV_E@C$9ZYJHI-V;L73C&4K3=EWW-"\NX;"SENKAML48R3_ $^M<?\
M\+!_TG_CP_<9Q_K/FQZ],?A3M3\&S)I\SV]_<W$BC<(G/#8_K7$>5)YOE;&\
MS.W;CG/IBO0P^'HR3;=_P/>P&!PE2#;?-]ZL>RV=W#?V<5U;MNBD&0?Z?6IZ
MXK3/!LS:?$]Q?W-O*PW&)#PO_P!>M[1]#_LB25_ML]QY@ Q(>F*XZD*<;\LK
MGE5Z-"#ER5+VZ6_4UZ***Q.,\E\%:'XF\4>#=-UN?Q[K$$UW&7,:1Q%5(8CN
MOM70>"/%-R_A_6V\2:C;RG0K^:SFU(*(TF5 #O(' ;YL$"N4^''PXT76?AYH
M]_=7.JB2>)BZ17\B)]]A@*#@"MSXA>%8=,^$T^D^';)X;6TEBF>"V7>[1K(&
M<_-]YAC=SUQ0!N:'\2/#/B#4X=/L[J=+BX4O;"YMI(1<*!DF,L &XYQUQ4>I
M?$_POI5Y?6=S=3F[LI#'-!%;M(XP 2V%!^0 CYCQ7!63Z#X@UOP_&GQ%U;6[
MA+V*ZMK1;5249.=SX0; !D'..":Z_P "01?\)GX]G\M?-?4T1GQR5$0('TY/
MYT 6;CXL^#K<V['4WDAF6-S/%;R-'"'QM\QL80G(X/([@5L?;X&\=162ZE<&
M5]+:=;((#"R^:H\W=_>Y QZ&O+M C1?V5+AE4 O:73,0.I\]QG\@/RK?:WGN
M_'-M;6S;;B;P5+'$<XPQEC Y^M &M<?%_P &6\LZMJ,K10EU^T+;.87=0245
M\;2V <<\]LY%:^K^.=!T33]/N[VYD']HH'M((H6DEE&T-PB@G@$9/2O*[OQM
MX5M?@9)X;F=8=6BT_P"Q2:<T)\Q;E1AF(QQ\V7W?UK8UKQ1=:3%X2TN/6;'P
M]%<Z*LO]KW5GYYW!4'EIG"C@Y.?;\0#L+7XCZ!J6BZI?V,MS(^FJ#<6S6SB:
M,G[OR$9(^E8?A_QPNO\ @'2]0OM0OK.[^UVT-Q-':[1+([C"+D8*-G!(Z"N?
M^&^I+JOC_P 53)K<VML^G1JM[);"#SMI8'8@_A!X^M-TW5K#4O@SX4BL[E)I
M+/4]/AN$7.8W$PX(H [_ %?XE>&]%U:\TJZGN&U"U*![>"V>1R&0/D!0> &&
M32W_ (JTC5O!D&MV&LSP6,US"BW-M'E]QE5=A5AQD_*?8YJEX5@B_P"%H^/K
MC8/.,EBF_OM^S X_.N)C 7X;:Z   /&& !_U]QT =3J'CJ#P[\2M6L]6OIOL
M0L;<VMG%&9'>1BV[8BC)X'/85V/A[Q+I/BG3C?Z1=">%7,;@J5:-QU5E(!!^
MM>?W7B'1O#GQPU6ZUEQ;1RZ5!%'>/&2D9W,=K,/N[L<9Z[?I6I\/;J'6O%GC
M'Q%IT;C1K^>VCM9B"JSO$C+)(H/8D@9[X]: .@\9ZU<Z/H\,6G[?[4U&YCL;
M(L,A9'/WR.X50S?\!QWK!UN;7-2\76/@W1]:GT^*UTX7E_J C22:4%MB(">
M20S$X_PJQXW!B\6>!KN1L6R:H\+<<;Y(7"?J"/QJCKFL6W@_XK1ZMK$GV?2-
M5TM;1;ME)2.>.1F"L0. 58X/M^- &EX-U+5X-=UKPMKE\-0N-.$4]M>[ CS0
M29QO4<;E*D9[\4_XEZS/H_A6,6NH_P!G75]?6]G%=94>7OD&XY;C[@?K67X2
MU*UUKQIXH\7V[,-$6VAM(;MP52;RMS2NN>=JD@9[\UH>+];\,OX?TO5M6TY-
M6T)[E'%R(_-CM\@A967NO4=#UH K>"?L]WJLD]G\1)_$*PH5DM&>(A<]&(4
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M.30!ZO1110 4444 %%%% !1110!Y_P#&W_DD.N_]N_\ Z/CKH/ G_)//#/\
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M 4M% &5XCT.'Q%HDVG2R-"S%9(9T'S0RH0R./<, <=^G>KJ0M-8QQ7Z0RR%
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MN'E5HR00R[CTX'YCD@T >O4444 %%%% !1110 4444 >?_&W_DD.N_\ ;O\
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MZ>E=!IU_;ZKIEKJ-HY>VNH4GB8@@E& (.#TX- %FBF32QP0R32N$CC4N['H
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M-I"JR?Z*ZG<A(&X'."!G/TH WJ*@LKR#4+"WO;6026]Q$LL3CHRL,@_D:GH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.6S[$T >JT444 %%%<IX^\3S>'-#6+38O/UO4&-OIT &29".7/\ LH/F)/'
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MVF@#C/"OPP\.^%I1>+ ^H:J3N?4+T^9*6]1GA?J.?4FNSHHH **** "BBB@
MHHHH **:[K&I9V"J.I8X K*NO%&CVF0]ZCL/X8OG_EQ51A*7PJYI3I5*CM!-
M^AKUQ_C>6>W-K+'--&A#+^[FV9/TZFI+CQH3Q::=)ST>Y<1#]>OYUY[XXUJ^
MNY8+F;4((=B%5B@0L"<^_?WZ5%2<*+]^=GV3C?[F>WE.65I8F/.DEYZ_D==X
M-N+FZU==]Q<2!$8N'GR/;Y3R:] KY[\+7EU<ZBK'4)-RJVZ)6$38QU#],5N7
M^MV<#$2ZIO8_P?:3.3^*#'YUC4Q^'YG)REKTM>WE=:?)N_<[\PR2=3$\L7TZ
M)_U^A[.S*@RS #U)J![^SC^_=P+VYD KQ>"'6M58'3- O90W_+6<>4A_%C@_
MG6Q:_#WQ/>X-[?V>GQGJL2F5Q_3]:<,33G\,9?<E_P"W'#/)J%'^/74?S^Y-
MO\#T>37M(B7<^IV@'KYRG^M<5XW^(UE;:,T&@:C'+?RN$+Q@GRTYR0<8ST'X
MU:L_A1HJ,'U&ZO=0?N))=B_D.?UIGC'0O".A^%]L^DF*.641)+9Q*TRM@D'+
M$$C@]ZFLYN+M[J\W_D@P=/+(8F"7-4=]K*WW;OTLCROPSXMU;P_JQN;:1YQ.
M^9X)&)$Q/K_M<]>M>H"]^).K@>196.E1D\/(,N/J&)_E7GG@S^PH/$D,FHQ7
MTI%PJVJK$NTDMA6?+<8XX&:^AJY\'3;@[R^2/6XCQ=*AB(\E%.36\E^2V=O/
MT//O^$"U_4P3KGBZ[D5OO0VV50_J!_X[6A8_"_PO9\O:2W39SNN)2?T&!^E=
MC177["GO;]3YN>;XR2Y8SY5VC:/Y6*=EI.G:<,65A;6W&/W42K_(5<HHZ#)K
M1)+8\^4Y3=Y.["LWQ"JOX:U561W5K.8%4&6(V'@>]/N-:TNTS]HU&TC([-,H
M/Y9KG]9^(N@Z?87#6MZEQ=JA\J-4;#-VR<8QGWI*4)ODO=OIU)I5HJJE%WE?
M;J>-?9=,\_R/[/U/SL9V;/FQZXS7T'H"+'X=TQ$5T5;2(!7'S ;!P?>OG?\
MX2?6/[=_MG[;)]NS_K/;^[CICVKU2S\6>-]<LXI]*\.6T<3J/W]Q)\K>Z@E3
MC\Z[)9/'"V<%:^]Y7^6MOP/I\X>+KQ@JMDEU<MGVUM^%ST6J.I:QI^D0/+?7
MD$ 52P620*6]@#U-<3+X8\>:M_R$?$T5M&>L=IE<#T^4+G\S4<'PBT]6,M]J
M=Q<,>68( 3^9-9-4H;MR]%^KM^I\_)4:>[<O\*_65OP3/-]5\8ZMJ?B&/6#<
M&*>!C]G" 8B7G@>O7G/6O=/"&MR>(?#-IJ,R!)G!60+T+*2"1]<9KP#4;&QA
MU?R+74(I[5FXF4$#'N",C_/6O>_!-K:6?A&QBLKA;B':Q\U 0&.XYQGGKD?A
M7H8^I3E2@HTW'U5K;Z>O_#]=?4S.M2G1IJ%)Q]5:V^GK?7\>JOT%%%%>4>(%
M%%% !1110 5GZG<:E (O[.LDN2<[]T@7;TQU/UK0HJ*D7./*FUYK_@W*A)1E
M=J_J<)XEU'6S8QQ7EF+2%VY*2!M_L<&L;0;R^M=4C^P*99'X,6<!_K7IUU:P
M7MNT%S$LD;=5-5;#1=/TQV>UMPCL,%B23C\>E>)6RJO/$QJJIHNKW^6ECV*6
M9T88=TW3U?3I^=RI:WNOR74:7&DQ10EL.XF4E1ZXS6W117LTJ;IJSDY>MOT2
M/)J5%-W44O2_ZMG)?$__ ))EXA_Z\WKGOA5'KAT+0VN] TF'318H8KV*7,[?
M*-I(V\$CKS7=^(=%B\1>'K[1YY7BBO(C$TB 94'N,USOAOP'?^')K%$\7:I<
MV%FNQ+*5(Q&5"X .!G X[]JU,SC_ (>:QXGUG3M6\2ZGXBGDL=&N;B,6"Q)^
M_P!B%SO;&?XE QTV^]<CXBE\5>(_@I/XMU+Q(TUO>W'[S3?LR+&B+/L4*1R"
M&7/N#SSR?;?"'@JR\(:1?:;!/+=0WMU)<R><!U=54KQVPM<I)\$M,?2;C1_^
M$@UG^R6<RV]B9@8X')SG&/FQS@'CDGD\T 1>+-?%A'H-@?%UYI1DT]'%EIMA
M]HN)CC[Y.#M48(QWY]*X'6=>UCQ;\#M6NM2U:XEDTO4_L[$PK']JC+1[/,7L
M023Q[9S7K^L?#F#4=6L=6L=:U'2]1M;061GM&7,D0[$$'G/?_ 50C^$6F1>#
M=7\-+JE\UOJ5X+MYY-K2*05.,XY^[U/K0!S^N76K^&H?AM91ZQ/=?;-2B6:2
M>-"61C&-G3@ ,0".:B\%Z%?_ /"YO%O_ !4-]_H<EM)-\J?Z4"I(5^.@''&*
M[_7/ UGKDWAN2:[GC_L*X2>$(!^\*[<!O^^1TJ-_ 4*>.9?%%EJ]_9RW)C-Y
M:Q,OEW&P87.1D#@9Q[^M 'F'_"8:_!\+O&FI0ZB\=Y::X8H)D1044N@(Z<]3
MUKH%U3Q7H'C?P>+[Q$=2M?$2R">U:V6..$A58>7CD ;P.3G@YZ\;C?"?3F\*
M:WH']HW7DZM??;9)=J[D;<IVCCI\OZUM:EX+M-2U;PUJ#W4R/H!?R5 &)=RJ
MOS?]\CI0!Y5K>LW^H:7\7K.ZN/,M[.6!8$V*-@,C \@9/W1U]*DM]0\4^#/#
MO@'63XB>[L+\VMK+IK6Z"-(70;0IZ[@HZYY//3BN^F^&&GS1^+5-_=#_ (21
MT><X7]SM8L-O'^T>M5[/X2:;;ZGI4T^LZK=V&DR"6QT^>8-%$XY';) (! SQ
M@#IQ0!L_$B9X?AKXB=#@FPE7\&&#^A-9.A:49/A!X<6STFQU.[ALK:YMK>]P
M(_,91N;.#@@.^#BNI\3Z2=>\*ZKI*D![NUDA0GH&*G:?SQ7$^"]+O?$OPMT6
MSN;S5=#U+3&,.^W/E.ICR@#!AAE*X."/Y4 <=X>N;O0_&?CJ35+!--\23:5+
M<6UI9*OV8HB9!5@2=Q(!Z#^(]3@9]WHVF0_LPVNHP6L'VT3+/]I51Y@D,Y4G
M<.<@?+] /2O7/#WP[L-%U>\UF]O[W6-5NXC!)<WS!L1G&550  .!6-!\&=*B
M6.Q?6M6FT&.Y^TII$DJF$-G."<9*]>/ZY- '3ZU?W=K\-M1U&*5H[V+2)9UD
MQRL@A+ _7->.W?B;QWIO@#PYXR'BDSS7UTEJ+&2U00[2K %C]YB3&23Q][C&
M*]XU?38]8T._TJ1VCBO+:2V9TZJ'4J2/?FN1O/A?I]YX'T?PL]_=+;Z7<I<)
M, N]RN_@\8Q\Y_*@#&T;4O$?A_XNVOA?5O$,NLVVH:9]JW2VZ1[) 6!VA>@^
M1N/<>F:X[1=;\>:Q\+-0\6?\)?)!)ICN(H5MT/G;2"QD8CDX;  &/E'K7L-U
MX.M;KQ_8^+FNIA<VEF;18 !L8$L<GOGYS7D7PT^&$FO^!IH]3U/6]-M[B\87
M6GJ1''.$P5;#+D'L3WVCTH A\7^-9K7QEX'\8&P:><Z%)<FWB&1O:*3_ ,=!
M.2>R@FO6_ATVH7/A"UU/4]:.JW&HC[49% $<0;I&@P, =#GG.?I27/P]TJX\
M3:+K 9XX](LVLH;,*#$T91DP<\X"L:L^#O!\'@NPN=/LKZYGL9)VF@@F(/V<
M'JJGJ1]?<]Z .$T6UMO$/Q_\3/K,$5R^F6L4=E%, RQJ0"6 /N2<]MYHO+.V
MT/\ :-T./1XDM5U'3Y&OX8$"JV%D(8@< DHO/J/>NM\0_#NRUKQ!'XALM2O]
M'UE4\MKJR<#S5Z8=2"#QC\AUP*P;3X=:]X;\:0^)-*UE=8DN%6"_&KC,H0L,
MM$ZCC  PO3COQ@ H?"S2M.U2]\=1:A8VUU&VM3*5GB5P1D\<BL_P+;I_PA/Q
M)T&-G?1[2XO(;,E]VU=C<+GZ*?J<UU"?"=[:\U26P\7:S80:G<O<7$-J43)8
MDG#8R.N,U)XAT6R\ _"#5M,\/V=P^^!H46,&26627"%R1U.#GV X["@"W\'[
MR2^^%.@RR9W+$\(R<\)(R#]%%=Q6!X(T:3P]X(T?2IAB:WM4$H!SAR,M^I-;
M] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <1\3-=US0='M9])
MT%=:MY9&COK5H&D!B*^@Z#/<@CVKS'PMKOP8U/41-J/AN+1M1)^:*\9Y+;=W
M YV ?[RK7J?Q$\<3>"--LY;329-3N[V8PPPHY'(4G/ )/3H*\LO/!?Q#^*EQ
M'=:]I^E:#9G!#/:*)]OZR?@S*/:@#W^TN;:\M8Y[.>&>W<?))"X9"/8CBIJY
MWP1X2@\$^&(-%@NI+I8V9VED4*69CDX Z#VY^M=%0 4444 %%%% !1110 44
M44 %>/\ B'_DZ'PG_P!@I_\ T&ZKV"O'_$/_ "=#X3_[!3_^@W5 'L%%%% !
M1110 4444 %%%% !5'5=5MM(LVN+AO9$'5SZ"G:GJ=MI-FUS<M@#A5'5SZ"N
M<TK3+GQ!>C6-87$(YMK8],>I'I_/Z5M3IIKGGM^9UT*$7'VM72"_'R0[2-*N
M=:O1K6L+\O6WMST [''I_/K76T45-2HYLSKUY5I7>B6R[(****S,#S7XS:/I
M*?#77=0&FV2WI$1^T"!!(294!^;&<XKS34/LWB/1_!W@3PW8V::E>6-O+JE]
M% H>-/+!(9@,]/F;U^4=R*Y7XO\ BG4M>\>ZG9W,TBV>GW#VUO;;CL78=I;'
MJQ&<^X[ 5>^ VL3:=\2[>SCC1X]0AD@D)7+* I<$'MRHS[?04 ?46B:/9^']
M%M-)T^/R[6UC$:#N?4GW)R2?4U?HHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ***XOQQ\0?^$+N;.'^PK_ %+[2C/NM5R$P0,'CWH [2H?M=M]I^S?
M:(OM&,^5O&['KCK7AOBGXZWLGAN\BT[PYJFFW4J;$N[A<+%D\GIUQG'O7S_]
MMN_MOVW[3-]J\SS/.WG?OSG=GKG/.: /OBBO!_"WQUOH_#EG%J/AS5-2NXUV
M/=VZY67!X/3KC&?>O1/ _P 0?^$TN;R'^PK_ $W[,BONNEP'R2,#CVH [2JN
MI7\.E:9=:A<"0P6T32R>6NYMJC)P._%6J:Z+(C(ZAD8892,@B@"#3M0MM5TV
MUU"SD$EM<Q++$_JK#(JM8:[8ZGJNIZ=:L[S::Z1W#;"$#,NX*#W('7'2N)\'
MZK%X-\/>)M%OW/E^&)9)(LDDM:N#+%R>IY9>_3%4UOK[X?\ P?DUEXT;7=3F
M%U.S(6 N+AQDE1R=JD#'?;B@#U2L^PUFSU&_U&RMV<S:?*L-P"N &90PP>_!
M%>1:-XRU>P\0Z0L>MZ[K<-W<I;WT%]HQ@1 _'FHP7Y=I_AY&"?2M:QT?7M:\
M=>-H-/U]]&LTO(6,EO"KRR2&!."6X"@ < 9.>O% 'I>I:E#I<$4TZ3,LDR0@
M11ESN<X!('0>I[5<KRBU\5Z[<?#G3+NXOLZC'KL6GSW$:!?.07&PDCH,KUQ6
MK?/XA\6>.=8T;3]=FT33=&C@61K>%&DN)94W_>;.%48&.^?R .RU;6K/14LV
MO6=1=W<5G%M7.9)#A0?09[UH5Y=K\7B"W\/^&K;Q)/!<WL/BJRC2ZA&W[1$)
M/E=E'"L>X'I67XF\;7MWXTU73%UK5M)L-,984&F:;]H>:0J&+.^"% S@+WZT
M >RU2U75;31K!KR\<K&&6-55=S.[$*JJ!R6)( %<W\-O$.H^(?#DSZJLK75I
M=/;?:)+8P&Y0 %9=A^Z2#R!W!J'7)!J/Q5\-Z3(<P65K<:F4[-(,1(3_ +N]
MR/K0!=U[X@Z+X=UC^RKR._DN_)6<I:VCS81B0"=H]0:G\.>.-"\4W-Q::=<2
MK>6ZAY;6X@:*55/1MK 9'3D>H]:Y35;GQ%;?%[4#X>TZRO9&T>W\U;JX,04>
M9)@@@'-,T>YUA_BW:S>+[*#3KV73I8-*2T<213@$/+N?.2P&"!@#&3]0#M4\
M6:5)9:Y=K))Y.B/*EZ?+.5,:[VQZ\5SH^,'A<0B>5-6BMMNXSOILNP+ZY Z5
M@VG_ "*7Q=_Z^M0_])Q7HWA@ ^$-&! (-A "#_US6@!9?$6EQ^'3KZ7(GTP1
M^:9X!O&S/+<=AR3Z8-::.LB*Z,&1@"K*<@@]Q7!?#FUM[>;QAH]O$G]EV^L2
MI#$,;$#(I>,#LH)/'O5OX77+OX0?3WD:0:5?7&G1NW4QQ.0GY+M'X4 =I111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1JS.K,5\TX.%!'/7D_3WKW/3_#^CZ5C[!IMK P_C2,;O^^NM>'_#W1KO5_$
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M'?%.E^*H+FXTF26:WMYC"9S&521AUV$_>'N*Y?7_ !?KU[X[/@WPG%9)=6\
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MS%LK.Y\5WZZEJ*F/3HS^X@/\?^>Y[]*[%5"J%4 *!@ #I0JJB*B*%51@ #
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?I5RT^&OA>U;>]@US)W>XE9L_AD#]*V6$@OXE9ORC&WXO4\V6%4GS5\2Y/\
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M*** "BBB@ HHHH **** "BBB@#S?XR:YKND^'],M= G-K=:G?I9FX!P4W X
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7- "T4$@#)X HH **"0.M&1^= !111D9QWH **,C..]'?% !11D?E10 444
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M'Y44@Y+8ZC '.?O5Z?\ #[Q'9^*?!MGJ=E8)I\;%T:U0#;&P8YQ@ $$\].]
M'445XE_:GB[7=<^(%O:^*)K"VT*1I8$2!&9CARJ;CT0>6>G)W>U94WC#QI;_
M  ZT3Q_/XE9P]XL$FGI:QK&\:LR,6/=F*$GI][C&* /H*LCQ)XDTWPIHSZKJ
MLCQVB.J,R(6.6.!P*\^OM0\3:U\8]4\+6'B"73-/33X[HLD*NZ8"@A,\ DN"
M3SP*XKQ'XBU?6?@YXDL-;NA>7FDZRMI]J"!#*H;@D#OG/X8[\T ?1:.LD:R(
M<JP!!]J9<W5O96TES=SQ06\2[I)97"J@]23P!7FGPU\1:GXTUS5-3GOWM+#3
MB+*'1L .I _UDV1G)YP!W!';FM\:I'N;[P7HD^[^R]1U9%O,/M#*&0!3[8=C
M^% '<Z=XY\*ZO?"QT_Q!IUQ=,<)$DZ[G/^R/XOPJ;6O%WA_P[/'!K&K6ME+*
MN]$F?!9<XS7GWQLT#1M/^'/VZSL;:RO-/GA-G+;1B)D.X#"E<'&.<?[(/:J^
MM+]N^-_@'[;&LAETR5I$D0$$^5*>0?>@#U+2-?TC7[=I](U*UOHU.&,$H?:?
M0XZ'ZU0\)^++;Q7;7SQ6\MK<6-V]I<6\I!9'7KTXQ7!:A8VGA_\ :"\/+HD4
M=L=2LI1?VT"A$90'(<@="2H^NVKG@9OLOQC\?V,>[R7:WN,9X#E22?QW?I0!
MZC1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ' ?%CP9KGCC
M0+73=&OK>V"S[[A;B9T25<< A5.<'!Y':O/4^%/Q=C0(GCH*JC 5=7NP!_XY
M7IGQ'\':IXRTVRMM*UEM+D@F,CR*6&\$8Q\I%>8W_P %/&MK837$'C5II(T+
MB-IID#8&<9R<4 >N> M&UW0?"T5CXBU+^T=165V:X\]YLJ3P-S@'@5T]<!\&
M':7X9Z?.^H/?/*\CO)(265MV"AR<\$$>XP:[^@ HHHH **** "BBB@ HHHH
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M3(JE^.V%[?6NYX"HJ7M;JUK]?\CD6,@ZGL[.^W]:G:T445PG6%%%% !1110
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MNLW%G-?P&5[-V>']XR@$C!R 0&'L<U /"FB+JMAJ:6*I>6 D%O(CL-N\;6R
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M>YX%XL;>DH*8_$\5JQRQS)OBD5U/=3D5E.G.'Q*QI&<9?"[E'2=#T_0_MO\
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MSS4UZ$5+DYTDO7\=#IJ9A*M"*A!J*Z?KYG7P00VL$<%O$D4,:A4CC4*J@=
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MO4/.0&.[<J@CS\QX(Y_'\^AMZU+JD.B7<FCV\$^IK$3;Q3MA&?L">./Q'U%
M%^BJ6G2:C)HMM)J$$$6IM IGBC<F-9<<@'GC/U_&J?A>XU^YT..7Q-9VMIJ9
M=@\5J^Y N?E/4\X]S_2@#9HK$T&X\13W>K+KEE9VUO'=%=/:WD+&6'LS\G!Z
M>G?CU6VN/$3>+KV"XLK-/#ZVZM;7*R$S/+QN##/3[W;L.3G@ VJ*Q;VX\1)X
MJTV"SLK.30GC<WMP\A$L;@':%&>A..Q[].Z>(KCQ';OIO_"/V-G=*]TJWIN9
M"OEP]V7D<_G]#0!MT5D>)I]<MM N)?#EI;7>JKM\F&Y?:C?,-V>1VSW%6KF3
M4ET2:2V@@?5!;EHXF<^69MO"D]=N[C/I0!=HK-T"75Y]"M)==M[>VU1DS<16
M[;HU;)Z')[8[GZFM*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S_P"-O_)(==_[=_\
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MN^IKLZ "BN?\<6VI77@K5DT>ZGM=12 RV\D#;7W)\VT'_:QM_&N(NOB%</\
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MBBH;;=V6E;1!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNUW*4E"9/JP^7T]O;%=-_P )5\1X"/M'@&*0$_\ +'48^GYFO1  JA5   P
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M:9?YI4O_  M7P1_T'X?^_4G_ ,371_V+I7_0,LO^_"_X5%)X=T.5MTFC:>[
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MPJ:J*.IKQ^(=$F)$6L:>Y'7;<H?ZU;BO;6;;Y5S#)N^[LD!S]*Y&3X2^!I0
MV@H,?W;B5?Y/527X+^")-VW3IX\]-EU)Q],DUYWL\N>U2:_[=3_]N+O/L>@5
ME^(=6TO1-$N+[6)$6R08<,N[<3T4#N2:XS_A2?A5?]3+JD [B.ZP#^8KG/&_
MP=>+PX\^A:AK&HW4+AS:W=P) Z8.=@"CYAG\LCKBML-A,OJ5HQ==I-]8V_&[
MMZBDY6V-KP=\0O ^J:\EE8V5Q87DQVP/= $.3_"#N;:Q]/PSSBO4*^3/"7@'
MQ%KOB""WCL[RQCBD!FNWC:/R #R03CYO0>OYU[:/ACJH(/\ PL+Q+QZW+?\
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M'W_RL7?_ ,11_P *L^+_ /T/O_E8N_\ XB@#W^BO /\ A5GQ?_Z'W_RL7?\
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M*/\ A5GQ?_Z'W_RL7?\ \10![_17@'_"K/B__P!#[_Y6+O\ ^(H_X59\7_\
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M#W^BO /^%6?%_P#Z'W_RL7?_ ,11_P *L^+_ /T/O_E8N_\ XB@#W^BO /\
MA5GQ?_Z'W_RL7?\ \11_PJSXO_\ 0^_^5B[_ /B* /?Z*\ _X59\7_\ H??_
M "L7?_Q%'_"K/B__ -#[_P"5B[_^(H ]_HKP#_A5GQ?_ .A]_P#*Q=__ !%'
M_"K/B_\ ]#[_ .5B[_\ B* /?Z*\ _X59\7_ /H??_*Q=_\ Q%'_  JSXO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU.SDL[^T@N[63&^&>,2(V"",J>#@@'\*D@@AM;>*WMXHX8(D"1QQJ%5% P
M.  .U 'D?_"H/&'_ $5G7/RF_P#C]'_"H/&'_16=<_*;_P"/U[!10!\X?$?P
MUXP^'_AZWU;_ (61KE_YUVMMY7FS18RCMNSYK?W,8QWKK_\ A4'C#_HK.N?E
M-_\ 'ZN?'S2=2UGP+8V^EZ?=WTZZG&[1VL+2L%\J49(4$XR1S[BO5* /'_\
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M2=2T;P+?6^J:?=V,[:G(ZQW4+1,5\J(9 8 XR#S[&@#U2BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH HMHNE/JBZHVF63:@HP+LVZF4#TWXS^M7J** ./^*6B:CXC^'&K:3I-O\
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MKFO&'C&W\(VUGNLY[Z^OYQ;VEI!@-*Y]SP!TY]Q0!POQS\$^(O&(T'^P=/\
MMGV7[1YW[Z./;N\O;]]AG.T]/2O7QTKCO#_Q$T_5]/UN>^M+C2KG0R?[1MKG
M!,0P3D$<,#M;&.N/<9H:'\4H=4U32[:]T'4-+MM8#'3+JX*E;C'." ?E)!&.
MN<B@#T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *B^
MU6_VG[-Y\7GXSY6\;L?3K6;XIU231/"6KZI" 9K2SEFC!'&Y5)&?;.*^=(_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y<,P_M*GSF"B
M;0/W(8_>^?H/^^6/X&E^#(9X_%]RC!K6;7[@PL.C=,D>W(KL?$O@O0/%R0#6
M; 3O 3Y4J2-&Z9Z@,I!P?3I6CH^C:=H&EPZ9I5JEK9P#$<29X]22>23W)Y-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1[55>/?:3]"*]+FM;>X*F>"*4H<KO0-M/MFI: "BBB@ HHHH **** "BBB@
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MX=K:99-I]#@\?C5^OF;Q+X<_X4I\0O#^JZ/J%P^GW;$2),PW%%91(C$8!!#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"4\G"EB[+DC!)Z C(S4WPZT34+/XF^(KA_"UUH6GWUABSC:']T@R@ ++E0Q
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M\:]/HH \D\)V^J>'/C%XI6\T/4Y+769U>WOH;<M;HHWMEWZ#[P&.3FO6Z**
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO[/P]8Q72MN1]F=A]5!X!^@K2U[PUH_BBTCM=:L8[R"*3S$1R0 V",\$=B:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gwpjrhodncoa000018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *6!T # 2(  A$! Q$!_\0
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MJMK/C;5+K)*+,88_]U/E'YXS^-<Y7J4(<D$CDJ2YI7"BBBM3,**** "BBB@
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MHHHK<R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2?KFHJU?$VGOI7B?4[%UQY-RX7W7.5/X@@UE5LG=7(>X4444Q!1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "O:_@GX=>"UN]?G3'V@>1;Y'5 <LWT)
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MA=D'J/.;_&J=%%D%V%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *]K^"?AUX+6[U^=,?:!Y%OD=
M4!RS?0D ?\!-><>"_"-UXNUI;6/=':1X:YGQPB^@_P!H]A_A7TU8V5OIMA!9
M6D8CMX$$<:CL!7'BZJ2Y$=%"%WS,L5D>(O#6F^*--:RU*'<O6.1>'B;U4_Y!
M[UKT5YZ;3NCI:OHSYQ\3_"W7O#Y>:WC.HV0/$MNI+J/]I.H_#(]ZX@@JQ5@0
M0<$'M7V+65JGAK1-:.=2TNUN'_OO&-__ 'T.?UKLAC&M)HPE07V3Y.HKZ5/P
ML\%DDG11R>US,/\ V>C_ (57X+_Z W_DU-_\76OURGV9'L)'S517TK_PJOP7
M_P! ;_R:F_\ BZ/^%5^"_P#H#?\ DU-_\71]<I]F'L)'S517TK_PJOP7_P!
M;_R:F_\ BZ/^%5^"_P#H#?\ DU-_\71]<I]F'L)'S517TK_PJOP7_P! ;_R:
MF_\ BZ/^%5^"_P#H#?\ DU-_\71]<I]F'L)'S517TK_PJOP7_P! ;_R:F_\
MBZ/^%5^"_P#H#?\ DU-_\71]<I]F'L)'S517TK_PJOP7_P! ;_R:F_\ BZ/^
M%5^"_P#H#?\ DU-_\71]<I]F'L)'S517TK_PJOP7_P! ;_R:F_\ BZ/^%5^"
M_P#H#?\ DU-_\71]<I]F'L)'S517TK_PJOP7_P! ;_R:F_\ BZ/^%5^"_P#H
M#?\ DU-_\71]<I]F'L)'S517TK_PJOP7_P! ;_R:F_\ BZ/^%5^"_P#H#?\
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M_P! ;_R:F_\ BZ/^%5^"_P#H#?\ DU-_\71]<I]F'L)'S517TK_PJOP7_P!
M;_R:F_\ BZ/^%5^"_P#H#?\ DU-_\71]<I]F'L)'S517TK_PJOP7_P! ;_R:
MF_\ BZ/^%5^"_P#H#?\ DU-_\71]<I]F'L)'S517TK_PJOP7_P! ;_R:F_\
MBZ/^%5^"_P#H#?\ DU-_\71]<I]F'L)'S517TK_PJOP7_P! ;_R:F_\ BZ/^
M%5^"_P#H#?\ DU-_\71]<I]F'L)'S517TK_PJOP7_P! ;_R:F_\ BZ/^%5^"
M_P#H#?\ DU-_\71]<I]F'L)'S517TK_PJOP7_P! ;_R:F_\ BZ/^%5^"_P#H
M#?\ DU-_\71]<I]F'L)'S517TK_PJOP7_P! ;_R:F_\ BZ/^%5^"_P#H#?\
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M_P! ;_R:F_\ BZ/^%5^"_P#H#?\ DU-_\71]<I]F'L)'S517TK_PJOP7_P!
M;_R:F_\ BZ/^%5^"_P#H#?\ DU-_\71]<I]F'L)'S517TK_PJOP7_P! ;_R:
MF_\ BZ/^%5^"_P#H#?\ DU-_\71]<I]F'L)'S517TK_PJOP7_P! ;_R:F_\
MBZ/^%5^"_P#H#?\ DU-_\71]<I]F'L)'S517TK_PJOP7_P! ;_R:F_\ BZ/^
M%5^"_P#H#?\ DU-_\71]<I]F'L)'S517TK_PJOP7_P! ;_R:F_\ BZ/^%5^"
M_P#H#?\ DU-_\71]<I]F'L)'S517TK_PJOP7_P! ;_R:F_\ BZ/^%5^"_P#H
M#?\ DU-_\71]<I]F'L)'S517TK_PJOP7_P! ;_R:F_\ BZ/^%5^"_P#H#?\
MDU-_\71]<I]F'L)'S517TK_PJOP7_P! ;_R:F_\ BZ/^%5^"_P#H#?\ DU-_
M\71]<I]F'L)'S517TK_PJOP7_P! ;_R:F_\ BZ/^%5^"_P#H#?\ DU-_\71]
M<I]F'L)'S517TK_PJOP7_P! ;_R:F_\ BZ/^%5^"_P#H#?\ DU-_\71]<I]F
M'L)'S517TK_PJOP7_P! ;_R:F_\ BZ/^%5^"_P#H#?\ DU-_\71]<I]F'L)'
MS517TK_PJOP7_P! ;_R:F_\ BZ/^%5^"_P#H#?\ DU-_\71]<I]F'L)'S517
MTK_PJOP7_P! ;_R:F_\ BZ/^%5^"_P#H#?\ DU-_\71]<I]F'L)'S517TK_P
MJOP7_P! ;_R:F_\ BZ/^%5^"_P#H#?\ DU-_\71]<I]F'L)'S517TK_PJOP7
M_P! ;_R:F_\ BZ/^%5^"_P#H#?\ DU-_\71]<I]F'L)'S517TK_PJOP7_P!
M;_R:F_\ BZ/^%5^"_P#H#?\ DU-_\71]<I]F'L)'S517TK_PJOP7_P! ;_R:
MF_\ BZ/^%5^"_P#H#?\ DU-_\71]<I]F'L)'S517TK_PJOP7_P! ;_R:F_\
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M%_\ 0&_\FIO_ (NC_A5?@O\ Z W_ )-3?_%T?7*?9A["1\U45]*_\*K\%_\
M0&_\FIO_ (NC_A5?@O\ Z W_ )-3?_%T?7*?9A["1\U45]*_\*K\%_\ 0&_\
MFIO_ (NC_A5?@O\ Z W_ )-3?_%T?7*?9A["1\U45]*_\*K\%_\ 0&_\FIO_
M (NC_A5?@O\ Z W_ )-3?_%T?7*?9A["1\U45]*_\*K\%_\ 0&_\FIO_ (NC
M_A5?@O\ Z W_ )-3?_%T?7*?9A["1\U45]*_\*K\%_\ 0&_\FIO_ (NC_A5?
M@O\ Z W_ )-3?_%T?7*?9A["1\U45]*_\*K\%_\ 0&_\FIO_ (NC_A5?@O\
MZ W_ )-3?_%T?7*?9A["1\U45]*_\*K\%_\ 0&_\FIO_ (NC_A5?@O\ Z W_
M )-3?_%T?7*?9A["1\U45]*_\*K\%_\ 0&_\FIO_ (NC_A5?@O\ Z W_ )-3
M?_%T?7*?9A["1\U45]*_\*K\%_\ 0&_\FIO_ (NC_A5?@O\ Z W_ )-3?_%T
M?7*?9A["1\U45]*_\*K\%_\ 0&_\FIO_ (NC_A5?@O\ Z W_ )-3?_%T?7*?
M9A["1\U45]*_\*K\%_\ 0&_\FIO_ (NC_A5?@O\ Z W_ )-3?_%T?7*?9A["
M1\U45]*_\*K\%_\ 0&_\FIO_ (NC_A5?@O\ Z W_ )-3?_%T?7*?9A["1\U4
M5]*_\*K\%_\ 0&_\FIO_ (NC_A5?@O\ Z W_ )-3?_%T?7*?9A["1\U45]*_
M\*K\%_\ 0&_\FIO_ (NC_A5?@O\ Z W_ )-3?_%T?7*?9A["1\U45]*_\*K\
M%_\ 0&_\FIO_ (NC_A5?@O\ Z W_ )-3?_%T?7*?9A["1\U45]*_\*K\%_\
M0&_\FIO_ (NC_A5?@O\ Z W_ )-3?_%T?7*?9A["1\U45]*_\*K\%_\ 0&_\
MFIO_ (NC_A5?@O\ Z W_ )-3?_%T?7*?9A["1\U45]*_\*K\%_\ 0&_\FIO_
M (NC_A5?@O\ Z W_ )-3?_%T?7*?9A["1\U45]*_\*K\%_\ 0&_\FIO_ (NC
M_A5?@O\ Z W_ )-3?_%T?7*?9A["1\U45]*_\*K\%_\ 0&_\FIO_ (NC_A5?
M@O\ Z W_ )-3?_%T?7*?9A["1\U45]*_\*K\%_\ 0&_\FIO_ (NC_A5?@O\
MZ W_ )-3?_%T?7*?9A["1\U45]*_\*K\%_\ 0&_\FIO_ (NC_A5?@O\ Z W_
M )-3?_%T?7*?9A["1\U45]*_\*K\%_\ 0&_\FIO_ (NC_A5?@O\ Z W_ )-3
M?_%T?7*?9A["1\U45]*_\*K\%_\ 0&_\FIO_ (NC_A5?@O\ Z W_ )-3?_%T
M?7*?9A["1\U45]*_\*K\%_\ 0&_\FIO_ (NC_A5?@O\ Z W_ )-3?_%T?7*?
M9A["1\U45]*_\*K\%_\ 0&_\FIO_ (NC_A5?@O\ Z W_ )-3?_%T?7*?9A["
M1\U45]*_\*K\%_\ 0&_\FIO_ (NC_A5?@O\ Z W_ )-3?_%T?7*?9A["1\U4
M5]*_\*K\%_\ 0&_\FIO_ (NC_A5?@O\ Z W_ )-3?_%T?7*?9A["1\U45]*_
M\*K\%_\ 0&_\FIO_ (NC_A5?@O\ Z W_ )-3?_%T?7*?9A["1\U45]*_\*K\
M%_\ 0&_\FIO_ (NC_A5?@O\ Z W_ )-3?_%T?7*?9A["1\U45]*_\*K\%_\
M0&_\FIO_ (NC_A5?@O\ Z W_ )-3?_%T?7*?9A["1\U45]*_\*K\%_\ 0&_\
MFIO_ (NC_A5?@O\ Z W_ )-3?_%T?7*?9A["1\U45]*_\*K\%_\ 0&_\FIO_
M (NC_A5?@O\ Z W_ )-3?_%T?7*?9A["1\U45]*_\*K\%_\ 0&_\FIO_ (NC
M_A5?@O\ Z W_ )-3?_%T?7*?9A["1\U45]*_\*K\%_\ 0&_\FIO_ (NC_A5?
M@O\ Z W_ )-3?_%T?7*?9A["1\U45]*_\*K\%_\ 0&_\FIO_ (NC_A5?@O\
MZ W_ )-3?_%T?7*?9A["1\U45]*_\*K\%_\ 0&_\FIO_ (NC_A5?@O\ Z W_
M )-3?_%T?7*?9A["1\U45]*_\*K\%_\ 0&_\FIO_ (NC_A5?@O\ Z W_ )-3
M?_%T?7*?9A["1\U45]*_\*K\%_\ 0&_\FIO_ (NC_A5?@O\ Z W_ )-3?_%T
M?7*?9A["1\U45]*_\*K\%_\ 0&_\FIO_ (NC_A5?@O\ Z W_ )-3?_%T?7*?
M9A["1\U45]*_\*K\%_\ 0&_\FIO_ (NC_A5?@O\ Z W_ )-3?_%T?7*?9A["
M1\U45]*_\*K\%_\ 0&_\FIO_ (NC_A5?@O\ Z W_ )-3?_%T?7*?9A["1\U4
M5]*_\*K\%_\ 0&_\FIO_ (NC_A5?@O\ Z W_ )-3?_%T?7*?9A["1\U45]*_
M\*K\%_\ 0&_\FIO_ (NC_A5?@O\ Z W_ )-3?_%T?7*?9A["1\U45]*_\*K\
M%_\ 0&_\FIO_ (NC_A5?@O\ Z W_ )-3?_%T?7*?9A["1\U45]*_\*K\%_\
M0&_\FIO_ (NE7X6^#$8,-%&1ZW,I'Y%Z/KE/LP]A(^:XXWED6.-&=V.%51DD
M_2O0O"WPCUC66CN=5#:;9$@D./WSCV7^'ZM^1KW+3-"TG1DVZ;IUM:YZF*,
MGZGJ:T*RGC&](JQ<:"6Y0T?1K#0=.CL--MU@@3L.K'U)[GWJ_117&VV[LZ-@
MHHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% '%?;KO_GZG_P"_AH^W7?\ S]3_ /?PU7I:]"R()_MU
MW_S]3_\ ?PT?;KO_ )^I_P#OX:@HI60$_P!NN_\ GZG_ ._AI?MUW_S]3_\
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MH^T3_P#/:3_OHU'119 2_:)O^>TG_?1H^T3?\]I/^^C4=%%D!)]HF_Y[2?\
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MIJ:LF%CT6N,\1?$&+1M9_LFSTV;4;Q0-ZQOMP2,X& 23CGI2^&_&5WK^G:E
M;)(M:LHV(@R=DC8('4Y'S#!&>_6O.].O_$:^/KJ[M].@EUDE_,MV'RKQ@X^;
ML/>E*>BL"1Z2OCZQ&JZ;ILUE=Q7-ZD;8*C$9?H#W^O%==7GVH>)KNV\=Z1IL
MVF:?YD\</FRM$6EC9OO!6SP ?K4GB?Q]=^'?%::?]CBGM/)#D*#YK,0< '.
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M1SVH4DP.NI:2EJ@"BBB@84444 +1110 4444 +1112 **** "EI*6@ HHHH
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M%% "T444 %%%% "T444@"BBB@ I:2EH **** %HHHH ****0Q:*** "BBB@
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MD)8EE"G![< 4[3_!^D:;X;N=!MXY?L-SO\P-(2QW#!Y_"E8+'-?!;_D1I/\
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MT/)K/\+^"M(\(_:3I@G+7&WS&FDW' S@#@>IH-+-2N=%1113*$HHHH&%%%%
M!0:*#0,2BBB@!**** "BBB@84444 )1110 E%%%,84444@"BBB@!**** $-/
MA_U\?^\/YTPT^'_7Q_[P_G0#V.:I:G^PW?\ SZS_ /?LT?8;O_GUG_[]FNZZ
M/,(**G^PW?\ SZS_ /?LT?8;O_GUG_[]FE= 04M3?8;O_GUG_P"_9I?L-W_S
MZS_]^S1= 045/]AN_P#GUG_[]FC[#=_\^L__ '[-%T!!14_V&[_Y]9_^_9H^
MPW?_ #ZS_P#?LT70$-%3_8KO_GUF_P"_9H^Q7?\ SZS?]^S1= 04M3?8KO\
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M\&BZ BHJ7[+<?\\)?^^#1]EN/^>$O_?!HN@(J*E^RW'_ #PE_P"^#1]EN/\
MGA+_ -\&E= 14M2_9;C_ )X2_P#?!H^RW'_/"7_O@T70R*BI?LMQ_P \)?\
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M2?\ /-ORI/*D_P">;?E0%T,HI_E2?\\V_*CRI/\ GFWY4!=$=%/\J3_GF_\
MWS1Y4G_/-_\ ODT!=#**?Y4G_/-_^^31Y4G_ #S?_ODT#NAE%/\ *D_YYO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YSQ[KEUX;\%:
MCJUD$-S $$?F#(!:15SC_@5='7$?%W_DEVL?]L/_ $='0!PNG^,OBE?^'_\
MA(+2TL;K3T#,<1KN(4D-\H8-QCM7??#KQXGCC2YWDMUM[ZT95GC0DJ0V=K+G
ML<'CMBO+?"7Q2M_#W@-=!M]+N;G40)=C<>7EB2">YQGIBNQ^#/A'4=#T?4;_
M %&&2UFO]BQ1NN'1%#?,1VR6Z'T]Z /3Y;JW@=4FGBC9ONAW )_.I001D'(-
M>$7W@_X=6330ZYXSN+G5FSYLZR;L/[@!N1Z%LUH_!#5KRZ\.Z]I\\[R0V:HT
M 9L[-ZOD#T'R#CZT >PR7-O%"9I)XDB4X+LX"@_6N3\>^/8_!%E9W L1?-<R
M%-@G$>T8SGH:\6^''@RX\<Q7EC/J4MKI5FXF>.,9+2N, XZ=$/)_#J:U?B[X
M,M/#UGI-]#=3S3/%'9N'QM(BB50P'8D*.] 'OEA>Q:A90W,3+B2-7*A@=N1G
M!JOKVH3Z3H%]J%M;&YGMX6DCA&<N0.!QS7-?#OP-8>$K)[RTNKF:34((FD$I
M7"X!/& /[QZUVU 'A>L>,/BQIEB=:O=/BLM/R,KY"$)DX&X$EQR0.:](^'GC
M!O&GAK[?- D-U#*89T3[I8 '*YYP01U[YKE?C/XL@MM%/A>T/G:A?%/,1!DQ
MIN!'_ F(  ],^U='\,?"LWA3P?%;78Q>W+FXG7^X2  OX #/OF@#LZ*\_P#
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M6]4NM7_9RM[V\E:6X<I&[L<EMD^P$GN<** /9))HH4#RRHBDX#,P )I]?/\
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MH92"I&01WI:\7^!E]>PWNMZ%/,SP6Q#HI.0C!BK8]CQ^5>T4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5QOQ6MYKKX::O#;PR32D0D)&I8G$R$\#V!-=E6)XA_X2
MG_1O^$:_L?\ B^T?VEYOMMV[/^!9S[4 8/PBMY[7X<V$5Q#)#)YDIV2*5."Y
MQP:ZO6H+FZT+4;>R?9=2VTB0MG&'*D*<_7%<M_Q='_J3_P#R9H_XNC_U)_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQTGVFW_Y[Q?]]BC[3;_\]XO^^Q7-T4?5EW#ZT^QTGVFW_P">\7_?8H^TV_\
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ML5S=%'U9=P^M/L=)]IM_^>\7_?8H^TV__/>+_OL5S=%'U9=P^M/L=)]IM_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY3KN(8  ,3ALC)R/2DW9V&HMILZZBBBF(**** "BLGQ-K7_".^';O5?(\_R
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8^:%Y^5B,8)_NUR7@Y$D^,&NJZ*P\RZX89_Y:UZO<6-O<65Q:F-5CGC:-]H
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MXZ,)R,_]LZJ>*/']GXGT"/0=,T^Y:>=HTWSA5P01]W!/)QCG'6KOQK_Y@?\
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M>E_VIX)OT5<R6Z_:$]BG)_\ '=P_&O-? HD\4>)]+@O$WV^EV+H0>C+E@/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPB=#*J@;8MIY)P>:]#T2VELM!TZTG $T%K%&X!SAE4 _J*Y;_A&?'7_11/\
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M+M[2:WMHVBFLYRH#* H3!)'0 ]&'7O4/_",^.O\ HHG_ )18/\:/^$9\=?\
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M</84^QE?V-_TW_\ '/\ Z]']C?\ 3?\ \<_^O6K11[>IW#V%/L97]C?]-_\
MQS_Z]']C?]-__'/_ *]:M%'MZG</84^QE?V-_P!-_P#QS_Z]']C?]-__ !S_
M .O6K11[>IW#V%/L97]C?]-__'/_ *]']C?]-_\ QS_Z]:M%'MZG</84^QE?
MV-_TW_\ '/\ Z]']C?\ 3?\ \<_^O6K11[>IW#V%/L97]C?]-_\ QS_Z]']C
M?]-__'/_ *]:M%'MZG</84^QE?V-_P!-_P#QS_Z]']C?]-__ !S_ .O6K11[
M>IW#V%/L97]C?]-__'/_ *]']C?]-_\ QS_Z]:M%'MZG</84^QE?V-_TW_\
M'/\ Z]']C?\ 3?\ \<_^O6K11[>IW#V%/L97]C?]-_\ QS_Z]']C?]-__'/_
M *]:M%'MZG</84^QE?V-_P!-_P#QS_Z]']C?]-__ !S_ .O6K11[>IW#V%/L
M97]C?]-__'/_ *]']C?]-_\ QS_Z]:M%'MZG</84^QE?V-_TW_\ '/\ Z]']
MC?\ 3?\ \<_^O6K11[>IW#V%/L97]C?]-_\ QS_Z]']C?]-__'/_ *]:M%'M
MZG</84^QE?V-_P!-_P#QS_Z]']C?]-__ !S_ .O6K11[>IW#V%/L97]C?]-_
M_'/_ *]']C?]-_\ QS_Z]:M%'MZG</84^QE?V-_TW_\ '/\ Z]']C?\ 3?\
M\<_^O6K11[>IW#V%/L97]C?]-_\ QS_Z]']C?]-__'/_ *]:M%'MZG</84^Q
ME?V-_P!-_P#QS_Z]']C?]-__ !S_ .O6K11[>IW#V%/L97]C?]-__'/_ *]'
M]C?]-_\ QS_Z]:M%'MZG</84^QE?V-_TW_\ '/\ Z]']C?\ 3?\ \<_^O6K1
M1[>IW#V%/L97]C?]-_\ QS_Z]']C?]-__'/_ *]:M%'MZG</84^QE?V-_P!-
M_P#QS_Z]']C?]-__ !S_ .O6K11[>IW#V%/L97]C?]-__'/_ *]']C?]-_\
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MV%/L97]C?]-__'/_ *]']C?]-_\ QS_Z]:M%'MZG</84^QE?V-_TW_\ '/\
MZ]']C?\ 3?\ \<_^O6K11[>IW#V%/L97]C?]-_\ QS_Z]']C?]-__'/_ *]:
MM%'MZG</84^QE?V-_P!-_P#QS_Z]']C?]-__ !S_ .O6K11[>IW#V%/L97]C
M?]-__'/_ *]']C?]-_\ QS_Z]:M%'MZG</84^QE?V-_TW_\ '/\ Z]']C?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU%%1/<P12+')/&DC?=5G )^@H EHHJ*:X@M]OG31Q[C@;V S^= $M%'49%%
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M9(N;ZV@(ZB655Q^9JI_PD_A__H.:9_X%Q_XU2A)[(ESBMV:M%97_  D_A_\
MZ#FF?^!<?^-'_"3^'_\ H.:9_P"!<?\ C3]G/LQ>UAW1JT5E?\)/X?\ ^@YI
MG_@7'_C1_P )/X?_ .@YIG_@7'_C1[.?9A[6'=&K165_PD_A_P#Z#FF?^!<?
M^-'_  D_A_\ Z#FF?^!<?^-'LY]F'M8=T:M%97_"3^'_ /H.:9_X%Q_XT?\
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M R?RH Y367?Q9XTATN)B;.V)5R.G'WS_ .RC\*]$1%BC6-%"HH"JH'  KE/
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M6+9R3U_&KGQHB=M/TF92?+261&QTR0,?^@FN\\+W<-[X6TN>!@8S;1KQV(4
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MXKK4!,8Y9/+41*&.<$^H]*PM0^*GANPO#;![FYP<-);QAD'XDC/X9K-^,O\
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M]S_:%]N&V3&4QGKZ4SXC>)]275+7PSHCR1W5QM\V1#ACN.%4'MZD_3WJ?2_
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M,\8] #P1]*5-:QZ?J54>DM;_ *%ZVA\,_P#"UY6C;4/[:4LQ4[?(!\ODCO\
M=/YUZ#7DUA_R7JY_X%_Z)%>LUO2=[^ISU5:WH%%%%:&04444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M:6DZ_JNAS"73[V6'!R4!RC?53P:]G\%^.K?Q-']EN56#4D7+(/NR#N5_P_G7
M@U3V5Y/I][#>6TACGA<.C#L17'BL)"O':S[G9A<9.A+>\>Q]145GZ'JD>M:)
M::C&,">,,5_NMT8?@016A7S$HN+LSZF,E))KJ%%%%(84444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ><>%/%9L
M"EA?N3:DXCD/_++V/^S_ "KT8$, 000>01WKPNNN\*>*S8%+"_<FU)Q'(?\
MEE['_9_E7LXW!<W[RGOU1XF!QW+^[J;=&>CT4@(8 @@@\@CO2UXQ[84444 %
M%%% !1110 4444 %><:@S>+_ !M'8H2;&U)#$'C:#\Y_$X'Y5U'B_6?['T.1
MHVQ<S_NXL=1GJ?P'ZXJKX%T;^SM&%U*N+B[PYSU"?PC^OXT =0JJBA54*JC
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MX+ ?AOJIXBM3JQC.*M)V\R(8:C4I2E"3O%7\CQ*BBBN\X HHHH **** /0/
MWBJ?0]$FM8K:.57N6DW,Q!Y51_2NG_X6)=_\^$'_ 'V:\XT+_CQ?_KH?Y"M2
MN&IA:,YN4HZG;3Q=:$5&,M#L_P#A8EW_ ,^$'_?9H_X6)=_\^$'_ 'V:XRBH
M^I4/Y2_KV(_F.S_X6)=_\^$'_?9H_P"%B7?_ #X0?]]FN,HH^I4/Y0^O8C^8
M[/\ X6)=_P#/A!_WV:/^%B7?_/A!_P!]FN,HH^I4/Y0^O8C^8[/_ (6)=_\
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M_CH_PH^K3#ZS WZ*P/[1N_\ GK_XZ/\ "C^T;O\ YZ_^.C_"CZM,/K,#?HK
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M )Z_^.C_  H_M&[_ .>O_CH_PH^K3#ZS WZ*P/[1N_\ GK_XZ/\ "C^T;O\
MYZ_^.C_"CZM,/K,#?HK _M&[_P">O_CH_P */[1N_P#GK_XZ/\*/JTP^LP-^
MBL#^T;O_ )Z_^.C_  H_M&[_ .>O_CH_PH^K3#ZS WZ*P/[1N_\ GK_XZ/\
M"C^T;O\ YZ_^.C_"CZM,/K,#?HK _M&[_P">O_CH_P */[1N_P#GK_XZ/\*/
MJTP^LP-^BL#^T;O_ )Z_^.C_  H_M&[_ .>O_CH_PH^K3#ZS WZ*P/[1N_\
MGK_XZ/\ "C^T;O\ YZ_^.C_"CZM,/K,#?HK _M&[_P">O_CH_P */[1N_P#G
MK_XZ/\*/JTP^LP-^BL#^T;O_ )Z_^.C_  H_M&[_ .>O_CH_PH^K3#ZS WZ*
MP/[1N_\ GK_XZ/\ "C^T;O\ YZ_^.C_"CZM,/K,#?HK _M&[_P">O_CH_P *
M/[1N_P#GK_XZ/\*/JTP^LP-^BL#^T;O_ )Z_^.C_  H_M&[_ .>O_CH_PH^K
M3#ZS WZ*P/[1N_\ GK_XZ/\ "C^T;O\ YZ_^.C_"CZM,/K,#?HK _M&[_P">
MO_CH_P */[1N_P#GK_XZ/\*/JTP^LP-^BL#^T;O_ )Z_^.C_  H_M&[_ .>O
M_CH_PH^K3#ZS WZ*P/[1N_\ GK_XZ/\ "C^T;O\ YZ_^.C_"CZM,/K,#?HK
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ME?;^= $/A?PI#HD0N+C;+?N.6ZB/V7_&NEHHH **** "BBB@ JCJS$68 [N
M?UJ]5#5_^/1?]\?R-:4OC1G5^!F+1117H'FA1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%<^WCCPPCLK:U:Y4X.&S6
MCIFM:;K4<DFFWD5RL9VN8S]TTE)/9C<6MT7Z*SM3U[2M&V_VCJ%O;,PRJR.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)3ERQ5V85%*058@]0<4E42%%%%, HHHH **** "BBB@ HHHH **** "BBB@
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M,'=L Z\$'''--\%.D?A._DE3?&LLC,G]X!%R*RY?&L5O:O!I&EQ6>[^/C\\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!M:1_QZ-_OG^0J_5#2/^/1O]\_R%7Z\^K\
M;/2I? CY6HHHK[ ^-"BBB@ KO;?X?Z9#:P/K'BBSLYYT5UA&TD C(SEA_*N$
M16=U11EF. />O2-4\,>%/!MI:#7%O[^\N%)VP,%3(QGTXY]2:Y,34<7&,6TW
MV5W^)UX6FI*4I132[NR7W'.>+_!EQX5D@?[2MU:7&?+E5=IR.Q&3_.NW\?6R
M7NB^%[66=;>.:5(VF;I&"H&X].GUJ/XG>4?!6BF&-HXO,38C_>5?+. ?>HOB
M?_R*>@?A_P"@"N*%2=5TG)ZW9VSI0I*LHK2T3H=:\,6-[X'T_2I-6MK:&W$>
MR\9%VR84C(^8#GKUKS'1/!5SKVM7UI:W<7V*SE9)+TCY2 2 0,\YQGK^-=AX
MK!?X/:,5Y"K;Y([?(1_.IOAS]F'P[U8R023IYLWG11G#NOEK\HP0>1TJ:52I
M1H2DG?6W_!+JTZ=:O&+5M+_AL8#_  XM;VRN)= \06^I7%N/GA5 ,_0ACU[<
M8/K6+X/\)-XKO+JW^V?9#!&'R8M^<G&,9&*Z?1O&O@[0;EYM+T&_@ED78Q\T
MMD9SC#.>]3?"NX6[\3:Y<JFQ9E\P+G[H+DXK:5:O"E-N^EK-VO\ @81HX>=6
M$5;6]TF[?CJ86N> 1H'AHZA=:E&;]=A>T4#Y=QQC.<G'KBG:=\/X_P"QH=4U
M[6(=*@GP8D=<LP(R,Y(P>^.>/2N9U>=[GQ#>374CR%KEM[$\XW?X5[#X_N?#
M]K#ISZYI5Q?0G>(6@D*JA^7(.&'48Q]#3JU*U/DA>[E?9+[E<5*E1J<\[64;
M;M_>['FWBGP7-X=MK>^AO([[3KC 2XC7')&1D9(P1T(-7O#?P\?5]&_M?4=1
MCT^S;E"R@DC.-Q)("C/3UJ?Q!XTT:^\'_P!A:5IMU;Q(Z[/-;(0!MW7))[UN
M>-%D;X4:*;3<;=5MS)M_N^6<9_X%C\<4.M7Y8PEHV[7TV_(:HX?GE..J2O;7
M?\[&KI/AYO#G@37[;[7%=PRQ330S1]&4Q =.>X/<UXA7KG@E+E/A9K1G$@C9
M+@P[\XV^5_#[9S^.:\CJ\$FIU%)W=S/&M.%-Q5E8ZKPMX+?Q#9W.HW-]'8Z=
M;$AYG&<D#)[C  (Y/K4/B+P[IFE6,-YIFNP:E'))Y;(J@,AQG)&3QQ[5I>#/
M&5OH6GW&EZK9-<Z9=.22J@D$@!A@\$8Q]/QJ[XN\)Z);Z+:^(]%D=;&:1=\+
M$D;3W7/(/;!H=6I&O:;:3VT5G^MP5*G+#WII-I:ZNZ_2Q6TGX<M/I$>J:UJL
M&EVTH#() ,D'IDD@#/IS4'B7X?S:+I:ZK8W\6HV'!:1%P5!. >"01[YKI/C"
MLK6>CO%DV@:0$K]W<0NW] <?C3_#F^#X-:HUX"(F2?R=WH1@8_X'FL8XBMR1
MK<V[M8WEAZ//*ARZI7O?^D1:'_R134O^VO\ ,5C:7IFK2_#.]O8M<DBL4W[K
M$0@A@",_-G(S]*V=#_Y(IJ7_ &U_F*-#_P"2*:E_VU_F*GF<>:W\Y7*I<M_Y
M#F/"7@2?Q+:S7TUVME8Q$KYK)N+$<G R, #OFO1_ GA5?#L]_-;ZC#?V=TL?
MERQXZJ6R#@D=QWK$B61O@7BRW%MC&3;UQYQ+_IG\*3X.)<BWU1W$@M6:/RR<
M[2WS;L>^-N?PJ,34J5*523EHG:WS*PM.G3JTXJ.K5[_(\IE_UK_[QKTOX2:5
M;M=3:J;V(W"AX!:%1O ^0[\YSCMT_&O-)?\ 6O\ [QKN?A(0/%\V3ULWQ_WT
ME>AC4WAY69Y^!:6(C==1_C;PI9P:P;J#6;>6:^U 1M:H@W0[B<DX;L>.@ZUB
M^,?"9\)WEM!]M^U>?&7W>5LQ@XQC)I^M_NOB7<EP1C4@QSZ;P?Y5TWQAAD;4
M]*=48JT3HI ZG(X_6L:<ZD)TX.5TT_R-JD*<X59J-FFN_<YO6/!ATGPCI^O?
M;_-^U^7^X\G;LWJ6^]N.<8]*T=/^&=SJ6AZ?J<&HQA;GYI5DCVB%,$ELY^;H
M!C ZUN^-X);;X5:)!/&T<L;0*Z,,%2(FR#2:Q))'\%+#8[+O6-6VG&1N/!]J
MR6(JRA&TM7*WR-7AJ,9RYHZ**?S,^]^$\S64-QHVJPW^]@IRH5<9P6# GIZ?
M_JI9OA3NTV:73];AN[N$'?"J#:6'5<AC@_4?E6EX'FDC^%&N2)(RO&+DHP."
MI$0(QZ<\U5^#9/VK5QDX*1''XM4RK8B,9RY_@?9:EQHX>4H1Y/C7=Z'"^'O#
MU[XDU06-F%# ;I)'X6-?4_X5VB_"ZPEF>R@\4VTFH1@EH!&N1[$!\CZ_I6E\
M*O+%YXB5<";S4QG^[E_Z_P!*X?PC#??\)]IZ;9/M2769L]0 3OS^&:VJ5:LY
MS49<JBE\]+F%.E2A"#E'F<F_EK8KP^&+L>+8O#UXXMYVE$9D"[@ 1D,.F1CZ
M5US?"?[,;MKW6HXHDXMV\L R_*"206XYR,9/3-:'B%XF^,VC"/&Y(XQ)_O9<
M_P B*Y[XK3RR>,/)>1C'% FQ2>%SR<?6DJU:K.$8RM>-WH5*C1HPG*4>:TK+
M4KZ!X&34=".MZIJD6FZ>20C,NXM@XSU&.>/4XK+\2Z%9:,]LVGZO#J5O<*Q#
MQ@ H1C@@$^M='X8\::;;^'U\/>([!IK Y\N0+GY2Q/(Z\'.".?RJKX]\(V.@
M+9ZAI<K&RN\XC<Y*G&1@]2"/6M(5:BK\M1M7O;16:]=[F4Z5-X?FII.R5]7=
M/TVL<31117>< 4444 =!H7_'B_\ UT/\A6I67H7_ !XO_P!=#_(5J5C+<T6P
M4445(PHHHH **** -OQ#XB?7_LV^V6'R-V,-G.<?X58'B^Z'A[^RO(7/E>5Y
MVXYV_3Z<5SE%9?5Z?*HVT6QO]8J\SE?5[FSX?\0/H$D[I;K-YP (+8QC/^-9
M#MO=F/\ $<TVBK4(J3DMV9NI)Q46]$;NJ^)9-4T:UTYK98U@*G>&SNVJ5Z?C
M5;0M9?0K]KI(5EW1F,J3C@D'^E9=%2J,%!PMHRG6J.:G?5'9M\09QDQ:; CG
MJQ<G^@KFM3U>]UBX$MW+O(X1 ,*OT%4:*FGAZ5-WBM2JF)JU%:<M#NM?_P")
M'X,L]*7Y9I\>8/\ QYOU(%<+3Y)9)2#)([D# +,3BF4Z-+V<;-W;U"O5]K*Z
M5DE9&[X@\2R:^ENKVRP^22>'SG./\*=9>*)+709=)EM5GB=6569\;0?\#S6!
M11["GRJ%M$+ZQ5YW.^K-W2O$LFEZ-=:<MLL@G+'>7QMW*%Z?A6%115QIQBVT
MMR)5)223>QM>'_$#Z!).R6RS>< #EL8QG_&MH^/R3DZ3"2>YD_\ K5Q=%93P
MU*<N:2U-88JM3CRQ>AM?\) Z^)AK*6L:L#_J0>/N[>M;3?$*7.Y=,A#_ -XR
M$_TKBZ*)8:E.W,MM ABJT+\KWU-35]?O]:<?:I (E.5B084'^I^M9=%%;1A&
M"M%61C.<IOFD[L****9(4444 %%%% !1110 5U?A7PJVI,M[>J5LU.40\&4_
MX4>%?"K:DRWMZI6S4Y1#P93_ (5Z2JJBA54*JC  & !7F8S&\O[NGN>K@<#S
M_O*FW1 JJBA54*JC  & !7&_$'1_M6G)J42YEMOEDQW0_P"!_F:[.F2Q)/"\
M4JAHW4JRGH0>HKQCW#R6P-[H]O!K^E,7MR?+N8NH1AU5O]D]0>V?7KZ7HNMV
MFN60N+9L,.)(S]Y#Z'_&N*T4_P#"->++K1+OYK*[.Q=XR#G[I/U!VGW^E+K&
MC7OA'4/[7T9F-H3^\C/(0?W6]5]^WZT >C45EZ'KMKKMEY]N=LB\2Q$\H?\
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M@T<Z=Y!O+HW)D#M<G!. "-H'0#G/KQ70>(O!UOX@M[$?;;FTN+%2()H2,C(
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M_P *[N_^?^#_ +X-'UVA_,'U'$?RG&45V?\ PKN[_P"?^#_O@T?\*[N_^?\
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M?67V#ZJNYS?V:X_YX2_]\&C[-<?\\)?^^#7244?67V#ZJNYS?V:X_P">$O\
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MIF4CNYY;]3C\*V*^2Q,U.K*2[GU^&@Z=&,7ND%%%%8FX4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >%4445]
M8?'!75^%?"K:DRWMZI6S4Y1#P93_ (4>%?"K:DRWMZI6S4Y1#P93_A7I*JJ*
M%50JJ,  8 %>9C,;R_NZ>YZN!P//^\J;=$"JJ*%50JJ,  8 %+117C'N!111
M0 4444 %<AX^T@W>EKJ,(_?VG+$=2G?\CS^==?3719(VC=0R,"&!Z$&@#(\,
M:P-:T2*X8CST_=S#_:'?\>OXULD C!&0:\YT9V\)^-)M,E8BTNB%0GW^X?\
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M7N/[D7Y'_&C^U[C^Y%^1_P :/J\P^L0-JBL7^U[C^Y%^1_QH_M>X_N1?D?\
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M>S_#_,/[(K]U^/\ D> 45[__ ,*W\)?] G_R8E_^*H_X5OX2_P"@3_Y,2_\
MQ5']K4>S_#_,/[(K]U^/^1X!17O_ /PK?PE_T"?_ "8E_P#BJ/\ A6_A+_H$
M_P#DQ+_\51_:U'L_P_S#^R*_=?C_ )'@%%>__P#"M_"7_0)_\F)?_BJ/^%;^
M$O\ H$_^3$O_ ,51_:U'L_P_S#^R*_=?C_D> 45[_P#\*W\)?] G_P F)?\
MXJC_ (5OX2_Z!/\ Y,2__%4?VM1[/\/\P_LBOW7X_P"1X!17O_\ PK?PE_T"
M?_)B7_XJC_A6_A+_ *!/_DQ+_P#%4?VM1[/\/\P_LBOW7X_Y'@%%>_\ _"M_
M"7_0)_\ )B7_ .*H_P"%;^$O^@3_ .3$O_Q5']K4>S_#_,/[(K]U^/\ D> 4
M5[__ ,*W\)?] G_R8E_^*H_X5OX2_P"@3_Y,2_\ Q5']K4>S_#_,/[(K]U^/
M^1X!17O_ /PK?PE_T"?_ "8E_P#BJ/\ A6_A+_H$_P#DQ+_\51_:U'L_P_S#
M^R*_=?C_ )'@%%>__P#"M_"7_0)_\F)?_BJ/^%;^$O\ H$_^3$O_ ,51_:U'
ML_P_S#^R*_=?C_D> 45[_P#\*W\)?] G_P F)?\ XJE7X<>$U8$:2./6XE/_
M +-1_:U'L_P_S#^R*_=?C_D>!P6\UU.D%O$\LKG"I&I9B?8"O7O 7P^;2I8]
M6U=5-V!F&WZ^5_M-_M?R^O3N-.T73-(39I]C!;Y&"8T 8_4]3^-7ZXL5F4JL
M>2"LCNPN61I2YYN[_ ****\P]0**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PJNK\*^%6U)EO;U2MFI
MRB'@RG_"CPKX5;4F6]O5*V:G*(>#*?\ "O25544*JA548  P *]G&8WE_=T]
MSP\#@>?]Y4VZ(%544*JA548  P *6BBO&/<"BBB@ HHHH **** "BBB@#D?'
MVCF]TM=0A7]_:<MCJ4[_ )=?SK5\+ZQ_;.APSLV9X_W<W^\._P"(P?QK895=
M&1@&5A@@]"*\ZTIV\)>-9=.D8BRNB I/H?N'\#E3^- 'HU%%% '">)?#$]A=
M?VWH6Z.6,[Y(HQT]2H]/45M^&/%$&O6WEOMCOD'[R/\ O?[2^W\JZ"N'\3^%
MIH+C^VM#W1W$9WR11]2>[+_4=Z .XJEJKE;/ /WF -<[I?CNQFTB2:_8174*
M_-&O_+0]MO\ AV^E;-W=1WND6UU%_JYMKK]"":TI?&C.K\#,RBBBO0/-"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **K2:A90R&.6\MT<=5:501^M/AN[:Y)$%Q%*5ZB-PV/RH
MN%B:BFR2)$A>1U11U9C@"JT&J:?=2^5;WUM-(/X(YE8_D#1<+%NBF2S101F2
M:1(T'5G8 ?K5?^U=._Y_[7_O\O\ C1<+%NBHI;F"!%>:>.-&Z,[@ _G38;VT
MN'V0W4,K>B2 G]*+A8GHHJI)JNG0S^1+?VJ3?\\VF4-^6<T 6Z*** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110!X5IWAZT\4?$_7+"^EG2(7%S)NA8!LB3
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M4.HI(]F))C*L1PQ4*IX]ZL:+XB\/^'/A[+?Z9;:@EM)<M%A]K2>:5X).0,8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ;6D?\>C?[Y_D
M*OU0TC_CT;_?/\A5^O/J_&STJ7P(****S- HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH Y3QYH_V_1_MD2YGM,OQU*?Q?EU_ U>\):Q_;
M&AQ.[9N(?W4OJ2.A_$?KFMQE#*58 J1@@]Z\YT]CX0\;R63DBQNB I/3:3\I
M_ Y'YT >CT444 %4-7_X]%_WQ_(U?JAJ_P#QZ+_OC^1K2E\:,ZWP,Q:***]
M\T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#B]"\$3Z1XWU'7WO8Y(KII66((0R[WW<GVKM***4
M8J*LARDY.[. \1?#&#4M4;5-)OWTV\9R[[02I;U&""IK)F^%_B#598QK/B8S
MPQ_=R7E('L&(P:]5HJ'2@RU6FD<KXM\(/XA\,V>D6UTL/V61&5Y%SN"HRX./
MKG\*V]$T]M)T.QT]I!(UM"L9<# ; QFK]%6HI.Y+DVK''>//!<_B\:?Y%Y';
M_93)NWH3NW;?3TV_K6SKV@QZYX:GTB1PI>,!),9VLN"#^8K8HI<BNWW#G=DN
MQQ&F>"=0M/ U_P"')M40^>Q,4J(<1J2"5QGD'!_,UB67PLUO35=;#Q9-:JYR
MP@5T#'WP_->I45+I192JS1S?A3P_JNA&[_M/79]4$VSRQ*6/EXSG&YCUR/RK
MI***M))61#;;NSSW4?A]J<7B:XUKP]K*V,ERS-*KIG!8Y;'7()YP13]&^'=U
MI?B^UUV;6&O'16,YE0[Y'967CG@<C\J[^BI]E&]R_:RM8XZW\%SP_$27Q,;R
M,PN#B'8=V2FWK^M'B3P7/KGBW2M9CO(XH[+R]T;(26VN6X/OG%=C13Y(VL+V
MDKW.4\=>$IO%MC:P074=NT$A<EU)!!&.U<U\6+<VG@W1[8MN,,R1[L8SB,C-
M>H5EZYX?TWQ':1VVIP&6.-_,4!RI!P1V/O4SIW3MNQPJ6:OLCSB#X:ZM>Z/:
M0VOB&1-*N(DF:VE+$(Q 8X4'!YY[?UKND\*6]IX+G\.V4FQ9('C\YQDEFZL<
M>];L$$=K;16\*[8HD"(N<X & *DIQIQ02JRD<=HW@N?3/ U]X?DO(WENO,Q*
MJ':NX =._2K/A;PK+X?\*W&D2W22R3-(?,12 -R@=/PKJ**:A%"<Y,Y/P+X0
MF\(VEY%/=QW#7$BL"BD  #'?ZU%X8\%SZ!XGU35I+R.9+S?MC5""NY]W-=C1
M0H15O('4D[^9Y[J7PZO8=<FU;PUK!TZ6<EI(B#MR>3@CMGL0<5J^&_#FOV&J
M&_UOQ#)?'RRBVZY\L$D<]AV]*ZVBDJ<4[H'4DU9G >)OAU/J6O\ ]MZ+J9L+
MQL%^H^;&-RE>1D=?6J+?"NZ:_L=0EUMKF]2<2W4LZD[P"I 7GL >I[UZ;12=
M*+=QJK-*P4445H9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ;6D?\ 'HW^^?Y"K]4-(_X]&_WS
M_(5?KSZOQL]*E\""BBBLS0**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "N5\=:-_:.C_:XES<6@+C'=/XA^'7\#754A 8$$ @\$&@##\)
M:S_;&AQL[9N8?W<WJ2.A_$?KFMVO.+,GP?XX>U8E;&ZP 3T"D_*?P/'YUZ/0
M 5%<P"X@:,\9Z'T-2T4TVG=":35F<U-!) VV12/?L:CKJ:*Z5B7U1RO"KHSE
MJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SE
MJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SE
MJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SE
MJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SE
MJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SE
MJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SE
MJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SE
MJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SE
MJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SE
MJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SE
MJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SE
MJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SE
MJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SE
MJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SE
MJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SE
MJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SE
MJ*ZFBCZSY!]5\SEJ*ZFBCZSY!]5\SEJDB@DG;;&A)_05TM%#Q+Z(%A5U9#;0
M"W@6,<D<D^IJ:BBN9MMW9U))*R"BBBD,**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#EO'6C_P!HZ*;J)<SVF7&.I3^(?U_"K7A#
M6/[7T*,R-FX@_=2YZG'0_B/US6\0&!! (/!!KSFW;_A#O&[P,2NGW?0]@I/!
M_P" G(^F: /1Z*** "BFM(B#+NJ_4XIGVFW_ .>\7_?8IV;%=(EHJ+[3;_\
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M*.5]@YEW):*B^TV__/>+_OL4?:;?_GO%_P!]BCE?8.9=R6BHOM-O_P ]XO\
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M 'V*.5]@YEW):*B^TV__ #WB_P"^Q1]IM_\ GO%_WV*.5]@YEW):*B^TV_\
MSWB_[[%'VFW_ .>\7_?8HY7V#F7<EHJ+[3;_ //>+_OL4?:;?_GO%_WV*.5]
M@YEW):*B^TV__/>+_OL4?:;?_GO%_P!]BCE?8.9=R6BHOM-O_P ]XO\ OL4?
M:;?_ )[Q?]]BCE?8.9=R6BHOM-O_ ,]XO^^Q1]IM_P#GO%_WV*.5]@YEW):*
MB^TV_P#SWB_[[%'VFW_Y[Q?]]BCE?8.9=R6BHOM-O_SWB_[[%'VFW_Y[Q?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %<QXXT?\ M+1#<1KFXM,R+CJ5
M_B']?PKIZ" 1@C(- '/>#=8_M;0HQ(V;BWQ%)GJ?0_B/U!K;NI_L]NTG4] /
M>O/8,^#O'#1'Y=/N^ 3T"L>/^^3Q]/K7<ZO_ ,>B_P"^/Y&KII.23(J-J+:,
M=Y'E<N[%F/<TVBBO1/,"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "G([QN&1BK#N*;10!T5I/]HMU?^+HWUJ>J&D?\>C?[Y_D*OUY
MU1)2:1Z=-MP384445!84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!Y[\1KHN;>V>PD78VY+IB-K9'*C'X=<=.E9GA>]N;W
M4IWNKB29EA"J78G R.!7I]W:6]];/;W4*RPN,,K"N0A\*C0=1FN()=]I*NU5
M;[R'.<>X]ZTI?&C.M\#+E%%%>@>:%%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 50U?_CT7_?'\C5^J&K_\>B_[
MX_D:TI?&C.M\#,6BBBO0/-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML9=%:G]C?]-__'/_ *]']C?]-_\ QS_Z]'MZ?</85.QET5J?V-_TW_\ '/\
MZ]']C?\ 3?\ \<_^O1[>GW#V%3L9=%:G]C?]-_\ QS_Z]']C?]-__'/_ *]'
MMZ?</85.QET5J?V-_P!-_P#QS_Z]']C?]-__ !S_ .O1[>GW#V%3L9=%:G]C
M?]-__'/_ *]']C?]-_\ QS_Z]'MZ?</85.QET5J?V-_TW_\ '/\ Z]']C?\
M3?\ \<_^O1[>GW#V%3L9=%:G]C?]-_\ QS_Z]']C?]-__'/_ *]'MZ?</85.
MQET5J?V-_P!-_P#QS_Z]']C?]-__ !S_ .O1[>GW#V%3L9=%:G]C?]-__'/_
M *]']C?]-_\ QS_Z]'MZ?</85.QET5J?V-_TW_\ '/\ Z]']C?\ 3?\ \<_^
MO1[>GW#V%3L9=%:G]C?]-_\ QS_Z]']C?]-__'/_ *]'MZ?</85.QET5J?V-
M_P!-_P#QS_Z]']C?]-__ !S_ .O1[>GW#V%3L9=%:G]C?]-__'/_ *]']C?]
M-_\ QS_Z]'MZ?</85.QET5J?V-_TW_\ '/\ Z]']C?\ 3?\ \<_^O1[>GW#V
M%3L9=%:G]C?]-_\ QS_Z]']C?]-__'/_ *]'MZ?</85.QET5J?V-_P!-_P#Q
MS_Z]']C?]-__ !S_ .O1[>GW#V%3L9=%:G]C?]-__'/_ *]']C?]-_\ QS_Z
M]'MZ?</85.QET5J?V-_TW_\ '/\ Z]']C?\ 3?\ \<_^O1[>GW#V%3L9=%:G
M]C?]-_\ QS_Z]']C?]-__'/_ *]'MZ?</85.QET5J?V-_P!-_P#QS_Z]']C?
M]-__ !S_ .O1[>GW#V%3L9=%:G]C?]-__'/_ *]']C?]-_\ QS_Z]'MZ?</8
M5.QET5J?V-_TW_\ '/\ Z]']C?\ 3?\ \<_^O1[>GW#V%3L9=%:G]C?]-_\
MQS_Z]']C?]-__'/_ *]'MZ?</85.QET5J?V-_P!-_P#QS_Z]']C?]-__ !S_
M .O1[>GW#V%3L9=%:G]C?]-__'/_ *]']C?]-_\ QS_Z]'MZ?</85.QET5J?
MV-_TW_\ '/\ Z]']C?\ 3?\ \<_^O1[>GW#V%3L9=%:G]C?]-_\ QS_Z]']C
M?]-__'/_ *]'MZ?</85.QET5J?V-_P!-_P#QS_Z]']C?]-__ !S_ .O1[>GW
M#V%3L9=%:G]C?]-__'/_ *]']C?]-_\ QS_Z]'MZ?</85.QET5J?V-_TW_\
M'/\ Z]']C?\ 3?\ \<_^O1[>GW#V%3L9=%:G]C?]-_\ QS_Z]']C?]-__'/_
M *]'MZ?</85.QET5J?V-_P!-_P#QS_Z]']C?]-__ !S_ .O1[>GW#V%3L9=%
M:G]C?]-__'/_ *]']C?]-_\ QS_Z]'MZ?</85.QET5J?V-_TW_\ '/\ Z]']
MC?\ 3?\ \<_^O1[>GW#V%3L9=%:G]C?]-_\ QS_Z]']C?]-__'/_ *]'MZ?<
M/85.QET5J?V-_P!-_P#QS_Z]']C?]-__ !S_ .O1[>GW#V%3L9=%:G]C?]-_
M_'/_ *]']C?]-_\ QS_Z]'MZ?</85.QET5J?V-_TW_\ '/\ Z]']C?\ 3?\
M\<_^O1[>GW#V%3L9=%:G]C?]-_\ QS_Z]']C?]-__'/_ *]'MZ?</85.QET5
MJ?V-_P!-_P#QS_Z]']C?]-__ !S_ .O1[>GW#V%3L9=%:G]C?]-__'/_ *]'
M]C?]-_\ QS_Z]'MZ?</85.QET5J?V-_TW_\ '/\ Z]']C?\ 3?\ \<_^O1[>
MGW#V%3L9=%:G]C?]-_\ QS_Z]']C?]-__'/_ *]'MZ?</85.QET5J?V-_P!-
M_P#QS_Z]']C?]-__ !S_ .O1[>GW#V%3L9=%:G]C?]-__'/_ *]']C?]-_\
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ML9=%:G]C?]-__'/_ *]']C?]-_\ QS_Z]'MZ?</85.QET5J?V-_TW_\ '/\
MZ]21:3&C9D<R =L8%#KP[C6'J=B32XV2SRPQN8L/I5V@  8 P!17%*7,[G=&
M/+%(****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
4H **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>gwpjrhodncoa000026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000026.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $K ET# 1$  A$! Q$!_\0
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MA1$$$%$0$'9!1/"(B]53X@>8Y$CCQOJ;'+,:)LVMPQ$$@C@<IY1^4!W;;_\
MB<>/8 '9=U04<-=MT%45-H3;UR629#;5KD[ZHRH+':,D*239I65_'D@$T"KR
MLYJ*B"J(Z#8D*.*L1$X.,S8WL/J#Y<>1&GC=%(U304\!D&1964\@D3\N41.2
M9)IQ13=44!A V'<66VVV0%$X@/G>K$WYV%_#(?WEGSTXJ W7ZS4+.;4+!J*_
M@^'6S]16T+;/9BW>10";:N+FZV7:RCUTUMRIK*V0!1&GH<R:\W(<>A_"0G37
MH'P62FN\N<BC5(GAU=3VDYDP'[ML;-RE;=CDG'>/-:ASV6GFT0.++L1&G1Y(
MK[*HF]4MSSXCPZ\5!U_J_;4I=O-<9R#"#1SBLRUC!)QYPD=%M":R.J?EU7 U
M5.VDN1$=<3959%5X]3.^N7*V?O=5/C'-1&Y@,'\0T\R\ .,NMF+@&![JA@:*
M2$A;(J$A*))LJ+MMTT%SZY=9#UR^9.0J*#86!Y'A]L]A&9%Q-R\I6&2CW! /
M%N/E=*XJ0,BA\$1M5DBU91VMUK[.$ZJ.)=5/IQOPZ\?<*4,0U2<EVL?#L[@1
ML<S!_D-7)BN.N8OF - ID_C<Z0(&Q,5L#=D8Y/,K2"@FC3UG%!)SA53"J;>_
M1$=$56/4CDKL@L=TY@.\4GFWDV5HV:HY]S0):C2UQHB\>W;V\=Q]Q#10.+32
M62%4?Z(J_6#KK,+MQ(R2YTN1&K:F$"\3G6M@^W!K(:$(DHH_-D,MDZ@DC+:F
MZ0\ )4(KX:;8+%TZQ&MQ]ESXN9YG7MHHH+MM=S$%VQG*G]1DG?W,&/Y&) 9B
MQ1519Z(HW]1N#/Y7A\>^IZLK7(<*E.VD.$VPLB594LP6X^25,>. DLE^5";9
MFQHJ(7Q$ZLA@**2HBNNN@BUW-X]';'[]TYM7<5L.1R!;KR):&9):-4<C7./O
M*D91YMJS+1EN%8,&BIW1=;X$/]>"*]OI<S']M*VRL)$1:ZWA,#57]:J[I NH
M$E6IK+:K\QQG"XR8CJI^]B/LFNQ*0I!QOUZV'CS^:*U[WX%_5.JBQ-_^GGHB
M-U_/HB.B+G=?S7_?^_\ JOY]$7'1$A5>+XW26>1W5-0U%5;YA81+;*[.OKXT
M2=D=G JH5'!GW4IEL'K*7$IZV!61GY1NN,P8D>,!"TV(H1+O1%P2H(D1*@B*
M*1$2H@B*>5(E7PB(GE57PGUZ(F\&7XFXXC(9)2DZI<$%+"/Q4T+BH(ZKG:4T
M7QQY[[^/?HB<2>40D5%%40D)%115%VV5%3=%]T]EVZ(CHB2KF[K:"*DJR=<%
M731J)&CM')F37]M_AXD5I"=?=XIR5!'@ (3CI V)$A$UOVWEH2&YB5L$8O8O
MCZ-92"NZHOPBV:#R5$15#XE23?9$(OE0BB:5=Q)UO<N#W&%=GR)KD2>R<26S
M&( 5#<CN\7. \"'O!W&#(%5IPD5%(B6Z@"CPFR%2$Y:E.=!Q2W95]>:,HA>0
M:CM]MH!38?W:EMR7P4X&_P#?TS/IG[E3.P*.VX\Z2*VV)$2HJ>P"IJB)OONJ
M;;;;+OM[[;(4 RL"1E< \+FX^EB,_K=AY'D62L5-W<QRGC%J(+\J3\+\.U%A
M*$<GFFI$M]UI"?4>"D".D1$8<0%#!%==:K))NF1#!P>DC\]R9IX@JJ[[D:1@
M0E)?*<E7=57SN7G=?/0=='Z<-$ZZ\TC:>T#]Q2O65I:+%@66397-^%B$Z<EY
M!R"PBQC1QS^CQ.4:*P#BMQGY*@&S4J.7$AFMM1QY>A_"*9N%0Q&"+#1EAAD.
M+;("C0HNZD1<^/DB\J1E\SA*I$YN2[58G>R(\;\LKVRUSOP/#1-FTLXT(-V]
MY4DFMACM)Q1%1$\NO*BM-)Y\JBD:BBD+9K\JE1QR^=[]?P,@F:TU8Y++XB2C
M##DA2^!? QA0R!QN'X3XV<J"X!/DJLL. N_:V6,<S/ CZY6RMXYCT\55)=74
M5M="&+%8_=DJFYWC)TG7"1$<==[BGS==).9F2JJ?* <6P 1JP<ZW#ES\SGY6
M]^.BS!@Q 7=MD6MU0MV"<CJ)"J$)BK#C2B0DB$*IYY(B_3?HL=\GD/>WD=??
M*W-0#(R6;19SE+5E)D/6+UJ,U'I!<I,JK>B1?NTVO ]Z-#C*U6H8<D%Z(]R4
M7>:)#?A:_CQ')?3EQ\1I]>/JE99&/Y'(=F=ZQI;=Y&B*WHYJP9CAMAP;^)8<
M!^!/  7R%A!E@@HG$15!5+Y]=9*K$LK',,9?KX<SOY/%N'RBU5O2UL@9+DDD
M56*^UKXQ2D;FR&P,V9<0FH$MP' ^%@'VF7 \[^/](ICPC3:7:/ID>H%6V)!'
M%BCI'I3QOPA==;>E3+)8SR,?$2$CQ&VH:%(".T#R/D3KZM,2W,\;\O3+[HIZ
M$0;!MIIMMIIH!::;:% ;!L$V$0!-D$139$%$1$1$1$3JHN>B(]_]_P _\NB*
MD689&FH.;V-TR\3F/XN[-QO%VT55C2'HSY,7U^(JJ@Y\?.:*!"D(FQ5<%MZ.
M:M6#BGBZYL!QXVT];Y?-%".>'*BY/B-W71WY,JB?D-WQL#O'B8A>2J^GF2IS
MRD(M@UD#^/G%!.XXZK<GM-J#<EQL!86USSOEE\[^ORT3KKK^9VTYLU9N+&$'
MSA.KVIPKO_6K9",N_P $5QNR:Y$FZD+ >-A^7)0@$6ZNIB.29+N@BFR+\R$J
MILOA=]D\^VWT7^2)L0"PMF1XJK6M=(6,6,?4:DFO5L6<_'J\U"-)<BQ4-X@8
MJ<F=0#$!?8?[%18ODB=V++B2'7!;K24BJ4]+<TN)C-N09"[/9'[N5IU)3<H$
MY?'(7!PD=VWX#NB&J?*GUZ(M@O1$=$1T1<I[_P"O_P!%_P!_E[]0Z=?+QY>*
M+Q6?;4Z$:\>DWUY5_KLQ;)[9G'M6,HPBSTTU6@A).ST:U0P3&*NG8TVR%]/Z
M,F%Y7 H'K*GK9#H5&3Q;/+L8M8KCYMK9=[]ED^S&T.#8GL%CE)24]97&:IPW
M$GLC;42SECG6CF(#XYZ1S&2P,WVB5KIHK.#G-=QS&!64LT6(TTCW-B^&2G#G
M;CF$_$2P9$V)N3^W=:X9!R]'_P!GS]HAICZU/3D.J5M;8W@.?X$D7']=<1LK
MF#!B83E+<17$NHLBRDM.?L%ES;+]OA=[-5L)\#OPW7%L:JR99Z=QK"I,$Q;$
M,)EGBJ7T%5-2FH@-XINY>YG>,S-@ZU]VY+3<$WTWVFF%1!%.&N:)6!VZX%KA
M?4$'/7W&8N%@:Q?:Z?9Z:,'(@V?J+QC/\@C]QL\7T1A76MUX,MO8?@9C>F-?
MDU?2RE<46R2^L*MI@BYRG8[(FX&UK[*U?IL]3&C/JUTMKM7]#<I_:C#YTRQJ
M)22J^PI+_'LAIY'PMMC>4X[;QXEOC]]7N<"?KK&*RZY$?B6,59%;.@S)!%/"
M*J;[?DJ+_!%\+T1<;+[;>?RZ(N43?^_;=?;S^:]$3,N\^Q>D>*$<_P"]K9#)
MI*2@;*YMD>%%_=OQH7=&O%53BLBS<A1&U_YLAM-U0B8,V^RZT<=GS;9W%H:"
MAQ:6F2N=EMM;^5MK69#F=^82_*K5:,6+'V5M')NPR"*7Y>7/A<'(Z>VONCPL
MHR9'"6'F<][MEXC7%923HQ(BINCIQ(-;8$VJ?U0G-FGC8]]A5<'0JIG.1\BC
MV"V4JMB6L-+.=8.%0O&W):.P<D..+]SSW%,FF"F/F(1K&>^2BWVV'#3P19ZY
M/6(7;)R4PZNR#'DU=I'ED1>PA#>AA(<-41=@;:,B39439%V(DBUR& 4EN.S)
M26ZVT1]BO:?LY R)&\9E2C5K4J2HQVRD.R![:=D>)&B%QW(NG6*Q6UQO'A@U
M\^#28I<XNL9N<C,9R<\MK%A+/6,R\\\VW':[8M_>+<9_G)>7LB2HO3YIUUUY
M)-RJ8MAI_DT5D"==?QFV;:9'8C=)RN?1&A1$55(^7!$WWW7QY\]3SRM:_6MM
M=?F$4E5-?EN31XLNDHS:KI45F3#M+R2U50I$>0R#S#C$=GX^U<0V2$Q1RNC
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M@>%K9997TOK]AFBEC0N5<6KM^Q<MQ4G4&066/2)->;Q5\^15D#$B7%"0B/L
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M0^=T8T4')DHUV&+&%7GU\;[D HG;;1-R)UU0:!/)&BJB=0 -T!^MO[_"*R^
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MKJY&ZN(&*:<M1F<"H68[BHL*:_26^3,B (_DDDQY==CT>$T-" ((&[P-^\D
M?(3GGO$$MUO9M@#HO2N#;+X#@,+8L-PZGB+0+SN8):EY  WG3OWGW\ 0W/(:
M6V3:H8PQ)T\DPZ:#&AAC P[2LKX+#<6)'@U2*W,BQHD< ;!MND<GMQ(S "*.
MHR(!X1%W"V7EIU;+T'DN0+31]H-Z< ]2_I>S['ZB,R]G^$05U2TKL4;!7V,T
MPYARS8KV'T#NC&RRG2SQ.>*&@'$NE=X*XRP0:/$*5M;1S4SA?O6[K,[ 2?\
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M+E;EV,S? F,Z@O8EA7.HZ#1N@PW+!M&7VR7M2":*HAAJ('%T4\3)6'DU[0X
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MS/8?"(KK#K"K]$YD)FON>Z[JM19C5YQ44FQD:%4\R(QJ\RWY_$\) V\ JGU
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M>(%S\QQT"EP4E3=2\/M\HQ&NA9EB=>5;83\AF.Y#D-7C;;;,.GG5+<07KZ1
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M.DJ3(0+9X^]_Y9DT&LF]GXKI;%<(KL'J705D=@3>*=H=W,[#<AT;R +VS+"
M]IR(W2TKVSL7MQ@&W.%LQ'!*D&5C0*[#9GL;B.'3#(QU=.'N(:2#W51'O4\X
M![MY>V1C+_JJ^-_Y?SV7W_NZVQ<P6/*E,08STN07%F."F7E-S5/PM B_B<=+
M9ML4\D9(B;JJ)T11!*?,OBK&4A*^\X<EP!V\&>Z,1P14V)6VQ;8!-O/%/!(2
MCT6)SRUN?3+73/WOF.&24Z* R*B5BIH!K\1,1MIYT9$E$!!9Y-MN<6&P$0X?
M*IM@([%W'"4KKZ'EZ'^_&W-/FPLH+E?-9;? .<.2TTV;9LKN3!@  +@!^?%!
M5-OZOOMT5ZZY*,X<M*]HH)N)NR*?#&I(O<855[3@$JJ)\1V:<1%(@=;7DB<D
M3HH2> Z]+^FFN>A55M6?45B6F^0'AL&LLLRS@JU<ALZ2IDQ8<>@J'1>[5OEF
M2VKS%33!*6.21*]R1(NI45DY<*I=@Q7'A>^9\]>O3R0D $G0"Y/@-<A]@JU:
M _:7X?K6&23M*L/JLYK\:EU;&3QJ/,;BKRB*%BW*6MLHU1J%I[@E?;4UBW#E
MMTUO77:T=H4*6L6R?<;?<ZTE+7T5=WWZ.JIZK]/*Z"?N)62=U,S-\4FZ2&O;
MQ!-P<C8Y'>,:V?Q[9U^'QX]@N*8.[%*"'%,.&)4-11FMPZI!-/6TPGC89J>4
M [LK 6FVM\C<S'O5UI/G=E!Q-ZRGX?J"XI5]+@VH,$\6M+B4+2O/2*"8Z](Q
M_+66&6A=DIB%U>DPV"MNJR9$(:M;0HB]6'I2TZ]66G$S"=0!?CWT:<M]A6>0
M$!;[!<K:ANPXUM4-N\H[E<[&><KKC'WT^[;FI>D190_%&W/:(O.[D_I:]7'H
MIO+#()VG<_/\18W;;U'TGK[#+:DX8D1I)M\;@MR<QQ0A:5"FNV=.]21G$(&L
M@F *.DZZY(DZ'ZE=,]5F5:S:HJK!YT?A;"Q:1AN4Z<8E XUFXTJQ[!&2'MN0
MKAF4VR8<#9$P01(I)TMU&RW&K:V;T!UKM\.IX4U8E5C65">88!,[;++DZ.>(
M2946OHHC=DLJ.CN$M8S.=1OOORWB=>[TRO?CIUU]D\ULDT@]8>;WN34^F.H.
M -4^IMK!F3:-K$,AB7.,Y["JQ:*TM,/?MUJYL=*YIQJ3:4-VK%O61W4?!;2
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MQL5@'OP+^J=5%B=$1T1'1$=$1T1<IY5$7RBJB*GYIO[+T114ZH0&)ZN[_P!
M*2*)_6+@XZ#2)XW5341%O?W+;\^B+"A1HDO%P164,'65=(G!_>K(3<B>5Q$4
MD>1]#-'44B$]C1?9.FO5E,[>_"_ED,SY#,^:I/ZJ/4?;XK I-'-)+1EK53+<
M>@6F691';&2FDV(V;+C+MX+9LNP'L\R"0W)C8-3S>;454D9?;0I=35L5EWR#
M9[ I<9J@'[T5%"0:J;=.A%Q#&3<&63*VNXP[^?P[W7?:)MY3;&87NP&*IQZO
M86X51%S3N?%N/KZIK7A_Z6G._N-W?^YJ&_IP]C6RR0T+HZ"JPZFBX]1,+'B1
MA<)PC??F2GY$EYR5,E3K"6Z_-L;*?,>?FVEE-D/S;">^_+E/O/NFZ7==+30P
MQ110QB&GA8&0Q-R#6BVO$W.9)-R;DDDDGQAB-?55E54U=94R5>(5DKYZVJD-
MY))7FY%[#2]K -:T -8UK6M ;6=YO2Z?XY-R.\D Q&B@J- I"CLF0J+VF&!)
M4YNN$FR"B^$W)=A$E36_" 2X[K&C,Y 9Z 'GEH.8XV7':^L;1P[X!?*]P9#&
MW]SWG.PY  $N-K-:">%DR_L_M'M3_5UK15^I?*;*5B^@.EF6/6F!1(:#%FZB
M:C4!.18;U0\+"._L3B4DWF[ZX;?_ /O-D#3V.1.=97W@GU1MCM&*G>PFE<Q\
M4;VFH?NM<!(P_#'$_/-AOORM.I+&W <O2789V85='+%MWM#W]/75$4AP>@#Y
M(/\ MIVF-U950M+0^*9A<*6"1IWFC]1(23$#Z<*BV;LH8&Z;;4UA.W8,*8BK
M<@$V-T4)14HS^RO1W>*";)"J[$BB/7R]2)KW-@5J^!-<ONV&JDPB"H_&2510
M^*V7=58;12&,FR(:D4A-A[2]%#H1IPN=!U?[7"PZ>F&\?>>?,A@1%41<#Y2=
MGIL0J&Z(A-PT^9Q"0FS>-L$559<42@&6EO"]Q;RN1^?"]DV]1LZP;1RG&XU
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M(LVUQO;VH-_A]?J>/DM_>FV=,:AZ<8%J"S'&&.;8;C>4E"%Q'%KW;RGB6+\
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M:R'!B S%A!$B@TD-&VP;$%[;B*!"3?5O,\3F;KV.      T!K0   &Z  9
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M$X#;,W'7J^75SX3TNHL89([6SY;+)D*U]?;*WKX_T+YW*S-I+&6T[&)ON-/
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MV"9K-T/<8Y""YIOZO_4+ZP_3CZ9*D)&LNI5)2VEA#-^FPJ!W<CS[)F5$@_\
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MO<YY)O<BP3HQN?8L6L#*L>LK7!\UIU,*_)L9FN4^15<B,_Q=A%,B<1L:X9+
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MQI,V'(,FP<!P@F2(IFK2&VZJD36X*'7>;7%S0XZD G7EXV/EEF%[^L+@B]B
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M3DT_$WL\H57V9^\WAW3WXU,QE$3W1?F>4TWVV0=_S1'7ET43_E3''L@NZ\4
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M.<H]DVXVUVC0T_<L!<VSSQ],M3RMGX\0%W/0T3:>-CG "0BY .GS^VGCIO\
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MZKV)_P!/E;BE-38KM76/PZ&ICCGAP^%C9*LQ/^)O>EQ[NG+FVR(D>"ZSFMS
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M&JKR<<,E-QU]TW'GW3<>><<=<,UTS: 5$QJZHOGFD))>X$D!W_%HO9C W)K
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M,.R+AU([FENGSB-U[0MBXPYB%23?&0\KW]51\@P._P!%1$3KS63O$Y\QK_\
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M-/;7[.SU=8]=.T$_T]ZR3YHO*TQ(I7X-]2S/FXBXUD5'?2:!EIPDW0[*QKU
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M7'M)7[,PU^TV&[4/K)8JS#H98.Y9&SNZID[)(W=Z[(LW>\+F!H(WFYY9+D^
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M2GD!-P8?8!XT1=I#Q<AZ*6'76GAHDHL@G0WC9M::QCO-[(ZC0C8"WQ15YN?
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MJ?71$=$25>T-/E%3,HL@KXUI4SFE:DPY0(39)NB@XV2;&S(9-!=8D,DV^P\
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M82*];2*6UQ:SEM6,PWK!ZNEJDYYY87Q)]\;(XI48KA+)JO=-3'(Z*1S6AN^
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MPQ8S% ('PRN;$VM;$2Z$"0D!LK&DM:7@AS;-+F[H!K_J[JY)D8_:NP[_ "'
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MP:F/IYG4""U7CJ+.L2K\/+&\3G766Y7DF(8H_:0+H+O(.]45;UE-BS#D2*.
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MG)>9I3O+[(3;\=*^2*KOL\V3>ZN,F*2V?I[W.?M8?3DB?.F[B[7**2[HM?\
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MV\HJ3=O;^._G_P":(17_ .B(Z(CHB.B() ,%;< 7&R7=1-$)%7;;V5%3V_\
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M_![.\-BH,C';(I$J#'<QUZ*\QZRV;VDH=I:".JI7L;,UK6U-/I)#,0 YMO\
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M!I#96[RCFN0%/H(\N:_6XM4*_%@"W(LID^.Y:V9$%A:/L#);:! 2$PTL=LP
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M9J?':1VY4X360.:;$2P31FX-M)&,-[@7T(/HNV?K1@M4!/V63T< !0B(IEM
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M7%ZYM[33'VL8]26(4=0;,G,M*7YL6!6ZA(%7'17+72I9DB5D=E*5MX-.EL+
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M0VULABX-2H[B8M@1#P\QR]=?#U274V:J(MNN<D%/E)5W54_7QY1=ME3POO\
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MEE7363BRH5A$-7(\Z'+BO&S(:>!&I#!F#S9 1"1+@6OQ_FWCG;3GDO%'Z_\
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M:?3_ #ZG@>/7Y19K)[JB[KN*IR3PF^R>_CSM]-OY]?.VZ;\+WXY"^7#4>?\
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M1$=$1T1'1$=$7>Q[E^B?Y]$60J(OA414_)4WZ(N. ?V1_P *?Z=$1P#^R/\
MA3_3HB. ?V1_PI_IT1' /[(_X4_TZ(C@']D?\*?Z=$7.R;;;)M^6R;>??QT1
M&R?DGU_Z^_1%QQ'^R/GW\)Y_Z=$1P#^R/^%/].B(X!_9'_"G^G1$< _LC_A3
M_3HB. ?V1_PI_IT1' /[(_X4_P!.B(X!_9'_  I_IT1' /[(_P"%/].B(X!_
M9'_"G^G1$< _LC_A3_3HB. ?V1_PI_IT1' /[(_X4_TZ(C@']D?\*?Z=$1P#
M^R/^%/\ 3HB. ?V1_P *?Z=$1P#^R/\ A3_3HB. ?V1_PI_IT1' /[(_X4_T
MZ(C@']D?\*?Z=$1P#^R/^%/].B(X!_9'_"G^G1$< _LC_A3_ $Z(C@']D?\
M"G^G1$< _LC_ (4_TZ(C@']D?\*?Z=$1P#^R/^%/].B(X!_9'_"G^G1$< _L
:C_A3_3HB. ?V1_PI_IT1<\13V$4_DG1%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>gwpjrhodncoa000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000005.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #: A # 1$  A$! Q$!_\0
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MX &>,U2Q[WR/?)(]TDDCG/DD>Y7O>]ZJYSWN<JN<YSE57.555555555>NT
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MT]GM_P"!#_A)_IH_JS>[G^^;YX_SJ[;_ &ST_I)XA_OS5O\ F%U_U:>SV_\
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M:%RN< 8 SZ#GG-4H_JS>[G^^;YX_SJ[;_;74#^DGB'^_-6_YA=?]6H_L]O\
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M1M+FPM)(%CVAX[F;VAHT'S.S8JH[E6/4.2A( [5LK758KAXXE1EDEW YQA<
MM@\YSM&>Q[_:,9O%/).YX?Y%R?)/&MNZAW62M6V&<M6"!G**=)#,$[R)80$A
MSLG'*G'>R>%Z>B9SFJR1K'M\MQG@<[L =O7@=^/6MD< $GL!D^O YK/WQAR/
MSSG+/D7G#G^?,7_..Y#A(XVH:FXN*N[X^U5J_5&ZG1JZC*;7EV_XMB!LD!FO
M[2O%K+)R6%<\F$U@W;Z?X%N+:WBN[V&,1WJ;NB'S*JL21U-HV .-K*$=CM/F
M )->;:GXXL[J=K72IYW6PGE2><1 02,R"-NGN/4(BE)21GC4;@>F6&TMCSY)
MY1KN3ATRNE;>7.?K[U=(14D'3SP6^[?7S5!EY%8C/&LYV%L->3%5#^A["Y$6
M8V<-PX0^W@T_2KC-M>R.\%@K-%;(O2)D("D"X&7*CRL(U4<C.?-@8X+B^LR;
MRV@5+F]"*]Q(YD+Q APHA.(T8$MF61B N5 !&3-?'DU-J^WK4\*X"MXTQ0FF
M@K<WHMY>Y<1FCU(RV1%]7)]?#CTMO9RUAD4T@;;"0N)C1XED]4P\+"]U'HT-
MQH3:5ID.G0R71(EO[JV/M,D?4,D>)UW,Q4' P@& !S7/76I7%IXDBUG59=6G
M6T<7$&FV=ROL4,_1,#EH78!5D5B6 <D,<@#N*Q]TO"=UP9VZ]O67NKRDOI+'
MF3N@OP#*1YBM=5%9SMIK@G&PEB#J(80E6\Q18I3(HQB1E0I[W/8SR[6M&NM#
MO#:731LQ4R1O&25>+>Z(_(!&_;NP>0#@\UZMH>N6>OV7MMF)$19.E)'*,/'*
M$5G0D$JVW=MW \D'BHR[<>0.YF6IT_!G"O(5[F,9O+"ITFZJ1K",2BA=0N>&
M/I#Y9(I2 5$8?'%.^I5AUFZ.M'2$TD2NBBNT+0-2\1ZA%INEQ=:X<]0Y8+'#
M&A7=-*3R(T)!8JKN>RJQPIVDUQ%;)UI7"!2 #C))/8+\3]GQ.*ME=DSYK.P#
M.M\WF1*W'"9Q+\*@'/9!J8*\+ZW.K8G.!L"KM]Y'+*5<$2OL)W.\V+CQY%#F
M]VC\+PZ9HSV<EU9:7=V\#QS:B%6Y?VTLO5"Y.YHFD7" J2-WT>2M:9KEYIMR
MJTR>8](G9E6!&26Q]W/.,<8Q$F"'XJGY>GV>X*-WEP6;',2/L1PSOQ@U5C-\
M9%;O!$?6!01"2BHXD$Q;X.9AR!%0H]\<_472?"GA*#Q L][<2ZI*59I+:^6!
M8[B_G EBE6&U2!8DC969X]UP"'5653C-TLUW[+LB5(MJ@ QDC8BXRJ[R2S;>
M%X49!SCC,U<S]DFGY,U]7L:J_P +EI]I9@QW00M':5U%30DL2,:VEE!,NIC;
MRS+>R$VFKJ@5(IG-F2<J-AAC;O%'R3:OK&HOJ6GOH]H;N5VELX8KJVM[:..%
MGZTC2-*3+*5'46*!4$KX& "3@@UJ&*-DD2Y?H]F9D=VW, J[5('8Y&6X4<9&
M*]1CZ/JFESO83V0Y^>>$J>B[0^VNFF*'25L!,M9PSBPI)X&SQPSMAF? LD:3
M112HQS4DC8_U-3Y^N8&M;BXMG*L]O-+ [(24+12-&Q4D E25)4D XQD \5T*
M,'1'&0'56 /<!@",_'GFK>=8:NHZ4HZ4HZ4HZ4HZ4HZ4HZ4HZ4HZ4HZ4HZ4H
MZ4HZ4I(O_G2V:?>)+_\ 5Z50\ GW U!?H3[U_5^SI6/>?</Q_.CT)]Z_J_9T
MIO/N'X_G7XY&,:KGN1K4^USG(UJ?F^:KX1/G]_2F\^X?C^=*(U);&-1PE6=,
MQ?FCW1L$C<U?L<R0YXL<K%^U'1.>BI\T54Z54,Y]!]>#C^==M^7T#$]2U!#D
M3YKZ"JUZHG_S&FJ]W^!C7*OYD7I5<O[A^OMI'F'D'E2$F$@69?*MB)AD'D>B
M?:Z-DS&.D8GZ<:.9_P!;I5N]AW 'V'\Z^/0GWK^K]G2F\^X?C^='H3[U_5^S
MI3>?</Q_.N2)B>[%\U_Y1GW?I)_)TIO/N'X_G5A^E9:.E*.E*U^_PGQ//T-G
M<8G_ .V7 /\ KQP?2E><WV[=CW,'+W(/&-7HL1LLQQIMQQ]$?R0/5"$5%7C'
M5IEU+?-L2S(*AC_JT)T\(9A<1KVSB>@.:0L.$CH=-\-ZI?SV0-I=16MV%D%W
MT':%8"3F7>H(  !)R01[JY36_&.C:/8ZC.M[97%[8;XAI[7*QS2W:D*MN$.7
MRS$+N"L#DD$]Q:_N17*U%!G(:F#4E5.;&)H*Z'0Z6O)+A*H[J.K$L"41Y)YM
MU]60T$1PJ20BQ,@7TQ>T,]6^P7D4-CIUO;-)-+;V^Q(A+(CS"1-N6WGOS@JN
M0%4 >E>8Z1+=7E[=R$64,MV[3R)# 0@CDB9V0!3R.6+2N@+NW ]\B;GB[@:K
MX$RW(FEL;RUUFDS SC/K6LM+#,T.E.!L+2GH*VPK6TEH$9%*@U79-+;812$C
MDR1"K# &-'(GMM'.F+<7D&YYXMT0D9HEBF )PNU59O3.1@'@'GB#9ZAK4NN3
MV&G(HMK:0AW0H)9(<J&=P[-&5 W;"N>"#R232?VO]LW-_+%:9R<W61Y7/8DF
MZ3*U>BI-M66&E*D'8!"VBL!Z,BG95R*Z2*XE#M##:V(3X5H$\QXC)(FEP:O?
M'VA98H;6WRD:2HX>2+&V,QLRC*%0ISR0,$CG S^(]5T/3@+-Q)+=W<49F:*2
MWEAC"D,_5VR;S(N2!O5=_8G(-=?OIX0Y+Y'$[7>-\=FR+S=W-CW!V@P1-Y5P
MFW<%3GN'[(@\@BXL H:TA];62L@J;%X-A'[ XGPTL\T,Q?%>+]+U#5_%$-AI
M]N;B[EL(G2/J11[Q$LI<AY72-0$B8@%ADC: 6(!] \!W44?AMKB1PMLEY.B$
M(<(,Q94*BECS*G(!!W'!\I 8/!?:9;\-<?WF]Y6J=GF.3+6\ML;5TE/IJ600
M3%FTU*='IUAS;[F<NQFLH[@,*.S+6D&97OLC0/>%"(=W_P FO@J]T>2[UG5X
M]1TS4H'FL+2&*1-LT-U%'$90T/5_JG:0^<["0A"G;FMKJNII-\Q!T98#''(9
M) <=3>Y,95BIQM522!QDC.>WSVR\=8+9TW,6GN-;>T"9<N@&"SGP[K[\:IXX
M[*PUQ]M\%!5G5M9!6APMB) *0F @MTTH9$4#H7]AX7BMKJ_UB6$7'L4$JPZ@
M;^ZAD626*)6N'18X(Y!U%QC8PVL,D;L@TOWD"01@1M-(KM'QM*@\*5)++P2"
MP.[( [ @TD9#B;E3DK=:2H[=\I1/XVEM9'1;RPBM L6@M816NC+EV%L'$L%B
M$\N,>84-LY,9*E(-\8CY"9->U[J<MQ<6WA33]-.FW-PO5N95E<7"0B,K/'>&
M-&,R$2#IP]39YPN\L6-[]"*&-K^21I50X12I8%U(*F,,%*\@')P<@G X%Z>0
ML3OZKCZCR=D$?K]?5OI:P.]S)=Z4/">)&)'6?!VX0%7]6PZ@CW10#IO?A^J4
MB?90,E>3&O?7PN7T)(W#F_58FC%O-)$);F%@P+S(HEB0,!$[O&OF=BQVGC46
M\T<EPX"CHX/ED"@J"?*-A9MQ]5P2>!VQFL37<SPSRUR5W6=U9N&X\T^KCS/.
M>W#T;,V 5?2TY=GJM$\6$AHS9C)O7]66*_$I#(WT"2RSO8U6J[XOET^_O;K4
M9+6RFF6*ZEZJP(\O1,LTFU"<;V\P90Q'(7G KKY]3TZQ]FCO;VUM&N8W, N)
M4B$BPJAE*EB!A Z9Y]0!D\5>BO[?J_MVX7#Q=U8[QVZW. SW(VJIBG4=,!F[
M&^'HYCL@.$:<7'"57U4%@'>6[XG'.E)"#*!%^'>-+ZWX9T8Z-IJM(]U[1?0]
M>>%SLAA0 ;E"'.9<-@.!P"01CBO&=;\0#7M9ZL5I8O::9=S6-M=*6EEN'4E%
MN%D4IF%6\R(I)!.22&&6CVO\<\8<J4')$>RL]!35V./"ESU!6.CT/XP3%,MI
M2FV0@U<.TVHJY:UJSS V0\TTMF(UK6C0>P=+T6/3[R:;JPD6<,CL3,Z;IU!<
M.NXA1M7CU!)Y [BH_B"^OM,ELQ BRWE^ I=(W01!1&$D.6;;(RL  ZE5PW);
M)6-,;Q?><I<NG<:]N]Q7"9:YB+1]^=5;1,P/#*,# 1'=& U>GL0V2&D-K)2'
ML?5@R,:DID(TBN6,&9KF2TT!4:SD:1GDE5F&=V=C28PVT@JI VKMVY!/.WN+
MJ"UTU;WQ&'6YB"[(5:W]HPI<JT:&5!R/,06)<'++GMD1W';WRW3\ =Q/&4 ]
MMR=>P\0_B_EY*-;HA#6B;GC"*(D"C-%$620J&.R))< ^U"H:L+WK:2O='-+'
M#\;PRIX<C6529!?6P').<QN!A1WW'/IW],U#^3W4+>\\3326WE2XLKF4I,J=
M2,F2/.TQLXP JC=N!/)((K#C1\9\:\/Q3'Z@>LYUY&K8Q"B:&HN3(.#</*08
MROA2^V.?.KKGERTA.EEB]OCV[S_'0)H=?9A<@<GT1MA2C^<67AW5[F)KI+62
M.&**TN6FD(B5(+V\2RL[D,Q!,,MTVT21A]BH\C *N3[<TJ\ $'<6 ^) R0!Z
MX'//V YI3Y/Y-V_*UZ&;S7RB??Q4U[=T\.;I(PV4>3$9!#-.9BLG2P56'H:F
MVL4:A$.<KZYIQ,1%D9%.5*^>3K)]&TR.^+^+/$TLTZ:I>Z9J*VCO?WL<%I!N
MANK:2579[=[A@D;;?)&&4(N/+&7*C$$2KE Z!@(E+2-YE(5=RLH\S97!) /.
M:B2&RJHQDCK,K$82N:/$MRK628YK293/*Z"MAB<.P"4$=T L'K4B)CU?(]'2
M2IXQ07&GPVQ72?"WM<O]&[];^[U;=*BLTVTZW9PEQ'![*&Z*%6P$"[>234DJ
MY/GF('55E"8&5 _JW)!W!CEC@*3P!QWZUO:79C2Y+.\CCF;1T<30PECBBM &
MPC.KPWLJV,$?,$,]L\S2U9,V6.1LBJ2BHK5[W6;A;XZOKMI#*=(T94TZS,0B
MU.U94>WMMEDH@$]O%-)).MP1B2/8Q"@"B)&I&Q"1OE.Y@258DECYSD!F&!MX
MP>.*0"9*QBV$ $1I;7,'>">6K8)1_0Q5+]\*!Q$4C9'*C(W.G:D<;$>OJ<_T
MIH)QHZ'5(-.M+[4 39RV-_=.UO-;(FQ[XW-G;=6*X$DNY8VFD543S.P#X.8*
M_E+%5R#D#)!_L\G!'H3WY/; X[!<-I-(6Z5HM/"<##9J$UT5<*2(B)\,X0=\
MB+.YZ_EPP0^Y)(Y'R+Y1KG)L;E-9E:^5_8-"MM3L+?4Y+*,0:79W%I"![.+2
MU9I))'G5,I%"SL[[G90,D6H4&.\A4E0W+$-Z[B, >XDCW"F^_P!MJ1(R99D6
M-JN5R*Q6+X^;$\^?5Z?'CU)X15^Q/'SZYN:"",PM%<>TF6&.60E'4QR-WA)?
M)<I@ NIVG) QBI"G(/&,''I_E5J^641>U?@YRHBJE[>)Y\(J_.6U=X3S]GE4
M1?E\O+45>O=O%RY^2/P0W'EGM/N]EO\  'VX/V#W"N<M,?MK5<>D5OV_^(]Y
MS\>]5S&O6ACUE<Y)&2%,:T>=)(XXHY?6C&I,Y[HVQQ.>]OKF?(WT(UR^4;\^
MOF[5]/,MU+*=I$2C>I3<2-J/P "2V. HR2>*[S2M7BTZTE242$2 2J8AO8&)
M#D;!R=V!C'/NSDU+]CSDFCD_%+N%RPW,=95-;3C:(JW96<MY<<%J#C#Y+EX<
M.ZL":^N@C42JS.[K^0^/:T:8J6FR(1Y$=K#&M(95ACD@D+Q2*K+'*&&U6 /E
MW /&0/W2 H.1MR:LFN;'45$QBZ;2+O6>*,QLQ;G$T+*A9L\,659,CA\59ZXQ
M7!:=N1EKV^:G?<@8K/35FBY*I+X\*JY$REG8A"4EP_7X<$6RJJ7'Q6B5Z9S;
M98R^SMA)85U3I=4+JIA<N#]">#]:\,0>$[K33=:E%<AWO-1TV6Y1&NE$+I(;
M#,,EN\:#:^8T]KR,2Q]-5E;B[VVO4OUF,<+PLIB2X1<E$!R@DRRLC$^4CD<^
M4\MA^&<8\597MSPVMT.R=H++18-+!**\#L(J*@UA8Q=Q29P&ZIQFJ=824CPJ
MXP"QK"WLN9YG0'O@D1O7IMK%8VGA6*\U:)&@%G$-/BNIDZ[&6-F@M\P1*'>8
M?-=-U8R,K(#N8YTKR7$NI=&W*H%D8S2(H/D& 6;<#MY)8%2HP0""!FE;MXX(
M[H+6PH=R;2U''>4SABK7AZ!2LGL;ZO@D"**JJ&G* ((L89X")H!S3XX16R,/
M>TI"8G^<&BR^);B\MM]GI]EI%HL<4(6*6"[2VRKFWD@";"A&55I63#,2'Y)6
ME[-8Q"3'5DN),-D%98PPW(&7+@*0.6"XR!]$@8J<>3Z+02KS#:BYZYCK@.V;
MGO\ &*Y]V["I+(>?B'9QAZ%%+8(#=QNMI?JJK&F!B-%@+F*E\*+*KM=\KL3'
M0+F:)I3M6VBN8S(ZP(HN%>+"H6CEF1V5&P3MWD\#BLFC2PM<Q\)NEWLAXW;]
MA#* 3N48R>>, 8SP:Q(=O_9GS'S-R#Q=3$X?:46!Y")"/GY#'H%,I:K(2_&S
MG:-QA! M:R$8"M.*CB,.&FFCCB?%'+\0*TCYPT_0=0OKBS3V2Z2VNV0K<K"Y
MC$)?:9 X 7 P>"03QQR,R=;\5:5I%EJ4_MME+>:>CCV%[J-)7N H*0%,E\L6
M7)"D#G)&"1='N*!RV:RE!65TVSM*K$1E9<1+ZXI8R9)\X8!2@6I;73'G26+@
M1:MA-,.T:,,9\*1^W% 5++[$\-OI-A[,\ES<0VCQQHTC;F+J4VEL@DC=@!0!
MA=JDC:0?*M*N+C4M2N+AK:RMI;YWN66!7,860.[(3D9.6;<[ [F&0IW T_+W
MBC@AO &7Y0V>EM#-'HL]%$</8"65GF\Q;S?6T]15C6]0RD/"LR7ABCVC)H+)
MD<B$1!1%1"00%3)+31CI?M=_ "UPN54NZ- ^<#8T49!+8&<DGNHXX,>WU/5O
MVS-IUA [1VLFXRH&!F0A588E9EZ<8+=,>7/TF[Y#?[6.W?F_EZ(C<U6F#R^5
MX]L;66DKKNMV=4?='"UL<, F>(BSY5,P6=9XJ\]4N'VM<*TCVJR=9H&$0-*&
MK7LA,2Q1V5DY6.)XI%8I]%"@*E0#@ Y.5X\N<&I/B#5-#TF'H3M*]]?("_2,
M$Z*V=[]8B3<7!)8$J%<C.X[2*[O?EP[R5N\_VJ<:YG/%Z#D#0;3N1+!"DN8$
M+OOJO"]O]L<;%+H9ZIU9%#5UA?PM99P59J#A11M%)GGBG,XWQCIE]JGB6TLK
M*V:>]N+(%(0Z+N*&:23#2.D:A$1N"PY7 RQ /<?)Y=PGP[--O18!?3$8385R
MD9\V!M).1D@L/0,5 Q&G;[VFW_$N5M^2N6JG:8[=-OOQ1SM-77%"H4M!<5Q3
M3=$0RJGM"[ @4T8D( *=R5#RX5FL(WQA2>.Y^3/P/?Z=?/K.KQZEI=Y:-);6
ML"8191/&@$CE&8N%,G]408VPC,""Q&]U/4HI-L$1BFBD0R.Y.-A3)">?:07*
M_NYX[E>,\_;5QIC=T[F:U.W%IG&9!*.$:J)#9>$;&WE+.)T$\D8 XIU74"TE
M5+)+8!D1%1$F#S+$5#!*.O;>'([>^U;6%MDG>U@G1-4DOI;<QRS*2TS1859(
MP4"!679ER"6."#BOI7C@BSTS)(&,:H&! QA!C+(Q5SDY)4C@ 8R$/-<9\B;S
MD'2YSMJQ='=XV4Y\2;,AYS<B/$&*"9\7-L;L.LK:TRN:5"-*,CD*4]R^F,R2
M6)[X+7]XMW?0>#]+TZXLYIU@FNIGEG$S1*AZT%T(A K1$,%BB=W1@V5D8\B(
MHX(FU&9S*JE]J>1B7)#)TU;+*>%); QCZ(!Q>K=9+?9WB^JQ^A@L=1M:AE37
M WV/L+JR" ,BD'6K.J[*J!!;!!<RJVJIS#&^B5L$LI0Z/(B<[O[D7+: L<YF
M74.D/-:R-'(]T@9L=50)-JCYIVE1<[_/@=]9:R0&Z=X\K "3B5E.U-V.Q)].
MPYP.V?3T5.PZ,R+L<[,HK >00^/M1[=HSA)B/BYAC&<0X]I(\I2JJDR0S(^.
M0A57WG-63S^5U\1ZAN-_?%TZ;F\N=Z;M^QNL^Y-W[VTY&[UQFN[0@HI7&TJI
M&.V"!C'PQ5KNH=74=*4=*4=*4=*4=*4=*4=*4=*4=*4=*4=*4=*4=*4DWWSI
MK)/_ )++_HZ51NQ^H_RJ$O0GWK^K]G2L%<PX<YA$0@D;IB9U5(X_5Z6HUOCU
MS32>ER1#Q(J.EE5KE3RUD;))I(HI%5 ).!4K4N5 JDCGE:TVQ1$52YF)Z87?
MG0.%RN:,U/FGN)ZB7HJI),YOI8U64*!\?K^%.?I5U'2E= QM86K:P]0IWDQR
M31@DNA=++' K&RSQ0/7W') Z:)'31M_K+Y(U];'.9Y4(SP:C/0Y=U0CC0W23
M5GG^NL>Y9)Z_ROR>Z1?+YP_^BZ6173C+X?.^:%TLX[]?K_M6)DQDCZ_L_7ZS
MW:_H3[U_5^SI5E?<3$26-?G\GL^[])/Y.E ,D#WG%6 Z5(HZ4HZ4K7__  G?
M^TW]Q?R]7_'+@'PGR\^4YQP:I]OR^WI3W8]X^/K^OA[ZU4.WK46U!VP<7T6C
MW&%).O.%X=#6PCC'25E;AQ:$&DA%M)(RS2 [6EC%JA;"48$!UMJ2"!AH(1 '
MV-G]">$[QUT#38;F>*21K,M L;C$<*E@%D56()51A]P7!'F&1FOEOQ;IUO/X
MMU6:&PO5BCU!UN6E:$A[EVW;T"\[6+%H1DN(POKY5K3R#W0TQ_&V.QNFSC;[
M(9RI2FC#>8.%5:74Y:^&MFE%50B"%/IR+.$7VT?&R"UBA;).U[WE,ZI=7UJ+
M413Q!Q"S-N8?[V02>,KD#!SAOJS6PL-&NH;^:Z@N)HI9XP@&2>G#)"(SP<JK
M!">>ZX&!P"'C1Z;4,R%-IF8M=-=[HBIM9J(*S+ ;C(1 S1SCZ:NN8:.J@M3Z
M8[+0P-:1;@_&5T,52.&&7 /),]KD>*"YD0NLR+LMS&&:-03DE&4D,5P#D>G'
M')C=")KIX(KKV<V2R1&8MCKY4$*[*22H.X@G!.YLD^DV\Y\X[/,6Y6(Q-=D6
M@!K2UE!6AA1LRU/7V+6B6E0\:(.7X":H:%0(6VK 01Q#72H.Z6)).I\]]-$(
MXQ$ CA!".%&W& H"X P-N0 ,>G;%:73=&M;CJ7%S+(6E=NHSY=V().58D%@3
MN.[.=O-5LYXO[X7D/L"C71GY2Q7D'F2CV5U72U5G!6!$R<1/V2UL0]$HC**,
M*:PDB@-K;$D(1'/GGE= Q8N!N+B[C^4'07MII+>:4VUNSQ;&DZ<\DL4\0ZBN
MGGCE<>="%+!N" 1[?X*C5?#-_"8P\274[PJ0P##I0,A')))Z49XR&Y]Y%3WR
M#SE*-I)[7C?9?6P^CXG+#>6P)E=%7!UMD-;K 9>CS&PF61-="73PQC#QR51#
M1Z4J%/8=Z?H=+B-Y87CZ5W;!+N5!%()8#<PL(S*\BC:H4I(O3(+;PSG!?BX0
MD(J21[)5E"NNT;WB9<A<=]P)'.0 !WX.()XMT=/K:[ENTSN2%9CZ^6QJZT.K
MN"4O]-K]';UI]H? 6X4R:RBEC$=\5$.P<Q'6M:./%%70RQ16Z3>K<"ZCL;95
MLXKBZFEF"J[3SR&220 IM"J Y &TL$*+P0"9-S;=/HL\S";: !DADB. HP03
MDL 2?4AN_&)=U?*UOD>/L"9E^/*'+UMF1<1V."?3R9J_I)J2S(,*EL EAJ4*
MKCF0-=5VSH5G+!;#[[)FL5DM;>]MK.RCF@L)XXS(\73VBWCCP&1S%$47&YD=
MV*KM)D$F"7%8UMS+.8FE5V!4]3/49MY#;,C/(S@@]L8R!BFQFN3MR1)#LK;*
M'ATS:ZP(&"O]]5U14TU@*ZPBN:YI) :+1/K# &.4<D"R<V*1T,DCE*]R4NJW
MDEL9UTIH[0(&>9VMX\)&K,)#U"H=#@'<X\N20IP!5CV474,:W(:56P%".,D,
M,#<!D$$;<<C QD \IO;SH[>N[H?I"ME)H<K2XH/G"X,U(1S9;"^+GNM)O8JR
M40..S@;85  [K-KQI1K"0RR*"6!\#(2S(/F;P-=2+JVO/OMTM3-)-*9&<RY%
MQ/T0FPA=F7)RRG=P ?=SWRJVEO-9Z'"T-U+=D7<5N8NGT53I6YFZA="=[80+
MAE. W!SS(O(?<$7QMM>8JQT%+;7^FH,L47-0.BB;15]%.2R_%L9K0(:*(TDN
MPKI7U@$DM?[TTZU\:H&OGT"ZU"&WG87$A96B"KG# ;QF09Q@<;=H[\$CUKS2
MQT66[L['H/+:I;W#LT88QJ[/LVG )+ ;&#'N?7@U W$V\IM.?H3,;FY*7'X0
MZPT;HQ+:U"M]Y87Z7$NH$-L!!R(S9+08DP2=RG 2 2R@0UDH<$DSDUUI<HZM
M#8(!;VTC2]0X5YC(2SIN8$29+," "0<8/>M_JMLT;Q>WW!EN+N,0Q@\K;"%4
M6*3.04.%5@<8?G(('%P..MC>TW$'UU%D\GQ:^:^LX^3;"\]NL6EX_K$KZ<FU
MM+$="'DX>AC-F'J:R22UOB];>NS.7K;K6FT]:=(75[?3[26?V7H2-*L2Q)$>
MK/+(0$BB0!6DEE;^K51DDY) #,-.= N_$&M0::D\E\$LUEB<RL88 I"O)*_F
M6,C/F) .W:%!R <87<OWP[/D>"TP_&,<V7XTEC?-J=$ZNCH=;S)\-:+&5/K!
MQC"6U6*?>/'L:_C44XH&,P&LL]07I+>FHI:+D[O6=>N'34GT^*!;(_M&Q]N;
M$,<5I.VDWD<UL)1U98[F\9GE=5=#;JL21*[]3W3PWX1TOPS ([9>K>2(L=Q>
M,,R,@\XABR,Q1 @$*#ND(5I"Y"!<=15C8S,:-,;)-% /'7Q,9(JQ()!*Z:&%
MJ-5J/@CDD?)&U[7(U_A4^:(O7(ZC=WVPVLNJ27D=DJ::L-K(1;G3[9UO8"X0
MJ)D264](2 G(7:Q8 'J@-K8 &#R<?VB ">3DG &3R<8&/6EF@R6GNK &&LKE
M>\FWBJ()C?;%"2P)#E)C")G+5D$+WC0SD^9E3PQGJ\_V*IM]#\.Z_<7-E[#I
M4:W U:2S%QJ"M' ;F:QEG-G<=50Q06JRSJQC SLP6$BFK))HX\LS<",N0.6V
M@X+*H!+8) ( R<COZ<Y=$*"($ZQU8"R3Y^TG##K7RVDXI8MB^.&@LDA6*(!Y
MTJRF1RN?/$R+TR*UWN-1,E[HL5C:0?M;Q5!N30M46SL['=<]*2UG'L^D7 AV
MJJSW#S3H7V@J(P"54,^6.5G)"0L-LBAB^%!4J"9$_M8X7& <@\#%-,B*"9SH
MJL4UT3X:V&)\_P"5,RP=$SXV%K1VK'(R4A)&!M5%E^'5GJ1\B*O7/7$-C)U(
MM'T_4KF*=M,MH+FY$F8;]E47,(%N&AE%Q+O2S25MY5AN).2,XW#!8J"-Q(&<
M%<G:<GD8&-Q[9SCBNO-,>#[J/641\?OUL\4?I&)5C/5\0.9$BI*]%5RM>LS4
M5RM2+RJ1^EN&1M4L48-NL3#'/HL\:!+>>1/*]Q#>QQMU9%=70223KND"JB/A
M !> K\#L,."3N'H 1Z#U(QZDGUKJ-8,BRK+)))Z862#NB:U6NFD?$LD<OK<C
MF,:QTJ>J-)$=(Q$:WT.5[8C+:JL_4N;B>06D#V;VZ*(C<R]/JQ7*W!6;HPEI
M(P8P7D= ZQA,[;<OD;<#)YY.<<XQCU^OWUQS2PO5GLP+ GM1-=&Z195=(C$2
M61'N:BHCY/4]L:)^0BHQ%<B>>L-Q-;S.K6]M[*BQQHZ&9IB\JJ!)*7< @2-Y
MEC&50$*"W<R "!R<\GTP /0 9/8<?'O5L.5/*]JO"7S\_P#&&];_ /Y-NBK]
MWR\?9_W=>[^*QN^2+P6,XS=VP]_>'41^ _EBN8M3_P#G-4]QAM_O$0_/G_+U
MJS( PN$(A[G-01Z1M^;4:_PON.C\O:YGES6.<C7JG]BJJCT\IU\^ZH66^G5?
MWT&3YA]"-5QD$'L,\$?;BNSLH(9;9#*S(%95!3 8JWT@C'(5L9VDY ;!Y]6Q
MH)B"KJQ-F@:,\LJ4A888(QAVJ]RJOLP0M9#'%ZO*QQQ-;&QOAC41J(B1K1$$
M$42NSA(U!9B68X&.6.2?CN)(QW/K#>'H/L7K!4\B&=V>9@@V@R.^2Q.W.XY]
M,<8PHXG::SC_ $]5KL5?6.;TU1)-)76M9/[,\:$C3!F"$,>KAC*VQ!()K;>L
M.BGK+:K*+K;,0H LD>66 4970NK*0RLC%65AR&5EPRD'!!!X.#]6)\D$N<@@
MY'<D8/!7USC'/U5L 83FKC'E=F, GXZJY^9*\:PT>EXRK11+#);.J@N)J>VW
MW$V.0$T6QO\ -U^>EN]3QJ+(Y:JM5=5QM$F1J+2AXZ^@O#?RF07KR>'_ !+&
MLDEO<I:Z;==)2+GHNJV\5TH3"7L19.C,BA9RA#;;@AI^8O-'"-[5:221Q2H)
MI(B2K+N7<<$9(4CZ2L<KZ97.%;DSFW<T_(5YE0\R+IV*1!55I>%.0.4QQ4C[
M<N.N<0](AG1B"SH5#()$D+$>P6:*-T:KZW<ZJUC(D*Z=//N$72W,KLTCHP42
M+MR&  (5B"V,DG)!T,5M'.ID,PB +;LY)V@KCD>I.1P#C'8TEV^TT</$'-M!
MI*9@MAI>%N>2'$R;JNLR1PH^%-;:  ETL9T%E-:#Q#O$L7.@L@H'"J4&Z%KI
MY^N%^5&\O9/!M\EY8BU,KV:PCJ6Y!47*2L0%<N&4+@JJ@?2+,1@#9Z/:PB[C
MEB</M#.?*Q&"I7ANV,' ;.3GL.]2+VI:?04G:WP]6Z34<>2$WW&=A8YH2)I<
MP%;D*^OGI)67!PY=I/5V]?$#[UX:&$#,5?&_4PHKI BRR.-\'W<O["L1.UH@
M2W:* )O$C0( 07+$Q]3=]-ACG(QFO#O'-A;2^*M2D@M+R2-+N.2]:9$"-.Z[
MB8EV*[Q$L @RX"@L6*D 0#N^Y+-&\6YK!Z*ACO,=G675/9-')% J]/IZ?3-T
M#Y4@'8#8OIS7+4I*3&R!UK'[RNF0M3%9*O+ZUFMNE(JE!)U,E@NYT;(RY_=)
MQG(Y'!SP*E:?I=]#?27<%S(DDP58H\DM#')&$;YKG:RY8C)\IQCCFE^BV.DF
MPH6O;B7Z(_9D5!(6-K33T&R,=%#<?%6P%43'75D-FZE?0-"59[$$4L0"4,>%
MSVM;<UTTL,=W<VO4B("K;(A880E0W37)W< @\>AX!%83;%;YK:*[,3VY<M?&
M0KU-Q!,>X'E%;<#@;AD@DXVU/W.G..EPDC<3B:;)QUP==2#T=  $T6AIV6R-
M M@;$.)C&U5C$*P0RX2N"?&XV>:?PA8;/3MY+R2U2..! 5:-6[A&VG@!U&"&
MQ@DG!]X!YK1V>D07K27-].[R]1F=RQD) R5"-GS+W51D<\9P356.X?0:D?5]
M@CVW1F1TY'-'.><TMP(E39Q4L.H#[?:S4.J((J B!M1%07)D<,5C56I08SGK
M*UR1100>>:E>WL/CSP]-:RM#=2&SMB8TCDD1+NX>"9%2170NT,S*I9<@D-Q@
M-7MW@2W1?#5_&8@;?VRX,6=PWHL2 'N3G*8.WL>/0YLAR'SA,#JZZVX_V4%_
M]?\ %FEJ4(4(<)H3P;(&XC(L;?XH@!Y9]?!9@@!L#B.JIK$2K+8Z1S_;^AEN
MHS+9%56Y@<W)Q'()$:XMT50SLA"QA75U;/TF!;A>!F@MT1#UHQ&!(BY"D^1\
ML%9><'# _NC)(/-5\XLTM#IW<M6&<RS8,Q3C6*S2U]P-!H]/MM7.!+83"$.$
M)A+;\..0PI PXS&0V0  \*1E3JRW2[Z.66^33K-(K>*>6YN)HE$G6N7WNRX7
M*Y"\AF/ "#TP9=Y#*AMU$N9, 1JV5VPXV]CDD@@$'&>2!G %2]=<IDX_B['F
M8WCBHRU=96ET':XF6KFS6F )K3_BR#;,51J5UF&<' ,Z"^<.A)D39'$-F6,A
M\M\-[:6UG)>064ZH)L/$L:6\:NV1(Z(R#SN^YSM4@EE?)!RN)+8RR;)[A7D"
M@AV)=F4]AD9P5'#8/88/.,M_,\L[NW+ VIN4T0U$L1I4 UYO*.@)64X,HFML
MZ..U( 9)3N"G ADFCDC-:-)+*+/+,R1J24U>>:V5X=*D6V(Q/+*+>-ECC#-O
M4R,HN%; 8G<JJW=&P0<;V5OUMGM )=]H"9P&!^B2 1DC.01DXY(/(]%3L5/6
MU[(^SFS5JM6R[5NWL]6K*DZM4SB3($*U9VOD294]SPLJ22))X]:/<B^I?A_5
M)!+J>HR@8$E_=R <<![B1@... ?3CW<5Z!$NV.-?[*(ON^BH';T[5:CJ!5]'
M2E'2E'2E'2E'2E'2E'2E'2E'2E'2E'2E'2E'2E)=VB+46*+]GPLO^CI5K?1/
MZ]:AGTM^[]:_MZN\W]G_ /1'Y5AJ3,A5L$ 2PD8GQ5FQDR*J?E1!+^4)"WS\
MV^N-4)F:J(Y)IEC>KFP1>FT_K&/\N*S*,#XG]8IW=*NKY>]L;'2/<C6,:KW.
M<J(C6M15555?DB(B*JJO5"0 22  "22<  <DD^@'J?2GV$_ #)/P K%#](G]
M)[QYV?\ !G)6OR>CPQ>\H\Y>LR)FS.E;C#MR/6E34F9&@KS [;76U@=%$.VK
MSTR)&V1Q!)T4(Q+&\JWBJWGU2#2M*MY=3GZZ1W<MNK-:VL3, SF<>1RO/T20
M,$9SP=RFC3"TDO+J1+6,+NA64XDF/!PJ]P!D>F<D8'K7FK\V=_W>!SYSU#W)
M[CG?D.3ERNLF6&7TU)?'YHG'Q#DJ2'78T6BG!&R=0*]$?#4TD(8GJ]<I49)$
MQ$DG<F%/-@#9DXX)8C)P=QP1Z9![?;@Z?GC..1Z>GP^L<9Y/UUL_?1=_A,7+
M)^MXR[<>]3%V7,<VRNZO'5?,6'J A^0JN:W)AK:V?=9"OC&H]76QS31?6%Q3
M145V/7K(:77:$YLC9,+P@ LI[<X[\#]?=]E4QGX\<\?KBMR&WK&U5C.$U%^'
M\,)#55<O_!)U>C(E557RX>2.4=/4KI'11Q2R*KI55< SZ '[ 3_+-86&#\.X
MKHQL;[D?R_Z;?SK^DG\O5?-[O_T1^56]JG?JVI%'2E'2E8'/PE0;,E_1"]PD
M&ONKG/4+M?P2I5K0YT356<$C>:L.X5L%*;H\H.2V8E(HIGOO!5'B>^=C"71H
M/(^S/Z^L4K0&XW[H>UO.U6+AV>HY@U-AE*,O)K$+PCDJZM,S0V6KL[G!Y4DY
M^)+D,KYZP:R+<Y[0"I(V1MKFR^HAW::7XL6T@M(;JU>46<:Q1B)TCWQH. ^<
M^9AG<V<$GZ([UPFJ>#&O)[R:SO([47TO7EZT33,)BQ9BN-H"Y^B,EE]&':D;
M4\]=EVA(:]8>2X(X"E+!B_@:SK(1F1U[0!Q)*\?GL:L(@:YC#")7!M)--9[Y
MDTSY)E?/N?&&EW*[6TJX4;LG_:(SN&.%(VX(SSGOR?MBVO@O4[8-_P#FHW9D
M*%A;.I SG@ER0<<#'8<'WU)%?W:]G=O:Y:'8W7/,&0I01Z^\I\EQ)CH#;<."
M",64<*2\YV/KJ]IPP@0[W2@&H&/&L444SOZZLD^.[-D2-M.N-JKM($T:Y7W9
MP<''!(/U8J"/D[N$Z\D>IP">5F>-WMY&"2-G!.TAL \]^<X/K5MUYE[:.];<
M9#BGM9LN1^*+?.<5[ =D7*F&R+JVS^HQF:1"Z2PBYR9*'I9'06CDELBI*Y(2
M%D*FK00B2>M)XG^5_3_#FE6]VVE:@T(NK:S;HI[8\;W<JP1S,D2=00Q$@RN>
M$0D]@2=]\GWR'Z[XCU:?28M3M=4U"9+B]M;:*&2":XZ,32/9VL)+/<3RCB&*
M)=S,I.2 =M).4G\"2</<77'(W+G/M-I:GE+N:BH),YPABF'A;047A <H>\8;
MSTK0JVDFB'\O +/L+I\A+)IZZ6'XLW2S:J][=MJ,LD_4VO):2PLJ.CG^KW,Q
MR!C;GIDLI.#DUU5MHKZ%&=*FM_9I[25[:ZMY@RS0W,!,,L<T;JK)(CH5>-U#
M*X93C;@.&A[O^T[.\?X'"5LW)A,&,SS*\FQ*X2RX\ES>&5EE#?W)L8//D$QC
MC[6[N+".,HUS/!CX28Y8I9H%]5T/Y5-,T?1;/2?Z.RSFVB DF]N2/J3$[IIM
MIC8@SLSM* X#%SC!YK53:-+/=37#7(42,-J*F0$  4$GU&.../J[]'*]VG:W
MG<Z/CZZ\YBSV>CO'V\\&:X=R S9?2*(' XD-W.<$=D6L00KS33R9"S)!85D)
M1'2>=EIWRR:9ID1AM?"[0(7+_,7L2,Q/=I#T9"S=@3E2P'FR. ET6689:[#N
M  I>/C_X^4@JH/(P"5[#XOG==Y_9I+19[.\7W?<A15Z:!MIN'ZWC7(:$G1AQ
MPQC#@5SG<ZRQ4438$G9+"$/$%++-(0\-99'*@?+/!',LT.CW&);E9KE)+F.4
M,@!WPQAU<+U3@LVT$8/!8DFV'191N:XFB9PNU#"A4C&0CDG:695QC)[\\<U7
M3D;N>XQY$BAK"^5^3 ,\-5.HX:>'M^QSHG537/C']WT\YQ(TMH'MBS3PHQ'M
M]YR,9ZV-BY[5_E;U34TDM5M$M["59XY+:-L[XY2VW<^00Z1D1X4;-H/E!/$J
M'1K>(AMS-(&W"3)W!MV2>XSSG@DX[5(6TY4[>N-^?^YZHO\ D+E<NBVG*.KL
M[6JJ>$LQ-.-=@6%]!6,'L3.>!(B01$N"O7*55OG<C446$.0B:1.!TC6_V7+=
M?-EK:ZX=%(ZH )* ,3CN1W!![8&,U'U[08]9]EEZHCN+,RB'J*3$1,J*S.%&
M<^0$!3]>1@'M:ON=[*=(.)$Z/E]T_P!61"6YA/$F9:;:EMS@](XF>P$YW'.D
MB:;%/=QC$S$1OL"'2%(0OGSTLGC.PE4!M.N2VT*S&:([L#&<8X^K.<\FN2@\
M!7\$A<:Q 4WLZ1K;2!5RV[DLQ/8  @9(![9Y[_$7-/;7:+#Q%QJ_F*:\V5F"
M#4*-Q7F*YR2*"2)<V%[8&=P@M2*(@$<5I=:.R(K*C/U];96UE.)6L))%I:^,
MK&U!6'3KA0Q/:9"23ZXVXR3[L?;66]\"W5_+'+<:G"QB#!5%NVW!((49.<+@
M@ Y&#[P,,[N'YGK[N*PX?XDUT=?PK1VQ-C<ZJU@4"^YNY#S-8RQAY!LJ3UF&
M46>D]3:?BW.33NEIZHN4^[1FHT.A2+J($U2X:XFOM3TW0()&DC19I8+K4(9=
M.@L-;M3;J,F*:[*QQEX]S2NL<!CD1=AZ+2=&M=&@Z<2-/<,%66XV!2R,[($!
M_=ABW,VQBV3ND/F( J\969.6<A*E=/NYX);LJ0R,28(%U7^+"%S&LC5'RQ25
M6E*E,-<K_9>$,V1Z-4CRNUN+'P](Q-FNN^+Y$EUF=G6.9+%K:73>M<RJ7,-N
MIM];N%NY8PYVB%BJ[@ =FK3X!?HP [!M+!F#]4A5.0 0\8"KQD,Q'FQRUR,K
M>B3.4T$.C8^2HH"D-GC1(B2:@>RB)>BK))&AP\"'2$1M5L;B$C\HKO"Z!O#6
MLP3,)+/2M#CNX;#PY=1S7$;JLLNE07?M61O DN$MA(7 =E,_3*@C?682QLN%
M8OG>XP#M*JS(5'OVMY<'GCGU)0TMI[ UBW%A:E#%$N(-A%D5\KB8PWP"$MBD
M<R!\R.]N!7^E7M&21K7>51J:M=1]ONK=M6UG4[L7L[W-Y8Z;UTECEBL6@LKE
M54K%[1_5Q2=-0!;Y0EF0L<JIL4E%3/92<#U!89'(&!NQP,@'%.$"-9Z^4>FP
MDII!V6(=-8GH88Z*6E*D-N-%3(Q!X&1PC0M$)C=\3$.QDOJ17O1&S[./=9,F
ME>"/:IKK0")[_41-,HN=-G+ZGJU@)@L:P!72%XXV1I.EM"R?1:QCAMTMRJ!9
MAA$VK_6+MCBD/))))(QM).,<#%%^9I+)+2>YNJ:HBMZJJUS:NN4,("TD%1E=
M61!A5$*P"VT(A$\RCR*/*R**>0ARSJSUW:Q<^(KOVQ]2UK2=*6^T[3/$JV%F
MT,,5XT;BVT]8(H0TD>H(D9D,:R)(%@S*69,A$L2; B2/M=X=[;F9 ?.VYG.X
MINP,C(R1@8'$?E-J6J2L11I[R*\&<8E84%:VQEC%G.'*BE?+*^$=TA8[)F/:
ML[XHYE:QDBL;Q5TFCI[:?;+S4;B>TLY;6<*MO&M_*MO+>I>"9WF:. &Y@69&
M5I#'U"IWA5DCJ>4E5498$9R=H)"D8  ) 4D'/<C.1D_#$G*690:MWM-!B=.Q
ML3RW0-A2!I!Z2*SU0-?,QSE>J^W$V5T*.5OA>JK%-=M<M8:*W1.GPF56AEO7
MMHX5B6:_CFE5O9C+*A<LG $AC\X&^KBPX#-SDX[#.<D+CN2 0,#OC('OZA0T
MXOPZS-8JRCQR0JR6&15B5/R'N;%(]8G.5%7T3(V1$7RK?"IYA7L%Y +5KQ5!
MFM8)(0KVSL8,;49Q;/($) )"R$2;0"P&:H"#G'H2#W[COW_\>ZK7<G_/M1X5
M=^=-/?M\?X"KI$7_ +_")]G_ -_7N7BLY^2+P=__ #EM_P#Z]2'^7XUH+<G]
MNZGZY@MSZ?V%![=_>3V^JH9RF/&TF2T5BEV/5V=7:"1"BSRI%\<)/D-W:&^V
MYRM:KF2T08*IZORWVD3/'E41WS#XFUB6PUR& VTL\%S [RR1)NZ+I>:5:H&P
M,L2E\\H P-D#@G!)7TC1M(DO]/DEBFC1X, 1LVUY!T[AV*>\HL1.,C.>_&#Q
M;+C':98N[@/J$M00#SX'V +%D'11B-+$YR1Q,5L,4BT-J8QCX6.8&$DC?98_
MRD#3O$6F7RP]&Y2&62))#%*=K9>.T<J.?,5-Y!&<8!9L=QFE]I6HZ>)!>6;(
M$9U)8%@61GS@@8QE"1CL.3R34+E0012^(V3#R)(K)()6^A&N\HGI]+D5Z*UR
M.1S55%3PB>$7SUTL,@< A@P;&"N-K!@,'OCD<Y]WUFN?F55P5R >2#P.>Q ]
M/Y_&KGYX&^L.:.W-F5L[&ITTD8I-%9U)$H=G6VX^[TI )]<;!)&0"<&1!$4*
M8-+$0-/$V:&2.1C7=:_Y2KN/2++Q;?EFC]BGN) ZLZ%'"PL) ZL&5HV;([\K
MWYXZSP-H8\0>*_#^CL@F%_<Q1F,KE7W*3M()Y'EYSC(]U9N^[#/E<9X@+NBN
M+/0C2YX3'9_:46(XKRVII,5HFEI41<F/J2-KB&4V5WCB!L_;AUP1%7F=Z<&P
M6>KJ=CF,W6YOD0_^K-_%>CW7AS5(8[[Q-HD$2V\\TBJ^I:?'(O3U%B07DNHA
M(+6]*,"I:"?GK.!VORZ__3M=_)I/::Y9)*_A?6Y2G50$G2-596E?3+@Y;$$Z
MQO<:?(YRZ)/;N"]N))<5?'?*G%/*&UW7U]RWR?9$3\&]S,HR2\%Y0)M>.1P3
MR(\Y\1$'.$\D[@:[XEH DL;&$*R,-Y0K9?BH>_\ $OCS4?%%O)!J*942![8)
MA1;^A7"DAE(.W) 8#N2:\*M;**TV]//$>PG&-V.QX/'O/IR>/?R\8=S?:]EZ
MC" ;35<P:B3$U<N;&'KN$LK75YF9AIP0JP4U)N?RI9"X3@_BS6QL@!,8Z1LD
M#I9O7#%TOQ:UG;VUM<0-,EI$T2"+:I9"<C>7)7<I]PY'OSFN0U?P9[=-=S6E
MXENU_*)YWFC>5ED&,+&!CR# QN/'IV KH:KG;LDT,B>(>5AX!B12 ((^(,R/
M#$P*NE!CA,#'YVB!.^*E="?9SNAB*/*B>\B=Z$3I)M)?&6ES ;]*N./_ -_'
M@GXK@@\<'U(]:B0^#-5@9F36;<E@P)%JZL Q!X8L2",#:><=QR!3\A[M.T:U
MEQ]??W_.X&8I81J^[ SG%&4>78UH\?P$D-;]:\[$!!2RT<0=7"XJ V,91T+D
MB-E5R223X^M#&D0TVX"H, ]>/Z/NY&>WKSZ9/K4%?DZND::0:I TDDCRYDMI
M#AW;=W5NVXG.,''' -6SFY=X.[RKG#\3]F.*[B1;[(8+6C6HV@X\QEI7M$C&
M?;KJ)[<[G^N&J+,6<:PC!9:7<D-H99P4P SB7A0]<[XI^6#P_P"&=+_:.JM^
MR;*%HX#/=3=4&29T@BVI$O6D"O(CS,JE(+=999"J(66?X3^1_P 0:IJ$]J+V
M/5KBX=KD0VEHUOTX8DDDF#22OT=H1?("59R-JY8[32_E27A@CAKB'4<E<G=P
M6;LQ.:.Z.?-D5? V8!NFZL'*=MM?%$<-<<Z1N"J:2SK1V&'#%65E8E,LPY(*
M\L53)],VM-J%W^U#<L98UCEMIK*>.39,"LMOMD+',6PHXD!RV<J,<UVMAI7[
M'M4L5C9$3.[JQLFYR<2DA@/,[=U.2O8CM2[DN[GM*R/'&&P@J\I'E9<%\EG=
MS\.9D.:_T!DMT996ASP.>F6$\1!US(0@[[.)DC8W#3Q*%*T.#U3P_P#*CI^B
MZ+9:7)H$US+:]5I)Q?QQK-+,Q:638T,C*TI9C*!)AF8XV@U N-&EGN99O:MB
M2 #I[ 0 JJH[\'!4$< CWUU<OW:]K>4SDF4I+OF'-TLU^R[)BSW#6/'0I860
M(QQT3N<6/L"Y70M0@LPN0E\$ P_Q"QQM]&TT[Y7])TV&:&T\,26XFD:1S#>P
MJS,Q!RS&-BQ(&QB3DIY<XJDFC32OO>ZW$*%4%3A,9SM]P/N[=Z?&P[U.S9<S
M4Y[CG0]R=?)/>@V&TL-IQEB]!)<5@GNJ^MI(DYW=%GV3J26LL8;8A99"%ED'
M=(GJ2O\ ]Z8XY"\.DW1ZDR/*L]VDRF+(,L:*4VH9<8W #:.W."+(M$EW,UQ/
M&YVE8S&A0KG/+?V\#& ?=4!<A]T_%NZ%$I6<I<E568KJV>C#J(.WW&>F2J22
M2,%27Q<Z0M4^ !Z".)C\(J.F5&^F1B1:75/E>O[\F"WL%M+%C,C6ZR*VZ&3*
MIEC@ATC"K@?-G+G8"1B5%H\46TEM[(596(PP<8).?7<<DDX.<<XSGU0_H]/J
MU>P/L<6F()+J/ZC[MG^JBC0F5IA-;_ OBO@2"ZZ,^UC )F%]J2<*.SL6"RN?
M P\QL:$2>/R,'DD<#:'=F [X#,2!GUP#BMP. ![@*N#U95:.E*.E*.E*.E*.
ME*.E*.E*.E*.E*.E*.E*.E*.E*3+K_FH_P#_ ':3_1U4=QCWU1NQ^HU#[H4G
M6(;QX^+G&"\HGS;\:1&+ZD\?H^]ZO^[J_:PR2W8'U/Y5A')'UBIR1$:B-:B(
MU$1$1$1$1$3PB(B?)$1/DB)\D3K'6>JQ]RO>1VV=HU)77//W+>/X]?>N(CS=
M-=6XL-]HI1HWOG^J:A)%-G&@5J,*L'11UPLLD,)!4<Y \<N*:1XHI)$@FN6C
M7=T;=-\KC.,*I('VD@#U-9(TZCJA=(PQQOD.U!CDDGX#FM:WOW^G]Q1^>/S?
M;/-#RI8GC3) E6^WJN-,XURJR&;D#52C5MGJ[#SYG;C,DQL#HO0EO;57J')G
MXUM)\2^)[@I?M)H&BAAFUCD07]S&QV[965G"B3S;@!P#MVC&YN@273-,16MP
M-0OF4@R./]GA+9!:/&<E>"N>03DMS@:I!N-[OOI)N<6@#3Z/F+?S*Z64LA_U
M7@N-<\00J22,B]4>;X^R@JHYJ+ZF%6A$:0^NYNR&1D]0X\/>"=-/,%A;QX4,
M,"ZN&(!(YXDD8]@-O)XQWK6_[?K%Q@[IY">0.(XUSP<9(11SSSZ5G3X@^B?[
M0.TOBFYU'= 30<MZUXD"ZC6Z$BYJ</F9I%<X>@X_H@" KFWM#)T008TV,G0W
MQ3((::FI?B9!)_([_P <^(_$%ZEMX=6XL($;IITHU-Q+EN&G+@J@"]U RH&2
M21SUUKH&GV$)FU%XIBJA\$D*H!!8  ]P"1W )]!DXN)]&I]!(-9\[UG=IMLC
M<=O' 5)R,#R5P[P;8BD,Y@WZ4=H!>96PY3=H9+0_!8%3Q(S0N/R9'ZXT+T#W
M,>8=ZW6'KNFM?K8VL6HRB6[2+$\@.=[Y;N0 "0N%/&,J0.]<3>M;M=3M:IT[
M<N3$GN7 SWYP2"1GT-;:NV@;XJBU1%<DY(/V?F('4M%7[T:M>J)Y^SW%\?:O
M6P4$G ./M(_E]=07' /QQ]__ (IEQHGN1_)/[-OYD_23J[:_]K\36.INZQU(
MHZ4HZ4K7[_"??[37W&_]LN ?]>.#Z4KRN_M^SI2K/9_LH[O]30S:FA[8.?;+
M-Q4@^D;?0<2;KZG)HC( BPK,"QDHXQ+(<\2Q!+K_ *OE*D/%*A)#9/#(U_1?
M,3MPV!DX(.T#.20.0/3/J<^XUBEFAAVB:6.(NVQ [JI9O< 2*@C7XC9\?7*Y
MW>9+2XK0(#6VBT>LHK/.VZ5MR#!9U%@M;;BAF(%:5Q(Y]>5[/L&!SPDCODAD
M8]: AN00?JK+637Z//D/CW$9/EA-?L:7+6!9F8GJWV]@ %Y0:GTHSRA(2(X2
M;">!Q;H70-.BB9&6Z!&HXV25O-ZU;7$]U9M'!;3111S;UN+071):6 D1Y8;&
M*AO-ZX(X%?</_P!(?B7PIX9TOY1K[7?$.@:'J@321HK:U/:V<QF6RUH=>SN9
MF$[+%,8HY;>,%&:2)OI-BJM<QG%6?;GP;8&F?6)AW-7=&878(BHAQ107 DQ!
M:(K6+Z2)G/F;Y:U?#_FUJ^4ZZ-  J@# "J /<,=L>F.V/3MR *^+-4N[F_U+
M4+Z\N!=W=[>W5W=70.5N;FXG>:>=3@$K-*[R D X89 /%17PIV^<V]QVHGQG
M!G&&PY0TH@;;*PK<E3DV7U36.*'"2TNS&-:!25:%E#COL[8H(&.65K9"&^>C
MNJ#+D*,XR2 /QJ#4L\B=A7=]Q%QI><P<I<#[7CSCS/ETX)^@V, &?]XF^LOJ
MFM;4U=F</<WL;SG0Q$$4M?8#@QEA$G2CBFBS2Y'5HRBN-ID02(./-&>SC&<K
M\:L21'SL8-M.#CT/N/QJH?5M7UD%^CM[3:CNMYMKJ+<6;*[B[-Q2V.YCK[@<
M3960Y %NM16X^G; =:7)Q5L"/&8X*O>/7A>Y(66$^<1\GGWRD>,V\&>'WN[9
M6DU.Y>.+3D:SFN;<,MU:QW+7#H%BB5(;DO'UI8S(XVH&VL!Z=\EOR>:A\H&M
M300VRRZ5I<0N-8E-[!9&VAG$D=O(9)3NV&=1U&1'"*/-@LN8)[OQ(@>Z3G\.
M%)$A&Y:W<$23)XE]N'1V$3/<3PGB3TL3UIX3\OU?)/L3OHBS10L^T.T,3N%7
M:NYXU9MJY.T;F.%R<=LFO.;M$CNKF.,YCCN)XXSNWY2.5D!WX&\>7AL#<.<5
M7L4 TYRL"$)+>CF-] T,DSO5(JHQOIC:Y?4]6N1J>/+E143SXZOQ^LBH_P#E
MR?J]]7*HZ:'@7BV2&\994O,G-=,/*8,H+AKS"<$G$K%]5.::L)='HN9T@?<&
M/<,":O$=?GX!3[/(\SWP3-WH\&E2&275)[R,12VG1AM(BSW,;7"B]Q-D"%X;
M?=)&"")6!0E>]6DDX*X((/FSQV.TC'<%N#CL.:B"N#,D5Z1U;B6SP&#1REO2
M%D<S!$/29CI%C8DT(<:S1M=Y9*U_EOGRU'=9IME=2/\ [-HC3O+#>6ANM4F"
MCVDV[:A;3KO.%F@T^)F0%")%E*[V& ,<FT@Y?&,' YX+;2/J+<$\$<\=ZEH3
M26TKXA;/:4N6J2[6)3!J$")[H:GD2L8[1$P,'@5RP5XE> $6$KT</+,QD+4\
M2*OH\>KWP95U'Q%I.CV-S=VLLT&FQ([+9^)K3K7NUG5G06JI;V[HB Q23JY;
M@ P.F@!9())75,AI'_\ 4MF'1#%CPS,[,&QS@ECVI*''H+4=_MU>PV%\7FR(
MWS2*0D 6DJ3U?(2QS55\]<)E(($EAE]UXSWHYS8V,:J0H;?2+ZW=A9^(?$NI
M3Z?,'DG%RL*:OI[JO48N8H\+IZP95UE:,;!B-PQ&1A*O)>"&(2C*\$M$Z8 [
M@*[3D\\9 QW)IR%V.DJRU,H,1F\2/#JLEI:\JP:(636)HJR02@@<0?[JSTQ<
M3";.>)P[HHI5=+*UGH8B[2XN]8M)P^C^&]#\/0IK.B7T%U>M#)+:C5[66TL>
MHH"CV>0":23&QK=PX*]B8X2)P%>>6<F&:%PA*HW3<=4[8P%5U;" @@^X\DU$
M-M<7$L0 Y^ED)8"[3!CA!R2^BL]TJ24J&)L*10(%>%S.F8C%?&L3E5T?Y+8N
MO.-2O=0800WWB@GI-XEMDM[#J*;1VF8O"'MS&6MM5GE$D.XLJ6Y51R,#8HD8
M+%8@"QB)9ARVU< Y.<M&HP/7/;@9IIBR01O'>0'*5Z'2J1 DBQ,<U[$8,UKV
MHY\;VRN=([Y>)/R&HB?/KF;5[%&M'FLKN_:.:X:YB$K1QR0NFVS5"NZ576>1
MY-N=C JH7#<9R#R <<<'&2#SG@_97=4RP!:QC*P81XXY5,5+,%ZGD2DK.Z7X
MII221Q'QQR+''-$T=\,<$;D1LB*]9R7.IV,<0CTJULGMH)] NIYK.,O<7%YN
M)-Q[07"7R1.J0SA8C&B@XPQ%8RJMGSE@2' !S@#&,8_=)!XYR2?=71(.L2E:
MTJQG=\+7QAP,DGE<GP,;_,(+/2JM;#&KW/;"_P!,:>%5/GX184USJ4^Z*\U1
MD-IIB6L,1N95ZEE&^8M/C:'<A1=^[I2$( G.#Y3> HSM4<L6. .6/=OB?>1D
MUTE9&B1^AZR(L;7KZF>E6O<WU2,]/E556.\M]7GPY$]7I;Y\)KG2!>D(9C,.
MC&S9C,3+*5S)'M8DD1L=H<'#C# +G%9%&[.3C' YSZ\'^7'O.,U;7DUOGM-X
M77\_XT7B(B+^="KU?N_P_P")?NZ]V\3^;Y(?")_LWT'U' U)O_\ D _77.6Y
MSKVI,>X@@(&/[2*#Z]AQD?5S4 9^</ZM,#)+E%DF?++"Y19)QE:M:>'(^:4>
M1"8/90Y/#V0SL1'^J2-Z(C.OG37@_P"T9'$*R@*H8Y"LN2CH%SPQZ@! ]Z]Q
M7HVF%?8%C]H:!W9V1L,RL0CH^=HPFU'))/W<U(K]CI1/K)U9?N,$L5M/B1FD
MM.'F8<)LQI/6&2R$J%S!KTED"*(OH<:^3UQD2M:O)MHNF7#1,;012(5*%1M9
M=CVKKB1<<'V2$$Y(VI70_MS5+<2(TBW5L6DW!]LD;;Q," KC(*&0 9'! [$#
M$;\JZ636W0=D37 UY+("VEN!':/$:5/<V-C(1[2,C<QS$-0;TR(LGMPL1ZKX
M^6X\/:4-*MG@,\DZ"2(()':1XT2-$QDYX\N[ XSG '-<_P"([^UU&XAEM;..
MT(B(E6)0JO)NY90O"K@J,9[@GTYL!G]=^(O+G;KLD;ZUH@&6*,<OR<@VTU7G
MU^$1/FUZJOR\(J>4^76;Y7--&JZ?XTTY20EZ]Q&<<_2C@9B#_:Y88)&#D=ZZ
M3Y*M731/'GA+59%#+8WT,S*1D$ ,A!X^.?\ Q6<-W=E7;&JFJC*2IT%!>@6U
M#ILW=1.(I])G+D2>NN\_;112P3O N:LDH$IPA QL$<ZS@%"FQ#DQ?%'@?P--
MH'B[1[ZPNI+>ZBOK4+*'*CHR2+%<1N,X:.>!Y(94;(D1BI'-?HEXW\9Z1XW\
M'ZWHE]8QW5AJ&GWJR12*N4EA@:2UGB(Y2XM;A(KBV<>9)8T<<BJXT?T;&-X-
MX([I>XPC2VM^+/QYRVO;=(!:"G/=QKHN(.3:2^7E$ .K9%6ZJC/E,QA7I+ '
M-TF8L;.G#GH;&J+,^E]0\;75O\J>A^ ;>W MKC1;_4]4GN;*<&214+Z:;"ZD
M*P21CHSBX>,2E)$$3;)%:OS?'@Z6/P=JGBB9DVVNJII]J?:;==W1>);E3 6$
MQF"7%O)L(R(I$DP5=2==.1/#WHJ^51[D\_?X54\]>E_KGD_:?6N$(P2/<2/N
MI:K,SH;E4;545S9*Z*6=J5]4><KH8(B9YI404>55BBA#*FED1%9'$,1(]R-A
MD5H9)PHW'DX')X[G'N'.?=BJ$@#)( [9/ S[LGC-),PQ _MK/!-"DS%EA6:*
M2))8TD?%[D7K:WUL26*2-7M\M22-[//J8Y$<^HQ\*5?;L6^D#Y)[&=+KK/)4
MP&NS6WK88-!DK(IU5"9;5(MI'FK=MP&-/9CI4$VI3B01GQ16P4Y DT@\RBFB
M>4_*K\DVC_*KIMA:7^H7VD7VF7'5LM4L"KRQ03O&;^V:WE;V>47<<2(DLBL]
MLZB1 ZF2*3M_!GCK4_!=S<RVEO:7L%X(S<6EXA*/+ DB6TJR)MEC:+JL3L8;
MN <]Q+/T@?=]I>\_A[MXY.T&2S^&AJ>2^XK%4>9SBS2A@557F>V^ZDDG+G2-
MYA9EQH;8M\WL#HR&: 962O@>5/MODU^3^T^3?P])H5MJNI:Y+<ZE<ZI>ZKJK
MJ;NYN;B." *43*1Q16]I;QH@9O,KL-H8*-=XI\2S^*=174)[:&TZ<"6\5O 2
M8XXU9I&;<V&>225W9W(&<]LY-8P:#.W^KMA*'+T=QI+P][F TU#6&W%J:]C'
M2O8)75T!)A#F1,?(]L,+U;&QSU1&M54] ) Y)P/>:YFI-E[=.?QX-N45PERP
M(-QH$=8\AD&\>ZP*'#@UA4 -B3JY"ZF%M!$"83 .6MFHWP\LB-E1GAWBN#@-
M@X)P#C@X[X/8X[G%*AKJE*RR_1E\]]HG&1/*^3[O>-..]-E[S+I>9'7:;C[\
M?-+7:>N:VK_%:GB^J[EPH]U4VAYPTWHKH!K< :0DM72#/$\1^6GP_P#*9JMG
MHE_\F.MZA8ZK9W@M;W3(KVULM-N;&9EE]NO'N&4EK.6%8]B%VDBN'"Q^4[O1
M_D]U+P?9W-[;>,[&WET^6,3I>&&:>[C>-6'L\*Q*Y FW@[B %,?)Y&/5-[+Y
M\25V=]IY/&D)0_'!';3P3/Q^.;&^(V#$R\79:3*0EQ2(DD145$X!A$;T1[)6
MO:Y$<B]>O:2-1&E:8-7,3:L-/LAJ;0$&$ZB+:,7IA(X,1N>J8R."F,5PFH&T
M:_OFL-WL+7ER;+<"&]D,SFVW \ANCLR#R#D'FK+=;"H='2E'2E'2E'2E'2E'
M2E'2E'2E'2E'2E'2E'2E'2E)UNBK6'(GV_#R?Z.@[C/;UJC=C]1J*D<L,HQ#
MODP8T J1?*?*(4R B5?S_9'$Y>KR$P<$Y]/UBL([CZ_U[JH[]+3W?<Q=G7;<
M+L>$\V!8:S7Z1^2?L+.*<\7C@%:@ZV(U,=*M673W![(*^8<"#26E%0CSO0LX
MLML+:\G [["G&=S;3\ <<^[T]:G01++U,MMV(6';DCTY_P JT4=O;W>XU]ES
MES]MM!W&:^WC+GDO-E9&$+"''$^R#BK0;XQ%CNJX+XVRBP.DK:&!E!+6W>-'
ML K$!Y&WBGB41JJD+@!L8+*QXPX)&0#^\"?7)XQ5I0D>4C"\GGMGX?#W_7WY
M)I1S1S'B'4HXN(>.299^A::JIPT>Y$+(>QL;:T>)OL%2SJ^.,51VD^_(UR#.
M5[$?(E95\P;L#CCZ_OQGGCOP1WQ0-CA>,^ON].WU?'ZR3FMF4WO1[3.QKMCX
M>Q? G'TM_P I\I83(:&@X5P=04O)>MUE]2B1)<\F$DPEWM<45:+."^SU#BK)
M_LRUN< )B#B%C^<]4T?5]>UC49M7O!!8:=/)'<:C>R8L[2+(9D0.5!D9&41A
M#R2-QS@'T&SGL+*TMA!"TD]Q$&BLX@6GE8Y\SY 5(@RDNS<J,D*>166GZ*WL
M:Y8TZM[ROI$>/JN7N&N[0>VX8XLMS2+3)]NN6$6:2F(S^)F(*S]=R08V9IEC
MN;&(W:BROE"#*I!VRP%=_P"$[.*VBD-G8&VTXK&MI=7<,D&J7Q4.);B:&15D
MMK-R5%G%+B5U#2211>0-S&NW;W$J"6=9)P"9X8,&UMV)XBC<8$KH .JX 4OD
M*6 !K/\ ]=E6AIF;)_JBJAV_V:G2E*G_ )F (D=Z_P#=*; G_?\ R]5&/4X&
M/UC]'_.K'[ ?']?S^%,^-KO<9\O^FW[OTDZNPG]H_K[*Q5,?5E2*.E*.E*U^
M_P )]_M-?<;_ -LN ?\ 7C@^E*\U7LYP/"/*/<CQC@>XS;F<=<.:6SLJ_7[&
MOM0J,VF\T-K+1206ME0Z6N#^)TD=0%+(=43#.@(ECE( :]3QJ'L>0,#.2"0,
M>I Y/V50D@$@9(!('O/NK;QX+[\G!W^5PF&T$FL[?NT&ESE-R-RM"0W8;&[R
M^7HS:K._CB9#)")8S<HV.8? /*)0K-G"$:4T2."'VIM-I=GJAO+^]6(+;31?
M-6RQ'VDJV2'ZJD@JW<#C:.#C&*A:I)I_1M5E)5VF#HSD,J2  $J@!VD8&2,8
MSWXS6OC]*+J<QW)\ETW.^8JM2+RQN[C1 ;?)W!EA96D>1HJ;*D<<WYH9S8EH
MRIL]9*'80!0PU1\POUM! $I#FS]BV@S6]O9Q6R3W5R\)DN(HXV=XRH!8L "V
M!GEB,5J-.UQIIKX78CMK2%U]GN97")*7=QL1G(W8V\;>V,=ZQY/X?/"X[-W9
M^KRX2QB5!0&9BLVF:"QAL)1HR)%''18 %KFEPO*B*G^*<]T@\4"RC%+!L)/"
ME[!H;Z[<W-C#%MMWM[3VB.6]N$G91O$2,S1=,.K,L@#<D*O!QF7Q##)J\6D0
MV5^[,\T<]Z;=H[*!H@[*IDE"M+U3&P1X@T6=K;P)$W.W?M<G:GVZ>I?4J<K=
MRJ>57YN_]RN E\_/[?DGS7[U3S\U3KF,8XP!CW5T!'UX]"> 0..,_5V^RLC_
M -&SW)=L/:5PQR'S3+O-3E.ZYIMMQ_5T%7\=85VDQ6K#%LQ[<FA-A)S=A%ER
M<S(,&]K +""QTT_QQZPNJHVQ+ZU]MMC;AC&[N,R#DI&"#E5[[C@@X)./0<BL
MD)C$@ZJEH\<@,%)//J?U^-6^Y4[[8^5N$\%Q#SEALJ;C,U/9Z+ET?0V]85-;
MC[/5U]]7CTT=#:0RA19]BT\0E71W#75!-"%$6R*#XT.3T[1?"5K;V\.J^(92
MEDEA'!;O*R!HX' ,,I)W.>IO38JC)92#C&:U4UP'$R6*@3&5F"X #=BW/8'[
M0& [FL!%7P9<<B\MZ;%<2#R668CO[B3-WND+&K8DPJ7KPZ326I14-<DD;ZR4
M(HMP%?[\BR2*+7_-L*:/3O"NJ:YK$NF:/;23J)G,<\BM'&++JLD5XY<*6A9-
MKET5L@\#.!662[B@@$UPZ)M5>H P($A RF0<9SD#)&<=_6EK.Z'ESLVYSBM,
MQ;AT_(."*)8);5)/QM>4';5,HSR!)HVP2.%MJ6UD]'K:,;"PE?<C%+B5L?.>
M+_"(CEO_  SX@MH;@1R0B>$-'-"X!ANH'4^92I^9F 8!EP RJ00.J\'>++WP
MMK&F^)=)2UGGLW9T@OX#<6-TCJ4D@N[8E5FB9=P(8C!.X$$ TE=VI;S^YOG4
MJ7PV4GE/:S2^GRJ))-H#Y7_;\U\.>O\ +X3Q]O6/@  # 554 G.T*  "?@*T
ML\K3S2S/M#S2RS,%&%#2R-(RJ/15+E5'HH R<9.R%]%JF%[ >!V\_IRS#R57
M]Q7%@^YY XRIW4M)-QQ+Q+%<Z,LAVPSVEM+E^@+I-'-CLK16@M%#)N[80*WA
MC,*"'"QQ65UJFJ:;I5DJF6ZN8DE=B^V&!R#)+A,!^G$DCLNX8"<]\C!G&\NH
MVB-P>S!@PQC '&3CO]O(Q6O+RSR=J^X#F+E#F7DO3#NUW(&WLM/?ERH7(C9+
M^VE:X2H$52'04N="6 "LK/?2.NI00J\-'101QM[RSTZU34-1B.L0:3:V-Z+9
M3(CS7#VEQ</9S.D:8WBWB)FN"6#!#E59O+6-251 J$C;Y54!54(,J/<,\!?3
M@ \<U'"QRF)!  ZSLYY&C.5D0\SFI,R&=LT21HLCI71BP0>S*Q&I[+)O+?2Q
M/3=) ;I(4L;G6=6GD-@S)';S"W$T4$]O<HL2DL9([2WA6&0$DQ/,KEU7"W9
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M0HR4J%KE>V\G )]PSBN&.><<G^=;HG#/<>7VKT7&'83QOL!N8UXE+6BM.94
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M&T#EB #BD<I,"RS+T21EU<[2I]00<'OVXY],Y%,3D/C/<<4:*?*[VA(SUZ-
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M=@7P-QG/1<6X\VKQ?(XF>L[(2VK+@+6QBY$2SJA;#8L46MCDGL;"WNHSD,K
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M3;6% )85EL/9RL4:A9EMI9VD+9C?J!D1"(]M@MH>6Z9));.]B3AF#GZ6<#<
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M]%<CE3T^?G]O6T\9B*2]\1(QW1/-(NX\!@]M&5YY&3Z _P QFI&A]1=0TF1
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M[V.2<<<8[5=UUWBR5(SN7#BODR-:1F!,]<6+(0+&EABD' +?>?'1N/%G"G?
M\:)?CXT$8A#?9549[_!8:/"E]H5C;G6(M-66*.PNIH(TE@E9V@=;IF5)0(V
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MM"EC("C$^'&<8;'(U)^(U'3M)UCQ[!I6JW;V]E-8Q.KB41GVJ:*6.VBC)CD
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M&H:8]0]1XTRQ&.7&2<C)P#Z=\GER_P#1J\N3$-POYY.FH ',49( '8 < 9X
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M8JT2"QT3&! SR&V#:BWA(EHQWQQ=(UJ+5O;Y[&4O;VUW/IK7"2EH[ET2)K@
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M()()"@?Z.\^7:PR21CGBMAIMC-JLYM[8QK($9SUGV+A2H(W ,,DNH4>N<#G
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MHB5P];5 A5H,2L%!$&%BBA9A)+$LS,S$DLS$LS$\EF8Y)8GDDG)/)JH
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M,@0L VZ%X9#C&_;D&;N\;N"VO<GPUP#R=N65D%[8;_GVFGBJ8R8PDBIL_P
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MPO="CV(YR+S[>&-&;53K36I?43(DAF:65U+1H(D(B9S&NU1^ZJC.6()KDIO
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M..((,$!WE1I0SD;9:QQ@9$1\N]0#DG;(P9\ GL3S]F :XB0O=&E(GUP2R1#
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M\8\5G;:"!A]1))=Q-9(?*,98>X-+<2PW=A$6^>H2:R%_:%3#-$A*F,%&S*^
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MYPH7MW^!^ZL;U?V^S\R\W:LV407BC"Z'07NR8"''!<)F*&VOYC!\H$)4N(#
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M-)?:W=+"ID^>L"D4UM;HRH=G[/M][NR;@RL"2 H-2 ' \TJ_109VCZ78G_\
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M%/Q!^&:[=F?'NO<3><M0X>IO<E41VN=K]!;6->'*#N(!:JP%K\]"7)(^>\G
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M:..1U9/\).7"TF=&^E3WB2Z4FJ0007"K&+E!,P188G(CG*S2";$AC+!#MVL
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M'A3!CVN!DQ)O'>1%STF^KPLC44^-CL=S*6%F"YI+!*A:VP%>&RJG/C"9&@C
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MZS8VUNUK;P@2)LMFA5!,LBHLG(<[G8' C6D?3PTD:I;NZ@]0%82?,6W#@@X
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MJRD<95@&'V$'D>_-175HW9& !5F4KP=K*Q4CG/8CO\!4 ?C)H?[NW'])&?\
MMNJU97./K=2)..6)H[T8H2:(@4H>VL(2!R(9$EAG@FC(;)%-%(U'Q21N:^-[
M4<Q4<B*BG^7;X9[X^OUJZ#-'8<\T9_).4U)^:YCR\+=+S)BP&2.!U]=EQ;&W
M=SKAZT=7*XD8QSS.7<4 (_\ %<\VSY7ST7\'AVNJ.)NX\.^(]1@:&V;Q-J&E
M=.2#HNX]HLHX+&&[N+57#,SJ8KPI%!"(F@(NI&<J(PCQY84;+&)),@@C RP<
MJ'&2.Q49)SDXQ[L5T*L[^Q&8/)HJP^)U?GZML4R,;*T>S/*N_@VN? Q?-9:O
MD6PF\HB2S-8BOCD5&;*6[U>\MUM_VWI=Y'/:Z%8E'CC20)J%[/JJVY)A&YK"
M_P B]D';J1J,AB%H$C'(B*G<[<$XRJA-QQGEE "@CLISC%=*NTDU*5&091TM
MO"^]J+J6 F-GM30YZ8N&6N5C$16!6#9WM+C1KO<1D;_FB^5P0Z[<:?-UKK2]
M)ODGU6PU-H]L:HR:')=6LEL(U4A+>[ZK;P8WW%=^U@2 :+J*5$CQY1D)4\@O
MC##/&Y<#:><'/)IQ"[/%%5S1K+C0.<EF9U8(]@"81 Z:WL;!3JR^GCC;Y5,]
M!Z@XXE<K)!O**K41.MC#X@\.7%FL=WX.B><:/KD*7-LP DO+FY%S;WSA%CD5
M--BW1AR79$9P"%X.%H9U?*73!>K$Q5E4@(J;6C!/\4^8L<X/;W4V=";@BGF2
M4]-?4[GP9=H$,Y?Q44:0A^UIRB$D<Z5?K$I&DU_H<QD4;I&>%1&>--JEQX3F
M]I:RTW5+!G31/9$>0ND<:H1K,THDFE9O:"4>T*D*<L<+D YD]H  =XWYE)(&
MTX)S$/<-JY!SR<?737A*%0FS4:TLH((9))Z='HY)R'L+8R#XA\3V_#3(.KWR
M3,D5J2,5C?".1S=-'-:B;4&@U"]@BA,DVE;U<S7#I<(L*SM$5$$W0R[S D!T
MVKG.:RG.U<A22 &SZ<<G)YQGCGWCBG),(Z.,\NOW@CDI'U-K7QR36@9-C9VL
M8WQ<E4UT:^T;3RR>V>3+(/[D0WO1NG_):NY> QB[ELO%T3_LQ]/O[-9);VUF
MN[W4$MS=26*L"4N-/D=DNIRR,ZPF0,P  QAN55H&\X92<*0%3.W=VR&!X SW
M.<&NA=XVU 6X&6]HK8+/."L"2*J^KB19GW21-9+7-=)%.?+Z_1&=$+#)(*L*
MJ1'%'&CEAZEX?O[0:E$=3TS4+;1V@N)IK'4[::&1M1*)U+0.T<ES*SHJ7*1Q
MF2/IAY5$>UF),&*$1R*9-P 9"I&SOD]@..,D!AC!]!N#?@=HM@'W0=XT%E'[
M9*<!<>O1/,*I\._<I(*[S YT?Y8[XW?V7J^?Y7Y2KXT>J07MM.D%^FR=8+?"
M@PL.B8(S;-N@9T.8"A[[L8W<UF4@C(Y&3S[SZG[^/LK?\<LJ*OI9&K?S*Z1S
M57Y?/RB1.1/G_P!9?*?/Y?9UK*NJ*Q^=.&B^3#>%1>6^*B>8ZZ)LY_$\'(F8
MEY)"@=5#WS9BL,PYVF@B6C+%N?7)6-;]5$CV"K\)-',Y2I3\S_Q<7_KG_P#L
M.E*/,_\ %Q?^N?\ ^PZ4H\S_ ,7%_P"N?_[#I2CS/_%Q?^N?_P"PZ4IJXG<Y
MCD?,UVRPUU5Z;+VS[".MNZPF64$Q]59F4UBV%[Q8W.42TKS0IO+$\3C2-3RB
M(JJ4T.1.8N)L$3^+O(NXR^9L#:@&X95V=NX>S?36VTS''%?;0CPP.+8'/NMK
ME,Q$=&U(X[>]KX'2,657- XI4.ZC"\18K,:GE2_Y-AI,ADX[=-/KW+A3PZ*&
MG(EHKD.RM8\8<7[M5/#-2V8Y$LID$T,X)K$E9+&C SG'/H<<_?WJ[<Q7868I
M_9R=OO\ HYQW)/:GHG;I2I_8Z"S1/S>:3CQWC^=@EZKN;^T?O-68'N'W"OU_
M;]40QOD?I[*..-CI)'K0<:^EC&-5SG.5>/5\-:U%55^[STW-C&35-J]\?KZN
MU(>1XZR')V4S'(6/Y--U>2V&>I[_ "NE"H^,RPKG.65>.32'@3$\;^ZX&>M>
M,X-JM8C!UC8D;$:C4KN;WG\!]G;\#38ON_$_G3B3@.!OGT[&U;Y^[+<4+_IX
MT7H78]V/WTVK[OYUS_P&R?#."_'FZ4-\\9+Q79;B1PSB8F21Q$.@=QBZ)T\4
M<TL<<KFK(QDLC&N1KW(MK9;&XDX]_/'NYSQ]57+E"2I*DC!*D@X]W'IQ3XPG
M'S,23=&.O+2^*NXZ>"6>RAH0V!B40LP=<$ #G*#/UPXT,$[V^E!7.^341WA/
M"*').222<YSZD^I]<UIA?3O=AXO>_P#2=Z"MK.X<7BG8X#L]X<N0\7-FC[PC
M24A6YYH'ENH2(=)00!CC7KJ:G*>R.P? VQ0HAL2,$@.\A^5/Y6[?Y*OV-=:G
MX=U/4](U662WEU6QEB6'3[I6B$5O/&ZL[23Q/+-$05#+ ZC<0<=WX+\#S>-3
M>PV6IVMM?6@5TLIDD:6XB*L7E0J0 J,%4@@G+9XXSMR]D>*N>->S#M%XZT4T
M)&@P/;#P'BKT@>928)[G*\4Y.BLYH"%55GAE- G?',JJLK'-?Y_*Z]3T^^@U
M.PLM2MBQMM0M+:^MRPPQ@NX4GB+#T8QR*2/0YKC+NVELKNYLY@!-:7$UM*!V
M$L$C12 ? ,AJSW4NH]'2E'2E'2E'2E'2E'2E'2E'2E'2E'2E'2E'2E'2E<4W
MSBD3[V._T=*4C^A?O3]?[.E*/0OWI^O]G2E'H7[T_7^SI2CT+]Z?K_9TI1Z%
M^]/U_LZ4H]"_>GZ_V=*4>A?O3]?[.E*/0OWI^O\ 9TI7ZC%\I]GVI_I_P=*4
MN=*4=*4=*5K]_A/O]IK[C?\ MEP#_KQP?2E>8;PMPUR'W!<FY?B#BFCCTO(&
MR(.&SE%):5%*ED1759UT5 EE>GUE4/(E?6ER1-*.@4B1C!H/<)FAB>)P"3V'
M)JC$*"Q[ $GZA_/ZO6MMWAGZ/GZ+(REX/XJWW MC%S_R#D<E1\IT(_*W)]O>
M\>[ C-U)VTN'V@FK'Q*OS10EI/J)0@X*W.^Z9)#!-7#HV'3V6KHU]>VLR-*M
MO'PRPLD08D[2+G<R,<8R HP<C.14:_CNPL#6TPB/5#,"(Y.K&5!QTV!9>?4-
MR,< BM?_ .D^[8^/.W[G&8S@?/"5';]=N7*XJ<;<F;\V74X.IIJW>MT=J:U'
MAWAEV4ZV045SZ4H,V,[/O;62L&$W*07:6UO/<Q&/VE2Z>XCW=AGOWQS5MO?6
MMU+/!#*'EMVVR(?*X!) 8IG(!(/U'CW52#%[_;XRJN&Y,DH$0EP4EJ3 )"2Q
MCF1RCC++-,/,P1'^^]D;O7&Z1ZHC55Z-\:R_T2QU4Q2WEL9O9<["#,JH92AR
MQC95.YD7 8]QQWP>[\->/O$G@Z"_M/#^IC3EU<Q>UJ8+2>2<6T<\:JGM,4CH
M MP^3%C QR,#$F\@S/G[5NWB:155\G+7<LYRJOE55U1V_*JJOYU7[55?M5>M
ME@#@# ]!DG ] ,UR+,68LQR6)8GWDG)/VFLF7T1_:/QQJXM=W+]S'"^>YD[=
MZ2IT&>%@(TUD+:YCD>G)H;*CDGRHMA2U^C@THLEP"(!9'6@RCU%S.;1N@^$G
MF@:C+/#;L]N"TN<(@P6<^H P2..=V"...:#]?AZ>[G]<U='N.X%^C]WO:K0X
MWMLP_$W%G,O-]\7)4:4X>_TEO3A8[=#LHG%6-M;;'0X$?6UL=I$=69,5T)$-
M[2#',)K@&N#Z+3-&U'6;E8K6$1>SV4;7&_(26X=-Y"NW8KSE<' /IQF-)(;9
M6>5BZ[L JF-HS]IX]?R[ZOFAS=OEM'?9.\%^#O<U<VE!<!)- 1\-:TQT];8"
MM(&DF&G]@P>:))AYI!Y49ZXI7QN:Y8$L3PRRPR#;)#(\4B]R)(V*,HQG)# C
MCO6<," P[, 0?@1D??5I^S[GVM[?>1%M]"'.1F[D24#0RTJ05^L8'&)9>U7U
M.C]B:PHPK(HF*"]0%/)U<UT4C'NC@5G$>./#=QXCT@VUI.\5U X>&)I62UG9
MGCWBZASMFZ:(3#O $<F6]<UZ9\F/BS3_  IK9EU2ST^6SO%$;ZA<V3WEWI<D
M DDAELA'-$RB>1A%<9#AH^=AV %B=V\K".YSGF:)%2.;E;<RQHJJY49+H[&2
M-/*_-?R'-1%7YJGA51%54Z[&/<(H5=0KK%&CJ&# .J@, P W8.1G )]:\[NF
M1[JY>-UD1[FX9)%4HKJT\A5@AY0,N"%.< XK)5]&K]&?QAW*Y[?Z_NUFYSX4
MR M#DM3Q)MA(J+!<=\A5-E8WE7>#C;+:Y'3P7%C\8-4)604 38!PW6)QYJL4
M.-T2]OH+%$DGD5%=Q&,D[BS$8VJ%8L?M &1WK OF.%YP"3\,#/WG/:K'=]7T
M1O;+Q3VQ%]P?:MJ.;=_;VZ$'YO'WUGC+*MKLQQW8.IN6M >7!34MMI7!2AV%
MI#!FHY8ZH80LN9I5>Q[ 9<>^:0I"CNJ1"9Y #M52$(!)'<AB<<$;34**Y92P
MNVBA+2[(!NP9 2VWOZX&,=R>^#Q6NSGM#H,??T^GRUQ99[2Y^Q$MZ.\IS)Z^
MUJ;0&5A 9P!HLC)QB1YF,DBEB>US7(GS^U.KJF_KW]ZNOG,IGN[&IOK#C?"T
MN9YZRV=N]7N,'2R@9K'\EC3G4-'#J>*Q7R"4^8UC;JU"4OA2!HM1=VUC)%P^
MZ!+.BXFHNDMM6TY[1;:]TN)[E(]0$=_#(89)9KJ*!+(W$8 C*V,D3NA7"N)<
M.JE6D?$48-N5CCCR^@P26V^XL"!V]/LJIEQ4?5MA:UUK77E 8#,@RUUJ,4&8
M&1 5$'9#'B$1QS02#SQFLFBFB9+#-$Z%S4?&Y$R36^GN]TVR]LH62UET\3(Q
M4Q22P).[D [HBC7,L;*=K% %))Q0,<#D'&0P&,@\GD>GH3V]2?3+DJ,G5V!$
M0U9M:P1LI^JKHFV*RCMBJ:RL::,5*[YHSZ^5S@H(5\>DAOH57(Y43H;'0+&Z
ME6'3_%-I")+SQ!I\8N<Q[=-M;)9XIV4N BZIEH @PN\>4N0P&)YF5<M"S8$;
M87!R6;:0.W]7D%L]QG@$4K3<?[N2J/L!Y*6X!?@LW='J(8)(4'1E'P#UD#(I
M$;)'91%"QQ$0Q>94C5?<56.7J9-X:\4/I]Q-%-INH6\WA?1;JXZ<D)N(=.-P
MALK>(,@9+F*:TVR;&.],C<2P%8_:8=RJ=Z,9Y(UR& +A2S'T\I&6!(P2,9I+
MU%+K*B33"W^!: =];4 )D\5>Z!E,<@,L@U8+["R01ONQGQ%RM:OKF]/JC1O]
MEU UFSUNV;6EU+PI!;SRWVD02SVUML2PG2W8Q6=HT+R1@ZG')'-)TR2[>7AF
M&+XI(I%C,<X8%'=<,#O7<-S'.">F>,^F0>],F:L+U>EN8\SGIJ]OD^PCHHI)
M97UH0(\A)4?N%.29S!88)'>)%65WI]'I5[FM7BM<O;+]H7MS#9+HUI)=;(=/
M9Y'%H7*HMOND'4.) 0-P&"<$*!Q<\T5K$CW$H528X^HW9I)&"(O&<%W8*/W0
M>Y')KCNL'M<^R5USE[H!L<KH7J17E1HR1DKH)(Y'>TL;7LF:Z+^S7R]JHGE4
MZU$6H6EP,0W$$A(!PLBDD$9R!P2,<_ =ZQV^HV%T%:VO+:8.JNO3E5LJR[E(
MP>V.<C(Q6X5^!KK)_5*]XONH]'?P$87^S\^I$3?O1$\.1%\(GCQU*<Y">IQC
M.<]@!@_5_P!_48F#'I\:]!/K'5:Q+:[L"W7(_,_=ARI?;FYH(K_D4ODCMMS%
M-8YRNHF\B%=F6:[=Z_DC7:"OSA/)%63G[4C5"@T%7IJ^I=\#5Z(FIL9XQV/K
MD8 ^&#[QSG]?6:5'^2[5^[[DC1<=3\WP7V/PX_*/ )^\RF=[B])/8FX3C#M4
MY9XSV:E7>,/S9CH]CS#9XK0V6>JSYVWM:1%979,Y8MD*(R.?C^'/Y4JOO%_;
MEWO\C9+D;89:7D'$MNP>:LO??CCW$<BAW'/$8/?%3:*CH*//V4TC^!FUW;_B
M.1N+J+54\=4TH/D>JMJ\E]?8V5J$)'N]WX#G\>_U?;2I]RO:OWB4>OX3TE4M
MW3T]!S?R1H ^/MES=:[[#\-<([/6Y8\.DLY&:2OTVHY.RE916UI@YZVQW>'&
M9I3N-M!7KD'2V;G'/V>G/;^7O]>Q]XI4A]D_:_W@<7TMZSD[F+9936DNXICU
MQUS<T'-.3Y*M\DW=-Y"U.7'OKHZ[RIG(TUUGR+G1'Q9ZW*'IZ4),F$^G>26/
M^9_7K2JN<;]D'>SQUEM.)DJPC(ET=)D[&6A'[D=%:5'-NQHN]+&\^BRT0!3Y
M*3B9M=PG1[#BT\=@E;47-EMY:\MEE11&7$K/O^/I\,#]?#/<FE2'?]HG>IOP
M[B;7?#0Q:;1[S63XPOEN73TN?(O?I&>$NX[(5,,Y4889[L?PCD=5259\-6)&
M X6+-UT D%C$/T/^0_ES2I&KNRGD^G[)N^#MNH\C#6:SEKE/N"N^.;,SE"QT
M%;L<SR/R5=;#$6#B;JQ.*Q9M9E[6OHKR$M(#C]!66%X;+8DG+;FL\@_5[O0#
MMZ?52H>YU[,^]9N6WG'?!DUA+F(N7>:MEPKH[?N#Y(GW/'H%WC>!BN.E@N+[
MD@=CZJ3=T7,AYA&D&W>GH[4^K@I1Z7.Z[6'RLCW?R [D^@^KW'N.U*D[D3LY
M[B#[#3:Z!FOY =JN\/D[;ZSCR'N=Y%XVATG )N0Y"KN$:VCT-1>.#PE=QUR)
MKP.0;3*YT&N+M'ANG)9<GU%)5J!_6![QW]_Z';-*@<#LH^D6XPR7"M5PYLJV
MOBXJX.[8MO/DBN32A:&U[DN%,Y#PYM.)Y1_ZZ O%F\XGL";Z>PB9#3KNL[76
M1E>27.D[JG!/KR3]Q]?K'_;-*>I?9KWNTO(5,'FKPN3+9'@_6<5KR#'S5M9;
MCDIUEV767'])<:X'2;FR2#2M[EF#:8A*+)9>DIXHZ3;"&7.E/UAT%..>/_.?
MY8X]:4^J?LO[E\ISCV^6P&SY*)XQQF3[?BK,H#FRXM[/,\@YK8:;5]QB;&/>
M:DLO74G,K[Z(.W,JP].7;T\;LM"'E*NFSYL3/P&>?0>H ';W<TK-#U2E>;Q^
M%8<C[OC?Z56B.P>OTN.-N>S'C"BMC,Q=6%&78TAW(?+<AM0817$#RD5Y3Q8'
MSBRO=#(^&)[F>N-CFP-1TK2]7BA@U;3K'4X;>X2[@BOK6&ZCBN8@1'.D<Z2(
M)45F"MMR S8[FIUCJ6H:9*\VG7MU8S/&T+RVD\D$IB?&]-\;*VUL#(S@XK>\
M^CF.,L_H]NQ&RL2B#K"P[-.V XXTR>4DLPPOA'#SDE%$S.?,001/(^6>>5[Y
M997NDD<YSE59J(D2)'&B1QQJJ1QQJJ)&B *B(B@*B*H"JJ@*H    J&[O*[R
M2.TDDC,\CNQ9W=R69W9B2S,Q)9B22223DU<OJZK:.E*@/9\QS5ED359P40A0
MY7P%6!J2RQ.GC<K98Q8(I8?+8GHK%GDD<V1Z.]$2L1DLEZIGD\#TJQGQVP??
M3'_AJV7Z%/\ Y#+^]]7;![S^'Y5;O/N'X_G1_#5LOT*?_(9?WOIL'O/X?E3>
M?</Q_.C^&K9?H4_^0R_O?38/>?P_*F\^X?C^='\-6R_0I_\ (9?WOIL'O/X?
ME3>?</Q_.C^&K9?H4_\ D,O[WTV#WG\/RIO/N'X_G1_#5LOT*?\ R&7][Z;!
M[S^'Y4WGW#\?SH_AJV7Z%/\ Y#+^]]-@]Y_#\J;S[A^/YT?PU;+]"G_R&7][
MZ;![S^'Y4WGW#\?SH_AJV7Z%/_D,O[WTV#WG\/RIO/N'X_G3LRO-1)%A %IA
M XAB9&0ML0FRPH,][D:UY4,LT[7P>I4222-\2PM\O5DB(J)0IQQ^/^6!50_O
M^^K$=8ZR5QR_\F__ .:O2E)GA?N7_$O2E'A?N7_$O2E'A?N7_$O2E'A?N7_$
MO2E'A?N7_$O2E'A?N7_$O2E'A?N7_$O2E'A?N7_$O2E?J(OE/DOVI^9?OZ4I
M6Z4HZ4HZ4K7[_"??[37W&_\ ;+@'_7C@^E*\PWA7DODKB#E+&<A<0:0S)<CT
M-O&F7O@9A8)Q#;*.6IEB?(<UX/PIPAQ !K36J*\0F=A'B)SU0$,AZ8&XOY O
M;);@#.1C)..X^L59(Z(CO(0J(K.Y(+ *H)8E5!9L 9PH)/8 G K,+EN:-OPY
M1<TZ'G+4UE_SMNX\]%F;Z(@P8[CZ:YJM3-R(_.6F;D'KS+0P>WJ*Z_)@L"D<
M$US8H7P) :_N+?P4-)M@FI1QI%/ LG1!5BC2!G*/(&8,VWSD D $'&*\[D\4
MOXBDC?P\MUT[>YDC:X^;195B*J'6-TWQ1,X94$JKN*G)R<5COY-Y?CW,@6?L
M:OXG$90PZ?+44]C8GA,LSJRFI[?01ED20V93KQU"+9-'F(<P59G#J\B" >.*
MX2Z=+\WJ,;RVUJ&CM8XF"  D*KHP"]0-@81BJJI)RW &^MM)GMP9K6?HW=YL
MDO+@*CRLP+.(AU%D1$4G:V$8D#R=-B6*;7[@^\QQ/&3[ ;,Y X>M@F8!GJTD
MRS6ID&DKRBD8^AD.)B^'9)$87*^5C9"Y$1TY,TDN_CG;5-%70(3::78/T(VD
M:SMVN+QK?:T<KL!;2RDD!MY,A&6.<L2T*;2HK35$UTQRW]]%UCO-W,EO 9@X
MDC6-VN1#$^XKTT4!=L8((C4*Z^X;CZ3CSMI[9JM]P!<I8[WN)O8I08RH7"C6
M /!D0@A\1,$38K)HPL!1<(DQP8ZEL'B/*=#(_KSO5])ET:Z]DFE2638) \>[
M8T;\QGS %7*X+KR 3@,>YZ'1]6AUBU:YABEAZ4SVTJ2A>)HL"3ILI(DB#9V.
M0C,,$HIXID<!%<^[BBT/"W'W(=]G.-[$V'8;"G_& D',QFU]=85HEH3713>Z
M29+ ?/6QQ5\+Y29BA7%-] T,XTWPQX5U+Q;J:V&F11F2-#+/<RMMCM81^_(<
M[MI8 #8C-D\C%3;BYBM8S)*VU>PQW)/N]/7_ ,]JMK?V[*JF+E'T-/E:V6@H
MZZGL\;GZ>?V+2HC#@D2A#BA!^!1;0"4:QLE5AI".]^R=8%O25_NY\/V=CI7L
MRZA!I<L,-O$^H6,:74K7>(HYHHMRID2$;.HX# ,"1GBM0MPS2L,/("78I(S!
M0O!7=D\9/*C!['L :C[B";CBLY8*U5L!+IM49:HT3\:HA=$\O3D'RGR:N0L@
M(2ICLI+")JN2268>0B8B*-D2LC*9&T'P]X2M?$;RE9=0O5(0V]ZOM6[4">K[
M6)HXH(()7?S+#B5,NR+]$-2ZENS;D*Q1<$[H=L;K'M "KN#$[1D[\9X]#Q4S
M<L]C5MR!R#5:Z#;9^CGWQ*F:) LA*%1UYLHP<4'U %57M[-?6)[UEL+MZD5L
M$4LDYROC8]\3<7B7Y(=1U35)M5MM0TFV%W-,]W;16L]K!;=.-$@,,.^9I&N&
M1FN"\D8,K-(@VL$7#;ZY;QHD)6>1P51"6#N[$\[WRIR">X!P"!6/[NN@<+W+
M\ZCJY)%@Y5V\/K\*B/6+1'Q^I&K\VHY6JJ(OS3S\U\]?.\D9BDDB)R8Y)(R0
M-H)C=D)"Y)4';D DG![UT@;>H8@@L V,\C/."??[_CZUDG[=.X3NOYVXRX0X
M6LJS*U7;[PS<U&>+V4M6_+MFR)UQG:[2U$=JGLTUWIA<ZR8DF:=6RI"BV=C,
MPI4(+V.F^&[W76,T%H9H;4&5G="8B(RI=4)5E:<#S(N P )RIS7/ZQXBTO06
MBBNKH1W5Z3;PP(0\H:1',<TJ*VZ.'*%1(0?,0 "<BI=[CNZ\JOUE:'GY]'E<
MUDJ9F3X>SUH:NF%J\4=7&AER$,GAK+ ^8^(X<JLMX24BED@EA:[Q/'8!=?;Z
M-!8"5#*D1O#TW,ZLY4%&56C5#G>"RE2QP.<CD$<@M\^J&)B))X[5Q,6MV"'?
M'(LH5V<9&60(X&&VLV#])6I5V[T'!>0Y$!,M\?4\DFE)6UU+1;N,.SKH-&,0
M,=]<%AQF5P*"/G8T6:JL*R[ G@]8TAK_ $DPE[S3?#>@V-\I,3:IF")5M[R1
M0!=*T3F5#"JK@@,IBE252C98D\F+XBU[7[K3>G;22:5OD;JWEE$&D6UE5XWC
M3K"4F1 _4CF1H&5T7:$P")+T? 6[J@N\7G8@'CL#([+@S6E.I\%:&2@YLBTY
M5XF>,,V&PH<^.3";*Z=\"Y^,P6'VIG.C%$0=TG'>)O#>I:9(^I7$-K%:WMQ(
MT45I(76!68E$(,42JH7&-HP3G  KI/"GB33;V.'18[F_GO;&T1&GU&-(YKOH
MJJO)N220O(,J7WA6.[.6.[%5<3W8&WE,F%Y_HR>3Z>4+/4=5R0.Z&3F;)5.?
MMH+.FK$M[-SJ[DK*ULD38DR.X6.Z^J1A,QD>1>/Z5LC%IHGC'6-'ADLE:/4+
M";V%&L;\-/&L=C?I?PPVK,VZW1Y]X>-,PNLTI:(N0PZV6UBE97(*.I<AD.W+
M/&8RS@<.0N,$\@J,' Q4P<A]K6]+'9K\7Q:O*N;M7[C7DP\>!G \GYZNT8<D
ME,'M^&)6R[G+18>1D9EQ:U0>IX^$>5$&-N[5DK)9NVU1R\4&H:WX$NK*WOKC
MQ!?K<6R;#(VJ0F+3HF=(U,2Z=<@S+'.5:0 -'%L9@\:%E8M%#>+(8A#$P."R
MF//4+<C+2*2&(!VGD<@BJ"64U3$V1 OK8*1M37(^&9%:PBT8^-;)KD:UK_@W
MN1SPHWKY\JUJ_-/EPEV^EI&WL3:E:RG3; F)^([B_P"HC7V64!C9L/G;16(Y
MVCG(S+4-GS;2"2<]^.<8Y^ECAB#QG..U*=7=7[XY)8MB0UT(XVM+A+.(9ZKF
MF(<-7QHV?UM,MAH',G!<JN:D4CHV*GH>G4ZTU#561GB\2R(T5O'XAGCN[F89
MU'3;CHVT"B;>MUJ"1+%-;$DKL(49$9JTI&>\*XRT7E ^@_)^CV1NS#@EL$CT
MKK'T>R4RYODDG*+BK1-1<V()L,RPAWDHS6$%R"O\QRSE&01$#I_7HB9429C%
M:J)"U/0M;N9K^^NXTOG6TM=<U">.:WF1(-2=#%-+L8A9'DF5)(E7>CMDJJ=P
M,3*D;*FTL4564X+(&X (YVA<^HV\@XI19R#RME; ETQ%S :Y@$Y27(DATRQ,
M_KX$TJV4,SV1R,E\Q/3T)+#(K$<Z-ZHO*WWAMH6,%]I-Q:O"BN8Y()K9HXYU
MPC%0J;8Y1RA(VMW4D\U$ETK2[F-8VMH1& ZA86,0!8;6 ,3+R../0@'&0*R(
M_1S?2\=QOT;_ "CR3RKPUB.&-C?\H86@X]T0'*.?U]A3C5F?M8[<*QJA\;N<
M04-:2$-D84X@PL*2*9R1A0O9&]MEI:1V\1BCZA4RR289MS N02,D9P.PSDX[
MDGFI=K:QVD9BB+LIDDD\[%V!=LE03SM7LH.2/4FM@-/PJ?OU7MV_A=3A'M$7
M1)K&T+@/Q/YE^I4#=*UGN_#_ ,.7QWQ/AR?E?6/M>?G[7CY=>LKX%TIODW/C
M$76H?M(70A-MU+;V+8;\6N>G[,+C?TO/_P#K&-W.W;Q4,WTW[5%@$CZ1M^J&
M(;J;]V,9W;=I'ILS\:9?&/X5!]*US'HES/&W:GVE:ZP@&0^T=4<=<[S T-8C
MO3+<:.V=S^RJSE&-]IEW>F5]2#&CIBS88F.>GF=W 82JVT5Q<NR*5BBB:>5W
M; VQQQ*7?OD@+D*"Q.T$C=VZ0N2;FX@M(ER7N+B:."!%"[MS2RE4 P".3DG
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M7Q^'-  2?@,]\9^OW?'W4S>(OI 9]6/PIG=3QQ:7NUWV9XST&UMN-!WV.7S
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MD,Y"CRQL<DCG(R:Z'Y/=1C?PL+N60=!;ZZ ?;@+OD5MF%')4RQJ2,@ELAL9
M;O$':4?PKQQ9:[DBFUE+RM?V6FS$%14:NKGKZK#2T6;MZW3(#GX;:0LXT]MQ
M#Z;HV>H%#KT,GIX[&*O)?Z-\F_@2?2/:=7U>&]LM51KFQMH8IE,8AGCZ9N2(
MED$C1-U $=I(SE7Z;%0:W&IZM'.XAA:!K4+'*7DSEIED;YH;@.,!"",?2(W<
MUUNV7COCS79/E[8WNCU%#!F;VIA R8@[[R#31!!G&[>PT+X4JS@@D'6N@K2*
MDYDPD\I#R YH_;A(ZCPE#;WMSK-Q!%/#I=O>R17PO;C>UQ-#'F\=%2%7"2,
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M'+Z@D0>)H))(U>[AP1)+)&<QIO&T]5,%F8.&+%:U-O,@N&< 1PLP8;U7*J2
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MQAAPR+VS=573#!Z (K,L@(^']#"6C/8WT01P201^IW%TBSAY5C,+0$(@P-N
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MT!3*JA5,JFT+A4<8).[:2Q)B'D_E[5<J=L_=Q:7=)/35<7$4@=3/&0XX2Y,
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MKJ(T*MU">&&>YR1@9/ R/OXQ*A\/Z=91QRVTCO<[E:V0@LAR ?,-RDG).%'
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MGV,XC2!06+]/"APJG(W;26&#DC.<$5<\,\-W'"E\8[Z*5I7NR55F249V"4J
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MBN+BT@/26\=GCAMT1/:)'!>5CC)9C("?,<C!4@#BXK--+TI9,_,JVXDD%"&
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M^7Q/Y=S7)\5KO[AU:?R+</\ *?R+X"<GE/S^%5/N5>G'O/W#\ZIY_<H^O/\
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M5^@6L:7CO;YZZ[@(K_;:BIG"IM01DK)])F#56)@IPF6L-A8BR3(.#70&$CD
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M',CEV+#I-R<X)R2>_':N8U?PFFIW=Y>+>M%+=B-2)(1,D8B0(NT!T;'E! W
M#XUQZC\&D72PO$3GVCK0FRU,\0PF*O$9-."R=+(@]9-M(Z6>\?+&IKQ'!,@C
MC]L*(=%:K9MQX@2X5D?39%#NKMLO@.PY 'L_&[L<8X^-1+;P?=VS!AJL3, P
M!-AVR!M./:.ZD C/J.<@D4^)?P?+D)F=S>;JNYZBJ J,:(.6.' WI,,PS%+$
M5!HB-VLL+G51+8').20CS&*0KFCN8'%-3Q?/#&L4.GE(T4*JF\#$=\Y;H Y.
M2<]\DU!;Y/B]S+<OJ8=I26P;3 #$#W7   (.  !@X '<R'R'] Q:Z',8BBQ_
M.E50FY@&[&N+?0Y.XU).E*L 8Q:NQ(GGUP]E!+2OB:Z$>6Q-@FB>L;D9Z$5]
MS>,[HPK$NG+E0<E[H,"3C&!T01C'OR:BVOR<S)/<2W>L1RI,ZNL4%A[.L>&)
M90!<LIW X!V#!]".*JERE^#4<V\H9_CJN.[T\U777'FZWVUK[V#B&XGE678U
M'%=>' -#)R0Q19J@KC53G3^[)$2^U:U@P[A9)"N-U&YO[^_34.()83&8"DA+
M1-$0R%6 7Z) *X P?>>:]#TG3;?2;(64(+H2Y=F&-Y=LG(R<9!QW/O\ 7%3)
MQW^#Q:;&\?462M^X'(:._!T1NINM>[CBY"L;NV-MU/E2-/QZGDJ )0AZRN)!
MK9X!R8!)8YF/A)?%UZ1X<^4)M&TUK2]T>;4[N2YGNYKYM5Z+O/-)N#JIM93&
M%14C*!BC ,< LV<5WISW$PDCG6%0@01F$. H7&!YU!YY!(SG!]!1DOP>/5X6
MHT%5E.XC)4OXRVXEK:%0<9V9))*CE&%K!*18;@N9&M4Z00=T#X%C"&"CD2>2
M&267;:;\J-KI1NVM/#,B27<SS2.VL!R6D;)!#61'E!*K@ !2!C@8Q3:2\[1&
M6Z#")<8$  8\G/$@P2<$]^<^^G?;_0*<@E9A]8'W.UQ^@-,K)3;?8X(K2@UX
M0CRISA\O6OU(A%'-8D'$^Y.ZR-1D,03&QH^&62>\_*W<*TC1:'_6.K-%-?Q2
M0#S$R%8ULD&YUPH))"XX')%6IHQ$A=[@, K*NR(HWF[[CU&!QQC 'KDG/$<;
M/\'QYRT-%49>C[L..L[0U(A8#1V<+74Y1 \L\\@DLI47)8S_ (P1A$C4F_*C
M>YRK[+6^&)%O/E8U.2'V:QTB&R@;JK(/;#)+LD)QT94AB,+#.25!#$ME>01G
M3285;>\CR,"I!/&-O&#R<@^[C'OK9V[<P;_@?M[X(X.(:%I9^&N&N,.*9M&R
M68!F@FX[Q%'D)+M@,[SY@FVKZ=Q[1)CC)1DG2&0LA[%F?XM/:333S38"]662
M7:7+D=1V;!=B68C."Q.6/)Y-;A7PJC . !QP.!C@<X'PR<5)UOS.3GH'6%QF
MBOJJ!/6:?6RL.:#"GS?.3 STE,'B:CGS$-@?#!&UTDSXV)ZNH[V<R L1D 9)
M7!Q]8!S]P-5ZGP_'_M4J93746SJH+>A.A-$G8CD=$]K_ $^?S.]*KX7J*05.
M#5X(/:J**OA%5$551%7PGCRO\B>51/*_8GE43[U1.L]8*QJ[3OWU^'XGO>1K
M7@ALMWF.Y?4<$WV& Y C/.#HL9@KSD71:D6V$R\HEI>BT&?L(H<P$.\(NQ1H
MPFB)B6,B>F3SQC!Y^ P"?Y_=]U78&<9]./B2,COV_7OXFCB[NTK^6>Y#=<+9
M?,#EX?*8A^DI>5A]!\2-K[>NGP\6@K:NB2IC:RJJ)=T'6+=?7$ZSW5/= H$Q
M!O=0"#V_7Z]W>J$8[]_=^OU^.(ET_P!(54Y*[[F83^,[.SSG"&4TVHP=K2WL
M11W+3.,]*#@N81XJ]U8UF9@X_P!W:@599ZE7<<],A]]-$)&#((YGO]8 ]/QY
M^)[=AGM@U7;VY[Y^SU'VFIMD[R^(!-%#F[03D"G(0^LSMK9V>&N1J'.;VXP/
M\)H'&E_;^AXP&ZFQKH;)]4GO"C$%!U15A!;%0@OKG]?R^W]>ZJ;2>V#]O<9Q
MGZOT*;>/[]N"]M>YBAK >5 9-;:\?5E7:7O%NLIJ*./EH"4[BRV/N# F!AU'
M(3QC ,N5)(LAI81$DPXU?[1\M,_7]Q_0^W%"I'N^\?:/K%-[?=Z1F([H ^WQ
MF)RUP-/I.',RZ6/D243DTY>7&7TDNIS7&B9 R*_R''<5&IN_LW:FM6EJ"X[+
MQ*Y&ARL\GW=OMP#]WZ]:KCC//O\ A[L9]_Z^-*PWT@7 I63J=M$#RHF<M<Q9
M<@2&R<8:=CJCC"F?2#6G*5P.X="!L$+8WC*V*Z@C*DLR:J](IP[&MJ2CVL\X
M_7YX^(X]]-I^'?'?N?U[\5TE[_\ B:J@WD^QSFZRWXH<N:?B:GAFID+DVYF2
MH"-/=7>?D?*"&T*MHPY[&Q')+;)!$70C"2GV>BJJ^=D8S]_KC_Q0J1CD'C_Q
M]>?3W\^ZN9>^SB^NGTY)K;G4TZZ00#CZ/C7):W4WN@HG\$83G<NSM*^2L"C#
M?#DM?+=I,/+)6PTX\4994%NPD)M<\9_7Z^K[*;>0/K_ D<>I[=N]7)RVEIMG
MF<YL,X8EAGM915&EH3TBF@0ZFO:\>TJS$@(CB(A0D$J"9(IXHYH_7Z)8V/1S
M4=ZM[5D)0AXF3A)B15DAHQY&(GV^IH4:IX_[^H]9A]$?4/CZ4A\8#1QXVKL/
M/N&7J2WED0[YRSFV,KY5;*[[54.'V0(T^QD(L;/'EJJM6[GX<#[.*(, ?'G]
M?94@=4JZH[Y3.Y1K\:=-PWG\=I.0)#J8:J WU]9YS)0"$VP<-U9V]C2U-U;.
M95TSSC1@:^OD(/,A'%:^%LCY&J50WE/G_O"RFP[7J@:DX4S>UY>Y6KLUI>V@
M8+1\H[8CB\;5FIR-RBSEVJT^/I,E0<<<;MJ;XT^?C>\JY-;; 9V6PG-LZFE.
MJ,<]^WX^[X_>. 32FW)SWWBUVK[WZ:FV_;_R12=L?%=3:5>GDX=W'']77<OW
M !?(5E@[.,3F?D"3:)AN'X*:WN4"*QDA^IVV;JIIJ04:T):XX[\_'/\ D,<_
M7]7O584[NLM<EVS]L_+%KAR=[R5W#B\&9K/8G*G5N8K[3D;EK(CZ4F'ZWTI\
M@6=SM<,+?V*D'%6)#!P1Z^)#328G.I2JH<2?276L6+[<P>3</+I^0.:M.F;M
MTH=+B:^VR%KNNX/DKAGC &ZQ]678*-5?6&2KZBVU<QH%&<]IYF7+UQM5?B5]
M<?Y_@,TIS#_2N8"WS=9KJ#B/;3Y:&?BVBY$UU[;5.>QG#VZWF<VNDTV&Y/T[
MH+ ')6?'29:GS]W;W+ <S-J-QF:TJYIQ9I[*-C]>_G'%*RO?;]G5*4=*5'^A
M:@&NREB-^1-9N,ISVM^7Q(T4/Q@LDJ?/U?!2(0QCO'E$-<CE5$8C:CL?<.?M
MR!^/^56G@C'<G!^(_P"WO_R[-?GZ_L,YQAI;*L5[2F $HQ[//J:JQ.\.3PBK
M\O\ !YZJGTAV_7N^-4<\>O\ V[<_?53^V>M@AXKJK]RH1;ZXVVN[LYZ^N8DI
M+4T >%\B^7I&$&)# V'U>B.;XF1C6NGD\[ZU4+"I&,MEB?CDX'V#C_S6*K =
M2*4=*4=*4=*4=*4=*4=*4=*4=*4=*4=*4=*4=*4=*4=*4=*4=*5\N5R-<K6^
MIR-56M\HWU.1%5&^I?*-\KX3RJ>$\^>E*Q_\J<R=Y_'W;]SUR7><8<$XO0\5
M<0:'DJEL4W&JY!H;DO/YRTU]Q1K0"TF.LV%45?6NS<A95R&!:W<L=\"]]0V2
MIZP,\P1V*HI52P.2P. 21C@Y &,DX)Y Q5P )')Y./\ OGZ_NY^V:.2.X,SC
M;#\)6<&&L^0]YS?I,OB<GD,_9TN=A,TEOA=#R#;3DW6F.'K*BKK<YD=$7$I)
M,\Y)<0%;&BO+<5!>\FQ5.W<S$ *"!DX+'D\# ![_  &>:H!GX8[_ '@?YU3+
MB[Z1BU_@^[=1MEA2>0>1>7,9G2;-V1OLF%9P;C8![@S(4AN0#E)^H@M 1CUJ
M8K6Q+KHI"#4+I0+T &Q(&P"YP(\KN+@=BHP3G&1Z X[G'P! )%<=\D#!^)]<
M?K\<5<WMJ[HL=W256CTO'M3:,R6?AP$":$Z41PQ^BV?'><Y'M\O%".Y\D-MA
M*W6T%/J&2N_X+H2#JKTL(JRFIFBE$H)4' V\G')*AB./5<@'XU0C'?\ 7./Q
MJS766J4=*4=*4=*4=*4=*4=*4=*4=*4=*4=*4=*4=*4=*4=*4=*4=*5^*B*B
MHJ(J*BHJ*GE%1?DJ*B_)45/DJ+]O2E03VW'$YGFSD[C^M>Y<T!:(77",55'
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MH]#/T6_S4_9TI1Z&?HM_FI^SI2CT,_1;_-3]G2E'H9^BW^:G[.E*/0S]%O\
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1U'?)K?L^Y/Y/Y.E*Y^E*_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>gwpjrhodncoa000022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *7!ST# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** $9@JEF("@9)/:O/O /CS4O&?B/6D%O;)HUIQ!(J,)&);
M"Y)..55B1CTK=^(-^VF^ -;N4)5_LK1J1V+_ "9_\>KE_@7:+!X$FN-@#W%X
M[%NY "J/Y'\Z /3:*\LN#\7=6NIY[-]/TBV21A%#($9G4'CJK'^56_A?X[U3
MQ/-J.E:W%&+^QP3)&NW<,D$,.F0?3U_, E\!>/=1U[Q'K&@:Y!:PW]DS>7]G
M5E#!6VL.2>AP1[&O0Z\0U7_B1_M&V4T(VK>F/>HZ'S$*']1FO;Z "BBB@ HH
MHH **** "J5UK.EV,WDWFI6=O+C.R:=4;'T)J[7S]XKTNRUOX_MINHEOLDQC
M63#[3@0 ]>W(H ]YM;^SO@3:7<%P ,DPR!\?E5;6M>TOP]9+>:M>1VL#.(U=
MP3ECDX '/0'\J\"\7Z':^"/'&CCP=>S/=R[3Y"R[V5MP &1U#>A]#ZUZA\6I
M] MO#5K)X@L+F\A^UJL26\FQE?:QR3Z8!_2@#N;6Y@O;2&ZMI5E@F0/'(AR&
M4C((J6N<M]<T/0O EAJK$V6D+9PM"CY9E1E&Q>Y+8('>N+/QVTH.)/[#U/[$
M6VB<A?Y9Q^M 'J]%9VE:YIVLZ-%J]E<J]E(A?S&^7:!USGIC!S7GM]\=-$AO
M9(K'3;Z]MXS\UP@"@CU /./KB@#O/$7B;2O"MA'>ZO<-#!)((D*QLY+$$XP
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M2N%4?B:R/"WA33O!^ER:?IAF,,DQF8S.&;<0!Z#C"BN-^.Q(\!6^#UU"//\
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MKJ[:EX!2VD;,EA.\ R>=O#+_ .A$?A0!Z+1110 4444 %%%% !1110 4444
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M,0 !DD]J\-M7?_AIMAN;!=QU[?93Q79^*OAM-XQU^2ZU+7KF+3%15@LH!PI
MY8YXSGVS[\4 =^K*ZAD8,IZ$'(-+7SMX=M[OP5\:(_#^E:A+<VC7"Q3*#PZ,
M@8[@.,KGK_L]NE:W[0#NM]H.UF&$F(P>ARG- 'N=%>-_%+Q)>^(-:M_ ?AXF
M2:5P+MD/!/783Z ?,WT'H:]*\*>';?PKX<M=)MW,@B&9)#_&YY8^PST'I0!M
M45P7QD8CX::A@D9DA!Q_UT6CX87]OI_PATR]OKA8;>!)VDED/"J)G_SB@#O:
M*\\A^-/A">^6U66\4.X03-;_ "?7KG'X5U^N^(=*\-:>;[5KM+>'.U<\LY]%
M Y)H U*0D $DX ZDUY_9?&?P?>7BVYN;FWW-M$L\.U/Q()P/<T[XK>*[/1?"
M$]EYT@N]4MW2V,8R"/E#9(Z<-0!TEEXP\.ZCJ8TVRUFSN+PYVQ1R EL#)QV/
M&>GI6W7A?P8_X1*6:TB>VD;Q-&TLRS$-M5<;<#G'W3W'>N\UOXM>$]#OI+*6
MZFN9XSMD%K'O"GTW$@9^AH [BBL+PUXPT3Q;;R2Z3=^8T1Q)$Z[73T)!['UZ
M5FWWQ,\,Z;J&I6-W=R13Z>N908S\QR!M7^\<D?J>@H Z^BN0A^)&@2^$F\2E
MKE+!9_(8-%\X?Z GU]:I:E\7_".FM"C74]PTL:R$6\6[8&&0&Y !P>1U% '>
M45Q6I_%;PEIEC:W1U W(NDWQQVZ;GVYQE@<;>01@X/%;GAOQ1I/BO3C>Z3<>
M;&K;'5EVNA]"* -FBN"U7XP^$M*U&2R:>YN9(F*N]M%N0$=1DD9_#(KL-(U6
MTUS2K?4["0R6MPNZ-BI4]<'@^X- %VBBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRV@UCQ7-=Z5:G$49WEPOHH8D+Q@9Y_2@#K/#DK-\%[>2[)(&DONR?X C ?\
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M/]VM#QQX#A\9>'[:R:<07MIS!/MR <8*D>AP/R'TH \\\36'C7Q'X;AT7_A
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M>Z:8-;LQ7!51CD Y^4]JR/A[\/=5\):AK4][>6K+?(%A-LS%EY8Y.5&.H]:
M.%L$\3?!Z]OS<Z)%J6CW# /<@<,H)Q\PSLSGHPZ]*]G\):QI>N^&[6_T>%8+
M1\@0A GEMD[EP..N>G7.:\]O?"'Q1O\ 3I=$N?$6FSZ=*OEO+(/G9/<[-V?Q
M_&N_\'>&8?"/AJWTF*8S-&2\DI&-[DY)QV'8>PH WJ*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "L.;P?H%QXC7Q!-IZR:HA4K.TCG!48
M!"YVY'TK<HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?7/"VB^(Y+635K%;A
M[1BT#>8R%"<=U(ST'!]*V** "BBB@#*U[PYI/B>RCL]8M/M-O'()53S'3# $
M9RI!Z$UI0PQV\$<$*!(HU"(HZ* , 4^B@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&7<C+DC(QD'D4M% '
M,>%/ >B^#I;J;31</-<@"22>3>V!S@<#O73T44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !117FGQR_P"1 7_K]C_DU 'I=%>"^&O#/PMO-2L/
MLOBC4#?J\;K%*PB5I 0=H+1#//& <UT7Q5U;4+[Q'H?@W3[V2T74&4W,D9P2
MK-M ..W#''?B@#UBBO ?%/A^7X1:IH^K:!J=Z]O-(5N(9G&)-N"00  003U'
M'7->^HP=%8=&&10 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ&I:3XTUOP9>7LEW;6@9K=I&SLVL!QGH"&!QT!'UH ]?HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "HKFZM[*VDN;J>*"",9>65PJJ/4D\"I:J:G
MIMIK&FSZ??Q>=:SKMDCW%=P^H((H \8O=<TE_P!H*QU)=4LFL%APUT+A/*!\
MEQR^<=2!UKU'6]6\*2Z?9_VW<Z;/87CYMWN-LD+L!G.XY7\363_PJ+P+_P!
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M1#-<'[TJNT;-V^8H1G\:UM*T?3M#L5LM,LXK6W4YV1KC)]2>I/N>: +M%%%
M'$?\*X_ZG3QC_P"#3_[&K7PSU*\U;X=Z3>ZA</<7+K(K2ORS!9&49/<X4<GD
M]3S76UQ'PB_Y)=HW_;?_ -'24 =O1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '$>&/^2H^//\
MN'_^B37;UQ'AC_DJ/CS_ +A__HDUV] !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7$?"+_DEVC?]M_\ T=)7;UQ'PB_Y)=HW_;?_ -'2
M4 =O1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% '$>&/^2H^//\ N'_^B37;UQ'AC_DJ/CS_ +A_
M_HDUV] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7$?"
M+_DEVC?]M_\ T=)7;UQ'PB_Y)=HW_;?_ -'24 =O1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
M$>&/^2H^//\ N'_^B37;UQ'AC_DJ/CS_ +A__HDUV] !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7$?"+_DEVC?]M_\ T=)7;UQ'PB_Y
M)=HW_;?_ -'24 =O1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116??:WIVFSK#=W'
MER,NX#8QXR1V'L:J,92=HJY,I1BKR=C0HK&_X2O1/^?W_P A/_A1_P )7HG_
M #^_^0G_ ,*OV%7^5_<1[>E_,OO-FBL;_A*]$_Y_?_(3_P"%:%CJ%KJ4#36D
MOF1JVTG:1S@'N/<5,J4XJ\DT.-6G)VC),LT445!H%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!Q'AC_ )*CX\_[A_\ Z)-=O7$>&/\ DJ/CS_N'_P#HDUV] !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7$?"+_ ))=HW_;
M?_T=)7;UQ'PB_P"27:-_VW_]'24 =O1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
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M>[JH10JC  P!2T4 %95YX9T#4+I[J]T/3;FX?&^6:TC=VP,#)(R> !^%:M%
M' ^#;*UT_P"(_CBULK:&VMT^P;(H8PB+F%B< <#DD_C7?5Q'AC_DJ/CS_N'_
M /HDUV] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7$?
M"+_DEVC?]M__ $=)7;UQ'PB_Y)=HW_;?_P!'24 =O1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7$?"+_DEVC?]M__ $=)7;UQ'PB_Y)=HW_;?_P!'24 =O1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7 >./\ D-0_]>Z_^A-7?UP'CC_D-0_]>Z_^A-79
M@?XQQ8_^"<S1117M'A!7?^!_^0+-_P!?#?\ H*UP%=_X'_Y LW_7PW_H*UQX
M[^"=N _C'34445XI[H4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '$>&/^2H^//^
MX?\ ^B37;UQ'AC_DJ/CS_N'_ /HDUV] !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6??:Q;Z?.L4J2LQ
M7=\@&,9(]?:M"N4\3?\ (2C_ .N(_F:WPU.-2?+(Y\34E3I\T31_X2:R_P">
M5Q_WR/\ &C_A)K+_ )Y7'_?(_P :Y2BO0^I4CS?KU8ZO_A)K+_GE<?\ ?(_Q
MH_X2:R_YY7'_ 'R/\:Y2BCZE2#Z]6.K_ .$FLO\ GE<?]\C_ !K7AE6>".50
M0KJ&&>N",UY[7>:?_P @VU_ZXI_(5RXJA"FDXG9A,1.K)J19HHHKB.X****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "N(^$7_)+M&_[;_^CI*[>N(^$7_)+M&_[;_^CI* .WHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7%X?TYKFYGE+!;A(QY.54L>2<GH>0,5TNLZUI_A_2Y=1U.X6"VCP"Q!))/0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXC^9KJZY3Q-_R$H_^N(_F:Z\'_%./'?P3%HHHKUSQ@HHHH *[S3_ /D&VO\
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M-M?^N*?R%<'7>:?_ ,@VU_ZXI_(5P8_X4>AE_P 4BS1117F'JA1110 4444
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MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *X#QQ_R&H?^O=?_ $)J[^N
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P DNT;_ +;_ /HZ2NWKB/A%_P DNT;_ +;_ /HZ2@#MZ*** "BBB@ HHHH
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M .0+-_U\-_Z"M<!7?^!_^0+-_P!?#?\ H*UQX[^"=N _C'34445XI[H4444
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M^*<>._@F+1117KGC!1110 5WFG_\@VU_ZXI_(5P==YI__(-M?^N*?R%<&/\
MA1Z&7_%(LT445YAZH4444 %%%% !1110 5B^*O#5IXLT"?2KPLBOADD7K&XZ
M$5M5PGQ=U'4]-\"RRZ9))$SS)'-+&2&C0YR<CIS@?C0!R+?#/QZD/]F1>+T.
ME_< ,\@.STVXZ>V<5Z7X/\,6OA'P]#I=M(9BI+RRD8,CGJ<=O3\*\XL/@JMW
M80W,GBNZD:9 ^^%?E.1G@EN?K7H7@WPHOA#29;!;^:\\R8RF24<C( Q^E '1
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7$?"+_DEVC?\ ;?\
M]'25V]<1\(O^27:-_P!M_P#T=)0!V]%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1BFJ"1\0#YOESG(^@_O4 :4OP?T'PS;/JOB+7;B?3+=@SQQP%<Y( S@D^F<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD#GFN!'PS\>O'L;QO.%*X*FYFZ>G6N_\#>$(_!?A_P#LY;@W$LDAEEEQ@%B
M.!Z8 H Z:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XCX1?\DN
MT;_MO_Z.DKMZXCX1?\DNT;_MO_Z.DH [>BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ K*\3_\BGK/_7C/_P"@-6K65XG_ .13UG_KQG_] :KI_&O4BK\#]#YKHHHK
M[$^,"M7PQ_R-FC?]?T'_ *&M95:OAC_D;-&_Z_H/_0UK.I\#]"Z7QKU/I2BB
MBOCS[,**** "BBB@ HHHH **** "BBB@ HHHH **** "N \<?\AJ'_KW7_T)
MJ[^N \<?\AJ'_KW7_P!":NS _P 8XL?_  3F:***]H\(*[_P/_R!9O\ KX;_
M -!6N KO_ __ "!9O^OAO_05KCQW\$[<!_&.FHHHKQ3W0HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\P^(^IZY?^*M'\'Z'?&Q>
M]0RS3JQ4X&>XYQA6X'6O3Z\\^(GAFYU?4].U/0]5M[/7[+(ACDE"F13V'OUZ
MC!R: .0UKPEXK^'6GGQ#I_BF6\C@=6N(9 RJP) Y!8AAD^QKV72-075=&LM0
M5=JW,"2@>FX UY!=>'/BEXQ1-+UZ:&STXD&5LQ_-@^B9)/MP*]CT^RBTW3K:
MQ@!$5O$L29]%&!0!9HHHH *Y'Q_X(;QSIUI9C4VL5MY3*2(?,#\8Y&X=/7ZU
MUU% 'E,'PF\1VMO';V_Q'U6&&-0J1QI(JJ!T  FP!73^*_A_9>+M'L;6]O)T
MO;)0(KU0"Q. "6!Z@D ]1SWKKZ* /.-$^$ZVFN6VK:]X@O=<GM"#;K."%0CD
M9W,Q(!Y ! KT>BB@ HHHH XCPQ_R5'QY_P!P_P#]$FNWKB/#'_)4?'G_ '#_
M /T2:[>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** . ^+W_(IVO_7\G_H$E>*U[5\7O^13M?\
MK^3_ - DKQ6OH\L_W?YL^:S3_>'Z(****]$\X**** /:OA#_ ,BG=?\ 7\__
M *!'7?UP'PA_Y%.Z_P"OY_\ T".N_KY7&_[Q+U/K,%_N\/0****Y3J"BBB@
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M .0+-_U\-_Z"M<!7?^!_^0+-_P!?#?\ H*UQX[^"=N _C'34445XI[H4444
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MW#__ $2:[>N(\,?\E1\>?]P__P!$FNWH **** "BBB@ HHHH **** "BBB@
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M"#T->+#X"3"4RCQ5()#U;[*<G\?,KT/P/X3D\'Z-+82:D]^TDQE\QTVXR ,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !65XG_Y%/6?^O&?_ - :M6LKQ/\ \BGK/_7C/_Z
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "LKQ/_ ,BGK/\ UXS_ /H#5JUE>)_^13UG
M_KQG_P#0&JZ?QKU(J_ _0^:Z***^Q/C K5\,?\C9HW_7]!_Z&M95:OAC_D;-
M&_Z_H/\ T-:SJ? _0NE\:]3Z4HHHKX\^S"BBB@ HHHH **** "BBB@ HHHH
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M+M&_[;_^CI*[>N(^$7_)+M&_[;_^CI* .WHHHH **** "BBB@ HHHH ****
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M@6;_ *^&_P#05KCQW\$[<!_&.FHHHKQ3W0HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?'GV84444 %%%% !1110 4444 >9^*_^1EN_^ ?^@+6-6SXK_P"1EN_^ ?\
MH"UC5]#0_A1]$?-5_P"++U84445J9'IGA3_D6K3_ ('_ .AM6S6-X4_Y%JT_
MX'_Z&U;-?/5_XLO5GTM#^%'T05P'CC_D-0_]>Z_^A-7?UP'CC_D-0_\ 7NO_
M *$U;X'^,<^/_@G,T445[1X05W_@?_D"S?\ 7PW_ *"M<!7?^!_^0+-_U\-_
MZ"M<>._@G;@/XQTU%%%>*>Z%%%% !1110 4444 %%%% !1110 4444 %%%%
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MX!7T&4_P7Z_HCYW-_P".O3]6%%%%>H>6=5\-_P#D?M,_[:_^BGKW^O /AO\
M\C]IG_;7_P!%/7O]?/9M_&7I^K/HLH_@/U_1!65XG_Y%/6?^O&?_ - :M6LK
MQ/\ \BGK/_7C/_Z U>?3^->IZ-7X'Z'S71117V)\8%:OAC_D;-&_Z_H/_0UK
M*K5\,?\ (V:-_P!?T'_H:UG4^!^A=+XUZGTI1117QY]F%%%% !1110 4444
M%%%% 'F?BO\ Y&6[_P" ?^@+6-6SXK_Y&6[_ . ?^@+6-7T-#^%'T1\U7_BR
M]6%%%%:F1Z9X4_Y%JT_X'_Z&U;-8WA3_ )%JT_X'_P"AM6S7SU?^++U9]+0_
MA1]$%<!XX_Y#4/\ U[K_ .A-7?UP'CC_ )#4/_7NO_H35O@?XQSX_P#@G,T4
M45[1X05W_@?_ ) LW_7PW_H*UP%=_P"!_P#D"S?]?#?^@K7'COX)VX#^,=-1
M117BGNA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^*<>._@F+1117KGC!1110 5WFG_\@VU_ZXI_(5P==YI__(-M?^N*?R%<&/\
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MK*\3_P#(IZS_ ->,_P#Z U>?3^->IZ-7X'Z'S71117V)\8%:OAC_ )&S1O\
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MBO1/."BBB@#VKX0_\BG=?]?S_P#H$==_7 ?"'_D4[K_K^?\ ] CKOZ^5QO\
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M_0VK9KYZO_%EZL^EH?PH^B"N \<?\AJ'_KW7_P!":N_K@/''_(:A_P"O=?\
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MNWKB/A%_R2[1O^V__HZ2@#MZ*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** .5^)'_(@ZG_VR_\ 1J5X!7O_
M ,2/^1!U/_ME_P"C4KP"OH,I_@OU_1'SN;_QUZ?JPHHHKU#RSJOAO_R/VF?]
MM?\ T4]>_P!> ?#?_D?M,_[:_P#HIZ]_KY[-OXR]/U9]%E'\!^OZ(*RO$_\
MR*>L_P#7C/\ ^@-6K65XG_Y%/6?^O&?_ - :O/I_&O4]&K\#]#YKHHHK[$^,
M"M7PQ_R-FC?]?T'_ *&M95:OAC_D;-&_Z_H/_0UK.I\#]"Z7QKU/I2BBBOCS
M[,**** "BBB@ HHHH **** /,_%?_(RW?_ /_0%K&K9\5_\ (RW?_ /_ $!:
MQJ^AH?PH^B/FJ_\ %EZL****U,CTSPI_R+5I_P #_P#0VK9K&\*?\BU:?\#_
M /0VK9KYZO\ Q9>K/I:'\*/H@K@/''_(:A_Z]U_]":N_K@/''_(:A_Z]U_\
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M#T7Y'R&)_CS]7^84445N8!1110!]4T445\6?;!1110!P'Q>_Y%.U_P"OY/\
MT"2O%:]J^+W_ "*=K_U_)_Z!)7BM?1Y9_N_S9\UFG^\/T04445Z)YP4444 >
MU?"'_D4[K_K^?_T".N_K@/A#_P BG=?]?S_^@1UW]?*XW_>)>I]9@O\ =X>@
M4445RG4%>=5Z+7G5>C@/M?+]3S,Q^S\_T"BBBO1/-"BBB@#1T+_D,V__  +_
M -!-=I7%Z%_R&;?_ (%_Z":[2O*QW\1>AZ^7_P )^O\ D%%%%<1W!7*>)O\
MD)1_]<1_,UU=<IXF_P"0E'_UQ'\S77@_XIQX[^"8M%%%>N>,%%%% !7>:?\
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M%%?'GV84444 %%%% !1110 4444 >9^*_P#D9;O_ (!_Z M8U;/BO_D9;O\
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MP"OH,I_@OU_1'SN;_P =>GZL****]0\LZKX;_P#(_:9_VU_]%/7O]> ?#?\
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M  MWP+_T'/\ R4G_ /B*/^%N^!?^@Y_Y*3__ !%=O16!1Q'_  MWP+_T'/\
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MPO\ ]!/_ ,EY?_B:/^%@>%_^@G_Y+R__ !->UT5O]>J=D8?V?2[O^OD>*?\
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M2?$]B][H]W]IMTE,3/Y;IAP 2,, >C#\ZU:*P.@**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "FR-LC9O[H)IU% 'C7P.1+^[\2:M
M<HLEY+,H:1ADX;<S ?4_R%-\"Q)IGQR\26%J ELT<I$:'Y1\Z,./;)'M4&FV
M_BOX7>(M7CL?#5SK.EWTF^$VP8X )*D[58C 8@@@=.*Z'X:>%]9AUS5_%GB"
MW^RWNHDB*W/559MQ)';HH //!SVH ]-HHHH XC_A;O@7_H.?^2D__P 17+?#
MGXC>%-!\!:;IFIZKY%Y#YOF1_9Y6QF5V'*J1T([U[!10!Q'_  MWP+_T'/\
MR4G_ /B*/^%N^!?^@Y_Y*3__ !%=O10!Q'_"W? O_0<_\E)__B*/^%N^!?\
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M+,<98D<A/0UZ71657$2J*S&HI'$?\+=\"_\ 0<_\E)__ (BC_A;O@7_H.?\
MDI/_ /$5V]%8%'$?\+=\"_\ 0<_\E)__ (BC_A;O@7_H.?\ DI/_ /$5V]%
M'$?\+=\"_P#0<_\ )2?_ .(H_P"%N^!?^@Y_Y*3_ /Q%=O10!Q'_  MWP+_T
M'/\ R4G_ /B*/^%N^!?^@Y_Y*3__ !%=O10!Q'_"W? O_0<_\E)__B*/^%N^
M!?\ H.?^2D__ ,17;T4 <1_PMWP+_P!!S_R4G_\ B*/^%N^!?^@Y_P"2D_\
M\17;T4 <1_PMWP+_ -!S_P E)_\ XBC_ (6[X%_Z#G_DI/\ _$5V]% '$?\
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M%N^!?^@Y_P"2D_\ \11_PMWP+_T'/_)2?_XBNWHH XC_ (6[X%_Z#G_DI/\
M_$4?\+=\"_\ 0<_\E)__ (BNWHH XC_A;O@7_H.?^2D__P 11_PMWP+_ -!S
M_P E)_\ XBNWHH XC_A;O@7_ *#G_DI/_P#$4?\ "W? O_0<_P#)2?\ ^(KM
MZ* /$/$'CWPS?:Y<7-MJ6^)]NUO(D&<*!W7U%9?_  F6@?\ /_\ ^09/_B:^
M@Z*[8XZI&*BDM#AG@*4I.3;U_KL?/G_"9:!_S_\ _D&3_P")H_X3+0/^?_\
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MF0/\V!Z\-4OB.]OQXBOY=6\/ZW<6NG::UKI[V]DTD*R/'^\F9R0!Z9&>![4
M>A?\)K;2>%['7[32-8OK>\;"06EL)9E'/+*&P!\O7/<53TOXCV6I^([;0GT3
M7;"]N59T%]:+$-H!.X_-G'RD9QUJI\*M5C?X;VGG6]S;162,'FN(]B2#)8LA
MSRHSC/J#5+X;QR^)->UKQQ=KQ=2&UL%8'Y(5ZD?7@?4-ZT 6V^+6E*UXRZ)X
M@DMK.9H;BZBLU:&,J<$E@_ [UVFFZE::OIMOJ%C,)K6X0/&X&,CZ'H?:O!K*
MY\36OA3QB^F)8G2&U&=+UF1FN45L!F09"D!3WYZU[/X,MM/M/!NDPZ5*TUD+
M=6BD<89L\DD=CDG([=* -VBBB@ K)\2^(;;POH<VK7D-Q-;PE0ZVZAF&X@ X
M) QDCO6M63XGTH:WX7U/32,FXMW1..C8^4_GB@"AXE\<:3X7T.SU:\6XFM[M
ME6);=5+'<I8'!(XP/7N*L:WXLT_0K;39YDN)QJ,Z06Z6Z!F9G&0>2./\:\;T
MT?\ "P;/0/#K;MVE:3<M,O\ =E&8XP>>HPI_&M'P?J!\6Z[X*T^0%_["M)9K
MH'G:ZML0'GK\J'\: .QN/BO96MY#9S^&/%$=S.2(8GL%#2XZ[07RWX5V.CZE
M_:^EQ7WV*\LO,S^XO8O+E7!(^9<G&<9'L17#>,_^2K>!O]ZX_P#017H] !11
M10 5B^*/$UEX2T8ZI?Q7$D D6/; H+9;IU('ZUM5YU\;/^2>O_U]Q?UH ZGQ
M+XIL?"NG6]]?17$D5Q.ENH@520S D$Y(XXJIXI\=Z/X25A>BZGF55=XK6'>4
M5C@,Q.%4$\#)&>U>=?$?1_$EAH.F3:OXJ_M6V.H0JMO_ &='!M;#8;<IR<#(
MQ[UU_P 9/^2::A_UTA_]&+0!U&K>(M.T/06UG4)3%:!58<98ENB@#J:RM"\?
M:9K>K_V4UGJ6FW[1^;%!J-OY+2IZKR<__6/H:YCXHOY7A3PO+*/]%CU"V:?(
MRH4(>OZU)XOE23XM^$?L@\ZX@@GFD6,Y.S:2.GKAL?6@#HO$_P 0M'\*:E;:
M?>1W<]Q.H;;;1JWE@G +$L,9.<=>E6->\6_V%?+:_P#"/:_J&Z,/YNGV7FQC
M)(P3D<\=/<5XGKE_=MH%Q=:OH&MPZS?ZK'<3W$]D4A5%R$A1B<G Z# _2O9O
M$OBY=&\!3:_Y$UM,\(^SV]VFR02-PJLOJ.I'H#0!5T[XE:7J.F:U?#3M5MTT
M=0;J.X@5'SS\H&[[PVG(.*KVGQ7T::6S^UZ9K6G6UZP6"[O;0)"Y/3#!CG/K
MTK&C\/OH'P-U07()O[RT>[NV;[Q=^<'W P/KFN8/]K76C^"--\4/9P^&9WA:
M":R1BY8+A$E+'"Y!.2HQU]. #WNBBB@ HHHH Q-5\46.CZ]I.D745QYVJ,R0
M2JH,888X8YR#R.@/6J]]XUTK3_&-EX8F6X-]=H'1U53&N=V QSD$[?3N*P?B
M[:NOARQUR!<SZ/?17(P,_+G!_7:?PK@-<SK3ZY\0+,L_]G:M;K;,.GE1@!L<
M]"64T >LZOXWLM)UN31UT[5+^]CM1=-'8P"0["VW&-P)/(/3I6/#\6+*XO)K
M.'POXIDNH,>="FGJ7CSTW*'R,^]0^ )(]>\8>*?%*8:"69+.U?U1%&X@^A^4
MTWPE_P E?\;?[MO_ .@B@#T8'(!P1GUI:** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\Q\76L
M/B+XJZ1X=UB9_P"Q_L37"VHD9%GERPP2""2 ,_@?4T >G45XOX&MIHO'?B>X
MT]GU5=$MFL]/@>X +*7)5-Y[#:1D],U=^(FIZ[J/@.4ZQH+:*Z7UOY)6^2<O
MDG)!0?*1Q^= 'K=%>-W_ (-TZP^)VD:/;7&H1V6J6;M?J+M]UR4W'YVSDY(&
M<8]L5EB+[!X/^)&B6S2?8+&Y06T3,6\L%^0,]N!0![Q6=9ZYIM_JU]I=M<^9
M>6.W[3'L8;-PR.2,'\":\NUNXA?_ (59&DT;2;X&VA@3C;&,X],BI/"7A30C
M\6?$P-F-VFRP3V8\Y_W;,-S'[W//KD4 >O4444 %<AX@\;7.G:]_8>BZ'-K.
MI)!]IGC6=85BC[?,0<GV]Q77UY+<VE[?_&+Q'::=JHTRZETN,+<>4LA49CR-
MI(ZCC/;K0!W_ (3\36OBW0(M5M8Y(@S,CQ2?>C<'D>_8_C6W7GGP?N@?"]WI
MBPPK_9M[);F:%B5G/7?R3R<_3ITKT.@ HHHH **** .:\9^+T\(:?:S_ &)[
MR>ZN!;PQ"41*6/\ ><\*/>KWA_5=1U2VE.J:+-I5S$^TQ/*LJL",Y5UX(KB/
M&L8\3_$;2?!^H7+P:0UL;MXT8*;F0;@%S[8S^?MBS\,[FZM=5\1>'/MTFH:=
MI4Z+:7$C;BH(.8]W?;C'YT >BT444 %%9?B2[N+#PQJMW:<7,%I+)$=N<,%)
M'%>%ZMIEAIOPJL/$MGJ,QUS4F,5W.;@L;D/N$B,I)!Q],\9H ^B**XJ&X\1^
M&].TK2-(\*C5;2"SB1KH:C'#\V,,-K#)]<^]<2GAFQ\1Z]\0FU!KAEM9#)#$
MLS+&LFQB'*@X+#:.O'6@#VNBOGNYT\6_PT\/^,!=WLFN_;$1;J6Y=BB!F4(!
MG 7"CWZ\UW6G2QP_'377F=8U_LE&RYP,#9D\]A0!W>LZUI_A_3)-1U2X\BTC
M(#2;&;!)P.%!/4^E7D97174Y5AD'VKYS>QM+OX*:K>R());;6&:"0,<+N,8)
MX.#D>M>Z^&=$TS0-$AM=)MQ!;/\ OBHD9\LP&3EB3V% &Q1110!C^)_$=IX5
MT*;5+Q))$0A4CC'S2.> HK%T'QS<W_B0:!K6@S:/J$EO]H@5KA9ED3Z@#!Z\
M>QK+^-) \$VY)P!J$.2?^!5G[;S0OC+IDM_?0ZN^K0210OY?EO9QC+  *<$=
MMQ&3@].<@'JU%%% !1110 445F^(=0ETKPYJ6H0)OFMK:25%/0E5)% '*V'Q
M#OM6UF\M].\+W-SI]G=?9;BZ6Z3S$.<;O)^]CWST!KO*\ >S;1?!FF_$"RUR
M=_$-W<!YQY@VW6Y\&+:/3'(]CQTQ[[&Q>)&92K,H)4]J '4444 %%>8^+K6'
MQ%\5=(\.ZQ,_]C_8FN%M1(R+/+EA@D$$D 9_ ^IK%\#6TT7COQ/<:>SZJNB6
MS6>GP/< %E+DJF\]AM(R>F: /:**\D^(FIZ[J/@.4ZQH+:*Z7UOY)6^2<ODG
M)!0?*1Q^=5K_ ,&Z=8?$[2-'MKC4([+5+-VOU%V^ZY*;C\[9R<D#.,>V* /9
M**\'$7V#P?\ $C1+9I/L%C<H+:)F+>6"_(&>W K6UNXA?_A5D:31M)O@;:&!
M.-L8SCTR* /4;/7--O\ 5K[2[:Y\R\L=OVF/8PV;AD<D8/X$UHUY#X2\*:$?
MBSXF!LQNTV6">S'G/^[9AN8_>YY]<BO7J "BBB@#A-:^(L]EJ>IVND^'I]4A
MTE VH7"W"Q"'C)V@@ER #T]/QKK-$U>VU[1;35;3=Y%U&)%##E?4'W!R/PKR
M&WTN]UC4?B+9V6LIIG^E[IR\882QXDRI).5!_O"N^^&.IKJGP^TR9;2.U6-6
MA$<9)7Y"1D9R><=R><T =?1110 4444 %<UXS\7IX0T^UG^Q/>3W5P+>&(2B
M)2Q_O.>%'O72UYCXUC'B?XC:3X/U"Y>#2&MC=O&C!3<R#< N?;&?S]L ';^'
M]5U'5+:4ZIHLVE7,3[3$\JRJP(SE77@BM>O.OAG<W5KJOB+PY]NDU#3M*G1;
M2XD;<5!!S'N[[<8_.O1: "BBN3^)>HWNE_#_ %6[T^1XKA451(GWE#,%)!['
M!//:@#K**^?_ !7X9TO2M,\,V.B7[JVO^7%>_ORRW()0B4@D@'<>HQU^M>MO
MJOB.VUU-.M_"?F:2KI&-0_M&-<)@9;R\;N.>.^* .EHKY[MO#MG>_#?Q)KDT
MMT;ZPOY3:$3L%@(=22J@XR<\GZ=*V9=,CT/6? &MVMQ=MJ6JR(+ZXFN&=IPX
M0D')QCYB !CM0![76=JNN:;HGV3^T;GR?M<ZV\'R,V^1N@^4''U/%>9:-/%;
MWWQ2,TJ1X9B=[ =5D Z^I(KF+K2-.N_AWX!N;J$,\E^+21B[#,+2.67@\?7K
M[T ?0M%4]+TNST738-.T^'R;2 ;8X]Q;:,YZDD]35R@ K'\3^([3PKH4VJ7B
M22(A"I'&/FD<\!16Q7G/QI('@FW). -0AR3_ ,"H U-!\<W-_P")!H&M:#-H
M^H26_P!H@5KA9ED3Z@#!Z\>QKLJ\IVWFA?&73);^^AU=]6@DBA?R_+>SC&6
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MWEU"WO=45++5[.^.ZV.XXA:,'D#&",=,@<\4 >U4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5FW.@Z9=ZW9ZS/;;]0LU9()O,8; P(/ .
M#U/44V7Q+H,$SPS:WIL<L;%71[M RD<$$$\&F?\ "5>'?^@_I?\ X&1_XT[,
MU]A5?V7]Q++H.F3:_!KLEMNU*"(PQS>8WRH<Y&W.T_>/:L&\^%G@R_O9[RYT
M;?//(TDC_:IAN8G). ^.M;/_  E7AW_H/Z7_ .!D?^-'_"5>'?\ H/Z7_P"!
MD?\ C19A["K_ "O[B#5/!?A[6M-M-/U#3(Y[>T0) "[!HU P '!#8P!WYQ5W
M1M"TSP]8"QTFSCM;<-N*IDY/J2>2>!R3VJ'_ (2KP[_T']+_ / R/_&C_A*O
M#O\ T']+_P# R/\ QHLP]A5_E?W$TVAZ=/KMOK4EMNU"WB,44V]AM4YR-N<'
MJ>HIA\.Z4?$0U\VN=4$7DK.9&.U/0+G:._;N:9_PE7AW_H/Z7_X&1_XT?\)5
MX=_Z#^E_^!D?^-%F'L*O\K^XEU70=,UM[-M1MO.:SF$\!\QEV..A^4C/T/%-
MN_#NE7VN6>M7%INU&S4K!.LC*5!SP0" 1R>#GJ:9_P )5X=_Z#^E_P#@9'_C
M1_PE7AW_ *#^E_\ @9'_ (T68>PJ_P K^XUZ*R/^$J\._P#0?TO_ ,#(_P#&
MC_A*O#O_ $']+_\  R/_ !HLP]A5_E?W&O161_PE7AW_ *#^E_\ @9'_ (T?
M\)5X=_Z#^E_^!D?^-%F'L*O\K^X-?\,:-XHMHK?6;(74<3[XQYC(5.,=5(-1
MZSX1T+Q!I]K8:GIZSVUKCR$$CILP,<%2#C':I/\ A*O#O_0?TO\ \#(_\:/^
M$J\._P#0?TO_ ,#(_P#&BS#V%7^5_<:26T,5HMK'&%@1!&J#H% QC\JJ:+HF
MG>'M-33M+M_L]JC%ECWL^"3D\L2:@_X2KP[_ -!_2_\ P,C_ ,:/^$J\._\
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MA2 ?QS6I10!6U'3[75=.GL+V+S;6X0I*FXKN4]L@@C\*SKWPEH>HZ!;Z%=V
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M-AHFGQV&F6L=M:Q_=C0=_4GJ3[FKM9'_  E7AW_H/Z7_ .!D?^-'_"5>'?\
MH/Z7_P"!D?\ C19A["K_ "O[C7HK(_X2KP[_ -!_2_\ P,C_ ,:/^$J\._\
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M'G2?*V2<[MVX\D]31K7@KPYXAO8+S5=+BN;B  (Y9EX!R V"-P]CGOZUO44
M8D7A'08=&O-(CTZ,:?>2-+/!N8JS-C)'/R]!C&,8XQ5G0]!TSPYIWV#2;46U
MKO+[-[/\QZG+$FM*B@ HHHH XKXH:!J/B/PM#9:9:BYF%Y'(R%U7Y!G)RQ [
MUJ:%X'\-^'+MKO2M*BM[EQ@R;V<@'J!N)V_ABNAHH **** "BBB@ I" RE6
M((P0>]+10!RUG\.?"%AJJZE;:';I=*V]269E4^H0G:".V!QVKJ:** "BBB@#
M&U_PIH?BB.)-9T^.Z$1)C8LR,N>N&4@X]LU6LO OAG3=4M=2LM(AM[NUC\N&
M2-F&T8(.1G!.">2">:Z*B@#/UG0].\06(LM4M_/MPZR;-[+\PZ'*D&DGT+3;
MG6K76);;=?VB-'!+O8;%;.1C.#U/45HT4 9$'AC1;:35'CL4)U4[KT.S.LQY
MZAB0.IZ8K-L?AQX2TV2&2TT:.*2&=;B-_-D+!UZ');./]GI[5U-% &'<^#M
MO/$46OSZ<C:I$5*3AW'*]"0#@D>I'IZ5N444 %%%% 'F&F?#2UU/Q3XDO?$^
MCK+!/>>;8N9\;E.[/W&SZ<-7I-I:6]A:16EI D%O$NV..-<*H]A4U% !1110
M 4444 %8VO\ A30_%$<2:SI\=T(B?+8LRLN>N&4@XXZ9K9HH SM&T+2_#UB+
M+2;**UMP<E4'+'U8GEC[DFM&BB@ J*YMH+RUEMKF))H)5*21N,JRGJ"*EHH
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M#.3EB!WKM:* .>T+P/X;\.7;7>E:5%;W+C!DWLY /4#<3M_#%=#110 4444
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MW<8/(-$:T9.R!IHRZ*FM;:2\NHK:$9DE8*N?>NM_X1?0H+F.PN=4F^WN.%7
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MOX<O1FE'^+'U1VE%%%>"?0A1110 4444 %%%% !1110 4444 %%%% !1110
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MP3_D5=2+G)1Z;B6B,6BBBMQ%[1O^0YI__7S'_P"A"O7Z\@T;_D.:?_U\Q_\
MH0KU^O.QWQ(T@?-?B?\ Y&S6?^OZ?_T-JRJU?$__ "-FL_\ 7]/_ .AM657T
M5/X%Z'Q]7XWZA1116A 4444 >U:C9Z#>^ O#L6OWTUG 8X?*>+N_E]"=IP,9
MY./K6+\2Y&TC1-,T"RM/+TS&])M^[>5_A_7/OFL#Q'XLL=7\'Z/I%O#<+/9!
M!(TBJ%.U-IQ@D]?85+?>,+#5? $&BWT-RVI6VWRI@JE/E.!DDY^[QTKR:6'J
M1E&33:N].WF>O5Q%.<9032?*M>_=&Q\(/OZU_P!<H_\ V:O,W^^WUKK_  )X
MKL?"[:@;V*YD^THJIY*J<8SUR1ZUA:!=:=::];W>J132VD3^88XE#%B.@()
MQG&:ZH1E"M4G;1VMYZ').49T:4+ZJ]_*[/<_#+2PZ!HUMJ\D7]IM"3"KK\X
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MG?M6154H34>2]K?B35J0<^>U[_@6;.REOKD0Q#W+=@/6M;6KN*"S33+<[M@
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M^6/W/_,^=O\ A6/C#_H#_P#DS#_\71_PK'QA_P! ?_R9A_\ BZ^B:*/:,/\
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M4$3RR-LPB*23\Z]A7G']C:I_T#;S_OPW^%>OT5K1Q#I1Y4CPG&YY!_8VJ?\
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M))_A7TI11_:T_P"5!_8\/YF?-?\ PC'B#_H!ZG_X"2?X4?\ ",>(/^@'J?\
MX"2?X5]*44?VM/\ E0?V/#^9GS7_ ,(QX@_Z >I_^ DG^%'_  C'B#_H!ZG_
M . DG^%?2E%']K3_ )4']CP_F9\U_P#",>(/^@'J?_@))_A1_P (QX@_Z >I
M_P#@))_A7TI11_:T_P"5!_8\/YF?-?\ PC'B#_H!ZG_X"2?X4?\ ",>(/^@'
MJ?\ X"2?X5]*44?VM/\ E0?V/#^9GS7_ ,(QX@_Z >I_^ DG^%'_  C'B#_H
M!ZG_ . DG^%?2E%']K3_ )4']CP_F9\U_P#",>(/^@'J?_@))_A7T#X=BD@\
M,:3%+&T<B6<*NCC!4A "".QK3HKEQ6-EB$DU:QUX7!1P\FT[W.*OK&[?4+EE
MM9V4RL01&<$9-0?V?>_\^=Q_WZ/^%=Y136.DE:Q+P$6[W.#_ +/O?^?.X_[]
M'_"C^S[W_GSN/^_1_P *[RBG]?EV%_9\?YC@_P"S[W_GSN/^_1_PH_L^]_Y\
M[C_OT?\ "N\HH^OR[!_9\?YC@_[/O?\ GSN/^_1_PH_L^]_Y\[C_ +]'_"N\
MHH^OR[!_9\?YC@_[/O?^?.X_[]'_  H_L^]_Y\[C_OT?\*[RBCZ_+L']GQ_F
M.#_L^]_Y\[C_ +]'_"C^S[W_ )\[C_OT?\*[RBCZ_+L']GQ_F.#_ +/O?^?.
MX_[]'_"C^S[W_GSN/^_1_P *[RBCZ_+L']GQ_F.#_L^]_P"?.X_[]'_"C^S[
MW_GSN/\ OT?\*[RBCZ_+L']GQ_F.#_L^]_Y\[C_OT?\ "C^S[W_GSN/^_1_P
MKO**/K\NP?V?'^8X/^S[W_GSN/\ OT?\*OZ+9W46K0/);3(@W99D( ^4UUM%
M3/&RE%QMN5# QC)2OL%%%%<1W!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5XQX[\">)-9\9ZA?V&F^=:R^7
ML?SXUSB-0>"P/4&O9Z*J,G%W1V8+&U,'4=2FDVU;7^EV/G;_ (5CXP_Z _\
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MS#_\77T311[1A_K'BOY8_<_\SYV_X5CXP_Z _P#Y,P__ !='_"L?&'_0'_\
M)F'_ .+KZ)HH]HP_UCQ7\L?N?^9\[?\ "L?&'_0'_P#)F'_XNC_A6/C#_H#_
M /DS#_\ %U]$T4>T8?ZQXK^6/W/_ #/G;_A6/C#_ * __DS#_P#%UZ)\+/#&
ML>'/[6_M:S^S_:/)\K]ZC[MN_/W2<=1UKT6BDYMJQABLZQ&)I.C-*S[7[W[G
M-^-;:XNM&ACMH)9G%PI*QH6(&UN>*X3^QM4_Z!MY_P!^&_PKU^BMJ6)=./*D
M>*XW9Y!_8VJ?] V\_P"_#?X4?V-JG_0-O/\ OPW^%>OT5K]>EV%R'D']C:I_
MT#;S_OPW^%']C:I_T#;S_OPW^%>OT4?7I=@Y#R#^QM4_Z!MY_P!^&_PH_L;5
M/^@;>?\ ?AO\*]?HH^O2[!R'D']C:I_T#;S_ +\-_A1_8VJ?] V\_P"_#?X5
MZ_11]>EV#D/(/[&U3_H&WG_?AO\ "C^QM4_Z!MY_WX;_  KU^BCZ]+L'(>0?
MV-JG_0-O/^_#?X4?V-JG_0-O/^_#?X5Z_11]>EV#D/(/[&U3_H&WG_?AO\*/
M[&U3_H&WG_?AO\*]?HH^O2[!R'D']C:I_P! V\_[\-_A1_8VJ?\ 0-O/^_#?
MX5Z_11]>EV#D/(/[&U3_ *!MY_WX;_"C^QM4_P"@;>?]^&_PKU^BCZ]+L'(>
M6:3I.I1ZS8R2:?=JBW$99FA8  ,.3Q7J=%%<]:LZK3:*2L?/WB+P[KD_B?5I
M8M&U"2-[R9D=+5R&!<D$''(K,_X1CQ!_T ]3_P# 23_"OI2BN^.:SBDN5'E2
MRF$FWS,^:_\ A&/$'_0#U/\ \!)/\*/^$8\0?] /4_\ P$D_PKZ4HJO[6G_*
MB?['A_,SYK_X1CQ!_P! /4__  $D_P */^$8\0?] /4__ 23_"OI2BC^UI_R
MH/['A_,SYK_X1CQ!_P! /4__  $D_P */^$8\0?] /4__ 23_"OI2BC^UI_R
MH/['A_,SYK_X1CQ!_P! /4__  $D_P */^$8\0?] /4__ 23_"OI2BC^UI_R
MH/['A_,SYK_X1CQ!_P! /4__  $D_P */^$8\0?] /4__ 23_"OI2BC^UI_R
MH/['A_,SYK_X1CQ!_P! /4__  $D_P */^$8\0?] /4__ 23_"OI2BC^UI_R
MH/['A_,SYK_X1CQ!_P! /4__  $D_P */^$8\0?] /4__ 23_"OI2BC^UI_R
MH/['A_,SYK_X1CQ!_P! /4__  $D_P */^$8\0?] /4__ 23_"OI2BC^UI_R
MH/['A_,SYK_X1CQ!_P! /4__  $D_P */^$8\0?] /4__ 23_"OI2BC^UI_R
MH/['A_,SFO %K<6?@C3K>Z@E@F3S-T<J%6&9&(R#ST-3^)+>:?[+Y,,DFW?G
M8I..GI6]17GJLU5=6W?\3T703HJE?HE]QP?]GWO_ #YW'_?H_P"%']GWO_/G
M<?\ ?H_X5WE%='U^78YO[/C_ #'!_P!GWO\ SYW'_?H_X4?V?>_\^=Q_WZ/^
M%=Y11]?EV#^SX_S'!_V?>_\ /G<?]^C_ (4?V?>_\^=Q_P!^C_A7>44?7Y=@
M_L^/\QP?]GWO_/G<?]^C_A1_9][_ ,^=Q_WZ/^%=Y11]?EV#^SX_S'!_V?>_
M\^=Q_P!^C_A1_9][_P ^=Q_WZ/\ A7>44?7Y=@_L^/\ ,<'_ &?>_P#/G<?]
M^C_A1_9][_SYW'_?H_X5WE%'U^78/[/C_,<'_9][_P ^=Q_WZ/\ A1_9][_S
MYW'_ 'Z/^%=Y11]?EV#^SX_S'!_V?>_\^=Q_WZ/^%']GWO\ SYW'_?H_X5WE
M%'U^78/[/C_,<'_9][_SYW'_ 'Z/^%']GWO_ #YW'_?H_P"%=Y11]?EV#^SX
M_P QP?\ 9][_ ,^=Q_WZ/^%7]%L[J+5H'DMID0;LLR$ ?*:ZVBIGC92BXVW*
MA@8QDI7V"BBBN([@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
3 **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>gwpjrhodncoa000027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000027.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !+ ET# 1$  A$! Q$!_\0
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M <>5E6D9%M""ZL @8DHY?/UV^ OC\55.6A<[@(828:+.\8:)[UWA))BIV!9
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M#)1FOF6'M#8@R")$^);]05*_HLIT1.B)T1.B)T1.B)T1.B+Q#?RN+^TO2/\
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M9T^-/23)]A2U?-*Q@? U@YRR0%?)1-BW;/\ EM^'))WQD]<\Y+9<\]%@N+@
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M^>6"J>7''/&>//))9H/N^U?4A3&]@E^+%%>Y] AA,XMFW"#2&G54LGYA=/\
M+RH@+9N;23<$%L.,\/SIM$UL\?S8_FQX_-Q^))9H/N^U<YI0V_S_ "=XL>Y?
M#WN3!VHP?8M-+ZP<9,GR.":BK)WPC9^?+9VDFLEFHV6_(MA@JGEEAQCGCSR2
M6:#[OM7!9TQO80*D@3#N?0)\;#XI9%P[/3JJ7)45BOQQRAD2'HVEF[8XK<<\
M<I<ND4N%..>.<.<NB2S.X8WWOM7,3HC?Q9\Y%H]S"'*DF:2*[L<GIC6&;YJ@
MX_'Y=9RTQL_EP@DO^7+X*BJ>."OX<_DRR_#GHDLSN&-][[5P'=.[T, N4E?=
MT.OF4=QPQ5R/N]/:G;A<4\U>$,%,BJUIX,>,,U^>$<<^5^,<E>>$^.><^>..
MB2R8PW3NO&?TKE-Z.WU=K-&S7N;0ERX?C^"S%!OII5JRSP5SDEAP3:))VAEF
MX'\YKH8\/4<<VW.2R6/"OXJ8<<DEF@^[[5]\Z%W^3?(C%.Y=$,"3ANL[;C\]
M+ZPQ?+M6^::;ARBTYL[A=5N@HLC@LM@GDFEFJGCGECEGCQR26:#[OM74/ZDW
MA%C'9LGW2:Y'!F#Q0<^+O]0:D9C&1!%?Y95B[?N+53:-GB3G_P NHV65P6P7
M_P#"RPX4_J]%>S_IN]Q_M7T)5!O*'09.B_=%KT4V))\JCG!+3ZIF*#]+'!)3
M)1DJZM1)-TGPFNAGSFADICQ@LEESS^53#GDDM_TW>X_VK\$JDWA#-A;TQW2*
MZ$LSBK=N%=DM0:D8MC"[O#%5JB+7=6JDD05<IYXJ-TVF:V:V&6.:>.6//'/)
M);_IN]Q_M7%,UANQ'#\8BI_NFUR%DLT6)MXB *:?50Q+R5<*)>GBZ00>XM)-
MT2S&!!I L^Q:)*\MA[)T[5_*B@IGB072"19F!_O\M/%%ZPW8:S!C7KGNFURW
MG1,"5E(Z'K:?50G)'L;!DXX%,'6P;*TN'ZPH87F$4&/7V"'+=N^D81JIGBL2
M:8*D[,3ANC?>\?\ ;P*,ZPW8(RTS F'=-KE[-H\)!'CL2:Z?50O(0X63O)./
MCI0D(3M+)\S8FWT*E[06Y71P2>N(P=20RSS%O.$2=F)PW1E-[[>(]5E?T[=P
MW^\AC?\ T35O_P!R^BDLT'W_ &I].W<-_O(8W_T35O\ ]R^B2S0??]JC9J2P
M[C.R]'B[=?[^Q.).2%@7E"L@C73FNBZ*250WI9%/MB'#Y6?#L\\SC:"(G%F_
M+7'%@L2488+.\&V+M<M.PVNBX<@>_O .GBI)_3MW#?[R&-_]$U;_ /<OHLRS
M0??]JZ!*H=Y%SZ\51[HU>+2AJAPZ<QM+3^IE#[=MSABIPX7#X6IR120YPSPS
MX64;XI\X9XY<9?AEQSR269W#&^]]J[_Z=NX;_>0QO_HFK?\ [E]$EF@^_P"U
M/IV[AO\ >0QO_HFK?_N7T26:#[_M7&>T%W 1K-V1(]RR),![!LN]?/GNEU9-
M6;)FU2S7<NW;E>SDT&[9N@GFLNNMG@DBEAFHIGCACSSP26:#[_M7#!4GOC*
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M8PS)7;,<H7UXPX''O_V:.2@Z5D*.A?/(GC$7AC"5T3WY9%R'4Y04P:XX<O\
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MGN"G3520^030)7_;1A\\E-;+"S*-?[-AZNW=%S^5:M2*3C4,%47D[CS+$XR
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MB[7>%;[[Q?@]HF0;KJ'?2)\U;U%]K-'X9&8[#XUM)K,,CL3!"(T '87W6:N
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M'EAUY^RU;>VNB)](NJ'EAUY^RU;>VNB*NWN/:R:VQ^':G*@=?*/"*E.XEHV
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MP.C96'B*,BR3%.%(<+Y,V6"+' "38FX;,1Y!9K^*U00#PR,;C0D9;-\+GT)
M[MG>UUB[9W)4RM"-%M?*XUX@59EYQ#)]+W^82>3NR+ G$@*5Z3.1$:$=D9'&
M(]"1K<X_-NFP,\:/LH_F28"4R'*,ZDSX@?,E'IOI=:C2-EN&L'C+:3DN[^PW
M&7?MR<<1?O*A0N8>74ESHDDMBJL>QK3!V+X#+KY'^166<?Q;_#4^3R*SEGW8
M/H1Z9*/DK[=>TBX )A7B@.&&[EO_ 'SI3:=?&4,D7JVAVVFZ%E[!,)Q&WS!U
MEPM9L6A;M07!!K59 W&G]XRQ1UPV6&D4D2U>'H&D4_$UH%=L=!Y6?ZAT?)J1
M-[=)F0 N.QJR]K2UCU<Q$.ARS/FM>:'H*O@^6+(<IEB$X;&*_/C$0[I-LY;M
M&#=?%#%HY:YJ%DF0W@"#XWG']U,OHLIT1.B)T1.B)T15K]I'_P!CT7_Q ;R?
MZZ-D.BIS\F_0*RCHHG1$Z(G1$Z(G1%3_ "_2JZ[FUU[@)28)1V-;.[=39X6@
M@XP90)1V%5Y01IHRU,K$X=C_ .I-T S]C$_X]G"P=,ER(EMQ3[-%(DJVQ25+
M4U:,VC9&_/SV \ 86>1@)M8;OBR]SCFL&,2E4?UKA6OM5Z]'+JKE>3SHN[M-
M]/[/EABP(JI*8)%8PP14C;&#)NG;Z0G,0TB=' L65("F&1*1'&2:Y 4$$"N?
M):-LG539PL,VOU0!5>++4]M;MR"OQOLAE8448!J[K&42.I)G;\5DE>NW6-AD
MK*&DH',0U>)1L,4B!MO(XL1/RJ*_IA=EP0$"#M J(VU@C,;JG:#0[9UWE1TD
ML7;#22V&D=#&8=0[_80K*B1-45D[CA2=UDQBL/)!F+[GEZN_6?\ #]GD\$I9
M.!S99;-91%!?+G,L_/%5TB^VQ9,YB5.5-9((?&8,)JKNY5W)3 4^&</:^=;4
M[75W:6LY^*-1SWA;DB"C$41EXC,5QQC##$<%#R'Z>]P;-^2U(\:MIO@568T'
MJ%MBI,]0-B]D!<1>;'+[6V-=.UB\8D(QW'X9#6&E%YZLU!&X8ODJCD9#M\BT
M)./1(9OERREEBSLUFW^!D2>\E21V@,B('N:9.><?0*[#HL)T1.B)T1.B)T1>
M$?\ EC']I^B7_ =[_P#^AK'HO18?C_Z__I>?:K.\KW-Z4KJ&5+5FW$]AU=5[
M'Q\6AD6'@X NQ @!:/" \8U6(Q!X^51;)<<889NG3A?+CC\<U<^?Z>BZFS82
M26U-34_L5GWCS=W7SNV3Z>K3V/T4PK/3S=U3QYN[KYW;)]/5I['Z)A6>GF[J
MGCS=W7SNV3Z>K3V/T3"L]/-W5/'F[NOG=LGT]6GL?HF%9Z>;NJ>/-W=?.[9/
MIZM/8_1,*ST\W=4\>;NZ^=VR?3U:>Q^B85GIYNZIX\W=U\[MD^GJT]C]$PK/
M3S=U3QYN[KYW;)]/5I['Z)A6>GF[JGCS=W7SNV3Z>K3V/T3"L]/-W5/'F[NO
MG=LGT]6GL?HF%9Z>;NJ>/-W=?.[9/IZM/8_1,*ST\W=4\>;NZ^=VR?3U:>Q^
MB85GIYNZIX\W=U\[MD^GJT]C]$PK/3S=U3QYN[KYW;)]/5I['Z)A6>GF[JGC
MS=W7SNV3Z>K3V/T3"L]/-W58#,^\KW-[",UQ(9GMQ/3QFHIKG8M</W0. )JQ
M6:J1*407.0,<6L0;I+.\HG-90%^$^3=M.&QAPIPWX<IMUT2HLV">SF(-3E(.
M_> L^\>;NZ^=VR?3U:>Q^BF%9Z>;NJ>/-W=?.[9/IZM/8_1,*ST\W=4\>;NZ
M^=VR?3U:>Q^B85GIYNZIX\W=U\[MD^GJT]C]$PK/3S=U3QYN[KYW;)]/5I['
MZ)A6>GF[JGCS=W7SNV3Z>K3V/T3"L]/-W5/'F[NOG=LGT]6GL?HF%9Z>;NJ>
M/-W=?.[9/IZM/8_1,*ST\W=4\>;NZ^=VR?3U:>Q^B85GIYNZIX\W=U\[MD^G
MJT]C]$PK/3S=U3QYN[KYW;)]/5I['Z)A6>GF[JGCS=W7SNV3Z>K3V/T3"L]/
M-W5/'F[NOG=LGT]6GL?HF%9Z>;NJ>/-W=?.[9/IZM/8_1,*ST\W=4\>;NZ^=
MVR?3U:>Q^B85GIYNZIX\W=U\[MD^GJT]C]$PK/3S=U3QYN[KYW;)]/5I['Z)
MA6>GF[JGCS=W7SNV3Z>K3V/T3"L]/-W5/'F[NOG=LGT]6GL?HF%9Z>;NJP&P
M>\KW-[4:1=A8.W$]DS2%SZ%VC%T'H2 (XAY]7AMO(X9)6_+*(-<E'@$VU;D&
MJ+C)9DJJECB[;.$N<D^2HLV#(;",SD1!VK/O'F[NOG=LGT]6GL?HIA6>GF[J
MGCS=W7SNV3Z>K3V/T3"L]/-W5/'F[NOG=LGT]6GL?HF%9Z>;NJ>/-W=?.[9/
MIZM/8_1,*ST\W=4\>;NZ^=VR?3U:>Q^B85GIYNZIX\W=U\[MD^GJT]C]$PK/
M3S=U3QYN[KYW;)]/5I['Z)A6>GF[JGCS=W7SNV3Z>K3V/T3"L]/-W5/'F[NO
MG=LGT]6GL?HF%9Z>;NJ>/-W=?.[9/IZM/8_1,*ST\W=4\>;NZ^=VR?3U:>Q^
MB85GIYNZIX\W=U\[MD^GJT]C]$PK/3S=U3QYN[KYW;)]/5I['Z)A6>GF[JGC
MS=W7SNV3Z>K3V/T3"L]/-W5/'F[NOG=LGT]6GL?HF%9Z>;NJ>/-W=?.[9/IZ
MM/8_1,*ST\W=4\>;NZ^=VR?3U:>Q^B85GIYNZIX\W=U\[MD^GJT]C]$PK/3S
M=U3QYN[KYW;)]/5I['Z)A6>GF[JL!K/O*]S>FX@W@59[<3V)1!H;F$C;@V 2
M +MDC<^F)Z?S ABH_B#QSRJ<F$G/'7.&2_**;DDLFU30:X(H)%39,-2WF1E3
M85GWCS=W7SNV3Z>K3V/T4PK/3S=U3QYN[KYW;)]/5I['Z)A6>GF[JGCS=W7S
MNV3Z>K3V/T3"L]/-W5/'F[NOG=LGT]6GL?HF%9Z>;NJ>/-W=?.[9/IZM/8_1
M,*ST\W=4\>;NZ^=VR?3U:>Q^B85GIYNZIX\W=U\[MD^GJT]C]$PK/3S=U3QY
MN[KYW;)]/5I['Z)A6>GF[JGCS=W7SNV3Z>K3V/T3"L]/-W5/'F[NOG=LGT]6
MGL?HF%9Z>;NJ>/-W=?.[9/IZM/8_1,*ST\W=4\>;NZ^=VR?3U:>Q^B85GIYN
MZIX\W=U\[MD^GJT]C]$PK/3S=U3QYN[KYW;)]/5I['Z)A6>GF[JGCS=W7SNV
M3Z>K3V/T3"L]/-W5/'F[NOG=LGT]6GL?HF%9Z>;NJ>/-W=?.[9/IZM/8_1,*
MST\W=4\>;NZ^=VR?3U:>Q^B85GIYNZJ'&TV\>UV[!"&E=I;GD5Q$*^9&1\.=
M2!A'&&8)E(5Q[DRW:\1T*&P4P?KBAZBO+K%QGCRUPX2R3XRSXS+36M;-T1.>
%9^J__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>gwpjrhodncoa000019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000019.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "F DH# 1$  A$! Q$!_\0
M'P !  (# 0$! 0$!          <(!08)! H# @$+_\0 5Q   00" 0( !PD+
M" <&!@,!!0,$!@<"" $ "1$7&%98EI<2$Q05%AG6U]@:(5-5DI.4F-/5XS4V
M.'5XM;?4"B(S-'2SM#=R<W:VN",F,3*RQ"0E05'_Q  < 0$  P$! 0$!
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M9'(#,TI2=!6@5O'9G9I6A8*,M,USR!V=-[Z:ZQ4%*I1(A->!:S0 "K<.\6@
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MK/'3%*Y<FIG,TT,51"B:J I(989HY$$;L;-8@,",:)*>1&"BDAENC2:HFJ7
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MN7DTHD:M(S! 3B4<$TNZ4"D:'<&U2 53OM-Y]S?8 ;EMA<[8PL$@PR;4F;V
M?:PZ-5S7+.02:&Q-W9UP[:Q0K:<WAL8'R^4P^MA7.T#Y<R5"!#4>S?/2F0..
M8DI&!!IG5#9)$?U.>=H:U*!<QSFHJ#''-**:DRN5*6&:4PQ35+<VC0KNDFE4
M$DFF.23AZ%+8BD>N(S&&E1 S*IDDG4NRKJ94''-R 1UV%R!>YMC]$J5OQ>6,
M8&CVA<%9N2CV,M81%.O.X+G)'46Y,MXYE(T@N.Q/)#D(C(7;8$Y*<M^&;4RN
MF,<K)/<N$.N&MH!$TY^E8$"R&)I349%PQ*$,G#U\@TZ^&"X6]RG2 *V. BF+
M!1E]V*Z@NBKN5OIU6XU[:B 3X#L<:X*@UGG1@<V%[54>*AY#."59@B@^);\.
MQYBQ W!3DQ!AKM'8_-!Y+!/Q$<^- "&>90?R$,<.VR/(M]PWM>>E1G1_I,ZN
MD*U+JTV1AEIWTZ)V!R^XB?6FF0]%M:6)U+?@21@"* $,Q0$+5$%Q>ZCZ[=A8
MW'6+&_4<8N2 )O#8W+IC+NV!#(O$:_E.4'G4ID,?WN#1V'3/'$)GS$I,;([*
M-QH.2>]R:.J\!"3EL2R1/!UL6W*1)GFM*.2&:2**+Z22RRSQ<:"*.3)'DFAN
MXXT2+EY9XKQR#B*"ET<7NIMQE=59VH554;0[,*H!6VZ+$S6!Z2['?<>,8A;Q
MYUAZ&FMOK1M_]JSK9R*I];9A[O*ORS%7%3T>'VJCM\2]9\XI>&QJBRXK3K7U
M5U9-0JSL_B]E^W"R*!G"V;5@_"0O!':-OFW'_$\)$*\H.%':_P /5?+?">$5
MD6S?)30UDTM<CYM76IJL01VBRL$H:2EGZ7_Z:;MKF<7%AI"BUP2;)&B182*>
M*[Q:VNU1U\21-OK^JR#Q[WQYJ1=CMA;1BE/UEI)K 1F,O7(\,<2L]VP!!1HT
M$&(R632(^<*;9-QP:.Q:,!C,DD)5XMBB."BGSO+C/E'A//M:#04TM74YQF*P
MPA=16#+'=F=UCCC1%RLL\DLKI'&H%V=U'AOA%::18TIH"S7M=YP  "S$DSV
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M=OAX\ZP]#36WUHV_^U9TY%4^MLP]WE7Y9AQ4]'A]JH[?#QYUAZ&FMOK1M_\
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MLB0(;.\/JW$,">P%O6Y=$=D 20H)GZRD-S5IC4LMCR):01.2O9!"<H8T&#4
MPQ>%D<VZ! :Z-K@S+X3D3Z*TR'+;5#,M!24E')&\9T5,='4BJBD*QRQK'-QB
MS%V$R@E6"!T5L&S%VX]T%YI)) 01>,R)PV6[*Q*Z0!8%#UB]C;&KR[N2 )G-
M]AIP8U>AKISM K$9?;81[9$[(QXM;L3M$;:J<K'CW7.60N"E##%88_K)NOSQ
MR&?*,TI=A@V:<(V1?1Z2&#+X$S.8#+!+#22"G@61*26E-*8F9;!IU4AUJ2._
M )B-S>+5RL\SF!;SE7D!D<CB+()-0!ZD)%N'XCWVPQX]F>Y4_P!@ZJ/TT'HJ
M#53""<?@$;$#XL]9((1P; KENZZ&S<<'CL4A\80;NS-X&0N#8< %HM!(08JI
MP])N"#YQW+OHXM!5I6/6SU4ZR3R.TH),C3T=%1DL\DLTI(2B1RS2,6=V'14*
M GKC-&T0B2-"J* I'1"2R2[!551<R$; ; =9).//CW!H$<F5<VO96H596+<T
M5K*.U+,9^:E1QX.F\=A5)O*,A,G;UM)1<LK@%98".-X>9^4I.-RZ/+R2$BR;
M2%#5'A#WZ7,-1'#4TM-FU33TDM3)5PP)$@:"2:M6NFB-1&T51)322&9.&LD4
M@CG96F;2N.<L0LDDE,CR+&(V8NUG58S&K:&#(' TMJ(8:D!T@DXWN?\ =PL>
M<'BYY.J(@!S*M=K4.1K(X57$H+;34Q3%.$%N1RS3!JY3@K2FAQT&U62Y1?N3
M;X>[]X;-TE%,\'T4IX41.52R!6RLZF10Y&65E95J-0-P9S6,CL#=0@87)($W
MS%V9FX:C4)Q;4;#CQ11D_MT\($>,DC:V,ZT[N1 1+KWF$8U^"Q K?]F@=@Y0
M2!V,5('@6Q0=U:[IS/(>9FT7F'R;BA#QNR!NC"A;%J:!MV0_@'/V*RQ98E _
M117BH89:]YDH*:2@B62G18WR]Q2@02I!)#Q)5Y)&3,[,CEFUP, H7HS$AI66
M%5,KB9B')(FZ=W0NKZ5.L]$"XL+.-[\Y]B+W-[$3H#-S@I &K'JBHRHF IH0
M=D&:0JCZ<@]0L"*&3SC#)LK(D87Q)2#)'#%LU*&'J2.2N&/"ZGT-!1)00/ C
M%P]775;,5"DO6UD]6RFW7PS-PE8[E44FW4,<TIF=6(TZ8XHP+WVBC6,'J'?:
M=1%NLXSFI'_;Q&O_ "O:_P#A%.^J\U_N,G[VD_\ +@QVF_2C_!+_ "9,;MIA
MM^:T\D]M2 /'CIW&W:=>TZ4<1*S954$QCPYW8U;V/\>16>PQ-0\')_#JW8B'
M.+;C'!X'+%&JN?&"ON<J<XRE,WBI8WDC3DM8M8HFIHJN&1EIZFGX<L$Q".A6
MI9A?<.BD=6)4U2:8R$*3Q(^&2LC1LHUH]U==P;H!]A.+/5MW8K JHQ"2,9JN
M.NF<#B%$0@.+D$MDI7%<)1E[3ZZV.;]_ABS?*%9+Q8!2+$2[=5L^8X(X2!BK
MP35S3Q\VI^BT%4DZ254@-1+73.T<4:$/74-/1MI7=0L?)UE5""K7,;#2+XO3
M,'C*E8Q95B4!G8[1S/+N=B2VLJ3L1WPWQLP'NUXQK.LQ@G6.*X0RC'>N<II:
M-N;5L!9[&;&U8EE\2>J)/+).GPW*3L&KC?DB:3.%.<0XTPL)%NH\]B#;E49U
M7)]%>+REVS*7C5RYA%62"EI],E/FD5#'5QQ1&ZP/_88S#,-;IK8.)39L3&8Z
M= $"Z8N"8@9')5X&E:-F/6X^M.I=@2!8J-L:W"N[59\/D$&D/-<1XJXA<HT7
MD_P921F6+(JII!%K6C8<>HU:-N$&+"R5;5?F)"W:I<H!W@EG@/1<XK*9IV3?
M16FFCFC%1(@FCSR.XC1F7GJ6EE=KDW8TPI52.YNX=BQ%MX+F#KHZ Z#4K=\1
M?DRNMNK;7KN?%;PX]@_NSS!%E130K4(1^A54/B\!FP@;*,(Y&[5CL,U?G^H\
M=(/&8J(X2 %,V-3V(=P0D#V4RL8/-JK+@8T%$OG@96+?1:+57,M6ZFJFEJ(7
M:+B24LDV9T^;2*"\ICDA:KIDN@BB=DL'D=U5QT9@UH@8E/#54<:K"15@>G!V
M74K"-S9BS6/4 "0= CW<E)AI#@]+45 YO#\:3U0H?.N9N:,GHJ]A&JMJ5C9X
MMF5;+H88D6T[6K5(-)ABR/ [A$\2>9(/>?=M7.B3Z.J\>E:Z>&7EN:UW*(42
M.59\TI:FE9D(/0, J=<;#I7C4 KL5@M;9KF)70101<-F)71!(D@!N-]>@!A:
MVY.^,)M-W##.S%6NZCXJ:,P",\F]>B8Q4.2;JNF+37>'[!PR/L<V 6-1.,XJ
M2!A?Y%X9S"1X ,:OHXTX#A6#)^HS9SRS($RZJ%7RJ2>717JP=2 QS":@FD;4
M\DLGU;4*A \CL5D.IR5!:,]89X^'PU1;PD6.X$*S*!8*J](3$FP4#3L #MO+
MWN0P.07&1V'F6FU5RJ[9I%^1EGS$O*39L3()@B&CPQM8L/@<Q$2Z%0.2NGD=
M1+&U% LHYR=$BV41<0IPNT=LLZ_1V>.D7+X<XJHJ*&7730I%&C1Q%Y'-/-/"
MT4T\0$A1!KBV5.,)@&#6&M0R&9J9&E9;2.6)#-I #*C*R(=KG9NLZ2IWQMA3
MO"6LZL<]9HVJX6P,E5KG(,!KLR<*@!I>X=XXCO&X>K#E,6OQDB"EL.&P?!IF
MLVR*Q[+)\Z<H/DDD\:U^B5**=*9JJ9D7D:LP1%=DH\EER4*&WTEXIGGU6.B3
MH@%;D].8R%VDX:@GB;:B5!DJEJKV\.EE"]>XWV(Q@L.Z%\20NYH%7M#,:^#6
MA,+!LL&3&V0_D,NAMA6U!34!LA[G*9C$3Y$G%) &+X((QD#\BB+5FT78O926
MP.R)4K9W-:YZ.>HKFJ&IH:>F=&IUCBEIZ6=)Z<".&6-5EC="3*_&4DAEB3AQ
MA><OLLJ)"$$C/(+.697D0HYU.K$J0=@ND@;%C<WHGLQ>YO9B[YU=TA%( BLW
M<!U5@K4@[)M!:(2.B(VS9M'C['%SFV39AT.4D\L,,&^.7O"6/"2>'7MY=1)E
MU%!1QL76$. Y4*6+R/(20NUR7-SX>L[G&2>4SRM*18M;:Y-@%"@ G]@QGMS?
MZ8.UW]I2]/\ %"4]5Y/_ ,)RO_EU%_XT6.U']XG_ 'TO^ML5KZ]'%..E-0=P
M4)5\/UE!D]> 4TD^M$9NRNA$N=6/*@>$IK#8%_;:MD1<E'AK'-D/+.!MQ2(>
M"E+5RLY#KLQC_(>]][6:K?.U>0O4S9DZYA)#%F4M'4/$*>)S%54"T@IY5D9K
ML@:CC+Q$ .&<!EV(W15BQK I@#M LJ!N(RZDF,FM2 + VD(#=8V.)")]U^5J
MOHEQ'J3BL7C<(X8LX]%VDRE)!HW"!M)4]( 8IT_)XN'Y#(=!DL9-R1>JKO'9
MA1RR6R^".55><Z_1>+3*)*V662<LTLK0Q*6D?.>>I'"K95U3_5A5 "I9AN ,
M2.8-=2L2JJ]2ZF.PIN3 $G<@+TM_#MU8W;>/N#U!95B:N7%K#S/!=@Z^6BXM
M,,QE\%AD1@XUZ*QJ$E$BAD/'BI@S-[7)2&M\L+*FAN1/N#T;#086D5(JCE56
M-.2Y#5TU/F=)F7 :#,*84SM%/--.P<U:RHCR(B0TJQU']FA2,:)'G<JH8 SJ
MZR.1Z>2#5KA?6 R*J CAD$@$EG+)TV)W4*+[8TVH^YE5E'7N8OZNM&JI&RXS
M,HS9G.9F=2&9N@5@ 9VM.':\,)3<%),X5$BZSE<6H*C+4;-&K)-FFG8ZK=%R
MT>VU?T<JJVA2@J,[JFB2&2FLD$<(>G> 0 3+"\?&E0 .'D+0EKGDX)!$8ZZ.
M*4RI21ABRR;NS$.'+74N&TJ;VLH#?_S\&/) .[#/X(X8>"IHH>&(1'6*!/Q)
M&32-!%U$]=]?KSUT(-&#ACP@Y!D["A]]R@JH88*<+1.1L!A <B0XX6PSE/\
M1>"8-_:I4<S9G.KK'&2)<PKZ+,5+ W#K3S4,2:&VFB9E;3L<<3,'0@B,$:8%
M(+'O88982!8"Q=96)([T@$7Q^L&[J).LJ]@=;5_2 N+@:HG*!FON6D[7>O\
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M67T]"9"4C4JI"..)IL</@8,_)9^5:37)Y)VCV.DQ[<B*#O#CGKRLL&?0T^7
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MB0:):>5;%6%_VO(0=4)5[B_ZTW2-K&PN"#;#CQL+,-OV(H.TP93U6VCNHO<
MFUK7./QJOML;,8HAV=OS$"[C,>;[D%HM"!5TV(0" I'=<(U994RT>- T-@8$
MU'X9-JXNF0$H^]!.(]'G4K&$10Z3$B)%\UZM/):SD$#BE0&:P+B+1<  ;,KD
MBQ O<7O@U0FJZ7%^$"2HN0K/KZRQN0RB][FUKBPQ%\1[7V\L<8T[%S]SM9''
MJ\R>I.ST-OJ3UW,N"KYG0[J'S)'X[I"R8TV<TP-KV54K%!D8"1GAU73*/GV.
M0DQ8-HAW45IIAH!:X7KM(0U^AI-RC :-)06 Z(!%KL,2-1$2QM8F_6EQ:[W&
MSKLVH,2;G5<;@+BZ9?0RT"&CUZT8C+F/%]7;<LIL O/BD[ELF$HB/*G>657N
M(]Q,!$C:@W,2IIM' #./CH;S&$)$+X9.&1-EDN6=VF!C \=QQ'8DL68C])J7
MK!M9 !8#K'AZ\4\9>,CVZ"*  % _4L;VL3=K[WO;Q'$46#VT;EC]F@W=&V,^
M-1@N2BDW*6=9-Q2J(6-65X.MF2EW7W=PB 597X>L+ -7=!B(^M%XN@QKB."1
M\6'!,VO$7-FT^H-3,&NAN"0VMG*NLAD+2.%5=!+K9;6 V M:^)K4J5(=;&S#
M2%!5ET:44EB6 0W-[DF_7MM%Q[ME;:SFK+3JB13.#-HI+ &XHF-M3MO3V:2@
M@3N^FHO'JS,6M,QE<05C/58U; E^3Y*9PID;:0A$6H=^6$A=E&O'.3RE&0E;
M$2VN[$DN@"ZCI4-TQ>^D64"]SB0J(P0;&X,>X4 #2QU!06.FZGP&W@L,9@SV
MVML\1IS&IYY&*2;3FP!<;.0D==EK2\5#-<K<U<JRJ-DF$2D1&,,GRUF!+;@J
M]BU4[^+AC#-;E=[P3BCHTY;MG)Y!?20@) TAV("-&JR6-@;AQJ7JO^SP<%1'
M^N"]@2#I4$NKEH[[V *FS=9^WPV.U6TLV#J*>[*&K.L)]+&]E [<CD8*96X^
M/QF2L9C9$BE%<DSM:O*C#EHJ?K^$E6,#1>JVA-VP4,W<QR-L5XWB&Q"V102(
M9-37U!P#J)!U,2I*Z!8J#:^IK;@;6M"29&$>D6TLC$:;$66Q ;4003OWHN=R
M<5T=:4=P*05'I%5RC2B*V6U-AE-0-65PC8*S"9HNI3YFB\G$T:YN*,CS-FSG
M,1A$]C[R#,&+0PR7>B6I"SS,5,'0.%9AG985LB\(( 1(Q-TTC5W@ N =@+^
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M6(%]14"Y N2$<_L L!J(NP%[U;JS9:\+!N_6=-E:-0R"IK.U=9[1W*%$5D>
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M,WH_%JDB)4!**@OBUMSQ@0XLCRR! KM7YP]4E7EU6M0V0U@ ;+J:2CCC$*T
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MJ"BJ5>$UDS21M2N:IV80S/2JSI% L\;PPBI*51$S]-G20:!.I5F-,\B$-PU
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M%IDD5GG5(GNZL(I(8TA58M<<C1C5K,CW32I0W4BVHC$AW_IUIM,\+[M=G(&
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M:/)95IZOAYX%Y.Y2/1 STLM6B5+<6P=HX)++%Q=U)8J"I.EJ-T:J4O'>EW<
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M.KM?";Y30Y6=:V1%*HG4O:%VL-<5LQ4"3"8,,4HJ9G8V7E @XV=8!%F38?\
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MS6'-%+T\<HC6*%WD?1I268%^371W#R1QZ))&C+1!98M,C%F"PGIGI[!RMRS
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MW/"EAN1I"@E96)*@%F 9B=\>BMM#N\G6T+IF -5M!C\<H>&E(#7>16<[##)
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MF,=DB#=3C/,49=PF"Q"6MV#KP<8KJQ^3@R>./^[$4,O];JN7Z>9/)%)&B9M
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MU/0$Q21%H"9Y%G>37/41DQ2S,A(Q.2&LD96)I%93*ZE3/M-+IU3#4C6<!1H
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M8GKQ])!"R00H62Z11J;:K75 #:Z@VN-MACJ(2_E%_P#\:Z_YZG7EQ_HX_P#
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M<]+?P6Z^BGC(0](<0;#4"8SH9B6Z(U"X'D[7^S'T+];\8<.F&);&_P G,/\
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ML!UCKA&H=&Z\CT&J0+ X=)1LSBD-&0P.SC,;F(<_\JQ4L"!$ F X;)ATI_\
MF1D?:-TBK<]SR72=XD.>7'/123 !12.%!N!ICL"#<$#5UWWOUWWZ\<,RDEC.
MI)&DDZ[D$6()T=5ML:H<UUTXDT<XB$BI77LY%<0$6BF$<+59$GX1.,0<P;D$
M,CR0QS&5&:06)G9+(S,;&)HXLPI0^:?#D6SDH^47X:.4BQHV(L!8I':PN0.^
MZ@22/$2;=>)">QN*@ W)N#)>Y !_5\( OX["^/-)-:-+)BB,;RVB=<9,W"E9
M"<$-SU1PLLW&&9:U'LI058(/HLNDT(2)J($HFG:&&"Y/ 4+^&9K<CF?*/#12
M&UZ-C8DBZ1]9ZSWW6;"_CL/$,!46ZJ@#8#8R=0O;]7P7/WXR[>B-2FLK/3MM
M4E$-YK*9(%F,DEB-;1A.1'9='),+F@&4E3&,=X?OI$(F(0-+!YIPOF1:R80,
M/).<2C!JZ2[R.4$MR1M1().B.Y(((-]77< WZ[@'K&.<<6MR@6L1:\EK$:2.
M]ZB#8^,8\Z^ONH#HV#DCJFM?W,@C(V8!HZ:<5=$UB@0183V1$IV+%O5(UDX9
M#YB0E\M?29FW43;FW<JDK@BFX5/%<G8T<I()HV) (!T1[!KW Z74;F_CN?&<
M./U_V@=(@G>3<BUCWO6-(^X>(8W>LX30U+1O*'5!&:TJ^)Y$%RV<;@$8'Q$&
MH4<H-6BY%08"$,6:CY5HQ8L\W6:.2_+-BR:>[X;M&Z:?5I9T%DI9%%[V54 O
M]@;[!]@ QQI5<W:96/5<ZR;>+O<2%\I8SYPC/RG7^5ZER>I]'E^Y/GQ'5'YU
M/\_R8R#Z0QS# ?[L\-PXS'IJ8<\Y.?\ 7PY7<\<9X^!MS_J\\XY<??\ !SX>
M.?O>#P<\U14]1>7ZB0_6M>P78V78]+KM8_81B;O&='UB#H*-]6]K[[*=OML?
MV8Q_REC/G",_*=?Y7JWD]3Z/+]R?/B&J/SJ?Y_DP^4L9\X1GY3K_ "O3D]3Z
M/+]R?/AJC\ZG^?Y,>,B4A)<>^$EB8 F+*,W0XD-(-U'K @/>H9MGC%\S<LE&
M[MF[;*J-W+9=-1%=%3-)7#/#/+'D:>H((--*0=B"$L1XCT\ \8((E0$&X/3V
M(_\ HQ6P1JIII&UH3A%:NJ*( :_?V": 0F(Q 3&8&I(K0A^=>3&2FH@&!LPA
M\Z2@#LS"OAQAJ\YQC,A-BLTU$'27#>L44@TVI' 7590J!;N-+$C58DK==_ 2
M,6\HN&O4 EM-V)D+64Z@ =.PO8G]H!Q[D-7=(VL?A43;T'K<C&*WDKN95_'D
MZCAF(:%2T@NT<OY-%QW$7^"!#KYR/'.'I0>DW>NEQP]5=911BTR1<BDL!R-K
M*=2C1& #XP-6Q-A?QV'BQSE&Y/*!=A9C>3<>(]'JQ(,.K;72NY?-[ @,)J6$
MSNRWG!"Q)E%(8'C\HG+[ARX>_#):>%!&I.0.,GSQX^S6*.76:CYX[>Y\Y.G2
MZJDA23*684KAF[Y@J G[3JN<1:56 #3J0O4"7('@VZ/BQ*'REC/G",_*=?Y7
MJ7)ZGT>7[D^?$=4?G4_S_)A\I8SYPC/RG7^5Z<GJ?1Y?N3Y\-4?G4_S_ "8?
M*6,^<(S\IU_E>G)ZGT>7[D^?#5'YU/\ /\F,@]D,<P1&99GAN/"H_E1/GG)S
MX,\/ASY/W>/@;<_ZON\,\/O^#GPX\_>\'@YYKC@J"90()3:2QV78Z$-N^\1!
MVVWQ)FCLGUB=[MWV_2;Q+_TWL;CJQC_E+&?.$9^4Z_RO5G)ZGT>7[D^?$=4?
MG4_S_)A\I8SYPC/RG7^5Z<GJ?1Y?N3Y\-4?G4_S_ "8?*6,^<(S\IU_E>G)Z
MGT>7[D^?#5'YU/\ /\F'REC/G",_*=?Y7IR>I]'E^Y/GPU1^=3_/\F*OO-4]
M,RJ\IX/5;44D"2V'0.OWT+D40$F( /AE:2.5S&'Q\!!WH12, F8V8S>42S-0
M<,1=NI 3X(.7*BC 9PRKY#(;WI'(("V*QE0%)( &JPW8G;PF_7BP5%@+3J+$
MFXUW)8 $DZ+G8 ;^ 8W)*C-34)6 G:%340C-8I"TZXB\K1K6+I2".U^B+=@D
M(0#+81S%Z*BC<&0(!&X!BL@+0#D" M%K@P>NFZO>1RW#<D;4!I!T1W"VM8'5
MU6VMU6VZL<X^Q'*!8FY%Y-S>]^]Z[B_VXV>KH%0%'QG*%TS$ZNJB(9DG9G.,
M5S$Q<+ *%WV""3PFH)CH8>Q4(.46C1NL\S0R<9MVC5ORI[RV033ZM+,@TI2R
M*+WLJH!?Q[-UXXTJN;O.K$"P)UG;V<2/\I8SYPC/RG7^5ZER>I]'E^Y/GQ'5
M'YU/\_R8?*6,^<(S\IU_E>G)ZGT>7[D^?#5'YU/\_P F'REC/G",_*=?Y7IR
M>I]'E^Y/GPU1^=3_ #_)C(#)#'%7J>"9X:IGRFYYXQQR<^'GC!JMGES]]MQQ
MX,<<<LN?#S_]..>JY8*@(28)0 5W(7R@!^MX3M]N)H\>K](AV;JU>2?&HQC_
M )2QGSA&?E.O\KU9R>I]'E^Y/GQ#5'YU/\_R8?*6,^<(S\IU_E>G)ZGT>7[D
M^?#5'YU/\_R8?*6,^<(S\IU_E>G)ZGT>7[D^?#5'YU/\_P F'REC/G",_*=?
MY7IR>I]'E^Y/GPU1^=3_ #_)BK<HU-TLE9N32EU4M,B)?.I#&I)84UBL(!Q:
M;6*YBUA1>U&(Z>S$& 9265@7\]A<7D,A"&"CD?)' =L@;1?-,ET%:S12$D\D
M<%B"Q"QAFLP:S$-<@L 2"=[;W&+!46  J%LH(4'60MU*W T6!TDB_@OC-NM9
M]+'PZQ1#RB]='(NWS;*26H/6JB'J-+%D(THY.#3LU0RC/*<D+CSCU\<8D2V+
MIVT-/WQ9NLF0>NG*O>12$,.1M9C=AHCZ1O>YZ6YOO]N_7CG'[W^T#HBR[R;
MBVW1\6V-C%4OJN"FT7LH'5]'AK#A$39P.&3@57<;'2R)0D</7$CHE&C[./(D
MP<<'B73L2P##'+8>R%NW8YL@DS=+H*!22A@PI'# :0P6.X%K6!U7 ML!X!M@
M9@05-0"";D$R$$GK)Z.^)F^4L9\X1GY3K_*]3Y/4^CR_<GSXAJC\ZG^?Y,/E
M+&?.$9^4Z_RO3D]3Z/+]R?/AJC\ZG^?Y,/E+&?.$9^4Z_P KTY/4^CR_<GSX
M:H_.I_G^3#Y2QGSA&?E.O\KTY/4^CR_<GSX:H_.I_G^3&0+2&.)%"22IX:FJ
MF0>)J)Y9.?=89X.%,<\,O VYX]UCEQSCSX.>>/#Q][GGC[_5<4%08HR()2#&
MA! 6Q!4$'OO",2=H];@R(#J:X.NX-S<&RD;8Q_REC/G",_*=?Y7JSD]3Z/+]
MR?/B.J/SJ?Y_DP^4L9\X1GY3K_*].3U/H\OW)\^&J/SJ?Y_DQBCR]>RD&9C$
MF<1B11N1BB(&01\XQ^-@AT&79K#RP<P*?L'#$F+)L'#AD0'O4%FCQHNLV<)*
M(J9X9#3U!!!II2"+$$(00>L$:MP<=#Q@@B5 0001KN"-P>\\&*YL-4-,12L<
M0$574 >,1:*6C#A->"(<(&5G\5W3S&,+0<$H Q!H1@T7F#"(B Y8L7'/7JP7
M(H+X4Q:&BR;RL44@M:D< !@%"H%Z5@Q*AK$D "Y!-KCPF\^4=?\ :%N2I)Z=
M^C?3OIO8$DV\>^,ZSUNTS'(UFW8TCKRT1I@@]+5&FWJN(I8UF5)%43Q$G!>,
M(SQ\ER#\^W;'WKT-\#<NCK9L9754)MT76'>12#3:C;H&Z]"/HDFY(Z6Q)W/[
M=^O#C]]_:.^V;>3?:V_1WVV^S&Z5[6VNE2$ID9JR$U+6Y>Q3'R@GQ2"PP/%"
M$T.>_OG7QM*7@,(Q<'2'#HH4=\.B2CE7%V3).N,N%W[M1;JTDR7*TKJ6-VTK
M&+GQFS;_ /\ L^/$6E5@ TZL%V%RYMU=71_8/NQ*'REC/G",_*=?Y7J7)ZGT
M>7[D^?$=4?G4_P _R8?*6,^<(S\IU_E>G)ZGT>7[D^?#5'YU/\_R8?*6,^<(
MS\IU_E>G)ZGT>7[D^?#5'YU/\_R8R#B0QW$>/4R/#N$U,WOO>?/+KW.?.&:/
M&?&/_P#&\/APYYX]UX>./_KQX/#U4E/4<67ZB0FT=QT;C9K7Z7A\'V8FSQZ$
M'$3;7OTK'<';HWV_:!^S&/\ E+&?.$9^4Z_RO5O)ZGT>7[D^?$-4?G4_S_)C
M0++AE$71%7$%N&,5C:L*=NVC]U$+&B8N;1AR]89\J,7BX&2!B0M9TS4RR4:K
MJ-<E6^>7.26>'////7&I9W%FI9&'B94(^XL1B2RJAU+,JD>$:P?_ &7$*E]1
MM)23*1H#J>I.&E9-6!2F7DOK^!1Z$3D=69B*?(9Y$X[,8['F)^.#>(=BE&FF
M(9ZSS'AFS)BQS;H,&6+>!H9#?^QN"5*758U.DBU@0UP+;;=0ZK8ERC<$U"M9
MM5F,A!:][D:;'??[=^O&VI:]:?(F#TBQIN@LI!*H$E5LH.K5G%W!F2ULD''Q
MW&"2$HXCBKXW$\P @2#7!$UW0YR($BQKANJS',T4.\BDW/(VN5TDZ(]UZM)Z
M6XM86ZMAXL<XXV'*!8'4!JDV:][CH[&]S?QD^/'F9ZVZ9#V]:-&-(:\-&U,D
MGIFI$$*JB*25:&"15 \1*P;'&,\<1@D0/-6IYZ^#_!'3LZT:&5U5";5!TFY'
M+T?[&W0-UZ$?1-[W'2V-][^, ]8PXXZ7]H'2V;>3?[>CO_\ ]\9Q87Y2QGSA
M&?E.O\KU/D]3Z/+]R?/B&J/SJ?Y_DP^4L9\X1GY3K_*].3U/H\OW)\^&J/SJ
M?Y_DQ-8I\/5%C5$WS91-1@SS34QY5]SGAFW3RPSQ\*7'/N<L>>,N/#QQSX.?
MO\<=>-*KB60%&!$C@@@7!#$$'?P'&]+:%(-QI6Q'4186.]COBC,G_G+(?Z\+
M?]>XZ^UI?[M3_N(?Y:X\6;]++^\?_4<8/J_%>'3##IAATPPZ88XV=V ?L(0*
M4MA1J]Y-/<5?M%RH[IP/L@532L[XOJ%2GTBRNO"N' 62.2"4G2@AZU$"-9"W
M7)MQ*!1$1P1:Y^3FG*"8>!QA]54W,2U)'$M%PKFG[UB=6AI08QTBP(N,;J(Q
M#7Q.'W\/Z0Q#H7?B6XHW7O=:I9R+ $&V(WF-U;T0#FT,H96EG0M<U+M@)C#$
M&]'S.\'5@6V#AVO>-.T_)'P]J_$0FN)V],62U,VL*PBL)S>15SF&DL8R&D\2
M=3S5J<71'+'=YW0<%YS)*J4_!A8@,$C<M(#*NE"4-G2Q+26.G;1J=#T8E:\B
MQZ$9I>)(+D%G4!"$(9K-NK7%LU85R]S<<\L>01=F83'"$-PY)%X,VUJ(2+)9
M+7^X8&#I>$-)&BHF].JWO#IA(G TT@R^&R.-POXT@K')ZD:D6<I)<R!D9;V
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M9R@ETJP)X;6TO8'O6N+'J-[C'3&ZKJ9&"ZBER"!J%[KOX18W'@MOC4RNU.N
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M!8D2,;*O2),D_=*)-63!@S06=/';E5-!LW24664P3PRRXXS!5+,0JJ"S,38
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M PXF<F#)N:2=/PK5LR**L9FMIQJZ;$(54LL4K*7<J%C1U0J\AUI]6A9P&N5
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MSS9S13.DG#K8Y$5D#Q-&C,C%2R,=9NI*@CJ92+J0=\6QTD\:LFJ!T8ABKJS
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MTOEQ_>WRX>3G*_QU'OSA+]W].Z*D\Q4?='VF'-TOEQ_>WRXR+^@).Z0%)8&
M..3 =RS5YR4(>#-3DB0>>Z3\##GGW'O;M/'_ %N,<O=XY_>]SX.>:X\_I4:4
MF&<\236+"/8<.-+'ZSKNA.U]B,2.7RD(-<?14@]]UZV;;H^)A_UOC'>3G*_Q
MU'OSA+]W]6=T5)YBH^Z/M,1YNE\N/[V^7#R<Y7^.H]^<)?N_IW14GF*C[H^T
MPYNE\N/[V^7#R<Y7^.H]^<)?N_IW14GF*C[H^TPYNE\N/[V^7#R<Y7^.H]^<
M)?N_IW14GF*C[H^TPYNE\N/[V^7#R<Y7^.H]^<)?N_IW14GF*C[H^TPYNE\N
M/[V^7#R<Y7^.H]^<)?N_IW14GF*C[H^TPYNE\N/[V^7#R<Y7^.H]^<)?N_IW
M14GF*C[H^TPYNE\N/[V^7#R<Y7^.H]^<)?N_IW14GF*C[H^TPYNE\N/[V^7#
MR<Y7^.H]^<)?N_IW14GF*C[H^TPYNE\N/[V^7#R<Y7^.H]^<)?N_IW14GF*C
M[H^TPYNE\N/[V^7&2$T!)V#Y-TJ8 YX8).T^<4U"'.?A<,UV^//'&3#'CP8Y
M*XY9>'GC_5XY\'AY\''-4V?TLD900S@DH;D1VZ+JQZI/$-OVXDN7RJUR\?4>
MK5X01Y/[<8WR<Y7^.H]^<)?N_JWNBI/,5'W1]IB/-TOEQ_>WRX>3G*_QU'OS
MA+]W].Z*D\Q4?='VF'-TOEQ_>WRX>3G*_P =1[\X2_=_3NBI/,5'W1]IAS=+
MY<?WM\N'DYRO\=1[\X2_=_3NBI/,5'W1]IAS=+Y<?WM\N'DYRO\ '4>_.$OW
M?T[HJ3S%1]T?:8<W2^7'][?+AY.<K_'4>_.$OW?T[HJ3S%1]T?:8<W2^7'][
M?+AY.<K_ !U'OSA+]W].Z*D\Q4?='VF'-TOEQ_>WRX>3G*_QU'OSA+]W].Z*
MD\Q4?='VF'-TOEQ_>WRX>3G*_P =1[\X2_=_3NBI/,5'W1]IAS=+Y<?WM\N'
MDYRO\=1[\X2_=_3NBI/,5'W1]IAS=+Y<?WM\N'DYRO\ '4>_.$OW?T[HJ3S%
M1]T?:8<W2^7'][?+C)&* DY$N5()& ."3XD^>)8**$.%,$W3I5?#%3C%AECQ
MGCCGQQEQCEEC[KCGP9<\>#GJN'/Z6.&*,PSDQQHA($=B54*2+R VN-K@8D]!
M*SNP>,!F9@#JO8DG?HXQODYRO\=1[\X2_=_5G=%2>8J/NC[3$>;I?+C^]OEP
M\G.5_CJ/?G"7[OZ=T5)YBH^Z/M,.;I?+C^]OEP\G.5_CJ/?G"7[OZ=T5)YBH
M^Z/M,.;I?+C^]OEP\G.5_CJ/?G"7[OZ=T5)YBH^Z/M,.;I?+C^]OEP\G.5_C
MJ/?G"7[OZ=T5)YBH^Z/M,.;I?+C^]OEP\G.5_CJ/?G"7[OZ=T5)YBH^Z/M,.
M;I?+C^]OEP\G.5_CJ/?G"7[OZ=T5)YBH^Z/M,.;I?+C^]OEP\G.5_CJ/?G"7
M[OZ=T5)YBH^Z/M,.;I?+C^]OEP\G.5_CJ/?G"7[OZ=T5)YBH^Z/M,.;I?+C^
M]OEQDG- 2=8:,98F /"C)1_FIGDH0]QGPZ41SPXP\##G+PX\)<^Z]UQC]_GC
MP>'[_52Y_2K++)P9[2", 6CN- 8&_P!9X=6V)'+Y2JC7'<%K]]X;6_5_9C&^
M3G*_QU'OSA+]W]6]T5)YBH^Z/M,1YNE\N/[V^7#R<Y7^.H]^<)?N_IW14GF*
MC[H^TPYNE\N/[V^7#R<Y7^.H]^<)?N_IW14GF*C[H^TPYNE\N/[V^7#R<Y7^
M.H]^<)?N_IW14GF*C[H^TPYNE\N/[V^7#R<Y7^.H]^<)?N_IW14GF*C[H^TP
MYNE\N/[V^7#R<Y7^.H]^<)?N_IW14GF*C[H^TPYNE\N/[V^7#R<Y7^.H]^<)
M?N_IW14GF*C[H^TPYNE\N/[V^7$ZB(.2'"18]5TQS58CF3-3-/)Q[WFHV;)(
M9Y8>Z0QR]QEEASSC[K''+W//'AXXY^]UX4U;%)-+(%D DD=P"%N S%@#9K7
3.^/12)E1%)!*JJDB]K@ >+'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>gwpjrhodncoa000020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000020.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &U ET# 1$  A$! Q$!_\0
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M5%\1?53Y#)Y+7Z23"?X'E/VMI[\ZI_+I_:'W4ZJ+XB^JK(8)X'.#SACD%)G
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M^Q3VUA] #]\A^HT][?Z;_E_]2GOL/D#_ +P?L4]M8?0 _?(?J-/>W^F_Y?\
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M2Q@^-&)0QC+#L#A&*]_":SY]*U&UT_3]5N+.>'3M5DO8M.O'3$%Y)IS0)?)
M_P##:U:Y@68?P3*G?7+GIZ$JT++62RS$97Z] Q[N7FYV:?-HR(B(J/0.Y?24
MG(O546C%BS;)J+N73E9-!!$AU%#E(41"J22.&-Y972**-6>221@B(B@EF=F(
M554 DDD  9-6K&QO=3O;73M-M+F_U"^N(K2RL;."2YN[NZG=8X+>VMX5>6:>
M:1E2.*-&=W8*JDD"O5$6.#GW$\TAY)O(.*O-&KD^D@)Q-%S9(N+FC1KGF(4
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M92'#8!)RB @ @(=>@]0Z@/</?Z]=5X1W?K^O.]? '6=F-QS'<?*,9'F->*A
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MKFB.2+%4EY785>#8,HJ)MD)[&3C68-.A8D)/E>)=M'-TP7[%P5G2=SC+ 8[
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M9HYT6QN;:5_"'$9!&Y ,A'"^^#E">(<(R#R&,D?.NK8][KI6B+JZ!/X/B.[
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M)U$C9);#/'R(B!XBT39]+;FPC:*6-+I57AA9V*.@ P S*K=8@QD \+8R./&
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M[9&^^#7T?[D/2NYU&V;HY=+"R:78));3)%)UKP1RI#P3ODP@0K)''&>!'=0
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M!E1ID#$M&R,RK)$6<'C#(2O$D?,>D_1XZ9&+B!VEM78H.,#K(G*DJCL,!E8
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MW=^^W78 W[]P\/'???5^Y/DY?3N/QYL5ID##;GV9\F._G^-O()+=-HNPU=[
MR"*8+*I"=FX.GN+5Z4HB@L78NX%YOE:H%ZG1.H4-A,&H@B:*YCGC)*@^,O$
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M6,[=7% [1QICD?%4,6QXS,S_ ,+%=9LXHX;"V6,Y4Q)(6Y\32#B<Y\Y('+
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M(4"#ITJDLVC&[Q0'K,Y2^XWC3(&4 O:GV$K90J3DH F*B!0,7?V\A2\"> S
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M@U>WU"\MM5\,+F=M2MKEX+Y)WD/6"\CN5DCNHI^&=90YD7B))MM%@42D$-A
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MCR]^U=]I6/77ON8""8O00V'I^0?L#\.E>H<-OR.WH([>7;Y]JC>9?+%YR;[
M ^(B'0=^H?#^/W]944(;&YSW]W[OUGG66LSJ0,X!&0>TC._T]GDR<<Z@.+9_
M_P!><3N0#<KG*&/5]^OS86R(*KN/I$Y!./7_ #P\=]9MZ<:'JRG^#IFH#EC;
MP24KCT >3S\JG-)?-W:[D_YQ!GL_C$ [^SZ.[L^@S7SQ74*:4K+:@H<'KE(
M$4U&W.<0[BF34(!!'WP4. >.X^@!$(_40.JC/:'P/,5)/U"I#3B>M=>PQY/G
M5@!]H_@5(>H>IBFE*:4II2FE*:4II2FE*:4II2FE*SJK?N)Q]=&^)2U#ZC^=
M3YL?::IW2_S$GSI^PE?&[K'K+K9QAZ,4J>)G"=>/Q=U:KW6;;*%GL88CI2L]
M/K+4JGN)5N:SEG&MT1JZ4HL^]KYF*[:NR<<L1X99667E&;&@XSOPG'>?/Y,?
MK'JJH9_G#/<N_9VYSC\=M4&RK6E:=DF\U9<L^16!M$Q&G"U&C3V0?-GBI /.
MGAY"6BCRBA=CO3Q\G(,S+F.9!VNF)5#5C< ]]4G8D=U?3AP:_O7,(_ZC1_QS
MG5E_A'T?4*O)\$>GZS4TVS^ ?SK^K:DM-_CO[/\ O*B=6_U?^U_NZP)Z BF.
MW\0P?#L/](A_<-2E0]5KR45?L%N0#" %'NZAW?FW[A[OQ69?+D#&W/G^K?'+
MR>:LN'&.8Y<LYY>8\L[;>C';I8XNL#5K*YT7TL@X96")(L2(L,:8J$FS(J8R
M@M5#'(=-XP,K\M%HX3.4AC*J-5&RJRBIIG0ND]]H#D0%)()2#-;3 F*3!^$,
M$-'(%P ZD$X =7  K%U'1;74T'6<22HI,<R'#J-C@[89,[\##OX2I8FM6L>]
MN&&+>SA[2H,C%JN01C9I(IB-W/(;F!)9,XG,S> 0.<6YSJD.4#F076*FH).W
M]'M;TWI%$3:@0748XI[1V!=0=B\;  2Q9(7C 4J>$2(O$O%RSI#H]YI@/7'K
M(6)$5PJGA8_$==RDF!NN2"/@,P5BNV_%,[4+="-G:[*/4>'33 ZYD42.]^4"
M[^<D*1?P#IS]^VP:G)H)T7A\<Q\P 6X0.[!. #S[<8] YK)(HG.X#9P=ADCG
MV\QRW !!/+85<VD."M6B39(XJI)  (J .XBG_F@;O]T4.@[#X"/=L&M)OK,^
M$.S @$Y(( S^.78 :V^PO6:)$XLL,#//&!L?W>3&.RI@9ND2)!S%*)MN\0Z]
M?Z ';W]1,D99CY/-V>?S?54W!-P+Y<'Z?,.W;T;[YQ4.<1,H9'%$P1$0*#R2
MAFBNP@ =G[(HN"AX" "HV3 >@[@([AMN(1%]"S21C'< ,]I.QSY^\8^C.S='
MIE\)+DXX%E;_ )9'KP2>P@'UZL+?67-SKTI66\R\KX2J)V3B09$*H[2;+' K
MA-$RH@5,ZY ,B8P>Z #F$!W HA3X&MS!<6LYG2.>">W=K:=K:YBZU&C9H)T#
M/#-&&8QRJ..-P'0A@I&]:-T@EZ/ZUI/2"WM--U*;1]0L]3M[+5[5;_2KN:SF
M2Y@BO[%W1+VS,B)UUK*W4W$>8I0\;,AQ!;A?Q](XK0Q=LJW(S=EE$9]-)(\J
M2:5$!4DA44(!%%%D@*W%'82%;D30*'(D4 Q="Z'=']%Z/7716UTU7T#4+>\M
MKZRN':5KR.[8F1YYP!(US&W5M!<C$ENT,!B*&&/&\=*_\H_W4NE/NM6'NTZE
MT@9.G.E7.FW&DWEE%X+8Z9'I*+%;6-CIX=X8=.D4S^&V?C07WAE\UTLK7EQQ
MT#RM&VCR;EXK>4ZC<DIW'%V>II9)Q).ST?%GM>PMFLA=*7$.7B(A;HM 8\CQ
M6-9N#O&Y6Y9$!9@N)(N/H]IO0;3;4:)<W"Z? QAFTK5+^.XG>!WSUMA)+U4C
MO;EU7J521UA9,%8E*B+Z;>Z5K/NT]+-:Z7]);'2+3I%K#1SWUWH&E>]MC/=Q
M0K$US<VT3S0I<7:QA[F963PBX$EQ(K7$LDDFS#A?XFHKB2I$]D*JLA;5IA?;
M'4X@KOM0D'<;")QQF<B^3,!/,7<HD]"1*P4+VC1DY:)J@*P',:1M)XM0AEN8
M,=4MQ+%&3L66/A\9E(XE+A@_"0"%90WC9SH%Q$]E-'!._P"4,*2L1C 9N+*@
MX/$JD$9'PB&'FLDM96Z^R1S"W5#8 !3_ "9S;B @578"B.Y1#E.!!$>7EWY@
M#5V)8PY5CPDD;'._=CLY;#)[<;[5Y,LG!QH>,>3F!_5SGEVY.._D:ZFRV,&=
M5GB*& Q5F1D0*(_\XN=-%/H/01 YP]8=1Z==5W4:F"3?&W=WG P?3OCF0,TT
MR9O#K; )'6<7H4%MN1P N^=M\BI6X4K<Y=528AC*G!".L!UDMS"()MW[)N<4
MBAMT)YPU<K=.@J+*#N._3"TB#JM420#/6PE6!Y;'([]^0[]N54=-7$D2$;$@
M$[;91COGS,!YA5SO.DE4P*14IQY=N@@(^D>@#N&_K](ZW$*5)RN!G? [,[>3
M//\ ?7-6((V/+?N^[D?I&.=8S*NRMTEE5!Y0(4PCN/38 ';[/HW ?>\,V)<D
M>H>8<\?4/36#*Q&W;YSY\CGCL'T^2M87$W=HQR1\R473YC%.3E$P;B ;]P;C
MX[^L0][4O!'@#;M\XY@GU#;;;.VU9%JC CGSR?(._P#'TBI+\E/Q.),;1,\,
MUI?E[)T:2M&*'+A4 #F*920M-/2YA_B><6>)2 OS!;("B@%(R1UI/3;1,!-:
M@3GP0WP Y' 2"X)[SM!(?F=MV-;]H-\60V,C9.[VY)QR),D8]!:1?/(,\A7T
M'MU"J("(?Q!$/>$NN=+S'G'UUL3?!/F/U5#>MGK6*:4K,J>WYEW;H0Z)I$1(
M/AS*FYS[>LH)% ?0!_7J-U%_%CC[R7/H&!]9[.RI+3DR\C_%4*/^\<GU<(]=
M5H\H-^]<NW_M>F?_ #7$ZE.A?_VAL_F[K_TTM8_27_Y3-\Y!_P":M?.YKMU<
MUK<_Y+#_ ,D<O?ZQU?\ ^&2FN6>Z'^DZ9\Q<?^9'6\]$?S%[\[%]AZVLZYU6
MWUK'K'E)(NU<3&1^'J/Q,!2XWMN2*5,R#G+5!99.:/,<5=_95+I+8'D3,;PV
MQ%;QCSQ].R+!N;,E("_AI*0A8N+D#.FU@3YD,?#R+#)=0V5!.2F>+@;'BL,Y
MYD"LLVA$22%_AA& X&*X<XP)!XO&O,H<'F =JR;%7E0N$K(6&*[EVPWXN.EG
M])PW;;139V!NKR:K#G-Z:K2F1$>HVJ*(WQ!Y9V4O34;#26<Q"+V6'?1!W+:1
M2,S*6XB9 Y;AV0D$-D%]@!MXWC KD C(-4O:3+(4"\6[A6!4 A-R3XWBG!#<
M+$'!VSSK(6WE%N&R.C;!+WVX)TQDSO\ ?Z95FZ,'?K58+4RQO2J+?K3,J5.#
MHI[/7GT'6K[&2]AK4C$J2%?B474E(KE09RI8SWKTW+'&&91LQ)X5#$X"Y! .
MX(R,&AM9<@*O$>%6.Z@ N64#B+8;)4@$'!.PYC/:T+CWP1><RWC#:5ACV4G"
M.*0OC^5:O7$^CE.JV_!M4SPZO<0RAXM=6OTNM5:W1:$O9YY="OHN'48"\JU<
MS48Q7]69&<ID9&.'?/$"@?(QR !W)V\N]>-;2+&LF"0>(.,8*%7*<)R=R2#@
M#?8[;9KLF7E N$60KCVSM<LF,R96JITKV+6H&3VMQD;)?(60LM*95_'[JEHW
MNSM[56XB8L<#*URN2D1*5^'EYMH_5BXI^[;A-$1GBVR%^"V26&5P,9.1D@@$
M$ G. :\\&GR!P<PQSQ)P@*<-EN+A7A) ()!!(&,USXGCTX19UYCAC#YLKTDI
MEE"*=4=RSB[2M%OFMANLICBL.9J9) C$4YM;[]"RM/IB]S?5]*XV)@XBJP>6
M=D[(?>NC)4!P>+&-CC<E1DXP.)@57..([#)KPV\PX\QD<&>+=<C"AC@9RW"I
M!;ASPCGBK=ZN59J4XWYWL?K1O\436N3_ )^;YV3[;5M5O^CP?,Q?86N/-_.I
MY]03XU/5=I^D1?UOU&K=[^BS?U1]I:C36P5K-?ANA3#ZA_)I2HDR"X%-BXV'
M;8@AW^@OP>OQZ;^O5$A\7T_CR]W+>K\(WSZ]^>W+]?K[JU:YM>B*JX<W=S]/
M[^OOV]?OZCW.P'E_5^^I./;S!=SZO./I[]ZUF0!A?W.UF$>8WLS)(DWZ^Y2>
MN4@ ![M@ H;  > !UU]@=&QU?13H\HP![QZ8V /CV<+.?/Q,>W<[U\[]*%SK
M6H''/5+TL<\\7#@=F>0 Y]OIJT-";@)$?^ER]!#?KOW_ (NGP^&VK-XVY\@W
M./-^H[^7NJ.X,8V\N^=L _J[._F.VK.LJZRFF -'B1%$U"<H@8 $.X.H=_IZ
M]>[NZ]-:S<2'B)V.^?+CF?JVY?KJJ(%""N1S.<\_)]'HY\\&H<MO"U#S+CMV
M*)$Q.;F$"E -]S>H-O';?;IX=!$=8AN,;'[^SS ]V,_>#,V]RRXSG.-]_+W$
M^4]H]%2K0,#0E1CP5,V(=TDGS<XD#H(!W[CX^.X#T[@'IJP;@M( >6<>CU9Y
M;]QW[>7ES([Q2;$#A/G/DV\_FV[.54UXJ*?.6>>L<-!2HP;QQ"PK-*2% ZHM
MF#A)8JX-RE,F(F,H*Y 5 P"D<QQ Y3% 2[*D OM&O+(7=YISW4-S;B_TYX$O
MK0SH8_"+1KF&XA2YB!XHI'@D".%<(2H(G^@6N0=&]9Z/:S=Z+I72.VTW5$U!
M]#UL73Z3JDMA<17"66J1V5U9W4EC<!%2Y@ANX3/#Q1,_ Q!KTTX6:D\Q*;':
M:@$>E6/)C9%DTQ<C.J=F"D@H  4.R*DD1LDCTY&B291,8X"J?4NC7N?]%>BO
M1*\Z$6]G+J&@ZG'?)K U"2.6]U9[\%9KJ]FAB@C-Y'&D"6T\4436W@UL8N%X
M@Y[U[H?^4[[J?3[W9],]W"\U*'1NEF@/I Z+VNA1W%OI'1JQT7B>STG2;6ZN
M+N5=.FGEO)]0MKBXN%OI=2U!;D-#<O"*XYEX*G.,\?-<T4;)A*3EO&#9>399
M%=O&,%%J11#@(URP+.S-6+JJNRJ*-EVTRNY23!X)>9=IVC!>*TKH%I71CH];
MZ;IFNZE'=:")9-%U[6[BRZ^ULR.-=&O[BWMK&";25<R"(3QEK59RH8VRK!4/
M[JGNXW_NV>Z)J73+7>AW1G0KGI-':1ZYI/1*UU2*QU'4X5:-]>%MJ&HZK<1Z
MQ<Q"!;M[:6..Y:V6X:$7DL]S-D7"1QV1'$C:(C'1Z\E6[Y%8[G[!>E64DDK7
MC6&!L<#!I-:D*2SHLK&3#22?3YEO.5BQ2";9@1U*D[21U+=&>F4>N7$>G/$L
M5[#9SRWPCE22#K[>Y@MU6T=&=+B*99'G+H[JB*BAY0>L/*]=Z,/ID,ET9#<6
MTEU%%:AX\3]5-%)(3.2JM&\;(L7#P@R$LY6,C@K8.WL:C-4221?E)C !726X
MB0NP=54R%#F#<1W.D CR[#R&W$=;SP"0;;,.0[_H'J[\"M6-MP@&')(&ZDY'
M;R))(/9AN1VV.U8!F62CY" C$&KQLZ5]D@<D!!9-400(T<$5$P$,82@)UDB[
M'V]T ^)1 ,O3$9)G)4J. J<C&264CF/(<X[,8VYY=H'!8L"HQR((WSMS\@/X
MYV7X<4E#XEKY3A[DB\Z5'O\ \G[.2!Q'O';Y:=3P  \/2.%JC!;R4CM$>1Y3
M&H/T#U;9K4M:0-JLY&,]7"6\IZI5&?\ NXJ854Q3,(==O ?Z-8J-D#EY/-W>
M@?1Y0:@V4JQ'GQVXW.V?QY^0KKW@;I&][\8;CJNO%V?/F_7GZZB2R_*^8_J'
MN_OX;_!N.VLZ D =H.!Z\;^O%900. !LV=CWX(._DY>0<\&HEK9R+Y>Q$("!
MCI9.HXCMO[D#6F'Z#OW#N7N[PV[@$0UE:GA='U8#.^F7_=_)91G]8QMY>52V
MC<0O;4,,9N(/6)5SCR;X&#W[XVK?SKYWKK%-*5GM/;[(NW0AU44(@41]"9><
M^WOBH7?PW+MX#J)U%\O&GQ5+'N\8X'V3ZZEM.3"R2=[!!YE&3Z^(>JN!ES(3
M+$>*,G96DHYU+QV,<>W3(3^)8JI(/9-E2ZW)61U',UE_E"+IZA&J-FZJWRI-
M54AU/< ;4)>W2V5G=WKJSI:6MQ=,BD!G6WB>5E4G8,P0@$[ G?:MQZ*:!-TK
MZ4]&NBUM<16EQTEU_1M @NIU=X;:;6=1MM.BN)DC\=HH7N5DD5/'9%(7<BM#
M?_C$V%/I=LI?]IJGKG'_ +4-/_\ NN\_WT%?<?\ _#]Z9?\ ^P.C/_ANJ_?5
MUN!?RJ&/>.C*%GQ?4L5W*BR%8H3Z^N)2QR\)(,W3-C8:W7CL$48SY>1R=>R(
M."J'^5 DV5*/NSDU/]'>F-KTBNYK2"SGMVAMFN2\KQLK*LL414!-P<R@Y.V
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MN-/]YQQ9_P#NSYX__:VU:@=?_P#D6M?[)U'_ -'-74/<;_TO>Y5_^)'0;_\
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M'02&'[)?7W==^[<!V^'5N3X/?O\ J-7X3OCS]O+[_-Z:U9YK8F!5<VP]ZGO
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MH9JI%+NB#FS*OK(%304I2%*0H;%(4"E#T%*   ?   &M:))))W)))/E/.ME
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M%<X!V/,8((W\U1&]X%N$I]CJ#Q4?"-6:4JMVB9NL*UB',]!3C*W61DYB[+9
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M]WU;2>!7<]I-#:WO!&K2'P>9TDS$K2QXZR-6D114"8FPSQ$>SK.,B<?*\/\
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M%LUFB1A:MI"$\_(MB-8ZB%,UO!*99$L(IF66 R\,6G%)1$%>%$"WX1F42*O
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M;7'Y5B:-!6?A]+?"V.ZYNIY[6UA\;YX;97/%OKS!4*]%E7MYL&/I2:C(GS5
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MM6Z1$4BB8/=J& H )U3B4!444$RB@AN<YA#<+K%YGZR1VED;FS')P.7/D!R
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M66V4@,W$TK@%DCBZAHF@^]5E<7%R!X;/!(O#L1;QE">J!&<R,0#*P)4$!5)
M9GV)Z@JQZEB ;^;Q+0HAL90@KF\!$5A%0N_O$$@?!J NWX[B0]BG@'_=&#].
M:G[1."WC':PXS_WCD?017<:QJR::4II2FE*:4II2FE*:4II2FE*:4II2LZJW
M[B<?71OB4M0^H_G4^;'VFJ=TO\Q)\Z?L)7QNZQZRZV!\-,Q#UO#3]YD>;Q!"
M4"<RD^BJP&0L'/,U2CV\-:Q7CS"Y&R4O%H5R!BX=]"=J^3!T^=KR#M)%LN1$
M2EI(WV&3CO(VW[N__'LKT<NS&=M@=]L^8<L_0#51LR0<Q6<KY%K]@CZY%34/
M<9^/D8^GLB1M4:N6TBNF=.N1R8%*QA!  /&LQ(F=LT,DBHFFH0R9:AR'FKP\
MSFOIEX-?WKF$?]1H_P".<ZLO\(^CZA5Y/@CT_6:FFV?P#^=?U;4EIO\ '?V?
M]Y43JW^K_P!K_=UA^I2H>O$Y0.42CXZ4K$9J%(\34*8@#S /,&P;CZP';O'I
MN'3?H("'AX0#M]/;^/WU4C%3GUCS<CZ.8[^VJQWZ@)'36/V91*(&'N#T#WAT
MZ]=A]X=^O36.\>.0':1W^;;ZN6^W*LV.3(R,;^3]_/<_5V503(E'1:N5E 2*
M =>@!W#U[MP#U^@/#T:Q'7F1Z?O_ !YZS$;.!W\COV=F^-N[ZMZUCV?*$:;*
M3OV/63"-J0K0:;H@E ';Y)QO*+%.&P&03<I@S1V$Q#^;'73$2.  .S]$=&DT
M_2%EF!$^HE+ED(/Y.'AQ;H0>3E&:1CC(ZP1D9CS7/ND5ZMY=]5'@QVO%$I^/
M)G\JP.-U! 48R/%+ D-BI>;\43TJ(-8=G+3!T  AB13)[('*( &P&(R16,4=
MN[< 'N'QU/2&SL\/=W-M;AMPUS/% I VSQ2L@[QMV8':*UDZ?<W>1#;R2G)&
M(XY)"/,%4XVSW"LQI?$S[/21H=^B\8OTE4T5F,@W69NT3J%(<@*MG*:*Q.T(
M8BA!,0 43,0Q?<F PRMG);RQ+<6T\,\+*Q6:&1)8GX25;A>-F1BI!5@#E2"#
MXRG&KZMI<\$ABEBDBFV#1NC(XR =U8 C(((R-P<YQO5H_;*P1:(.'"Z13*E*
M;L]]A ! !#O$/3^,/3K*CN%D)"@X&=_-S]6Y\O+:H">PF@QGM.P([/HSN.WO
M[:P^7R;5V_,@Y<I;]0#94"G*/I*8ONBCOW[#L/<("&X#=(XQ@J""-L\]QV8S
MZ]O-5"6LV0PSMS 7GCU[9/?M]<6DSY 5^:D8]^],HF5 B\>OO^Z$%R;D$.H%
M$Z2I5$%.7;F42,8 * @4*SI3W<<;0$'QB'4MDKCGY<$8(R,8/;@UEPE8BYG!
M!X?%P.>1V[8W.?+GNSBK%U=<92+:/C',+AV@F[6(H(@= 7!05*WY!Z%.B4Q4
MU #J*A3=>XH6&6& E3@E24#9.#PDC8]VV?+GU83++*25!5>8&PV.<=G/&V,5
MV3F0;-#BFNX*0P>'-^,!W[O#W]5 QD<0Y'R[^K/X\V]6C%(I(()QCN[?5^.5
M=JRG(<J0F.Z3$0*(@'.7;H'O[C_1U](:P;AB&PN?)YO1]6W//FD[> D#((YC
MEG_$XV\G<=JHIQ6Y&(SAGY&+KD$J"O()#@&VP#L/0>H;_!L&WJU>MRQ&YP<\
MN[/,9VSV<N1/F-2MM:+QKD=NYQG]VV<8_=G,\=<)U)E*Y!+3M+CI9X]BV#J1
M>2J"KM\L\=-4EG1SN5CBLGS+**""*)D44P]PBDF0I2APF_Z4:]+?W4D>JW44
M0N)1#'#)U<2Q+(PC58T 0@( .)@SL=V+$DUW.UT72H[2%&L+=CU49=W0N[.4
M!<EV\8<3$G X0.0 JVF-N"#AY;OFSUYAJG23@BA%=IB/5F6HG P'#F82J[Q@
MH3</\F=L*8E]SR<O35L]*.D<HX&U:]X3L>"3JVQCX\85\X[>+.<9.]>^\^DQ
MMQ+8P9!SXREQY,*Y9<;]P'HP:VPT^-1C(UFQ:MT6C1FU1:-6K=(B#9LW1(5)
M!NW12*5)%!%(A$TDDR$(F0I2$*   :CLLQ+,2S,269B2S,3N23N23VG<\R35
M;<(("C 4!0 ,  ;# [/-R'9M4@ &P 'H#;2J:\3_ #!OJ3?D'7J\QYQ]=>-R
M/F/U5"0 (B   B(B   =XB/0 #UB.MG)P"3R&YK6.?*IG:( V:MVX;?*44T^
MGB)" 4P_"("(^L=:U(W&[O\ &9F]9)K98UX$1/BJ!ZAO]-<C5%5TTI32E-*4
MTI32E-*4TI32E-*4TI32E2I'?.]C]9M?B":UR?\ /S?.R?;:MK@_,0_-1_86
MN--_.IY]03XU/5=I^D1?UOU&K5[^BS?U1]I:C36P5K--*4TI732C(KA(Y1 !
MW 1#I[^Y>[Q\ ].E>@X.?Q^,9_ JHV4Z65PFX,5+<IP,/S/3<?$>FW4![O1\
M&L61"#D=O9SP-^7U>4^>L^%\X&^_F[>1^H']>*UG9.I1FJ[@HI;D$3AU+N E
M][;8=MQ 0'J(#UUB,.$Y&W:/(?QO_A6:C9V[AW[GGFM==I92>([?[:8Q-3VO
MR+D!E$4P-R,W!S !G E#IV"V_*MT+L8>?<1,(E[E[G?2I+NW70M0D_+PKBQD
M=OSL(!)MMS\.+!:'GQ19C&#&@?2>D^BB3BO(4\1_SZKL4D_@S  <FY/MLWC'
M/&:[7'O"MC>Q0U-&CW2ZUP\)8,3. ?*V1W*2<33\32EUEZM5:FX,9$L(6.<7
MF5!@\72DD%42IIR[.4%1YYS(ZCT0M8%A%E/<QB%[+@=Y6D:.WL'NGM[> ^*(
MA&;J0*2'!  D60Y+0$6M7:S2B[A@DZU+LX6)8TDGNUMTFFF'C<;.+="Z@J0Q
M)0J E7<A^ _!2T25DV6O;6,5A*#&OTF]K\\2EI#&]\LV2:W:;"RF8^58SEC"
MTW6WNY!Q)-G41(%L+T5H@CE&-<,=8N=#LE_)J)D\2%&'6EA(UO-)<)*X<%7E
M,LTK.2"&XVRI/"1+0:M=,0S&(DM*RYCX>%9HDA>-"I4HG!%&% PR\  ?!(.9
MU_@6X7*V:,69UV<5=Q=7BZ(E(.[&Y5DW-!CJM?:4]HTA)D22?OJK8JWD>PL;
M'%N7!R2;E&#F>T1G8&,DV^&G1^T4J1&^518@2228E26,Q$[DHRS.'4\R%;9T
M4U<FU>[/$.-3EFDP$V$I>.02!2<<:/"A5@,J"R_!<@YO4^&+"-/PGD+A_C1M
M*M$R>Q<QMI6<V$$IU1@K QU:;-&#^+91K1DBPBHMHF4A8\X2CHS^0L7LV_F)
MEP_R8]#@CM);8"0QS*5<EL-P\*I@, , *H&.$Y/$7XBS$QLVK7+W<5T2G6P,
M&0!/$SQ,Y+*Q))))/,$#A"\(5>'H(S@HX=(VOVBN)HVU=C<*=DZD3IU;$B@H
MM"Y?L=(MMY\T1CXUBPC7#V>H$"\CTXYDV8PR1GK",8MHY1!HVM+H%L$DCQ(1
M(D\39?!X9WC>3 "@ EHEQP@*HRJ@#8>/K5XSI)F/,<D,JC@Y-;I)'%DL[$@)
M*X8L26."Q+9:LVJ7#UBC'^4C99KKNYDF4'V5Y*$K[^V/G]*JSS.%CB;AE-6L
MUQ<O8QOMOML,WL3TO;K%;R"[I./*T8*)LDLN#188;CPA.MX\SE4+L8T-TZR3
ME$W4=9(H<[[-RP,"L"XU2XFMC;.L7 1;J\BQ@32"U5X[<.X."(XV*#89 '$2
MVYB>_<(/#[=(>L0\NPL"9*?;LPW"(D6<]V,HFXSS=G60<H1!WBS1P*438;*X
M0<(*,4F<Y!IQL<6!FHQ9 ZZU_P#[/6DRQ*ZRCJY+F1&5\,#>2F>X3BQLKR$$
M8PZ87@=2,U;36[Z!I'1HR98[6)E:/*8LH1#;OPY^''&"""3')Q-UB.-A6&5X
M+HJ8R=D"<NER;N\4V=IG1O"X[JXW*&4B5\^3%9G;5((K2EUGX:%DT96!=2[I
M[6(>,1GYZ3]E#,89FT"&<W(>BW6W5Q)<3!K.1;]4MH1/&5-^\+RMEII%1PT;
M.6C11)(_&511P-4_2%DM8([>$B\B>Q9[F7J7#>]R2I$I"P1O(A20+B5W,<:\
M(:0MQKZ;?PL88E6$NUEWMYF'DRM>7LM-R=K4=R\C*9#DL7R]GD':JC/S)P9W
M)8@IBY(Y5B:#(V1DHD\2K"R*T<$]'T2L)D99?"7:7PCBD:<EV:Z>RDE9LJ5;
M+Z? 0A5HB!)&4,3E*CEU^_B=&C%L@C%N$C2 "-$M5O(X4&_$.%;^X!8-UN2C
MB02*KU!\MPXX?B&)(Q@K:D6*3"9C7+4+#\ID&TSDU3+RY7Q2LR@<S6\+O)%D
M+<&Y6[=XNQ,55L5L1"9MNAVFJBQCPH)P21LHGVD674!J9XQPX)6[XI$*\.$9
MDP5QPV7U_4&<N?!V<O&ZMU.\9CL?>\%3Q8 :U"H_%D,45]FXLPV]P'07\L,9
M#,;3+N7[XB59@2S3^0;UT'5_A\E/8BI,!*H9@QE[E 1,B^;F%T<&[%&.:K,X
MQ%-N24/1;0K.&XNKN2:*UA'7!KB\86^G0C4;?5YEM^/Q(8IKVU@DE#%V*QK#
M&4B 2JH-7U:X>&&&.%IWPC=5;+UUY)X#-IT;S<.#))':SRQH0$'$[2.&D):M
MQ?!AP71.*DUK)-L_/;=.3UBM78+K ^;UI]<)A[/3*;)40$BCU=[).@6=I@9-
MJ@?V/8'% JSE[Q'I7TN&I>$:/H9GM]">^O;V8NS"74KJ\NI+N:608#1V@GD9
MK:U.#CA>8<81(>D:1HW@BPWFH".345MK>VCX0."UAMX$MXT4Y(:8Q(%DF W\
M9(\ N\FXZNU\L;$N!Y.42,UA$=A#J5$VWV1#N\ ]\0UIULH66+L_*)W';B7R
M_K&>WL-2-V^89<=D4G?V(<^3GL<'R;UP6Z)G"Z*!?FEE4T@\>JAP* _!OOK9
M78(C,>2J6]0S6KHI=E4<V8*/2<5-!"E(4I"AL4A2E*'H*4   ^  UK1)))/,
MDD^<[ULH   '(  >8;5Y:\KVFE*:4II2FE*:4II2FE*:4II2FE*:4K.JM^XG
M'UT;XE+4/J/YU/FQ]IJG=+_,2?.G["5\;NL>LNMLW"S$5B%H$K8*OF;)V/*$
MDFPFKC:,A8EQ>^Q?#WAG'E1,>JR%OG95S(69)<#1T>-7AUYQXD5@209$*#4B
M5#<\$ D\ADY(\NWIW-5#SD#R@8SY,GGYAFM9F17K&2OUTD(RS2ESCW]HG'C2
MW3;91E+V=!U(N%R3TDT6$56SV5 _GKA!791)18Q#E*8!*%8Y#L\G=5)YGM\O
M?7T^<&O[US"/^HT?\<YU9?X1]'U"KR?!'I^LU--L_@'\Z_JVI+3?X[^S_O*B
M=6_U?^U_NZP_4I4/32E>AP "F([=0_XZ4J&;TJ4K58 #OYN[H  /0/#P'T>G
MT:MR' ]9]0/W_P"/9D0CR]NW/S]N/+O@CRYQ6BKR@&3LX4]S7ZIBBD3SQG;6
M[A.0O$'#OIYXR?&<';IUR+;L6[D(N470Y72<@Z2.LNFN!(@$W3-RX0VSH=I&
MAWTEQ<ZO>6X-HX,=C/*D"2(!Q&>4R,O6PJWBF-" I7,O$CJC1FMWNHVPB@LH
M9&$P*M<QQM(R-G'4H%!X'(P0[#.">K'$I*Q/P[<#KUM"M+5EU@H\L#\I';6G
MK*&491"2@<Y#3H)F$LE+* /,NR.HJP: 84ER.W',+?,Z2]-)9I7LM$D-O;1Y
MC>]5<2SD<Q;L1F"$<E=<2OC*E%V:UI.@I&BW&H())FPP@;=(\Y/Y4 _E'WW4
MDJN2K!S\&TUAQ,,8P!JPCT6C5$@E1;-&Q&[=$@;ARD11(1),H;]Q"@7J'37.
M93+*[222/+(QR[R,SNQ[2S,2S'RDDUM2%(U"(BHBC 5 %4#N"@  >;%4#R3@
MNW-[J:ZU&8;1[Y5!NB_CI-!SYLNNT**2+I)VU[15$PMP3152%JJ0>Q*J4X&.
M8NMZZ-=,XM&L#IE[9RSP++))%+;NBRHLIXGC:.0*K8DXG5Q(I'$5(( -:QK?
M1HZI<B[@N$CD:-4=)58HQ0%5967)7(PK*4(VX@<Y%11,9AO=9E7%<N@"TE&S
M<BS<4EU%63QF?G(D\8+F*F*[8YR*)[G22635(HBJDDJ0Q ZSH^HV.JV2WNGR
M%HF<HZN@66&08+13(.()( 0VS,C*RLK,I!KFFK:-<65UU%THXP%96#%HW0DA
M7C) X@2"N2H*D$,H(Q7?8YJ$AFF)F;,]M,XS(QFEXE&/A5VB!FW8-6;H%WAG
MC)\90[D'0"@4A$DRID,(F6.82HZATNZ6ZCH5_!9VEK;.CVRW#3722OUA>21.
M"(130\*IP8?)+$D8"+N^T='.C&GZA9R3W,LH=96B$<+1IPA41^-B\<A);CR,
M8  WR<A>38,366M%3DH"=?3;V,.+E"/LR,<Z,L*?NA28O6S%F+)T82@*)SI*
M)G4 B:AT $5R1>D^Z5<^$)%J=M!#;2E4>>P-Q&8LG'62Q2S3B:, ^.%96"Y9
M0Y 1L[4>@=FT#-8R2-,@++'<]6X? )X$=(X^!B?@Y5E)P"5'C"><3<0C8:NF
MZ?.Q*86H&]T?W7,)-]A#PV'X0]74-=&NED9P ,[[G'(=N.?/]1QBN>QV,:\2
ME<[$# SV^<[#Z3Y.4<V3.5TNDVX9T6)D9DK504W+Q P(1S0X@!^1U).#)-"*
M\@@<&X*F<F((F20/MUQKS6=-T6 -J%W% 7!*0X:2XD'+\G!&&D*Y\4OPB,'
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M>L@/CO'W;;GEL=O.>6=JS")Q>V @ HD'-L ;<NX[#Z@]'P>O5Q8N_GY1G?\
M?Z<;\N54-,,XW/+GGM\O+ [?QG@V+%399NH":)=^40$.0/7Z0WV]0]_I]/C1
M=H[_ %YY]^/QMBBS;D^4^?S^4>7:J>9 PT43K&(UY3;F'H7H/7U=WI\-^F_H
MUCN@S@\^P_C\<ZRUD\N-MN[T=W;Z]N=4<S3P?I9<B$&:#H*_9X995Q 3HMQ<
M(D%7E\XC9% ADU%XU[V:0J"D?MVBZ2+I$%"E7:NMBZ,](;CH[=22!/"+2Y4+
M<VW%P$E<\$L;$$++'Q$#(*NC,C<)X72,UC2HM6@16;JIX6XH9>'(&0 T;C(X
MDDP#V%& (R,JWCPN<+&3</O;DMD-W4G4-,1#9FT9UM])OSO)1H\[5O*N"R$1
M%D:D;,U'K<A0%1=4STP*$(1$HGE>EW2'2]=@LULX;E9X97=Y+F.-.")T >%>
M"67B+.$8G95ZOQ3XVV%H>FW>G23]=)"4=%4+"SL&96R')9$X0JEAC<DMC;&\
M"\7&88'$;I6G1C4TC>9:+.[03 038P#)X9=LVDGZOS:SDZB2RC*/1*!E"H]L
MZ6;(';^<V>B71"77)1>W#B'3+>=5?^%+=.G#(T,0QPJG"RK+*V>$MPHKL&X+
MNMZ\FFH;>)3)>2Q%E)/B0JW$JR/WME24C'/A)=ERO'3/AMQ7?<YV1M4JZ#YI
M5(XZ2MNLJ:9_-HN/$0-YFW6, HJS,B4#(Q[794R>YWJR0M&JXZZQTDUNUT*S
M:>3@DO)019VI/C228^&ZC#+!$=W88!VC!#L"-$TC3)M2N1&.);="#<3 ;(N<
M\*D@@RR<D&^Q+$$*:W8,>'N/JT SB86+181\>W[)NV1)L   ")U55! RCAPN
M?F6<.5C'7<+G.LN=14YCF^>[NXN+ZXDNKJ=Y[B9N*21]R>X+OA45<*B* J*
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M1]I:C36P5K--*4TI32E>A=$%2" @ [AL(>D/SAX;[]VE*BJW5)&114'LP$1
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M2.KO_:OH>FYURQV/892?4L1)[?3@>0VO^SFMXP(+G'<40[>3B?&?5CF!V'C
MRR))"((U\R &[CN'S4A0] "4KD5.GCL3NZ;==M8TO3_H7;C;5.O89/!!8WKD
M]F SVZQ;X[7JI.B.NRGQHY$!W):>V3!\P=V_X3C//-=O'X<OD\H7SZ081J1Q
M#<&J;A\N #X"0Q6B7,._@N</'N[X*\]UO1(@1IVE7]Y(,X:X:"SB/E!4W<F.
M_BB0Y[*E+;H/=C])O8H@W/A,MQ)C&XPW5(O=XK$?0*L%0^%:#[=!S,MWD^N!
MBFVE#@+0#=-P*P2*DW.F/BF[\[+U][;1-5]TOI-J2M%!+#I,#>*4L$(N&7?X
M5W*SRHPS\*V\'. -LYSL5GT5TFT(>2-KR08/%<D&,$9QB%.%"-^4O6;UL"Q[
MB)NQ2:HMV*2"*)2$3321*FDF0H; 1-,A2E*4H; !2E H &P &M%/63NTDCM)
M([%GDD9GD=CN69W)9F/:S$DG>IXLL:A4"JJC"JJA54#8!5&  -@   /-RM[5
MJ<WCDR#V0%$O+N/*'Y-NH_8[^O=K(5 H[]L<MO+6))+D[=A[_7Z^1SR/+MJ4
M&[8B)"@!0#8 V#I]DWI$?'['=TU75CG7A)?.Y_\ 63KXA35R'\[%\XGVA5J?
M\Q-\U)]AJQ>G-]DWCH0^:.FW(/HY [10/AYTOL:S]1?QHX^X%SZ3@?4?76#I
MR;22=Y"#T#B/UK6:ZC*DZ:4II2FE*:4II2FE*:4II2FE*:4II2FE*SJK?N)Q
M]=&^)2U#ZC^=3YL?::IW2_S$GSI^PE?&[K'K+II2FE*^J_@U_>N81_U&C_CG
M.K+_  CZ/J%7D^"/3]9J:;9_ /YU_5M26F_QW]G_ 'E16K<H!Y9/[O[ZP_4I
M4-32E! !#8>H#I2NO78D5WW !#U]X?#Z?Q?".E*X18=$#<P$'?\ Z6VW>'HV
M^#K]G2O<GO/X^JNR29II@   !ZB@ !X>KJ(>GO\ 7I7GX_'[J\'#)-8HAR@/
MIWVW^ ?[_8Z:4[L?C'XY?X5&MBIK:0*?=(H[@/7E#OW\0VW#;[ ]W38=4,@(
M.V_JSGG]&=ZO)+CG^-N[8?6>6Q[8F<XQ3*J8Y42B COT*'X^G3T[ '0=6C%G
ML\F?-Y\9&^/,/35\2Y[=CWD\^[&_>.[S=E8Q.4PZ3<Q"HCT*/AOOT\.[NW][
MUAJADQG8[?1CZ^SEY]^VH.,C!WW^G._G\GFR,U3F^\(V*,E6DEHN>/8>?G4V
MZ#+V0>D= HJU;G.=!%RDBX1;NBI"H<J9G**QBIF[,#=F %"2L]=UC3H#:V5_
M/;0,Y?JXV4 .P 9E)4LI.!GA(!(WW%8\]A874@GN+6.64*$#MG) R0& *A@,
M[%E.,X&U6>Q5@NN5*,:P]<KD378AL BA&PT:TC&*8GVYSD;,T4404.)0,HKR
M=HH(<QS&-N.L.66XNY6GNII;B9\<4L\CRNW: 6<LQQN,9( S@ #-75$4"".&
M..*,$XCB544=I\50/&VW.-^WRS5+8Z;G9&*1$HFY!#8";>GTAWA_??OU28AC
M;&?-^,_0>[!HL@)&YY'&>S!QW#&^<\\'<8J!9+&(@],8&_\ G[C[D/ ?2'V0
MVV^'QLE&![_K]/=5Y9-N\=^^>?EYUGU.Q)5CRK.<DZG7GTNQ416:2[V#C'4F
MU60$ID56S]PU4=H*HB4HI*)+$,F(%Y! 0 =9<,URB&)9YTB8$-&LLBQD$8*E
M%8(<YWVW!-8\JQ%A(T<9<'(8HI8$9 ()&00>6_,=_.WL8EV2)"[;"!>O@.XC
MX^'</J]>JJQCC.V?3SKM=*\II2FE*\3_ #!OJ3?D'7J\QYQ]=>-R/F/U5CM6
M;]C%E5$-C.5E%=Q[^4H@D4/>^5F,'U6_<(:S+]^*<KV(JKZ3XQ^T!Z*P[!.&
M -VR,S9[< \('K4D>?NQ62:PJS::4II2FE*:4II2FE*:4II2FE*:4II2FE*E
M2.^=['ZS:_$$UKD_Y^;YV3[;5M<'YB'YJ/["UQIOYU//J"?&IZKM/TB+^M^H
MU:O?T6;^J/M+4::V"M9II2FE*:4II2O0L@54! 0 =^\![A_,/KTI6$S-6;/B
M& R8#N [@(!OUZ[CX#W^_OMJEE#<_P >3MVJXLA7M[,'U\_+W'U\S4)V+%Y%
M^T%)(![^@EW$/A[P\?Z-66A&^V1GR>8#'+S<SWUE)/D8V\^^WT[#]]038<.]
ML)^=MOU'N)X^H0Z]VX; /P:LF,C/;Y//Y#RQW<AGU7A+^_'<?)YN_P#PB62P
MD B82H" !UVY-_$?2 :H,8&V"/7O]=7!+Y>78?QD^@UB3C":H"/RCQ'_ )L!
M[^_??O[O#WNNV^J>K'>?)^,55UOE'ZO7G\8/<:X0826W_<W_ .F'Y!';X ^#
M<=M>=7Y?H_?7O6'GMCU?KKLVN$U!$ % ?#_, -Q[]O\ CW=1U[P#R_1OYJIZ
MP]X[QG;//UC?R\N_-9I%82*!BB9N(]W>7?\ ,.O1'V8R<]N_K&WI^NJ3+G;)
M]6.7HS4O5_#9$Q)LT -N4-Q(&WH]'7T^/XNEU8R=L;=H ]>WW_35MI1YN?/?
MO_<?/MOVSQ7,8MVO9B=$!VY>@% .X.@;>'4._IUW#J(ZOK$.W;ZSW^ONY>2K
M#S;<\^K8^O'('R=V^09FBJZW9E*!4B@(!W  !MZA-Z Z;@'X]70 .0K&9R>W
MS^?EOWX&/.<YR*RI)$B8   &X=VP; '@&WY]>U17NTI7"DOG<_\ K)U\0IJY
M#^=B^<3[0JU/^8F^:D^PU<.OM_-XEH40V,J07!O7VQA.0?@3$@?!J[=OQW$A
M[%/ /^Z,'Z<U;M$X+>,8P6'&?+QG(/L\/^%=SK&K)II2FE*:4II2FE*:4II2
MFE*:4II2FE*:4K.JM^XG'UT;XE+4/J/YU/FQ]IJG=+_,2?.G["5\;NL>LNFE
M*:4KZK^#7]ZYA'_4:/\ CG.K+_"/H^H5>3X(]/UFINM*"ATFJQ"B9-$RQ5!
M!'E[4$A*8=NXORL0$P] $2AON(:D-.=0TB$X9@A4'MX>+('E\8''/&3V&HS5
M49DB< E4+AL=G'P8)[AXI&>\BL*U+5"4TI32E-*4TI32E-*5ZSI$4[PZ^G^_
M]^HZ4K@JQZ1]QY"C\&P[?BW'^_=I7OI]?:/I'8-JQV0@$G!1 2 />'*(!O\
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MT9_\/U#_ />U/_&"^.'_ ,T^';_L'=__ .)^G_NW= /Y9TF_\1L/_P!TT_\
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M?.Y_H_8/[5/;))>E#[E_:T\ M_Y_M?NI[YW/]'[!_:I[9)+TH?<O[6G@%O\
MS_:_=3WSN?Z/V#^U3VR27I0^Y?VM/ +?^?[7[J>^=S_1^P?VJ>V22]*'W+^U
MIX!;_P _VOW4]\[G^C]@_M4]LDEZ4/N7]K3P"W_G^U^ZGOG<_P!'[!_:I[9)
M+TH?<O[6G@%O_/\ :_=3WSN?Z/V#^U3VR27I0^Y?VM/ +?\ G^U^ZGOG<_T?
ML']JGMDDO2A]R_M:> 6_\_VOW4]\[G^C]@_M4]LDEZ4/N7]K3P"W_G^U^ZGO
MG<_T?L']JGMDDO2A]R_M:> 6_P#/]K]U/?.Y_H_8/[5?OMEDO]'^Y#^GIX!;
M_P _VOW4]\[G^C]@_M5Z7-JDD&[A?9N/8HJJ[=D/7LR&/M\WX[:J33K=G1?'
M'$RKGB[R!W52^JW*([XC\16;' ?X()^-Y*]H6:1, &#S<0$ $!!(=A 0W 0]
MWXAJDZ? "00^1L?&_=57OG<GEU?LG]JOWVRR7^C_ '(?T]/ +?\ G^U^ZGOG
M<_T?L']JGMEDO]'^Y#^GIX!;_P _VOW4]\[G^C]@_M4]LLE_H_W(?T]/ +?^
M?[7[J>^=S_1^P?VJ>V62_P!'^Y#^GIX!;_S_ &OW4]\[G^C]@_M4]LLE_H_W
M(?T]/ +?^?[7[J>^=S_1^P?VJ>V62_T?[D/Z>G@%O_/]K]U/?.Y_H_8/[5/;
M+)?Z/]R']/3P"W_G^U^ZGOG<_P!'[!_:I[99+_1_N0_IZ> 6_P#/]K]U/?.Y
M_H_8/[5/;+)?Z/\ <A_3T\ M_P"?[7[J>^=S_1^P?VJ>V62_T?[D/Z>G@%O_
M #_:_=3WSN?Z/V#^U3VRR7^C_<A_3T\ M_Y_M?NI[YW/]'[!_:I[99+_ $?[
MD/Z>G@%O_/\ :_=3WSN?Z/V#^U3VRR7H;C_]T;^A33P"W_G^U^ZGOG<_T?L'
M]JLMB9 9%KVQB FH0XI*%+OR"8"E-S$W$1 I@,'01$2CN&XAL(QES!U$G""2
MI 92<9P21@X[01SP,]U2]I<>$Q<9 5@Q5@,XR #D9[""-LG'+-?S M?K!7Y4
M4TI32E?T)/)C_O ^%7_9/#?[R^U^;/NK_P"D;I?_ +8F^Q'7Z0>Y5_H[Z(_[
M'@^U)5O+9_ /YU_5M:CIO\=_9_WE;1JW^K_VO]W6'ZE*AZ:4II2FE*:4II2F
ME*:4II2FE*ZR7FH:OL5).>EHR$C43IIJR$N_:QK%(ZQP31(H[>JHMR'54,5-
M,IE $YS 4H"80#7A(&Y( [R<5Z 6. "3W $GU"O1'V2NRR;!6*GH632E4WBT
M6I'RC%XG)(QYTTWZK [9=0KQ-BHLDF\4;BH5L=5,JPD,<H"R#C!!SRWY^:A5
MAG((QSR",9Y9[J\FMA@'WL6+*<AW@3:;I:%\UDV3CV718@47RL7V2Y_/TV8'
M(+I1IVI6X&+VPDY@W]R.\;\O+0JPSE2,;'((P3R![L^6NM)>Z0HO+M27*JG<
MP";I6>;$L,09>$28J]@]5ET0>"I&ILU_E+H[PJ)6ZORM82']SKSB7?QAMG.X
MVQSSW8[:]X'V\5O&^#XIWSRQMOGR5S3VBLIK2;92Q02;B%48I3"!Y>/(M$JR
MBA$HQ.32,X [!2155238D=%2,[44(1N"ACE 61N,C(YC(V\_=7G"VWBG?.-C
MOCGCOQVXY5[36& (+\#SD.48IXSCI0#2;(HQLA(F;DCV+\!7 6;Q\=VT(S:N
M.S7<F=-RHD.*Z0&9&^XVQG?EGEGS]E.%MMCN"1L=P,Y([P,')\AKWMYB(=R#
M^):2D<ZE8HK<\G&-WS9:0C2/""JT,_9)JF<LRNDP%1N9PDF"Y $Z0F*&^O<C
MEG<<QW9Y4P< X.#R.-CCG@^2NH]O%*\YCF7MOJ_GDN"!HEI[8(GSF4*Y<J,V
MQHY#SOM7H.':2K5 6Q%05<I*()\RI#%#SB7(&1D\AD9/FKWA;?Q6VY[';;.^
MVVV_FWK*->U37B?Y@WU)OR#KU>8\X^NO&Y'S'ZJZ&LN.WB4BB.YFZBB!O3L
M]H3X 34*4/J?3OK*ODX+ACV. X](P?I!K$L7XK=1G="RGU\0^A@!YJR#6)69
M32E-*4TI32E-*4TI32E-*4TI32E-*4TI4IQOSO8_6C?XHFM<G_/S?.R?;:MJ
MM_T>#YF+["UQYOYU//J"?&IZKM/TB+^M^HU;O?T6;^J/M+4::V"M9II2FE*:
M4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4KA27SN?_63KXA35R'\[
M%\XGVA5J?\Q-\U)]AJX\(X\YBF:@CN8J0(G]/,@(I"(^LP$ WPZN72<$\BXP
M"W$/,WC?KQ5-J_601MVA0I\Z^+].,^FNUUCU?II2FE*:4II2FE*:4II2FE*:
M4II2FE*:4K.JM^XG'UT;XE+4/J/YU/FQ]IJG=+_,2?.G["5_,5U^K%?EE32E
M-*5_0D\F/^\#X5?]D\-_O+[7YL^ZO_I&Z7_[8F^Q'7Z0>Y5_H[Z(_P"QX/M2
M5;RV?P#^=?U;6HZ;_'?V?]Y6T:M_J_\ :_W=:3;CY1W(-&RUQFX\FJ72C,<-
M5>:' +M%O/)OKYD.)#%\62I6H5)\Z$@=U8LS4($T(!&"=#&K/P*H*O(X2Z?!
MT3M;BQZ/W4=Q<<6H31>^@)C*VMK)X8_7PXCRO##I]UDRF1>,)L!L<=+-'CMW
M#-F1AUHRN%0]8>)=LC:-N?%O4\<-W'5"Y&Q'4[!EAFW@\FNL!Y*XB+?$TN&D
MSU1G1,:9&FZ#+JPRLI*R3Y22%:.;*(Q;AZNJY,HLLFNDD)$21FK=')+6^GBL
MF,EHNIVFE0/<2()VN;NUCN8Q($1%"89@750%P 03N;4UJ4D81Y,?6I"I8CB+
MN@<9P ,;\\"N15./NL6K)V0ZRTQIDY>@TS N+<X1%NA:/9;)+6ACDZ-5G(V-
M;5R%CW;E!=Q'N8MC")(&?GE9EO9TEE8]K7':X^3]&9H+.UF:\LQ<W&IWNG20
M27$4,<+6;B-W,LC*" X=I"0H2,PD!C*HHUHRHA+IQM*\14NJA2AP3Q$CD0<]
MPP=\XK)B<?F#PKX3#V(RK&S!,SQF '5 =8[E5\A,LH3E4?W* @5JU&*R!UB3
MD-'G&/>L'3QMYTN@@[.UV<'0L_\ 9G43+P*]FT9T]]46Y%T@M6LHYTMY91,X
M4 QR..)6"MP@E0WB@T^"2DX!C(,9E#AQP<"L%8\1P-B=\]QK$6OE!*E9\G\.
M%"HF.\AR['-=URQ1;6]E:M+14[C2R8I3-'3E?FX'L5DRR4/.KM7EP<&DA:5:
MJ(JRZI7OG1?,K[=&)X;/5KFYNK6-]/M[&YA1)XWCNXKW#Q2QR9&4DB!6 !>*
M:8A!P\/C5>",J3.[H#$L;* P(</N"#GD0"%&/&8X'+?85K5ZQ*:4II2FE*:4
MJK>:(AWGJKOZ12@>HK4C.>+6E@G5$*\=HFA69ZGW&U/Z^G849B%GE*W%OS-7
M+.5AGK!>Q1TC +QT@=F\;#<O+.6**U+E ;J)+I$!S)'#X1)&ID5EX5:00M+&
MOC<4312$<,BYQM-U2WNKC4HX5E(TZXDT^65E AFN?!(+AU@=)"\B0^$I;SOB
M/J[F.> $O"Y$'T3#>7\2V>B3S>@$OKRK6;B%/99*$L-'JR=N)DE;'2M8N$=
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MXX1(/9HK/SI) 5,A"@U"[\-O)[D)U:.RI!#GB$%M"BPVMN#S*V]O'%"I.Y"
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M>GX]*J"D]GXSC'GS6+SN1ZA64?.+'9H*OMQ 1!>:F(V)1$ Z"(*OW"!! !W
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MII7N">P^JFE,$=A]5-*\KA27SN?_ %DZ^(4U<A_.Q?.)]H5:G_,3?-2?8:L
MJSCL90J8CL5RBHEMX<Q0!4HCZ_E9BA]5MXZE[].*#B[496]!\4_6#Z*B+!^&
MX SLZLOI'C#T^+@>?';4F:A*G*:4II2FE*:4II2FE*:4II2FE*:4II2FE*SJ
MK?N)Q]=&^)2U#ZC^=3YL?::IW2_S$GSI^PE?S%=?JQ7Y94TI32E?T)/)C_O
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M,OOE>+-9PZ?)',\36=O&L45OU9X!&H4#CP "9229<]9Q$,*C)\]:X*+&0Q'
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M^H59$N3C)'/'ZN[/9S_7BNO=\.3A8AO8^78+" ="NV[AF(^@ %(7H==PV$P
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M)[#G [<\CW;>D^;%9&+ I [A'WO3T_*(;^/7<1U:XCY-_)GO[\]AQYMJQ6F
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MJR%-V0 \/>#G./**SHAR*%*<ABG(<I3D.0P&*<A@ 2F*8!$#%, @)3 (@("
M@.VKE6>7.M=_E/X4]@X8T8Q27R' 1A\K8R=3LO2<<V3+-::0\?.&?N"9NQ_2
M+54+[8,%/EVS:-R 6D23JP1Q'D9+>Q;^)82A"V+@9CQXP'$N2%+C&<^.H(8I
MG'%PG/(\LUE69Q-G"$\#X#,%.<;=6Q5E$GQ<@ [C(K4?6^);C:Q!A?$M7PS0
MGN,*2K,\3#JK6M[0,_9!H>5+97LC4XN*ZK4:M?L:Y.SACO#=ZB[);GU4Q^Z8
MQ5S>1<&Z)1+ZVC81)K*8XDF5%"*5&9,$B1@Q!' H#*SJA!.%V) \4C!%9IB@
M>1S(P=L1 CBC1D!1N)F976-G! RWP<XRN^:O(_XAN,*G3=CRM>[+/M<3PGE"
M&.!YBA1.$$I9K5>&YO"O5WF0#3<557M[GT)&V2T'726QHV2CD&+5D=)(KYQ)
M.E;O'*"6)/#U_!P\&<1X^$"!Q')(&>7D[3C".!@$51QFV,@8R$$RYV7!8*"
M"<=^>ZJ]?\JORCMKJ:%M@9>S5!S"8TQ!;?8"6X;VRY[59,@>4+S)@":BY^.E
MX",GXAM6^'V*IUOEH")/"6!IYA%6AW(14?(3 S- DN",C((53^;YL9W0@C .
MT8!P""-CG&<W>IM@Q4@$%Y%SUA'"%MDD!!#8/Y3B&3D;D8. !MMX-[CF&UX_
MR*PS;(R$_:L>\0N=L7PMME:DQI<G=:'1<@2L11[6^AH=A%0!UY:O$:",G7HM
MA#2I$B/F;8!64.?)B+E3QY)5W4$C!90Q"G P-QV@ 'L%84XC#*8P K11N5#%
M@K,H+#)).Q["<BK;:N59II2LZJW[B<?71OB4M0^H_G4^;'VFJ=TO\Q)\Z?L)
M7\Q77ZL5^65;P+I=JKQ#3F(Z!)\#-TSM4H'AUPS7H7(5!A+;@_,L),47#4/_
M (0VR-S<UN3J&1*U'OH.;D8)"YUN6,L4R@5J?2:/6C37 ["PO.C4&M:E%[H%
MAT>O+GI/KES/INI3V>OZ'/!J&N3^]CM8I=PWNF74D=Q!%<-8W4 78W=L7C=Q
MWJ^OK3I+/HVG2] +[I!9V_1G0[:WU/3H+S0-;@GL-$@]\E6^:UELM3M(W@GE
MMEO[6;.3X+<*DB1G3AD-G7H^]V]C4X6WURL-+#*MX"!OZS1Q=X:)2>*D8QMK
M781D,R6GV: $0E%&L3'('=D5,FR;E$$B]NTQ[F33[*2]GLKJ[>VA:XN=.5UL
M)YF0&26S626>1;9VRT(>:5@A&9'/C'B6I);1:A>QV<%[;6J7,RV]OJ)1K^"$
M2,(XKQHXH(S<HN%F*0Q*7!PBC8??GY,?]X'PJ_[)X;_>7VOSG]U?_2-TO_VQ
M-]B.OT3]RK_1WT1_V/!]J2K>6S^ ?SK^K:U'3?X[^S_O*VC5O]7_ +7^[K#]
M2E0]>LRI"]X[C_?Q]?AI2L2G90K5%0PGVY0$1'<._P!'A[X]0]X!UX3@9_'Z
MZK1<_J((Y_?W?1V53C-^3G\'1[Q(1+@4Y2-J=D?1ARB B209P[QPR,!1Z"8K
ME-,0 >@[;"'?I:E)KVUBD_-R75O&XS@<#3(K@_\ =)!//NJ[*&CMYV099(9&
M7&_C*K%?/D@''/.YY;?.%P[9IC:;5K95\@H2ULJ.3#MI&6754<S#J.L2(KF6
ME%D3JF>+J2W;(*NY%HJ:5:R$;&/6_,JF*R78.E/1^[U!K6ZTDQ6]]I_$D2'A
MA66!N'AC#XZL=5AE6.0"*1))$?; .G:)K4.FE_"7?JIRKEP2YCE&06*\V5P?
M'(!;( PPSA9[Q/6:9A&,J>6=4..FT25V>F6OF\A8GIA!./:V=0#G(F\:(*."
M1KE<C4TZ<I7#Q%.9Y$C9/1;HQ%ILS:E+'##J4\)$UM$W';68W:7P0X&.O(1F
M3+"W/Y.%VAR6ECJT>N7]I!82(+>TE-S<PS I)*L2DK-$F29(E8X5!PR1N5E=
M2@'!<VL5*LSB$'8'+R-B(8LDA%R"K04E';8A3'1<+G'F, &2<I=BL0 W2.)@
M.)1*(!,W%W- 9H%5Y93&SIQ;(S'!" G'-3MD[G89VK8L<9!.P[0.T=_9D8&=
MAY>59U8K'5'%FD\9UJKR&5+/8%&T31Y521:0J4>V(HHU3.H4&;H![==!RJW
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MRFS=&W60&.7D5UU#H=JW,H58$4M'O]* 0W%H6FME4,S%D+Q-G!# 8+*-CQA
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MD<OQY_+5<,B\-3,[MK,-YJ<6?KR* +,U9%8(08XO,=ZC[%%$&8G41*<B9^R
MQ%!*8H@<"F#,T_6Y'X[62VMFA,<G!*L2]>),$HQEQQ@ @97BP=QC&0;]S8PV
M\'7"67K^)05+_DN'._B9X22#@$C(YU3VRX,OF,;<3(F,)YQ6[$S3434.FB"L
M;*QYU"*KQ4VR,()/XQR9),RJ!^51)5-)TS5;/4&SE+)N3:ZC ;2\@$T3$%<_
MG(W&0)8G&Z2("0&Q@@E6#(64Y%A<R6SB:.7@8##9W4C;(=21E3@9',$!OA8(
M[;(N;<@96Q-?\;3F/V19*S4^5ADW<79_.&A9M5J<8Z0+&OXUJY0:-Y)-L]%
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MUK]:J5.HT+9+?;)^75*H9G$5N#E'ZC=!T\\W!HT<KI2#.J %C@$@# +$D\@
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MJI)5I&M,GLRO+)L&;E9+SKH\ Y."< <#@DXXMEX>(CA&<@$8WS3P:;B*\*Y
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MFBB01O.T5LGC\7&3,LSX7 (58HY>6=V )&0*V;08Y[C4!+*_&J!I3MC@"H4
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MES:R".%6MY6)> K#$@C*A(T4!1]Z'DQ_W@?"K_LGAO\ >7VOSP]U?_2-TO\
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M2:A.')P.K!*19[E"@2N1L=N#8'*]M8FWJ^39Y8'TI=WHNC&YR]O.2ZID1ZB
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M!ROC#&<-Q8R#@B+*5D"-JT:XDWJS]:2,@JS&,2D'B+I$XEV[-$$E""9+?<0
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M6,AYPG,H-Z9,&4CW,5=).K3D*RE)-9>,-/%F&#!>2<AVA4,1XV#S-&F"8X^
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M7VP  &?LEE8^04*4.A2*/&JRA" 'N"' NX[;ZC[F,6UQ)%OPAMN\ ^,H]"L
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M5.(HI%7-[IRT-L*:9UO\92.)"*J.!4,J7N'0[I8NOGP&^14OTC+I+&@6.Y"
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MFVO>DM_<:M?0Z3:1:5:IJ-R>LN;G3[&$-!"US<=9<W,,95&FFGE6,([QF\'
MUQ*63B:Q-8<GSK=.%63R?:H".B&PI"VBX9FSA'\1'"LFBD:44;,9-,SF2=)(
MK.'QG0E12;$;D+5I=RVJVDMT$,8-U-&D8P>!%"-&O%@<9"NH9L#B<D@  "M9
MOH4TZZBM@>LS;QNS'.6<LZLW;PY93PJN<+PY)))-R5K&X#Y6Z2$Z?0"K(AN<
M-C" B*1>;G#80'<@%, = *80VU?5EA?$HV)Y\AY>(8W.1OC?;EV&IH3,F8B2
MXWX6[1MMGF#SV.P[P-ZZ*V6@C*M2I"+D$SQ K1%,#%$RAEU"%. $ >8!(GVA
MS;["4"B AS=-5W)C,#;@\8 4#?/C#;'9C.2, ]OG\TQ)Q?0Y5E,3%W!! 4*&
M(R0,;G !',D$9'*5^$Z;=*05C9+F,#=K.H/"$W'8%'D>DBH/J$08);^GW]QU
MC:7"$U*%E&"8V4X&^,Y [>6?-V;U8Z92"2",GEPG)Y? ;([OCGG^NKMHS#1T
M!44S@4VP  ".PF'P#OZ[?CVUN!B="2>1(P#SY_5] KFI96&V3V[=F._!_&?1
M6/3SXK!JY74,  F0QMQ'T .WI[MAW$!_%K+A0DY\OT?O.WHK#E)SP\^7J[!O
MY?+V=U:C^)K+D45V\C5G!.<P*>X$P#[@ ZF$ '< * \QAZ 7KOT'4Q!'L">\
M 9[\YQDXY[X'D]>9:P.<8!P-R<>L<N0WSD;>>N=Y,3B?'&F<5\1SCT0Q]F*0
M33AU55-FL%D@$BHQ2A!$W*1*W-TD:^Y*4#*+2B5<V%)(CDY]:Z9Z,+NQ74H4
M_P ZL4_*@<Y;/.7SWFW8M*I[$,W/;&XZ#>-#*;60GJYSA.Y)ALNXY+(!P'GD
M\!! S7U"LU@5;B(#ON01#[780V]_\F^N3+S'G'UUM;<CYC]50_K9ZUBFE*S>
MG-^KQT(=P)MR#[^ZBH?B2_I\-1>HO^;C\[G[(_\ ZJD].3>23'8$!\_C,/H6
MJQ^4&_>N7;_VO3/_ )KB=2W0O_[0V?S=U_Z:6L;I+_\ *9OG(/\ S5KYW-=N
MKFM;G_)8?^2.7O\ 6.K_ /PR4URSW0_TG3/F+C_S(ZWGHC^8O?G8OL/6UG7.
MJV^J=)<!/"ZCE![ELM$G36-[<+3D<(!7)N4%L81^3+O$RD';LF0V(%;B?%\+
MD*P1DU+I2%OBJDTFS.9)])I.TI5VX?*6NICXN+A.>(MCB?AXF&"W!Q< 8Y.X
M7.=^=7_"9N )Q# 4+G@3C*J<A2_#Q%00-B<; <JYC/@4X6X]7&RS3&BJ2F(J
ME@2C8^,-UOZGL#6.&.Y/K_A*-,52T'+*C3;9(O)0[V9"0?V,%08VIU-QR:;0
MCJ8_%\7X 15W;81GB0<]^$[[Y)[<BO/")O'''\,R%O%7<RKPN>6V5 &!@#&0
M <UWQN#KAU/:I2ZFH*@V6:L>7[9)2/MLNH XG\\T^LT+*CX&86(&*(6:JTZN
MQA&J#9)G"#'B^K[>*D';UVY]ZJ/)/#N2S'<\W 5CS[0 .X=F#7G7RX"\6P"+
MCA7E&Q9.S^"6/G[<UA;+R>_")'@P%GB4B*L8A463-V6YY %^2+I.#PX;X2$4
MD!M0OG%?7PL 4FPP+APK$6UN4DO:&4O8$TY4OG41?$'(#FV<!.K SG..#8CD
M>9R=ZJ\)F^/VL<<*XRS]83CAQGC\93S4_!(&U0;D?R7&(7%$CX#!4@\QO<(Z
MXXCM"=SR);>('+;XS+"M7N=+HL%%SC'B"QSDZC%A:K=Y6NL)3'.3*DZ]KI25
MN51F( YXT*6MUP GBD,IRQD<^("!@]8K# )&58;;'(VJXEV_$3(.)2KC""-,
M&0JS$@QLK9*@D.K;^,,'GG&"/)N8(PU4<*Q[U2SV.\XAK<# N[E7KCD+&4-D
M'VMWNR9.KZ5WQW4+PG5[;7ZI>K?89>F5Z\EN18!O(*QZDA))+.SN_4@1 O,L
MH X@S+G#%AE0V" 2<!N+'+/.J9+J1S)C #DG!57*Y55;A9ERI8*,E>'/DVQL
M)U>K&J4XWYWL?K1O\436N3_GYOG9/MM6U6_Z/!\S%]A:X\W\ZGGU!/C4]5VG
MZ1%_6_4:MWOZ+-_5'VEJ--;!6LU^&'8IA]!1'\6E*A_(BXD8.>O_ #9@^P7;
MWNGIV'?PZ]=6Y,</X[CYMN6=QY2*OPC?.._MY]GZ_)]^J_-3P>U7#F !#M/'
MO]0[==_S^.^^L!\G [S]/X-2<0^@;^<]_EYUK5JP@\N5KW'F$\Y*$+UWV*20
M=)E_%L'=[VVOL'H]XG17HZ.7_P "TH]FQ-A 6'+?<D^3<=A-?/'2A<ZS?G_^
M9WVXYD^$OS]0P>>!5J*$@ $0 0V'W)1 >@[[CW[[]>GX@#KMK'O&W8]@[O1G
MZR.[&W*H_@V'F/9ORR!Z]NS[K7U]DDL@0BA ,4Q0 0,4!#EZ>G?;?P\=PUK%
MQ)DMOY?4.WRY S]>**A)!'/;T_JY<CV<MMZ]TOB>M3YRG<L4.;?F$03+W[@(
M>'Y_QZCVF*CF1YQY#V;'GWCD2=^V2A:1=E.WEWW/8,@]ODY=F<5F4+1HFO1J
MB+%HD3D2-L8I"E$>FVX;!_??WM61/F1<G^%]&>[;Z@!]-53!GC<DECPGS>CR
M[#D/3VU17-L.=7(DHJ*8%$L3".D1$-S"@*;AJJ8H>!2JH* /0 Z=-;EI\@-F
M!MD2.1R.3@;9V["#MWU>TIS'!;[DQN]Q$ZY( ?B21">S+9P,#;.,XVK$HV+,
MLT7*C\I<)I'!%44>W,43!\V5,2F!0!V#F H"',.PE$ #F2/@C).#SX<9SG<>
M0XY9VVY;5(W!PRXW#<QQ<(&-L$Y&".PD[]IKYYO*)<+7$\TLBV19]<V3J4V*
MY.QD8FJUZ+L%>CCJBJ*,LWK4-&&E&R9#%.J_02,).S6<.X]FFD9TKR+I]T>Z
M17X74(+QM>T^S5RL0M;6/4].B8@NLBVT,<EW; X8RPY"89Y;>(!I7Z)T5UO1
M0@LT3P"Y?AX@\\[V\[@8S&T\CB-R<C@;'%D!7<GA&:>1IM::=ISA0' B<9.N
MU:X,2>Y 4?8"2D(63,0>8IS"X&RPY3$Y3A_BQ.42&$2+8ON47?!<:O9$G$L-
MK=*-MNI>6&0YR/A=?%GF/%&XWXK?3ZW9XM-N%P."6>W;.=S,B/&.X8$,F_\
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MX[^S_O*VC5O]7_M?[NL-.4#E$H^/Y=2E0]8+98A)RV5 Y0'W)N\ '80#O^$
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M14MYU%CV4\$*?L>:;,JH:1%#SH3F%3<>N]'[H7NAZ1>+J8UH7.GVDXU9;06
MU(20HWAHL@%%J+C/6^#A1U7%P8&*Y%T@M39:YJUH=,.C&VU"[@.DM=F_.FF.
M9U\"-Z2QNC;XZHW!)ZWAX\[U]YWDQ_W@?"K_ +)X;_>7VOSQ]U?_ $C=+_\
M;$WV(Z_0GW*O]'?1'_8\'VI*MY;/X!_.OZMK4=-_CO[/^\K:-6_U?^U_NZP_
M4I4/6,6!7LVRHB.W0P^'@4?[_P#';7AV!_P^GL\_952C+#S_ (_'Z]JUUYR?
MB*+L"CW\P>KKN'KZ[#_<-8,A^%Y 1^/34E'G!Y]G/]VW=RKYLL@Y&<L^(3($
MBP*JY<C9D()HU;@9155S#MF4$#=!,NYC*J/&BA0(4-Q5.8.@CKOW1BV2SZ*Z
M89BL48M)+R61R%58YY);LR,QV 6)U.>Q!VXKENNL]WK5XL0+N9EMT5=RSQHD
M& !VLZG &_$>TDYNSB/,\S,21:O.,749)(BB"K5X4"J]FIOV:J1RB9)=$PD.
M!5D3J)F,0Q>;G(8 F=,NK"[A\+L;B*XA)=1)$3@,N R.#AD=0RDHZAL,#C#+
M6E=(=,O;=S!<Q/$^,\+]H)/"P(RKJ2#AE++E2,G&!8+(%EA<%4M&VF862V.)
MJT56ITZA1[Z/;A.W:_6*/K59A6SI_P":,XYHO+2C<[V0E7JC2+BT7;Q0CHR"
M;95JVHPV\ NVMUFF>6WM(8X@JRW%Q<R)!!&7=NK0-(ZF1V"JJ!GQMPF*TNSN
MKJ86!N!;V\4%S<W$TO&R06UI ]Q/(4C5GD(CC8(B@M)(57(!++'\CQ8P4M19
M>%MC0:3D%YD!7&415Z-/)YK/8YB*9,+/,-X9_BYA+R+)!.MIS*<RE;(*J/88
M8></(-4XYG[(+1^FZY8BZA&HJEM(;V6R2.&0:DK3B!I%97L4E=4BSQR]?%"8
MNJD:10B<9E+C0;H#CLG:Y@6SCOI)KB(Z6T=NTW4X9+YXD<R,%6(VTMPLHEB$
M;&1N =YCCB]P3.()O3WY>FP#1"+)$$DJQ;(<T^QDH.V3[*VQ[R3KJ+25I,FP
MHEK)#W*,4=5B9DXM2'CYE66<1K*0C[K4-#DX\7Z74DCEC,T%U'%U;+/)%)"T
MT,:S0.MM,8[J(M;R% B2/(ZJ9EK+64>-(; Q1HA!C2>UD</&\$,L4R0S,T5S
M&]S!QVTG#<QK('>)41W6)<J\46#8>>82N,'5GR]'WZCVG(<M&52DVTL/&(U_
M%<-F%"1?6-Q"EC85_/TVR5^6>L' %>099))Y8DXA95LT'5Y=7L[9EZAGN(Y+
M>2X'512]6$6U2\7CD9 (VDADC.#@H) 9 AP#M]E8WMW!P7?5VD]K.EO'+--%
MUC%KJ6S>+JUD+2+'/%+&K#Q9.$B,N,D\FGY5H%PH5OR9!3CQ.HXZ@CV'(HRM
M>L\9,45DA4&UY>+/XB5@V$K,,4JRZ2E8Z9@HU_'3K$ =0ZKLARDU*6^LV;6T
MET)"J0)QSJR2(\2]2LY\5HU=QU;!E>-660;H6S@X]SI=R+B.UDB EG?AAX7C
M,<V9#".%DD=4)D!5DD8,AR&P=SQE>(_!Y"QK,MME!F9*PJ5B/AWE"R(UL!9I
M*%B[ 95Y!.JFA)Q4.:M3L=94K+(-&E<7K+HT\E*GAT'3U&XO26RE*()GR\IA
M"=1<<7%PI)DJ8>-4$;K*9758S%F0-P M5N3HW<Q*T@B7A6/K'(F@ZOJS(5"A
MNLP[%T*=6I+]8H4+QX%1/*\8&,G+.,=U>1=V09"?K\01)>+GZRJFPLD38Y6&
MM;-.>AF*\S5I9G69@8B?AD'D-*BV5+&R#@R*A2XL^LV,J(T+M,7EB3A,<D+%
M9TF>.9>NB0R0R+#(4E0-'(5;A8X-9EMI%U$SK(JQ<$<KDJ\<@+1/$LD+&-WZ
MN6,R1\<;E77(XE4$9BN-XSJ7.6!TTEHN<A85M7Z7))3B4/;YP9B:NE43NB$#
M786+J)Y.:;Q]:(_F74JV3-V;"-D)%U&LH]('@P9U>V=I$='1.JMV63@FDXY)
MX?"%CB06_&ZI%Q,SH!A49BH49K9(-/F15\9&8O*I3,:E5@EZHO(QD(5B^%"]
M[!0S-M4T-N(;%+H\Q&1$U.V-Q"IPRTF-4Q]D&VH(DGH**LD7YDXJM3ET9<[F
MO33"?,E%*R#A")57?.2)MF3P[>--S;EY.%V9(^$L8X9I5RZK(A5DC96)C='P
MA)X27Q@,:FUXHHE+\*Y!&9)8TW#%<'B<8/$.$9X06V&^,W=Q1Q8X+37@\?P#
MB5=P[::Q;!FO\U#V&LTB;;9>Q+:<WQ5HK5@?5]6-DV9:S!'>+M))W!JHMW:S
MA1=-JR04D,ZPU6%)2(P2'D@B$K(Z1E9H'G5D<J58<"9P2I R3R&=,U6PN;@R
M7$N 2D[B!72251;SQ6@C=0VS!G494."W+<D#*U>+WAC7;-;5%W.4?D7GH"NP
M[$N)LKJW&4D+;5K/=:@XKM0-0AN<U!6^K4VTS%2M$+#.ZS9F\*]3@IA^Y("!
MMG@UVP>'>:4<4D<01;>Z,DC2Q22Q%85@ZV59HX97BD6-HY C!&8BM2N=$U))
M658HAPI)(S-=6BQ1K%+'#+QS&<0QR12S1)+&\BRQEU+HHW';7'*E/NF.(6ZU
M6<:S=6N==C;)6YAL"R*$I"33!&1C7Z2+I)N[1*Z:.$510=-V[I 3BDX026(=
M,NPV/5W,,,\#"2*:-)8I #AXY%#(PR 0""#@@8.00",#6I8YH+R:"=#'-!))
M#+&Q&4DC8JX\4D'# [J2IV()!!K6# 9N982RI-6QW#KV.#G(L8Z291[E!N_1
M6;.BNV#UJ9S_ (LL*8BY;JMU3H\R;KMB+@9 $5L+I%T>;7[2"".9+>>VF,D3
MRJS1LK)P21MP9=<X5@P#? X>$\7$NY]'M6][&=I(VECECX652 P(;*LN=B!N
M""1\(G.00;!5WRHT["R:;Z+P8Q=59L8H+)OKXHUG5T0,416(JWK3A@S4Y>82
MM3(OBB8"E%V ;FUK2>YU$L>)-68W'>EIF%3N.'#3AV'+QLIS/B\JV-ND[R,2
MEDHBY;S_ )0C([1'P@D'EAL=YKZ),(7]GE+&-+R+'1$S L;G7(VP-8BP-09S
M#!"1;E6(@]0*=1,3 !N9%=%11N[;F2=MSG16(8=%NK5K*[FM'DCE:VF:%I(6
MXHW*-P\2D@'&VX(!!RIW%3"2B>%)@K()(PP5QA@",[CTG!Y$8(SO7HU/5K=>
M::9E5$TB!N=0Y4RAZ3',!2A]D0UXQ"J6/)02?,!DUZH+,%'-B /.3@5,*H+M
M(]0K!NFZ<MF9P9M55Q:).%T41!N@HZ!%P+9-90I$SK@@N*)3"IV2G+R#K>0\
MF78J'?+L!Q$!FRS!<KQ$9) RN>61SK9 "B!4 )1,(I/""5&%!;#8!P 3@XYX
M-:9>+[C#)>*1=,%3>*;11;:G,0Q'XS<K'.2,E(:792H_*FK<OG3=\W0*=B\;
M+*-'3=P@\;JK-E"'/U+HST8-I=VFL1:E;WEL8I2G51NI<2Q/%S9O%9&8AT8!
ME961@&! T?6M:\(@GT^2SEMYA(G%QNK<)1PW(*,A@,JP)4@A@2"#6JW70ZU*
MKV<'O%;%\/$=;(!Y1YRY/KG-0B\>G"OFS=8JS1!RR39D;JMG"SIP[6=IE0(@
M7F,;9,I3&,4-:ATGZ.2:W);3+=PVJ6L4H<RHS ABKEBP90JJ%.2=L;YP*V#1
M=833$FC:WDG:>2,KP,%(*@J%P5))).V/-6^6FS,W8:S$3=AK+BG2LFU*[<5I
MX_0DGT2541,BVD'+5%%N5\"(D.Z;H]H5JJ8S<RQU$S[<>NHHH+B6*"X6ZCC8
MJLZH8TDQS9%8EN#.0K''$/&P 170X'DDB226(P.Z\1A9@[1YY*Y  XL8+*,\
M)/"3D&LGUCU=II2FE*:4II2FE*:4J5([YWL?K-K\036N3_GYOG9/MM6UP?F(
M?FH_L+7&F_G4\^H)\:GJNT_2(OZWZC5J]_19OZH^TM1IK8*UFOPW4!]X?R:4
MJ*;\U%9@XV =^S$=A#QY1]7AL.P?!XZHD^#OR[?W_3VBKT)P3Z/IV[]^SOY9
M%:M\UQI@47/R]/=^'I#X.FX#OMOZ-1[\O3]_X]-2D1Y>4?2/1Y^ZM4M]34J^
M3HJ9*'(A*D*W5'?8HN6BO. &\-U45!(&_42I>K<>^^Y-J8N-)OM)=LR6DXN(
M03OU-RH1@H./%CFB!.,>-..>3CG?3FPXI8;H# FB,3L!G#Q$\)/E97&,'E%R
MVJY59=INV3%\F;F!,$Q,(>*"O+L8?3R'$-O  .??QUN]T"K2+N<@X\X]/,[C
M',X%<YA5@2I&^W/;!!P>1V/,$>0=E6FICL#D1ZAW!Z._T#T#J.W=T[P\.NM9
MNUQQ>8\_U';//N]%9*J<XW[SGLSY^_\ ?@[YF]S+MX*NS%@=)++MH*'D9EP@
MWY!<*MXMFJ]620!0R:?;*$1,5,%#ID$XASG*4!$-:N7ZM78C959B!N>%020,
M\SV \O*#6=!&7=%&Q=E1<C8%B "< G'F[,X%57Q#Y0[AWRE6H"XIRDE3JS*8
MG#*,Q*7$C".&HN"WV.QLIC^>CVKU[)>WI6U2L>TB8J/:/B6)*1BEH%:0"9BR
M.]>BUFTN$27+1HT'7$R84QGK1#U3@$D2]8R@  ALKP$\2YV230KRVD>)E621
M+@0*(\MUB]49Q.AP!U7 "6)*F,AN/&&(RW(O$YPER,$Q/+YAI#B+M--G;>"0
MK/EDST^N/)Z+L<](B@P5-!MJS+UB=B)Q28"/7@IZ+5AY(C66[%HI(V6O6EN0
M&NT0%6E1\G"*A8.Q[E0JZN& *D%3XVU1]QHFI"5;BVM)#+%,D;*.'+2L$9%7
M<<1D5T8!20ZMQ#*Y(IE!\1& !E;%4IK*5<?PM=86:<CY]JA)IN(B/I[MHQL<
M=(1Z[$C\): 6?Q2<A7B(JS2"$O!NB,#QDY".U-@/2#3G5I;6\B,T<4LES W$
M"4A8+,R@J/RB%TXHP#)AT;A\=>.5ATR[G1)3:O&\AC4HQ5@3*&:-E8'#1R ,
M5D'B'AD4GC1U&95;,-(NUQ84>@JOK@A+8_L=^1LT0R52@V+6KW=O0)."F6CT
MK*Q0UH1L9I!JYAI*&0=,#0\B21\T6%JDXLVNN6E]<I# [,6A><LP"+&8YEA:
M)PY5Q-QDG@X>2-Q;[&[<:0\$/73!8RLJQ%6)+$O&9 ZG="G#P[AL'B7ASO4(
MS'$9CR5]AG%2F6MF8S5OBJHJ_9N$XUBS--Q-BFF,TBYG"QR4S".FE9DE6+R"
M-((RB39TYCE'"+)ZLC-6^M:>Z0-#,DX>ZBMF(=8ECZV.:59LRE.MB*0/PM%Q
MAPK,G$JL5CWTJ5'E$J=5U<#2@."Y;JY(HV0A"W!(&E0,'X>#*A@"R@P_(<2.
M%WS)Q+M<@PZ[$KB$9]ND62,=9W96$]*UI%LU\R\Y=FGXJM33^",U16"69- <
M1_G"+IB=Q(0](-%,9D6_A90T*$KUA)>X2:2!50)QL;B.WFDAX5/7*G%'Q!E+
M7AIEVK+%X._&1(V/%.!"\23$D,0O5/-&LH)' 6P^X;'#KV2<62TTV?O;(SD(
M5O3I;)R#)CV@J72!@*?+9%&#K3YR1&(>3L]5H&3E&<8I(H._81L_F#(@S9G4
M&[=])](M;9F@O(;B>2T-S;1PDMUL1MY+E61]HRY@C>=8RX=E7B(X S+9NK6[
MCB94C*RM<)9EFQBWDEGCM!+,B\3B**>5%9^$J9"L9/&RBM@S'C%P4RA'TK=+
M0RQZ@TD#LFR%@>LGKM^@SQOCC)\T_*UKB\TO'-ZY7LFP2LZE+)L'4:T1=3JZ
M!*[YO*K:C[_:>0SSS"W 8JO6E69N&VMKJ0\,1D*B..Z0R<?"5 ,A CPYU,]'
M-17A2"%KHN@9VB5E52UW=6D2EI1%QM-+:OU?!Q!R1&IZS*#+RYXPU,7XN+XK
M(5>DKXJZ=,4:^R<*N57+YA7T[5(L6CQ% \:[>1=>7;2TJT;/55XQJ]8&?IMC
M2#(B\I!J=B]R+1+J)KDDJ(E))+I'USJI *%EBP[@$E%*<0'$H,3/I.HQVIO9
M+29;4*&:9@%"JTI@1BI(D57E!1&90'8-P$\#$=],F!,#AZOZ/Z>O]'76PQ[A
M<=N_F]7D%0)7#_7W;<SW]W9OFH4M#D *J.X= 'KOZO#KN'78.[IZ=24(R1MV
MY_4#R\W?WUE1CEVX'DYGLYG&Y .P/;YHFI"X&S#BP.FYLF47N\-[3%!_?\?7
MIK(U0?\ P?5?)IE]]-M*?U?O/.I?2P?#;0[X\(@Y]_6KY!G'FSVU]!>OG>NI
M5RF2 NGC9N "/;+ID-MX$$P<X_ 3F'X-6Y7X(Y'^*C$>?&WK.!5R).LD1/C,
MH/FSOZADU,P  !L ; '0 #N /1K6ZV2JL9XPMAUOB#,UA;XHQNA/H8VR),HS
MB5'K*<NE,)5B8?)RJ<D2,!X223>E*[(^*L#DKH <%5!4 /K8='U34VU/2X6U
M&_,)O[&(Q&[N#$8C<1(8S'UG 8RGB<&.'A\7&-JB-0L+$65](+.U$@M;EQ(+
M>$2!Q$[!PX3B#AO&# \0.^<U\UVN[URZM@?DY:94+OF"X1ESJM<MT:VQK(/F
MT?9H2-G63=Z2T55N1X@UE&SI!)T1!PX1*X3(54J2ZR8' BAP-I?3FZN;32[6
M2UN)[9VOT1GMYI(79#;W+%2T;*2I*J2I.,@'&0*V/HS!!<7TR3PQ3J+1V"S1
MI(H;KH!Q .& ."1D#."1VUO.J])IE':N6-+J5:J+)XN#IVSK$%%P+5TZ*F5(
M'+AO%M6J2RX)$(D"RA#*=F4I.;E* !R.XN[J[97NKF>Y=!PJUQ-),RKG/"K2
M,Q"YR< XR2<9)KH$-O!;J5@AB@5CQ,L,:1J6QC)"*H)P ,G? Q4+<3W#PGQ)
M4NH5A/(%CQA-4++&/<R5*Y5>+K<W)Q5OQI+FFZZH>*MT7,P#]F$AV:CIK(1S
ME%<J0)*)F3,<IL.2/K HXBI5E<$8SE>7,$?165#+U3,>$.'1HV4DC*N,'<;C
M;NJLR7DXHV+=1.0JUQ$9<B>)1ID^_P"5IKB*>PF+9JQVB;R=CZ Q7:H>4HKB
MC(8Y9U=M1JG4XNJ14+78U2M.JU'2"3QZJYFTY>@0 >,';K.)F,A"DDLH4@@K
MP\. ,  8P-SOF[X43E6C0Q%%01@L  K%P0V2V>(G)).QP,;8PB \D5@RK7W$
MMH@+Q>8VO8FI-3HC*"8QM'A[79Z_5:1(T=6 MN5ZW68*^V*H6UO)+SMNJD](
MRS%>;.HE75ZU7#EKZ7@MD!0@D!%"X 4,0!C#. &((.X/><8& *C>R%7!5278
MMDEB 2P;(0DJ&&, @#;<@G<SUP9<"=$X,&UC;5.TOK@>7K5$HD6_EZ1C.LS$
M71\;H3*%7BY6=H]1K\W<I@P3CM::G;1(OR/7:9'L=%0SMW,K2U<4*Q9 .<A0
M,A00JYP"0 6.YR23OR WS;GN&GQE0N"S'#,06;&<!B0H&, #LYD[8O-J[6/3
M2E-*5G56_<3CZZ-\2EJ'U'\ZGS8^TU3NE_F)/G3]A*_F*Z_5BORRK?1C?A7I
M;:A\/]P^1>9DOT_D-G0#0TO6N,6*(^EYN8KREDA[?8J(RJ<A)8TJUP9P<Q:8
MQU;@CH./AT%2/)5(B29UOG?5.E]\^H])++_VMZ'IUMICZEX1!==")3'!;P70
MM9[&VU"2]CCU6[LGN(+25++K;B69E,<3%B%^@]+Z(V2V'1R]_P#91KFHW.I)
MIW436O3: 237$]L;J&]N=/CLI9=*M+U()KN)[WJH(H%(>8  MJNXS)^1M/%E
MQ&V27CXB(EIO,N09.3B8&RMKE#1<@[LC]9[&QUK9LHUI8FK%R91JG+M6#1N^
M!(5T4$TSE#77N@]M%9]#NC%K!+-/#;Z'IL44US:/8SS1):QB.66SDDE>V>10
M',+R.T>>$L2,UR3IO<2W?3#I/=3Q0PS7&N:E++#;W2WL$4CW4K/%%>)'$ERD
M;$HLZ1HLF.)5 (K[C?)C_O ^%7_9/#?[R^U\!^ZO_I&Z7_[8F^Q'7WQ[E7^C
MOHC_ +'@^U)5O+9_ /YU_5M:CIO\=_9_WE;1JW^K_P!K_=UA^I2H>L+LX&,T
M5 -Q$2'\1]/K';J ;>_KP\CYC5<9PWG[?I\OU&M?V68E5[YT0"B/,)_3Z_5^
M(>OV>F"XR6'+]_;^/HY"1C8>G8CZ^?+;\$YVT,XZX6K]$Y-N61,GQ3>.!*?G
MW]=8@_8R2DD_E)%VL,XIYBNZ30:(-UE#,TG1DGIW:Z;@R#<6A.UZ-TFZ6V4V
MA66BZ1+(X>VMHKR4QR1".&")%\%'&J%G=U7K2F8Q&I0,XD/#J^CZ)<)JD^HW
MZ(I6:9X$#+(7DE=ORQX20JJK'A#'CXV#X0+OQK<[7IN9JX_'F1;R4$FT14'W
M)#N(Z4?*K$ W0#&(21;&$!Z@4Y1VZ]9?W-I4?2M0MN(<<5_USKG<)/;PHK8[
M 3;R@8YD'NJ$Z>P,;BVFQXK6G5JW\Z.:1F />!*A].XQ5_I.L5C-^,AJMN(^
M4CEW4#+,G\/).HB=@I^ORS&=KEB@)ED=-Y%3<#.1["2C7B)A B[8J:Z3AJJN
MW5WF^L[>ZM7M[A7ZOCBE5D=HY8I(9%EAFBD4\4<L,R+(C*=B #D$J>2PW=S8
M7ZW%N4$@2:(I)&)898IXFAG@GC<<,D4T+O&Z$#(;((;##]Q_P;8RI-@C;P61
MN%GN*%MF;U)6*U3C=^\GYR=H+W&C@9AHRC(V%\S;5)^LS:,XJ+BD_.-GCH7:
MPJ"I V^F:=#.)U:XFN%N);AYYY0SS2R6K6;=8J(D840,0%CC0<7C-DDDS-SJ
MNIS6YMW2V@MGM8K9(+>%D2"&.[2]'5,TDDI=KA59GDD<XRB\( QCRG '@1U2
MYG'TX>]6&OS<#0Z'$)3EN6=O*70,>6):R5*@TQZ1F@M&UMB\=/6CL7HR<W+0
MSE2(E9EXQ2:HML230=,6UFBE\(EA,5O;J'F):"UM)3-#:V[!04A0LRDMQ221
MG@DD90N,N'I'J[WL$\'@D4XFN;B0Q6X5;B[O(1#<7=PI9@\S*JE0G!%'(HDC
MB5RQ,D)<"F!(B'+#P2EP@&YY_-$[(C#V%NBI)%SS7"U*\0+H7D4^(6 ;UUO#
MQ%::-DVSJ!85V#:MWQV[9=)U&KI-A,"B=;$C2WLH59%R1?KU4J$LK9C$:HD0
M RBQHH;A!#3+:UJ$)$CF*:18;&+B:,^+[WR&6"0!74B0RM))(Q!65I9&*@MM
MDDYP7XRL.,^(*J4*>E:5:,YXM?8[?RSQR21@VRJ6)O\ !1!/W<(@@S!PFC&H
M,W\N*"Z3R0?^=NB.$CK@D3&U#1N""[BMPP\+A6$EO'5>&V%LC8PIV15+;^,<
MG )($EI72(M);/=%)1;3M*H(Q(.*X,[@.2<88D+GQ0N%P0*K[.\$+>JSK&<"
M92R1:R+R2LE9[K87[N2F4Y/'T)C/V.D6R40DR&'B:C ,8R%;(<KPAQ=2,J^E
M91Z]?+UZ7HB0LD\B/-(O6%FF;(<20+;E6'""46)0H&01G)9F))RM1Z0V\J-
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M2,$J&('(,V,GHL'1"%$7KKN3B('$(HT4 D?!#OUF0#@ E1G&<;XK9+PZ\!6
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M)'&6ZX2AD8R1IPPJ"2('5ND<6I:2UK+:<-V60B12&A3A/C21$GK%9P.KX"&
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MY5JME_&.28")G\MW!Y+V9I4LGS]GLD++VAE18F.BXJ5J4NWCVOLC3;'8';I
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M" G.0BQF; .R,#=RJ"O(_=%U&X\(M=,C,B6_4BYF !1)I7=E1>6)%A$9*X)
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M#WQ[NNJ' (R>S\?OJ]$V#@G;ZAMG\#<G??D=<^8*6)@<G*C[HHGWV*/AWAN
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MY4/4NPS?S6+9)"&QNQ*H<![P.L(JF >_J GY?@Z:UZY?K)Y&[.(@>9?%'?S
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M8Z:2""*1#'46554$J:229"F.HH<Q2D(!C&$ *(ABE"Y"HI9R0JJH)9B3@*
M2Q).  ,DG YUFHX XF(5<$L20   2223@ =I)VWSN-M,LOF$MCR3)3,8*KB/
M0=##5=JV(HLLX8-ECD2<)() 8ZB\HN*CSD*05 (L@WW,"!-=UT'18]$TB*.4
MJD\B>%7TC%5"RLH)0N=@D"<,62> D/(,%S7-]7O7U2\9H^)HU;J;95R3P*Q
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M;#@_ ->H\:WC8")3:IF,15VZ4 5GS]P!>47#YV<!4<K#N($ 1!-$INR;I(I
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MKUK%$R9@#2E1W8847I#EY=P'<0';<.H=P[!ZQV]?JZZ\89&*N(V,@^@]V/\
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M[^&_<(^\(]PA2RAAC\>;S5=20J=_6?J/XV\W*J%ZQ<1853>;@8/=" \H= ]
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6I32E-*4TI32E-*4TI32E-*4TI7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>gwpjrhodncoa000025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000025.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $? ET# 1$  A$! Q$!_\0
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M+_2EN=;M]>M-6LK%=2!FCMEM)[6[MO6;:5E:-0\++(5$KL[E?#"R^B]3=/\
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ME*:4II2FE*:4II2FE*:4II2L?V?)]-J+H6,Q)* ](4AUVK)F[?K-4S@!BG=
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M1K,R)BNSI@J+-DU<OW2:)M^599)JFIT4S;#R"J8AE-AZ93;#J$B=^57([9)
M&?<,]_?6'I73FKZRAEL;8- &V>/-+%;Q,_'L(TK+O;GG8&"]F*G&>;&WJI2T
M M:&,VS5A&_4!R\,8Z/A5$N4#H.6ZQ$W*#D!,0 ;*(@L<3D A#<Y-X*,&V$'
M=G 'OSVQ\/C5BZT+5[/4%TJXL9DOY-IB@&U_&5@2)(I$9HY(L YE5BB[6W,-
MK8^/WVD<W'S_ !V6:8BU%%F#N5AS-U%$56YCE3J<*@8W26(14@"=(PEYR@)B
M[&   =?8'HS4IT'9 C&(IP?FU[.?W_NKR#JZSGT_JB2SNE5+B&1!(BND@4M:
M1.!OC+(V%89VL<'(SQ5 X89)I$<=&.)5^H9)C'9 I;QV<J9U1(W;3K918X))
M%.HH()D$W(F0QS; !2F'8-;+JP%^A-5  RVG7^.1P3;OCD_,\_.L;0[::[ZH
ML[.W4-/<W5K!"I94W22W 1!N<JJY) W,P4 \D#)K[0PO%3&NIVPLXQ/ +% 4
MI!,YE"*G$QB @FD0@N#.NH4R8M02\050IB&2 Q3 'Q;L?=LVG=[L<_/Y?'M7
MLYT/5AJ+:2UA<+J*?EVS*%95V[O$9R1&(MI#";?X14@AR&&8>M93I5LDAAXF
M5,$KR**)L'S1TP<.$DP$QU&I72297($( G4(B<RJ9 $YTRD 3!+Q.@RPX]X(
M(_5_RK-U/I76])MA>W=H/5-RHUQ!-%<1QNQVJLQB=FB+-E5,BJK-[*L6XKB3
MF8*#7GZL=(3!^LV4%)VJT8O7K5FH4=CD<N6J"J1#ICV5*03F2, E5 @@.TK#
M(PRJYR,CD9(^ )S5VPZ/Z@U&W6YM;(%)$WPI+<002SH02K0Q2R([!A^06"AP
M04+ C-CD[Q5HB%:6!W,-1BI A#QSAL)W8R *$ZA 9)-B*JN#"3XA!,@\@ (J
M"0 $0I",S%0#D=P>,?//:M;:Z'JMY>RZ=#93>MV[,MS%*%A]6*MM8SO*42(
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M@Y\-MKD9(4KS4 OFO'#:0!@O/@D K @$@9F]\IZHFY0 9+P_A@)S" "N)_#
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MR1D#N3P/ED^?P[UK=*T#5-9+FQMPT<3!))YI8[>%9",B,22LH9\<E$W,HP6
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MF+J^3Z7;WRL7#RHC*)$,MY>]:N6#M5 FW.LV3=))@Y3)N J= QSI ("J0@"
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MC#)QW)[>7) )'/GCG@5M=4ET:?J.WT!+J :XFA/:M<!U_C7NDGCTXR X]95
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MON749=%O^I9M"MKFW.MQZ%;V[7*NF)98KBXGDL!("0UQ%')%*8U); *CVHV
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MMXA)O8+@A_#&2V#6IS(L:ZKQ:\2/.64+NT%IX8WB_$[](4!0Y06ZO4#DZ8D
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M6KLNUGMII('9?YI:)D8KWX)(Y-51.230QY<EDBI)(L;-),B)ID(1---*39H
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M9 P..U>UDQAYRTWA*5BXR3&*5AQ;C(,6KT6QU8]503(BX14%(PB0H[DY1W*
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MJU\08D]6N)8/$'N?PG7>/@V14SCIR5U5&2Q  ">)DDR 4 *4"I2#E("E*4
M +R;  !L !V[=M1]C6,2226)+$DDDDDD\DDG)))Y)))JK5!WU<LYB:[_ *T0
MH [?9UX)ZI_>["/]_P"S3]]4^?T?\_W5B,\L'T!L7_.&QKR1#?<! =[PLAL'
MR^6WY0^W4]B<?'X\<_N\ZIY(YQG(^!!X[X\_JX]U9>MKSI9:Q0TWV\4SNYMO
MMZ,8S,/\@_\ AVW#S^7[Q51[K\_W&H>EONJ&<]S (,;?84OEVY(9%38>^VX;
M_/;MMJ/=]O,_;Y\>53[_ +9X%4Q&4_K;8!<\P??UTJR/-N @;JA*=@$>W?EW
M]?EMJ<$;A[N#]8_?5.>WN.?(@]CR//MQ\<Y%9),\#Z>4V&_<<7'=;?\ M,">
M_I_CT\C\Q^QJ?RA\ ?I[?3_RJAQ$GSX*R,^ WZW>7XN_;8/#OG!1V].P;?/;
M\>VH//E[N/?Q^_\ 70#AAGS/8G/UGS^W?-33Q_R6'AV2YO[(1TR;U^MTZDQ5
M^??]EO\ X]]M/M]A]L?3552<<]YLG9?;;_K2K5=7;;TZL9(&]?\ U=*5CR2E
M>7ABB9/F^N6"'FWW#X[8W2]?0=_3[-2<YYXX'[!]L>7:H'[S^T_;Y5DYV\VS
M;6&>_P"JXZDW&W;]C*D+O]O^+MJ/H^&?KJ?M^W[?854D)$/"<2)@-_8YT_ 1
MWVY>6LF5[_DV$>_R_%WTQY?+]?(I[Z\K'(]/'V#7&_9[:L;I;^F_B&)S!_?V
M[?/?;T'3'?X=_P!E*N$,[Y\V7-EOOT:=75A#[!4<JA_*'_Z^>E*Q(K+\N%LK
M/-P^]<ASR&XCZ<ECBDA#T_VVWV[CZ[Z'/[/J_5Y?U\U2!Q@\YR?+S.?B/VBO
MF8]IB81X\;(8?V3VK[;?/>E5\?\  ._?7V#Z,"/P"L3Y>#<'_P",N":\NZB_
M^OQ[]Z\?#P$Y_;]7QK'?"P;DX[L8?:7(-*-^/?SY#</L]"CW_'K:=6 _@)JQ
M[?\ 5U]D?*WD_K_55G3LGJ"(^7B1'/\ _. 'Q\_=7U51LN!L%8Q?<X;.+W$H
M;CMWY[5+);?E'E_/\OEKXK/=OI'ZQ\OU?\O5P.%R#W!^G'&?EP/V^=9:G78$
MS91&>_=:I6A8 _W-1 -]MOQ_(?Y-14^8^GY_M^OOY55J[(]6DYW7Y@'P-GR&
MEN'8 !O$)'V_-OW_ /SIV^KM]?R[\>>/E0>?S_</MS^S%<,9+^HW#<?F /,7
ML.7U^MSUX#CMOW'[>WY?EJ1Y_+CZQ0^7<\\_+]0[X^.,]^:N;5Z YTFF/,'W
M+&S!R)=PW#FG#$WV]>_IW^P/3YO(_,?L-/Y7T']HK%[&5WX9)62YOJ%D_BW#
M]A:!2]?3\7\FA[X/F%'U@<?'W?&@[<8')_::R-)/>7)V'VVX_?=9M*NV_KTH
MAH;<?^-IY'WY'[\_NIS^KGY\?\:C&,AS6GB$2W_L?%PY_P 9>>I.E0'_ -T1
M_P"^VHQ_5]OKH>Q\^*KLK*<F *,_ P?=W--#F'80'K2J)/R!OOZ^GR#Y:D]_
MH'?Y#WU [ ?%AW_SOI/[?/RK((O ^GLK#?O]%:CK;_VI32W_ ,7YAU%55CU:
M4 *'Q#+\X?U/M]L1$>WP](C3L(^G;F^?I\^VVF"._P Q\L>?V[8I5HM3[I1N
M"#;_ *]M=02W[]^M#G/MZ_/;Y_WAT_=3Z?V<_J_94U4W?5R_E=IOOX5A1S;?
M9UXIP;^7E]?^X*CS^WP^KY?\<X?=R_\ 6"D'W, \M[.WYNVW:[)(?D^P._Y?
M74GN?/D]N:A>P^CL?@._]7NP.U9>N3SHY;Q&UWV\6WNW;[11C&)_S]A'\FV^
MHY_K^%55&T=]UI+.11'LRM#Y/\G+#@?_ !?ETJ#Y]_M[JH19;^M9@9T!@'Q^
M1*HAN AL/5>S/8/D._)V_%JKS;[?RA4#LO?COP1Y']7[:RFY>;9TC6/-];'#
MMR!>WRG>3?;U^WO^;\D>1^8_?_74^8^1_=5!KTESX8RH\YM_"S&0R;]NWASF
M /MVVV[AZ[[_ #T'<9X['CW'G(IV!X]Y]V?GG[8J2=2.TUPUD =_,8^3'\8\
MM/8J[A^(=Q$?Q?9J/+/R_7G^JH(Y'P!_=_SJP,GO-EC)C3</O6EU];;?N'40
M=#N/;<-]OQ^G;4^7PS^O'E]7/VS/G]!_:,?#C)^NL:+RW+PO,9/F[B9G\6_V
MW4$O7\G\FAY./> /=Y#Y?0:+V'PR/=V./^=9.D'G+FFD,]PW6H<XOM]H$=(A
MN'X@$?D/V;ZC^O'[?ZJ>8^1/TC']=5=.1[\2FXA_4Y(WX^4/=1RKW_O;_P"'
M3';X\CZR/V@U/V^WV_?7IGY'DQ5A9SS 'C)_&J>X_LO$-=]N_<!'^_OJ3W/S
M/VYY^NH'Y(^7S^K'?X=_IJ[1CSFSC9V._P"IT*$7V[=N>35+N(>NP[>O\OR"
M/M]OU4_=P?V_3Y5B1Q+;8:S&\YMO"9&L#<!$=MNG889/;T^7/]FF#QQC/[_=
MVSGWTQQC[?+]WQ%9/O#WH6C"26_Z]GG9/R[08'__ '\O\6F._P .]!S@^\5[
MJ<\%;(>:&^_ZS<5<-OLZL$X4#T^WU^W^33X_/]536)V$MS8&I#_G#[O>XY'F
MW#OS7%ZCMW^8"78/GV^8ZD\EL>\_JS4+V'P _8/MSS]&*RU8WG3S7C=GN'WQ
M7+>IMVW'I((C_>[CJ.?H_KS_ %?&GF/I^W_.JY67_5J>>5>;]8VS(*6_;MX>
M)2/_ "#O_+^:1D$>_@@>7P^OY_50]C\C46G)?ZE>'-7F#^J,[7T]]_K=2*7/
ML _/T_\ '0=CQ^SCG]__ #Y(J,<C'EGX#Z?+S/EW]PS5V;N]\]2C'?ZN+VCG
M;?[;#T]]O[_]_3R/S'[_ .JISSCC&,_'O^RL;MI0#<-EDD>8-DCSWQ;]ON=H
M.GOO^;M_+\],<X^/O'/R/(IY=C\N_?YGM\.,#W5>7KX"Y PDWW_7M=L*@!]O
M3KS<^_I\@,/SU&>X^1_;\/W_ $>YYCY']U>J.?\ -D+/;?</O&OU!3;[.K6)
M%3?;\?+N/^'Y:>7TG]U/,_(?/NWOX^7ZZI\Q*<O#K4)#?]55J8;[@._5FDDQ
M[AV'??;MJ3DGMR?+Y_;^NJ0,J!G/Q]QY^GCR[>7E62U'?]?9!COZXQ4<[?DL
M@I[_ ,NW;\6_KIY#OW/R[#['Z/A57GCX#Y]S_P ,?36/$Y,/='B-6Y@_J=:+
M0GON'PBG'MC=]^P &^_S_P 6F.WQS]L_;'TTYY![>1^?R]U6"UO^E!X%4W_7
MUMHZ._V^(AU#;=MO7U]-#W/S/[:#L/+@?\N<_P!?QJSUQWU,O9(:;]FT)3#@
M';MUFKPP_C[[!_W'4?;[?JH//Y_N'VXK#"\OM@&S/^8/N=W?([[_ &6]LCM\
MOMVV_P 'RG!!''/'!\\\CZZ>6"<X')\_?GYCN/.LP7=WT,H8?;;[>,<7$NWR
M'HPJ"@_B[>OVZCGZ/W^7[#4UQ*:]ZT_F]/?]93R2>WV?ZGR*?8'KZZ?85&,@
M^><_U?1C[<UC=E*@.)<)N^</OS(M=0W 0V'J3DN0>_H/U?SZG!)/'O)';% ,
M #W#%96?O.7., RW#[ICV67Y?GL281+O_?'_ +]M13S[?3\?M^VJ+%2//B+,
MCK?]9S^22?D\,41V_P#'\^@[CSY^?_/Y4(X//OY./=\/+_C4@YD-G?#E\0?U
M11./R^(!J**VX;_EW^W4^1^8_8:>8'P/P[8]V./>.U6..><V9;TSWW!"D0"W
M+N';J+.0W^T-]OG^;YZ>7TG]@_7[_HIYGY =C\?K[^1K&:<KMPN%E!-Z(&'F
M[?*Y&1[_ )=MM_E^0- #GC]OPY_5WH>WOY'?XGY>59(D7O+F#'+3?;Q-+L:V
MV_KTRM-_R[;AZ?X-M1Y?;'P_?48]K/'Y/T]_M]=0*4AN\XCR[_V.CVYO7ZN]
M2?J_]7?4\X&?>WU<5/F?D/WUP)N2Y,/XC=@;;Q<MCA/?MW\0"7S'Y?R_(=",
MD_,GW>_/ZL\4';R^0[?;X_35T9/.;.\VQW^IC:,<;;A^SG52;[>ORV[;?_EY
M#YG]WV/'N]U//Z!^_P"WUUBUW*_UG<U/ .'WE>;*AOOV $I>*+L/8.P<_P"3
MY[Z=MI/VY/'TT/9L?UGL/IS^NLC71[T9+")1']>V9HG^7>#54_+\O^_RCS^@
MG]G]?[*#.![\#_CVKE4QYULGYG; ._@STKMV["O NCC_ /*&V^E3Y_N^7_/G
MZ*Y.#W8/<=1C@!WYI&P$W]?U.<D"?]74D$'!J!]O^'P\O*KK&/:JM9+0SBPC
MPLS(D*:UBW:@D_$CAFLI!C(.>D070 R*L#7=5;H)<Q/N8&Y1BIJM>=8N]S$I
M': ]R!F2MT0\L+Y7YUY\*!3$9>%V!QYZ!E.OT  %MW(J=/=32F?U\59I)[5D
M;+6V<F$?[SO$)D:R*[8%'P(-T&YYD&+D4C"V 4#-_$%!5(5TPY0!0"& %*XT
M5(4U8;>,1Y8 L)1XE<1;M"I;RJ3)([T9+[B0':W@^F594>L!R%%,3F$IB@I4
M226QMY#2') A K\A)Q:%& (X :$E54G'E?EB MOO%R5,C@B2HIH"B83D,<AC
M;"I4\+VK>^)8\?+_ 'T]W3.BCX8!E K?F)4C!XSI;@R&1Y1\,*P;K *H)#L)
M@4]WZOM]N_QJ&;RN.U*=/2#8(7W,;*3Q; 5./*6,,JW77">\6R!L .#'7!87
M @@IXDQN8HJ <HBJ..?G@X]_T?8?17-5DJ0$A24EO*?,)-!X>BB9F45?#DC4
MEGGE*G0$&1!C#(@<I3( =#D2 #; 0'V-37(;OZB:P69JW\M"Q,X^+6M D:E(
M\&.50=&B_'N>B'BD2MRN>BF*JO13,8HE(!P 5/W?OJ!7F,9$QZTE%RP7T='3
M8>$(I&@,,!#R*23 "1PM1Y.62%(2 +8HIK@"IN42B8%/M]56%5]5"VR.8*^7
M>]ZL&[<QHF:E-(A E<I$= B[Z0BDT,YZ8F0ZQ04.43E3-R&$%*C"RE!%&^F*
M$0*,6HN%_ & <IE"19%5_-B^'^_Q\K I3#LXYD@%'<3 8@*5Y/Y.A)PM1<OP
MA_(W\E (T[K,2G:!)NDA-7AC4?#F!FL"6_A% 31!N3<.9,-PTI4DU>U92V2K
M%IY?[WH14>M+"FV LCY2JJL$>#AWT@%5N"O5%)'K'Z0FYA(4#E$5*K9YG%_N
MI9'QP@?=)I./V]E 8THQXSJ<DBD_%ZT\+]\NS21FYCK]%455136*H8 *<'(^
M!I7R7^T[,F;CWM)TA 4S2M<%(2AL3IC3X$"<H?(!+R[?+;[-?8/HQ'_L%9 <
M_B+G_P#O+@GW"O+.HP!KX//+H/\ X=#^UA6..%$2!Q[XJ,<2],,D483\WU0(
M%A;B;F 0VVY1W$!^0]];7JL@]!ZL??IU_P#KMGQ5C3>-?B'_ .)%^J7GZCBO
ML6;S.+CTZOOVX0 4QW+LV]>*2,*6-"8-*+),_!LO"AT')90BYBJ@@F*:P*+&
M.4!,<?BG!^/'?_C7K/''ZOM\JLKM[5D[9#L'@1_O<XBY-:&%5J!Y$(I%1OYF
M#9V*0BBB8XH"JCUB"KR"8"& AQ!3CC]7U']V:CV$G1%8FX+L/* AX^1G4KGT
MF14VWF39N4\^,FET"@[6%L)?%JB1;Q"?P\RGII]OZJFO5YIC\&E".(0X-)-9
MH7'X> #IE64C#JM/*2>'_J>8(WF(F;9OR)F!'<#F*05/M]OMC]52B3VJC;WC
M!+R_WR3@6SIX)6H!)^[YGBI&P*/.D G: \YQ!OUC<BA@.*8 8IA4^WV^NJ^G
M,8R-C]Y*)!!?1V0KWQ921I0AC%+)J)/.>/!J *<\GSF-LV-U5C L7FY@.*GV
M_=]OA4ZY?U MAK+5SY:-C>Q\FK5C':%,\\N20;GE CW((CX9$S8R JI@JEU4
MB[ 4X$, *C^H?O\ M^VN.A(T@TG=44/*@DXU!F>\"#,I5A;GC#K,QE510 'J
M18L% (43K@FCS)B!=Q**IS4>XEL<)TJ%D7(0H4=P>$"$*K'@:+*=9TB2$\.R
M%L/AS)NND*(F03%L<HG.*7(80'/G^NH&#R/C^WG]?UU.>-JOOD$=M'^^ONX+
ML!\*'FGNUYB"0AXSI;^!\RY1%MU]NMLKTN_-I4U!J2V.0A;RX4"%&$C9*40O
M9?+P%L:3211\T\T0!L/CG!DC(E74!-<5A "@8YRB *<'X_UU)24C2T4J>:3\
MJZ,A*1R-,%=H50@2B[)8\:,8'1,#-8675*W5 $03(8$P.43E**GV\_\ E]?T
M5R8U[5%K/9&48$<%J:-X<UF%!J"4@+==!<\,#YT")!<E!N"PMBBJKT$S;;$
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M[?KNK5A/?YCTHV0+Z^O;F_-^?2E8]DXKFX98F,  ^ L&&VW;X+6W5]/RAO\
MEU)[_0O[!4#M])_::R:[9[YKK#W;NGCR3;C]@<TH4WX_7\NHJ:J2$=]Y\1Y>
M4 \Q=/Q[=A'FK)DN_I^/O^/UTS^[]?%/M\Z\K''=2@8/;\H;,K1CE3;UV\.Q
M.4/\/J&GZZCY?;]O;R';RJX0S3DS3<GFWZM3Z\EO]O3<*C_CTJ?M]OU5B56)
MYL,Y49@ #XK(4XXV';N![%%*;_8(CR?/[-2>_GV'ZP/U>7RJ%[>7F./@2*^9
MCVF90#COL8".P%>UGN'VEIE?-Z?9OL'Y!U]?^C$D=!6)')\*X!&>^;RX7]O/
MD//%>7=1?_7H_P!(OT?B(R._^::QIPL@(\>6,"[_ %LC4L/7U#SML&W]X! -
M;7JO_P"PFK9\]-O3]/J\HS]8YK'TP_\ M A]\D  ^4H.,>[FOJQCHD"X,QFQ
MV[-[S%+@&VVPEM,LKZ#Z;"8?S=_77Q9_.^WF/MYUZN#POOR!S\1W^D'Z^]99
MG&G/FFC/-OU"IV=+?_=5$!V_]W5-5'N/I/U<?O\ A56KL?TZ5G5#E#[]LV0E
M-OD8'$0F7?\ 'OMM^/;0GW^0^GSY\_HX\J#'./?]1//_ !^FN*,:'DW#D3E_
ML<]AS;"'U>6O 3[.PAJ1R#\OWBH).5^>>WN'Q^9^-7%JSVSE-/M@^Z8X8-MP
M]?AFS'V$?\';3R/S'[&I_*\^Q^7EV_XUC%C% '#-*1O*&QRR78 ["![.*O8.
MWJ'V_P H>H]_H7]@J1V^D]_F?G61))D!LF8A<[?K.M6A(.WU>K$,R#Z^GU0#
M[?MU'E\?MG]U3[OU_"HQBP MHX@E=@_JA%Q!!_'R5-TD&^_;Y_RZ5!\Q\/VY
M]W/EY57I6+ZF J.PY?U%Q3AV#OMT95$_^+_QU+=^^>!S\P/M[ZI&<#'D3W_]
MX>7S^%9 %G_7Y*^V]<6*-0';[+0FKMO\_P#Q[:BJZQ\M&;T3B$;\O]D+=:UM
MNP\W53:!N(#N'['T^8=M*CMG@9SY?/C/R[D^7-6:U,>K&X*+MOX&UU!;T].E
M$')\OL$?MV_+I4_;Y5-U1ITLO96=[;"Z84@N_P!O0BG!?S[;_FTI6'W41_6#
MD&(@'Q7LZXA^6Z)K#^?_ +[:ENY^9^/[>]4C\D<9X'VYK+MQ9];+6)7>V_A&
M]V#?UV%:-8D_-OMZZC]]55'4ACT9+.)M@#QMG>J>GKS0_)N/V^NE*HA(H Q=
M@AMRA]XY"JK@ 'T 4GDR(#WW[_$&WIJKS;]_^</?S5'.%^/N^7T#'F?U>591
M<L]\Y1S[;ZN.73??\0SHGV_OC^?\VH\OI'[_ /A57F/D?W50J]&@7#.4V?+V
M=2^03<OV^(.;Y>GY0_-J/=GX?'Z.>_N&:>_]W_#S^52+F/ 9GAN/L']3X^3+
MZ>G-3V*0[=]_V/Y [[ZGR(^(_5G^NA[CY']H_P"7TU8&3+ERMDMUL&[FF0".
M^WKTT'(>OV!OZ#ISCX9_74<!CWSMS]&?+GS^W>L:KQ0#PPLHWE#8!9_#M]ET
M*KW#Y_G_ ,(:'ZN!Y_#[?*I_K/?YG/U<X^59-D&?-F>DO-OU&B3B&^W8.=R@
M/YM_\'Y U'V^WUFGF./?S[JK"<=L/$AV ?,4C;[@&P@-6<I;#]O8=AWTSY>[
MGZ_^537HGH[GQ9AAKR[^#GL;J;?9X=KM]GR]/34GN?F?VU"]A\A5UC&@%SA9
MGNP[J4.%0W^7P22AN_S]!_)^?45-8F<1/]9O,+/E#[\R)/K[=]AZMAAS[_/U
MY.^WS^S2E9.N[(%K/A100W\%/.S^@]MX,$P_)W^W2HSVX[_+[?4?EFO=3V?1
MR#F9QR_KM>KCOM];IP3@GY]MQ#_%I]OM]%#[O?GGW5BAA$@&!Z2QY0^XWJ-7
M$-O[FX/5A_/\6^_R'4GN?F?MYU"]A\A^S]7T?/SK+-C9]3-..7FP?>]=MR>_
MV=5!(-@U%5?;]GV%5VM1_1JF=TN4-GUKOZOIV'Q$0D0=_3</E^3\7<9'<>7(
M^W/'V^%0>Q^1J+3C=JMP[)"']CYV /\ DZ<6N3?U_'^4/LT\C]'V_P"?_-GD
M$#@Y^C[8^1^JKJW:;9XE7VWUL8M&V_Y+ *FWY.W_ '[:>7TC]_\ QIY_''[^
M?C[OW>=8X;1?+PW62.Y?U0\\.W^Z6<ZH=OQ?RZ@=Q^[O]%35X>L>:_847V#[
MRKU@3WV[AU*^W)V[]M^7;4^1^8_8U1YCX@_N[UZXUCRY SRXV_7L#44_R]*L
M2*??_C#IY#YG]U1YD?\ A'[3_75.F(OFX=Z?'B4-DE:F(@(=@!*:14'L #ML
M ;AH>Y^?[*+^2/>,XQ[^??\ \JR4HS_KZH/MO3&2C;?;[;'U-M_Y=14Y&<>>
M,_16/TXS:I<1:7+_ &1M%H5$-O7JQ[8OSVWWV[C_ 'A[=F3@#W?OQFGO/;/O
M[<>?VQV\N]3UJ8=6#P.3;LQME(5_)T(=0F_YM2W<_,_MH.P^7]56:N-.GEW)
M#O8/OF$IA-_G]Q:O0[_\;M^?\>HIY_\ #OV^WT?"L-+1.^ [,PY0#J79\MR_
M+O;VRWR]1^'?[!U(/(^!_?4>6,=^#CXXR>>?/DGG@YK+]V9]?)V(7.W9FO<!
MW^P5H9!/;\^HJK[?57%IS/HSV;%-MO&3J2F_;OM7R$[_ &_G[?RZ5!['Z?MQ
M6-V46!<3X5:\H#X+(E=7 /D'3G)<^_Y=C[_E^>GV^W:G/'Z_AQ_764WS3FSC
M!OMOJ8]E&^__ *4PF?;T_'OZZ5-4B*CA)B3,;3;N[GLCG[_/Q!?7M]OK^/0=
MQ\Q[_P!W/U5![$_ ]_EYUSW,>/B^'0=O['(F#\@#4D4OY0#;4^1^8_?3S'R;
M]HJR1S3ES'>'>WZO28%'?MO]S7<CM]O[+4>7TG]WVS_53 R?ES\OC]1_76,T
MHH/T+Y8SE[= 0 -MO6Y"L/;T^8_B^>GV^NG?O[_V=OZZR/(L^;+V.G>WZWI=
MB1W_ -T*UW#?O]@?XQ]-3Y=_/M^_W<9_73/('PR?W>?[OWX@DX\ ><1AM@_J
MBP;@.^P[[5-^E_UNWV?/OZO(?,_N^F@/)^0_:?MFN!-QO/B'$K3;?PLKCD^V
MP]O#E1W$ ]>P;Z-W/S/[:#&!CMY?;W^_XU<V;0"YUFGVW<^.(QOO^(LZL?;^
M7T_/]NHYX]W/U\?M_=3C)_7]O/M6+W47OA_-#38/OR\61<0V]04EXHW<!'N/
MP?:.X?CU/\W]7?WGY_J'ZZCR;'!YS]7]1Y^)-9$N;+K26$S" #X*RM5/EV$(
M-0G;U_O_ ,NHJ>P&/AC/NX_7[OC7*IK3I9.S*XV /%GI??[>C!.2=_SC_ATJ
M:Y.$6G@L=QC?8"\DC/CL'^WG'Y_M'^Z]?GIWJ  ,X\SGZ:EHY1E%W.[NWKMJ
MS+(%K*:1W2Z+<JRB,<X("9!5.0#G#F^J7<PAWVT ))P,_(=L9[U>B@FG+>##
M+,44LWA1O)M7S9MBG:OO)P!QGRJJ'BB_1JW8[!L6P$<>H;;#8#K\P#Z;;&W
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M[A<>9) YRJG =A^H0?0=,'!('EW(./IQ\>*E8)FB>9897A0X>98W,2%CD;I
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M=S'!#+,X&[;%&TC8'F50$@?'&/C51+%%5Q_<6Q.4Q7MFDG11 0$IRJ2;-4#
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M[DXB(%*0B"\@85#&-L %*!A,(B( 'V_/3W]SG^L'R^56@"2B@$DL%  )))!
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M (^OXQ !#)X R?@.:IBBEFD\.&*25R,A(D9V(7.?94$G&?(<9YJNMF":T%E
MJ)B*IRDO+."*)F*=-4J[1'E.0Y>8IBG /A$!$!#N ]]]15!#*SJZLC*VTJP9
M6![8*GE3[QP0>X%<F2\"^;8]9-W35PYB9J 4<-TET55FXH1YR;JI$.8Z0@.P
M?="E'\FI8'.>P))&1W^7U@_\ZNM!<11QR2031QR >'(\;)&_;E'8!7_]TGGZ
MZF&IV<;=;._>NFK--XR@6Z:CI=)N10Z2*^Q"G5,0IC_$.Q0$1'MMWW#4 $]A
MGY4BAFG9EAAEF91O*Q1M(548RQ"!B%'F2 *IHQ0&QI+L@ HE5GG3@.4?A$!F
M4UP, AV$!VW 0["&P[_/4'..^#[\5;Y&<Y'/8]QC@C'<$'.0>0?HJW2QV,K<
M*8Y9/&KP8U6=!;PSA)<43+,4B<JH)&.*9AY1V VP]A^S56#[L?,'[=\5=E@G
M@V>-#+")!N0RQO&''O3>!N&.<C(^->B+,QC)6]^,=M&BDK)D%N5RX10,X-Y8
M1,"I H<HJ&W';E+N/<  - ">V3CG@$D#WGC]_P!-1'!/.)##!-*L:Y<QQNX0
M8.2Q56"C [MCW]L57DHLJ5)H+<X 4K&T1KHPF$"E(5*0?J"<P^@%*!N81$=@
M#U'YA'R^'V^FK2Y.  220 J@DY/ &!YY^'P[][44S*0O["28NFSQ)&M/&AUF
MJR:Y"J"_*<4Q.D<Q0, >I=]PW[AN/9CGY?OQ_55V6&:!PD\,L+E0P66-XV*G
M.&"NH)'Q''[ZVD5BUJ%XB5W31!U)25K40:*N44W"X."^J2!S@JH B A\!#;C
MOJ0#G."0#DD#MSY_N^5%@GDBDECAE>).'E6-VB3M^7( 47OYD'W5)O&B2"F,
M%US)I)Q1#@HHJ<J::)2PA$1,=0W*4H!ML(B(!_BCX?$']1'T]Q5M59V145G9
M^%5%9F9B00  "23SQW/-2,85LZNL_)M%T'2#FOQR!%VZJ:R1^DJMN!54C&(;
M81$!V-N'SU)X&""#D\$?+^K]O;SJDBEAD:.:*2)PHW)(C(X[XRC ,,@\9 R.
M1D<U32),0Q42NBZ:@^,B(@Q%PB#HQ!GC+"?P_-U1*!=S<W)ML&^^H ..W'P'
M%5FWG,7C^!,8 P4S^&_@A@1[/B;=F<^6?(@XJW29&S6ZU>2=+(MD&<!*I'7<
M*$122!4$ #F44,4A0$0 /B$.^VI&3P!D_ <U;CCDED6.*.25V!"HBEV)[\*N
M6)P#G:#CCRK@MVR+@V47#<Z:Z,JS2%-9(Y5$UBA".4MR*$$2G#OL @(AZ:@]
MOCS^['[Z,CQNZ2(T;J0K(ZE64\G#*P!!Y!((!^@@F.=D8.:=38=-VU4>1SNK
M*K-"+HG<HE;\@;J( <52!N(=S$#L/KWU+#.3@X)R,_/(JLV\Z1),T,JPO[*2
MM$XB=AY+(5"L1@\ FK <S./R(_DGKELS24JK-H"[I9)!/G"2.<I.HJ8A0$0]
M WW'09/ &<9/'T9_9410S3R%(8I)GVYV11M(V!G)VH&.!GDXP,C/EFKJQA%:
M!>VY.4Y)"?E')1(8#%4*M(-%"G*8NX& P% 0$NX#V$.W?3/Y/P_K)^'V\\U;
M(8%U8%2"05((8$#!!!Y!R,8(!!R#SP+#+"QD7M%(U=M'*L3,MQ<)(.$556YO
M+U$P!5-,YC)#N @ ' H[[AI@X!Y X[CN#GMD?75UX)XEC>6&6-)1E'>-T1^W
M*,Z@,.>-I/\ 5[(H[&+M]Z=/7;5GYBI7R)&<KI-P6.C&K%Y$Q5.4#G#F#X2B
M)NX=O0-0 <G&3G'EVX_?]O.IB@GG+B"&68HNY_"C>38O/M-L!VKP>3@?'@U)
M8\:^#JS-#8 Y74D?M_\ V2#E3U^>_-OOZ=^VE6OHQY'YCOWP>#QR!6A%\I\E
MD*XWB:L3Y?Q$?-2D>Q9JK"FDPCXUTJS8H-T.8"$ 6Z*2ISD(!EU#'7.)S'$V
MME&5C1 H!R Q/O)[Y]^#D8/;MY#'TOT_KEITSI.A66F6T02[LK.YNKA(U,EU
M<W,4<DTDTFW>^'=D56;\6B+&H"#:86!E;O(8W=8\4DGP5E"YHQI)83J L+(\
M8J]/ %=]CE:%<$3="GU ,9,_AQ'PQA1U+*@EWX&XH6P!\0 ?HR5SY8^&:S]1
MLNGK;J2'J1;*V^^;Z*]ZUGX<9C%VMVL(U,VY!'K'A[HQ)L&)%\;^- DKB1$#
M,XLR)39"K/%SNGTW%QSI@BL8R4HSD'B+9RR73 3%4*JFJ;E,(#T5 *L42J$*
M(&VR1N"!PI(/N\P0?/ZB<?"KUYJ-CUATWK4&L6Z"*UL+RY@N710]I<6\$DD<
M\38W(49 #@C>I,; JQ!_9JDR-V4G[?9)%=2:</GBRY%%A(+(X*GY63=(3!X=
M%J4@(II)E#D!/<_,<3":I65-J(HVX !X.<COVY)SG]7853I^OVG3PL-$TJTC
MCL5AB4%(U/K&Y5WW$KA<S/-S(TCEBV[W8 D6K^Z7/'5-I<Q(O@@6L]8V1'YU
M#$4F&T2$7Y>U=.OA,X2C1D':12&.<BG(B"H*':IF+1M1)'< ;MJG'NW9R0#V
MSQSSC)[5CSVW3^@]1ZOKEC9VQOVL-,N!;(B%-/FO#=BXFAA 98I+@6\+EE"L
MH9S&52=PWHIK6R8JR5')U!9=Z,FTE6KR((H=9H^32BGCLBBB "<HF9K($=D.
M78Q02,F!@(JH4\R;'C)<8PPY]QR!QCWYQC'GQVYNZS/I?6/3%S+K44<#6DMK
M);W[*D<]N7O(86C20J"%N$=HF4^RQ=7*[HU*U^5QXXE(ES;Y&7=.9ETHH]7>
MJN3>*%T<14,8I@, I@4VW(1,"$3  (0A0*!0K5@IV!1@#'8X^?S/.3R?/.#6
M;9]2P65W'H-II\$&G0J+>.V2%!;B( J0R[2K!E&69LM(2SLQ+$FY/5+EE&O8
MXAK2_=DCVE;<N$S'.=$)MRA.R\0G)/3 ) =*%CHUDD0R@G#F,LY+N9V8PVU"
M1-*0H+;L'SP"JL0,=N2<X\\# Q6FA70^D=2ZDOM(M(&N7U**(;$1FTV&2PLK
MM[2W!#> C7%S,6";!M6.$^S%L6-HKBWXTL=NA*F\<+LY"H3CAR@ BX0C5V:2
M8MYI-(P*$379"H8G.(=,Y5@(L4X F!9D6.01LP_EJH[AB"?R3Y8/8>8]U9FO
M1:)U7IFCZEK-M#'<0:QI\*RX6*6[BG<B73Y'&UFBG"[MN=R["T94ELU:>QPK
M$1"-I;R[PLN!@?%?@\4,]\2!@6ZXK=4515ZGQB<3 8P[#S;CJL,"2FT8/&#V
M(YX/;CWCM[QBMGI_5$5[=2:)+I\!L-IMO5#;QBV$'\7X0BV! @&%5=NU1QCB
MLA6-K:LN.JZ>XN5VA6=-K[ALT,86Z#I5[&).W<N=+<A#KOUU%# <2B"9"%23
M H%,!K:!(MQ3VCXC#/8X!QCY#S'Q^OF].FT?HM-2;1(8Y9)]:U"*6Y55EEBB
M@NWBAL%DPS"*W10-H8;G8NP)VD05)D[M36&2:;7Y!X,.ZB&"RC@ASJ^1+.IE
MC&.'+-01'PBCQB\<HB*8E$IDTW)!*J@50)D5':)F SG&./:&TD CDD @?02,
MULM<M.G]<GZ:US4K.W]>6\N(S$R(OWRCBL+FZCAN$('CK!/#&^'# J[1,#'(
M5-7GZ2\H:4;;8&5<-9EFJB_;.47!CK"X3,"A04W$W5!0Y=E4U .54@B0X&(8
M0&L%7RI'!SGN1CMVR#[C[_JYVFG:_;=2/<:+J5C#-82JT$D,D2B-48%<H H$
M9B!W(R[2A 92& (R/=Z[.Y/M<W)VQPX:KQR+5!G$J*'2;QK<K-%0")("8I0.
MN=05U%!**JAC["82D(4MN,K'&NT9#$D^_()'OSQ]&//C!KF-"U33ND=+L;;1
MX8YENY)9+B^1%:6[?QG4&23:6*Q(HC1=VU IV@,S%H"K2=X:T2W8^9R+WW;&
MSP3,TB"B@J,&DFVE57L8@[ >9!!ZK'-!4(0X"0JBY2B .S\]3*GBJY +!6."
M.^,<X^&>.WE[JV6KV?3LVNZ/U)/9VWWR;3-0N39^$GAW=S:S6:6]Y-!M*RRP
MK<3;7=26*1L<F!=OST<;D.6O<6CJ)(<5$V4C'$ _-SB8%J[&.!'F$1W^)4=Q
MWWW]>^^OK+T<'/0UJ<8S#./KNYA\/F>/E7Q5Z4;YM2](.IWSKM:>ZB)7:%V[
M-.M(@ H  &$'E5*PNS!]Q=UQD81*#RS5YN)@'82]:313W 0].P^OJ'J'?6SZ
MH/\ [#ZGVR-/OOE_$2']N:UO1$YMO2#H%R &\#6=*D (SGP[Z-^1_P J^E*&
ME+O/XS84!Y(OO=MO<I"."5%50JZ[-M',7C>#.[W*<[9%=VNXZ8J"8Q2D0WZ"
M()!\<%464O@;MF<<]\E=WP8D ?K]]?<M]9]/:=U+-U%#96OWR?1;>\]2V(8H
M;B6YN(9=22$ JLSK%'$'V8#%Y1^-D+UZJO#SF+,GU%>J.'#E63DVL6^C$E#J
MH2+%\8$7*3A$HF P))G,X(KL(H*I%6 0Y!'4OLDB?<,8!()XP>,8/'T@_5[[
MFIWVG=8=+:PNLPQ1BSM9KNVO'5%EM)X%+1M%(=K#Q"JQNH/XQ7,9!) J-EJ(
M^M;25N<]*N7,Z\<N'3E998Q5$ES',;HHI<P>'00[)(HID(FBF0I"E#;5895V
MHBC:.!Y^7GG(/8'Y_'@W[/J*VT:>UT'3;&&'3XHTB2-(E*2+CF21L?C7E/M2
M2R%C(S,Y)#581=W3(5(Q_5K#(/BPS3SQ%-VHJHF:?\LD?!,3O5N8!=!&MP%L
M4#F,!CDZRG.J!#A0%2.24J,$[>.,*""&Q\3].,BM:T.@=,Z[U!J^FVEN;UQ8
MN(4C1AIGK5J)IUMDP? -U(?$;8JLJDQIM3*GB4<+3BR^NV=/77>%DJ[90=1I
M3&<M1.QA'T@S>B@(G3!1F\:H'*IMN<AU$-Q!<P"D"2("PP R^UVQD@$$C/!&
M?IYSD5D:XVD=7]/PW6M110R6NHZ6(KPA8Y]EQ?6]O<6PE&'*3PR2 I^2"J2_
ME1AA6)C'*WDIK8K,.U9=8QGIY [Q07AG9AZIE^KU05*?G^(HAR\@A\(%V  K
M4@'8%P!QVSQC';W<\>_C-;*QZGA6]&AI86\>GQKZLEHEN@MA  4\/P@FPICV
M=I!!&<Y!YOLT%NRRSHS6W/72+9G3V;I)$YCMDI1THX=MCS3@NY"N'#QNT0$J
M@@*9-SF1 O74$]"".(N5Y)<C(YP  2N/(<]N_P"[069T7HRXUV?1K:%YI-9G
MA,JJDDEG L<$@L(F(9H8H7E<,JE2_LA\^$@2'HKZYX]>9 K-6>NUH][4GCA8
MA3&52AW!'\<Q\Z; <# @NBT?." 8O8QA244*;PY.69%CD$;-C.\#W9&TX7';
MDCX ?36=K]OH/4L'3^K:O:P)<QZO##N*HKZA";6ZG^]\Y]DR1230H2I.0 ZK
MCQ6W5:?QZO6HUM:XZ8=H3")BOD7Z3U7Q971# J"QE>H905!4#<PG$1..^^X&
M$-5JP;V-H(/&/@>,'X=N#G]6:V>F]30:M<RZ)=6%O)I[*;9K1K>,VYA($?AK
M'L\,*%]D  *!C';C)-NC+)EJ;:O+BX69F85BNJ-8LPF;-D3OH-A(O796HB0H
M+/'KIP<YA+SE(5)N4P$1(4MJ/;$I"@-N9P3YX!( /R 'TY.>>>:TB\TKHRSE
MCT2*.8W&J:E'->!5EGD2WU&XMH(6F 9C'!!"BJH)4L7E(W.6JO5"4NT!6,B4
M*(D'PU]16"*+\IU3'@2R;]5L\19N0-NU+*HIBD?D,7DY#*)"FL<5!ET0R1NP
M&2&.!W.T#!8?#O\ &MEK5ET_J6I].=07MG;??';?LUL8X]NIFTMTEADN8]I\
M<V;-O&\$L"JN#&FT5R7J,CC5Y"6NLR3A&99NVSIN**QE3+J<Y!\.JF FZZ3D
M!Z2S<X'!8A^02&WVU6") RL/9/?)]^><^1')SSCO[JV5EK=IU7#>Z/JUG')8
M2121.)(T58E56Q+&=H\)X<;XY$*M&R@JP[U?;M4Y;(UMM\W:'*R#MA(.V32-
M45,1*-9,3F0:MFZ0F*4HBBF1514A0.X44,N<QN<-41LJ1HH ((#$^9)\SCO[
MNW;XUSVA:S9=+:5H]CI$$;QW=O!/<W:1J9+V>9%>2660!B^"QCC4MMB11&@7
M;@PU?E+NZQO*X\&2?!6D;I'QQ97G5!8K)S'/WJ\"1Z \P-!<M6SH4B'*8J9S
M("((+"F(JGBARHW;&./+(*X;'!R 2!S[O=6=J=GT]%U):=2>I6OWS?1+F\-E
MX<9C-U#=V\,6I-;D%?'$<LD8E*'+A91F6+>O!CH"8Q7?J?*51XN9\YF8UDNQ
M15.=.3:/G:3=RQ<) 8Y52+IJ"  ("*:@%5#D43*8M3%9(WW 8 8@GG! )X.0
M?V_K-9%QJ=CUCT_K-KK,$0AAL;N>*X=$#6<T$$DD=S&Q"LAC**3@KN7*'*LR
MGDS])D;PZLENLC]P:86D7JBJ*RQR^ $BRA$V+=$3 **+0I01(0A2[=/F-S'$
MPB1E0*BJ",#!YY^)^)S[_=[N+.FZ]:=.KIVBZ3:1)9""#$D<:DW)>,,]U,X4
MF629V:1G8G); .  .6QD+K<,;U6CRTB]"OM+-86)9 RBI5)1K%-HE2/8N'0[
M'718'DWI"D$XD.!$"' PLB\M.U%E=\ MM7CXDD9QS@G S]..]6;JTZ>T3J34
M]>LK.V.H/I>FW:VHCC9+&>[>]2YN8H=I6*6Y6VB)<*&!>1A@3-GUTYE8L59+
MAR5%9=X,JD]9/8<BAUFL@D#!RN4RJ)1$#&:J(E=$5*!3)](P /*=0#) DD1+
M# 4@@G@CD>?;L3W'P\JNZQ<Z9UCTO>R:U'%;FS,,]O?NB1RVS>L11E4D(4@3
MJ_A,F2'RI(8JN*]*8]<S,2[N,I+N74T\55>N'BCD_B!<*"941+\?W(I#[@F1
M,I4T@*!"$ H 4*U=58(HXP ,]AQ^OW ^>36;9]30Z?=PZ!9V,,&GPQB".WC@
M3P?# P<@(?%,@]IF<EI"2S,Q+$W!XM<LG5W',':'SHD8R@7:J*ISF1"<7;S4
MC%IR#LX"0'2B+%@T2**@F$#&5<#N9T)QMJ$C:5@!RPX\A[(;'P!)/RX]V:TZ
M1Z%TGJ?4>HZ1:P&ZDOX4"*B2-ID4MC:74EM;J ? 22>YF9@@4%4CB'LQ!1'T
M=>VXQM-EAJFZ=.&DE4K"JY; )G+=BNQ8*KM9HB1NH0BS)4I0!0P 14JG1/S@
M8I0JD"2!"P PXQ[\%N5'8X[GO\>,5EZ]'HO5FD:9J&L00QW%OJ^FQQS%5CEN
M8;BX2.;3WD&UGBG5G.S)*E3(NTAB:O.8Y6CX=.U)2[L)<3 ^\P\:IXWQ0&ZO
M7%?G!4% 4#F P&YM]C%$!]*P5)V8 !X[# ^0^6<Y^GGMLM/ZGBN;Q]$>P@^]
MZKZMZH;>/U7P,>%X7@A!'LV9 7;@@>8.#?["A:\N+5?WP=.&Q&=-A'#9H83-
MD'JSMJ*SF941W3*HN^/Z'$.5,A (D4@\_-:4)%N*C.6(/<D#GV>WEQY9\_+-
M<]I\FC=%C57T2WBEEEUF^A>X"K++!'#,5BL%D.YDB@'\D',C,6?/LD0E*DKK
M2FV2:?7'[L\.[@&ZZJQ#G4\C76F8V*6>M#B)O"*+L'[I(3$$!!0B3@OQMBF"
M9%1S$S 9+8P//V<@'N2,@=^.3G.<5GZ[::!K\G3>MZG:VZWBZA+$8VC1/OG$
MEC=726]RI ,Z17$$) <-[+O&V5E(-7L%&=TAM'6R$EG+69:*(OV[M%R<RX.$
MS H!CCS"*@*&[*D/S%5*8Q% ,0Q@&X"LF4(.T]QQCG'SP<]O/ X-;33.H+?J
M"2XT2_L89K"1'MW@DA3PA%C: H*X0H.49<&,@%"K#(R/=8*?RG9Y*4MRZS1=
MA'QB36(.8R#>/(,6T<G%)N)B%ZCE=91PHH)14.*A"";IIIE):39&@" ').6Y
MRV"1R?(<8& //GGGF=$U'3NC]-MK?1H4E6YN;DSWR*KRW16[FB3Q) &)2)$6
M-$#!5"D\,S,U>JLI=V5'NV/F4@^-6PL%>:C(@H?J13:4)+*/F#=UOSMT7ZD:
MS Q2*%!,#K@42F=G$:G5#,CD#=M8E?)L8&>_<9)]Y^C-;/6++I^YUS1.H[BR
MMOOD^G:E.UHT:&.]GLVLEMKJ6#;MEDMUN)<,ZMO*QD[A;J%A7-8EL76&LV2J
MOG'FZ4E'BFW15.H$CXAPFF=@ND4QNNF](<4%$MC"?F#;8_*(22LBLK<#!)R<
M]@2"/B#^T?'.;#J]GUAIVIZ9K-M$;/U:?,DJJIM#%&[I<Q.0"DD&SQ$D&-NW
MDE215KMU.E,@6&WV*ROEPD$)61;(,UE1(2-;,W"C=LR;H[@4B:"292B)"@90
M_.NIS'4.<:498U0 8R <@'DD9SSY\=^,>_(Q6GT;7+3IJPT?3-*MHQ!-:6TL
MTZ("UY-/"LDMS,X!+F1F;DD[%VQIM10M<6%D[O,8U2Q\YDGX5MO=5XTLIU%"
MK*,DHY%ZG B\ 04.T(X74<BES@(D!-N @V3Z.A2,2^( -VS.WRW9P6YSY<<]
MSDX\JR-0LNGK'J4]1QV5J=2?0X[WU/PXVCCNFNI8&U)8,%1.T48C\39G>6F_
MCF+GT5V%F\69+ISNJN%G"\A+L(M[&(J&41DF,BN1LZ;K)%$P'Y453+$4V'PR
MJ95P$HD$=3)MDB;</R02">",<]\^_'O\ZN:A?Z?UCTQK,>L01H+2SN;NWNW1
M%DLY[>-I(I(I& *%BHC=01XL;M&05;%<.7HCZW(3%RL$DX7G7;IRY<F66,0Z
M"IE#&Z"*7/\ <$6VW2203 I$B$*0I0V$-5*P3:@ V@#'U=SCOGSSWSVQBKMA
MU%;:)+::%I=G%%I\4:1HL<:E95(YED;;F22<G?)*Q+.S%F/)Q.IO+I?J%1*G
M/23TL*S>6!LF[.H=,TXG%N&K=B#QQN NB1R2RK<@"<P',!5%N=5,ABVPJ))*
MP R ..<@G.2!Y9XXY(''SP)+?0.G.H-=UG3;*W]=>#395@6-"NFM>1RO<>K1
MA2(#=,JR':%(!*QX1G4\6CIVC%60Q:5%=9X25A+"D\C ,*[94S&$?R#1V9 P
MF)U&+QHBN50  QR<Z',)%SE/5($DCRP"@$$'L1E@,9SY@^[CMW!J_KCZ3UAT
MYZSK4,<4MG?::8;S:(YD6>_MK>>W$@VOX<\4SH4R0&VR;<Q@BM2^.5EH56V.
M9=TO,N#G>J/SNU!=BZ,(K"MS]0%"""@[D NQ2; !"E H 6I6'Y&T 8QC QQD
M8Q@@<$_#CXG.PL.IH8KQ="AT^"/3HT%LMFENBVXAQL\,QA-K*5R&W9R3ELY)
M-YE36_+$70&%M>ND632I(N$4SG.W3EG 2,DP"8<=TP7<.&C)J7G,)B%^Z*I@
M7Q)^:TBI'XFT<[\?(8!V^9P#GZ>,<9K16PT/HV]ZAN=&MH7N)-7DA\0*DCV,
M+6MK<&P@/M>%%'--*2HVDX16W&%=L70W=PQS,WBNU5ZZ582%.E7:Z8#UT8IR
MT6;-T9Q I@5!%=J1VLGS!\"@JI"L10$4@)6ZHXC9@.' [\D$G((X)!X^HY.*
MSNH(=#ZHL=#U76+:%+F'6;2W#E1')>PRI/(VG2L ADBD:-& ))3#["GB2;JI
M/X\7@(EO:F<N\2F$SD?)OR/5!>E=%,"I5A<=3K"H!PWYC&,)NXB(B&^J@X;*
M[01C'(XQ@#ZB,=^QR!6STWJ:'4[F71+BP@DT\KZNUJUO'ZMX! C*"'8$V!?R
M5"CC  ':LDVV/LV7)>-=W!PNU%I3ZLX;1IC"V;@K(UYA)OWX-R],G6=OW;DP
M[E$Z!")M0Y00VU;CV1J0H!R[C/\ FL0!GX#L<'WC&:YK2;K2>B[:Y3188Y6F
MUG58)KQ56:8Q6NI7-M;VOC$.WAP6\48 #;7=GF(/B;C 4R4NU;K^2J-#2+WR
M-5*%,+TISJ&@C/Y9./=@S<?$9H,HU$Z!MC;E,GUD.FN JZETC9XW8#/N[;L*
M2,\XXP"3V\C6SURSZ?U6_P"F=?O[*V]?WWP:!DC U/U6S>XA-S&<"?U258W4
M.IR&\.3=$-@JTY3Y'&ZD1;:U*.&TTR<(/6JJ"YE3JJD.0W263W-UTUQ^Y*H*
M%,58AS)J%,0P@-T,LF5(&",'/8#W Y.!\/J^&ST_7+;JE;O1]5LXIK"6-X'2
M2--J)M8!T?:#$\?#1RJ5,;!64A@#61KW5I?)%OMDQ:7*[=S'.EF+.+56,1&,
M9-0 C=%!'F*0!4*'B%%2% RZBAE#&, E +2%41 H!!'+9[D\D_$CGW<<>\5S
M.@:Q8]*Z1I5GI$$<D=W%'-<WD<0,EY/+R\DL@!9PG\4B$A8T0*H7!#0=;D[L
MKCF?QX22?%K:5RB8XDF"B@JHL7S"3=.X,CO;F3:JN6#1<R::A3%(HJAW1<F3
M&65!*KD#=L)QQR000V/?@^?U>=;#5+/I].H[#J-K*V.I2:+>7C69C3PY+NVN
M;6*+47@VX,T:3R()&0[G5)/XV(,(MK7);%MVJ4S5'BYI!68C6AVB"ISDDF[]
MTDV<,%TP$P*IN$EC%Y3 /(?E5+RJ$*8LMB2-PPX"DCSVX!(/<$8YY^8YS67+
MJMCUCH>KV6LV\?@1V5U,D\B*&LY;>*22.YB<@>&\;*"65AN7<IRC,#*66E25
M[DK1:[(_6-+&DGQ1066.0(\C==1%!BV1$WW%%JFF1(A"E 1$HJ'$QS&,:$98
MU50,#:#GN"2.2?I/&,Y''O%8>EZ_:=.P:7H^DVL:69MH&,L<:DW32Q*SW4S[
M299)78NS$D %4'LJ%'NCW]TM.-:Y1I*1?>[S:V3S ) RAR*/VD:RAW#&-6=;
M@HLW:K23XP$.<2G J21@,5J4I:=J+*[@#=M!'P8EANQGV3P.,^\CRQ3=VG3V
MD=3:AKUI9VIU!](T^[6T6*,I:7%W/?1W%W%#M*12S);0_C%4,I:1P09F8^FG
MQ\_BO)]>+5'"[D98Z\<_BB&.L@_;*-EE3 JB7F 3-C)E<IJ@ &2Z9A 0*)P-
M4X62)BP"A0,''(.1R3[^<8JYK%UIO6'2VHOK,4<)LE2XM[U@J2VTBRQKA)"!
M@3!O"9-VV0,"0S*N(&5Q\[L$6^N4O+.G<X]55?.G:K@P./$J&%00(4#?<2D,
M/*FDF!2)% I"%*4  *@RJ0@4 #V1Y@#GS'?).?>>X]U9MGU)!IEU!H5A80P:
M?"@@B@CB3PC$ %);"^VSCVI'<EG8LSECDU;73BYY+J>-X&S2#T(QI%R@D<**
MF2\]68S;^*;NGBFY1<G:,6C= HJF-S',HY4YU5NH-"K'&\C  DG [\97/'S.
M?(8/EC&-0L6@]*:QU)J>EV<!NVN[-518T;[W)<V%M=S16R880+///)(WAA,(
M%A4A8]E<&BJ6S%]PGHFHNG#AO)5*RKN6I1\0@U7CHAT\8RI4C HF59FY23V4
M$/NI3B@?G*<":2A)45F 4JR@8\PS $9XXV]O,=_GDZ\NC=6Z-I]]K,,4<]MJ
M^EQ1SD".::&XO(X9K(R#:S1SQL_L%L(1XJX92U52;QNJUABVDLN[&7,(OAD/
M&*F>BY W5%<5NJ94%><>8#[\W-W*(#OM6KC.TJ,8(Q@<8R,8&!V_J^-;/3^J
M(YKTZ)ZA;KIZJ+86@MHUM1!PGA"$1B/P]A(VD%<<8Y &0+ E:\MA3D[<\<-T
MF=+B'*#8QA;(OW#HJH.)E9,.F11=[T4_BV$B92B5(I ,H)[:".+?M )W[3WR
M.QV^9&">?F/IY^QDT;HM]9DT6VBDEFUN\@,X19);:&)D\.PCD8,R0P%FRJD>
M(Q!?=M3;"TE_<J,3)53K;]V:+=U@CHRA3"H6&<J3<3%+2383 <&RQH^1>)[I
MB3<X).=A,U()9D5'\)F _+VXQW&TD \=L@9]_ER2:S]>MM!Z@_!K6M4M(!=K
MJAA(9%1M1A6POKJ.TG"[3/&L]O"P5@WLEXA@2L&JL_1'5-9L+9#R[EM,M5$G
M[=ZBY/XD'"1@4*<Y^<QE!,8/NA5>8%"F$IRF(8Q37 5;<I4;<8QSC';RQCR[
M#L.,5M--ZBM]>EN-#OK&&;3Y5-N]O)"@A$1&P;4"A5V@9C9,,AP4(901DFZ0
M<]E2RO9&VN%FBT?#PA6L08YF[=B1:%9/5S)M]R@"KIRZ6<*'.!E?NA4A-TT4
MB$M1[(TPHSN9O:&23@D<\XP!Q[OKKF-%U#3>CM.B@T6".475Y>F>_"J\MSX5
M]<01J\^"6CACC2-%#; 59PNYW9Z_5)6ZQU*O6/F$B^&N^<UYOXX%3"K$MY4\
MF+]DV=!\;=*0,P;%,0AP FZW)R'=B8TNJ>)&^!G:Y(_G8QCSYX)SY=JVFL67
M3]WK6@]175E;??!K+4YFM6B0+?368L_5KB>'&V:2V%Q(59T;>5C+EA$H6!?5
M:3Q?,UZS59^N270D&2B)$%3J>,ZBI"&9KH@8W73=$.**B)RFY^;80WV'5>5D
M5E8>S@YR> ""<\@]N_P(SR1QGV^LV?5UEJ.EZQ;1/9M;SAGDC1?5RD;LEQ&^
MT>$\) D$J$%2">P-7&Y4^4R#9KC8+*\6*^:RTBS08J*B0D:T8.E6K1DW2YRD
M(1%!)/<R90,N<3K'$YU#&&B,JJ(H P0#N]^1R2?GQV'89-:/1-<L^F--T;3M
M)MX_ N+2UGGN$C!>\FGA1Y9YI,%G+.[8#,?"0+$H55"C8;A.DIY6JV> E';A
MY'5F>29P;IR<RABMW+7Q#A@14_Q'2:* FJF43&Z178)EY4RD*&-=JH=6 P67
M+#RSGO\ 2._NKSWTN6FG1ZKI6H6,4-M<:I8/<7\,2*BM+'-LCN2B[55YU+*Y
M"C>T)=BS%B<WV;%]3M;P\A(-WC9ZL!2.G,8\49'>$(4"%*Z*4#I*B!"@0%03
M*N! *4%0*4H!965T& 1CO@@''OQGMGSKA],ZHU;2H5M[>2&6!"3%%=0).("Q
M+,8F.'0%B24WF/))V99LR+;']0:5L*FWA6R<&!A5%J4504.Y$W.9Z=UU/%&>
MB< -XL5A7 0 H' @ 74&1RV\L=WO^'NQVQ\,8K&EZ@UB;4_OO)?2O?XVB4A-
MHB P(!#M\(6X&0(=GA\D[=W-0T!B2EUZ6).-F3E]*H 8&3R5=J/3QX' 2F%D
MF8"(I*"41+US)G< 41*58"F,!JFF=AM) 'F  ,_/'RK-U#JW6M1LVL))HK>T
MDQX\-G"L N,$$>.PW2.N0"8PXB)P2A(!'A8,14RQO5GSQJ];+.E!5?)QS]9D
M@_4-W.=RDGN4#J;?=56_054$1,<YCCS:+-(H !'';(!('N!/E4Z?U=K6FP)!
M#+!*D*A+<W5O'.]NHSM6)V ;:O&U)#(BX 50O%3KF@5)S7VE7&';HPT> >7M
MVQE&ZC%0.8>NV<)G*N1P8QSF56,H8[@QSBX%43GYJ1(X8L&.X]S[_@1V(K!C
MU_5X]0FU3UR22]N>+F64)*MPO \.6)U,;1@*%1 @6-0!&$P,1M6Q=4*E(*2\
M<R7<3"B1T/-))R=Z[1;J;<Z#;F J+9,^P H9%$BJA?@44.38NI>5W !/ _D@
M #YG'?\ 9\*R=5ZHU?5[=+.YFCCLT=9/5;6)8(7D4$+)*%R\K*#[(=V13[2J
M&R:BY3"U"EWAW3E@\2166,NYC&C]=K&.53&$QQ4;)"!DRJ&$1.FV5;I&W$!)
ML(@,B:11@-\,D G'S_KSBLJTZTUZSA6.*XA:1$\.*ZFMXY;J)0 %"R."K%0/
M9:5)&!YR:LLS0:M.1K&*=QI$&T4D",49@86*T8D4I2 DS40Y031Y2$ R!RJ(
M&Y"B9,PE*(4J[*20>_)\P><\@\5K;/7]4L;FXNH[EI9+MS)=BY G2Z<EF+3+
M)DL^68AU*R#)"L 37%JV-:E4 ?GBH\RCN43%"1D)!4SYZ[;B(_>RBJP"0C;O
M\3=!-)%0?B4(<P ('D=R"Q[=@. /D*N:KU)J^L^ +NXV0VK"2WMK9? @AEQC
MQE1#EIO=*[-(HRJ,JG%5];"&/7#TKIQ&NEFI%06)#J2#DT.!P'F !:";G,CS
M=_#&7,V$-B"D*?P!7X\N,;O+&<#=]>,UL(^M^H8H3'%=11RLA0WJ6\0O2I&,
M^-MP'P?XT()1W#@\U9[+CZL6I-N619G079H@V:/(Y8S)TW;!Z-B&2#IG;E_8
M(JI*)I[B*92"81&E)'3L?/.#R,^^M9IFOZGI32FWF62.9S+-!<H+B&24XS*5
M?VA*<#=(C*[\!RP  \*[CFHU>-?Q<9%)F0E@$)=5Z87CF4 2F(!7BZ_,8Z9"
MF,"2) 301YCF23(8YS&AI'8AB>1VQP!\@*G4>HM7U2ZM[NZNV$EH<V:P 016
MO(;,*)@*Q(!=V+.^ &8J% KS;"E!;R;>34CW;T6:Y7#%@_?N'4:T6(<#I'(U
M4'=;I&* IE=J.$RB #R<Q2B%1GD*[<@9X)  )^9_JQ6QEZUU^2UDM5N(H!-&
MT4\]O;QPW,R."KJTJ#V-X)#-"L3$$C.#BINT8UJUL< \D6[EN_Z94E'T:Y,S
M<+HDW B3CE*9)<I '8ACI"J0H 0BA2@ :I61T& >.>" >^.1GMV\JP=+ZDU3
M2(_!MI(I+<,SI!<Q+/'&[?E/'G#QDGDJKA&;+,I8YKE1>/*?$5YQ5V<*W"'>
M',J]05,JJL\<FY.9VY='.+E1T D(9-?J@= 2)@@*14R%*+N6W%CN'8Y[>7'T
M5;NNH=8O-1CU2>]E-Y" D,BA42&(9Q#'$JB)82&8-'M*R;F\3>68GY"?:0PS
M*O<<UEB(_K>#9S,2" +JF75*56IPBHD,J?XC@4RQ@()MS 0"@(F$-Q^P/1FQ
M;H2R8]S#<9X]UY<#@#[$5XYU?>2WW4\MW<;/&FE1G\- B%A:PQY"#V5R$!(7
MC=D^>*QWPR1K69XY\<13T%#,Y'(-)9.BI*&14%!S.M450(J38Z9Q(<0*<H@8
MH]P'<-;/JLE>AM68=QI]Z1_J)*Q="N9+/JBSNX=HFM[JUN(BRAU$D,ZNFY6X
M9=RC<IR",@]Z^SLN/J>2N)U-*$;(P2)A41:)"HF=-P(B87A713@[\88YC&.Z
M%85U!,8%#G*8Q1^+/$?=OSEO>>>/=\L<5[6>H-8;4FU=[Z5[]QM>9]K!H\ >
M"8BOA>   %A""--JE%4J"(JMXHIM8E0G&;-R[ETR*)-G\F[4>+,TE2B10K,A
MN1! QR&,F9<J0N3)F,F*PD,8HU/,[C:2-ON  ^WOK,U+JO6=4M/49IHH;-BK
M2VUI"L$<[(05:8@M)(%8!E0OX88!MFX CBSF'://O5GKMF];^*5%9ZU82"[-
MF]5,.ZAUT$AW(94=Q5,U.V,H)C',/.83"6:1!@$<# R >/\ A]N*NV/6.N6$
M,<,4T$G@H$@EN+:*>:! ,*J2./:"#\@2B0*  /9 %6"1H%3DH1C7E8E%",BT
MRIQ:;(3-%8T"E$O,T62$%"&, [J\PG*N;XERJB(B-(D=6+!CDG)^/.>1V_J\
MJUUOKVK6U]<:BMY))=7C%KMK@+.ER2<XFC<%6 /Y& IC'$108QPJIC.HTYTY
MD(IBHM*.TC-UY21<'>O1;&$#"U3.?9)N@82E%0C=)+K"4HK"H)2\LO*[\,>/
M<!@9]_SJ_JO4VKZQ#%;74ZI:0LLB6MM&L$'BJ"!*RKEI) "0ID=@F3L"Y.81
M]A+'\B\%RXCG?AC+"NI$HR#A&)44$1,.[5,2G(F)A$1;HK)MQ#X>ER")-5">
M0# ([8S@9^O%9UOUMU!;0^''<P^,%V+>O;1/>JN !^.8$,ZC.)'1I.=Q<M[5
M6BP4&L61HS:/F'0".1!O'+QR@L7#%N!2E!NW.@ $!ORD* -U4U$"\H"5,I@
M0H5V4D@]SDYY!/R-:O3]>U/399Y8+CQ/6G\6YCN5%Q'<2Y+>+*),L9=S$F16
M60Y(9B"0>/6,;U&I-WZ,5%D,I+)BC*NWQS/7<BB(&#H.55N8/#\IS%%LD1)N
M.XF,D)Q$PGD=R"Q[=@. /EC]O>KFJ=2:QJ\EN]W=$+:,)+2&W4006TF0?%B2
M/'XW*@^*Y>4=@X4 "O?0CC\S])ZO&NG*""P+H1+E^X7B$U2FYR"+0X\RJ9#=
MRMUUE6VWPF1,7X=5^/)@C(R?, !OK _XUL!UOU"D#PQW44,DB>&]W%;QI>,I
M&TGQ@/9<KP98U23S5U/-6.T8\K-L,DM)-ET'J*16Z;^.<&9N_#%$1*W4,4#)
M+(E$PB0BR1Q2W,"0I@8V]"R,GY)X]QY&??@\9XK6Z7U#J>D*\=M*DD#N9#;W
M,:SPB0XS(H;#(YP-Q1EWX&_=@8\X/'E0KT*\@(Z'0\ODQ$TJ5R8[I>34$-NJ
M]<+&,JJ8GJB!3$(W'NW(EL&C2.S;F8DCMY8^0' _?YU%]U#K&HWL%_<7LGK%
MK@6ABVQ1VJ@[MD$: (JMVDR&:49\5GR:@([#-$CI9M, P=/G#%8KB.0DGRSU
MG'KD-SI+-VZ@['40, "@=T9R*1RE43Y5"E.%1FD(VYQGN0 "?F16PN.LM=N+
M26S%Q%;QSH8[F2U@C@FN$8%72251E5<$AQ$(MX)5LH2IDK/C"J6MT9^_;NVK
MY4I4W+N,=G9*O$TR@0A712E.DL8I  @*BF"X)E*3J\I2 6%E=!@'CW$ @?+/
MV_76-I?4^JZ3$L%O)#+ A+10W4*SI"S$LQA)*N@9B6*!O#W$MLW,Q,@TQ]3V
M-;&IMH1L2#,<RRC415,JJZ,(&,]4=B?Q1WPF*40=BMUR\I"E.4A"E"#(Y;>6
M.[W_  ]V.V/AC%8\W4&L7&I#5Y;Z5K\*$67"A$B4$"!(0O@K  2/!V;#DE@6
M))A('$5*@)=*=09.7THV$PL7,J\4>^ $Q3%$S-(P%234Y3"4JYR*."!OR*EW
M-O4TSL-I( \P !GYX_Y5G7_5VMZA9OI[SQ6]I* )XK.%(/6 ""%F<;G9 0"8
MPRQG^4AP,+#B.F61ZL_>-7K5=V<5'Q8U\JR1?J#]8[E(@&*"BG?JK-P054$1
M,<YC[& LTB# ((';(!Q\CWQ\,X^'>HT_JW6=-@2WAE@E2%=EN;J!)WMU'*K$
M[8;8I_)1RZ*/9"A>*FUJ!45JZVJP0S=&%8[&8MFXJ(*,U@$P^)0<IG!P5R<Q
MU#*KF4,HX,HH+@504.!J1(X;?N);WGGZ.?+X>7E6"FOZNFHRZKZ[))>SC;/)
M*$D29, >%)$5\,Q!554C"JL85?"V%5(C:OBVH5*14F(YFNXESIF1+)23D[QT
M@@?8#HM>8"(MB' .50R*)5E"? HJ<GPZEY7<88\=\  #/O.._O\ =FLK5>J=
M7U>V2RN9HXK)6$AM;6)8(9)%)*R2@$O*RDY4.Y13[2J&YJ-E<+T.8>J.W+!X
MDDNJ*[N-9OW#6-=*F-S',HW2$ID@4'?G(U5;D,(B(EW$PC*S2*, CCL2 2/D
M3^_-9-IUGKUG$L<5Q"[QIX<5U/;Q3742@;5VRN#O*C\EI5D8>9.!C7OBAS'C
MC$T;!4L*L2?LY8\',+%L'HPC:LQ(B=H@Z<OFJ*RQ"N3MCD;1:2!P=%:G6<J-
M2E;*+_*WW0WW4FC>@N2QT2TTH]3]9:I:??!-+:[]2L--TYY)((;[5+I8;B5G
MN9H9EM+&WB\69+>:2:XLX_5VN.[]&?274/5%U?ZR=4:RTYK@QWUS<PB^DU.[
MQXKQ)!*Z*3$)%:2Z:13"956)929533.K<8<E4#O5XG&514>R20H/I&0?SKYZ
MY;"(#X8ZBKL$TVXB "=!!%%)4P =4AS@!@^0G_Z0[TAOC=T+T=@=@+C6@!]5
MX.?C7K^J^B>#65@CO.I-56"U8/!;6T%C;P1R@8\4(D.YI<9 D=W9 2$*J2*@
M7/$^#MZ#IQC"LJ-@5ZWDXS-C"($X#S  M0>@?H\W?PW6\+L(D%'I_!JK_P"D
M0](F,?@+T=GGGQ]9SSWY]<SGXYS^VMA%Z.GAB*1]2ZBLQ0H;WU+33>;3QGQC
M;XWX_P#O=GB@^UOW ,+/9.,V9M*38DCC6H(*LD0;LG<<^G&+IJW#;9NF=)WT
MS-P -BH*I*)$W$2$*(B.J$_Z0WTA(<CH3H[DY(-QK1!^>;SO\>]:O3/1%::4
M\K6W46JR)._BSPW,%C<12R]_%</#N$A/Y4B.KM@!RP&*_*MQD/*HT>Q[+%5.
M6:2P@$X9P_FEWTLERG(9)P[=+N2@3D44*FD5 6R0G,8C?F,837$_Z0_KXRQM
M<=!=)20JP+QPWFL02%,C<L<K3S)&Y P':&0 \E&'%-5]$L>K307$_5.L)+9Y
M-B(H+.*"S<D-OBABCC.XNJLSM(97P%:0J !M/1;[@2UT@^3AAI4LA!2;=@O0
M9&5-($8V!9,[M@FV Y4DWT:LDW7<M9!X4R()-70*,BO&_A=?H?\ <]>E_2/N
MB= ?4^G89-)U+39DM>I=&O)$GGT29T\2*07,4<7KMA>(&^]]VL-N;EXIH9(;
M>6WN(X_!?2AK/4_HR22SU.\@EM[^$K8:EI]JEM=:HC922(L=WJDZ ?Y6$.8X
MRKI)*LJ>)5K=F5*W/#/75,C&;GE!$KIG*2*+T[8NX$0=+)=%!WR@.P*G:E.4
M/A3%,O;7U+%T+:(H#:A=,<<D1PJA/F51A(5S[M[?,]Z^>M-]-/4>DJ8;.RT]
MK7>9$MKP2721N>[HV8BK'NVP(K'VBF:]D5FEO#5]S6&6/JP$0^,95^BLXE5U
M7S@W+N[=.5'1G"CH!(04UNH!D!(0&_2*F0"R>A+(MN-_>[AV.(>/E^+X^V:M
M7?IFZIO=0BU.=;;UN !+=T,L:6\:YQ%#"K")8O:;<FPB3<QEWEF)@H?)3"'E
MV\X2EQ3Y^R4!6.-)R<L]1CE2[\JK5 ZX)]5/?=)9<JZR)@ Z2A#AS:J;H>S8
M$&_O #WPMN,_,B/-9]YZ=NK;RRDL#;:9;V\Z[+D6D,D#W*>:32*Y;8W\M(S&
MKC*N"I(KE63+"-H>*OWU0C&KMSMXU6-DI5EX[E "@+HA%C)G/RARBL0A%S%
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MNW[QDJ"T<63?+/6T>J4=R*MFY^4@JI[!TE''B%$1 #)G*H'/JIII&!&0 >^
M!D>[CRYY]_G6?==8ZY=6<MB9X;>"==ESZK D$EPA_*261<L$<\ND7AJ^2&!4
M[:YMEQ74;2[4?OF[QJ\7Y0=KQCQ1D9Z!2@4OBB% Z:A@( %%4I"+&* %,H(
M7:$E=!@$$>60#CY?;%6-,ZIU?2H4@@DAFABSX,=W LX@W$DB%B5=%W$G869
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M9U*.R2QJZLR$*48JP+*0"I)&!C%;6<+9C%R6X #&*!ZQ*E, &$ .4'<6<"F
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M+GB%07_&.J9]D C()&ZKD$=I.VF*UE:QBZBNY92K78&;<W2HHW7+D1GPD9\
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MY7[7M -SGV@#W J1_0_Y<_<E_P#'JS_GK4_A=T]_2'_PE]_AJI_ SJ7^C?\
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MIZ;(UCI$=I9C2M"ZBTR8F\AUO3K&=O7=/@+3-%.CQ3V]W*%N["[EBN)8K+X
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M=N*R QSW;8QL1G&PU0CVB7ZFU8PSAHV3WV >1!O(II$W  ^J4/0/LUEK86Z
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ML11%--))0@*JBF94RIC$(*72$RO0Z7I4,T*W-R"X<GPX\E1M4E=S$$,26!P
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MF*JDHF<Z9R&*8AC%$!'8=^U<YV[U>6_ZW0_W%+_Y"ZT4G\9)_GM_O&N_LO\
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MV"DQUE>D=R4O<&Z:;9-N1A 76TU-ES$454%RH%5EH9TNX4!4$U!<.E41322
MJ)3%,8RE0I,.XNYR+/*+79QVF8#DD;0Q);94IRCN!PEK.,M)<_, &$PNA,)@
M PB(@ Z4K(+-DSCVZ;1@T;,6J0;)-F:"39NF'V)HHD(F0/Q%* :4KDZ4II2F
ME*:4II2FE*:4II2FE*:4II2FE*:4II2FE*TOX@<KKVN@WZNXUK*EPA81VSB;
MQD)U*%@J-!.(^R1K6:@J[) PE'M\N46X(JT>Q<!'A68B1:2,)9[I7["P4A5+
MT2X=2QP2"0N#N/!Y/D!\SD\$ @YKUWH7IE-,US0[_J#45TJ[O(Y;K1M"BMC>
MZS>QSZ?<2VE[?V_CVT.B:3<QLLL-S?3_ 'QNK>6WO-.TB_L)UNUXV2"F)>+$
M!BB41>E, "&P\IVR!R&_(8ABF ?F @.NSTL@V%M@Y]AA](D<$?0>#\:\5D_+
M;Y_M%=9/M1:;<<@\#F8J90J[)VRU3\OAEI'U^)@IBS.9!L3.^,G,P#F!@=I:
M2AVT(A(O+ @T.CM MY)5=PV;)K+IU:BC/9RJBEF)BPH!8G\=&3PO) &2V/('
MM54) D4DX #<\?S6]_%=/\WP_<1UMP5/<!C+"&05U+3Q=\2-YRNRJ!K1B? U
M;Q=2:A7'>'6& KQ=/-(N#QQ9+S<L5Y(K]24L4Q)GM-.RU"D3 C!XHSUC0W#0
MFS$+Y:YG>3;NBA6-%4Q"%WR!&SLCJNXDLD@K(#('$I<<(@7.&?))W;E'=@ 5
M/ &"I/<5GSAVQMGWB.XO\"9XS/AN(@IC&W!EP[Q619+/.)<@.I",S7C3/&?X
M#(;C#L^$W5X*NW>1D(5G<V4H_:VM!U4+!3IU%@XBG\>^?7X$GGN8)I8@K1VL
M(D,T<F1+'/,'\,Y50[;0P)W#:RG!!YI=D2-U5CAI'VA64^RR1D;AR<8R#C&"
M",U] >MS6)6R.!BF!G9#B4>0SF,*4VW83$2>"8H#\Q*!R"(?(#!]NN8Z@_C+
M;_,D_P!Y?ZC63!V;YC]E?/\ 9.15;Y)R$@NF=)9&\6Q)5)0HE.FJG//R*)G*
M.PE,0P"4P#W 0$!U]+Z0ROI6F,I#*VGV3*P.00;:(@@^8(KQ"^!6]O%8$%;J
MX!![@B5P0?B#75/QN84N^<<K\/\ 5ZM7H:0CE:!Q)Q\G9[9'V=S5*'+34=BQ
MI6K,9Y6TBG9W&/62D)"E).)&).\?1[T&T@@"#A0G,]4Z7=:KJ.D000Q.AL]:
M1Y[A)S;VDDB6*PS[H![-RAWO:AGCW,C[7&"1N]"OH+"TU&66616%QIC+%"T0
MEN$1[MI8MLA]J!@56<A7VJRY4Y .M.6\4SK#'/%72K3#6BVS3S(D PQW;;9@
M?+>8QN$A#\*N-JL>Q5Q"AK%3K=RF[*U5)7\DS 3U=KMF;RJ"C-Y);]'1:AI\
MJ6?4%K<13W$KWL*6=Q/I.HZD;EX]!LK<S0"T($%S+.A\&^E$T$,RR(5:0\;*
MSNXVN=(GC>*%%MI6N88=0L[+P%DUB[F$4IG!\6!(6'B6J>'))$4(95[\ZL4K
M+Q.(.FVW(&-LG*X;3-PF!=Z:LVG;%-,,CML,GC*?:K!,,HXB60:UBB_F7:Y$
M+&MVS=A9W\)=9M!1I7U6*-=O:ZB-8MKB\L;XZ8/P=%U:E99I4O5TPI;3S2*@
M%Y!I]WE;T(H$<[Q74H*PE1$L]F=-FA@NK47O_6_@3 QQQM;&]W3Q1QECZM+>
M6P#6Q8DM$LD$9S(&/=1KU"N)KNIX'&ZX<*MQW24#Q<_?3M?A'[N3W<BFW,E_
M=AXA%5'</[8F<OJ Z\ ]([*>J[< @E+*Q# <[3X\[8/N.UE;'N(/G7HV@*QZ
M6U,!22ZZCL&/RLVBJ,>_V@1\P14-KGJ\YKY^_:LX$S3EG/3VT8YQM*7"&H?!
M3/RYYJ/J%RF+;#R\?GNH/IS]#W8Z](1L=!<3#&C^=36/6[PLVXEDF;F*\A<H
M2(.$,&Y21WRJD@0DYP200X)\,@@"3;DJ.YQC'-=CT]>6MM:+'/.L3S:JJ[#)
M$L;H;.14]=1U9GL3+M68C:%)W;P5P?0^-Q3/N/"*XSJ]A7+I\9-LLQW"'%R\
MX2=;R9^'B1JXTM6W36&W$0UN(0*'$O)%RX_OAXE&."BQP.5 "/3&1"?QOC^,
M$?;N\(9!!\/&-Q3 ./$.\MC\D<<<U*_>]=(?3'NK;U@VYU)D39M]<602^$MU
MO,1<V"^K"'?N\8X'/%;%^RXJ=#J]?C&EPPKF6G<;#6C6-MQ49,R5C+*L.2ZW
M%:[L7,TX?9>L48AC?*0V.6!"P8\/4[!9S15*;.TXLT%%F=LG==L% Y1Q-M/B
MLRL,G=SER-K9/*[20!G&!Q6%U!)-([&*ZM9=*,R'3X()[=_"B$3!0+9&,]OL
M7*3>(D>Z4C=O8 CN UE5S5;QT.;AFU-K2#B6CD5TXAF51)5ZW(HF(I@/*<AE
M ,4P (;@( (:TUQ:W+S2,MO,REB01&Y!'O!QR/C7L>C7=K'I.GH]S K+:0AE
M:5 P.T<$%L@^\'D>=6SWB@/V[BOW^U_G=6?4[O\ -I_]4_\ 56S]>L_SJW_U
MT?\ :I[Q0'[=Q7[_ &O\[IZG=_FT_P#JG_JIZ]9_G5O_ *Z/^U7Z%B@!'8)J
M*$1__P![7^=T]3N_S:?_ %3_ -FGKUE^=V_^NC_M5*IJ)JD*HD<BB9P Q#IF
M Y#%'T$IBB(" _(0';6.05)5@58<$$$$'W$'L?A62K*P#*P92,@J001[P1D$
M?$5YZBIII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2N&^D&48V.[
MD'2+1LG]95<X$+OL(@4H#\1U#;#R)D QSCV*41[:NPPRW$@BAC:21NRH,G'F
M3Y*HSRQ(4=R0*LSW$-M&TMQ*D4:]V<X&?( =V8^2J"Q/ !-82LN5EENHTKB0
MMTQW(,FX( KG#T$6S<P"1$![[*+@=00'<$D3@ ZZJPZ=5=LE\V]N"($/L#X2
M..6^*IA<_P IA7&:CU0[[HM.4QKV-S(H,C#S\.,Y5![F?<Q!_(1AFL/.'"[I
M91PY65<+JF$ZJRQS**J&'U,<YQ$QA^6XB/;MZ:Z=$2-52-51%&%1 %51[@H
M 'R%<D[O([22.TCL<L[L69C[RQ))/S-9.IF-PGFYG\^5PA%.$3D;MD%UV3QX
M14@D%<KELHBZ9H@ B**S=5%R<W*J@HD4I%#\UKFK*D<MC;.WBR(\4TT4CQO
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M[@I6S=1K#2HP;:&:J&7%,QUW3HQ0(9T[6VZRXD 3 0NQ2))$YC"1%-,ICG,
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M3Q@XC)!<I0,^62.Z;O52 N9HD[6=.E^^Z;](=WHEG'I]Y:#4+6 %;9A-X-Q
MA)(B+&.198E)Q&K!&C4[0[(J(O*:OTI!J-PUW!/ZK-(<S*8_$BD;MO #H4<_
MRR"P<\[0Q9CKQ_I9EG_"O _\V)#_ #KKIOX6+3^A;C],C_N*TWX#W'](0_ZA
M_P"W4-*>SIF8A]7(]WEB'\1:)E>"B^E5) Y!?-Z].V93Q!O-R]%'RRNR(E4
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M6RNA;QN2W@21&18R3DB-U=3L_FJRDJ.-Y':#_0^2/[I67\'K_P"4ZN??)/\
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M*5XF,4A3'.8I"% 3&,80*4I0#<3&,(@   =Q$1  #N.I )( !))   R23P
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M/R.0OM\IU^AZ!XNR\OD(BX:"W<8,OF))1_W?FJ'^,[L/#P),\@
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MU3WNM'[?RW[^7_[>GWMT_P#,[;_4I_9I]]-2_/[O](D_M4][K1^W\M^_E_\
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M>VGWSO\ \Y?ZD_LT^].F_FD7_J_M58FK5LR1(V9MT6R"8;$103(DF7[1 A
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MJB_YFJ]-:1J2'Z4NE-9RU37&UT)\422B6?LG%5(8AAGDU0 P" BFM&,%DC@
M_L5$E"'(/H)#%$.PAKZSZ$96Z1T,J00+1ER#GVEGF5A\U8%2/(@BOCGTA*R]
M9Z^&!4F\5@",95[>!E/R92&!\P0:Z;?:$XTR)E1KP]US&I[*SL++)UVLT9-0
M!9(K2!M56P/E:P8ZD;$Z8\J#.&-D:.JS)4TBJBT=+.TF &,N[23/C=9V-[J
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M,AK)&%:5)Z[A&3QU3:W-XR6Z"42OLO))@T1,A:WDA"VY.\;7<2$;B"0K#"<
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MU;+L9!A)MB/(UZTD&:AE"INV+E%VV4,BH9%4I%VYU$C&25(=)0"G$2*$,0P
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M0C3^#'K/^C(O]H:?_B:?A=H/YV_Z-<_W5/TPI[*G\/EF_B4S)_0C3^#'K/\
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MJ2E8<0X#,QW*M8_WBF%L9FN;=)O5[RY6U(F,K1V$TL5U[:QF$%?"+)F3\9G
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MI"WRV@>5WS]\@PO&GW9\=IMS,6DR0S$CO5R?5;VX:\:212;XVYG*HJ_]EQX
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MWZY*+M9"=.:2.*[FC@F?2I1+8R30JVR1H3E0"-C DLI<*ZZR'5KR"#U=#"4
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3@&<  *BEE/=7K@*Z6FE*:4K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>gwpjrhodncoa000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000015.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "P ?H# 1$  A$! Q$!_\0
M'P !  (" P$! 0$           <(!@D#!0H$ 0(+_\0 9A    8" 0 ""@@.
M"PT&!04  @,$!08' 0@ "1$2$Q05%E97E=35%Q@9(562EM,Q-T%24W>3E)>U
MMM'2UB(C-CA16'5VD;37)#(S-#5486)R=+*SMR=Q<Z'!\"5"0['")F."X>+_
MQ  > 0$  00# 0$              04&!P@" PD$"O_$ &\1  $"! $$!1$1
M"PD$"0,%  $  @,$!1$&!Q(A,4%189'1"!,4%1875597<9.4E9;3U-48(C4V
M-U-4=7:!DJ&QL[76\!DR-%)T=Y>TML'2"2,S0F)SHK+A)CA#<B0E9(2WQ=?E
M\45CPR='9Z3B_]H # ,!  (1 Q$ /P#W\<(G")PB<(G")PB<(G")PBP6-1J.
M*6%I4*&!E//.1$F&G'-2$TTTP0>L0S#!D"&,8LYSD0A"R+.??SG.><B2";$C
M2=E<0 0+@'0-A=WX*1;Q:8/,[=Z-R+G;.^5-AM#>">"D6\6F#S.W>C<7.V=\
MI8;0W@N(^-Q!,28H4L,;3D%!R,T\]K:RB2@8^B,PPP@( !Q]40A8QC^'BYVS
MOE+#:&\%R!BT4&$(P1R/# (.!!$%H;1!$$6.L(@BPGSC(<XSC.,XSG&<9Z\>
M]Q<[9WREAM#>"_?!2+>+3!YG;O1N+G;.^4L-H;P73/">MH\)H _D0=C'('E)
M'&$#P4PM@GN0KRE)Z%A: K0D9<GE:0C5G)&M%@Y<I*2J3"2!@(-R%<[9WREA
MM#>"[GP4BWBTP>9V[T;BYVSOE+#:&\$\%(MXM,'F=N]&XN=L[Y2PVAO!/!2+
M>+3!YG;O1N+G;.^4L-H;P3P4BWBTP>9V[T;BYVSOE+#:&\$\%(MXM,'F=N]&
MXN=L[Y2PVAO!/!2+>+3!YG;O1N+G;.^4L-H;P3P4BWBTP>9V[T;BYVSOE+#:
M&\%T:",QL;V_%#C[((HD+5VHL34@$65VQ,:(SM8,I\A!V8L8R/L<8[+.,9%U
MYQQ<[9WRH %SH&O:&T%WG@I%O%I@\SMWHW%SMG?*FPVAO!?F8K%<=77&X_CK
MSC&.MG;L=><_0QC^Y_HY^ICZO%SMG?*6&T-X)F*Q7&<8S&X_C.>OJQEG;NO/
M5CKSU8[G]_JQ[^>KZG%SMG?*6&T-X+XW)F@K,W.#P\-43:FEJ1*G)T=')"SH
M6YM;D)!BI<O<%RHHI,C1(TQ1JA4J4&ED)R"S#CC %@$+"YVSOE,T;0W@OUN9
M(.[MZ%V:6B*.;6YHTSBVN3<@:%K>X-ZTD"E&N0K$Q1J=6C5IS2U"92G,,)/)
M, :4,98PBRN=L[Y2PVAO!?9X*1;Q:8/,[=Z-Q<[9WREAM#>"Z9Y3UM'>]6)
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MRS3<"VD@$=8Z0HLGW2=ZJU#KTJV8NM7;](0 B5*X8C8K@H.X:]M%]>TC0ED
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M[;=<;$0:XY@E@]B4K!&^L874&Q[+;K=#7]VG-QG-\ZE<[0&/RAI?82K[QM@
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M:VR]'UJO*=28GMO!G:&)(/!Y?OL[3^BVM$\,CLG4T:9#]=H-!5P2V9P7C9\
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MB\=A9!5\'A72 0MBO/7ZCI'$T,8IJH;WNZ96$W,][0XY:\3=UF+)B:6:@;4
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M$=3C%7=2D<"[N96;]ER_P(B>W5SXD8\Y9^;X^Z/8(ZG&*NZE(X$YE9OV7+_
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M#R7XPJ.-\-Q:S4X,C F&52:DFLD(4>% ,*! E8C7%LQ,S<3CA='>'$10T@-
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MW%3DX1.$3A%:S4'Z8DF^UZ[?E#%N6;E/]2/*G[E9']L\)K)&2GTX2OY+,_\
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MCD+[9O\ HO1!T6A/:-:G,'5U?]J4H%CJZ^KWV2*8][K]_P"I_3S>;B<XG',
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M.3A$X1.$5B-4OI]0G_=9I^04HY\5:]*647\U&5O_ ,,\5J]\FWI[PO[:P?\
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MZ@?KQ?ZO/$.-/_SL7S__ !'_ .8[JQX9;2=%M)^WWRX>]V/K/_(/Z/.OD_\
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MS4.!&+!#BOEH[(;G.@Q W7W+%"BU&JTF)3X<2?APY"*R(^28Z:8QYF"0U[H
MB-:XC2&N()&FUE2_V'[:\EUB_(F2^K.93YC,8=*>)>X54\56'N5-5Z&5#M*9
M\&GL/VUY+K%^1,E]6<<QF,.E/$O<*J>*IRIJO0RH=I3/@T]A^VO)=8OR)DOJ
MSCF,QATIXE[A53Q5.5-5Z&5#M*9\&GL/VUY+K%^1,E]6<<QF,.E/$O<*J>*I
MRIJO0RH=I3/@U(%:55:"*1N1RVMYZD)'7]LI &JH?(4Y8U;A5DR0($H3#6X
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M":Q: 1Q=(HW$D;W+7= QMBF3S!Y21Z+L1"Q>:228Z/KTN2-K:D"/)JE4>
M]799P0 G4+]9<-=VG7%M(9,Y5O+&:8((;/)E5\I5,Y@CBF2P*]>CX[-8HNR8
M45DMUCCVE/;G$H.!  H+%@LPP&<#R0BVO<.^+CXE(/8 ^M#\7'YN$7^>-NN>
M>';K9,(3C0AQ<]@XQC!@\8QC$C7=6,8QGJQC'U,8YJ'B\D8IQ  3;EO/;/\
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M)$NFZ0!SLS3G/=BC),--/+3EML3<#0=R@$G$:-4!. SNHO"<1V2U&"=S<CN
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MFXQD. YSV>>RZ^K'5Z:<2UE'QOB7(?*U:O8BG:I4N>/C61Y+FFRSXO(DK0,
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M1V)'F)D5O*!*)C)86L YPSVZM&L7U$=< Z-NZF,72'W%&9?>UT,T/J:C;.V
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M8J'[4Q?UIRU[<V26NZ<(G")PBL?J3^^ @W^Z3?\ Z?2KE!QCZGV5/\S^5_\
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85K6MM5J&TM,<H0(SAC3EDSA^*/BX%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>gwpjrhodncoa000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -1!TP# 2(  A$! Q$!_\0
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M$^>!]3NB2QLCJKHPPRD9!![5XMX]\!-HKOJ>F1EM.8YDC')@/_Q/OVJ_\/\
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M%38Y2BBBO:,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%%% !1110 4444 %%%% !1110 4444 =UX$\=R:#*NG:B[/ICGY6ZF GN/\
M9]1^(]_;(Y8YHDEB=7C<!E93D,#T(-?+-=UX$\=R:#*NG:B[/ICGY6ZF GN/
M]GU'XCW\G'8'G_>4]^J[GK8#'\G[NIMT?;_@'M]%,CECFB26)U>-P&5E.0P/
M0@T^O!/H HHHH **** /G.BBBO0/S8**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *][\/_ /(M:5_UYQ?^@"O!*][\/_\ (M:5_P!><7_H K"OLCZ#A_\
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M_P#(M:5_UYQ?^@"L*^R/H.'_ .+/T-&BBBN8^I"BBB@ HHHH **** "BBB@
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M]E.=P /RD=CTKTA(]<3Q3]IN=9LTT63Y;>T5%WR,5Z9(SUR>"<XZ"N9\)_\
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MU&.1H4OI8E%LTG?D[@/_ !W@>E=W8Q:W;Z/JT6OZO:WMV;=W2&!%7RDVMSP
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M/3] TJ16GAE;S%PD2,3C'\77^M4-4TVS_L&UU&QB*9P)?F)]NY]1^M3^-/\
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M=X1M/%-AL?$5[$#Y$^.G^R?537S_ '=M)97DUK+M\R%RC;&##(.#@CK7J/Q
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M9?\ HI*^@Z^?/B5_R4#5/^V7_HI*ZLN_BOT_R(J;'*4445[1B%%%% !1110
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M_>5-OS_X 111PQ+%$BI&@VJJC  KS#X@?$#9YNC:--\W*W%RAZ>JJ?7U-'Q
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M-J,J_O9L<*/[J^W\_P @-;7M>LO#NF/>WKX XCC'WI&]!1KVO67AW3'O;U\
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M),/<.,10@\L?4^@]Z\@U#4+G5+V2[NY"\KG\ /0>@HU#4+G5+V2[NY"\KG\
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M **** "O>_#_ /R+6E?]><7_ * *\$KWOP__ ,BUI7_7G%_Z *PK[(^@X?\
MXL_0T:***YCZD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *\2^,/_ "-MI_UX)_Z,DKVVN&\>^ Y_%5Q;7MC<PQ742>4RS9"LN21R 2""
M3V[]JZL'4C3JIRV)FFUH>%45Z#_PI[Q#_P _FF?]_9/_ (BC_A3WB'_G\TS_
M +^R?_$5Z_UJC_,8\K//J*]!_P"%/>(?^?S3/^_LG_Q%'_"GO$/_ #^:9_W]
MD_\ B*/K5'^8.5GGU%>@_P#"GO$/_/YIG_?V3_XBC_A3WB'_ )_-,_[^R?\
MQ%'UJC_,'*SSZBO0?^%/>(?^?S3/^_LG_P 11_PI[Q#_ ,_FF?\ ?V3_ .(H
M^M4?Y@Y6>?45Z#_PI[Q#_P _FF?]_9/_ (BC_A3WB'_G\TS_ +^R?_$4?6J/
M\P<K//J*]!_X4]XA_P"?S3/^_LG_ ,11_P *>\0_\_FF?]_9/_B*/K5'^8.5
MGGU%>@_\*>\0_P#/YIG_ ']D_P#B*/\ A3WB'_G\TS_O[)_\11]:H_S!RL\^
MHKT'_A3WB'_G\TS_ +^R?_$4?\*>\0_\_FF?]_9/_B*/K5'^8.5GGU%>@_\
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M1_PBVK?\\%_[^+_C1]8H_P R^\/JU;^1_<8U%;/_  BVK?\ /!?^_B_XT?\
M"+:M_P \%_[^+_C1]8H_S+[P^K5OY']QC45L_P#"+:M_SP7_ +^+_C2'POJX
M'%LI]A(O^-'UBC_,OO#ZM6_D?W&/16O_ ,(SK'_/G_Y%3_&C_A&=8_Y\_P#R
M*G^-/ZQ2_F7WH7U>M_(_N9D45K_\(SK'_/G_ .14_P :/^$9UC_GS_\ (J?X
MT?6*7\R^]!]7K?R/[F9%%:__  C.L?\ /G_Y%3_&C_A&=8_Y\_\ R*G^-'UB
ME_,OO0?5ZW\C^YF116O_ ,(SK'_/G_Y%3_&C_A&=8_Y\_P#R*G^-'UBE_,OO
M0?5ZW\C^YF116O\ \(SK'_/G_P"14_QH_P"$9UC_ )\__(J?XT?6*7\R^]!]
M7K?R/[F9 !)P!DFNW\.^'Q9JMY=K_I!&40_P#_&F^'_#ALV^U7R#SP?DCR"$
M]_K713&40N8%1I<?('8A2?<@&O,QF,YOW=-Z=6>K@<%R?O:BUZ(RO$/B&VT"
MR\R3#W#C$4(/+'U/H/>O(-0U"YU2]DN[N0O*Y_ #T'H*[#4/ _B'5+V2[N[V
MQ>5S_P ]'P!Z#Y>!57_A6^L?\_-C_P!_'_\ B:Z,(\-0C=R3D<V,6*Q$K*#4
M4<?178?\*WUC_GYL?^_C_P#Q-'_"M]8_Y^;'_OX__P 379]<H?S(XOJ6(_D9
MQ]%=A_PK?6/^?FQ_[^/_ /$T?\*WUC_GYL?^_C__ !-'URA_,@^I8C^1G'T5
MV'_"M]8_Y^;'_OX__P 31_PK?6/^?FQ_[^/_ /$T?7*'\R#ZEB/Y&<?178?\
M*WUC_GYL?^_C_P#Q-'_"M]8_Y^;'_OX__P 31]<H?S(/J6(_D9Q]%=A_PK?6
M/^?FQ_[^/_\ $T?\*WUC_GYL?^_C_P#Q-'URA_,@^I8C^1G'T5V'_"M]8_Y^
M;'_OX_\ \31_PK?6/^?FQ_[^/_\ $T?7*'\R#ZEB/Y&<?178?\*WUC_GYL?^
M_C__ !-'_"M]8_Y^;'_OX_\ \31]<H?S(/J6(_D9Q]%=A_PK?6/^?FQ_[^/_
M /$T?\*WUC_GYL?^_C__ !-'URA_,@^I8C^1G'T5V'_"M]8_Y^;'_OX__P 3
M1_PK?6/^?FQ_[^/_ /$T?7*'\R#ZEB/Y&<?74^$_"<FM2B[NPR6"'Z&4^@]O
M4_Y&GIOPXN5OD;4KB!K9>62%F+-[<@8%>A111PQ+%$BI&@VJJC  KCQ>814>
M6B]7U.[!Y;)RYZRLET"**.&)8HD5(T&U548 %>8?$#X@;/-T;1IOFY6XN4/3
MU53Z^IKL_%=EK^I:=]CT2>UMO-!$TTLC*X'HN%.,^M>:?\*A\0?\_FF?]_9/
M_B*Y,%"@G[2M)>AV8Z==KV=&+]?\C@**[_\ X5#X@_Y_-,_[^R?_ !%'_"H?
M$'_/YIG_ ']D_P#B*]GZ[A_YD>+]2Q'\C. HKO\ _A4/B#_G\TS_ +^R?_$4
M?\*A\0?\_FF?]_9/_B*/KN'_ )D'U+$?R,X"BN__ .%0^(/^?S3/^_LG_P 1
M1_PJ'Q!_S^:9_P!_9/\ XBCZ[A_YD'U+$?R,X"BN_P#^%0^(/^?S3/\ O[)_
M\11_PJ'Q!_S^:9_W]D_^(H^NX?\ F0?4L1_(S@**[_\ X5#X@_Y_-,_[^R?_
M !%'_"H?$'_/YIG_ ']D_P#B*/KN'_F0?4L1_(S@**[_ /X5#X@_Y_-,_P"_
MLG_Q%'_"H?$'_/YIG_?V3_XBCZ[A_P"9!]2Q'\C. HKO_P#A4/B#_G\TS_O[
M)_\ $4?\*A\0?\_FF?\ ?V3_ .(H^NX?^9!]2Q'\C. HKO\ _A4/B#_G\TS_
M +^R?_$4?\*A\0?\_FF?]_9/_B*/KN'_ )D'U+$?R,X"BN__ .%0^(/^?S3/
M^_LG_P 11_PJ'Q!_S^:9_P!_9/\ XBCZ[A_YD'U+$?R,X"I[*RN=1O(K2TA:
M:>5MJ(HY)KN/^%0^(/\ G\TS_O[)_P#$5Z#X-\%VWA:TWN4FU&48EF X _NK
M[?S_ $&-;,*4(7@[LVH9=6G.TU9">#/!EMX7L_,DVS:C*O[V;'"C^ZOM_/\
M(#6U[7K+P[ICWMZ^ .(XQ]Z1O05IMNVG: 6QP"<"O+?$7@+Q;XDU-KR\OM,
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M\_FF?]_9/_B*/KN'_F0?4L1_(S@**[__ (5#X@_Y_-,_[^R?_$4?\*A\0?\
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M[?:1[GPLLLQ:=N1G%45VO_"L=:_Y^M/_ ._C_P#Q%'_"L=:_Y^M/_P"_C_\
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MQ_\ XBCVD>X?V;B_^?;.*HKM?^%8ZU_S]:?_ -_'_P#B*/\ A6.M?\_6G_\
M?Q__ (BCVD>X?V;B_P#GVSBJ*[7_ (5CK7_/UI__ '\?_P"(H_X5CK7_ #]:
M?_W\?_XBCVD>X?V;B_\ GVSBJ*[7_A6.M?\ /UI__?Q__B*/^%8ZU_S]:?\
M]_'_ /B*/:1[A_9N+_Y]LXJBNU_X5CK7_/UI_P#W\?\ ^(H_X5CK7_/UI_\
MW\?_ .(H]I'N']FXO_GVSBJ*[7_A6.M?\_6G_P#?Q_\ XBC_ (5CK7_/UI__
M '\?_P"(H]I'N']FXO\ Y]LXJO>_#_\ R+6E?]><7_H KSN+X8:L95$MY9+'
MGYBC.Q ]AM&?SKT^TMDL[*"UCR8X8UC7/7 &!_*L:TDTK'MY+A*U&<Y5(V)J
M***P/H HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_*C[7)Z+^504460$_P!KD]%_*C[7)Z+^504460$_VN3T7\J/M<GHOY5!119
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#1B_U2?[HI],B_U2?[HI]9#"JC_?;ZU;JH_P!]OK5P(F-HHHK0
MS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M45R/_"S_  =_T&/_ "6F_P#B*/\ A9_@[_H,?^2TW_Q%'LY]@YEW.NHKD?\
MA9_@[_H,?^2TW_Q%'_"S_!W_ $&/_):;_P"(H]G/L',NYUU%<C_PL_P=_P!!
MC_R6F_\ B*/^%G^#O^@Q_P"2TW_Q%'LY]@YEW.NHKD?^%G^#O^@Q_P"2TW_Q
M%'_"S_!W_08_\EIO_B*/9S[!S+N==17(_P#"S_!W_08_\EIO_B*/^%G^#O\
MH,?^2TW_ ,11[.?8.9=SKJ*Y'_A9_@[_ *#'_DM-_P#$4?\ "S_!W_08_P#)
M:;_XBCV<^P<R[G745R/_  L_P=_T&/\ R6F_^(H_X6?X._Z#'_DM-_\ $4>S
MGV#F7<ZZBN1_X6?X._Z#'_DM-_\ $4?\+/\ !W_08_\ ):;_ .(H]G/L',NY
MUU%<C_PL_P '?]!C_P EIO\ XBC_ (6?X._Z#'_DM-_\11[.?8.9=SKJ*Y'_
M (6?X._Z#'_DM-_\11_PL_P=_P!!C_R6F_\ B*/9S[!S+N==17(_\+/\'?\
M08_\EIO_ (BE7XF^#V8*-8&3ZV\H_P#9:/9S[!S+N=;16/IWBK0=6D$=CJUK
M+(>D>_#'Z X-;%2TUN,****0!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"?B'4?$%O<R:AH%UH[1.%1+@MF0$=1E5Z5T-4@"BBB@ HHHH **** "BBB@
MHHHH **** "BB@\#- !17E5M\7]2O_/;3_!=Y=QPG#O!.SA?KB(XZ5U_@_QM
MI_C&SFDM8Y(+BW($T$G5<]"".HX/Y=*+H#IJ*Y#P9XW;QC::C+'IOV:2S8*J
M&?>)"0<<[1CIZ&CP7X[3Q9<7]G-I[:?>V;8>!I?,)&<$YP.A&"/I1<#KZ*Y#
M1O'/]N^,K_0[/3=UK9;A)?>?QD<8"[>[9 YZ#-=?0 45S7C/QC;^$-.AF: W
M=U/)L@M5?:S^IS@\#Z=2*3P3XN'C'1IM1^Q?8_*G,)0R^9T4'.<#^]1<#IJ*
M\UO/BV#>7*:)X=O=5M;4GSKJ-BJKCOPK<<'DXKJ/#WC32?$6@3:O"[00VP/V
ME)N#%@9.<=1CD$?SXHN@.BHKR^3XQ,WFW5GX7O[C28FVO>[BH7Z@*0/H6KK5
M\;Z*WA ^)O-D^PA>5V_O-^<;,9^]GCKCOG'-%T!T=%>7-\7[F*)+V?PAJ$>E
M.P"WA<X(/0C*!2?;=7H^FZA;ZKIMO?VCE[>XC$B$C!P?7WHN!:HHHH ****
M"BBB@ HHHH T8O\ 5)_NBGTR+_5)_NBGUD,*J/\ ?;ZU;JH_WV^M7 B8VBBJ
MNI7T>F:7=7TW^KMXFE;W &<5H9G(>/\ Q_'X7B%E9!)=4E7(!Y6%>S-ZGT'X
MGW\)U#4KW5KMKJ_NI;B=NKR-G\!Z#V%&I:A<:KJ5Q?W3[YYW+N?KV'L.E5:]
M*G34%YG-*3;"BBBM"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ,B7>?\ 81?_ -%QUZ57FOP1_P"1+O/^PB__ *+CKTJO(K_Q&=]/X$%4KO\
MUH_W:NU2N_\ 6C_=K..Y9!1145Q<0VEM+<W$BQPQ(7=V. J@9)-6(EHK)\.^
M(+?Q-I8U&TMKJ&W9RL9N$"F0#^( $\9XYQTK6H **** "BF3316\+S3R)%%&
MI9W=@JJ!U))Z"F6MW;7ULEQ:7$5Q _W98G#JW;@C@T 34444 %%%5H]1L9;Z
M2QCO+=[R(;I+=95,B#CDKG('(_.@"S1110 445F:3XATO7)+N/3;KSVM)/*G
M'ELNQN>/F ST/2@#3HK(M/$^C7VNW&BVUZ)-0M@3+"(V&W& ?F(P>HZ&DO\
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M.EZ?#9[$A:Y\Q-Q5<8SASZ#HN:]'\*Z$/#7AJRTGS?-:!3N<# +$ECCVR::
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?]L?_1*5U8/^(_05?X3CJ***](Y HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ]\^"/\ R)=Y_P!A%_\ T7'7I5>:_!'_ )$N\_["+_\ HN.O2J\BO_$9
MWT_@052N_P#6C_=J[5*[_P!:/]VLX[ED%>>?%;4+A[#3?#EF^VXUBY6)C_L
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M^Q__ !%'_"F/#G_/[JO_ ']C_P#B*/K$ ]G(\+HKW3_A3'AS_G]U7_O['_\
M$4?\*8\.?\_NJ_\ ?V/_ .(H^L0#V<CPNBO=/^%,>'/^?W5?^_L?_P 11_PI
MCPY_S^ZK_P!_8_\ XBCZQ /9R/"Z*]T_X4QX<_Y_=5_[^Q__ !%'_"F/#G_/
M[JO_ ']C_P#B*/K$ ]G(\+HKW3_A3'AS_G]U7_O['_\ $4?\*8\.?\_NJ_\
M?V/_ .(H^L0#V<CPNBO=/^%,>'/^?W5?^_L?_P 11_PICPY_S^ZK_P!_8_\
MXBCZQ /9R/"Z*]T_X4QX<_Y_=5_[^Q__ !%'_"F/#G_/[JO_ ']C_P#B*/K$
M ]G(\+HKW3_A3'AS_G]U7_O['_\ $4?\*8\.?\_NJ_\ ?V/_ .(H^L0#V<CP
MNBO=/^%,>'/^?W5?^_L?_P 11_PICPY_S^ZK_P!_8_\ XBCZQ /9R/"Z*]T_
MX4QX<_Y_=5_[^Q__ !%'_"F/#G_/[JO_ ']C_P#B*/K$ ]G(\+HKW3_A3'AS
M_G]U7_O['_\ $4?\*8\.?\_NJ_\ ?V/_ .(H^L0#V<CPNBO=/^%,>'/^?W5?
M^_L?_P 11_PICPY_S^ZK_P!_8_\ XBCZQ /9R/"Z*]T_X4QX<_Y_=5_[^Q__
M !%'_"F/#G_/[JO_ ']C_P#B*/K$ ]G(\+HKW3_A3'AS_G]U7_O['_\ $4?\
M*8\.?\_NJ_\ ?V/_ .(H^L0#V<CPNNH\'>"=0\5WJE4:'3T;]]<D<8[A?5OY
M=Z]<T[X5^%M/D$CVTUXPZ?:9-P_(  _B*[***.")8HHUCC085$& H] *B>)5
MK1&J?<BL+&WTVP@LK2,1V\"!$4=@*L445QFP4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_B'1([=[B36-/2%)#"\C7*!5<=5)S@-[=:OQ313PI-#(DD3C<KHP(8>H(ZT
M/HKSR;4]0USXQ0Z997D\.FZ/;^9=I'*RK*[#@,!P>J\'T-9$/Q5U9/&TFGW=
ME9+HZ:D;!ID5Q(A)(4DEL=L].QI7'RL]:HKF_&_B:3POH'VJUB2>_GF2WM(7
MR0\C'OCG& 3VK,\">-+O7](U2\UW[!:&PN3"\D1*1@ #))9CW[YH"SM<[>BJ
M<NKZ;#IRZA+J-I'8N 5N7G41G/3#9QS7->+/B'I_AB\TVV M[MKR55DQ=*GD
M1G&)",'C!SV''6@239V-%06=[::A;+<V5U#<P-D++#('4XX.".*GIB"BBB@
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M+_5)_NBGUD,*J/\ ?;ZU;JH_WV^M7 B8VBBBM#,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF6Z*BGN(K9 \S;5)P#@GFF07UO<N4ADW,!DC:1Q1<+%BBJ\]];VSA)I-K$9
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M%1)LLQ  VMU_*@+,N45%<7,-K&'F?:I. <$\_A4=O?VUU(4ADW,!DC:1Q^-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!HQ?ZI/]T4^F1?ZI/\ =%/K(854?[[?6K=5'^^W
MUJX$3&T445H9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^WUJW51_OM]:N!$QM%%%:&84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO Z]4^&[LWAN8$Y"73!?8;5/]3652"2NCU,KQU:I5]G4=SL****Q/>"BBB@
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MX6-G2/@Y/&-P'/?'O1=@>\T4V.1)HDEB=7C=0RLIR&!Z$&G50@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **QV\6>&U8JWB#2@P."#>QY'ZUJPS17$*
MS02I+$PRKHP*D>Q% #Z*IVFKZ;?PRS6>HVEQ%#_K7AF5U3OR0>/QIUCJ=AJD
M;2:??6UW&AVLUO*L@!]"0: +5%4QJVG-J)TY=0M3? 9-L)E\P<9^[G/3FKE
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MT(;]SH,CKZO=!?Y*:C_X7A_U+O\ Y.__ &NO(J*W]A3[$<\CUW_A>'_4N_\
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MHHJSD"BBB@ HHHH **** "BBB@ KGO''_(G7_P#VS_\ 1BUT-<]XX_Y$Z_\
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M([*YM+::Q5YY(KLMA9'?</EVL"0.""*P/%UAXS@\5^'XM9U>RN-1DE464L2
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW'._.<_A3X?.V'S_ "]V>-F<8_&I** *K?;M[;/LVW/&=V<5/^\\G^'S=O\
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MS"<+:K8Y^BBBK,PHHHH ]\^"/_(EWG_81?\ ]%QUZ57FOP1_Y$N\_P"PB_\
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MZUUWPAT9]/\ ")OYU/VC493,2>I0<+_4_C0F!Z#1113 **** "BBB@ HHHH
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M3_>(VC]2*\C\#^/Y? WPWTB1_#=W<:0]PR7.I><L8\QF)^1""7P!C/ RI&:
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M=I'0_$*\ATBTL/!VFDK:V$:M.>AD<C(S^>X^[>U</9VD]_>0VELF^>9PD:Y
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG7[H^E05.OW1]*EFM+<6OFKXJ?\ )2=6_P"V/_HE*^E:^:OBI_R4G5O^V/\
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M LVUB< 9ZY'<'OWJQK&AO\._'>@3Z9J=Y+]OE"W!G8$O\X#9QC(.[H>A[T7
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 /B_UJU:JK%_K5JU6<]S2&P4445!97HHHJSD"BBB@ HHHH ***IZ
MM?)IFCWM_(P5+:!Y23_LJ3_2@#D[OXO^!+&\GM+C7@L\$C1R*+69@&!P1D)@
M\]Q74:/KFE^(+%;W2;Z&\MR<;XFS@^A'4'V/-><_ 33]O@*YOYQODU&\DD<O
MSN PO\PU<EX;U-/"'C+XEWVF(BZ?8PNT<2#]V)=^$&.@P2PQZ9I7+Y5LCV#Q
M!X^\+>%IUM]9UF"WG//DJK2.!V)5 2![D5H:%X@TGQ+IPO\ 1KZ.[MBVTNF1
MM;K@@X(/(X([UY_\%/#T:^'&\67X^TZSJ\CR/<R_,ZH&(P#VR02<=>/05Z=!
M:V]MYGV>"*+S7,DGEH%WL>K''4\#GVH$TEH2T5YA>>*?$GBWQWJ'ACPI>P:5
M::4/]-U-X%G<OTV*C<=<CG^Z>1T-?PIX]UJ)?&6F^(;F"[N/#J.ZWL<0C\T#
M=U4<?PCH._>BX<K/5Z*\>^&VK_$GQ=%I>K7FHV<6B1S.+@O"@FO "?N@)@ '
M"\%3P>M=;\2/&LW@_2;5-.MTN=8U&86]E"_3=W8^H&0,<<D4!RN]CM*XN#XG
MZ'<:)KVKK!?BST6;R9V,2DR-G'R ,<C..N.M4X8O&OAJPO=7\0^)[34K&*PF
MFF@6R6(PRA<J$9?O#J,MCH..>/-M&UK4/!'P%AU73+DPZKJ^IL8Y&17/4@\,
M".D9ZCO0-1/>="UB#7]#L]6MHIHH+N(2QI.H5PIZ9 )'ZUH5Y-XI\6^++#QQ
MX7\,:+<Q3WT]GOO5FB4)(Y!&]R%RJC:S$+CTJ?PEXF\30_%'6O"NNZI%JEM:
MVHN!<):K#Y1PAQA>WSXY)/ HN+EZG7Z+XUTW7O$NKZ%9PW8N-*;;<2R1A8R<
MD84YR>0>H'3BNCKQ;0OBGJ=OX'\1>*]6N!>1#4/LNEVQC6,9QD#*@$C# G.3
M\IKI-%C\>VUO:^(O$'B2R%AY9N+[3/L*J((MA;Y9!\Q8<<'CKR<<EQN)Z+6?
MKFL6WA_0[S5KP.;>TB,L@C +$#L,D#/XUY1:>+/'7B'P[JOCBRU.TTS2+(N]
MMIDMHLGVF./[Q>3[RGMQU([#FLGQ+XFUG4/V>[>[UF]-QJ&LW@C0B-4^0.2%
MPH QB/\ 6BX*![9H&LP>(M"L]7M8IHH+N/S(TG #@=L@$C]:T:S]!TY=(\/:
M=IR?=M;:.$?\!4"O//'WC;5+'QWIWA>TUNU\.VT]M]HDU2Y@67DE@% ;Y0/E
MZGUZCN"2N]#T^>XAM;>2XN)HX88E+R22,%5%'4DG@"F6=[::C:1W=C=0W5M)
MRDT$@=&YQP1P>:\C^*#^)=-^$Q.H^([>>1Y?)E>WM% OHG/R9_N$ $G;UZ>]
M6;*]U'X3_"H7^I:H-3W0PII]B;9(5@D<%BI8'+\DDDG.%XZT7'RZ'K5%>&>*
M=?\ B5X4\*6&L77B"UDN-6=(Q9BQC5K-F^<!6P=_ *G<.,]^M:_C?QAXLTOQ
MMX<\,^'IX[B_GM=URDL2[97((#,<94#:S$+BBX<K/5+V_L]-M'N[^[@M;9,;
MYIY B+DX&2>!S4L,T5Q!'/!(DL4BATD1@RLIY!!'45X#\4;3QE!X3T/2_$'B
M*"\NM0O/)DMK:U0(YW95M^U3QE1C:.O6O9O"NCZEH6B1V&IZS_:LD9VQR_94
M@"1@ *@5?3'4G/- FK*YMT444R0HHHH **** "IU^Z/I4%3K]T?2I9K2W%KY
MJ^*G_)2=6_[8_P#HE*^E:^:OBI_R4G5O^V/_ *)2NK!_Q'Z"K_"<=1117I'(
M%%%% 'K?ANYM_B#X-7P[=3!-<TU2UG(Y_P!8@& ,_3 /T!YYK@KJUGLKJ6UN
M8FBGB8JZ,,$&LFRO;G3;V&\LYGAN(6W1R(>5->IVOB'PW\0[.*V\02)I6N(-
MD=XHPDOUSQ^!(]CSBHA-T7WB_P /^ ;QDI*SW//02K!E)!!R".U>I>"_B%#<
M36MCXC93-"<6U^W49&-KGW]?IGUKF-8^'7B'2G9H[4WUMU6:U^?(_P!WJ/RQ
M[UR\L$T#;9HGC;IAU(/ZUO.-+$1M>Y:;BSN?BAX9&E:P-5M4_P!#OB6;;T27
MJ?SZ_G7!5KK=Z_J]A;Z5&][=VL1_=0(K.!^77';TKH=*^&FHR1&\UV>+2+",
M;G>9ANQ],X'XG\#1&:HP2J2V!J[T.=\.^'[SQ)JT=C:+C/,LI'RQKW)_P[UK
M?$G7[-(+3PEHKYT_3>)G!_UDH]^^,G/N3Z59U_Q[IVBZ6V@>"E,<)&+C4"/G
MD/0[>^?]K\@.M>95@Y2JRYGHELOU,YR27*@HHHJS$**** /?/@C_ ,B7>?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!\7
M^M6K558O]:M6JSGN:0V"BBBH+*]%%%6<@4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5.OW1]*@J=?NCZ5+-:6XM?-7Q4_Y*3JW_;'_P!$I7TK7S5\5/\
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M/N/^?^7]?\:+L#1HK._L^X_Y_P"7]?\ &C^S[C_G_E_7_&B[ T:*SO[/N/\
MG_E_7_&C^S[C_G_E_7_&B[ T:*SO[/N/^?\ E_7_ !H_L^X_Y_Y?U_QHNP-&
MBL[^S[C_ )_Y?U_QH_L^X_Y_Y?U_QHNP.BB_U2?[HI]8R:1>%%(U:<9'3G_X
MJE_L>\_Z"T_Z_P#Q59C-BJC_ 'V^M4O['O/^@M/^O_Q50-I=T&(_M*8\^_\
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M5F?V9=?]!*;]?\:/[,NO^@E-^O\ C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO\
MH)3?K_C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO^@E-^O\ C1=]@LNYIT5F?V9=
M?]!*;]?\:/[,NO\ H)3?K_C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO^@E-^O\
MC1=]@LNYIT5F?V9=?]!*;]?\:/[,NO\ H)3?K_C1=]@LNYIT5F?V9=?]!*;]
M?\:/[,NO^@E-^O\ C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO\ H)3?K_C1=]@L
MNYIT5F?V9=?]!*;]?\:/[,NO^@E-^O\ C1=]@LNYIT5F?V9=?]!*;]?\:/[,
MNO\ H)3?K_C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO^@E-^O\ C1=]@LNYIT5F
M?V9=?]!*;]?\:/[,NO\ H)3?K_C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO^@E-
M^O\ C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO\ H)3?K_C1=]@LNYIT5F?V9=?]
M!*;]?\:/[,NO^@E-^O\ C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO\ H)3?K_C1
M=]@LNYIT5F?V9=?]!*;]?\:/[,NO^@E-^O\ C1=]@LNYIT5F?V9=?]!*;]?\
M:/[,NO\ H)3?K_C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO^@E-^O\ C1=]@LNY
MIT5F?V9=?]!*;]?\:/[,NO\ H)3?K_C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO
M^@E-^O\ C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO\ H)3?K_C1=]@LNYIT5F?V
M9=?]!*;]?\:/[,NO^@E-^O\ C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO\ H)3?
MK_C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO^@E-^O\ C1=]@LNYIT5F?V9=?]!*
M;]?\:/[,NO\ H)3?K_C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO^@E-^O\ C1=]
M@LNYIT5F?V9=?]!*;]?\:/[,NO\ H)3?K_C1=]@LNYIT5F?V9=?]!*;]?\:/
M[,NO^@E-^O\ C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO\ H)3?K_C1=]@LNYIT
M5F?V9=?]!*;]?\:/[,NO^@E-^O\ C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO\
MH)3?K_C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO^@E-^O\ C1=]@LNYIT5F?V9=
M?]!*;]?\:/[,NO\ H)3?K_C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO^@E-^O\
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MU9M4M S&&X8_-M)R%/N.G;Z"N@I@%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &C%_JD_W13Z9%_JD_W13ZR&%5'^^WUJW51_OM]:
MN!$QM%%%:&84454O]4L-+A\V_O(+:/L99 N?IGK0!;HKE9?B3X1A;:VLQD_[
M$,C?R4U'_P +/\'?]!C_ ,EIO_B*OV<^PN9=SKJ*Y$?$[P>6 &L#DXYMI1_[
M+6II_B[P_JL@BL]7M9)#T0OM8_0'!-)PDMT%T;5%%%2,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M \O>J\J5SR2!V/>LS6O 5YKOP\T73MR6VK:=$A4.V5W!0&4E<_F,]*]%HIV
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M7D>X/(KTFBG8#E/A[X6N?"7AK[#>3I+<2S-,XC.53( P#WZ?K75T44 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &C%_JD_W13Z9
M%_JD_P!T4^LAA51_OM]:MU4?[[?6K@1,;115/5;^/2M)N[^7&RWA:0CUP,X_
M&M-S,XOX@_$(>&Q_9NF[)-3=<LQY$ /0D=V/8?B??PZ]O[O4KI[J]N9;B=_O
M22,6/_ZJ+Z]GU*_GO;I]\\\AD=O4DU7KTJ=-01S2DVPHHHK0D**** .]\%_$
MJ_T.XCL]3EDN],)"_.=SPCU4]2/;\J]X@GBN;>.>"19(I%#HZG(8'H17R57M
MOP<UU[S1KK2)GRUDP>'/78V<C\#_ .A5RXBDK<R-:<NC/3****XS8**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^3'_ -C1_P +!_ZA?_DQ_P#8T<R [:BN)_X6#_U"_P#R8_\ L:/^%@_]0O\
M\F/_ +&CF0';45Q/_"P?^H7_ .3'_P!C1_PL'_J%_P#DQ_\ 8T<R [:BN)_X
M6#_U"_\ R8_^QH_X6#_U"_\ R8_^QHYD!Z/%_JD_W13Z\^7XF;45?[(Z#'_'
MS_\ 84O_  LW_J$?^3/_ -A68ST"JC_?;ZUQ7_"S?^H1_P"3/_V%0GXC98G^
MRNI_Y^/_ +&JBTMR9)L[FBN%_P"%B_\ 4*_\F/\ [&C_ (6+_P!0K_R8_P#L
M:OF1'*SNJ*X7_A8O_4*_\F/_ +&C_A8O_4*_\F/_ +&CF0<K.ZHKA?\ A8O_
M %"O_)C_ .QH_P"%B_\ 4*_\F/\ [&CF0<K.ZHKA?^%B_P#4*_\ )C_[&C_A
M8O\ U"O_ "8_^QHYD'*SNJ*X7_A8O_4*_P#)C_[&C_A8O_4*_P#)C_[&CF0<
MK.ZHKA?^%B_]0K_R8_\ L:/^%B_]0K_R8_\ L:.9!RL[JBN%_P"%B_\ 4*_\
MF/\ [&C_ (6+_P!0K_R8_P#L:.9!RL[JBN%_X6+_ -0K_P F/_L:/^%B_P#4
M*_\ )C_[&CF0<K.ZHKA?^%B_]0K_ ,F/_L:/^%B_]0K_ ,F/_L:.9!RL[JBN
M%_X6+_U"O_)C_P"QH_X6+_U"O_)C_P"QHYD'*SNJ*X7_ (6+_P!0K_R8_P#L
M:/\ A8O_ %"O_)C_ .QHYD'*SNJ*X7_A8O\ U"O_ "8_^QH_X6+_ -0K_P F
M/_L:.9!RL[JBN%_X6+_U"O\ R8_^QH_X6+_U"O\ R8_^QHYD'*SNJ*X7_A8O
M_4*_\F/_ +&C_A8O_4*_\F/_ +&CF0<K.ZHKA?\ A8O_ %"O_)C_ .QH_P"%
MB_\ 4*_\F/\ [&CF0<K.ZHKA?^%B_P#4*_\ )C_[&C_A8O\ U"O_ "8_^QHY
MD'*SNJ*X7_A8O_4*_P#)C_[&C_A8O_4*_P#)C_[&CF0<K.ZHKA?^%B_]0K_R
M8_\ L:/^%B_]0K_R8_\ L:.9!RL[JBN%_P"%B_\ 4*_\F/\ [&C_ (6+_P!0
MK_R8_P#L:.9!RL[JBN%_X6+_ -0K_P F/_L:/^%B_P#4*_\ )C_[&CF0<K.Z
MHKA?^%B_]0K_ ,F/_L:/^%B_]0K_ ,F/_L:.9!RL[JBN%_X6+_U"O_)C_P"Q
MH_X6+_U"O_)C_P"QHYD'*SNJ*X7_ (6+_P!0K_R8_P#L:/\ A8O_ %"O_)C_
M .QHYD'*SNJ*X7_A8O\ U"O_ "8_^QH_X6+_ -0K_P F/_L:.9!RL[JBN%_X
M6+_U"O\ R8_^QH_X6+_U"O\ R8_^QHYD'*SNJ*X7_A8O_4*_\F/_ +&C_A8O
M_4*_\F/_ +&CF0<K.ZHKA?\ A8O_ %"O_)C_ .QH_P"%B_\ 4*_\F/\ [&CF
M0<K.ZHKA?^%B_P#4*_\ )C_[&C_A8O\ U"O_ "8_^QHYD'*SNJ*X7_A8O_4*
M_P#)C_[&C_A8O_4*_P#)C_[&CF0<K.ZHKA?^%B_]0K_R8_\ L:/^%B_]0K_R
M8_\ L:.9!RL[JBN%_P"%B_\ 4*_\F/\ [&C_ (6+_P!0K_R8_P#L:.9!RL[J
MBN%_X6+_ -0K_P F/_L:/^%B_P#4*_\ )C_[&CF0<K.ZHKA?^%B_]0K_ ,F/
M_L:/^%B_]0K_ ,F/_L:.9!RL[JBN%_X6+_U"O_)C_P"QH_X6+_U"O_)C_P"Q
MHYD'*SNJ*X7_ (6+_P!0K_R8_P#L:/\ A8O_ %"O_)C_ .QHYD'*SNJ*X7_A
M8O\ U"O_ "8_^QH_X6+_ -0K_P F/_L:.9!RL[JBN%_X6+_U"O\ R8_^QH_X
M6+_U"O\ R8_^QHYD'*SNJ*X7_A8O_4*_\F/_ +&C_A8O_4*_\F/_ +&CF0<K
M.ZHKA?\ A8O_ %"O_)C_ .QH_P"%B_\ 4*_\F/\ [&CF0<K.ZHKA?^%B_P#4
M*_\ )C_[&C_A8O\ U"O_ "8_^QHYD'*SNJ*X7_A8O_4*_P#)C_[&C_A8O_4*
M_P#)C_[&CF0<K.ZHKA?^%B_]0K_R8_\ L:/^%B_]0K_R8_\ L:.9!RL[JBN%
M_P"%B_\ 4*_\F/\ [&C_ (6+_P!0K_R8_P#L:.9!RL[JBN%_X6+_ -0K_P F
M/_L:/^%B_P#4*_\ )C_[&CF0<K.ZHKA?^%B_]0K_ ,F/_L:/^%B_]0K_ ,F/
M_L:.9!RL[JBN%_X6+_U"O_)C_P"QH_X6+_U"O_)C_P"QHYD'*SNJ*X7_ (6+
M_P!0K_R8_P#L:/\ A8O_ %"O_)C_ .QHYD'*SNJ*X7_A8O\ U"O_ "8_^QH_
MX6+_ -0K_P F/_L:.9!RL[JBN%_X6+_U"O\ R8_^QH_X6+_U"O\ R8_^QHYD
M'*SNJ*X7_A8O_4*_\F/_ +&C_A8O_4*_\F/_ +&CF0<K.ZHKA?\ A8O_ %"O
M_)C_ .QH_P"%B_\ 4*_\F/\ [&CF0<K.ZHKA?^%B_P#4*_\ )C_[&C_A8O\
MU"O_ "8_^QHYD'*SNJ*X7_A8O_4*_P#)C_[&C_A8O_4*_P#)C_[&CF0<K.ZH
MKA?^%B_]0K_R8_\ L:/^%B_]0K_R8_\ L:.9!RL[JBN%_P"%B_\ 4*_\F/\
M[&C_ (6+_P!0K_R8_P#L:.9!RL[JBN%_X6+_ -0K_P F/_L:/^%B_P#4*_\
M)C_[&CF0<K.ZHKA?^%B_]0K_ ,F/_L:/^%B_]0K_ ,F/_L:.9!RL[JBN%_X6
M+_U"O_)C_P"QH_X6+_U"O_)C_P"QHYD'*SO8O]:M6J\Z3XC[6#?V5G'_ $\?
M_8U+_P +-_ZA'_DS_P#85$G=EQ32/0**\_\ ^%F_]0C_ ,F?_L*/^%F_]0C_
M ,F?_L*DH[BBN#_X61_U"?\ R9_^QH_X61_U"?\ R9_^QJKG/R2.\HK@_P#A
M9'_4)_\ )G_[&C_A9'_4)_\ )G_[&BX<DCO**X/_ (61_P!0G_R9_P#L:/\
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MH_X1'0_^?'_R*_\ \56W119 8G_"(Z'_ ,^/_D5__BJ/^$1T/_GQ_P#(K_\
MQ5;=%%D!B?\ "(Z'_P ^/_D5_P#XJC_A$=#_ .?'_P BO_\ %5MT460&)_PB
M.A_\^/\ Y%?_ .*H_P"$1T/_ )\?_(K_ /Q5;=%%D!B?\(CH?_/C_P"17_\
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M[0?^?#_R-)_\51_PAV@_\^'_ )&D_P#BJW:*+(+LPO\ A#M!_P"?#_R-)_\
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M )\/_(TG_P 51_PAV@_\^'_D:3_XJMVBBR"[,+_A#M!_Y\/_ "-)_P#%4?\
M"':#_P ^'_D:3_XJMVBBR"[,+_A#M!_Y\/\ R-)_\51_PAV@_P#/A_Y&D_\
MBJW:*+(+LPO^$.T'_GP_\C2?_%4?\(=H/_/A_P"1I/\ XJMVBBR"[,+_ (0[
M0?\ GP_\C2?_ !5'_"':#_SX?^1I/_BJW:*+(+LPO^$.T'_GP_\ (TG_ ,51
M_P (=H/_ #X?^1I/_BJW:*+(+LPO^$.T'_GP_P#(TG_Q5'_"':#_ ,^'_D:3
M_P"*K=HHL@NS"_X0[0?^?#_R-)_\51_PAV@_\^'_ )&D_P#BJW:*+(+LPO\
MA#M!_P"?#_R-)_\ %4?\(=H/_/A_Y&D_^*K=HHL@NS"_X0[0?^?#_P C2?\
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M[,+_ (0[0?\ GP_\C2?_ !5'_"':#_SX?^1I/_BJW:*+(+LPO^$.T'_GP_\
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MPAV@_P#/A_Y&D_\ BJW:*+(+LQ8_!N@-( ;#C_KM)_\ %5/_ ,(1X=_Z!_\
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M<C[IY_.NP^ 8(\-:KD?\O@_] %9GCB^;PE\9]/\ $M]:7$FG>0 'A7.3L9"
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MAN+8S@8!ZXXJWK/BKQ+X"\%"37Y[/4=;N;HQVSQC;&J;0<MA5Z<^G4<UE>)
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M_P#84?\ "T/^H/\ ^3/_ -A7GM%/V<>PO[4Q?\_X+_(]"_X6A_U!_P#R9_\
ML*/^%H?]0?\ \F?_ +"O/:*/9Q[!_:F+_G_!?Y'H7_"T/^H/_P"3/_V%'_"T
M/^H/_P"3/_V%>>T4>SCV#^U,7_/^"_R/0O\ A:'_ %!__)G_ .PH_P"%H?\
M4'_\F?\ ["O/:*/9Q[!_:F+_ )_P7^1Z%_PM#_J#_P#DS_\ 84?\+0_Z@_\
MY,__ &%>>T4>SCV#^U,7_/\ @O\ (]"_X6A_U!__ "9_^PH_X6A_U!__ "9_
M^PKSVBCV<>P?VIB_Y_P7^1Z7:?$NTEE5;NPE@0G!=)-^/<C KM8)XKF".>%U
MDBD4,K+T(-?/]>K?#J9Y?#+HQ)$5PR+[#"G^9-9U()*Z/2RW,*M:I[.IJ==1
M116)[@4444 %%%% !1110 4444 %3K]T?2H*G7[H^E2S6EN+6%J'_'])^'\A
M6[6%J'_'])^'\A2-BM1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT4459R!1110 4444 %%%% !1110 5SWCC_D3K_\ [9_^C%KH:Y[QQ_R)U_\
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M^OMO_0$KRRO4_AK_ ,B[<?\ 7VW_ * E9U?A/4RC_>5Z,[&BBBN8^J"BBB@
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M0/B)H/B*RU.]MY)K>UT['G372A%(.<$<GCCO@^U8+?''PDM[Y 346CW8^T"
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$0NH5CD'YLJ>ZCIBNDJ-IX5F6%I4$C<A"PR?PH DHHHH V-*_P"/5O\ ?/\
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MBBM#,R98S%(5/X4RM6:%9EP>".A]*SY+:2,_=R/45E*-C6,KD5%%%24%%%%
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M["WTRPBL[9=L42X&>I]2?<U9HJ93<MSIP^#HX=MTUJPHHHJ3J"BBB@ HHHH
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MC_?;ZU;JI(,2-]:N&Y$]AM%%%:&84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 ^+_6K5JJT(S(#Z59K.>YI#8****@
MLKT4I&#BDJSE"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME".KLQ=-VYAP0#M]C0!V,%Q#=6\=Q;S1S0R*&22-@RL#T((X(J2O+[ W6G>
M/"5OISRG^TY(8K@RZA+&.8V.Q9/F,0+*!\@'H,9S70V%G<0Z-?VFLZT+.*.]
M0Q/;ZFTLEN#L81/-(H8Y)Z$9VN!GI0!T>IZK::/:"YO7=8VD6-?+B>1F9C@
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MG/=0RLSX\[8K!=W9C\N?KDU&NLM=V=Y!'<W%XUYKLEK:B*^:%" @;:9ERR(
MK'Y.2>.A- '9ZCJ<.F"U,RR-]IN4MDV '#.< G)Z5=KS*QO;JZTR"&ZF$GV3
MQ1';QXN6N-J@@[?-8!GP21EN>W:NH\1K+<^(- L1>75O;W#SB9;:9HS(%CR
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M(/E<'H=P/MBE\9:O=1MK%]I\DT;:5)#$TTFIR0JDAVMM2!5V2@AADN<DD@<
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MO;ZM*6B!C\PI+<E!(HX+# W8*C)!H [B>Y@M8Q)<3QPH65 TCA06)P!D]R2
M!4M>3W!GU3P?=17UQ*XL?$44"&+4))-B>;'E?-^5GQN."W(]B!757-@;CQ?;
MZ1_:&I1V$>EF0Q17LBL["0 %GSOR,]=V3WR.* .NHKSG2WO8=%\.ZM)JNHW%
MW-J"VDGG7!*/$7>/:4&%)P =V-V>I-)92Z_JE[-J8N8+8V^KM;L\NJRHJQK+
ML\HV^SRR64C!)W$L#GH* /1ZB6Y@:Y>V6>,W$:AWB#C<JG."1U .#S[&O/KY
MKM=+\1:P-4U$75AJ;+;*+IA&BAD^4H#M8'<>&!]L5J6>F0_\+3U6X:2Z#BQM
MI5 NY I):4'*[L%>!\I& >0,F@#LJBN;B*SM9KF=]D,*&21L$X4#).![5R'B
M>_O=*UB>.&XG4:K8>1:X<E8KD2! 5'\)(E!X'.SVK.LM2U&[A>U:\N1+HFFW
M*7;^:0TDVYHXV;!Y.V-GY_O ^] '=P:C9W(MO*N8RUS#Y\*%L,\?'S!3SCYA
MVXR*9I^IPZD;P0K(OV6Y:V?> ,LH!)&#TYKB;>Q2_P#%7A.ZN9[QI)=%=V9;
MR5"SKY)[,.N3D=&[YQ4%Q#+:Z7XFUBWOKV&ZM-7=H5CG98QS'D,@^5P>AW ^
MV* /2J*Y[Q7=21+I5H+B2VM[V_2WN)HW*,$*L0H8<J68*N1@\\8.*YK6+NZT
MB/Q38V.H7;6EI:VTZR273R26TC,=R^8Q+8*J&P2<9[ T >C45R&K:F__  DV
MH6]M?-B+0I9C''+]Q]WRM@'@XZ'TK4\*VK1>'[*YENKJYN;JWBEFDN)V?+%0
M>%)PHYZ*![T ;=%>96-Y,GA[2=9BUF^N=2?5DM&C:\+(RF8JT1CSMR$);)&X
M8!S@5J12WL5EXKUE;J\N+JPN+I;.%IG,2!4! \L'#<GN#CMB@#N:*X92=+OO
M#,^GZM>7;:EN%P)[MYDGC\HN90K$A<,%/R!1\V,<BL7P;J/]O:SH\QU2Y-RD
M,LU\CZT'6X<XV[($E.T#D[2B #@@GH >IT5Y_I]PUIX$;6+R]U.ZN[J0VXQ>
M,OWIRB*/X4'0%P-P&2#G%9[ZAJMGIWB^R^UO ]D+9H?*U"2[:!G^]B60!N<
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MO;Z'I%I9R6=MI=C#:RG=)!';HJ.>.2H&">!^57Z* (7M;>28S/;Q-*8S$7*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
; %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>gwpjrhodncoa000029.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000029.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ": ET# 1$  A$! Q$!_\0
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MX77<5YZIF1$FZ3-\H&28D6NZLP(GL)F>TC;T:Z1QE%F:N/(/.Y/Y#B-4$I!
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M8::QK.NO9/N1;K>.3M+;_8B6]@0,OFX>WZYK'2JFD9M36HC-#RK,\E<8>GK
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MV2RZ#)1!]&I]$_M16A'/)Q9H*/\ 9&66YUBD&X:J.Y++JO &E<R.&/3TG+R
MC#PX2,/QY";OM7DV8KR=H4(FVR@*%E6AP.+&*-R0TVIHC:#N"3/9/P15_'D
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MNGLG,GU1YIGVHL^S2A:]L"U*\MZ4LWI&25K#+2@0,<JNW4C+^.7"C$V\T:2
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MXA-QMLWW;1)T[!'FU^,(ONM>A-(5<=JN3 R-BE3U16K=ESQ\K)Y8F:>EY]V
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M&Q,Q7$HFD*?*/&C=N41W R<L@FU?((.54'Z3MHW+-2W&L^)PG\MW,!7EV/\
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MD8?F3>8+]LX;A2_[W2[V?9*U!K/^#N=F/TF]2_L1;\*Q^_-^I[RKV[_?O:O
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M: RY=<];]*-N2274:.3)U B,V;,=HUW'HIT49T79?-9>NO?IKK=Q+J H=7U
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M91+U4U4O4TQOG;3U$E$_>QCWT]]?;KDJ*&HCX;XL33)R5;LK9K2YE]@((3;
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M4=UD]=BF#R/H656$HC)5P/:"Y$").BP)&4"VS N/>."49<;H)(2(>BW<**/
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MD8?F3>8+]LX;A2_[W2[V?9*U!K/^#N=F/TF]2_L1;\*Q^_-^I[RKV[_?O:O
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MKF?#=W]_O*.V9W>X++/D_P#K.>NG_@KJ9^M6W(;Y#O/[ H_&;^C[ I39W];
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M#G5;1KC.R&NJ;E+.FV_WM\YVQC[^.;'T=Z*XQTIJW5'"*5&J^TITZE85J[*
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M"JXM ^Z4*N,IDU FO4>NVCN%3:YJM@]DDMSW8RX'@1NUC$<BYEV"*'5U2N3
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C$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>gwpjrhodncoa000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -1!TP# 2(  A$! Q$!_\0
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M$^>!]3NB2QLCJKHPPRD9!![5XMX]\!-HKOJ>F1EM.8YDC')@/_Q/OVJ_\/\
MX@?9?*T;69OW'"V]RY_U?HK'^[Z'M].GK3HDL;(ZJZ,,,I&00>U> G5P-6SV
M_,^@:HX^C=;_ )'RQ17?>/? 3:*[ZGID9;3F.9(QR8#_ /$^_:N!KZ"C6A6A
MSP/GJU&=&?),****U,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *LV%
M_=:7?17EG,T5Q$<JZ_YY'M5:BDTFK,:;3NCZ#\'>,;7Q38X.V*_B'[Z#/_CR
M^J_R_+.AXB\.V7B33&L[Q<$<Q2J/FC;U']1WKYUL+^ZTN^BO+.9HKB(Y5U_S
MR/:O>O!WC&U\4V.#MBOXA^^@S_X\OJO\ORSX&+PDL/+VM+;\CZ#!XR.(C[*K
MO^9XAKV@WOAW4WLKU,$<QR#[LB^HK+KZ3\1>';+Q)IC6=XN".8I5'S1MZC^H
M[UX!KV@WOAW4WLKU,$<QR#[LB^HKT<'C%75G\1YN-P4J$N:.L69=%%%=YP!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 =UX$\=R:#*NG:B[/ICG
MY6ZF GN/]GU'XCW]LCECFB26)U>-P&5E.0P/0@U\LUW7@3QW)H,JZ=J+L^F.
M?E;J8">X_P!GU'XCW\G'8'G_ 'E/?JNYZV Q_)^[J;='V_X![?13(Y8YHDEB
M=7C<!E93D,#T(-/KP3Z **** "BBB@ HHHH ^?M1U&ZU2]DNKJ5Y'=B?F.0H
M]!Z"JE%%>AL?G$I.3YI;A11102%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!)!<
M36LRRP2O%(IR&1B"*]\TFXDO-&L;F4@R36\<CX'<J":^?Z][\/\ _(M:5_UY
MQ?\ H K"OLCZ'A^3YYQZ6-&BBBN8^H"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "O$OC#_P C;:?]>"?^C)*]MKQ+XP_\C;:?]>"?^C)*
M[<!_&(J?">?4445[A@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% 'T'\-?^2?Z7_VU_\ 1KUU=<I\-?\ DG^E_P#;7_T:]=77S=?^
M++U9TQV05\^?$K_DH&J?]LO_ $4E?0=?/GQ*_P"2@:I_VR_]%)75EW\5^G^1
M%38Y2BBBO:,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%%% !1110 4444 %%%% !1110 4444 =UX$\=R:#*NG:B[/ICGY6ZF GN/\
M9]1^(]_;(Y8YHDEB=7C<!E93D,#T(-?+-=UX$\=R:#*NG:B[/ICGY6ZF GN/
M]GU'XCW\G'8'G_>4]^J[GK8#'\G[NIMT?;_@'M]%,CECFB26)U>-P&5E.0P/
M0@T^O!/H HHHH **** /G.BBBO0/S8**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *][\/_ /(M:5_UYQ?^@"O!*][\/_\ (M:5_P!><7_H K"OLCZ#A_\
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M_P#(M:5_UYQ?^@"L*^R/H.'_ .+/T-&BBBN8^I"BBB@ HHHH **** "BBB@
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M]E.=P /RD=CTKTA(]<3Q3]IN=9LTT63Y;>T5%WR,5Z9(SUR>"<XZ"N9\)_\
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MU&.1H4OI8E%LTG?D[@/_ !W@>E=W8Q:W;Z/JT6OZO:WMV;=W2&!%7RDVMSP
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M/3] TJ16GAE;S%PD2,3C'\77^M4-4TVS_L&UU&QB*9P)?F)]NY]1^M3^-/\
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M=X1M/%-AL?$5[$#Y$^.G^R?537S_ '=M)97DUK+M\R%RC;&##(.#@CK7J/Q
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M9?\ HI*^@Z^?/B5_R4#5/^V7_HI*ZLN_BOT_R(J;'*4445[1B%%%% !1110
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M_>5-OS_X 111PQ+%$BI&@VJJC  KS#X@?$#9YNC:--\W*W%RAZ>JJ?7U-'Q
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M-J,J_O9L<*/[J^W\_P @-;7M>LO#NF/>WKX XCC'WI&]!1KVO67AW3'O;U\
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M),/<.,10@\L?4^@]Z\@U#4+G5+V2[NY"\KG\ /0>@HU#4+G5+V2[NY"\KG\
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M **** "O>_#_ /R+6E?]><7_ * *\$KWOP__ ,BUI7_7G%_Z *PK[(^@X?\
MXL_0T:***YCZD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *\2^,/_ "-MI_UX)_Z,DKVVN&\>^ Y_%5Q;7MC<PQ742>4RS9"LN21R 2""
M3V[]JZL'4C3JIRV)FFUH>%45Z#_PI[Q#_P _FF?]_9/_ (BC_A3WB'_G\TS_
M +^R?_$5Z_UJC_,8\K//J*]!_P"%/>(?^?S3/^_LG_Q%'_"GO$/_ #^:9_W]
MD_\ B*/K5'^8.5GGU%>@_P#"GO$/_/YIG_?V3_XBC_A3WB'_ )_-,_[^R?\
MQ%'UJC_,'*SSZBO0?^%/>(?^?S3/^_LG_P 11_PI[Q#_ ,_FF?\ ?V3_ .(H
M^M4?Y@Y6>?45Z#_PI[Q#_P _FF?]_9/_ (BC_A3WB'_G\TS_ +^R?_$4?6J/
M\P<K//J*]!_X4]XA_P"?S3/^_LG_ ,11_P *>\0_\_FF?]_9/_B*/K5'^8.5
MGGU%>@_\*>\0_P#/YIG_ ']D_P#B*/\ A3WB'_G\TS_O[)_\11]:H_S!RL\^
MHKT'_A3WB'_G\TS_ +^R?_$4?\*>\0_\_FF?]_9/_B*/K5'^8.5GGU%>@_\
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M1_PBVK?\\%_[^+_C1]8H_P R^\/JU;^1_<8U%;/_  BVK?\ /!?^_B_XT?\
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M[?S_ $&-;,*4(7@[LVH9=6G.TU9">#/!EMX7L_,DVS:C*O[V;'"C^ZOM_/\
M(#6U[7K+P[ICWMZ^ .(XQ]Z1O05IMNVG: 6QP"<"O+?$7@+Q;XDU-KR\OM,
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M\_FF?]_9/_B*/KN'_F0?4L1_(S@**[__ (5#X@_Y_-,_[^R?_$4?\*A\0?\
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M[?:1[GPLLLQ:=N1G%45VO_"L=:_Y^M/_ ._C_P#Q%'_"L=:_Y^M/_P"_C_\
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MQ_\ XBCVD>X?V;B_^?;.*HKM?^%8ZU_S]:?_ -_'_P#B*/\ A6.M?\_6G_\
M?Q__ (BCVD>X?V;B_P#GVSBJ*[7_ (5CK7_/UI__ '\?_P"(H_X5CK7_ #]:
M?_W\?_XBCVD>X?V;B_\ GVSBJ*[7_A6.M?\ /UI__?Q__B*/^%8ZU_S]:?\
M]_'_ /B*/:1[A_9N+_Y]LXJBNU_X5CK7_/UI_P#W\?\ ^(H_X5CK7_/UI_\
MW\?_ .(H]I'N']FXO_GVSBJ*[7_A6.M?\_6G_P#?Q_\ XBC_ (5CK7_/UI__
M '\?_P"(H]I'N']FXO\ Y]LXJO>_#_\ R+6E?]><7_H KSN+X8:L95$MY9+'
MGYBC.Q ]AM&?SKT^TMDL[*"UCR8X8UC7/7 &!_*L:TDTK'MY+A*U&<Y5(V)J
M***P/H HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_*C[7)Z+^504460$_P!KD]%_*C[7)Z+^504460$_VN3T7\J/M<GHOY5!119
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#1B_U2?[HI],B_U2?[HI]9#"JC_?;ZU;JH_P!]OK5P(F-HHHK0
MS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M45R/_"S_  =_T&/_ "6F_P#B*/\ A9_@[_H,?^2TW_Q%'LY]@YEW.NHKD?\
MA9_@[_H,?^2TW_Q%'_"S_!W_ $&/_):;_P"(H]G/L',NYUU%<C_PL_P=_P!!
MC_R6F_\ B*/^%G^#O^@Q_P"2TW_Q%'LY]@YEW.NHKD?^%G^#O^@Q_P"2TW_Q
M%'_"S_!W_08_\EIO_B*/9S[!S+N==17(_P#"S_!W_08_\EIO_B*/^%G^#O\
MH,?^2TW_ ,11[.?8.9=SKJ*Y'_A9_@[_ *#'_DM-_P#$4?\ "S_!W_08_P#)
M:;_XBCV<^P<R[G745R/_  L_P=_T&/\ R6F_^(H_X6?X._Z#'_DM-_\ $4>S
MGV#F7<ZZBN1_X6?X._Z#'_DM-_\ $4?\+/\ !W_08_\ ):;_ .(H]G/L',NY
MUU%<C_PL_P '?]!C_P EIO\ XBC_ (6?X._Z#'_DM-_\11[.?8.9=SKJ*Y'_
M (6?X._Z#'_DM-_\11_PL_P=_P!!C_R6F_\ B*/9S[!S+N==17(_\+/\'?\
M08_\EIO_ (BE7XF^#V8*-8&3ZV\H_P#9:/9S[!S+N=;16/IWBK0=6D$=CJUK
M+(>D>_#'Z X-;%2TUN,****0!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"?B'4?$%O<R:AH%UH[1.%1+@MF0$=1E5Z5T-4@"BBB@ HHHH **** "BBB@
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M.P"WA<X(/0C*!2?;=7H^FZA;ZKIMO?VCE[>XC$B$C!P?7WHN!:HHHH ****
M"BBB@ HHHH T8O\ 5)_NBGTR+_5)_NBGUD,*J/\ ?;ZU;JH_WV^M7 B8VBBJ
MNI7T>F:7=7TW^KMXFE;W &<5H9G(>/\ Q_'X7B%E9!)=4E7(!Y6%>S-ZGT'X
MGW\)U#4KW5KMKJ_NI;B=NKR-G\!Z#V%&I:A<:KJ5Q?W3[YYW+N?KV'L.E5:]
M*G34%YG-*3;"BBBM"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ,B7>?\ 81?_ -%QUZ57FOP1_P"1+O/^PB__ *+CKTJO(K_Q&=]/X$%4KO\
MUH_W:NU2N_\ 6C_=K..Y9!1145Q<0VEM+<W$BQPQ(7=V. J@9)-6(EHK)\.^
M(+?Q-I8U&TMKJ&W9RL9N$"F0#^( $\9XYQTK6H **** "BF3316\+S3R)%%&
MI9W=@JJ!U))Z"F6MW;7ULEQ:7$5Q _W98G#JW;@C@T 34444 %%%5H]1L9;Z
M2QCO+=[R(;I+=95,B#CDKG('(_.@"S1110 445F:3XATO7)+N/3;KSVM)/*G
M'ELNQN>/F ST/2@#3HK(M/$^C7VNW&BVUZ)-0M@3+"(V&W& ?F(P>HZ&DO\
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M.EZ?#9[$A:Y\Q-Q5<8SASZ#HN:]'\*Z$/#7AJRTGS?-:!3N<# +$ECCVR::
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?]L?_1*5U8/^(_05?X3CJ***](Y HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ]\^"/\ R)=Y_P!A%_\ T7'7I5>:_!'_ )$N\_["+_\ HN.O2J\BO_$9
MWT_@052N_P#6C_=J[5*[_P!:/]VLX[ED%>>?%;4+A[#3?#EF^VXUBY6)C_L
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M^Q__ !%'_"F/#G_/[JO_ ']C_P#B*/K$ ]G(\+HKW3_A3'AS_G]U7_O['_\
M$4?\*8\.?\_NJ_\ ?V/_ .(H^L0#V<CPNBO=/^%,>'/^?W5?^_L?_P 11_PI
MCPY_S^ZK_P!_8_\ XBCZQ /9R/"Z*]T_X4QX<_Y_=5_[^Q__ !%'_"F/#G_/
M[JO_ ']C_P#B*/K$ ]G(\+HKW3_A3'AS_G]U7_O['_\ $4?\*8\.?\_NJ_\
M?V/_ .(H^L0#V<CPNBO=/^%,>'/^?W5?^_L?_P 11_PICPY_S^ZK_P!_8_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 /B_UJU:JK%_K5JU6<]S2&P4445!97HHHJSD"BBB
M@ HHHH ***\QTCQ;XX\2ZOK5KI$/AZ.+3;EH2;M9@S#<P'W2<_=YZ4AI7/3J
M*S+343;Q65GK5YIT6KSK_J89=HD8=?+5CN(JU_:5C_:']G_;;?[:5W_9O-7S
M-OKMSG'O3 LT50?7-(CU :>^J6*WK':+=KA!(3Z;<YK&:?5_^%AK ->TP:7]
MGW'2]R_:2V/O8QG&><YQ[4@L=116?>Z[I&F3K#?ZK8VDKC*I/<)&Q'L":GNM
M1L;&T^UW=Y;V]MQ^^EE5$YZ?,3CFF!9HJDNKZ8^H'3TU&T:] R;83J9,=?NY
MS5V@ HHHH$%%%% !1110 45Y1IOQ6O[SQK!9S6=K'H%U>26EO=!6WLRX .=V
M.2R=NC>U>G76H65B81>7=O;F9Q'$)I GF,>BKD\GV%(IIHLT52@UG2[JYEMK
M?4K.:>$9EBCG5F3_ '@#D?C3K'5=.U,2'3[^UN_*.V3[/,LFP^AP>*8BW16:
M_B'1([=[B36-/2%)#"\C7*!5<=5)S@-[=:OQ313PI-#(DD3C<KHP(8>H(ZT
M/HKSR;4]0USXQ0Z997D\.FZ/;^9=I'*RK*[#@,!P>J\'T-9$/Q5U9/&TFGW=
ME9+HZ:D;!ID5Q(A)(4DEL=L].QI7'RL]:HKF_&_B:3POH'VJUB2>_GF2WM(7
MR0\C'OCG& 3VK,\">-+O7](U2\UW[!:&PN3"\D1*1@ #))9CW[YH"SM<[>BJ
M<NKZ;#IRZA+J-I'8N 5N7G41G/3#9QS7->+/B'I_AB\TVV M[MKR55DQ=*GD
M1G&)",'C!SV''6@239V-%06=[::A;+<V5U#<P-D++#('4XX.".*GIB"BBB@
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M+_5)_NBGUD,*J/\ ?;ZU;JH_WV^M7 B8VBBBM#,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF6Z*BGN(K9 \S;5)P#@GFF07UO<N4ADW,!DC:1Q1<+%BBJ\]];VSA)I-K$9
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M%1)LLQ  VMU_*@+,N45%<7,-K&'F?:I. <$\_A4=O?VUU(4ADW,!DC:1Q^-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!HQ?ZI/]T4^F1?ZI/\ =%/K(854?[[?6K=5'^^W
MUJX$3&T445H9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^WUJW51_OM]:N!$QM%%%:&84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO Z]4^&[LWAN8$Y"73!?8;5/]3652"2NCU,KQU:I5]G4=SL****Q/>"BBB@
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MX6-G2/@Y/&-P'/?'O1=@>\T4V.1)HDEB=7C=0RLIR&!Z$&G50@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **QV\6>&U8JWB#2@P."#>QY'ZUJPS17$*
MS02I+$PRKHP*D>Q% #Z*IVFKZ;?PRS6>HVEQ%#_K7AF5U3OR0>/QIUCJ=AJD
M;2:??6UW&AVLUO*L@!]"0: +5%4QJVG-J)TY=0M3? 9-L)E\P<9^[G/3FKE
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MT(;]SH,CKZO=!?Y*:C_X7A_U+O\ Y.__ &NO(J*W]A3[$<\CUW_A>'_4N_\
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MHHJSD"BBB@ HHHH **** "BBB@ KGO''_(G7_P#VS_\ 1BUT-<]XX_Y$Z_\
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M([*YM+::Q5YY(KLMA9'?</EVL"0.""*P/%UAXS@\5^'XM9U>RN-1DE464L2
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW'._.<_A3X?.V'S_ "]V>-F<8_&I** *K?;M[;/LVW/&=V<5/^\\G^'S=O\
MP'/^%/HH JK]NWKO^S;<\XW9Q4TWG;!Y'E[L\[\XQ^%244 00_:MY\_R=N.-
MF<Y_&B;[5O'D>3MQSOSG/X5/10!'#YVP^?Y>[/&S.,?C4+?;M[;/LVW/&=V<
M5:HH 9^\\G^'S=O_  '/^%0+]NWKO^S;<\XW9Q5JB@".;SM@\CR]V>=^<8_"
MF0_:MY\_R=N.-F<Y_&IZ* ()OM6\>1Y.W'._.<_A3X?.V'S_ "]V>-F<8_&I
M** *K?;M[;/LVW/&=V<5/^\\G^'S=O\ P'/^%/HH JK]NWKO^S;<\XW9Q4TW
MG;!Y'E[L\[\XQ^%244 00_:MY\_R=N.-F<Y_&B;[5O'D>3MQSOSG/X5/10!<
ML_M'V<?:?*W?P^7G&,>_>H9/[5\QO+^Q[,G;NW9QVS5N+_5)_NBGUD,C_??9
M_P#EGY^SWV[L?GC-9@_M'SOWGV7;N^;;NSCOBM>JC_?;ZU<")D$_G[!]G\O?
MGGS,XQ^%,@^V;S]H\C9CCR\YS^-6**T,RO/]LWC[/Y&S'/F9SG\*?!Y^P_:/
M+WYX\O.,?C4M% %1_P"T=[;/LNS/R[MV<>]6/WOD?P>=M]]N['\LT^B@"HG]
MH[UW_9=F?FV[LX]JFG\_8/L_E[\\^9G&/PJ6BBP7*\'VS>?M'D;,<>7G.?QH
MG^V;Q]G\C9CGS,YS^%6**+!<B@\_8?M'E[\\>7G&/QJ%_P"T=[;/LNS/R[MV
M<>]6Z*+!<9^]\C^#SMOOMW8_EFJZ?VCO7?\ 9=F?FV[LX]JMT4 13^?L'V?R
M]^>?,SC'X4R#[9O/VCR-F./+SG/XU8HH KS_ &S>/L_D;,<^9G.?PI\'G[#]
MH\O?GCR\XQ^-2T4 5'_M'>VS[+LS\N[=G'O5C][Y'\'G;??;NQ_+-/HH J)_
M:.]=_P!EV9^;;NSCVJ:?S]@^S^7OSSYF<8_"I:*+!<KP?;-Y^T>1LQQY><Y_
M&B?[9O'V?R-F.?,SG/X58HHL%R*#S]A^T>7OSQY><8_&H7_M'>VS[+LS\N[=
MG'O5NBBP7&?O?(_@\[;[[=V/Y9JNG]H[UW_9=F?FV[LX]JMT4 13^?L'V?R]
M^>?,SC'X4R#[9O/VCR-F./+SG/XU8HH KS_;-X^S^1LQSYF<Y_"GP>?L/VCR
M]^>/+SC'XU+10!4?^T=[;/LNS/R[MV<>]6/WOD?P>=M]]N['\LT^B@"HG]H[
MUW_9=F?FV[LX]JFG\_8/L_E[\\^9G&/PJ6BBP7*\'VS>?M'D;,<>7G.?QHG^
MV;Q]G\C9CGS,YS^%6**+!<B@\_8?M'E[\\>7G&/QJ%_[1WML^R[,_+NW9Q[U
M;HHL%QG[WR/X/.V^^W=C^6:KI_:.]=_V79GYMN[./:K=% $4_G[!]G\O?GGS
M,XQ^%,@^V;S]H\C9CCR\YS^-6** *\_VS>/L_D;,<^9G.?PI\'G[#]H\O?GC
MR\XQ^-2T4 5'_M'>VS[+LS\N[=G'O5C][Y'\'G;??;NQ_+-/HH J)_:.]=_V
M79GYMN[./:II_/V#[/Y>_//F9QC\*EHHL%RO!]LWG[1Y&S''EYSG\:)_MF\?
M9_(V8Y\S.<_A5BBBP7(H//V'[1Y>_/'EYQC\:A?^T=[;/LNS/R[MV<>]6Z*+
M!<9^]\C^#SMOOMW8_EFJZ?VCO7?]EV9^;;NSCVJW10!%/Y^P?9_+WYY\S.,?
MA3(/MF\_:/(V8X\O.<_C5BB@"O/]LWC[/Y&S'/F9SG\*?!Y^P_:/+WYX\O.,
M?C4M% %1_P"T=[;/LNS/R[MV<>]6/WOD?P>=M]]N['\LT^B@"HG]H[UW_9=F
M?FV[LX]JFG\_8/L_E[\\^9G&/PJ6BBP7*\'VS>?M'D;,<>7G.?QHG^V;Q]G\
MC9CGS,YS^%6**+!<B@\_8?M'E[\\>7G&/QJ%_P"T=[;/LNS/R[MV<>]6Z*+!
M<9^]\C^#SMOOMW8_EFJZ?VCO7?\ 9=F?FV[LX]JMT4 13^?L'V?R]^>?,SC'
MX4R#[9O/VCR-F./+SG/XU8HH KS_ &S>/L_D;,<^9G.?PI\'G[#]H\O?GCR\
MXQ^-2T4 5'_M'>VS[+LS\N[=G'O5C][Y'\'G;??;NQ_+-/HH J)_:.]=_P!E
MV9^;;NSCVJ:?S]@^S^7OSSYF<8_"I:*+!<KP?;-Y^T>1LQQY><Y_&B?[9O'V
M?R-F.?,SG/X58HHL%R*#S]A^T>7OSQY><8_&H7_M'>VS[+LS\N[=G'O5NBBP
M7&?O?(_@\[;[[=V/Y9JNG]H[UW_9=F?FV[LX]JMT4 13^?L'V?R]^>?,SC'X
M4R#[9O/VCR-F./+SG/XU8HH KS_;-X^S^1LQSYF<Y_"GP>?L/VCR]^>/+SC'
MXU+10!4?^T=[;/LNS/R[MV<>]6/WOD?P>=M]]N['\LT^B@"HG]H[UW_9=F?F
MV[LX]JFG\_8/L_E[\\^9G&/PJ6BBP7*\'VS>?M'D;,<>7G.?QHG^V;Q]G\C9
MCGS,YS^%6**+!<B@\_8?M'E[\\>7G&/QJ%_[1WML^R[,_+NW9Q[U;HHL%QG[
MWR/X/.V^^W=C^6:KI_:.]=_V79GYMN[./:K=% $4_G[!]G\O?GGS,XQ^%,@^
MV;S]H\C9CCR\YS^-6** *\_VS>/L_D;,<^9G.?PI\'G[#]H\O?GCR\XQ^-2T
M4 5'_M'>VS[+LS\N[=G'O5C][Y'\'G;??;NQ_+-/HH J)_:.]=_V79GYMN[.
M/:II_/V#[/Y>_//F9QC\*EHHL%RO!]LWG[1Y&S''EYSG\:)_MF\?9_(V8Y\S
M.<_A5BBBP7(H//V'[1Y>_/'EYQC\:A?^T=[;/LNS/R[MV<>]6Z*+!<9^]\C^
M#SMOOMW8_EFJZ?VCO7?]EV9^;;NSCVJW10!%/Y^P?9_+WYY\S.,?A3(/MF\_
M:/(V8X\O.<_C5BB@"O/]LWC[/Y&S'/F9SG\*?!Y^P_:/+WYX\O.,?C4M% %8
M?VEYY\K[)MR=N[=G'O6E^^^S_P#+/S]GOMW8_/&:AB_UJU:K*>YK#8HQ_P!J
M^8OF?8]F1NV[LX[XJQ<_:?+'V7RM^>?-SC'X5-14E&=;_;?,/VG[/LQQY>[.
M?QHN/MOF#[-]GV8Y\S=G/X59HJCEN16_VCRS]I\K?GCR\XQ^-0/_ &EYC>7]
MDV9.W=NSCWJY10%QG[WR/X/.V^^W=C\\9JLG]I>8OF?9-F1NV[LX]JN44!<B
MN/M'EC[-Y6_//F9QC\*CM_MOF'[3]GV8X\O=G/XU9HIA<K7'VWS!]F^S[,<^
M9NSG\*DM_M'EG[3Y6_/'EYQC\:EHI!<IO_:7F-Y?V39D[=V[./>K/[WR/X/.
MV^^W=C\\9I]% 7*:?VEYB^9]DV9&[;NSCVJ>X^T>6/LWE;\\^9G&/PJ6B@+E
M:W^V^8?M/V?9CCR]V<_C1<?;?,'V;[/LQSYF[.?PJS10%R*W^T>6?M/E;\\>
M7G&/QJ!_[2\QO+^R;,G;NW9Q[U<HH"XS][Y'\'G;??;NQ^>,U63^TO,7S/LF
MS(W;=V<>U7** N17'VCRQ]F\K?GGS,XQ^%1V_P!M\P_:?L^S''E[LY_&K-%,
M+E:X^V^8/LWV?9CGS-V<_A4EO]H\L_:?*WYX\O.,?C4M%(+E-_[2\QO+^R;,
MG;NW9Q[U9_>^1_!YVWWV[L?GC-/HH"Y33^TO,7S/LFS(W;=V<>U3W'VCRQ]F
M\K?GGS,XQ^%2T4!<K6_VWS#]I^S[,<>7NSG\:+C[;Y@^S?9]F.?,W9S^%6:*
M N16_P!H\L_:?*WYX\O.,?C4#_VEYC>7]DV9.W=NSCWJY10%QG[WR/X/.V^^
MW=C\\9JLG]I>8OF?9-F1NV[LX]JN44!<BN/M'EC[-Y6_//F9QC\*CM_MOF'[
M3]GV8X\O=G/XU9HIA<K7'VWS!]F^S[,<^9NSG\*DM_M'EG[3Y6_/'EYQC\:E
MHI!<IO\ VEYC>7]DV9.W=NSCWK33.Q<]<5!4Z_='TI,UIO46OFKXJ?\ )2=6
M_P"V/_HE*^E:^:OBI_R4G5O^V/\ Z)2NK!_Q'Z$U_A..HHHKTCD"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#WSX(_\ (EWG_81?_P!%QUZ57FOP1_Y$
MN\_["+_^BXZ]*KR*_P#$9WT_@052N_\ 6C_=J[5*[_UH_P!VLX[ED%%%%6(*
M*** "BBB@ HHHH ***JW>IV%A+#%>7UM;R3G;$DTJH9#Z*">>HZ>M %JBBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#1B_U2?[HI],B_U2?[HI]9#"
MJC_?;ZU;JH_WV^M7 B8VBBBM#,**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH ?%_K5JU56+_6K5JLY[FD-@HHHJ"RO1
M115G(%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %3K]T?2H*G7[H^E2S6E
MN+7S5\5/^2DZM_VQ_P#1*5]*U\U?%3_DI.K?]L?_ $2E=6#_ (C]!5_A..HH
MHKTCD"BBB@ KKO"GP]U7Q1']KREEIJGYKN?H0.NT?Q8_ >]7?A_X.M]5,VO:
MX1%H=CEG+G F8?P_0=_7@#VF\6>-+KQ"XM+9?LFDP_+#;1_*"!T+8_ET'ZU'
MO3ERP^;-805KR-8K\.?"S>7#92Z_>(.9)&!BSW_V<?0-]:7_ (6?Y!_T'PUI
M5NOILSQ^ %>?TH!)P!DFMEA:?VM?4TO;8[[_ (6-87GR:KX2TRY1OO%5 /U&
M0:!X;\">, 8]%N9M%U)ON03G*.?0 DY_ _A61HWP_P#$.LA9%M/LMN>?.NCL
M&/4#J?RK3\0^ [#1/"AU6'6ENYTF$1\M1Y;'H5!!/(Y.<]NE8RA04N6$K/RU
M*LVM4<-XD\*ZMX5O1;:E!M#<QS(<QR#V/]#S6+7JWAGQ=;ZE:#PSXK5;K3IA
MLBN)3\T)[9;T]#U'TZ<3XP\*W7A+7'L9B9('^>WFQQ(G^(Z$?_6H3E&7)/?\
MS"<+:K8Y^BBBK,PHHHH ]\^"/_(EWG_81?\ ]%QUZ57FOP1_Y$N\_P"PB_\
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MZUUWPAT9]/\ ")OYU/VC493,2>I0<+_4_C0F!Z#1113 **** "BBB@ HHHH
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M3_>(VC]2*\C\#^/Y? WPWTB1_#=W<:0]PR7.I><L8\QF)^1""7P!C/ RI&:
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M=I'0_$*\ATBTL/!VFDK:V$:M.>AD<C(S^>X^[>U</9VD]_>0VELF^>9PD:Y
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG7[H^E05.OW1]*EFM+<6OFKXJ?\ )2=6_P"V/_HE*^E:^:OBI_R4G5O^V/\
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M LVUB< 9ZY'<'OWJQK&AO\._'>@3Z9J=Y+]OE"W!G8$O\X#9QC(.[H>A[T7
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD/0[>^?]K\@.M>95@Y2JRYGHELOU,YR27*@HHHJS$**** /?/@C_ ,B7>?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!\7
M^M6K558O]:M6JSGN:0V"BBBH+*]%%%6<@4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5.OW1]*@J=?NCZ5+-:6XM?-7Q4_Y*3JW_;'_P!$I7TK7S5\5/\
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M/N/^?^7]?\:+L#1HK._L^X_Y_P"7]?\ &C^S[C_G_E_7_&B[ T:*SO[/N/\
MG_E_7_&C^S[C_G_E_7_&B[ T:*SO[/N/^?\ E_7_ !H_L^X_Y_Y?U_QHNP-&
MBL[^S[C_ )_Y?U_QH_L^X_Y_Y?U_QHNP.BB_U2?[HI]8R:1>%%(U:<9'3G_X
MJE_L>\_Z"T_Z_P#Q59C-BJC_ 'V^M4O['O/^@M/^O_Q50-I=T&(_M*8\^_\
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M5F?V9=?]!*;]?\:/[,NO^@E-^O\ C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO\
MH)3?K_C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO^@E-^O\ C1=]@LNYIT5F?V9=
M?]!*;]?\:/[,NO\ H)3?K_C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO^@E-^O\
MC1=]@LNYIT5F?V9=?]!*;]?\:/[,NO\ H)3?K_C1=]@LNYIT5F?V9=?]!*;]
M?\:/[,NO^@E-^O\ C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO\ H)3?K_C1=]@L
MNYIT5F?V9=?]!*;]?\:/[,NO^@E-^O\ C1=]@LNYIT5F?V9=?]!*;]?\:/[,
MNO\ H)3?K_C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO^@E-^O\ C1=]@LNYIT5F
M?V9=?]!*;]?\:/[,NO\ H)3?K_C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO^@E-
M^O\ C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO\ H)3?K_C1=]@LNYIT5F?V9=?]
M!*;]?\:/[,NO^@E-^O\ C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO\ H)3?K_C1
M=]@LNYIT5F?V9=?]!*;]?\:/[,NO^@E-^O\ C1=]@LNYIT5F?V9=?]!*;]?\
M:/[,NO\ H)3?K_C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO^@E-^O\ C1=]@LNY
MIT5F?V9=?]!*;]?\:/[,NO\ H)3?K_C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO
M^@E-^O\ C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO\ H)3?K_C1=]@LNYIT5F?V
M9=?]!*;]?\:/[,NO^@E-^O\ C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO\ H)3?
MK_C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO^@E-^O\ C1=]@LNYIT5F?V9=?]!*
M;]?\:/[,NO\ H)3?K_C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO^@E-^O\ C1=]
M@LNYIT5F?V9=?]!*;]?\:/[,NO\ H)3?K_C1=]@LNYIT5F?V9=?]!*;]?\:/
M[,NO^@E-^O\ C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO\ H)3?K_C1=]@LNYIT
M5F?V9=?]!*;]?\:/[,NO^@E-^O\ C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO\
MH)3?K_C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO^@E-^O\ C1=]@LNYIT5F?V9=
M?]!*;]?\:/[,NO\ H)3?K_C1=]@LNYIT5F?V9=?]!*;]?\:/[,NO^@E-^O\
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MU9M4M S&&X8_-M)R%/N.G;Z"N@I@%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &C%_JD_W13Z9%_JD_W13ZR&%5'^^WUJW51_OM]:
MN!$QM%%%:&84454O]4L-+A\V_O(+:/L99 N?IGK0!;HKE9?B3X1A;:VLQD_[
M$,C?R4U'_P +/\'?]!C_ ,EIO_B*OV<^PN9=SKJ*Y$?$[P>6 &L#DXYMI1_[
M+6II_B[P_JL@BL]7M9)#T0OM8_0'!-)PDMT%T;5%%%2,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M \O>J\J5SR2!V/>LS6O 5YKOP\T73MR6VK:=$A4.V5W!0&4E<_F,]*]%HIV
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M7D>X/(KTFBG8#E/A[X6N?"7AK[#>3I+<2S-,XC.53( P#WZ?K75T44 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^3'_ -C1_P +!_ZA?_DQ_P#8T<R [:BN)_X6#_U"_P#R8_\ L:/^%@_]0O\
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M_)C_ .QH_P"%B_\ 4*_\F/\ [&CF0<K.ZHKA?^%B_P#4*_\ )C_[&C_A8O\
MU"O_ "8_^QHYD'*SNJ*X7_A8O_4*_P#)C_[&C_A8O_4*_P#)C_[&CF0<K.ZH
MKA?^%B_]0K_R8_\ L:/^%B_]0K_R8_\ L:.9!RL[JBN%_P"%B_\ 4*_\F/\
M[&C_ (6+_P!0K_R8_P#L:.9!RL[JBN%_X6+_ -0K_P F/_L:/^%B_P#4*_\
M)C_[&CF0<K.ZHKA?^%B_]0K_ ,F/_L:/^%B_]0K_ ,F/_L:.9!RL[JBN%_X6
M+_U"O_)C_P"QH_X6+_U"O_)C_P"QHYD'*SO8O]:M6J\Z3XC[6#?V5G'_ $\?
M_8U+_P +-_ZA'_DS_P#85$G=EQ32/0**\_\ ^%F_]0C_ ,F?_L*/^%F_]0C_
M ,F?_L*DH[BBN#_X61_U"?\ R9_^QH_X61_U"?\ R9_^QJKG/R2.\HK@_P#A
M9'_4)_\ )G_[&C_A9'_4)_\ )G_[&BX<DCO**X/_ (61_P!0G_R9_P#L:/\
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MH_X1'0_^?'_R*_\ \56W119 8G_"(Z'_ ,^/_D5__BJ/^$1T/_GQ_P#(K_\
MQ5;=%%D!B?\ "(Z'_P ^/_D5_P#XJC_A$=#_ .?'_P BO_\ %5MT460&)_PB
M.A_\^/\ Y%?_ .*H_P"$1T/_ )\?_(K_ /Q5;=%%D!B?\(CH?_/C_P"17_\
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M[0?^?#_R-)_\51_PAV@_\^'_ )&D_P#BJW:*+(+LPO\ A#M!_P"?#_R-)_\
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M )\/_(TG_P 51_PAV@_\^'_D:3_XJMVBBR"[,+_A#M!_Y\/_ "-)_P#%4?\
M"':#_P ^'_D:3_XJMVBBR"[,+_A#M!_Y\/\ R-)_\51_PAV@_P#/A_Y&D_\
MBJW:*+(+LPO^$.T'_GP_\C2?_%4?\(=H/_/A_P"1I/\ XJMVBBR"[,+_ (0[
M0?\ GP_\C2?_ !5'_"':#_SX?^1I/_BJW:*+(+LPO^$.T'_GP_\ (TG_ ,51
M_P (=H/_ #X?^1I/_BJW:*+(+LPO^$.T'_GP_P#(TG_Q5'_"':#_ ,^'_D:3
M_P"*K=HHL@NS"_X0[0?^?#_R-)_\51_PAV@_\^'_ )&D_P#BJW:*+(+LPO\
MA#M!_P"?#_R-)_\ %4?\(=H/_/A_Y&D_^*K=HHL@NS"_X0[0?^?#_P C2?\
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M[,+_ (0[0?\ GP_\C2?_ !5'_"':#_SX?^1I/_BJW:*+(+LPO^$.T'_GP_\
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MPAV@_P#/A_Y&D_\ BJW:*+(+LQ8_!N@-( ;#C_KM)_\ %5/_ ,(1X=_Z!_\
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M<C[IY_.NP^ 8(\-:KD?\O@_] %9GCB^;PE\9]/\ $M]:7$FG>0 'A7.3L9"
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MAN+8S@8!ZXXJWK/BKQ+X"\%"37Y[/4=;N;HQVSQC;&J;0<MA5Z<^G4<UE>)
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M_P#84?\ "T/^H/\ ^3/_ -A7GM%/V<>PO[4Q?\_X+_(]"_X6A_U!_P#R9_\
ML*/^%H?]0?\ \F?_ +"O/:*/9Q[!_:F+_G_!?Y'H7_"T/^H/_P"3/_V%'_"T
M/^H/_P"3/_V%>>T4>SCV#^U,7_/^"_R/0O\ A:'_ %!__)G_ .PH_P"%H?\
M4'_\F?\ ["O/:*/9Q[!_:F+_ )_P7^1Z%_PM#_J#_P#DS_\ 84?\+0_Z@_\
MY,__ &%>>T4>SCV#^U,7_/\ @O\ (]"_X6A_U!__ "9_^PH_X6A_U!__ "9_
M^PKSVBCV<>P?VIB_Y_P7^1Z7:?$NTEE5;NPE@0G!=)-^/<C KM8)XKF".>%U
MDBD4,K+T(-?/]>K?#J9Y?#+HQ)$5PR+[#"G^9-9U()*Z/2RW,*M:I[.IJ==1
M116)[@4444 %%%% !1110 4444 %3K]T?2H*G7[H^E2S6EN+6%J'_'])^'\A
M6[6%J'_'])^'\A2-BM1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT4459R!1110 4444 %%%% !1110 5SWCC_D3K_\ [9_^C%KH:Y[QQ_R)U_\
M]L__ $8M./Q(PQ?^[S]'^1XY11178?$!72_\(7<I:V\]QJVDVRW$8DC6>X*$
M@C/=?>N:KN'U'PUXB32;*^?4H)H(5@61 @3=@#GJ>OM42;6QV82G2GS*>^EK
MNQSUMX?GO->_LBVN[.64@D31R%HCA<\,!_2K-WX5:SAFD?6]%=H@28DN\N2.
MP&.OM5^."+P+XVB-V\D]NB%U:-1N964@<9]?>K$6@:)XHBO[C1[J^CO4)E:*
MZ"X;.3QM[9XZTG)[]#HAA8M.'+^\N]+]/+OU.(K9TKPS?:M:27BR6]M:1G!N
M+J38F?3.*=9>$==U&SCN[6Q\R"3)5O-09P<="<]JW;1['6? <.C_ -HVEE>6
MTY=A<R>6K\MW[\-V]*<I=C'#85N5ZJ:T;72_HV<YK/AZ^T.2$7(CDCF&8I86
MW(_T-:47@35)%B5[BQ@N94WI:2SXE8?[N/ZUU<]I GAWPS:O<Q7874(T$L9R
MK#+9 /<=OPK&UV:0?%2WPY^6XMU7V!"Y'ZG\ZA3;T.RI@J-+WY)M-Q5K[75W
MKU\CG]+\,:AJNJ7&G)Y4%Q;J3(LY(Q@@8X!]:;HWAR^UMK@VYBBBMUS)-,Q5
M![9 //>O1[%%7XF:H5_BLU+?7Y:P_$Z-IW@JQAT<AM,F.;B=?O.QZ;O0$YS]
M */:-NPY9=2IP=26JBY7[NS27_!9Y\PVL0&# '&1T-)116QX@5ZG\-?^1=N/
M^OMO_0$KRRO4_AK_ ,B[<?\ 7VW_ * E9U?A/4RC_>5Z,[&BBBN8^J"BBB@
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M0/B)H/B*RU.]MY)K>UT['G372A%(.<$<GCCO@^U8+?''PDM[Y 346CW8^T"
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% #XO]:M6JJQ?ZU:M5G/<TAL%%%%065Z***LY HHHH **** "BBB@ HHHH
M *Y[QQ_R)U__ -L__1BUT-8'C5&D\(:@JC)"HWX!U)_04X_$C#%?P)^C_(\:
MHHHKL/B KJ+._P#"4%Q#>M8:FD\9#BW616BW#IR<-UKEZ*35S6E6=)W23]5<
MZ"\\06NM:_)?:O9R/;/'Y:1PRX:(=B#W/7KQS5^W\2:/H6GW46@6U\;JY7:T
M]XR_(.>@7KUKD**7(MC:.,JQDYZ<SOK;74*V=-?PW]B5=4BU(7*N3OM2FUE[
M [OZ5C44VKG/3GR.]D_4Z'6?$YO9;"/3X#:6>GD&WC+9.1T8^_'\^>:V)/%7
MAZ[U2#6KG3[W^THD'[M&7RF8="2>?T[=ZX:BIY$=,<=64G)V=[=.VUO0Z[0_
M&$5KXEOM7U**5C<QE0L"@[>1@<D< "HO#WBBVL;"\TO589;C3K@$JL>"R$]<
M9(^O7@BN6HHY$$<=6BT[[7^=][CI-GF-Y98ID[2PYQVS3:**LXPKU/X:_P#(
MNW'_ %]M_P"@)7EE>J?#=67PW,2,!KIB/<;5']*SJ_">IE'^\_)G84445S'U
M04444 %%%% !1110 4444 %3K]T?2H*G7[H^E2S6EN+6%J'_ !_2?A_(5NUA
M:A_Q_2?A_(4C8K5@>+?".G^,M,BL-1EN8HHY1,K6[*K9 ([@\<FM^J\U_9V[
M;9KJ&-O1Y #0DV ZSM8[&RM[2+=Y<$:Q)N.3A1@9_*L'Q'X)TWQ1J>F7]]-=
M)+IS[X1"ZA6.0?FRI[J.F*Z*.2.5 \;JZGH5.13J *U_86NJ6$UC>P)/;3+L
MDC<<,/\ />O/A\#O"0O?/+ZB8]V?LYG79CTSMW8_X%GWKTJB@#R_XO:==6O@
M"UTW1=,5M/BE42K%%N,**#@CN.>K?XFO)VAT.;R(_!*>*6UHNO\ K/+V@=\>
M7\V:^J** ./OO \'B2+P_>:]<W(U+3(T9C ZA7D^4MNRIR-R]L5J>*?">E>+
M]-6RU2.0JC;XY(FVO&V,9!Y'X$$5N44 >=6GP6\+V4EK+%-J/GV\XF$K3*6;
M!!"D;<8X[ 'WKH=1\%:;J?B^Q\2SS70O;)0L:(ZB,XR1D;<_Q'N*Z2B@#G=:
M\&:=KOB'2];NIKI+K36#0K$ZA&PV[Y@5)Z^A%-\1^"=-\4:GIE_?3722Z<^^
M$0NH5CD'YLJ>ZCIBNDJ-IX5F6%I4$C<A"PR?PH DHHHH V-*_P"/5O\ ?/\
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MBBM#,R98S%(5/X4RM6:%9EP>".A]*SY+:2,_=R/45E*-C6,KD5%%%24%%%%
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M["WTRPBL[9=L42X&>I]2?<U9HJ93<MSIP^#HX=MTUJPHHHJ3J"BBB@ HHHH
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MC_?;ZU;JI(,2-]:N&Y$]AM%%%:&84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 ^+_6K5JJT(S(#Z59K.>YI#8****@
MLKT4I&#BDJSE"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME".KLQ=-VYAP0#M]C0!V,%Q#=6\=Q;S1S0R*&22-@RL#T((X(J2O+[ W6G>
M/"5OISRG^TY(8K@RZA+&.8V.Q9/F,0+*!\@'H,9S70V%G<0Z-?VFLZT+.*.]
M0Q/;ZFTLEN#L81/-(H8Y)Z$9VN!GI0!T>IZK::/:"YO7=8VD6-?+B>1F9C@
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MG/=0RLSX\[8K!=W9C\N?KDU&NLM=V=Y!'<W%XUYKLEK:B*^:%" @;:9ERR(
MK'Y.2>.A- '9ZCJ<.F"U,RR-]IN4MDV '#.< G)Z5=KS*QO;JZTR"&ZF$GV3
MQ1';QXN6N-J@@[?-8!GP21EN>W:NH\1K+<^(- L1>75O;W#SB9;:9HS(%CR
M2O(Y'4$'T- '2T5Y^E]=VE@D!O[DQ6OB1;022S$L82PPCN3EA\V/F)SQG-&N
M:M<X\9?8]2E4VJVJQF*;/D.?O8[*?4?G0!Z!5*YU.&TU*QL9%D,MZ7$94#:-
MB[CGGT^M<O\ V.P\9?V6=7U@V4NG_:)8S?R9>02;=P8'<GWL[4*KP.,<5E13
M-JD7@H:CJ,T;2274+3K-Y<DNT,@&_KN; !*X.3P10!Z517F4VJ:G%')I-G<R
MW%I_;YL$GGO7C8Q^5O\ +,X#./WF5W<MVSWJY/%K-GID-C/J9B9];AA46M^]
MQ+#$X!,;RNH8GDD;@2 R\\"@#T&FNZQQM([!44$L3V KGO$TSZ%X1D^QW$T*
MH\41N9)6E>)'D57<LY))"L3ELXQ[5CZC:BRUJ71[:]OYK.ZTF:>YBEOY9&B*
M%0CJ[,77=E@0#@XZ<&@#I]*UR/5=*_M,6ES:VC)YL;S[/WD>,AP%9B!CL<'V
MJ6;6M/@T5=8EN-M@R)(LNQCE6QM.,9YR.U87A.R6+X9V$<'G.T^FH^))GD^9
MHAPNXG:/11@#L*RKZ6.[^#FGQ0.KR306EO&H/+2;T4ICU!!!';!]* .KO/$N
ME6%ZUI<7#^;&%:4QP22)"&Z&1U4K&.^6(XYZ5K5Q6O+<>'Y=7\3Z+J-LZH V
MHZ?<8*2,@7[KCF.39QSD'*Y'>KGC"]>+2-+E6^FTY)[^W2699!&R(V<@D\?G
M0!U-1SW$-K;R7%Q-'##&I9Y)&"JH'4DG@"N#N=1_L2\\1:<EUJ%Q9Q):"(&[
M9Y(YIF*>7YK[F53\A)R2H8D<XK)O_MD_A_QUI-W(^RRM4ECB34Y;GRV,;$@R
MOM<@[02C<?G0!Z9+J5I!>VEG),!/>!C H4G?M&6Y' X]:M5R,@?3-0\,VUE/
M=-#(EPS))<R2^81%D EF)(ST!/':LGPH^NWYT36I[J"-+PM]I\S599//)5B4
M6W9 B,I7HIR K9SS0!Z)445S!/)-'#/'(\+;)51P2C8!PP'0X(.#ZUY]IK7<
M6D:!K!U349;NXU,6\HENF:-HFD=-OEYV\ #!QNR.M6-)TX6VH>-9[:_EM+I;
MDK%/<7<C11%H(R'968J<$]2"0!@<#% '?45ROA.9[>]O=)O([V+4((XY)4FO
MFNXG4E@)(W<[ANV\J0N,<#J3SVIZGJUM]JTJVN[LW6F7TVH,1(2\UJ@$JQY/
M4'S F/\ 9QVH ]!O-0M=/^S_ &J7R_M$RP1?*3N=N@X''3J>*274K6*WO)EF
M27[&K&=(F#,A"[MI&>#C!P?45QAU.[O"FJP7L_V2[UZ""W5)3M,*?(V #C#,
M')]>*9I^F0V]QXZF$ET9%ED 5[N1UPUNAR5+$$YS@D9 X' Q0!W5E=QW]A;W
MD081W$2RJ&'(# $9]^:A_M.'^VQI6V3SS;&YW8&W:&"XSG.<GTKD=$AETRZ\
M(^3?7LBW]DRW$<T[/&VV%64JA^5",8^4#CKFK>M7T6F>+;N^F:58[?099&:%
M07 $@/R@\9],\>M '7DA5+,0 !DD]J9!<0W5O'<6\T<T,BADDC8,K ]""."*
M\]TMKUO$%UH]R\D5O=:.;@P+K$UTX;< &WN%:,D$C"G!Q56P-UIW@#PE;Z<\
MI_M.2&*X,NH2QCF-CL63YC$"R@?(!Z#&<T >H5D7'B33K2;4DNGDA33Q$9I&
M3*_O/NXQDG\JS-&3Q%86=U;JNGWLB71V0S:M+(;="JMM:5HBS')R PX5AR>*
MQM8N;JV;QC<)(UO=+#8G=#(?D..<-P?7G H ]#HKA]3@GOM7\4[]2U&%;&UB
MDMDM[IXEC<QL=V%(SRHX.5]JHS7>M^(-3M;%""#HT%VNW4Y;$F1\AG!B1B^,
M#@\#/0YX /1J*Y'6=1U&R^']M<O?0M=2"VCN+ZV8% KNJO*AQC&"2#CWI-76
MVTF"'2K.ZU"YN+ZZ2-+=]4D!!*LWS3'=)&A"$_*>2N ,%J .OHKS*SU#4KG1
M/LCZA/$8_$:V(DM[QIF6(XRGFL-S]2,L,_D*M:E?7NB0^(K*UO[H6T,]DJS3
MSM*]LDQ"R$.Y+8 R1DG!H ]#HKAO$0ET=+#3-*O)Y1>WT<=PESJDH9%*.5 F
M.^2,.4 X]#C&2:KSQ:S9Z9#8SZF8F?6X85%K?O<2PQ. 3&\KJ&)Y)&X$@,O/
M H ]!HKA?$<4VDSFZ%Q>W&D6%J#-%;ZK(ES;'+,9B&;]\" !AV_A. >16KXH
MO)=NAVT=Q+!::A?)#/-&YC?849@H88*EF"C(P>>,4 =+17'7:1+KFE>'TU2]
M^PRFX>0B^?S6D4(5A\W=Y@X9GQNS@#^'BLJ2ZO\ RI].M]4O!:P^((K.&Z6;
M=+Y;*"\9=LEMK,5RV3Q@\B@#T:BO/Y=-E%WXHM5UC6%M["!)[5/M\A,<C1DD
M[R=[#*CY68KR>*FCN'UKQ#H]M?:G<P1W>BK<M;V]TT'G2Y!)!4AN 2?E(X'.
M10!W5%><6.JW6J:-I&GF6ZO+B1KMHI6U%[-98(9"BR/-&I=FP5X'!R2>@INC
MWM]KFF^$([C4[H)=/=I</;W#*9DCW;07&"?NCYA@GKGF@#TFH;JX2SLY[J0,
M4AC:1@O4@#)Q7GVH'7+_ %;7H;.YCMAI1B6VFGU>: 0*(U<2.@1EE!.[)D)R
M 1QR:FU5FU";Q6VI:K<6@TZ"-;=(;HQ1JK1;BY7.UPS$K\X(XP.] ';0ZE:R
M:1%JCR+!:O"LY>9@H1",Y8YP,#WJT"&4,I!!&01WKB==MQ<_!J527&W1U<;)
M&3D1 \X(R/8\'O4L\*1W_A[0Q>7L-A=0S3,PO9?,F=0I5/-+;P,,S8##[OH"
M* .RHKF?#%S<#^W;19Y;RVL+UH;6660R.1L5F0N>6VLQ7))/8GBL?3KN6+P.
MOB8:C=3:Q/8S2^4]R[1O*%9BBPD[1M*]% /RG/?(!WU%<1%G3=2\,2Z?JMY>
M-J;,MPL]VTR3Q^47,H5B53#!?N!1\V,<BLJWBO9/#^AZE_;>K+>76I"VD<71
M*^4TCH5V'*=!PQ!;/?@4 >F45YYJMS=:1IGBZTMM1O$BLUMY8)9;EI)(=X&[
M#N2<?+G!)ZGMQ5BXE?3-:GM=/U.\NH+C1)[N1I;MIMKJ1Y<J$D[-VYN%PO P
M!B@#NZI:CJ<.F"U,RR-]IN4MDV '#.< G)Z5Q-T^H67AKPZ(+NYN)]7F@2[F
MN=0DBW9B9@JN WE;F 'R*"?J<TV\L]1CTVUL;^]4$:];B(07K7,MNC '8TDB
MAB<DD9!(##GI0!Z+17G6JW^H:#;>)+2QN[AXH)K,1/=7+.T"S$+(?-;<P&.<
MG.W)(]*6_36]'T'7]]\ML/)AD@BBU26\F@8OM+[Y5#!6QP#D95O>@#T2JNH:
MA:Z58R7M[+Y5O'C>^TMC) ' !/4BN5FCN=*UW4-/L]7N(DFTAIUFO[AIEAF#
M[1)ER=H^;D#"\#BLNXOKK3?#VN6#MJ-IJMK!#*Y;47N4(9RHDCD8[UW8.5(7
M&.!U) /2**X?5;K4;.^UG18KN<7&IR0MI\AD),2R?)+M/4;-K/[;A5'46US4
M=8U^*UN8[;^RS&MO--JTMNL"^6K^8\:HRRJ3NR7/(!'')H ]&HKGO$]VT=C8
M68$SW-]<+!&D%TULKMM+'=*H+(N%)^7DD =":Y.SU#4KG1/LCZA/$8_$:V(D
MM[QIF6(XRGFL-S]2,L,_D* /3:*\]U.>[TK3_%ME::A>B.T%M);/)<-+)$7Q
MN =R6(XZ$GJ>U7ITN-(UK4K&UOK^2*31I+G$]R\K+*K$;E+$E<YZ+@<# % '
M:45Q5MK!>Y\%H-09VN+-YIT6;<90( =S#/S?-GD]ZS-'U6\?Q-X>N8I)DL]7
M6=]L^IO/),@3<K-"5"1'('^K.!G% ';66MV=[H9U@>9%:*LCL9%^90A(8X&?
M[IZ5=MKB*[M8;F!M\,R"1&P1E2,@X/M7*>'G>+X9O)&[(Z0W3*RG!!#R8(-5
M;*.?6-5T>TNM1U!;=]"CN)$@NGB,DFY1N+*0V>3T//?- '=55_M"U_M3^S?-
M_P!,\GS_ "]I^YNVYSC'7MG-<-I=]>:LOAG3;^^NA;W$%TTDL<[123O$X5%+
MH0WW<L<$9QS5K4=0NM-OKQ=,OIKM;709Y80\WFAI4DP"?[S#&,G)XY).: .L
MN=3AM-2L;&19#+>EQ&5 VC8NXYY]/K5VO/(8(+7Q#X4F@U6YOKBXM9IF2>[,
MPD/DY\Q02=H)./EPOM2>%'UV_.B:U/=01I>%OM/F:K+)YY*L2BV[($1E*]%.
M0%;.>: /1**\YTUKN+2- U@ZIJ,MW<:F+>42W3-&T32.FWR\[> !@XW9'6M3
M1'-^+W5[W4+I+Z#49K=(!=LD2[7*)$8L["6&#D@L2V0>E '95$US MRELT\8
MN'4ND1<;F48R0.I R.?<5P'A1]=OSHFM3W4$:7A;[3YFJRR>>2K$HMNR!$92
MO13D!6SGFM+5M,AN?B;H\LDETNZPN"/+NY(QE7BP,*PXYY'0]\X% '2Z?J<.
MI&\$*R+]EN6MGW@#+* 21@].:NUYK<0RVNE^)M8M[Z]ANK35W:%8YV6,<QY#
M(/E<'H=P/MBE\9:O=1MK%]I\DT;:5)#$TTFIR0JDAVMM2!5V2@AADN<DD@<
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MO;ZM*6B!C\PI+<E!(HX+# W8*C)!H [B>Y@M8Q)<3QPH65 TCA06)P!D]R2
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M,OWIRB*/X4'0%P-P&2#G%9[ZAJMGIWB^R^UO ]D+9H?*U"2[:!G^]B60!N<
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MO;Z'I%I9R6=MI=C#:RG=)!';HJ.>.2H&">!^57Z* (7M;>28S/;Q-*8S$7*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
; %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>gwpjrhodncoa000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000006.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "U EX# 1$  A$! Q$!_\0
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MZ"9/)! HM\>FWSZ3INLO%61,=5,JJ1CHB0%B%4*)TA4*!B J4!Y3$Y1 Q .
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MLC,I;B<AW":O;/>(XM=I95"F5=^\M>\&7V]V:<L$?&QB2D)',Z%9=OD,[KD
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MJKY:IS?V-"-)#'455YRHY"9S#V4@K6K=\85AXI7$%#BY;O#E\^I"X&YM^D;
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M&F>*2,1EX <^.0]H7%C2.TX/Q2H?*_#IGF2,1/D@S&YC+"S,P'?(0ZX%[-(
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MJAHB:(FB)HB:(FB+'^5L<P>7<:WK&%D[P(.^5::J\BJB'*[9"78K- >-N1*
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MX:F_UM7?[%ZR5C)W$;_#4W^MJ[_8O1%$K>-,8H=[3O,0#X,K73&\QX^"7Z#
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M= B9#F.< (80^:6-=(YK(VN>][@QC& N<][CE:UK6@ESG.( : 22; 77HI(
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M WY#7V[;>-QR4!A3 7J\+ ^11$0"&#S]_O>>[^?UXXT4V'06\WKY_/BHC"F
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MQK9S6N!LT6 [PM:VENMS$#VRPQR/<02VVFOU21?4WN;7-U7>E(/4YP_]@/\
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MY_C(?*(:*.?H^?W^CP5.;\^#K?/ !WP^?/\ Z'D_3D. Y_*/EHI1KSX2IB/
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M;'-2N)CL<8@IIXCFNYD]'41ST50'@6J:>0-#F9"ZW,;VU61PW68U>06=*-L
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M TS.K9G2O?/6F2>26.)[W',VGC:YH,=SVCFW<<C6M%EM-&V9TUA<VRBP 98
M$@?:)&_+ES*VLURZR%BO.&+H_->(,D8GDW1F+6_U";K02!2=Z:.=2+)5-A)
MER7O1CG_ (9Z"0F*"HH=V(@!AUM,$Q.3!<8PW%HFB1^'UD%3V9T$K(W@R17Y
M=I'F9>QMFO:X6-6TS:RDJ*5QRB>)\>8?HEP[KO\ )=8^A?B(S/MLS3@2ZO:-
MD>AS\7)(/E6<9(MXQZ\@;*D54R;=_6IA%N+28:/"@51'PQQ<I]?<.V[9T15!
M/[>P3B;!>(**.NPVN@EB<P/D896-GIG6!,=3$79X7MYYP&G1S'.86N/B]9AE
M;0RNAG@D:YKK-(8XLD%[!\;@"US2=K$GDX-(LKRI^V[<DPO>,Z@&WZW9(@\E
M0C[)&9<+0SZ+K&7[)M5Q;?<=2UV3AHBX/(&'!GEFP&AL9M8&P3,*^OE8>7N+
M@BJ% 79?$/IBXTPROI(.&\*J8JU[:IE5B%13O;+!%V+'B*F;*TEDDA>\22B-
MQ[+LPQQS.>&]MPE@]33225]2QT0=&8H&/:6O=G(+I"TV+6@-LS,.]F<0+ $]
M.=W.7Z!VN+5[B[:A='6!I+:55;3DG/FYV\0EUQIE/;I(2]7MM3DMK[.ELY&F
MY")+7Q*.D&&>$P>?0G7:7%LR1AYVYR%7<0?@=-33UM3!1TT9FJ:F:."")OUG
MRS/$<;1TS.=:Y( W.ER.XDD9%&^65P9'&TO>X[-:T$N/H VYK3;;#VG&=MJN
M!,=[?<<4S%J5+QLM8FU99S+>UV%6#J$S9Y:Q0=!92QIZ#=R,5164L6IP<_)L
MRS,M"Q4>]ET"2)W #](81]!V%"C:<:Q*OEKGL:Z1M ^""F@>X7,;#+!.^8,-
M@9#V8?OV;;KSRLXTJ>V(HZ>$0"X::@2.E>!IF(8^,1WUL.\0+:W"Z";6][&!
MLQ9GR%O,WO9@QKB:7P;5XVGX%HUSG&%7QEBRNVR*:H9$O]9D;/*BM:\PY'GT
M7=<=O&S9.:K]!;P]0@$7B<W8W4EY9Q]]']3P9-!-'4&MPFL>Z*GJ7L$<T4[6
MYS3U+6]PO<P.?')'9LC6/[C"TA=-@6.Q8Q&]A8(:J$!TD0=F:YA-NTC).;+<
M@.#KY20+N!"V4S5NBM>^S%=\PCM)VI9FRI2LAP@P@[B\KMU=M.!&"*SMLX96
MFK2N185SDW):$:Y;(RC-*EXL?P\N+4C4;%'HN2O2<IP[B[L!QS"\8:SM?(*N
M.9\0(:98=63Q-<=&NDA=(QKB" 3<@@+:U]*VNHZFD<[()XG,#]3E=:['6&IR
MO#76YVLOS<9=V\YDP;<'=(R70;% S"+Q=HR6-&O'$1/D24,F1[7)9% S*;8N
M2@"B"[%50W2<"+)HK =(GVYA'$6#X[1,KL-KZ>HA<P.>!*QLL!(N65$+B'P2
M-V+9 !<:$BQ/C55AE71RNAJ(9&.!(:2PEKQ?1T;A=K@>5CYU^AGL;:)G7"F.
M[A!9<@'=4QQDZR,;?B:.G04:3J,XI%%8V9PYC5N5XF)LK%A GAFS\K-RJ_B9
M%P1F)9=LNY^9_I@Q# <1QZF=A-0RJK*:G?3XE+!9U,,LF:GC$H[LLT1=,)7,
M+VAKHX\^9CF-]%X3@K:>CD;51NBBED$E.UX(DN6VD<6DDM8X",L:ZQT<ZUG
MGM_KR)=6FB)HB:(FB)HBM^SS[>LPKN56)WRJ92HL&93=*LA).![MBP1\A'K<
M+B4IS@4P(H@JX4 $D5#!(%S;Y"@FPO\ )5*H<&XA8,@R!^^EI)9:4EG'3TBM
M(/U#.71^.1Z2BLH;H)R($+P0/(H!HXW.FPT'F"AHL/$ZD]?GU+2]WVI&Q]EB
MN[YF<YB62HF/,^N-L=J=#0<BC.,\S-1(JK66E4"J#9Y9D$6*]A)9XJ)>5<]<
MCY>:++BQB)-5K3<>_P!F_N5>4GERORV65LN9PVK41U+W6W/L;W"Z42Y8@Q'8
MV]=0IUTR=2);/F4JOA2B1<]'HN5;'68>2MF36*,B1^+-)*%?33PC9V4%VZ\H
M =A>QN? V%SZK*Y@MNTR"JUE1"S;=H>E8R<RF/KBD$SC6/JV/G=J?-0FJ194
MP<HQ-3<V22:L0E*U* P5F'S=J#MDX721Z2:^/(_ _!:RLZ=L'V/OLA;EZFBV
M:V6RO+% 3SB&R?;,G3)$[QGROJY&B:53;-?)R,K$0GG+)T),Y&CZ='0[6(F9
MB-2ET$2MX2.3*;N-AZAH.0MY]!I?ELMGWV2-J2L391DK[M[4@Z5/3\#<1?6G
M&YXFI6>QDEI>T0ME%=\+.!GIY-E.R<_'2GA)"4(TEGLBBN5!XJ0HU\==O%8>
MS3N]V=X+RJ]Q+ESQ$+9PIU<O5RGDL&Y M6/:;3<YVZ?QO"3V5,H5JB3=#Q_"
MY"M6/I:OR,E>[#"QKH81LI872,>5HX$@!M<=>O,:Z#?2ZR^2<VGTII"3Q)C;
MQ4F,36YQM6YHDAC:!:1E0"6>LK(WA)$%FB+*MA.A(M)Q)@LE&!+ ]0?E\9WY
M-$U)MJ3[=/@I5E,[0X^4JT7&RNV]C-)4-S<*3',GV,6THGC PN;2[M-6:(*D
M=DH8F(\L;F;B4PKPB5S+JNN2JN *-?CY_FZH,IFK:'4&%DR7!V7"MAGL:8UO
M$BHGC5[0+-D=*A8EBE']NKM8CJ^[4GW+*KMD4VCJOL3I,HMTNT9NDF9ETP$I
ML=M=;>;7990E-P&"X$9A.R9CQ=6'5;1KBUHC[-?ZE R55^B]--2KI6=C*2[9
MS +V %2%AD95-J>3./0Q!P.BBQZ++VB*F2*4D<6QF+MHW;IG4-(I.6*KI5TV
MZ/W)JLF]:E9+ (#\<JB\((" =R'3R).GM^?GS\CQ[WETEO8Y5I,BV7-[%P_=
M7XK@;K20<Q5DK2K 3  %X5,G)2J!. ZA!<Q^DQ4C!K $3C](7"Q>PR4LS:!E
M0"W-$9(>*< ?2B0.:Y@)$M4 ",SXG2MOES6[.BJ>S^C[BD,>V.ICJ*LT[LV6
M;LJGA+B*.L+"TB3+>GHS<&S)&0O'>L#H/#3X2D/7Y%HHX096V'V^5EXV,N4[
M91^PQ+*R,J8"" ]VH>2>K.AXZ0(=PHD/4('UVM;A5-PW!Q (HH6BDAK1%(\W
M>R/$JS&L.==SG!]GQNAL22))(VNL<C@.=H\2J>(:C A+)+(ZHJ62OC8+-<^@
MCP6NCLUK<I,<C)00T9F12%I(#M<I2,@W)&X]C4 3;MTL<9G:.4@*0JZZDK0W
MA"+.%C"0HB@6#(U$JA.3%*@0IT^X #:.G?!@_#CL*J(G0U$]!PO++$6'MWU/
M\#I\.F:YARDO;(:*%U[%MPVQNY;6>.?&>)9,6@E;/3P8ICT4,V>\$5(>,:7$
MHG-D[P;&YCZR< 78[O$: 7L=:5G<46"3I_?/)(851"B-TX_O$TWZC]H^:@<R
M10!== L_-GDTD% %0RQ$!Z04(F4/*8G55+QOQ%@<=))!AN*UF$'#J>S3'#3?
ME.KCPZ!K^]:0LJG!@S NCBFU#;E>LR-HL1X%X<Q^2JBEQ'"Z3%Y,1J+N$DE0
M,-I),1G>T!H=&TTC ]Y%FNDAU )M]XOL"41G&=4>"=-"34=O7@MN.A-R=;&Y
MWIBE/R()E39NDT0ZE!* )IG.?I.<>QP_B>HG=-/5QD?DJ!\,;2T%LK:3$L=Q
MAACME>V)IQ*JBL7R/>YN=S]1;D,3X5@@IZ>GHWAQQ.9DLCB\AS3589@^#D/)
M+FF5QH*:6X;&QK"0UA L;<8RQJQBVH5B,3<&DC05XM!UA*!B"Y3A6<\R$H]V
M(&74<1Y.[*<AA.T(  )Q)R&BGQR6AJ*/B"EC<V4895<000RMS@2XMBM?C0IR
M 0T2--49F,.8Y(W7!W&^I\#BKVUN!U<C'1'$Z'AV>:%Q:>RPG#*+!'U(N"_L
M2*=L;WC*WM96AI (5K1%K>R1I=B91;O+*:'5>)B"ASN6T]?2+3+(@@57ZE22
M80R:1."KIJ%(83G$J9D[-;B5;A&&</X[31%LS\"Q>NF;&QHD@FXA:W!8F.;(
M'![&'">V?W"&!CG.MD85DT>%4&+8ICN!U$N>&+',,HH'2R.,<\7#S9,9=(US
M,@9)(S%WP"SP'%[0T />%\R!7U9.UJ383-5[4-=AV:Q#$.+9@PN3>)(YZ0 Q
M3I*MY1^\.!^@Q>@""3J'I-J<)PJJXJQ;AS!RXM.(X!"[$JEK<CV&AH,7P\NB
M99K28Z6E@:T!CR]S ]X+3(X[;%<5I>&<)XDQK('?DS'IVX=2O[S7^75F$XF&
MS.#BX9JNIE>[\X QLIC:X$1EME7I=TO*MFSHACGD4[*V6*)C&436<Y(C%O"$
MX   QCO"$*/'("B/P0-\$<RDX8Q 8;Q+-A8=)54%+3XMA\!B,@8V6DXAJ1*8
MFM!,<LF'02M;'H]U2]]R"+8M1Q/0?E'AF#$S''2U]7-AF(3B4QEQBFX?IG1M
MF<YV62./$)X7.DUC;2L9N"!O=!TA0^U]U-/2.3@K#Y+E"OW9CKD</%:9./7R
MB E( ]RFM"N&A""8Y41$ 3'I2*4F75Q5^*TF!XD( V?\G-=2%[799'U&!35L
MH%W,:T1O;+ QI+0P-;879KHZ:IH,+Q3',+\H#H78E%'5B,M:YD5)Q%!0Q7&5
MSGNDCDAG>X-)?G<3;."MYX>'=V39!*Q+4JR<B]VLL.Z( &454=(T:.<D;$2(
M4AQ4<J(@W*4#";K5#R'@0'M\0RC IA)&V9IPJJ:&. MG&'3"-W,7C?E>P@7!
M:"-5YO1O+>+:62.0Q._A'3/=(#:T;L489!>[>[)&7-=K8M<0="MR<5P3F!Q'
MC^N0;Y%O["K$+#MW<BR._P"MI%-2,B"HW0>QXBLHD@01."X%*;D>@WD 9,;F
M9@Z5CW-(U8V0,<";6[[HW@@;'N"_ALM#5]J^2;LY&,>Z:1Q>Z,O8;O)-F"1A
M&:]QWS;G=7CX*W?[88/_ (KN_P"U&K^>C_5JC^5Q_P!$6'V=;^M0?R1W]*5,
MEF=O(T,L-O:,"(F(<ZD72UGSDX&'NP3!LI+RAU""8Y3&[EMUE O68X)%/JY&
M^C+P/(Y)"X$ 2UH8T<R<[880" "!F?K<@"]E:FCK0PN\M9&&V),5"9'FYM8-
M,TI(N=<K+\[@ K$@W"] (@"V3#  B &+B>"Z3  ^0AS-@/ ^H<@ \>H /EK;
M>0T/V<-_G>H_X2TQK:\$]_%3XC!X+?\ \RI;[(=Z8G3)X3+[SO"B;K8X>KZY
M"<#QTG$;"F)3#Z@' AQY\^[5V/#:!X),F#QV-K2XW4-)\0.Q-P.:LRXIB$1
MR8W)<7O%@=.X#P)-0+%>]/N]]F[))^(@\H"P:1,9PK/URM4\A%W3B7[PL?$\
MS(R*@@U;@[>N7+8K8@HI-2&$[GKXGBQM708AAWY,IG55-)2U7E,V"XE'5MCE
M$D79,EBKZ5\1D<">S+!&Z.(R9GOS-8.UX3EIL1HL1_*50:6HBJ:3R:/&L-?2
M/?&Z*82NADH*ILHC! SA_:,=)D :S(7G*?MJR_@BX?S5;]7:YWR_%OU+B'[N
M!_T1=+Y#A7Z]@7_UG^DI[:LOX(N'\U6_5VGE^+?J7$/W<#_HB>0X5^O8%_\
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M7 W#FN%P01H0000>85IS7,<YK@6N:2US2+%K@;$$<B""".JJH<\F\P]?D'Y
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MT<9(Q?<L:S4/;5_;35T@DVGJ0O"I.T"D.LC+6>&DGCLBO >*([3336+\$2F
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M;3@:XUCGB>UX('_^9=;V4'_=&"_Z+C/^D*IH)G52*<^0IEN<P?"16-0#*IB
M\=)Q0KBR(C[_ (M4Y>!#X7/(!E1M<]C7.XJQ*)SA<QO=PLYS+\G&+!Y(R?XL
MCAXE8CWAKG-;PS02 &P>QO$H:[Q:),5C?;^,QI\%Z^''_=(E?YZ+_9C5?9?^
M]V(?_MK_ )(J>U_]UJ+U<1?\W7NW(1(YA4OS]V4Q>D"+J4X@%-R ]11:P#<_
M/ "'PCF#S'X/( (7(@V,DOXHJYP18-E.   ]1V.$PF_*Q)%N5]K<I=( &\.4
MT-C<F-N.$N%K6/;8G*VW/1H-[:VN#&<=&;14:X:*C,&3F(WH4,?K,X$7H$,
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MV2L/"5<UKD0A'GL*,CP>19<J3"ZJHI74]0::1E5 \5D,TM;(WM@^$P-C?%-
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MX'S_ #N5ZFR61BDH>=J5KB103.HX529-I5F4B91,<Z2S!T=VJ0I0$W)V")Q
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MT1-$31$T1-$31%3'[!R\<,%49=_'HM%5#NF;1...A*IJ%*4&[TSU@[<II)B
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M)8U CUPT%A)NF_=O61)'VHU0-WG5T(NQ9,#+@($(8%#-41X$2BF''.J'ROD
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#A?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>gwpjrhodncoa000024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,A!U@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'ARXFQ<1Q*UL0<$L^$R/P=#^% 'HVN?%;0+;PM=:GH^H17-PK&*W62WE"O*
M#M/ XP<YR![U)X%^(MEXNTM+>>>)-<\F22:VABD544-@$$Y'0J?O'K7)P^&;
M73_V?9I+JRA>[>!KU7DC#,C.1@J2,@[ HXKH/A+I>GQ_#NQU%+"U6^D2=7N1
M"HE8>8W!;&2.!W["@#DOA#XHT;PUX>U>;6=1CM4DO%V*V69OEYPJ@D]LD#TK
MV/1=>TOQ%8_;=)O8[JWSM+)D%3Z$'D'V(KQOX*^&-%UFTU>\U/3H+R6.584$
MZ!U52,G /&??K6I\&8ELO$_C"P@RMM#<*L:9R %>0#]!0![#1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!X9\$P;+QKXCTZ08E5#D>FR3:?U853\<:K;Z)\=K;4[H
M.;>W\AY-@R0NW!./QK;N=+O?"OQXMM1MK:9]/U<_.T49*@R<,&(]' ;Z$5Z7
M=>$]!OM8;5;K3(9KUHS$TDF3N0J5(*YP>"1TH \?^,?BW1_$MII&FZ+=+?3>
M:96,() R,*OU.>GM7H/BV-]'^#=W;3?ZR#3([9N<\X5/YFM#2?AUX3T34AJ%
MAH\<=TK;D=Y'?8?]D,2!7.?&J>_E\,V>CZ?:W$\NH7(#B*,L-JX.#CIEBO7T
M- "_ Z!H?A\SL.)KV1U^F%7^:FO2JQO"FB+X<\+:=I(P6MX0)"O0N>6/_?1-
M;- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 4=:N9;/0M0NH&VS0VTDB$C.&"D
MBN+^&GBV]U7P+>:UXBOO-^S3R;YO*5=L:JIZ(!G&3VS77>)/^16U;_KRF_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "JVH6%KJFGW%A>PK-;7"&.1&[@_YZU9HH \J7X-W.G3R
MC0?&>J:99R'+0("23[E74'\15JZ^$27=MI-I/KUS-:V=P]Q.D\6]KEW*[LMN
M^487'0]3ZUZ710 R6*.:!X9$#1NI1E/0@C!%<)X8^&C>&]&U[2EUEKBUU2,H
MH-OM,!*LN?O'<<$>GW:[ZB@#R2Q^#FMZ7;_9]/\ B!J%I!N+>7;PO&N3U.!*
M!FMC5?AG?7D\5Y8^,-5L+\V\4-Q/&6Q.44+N(#*<G&>2:]#HH X'PG\+;'P[
MK!UJ^U"XU;5<DK/.,!21@MC));W)-0ZS\,;Z[U:\OM'\8:II*W<IEF@C+%"Q
MZX"NOZYKT2B@#C/!?PXTSP=-+>+/+?:E,"KW4PQ@$Y(4=L]R2379T44 <=XB
M\"?V_P",M'\0?VEY']FE#Y'D;O,VON^]N&/3H:U?%GA>R\7Z#)I5ZSHK,'CE
M3[T;CH1^9'T)K<HH \F'P3\_2VL]1\4WUX8DV68=#Y5MTY$9<YX&."!6_K_P
MY&N>!])\-_VKY']G^7_I'V?=YFU"OW=PQG.>IKNJ* .6\5>#1XF\'Q:!]N-M
MY9CQ/Y6_.P8^[D=?K2:YX,_MKP%%X7^W^3Y<4,?VGR=V?+QSMW#KCUKJJ* .
M1N?A_IVH^!K+PQJ,KS):1JL=S&NQU=1C<!R!U/!SUKED^"\UP8+?5_&&I7^F
M0',=F5*A<<  EV XXX7\J]7HH XWQG\/[?Q5X>L-&MKM=-@LI T>V#S %"E0
MN-P]?6NMMX?L]K%#NW>6@3..N!BI:* ,;Q-X7TOQ9I1T_5(F:,'='(AP\;>J
MG_(K@&^#6H_9CI\?CG4UTLC;]C*,5V^F/,V_^.UZQ10!Q%S\-K1OAVWA"SU"
M:&$N)/M$J"1L[]YX&T>U=)H&CKHGAVQT@R_:%M8!"9"FW?@=<9./IFM.B@#R
MZY^#C6]]<2^'/%.H:+;W!S);Q!F'TRKKP,]#GZUU?@SP1IG@JPD@LC)-/.0T
M]Q+C<^.@XZ <\>_>NFHH \XU#X26E_X^'B;^TC'$;A+A[,6^=S+C/S[NY&>G
M>E\:_":W\8>(DU;^U6LR8UCFC6W#[]IZ@[A@XXZ'I7HU% &?J.C6FIZ!<:-,
MI%I- 8"%ZJN, CW'&/I7)>#/AS<^$+N9O^$DN[RR:-TBLV0I'&6(.[&X@GCJ
M .IKO:* .1\!>!AX'LKVW&HF]^U3"3=Y/E[<#&,;CFD\)>!O^$6US6]2&H_:
M?[4E\SR_(V>5\S-C.XY^]Z#I77T4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** *VHV8U#3+NR+[!<0O$7
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M*Q_!_46B6SN_'6K3:8!M^R*&4;1T'+E?_':]5HH ;&@CB2-<X50HS[4ZBB@
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M_=Z X% '27TNK^._B?KV@6_B+4='T_1;:/RAI\OEM+.P!W.1R5!)!7V'0YK
M'Q/US4?@_I,D%Z(M<O=4&E27H490?>+@?WMI0'ZDC'%:<VK6OPV^+OB;5-<C
MN(].UBVCDL[B.%G6210,QY .&)#?A@G&17*Q>"=7TGX+Z+J+:=<-=6NM#59[
M54)E$) 3.WUPB'V!).,&@#N]"O-2\'_%N#P;<Z[J&KZ?J6G?:H7U&7S98Y07
MR W7!$;<>X]#GOK[Q9X;TR\DL[_Q!I5I=1XWPSWL<;KD C*DY&00?QKS71KN
MU\?_ !OL_%.BK-+H^DZ686NWB9%:9O,&P;@"3B4_E]*VO%/P4\-^+O$=WKE_
M>ZK'=76S>D$L80;45!@&,GHH[T =1_PG?@__ *&O0_\ P8P__%5T%?*'Q@^'
M&C_#_P#L;^R;F^F^W>?YGVMT;&SR\8VJO]\]<]J^KZ "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\?\/?\G0^+/\ L%)_
MZ#:U[!10!\W_ !(\;V?B_P =MX7U#6VTCPMI\Q2[E2)W>XD0X8 *I[\+GY1@
MMSP*]K\//X8\2>"%L]$VW'A^2![+8J/$"F-K+R PX)YZ]\UTM% 'G_\ PI+X
M>?\ 0O?^3MQ_\<KE_@C8V^F>,OB+86<?EVMKJ"0PIN)VHLEP%&3R< #K7M%>
M/_"#_DH?Q._["H_]&W% 'L%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% '@'[37_,K?]O?_M&O?Z\ _::_YE;_
M +>__:->_P! !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5X_P#"#_DH?Q._["H_]&W%>P5X_P#"#_DH?Q._
M["H_]&W% 'L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% '@'[37_,K?\ ;W_[1KW^O /VFO\ F5O^WO\ ]HU[
M_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %>/_  @_Y*'\3O\ L*C_ -&W%>P5X_\ "#_DH?Q._P"PJ/\
MT;<4 >P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 > ?M-?\ ,K?]O?\ [1KW^O /VFO^96_[>_\ VC7O] !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5X_\(/\ DH?Q._["H_\ 1MQ7L%>/_"#_ )*'\3O^PJ/_ $;<4 >P
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 > ?M-?\RM_V]_\ M&O?Z\ _::_YE;_M[_\ :->_T %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7C_P@_Y*'\3O^PJ/_1MQ7L%>/_"#_DH?Q._["H_]&W% 'L%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%9]T^L"<BS@L7AP,&:9U;WX"$?K2;L7"#F[+\30HK EU'7HM0MK,
MV>FEYT=U87,F!MVYS\G^T*MQ2:]YJ>;;::(]PWE+AR0.^/DZU*FF:RPTHI-M
M:^:-2BBBK.<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** / /VFO\ F5O^WO\
M]HU[_7@'[37_ #*W_;W_ .T:]_H **** "BBB@ HHHH **** "BBB@ HHHH
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M?0U]'U\H?&#X<:/\/_[&_LFYOIOMWG^9]K=&QL\O&-JK_?/7/:OJ^@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X!^TU_P RM_V]_P#M
M&O?Z\ _::_YE;_M[_P#:->_T %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%<OXK\2RZ<8]*TI//UF[^
M6)!SY0/\1_IGZGB@"OXH\0W4EXOAS03OU2<8EE!XMT[DGL<?E]<5L^'?#]KX
M<TQ;6W^>1OFFF(^:1O7Z>@JOX6\-1>'[-FD?S]0N#ON;@\EF] 3V_GUK?H *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /+-6^(WB2[UOQ%;^$]-T
MRXLO#:@W[WLC[YB-VY8@N "-CCG/W?H*[GPGXCMO%OA>QURT0I'=(28V.2C
ME67WPP(SWZUY/JVFRZ=XI\=?\(QXCTF"WO+4S:W;WD$GFVO#9:/ "L3N;OQO
M''2NF^#VG7Z?!FUABN6L[JZ6X>WG:,/Y)9F"/M/# '#8/!H ],KQ_P"$'_)0
M_B=_V%1_Z-N*Z#_A$OB'_P!%/_\ *!;_ .-<O\$8;BW\9?$6&\NOM=U'J")-
M<>6(_-<27 9]HX7)R<#IF@#VBBBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#(O/^1HTK_K
MA<?^TZUZR+S_ )&C2O\ KA<?^TZUZF.[_KHC>M\%/T_]N844451@%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116%XG
M\8:%X/LDNM;OTMEDR(H\%GE(QG:HY.,C)Z#(S0!NT5Y*WQNDN#OTKP-XAO;8
M])?)*Y'J-H8?K6GI'QJ\,WMXMEJT5]H-TQPJZE#L0_\  N@^K8% 'H]%%% !
M1110 4444 %%%% '@'[37_,K?]O?_M&O?Z\ _::_YE;_ +>__:->_P! !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%8WB3Q%;>'---Q*/,G?Y8( ?FD;_#U- %?Q3XF30;5(H$^T:G<G9;6Z
MC))/&2/3^?2H?"GAE]*634M2?[1K%W\T\I.=F?X1_7'\A4'A7P[<BY?Q!KO[
MS5K@95&'%NO90.QQ^73USUU !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<9KO
MQ6\%^'KAK>\UN%[A20T5LK3%2.H)4$ ^Q(KJ[^RAU+3KJQN0Q@N8FAD"L5)5
M@0<$<C@]:Q=*\!>$]%15L/#VG1L@P)&@#R8_WVRQ_.@#!T[XU> ]1G6$:S]F
M=C@?:87C7\6(VC\2*[R"XANH$GMYHYH9!N22-@RL/4$<&N*\8S>$=*OM"T[5
M_#5I>MJ]V+2 BTB81L2HR<\@?-VYZUT?A_PUI/A:RFLM&M?LUK+,TYB$C,JL
M0 <;B<#@<#B@#6HHHH YG7/AYX3\2:JFIZMHL%S>( /-+,NX#IN"D!O^! UT
M<,,5O#'##&D<4:A$1% 55'   Z 4^B@ KQ_X0?\ )0_B=_V%1_Z-N*]@KQ_X
M0?\ )0_B=_V%1_Z-N* /8**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,B\_Y&C2O^N%Q_
M[3K7K(O/^1HTK_KA<?\ M.M>ICN_ZZ(WK?!3]/\ VYA1115& 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8?B_Q''X3\
M,7>L/;M<M#M6.!6VF1V8*JY[#)&3Z5PDOC'Q/?:S/9-X#T^XUK18C-</)>*5
M2-P&40L5SN8+SVRG->A^(M LO$^@7>C:@)/LURH#-&VUD((*LI]00#^%07WA
MXWOA=M%.IWL4KVZ6\FH1L!<,%QD[L=6P<_4T 6/#NN6WB3P]8ZS:*RP7<0D5
M7ZKZ@^X.1^%6[VPL]2MFMKZU@NK=QAHIXPZGZ@\5Y?%\8/A_X0AC\/637LEO
MIP^SJT$&Y<KP?F)&XYSSWZUUO@OXA:)X\^W?V.+H?8O+\WSXPGW]V,<G/W#0
M!U=%%% !1110 4444 %%%% '@'[37_,K?]O?_M&O?Z\ _::_YE;_ +>__:->
M_P! !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!115:XU"RLV5;J\MX&89 EE"DC\30!9HJA_;>D_]!2R_\"$_QJ&[\2Z+9VLE
MQ)J=J5C7)"3*S'V !Y- $FMZW9Z!IDE]>/A5X1!]YV[*/>N:\-Z+=ZOJ0\3Z
M^O\ I#\V=J?NP)V./7T_/KTAT73KKQAJJ>(M9C*6,9_T"S;IC^^WK_7Z 9[R
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YT\$^.X_"]IJ.EZ)X+O=<T
MF.^E:VO[> AI%)X#_*V2!P#D'&.!7K7@3Q=/XI_M#SO"][H?V;R\?:D*^=NW
M=,J.FW_QX5YQX7N?BQX4L)M/L?!%HUBT\DT,+S(/(WMN**1)RH)XSS[UZ5X(
MU?QAJOV__A*] @TGRO+^S>5(&\W.[=GYCTPOYT ==1110 4444 %%%% !111
M0!X!^TU_S*W_ &]_^T:]_KP#]IK_ )E;_M[_ /:->_T %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 9%Y_P C1I7_ %PN/_:=:]9%Y_R-&E?]<+C_ -IU
MKU,=W_71&];X*?I_[<PHHHJC **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M* ,'2_!DUW>+JOBF<7][U2WZQ0^V.A_E]>M=D      .@%+10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y9X_F\6:S\0M)\)Z!
MK)T:UEL6O);I1\SD,5*CN2,+P"/O$GH*]/N+B&TMI;FXE2&")#)))(P544#)
M))X  [UYSXX\ :EXYU[3=<T?Q;_9\=G!MMS A?:Y+;G5U88W J#CKMH ATKX
M>>-[+6+&[N_B->7=M!<1R2V[1,!,BL"R'Y^X!'XUZA7EVE_#WQO8ZO97EY\1
M[RZM8)TEFMVB8"5%8%D/S]" 1^->DVM]9WPE-G=07 AD\J0Q2!]CX!VG'0X(
M./<4 6**** "BBB@ KQ_X0?\E#^)W_85'_HVXKV"O'_A!_R4/XG?]A4?^C;B
M@#V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#(O/^1HTK_KA<?\ M.M>LB\_Y&C2O^N%
MQ_[3K7J8[O\ KHC>M\%/T_\ ;F%%%%48!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 ?,D.KS:OJ>A>*-8\4R_VH
MWB>"WGTAIPD=E ').4/8;0-W Y.<G->I_"[59KS6?%UC%JSZMI%I?(UE>,VX
M'S S.BGNJG &..<CK7GWB3Q#\.?$NOWEW%X%U75F24I)?6):-)F'4X1L'/7)
MY->F?"_7-+U'3;S3](\+7>@6MD4(CN(]OFE]V3GJQ&P9)R>10!WM%%% !111
M0 4444 %%%% '@'[37_,K?\ ;W_[1KW^O /VFO\ F5O^WO\ ]HU[_0 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ([BWAN[:6VN8
MDF@F0QR1R*&5U(P00>H([5YGJ'P/T0W3W.@:KJN@RN<E+.<^7GZ'G\,XKU"N
M8USQK9Z+XKT?P[]FFN+W4LN3&/E@B&<NW?'!]N#DC% ''P_ ^WN& UWQ;KVJ
MP Y\AYRJ,/0Y+'\B*]$T+P_I/AG3%T[1K&*SM5.[9'G+-@#<Q/+' '))/ K@
M/#_QKL=>\3P:=_8EY;:;>7#6MEJ;G]W-(!]TC:-I.1P"3\PR!FO4J "BBB@
MHHHH *\?^$'_ "4/XG?]A4?^C;BO8*\?^$'_ "4/XG?]A4?^C;B@#V"BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC;B@#V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /E*[_X_)_^NC?SJ&IKO_C\G_ZZ-_.H:^9>
MY^WP^%!11104%?2G@C_D2='_ .O9:^:Z^E/!'_(DZ/\ ]>RUZ&7_ !OT/D.,
M/]UI_P"+]&;]%%%>L?GH4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 445S'B_Q[H/@?['_ &W--']LW^3Y<1?.S;NSCI]X4 <6
M?@Y\,""//Q[C4?\ Z],^"UAHVD:YXTTK2)OM4=K=0JMX)-PEC(?8O'&5.\$C
M /%<'_Q8G_J,?^1*]8^%.H>!Y].O['P5%,D5NZ/<F9&#,SA@I);K]P\=!^-
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M-H5S,TT,%X/FMRW8<'C&.AP<9P._7_#OP9>^%;74;S6;];_7-5G$][<+G;D
M[5'3@9;L.N, "@#M**** "BBB@ HHHH **** / /VFO^96_[>_\ VC7O]> ?
MM-?\RM_V]_\ M&O?Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M >@% #Z*** "BBB@ HHHH **** / /VFO^96_P"WO_VC7O\ 7@'[37_,K?\
M;W_[1KW^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHK*U_Q!9>'=/-U>/\QXBB7[TC>@_QH FU?6++0]/>
M]OI0D:\ #[SGL .YKD-/TF^\:WT>L:]&8=+0[K2PS]X?WF_SS[#K+I'A^^\1
M:@FO>)DP!S::>?NQ+V+#U]OS]*[F@!%540*JA548  P *6BB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@"IJM]_9>CWNH>1)/]EMY)_)B&7DVJ6VK[G&!7DU_P#&"QU6
MT:UU'X>:S=V[')BGM ZG\",5[)10!X[X5^(&B6NL6MAI/PYO]*-]/' \\=FL
M87<P&7('09S7L5%% !1110 4444 %>/_  @_Y*'\3O\ L*C_ -&W%>P5X_\
M"#_DH?Q._P"PJ/\ T;<4 >P4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\I7?_ !^3_P#71OYU
M#4UW_P ?D_\ UT;^=0U\R]S]OA\*"BBB@H*^E/!'_(DZ/_U[+7S77TIX(_Y$
MG1_^O9:]#+_C?H?(<8?[K3_Q?HS?HHHKUC\]"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM9!GW)X-;LUZ?AW\6O$FKZEI][)INL6T<EK/;0M(&E4#,9P.&)W?ACUKE8O
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MHH **** "BBB@ HHHH **** "BBB@ HHHH *\K\9_$.[2^FTW191%'$VR2X
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M*** "BBB@ HHHH **** "BBB@ HHHH **** /E*[_P"/R?\ ZZ-_.H:FN_\
MC\G_ .NC?SJ&OF7N?M\/A04444%!7TIX(_Y$G1_^O9:^:Z^E/!'_ ").C_\
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M 4444 %%%% !1110 4444 %%%% !1110!0UV5+?P_J4TEC]OCCM97:SV;OM
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^4KO\ X_)_^NC?SJ&IKO\
MX_)_^NC?SJ&OF7N?M\/A04444%!7TIX(_P"1)T?_ *]EKYKKZ4\$?\B3H_\
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MHO@S1M$(EBM_/NLY-Q<?.^?4=A^%=!110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /E*[_X_)_^NC?SJ&IKO_C\G_ZZ-_.H:^9>Y^WP^%!11104%?2G
M@C_D2='_ .O9:^:Z^E/!'_(DZ/\ ]>RUZ&7_ !OT/D.,/]UI_P"+]&;]%%%>
ML?GH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M445XU\:]7M] \7^ =7NDE>WL[FXFD6( L0##T!(&?QH L_\ "_M(_P"A:\0?
M]^$_^*JY\(9]0U*]\5ZU)I<NF:5J5\DUG;2J5);:?,?&!][Y"2.,Y':L_P#X
M:.\'_P#0-US_ +\0_P#QVNP\"_$?1_B!]O\ [)MKZ'[#Y?F?:XT7._=C&UF_
MN'KCM0!V%%%% !1110 4444 %%%% '@'[37_ #*W_;W_ .T:]_KP#]IK_F5O
M^WO_ -HU[_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7DOQ9U"=M5L].W$6Z
M0B;;ZL2PR?H!^IKL=8\<V%C/]BT^-]3U%CM6"V^8 ^[#^F:Y/7?"'BGQ)"VK
MW_V9;M%"Q648 (3).-WKST)/U'2@#S6MOPI:+JFO6VESS3I:7+8E2)]N[ )&
M>W7^M9<EG=0W/V:6VE2?./*9"&S].M>G_#OP9<V%S_;.IPF*0+BWB;[PR,%B
M.W'&#ZGVH [K2]%TW18?*T^SC@7')499OJQY/XU?HHH **** "BBB@ HHHH
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MBBB@ HHHH **** "BBB@ KBO&/@_4/$/B_PAJ]I-;);Z-<R37"RLP9@QCQL
M4@GY#U([5VM% !1110 4444 %%%% !1110 4444 > ?M-?\ ,K?]O?\ [1KW
M^O /VFO^96_[>_\ VC7O] !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !161K?B;2O#\6Z^N0)
M",K"GS2-]!_4X%<UYWBOQAQ IT/2F_Y:-_KI![=_Y?4T ;FN^,M*T)O(>0W-
MZ>%M8/F?/OZ?CS[5A_V;XH\7_-JDQT?2V_Y=83^]<?[1_P ?^^:Z#0O">D^'
MUW6L&^Y/WKB7YI#^/;\*W* ,S1] TS08/*T^U2,D8:0\N_U;K6G110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!4U6WNKO1[VVL;G[+=RV\D<$^,^4Y4A6Q['!_"O+_\ A OB?_T4?_R7
MKUNB@#S#2O!7Q%M-8LKF^\??:K2*XCDG@\C'FH&!9<^XR/QKT^BB@ HHHH H
M7^N:1I4T4.HZK8V<LQQ$EQ<)&S_0,1G\*OUY)\4O#.A:1H_B+Q'-HM[K.IZI
M!Y"L8Q,MB51L2@XS&HP,G)Z <9-=9X(N[?2/A7IEY>ZK%>6UG8&6:\B+.NQ
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M37_,K?\ ;W_[1KW^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH @O;R#3[*:[N9!'#"A=V/8"O)-7^*6K7-R
M?[,2.TMP?EW('=OKGC\!^==1\4[U(_#*VJW$:S23H6BWC<R 'MUQG%>-4 >H
M^'/BEN;R->15&"5N8D/8=&4>OJ/R[UI'7?$?BPF/P_:G3M//!OKD?,P_V1_A
MGZBO'!UXKZ6T\2KIMJLPQ*(4#C_:P,T 8>B>"=,TF7[7/NO]0)W-<W/S'=Z@
M'I]>3[UTM%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&TW_ )\8/^^!4D.F6-O*LL-I"DB]&5 "*M44N5=BW5J-6<G]X4444S,****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU/3?M,8U"?S9(Y5WYPV.A$;<>_M7H%]XL\-Z9>26=_X@TJTNH\;X9[V.-UR
M1E2<C((/XUYSH[CQS\;;3Q5I]G>)I.E:88!<7$+1!YF,@V@'&2!*<_3W%:WB
MGX*>&_%WB.[UR_O=5CNKK9O2"6,(-J*@P#&3T4=Z /./VA]=T?6_^$;_ +)U
M6QO_ "?M/F?9+A)=F?*QG:3C.#U]#7T?7RA\8/AQH_P__L;^R;F^F^W>?YGV
MMT;&SR\8VJO]\]<]J^KZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHJ*XN(+2%IKB:.&)>6>1@H'XF@"6BN-O/']O-<-9^'[&
M?5KKUC4B-?<GKC]/>H/^$;\2^(OF\0ZK]CM6ZV5D<<>A;I^>Z@#5U?QQHNDO
MY(G-W=9P(+4;VSZ$]!^>?:LKS/&GB7_5HF@6+?Q-\TY'\Q_X[72:1X;TG0T
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MI2=Y.X4444R0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ_X0?\
M)0_B=_V%1_Z-N*]@KQ_X0?\ )0_B=_V%1_Z-N* /8**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ^4KO_C\G_ZZ-_.H:FN_^/R?_KHW\ZAKYE[G[?#X4%%%%!05]*>"/^1)T?\
MZ]EKYKKZ4\$?\B3H_P#U[+7H9?\ &_0^0XP_W6G_ (OT9OT445ZQ^>A1110
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M.:Z6-$BC6.-0J*,*!T IU%*,(QV+K8FK6?[QW"BBBJ, HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_(DZ/_U[+7H9?\;]#Y#C#_=:?^+]&;]%%%>L?GH4444 %%%% !1110 4444
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MO)-!=$M%%%0,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_@&O]LM?^?F'_OX*Y7QCKS0QQV-E-@R+NDDC;^'IC(]:UAX1T,#!LB?<RO\
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MCGP_\K^__@!RUOYE]W_!.=_X3;3"N4AO'Q_=C'^-'_"96K+F/3]0;G_GD/\
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ME]:2?<NH&_W9 :I/X=T>3KI\(_W1C^50/X1T1_\ ES*_[LK?XTK8=]6ODO\
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MH^KKK./W_P# #VSZ19TE5[Z\CL+&:ZE^Y$NXCU]!6'_8>N2?ZWQ"Z\?P1?\
MUQ5?4/"]_+83YUF[N7VY6%R=K$<XQFJA1I<R4JB^Y_Y"E5J<KM!_@<=J6K7>
MJW!EN921GY4'"K]!3])UJ[TBY62&1C$3\\1/RL/\?>L*\U2TL7\N>7$@ZHHR
M13K#4+;4I!%:OOE)P(\?,?H.]>[[;"M_5^97[71Y_P!1QRI?6_9RY?YK.WW]
MCW"VG2ZMHKB(Y210ZY]#4M4]*M7LM*M;>3[\<8#<YY[U<KYF:2DTMCUHMN*;
M"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *\?^$'_ "4/XG?]A4?^C;BO8*\?^$'_ "4/XG?]A4?^C;B@#V"BBB@
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M8=*L?_)O_D1I4.KE_P" K_Y(]EHKQ:3X0>+PW[KQL6&.2R.O]33/^%0^-/\
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MEWM)/U+T\>$/%<(7[1\/Q)D\^5JB\_DQQ7S'U+$/9P_\#1V^RRY;UI?^ ?\
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M]?'GA9P"-:MN?7(_F*L)XP\-NVT:[I^?>X4?S-*_A#PW(<G0M.';Y;91_(5
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M^*?_ $/=E_X+HO\ XBO2:*/K\_Y8_P#@$?\ (.5'FW_"-_%/_H>[+_P71?\
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M\'_]#7H?_@QA_P#BJ/\ A._!_P#T->A_^#&'_P"*KS__ (9Q\'_]!+7/^_\
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M,X^#_P#H):Y_W_A_^-4?\,X^#_\ H):Y_P!_X?\ XU0!Z!_PG?@__H:]#_\
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M#T#_ (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJO/\ _AG'P?\
M]!+7/^_\/_QJC_AG'P?_ -!+7/\ O_#_ /&J /0/^$[\'_\ 0UZ'_P"#&'_X
MJC_A._!__0UZ'_X,8?\ XJO/_P#AG'P?_P!!+7/^_P##_P#&J/\ AG'P?_T$
MM<_[_P /_P :H ] _P"$[\'_ /0UZ'_X,8?_ (JC_A._!_\ T->A_P#@QA_^
M*KS_ /X9Q\'_ /02US_O_#_\:H_X9Q\'_P#02US_ +_P_P#QJ@#T#_A._!__
M $->A_\ @QA_^*H_X3OP?_T->A_^#&'_ .*KS_\ X9Q\'_\ 02US_O\ P_\
MQJC_ (9Q\'_]!+7/^_\ #_\ &J /0/\ A._!_P#T->A_^#&'_P"*H_X3OP?_
M -#7H?\ X,8?_BJ\_P#^&<?!_P#T$M<_[_P__&J/^&<?!_\ T$M<_P"_\/\
M\:H ] _X3OP?_P!#7H?_ (,8?_BJ/^$[\'_]#7H?_@QA_P#BJ\__ .&<?!__
M $$M<_[_ ,/_ ,:KS _#C1Q\=1X'^TWW]F?\]=Z>=_Q[>;UV[?O<?=Z?G0!]
M'_\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5>?\ _#./@_\
MZ"6N?]_X?_C5'_#./@__ *"6N?\ ?^'_ .-4 >@?\)WX/_Z&O0__  8P_P#Q
M5'_"=^#_ /H:]#_\&,/_ ,57G_\ PSCX/_Z"6N?]_P"'_P"-4?\ #./@_P#Z
M"6N?]_X?_C5 'H'_  G?@_\ Z&O0_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\
M57G_ /PSCX/_ .@EKG_?^'_XU1_PSCX/_P"@EKG_ '_A_P#C5 'H'_"=^#_^
MAKT/_P &,/\ \51_PG?@_P#Z&O0__!C#_P#%5Y__ ,,X^#_^@EKG_?\ A_\
MC5'_  SCX/\ ^@EKG_?^'_XU0!Z!_P )WX/_ .AKT/\ \&,/_P 51_PG?@__
M *&O0_\ P8P__%5Y_P#\,X^#_P#H):Y_W_A_^-4?\,X^#_\ H):Y_P!_X?\
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M /%5L6-_9ZG9I>6%W!=VLF=DT$@D1L'!PPX.""/PKR?_ (9Q\'_]!+7/^_\
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M;W/SYX]C4?V=_>_#_@G3_KG_ -./_)O_ +4\/KUSX*?ZK6O]Z'_V>M1O@?\
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MN+T/;ZUZ*_P/^'S.C#0W0*<E5O)\-['+_P L4?V=_>_#_@A_KG_TX_\ )O\
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M?PQ7(_$WX5^#?#7PUU34]+TEHK^V$(CG:YE8\RHI)!;;R">W>O=_UG_Z=?\
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MX7OOB)XQT:[L9YM/TS[&;.%KV8>5YL9=P"'!.3CKGI76#X*^ B&$FCRRAFW
M/?3X7V&'Z?7FG_:Z_D_'_@"_LU_S?@<M#_KX_P#>'\Z]H'2O/(_@?\/D+[M#
M=]S9&Z\G^4>@PXX^N30GP/\ A\A<MH;ON;(#7D_R^PPXX^N:X<9B_K-M+6.O
M#8;V%];W/0ZXOX@?ZO3_ *R?^RU03X'_  ]5G)T-W#'(#7D_R^PP_P#/-"?
M_P"'JLY.ALX8Y :\GPOL,/\ SS6&'K>QJ*I:]C6M3]K!PO:YR]%=0GP/^'RL
MY.ANX8Y"M>3X7V&'_GFLCQ1\'/ VE^$M>U"UT=UN(+&>> F[F(B=8R1@;N>1
MGG->I_:_]S\?^ <']F_WOP_X)G457^%7PK\'>(OA[IVKZOI;75Y<F7>YN94
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MH-)#@J5P4Z< \>A JO>_"?PI?ZM-?36]R$N)OM%Q9I<LMO-)UW-'T)S0!K>
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MS7+^&? .A^%KZXU"S6YN-0N%"27EY.9I2@QA<GH.!^0]!744 %%%% !1110
M4444 %%%% !1110!4U'5+#2+-KO4KVWL[93@RW$H1<]AD]_:O*-1CF\/?'30
M]1O[E=976DEALR\9#:>N3@1X.",-@DC.-Q]<^IZSHVG^(-)N-+U2V6XLYUVO
M&WZ$'J"#R".E<[X>^&?AWPWJL>IVZ75S>01>3;R7MP9OL\?]V,'A1C(^A([F
M@#SGPF3#X-^+<,\B^<DUZ'!/.3&X_4@UWWP=BGA^%&@K<9WF.1QG^ZTCE?\
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MDM-&"&V\YVRC 4+D#YNG.6]GU+P;I6IZ[I.M/Y\.HZ:W[NX@DV-*F#^[D/\
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MN?4T 3^$/#^K^'K.6VU3Q%/K"#:EMYL*H8HUS@$CEF.>6)[#\>DHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M...G%6-:^'.A:[K4VIW37T;W*(EY!;W3117BI]T2J/O8'':NL551%1%"JHP
M!@ 4    P!@#I2T44 %%%% "$@ DD #J36=9ZKHWB&WNHK&^L]0A4F&X6&59
M%&1@JV/44WQ)I#:_X9U+2%N&MVO;9X!*!G;N&.G<>H]*\+O+S4/"FJ:XR:OI
M>EZ]8PVEI#I5GIO[K5(P!CALLQ8N5^7!&WZ$ $DMG8Z7JD>E6^HW.K_#F+51
M'<6MLID-I<D@K$YQEX2[ _+G)X.6^]]!X!() XZ<=*H:+I=EH^D6]E86$5C
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M2*< !5+ [0<DDCG@#BM[QIX)\0:AX^T3QCX>?3VN["W,#VU\[*G\>""H)/\
MK&].@JYX2\'ZOH_Q"\2^(-0:T,&J+'Y8A=B0PZY!' ].: ///"5]XS\5^#_$
M,]SXPO8!H8D%NT"*LDSJI;]XV,E> , YY.>@JS=_%/78OA%X<O&O8K?5=5N7
MM9=1:,$11HY4R;<8W8V]O7 Z8ZKP-\/]8\.>%_%.G7KVC3ZH\K6YBD)4;D*C
M<2!CD^]9D?PCU.7X7:1HKWMK;:_I-V]W:SJ2\6XN6"G(S@Y7L>1T- &?X?\
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M>V=S]KT/1)9ET]U),8:1B!M)X.%#9([X/>OH2@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*2UMY9XYY
M((GEC^Y(R LOT/:I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** $95="K*&5A@@C((ID%O#:PK#;PQPQ+T2-0H'X"I** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "HGM;>2X2X>")IXQA)&0%E
M'L>HJ6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&5
M74JRAE88((R"*6B@"."WAM85BMX8X8UZ)&H4#\!4E%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% $3VMO)<)</!$TT8PDC("RCV/45+1
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !4%[96NHV<MG>V\=Q;2KMDBE4,K#T(-3T4
M4]-TK3]&M!::98VUG;@Y\JWB"+GUP._O5RBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]_!1]OL_^?N#_OX* +%%5_M]G_S]P?\ ?P4?;[/_ )^X/^_@H L457^WV?\
MS]P?]_!1]OL_^?N#_OX* +%%5_M]G_S]P?\ ?P4?;[/_ )^X/^_@H L457^W
MV?\ S]P?]_!1]OL_^?N#_OX* +%%5_M]G_S]P?\ ?P4?;[/_ )^X/^_@H L4
M57^WV?\ S]P?]_!1]OL_^?N#_OX* +%%5_M]G_S]P?\ ?P4?;[/_ )^X/^_@
MH L457^WV?\ S]P?]_!1]OL_^?N#_OX* +%%5_M]G_S]P?\ ?P4?;[/_ )^X
M/^_@H L457^WV?\ S]P?]_!1]OL_^?N#_OX* +%%5_M]G_S]P?\ ?P4?;[/_
M )^X/^_@H L457^WV?\ S]P?]_!1]OL_^?N#_OX* +%%5_M]G_S]P?\ ?P4?
M;[/_ )^X/^_@H L457^WV?\ S]P?]_!1]OL_^?N#_OX* +%%5_M]G_S]P?\
M?P4?;[/_ )^X/^_@H L457^WV?\ S]P?]_!1]OL_^?N#_OX* +%%5_M]G_S]
MP?\ ?P4?;[/_ )^X/^_@H L457^WV?\ S]P?]_!1]OL_^?N#_OX* +%%5_M]
MG_S]P?\ ?P4?;[/_ )^X/^_@H L457^WV?\ S]P?]_!1]OL_^?N#_OX* +%%
M5_M]G_S]P?\ ?P4?;[/_ )^X/^_@H L457^WV?\ S]P?]_!1]OL_^?N#_OX*
M +%%5_M]G_S]P?\ ?P4?;[/_ )^X/^_@H L457^WV?\ S]P?]_!1]OL_^?N#
M_OX* +%%5_M]G_S]P?\ ?P4?;[/_ )^X/^_@H L457^WV?\ S]P?]_!1]OL_
M^?N#_OX* +%%5_M]G_S]P?\ ?P4?;[/_ )^X/^_@H L457^WV?\ S]P?]_!1
M]OL_^?N#_OX* +%%5_M]G_S]P?\ ?P4?;[/_ )^X/^_@H L457^WV?\ S]P?
M]_!1]OL_^?N#_OX* +%%5_M]G_S]P?\ ?P4?;[/_ )^X/^_@H L457^WV?\
MS]P?]_!1]OL_^?N#_OX* +%%5_M]G_S]P?\ ?P4?;[/_ )^X/^_@H L457^W
MV?\ S]P?]_!1]OL_^?N#_OX* +%%5_M]G_S]P?\ ?P4?;[/_ )^X/^_@H L4
M57^WV?\ S]P?]_!1]OL_^?N#_OX* +%%5_M]G_S]P?\ ?P4?;[/_ )^X/^_@
MH L457^WV?\ S]P?]_!1]OL_^?N#_OX* +%%5_M]G_S]P?\ ?P4?;[/_ )^X
M/^_@H L457^WV?\ S]P?]_!1]OL_^?N#_OX* +%%5_M]G_S]P?\ ?P4?;[/_
M )^X/^_@H L457^WV?\ S]P?]_!1]OL_^?N#_OX* +%%,CECF7=%(KKTRIR*
M?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !65I]M!,UZTL$<C"Z<99 3VK5K/TK_E]_Z^Y/Z4 6/L
M%G_SZ0?]^Q1]@L_^?2#_ +]BK%% %?[!9_\ /I!_W[%'V"S_ .?2#_OV*L44
M 5_L%G_SZ0?]^Q1]@L_^?2#_ +]BK%% %?[!9_\ /I!_W[%'V"S_ .?2#_OV
M*L44 5_L%G_SZ0?]^Q1]@L_^?2#_ +]BK%% %?[!9_\ /I!_W[%'V"S_ .?2
M#_OV*L44 5_L%G_SZ0?]^Q1]@L_^?2#_ +]BK%% %?[!9_\ /I!_W[%'V"S_
M .?2#_OV*L44 5_L%G_SZ0?]^Q1]@L_^?2#_ +]BK%% %?[!9_\ /I!_W[%'
MV"S_ .?2#_OV*L44 5_L%G_SZ0?]^Q1]@L_^?2#_ +]BK%% %?[!9_\ /I!_
MW[%'V"S_ .?2#_OV*L44 5_L%G_SZ0?]^Q1]@L_^?2#_ +]BK%% %?[!9_\
M/I!_W[%'V"S_ .?2#_OV*L44 5_L%G_SZ0?]^Q1]@L_^?2#_ +]BK%% %?[!
M9_\ /I!_W[%'V"S_ .?2#_OV*L44 5_L%G_SZ0?]^Q1]@L_^?2#_ +]BK%%
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MW[%'V"S_ .?2#_OV*L44 5_L%G_SZ0?]^Q1]@L_^?2#_ +]BK%% %?[!9_\
M/I!_W[%'V"S_ .?2#_OV*L44 5_L%G_SZ0?]^Q1]@L_^?2#_ +]BK%% %?[!
M9_\ /I!_W[%'V"S_ .?2#_OV*L44 5_L%G_SZ0?]^Q1]@L_^?2#_ +]BK%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/AGXLNO%WA=KF_11>VTS03,@P'( (;';@\^XK#^-L[/X>TK3$)'V[4$5L=P
M?ZD?E0!UL_C;1;'PW8Z]J<D^GV=[CRA/"S/R"1D)NQD#-0Z/\1/"NOZG'IVF
M:KY]W*"4C^SRKG R>64#H/6LOXD^']3U/0-(MM#L/M4EE?12^2)5C^1%;NQ
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M^,?BC4-119Y=-;R+4.,B(!RH(]#A3_WT:;\8X4TO5O#7B&R5(]0CN]A=1AI
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M 4444 %%%% !1110!GZ5_P OO_7W)_2M"L_2O^7W_K[D_I6A0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC.<>U?0-% '@\4/@SQ);6=C-XF\9ZE=,R'^S'=I#&_0Y#1[1C)YSP*]W "J
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MFD$DJH [A=NXXY..V?2I* /$_!GB2T^&MGKF@>(([B"\2Y>:T A8BZ!4*-I
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MA*U6/-!77R.6KC*%*7+.5GZ,[6BN*_X3_P#ZAG_D?_[&C_A/_P#J&?\ D?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]]N\G^RRQ\CR=WFY_P!K<,?D:Z>B@#Q;3=%O-6^,'BU].UB?2KVW"F.>.-9
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M 4444 9^E?\ +[_U]R?TK0K/TK_E]_Z^Y/Z5H4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG^^_[_?_ %J -"BL_P#LK_I_OO\ O]_]:C^RO^G^^_[_ '_UJ -"BL_^RO\
MI_OO^_W_ -:C^RO^G^^_[_?_ %J -"BL_P#LK_I_OO\ O]_]:C^RO^G^^_[_
M '_UJ -"BL_^RO\ I_OO^_W_ -:C^RO^G^^_[_?_ %J -"BL_P#LK_I_OO\
MO]_]:C^RO^G^^_[_ '_UJ -"BL_^RO\ I_OO^_W_ -:C^RO^G^^_[_?_ %J
M-"BL_P#LK_I_OO\ O]_]:C^RO^G^^_[_ '_UJ -"BL_^RO\ I_OO^_W_ -:C
M^RO^G^^_[_?_ %J -"BL_P#LK_I_OO\ O]_]:C^RO^G^^_[_ '_UJ -"BL_^
MRO\ I_OO^_W_ -:C^RO^G^^_[_?_ %J -"BL_P#LK_I_OO\ O]_]:C^RO^G^
M^_[_ '_UJ -"BL_^RO\ I_OO^_W_ -:C^RO^G^^_[_?_ %J -"BL_P#LK_I_
MOO\ O]_]:C^RO^G^^_[_ '_UJ -"BL_^RO\ I_OO^_W_ -:C^RO^G^^_[_?_
M %J -"BL_P#LK_I_OO\ O]_]:C^RO^G^^_[_ '_UJ -"BL_^RO\ I_OO^_W_
M -:C^RO^G^^_[_?_ %J -"BL_P#LK_I_OO\ O]_]:C^RO^G^^_[_ '_UJ -"
MBL_^RO\ I_OO^_W_ -:C^RO^G^^_[_?_ %J -"BL_P#LK_I_OO\ O]_]:C^R
MO^G^^_[_ '_UJ -"BL_^RO\ I_OO^_W_ -:C^RO^G^^_[_?_ %J -"BL_P#L
MK_I_OO\ O]_]:C^RO^G^^_[_ '_UJ -"BL_^RO\ I_OO^_W_ -:C^RO^G^^_
M[_?_ %J -"BL_P#LK_I_OO\ O]_]:C^RO^G^^_[_ '_UJ -"BL_^RO\ I_OO
M^_W_ -:C^RO^G^^_[_?_ %J -"BL_P#LK_I_OO\ O]_]:C^RO^G^^_[_ '_U
MJ -"BL_^RO\ I_OO^_W_ -:C^RO^G^^_[_?_ %J -"BL_P#LK_I_OO\ O]_]
M:C^RO^G^^_[_ '_UJ -"BL_^RO\ I_OO^_W_ -:C^RO^G^^_[_?_ %J -"BL
M_P#LK_I_OO\ O]_]:C^RO^G^^_[_ '_UJ -"BL_^RO\ I_OO^_W_ -:C^RO^
MG^^_[_?_ %J -"BL_P#LK_I_OO\ O]_]:C^RO^G^^_[_ '_UJ -"BL_^RO\
MI_OO^_W_ -:C^RO^G^^_[_?_ %J -"BL_P#LK_I_OO\ O]_]:C^RO^G^^_[_
M '_UJ -"BL_^RO\ I_OO^_W_ -:C^RO^G^^_[_?_ %J -"BL_P#LK_I_OO\
MO]_]:C^RO^G^^_[_ '_UJ -"BL_^RO\ I_OO^_W_ -:C^RO^G^^_[_?_ %J
M-"BL_P#LK_I_OO\ O]_]:C^RO^G^^_[_ '_UJ -"BL_^RO\ I_OO^_W_ -:C
M^RO^G^^_[_?_ %J -"BL_P#LK_I_OO\ O]_]:C^RO^G^^_[_ '_UJ -"BL_^
MRO\ I_OO^_W_ -:C^RO^G^^_[_?_ %J -"BL_P#LK_I_OO\ O]_]:C^RO^G^
M^_[_ '_UJ -"BL_^RO\ I_OO^_W_ -:C^RO^G^^_[_?_ %J -"BL_P#LK_I_
MOO\ O]_]:C^RO^G^^_[_ '_UJ -"BL_^RO\ I_OO^_W_ -:C^RO^G^^_[_?_
M %J -"BL_P#LK_I_OO\ O]_]:C^RO^G^^_[_ '_UJ #2O^7W_K[D_I6A5>TM
M$LXV1'=][EV9SDDFK% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>gwpjrhodncoa000028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000028.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &/ BH# 1$  A$! Q$!_\0
M'P !  (# 0$! 0$!          <(!@D*!00# 0(+_\0 5A    4$   &"PT%
M!0<# P4  P0%!@<  0(("1(7&%B7$1,4%CA6E;?5UM<5&2$V5%=W>):8MM/4
M4E5VDM$B,9.XTB,D-3=!E+4E='4T46$F,D-$>?_$ !T! 0 " @,! 0
M       #! $"!08'" G_Q !=$0 ! P(" PD("PL*!00# 0$!  (#!!$%$A,A
M,08405%35)/1TA4B4G21DI33!Q8R,S1687&5L[0C)#4V<H&$H[+4U1<80E5U
MEJ&DL;4W8V3!\ AS=K9#X?%B@O_:  P# 0 "$0,1 #\ [^*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B+A:X09G-1>WUV^.K3=1E4WA+Q0OB94$XJ:'Q PC6/A
M,0K"C!YYV#QS%$SQPM?BVR$SO:W9RO4S/<C\_P#J5&\D'42-7'\I51>32/?$
MIL>12'Y%;+2YXSY2G)I'OB4V/(I#\BB7/&?*4Y-(]\2FQY%(?D42YXSY2G)I
M'OB4V/(I#\BB7/&?*4Y-(]\2FQY%(?D42YXSY2G)I'OB4V/(I#\BB7/&?*4Y
M-(]\2FQY%(?D42YXSY2G)I'OB4V/(I#\BB7/&?*4Y-(]\2FQY%(?D42YXSY2
MG)I'OB4V/(I#\BB7/&?*4Y-(]\2FQY%(?D42YXSY2G)I'OB4V/(I#\BB7/&?
M*4Y-(]\2FQY%(?D42YXSY2G)I'OB4V/(I#\BB7/&?*4Y-(]\2FQY%(?D42YX
MSY2G)I'OB4V/(I#\BB7/&?*4Y-(]\2FQY%(?D42YXSY2G)I'OB4V/(I#\BB7
M/&?*4Y-(]\2FQY%(?D42YXSY2G)I'OB4V/(I#\BB7/&?*4Y-(]\2FQY%(?D4
M2YXSY2G)I'OB4V/(I#\BB7/&?*4Y-(]\2FQY%(?D42YXSY2G)I'OB4V/(I#\
MBB7/&?*4Y-(]\2FQY%(?D42YXSY2L08D?L<\V"1DXTF\:,9FUK',<=))"BY8
M@KBD"%CEGF#?*^(8(886%KW[&(>&.%NQCC:U$S'C/E67\FD>^)38\BD/R*)<
M\9\I3DTCWQ*;'D4A^11+GC/E*<FD>^)38\BD/R*)<\9\I3DTCWQ*;'D4A^11
M+GC/E*<FD>^)38\BD/R*)<\9\I3DTCWQ*;'D4A^11+GC/E*<FD>^)38\BD/R
M*)<\9\I3DTCWQ*;'D4A^11+GC/E*<FD>^)38\BD/R*)<\9\I3DTCWQ*;'D4A
M^11+GC/E*<FD>^)38\BD/R*)<\9\I3DTCWQ*;'D4A^11+GC/E*<FD>^)38\B
MD/R*)<\9\I6(,6/V.=;@)@XTF\:'NJN4*XPZ22%$N&6<RN6+AWSS!OE? $N"
M$"'CV>Q@$'AACV,<;6L623?:=@X3Q!9?R:1[XE-CR*0_(HL7/&?*4Y-(]\2F
MQY%(?D42YXSY2G)I'OB4V/(I#\BB7/&?*4Y-(]\2FQY%(?D42YXSY2G)I'OB
M4V/(I#\BB7/&?*4Y-(]\2FQY%(?D42YXSY2G)I'OB4V/(I#\BB7/&?*4Y-(]
M\2FQY%(?D42YXSY2G)I'OB4V/(I#\BB7/&?*4Y-(]\2FQY%(?D42YXSY2G)I
M'OB4V/(I#\BB7/&?*4Y-(]\2FQY%(?D42YXSY2G)I'OB4V/(I#\BB7/&?*5K
M?=Q< H['.5*@AERQ9PK1<N #AB&$  "I&0P@0L,;6QP###QQPPPQM;'''&UK
M6M:U%,-@^8+_ *O]5UE*(E$2B)1$HB41*(E$2B)1$HB41*(E$7#]OAX=FX'T
MQEO-E'53,]R/S_ZE1/VCYO\ N55BMEHE$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(L(CKXHD/_ 'J_^(56B+-Z(E$2B)1$HB41*(E$
M2B)1$HB41*(L(COXK ?_ #+L_%BW19.W\S?] LWHL)1%=!@Z![)22QF=(K:0
MF9BUW^6-&FD879-8+;/+(1-0&2C%BJ6NKY!0N(&>!R N%<O;/LY@Y=CBC!7R
MQF&OY-NHZO\ !9L=NK7QD#_4J.CVJ,[I)N;$];9(B(HZ])2:MRHGJBLC%C2$
MEK%[^Y9TE:Q_,)P%E +B&B8Z$*H &28P!L 00N,&)DN-7R[/_/S)8Z_DV_\
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M,6#R$PMDN#L-TL1M%E@C>;RX[%U(;#923ZZXG HE$A$14LL(<4E54/CX%B1
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MIDTJ1S,NPMJVDN>&98<Z1!FR*DIL!_1&ZF5BW$]34W D.];QG%,/"FG*T4-
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M+F5//&YD4(43#+.]LKUFPXOD_-Q+"R6-]AIRAY+/HD62N^F D*BA[JJ*:U7
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M5T,>'7G S9),5,3RF1^X2PAR86,*V5G$4%3+X E%? +(<$X)D=N5*6+WQ-;
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MW]:(G'P_:Q_FM_6B+"([RQ[U@/[6/_&77_UM_P!78MWM_P!?_M19.W\P_P!
MLWX^'[6/\UOZT6$X^'[6/\UOZT1./A^UC_-;^M$3CX?M8_S6_K1$X^'[6/\
M-;^M$3CX?M8_S6_K1$X^'[6/\UOZT1./A^UC_-;^M$3CX?M8_P UOZT1./A^
MUC_-;^M$3CX?M8_S6_K1$X^'[6/\UOZT1./A^UC_ #6_K1%JP>WPO-W7M_=W
MSK__ )4W13MV#YA_HNU;3#3C4YW:DZV.ETZVPBXG(X82C997EY:C-HJ2NL*R
MBU4PT?4E)0-I0IHZ=.&11!S)DP*(*,+GEGGGEE>]Z[W0T5&^CI7OI:=SG01N
M<YT,9<XEH)));<DG:2O,L1Q&O97UK&5M4QC*J=C&,GE:UK6RN:UK6M<
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M_3K=)9V4>NPT+R?!BYKML'J^LQR1E6-3[Z;$HH8"3+K5-O*.5YN2&T0222N
MK2(GGQ3Y&Z:2-HHX(9<SB)F/_L]X9]*Z1CF&.2(MS-+@X6<+M(< !QW%M7^D
M533"!L4C)6S13!Q8\-<PW8<K@6.UBQV&Y!5[ZL*JE$5.M"/!<97\8SCY^9,J
M"F]Y9\[_ *QRL57O[OR8OJF*XM3JNE$2B+$G^Z;,9B/5[7(^ZEF>TG(Z;IEC
M/<5U&S?1SBMW#W9W.;[D[K[D[G[I[E,]H[9VWN<;B=KRPXY6N=:^5I-ME["]
MELQN=[6WMF<UM]MLQ O;5>U^-:38$X8V7)"MIL]IHT6'A> -XI!28HAN8&WL
MNTY=/!/]SX+.#22W/&X4;L-R)":LG$%1+F%FYD4)*" R,F"PO' !'I,K'NT)
M?!DCG=D8\2AQS$V%VY6D"X.M<E+AT;-\MCJM)+2L,DL;H'1C*VURU^=[21<:
MN%8RF\-/.>,2/7:AQ<'BJ!Z=1G+3JC21)E9FSS0=[Y;::SY!O':R] H448R:
M"XK)Y16$*CFB)-R6S+%#&9G([D0*&CX6HK9,AE-.="UY:YXE!( -KY,H)UVU
M _G6QPV+2-@;6#?#XVO9&Z!S6N+F9PW2"1P!(U"X_P ;!6.WJX7*.-*9/UJ8
MN,<G9:;<T):/(DH/]$=MD!,@"!'!(D>QDAS4OI^357[N-"5W,_<2:>1S4&L$
M.:2<B6:P$942F.,L]6V!T;<N</ <YP=8,87-:'D6-P2>,;-NM0TN'OJ8YWYQ
M&Z(ED;"VYEE#'O,8.9H:0&ZSWVV]M2DO:K>R28TV)8.G>J^NX>S.RKOB]4G%
MQHRY)B9$D>1A#R<OY-,J[W<\3J$YQS1UP.H,1!16^FI/=.8UPSADV"$,4"-[
M2U#FR-ABCTLCF:0C,&M:R]KDD':=0^6WS'2"E8^%U143&"%LFB!##(]\F7-E
M:T%NH#62=7!QVL!I_L2]]D(T6W%*&OLBZS2>QW\YXS?\7R $.?*@.)K9E>W+
MT=OFR2C),H1NMESQ<9NOYOD0T96&"42I6XMB%S \D,CI6DNC=&]KBUS77VCA
M:;#,T\#AJ.M0U$+(7@1S,G8YC7MD9JU._HO;<ECQPM.L7%[7LK65*H$HB41*
M(M"L _$)6^F#8C_,#)U?#?LG?CWNA\8IO]OI%IB'PN3\B#[/$IJKH:I)1$HB
M41*(HOFF2\X>BUYR2"RGE(QIJI6)PBQH_1C*\[W0I&CA9-34E'32@8PV69D^
M=+6.'+A9@):=B;535NY20U7\,H1B5?341JJ:B;42%KZNLD;#34[&M<]\DKW$
M"S6-=E;?-(_+&WOG!2P1::6.(R1Q![K&25P:Q@ )+G$ZM0!L-I-@-94'ZT;2
MKDW/B;(ED&(%*%Y:@<PP<WDU\GJ@2.A"I<F(9]?:AM,>+;+$20Q_(DF&[*Z.
M.0+C)N>16X0Y[ 87(ORF.8#%A=+A>(T>),Q/#L6;5[VGWK-13"2AE9#4,DII
MG/<&!TC='('D2#-=K"!>Q54C:>.GFCF$\-2),C\CHG Q.#7@L>2;7(RN!(.O
M4-5[@5UQ4DHB41*(E$2B+BJV)\(&=?ICD[\;+=?;VYO\7< _L7"OL,"] I/@
ME+XO#]6U=UFA_@5ZI_0!%7X-2:]>P_X#2>+Q?L!>6XG^$J_QRI^N>K8U<5%*
M(E$2B)1$HB41*(E$2B)1$HB41*(JF:O_ !KW!^MFXO,Q!U4Z3W=;XX[[/3J_
M6^]X?X@S[35*V=7%02B)1$HB41*(E$2B)1$HB410-%7AVS5]4K7#SQ;2UP.(
M?#?T6+ZZH79L,_!OZ=/]GI5?&JJM)1%RXN+@C=KUF9'6[4\)C([2F7A*=G7S
M.-K.LJ*HN;1>:YCU5F8B5!"P![&3H&5]=SZ6.UQK9C%BSG.V&XV)CMH'%FDE
M+W&S<KZF5S]8UPO=$\?+>\9%MHN?G7.-KZ<1M:2XNCHH&Q]Z;"ICCGC/%WMI
MAKV$M"DN N#@VVAUW\'"]CC392H-J9,G"A26_D<L_$P&YDCLTC+V,*IZ0:S
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M4A7AVYADK0MT3:YHNBYG[2LV4( )&&&937AA&[U@N?9?28[;TL,@@,]1'(9
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M!Q#7O<=^%[)!);*D0;!CD2PEC$CH)V/E=!(QK9CF<'M<2QUK%S"#MX=>JX'
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M,&,.MQS':]^NPL0>"3]!N#6FO7O8)F3Q-:[K8BBQ%J,C:@,9K:NLMTM,I(R
MF.)%71)2F<ZY,"-SKT&Q0"H6"(EDSZ4$=/&5()4"S+!@&MX*9\<C9'F(9(A$
M!$T@. ([YY-KNL-@U<7$HZJMBEA=%$)CI*@U#G3N:XL-B!''EV-%]I(-M5M>
MK=E5U<:E$2B*G6A'@N,K^,9Q\_,F5!3>\L^=_P!8Y6*KW]WY,7U3%<6IU72B
M)1$HBTIJFF7")11N3N3LGJ9,6H20U=N5J&%A7;<[Q]+;L<"%E#T9%F&G!DS+
M(=#53@+'C1E<.F;9Y*7;2XB9CAD4$ ,X#4C#4,FFDB?"!*6$AX>2,C<H]R0.
M/C7)BIHY*:FAJ(ZDNIQ* Z)T;6G2/SF^<..H6'!P[5#NS/!;;IR\X]YP6#.N
MMK>9'"'1MKZ4G+-TL.1SSL:$CP5'B.RQBL6^YB[BCEF.]C*3F:/*3JQ7%Y$3
M3]R2>DBGR6*J;TDI9WF;+)&&U#8])=KB0Y@ [RVK*XC:;D#5:^M205U-&*4O
MBF+J-\NBRN9E<R1Y=W]Q?.V^QM@2-H!(4L/K@M))=B#PIB05DUCE1=^HCU8C
MECC&""]D&Q3\ 0N%&*XH.NP9:^1LFO*0=U)*#2.WC DKVP-XX#]G&MC2O(JA
MF;]W;$UNWO3&W*<VKA.RUU&RN8U]$XL>12OG<\:N^$KRX9=>T"U[VU[+[5JU
MX0..IEU[?>\D40FJOLT>W7U1@N/WTS#>FLY2_:6GY&4-B1$A)>L,N1D9/,A$
M&7TRX:!(@<P$DH9D9'3R^WB*T:LE6PJSM?$Z9C"[[M$QKAH7OSN:S):-[;C6
M-3LULNL@$VO>I7Q3-I9) W[VJ)7-=OB.,QL?(9"9HWV<;;6:/-FU D:UU)ZT
M-!>C[7'7]A.DG9/<[(A**6@XR%A0A[$5YM,1!1E<G8<#,0 :Q90)& >V@B9A
M"<3CAYY87ME?E8FEL4;3M;&QI^<- /\ HN#G<'SS/;K:^61S3QASW$?X%3;6
MZB2B)1$HBT*P#\0E;Z8-B/\ ,#)U?#?LG?CWNA\8IO\ ;Z1:8A\+D_(@^SQ*
M:JZ&J241*(E$2B*J6U&OB[/XFM>:&OI*#:$-K(EV"6;*P)P:ZTA1V7<X)]!3
M.XPQ.U*RADO 7)C&N(3PL +VX3&]\.SV' ,9BP<8X)89)NZNY_$,'BT9:-%+
M6& LFDS$7C9HCF#;NUBP.M6Z2H;3[YS-<[3TDU.W+;O72%A#C?\ HC+KMKUZ
ME_J=]?EV69HU.D]+7DE*3M>9#>3S7DP^"<$.KY1S,10:9<FD"%P\P 3)8T<P
M-#9',@PLB^&6(>5Q.QC?&$XQ%A^%[H:"2&21^,T=+30R,+0R%U/5LJ7.D#B"
M6N:TM&6YS'7J6::I;!!61%KG&IB9&T@BS2V0/)=?78@6U<*M777U32B)1$HB
M41*(N*K8GP@9U^F.3OQLMU]O;F_Q=P#^Q<*^PP+T"D^"4OB\/U;5W6:'^!7J
MG] $5?@U)KU[#_@-)XO%^P%Y;B?X2K_'*GZYZMC5Q44HB41*(E$2B)1$HB41
M*(E$2B)1$HBJ9J_\:]P?K9N+S,0=5.D]W6^..^STZOUOO>'^(,^TU2MG5Q4$
MHB41*(E$2B)1$HB41*(E$5*<IRCN%-YI/,2 9=I8)Q:GZ_@I?>K&4FR0)F(F
M2_LUF;[M!C=H.T9)PQQ.E^T"*X9$,Y>XN)/,QD6,V"Z]B<C(ZT9B1>EBM9CW
M;)9[^Y:ZVWALNU81$^3#2&9=5=,3F>QFV"FV9W-O^:ZL7S\-;_WG+_W7=HO8
MW5'?,7&_HINPKV]9N*/IX/6)S\-;_P!YR_\ ==VB]C=-\Q<;^BF[";UFXH^G
M@]8G/PUO_><O_==VB]C=-\Q<;^BF[";UFXH^G@]8G/PUO_><O_==VB]C=-\Q
M<;^BF[";UFXH^G@]8G/PUO\ WG+_ -UW:+V-TWS%QOZ*;L)O6;BCZ>#UB<_#
M6_\ ><O_ '7=HO8W3?,7&_HINPF]9N*/IX/6)S\-;_WG+_W7=HO8W3?,7&_H
MINPF]9N*/IX/6)S\-;_WG+_W7=HO8W3?,7&_HINPF]9N*/IX/6)S\-;_ -YR
M_P#==VB]C=-\Q<;^BF[";UFXH^G@]8G/PUO_ 'G+_P!UW:+V-TWS%QOZ*;L)
MO6;BCZ>#UB<_#6_]YR_]UW:+V-TWS%QOZ*;L)O6;BCZ>#UB<_#6_]YR_]UW:
M+V-TWS%QOZ*;L)O6;BCZ>#UB<_#6_P#><O\ W7=HO8W3?,7&_HINPF]9N*/I
MX/6*J^EFYL"-/7-I(2VH2B&I%G5,!D;%-UUV+7B=@E29Y!5B=PU1!BI32QA,
MB1XOD8!!."#$3-QB!X,L?+&2P,,$\;8F@E]P7[(I2-;W$:PPC8>-3U--*Z9Q
M 9;+&-<T+3JC8#J<\':.+7M&H@JU'/PUO_><O_==VB]C=3;YBXW]%-V%!O6;
MBCZ>#UB<_#6_]YR_]UW:+V-TWS%QOZ*;L)O6;BCZ>#UB<_#6_P#><O\ W7=H
MO8W3?,7&_HINPF]9N*/IX/6)S\-;_P!YR_\ ==VB]C=-\Q<;^BF[";UFXH^G
M@]8G/PUO_><O_==VB]C=-\Q<;^BF[";UFXH^G@]8G/PUO_><O_==VB]C=-\Q
M<;^BF[";UFXH^G@]8G/PUO\ WG+_ -UW:+V-TWS%QOZ*;L)O6;BCZ>#UB<_#
M6_\ ><O_ '7=HO8W3?,7&_HINPF]9N*/IX/6)S\-;_WG+_W7=HO8W3?,7&_H
MINPF]9N*/IX/6)S\-;_WG+_W7=HO8W3?,7&_HINPF]9N*/IX/6)S\-;_ -YR
M_P#==VB]C=-\Q<;^BF[";UFXH^G@]8G/PUO_ 'G+_P!UW:+V-TWS%QOZ*;L)
MO6;BCZ>#UB<_#6_]YR_]UW:+V-TWS%QOZ*;L)O6;BCZ>#UBTN0ILS$:0RU,H
M>./S$<24IT4<;%H8F=0"[E69ND-7(7R,)\?FB^ ^1$\7R-$\Q<3B<9N,GJ(!
M50*FBH/Q[[(6YW%*[=ECE73LH3#-/3NC,V+X12R$-HJ9AS055=#/&<S3821,
M)%G %I!.E=2S/J7N;HK%D([ZHIV'5!&T]ZZ5KAK!M<:QK%P03+7.LACY=(G4
M7.GLWKIGM3QKP,-^GL!_B:J;SG_Y/I5-ZY.=9#'RZ1.HN=/9O3VIXUX&&_3V
M _Q--YS_ /)]*IO7)SK(8^72)U%SI[-Z>U/&O PWZ>P'^)IO.?\ Y/I5-ZY.
M=9#'RZ1.HN=/9O3VIXUX&&_3V _Q--YS_P#)]*IO7)SK(8^72)U%SI[-Z>U/
M&O PWZ>P'^)IO.?_ )/I5-ZY.=9#'RZ1.HN=/9O3VIXUX&&_3V _Q--YS_\
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M1!]GB4U5T-4DHB41*(E$5==AM>D[8'."<U!S'6U>#=B8WV$(V))P"AWP*,=
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M+T,-/+25 F:T.?-'#',0+Q/>UQ8;[0TO #@. WX%3MP<(3.<CL+8<M VQKE
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M9G;MV/A(5@%@=0;)<V ]E:/FWQU%S);@>Y<=65"Y8#-&2"!$(V83MZ/>DE9
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MA($[,8!;+ 7/B<R2,F+3Y@_,TN;%'(<KAI+=\+DBQV7*I2N<'053&Q3LD@D
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M!\JD8H,L1HMR4AV,9+4>)#[:RD^4C$I_]5DJ-,FJC+Z?8M__ &+FT\&P/_\
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M0-<07!I+1M(!('SG8/SKU:C6$HB41*(E$2B+BJV)\(&=?ICD[\;+=?;VYO\
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MPAQ:P:R ==]:SLKO5NXXDE@P:S-K2JV=)<+Z5T7);@H<7Q0N"RQ"ZQ%:\Y3
MIQNY()R.#SZ8JL,4",N%J$TM+4CZ<B9*!4Z5S6PEP9YSEC$M_OK0B5K6]^PC
MBME):>$ #_&^-ZTPSRN@L.Y^^C3E\@$<C9 " ;YPUPN+.)MKM8VMM?X+F79S
M?13="*)XE4]-RUJ[N;(T$L^3UULM9JNMQL-':[)<*)BZB#+2T1N&EDB8<"@
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MMF,!EF +D!G?(+(4'/,(2^%\@\LL+VO?QEP <X!P< 2 X @. .IP! (!&NQ
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MGZ019;E,D846(SQTU=''7"9>ZEC<;)6)I1E!2>Z!4A2+)X:VJIHJH<*"$DW
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M$ R71   3.&17)<'3KJF09H-*L=%)', +)GB$K(#(W2O#G-8+EUF %Q-@0T
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MTI*34S Z9%.',$\B5)8&S8_8[<:-8E@@[#F1NQ;MHXMLQ1.Q;CY7[%8  O8
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MXO%^P%Y;B?X2K_'*GZYZMC5Q44HB41*(E$2B)1$HB41*(E$2B)1$HBJ9J_\
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M+ZM0N2KTP].L;SE";(V%8RUGR6/]EE9!05]PEA&Y<)JFR>9_%36"RI<#-'#
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M0ID4!M;/+"^4CZB)DK(7.^Z/L6BVK7<"YV"Y! &U11TD\L$M2QH,41L\WL>
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MLK7M4P-P"-A /E58@M)!V@D'YP;%??65A4ZT(\%QE?QC./GYDRH*;WEGSO\
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MQ2/:R2KD8US6-8TS/:'!H(!"Y/#YLC*^-\N5CZ"I#6.?E:Z5QC #6D@&0@$
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M=&,&QQQQ/FS=AB%13[I,4AC;29(Y80W28?03OL:: ]]+/322OUDV+WN(%@+
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MES7$1AQ<XEP(OG-KV-[$ZM2KB>-M74U+YV2R-A<ZG>UCVM,Q:&,:UI%P(FW
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MJ*YD=4PR0".>1[ YS2='"]XL6.:ZX+00 X7V'5=5F9>_SB<<N0QD[U7!@--
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MIJQABNQ)=A4GV@UF&%<$^.E!DS G&XX0(V8@=LL\;6O7JJ=M5$8G.+07QON
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MHTG6+F732>28HG0@E%)&P$&*F.VW"R VFHP[1NIY32/B+RTQ,88W9P&N$D1
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MY6'#<JSBLZ_1Q)"\[@BKX6'@G65L4EPJ<0'VRGJJ6QG0.C'O<I<P<!W,!/#
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MP4%101U53/))AKGT^]S&YCM)G9/L"S0;E]-?!5P-.S&?,9/Q6CU[M@);"<A
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M91:R=)75&C2CMJ;'0M+<7N6>'PCKRZ4[]8_3BBV4E!%33N1+,NL'E\(TG E
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MARDL#WUM-4#+DACG:^Y.8F4,#<HM8CO3>Y%M5KKA8:F./#ZVE<':2HEI7QD
M90(3(7YC<$'OA:P-_D526' >YIK;3*>IQ9D(R40*O4Z1CE0/2R\,@X$BA2-V
M)&PXTC<)@%VV,_C:#\*XZ594$5ULS@$3#44PI8?NBG'35IK-\5#*>4!Y$1,T
MEJ>$ZB(HA'D,A;[I[C=QL 6B][\E5APH-ZTTM5"XQ S 4\=ZJH N-/,9B\0A
MVID;1E8+G*XVM$:+IAO"8@%[:>&^;^TH?DJ3'<X'9*I=WO%Q2"49#MD')Y*J
M8@L[O/3D+)=,%,0TL+-06L26((IK'(P7&S!.EX6T-?O9]$=[LAEE>Y\P>]T@
M8^3.0UAC#<Q&H7=;;?@5A^)88*N+$0*N2HA@C9'3F.)D)ECA$;7/ETKGY >^
M[UA-P-1&H[M$-&(-U$1V^E!7 2T)+3T9- RROGD"02R@)$F%?._PYW#+@!X7
MRO\ #E>W9O\ #>N=:T-:UHV- :/F L/\ NM.<7N<YQNYQ+G'9<N-R;<%R5#4
M5>';-7U2M<//%M+7!8A\-_18OKJA=EPS\&_IT_V>E5\:JJTE$2B*HF\<7S=+
M^O3C9< 90NH/DPLME2-L?89F)[WAR5&DE*P!MSQD]D]01')[ED70GX98DW 3
M1#IY+5"A'(*Y,,490*0SL>^,MCR%UP2V1H<QX&UI!!M?CMM'!M5BE?%','3:
M4,LX9H7%LC'$=Z]I!;?*=K;BXX]AT;M7@D]CEA,WO<;:A37325,V1TR<.N+4
MU?AZ7GB^8V=4LJ[D 709N?:AFST1KL^Z4EE>])OIC/:ID8LEJBN,.7)C"',U
MVBVDE(G(CCATD)C;&QY+7.)OG=P"P%A8<)U<?*.Q"$&E:Z6:I,-2V9TTD;6O
M;&&D&-@S%SKGOB7.VBU[6M;+5+@V)ET'G>!WUJW>/DV$I&A".HSWP@L\Z5TB
MC\J3"::2CI^P<-&!413#4G8:4LE>SK3E;O?#<I'W0.CBB+3EP.MV:*FD@?&Z
M++D=&UL[,QMG: -(RXL3MO>U]?";BO/6QU<4K)\QD9*]]+*&B^1[B=%(+BS;
M6L1>VH6U:_&X/. .%*TN8S"UN5(LT]<D'$9B=KA=<@!33)-Y'*L62904W<Z3
MB,V,(T+()UPHB,N'L41.,JI4F?.E2P!PZ &*(-ABGCJH6MC+(BS.279W9@US
MKNL+6) )MKVV6:R:AJ7/F#ZD2Z-K6MT;-&7,9E;<YRX D:R!<#@58&YP8'"#
ME-9HPX+]5(ZZ8:DQEL<2D[':,J_G4+)R[$R=-"Q-(#8"B#)HAEB4CCJRP,2&
M/#.3)K !88)V!H<,*Z^9B%-4:)M*1'HFR9M+F.8LSY[9+>ZN3PVX/E,^_:,3
M25H,V^)(2S0%@R"0QMCS:2Y[RPO:U[W^9;BYEUFD9^\(/I9L^AF&UA&^O\:;
M-M)]%SZF;+N8=5EY#9Z<U<D!+"3#!-0*!&$([=7&-*:?F3#N!D $<N)EB'<?
M$YU1#*+98V2-=KUW< !8?ZKCHYV,HZF YL\KX',L.]M&7%US?4=>K4;Z]BO]
M5A5$HB41*(J=:$>"XROXQG'S\R94%-[RSYW_ %CE8JO?W?DQ?5,5Q:G5=*(E
M$2B+1C;7WA*]?MY-[=@]:8WU0DJ.=N5^!E=/PEZ7I!9;F0,(=B<%CB!B)C8C
MM>)VNI*J@L"=C)2,=@H4(#8WPS,# A4<E3'//)&R)S92PC.\M(R-ML /"3Y%
MRFFHI:6EAG?4,?3B4'1QL<TZ23-M<\'4 . :[J!=J>#XX0N2G%PC:3&+?UG.
M-3A(HSUJ,.QRNJ3WJB*,//N$HQ1&6ZFBC(!&/ECOR3G2J)ACO><9E20P4=+-
M!*2D4/GBV2&9CEIZAQJ T1D5#8R27$9',: 0!8W!.H'5;:1P*:"KHV-HS(Z8
M.HWS96M8TB1LCRYKG.+AE(!U@ W.H&VL2?(G!E;!NI X7I/3S,8]W[R0II]'
ML+C&W$IAV)K4$P8!'CRN]QL6R*(A)PCE"[H01D[%<$.D;8G!RY ?_=[;&ED(
MJ_<WG9"UFOA8VSLVK5KV6OL4;*V%KZ!QSVII*AT@ &L2/+FY1FUFQUWM9:NN
M$'45C4I[<(I$2%)&NZPX]S]/-<&P^8[E=,FI$EY,=T7PAG$J BZU!%XP-,78
M -]98XA(N3>>F D>O@S<PZ2B*&V3158JSWA=4,#HR988@YKP\/NU@:!'9MGW
MX+.U':!;7>I *AM)(8Y@*>IE<U\9C,9;)*7DS=^'1%NTW:<[=0/?"W6+JNW5
MMH:PZXM-RIII&<;7@:(&ZOI!X+($ZE+:)'K>355-. Y6MD$:(GBPY4P%E:V0
M8H6>-[=FUZY:$%L40.HB-@(^4- *X&H<'5$[FF[732N!XP7N(/YP5/-2*%*(
ME$2B+D&2O^(2!],\\>>E^U\L[M_QIQ?_ -Z'[)3K]GO_ $V?\$=P?B>*_P#V
M'%U[-=57N241*(E$5(%?61SNE;WD"5E)(3D/99$8Z2RCQ<P8-G$LPW(S$:A@
MXND>Y0<00@%ZP!D( J:-9G$_#.]\RXN5L+=ECQJ&"/<R8V2/EP:2IDJ6N :U
MXFKM\!L3LQ))B):2YK0UY&IP"\5K/8UQ+%*SV;F55324]%[)%#@E)@L\<DDL
MU+)AVY@X5)-70:)@8R.O#)&QQ2R&:G:[OHG. %>W)IU.4WH;N$E#%BL1P)NM
M32@-A%D%S*3H3UM=:;Z0I"$?"V;NWTH5"2U=6:Z4G@)(196/$21LZ,/V\8J#
M@:Y>'=#A>&2TXH=]54+\9J,5JC+"R!T45132T@I8FZ9XE?''-(\R$QL>YK ,
MH)+?/L2]B#=ONVH<8.Z?N%@=?![&V%;@L"CP_$JK$X*VNPG':#="<<KICA](
M^AI:RLPNDIXZ2.*KG@IYIWR-D?$P3>T\M6)XF,])LN/$DP61*AS.%!(W9Z>Y
MU)QMW$:'ET1Q* CD<6"$GB !NXZ8- IH1--,9(P.0-CPAF^.8N4=-CN%X<VB
MH*9U74T#>Z6_*A\+(9K8A$(6"&'2O!-.UH+RYXTIN6!NQ7<9]B_=UNPGW3;K
M<7@P'!-U,SMQ;MS>#P8I4XEAS7[D*YV(U#L1Q$4%,YC,7FDD93,AIY'43<@G
M?*07G]EG5F<'>J/.>%-.8Z%,JGL!"$T-Z-@G8?4VQ9$@]KG6>1:BL]L&Z5R"
M4W$F+2R9$4"J ,3*F0TZV66&(YGN/6/',,IV4V%L=4RX<S"<3PV:L,#&3&3$
MYV5#ZB.F,QNR&2.-H:Z4.<W-8:FYI*WV+]VN+U6,[NJFGP.AW8U6[[<1NSP_
M<XW%:BJPP46X?"YL(I\)K,;;A\3FU.(TM;62/J(</=#'*VFNYHDDT%I-:(K>
MS$M+KUDD!#37K,\GJ;_/MQNJAA<2VJE734Y(0F_[MF$]+NL*!0J1$&4%$!/*
M%AA3.(8 ..(-\LN$QFNIJKN?349D?38=1,I&331B*2>3.^26;1!\FC8YSP&,
M+W. !)-S8>G>QMN7QK ANMQG=&RBI\:W9;IZG'Y\.PZJDKJ7"J0TU-24.'[]
MDIZ4UE1%% Y]14LIX8I'R!L<8#+NL_7"+TQ*(E$2B+GEE;_FC)/\?/'\1*-?
M2V#?@?"O[-H?LL2_%GV1?^(.[O\ ^9;I_P#>ZY=Z.A_@5ZI_0!%7X-2:]6P_
MX#2>+Q?L!?.>)_A*O\<J?KGJV-7%12B+61PCK#57<=U<67#&;YFC7UE3"HJ\
M\1?'Z K/!96"!MJGB+(7SK,0\KJCF06LXLQ32PGE@#=KESEK"E1 A,^QQ6)Q
MN>:1SHI)Z:.<NJ(8VE[G M(C<6-UO:QU\PL=1UBRYK!Y6QBN:R>*FJY:=K:6
M>9PC:TB1IE8)7=[&^1FIA)&L:CJ6JLQKM*W>.I&$B!Y;9VNY?A 97?ZQ$[KA
M-VR:LVC5:BAC)L2.E4A !R-Q>D%G-M3)J:<93$]P'@F^*+8,SBJ9(AH@+Q)I
MIM&ZU/,RF[HS2.A? ^5VB=#&('F .8Z2-A!! <<AU&^4A<V*N#3#-5025AP>
MFA;4QU,<+=,VHF=4QMJ]&]D,CVEK@2P%XV9<P(]0Q%R.P3O!^M:8HVFJ3XO4
MI7W=<Z9#2M$)QIO8C'IUA-%5(-Y'A=-D-_N6['15PHI.\HSE5;P<QIM9&2)Y
ML&[V#)J^3"V,X:V:*>6%TU>\0&$LD$9C80UL#99'Y&N!>&%V<LN"T[#@5#I1
MBTE/-34\X@PQAJ6U DB=,)7@O?4NAAC$KVD1F1K<@D <)!K+?E.:[3D'',(G
MUJ)Y+3M6T[9;:UW-N%G)"SJG-;C*,GL1;X4#X/O7Y-=K=="H533A5]7)X&%(
M7-G&7#@L&P3ME4,,V--/HJ<NAE;2"JK'M@? ^H=%%(&BGTE,',<;$/M<G(7W
MU@W.164NFJ@VHA-<ZAP^)]3'4QTK9YHW.-5HJMT;V-+@8;G+]U$>09<NJ>X?
MT]6'*\="VA+D:2B_(;;C&VJ%6$R6HW.M,LSDA?5D15CEEOY!3WM(9!!)X&2^
M1QEMEUN\PI!$RB25-)9)11K$B=B&B+WX='-%-)"V.L+FS1%@C#G-,4<@#Y T
M:KQM?(76#;@%MA4GQ%K&8M+3S00U$DM!E=3SB0RN8V032PO,4)<2#:1\<8;<
MN(<6ON8R8D&O%O,C2##9776<)5@2.P=IVJJQ,FL!YN]<9;P69/<&<5N%RQ\%
M8%?-(!QF]SIK05S)8=/1PKE#01@F6,E,S,3*=[8Z 55+/-31[\:Z$1R/=&]T
MK]$Y\0 <6EEA&3<-VBUP3/+51OEQ3>=93054QH)&U#I8XVR1MIV;X8R8]Z'B
M6[I&@ASC<$$@@1T0URF<E%.K]GY#,H%8<:SRVNR<,<.2 WE/ZLT7([7L:,L%
M>>L/([M:"^Y,%5M9C)S>?0:BK$$90N,IX"VQ62QX>(4TXAI-)!*((WU>:)U-
M)4N8]\A,;GP->QS[LU-DNX W(]T"9W5E,:BMT53":B2.@R3LJXJ02,CBM,R*
MH?'(QA:^SGQ96N>W5;O"!9^&--E-UR)IRSYTC639%BMJZK3*F*8LO,8VW;(9
ME3E*ZO'C*?A!%>+[0DI816X:+9-=LJKR4E1.)I**9&(IJXB6+)EN"B+Y*%E1
M%-+$RDG!T\9;E)F!CCD#7R-:6L(R,,A(#6FP+;-HU&)!D.(RTLT,,\E?3O:*
M>429@*?+-)"Y\43W,=(#I'MB:UQ<X N8^[L3U=@)X-=Y\%X^);U]D0ZJMF-9
MH8;S7%:+G$K+,?N9.D4_G"@K_P QTL119J8W$L[D9:BRX,2)!&2Q<QT\<,MA
MG?".DIWL?A,DU-*7-BGCD<Z%Y=&X2'0:2XO&&M-V%U@T:QL4E=5QOCQN*GK(
M0V2:FEC:V=C6S1F$;Y$-G 2%[F@2-9<N=8.!)LNB6NRKJ*41*(JF:O\ QKW!
M^MFXO,Q!U4Z3W=;XX[[/3J_6^]X?X@S[35*V=7%02B)1$HB41*(E$2B)1$HB
M414JRGR%8+WFD\Q,DHLB,@')J?K^"@#/1P$$$-8&2Y@V:$40D_,^,%B9S)8'
MR>1G$.^5PL3(-\K6MG:NO8G)''6C.]K;TL5KFU[2SWM\R[5A$4DN&G1L<_+7
M37RB]KP4UK_/8^16+]\%T?Z5D%]8C>_651WS3\JSRJ]O2IY"3S2GO@NC_2L@
MOK$;WZRF^:?E6>5-Z5/(2>:4]\%T?Z5D%]8C>_64WS3\JSRIO2IY"3S2GO@N
MC_2L@OK$;WZRF^:?E6>5-Z5/(2>:4]\%T?Z5D%]8C>_64WS3\JSRIO2IY"3S
M2GO@NC_2L@OK$;WZRF^:?E6>5-Z5/(2>:4]\%T?Z5D%]8C>_64WS3\JSRIO2
MIY"3S2GO@NC_ $K(+ZQ&]^LIOFGY5GE3>E3R$GFE/?!='^E9!?6(WOUE-\T_
M*L\J;TJ>0D\TI[X+H_TK(+ZQ&]^LIOFGY5GE3>E3R$GFE/?!='^E9!?6(WOU
ME-\T_*L\J;TJ>0D\TI[X+H_TK(+ZQ&]^LIOFGY5GE3>E3R$GFE/?!='^E9!?
M6(WOUE-\T_*L\J;TJ>0D\TJJ^EF[VH#/US:3?=.R4.-];*NJ8#1E*5GTADCP
M!=6F>05A,&%+C&L1, SR6?)'RN5\;6&*F@!L.S@)C>\,%1"V)K72,!!?<$\;
MW$?X&ZGJ::H=,XMA>1ECU@7&J-@.OYQ96H]\%T?Z5D%]8C>_65-OFGY5GE4&
M]*GD)/-*>^"Z/]*R"^L1O?K*;YI^59Y4WI4\A)YI3WP71_I607UB-[]93?-/
MRK/*F]*GD)/-*>^"Z/\ 2L@OK$;WZRF^:?E6>5-Z5/(2>:4]\%T?Z5D%]8C>
M_64WS3\JSRIO2IY"3S2GO@NC_2L@OK$;WZRF^:?E6>5-Z5/(2>:4]\%T?Z5D
M%]8C>_64WS3\JSRIO2IY"3S2ORSW^T9$$"%$VF@804"^60 F<@-O(0'+/&^.
M>06>1N^0=\L;WQROA>U\L;WM?LV^"F^:?E6>5-ZU/(R>:5^OO@NC_2L@OK$;
MWZRF^:?E6>5-Z5/(2>:4]\%T?Z5D%]8C>_64WS3\JSRIO2IY"3S2GO@NC_2L
M@OK$;WZRF^:?E6>5-Z5/(2>:4]\%T?Z5D%]8C>_64WS3\JSRIO2IY"3S2GO@
MNC_2L@OK$;WZRF^:?E6>5-Z5/(2>:5RZ)LXP\&>>V8DE,W# Y+$S*A3+)=(V
ML83EB6GHJI9T&]Q?[98^FG"IXJ+CV<!BQ@(7"]\,\;W^<]UV#8M5[H\4J*;#
MJN>"66(QRQ0/?&\"FA:2UP!! <"#;A!"_6'V O9'W!8%[$.XS"<9W7[G\,Q.
MCI,2;54-;B=-!54[I<;Q.>,2PR2!["^&6.1H<!=CVNV$+U>7:&OG-9?EXC^;
M76_:[CO]4U_HTG97L/\ *][%WQ^W*_3-'ZU.7:&OG-9?EXC^;3VNX[_5-?Z-
M)V4_E>]B[X_;E?IFC]:G+M#7SFLOR\1_-I[7<=_JFO\ 1I.RG\KWL7?'[<K]
M,T?K4Y=H:^<UE^7B/YM/:[CO]4U_HTG93^5[V+OC]N5^F:/UJ<NT-?.:R_+Q
M'\VGM=QW^J:_T:3LI_*][%WQ^W*_3-'ZU.7:&OG-9?EXC^;3VNX[_5-?Z-)V
M4_E>]B[X_;E?IFC]:G+M#7SFLOR\1_-I[7<=_JFO]&D[*?RO>Q=\?MROTS1^
MM3EVAKYS67Y>(_FT]KN._P!4U_HTG93^5[V+OC]N5^F:/UJ<NT-?.:R_+Q'\
MVGM=QW^J:_T:3LI_*][%WQ^W*_3-'ZU.7:&OG-9?EXC^;3VNX[_5-?Z-)V4_
ME>]B[X_;E?IFC]:G+M#7SFLOR\1_-I[7<=_JFO\ 1I.RG\KWL7?'[<K],T?K
M4Y=H:^<UE^7B/YM/:[CO]4U_HTG93^5[V+OC]N5^F:/UJ<NT-?.:R_+Q'\VG
MM=QW^J:_T:3LI_*][%WQ^W*_3-'ZU:-)*.%5&17^H$3 1LD>>KJ.$S0&>(@!
MDJ973XQ<P")C>^(@0P.> @>>-[XYX98Y6O>UZ^@,*C?%A>&Q2-+)(Z"CCD8X
M6<Q[*>-KFN' 6N!!' 0OR8W=U5-7;N-V5;1SQU-)6;J]T-52U$+@^&HIJC%Z
MR:">)[;A\<L3VR,<#9S7 C45WM:'^!7JG] $5?@U)KU/#_@-)XO%^P%\]8G^
M$J_QRI^N>K8U<5%*(E$2B+!'!&;$=3UCZ17 W"BF]8KS=(D?+XPIS TV<WJB
MXMYTY$@@#(10:ZPBXXD#'=I<U8,*W&+V!%_VE1NBC?)'*YH,D.?1NUW9I&Y7
MVL;',W4;@_(I&S2LCEA:\B*?1Z5@M9^B=GCOJOWKM8L1\MPL[J11I1$HB41*
M(E$2B)1$HBJ9J_\ &O<'ZV;B\S$'53I/=UOCCOL].K];[WA_B#/M-4K9U<5!
M*(E$2B)1$HB41*(E$2B)1% T5>';-7U2M<//%M+7 XA\-_18OKJA=FPS\&_I
MT_V>E5\:JJTE$2B)1$HB41*(E$2B)1$HB41*(J=:$>"XROXQG'S\R94%-[RS
MYW_6.5BJ]_=^3%]4Q7%J=5THB41*(E$2B)1$HB41*(E$2B)1%R#)7_$) ^F>
M>//2_:^6=V_XTXO_ .]#]DIU^SW_ *;/^".X/Q/%?_L.+KV:ZJO<DHB41*(E
M$2B)1$HB41*(E$2B)1%SRRM_S1DG^/GC^(E&OI;!OP/A7]FT/V6)?BS[(O\
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)KV$Y7M#@0/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>gwpjrhodncoa000021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000021.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %3 EX# 1$  A$! Q$!_\0
M'P !  (" P # 0            <(!@D$!0H" PL!_\0 8!   00" @ "!0$1
M"P@'!@0'! (#!08!!P ($1()$Q05(5<*%A<9&B(Q-C=!=7>6M;:WUQ@X.598
M=I>FN-;8(R0R46&4U-4T-4)4<GB5)28S0U*!)T;B\$158F-QH;'_Q  = 0$
M  <! 0               0,$!08'" ()_\0 7Q$  00! @,# PP,"P8#!@8#
M 0 " P0%!A$2(3$'$T$446$(%R)5<8&1E:&UU? 5%C(U-G5VI;'!T=08(S="
M4E9S=)2TX20SEK;2\9.STR4T16*#DB9#5'*"HE-EH__:  P# 0 "$0,1 #\
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M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(M/N^>P/;W57;#6]6CMDZHG
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MWUDN/9;MO-7>#%>F)[8?7P_5M>FNMVG(8^09R#=I@/9%[L<*953%K9EFM;#
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M&QZC6FT$J!$R[D=LBM-PBTZVK[9['^'IC\X$<J%3KH>$3A$X1.$3A%?'J/\
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MWF3I*\2,?3W62&DA*]E><=>+#?'<<<)*=-&9%4QX)<?6^AE!L+)7/;'*UNQ
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M=">UVJ?\!B_II/JA?I-\GW9C\A]:?M@X_@U:\]L]*?X_+?0:?PD=">UVJ?\
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M65X1:=;5]L]C_#TQ^<".5"IUT/")PB<(G")PBOCU'^UFV_AT3\WIY+D\/?\
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M1O&YNW)I4Y\IU@:<(G"+SZ;5]()OK1W>[O'5+1>,3&A->Z>LT?IBA+K-397
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MLK*^D,WWH7;LUKW&MZKU^HNRM;5?7L86IH5BR[)N$ /.6JP6&.9L9EP-BX9
MTO&@&(IP3+ /NF/4=[PDSO/@#Z3\FW[46R'D$3A$X1.$3A$X1.$3A$X1.$5.
M;OT1ZZ[';[2,7:MREA%[?KHA.W!3I=:F6Y+6E9%J])F:=Y&$.UB8@1@09,,X
M=U]Q,T(R;G&4>=A<=SR]'3Z^^BR77_4?5^O;=:[V+)7JS6V\:=H^C;5.W.T+
MG)";I&OA94* </)P$(Z38G!IDQ,O8'EN'R[N4%FJ<,R\0]#?]OPHHGH'HT>I
M=%D*$>?0L;09UAIMG1=$A=Q-PFQ:Y6Z.U<9"[J=CZ_-P2HINSOR\BZ.3:<BJ
MF'HAIF+43[-AW#T=SS])W*+'L^B]ZX1D#48F@3FY]0RFNKCM"V:VN>IMFGTN
MW:^!W'(L2]]H-9.$ >CD:YE)(=LT:JRL3*,QCZR%QY ^2RO7-S^CKL>@V\45
MJ>OO7K7/6BA/Z_UNU/O!REGL5ZM5DM]ADK;=;S>[<9@^T76YV:6=<-F[).E)
M;6>:YAIO*&6&&!V&&6VTP)W13CPB^#B<K;<0E>4*6A24K3_I(RI.<86G_:G.
M?''^W'"BTAKFD@. ():>C@#N0?0>A5>^L=DG)_6SPEIDI&5M%8M5DK<Z5+$O
ME'Y,#/R2AMY\E2GEI8',9&;\RLX1AC+6/#U>4IJ;;6MEW8 UCV,>T ;  MVZ
M=.9!*V1VJ8RACM3LFQ-6M4Q.5Q&+RF/BIQ1PU^XGK]TYS&1 ,!DE@?*[8 DR
M!Y^[!-A^4RULG"*%9[06O['OB@]C))J75LC6U(N&OJR\S)J:A45Z\%QIDZ@Z
M*PRI)9BGHH7V0K+[>1T^L3A"_/XX?7Z_"BCO>'2W0W8FY%W;:\#+6&0/TK<]
M!FQ[<X5'0Y% O4K'S<RG(X26BF)UB4BP3(F;%-8*C'QVW6,>L2E:8[D?"#[X
MZ(H:8]&-UW(INR:I<+!N?9DEM<K4N;AL'8^RBK+L-^&T=80K/K.J1TZJ-%#B
MZU 2X6'W@PXILN8422[-'R!.6"&&Y_3\O5%G6R_1^=<=J7'=]TL4-9@2NQVO
MH/7^YH.N6<N#K-W^=.0&DZ9>)"(%:REC9%-, C7*Y<0GQCPVP&QWD$CE231S
M<\N?3HB[G072W7?7;95ZVS5+]N^V73:-?B8;9AVS=F'W8>^2E??:37KI/B&A
M,-8M\!!,M4^'-B_=L6!54*C68?#SQ!CHG?WNGU_:BN!R")PB@#<3E-E;?IFH
MV!=A7.%7IBTUIFO(CG4)*JS>"'')_!SJ76(52",K>=#;<+4D9_U./!IS.*B'
MO R=[.'A$98\NWZ/Y>QV_G<N6_+?;?DMAZ+;FZF&UOF,<W&BA%@),3E),DZR
MQQARSC&UN.[AI9)>#H@UC)W-A!ECX_NV[S_RG6O$X1.$5%]G^CKZT[@N]LV!
M>H:SR,_=-T:?WO.>HL;HH3EWTE1"-;U%@<9L3*F:X;4BB(^S0>77&)Q3N7G7
M&5)1Y8[GY-O>WW_2BRPGI%HTKK_N#K2Z+:?H9;PMM^NMZ8185IFW)O9-K^?*
MRJB9; GC'"JFOK@1TCO8$%_S?"G,?7<;G??S;?)T1<C?/3+4N_V-7F3<MLG7
M][TLV:-J_;>H+U):^VC4 )>+&AIZ*!LT<V^V5$V&."%'F8V4CCA"DLXRAIG+
MK^70.WUW_2BD#KSUUUGUCH+VOM8B37L4I99V[VRQVN?D;7=KY>[0\T19+O=[
M3+.NR-@L\VXP-@V0(4A.&!11!6!Q!1V&X$[HITX1.$3A$X1.$4']CNONO^TF
MG;7HW:'O[%(N+]:)EEUB8<@)UHBI6N#N<,]'R[3+[@3C,Y7HUUQ:&E*6RAUI
M.49<\Z8@[?+\O)% 4;Z/C4+M.V5KS9&R.RN_*%M6JHJ5FI^_M_W[:,$*,Q*@
MS84U6AIL_#E:M49*1H1L79(AX:5CWQVG17VW$)5AN>73EY@!^@(L8K/HRM$P
MUDB;G9[_ -C-MW&OT^^:\KEFW%NNQWV2KM#V+2YFB6*IPC4@RU&1\<Y#SA9#
M134?[Y?E&0#)24DL "LMPW_;]?KR16)_<MZK_<M_N/\ U$_]!SZ$GT%/9_?"
MOGD^<CW!\[?J_?OL_F]Z>[?A[P]E\?7_ .5]5_V>1W.^_COO[Z+XN]6M6.7O
MK=L;#5@:LO5:GV^BZL=;F/\ -,5R\5.!IDZ+9!5BK3,NJB*W%K$)2L-X4UMT
MA*E)?6UF'U^OPHK&\(G")PB<(G"*G?8'I-K/L1L>F[:G;SO+7&PJ+4YJD05H
MTCMBP:JF,5JP20LM+1ALC6\-'E#%FA"..LY*0PY[.SAQI>6T*3$';_L#^E%V
M.O\ IOK6@WG5>RW+=N'8%^U!3MB46K6[:VRYO85B,KVS9T2P6!BQS,^E^2G'
MA"@1 X)T@I.(B+8:CV&U,MH\K?Z^XBB2P>C,Z]3<;# QUBW91C*UN_;'8&LV
M376TI2E6VM[ W2UAB]*A+-""#RX,,8PHD<0!!.7AACC1%&/BO>I2W/R;= >0
M_P"R+C'>B]ZU'Z^>HRY?=R)@W=M8[#S&W\[DMQF\IO;5+@Y&NU*T2.T91\^P
MI>K<5)O-0C,>X"U&$-M'!X9-42^0W^NP_1T\47737HJ^LUGH.SJ-:Y_?-O-W
M++4&1V9LBX[KMUMVG;0M8/D&4:L2%RL;TF0W5("0)S(CP@@HS#QPX#Y2W\QL
M?@9N>7HZ<AX^\BMMH;1$7H"LR=6B-C[JV2)(RJ)1$AN[:-BVI-Q*6X\..;B8
M.5L;KA$3!-M!H?;B1?(*@MXDE*<+?7R&^_\ V _0BG+A$X1.$3A$X1:T8/T4
MO6>()!$,M'86SZ^C]AN[39TE9M[78W1SET7:W[PB3+U@&3'UPQIJV/KG/8BA
MW1"C?%4@T8AQ]#L=S\FW0=-MOT(IKE^C6AYS5W9G4$@':7:;VSV19MK;<:18
MG&Y%^W6QJKLRCU=.2+YH0%.*A"N"!);)2PXV_E2W$OJ3AN>7HZ?#NBZEST>G
M5*6GMP6J\ZRAMIVK=H,%%VVR[/C(&Y3<5%UJE,4&$CZ0?(POK*4.# #-9;S7
M_8W\R242*GE$,CY9AO\ (BR?1O3+3O7VVPUVHSUS+L,#HBE=<8XNT654VE&K
M]>RYTQ5(YQO(0WK)&,6>H!,CE6%KC!A!5-YRSEU<22?A)]\]45LN01.$3A$X
M1.$41;UT7K/LCJZSZ=V[7_GCH]K9#P>(T:9%R(1\6<-*PTW"R\<\/(1$W"2P
M8DE&2(;[;K!(Z$N8>&<?'=(JUT/T='7JK";43=R]I]A)S<NO,:BO%S[$[)G=
MG7%_52'G#&M?0LV5F.77*\S*.^^TY@V095R>9#FWY-Z4 "*'CN?@Y^;]"+&J
M7Z,3KU546/WY:M\;8)E=/W70M6-W%MZ>OY&I]5;"@W*W:JOJA$DRV'4\2,(I
MB,][*%D9IL 0<!,A[ HD8AN?EWZ#J-_VHI0?Z)=>"+UU:V4JO2Z+OT_IK.O]
M16%F96T<JHC5=%3"AK@M(^,6<8"/]I*C\$X8R#*24J8+EKWD6VZW//T]440Z
MA]%=UDT])ZN)!F=Z7JNZ3L/SXZDUML[=-PN&J=>W-LDXT2W5K7#I =5#L$<=
M)R4A'&KCGL!R1Q$FRTF0R@I DGKX^@?L17!CM%T.+WQ9^QHC4MC9-NUI6M3S
M#SDCE<*JI52?F;+$MC17J<)8D$R<Z>H@W#ZLO,999]6GU?F5#Z_7X$4Q\(G"
M)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"*O>TI;9^O[!%WFJ@KMVO!PR!;
MA1(T(5N8$<)*44_:HEUEC!4@1C.4Y)'=6ZEKROK4WADT@Z.J86Q2M=&\ADA(
M,<CB>$[#;@=SV \Q WZ#PV.QM)T]*ZBQUO Y>PW#:DEFBEPNH+4\SJ4S8HA#
M'B+C'R=S6CZB*1C6%^\;0XOKQ5[,D.[-H83P84W:8*M2QD4!,8A+)+QL-+CB
MR+676$DB%EHPDA'E6V^TTX[ZIQM6,JRC*%JE=U(02UCGM#BWB8TN:2.NQ Z>
M;SK&6:5U!.R>>CB,AE*<-NQ2\OQ=*U>IR2UG\$CHIH87;QG=KHWO:SB:X<@=
MVCM#+Q2X\< L^WU<$24961&%&6")&'D1T92E;X#[Q:&C&4*4E*W1U.(3E2<9
M5C.<>,!'(20&/);R(#7$@^8C;E[ZI8<#G+,EB&OALM/-4>(K44..N2R5I' E
ML=AC(7.A>0"0R0-<0"0.115XI:(Q$TNWU=,,Z7F/:EE6")3&.'I;4]D)!^2\
M"K+PRA;N1DNY>PVA3F4>5.<X=W)Q</ _B W+>%W%MY]MM]O2H# YPVG41ALJ
M;S(19=3&.N&TVN7!@G=7$/?-A+W-8)2P,XG!O%N0$&O%+,!/DQ+?5RHV*]G]
MYR T_$O@QOM:\M"^WEM%J8#]I=2IL?VAQOUR\90WYE8SC@QR @%CP3T!:X$[
M==AMN=O0DN!SD,]>K-ALK%:M]YY+6EQUR.>SW+0^7R>%\(DF[II#I.[:[@:0
M7; [I'7BER[A#43;ZO*.BB/'E-1U@B37!@1\HP0:0@8MU3(C&7$8>(<PEEK*
MT>=:?-CQ&.1NW$Q[=SL-VN&Y/0#<=?0HV<#G*38WW,-EJC)IF5XG6<=<@;+8
MDW[N"-TL+ ^:3A=P1-)>_A/"T[%?6!?J+*F,1\7=*G)'E*R@8$"QPYAA"\)4
MO*&!AS''GE80E2\I;0K.$I4K./#&<X&.1H)=&\ =26. 'NDC9>K&GL_4ADLV
M\'F*M>(!TL]C&7888VDAH=)+) UC 7$-!<X#<@=2%]>=AT!)6057FG)-21D5
M0>;-"X*P5ASU.1LCY-];@C#O^2RSE'K,.?6>7S?#CNI-M^[?MMOOP.VVZ[[[
M;;;>*]#3>HC$)Q@,T8#'WPF&+O&(Q%O&)1)W' 8RSV?'Q</#[+?;FOMD;Y1X
M@Q^.EKG5(N0&RA)($C8H@(P=3C:'6\/BDF-/M96TXVZC#B$Y4VM"\>*5)SD(
MY' %L;R#T(8X@^X0-EXK:?SUR".S3PF7M5I03%8K8V[/!(&N+'&.6*%\;PU[
M7-):X[.:6GF"%@^P]Z4#7+0K,A(.S$[*A#G0%;K[#DG*3C!RG&P'@\L)4(@4
MQUM:6"GB$-O80OV;!#B<-*F15Y)=R &L:2'/<0UK=MB=]^>X!'(#?WN:OVF]
M ZBU,Z:2M692Q].>2OD<ID9&U*E!\ :ZPR82$3.E@8YIDB9&YS.)O>F)I+Q]
M-2HP\Y<0]VSHL_'624J,?% 5&P*#<Q2$N)6J29#R,A"L.F^;.<^T)06U[5(>
MT(96:H  ^0M8:[2TL$A<7MW_ (SP&^_@/1R/+;?;<^\QGY:&$FT)CYL=9Q=3
M,V;=C,8X3-^SQ:6BK)/WKB"V#A '=ET+^YK=TZ1M<6+$T\D+!TX1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$3A$X1.$6 6?5>N+F9F1M%+KTU(Y0AM4B7',>\'&VDX0TVZ
M<TELMUMI&,):0X\I+:?K483CX<F,FEC&S)'M'F#CM\'19%BM6ZFP</D^)SF2
MHU@YSA6ALR>3-<\\3W-KO+H6.>>;G-8'./-Q)7$EM.ZQG (2+EZ9#GQ];$<
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M2]QF<3D<7,20V/(4[%1S]NIC[^-@D;XAS"YI',$@[K9.,S>&S47?X?*X[*1
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MZCUOIF3["VR[1HVF8FJQUW*OL2/)6F)>J4N@)V+GHQFK!3,C,Q\@S(@OANQ
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MC03R5GT>C5[JJLS-1>TVU'S9%(F]D-(EME:CAXS-(KDW"5R:L*K!*7T2OM"
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MDBLUF^R,<$;WN>=0Z][&M,ZVDER#"_"9V0;OR5*-KXK3@-FNR%)SHX[+A_\
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M;I[3;89HV306*6)QC8Y8I&AT<L4L%<->Q["',>UQ#FD$$@J> @0HT9H*.#%
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M!["6N','8KY_1<F?D/W/_P"FT+]H7(?8&O\ UDT]_P"-E/HI1^V&S_5?4O\
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MI)>.1Y<][G'&M,M$,>9ILY04M0Y2.LP=(HK+XLD^)HZ"-EB],V%@V;%"(XF
M,8T#X;N;]\AZ]U\0MQ$/M#8\?4;,EM:D9,K$95K=L&<@WLISA2@+4#1W*I,-
M8SC+T-.2#*5-J<PXB.G'>3R97*M -C#8B6]3)&_=W9KM#%5K+=^DM*7)"]7=
MS#;%:)Q! (+4[?*8\1B'$BMG,S#C[P:2.]HP4<AE[55VVQ,-^+%NH66C8NK6
M9F@@D$5PN.VMZZE[%5K6%M1JPS1NX8J0BM8V9QN;HY=7M$&D\HC7CON;YYG)
M:<D*F@<JO.*9K@DH<$2'%OB&):CW:)E>"U0L6A)8=>KS&2RUW#*V2"4M L%S
MBUPX9R6S%QD)[QCO!V_2>#T/HG4G95F-18.34-;6NA[<,VHL%!!2R6.L:6N1
MUJE+/UA(<8:%/'9?>IE(F/R+ZU>W5G?$*[)9FRO;.RU/T=C2M9WK,QU5G=F5
M.V2#MEEY6%@JT%,T"%KLC,1LB;,2$?Y)685/-MQ8HC3R7BAC$+P.VAKS3L9I
M_(YFOD+&-A?:./DILDKPQ336'MNR31QR,CBCD_BXC"3,YQ'"'-VXMSMIJ^ZJ
MR[9;5=_LIGG\G<X@;PM>> _=.Y<)'#[)QX=MR3N5&-.])/U+M=;K,X]?9*!D
M++7JA,L5DNF768ET2=S9HRHRF@/UBO3<1:+HP3L>F@G5RHR,[(CDS+?G9]4,
M:X+=+6A=2UI[,0HMFCK3VX39;9JQ0EE-UX2VGBQ-#)7JEN.MO;/:9#&6Q'V6
M[F!U&)6';V6Q(&P/7GP[#EOS]D.0WZK.BN]76 $4DXO8$J,(R:B)%(?UMM%A
MN;GO>\; %UJLY>I:/GGM,1-RP458:S >\9VN&Y+9G@(Y4;)^QT3=)9][Q&RB
MQ[^ RN:R]CW.BA$4D[9YPVT37@DAC=)#/.(XIV\!A?)WD?%'C9UXN6^WCUWV
MV'+F=SL=NGO%8?+^D@ZCQU:/M4;?I^VQ07LS#3E3UML:4:E)<FO0UO75XB2=
MJX<&?< *A/ 6F6J3<JFQ1,$DXV1CAL1IZ!ZN/0NIGV&5I*$=:5P>\BS=HQ&.
M)D\U7RB5OE!DCJOM025H[3F"O)-P,9*>\870[UFV^_+ET!/,@. Y [G8@[#G
MMSV641?>GKH=/%U8NT3L78A+*75WHIZ@[",<#D<6VSTJ"&FB8ZJE!UJ5M=AI
M]@BZ]7+$1&6(Z3CGHE,9B2\@JZ6;2>;BK-M^31OK.K^4"5MJH.*-M:"W.Z%C
MIVR6&5Z]F"6:6NR2)L<@DX^#=PCQMWVWY[@;;'J20-_-N00-_$;=5;$^5"C!
M'32W'<,,H0XI XI9Q2DK4E",,@ L$'$+6I24I:8'<<SG/AA'CX\QP-)( \3M
MU &_ND[#W2=D?(V-KG.)V8TN(:USW[#S,8'/<3T :TDGD 2J[&[CV9)WMRKT
M;4<V?!N1S)*+;=X^9HD" ZIAY];CQQ(LD5(J<PUZEB)5$0IK9.<-&$#-N-/+
MMT-R0YNSCK,-B*K#%"8K,=&U*R>62O).]\=UH..=!&6LK/:Z>.TRR7 0/BX)
M7XY8S.5EE;%B,)+.UVW'<RDIQ5. <9:XD.9/>FD#6E[(FTHF/W:U]F+B!4D0
M=-*DXFQQ^RLQMO7;!7P)T-\S,G75PY+;K68&/@7XH 0"(RP^\E[#N#9&15Y7
MI.1-4V-[-?66Y*L]>S1?+4FJR-E@EB)CFCFC<'-F$S7%YE:\ @CA:T@!C6[D
M&LKXYT]>Y!EW19,7V.BM1R$25'02-<PU8J9A9'#6X"=PYT\TI)=//*6L+>#H
MH^0,UP(')GERI%5M>RM>LRD@^X5)2<;K795MU_#2$J6ZI;QDL;#UH$F5->6M
MXR1=))=6MQU2U7'4T<3,O))#$R!EVEA\JZ&)H9##-F,/0RMB*"-NS8X([%R5
MD$;0&QQ-8QH : )&EI9I,-''/+).^C?S6(;/,]TD\T&%S60Q%::Q(XETMB2O
M2B?/*XETDSGO<27$KK+0&Q:]W42NRR<%0-.J$]L=J)>3AP,ZY>_(.OU68*:S
M]8^NJA.64F.8?2ZRW+RT?,M(;DX*-)8G4I'4=.9.W >"SD+]7$.G:=I(\?Y-
M9M7:['=6B](VFR5S2UQ@@EKN+H;,S'2+T;+^I\52L#CJX['6\RV!VQCER/E5
M6G1L2-/)YH1.NOA:_B:VQ8ALM#9ZL+VQCV/[AP'6>:BHVU:HVK;HZ6KEDM#4
M_0OH;R8P\73H:1G[647"3.Q8&VC@5V,!8<E9UZO(KPY,O#1R9=R1D1Q%62"L
M9VN+98F%KF,X'B4.)D<UC "V)[-W$G9I>';->>'9JV]I;0]K5E>S-2S6$I2U
MK5&F:F3^S,,TL^2MP4J#(9ZN&N8Y\MJ>=W<UC>;<=%5MS^3]S YYZ'3O?+56
MYO?.(*O6@'W)K2T[6??;L&HKI'$5FHFQ8$F*S+:PV?>8T>QY)E6D)@90F.-&
MPRZJ1P"EP3)*:K) [A<03Q-:?831D%_$1NV:*)^WL>9X=N8V)Y[3L_V>YC3K
MHV7+%1Y?DJ>*+33U#C98[5Z.Q+"7UL]@\/:=7[NLYYL1021/#V"%TKA*(X]U
MSZ2W6NXVQP-2ZFVQ?;B6)F8'ID)*:5.,S6AX$>PRLX38HO;LG3(QZ%'/BHR4
MJTM8@+J)/3,5&/UQKVK)#4V6A)"XB66)C1R+W-L-;Q<1:&AKH!*=RUQ#A'W9
M#7$/)!"OF7[(<UI]TLF<S.$QF/@?W$N3MU]3P0MN.MS4Z]5M.QIR#+2BT^M9
MFKW8<=)C):U6S+'=<Z%T9^RK>D^Z]VR7E! 8B^,0D;5+%<,69]-!?;=C*OK>
M,VA*X*J4??C=BP:50,J/'1TI/TV+KLE94N00TUDU3*73\?/&QKG<.[GB,-VE
M!XC(Z+;C=$(2>)I)#97.#?9%NP.S)=C>K<77JRV7X\SV[U7'QU&,S(=Y1;S%
MG"1,&0FP\.#G>+=6262O5RMBY'2+;;JPA$CF1SN;MS3M]1FL]0T,.\P=@VK$
MP%T=AY<_3M5EVDCW>RU4B@R -PVA#V5=UK]RHTDU. Z[@KY( 9"80*,6_(!+
M18-286]=Q-QM9U640"1SZTU:>S'?#(>\BCB>SNVUY'/?#+6GG<(S(UH?'L2Y
ME-)V:YG%4<UF;5K%STL)<LT'2U8-0Y"&V68ZED(+]6SC\%8I04+E3)5)J%K,
M6L7%.7D2-:V.4"[G6?85JV)K<4^TPBH]^$?16AIE9^2G;2J$&9!D)@H-UM)<
M4?[Q9)8D B7"%I+0[YW&24D@AV?2&1N9'#5GW V1]>.*H+HF,C[TE:-L%F:Q
M$Y@?6M"Q'(RS Y\Q9*'-=()&R11ZVG8UDA#3R/LMMM@W<[@ ]"-NA'+;IOU-
MAN92I*<(HEWC7F)[6%M?0O <]5X>1N5-G4(QDRM7*L %2M>G05X\%I6*:PED
MX?"TLRL03(PIZ7XR2-&>ONF[3JN9HM(,E6[8BQ^0K$[1W,?=E9!:K2#F-GQN
MXHG[%T%AD-F(MFAC>W']44VV\'D'-(CMT:\V1QMH#>2EDJ,3YZ=J,]062L#9
M6 AMBN^:M*'0S2,=(5>E??L!!S?JO9_?,/&2OJ/-YO4^\0F"_5>;X>;U?KO)
MYO#X^7Q^_P M-J#R:U9K<7%Y//-!Q;;<7=2.CXMO#?AWV\-U=Z<_E52K:X>#
MRFM!/P;[\/?1-DX=_'AXMM_'90_J1@:3;VIL.1>PQ-V38NPJV7+K4UAZ)K&J
MK58-=5Z+"((2X@6*!:KTA9L"*QD-N>LD_)+:R](E*<O^?<^#["XJ(;UJ>(Q=
MQD(WX9KF;HU<O;L2,:1QSO-N*GWGW9JTZL(/#$P"PZ;8VP_-9>0!UN[G,K2=
M([FZ.G@<C:PU*K&[JVNT4Y;G=-(8+=ZW-MQS/)T3S_</>@^KM4S<-V?.(E97
MJ_M/84;8Y/8VA:2/:]I0&X;=7X9@T:T:ZDH^_P"8N.C08C-#J:8&6/&&PTZ:
MDTKVS&TJ^E\2[(9**73S6QQ:@QU*2!E#,VW5L?-C*TTI8ZO>C?2[R21\OEMG
MOHV.=OPEC>!9B&-+GC@VV<T;<).P(&_\X;;^!._7H>JLO%]B>P\SV3PH:U;<
MA:/*]JM,:UC3;3$ZK@>OT=0YSK9HS;5YH5IA#(X[<=?VQ8UVRX8I;JSF:_BY
M3%;K.9UX@.0C7+!)@\)%@=G5L9+;CT[E;[VUY,C-FY+<.=R^-IW*\K'LQDV-
MKBM6\K' 9O)HYI^Y#7QR#R&-X#R:2&..W/BW#W-!!! +1L-^1][?EV$'W0W7
M)67L+9I-B^06J]MZGW18.I4S-:^3#5NOSFFZ=8)&J%5NSEAY1<5[JID3(;DC
MV)))"8QJ%=B667&',HSXFTIBHZ^$@C=3FR.-R6*@U+#%=,MB:'*6H8[#;%=K
MMZHQ5N5F+>YG#WAE$A<' )P-V:!L7-<T/_\ Y$ @CP+7'A]/CL>N&_NNNXL-
M'$T^S,R(FPZ3T\%V#.W.+H[,S3[A'V?;6D843L56(=@%UT^>HVK[-L"6MFN6
ME*$ MU9EA<Q1T$9 D%57VLZ8ED;9KNC?1MZG?2AJR6S%:JR5\;EI78*Q*7@,
MAMY"O2CK72 ^2K8C<)&3-F#8]W'N".;3)P]=B.1]B3YB0-CUV/4'=9CN[?S5
M*HVJUZ=[OSFVJS9.Q(%5O5_+V9U_JZ:]$$:%VM;FZO\ 1;)U@1KZ)9D[+7*]
M-."2D,?*,$X9K@A,?[R89Y38C"FW<R(RFD8<;8@PC[%2DVAF[)FD;F,=6-C[
M&,R+;TAC@GFB#HY61EI,[FR=VXJ#6[N=O&&D-)#0USN?&T?<\0/+?;?D-MSL
M5M-T2>F:U72["W=S-@-S\!%R/SQ$VBHW5HAY0;3)B [71H.OUJ?908R0EV3B
MXU@0HE+S@[3#64L-Z\S+.YR5N TV43!-)'W#:]JH0 XEA?6N33V("6%I$<CR
MYK=@XD\S)<-G$;;;$C;8CY"3M\*EWEK7E.$5 ^^=WLNDZG4=S:X($B;X_8F-
M9'2#XR2&)&HS,9.6I0<@-G'JS7HN8JX[T(^3AQ<0B5L+8.6$S<C@C:/9AC*>
MI+]_3V79)/C&U'9F.)CRQ\5^O-6HB2)XW,;9J]U[;+&;"<P5#)Q&M%PZE[5\
MI=TSC\?J3#/96RKKK<)+,Y@>R;'V8+5\QS1GV,KH+-!CJKW[FN)[C8N$6IN*
M_G-7+;2<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"
M)PB<(G")PB<(G")PB<(G"*%]W_\ 4]!_'1J'].HCF0Z<_P!_E/R>SOS=,L:U
M/_[OB/RET]\Z5U-',>62KS:>FD]&/N[M7M?3][ZX04Q8Y.ZE2%6W!B0N8T14
MZ]'QD?7QJC-R0)I(N,0(P@T[[P8$8EWWS5-^JCW7R66U9K@M424<;8Q=B:1E
M6,/FK-@FFKN?*_C,D<G<\IHY=PQT<FS'-<X.W#G*WX71.@!JJ[K7.8B&[J(5
MJ<=&Y;9Y8*[:;9@UE2O/Q0UY3QM<V5C0YK]W]5D/I _0\36P>BG6C4_7UL*>
MVUU*AGP(L99C->=V('9VA9'8BXR0+(&8C)T^YB,VZ$;-/%';]9(@I+;)(87F
M@Q><\FR5FT]\]=MIX<):\SX)H"U_L>&:(=XW>(N87,&_,<MB5F<60Q^2LY.O
MGZL60Q69X66ZMV-L]62*-VT4-JOPEDL BV:6  ![(G ;-6P'T4_5.Q]4.I%(
MK>P69T+;-R'Q;MHQ4Y-IFUQ5C)>*9 CD/-N$,M%@5S$/'RN&2S&W) -W*"7$
MI2I5+G\L_+7G2GG##O#7<YSI)70@[@RROV=*\NXCQN )!Z+7^'T;I71UK-Q:
M1H#&8S*Y)V1=3BED=4CG,;8G.JQ2$BO&]K&CNF;,]B"!ON3?RW56M6>-+:LV
M'T )C)(0LAF;DX-#<::TC,A@DF./!3EC#;"'<K)4ML?+7K4^3/FSFQN.\4D3
MB1'(US7['A.SFEI(=R<P\)(XFD$=00KT86RR,/ 7R?<,#2[B=Q.:> !A!=Q.
M#=F\]SML%!=:A>NFP*=.T:J["KUVJ@2(<29!K5^AY)B"&A3'3! "":X4CW0V
M6Y@E)*'W&2#V$$^#BO4N+;HJC*D;I)*\K)"X-8\B5CVMX'2. V;[%IXI'DG8
M%QYDG8;72YB\ICO)X[V,NX\R,#JS+5.>L96<+ #$V>-KI&AO !P[AN[>A=S[
M$#K)H,H?#T=7$&,)*&(9*&M$Z8EDJ/7&K&RT^B7=2G(V8J.QAK*E)\HZ4N(5
MAQW#E:';CD01Z-CYQU]\_"J%P>P[/:YCMNCVD'8^APWV/7TGGU7>3/6_45AQ
M&XFJZ2?[JC 8H;S3<R.G(T>$#'L*=;".&96_D6,!;==PVG+GLS?CC&,>&8[D
M?7Z^=>02.AV^O^JD&FZ_JM &,#JL>N.&.6,X2SDLLI"EB,8&94G!+SOJ\X:Q
MA*\H\OG\$^;QPE&$PW^OR?J4%AFH/^G[D_'-8OT:J',AS_\ NM/?D]4_SE]8
MWI[_ 'VI/RDN?Y+'+X;5^W'KK^.F1_41N[C"?>_5GY/0_P#,VG$SOWQT?^4D
M_P#RKJ=8=MW1D1O^VQXMX9.8J6NHQ\^H/!//Q\BUM*9]0Z#=HPX9YDEHK7L<
M&*N!6G.1'YF>/42AQ<.TG%IKVWU6/[D[/EV9(3L0Z  AT):1]S,3[/GOPM &
MP<=]V:/U[>T#B[KL"Z$Y74,\=3,&=C+%:72]9LC;6!LUI8W125]0S3O;D0?X
MUM.C#'$YK;DR^]V!M4\3KJTV+7T-8]A4*F;6K[\X0<;#L#VB0"KT9Y(9I1*&
M<UK9B8C)JS7Q))V'#: 82L<G)7GG16G0U[=:.S)%6M3TY)(6M:[O6P.F?&]Y
MV)[RL9#PAKF!Q>[?< ;87FH<='D[+L4Y[L9,_P IQ[99&23P5+($L=2TYGL3
M:J!WDMAW"T/EA=(QHCD8JYQG4?6U2M+0]<ZI1B("OWW3 L&6/M>QI@FHJO-5
M.8.V)$4\VP.1PDQ1)_75&9<?>$$G;<%'(]L69ZL\:3ODNI<K9B<9\TYTLM?(
M=XYU.#RAWE0L1R5)+3*_?&*S'=N?Q?&Z&$R.+.#B:66D,:.@\W+GMN-MB!OM
MN-AL=@>2[ZY=8Z;87+1(R/7HF=G9:/D-C,.C;;M\-! ;9/N;$U)?.?$CVUIK
M7\].20(EJF[A46(LJ54HGVY9A!) )/FMJ+)0L@CCRD<44893<'8^K+))1CJF
M&)EI[JQ==@AA>^O#6LNE9%LT-#&M:]K@:?#QWZGD2=R1SY$GGN-CU\Y47/=&
M:=6<[8>@M''; 'L^PPCJ[4K1M^S0=8KD$9J6#U3,SM-;#L#B!;0JNT^,P]=I
M$9B_OE6V>C/?BH^+9?*N;=87YH\<Q^2AQYJ49(9)J^,KRS6GLR=C)0PVB8>=
M=T]I^U1I-)@K12&'CD.T!&W<[[G<@\R>6S&LY;<^C>O,\SSYJ6H_KS!PM]=D
MH3KA$-"&[KJDG/VR8OLS-3]@BJG+V#8]?V@Z^99R"<2\-LVWV6<>%D$2)DRJ
M0>8/%\7&G!+0_.79JPAFR\I;'0L1P0,@CCAB\JKQ4K%-K&P- 9)4KP5QP<+(
MV,#HR .<0UHW(',[;GQ.Q)'/QV))]TE=/VD%!$OI@P.E%;&GK%7ZG,JL;^X*
MSKA<8-%2TH,4%% 6>/)"D1HP:$&(G7T-21+;5D'1ZD!G/MK5DAO3P-8QA;P,
MX]FD<B9.(.).X<".+D6EO0==MECN3TEA\O+:LVVS"S:-7>Q'(1)$VJZ%S(XV
MEKHN!YA D;+'*2'R<!87;B%IV:H[438HX6CPY,1-.DIN\M7.R6KFH@O !\L=
M"FQCDQ#LHRZ<39V%/!K9JX3((07E</PTEF6]C(V Z-Y;&\Q[]WQ-=LT%K&.Z
M.'%[%@YOXB-W$'?;:D?H?"OKW*[)+D+,AW?E?=2QM,[HYK$[#LZ![8N&2R3P
M5Q'&6QQ,<SA#P_O:6="7+;E'K+.JZLU%H'AFCK;3.P^M+"#F6AVB!8?)5:B:
MW%SELD':JJRYD0)</,25#M6$-++KV G3?+KT[FO:YK'-?Q@AX<_A:\DN:TN<
M>$<1:X$;.#FM._+8U<>D<5#+5L1.LPS5#6?&^$Q5W2R5&-BBEL.AA9WSNY[R
M!S7DQNALV8RS:4J^>A/M(G_QT]CO[0FS^734_P!\JWY/:1_Y4PJ:5^]=K\I-
M9?\ -^<7R7^^'8_$P7^G 7 _!1WY0Q_-LB@?PP;^34GSI&J3=J]5&6W:=SLC
M6BMI[.>D=:PNO"G*?NJ]:_@YFBRA)F;! S$-!Y+ .$/DIIM*8X&-6LCW++3,
MVZEJ.CDN6>.P]D8C:6 "3O6[QL<X/ ;L0]PW'W(V]EL-SL.9WW=IO4=C'8:G
M0BRN*HQU\O)FH?*L'C<A:@R<0@$%B"Q89',Q\<=1H!FL=TP3-BA&\TX."JT/
M*,6"&Q):.[!ER)E 'K$=8QNV&Z)-ABO3\W!^\=87617&-O#5F,"03-'!X09"
MN/1;X; ^2)5I37KRAQ#O]R [[H"O$-BWBX7, ;R<>([N&QZ;[[<KF=2A\5N%
MF7TU'6DG?<FC;HW"0AMVE#;%6]1A:[<7;!F=")XC%*T/B<\N;""V,ZEH&QC3
M4,J*ZM[?@2R@8^GP&QU=@]IPVP*/5( 4FK-5"0M!D<>>SKTBOR#9**]%@@QF
M, )=%>*EQ03P/3KDIWW,1&Y)9W,1C<YQ!+^#AX2_<<W'GRVY [&NN:SL/9,)
M<_A+41=8N6L9]JF#EQ5R]9E;=-QM#V$#LCY3'P^6.=+*0\QN$-5\D<O8-Z7B
MRH-NM3_1*8>J\&[)7%JLUVT7",.>R_BC41BF%9?80BQQ[]%@H]J3BT$'UR9;
M',>+9BBESK///E4[7<;9O9. !<&M!'LG2<0.P(<V1SG-<-G D;;<EYGUGF:]
MN2Y3ULV6W8BJ47WI*5#C:(Y+V6%N,@"6"Q#EK]R6O::V&S5>6!KI&^3N;-'7
M6K_.!>PW:[TQV/IX>ZR4"S8I6-O,MBKUUA$W)65L<&O(<R,!5F;%/VR3FXA+
M<6"_[6RA\(C!@Z7/$L\LX'>R%Y!W]D!Q$AK& N/4GA:T#<G8-]Y8YJ7/9'/X
MZK#E=4P9<T626(FS5(A<DL^35*1%JZ#WUF;R.I4@ADDDG]A6#0YG#N=I3KK0
M[3K[SC;+++;CSSKJDMM--MIRMQUQ:LX2A"$XRI:U9QA*<95G.,8SGD@ N(#0
M2XD   DDGD  .9)/0#F5KASFL:Y[W-:QH+G.<0UK6@;ESG'8  <R20 .96L"
MK=UK=MR5V- :BKQLQ+2NQBZOK<EP3QC0*+!0\.*_<WU+\B'7)V<=G) -PO+0
MH<6F/<+RM"&TD:S[9-<C3&9P?9SV?]WJ3M R&/;-G)*S39Q>GK<CN_?6LV(I
M!$Z:M4EKQ2D2".&<2F=T;>#?76D=96M5?9ZU4J/%*'//Q^&>^)\??XRM!7CD
MR!XW#C;8MBU)$0&,; 8R>,M/>;. &R600FC'?7F-"#ME/^&,>N)0RA+[OAC&
M,8]8[A2_ACP^/-AU63,K5V6'!\[8(FSO'1TH8T2$;DG8OWVW).WBMD'J?=]Q
M8EL[[FVPOYCVS\PR'+UAOOQBOQE1_P U$K7FOO-EOQ9?_P K*N1KS[0*-_,^
ML_F4+GC*_?3)?W^Y_F)%ZP_WIQ?XNI?Y:)8+H?&,TRR8SC&<9W1V(QG&<>.,
MXSOG8^,XSC/PSC./LXY<]3_?"G^3ND_^6,0K7I3[VW?REUA_S7F5!^P+/OQ<
MO=('7NIH(Z'BI+$%5+#FOC@E@J+A+"^>?&D2,W[*01%RF*U)"2>(8>$(?+D(
MEY+IPJ'"+%WTWLOXV3=X]G_&/]EL-MG<_9<O/ORY>A9&XGP!/P^8=-O@]T\C
ML#MQA+EVGC79$ O6D7,@HO&P5(F3*\T2>Y6(YT<RISBA ;<"S('@^M1%1833
M YUG" &4PN'>"?()\<3AMLYPV:6]3R:226CGR:=R2.A))/5&[[<R>GO\P/1S
M\1^G==E,V#LL4]'"@:_":&AY"X&I 1&@-!RT8FO[KCJL.5)D6LUN/05(#:R>
MQ"18_M@2CTJ?FT1KCX7'$X$GB=N[FXAQW.Y#N9\3N [GOS /4*/,[]?'K[OU
MZ^8>?=2WK"3V:Y2$'[#K;^+1#+F06!@ X\"4GXT&'%>&_P W<E'HT8PV929'
M"J6>#&'^R!2F&@1"T8;IY#-WU<-+^Z+I3* 3PD]V> O'3?B)V)\2AWY;>?W/
M ]?D_P"ZK0P_OT$82/C*3MX\)BZM'R(\[2-!. $PN3,X.9$%=O+2VFWA/,V@
MT+(\AYRW3DY4EA,6NK[V7CX^]DX^$-#^-W%P\M@7;[\( '+?EL.7+90)=U\?
M'J?U#<[[;>?P('-7,?V/KN#E?G6*L41#R8DFU!JBGDJ!2(<[53+LAI65,MB,
M"?.S'G2:I#+J8Q'LSP:B\2"<B\J10OS1.M-@EEB[DV72@A^\(MQT2\^R+B?*
MI8X>#8R;O:[AX#Q*UR9W$17!0EOPQW#<;0$#^-KO*W8R;,MB)+0T;XRO/;[P
MN[K@B>SC[T<"@S?>]+AK^<HL5K<6K6\VTV2!K/N!;!TK(%R4M88P,Q)<G$RX
MH=)BXFNNR4T1/SXA@3KHS0#+*S'AQR*BA5JR1V3<AN^QA>^&:![(XXBUCR#)
M')7D=9#G\#1'%)"0.(E^P);"Z_(26*8QN3PM:)DA-^#(0S6+%J(\!;%2D@OU
M15FX>+:22O>:YSX]X6M:2[J;QLOL7$3LT96#^MQ%#0)+2=?<E)"U'6HR-;?9
M&B2WA(2>6T6&A>'U2YT<&K+?CZH4)2AE+)IXZH?LTQV _B:QVX$;&N()(<^1
MH8TD$$![F\N?%S 5P?>HQLXWS;C@,@[IS9G/C:2"^.*+CED (V]@QVVQWZ':
MG'=V<V]-=:(C.X5:K5,A;TKP,>O51\J=%O-"T;8*)%<AB7D#R!#635>RK!\R
M5#+9<]8MSUB/)MCL:8UFK+X8V5H.G;3@)F\+B#DL5PD#8;@CF';;'P6G.W22
M&32./,,@D U+5:XAS7;.;C<N'-)82 YIW#@=B#R(W6Y'FF5NI.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A%"^[_ /J>@_CHU#^G41S(=.?[_*?D]G?FZ98UJ?\ ]WQ'Y2Z>^=*Z@'MM
MK':$S9*%M+43%D/L]&K>Q$YC,;EM^OM?.SZ:T:YJ^2O=9 N,)5Y^O0-X.3-6
M9TV"F3":\"2"6/)C,@1F<>62_K^OU\5KI,3VTI\*57[9,)W$3KFJEPNB+%!]
MK'7:C)VPBVB7L&V;SGPMO]:K?/L%U2QP^JHF=F7)&3KZZ'.VH&C6J+M3V9(B
MQ2OZ^[352N3#6S=^6MT(ZNUN3+QK_L+&2:G"90*!F0 R8S8/9$"5,ML]..34
M/L/-/V#K>BV76:*L;JUNEVJ5L#R7AM_W^'K\J?KY?4]1TVY<_>W7>9E-]!7"
MD8LWS\,U:[15 ^BK4X_L7)1DXE58JFNR)32&F;<_V:EA81B7&@;!>;(O:85"
MOJ9>"NE$"WE>8_:@[V"'GMZ!MRY>?KMU//Q\P5_J=H':$WI:T5^SEW"'!LVX
M8ZP1FM]LWR9VG,P^@JY<69X/6-HE!K7:F).5FQ\S+AHH%JF%/U\^!H$O9Y *
M#08S2W('68#""T!SXW/#@7-?&R1KWQN#2TEKVM+2T%O$"6D@'<7S3F4CPN3&
M0?'*]\56_'5?"^..:K=L4YZ]6Y#)(U[8Y:DTK9XI>!SH9(VS1L=)&W>4=0]7
MH:&A+7*;ACJEL2[7]N=CYM<A2ZRQ%QU)EGV%1VO?=H@CP9\'#@A@"(!)</C@
M\M$#Q6,-E2)LO1XVA)6BE-N1EB>>1[W;1,8R.-Q'!"UK01PL:UHX02QIW$?+
M=S\IUKK6KF+V.9I>E9T[B<13Q\4$3,E>LV+64JQ/%K.2V)Y.\9=N3RRR/E8(
MY9!P.EX>&&"M0O2_3#LGKH2C5^N;S"HNE$U?6#4[7M69V32CIAJ($HTI;["F
M+<@ U5^WV8:G;! DYD)^.F9I-GK[$Y&@GI;)<]QTYX^%HFX8QP<36.>W?;AX
MO#DYVSO9 CBW&_/FKOE]=::RKLA=L8.Q>RUF;(S5K64BI6A6-D9-M2(R&3CF
MJUO*,=)'7F;*R"2I-W3G12B,9:SUN[F2I]>)+[=7.&J\?#6_%IDZ[8MBR-@G
MC9FN2<G$7F.@I:J*!#?/&+B&4:X"_P#9%&-A%.520(G)DT9'H5K6XWLD#9P<
M0]Y))!V< 1L.H]COLSAW:225;SJG2$<4QBTM7FF,U*2O'9HU&PQP0/A=)1?+
M#8$S^'@F)R#FNL9 3]U<@8R)A4MZ<T]VRK>_*79]P[\;N53.KUH+LE3A#MC!
MP1]KD,MV?V:.KTBPY7XF%J$E+@QE5*47%%&U>/\ <DL 9),R#ALV*&PV4/DF
MXV;.XF\3]BYQWY,(X0UIY-V(]CR(5LR^:TI9Q-FEBL'+4M&>OY':GBINFCKU
MFM@+YK,/#,^:Y"TRVXG-DA%MSI87,;PM;<+4'_3]R?CFL7Z-5#F6Y_\ W6GO
MR>J?YR^M1:>_WVI/RDN?Y+'+X;5^W'KK^.F1_41N[C"?>_5GY/0_\S:<3._?
M'1_Y23_\JZG46Q^S=D"[>N](M.P=1L%Q4:-8ZI3(T; ?ME>F;%8(J CIF:E;
M*N:S<7@H1MX_(L,'#I+.RR"&2.+[4]I?462U53U#+'B\KAZ]./%5+=#%9F@(
M8,Q:?++#9HLS(R$4T%U\L;!4,56>*&.9CIZU@D;;LKX7 VM*X_(5\)GY9WW[
M%+*Y:*T;'DTM>K6LOG@QT..[AN.C;9 ?W]M]A[HR>_AXN[%>I/TF]'C]G72B
M?.4XF#U]7QK[9;=)6V$KX[U!50J39BUU@:PXB0;+>&K)>8ZNXJ0LRRT+%C.V
M25FH]!T-&R6RM.!FI=-X/4E,OC@SM.O9KU7Q.?/!+/),QU>SW7&6=R8)6NE#
M"U\K3'$UX;(YE-?[/LEC3W5F=GE3K;Z#*\4$T[O*VW+==IE$ EDAJR05'V(Y
MWQ<4CGB"**0QSOBZ=7I<NOTD3KDRI5;8U@J=PMDE1K!.N0P$<76;JB%FRH"C
MB1#LJ\Y/VJ>FX^(C,+')%J,>#8!)4JVX]00&B^C3MP"P'R0,DAB;,UG$X]Y#
MQ,XYN+A 9&R-SGD.'>DM+!%NI#=!98"ZV:>G%/5KLMQP]X]PGJE\/>VN\[L"
M*"&&1\A#P;+G1.C;7XB"LTV-Z3;3>OCX*'.K%O"G"+U-5*VQ-F>JM?53PJG&
M4R6MLF=+-V24KCKX M_K>(QIR:%B9-Q4GER=!' P^1(@PEJ<.<US',[L/B<P
M2/[TO=.V(-9P"39YKR;G@+FCAW82=A24M'Y"ZV62.6%T;8&30/B;/+Y2Z9]R
M.NR./NF3;2.HS\1[LR,'=_Q3G/X1.FENW^N-UZ>V1ON($F(/6.NCK<Q('2S"
M'Y_(5"KHDY;2RH6'7),MN!*68B/8B9.;1*A-"%L/H(+6 -Y9A;TN4H8>%K)+
MV2GJ5JK \1L?->F;!6:9)>[$8?(]K7.E# SF7;-'$<:U3 -'U[EK,RM9!C\7
M-F+DL+)91'1@@EM22,C$8GD<V"%[C%W+9>,&-K''A+LH5V@U<AM;*T71J>]\
M!0S%-(HEG%N1CTA7E6L0\2O%1S!CL,N ;=/<F,X1'C.,NQI3[,LGV#-U&B\T
M2'#['NJFO)8=D&9.F_'QMBMBC)%);9*Z,6!;+8A -Y'APEC:Z#>48,-<X$DQ
M_P#M(7!9BJMQCL3D&9.1\U(Y".6.D^!LKJQIATSK.PAC+3#(]D^T1P*Q=J]2
M2,C4F:W '["(DK!0XLHW%4EFVH$&_ 3,G&9&,/A'$DVAO$(8R]2FEC3PYHY0
MQ[ )(V6UUT&@<L([DF1DJXX5ZN3FA;):JROGEQDU>&;=C)^*.D39C>W([.JO
MC?&^)TK'[BW6>T?"][0BQC+64=:NXFM8=%5N1,JQ9:"U/ >-]8LEOM%65C\6
M"RXR5DD4S(7QEIR4O>G7X-FN@1L=BQM74.B&5^/J.OS; B8QL* N-LIPZ!HR
M*=;26;7J!9)IU@E+2H@ 00N4R"U(QRR+?%HW.O\ +#+%6IMQ\F2CN/O7:U1L
M!Q%O'T;[W&:1N[(K>4IUV.9Q=_*^1D D=#*&7.376G6^0B&S9NNR4>*DHLH4
M+EQ]@9JGD\CCFM$$+^&2:CB+UI['EKJ\,<;['="Q!WG+K^_NOLBJ/,@S8UB7
MDI&I 1T9FLO1%J(D;HP?[F0W"%@!S;;C.1IT.8==%;3"%15A$DUC.1LBAJ%C
M1FH:SI>^IM$<,5Z:6RR>&6HR/'N8VPXVHGO@/$)8'UVMD+K$=FM)"'MGB+H5
MM=Z8MB+N+[C+/-CJ\-5]:Q%<DERC7NJM;4EC98 !AL1V'.C#:LM6U'8=&ZO*
M&Y3H!>'*)..82I&'-S=C%X2O'E6G"^P6SE>5:?'/E5CQ\%8\<^&<9QXYY(U0
M.')UV[@[:?TD-P=P=M*X4;@^(/@55Z3.^*LG8C?4>L3L>1&^K\X=CZ?.OM7^
M^'8_$P7^G 7(#\%'?E#'\VR(?PP;^34GSI&H_&[<ZO9OMDU[95R%4FX*89B1
M42@AR_>ZW4NN9=8]0#ED=3;+23G&'"7%HC"0SEY2DE#?.=J_;)7KX[4>H=5Z
M3U'H[2>#U;%I&IJ++UI)*V6LRVSC1<;7JP22T*@R+3 V>V15FA?%/!;E>]]>
M+.G4L?-G*&EL5G,=E]3V\._,V,-3D;WM.%D!N& SN>(+%IE MN3UH7>45XW;
MRPM9PR/M,E6%)PI.<92K&%)SC/CC*<X\<9_^^,^/-S,>V1C)&.#F2-:]CFG<
M.8X!S7 ^8@@CT*UD$$@\B#L1YB%_>>E!.$3A%5'N;\]R-*NN4^6EH\HF]ZPK
MTR!&5VNVAN<JUUV)6*5: 9&*L5?L##@@L#8)"5PXP.SAL@!E4ADJ*]N!)OFG
MHZ$V1,>0KQ3Q"CD9X.]N6Z CN5:-BS4<VU3GKRQO?8ACA:!(#)WA8PM>YKFV
MO,1NFHR0\(DCE?#%8A=&R5DU:65L<\<D3VO;(QT3G<3'-+7 $.!;N%K%C>P6
MWX*3KTMI_6450*=$3IHE@!IFMVH&1V $W<.MT> FR8+C;)F"D(N*VA;XV=A1
M7&UBEQ4T4MJ&E 6!X*^X+LR[/M.LR$E6+&4\GDR72SUC$UP<RMGWM#Y0Z.>R
MPS4Z3XY97ELC[$;@V1LO%)CK+DU5S8\;CXJE.N0',JU6013MXZG" (XRUO")
M96\#3N.%_P!R6\(D-?>[L<-A%RFM=-1?N[4TW)M502K6<BIRUFGH7K!L*MKF
M"C"0Y>(/B8K95RH&2O?60'9X @AJ)*/?9@6[J[1N&$<M:MEHK4PR,+&V#-$)
M?(X;&HJM@PQ N[WO&4<?< VXN"PS=P9L]5?V9O<8F=4>R-E64]UPOX7SR1XJ
M6,.W (<TRW(AS.Q8X;%P(5Y]>;9MNXM#[BL]QK@5..%5MN!B:RVQ*L28E>KS
M<W QTA,JELMN$%3#\::>R^*$$%@5QEEIIU33A#N/S8NKB=1X6M3MF]$ZQB)G
M61P=V9YY*\TT3. N [@R-8X%Q<';[@<@JZ_.^Q@<O)(SNG?8[) ,.^X:VO.U
MKCOS]EPDCD%8[7GV@4;^9]9_,H7+!E?OIDO[_<_S$BK,/]Z<7^+J7^6B6#:&
M^TVR?CI[$?KYV/RYZH(&0I[G;_\ #ND_^6,0K7I3[VW?REUA_P UYE2^V<"\
M2\$T8*Z8,EM9 C9#*R6$.X\6EO,)7EUI+F/BVI:$X7CXISGF+ML5WRR5V3PO
MGA#'2PME8Z6)L@WC,D8<7L$@YL+F@.'-NX65.@F9$R9\,K892X12NC>V*0M^
MZ#)" UY;_.#22/'9<KDY2DX1.$3A%2OL3U5"VM9I/8N+4F$<#J%>95$D1)$I
M&O3=)N@-M$L!#0DI%E.$/5T>9J#K8Y+#GL4JEY+N5C(;7EV$U4[$4A2-4S-\
MIN2]\R813-@NXZ:E)7871RM#6S/AN#=I!D@#=AQ\;=7ZN[-HM3YEV9;D6UGG
M'XJJ:4U,6:DMO$:@IYFM>EX9X)>]=5AN8EW"\$5[KG\1$8C?4.,ZZ1;^N(&C
M0A8?F&3?IF2EC-4K,LS[EFB54:!DXZ9;OK1,>54 6)PR"B)B<D&A2EU\^1&3
M@>K/R=U&NW.OSWY*]YSWFGW4#<@QM<15KLE^>&:%M-L+Q=F[D3OAA@(C%AC6
M\-E[1CCNQB%N%J82"[B8HHXLL+-PX.5]]UJ_A8,'0N5;DF4DN1OP],6GTV7+
M5X.G?1FDD[S'0O?];?5J 5#V-O%E(:G9&:KJLG 4A(2X-<?![E$.BX0B:O)I
MPH,K\_XI1;J#VXYF5K>&B6U%RT2UD[7C]HXQ5L201LL,,<]QCN],QPQC?,(J
MT4<CX/L46QN<QSPR9K>/^*W>;V+5^]LVOLE2@N6),<\2U<5(P5FTAJYLT59U
MC(V9HH[@U3Q3QQ2QPF2H]W<[62(HV[':W8U[U2CF\%!ED2.[M>L)6%66:TC
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M,O%QO@#X7T.[DA!+,C=PPYB.6X2DM+L2C! C.6DEME.N&/);VUV,O$FK+Y
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MFBL.K]Y%(^2-DC(;4,[F&2%S9&$B(AKFN!#MB>6X5%A_1U1 P#9+U3U5,65
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;0_NV&29\CHJT/&_R>G#W=2L9)3!!&99.+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>gwpjrhodncoa000032.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000032.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" /B!&8# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOEOI<WBGX9:/XPE\9V"Q)<3WG@#P[/)#$UA?-)V?_!YY^WGX_P#$7[17P?\
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M/48_+N;.\MI,,CHPCN;*]MI(+_3;^"UU'3KJUO[6VN8@#^03_@V'_P""OO\
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MNO\ PUTO4+KQ[H>G>&_'NI+IWB#QTNG2>%;70].O/$VD^(M2TQK"]O/YH_\
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M_9__ .QO_P"M%?#F@#_;YHKY _X*$_%+QW\#OV!?VX?C7\+==_X1?XF_!_\
M9 _:6^*7PZ\2_P!F:/K?_".^._A_\%_&OBSPCKO]C>(M/U?P_J_]D>(-(T_4
M/[,UW2M3T>_^S_9=3T^]LI9[:3_+$_XBC?\ @NO_ -'R_P#FLW['G_T/M '^
MOU17^0+_ ,11O_!=?_H^7_S6;]CS_P"A]K_7ZH **_ '_B*-_P""%'_1\O\
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M_P#$VT&P^V?8/M]A]JTRZL[RX /?Z*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYS_G%U_W>S_[Z/7\ = '[_?\&N/_ "G7_89_[N9_]8\_:"K^OW_@]6_Y19?
M/_L__P"%G_K.O[55?R!?\&N/_*=?]AG_ +N9_P#6//V@J_K]_P"#U;_E%E\
M_P#L_P#^%G_K.O[55 '^8)7W_P#\$G?^4IO_  33_P"S_P#]C?\ ]:*^'-?
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MV?:_ &OW^_X.CO\ E.O^W-_W;-_ZQY^S[7X T ?Z??\ P94_\HLOCY_V?_\
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MHY+&+1[NQN]'C5I+V&]9;7^Q"@ HHHH ^'_^"B_[=WPV_P"";'[(OQ-_:_\
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MJ=MI^C:#H&C6UGI6CZ586Z);V6GZ?:6]I:PHD4$*(H4?JS_P:D_\H0_V8/\
ML<_VB_\ UH'XC4 ?A?\ \'L7[9?BW3]4_93_ &"/#.NW.E^%=:\,ZG^T[\6M
M(M)KB ^*"_B+6?AY\'[746AEB2YT?1M0\,_%#59=+NDN;6ZUK^P=5,<5YH%C
M,/=?V+_^#3/]BCXR_P#!+3X7>+?BE?\ Q)M?VT/C]\!?#WQATSXMV?C74+/0
M?A1XN^(_A.R\9^!_!MM\.[.23PAKWA7PO!J.C:)XV_MF#5O$/B*X_P"$GO-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *Y#X@W?@2Q\!>-[[XI2^%H/AE9^$
M/$MU\19O'(TL^"H? EOHU[-XNE\8#6PVBGPM'X?34'\0?VN#I?\ 9(N_MX-I
MYHKKZ^<OVP_@?J7[3?[(_P"U-^S;H^O67A75_P!H3]G+XW_ _2O$^IV<^H:=
MX<U'XL?#/Q/X"L=>U"PM9(;F]LM'N=?BU"[M+>:*>Y@MY(89$D=6 !^+?_">
M?\&I/_/C_P $-/\ PW'[%W_S+T?\)Y_P:D_\^/\ P0T_\-Q^Q=_\R]?S#?\
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M_@]]H\*>(O#=W(OF0VLX\ 2?#C5],,SV[:HEQK"6EO)_8E_.?]$/]C']A_\
M9@_X)^_!;3O@%^RA\+=(^%_P\M-1N=>U2*UFO-5\1>+_ !3?P6MMJ'B[QQXJ
MU>>\U[Q9XEO+6QL;#^TM8OK@V.D:?I>@Z5'I^A:3I>F6>Y^UE^R!^SC^W)\&
M-?\ V?\ ]J7X6Z#\6/A?X@F@OI-%U@WEEJ&BZW91SQ:;XG\)^(](N;#Q#X2\
M4:8EU=16.O\ A[4M/U**VN[VP>>33[^^M+D _F,^/O\ P=5?\$^O&/\ P2P\
M?^,/!_Q$O[G]M/XC_L]:O\/+3]FZ3X?^-FU7PK\>_&W@,^'=1O=6UV^T#1_
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ME-_X)I_]G_\ [&__ *T5\.:^ *^__P#@D[_RE-_X)I_]G_\ [&__ *T5\.:
M/]?K_@K%_P HLO\ @I9_V8!^V1_ZSK\1J_Q!J_V^?^"L7_*++_@I9_V8!^V1
M_P"LZ_$:O\0:@ K_ '^*_P  >O\ ?XH _P  >BBB@#_;Y_X)._\ *++_ ()I
M_P#9@'[&_P#ZSK\.:_R!?^"L7_*4W_@I9_V?_P#MD?\ K17Q&K_7Z_X)._\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[;]CK_@T*M+BWNHO%W_!*EI;:>*XC6Y_;H\#7MNTD,BR(MQ9WG[0D]I=PEE
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MS/\ ZV'^T%7^0+7^OU_P:X_\H*/V&?\ NYG_ -;#_:"H _@#_P"#H[_E.O\
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MS /BG_ZT5^RK7^GW7^8)_P &5/\ RE-^/G_9@'Q3_P#6BOV5:_T^Z "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
M\M?^"S_["WQ*_P""D7_!.?X[_LA?"#Q=X-\$_$CXCWGPOU3POK?Q$O=?T[P*
M;KP#\5_!7CV[L/%%]X8T#Q3KUK8W^F>'+Z"TN-.\.ZO)#JYTV66T-NDTD?\
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MA3PAX<TN"\USQ7XIU86UR]CHFB6-W=_9+6^U2Z6UTC3=2O[0 ^FJ*_D-L?\
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MP!T ?O\ ?\&N/_*=?]AG_NYG_P!8\_:"K^OW_@]6_P"467P#_P"S_P#X6?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %?AO_P ')_\ PF__  Y%_;T_X5_]M_MW_A"O
MAA]O^P?9_/\ ^$)_X7[\)_\ A9?F?:OW7V+_ (5Q_P )7_:6W_2/[.^U?8_]
M+\BOW(K@OBI\,/ OQL^&7Q!^#OQ/\/6?BSX<?%/P7XF^'OCOPS?^:MGKWA'Q
MAHUYH/B#29Y('BN(5OM+O[F 7%M+#=6S.L]M-%/''(H!_'1_P9C^$?V,[O\
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M3_PCG]K^'_\ A(/^$?\ ^$@_M;^Q/[>T3^U?LGV#^U]-\_[9#_$%_P 0,?\
MUE%_\TF__*XH _@#K_?XK^ /_B!C_P"LHO\ YI-_^5Q7]_E '^ /17]_G_$#
M'_UE%_\ -)O_ ,KBC_B!C_ZRB_\ FDW_ .5Q0!_7[_P2=_Y19?\ !-/_ +,
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MVM_PWG_PI?\ X71_PK+_ (MI_P ,N?\ "Q?^$:_X5U\'?A]\)_\ D<O^&BO
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M_P +;_M3_A&?B+\5?'__  E/_"1_\+S^&7V+[;_PLW^R?[$_L&[^S?V)]O\
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M (7G\3?MOV+_ (5E_9/]B?V#:?:?[;^W_P!KP?V;]CO_ .GV@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6T:V4 +;:5X?\/V6GZ3IT"A0%AL[2&,  !< 5U] 'XK_ /!*S_@@_P#L4?\
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M:OXOU/2M9URUTBP\-?#;PMXQ\57)_LGP_J]]=7T>B-IMA#:9O[RV:>U6;O\
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M"_MGQ%J&K^(-7_LCP_I&GZ?_ &GKNJZGK%_]G^U:GJ%[>RSW,@!_HN?MN_\
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MVM\+/^"B7[)WPI_;%^"F@?$#PO\ #+XP?\)U_P (UH7Q2TKP[HGCNQ_X5_\
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M^[)O_?N* /Z?O^"K?_!:O]EG_@CY_P *%_X:7\ _M >./^&B/^%H_P#"%?\
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MC_@[)>'<^X=R_+88F.&S)P6*5;$2JS=\93H/DFTG#W)/OKJ>)_\ #6OPY_Z
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%>.?M$_!;P[^TE^S]\=/V=?%]_J>E>$_CY\'/B=\%O%&J:(T":SIOAWXI^"=
M;\#:U?Z0]U%-;)J=GINNW-Q8-<0S0+=1Q&6*2,,A]CKP_P#:7_:!^'_[*7[/
MOQD_:2^*EW<6?P]^"/PZ\4_$?Q4UE$)]1N]-\,:5<:C_ &5I-NS(MUK6MW$4
M&CZ+:,Z+=:K?6=N9$$N\ '\@_P#Q!&?L??\ 1Z'[2G_A*?"__P"55'_$$9^Q
M]_T>A^TI_P"$I\+_ /Y55_-[^T-_P7$_X+D?\%7/B]XQT3]EW5_VFO!?@W[3
M>7_AG]G/]@G0?B1<:]X0\'/<W"Z;#XM\:?"'1$^+'CF_ET^..#Q)KFNZAIWA
MG6M1BU"XT7P?X5TFZ'A^T\_O]0_X.<OV-()OB_KNH?\ !6[P!X=T&TNM<U_Q
M-XHO/VB?'OPVTG3= 5+BXU'X@6.OR^+_ (?6FE64=V\D<OCFP2P>%K\V_F11
M7^P _O3_ ."1_P#P;N?L^_\ !(S]H'Q[^T5\,?CO\7?BUXL\=?!S6/@M)I?C
M[3/"&EZ-I7AW7O&W@3QSJ=_;IX<L+>YN=3DU+X>Z%;P-/-Y$%J]Z/*>2=7B_
MH7K^3_\ X-P?^#@'Q=_P4\_X2W]E?]JRST&R_:V^&?@IO'^B>._"^CQ^'_#W
MQQ^'FF:IINA^(]7OM!L8H]"\+_$+POJ.N^'WUC2="6QT;Q)IFK3:UX<T'2+7
M0-<L[7^L"@ HHHH **** "BBB@#\*O\ @N'_ ,$5O^'S/@K]GWP?_P -*_\
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MEVM[J)M;>&TT_3=)TO1_#FA6,8L]"T73H7G69_\ P4*_X)S?LO?\%-_@)?\
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M?]WL_P#OH]?P!U_?Y_P?.?\ .+K_ +O9_P#?1Z_@#H _?[_@UQ_Y3K_L,_\
M=S/_ *QY^T%7]?O_  >K?\HLO@'_ -G_ /PL_P#6=?VJJ_D"_P"#7'_E.O\
ML,_]W,_^L>?M!5_7[_P>K?\ *++X!_\ 9_\ \+/_ %G7]JJ@#_,$K[__ ."3
MO_*4W_@FG_V?_P#L;_\ K17PYKX K[__ ."3O_*4W_@FG_V?_P#L;_\ K17P
MYH _U^O^"L7_ "BR_P""EG_9@'[9'_K.OQ&K_$&K_;Y_X*Q?\HLO^"EG_9@'
M[9'_ *SK\1J_Q!J "O\ ?XK_  !Z_P!_B@#_  !Z*** /]OG_@D[_P HLO\
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MVDZ'::+8:9#_ $#4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_!6+_E%E_P %+/\ LP#]LC_UG7XC5_B#5_M\_P#!6+_E%E_P4L_[, _;(_\
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M!7^OU_P:X_\ *"C]AG_NYG_UL/\ :"K_ "!:_P!?K_@UQ_Y04?L,_P#=S/\
MZV'^T%0!_ '_ ,'1W_*=?]N;_NV;_P!8\_9]K\ :_?[_ (.CO^4Z_P"W-_W;
M-_ZQY^S[7X T ?Z??_!E3_RBR^/G_9__ ,4__6=?V5:_ '_@]6_Y2F_ /_LP
M#X6?^M%?M55^_P!_P94_\HLOCY_V?_\ %/\ ]9U_95K\ ?\ @]6_Y2F_ /\
M[, ^%G_K17[55 '\@5?W^?\ !C'_ ,Y1?^[)O_?N*_@#K^_S_@QC_P"<HO\
MW9-_[]Q0 ?\ !\Y_SBZ_[O9_]]'K^ .O[_/^#YS_ )Q=?]WL_P#OH]?P!T ?
MU^_\&5/_ "E-^/G_ &8!\4__ %HK]E6O]/NO\P3_ (,J?^4IOQ\_[, ^*?\
MZT5^RK7^GW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!XG^T5_R1OQC_ -R__P"I3H=?EW7ZB?M%?\D;\8_]R_\
M^I3H=?EW7ZUP'_R)\3_V,JW_ *BX,_J7P0_Y)3,/^RAQ?_JMRD[;X:?\E'\
M?]CMX5_]/MA7ZB?$O_DG'C__ +$GQ5_Z8K^OR[^&G_)1_ '_ &.WA7_T^V%?
MJ)\2_P#DG'C_ /[$GQ5_Z8K^O-XR_P"1QDO_ &[_ .I4#Y_Q<_Y*O@[UI_\
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M%TR[MYK=3-#(/ZDZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLO\ @FG_ -F ?L;_ /K.OPYK_(%_X*Q?\I3?^"EG_9__ .V1_P"M%?$:@#X
MK_7Z_P"#7'_E!1^PS_W<S_ZV'^T%7^0+7^OU_P &N/\ R@H_89_[N9_];#_:
M"H _@#_X.CO^4Z_[<W_=LW_K'G[/M?@#7[_?\'1W_*=?]N;_ +MF_P#6//V?
M:_ &@#_3[_X,J?\ E%E\?/\ L_\ ^*?_ *SK^RK7X _\'JW_ "E-^ ?_ &8!
M\+/_ %HK]JJOW^_X,J?^467Q\_[/_P#BG_ZSK^RK7X _\'JW_*4WX!_]F ?"
MS_UHK]JJ@#^0*O[_ #_@QC_YRB_]V3?^_<5_ '7]_G_!C'_SE%_[LF_]^XH
M/^#YS_G%U_W>S_[Z/7\ =?W^?\'SG_.+K_N]G_WT>OX Z /Z_?\ @RI_Y2F_
M'S_LP#XI_P#K17[*M?Z?=?Y@G_!E3_RE-^/G_9@'Q3_]:*_95K_3[H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \
M3_:*_P"2-^,?^Y?_ /4IT.OR[K]1/VBO^2-^,?\ N7__ %*=#K\NZ_6N _\
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MEIQ%_P!C"7_INF%%%%>(?&A1110 4444 %%%% !1110 4444 %%%% !1110
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ML_"77/#VG_VAHVEM,VE:5<>*?A]XJ\0P^*]4AMH;[65\$^"+*\N)X=&TZ*
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M?_9@'[&__K.OPYK_ "!?^"L7_*4W_@I9_P!G_P#[9'_K17Q&K_7Z_P""3O\
MRBR_X)I_]F ?L;_^LZ_#FO\ (%_X*Q?\I3?^"EG_ &?_ /MD?^M%?$:@#X K
M_7Z_X-<?^4%'[#/_ '<S_P"MA_M!5_D"U_K]?\&N/_*"C]AG_NYG_P!;#_:"
MH _@#_X.CO\ E.O^W-_W;-_ZQY^S[7X U^_W_!T=_P IU_VYO^[9O_6//V?:
M_ &@#_3[_P"#*G_E%E\?/^S_ /XI_P#K.O[*M?@#_P 'JW_*4WX!_P#9@'PL
M_P#6BOVJJ_?[_@RI_P"467Q\_P"S_P#XI_\ K.O[*M?@#_P>K?\ *4WX!_\
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M$O\ Y)QX_P#^Q)\5?^F*_K\N_AI_R4?P!_V.WA7_ -/MA7ZB?$O_ ))QX_\
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M5=1^"UGKW]GPN?![_$"Y\9:=XTOM._M03P'Q^GP\L95M)(IA\/))(&2X]/\
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M'X4^((P[D#"J9)$0,V!O=%SN8 _T9?\ $7'^QM_PZX^S^1\1/^&^_P#AGO\
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M/V?:_ &OW^_X.CO^4Z_[<W_=LW_K'G[/M?@#0!_I]_\ !E3_ ,HLOCY_V?\
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MY-GGG_9=9G_ZH.&#]P^DO_R7>4_]DE@/_5QGP5_:Q7\4]?VL5\+]-+_FVO\
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MMOB7_P E'\?_ /8[>*O_ $^W]<37UN#_ -SPG_8-0_\ 343]2R?_ )%.5_\
M8NP7_J-2/T._9*_Y)QK7_8[:E_Z8O#=?45?+O[)7_).-:_[';4O_ $Q>&Z^H
MJ_$^)/\ D>9G_P!A,O\ TF)_'7B%_P EIQ%_V,)?^FZ84445XA\:%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5_E!?\&MW_!0_]CS_ ()S?M5_M&_$G]LKXO\ _"G/!?CS]GVV
M\#^%-:_X5_\ %'XA?VKXHC^(_A37GTO^SOA7X)\<:M8XTG3;V[^VZE8V>G'R
M?(%V;F2&&3_5]K_&N_X(D_\ !(#_ (?&_'+XO?!C_AH?_AG/_A57PHA^)_\
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M1W_*=?\ ;F_[MF_]8\_9]K\ : /]/O\ X,J?^467Q\_[/_\ BG_ZSK^RK7X
M_P#!ZM_RE-^ ?_9@'PL_]:*_:JK]_O\ @RI_Y19?'S_L_P#^*?\ ZSK^RK7X
M _\ !ZM_RE-^ ?\ V8!\+/\ UHK]JJ@#^0*O[_/^#&/_ )RB_P#=DW_OW%?P
M!U_?Y_P8Q_\ .47_ +LF_P#?N* #_@^<_P"<77_=[/\ [Z/7\ =?W^?\'SG_
M #BZ_P"[V?\ WT>OX Z /Z_?^#*G_E*;\?/^S /BG_ZT5^RK7]W7_!6;_DW/
MP7_V6OPY_P"H+\1Z_A%_X,J?^4IOQ\_[, ^*?_K17[*M?W=?\%9O^3<_!?\
MV6OPY_Z@OQ'K]7\#/^3M\!_]CVE_Z8KGYWXL_P#)N.+_ /L4S_\ 3U$_GHKV
MO]FO_DXSX _]EK^%?_J=:#7BE>U_LU_\G&? '_LM?PK_ /4ZT&O]7.*/^29X
MB_[$6;_^J_$'^>7#_P#R/LD_[&^6_P#J91/Z%_\ @HE_R9S\8/\ NG__ *M+
MP17\OM?U!?\ !1+_ ),Y^,'_ '3_ /\ 5I>"*_E]K^;OH>_\FSSS_LNLS_\
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M_!\Y_P XNO\ N]G_ -]'K^ .@#]_O^#7'_E.O^PS_P!W,_\ K'G[05?U^_\
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M73QY_P B?#?]C*C_ .HN,/1\;_\ DE,O_P"RAPG_ *K<V/SQ^)?_ "4?Q_\
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M@7_G::_[S_?_  12O]?JO\@7_G::_P"\_P!_\$4H _?[_@^<_P"<77_=[/\
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M^O\ @UQ_Y04?L,_]W,_^MA_M!5_D"U_K]?\ !KC_ ,H*/V&?^[F?_6P_V@J
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M[, ^*?\ ZT5^RK7]W7_!6;_DW/P7_P!EK\.?^H+\1Z_A%_X,J?\ E*;\?/\
MLP#XI_\ K17[*M?W=?\ !6;_ )-S\%_]EK\.?^H+\1Z_5_ S_D[? ?\ V/:7
M_IBN?G?BS_R;CB__ +%,_P#T]1/YZ*]K_9K_ .3C/@#_ -EK^%?_ *G6@UXI
M7M?[-?\ R<9\ ?\ LM?PK_\ 4ZT&O]7.*/\ DF>(O^Q%F_\ ZK\0?YY</_\
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M '9Z^)Z^V/V._P#FHO\ W*/_ +L]?2<7?\D]F'_<I_ZG88_0?%7_ )(+/O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSBZ_[O9_]]'K^ .O[_/^#YS_ )Q=?]WL_P#OH]?P!T ?O]_P:X_\IU_V&?\
MNYG_ -8\_:"K^OW_ (/5O^467P#_ .S_ /X6?^LZ_M55_(%_P:X_\IU_V&?^
M[F?_ %CS]H*OZ_?^#U;_ )19? /_ +/_ /A9_P"LZ_M54 ?Y@E??_P#P2=_Y
M2F_\$T_^S_\ ]C?_ -:*^'-? %??_P#P2=_Y2F_\$T_^S_\ ]C?_ -:*^'-
M'^OU_P %8O\ E%E_P4L_[, _;(_]9U^(U?X@U?[?/_!6+_E%E_P4L_[, _;(
M_P#6=?B-7^(-0 5_O\5_@#U_O\4 ?X ]%%% '^WS_P $G?\ E%E_P33_ .S
M/V-__6=?AS7^0+_P5B_Y2F_\%+/^S_\ ]LC_ -:*^(U?Z_7_  2=_P"467_!
M-/\ [, _8W_]9U^'-?Y O_!6+_E*;_P4L_[/_P#VR/\ UHKXC4 ? %?Z_7_!
MKC_R@H_89_[N9_\ 6P_V@J_R!:_U^O\ @UQ_Y04?L,_]W,_^MA_M!4 ?P!_\
M'1W_ "G7_;F_[MF_]8\_9]K\ :_?[_@Z._Y3K_MS?]VS?^L>?L^U^ - '^GW
M_P &5/\ RBR^/G_9_P#\4_\ UG7]E6OP!_X/5O\ E*;\ _\ LP#X6?\ K17[
M55?O]_P94_\ *++X^?\ 9_\ \4__ %G7]E6OP!_X/5O^4IOP#_[, ^%G_K17
M[55 '\@5?W^?\&,?_.47_NR;_P!^XK^ .O[_ #_@QC_YRB_]V3?^_<4 '_!\
MY_SBZ_[O9_\ ?1Z_@#K^_P _X/G/^<77_=[/_OH]?P!T ?U^_P#!E3_RE-^/
MG_9@'Q3_ /6BOV5:_NZ_X*S?\FY^"_\ LM?AS_U!?B/7\(O_  94_P#*4WX^
M?]F ?%/_ -:*_95K^[K_ (*S?\FY^"_^RU^'/_4%^(]?J_@9_P G;X#_ .Q[
M2_\ 3%<_._%G_DW'%_\ V*9_^GJ)_/17M?[-?_)QGP!_[+7\*_\ U.M!KQ2O
M:_V:_P#DXSX _P#9:_A7_P"IUH-?ZN<4?\DSQ%_V(LW_ /5?B#_/+A__ )'V
M2?\ 8WRW_P!3*)_0O_P42_Y,Y^,'_=/_ /U:7@BOY?:_J"_X*)?\F<_&#_NG
M_P#ZM+P17\OM?S=]#W_DV>>?]EUF?_J@X8/W#Z2__)=Y3_V26 _]7&?!7]K%
M?Q3U_:Q7POTTO^;:_P#=X_\ OJGUOT7/^:Y_[MG_ -^ ****_A<_K0**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q/]HK_DC?C'_N7_ /U*=#K\
MNZ_43]HK_DC?C'_N7_\ U*=#K\NZ_6N _P#D3XG_ +&5;_U%P9_4O@A_R2F8
M?]E#B_\ U6Y2=M\-/^2C^ /^QV\*_P#I]L*_43XE_P#)./'_ /V)/BK_ -,5
M_7Y=_#3_ )*/X _[';PK_P"GVPK]1/B7_P DX\?_ /8D^*O_ $Q7]>;QE_R.
M,E_[=_\ 4J!\_P"+G_)5\'>M/_U943\A:***_2#^@S]>OAI_R3CP!_V)/A7_
M -,5A7Y"U^O7PT_Y)QX _P"Q)\*_^F*PK\A:^ X*_P!\XA_["</_ .G<>?A?
M@]_R->/?^QA@/_4G/ K]1/V=?^2-^#O^Y@_]2G7*_+NOU$_9U_Y(WX._[F#_
M -2G7*Z>//\ D3X;_L94?_47&'H^-_\ R2F7_P#90X3_ -5N;'YX_$O_ )*/
MX_\ ^QV\5?\ I]OZXFNV^)?_ "4?Q_\ ]CMXJ_\ 3[?UQ-?6X/\ W/"?]@U#
M_P!-1/U+)_\ D4Y7_P!B[!?^HU(_0[]DK_DG&M?]CMJ7_IB\-UXG^UK_ ,E'
MT7_L2=-_]/OB2O;/V2O^2<:U_P!CMJ7_ *8O#=>)_M:_\E'T7_L2=-_]/OB2
MO@,M_P"2YQ__ '-?^FZ9^&\/_P#)Z,\],R_],4#Y=K[8_8[_ .:B_P#<H_\
MNSU\3U]L?L=_\U%_[E'_ -V>OI.+O^2>S#_N4_\ 4[#'Z#XJ_P#)!9]_W2__
M %<Y<'[8G_-.O^YN_P#=8KXGK[8_;$_YIU_W-W_NL5\3T<(_\D]E_P#W-_\
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MN19^(++PWXCT?7+O0KPR3PBTUFWTR\NIM,N3-:W40@O4@E\RVGCV[H9 O64
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MO@"OO_\ X)._\I3?^":?_9__ .QO_P"M%?#F@#_7Z_X*Q?\ *++_ (*6?]F
M?MD?^LZ_$:O\0:O]OG_@K%_RBR_X*6?]F ?MD?\ K.OQ&K_$&H *_P!_BO\
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M_P"[Q_\ ?5/K?HN?\US_ -VS_P"_ %%%%?PN?UH%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!XG^T5_R1OQC_W+_P#ZE.AU^7=?J)^T5_R1OQC_
M -R__P"I3H=?EW7ZUP'_ ,B?$_\ 8RK?^HN#/ZE\$/\ DE,P_P"RAQ?_ *K<
MI.V^&G_)1_ '_8[>%?\ T^V%?J)\2_\ DG'C_P#[$GQ5_P"F*_K\N_AI_P E
M'\ ?]CMX5_\ 3[85^HGQ+_Y)QX__ .Q)\5?^F*_KS>,O^1QDO_;O_J5 ^?\
M%S_DJ^#O6G_ZLJ)^0M%%%?I!_09^O7PT_P"2<> /^Q)\*_\ IBL*_(6OUZ^&
MG_)./ '_ &)/A7_TQ6%?D+7P'!7^^<0_]A.'_P#3N//POP>_Y&O'O_8PP'_J
M3G@5^HG[.O\ R1OP=_W,'_J4ZY7Y=U^HG[.O_)&_!W_<P?\ J4ZY73QY_P B
M?#?]C*C_ .HN,/1\;_\ DE,O_P"RAPG_ *K<V/SQ^)?_ "4?Q_\ ]CMXJ_\
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M5?Z_5% '^0+_ ,0N/_!=?_HQK_S9G]CS_P"B"KW_ /X<0_\ !S[_ -$O^/\
M_P")^_ #_P"BEK_5[HH _P @7_B%Q_X+K_\ 1C7_ )LS^QY_]$%1_P 0N/\
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M%:?LR?$#X=_VY]A_MK_A!?VR_P!E[PE_;']F?:_[-_M3^P/VE-/_ +0_L_\
MM"_^P_:_.^R?;;OR/+^TS;_];JB@#_)%\=?\&Y/_  <5?%#^R_\ A9?[,GQ
M^(G]A_;O[%_X3K]LO]E[Q;_8_P#:?V3^TO[+_M_]I34/[/\ [0_L^P^W?9/)
M^U_8K3S_ #/LT.SS_P#XA<?^"Z__ $8U_P";,_L>?_1!5_K]44 ?Y&O@K_@V
MS_X.%?AKJMQKOPZ_92\8> -;N]/ETFZUCP5^U_\ LK>%=5N=*GN;2\GTRXU#
M0OVC["[FT^:[L+&ZELY)FMI+FSM)WC,MO"R?8W[/7_!)G_@Z'_9Y\::GXTM/
MV7-8^+LFI^%[WPNWAOXY_MC? 7Q]X2LDO=5T75CKFG:/%^U[HC6WB*V;1%L+
M34C=2"'3-2U>U^SN;P21?Z@E%>AE6;9CD>8X3-\HQ=; 9E@*RKX/&4&E6P]9
M)I5*;DI)22DUJGN<68Y=@LVP6)R[,L-3QF!Q=-TL3AJR;I5J;:;A-)IM72>C
M6Q_G@_\ #,/_  =,_P#2-+]FO_P]/P,_^CEKE_&_['/_  =*^-_!?B_P7+_P
M3M^!OAF/Q?X7U_PO)XD\'_'SX%:+XM\/)K^E7>DOKGA?6&_;=NUTGQ%I*W9O
M]$U)K6Y%AJ=O;71MYA%Y;?Z,U%?H5?QK\5L50K8;$<<9W5H8BE4H5Z4ZM%QJ
M4:T'3J4Y+V*]V<)2B]=FSXVCX6>'F'K4J]'A/*J=:A4A6I5(TZO-"I2E&=.<
M?WOQ1E&,EYKS9_EI_!G_ ((X_P#!T)\&?B3X;^)5M^SQXZ^(\WAO^V-G@SXL
M?ML? /Q?\/\ 6?[8T'5- ;^W_#L?[6NEOJ/]G)JC:KI6+^#[)K5CIM\?-%L8
M9/N[_AF'_@Z9_P"D:7[-?_AZ?@9_]'+7^A]17A\-^)''/!^!JY9PSQ-F638"
MOBZF.K87!SIQI5,75HT,/4Q$E.G-^TE1PN'IMWMRTHZ;W]7/.".$^)<73Q^?
M9%@<SQE'#PPE/$8F$Y5(8:G5JUH44XSBN2-6O6FE:]ZDM;.Q_G@_\,P_\'3/
M_2-+]FO_ ,/3\#/_ *.6OS?\+_\ !#7_ (.*M$\3>'=:^.?A7]I+P7\$M(UW
M2-4^,7C'1?V\/@?J6L>$_A9I^H6]W\0?$VDZ=I?[1'BC4[_4]!\)1:OJEA9:
M=X:\17UU=6L4%IH6K7$D=A<?ZKU>*?M*?\FY_'[_ +(I\5/_ %!=>KMK\9<4
M<?9_PKAN,<ZQO$-#"YQAJ&'I9A*$XTJ.98W T\=3BH0I^[B88>A&K=NZIQM;
M6_+1X8R#@_*.(*_#.587)JV(RVO5K5,'&495*F!PN+GA)RYY3UH2K590[.<K
MWN?YZO\ PZ_T3_H][_@HG_XDI:?_ #OZ/^'7^B?]'O?\%$__ !)2T_\ G?U^
MGM%?Z;?\0,\(_P#H@\B_\%5O_EY_!_\ Q%GQ'_Z*_-__  92_P#E7E_5V?S\
M^*/^"&O_  <5:WXF\1:U\#/"O[27C3X):OKNKZI\'?&.M?MX? _3=8\6?"S4
M-0N+OX?>)M6T[5/VB/"^IV&IZ]X2ETC5+^RU'PUX=OK6ZNI8+O0M)N(Y+"W^
MK/"__!*SQQHGAGP[HOQS_:X_X* ^"_C;I&A:1I?QB\':+^U#HNI:/X3^*>GZ
M?;VGQ!\,Z3J.E^'/%&F7^FZ#XMBU?2["]T[Q+XBL;JUM8I[37=6MY([^X_T1
M_P!FO_DW/X _]D4^%?\ Z@N@U_+[^TI_R<9\?O\ LM?Q4_\ 4ZUZOY"^CWP-
MPCQ1Q]XBY9Q!D.!S7 95[;^SL+BHSE2PG+G6(PZ]DHSBU:C&-/5OW4?TCXS<
M6\29!P?P3C\FS?%Y?C,Q5+Z[B,/*"J8F^5T*S]HY0DG>K*4W9+5OIH?BO_PZ
M_P!$_P"CWO\ @HG_ .)*6G_SOZ^4_B5_P1)_X+K^,_&NM>)?V*HOVI/C#^S-
MJ7]G?\*T^(WB_P#;C^#OAWQ%XB^QZ386'C+^T='\2_&SX;:W9_V1\0+7Q5H5
MI]M\%:+]HL=,MKJV_M&TG@U:_P#WIK^H+_@G;_R9S\'_ /NH'_JTO&]?8?2>
M\-^!N#^ <HS/AGAG+<FQ]?B_ 8&MBL'"I&K4PE7)<_Q%2A)SJ37LY5L+AZC5
MK\U*.N]_F_ 7CCBSB7C#,L!GV>X[-,'1X:QF+IX?$SA*G#$T\TR:C"LE&$7S
MQI5ZT$[VM4EI=W/X!_AK_P $F/VB_!G@K1?#7[:O[27[=WP>_:9TW^T?^%E_
M#GPA^U=X7\1>'?#OVS5K^_\ !O\ 9VL>&H?B3HEY_:_P_NO"NNW?V+QKK7V>
M^U.YM;G^SKN"?2;#N?\ AU_HG_1[W_!1/_Q)2T_^=_7]"?\ P42_Y/&^,'_=
M/_\ U5O@BOBFOU[P^\&_"_-. >",SS#@K)L5C\QX0X:QV-Q56E6=7$XO%Y+@
ML1B:]1JLDZE:M4G4FTDN:3LD?FW&?B=Q]@.,.*\#@^*<TP^#P7$N>X3"X>G.
MFJ=##8;-,51H48)TFU"E2IPA%-M\JU;UO^&7Q@_X(N_\%A/B%XFL=:_X)T^(
M?VM_C]\$K70K;2_%'C'Q]^VM\+/">L:;\4X=0U.[UOPS;:=XP^)_P?U.;3;/
MPE>^"-4AO8/#5]8R76LWD$6NW-Q;75AIG=?!_P#X)"?MO?#WPS?:+_P46^-G
M[;GP!^-MUKMSJGA?P=X!_:[\$>+-'U+X63:?IEIHGB:YU'P?JWQ@TR'4[SQ;
M9>-]+FLI_$MC?1VNC6<\NA6UO<VM_J?]U7_!)G_DW/QI_P!EK\1_^H+\.*^*
M?^"LW_)QG@O_ +(IX<_]3KXCU_.7"/ W"..^DKQ/PEB\AP%?AO!_VU]5R>I"
M;PE'ZOA,-.CR14U)>SG.4HWF]6[W/V_B3BSB/">!F0\1X;-\71SS$K*O;YE"
M4?K-7VV(K1J\TG!Q?/&,5+W=4C^8'_AU_HG_ $>]_P %$_\ Q)2T_P#G?UX9
M\:/^".'_  4Q^)'_  C7_#M+XC_MD_M$_P!C?VQ_PNK_ (6'^V1\.O!__"'_
M -H_V5_PKC^Q_P#A-/&?P7_M'_A(/L/CS^T/[-_X23[)_8EE]L_L?[3:_P!J
M_MA7[6?\$>_^;B/^Z2?^]-K]>\>?"GPZX:\*.*L[R+A+*<LS7!?V']5QV&IU
M8UZ'UGB3)\)7Y'*K)+VN&KUJ,KQ?N5);/4_-?"'Q#XUSSQ$X>RK-^(\QQ^7X
MK^UOK&$KSINE5]AD>98BESJ-.+?LZ]&E5C9KWH)][_Q1_!?_ ((X?\%,?AO_
M ,)+_P /+?B/^V3^SM_;/]C_ /"E?^%>?MD?#KQA_P )A_9W]J_\+'_MC_A"
M_&?QH_L[_A'_ +=X#_L_^TO^$;^U_P!MWOV/^V/LUU_97N?_  Z_T3_H][_@
MHG_XDI:?_._K^NG_ (+"?\V[_P#=6_\ WF5?BG1X#>%/AUQ+X4<*YWGO"64Y
MGFN-_MSZUCL33JRKU_JW$F<82ASN-6*?LL-0HT8VBO<IQW>H>+WB'QKD7B)Q
M#E>4<1YC@,OPO]D_5\)0G35*E[?(\LQ-7D4J<G^\KU:E25V_>G+H['XV?&#_
M ()"?MO?$+PS8Z+_ ,$Z?C9^VY\?OC;:Z[;:IXH\'>/OVN_!'A/1]-^%D.GZ
MG::WXFMM1\8:M\'],FU.S\6WO@C2X;*#Q+?7TEKK-Y/%H5S;VUU?Z9POP?\
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MG"G3E4:E&3YG"C2B];6@M-[_ ,$OQ3\*?\':7Q6^&/Q&^%VH_P#!-?\ 9?\
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MG.-S_ 87%YAB*^'J_6O:4IN+C+DP6(J1O:*?NSA&2UW7J?R4?M,_L^_\%/\
M]A;QYI/PD_;5^)'[2/P9^*?B+PC8?$;0/"]G^U'8^/(K_P"'^KZSKWAG2M>;
M6/AI\2/'^A6TEUXB\(^*M/.FW>L6VK0KI:W4^F0V=Y875Y\[?\+/_: _Z.D_
M:<_\/;XU_P#EA7]/W_!WK_RDG^"/_9COPU_]7U^TO7\K-?:?0T^AG]%SC[Z+
MO@IQEQCX*<%\0<4<0\%X7,,ZSK,,-C)XS,<;/%XN$L1B)0QE.$JDH4X1;C"*
MM%:;WY^(N(L[PN=YEA\/F6)I4*6(<:=.$H\L(\L'97B]+_KW/K']F;]GW_@I
M_P#MT^/-6^$G[%7Q(_:1^,WQ3\.^$;_XC:_X7O/VH['P'%8?#_2-9T'PSJNO
M+K'Q+^)'@#0KF2U\1>+O"NGC3;36+G5IEU1KJ#3)K.SO[JSZ[]J7]CC_ (*_
M_L!_\(+_ ,-S^*OVCO@C_P +9_X2?_A5WV+]K7PU\0?^$G_X03_A'O\ A-O-
M_P"%7?%KXB?V1_8O_"9>$=G]N_V/]O\ [6?^S/[0^Q:A]B_<?_@T*_Y23_&[
M_LQWXE?^KZ_9HK[B_P"#S/\ YQO_ /=X'_OKE?QAQ1]'+P.P?[6+PX\$\+X:
M\-T?"G->#,=F&8\#PH8A9)B\92\)./,\IXBM2>(=9U(YMEN QR:K)>WPM)M<
MJ<7]#0SC,Y<"XS,I8RL\=3Q,(0Q+:]K&/U_"4[)VM;DG*.JVDS^)_P#X6?\
MM ?]'2?M.?\ A[?&O_RPKUOX%> _V_\ ]K+XJ>%OV?OV7/C/^TK\3OCMX_\
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M_H^L:=/M7S;/4+.XMW*J6C)4$=?10!^2WA;_ ((1?\$?/!OCE?B+HG_!/?\
M9S;Q(ES)=Q0:[X4N?%?A*"XDDCE$EM\/?%6I:U\/[8PR1(]HMOX8C2R(/V-8
M-[[OUCMK:WL[>"SL[>&UM+6&*VM;6VB2"WMK>!%B@@@@B58H888E6.**-52-
M%5$4* *FHH **** "O\ (%_YVFO^\_W_ ,$4K_7ZK_(%_P"=IK_O/]_\$4H
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MDDT]&]S\OJ_:S_@CW_S<1_W23_WIM?BG7[6?\$>_^;B/^Z2?^]-K^A/I*_\
M)E.-/^[<_P#6LR$_%_ S_DZ?"W_=;_\ 6=S</^"PG_-N_P#W5O\ ]YE7XIU^
MUG_!83_FW?\ [JW_ .\RK\4Z/HU?\F4X+_[N/_UK,^#QS_Y.GQ3_ -T3_P!9
MW*#]0?\ @DS_ ,G&>-/^R*>(_P#U.OAQ7VM_P5F_Y-S\%_\ 9:_#G_J"_$>O
MBG_@DS_R<9XT_P"R*>(__4Z^'%?:W_!6;_DW/P7_ -EK\.?^H+\1Z_"^.?\
ME+?@_P#[M_\ ]0L6?K/"?_*./$WKG'_J5A3^>BOM;_@G;_R>-\'_ /NH'_JK
M?&]?%-?:W_!.W_D\;X/_ /=0/_56^-Z_J[Q0_P"39^(G_9"\7?\ J@S _GG@
M'_DN^"O^RMX<_P#5Q@S^H*BBBO\ &D_T["BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#Q/]HK_DC?C'_N7_\ U*=#K\NZ_43]HK_D
MC?C'_N7_ /U*=#K\NZ_6N _^1/B?^QE6_P#47!G]2^"'_)*9A_V4.+_]5N4G
M;?#3_DH_@#_L=O"O_I]L*^F/^"G/_*-C_@H5_P!F._M9?^J%\?5\S_#3_DH_
M@#_L=O"O_I]L*^F/^"G/_*-C_@H5_P!F._M9?^J%\?5]+DO_ "=_PD_[+?A'
M_P!:C+3X3Z0/^\9;_P!B7,?_ $MG^.C1117_ &\G^=I_N(5_AWU_N(5_AWU_
M@'^PS_YRB_[PG_\ !</U3Q,_YDG_ '4O_= *_P!B[_@F-_RC8_X)Z_\ 9CO[
M)O\ ZH7P#7^.C7^Q=_P3&_Y1L?\ !/7_ +,=_9-_]4+X!K[_ /;=_P#)K? _
M_LO^(O\ UG:9R>&W^_9E_P!@E+_T\?Y6?_!3G_E)/_P4*_[/B_:R_P#5]>/J
M^':^XO\ @IS_ ,I)_P#@H5_V?%^UE_ZOKQ]7P[7^OOA-_P FK\-/^S?\&_\
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MOV3?_5]> :_U3/\ @IS_ ,HV/^"A7_9CO[67_JA?'U?@/[6+_E*;Z(GKE_\
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MRAJ'Q;_9Y_;2T;2K.PD\8S>*_A%I_C_6?V>=>\5:.FM?!_XQ3^#/%_AO6H?
MVI_$CQ1X<^(.E:;X:\41V^IZKI%KJ%UH6H:?'%>?KC_P0/\ '?QF_P""MO\
MP<6_%G_@J#XV\#V'@_3OAKX+\:?$3Q-9>&7OKOPKX-/BCX.-^RG\%OAQ+K-X
M8IM7\0S_  XFU*[?4I[2P7Q+<^!/%/B"WT?1HO+TRR_H'_X)Y?\ !8O_ ()Z
M?\%^O'OC;]AGQ1^PK++X:^'?PBN_CE:>%/V@_"?PI^(7PY.D>#O&'@?X?;?#
M^C6Z:I#X?\1Z3=_$?1FT>]L[.TE@T]M12TN[8Q^7-_0I^S_^S+^SQ^REX'/P
MU_9J^"?PQ^!?@.349M9NO#'PN\&:'X.TS4M;N((+:XUS68]%L[636M<GM;2T
MM)M9U:2]U.6TM+2UDNF@M8(XP#W*BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *_R!?^=IK_ +S_ '_P12O]?JO\@7_G::_[S_?_  12@#_7ZHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "ORQ_;@_8?^+'[2WQ
M7\/>._ GB'X>:3I&D_#S2?"5S;>+=6\26&HOJ-AXD\6ZQ-/!#H_A+7K9K)K;
M7K...22\CG,\=RK6R1I%+-^IU%?6\$\;9[P!GM/B+AVIAJ>94\-B,)&6+PT<
M51]CBHJ-5.E)Q3DU%<LK^Z?.<4\+93QCE,\ESJ%>>!J5Z&(E'#UI8>I[3#R<
MJ=JD4VE=NZMJ?ST?\.F?VC/^AT^"G_A1^.O_ )W%?H9^P;^R9\1OV7?^%J_\
M)_K7@K6/^$Y_X0;^R?\ A#]1UW4/L_\ PC/_  F'V_\ M'^VO#?A_P GSO\
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M%XN_]4&8'\\\ _\ )=\%?]E;PY_ZN,&?U!4445_C2?Z=A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!XG^T5_R1OQC_W+_P#ZE.AU
M^7=?J)^T5_R1OQC_ -R__P"I3H=?EW7ZUP'_ ,B?$_\ 8RK?^HN#/ZE\$/\
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MLF_^J%\ U]_^V[_Y-;X'_P#9?\1?^L[3.3PV_P!^S+_L$I?^GC_*S_X*<_\
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M&Q:?=^&]'2]\ >*C=R^)97:UT+^G_P#XA'O^",7_ $2[XU_^'\\;_P#QRO\
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M^-Z_J[Q0_P"39^(G_9"\7?\ J@S _GG@'_DN^"O^RMX<_P#5Q@S^H*BBBO\
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M '4O_= *_P!B[_@F-_RC8_X)Z_\ 9CO[)O\ ZH7P#7^.C7^Q=_P3&_Y1L?\
M!/7_ +,=_9-_]4+X!K[_ /;=_P#)K? __LO^(O\ UG:9R>&W^_9E_P!@E+_T
M\?Y6?_!3G_E)/_P4*_[/B_:R_P#5]>/J^':^XO\ @IS_ ,I)_P#@H5_V?%^U
ME_ZOKQ]7P[7^OOA-_P FK\-/^S?\&_\ K.9:? 8[_?<9_P!A6(_].S/]4S_@
MV\_Y0N_L:?\ =Q'_ *U;\<Z_AW_X.0_^4T7[9?\ W;O_ .LI? RO[B/^#;S_
M )0N_L:?]W$?^M6_'.OX=_\ @Y#_ .4T7[9?_=N__K*7P,K_ !#^@-_RM,^F
MG_WL;_[$3P:?I7%/_)$<.?\ =(_]5&(/P[K^XC_@S,_YR0?]V?\ _OT=?P[U
M_<1_P9F?\Y(/^[/_ /WZ.O[^_:B_\H*>.7_>,_\ U\/A\?*\$_\ )3Y9_P!S
MO_JOQ9\._P#!WK_RDG^"/_9COPU_]7U^TO7\K-?U3?\ !WK_ ,I)_@C_ -F.
M_#7_ -7U^TO7\K-?H'T!?^4-_H]_]F_P?_J=CCEXJ_Y*'-O^PI_^D0/ZIO\
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M /NH'_JK?&]?%-?:W_!.W_D\;X/_ /=0/_56^-Z_J[Q0_P"39^(G_9"\7?\
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MAW_X.0_^4T7[9?\ W;O_ .LI? RO[B/^#;S_ )0N_L:?]W$?^M6_'.OX=_\
M@Y#_ .4T7[9?_=N__K*7P,K_ !#^@-_RM,^FG_WL;_[$3P:?I7%/_)$<.?\
M=(_]5&(/P[K^XC_@S,_YR0?]V?\ _OT=?P[U_<1_P9F?\Y(/^[/_ /WZ.O[^
M_:B_\H*>.7_>,_\ U\/A\?*\$_\ )3Y9_P!SO_JOQ9\._P#!WK_RDG^"/_9C
MOPU_]7U^TO7\K-?U3?\ !WK_ ,I)_@C_ -F._#7_ -7U^TO7\K-?H'T!?^4-
M_H]_]F_P?_J=CCEXJ_Y*'-O^PI_^D0/ZIO\ @T*_Y23_ !N_[,=^)7_J^OV:
M*^XO^#S/_G&__P!W@?\ OKE?#O\ P:%?\I)_C=_V8[\2O_5]?LT5]Q?\'F?_
M #C?_P"[P/\ WUROX XQ_P"5V?A1_P!D!F/_ *X_Q*/J<-_R;?'_ /87#_U9
M8(_AWK]Q/^#;S_E-%^QI_P!W$?\ K*7QSK\.Z_<3_@V\_P"4T7[&G_=Q'_K*
M7QSK_3[Z6'_*+/TE?^S >,G_ *[KB,^+R+_D=Y-_V-<O_P#4NB?W$?\ !R'_
M ,H7?VR_^[=__6K?@97^5G7^J9_P<A_\H7?VR_\ NW?_ -:M^!E?Y6=?P#^Q
M6_Y19X^_[/\ \4_^NZ\*CZKQ&_Y'>%_[%5#_ -2\<?<7_!,;_E)/_P $]?\
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MP6 ESSIOD?//"RJ1MM&44];GXI_\$F?^3C/&G_9%/$?_ *G7PXK[6_X*S?\
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MHIL_>&BBBO\ )P_T4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#Q/]HK_DC?C'_N7_\ U*=#K\NZ_43]HK_DC?C'_N7_ /U*=#K\
MNZ_6N _^1/B?^QE6_P#47!G]2^"'_)*9A_V4.+_]5N4G;?#3_DH_@#_L=O"O
M_I]L*^F/^"G/_*-C_@H5_P!F._M9?^J%\?5\S_#3_DH_@#_L=O"O_I]L*^F/
M^"G/_*-C_@H5_P!F._M9?^J%\?5]+DO_ "=_PD_[+?A'_P!:C+3X3Z0/^\9;
M_P!B7,?_ $MG^.C1117_ &\G^=I_N(5_AWU_N(5_AWU_@'^PS_YRB_[PG_\
M!</U3Q,_YDG_ '4O_= *_P!B[_@F-_RC8_X)Z_\ 9CO[)O\ ZH7P#7^.C7^Q
M=_P3&_Y1L?\ !/7_ +,=_9-_]4+X!K[_ /;=_P#)K? __LO^(O\ UG:9R>&W
M^_9E_P!@E+_T\?Y6?_!3G_E)/_P4*_[/B_:R_P#5]>/J^':^XO\ @IS_ ,I)
M_P#@H5_V?%^UE_ZOKQ]7P[7^OOA-_P FK\-/^S?\&_\ K.9:? 8[_?<9_P!A
M6(_].S/]4S_@V\_Y0N_L:?\ =Q'_ *U;\<Z_AW_X.0_^4T7[9?\ W;O_ .LI
M? RO[B/^#;S_ )0N_L:?]W$?^M6_'.OX=_\ @Y#_ .4T7[9?_=N__K*7P,K_
M !#^@-_RM,^FG_WL;_[$3P:?I7%/_)$<.?\ =(_]5&(/P[K^XC_@S,_YR0?]
MV?\ _OT=?P[U_<1_P9F?\Y(/^[/_ /WZ.O[^_:B_\H*>.7_>,_\ U\/A\?*\
M$_\ )3Y9_P!SO_JOQ9\._P#!WK_RDG^"/_9COPU_]7U^TO7\K-?U3?\ !WK_
M ,I)_@C_ -F._#7_ -7U^TO7\K-?H'T!?^4-_H]_]F_P?_J=CCEXJ_Y*'-O^
MPI_^D0/ZIO\ @T*_Y23_ !N_[,=^)7_J^OV:*^XO^#S/_G&__P!W@?\ OKE?
M#O\ P:%?\I)_C=_V8[\2O_5]?LT5]Q?\'F?_ #C?_P"[P/\ WUROX XQ_P"5
MV?A1_P!D!F/_ *X_Q*/J<-_R;?'_ /87#_U98(_AWK]Q/^#;S_E-%^QI_P!W
M$?\ K*7QSK\.Z_<3_@V\_P"4T7[&G_=Q'_K*7QSK_3[Z6'_*+/TE?^S >,G_
M *[KB,^+R+_D=Y-_V-<O_P#4NB?W$?\ !R'_ ,H7?VR_^[=__6K?@97^5G7^
MJ9_P<A_\H7?VR_\ NW?_ -:M^!E?Y6=?P#^Q6_Y19X^_[/\ \4_^NZ\*CZKQ
M&_Y'>%_[%5#_ -2\<?<7_!,;_E)/_P $]?\ L^+]DW_U?7@&O]4S_@IS_P H
MV/\ @H5_V8[^UE_ZH7Q]7^5G_P $QO\ E)/_ ,$]?^SXOV3?_5]> :_U3/\
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M[SP_>:OH5W<:-=:IH>C:C<:=);37VE:=<O+:0_[3-?Y O_.TU_WG^_\ @BE
M'^OU1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5\._P#!3G_E&Q_P4*_[,=_:R_\ 5"^/J^XJ^'?^
M"G/_ "C8_P""A7_9CO[67_JA?'U?H'A-_P G4\-/^S@<&_\ K1Y:<N._W+&?
M]@N(_P#34S_'1HHHK_NX/YA/]Q"O\.^O]Q"O\.^O\ _V&?\ SE%_WA/_ ."X
M?JGB9_S)/^ZE_P"Z 5_L7?\ !,;_ )1L?\$]?^S'?V3?_5"^ :_QT:_V+O\
M@F-_RC8_X)Z_]F._LF_^J%\ U]_^V[_Y-;X'_P#9?\1?^L[3.3PV_P!^S+_L
M$I?^GC_*S_X*<_\ *2?_ (*%?]GQ?M9?^KZ\?5\.U]Q?\%.?^4D__!0K_L^+
M]K+_ -7UX^KX=K_7WPF_Y-7X:?\ 9O\ @W_UG,M/@,=_ON,_["L1_P"G9G^J
M9_P;>?\ *%W]C3_NXC_UJWXYU_#O_P '(?\ RFB_;+_[MW_]92^!E?W$?\&W
MG_*%W]C3_NXC_P!:M^.=?P[_ /!R'_RFB_;+_P"[=_\ UE+X&5_B'] ;_E:9
M]-/_ +V-_P#8B>#3]*XI_P"2(X<_[I'_ *J,0?AW7]Q'_!F9_P Y(/\ NS__
M -^CK^'>O[B/^#,S_G)!_P!V?_\ OT=?W]^U%_Y04\<O^\9_^OA\/CY7@G_D
MI\L_[G?_ %7XL^'?^#O7_E)/\$?^S'?AK_ZOK]I>OY6:_JF_X.]?^4D_P1_[
M,=^&O_J^OVEZ_E9K] ^@+_RAO]'O_LW^#_\ 4[''+Q5_R4.;?]A3_P#2(']4
MW_!H5_RDG^-W_9COQ*_]7U^S17W%_P 'F?\ SC?_ .[P/_?7*^'?^#0K_E)/
M\;O^S'?B5_ZOK]FBON+_ (/,_P#G&_\ ]W@?^^N5_ '&/_*[/PH_[(#,?_7'
M^)1]3AO^3;X__L+A_P"K+!'\.]?N)_P;>?\ *:+]C3_NXC_UE+XYU^'=?N)_
MP;>?\IHOV-/^[B/_ %E+XYU_I]]+#_E%GZ2O_9@/&3_UW7$9\7D7_([R;_L:
MY?\ ^I=$_N(_X.0_^4+O[9?_ ';O_P"M6_ RO\K.O]4S_@Y#_P"4+O[9?_=N
M_P#ZU;\#*_RLZ_@']BM_RBSQ]_V?_BG_ -=UX5'U7B-_R.\+_P!BJA_ZEXX^
MXO\ @F-_RDG_ .">O_9\7[)O_J^O -?ZIG_!3G_E&Q_P4*_[,=_:R_\ 5"^/
MJ_RL_P#@F-_RDG_X)Z_]GQ?LF_\ J^O -?ZIG_!3G_E&Q_P4*_[,=_:R_P#5
M"^/J_ ?VL7_*4WT1/7+_ /UXN4GK<"?\B3/O6?\ ZB3/\=&BBBO]^S\J/]Q"
MBBBO^ <_J@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#DO'WC?P
M_P##3P)XU^(_BVZ:Q\*_#_PEXC\;>)KU55VL_#_A31[S7=9NE5WB1FM]-L+F
M8*\D:DIAG0$L/X8O^""'_!4+_@KC_P %=/\ @I_\2/%_C+]H"X\#_L3_  AL
M/%/Q4^(OP0T#X=_"2\\(Z;I'C*XU;PW\%O@-I?BZ;P-:>/FNS=RW7B!O&MWJ
M,^MZQH_PP\2_;KZQU76[*1?[&_V\OA3XB^/'[#?[9OP.\(I))XL^,W[*'[1/
MPH\,1Q6_VN5_$/Q$^$'C#PAHJ1VIGM1<R-J6L6RI;FYM_.8B/SXMWF+_  &_
M\&6W[7OP<^#'[2_[5_[+_P 1_$FG^%/&_P"U?X7^"VK?!V\UN^M-.TOQ/XH^
M!]]\54U7X>6$]S+&9_&'B+2/BTVN>'--1?\ B96OA#7K6%VU%M.L[T _TH:\
MI^.WA7XE^.?@I\6O!GP9^)/_  ISXN^*OASXST#X7_%@^']+\5Q_#CX@:KX?
MO[+PAXUG\,:W;W>E>(+7PWKTUAJMWHU[ T6HVUM+:;HGE65/5JXCXE?$KP!\
M'/ 'C#XJ?%3QAX?^'_PX\ >']2\5>-/&GBK4K?2/#WAKP]I%N]UJ.JZKJ-TZ
M0V]M;PH3R3)+(4@@26>6.-P#^+C_ (-O_P#@M)^W1\??VY/V@/\ @G9_P48^
M(0^)7Q"T?1/'NJ> ?$6M>&O!'A;Q5X2^)7P6\26WASXE_"J9/ ?AOPSINO:?
M?Z2^M>);:YOK2:^T6Z\#ZK%#=7%GK2Q6']OU?Y;G_! [Q5?_ +87_!SOXD_:
MJ^'NG:K8>"/$OQ5_;]_:GUJPO(?L]YI?P^^,>A?%_1M MM:@M[RZA@EMO$_Q
MF\$V=Q";J^@CU$PI'-,XBN!_J1T %%%% !1110 4444 %%%% !7@DG[*O[+\
MWC(?$:7]F_X"2_$);UM37QW)\'_AZ_C(:BX=6U >)V\.G6Q>LLDBM=B^\\B1
MP9"&;/O=% !1110!X?9_LR?LVZ=XY?XH:?\ L]_ ^Q^)<MZ=1D^(=G\)_ 5K
MXYDU!@@:_?Q;!H":^]Z1'&#=-J!G(C0%_D7'N%%% !1110 5_D"_\[37_>?[
M_P""*5_K]5_D"_\ .TU_WG^_^"*4 ?Z_5%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E7QV^$/AK
M]H/X(?&3X!^,[[7-,\'_ !O^%7Q#^$'BO4O#%S867B73_#7Q*\(ZOX,UV^\/
M7FJZ9K6EVFN6FEZU=3Z3<ZEHVK6$%_';RWFF7]NDEK+ZK179EV88W*<PP.:Y
M=B*F#S#+,9ALPP&+HM*KA<;@ZT,3A<12;32J4*].%6#::4HJZ>Q,XQG&4)I2
MA.+A*+V<9)J2?DTVC^5G_B$*_P"";'_1;OVXO_#D_ 7_ .AHH_XA"O\ @FQ_
MT6[]N+_PY/P%_P#H:*_JFHK^L_\ B?OZ9'_20GB!_P"%F!_^8/+^KL\+_57A
M[_H4X7_P&7_R?]?-A7^'?7^XA7^'?7^GO[#/_G*+_O"?_P %P^*\3/\ F2?]
MU+_W0"O]B[_@F-_RC8_X)Z_]F._LF_\ JA? -?XZ-?[%W_!,;_E&Q_P3U_[,
M=_9-_P#5"^ :^_\ VW?_ ":WP/\ ^R_XB_\ 6=IG)X;?[]F7_8)2_P#3Q_E9
M_P#!3G_E)/\ \%"O^SXOVLO_ %?7CZOAVON+_@IS_P I)_\ @H5_V?%^UE_Z
MOKQ]7P[7^OOA-_R:OPT_[-_P;_ZSF6GP&._WW&?]A6(_].S/]4S_ (-O/^4+
MO[&G_=Q'_K5OQSK^'?\ X.0_^4T7[9?_ ';O_P"LI? RO[B/^#;S_E"[^QI_
MW<1_ZU;\<Z_AW_X.0_\ E-%^V7_W;O\ ^LI? RO\0_H#?\K3/II_][&_^Q$\
M&GZ5Q3_R1'#G_=(_]5&(/P[K^XC_ (,S/^<D'_=G_P#[]'7\.]?W$?\ !F9_
MSD@_[L__ /?HZ_O[]J+_ ,H*>.7_ 'C/_P!?#X?'RO!/_)3Y9_W._P#JOQ9\
M._\ !WK_ ,I)_@C_ -F._#7_ -7U^TO7\K-?U3?\'>O_ "DG^"/_ &8[\-?_
M %?7[2]?RLU^@?0%_P"4-_H]_P#9O\'_ .IV..7BK_DH<V_["G_Z1 _JF_X-
M"O\ E)/\;O\ LQWXE?\ J^OV:*^XO^#S/_G&_P#]W@?^^N5\._\ !H5_RDG^
M-W_9COQ*_P#5]?LT5]Q?\'F?_.-__N\#_P!]<K^ .,?^5V?A1_V0&8_^N/\
M$H^IPW_)M\?_ -A</_5E@C^'>OW$_P"#;S_E-%^QI_W<1_ZRE\<Z_#NOW$_X
M-O/^4T7[&G_=Q'_K*7QSK_3[Z6'_ "BS])7_ +,!XR?^NZXC/B\B_P"1WDW_
M &-<O_\ 4NB?W$?\'(?_ "A=_;+_ .[=_P#UJWX&5_E9U_JF?\'(?_*%W]LO
M_NW?_P!:M^!E?Y6=?P#^Q6_Y19X^_P"S_P#%/_KNO"H^J\1O^1WA?^Q50_\
M4O''W%_P3&_Y23_\$]?^SXOV3?\ U?7@&O\ 5,_X*<_\HV/^"A7_ &8[^UE_
MZH7Q]7^5G_P3&_Y23_\ !/7_ +/B_9-_]7UX!K_5,_X*<_\ *-C_ (*%?]F.
M_M9?^J%\?5^ _M8O^4IOHB>N7_\ KQ<I/6X$_P"1)GWK/_U$F?XZ-%%%?[]G
MY4?[B%%%%?\  .?U0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+\%_!G[//[//@S_A7WP?^'W_  D7_"(>$/\ A(O%?BS^R/\ A+/%>N^-]?\
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MV/\ @H5_V8[^UE_ZH7Q]7^5G_P $QO\ E)/_ ,$]?^SXOV3?_5]> :_U3/\
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M3Q%\-? 7Q4_9._:;M[*;Q7\5_P!C3PW\>=4L+.QNI[A)_$&M_"I?%^E^(/\
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M1J&K>(=8738[N^71=*>^BT'P^NHZDGA_2=+BU"\2;[;K^5+_ ((N_P#!:/\
M:[^)G[2US_P2D_X*J_L_^)_A5^W-X+\&:OKGA?XGKHECH^F?%_1O!NGW-YK=
MQXR\/Z,O_"+V.N76D:==Z_H'Q(^&5[J?PJ^(T%OJ\.EV'A*[TS2QXO\ ZK:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_P @7_G::_[S_?\
MP12O]?JO\@7_ )VFO^\_W_P12@#_ %^J*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;]UM*S::_P K/_B&\_X+1?\ 1FG_ )L1^RE_\_.OU3_X(F_\$3?^"G/[(O\
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MN_AMX]TSX6/%\%T\ ^.+S5U\7?$/4=;\-/H'@Z;Q+!X:AUJTT_7+>[\2PO\
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M5"S6KKH!\+_%&PO)XC<11K/:W7P_^SVUT(;F>%-0N;:...&^N9HP#_59HKY
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MZ#X:AMM>.G:UXBUOPWHO8_\ !TM_P13^+W_!0_P1\*OVK?V2/"$'CO\ :4^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ?[17_T*M'_$%3_P5-_Z+Y^P!_X=/]HK_P"A5K_3[HH _P P3_B"I_X*F_\
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MO_! []J_1/\ @X:O_P#@K->?%+]GE_V<)?BMXL^(UKX,MO$'Q)D^-LEOXB^
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M\;C16\.+XJD\ ^%=,\./KL7A]M5UUM$AU)M/-S!I3:UJK6$,B6IU"[,7G/\
M3-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%?SF_&_]
MO#]JWPA\:?B]X2\._%3^SO#_ (7^*'C_ ,.Z%I__  @_PWN_L.C:)XKU;3-,
ML_M5]X/N;VY^S65M!!]HO+FXNIMGF7$\LS/(WE__  \2_;&_Z+!_YC_X6_\
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MEBG\>^--'T<:CI6B>+EU7P_?:^ ?Z2E%?S<_\&X'_!:'QM_P5C^ 7Q2\-?M
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MU]J&A6.J?W-_\$X?^"@'P]_X*!_L(?!K]MJPATWX=Z3XY\*:G/\ $70=6UJ
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M/>%K:'QE>Z1X6O/!Y@UM-<TD _N HHHH **** "BBB@ HHHH **** "BBB@
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MB)\5OB+K-U-87^BV&I>$/A5HWA;X7?#:TU*Q72[O5?"_@GP]=:BUYXK\J/\
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M4ZO%;:;_ %[?M8_\%BOV6OV2OV#/@M_P4:\1Z)\5?B'^SI\<[_X2)X1;X?\
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MN1P-8)\6/BM^RE\1'L5W1K;Q^-_AGXP\5K9NF]_DMWU"-1&[R;7A0[F9 U?
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M:\/Q8\(?%#XK>#= \1W[6K)(^L6WAGX5> 5%Q.4NGM=/L&W%!%(W[I?L@?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#-O7VM16G_ !%'Q,_Z.)QU_P");Q!_\\"/]0>!/^B*X2_\1O)__F,^*?\
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M9W)O++5/#2ZYI^IV_AK4;&Y(FL;W08=.N;)XX?LLD0@A$?Z/T4 %?"_[0?\
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M'AZV%GH'@WP+X;T;PCX5T.S4EA:Z/X>\/V6GZ1IML"21!96<,0))"Y-==10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>!_$'Q(\/?!FS\$O<>"/"^H:=I.L^(-0\?\ Q*\&_"W0;:'5-6#V.FV<&O\
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M]%/P]_X>LM_^:3Q.BO;/^&=?C)_T)W_EP>%O_EY1_P ,Z_&3_H3O_+@\+?\
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MO$MOH_B?P]>7MB-9\)>,- ;4/#/BSP[J-S'9:WH^F>(-"OY&M[2Z/\9&K?\
M!O[_ ,%W_P#@D=\<?'?Q2_X(\_'@?%'P#XLWVJ1>'O%_PO\ "/CO4_">G3W]
M[H6F?&3X._'E+;X*>/M:\+1WU[;Z)K&C3^)[RXN;W5-1T#P]X4EUVZT- #\W
M_P#@M)_P1F_:1_X(Z_"3X.?%;7?^"@7C3X]P?%WXC:K\/8=$TG1?'GP[ET*7
M3/#-UXD.J2WUY\5_&*:A',EL;06B6MFT;.)OM#@&,_U@:!_P4%_;;_8[_P"#
M>[_@F)^T)^R[^SMXB_;9^.'C#P]\%/ACXK\*W/A3XI_$W5M.\ 3?#/XHZE/X
M[U2T^&0F\52+I.H^ O!OA4ZSJDPTT2^(K:*_N)=2O+%9OP9_:G_X)R?\'5/_
M  6#N_A]\/\ ]M/X>^"_"OPX^'>M7.N>&+CQMXF_9>^&_@3PSXDU2VCTF_U^
M]L_@U>^)_BCX@O)])G>(LNB>(]-L;2UN4T^UL[^Z>.__ +U/^"=G[,OB']C/
M]AG]E?\ 99\7:[HWB?Q;\#?@QX,\ ^*]?\./?2^'=4\3Z5IRMX@N?#TVIZ=I
M&IS:$=7FO$T:;4M*T[4)M-2VDO;*VNFEB4 _G5_X)K_\%Q_^"P'[67[;7P-_
M9^_:/_X)7:W\"/@E\0]1\86OC[XN2_ _]IWP?#X(LM$^'?B[Q-I.H3^(_'R2
M>$--BO?$>BZ-HS?VRH2].IC3K)X]2O+-U^AO^"@G_!KA^R3_ ,%%OVS?C!^V
M;\6/VAOVB_!GBCXQVOP_36?!GP\/PTM=!TJ^^'OPU\&?"W3KC3+[Q)X(\1:B
MUK?:!X(TV\O;.Z\Z8:Q=7T\%_'9-!I\'].5?Q6?M@^&_^#N?X!_M9?M&Z]^R
M)XIT3]H?]EGX@_&/XD^+/@MHYD_92\0I\//AWXH\77NM^ /!TND_%R+P?\3]
M(OO!7A6:S\)S0:?>ZSX2D>QN[V6YN[NZL+V@#^9[_@K3_P $ZOB__P &Z'[:
MW[.WQ(_90_:A\8ZC9>-]'O\ XC_!SQ\HMO"OQ+\,ZO\ #_Q#I%KXP\"?$+2]
M#N7\/>,_"5^-0\.3SO=:=8^&/'>CZUK7A'7_  :]GHM]/K?^JI^SU\2[OXS_
M  "^!WQAO]/ATF^^*_P?^&GQ*O-*MY&FM],N_'7@O1?%%QI\$K@/+#93:J]M
M%(P#.D:LP!)K^!OX9?\ !O[_ ,%GO^"L7[6?@S]H?_@MGX_7P#\-O";Z1IVL
MZ+?^,?A;JWQ$\1?#S3+Q-<_X5[\*/ ?P NKSX<?"[2/$-S>ZCI^M>(-5O?#O
MB32[R:^\03>&_$^JF"6Y_L8_X*AWO[=OPU_88\5)_P $K_!&@:U^TWX=U3X9
M:)\//"<UAX$DLK#P+;>)]&TWQ1!H>E?$+4-)\$O)IGA1)8(+74[E%MM*6[FT
MR-M2MK): /X3O^#KW_E.G^S5_P!D$_9>_P#5Y_%BO] [_@H_X7UCQQ_P3Q_;
MS\%>'9+B'Q!XP_8P_:C\+Z'+:Q74]U%K'B#X'^.=)TR2V@L0U[-<)>W<#0Q6
M:M=22!4MP92@K_.$_;/_ ."87_!S)^WU^T'X9_:A_:1_8^U?Q'\9/!WAGPGX
M2\.^(/#^O?LK^$["PT?P1K^M>)O#B'0-%^)$&BW=Q9:UK^I74D][9W#7:RQV
M]T)K>&.(?V@?\$3_ !K_ ,%O?B/??M,:;_P64^&6A>%/"\6B?#*V^"$(T'X&
M62ZY=:G-\08/B;8W-M\(]=UN/4+$:?%X/2[B\3VZ0@7$<>FLZSZFA /Y^_\
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M6UU&ULQJES!XB\/>*]5D\2&[OIKCQ'K8L]?UZXU'5[6.[KY)_P""ZW_!)O\
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M&==;Q5H.CWOC?0_^$6UWQ5>Z]X=T;^B'_@YB_8H_:/\ ^"RWP0_X)H_M#?\
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MX(^&\>A6'Q B^)>G6RVGB>'P!IVJ/JMQX2,VBRZO>VRZ;JR:=!)?_P!,=%%
M!1110 4444 %%%% 'RC^UO\ L-_LD_MW_#^/X9?M;_ ?P)\;?"EF;^31!XHL
M+BW\1^$[O4[46=_J/@CQMH=UI7C3P/JMU;+'%/J?A+7]&OY5A@$EPWD1;/4?
M@'\"OAC^S'\%_AG^S[\%_#S^%/A5\(?"&D>!O GAZ75-6UR;2_#VBVXM[."X
MUC7;W4=8U2Z;YYKJ^U&^N;NYN)99992S<>NT4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!_'1^T[_ ,'9O_#./[2G[0O[//\ PP'_ ,)E_P *
M'^./Q9^#/_"7_P##5'_"/?\ "5?\*O\ 'NO^"/\ A)/[ _X9PUS^P_[<_L/^
MT_['_MO6/[,^U?8O[4U#R/M<WAW_ !&9_P#6-_\ \W __)<K^5G_ (*<_P#*
M2?\ X*%?]GQ?M9?^KZ\?5\.U_P!97AY^S.^A'GG ' ^=YKX*?6LSSC@_AG-<
MQQ/_ !$CQ;H?6,?F&2X+%XRO['#\>T</1]MB*U2I[*A2I4:?-R4J<(*,5^$X
MKC/B2GBL33AF7+"GB*T(+ZG@':,*DHQ5WA6W9)*[;;ZNY_<1_P 1F?\ UC?_
M /-P/_R7*/\ B,S_ .L;_P#YN!_^2Y7\.]%?8?\ %+GZ"G_1C?\ SIGC#_\
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M/$,GAWPEK/ASQ?#H-CJFN6GA[5]&OM.O]-T;4A:>*9M6^QZ1=?@#_P &W?\
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M^RM\#/V3_A-;"/P3\$? .D^$+74&L[.QOO%&N*)-2\8^.M;M]/B@LAXD\?\
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M>QNO[>O^"SW_ "B6_P""CW_9F?[07_JN->H _DL^ _\ P>Q^+]=^+7PZT?\
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M^2(I7'\IO_!1#_@\A^ ?P(^)W_"K_P!A+X/:=^UI9>';Z_L_''QG\5^*-:\
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M#^]C]B#]HB__ &M_V//V8_VG]5\+VG@K5/C]\#OAK\6=2\(Z?J<VLV'AR_\
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M_0T4?\5=_H;_ /0Z\0/_ !!,=_\ -7]6]+G^H/$/_/O"_P#A5'_Y'^K>E_\
M.5K_ $:O^#0K_E&Q\;O^SXOB5_ZH7]FBC_B$*_X)L?\ 1;OVXO\ PY/P%_\
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MW=Y;17L5M>6=S):22K.D%U;3-&(YXF;^+_\ X@C/V/O^CT/VE/\ PE/A?_\
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M*#PU\++:>6 .#-'#<2:%=1P2O'N6.9[6Y2)R':"95,;?O[_P3-_X(K?L)_\
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MW]GV6L>)_#$5GXMO;@Z9=RSZ?/<'3]!\1W%G-&L6L1,?]/K_ (*1_L,>'O\
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M  DOA37_  CXKT/QMX7\1Z&VHP7%K]JT[7_#VGFZMIHQ#JFDRZCH]TPL]1N
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A%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>gwpjrhodncoa000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000004.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %5 ET# 1$  A$! Q$!_\0
M'P !  $%  ,! 0            <$!08("0(#"@$+_\0 9A   00" 0$$ P@+
M!Q (! (+!0(#! 8!!P ($1(3%0D4(187(C%7D9*5&4%14E9A8M/4U^$8&C(W
M=M'P(R0S-D)457&!E*&BM+72U24U<G-UE[&V"CA3P29'I"<T0T9D98*3H[+_
MQ  = 0$  04! 0$             ! $" P4&!P@)_\0 6Q$  @(! P(# P,/
M!P8,!0,% 0(#!!$ !1(3(084,2)!415AD0<6%R,R0E)5<9*4H='2TR0S5&*!
MX? V=+&SP=0T-4-38W)UD[*TM>(()7."HD1DPL/QHZ2E_]H # ,!  (1 Q$
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M$$$9!SK[Z?0O>F@"=9H01TY]1A<97^JNOC/!!G'O5A@??8<7&RMXJ*91AF'
MV/ ALKE6BKQ4-1R\=J19ZQ'1"09#5OYK\?> I-ADDW7:D>79I7S)&,N^VR.V
M CGNS568A893DH2(I3RX/+ZMX;\2KN*K2NLJ7T7".<*MM5'=E'8+.H&9(Q@.
M 9(QCFD?T0\\NUV&G&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FL/
MV#KZD[6I-HUOLBKA[I1+H'F +35C\-N>(-")[>6Y$27'<Q_V76'VE-R8DEMF
M7$>8E,,O(SU;5BE8AMU)I*]FO(LL,T3%7C=3D,I'T$'(8$JP()!QS0Q3Q/#,
MBRQ2J4DC<95E/J"/]!]0<$$$ Z_GD^E^]$%=O1]79_9.MF#%TZ3KH94U5[0Z
MER<7UB7G.+<CZ_O\AM'Q?PFJI:W4MQK%&;Q$F98/,/,ROI_P-XYK^)ZXJ6S'
M7WJO'F:$85+B*,&S6!^F> 9,1/)<Q$%?(O$/AZ7:)3/ &EV^1L(Y[M Q](9C
M^J.0]G'8X<=^(O/0M<QIQIJK'H@.3X+91^5%&+F1D$94&*U.FQH"GD)F/PX3
M\N Q+E,Q\N.1XKTZ&U(>2AIR7'0O+R+7+!6*!6<*Q168JI;!XAF"L54G +!6
M(&2%/H:C&1DD#(R0,D#WD D D#T!(SZ9'KKIYO+HAZ>ZK4^FV5I/J%OEJN?5
M!29FU*1%WO0=0]/6N*[K<&>V)6[)/ONSC'419!-<LL(AKLB^+!M0R4,]%EP8
M8\RNQS(0&1R&W>(MTGGW5=PVNM#7V>P*5EMNLW=TM2VY(ZLL25J<>UPO+$RV
MD#R%E,95F:/I*THW-K;:D:4C6N2R27HC/&+4->G"D"O/&YEG:[(J2!H&*H P
M<$!6ZA"&+IWHU^J<;%VJ5FAM<1ZWJ"O:WM=BMSNY=7-5,]7]R4H[?-1$->GW
M;2B!L-6S0X!Z'2QU1<*EC-@(":^U 04FXCMS%\6;,YI(LEHRWI;4,4 H7#-%
M+1L1UKRVHQ"6J^4DE#6'GX)'&KREBBYUA.S7E%ABL(2LD$CR&S (V2S&\M9H
M7,@$W75,1+'R9G94 Y'&KT?]%UU9UHD$%E1>J4R"4_;0TX]%WGJ:</UW)T&,
MA%=W^^83B6QX=26-4-$QD*Z2"\EMD<9*AP;*Y1<T(ASL<?C'9)4D='N$(M)H
MP=ONJUH;D[)M_E$,(:P;I5VKA 2Z))(0J1NRWOL=]"JLL&2; ?%JN1":BAK7
M782%8O+Y42ECA695&690?9<O1J[GUST_;FWM?K=J2LKTYL#6U/D4A_9^OYI6
M[ MHZZD[.JEYH1&%:WHMJ$6.K.!B=+@ V")"[#Y5AF@D.>X:UL#U?Q;0M[G0
MVZM7O3"_6MSBP*EE4KR4[0IS5[*-"&A>*8.MAI"BUV$2R8\Q"62;-9AJ6;4L
ME=/+301&+KPEI$GA,\<T1$A$BO'P:()R:52[*/M3@9.-]&V<M_0GJWJUUO?)
M5RV)?MBQ*F2T.Q44Q98NL&]L&M(UZW"+:FPR5&\R-ELT^N$1;E<&HA2+\$S@
M@YX79+POXKC@\1W-DMUE@JUJK3IN1G+!YHZ4>X2P/!TAT\5#/*CB5RPK2>QW
M]G(-F:3:H-PAE,LTLPC:H(\%4>PU5)%DYGGF<1H5X+@S)[7;O(G4CZ(Z\:LV
MW&U]I[;5&VE2Q.F*?L[86ZM@&:9H36%/.6S;.Q]+#ZJBS7F[NB2F+!=M;DH]
M(DM$&B5GB/NS&@T> ,FSDQ=I\;U[M$VKU*Q3G?<)Z=6A5CL;E<GC@I5+[3F&
MM7#ITJ]M#8!4I"0%,A9U766[L$M>P(:]B*>(5HYYK,K15((FDL35ECZDLQ5N
M<L+"(A@T@.0@"EM6CIK]$OO38FU)%8WP.BZ;IP"X;RUU84$=A:S#[),7;2.M
MS%PM,+65*-G)!;98FM%E5&/:CE+%'Q,8'8,E(4YV)&F3X%^[>-MMJTA-MKM?
ML25]NM1<:MMZB5]PMI!"UNQ'&$J/*@G,,<[Q.9(N#*&95:VEL-J:QT[2BM&L
MMJ%^4T"S-+5A:218(G?E.J-TQ(\2NH1^08J"P@;6W0#NNQW6GP+@#9"T6<'Z
M2]B7,Z+LM9E% VHNKZ[4>I:QLPR$J9)5++D\WD4MP-B+)G!'G,K.08[,>1W=
ME;\3;?%7L-!(9+*R;W5KQO#,$DO;'6L3W(7;B.,:>7<"3D%D ^UL21J+#M5E
MY8Q(G&(K0FE=7C++7W"2*.!U&22S=5?9P2A^[  .KC<_1];-Q9NH3.L#VL[)
M3]';"VB'F#3FZM2C-K0=:ZZVT]JB7LZW:]=LL&P@*L/+.C%'SI,.)@QH<ERP
M,1_<VE)'%L'B>GTML%R*Y%/N%6FZO'M]UZ36[5$75IP6A"T4LSH'Z4222,6
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M/""FIHD?=AXE=BT7O2NHAF)%=DF(;,V&M,R$]X5IUW:6O4G#05N;F(1B9BF
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MXTTXTTXTTXTTXTTXTTXTTXTTXTU=@)XY53@>S5DP3KUCKQ.": G@LZ2,,!3
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M*M(0HE5@DB*0.*@IQ<LQPNP>DJL2JP2UQK?1.K=3:GEZ?ZC]6PJ!7RNP3S4
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M)(<"2 =@68Y,D2^X-(H #C7R4\]LUP&G&FG&FI\Z>>H&R=.ECOUEK 8.:F;
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MHD5H1760B#2Q[29*E$YCI!7%GQ!/1G\;V;C/9J;"].2I618T94?:*UEX5D5
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MVEDEZA(=59=C'O\ 9CBF+)%+<EO0W!/-##(D?0@:*/I1,G&*2(],PM&%"*G
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M/LQ[#^+-W_-I?[WI]8NY?TNC^=8_@:?O63K.^7WIA^L]K?JQX^S'L/XLW?\
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MC33C33C33C33C33C36L/63_\N>P/^\J7_O:N<[?ZG/\ ECM'Y-P_],NZ\_\
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MJW7QSK7X5U)Z^+7S:5+0R<'C=,*?C;'V092!$:YK!2( #VB6*)EYY]@Q!7'
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MBY%(<.T!9%Q/'CN58K-=:<JQ%H)*$GF*(M47AIR4@@E79U@:N8I#B*K5HRH
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M<0NQW@SYNV;[-E![E0B$(CH+?U0H=8L &(I)N"N)-$2=?"2PX[V/)>S+)0Y
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MIVKK8$$3#$*?O 3MA=?TG3-@BQ1M]$*NG:BQ8CN5/10U@Q41=7FSBI.>1GV
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MIZMG<((UA%G<8*;4X:4T$6X35=G6-3;%ILSW)-F\JJJ6K32+/%#7=(?4Y?\
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MKW+#[@U7;=LNR-20PP5TBD-17?KRR;A QAK-=4]>NYIZ]O+&T36$;-.N8ZG
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MF8)8M%VDD0]:18+J<V.6]W&#M"BBX;\%Z"Y9];RA5L8F8?@WM@PCW..5\/\
MB298MLK[G:KB$[#%?ELR2"Q:9XH.M;FO2>;ZU)8T*%/,4FCLJW)+8E^T:IXF
M\)0O+NUK9Z=DSCQ)-ML-2*,UJ:QS6#!3AVZ+R1AOO(X=9!6W!9:I3#TFA_E
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M+6J3)<HV9-OJ5FC=YY%->O9W()&()3;/5*+U-T%_';JC^7U7_P![1>3/%?\
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M6Z+26$\U36.Q=AWFO/6&T!)<PP#;$L!DDZ >1JR2!ITD(S5=R\'4;FW35SM
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M=AI M,FFP$R"#LAJ1BPR!ZGDUJ&[&J)N Q((9C-2"L+(M'>DI6AN]KE99H(
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MU4Z"S.3C"VG7VFD2<8PI"EX[,\RB6%I&B62-IHP"\8=3)&KC*ED!Y*&&""0
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M$R".78ZV-#8-PW,D4ZK2*I >0E8XE)[X,DG%2P'?BI+X[A3D:D;'3!LCL_\
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ME*<82E*4X[,)3C'9C&,8QC&,8QC&,8[,<\1)))))))R2>Y)/J2?>3KW$
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MP\U2"05((."",$$>H(X]B->/E/XL?ZG\W'FA\!^O]FGE?F_5_P"W3RG\6/\
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M*6[>:JKD5ZQ"(@^Y:9@.<A&>[9/37.<!>P!9L^E>&MNAH;>+;JOF+"M))(0
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M29["8L2>Y$S-C0XS#[;6+9XA$5 )(9<Y."#\ZX ]D^X]Q\"?75FV7S?BDD/
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MUYMOVTI2W"18%"PS*)XUX]D#E@R+V^Y5U;C\%*CW=\&\K:^\Q\V>;OS!^?\
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M<XS[8CF<M8QG.5>#X+BO:YCGH^U;HURHC.Q,T0$<W<Y+*.SGN/YP88D #ER
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MM+M6>D2K/#L,>>'F6T#8 UT%EZB$DUZ<L@1?!6A-7EDX\%]N;/&,E"D<<^*
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MMRJ&SGV=BDMK3F2[CVX[&FVUX[KV.W2;[N;05# C$3604!!(*Q?\HV<GN0>
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M8(@!'E*YB21HRSL2XRP['.NNM)UN,JVOH&OW9$R<*A-]QF,N=+RR.CXF>O1
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M);$B*Z-R1U#*PSAE89!'M>A!SKS=ZKH[(R89&96!Y9#*2"/[""->GRG\6/\
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M(06N2R$@M?QE. # 2KK-D2HF8D<V0,CC,.S 1]AN::V>@3A,ZUE2+$EQ._\
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MH?:XC&./44=)\DG#(<-@L,KC&/\ 7H4ZA->7ZBW>IP'K?0S%OJM<P+9;ES$
MQV(=D*W-R0-'26W6\RJU"*0?6'0A2/,C3WG"IZ&P/A!W:[<*TG..4A6*L5)Q
M@L%)7!/<=QWQ_H[:M\12;E5EKV*RO/69XXYD&3TU+ .>*88@H3@GW^K8UD?H
M\ %B&E]HV-D4[&K%GFQ(BES!%M!PXS *23(@H=438AH^1/0/GVNU!K(V4"U*
M3'>'"I0F!/&R,NHIN0"F)>2DA<$ CV1VQZ>YNQ'SGXZR^&I'E6VZHRU^LPC+
MHZ!O:)?B'PP*OS1@RCVERI*L-:]=7Q3J3JFZ"$2'6)-DUA?91^%A\CYY*F8
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MW=6)+(QO9=V/33#4SQ81<@[%D198-22"?#<$QR@V;&Q'0)BS"6>UZ(^ER,W
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M((P[EE.4YPWGX?PL?V3[>/C_ +G&>S/X\JQ]KERMQSVS_;J9%3:5 [!L-W4
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M38)<5J/9R4GQ7_\ "QX9B^J8WB$^*=UH^#]YHP[S%MFVU+%?>98K4O1X)_\
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MY;EVWN%B2W>LS6K,S,\DT\C2.Q9BY[L3@<F8A5PJY(4 =M41%10J*J*!@*H
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M]"%LEV(1CO?$E./C_%C@YR?N?7W\<_KUU'EA\0/I_P!FO/S+\K_3RG?^K_\
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MPTS[@J4WXKF?X*,N*V5E*,9S\:LXSV8[<X3G/LRP1Z@C^S0;+<) ^U]_G?\
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M!]YDDZ^G+T=G0Q6^G2!FP-4V)1HS\I96" 5.69.3BCT""+\_M]A>C0UFSB!
MT:)B^K01044-AMQ 0,2T_-3*GI&%'T^OSYSGW>_Z-;/;-E%5![))/=F*^OO
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M\1^:-/*I^ /S-/4 G^"!_P#FT?\ -\<#\1^:-/*I^ /S-/4 G^"!_P#FT?\
M-\<#\1^:-/*I^ /S-/4 G^"!_P#FT?\ -\<#\1^:-/*I^ /S->UJ,)87AQD;
M":7CXEH882K'^+.&\9XX'XC^Q0/]&JBJ@]$'YFKEB?V8[,=N,8^+&%)QC'^3
MLY7#?A?_ (C5?+CX'Z#^W7[YCG^F4_S<8/Q_TC_0P&GEQ\#]!_;IYCG^F4?\
M/'$_'_Q?O:>7'P/T']NGF.?Z91_P\<3\?_%^]IY<? _0?VZR>F%WV;0$PRO*
M,OSV(KG9E.<+9DKPRZA2<8]N%(7GL[?X*L)7CL4E.<62+[#>_ S]][ORL?\
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MY7T&8J<"*YW)40V,FPBC,!R.YW:Y!^^/N^'O.![O>>VLJS4G4,EB%E(KD,K
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M60(/U4,7Z:H%/W##"GB4==;S:XA=TD2#R84)8NP[$#) (['O[9!/?W%<'O\
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MVJX6J;ONW584W'L6E%J8FS"P14#K[1-K>U./"60),JKX,0V#BB53X\%<5AR
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M@EC601RI,@<9"RQ'E'( ?OD;VE/WK $=P#K*>-9-;<]-?_5-H_\ $1_^S/\
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M6MAAIE2VT.OOH;4IM"<J0AZ3)>2C.<I2[(?<QC"W7,J?X_Q])U4 #N  ?3L
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M1/PAI]=GAS\;U/SG_<T]ZO8?X*%/H,_GN.HGX0T^NSPY^-ZGYS_N:>]7L/\
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M[+>;C1:=(DR'E80TPP64\\ZO/Q);;;$*6M6?N)QG/'#^M^K^_3J?-^O^[4Q
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M$(1AU>?[J7%^"S([<^U:\>%(7]M_L]G+@Q'SCX'_ &?#5I0'YC\W[-6>L:>
M!LHDEU>?3DY[R4OM^&.:SC/L[L/O+]85CVXSF4MQI7LSAA"L8SP6)^8?X]=4
M" ?.?[_\>_4N(0AM"6VTI0A"<)0A"<)0A*<=B4I2G&,)2G&,8QC&,8QC'9C'
M9RW5^O+C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C3
M3C33C33C33C33C341;H/V(/6 HRJLF,&;M>J914EQ-;DV=%:%6$W';LAXG&@
MW"D3Q$&-6V"\2/:H)F0_5#4T2?R!L;$!X'.G4(HI)I'F,9CKU[%GIO*(>J\4
M9,4:%H+"NQF,9,+1@31J\74B+"18]EW6-5C#<I98HN2H9."NX#NP$L14!.0$
M@8F-BK\'"E#;!O3AIB L=,E48583HZ4*)^ZFTX<L5HGFP]@IUOBGR)LFM^7*
M-*N&OZ=;)$WO-Y=L8" 6\-,IK"\W/NM]^:BP\4;JZ=&'$4*QR13P-$D: *(^
MA9G@"]_M4C)D@ZM6E64J3$KNI5NI)[<C.KQ2!V8]RW4ACD)_#0, #JD1TM=.
MC8Y A&E]>)&-B6@3<'%;@8C(#,U>%261J6O#[N(;=1'0*ZAG&.ZD3$8AXQX3
M:4XN.\;H6+F_:+ES(6ZK9,AF:P7SG[HSLTI/O=BWJ=4\A3X\?+0\>/#'!<<>
MF(N/IZ=-0@'N4 >[5P>Z<-#2'WI3^I:*[(DR9DQ]YP!"4X[*('=AV:=(6K+?
M:IV58-M;,,/KS[7"%YLDE6<N$Y&56C==R  %VR  J@"5L!5BJPJ,9]%BI5(P
M/<M>(>B#5?)5"237BR223P'<EYG)/SE[$['XF5S]\=?C/3=H2.ZR^QJ.B-/1
MGHC[#B*_"2MEZ 6UN=ANMYPWVI7&,Z>U:29SC^!,H57>Q\(5&R@=UW(@@W;)
M!# YE;N&2W&V>_OCO7$/]6S,/OSH*50>E>(8P>R#U#0N#^4-7@;/QBC/WHU0
M.=+?3H\/=$NZ7UXX-?%2 3T%5;@9C.AY=7,4F2-6UEONJAOU&P&ZZXSG'<4)
M*S8><>$^O&;AO&Z!Q(+]H.'$@82MD.)H[ ;.?43Q1R@^YT4CT&J>0ID<?+0\
M>)3' 8XF-HBOY#&[(?BK$'5U>Z=M%R"#Y5_5-'=)2BLPY(FK PU27C!"T62[
M3B3CN6^\J9*MMPM-B?>SGON%CY28K.79;N<V#=-Q"A!=L! BQA1*V B0Q5T0
M#/95@@AB ]R1HOHHU=Y.KDMY>+)8L3P7)9G>0GT]3))(Y^+.Q]3JD9Z9^GZ.
MB.VQI^@M-Q$QT1D(KT%*6$18FLH$9+>,-]B<,PM,:HBMXQ_!9U]548]@B+W+
MCN^YDDF]9)8DD]5LDEKC'/?WM?ND_/:F_#.J"C3  %:' QCV!VP(%'T"M7 ^
M AC_  1KTO=,'3S(BOP7]-Z^=B2H$\7(CKKL%33PXI7+U42,)Q&6^Q4>;6-G
M;"!2&\_!<&7*P158\,B_A0;ONBL&%^T&5E<$2MD,DM:=&'?L5FJ590?<\$3>
MJ#0T:9!!K0X(*D<%[JR2QD'MW!CGF0_U9''HQU<OW/&C?,?-O>JI'F?FWGOK
MWD,/UGSG%IQ=O,O%\/O>N>Z[&+'XW;W_ #?&)G;XOPN6_*FX\>'G;'#AT^/5
M;'3Z/E^&,_<]#[5CTX=M5\G4R&\O%D-SR$ //J=7ED??=3V\^O+OJVL],'3S
M'BL06--Z^:B1H$ 5'C(KD%+3(X76Z-3QT)M&&^Q,>%5]9:^ QVL?!;&4\!%3
MC#8YC";CN^YL2QOV269G),K9+O+9G9CW[EIK=J4GWO/(WJQU04:8  K0@!0H
M'!<!52*, #'8"."%!_5C0>@&O:_TS=/TIN2U(T]07FY:9"92'*]!4E],J+LZ
M#)PYC+?PL/P]T[9C.=O\)G85K1GV%Y/?#=MS&"+UD%<8^VMVXFFPQW]S;?2/
MY:L)^\&AHU""#6BP<Y' =\B<'Z19L#\DTGX1U6L]/&C(Y&.68U32&B<4M#.Q
MIS8&&F2R9@6BO7:$3;=PWWDS(MNJ=:L3+^,]]!8&-F8SXL5M6+3NFXE"ANV"
MC(T14R,08VAEKLA&?N3!-+$1^!(Z^C'513J@AA7B!#!P0@R&$B2A@<>HDC1Q
M\&12/35I9Z6NG...8$LZ7UXT,C"8H&/!16X"8S(:%5P=)B#&VL-]U,./4:T
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M-UW( *+M@ !0!U&P L=6%0._H(J5.,?U:T(^\7%32J$Y->(G).2@SDO,Y/\
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MD\RO&SO&RRNK1N^.;HP8%6? YLI!; R3C5Q53D%000 00#D#T!^('N!UY1@
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M@Y;G/^*:>VU)*R4:K5FZEQ'*LK5YX(WB\I+%G<]RE9N#2"2=F@CL#@\<*L)
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M_N6A2X:B)V%.;E1VTZ/P\=KCO[A):M4&ABFBZ*VZE3IVZQM,)WB%VO9CK@0
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M0RRPRPH-OEIRST[%DB-N;QK0FK2=<8G#QNI&...PO14F1 L<(7B&*J0QZBN
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MW'9\?VN:/6?6',7^K3)(N,,G/&?-K$=JC<D(.(EX$$]6FR"C<$T0'Q9$('F
M\,EPG'2K\1E1!"(+;BY#B&\S&H6D65I46'I5X+96>2.&22"R8^A)#'(RO/U%
ME1P(E=A&2Y 4$ZLZBD@ ELLR94%@&3/(,0"%P01[6._;UUF.<X3C*E9PE.,9
MSG.<XQC&,?'G.<^S&,?;SGD/5^L69N8*1=B.OFWG\V476!-OEQ\QG,1DA310
MN'@NHEYQX2WU30D]#D?&?$;0EMQ7P7,<E-3G6E'N!5?+2VIJ:-R'(SP10S2
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M21@#OZ:\RNR==@HKTTW?*8(AQA@LU(DDK.$@L,ASCK[ 0JX[)FMH0.,OQI+
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MY-OC,C6X6@K&)GD:1RRQV2:TG4FDG29RJG6-4DZ*1A$Y%9.9]DL)#@(W)@<
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MIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIJ!.IA YS4<]!1
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M7Y2)X&49\H!GIVO%-;^DG&?K;#^_'G"O?H!IK!X@)"'R@]L(<=<]N<.S2_\
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M^L>3F/2-"L9SCW"K\+UC'0/&?SCM<\+.TGV^USW&-N6C$G@M7"'Y1(Y],_\
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CTT=RSM(HD0-(IC/%&4AD*E)58JZX[:Z%<YC6XTXTTXTU_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>gwpjrhodncoa000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gwpjrhodncoa000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *7!9D# 2(  A$! Q$!_\0
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M?(RS15,W;KU04Y;Y#]X%:+#]G(M44Q)HY/NN#3Z"6FMPHHHH$%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4GTHZ]:6@!,>M+110 F*6BB@ HHHH 0@'J!43VT3]5 ^E344
M#3:V*$NGGK$_X&H/M%U:-B0%E_VO\:UJ1E5AA@"/0T[FJK/:2N5[>^AG.T':
M_P#=-6:S;G3 ?G@.T_W:AM]0DMG\JY!('<]11;L4Z2FKT_N-BBFHZR*&1@RG
MH13J1SA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !28]:!2T %%%% !1110 4444 %%%% !1110 4444 %
M5[FTCNDPPPW9AU%6**!QDXNZ.?26?2;C8XS$3T['Z5N0S)/$)(SE33;FV2YB
M,;CKT/I6'#-+I-X8Y,F(]?\ $4]SKLJ\;KXE^)T5%(K*Z!E.5(R#2TCC"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXWOK==TL(^\@XY/YBO-KJ\@T_P"/L,UY,D,<VG[5>1@H)V^I^AJGX>U"*_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN:MM4N+? )\Q!V:MNUU"WN^$;#_W&ZTFK'/5P\Z>O0M4444C **** "BBB@
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MFQR6=J"(%+',>>N&SFI= \'Z%X9WG2;!('<89\EF(^IYK<HH **** "BBB@
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M-AX@>Y DM5B81OSRV>F*O>+](FL_B%;ZQK,6HC3[FT199].)W1R!<$< G&:
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MC$_I6-*?WS_[QI8;5R9,NER;[2O_ #Q'YFD^TK_SQ'YFJV:"17786A.;I?\
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M:W::Q;AX)!Y@'SQYY6M*N&47%V>YNFFM#SV]\;ZKX.O%M?$UD;BU<XBU"U7
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M/_+_  ?G1_PKV;_G_M_SK3FI?S!S'"$5T-\N+'PO[W(_]"%;!^'<Y_Y?[?\
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M6FW.7O6*GJDDCL/[$;_H,C_OY2_V&W_08'_?RO/_ +%J7]R7\Z/L6I?W)?\
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MK'4VC53W/7J*S]+US3-9@$VGWL,ZD?P-R/PK0KF::T9J%%%%( HHHH ****
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M:Q-/V<_B6QVE%4M,OUOK8,>)%X<5=J3SIP<).+"BBB@D**** "BBB@ HHHH
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M5Y(Y+>-V &21S63_ &KI_P#SZ0_E770G+V<?=Z&;T9SOEGV_.FF,^WYUT?\
M:NG_ //I#^5)_:VG?\^D/Y5KSR_E%<I>&(F_X2*T/'#^M:GADV:>-/''VS&W
M*[O]WG/]*MZ!JMA)K,$:6L2LQP"!R*B\."PF\<^-S=;0F4#?[N#G^E>9C9-U
M5S)HTIK1LK?:/!@_Y9/_ -]&C[3X,_YY-^9K0%IX'_YZ?K3OLO@?_GH/SKJY
MX=IDV?=&;]I\&?\ /%OS-'VCP7_SQ;\S6G]E\$?\]!^=(;7P.?\ EH/SI<\.
MTPMYHBOI]!/P]UP:>NV,PMN'?/:N#N=2OSX,T& 0YC2(A3LZUZ+JL&@I\/\
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M !5+4[%;ZU*])%Y0^]7:*"H2<)*2.*LKJ33[T,01@[76NSCD66-9$.589!K
M\06&#]KC7@\/C^='A^_Y-G(?=#_2J>JN>CB(JO25:.ZW.AHHHJ3S HHHH **
M** "BBB@ HHHH **** "BBB@!,4<T9HY]: $+8IOF8ZBG$$TWR\]Z"E;J)YZ
M]P::;E1_":=Y ]333; _Q&@I<A&UX1T3\S41GN9>$4_@*E:S)Z,*C,5U%]TD
MCV-,T7)T&BRFE.97Q^IJS#90Q'(7<WJU5EOI8SB5,_A@U9BO(93@-AO0T:A/
MVMO(L4444CG"BBB@ HHHH **** "BBB@ HHHH *8T4;C#(I'N*?10!3FTG3K
M@8FL;=Q_M1@UF77@GP[=G,FEPC_<&W^5;]%4IR6S%9'%7'PM\.S'*)/%[+(?
MZU#;?#&QLA<BWO9OWT93YU!QFN[HK58FJOM$NG%[H\S_ .%874'AM=+@U")V
M28R!F0C.>U<]/\,/$,0)1;>4=MDO/ZBO;:*VIX^M37*MB71BSY^N/ _B2W&7
MTN8C_8(;^59EQH6K6O\ KM.ND^L9KZ4HKHCFU3K%$/#KHSY=>WG3AXI%/NIK
M>U=773_"6Y&'^ECJ/<5[_+:V\W^M@BD_WD!JI=Z'I=\(!<V,$GD.)(LKC8P[
MBBKF2J1MRB^KN][GCOB[_D8I^.P_E6'^%>Z7WA72=1F,T\#>8>K*Q%94WP\T
MQ\F.XN8_H0?Z5TT<RHQ@HN^AF\/,\>P?2D(/I7J4OPU!_P!5JC_1HQ5&7X;Z
M@H/EWL;^@QBNJ.84']HS=&HNAR/AC'_"0VG!^_4FEC_BL/'?'_+.NKTCP9J^
MGZO#<2@-&C<E6%4+'POK$/BCQ?=S64JV]Y'B!_[_ -*Y,17ISK1<64H2Y7='
MFN,D\TN/>MB7P]?P_P"LLYU^J&H/[.=1\T;CZBO852^S,V9VWW-&TX[U=-I@
M\YH-NH'?\Z?-(5T;%DI'PV\19)_U=4KBZL4\"^'EEL!(WDD;MY%:L$6WX:^(
MO^N=4+JSA;X?>&W,<I)A/(KR[WQ;O_6A=DX+U,#[7IW_ $#!_P!_#0;K3_\
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M\"4,#D9!%=WX7\9O'LLM38LO1)CU'L:X*^%^U Z(5.C/02 1@C(/45Y9X_\
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M.9?XAR/0]ZGKF/#UYY5RULY^67E?][_]5=/2:LS'$T?95''H%%%%(P"BBB@
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M!&0<BN247%V:-4T]A:***D84444 %%%% !1110 4444 %%%% !1110 4444
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MO.<PN1PI_N_A7')<W$[[MC''.:[8N/0\>M3J0DXRT:.ACUS6[79,^N7189)
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MXII(?WFF.H]I,U?U&O\ RF?]I8:]N;\ST6BN-3XC::V,VMP/RJS%X]TA_O\
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M10(**@>^M(W*/=0*PX(,@!%2HZ2('C974]&4Y!IM-"33V'4 8I.]+2&%%%%
M!114/VNW^U?9O.3S\9\O/.*:3>PFTMR:BBBD,**** "BBB@ HHHH **K#4+4
MWQLA,OV@+N,??%6:;36XDT]@HHHI#"D(# @C(/6EHH \^\;^&(=4TZXL)%&V
M4;X7/\#CI7@,&BW%O>3VMQ$4>-MDG'>OK/4[07=DZ@?.OS+]:\$^*%M<VD<=
M[;?+%*=DQ'7/:NW"5(J7OAF%.6(P_M(?%'1^G<X'4C")EM(I%VH?F?' _P :
MW/#WPYO-;"7EQ.UK;@Y3*?,P]<=JXV&4"ZC+<@,"17HFI^)M8OM!:+3MEG;;
M=GR@[R/9C6M6;G+0\FE!0C9G.^,-(T^RUE;#3KMYS!%F9W;=EB?NC'2H;&&/
M3HUD=0\A^Z,\9J 6UOI]MYEQ(SW3'/E#^9-56>X>99&!8$_*%Z"M:3Y-7N95
MDY^[T/4M#N&N=,BD?&XYSCZUIUSGA*<2:?(F?NOG\"*Z.O4B[I,\QZ.PZEIM
M+3$+2TE+3 *<*;3A0 X5GZUHT.L631L,3*,QOZ&KXJ05,DFK,J+LSQ.>2\TJ
MZDMYF*R(<$$5#-+<W062=CY?\*YZUZ1XST9+BW748T7S8N)"1U6O.YDQ=DLX
M=>BA>]>76C*#Y;Z'H4G&2YK:CQ(V5.W>_1!V%;6FZ=Y8WO\ -(W4U#IMG\WF
M.,N?TKI[.UX!(KMP]"WO2.#$XAM\D!MO9],BM2*V '2IH8  .*MK%@5UW.6,
M"NL-/\JK(2EV4B[%7RZ3;BK)2F,M 6*[5$S'UJ=EJNXH)9&TSI]UV'T-5I;Z
MX7E;B4'V8TZ4D50G:G9&;DT3'7]7A7$6I72#VE-5V\6^((CE-7N_QD)JG*:H
M3'K7/4A!]#HHU)KJSI].^(WB2&\C$^J2R0EL$,!_A7HL7B;5"JN+HL",C(%>
M#L^&VXSNX%>D>&;\SV(MIF'GQ#!&>HKGC2IM6Y5]QUNM53^)_>=Q_P );J8&
M,Q?BE/3QCJ*GYTA;_@./ZUSYI*?U:D_LH?UJLOM,Z?\ X3:Y_P"?2+_OHU)'
MXW?/[RS7_@+UR=)4_5*/\I7UW$+[1V7_  G$7_/D_P#WV*D3QM:$_/:RK]"#
M7$4E3]1H]BEF%==?P.]_X333O^>4_P#WR/\ &GIXQTMCAC*OU2O/Z2E]0H^8
MUF5?R/1_^$JTC_GY/_?MO\*EC\2:3(<"\0?4$5YG14/+Z?=EK-*O5(]3_MG3
M?^?Z#_OL4]=3L'^[=PGZ.*\HI14_V='^8M9I/K$]<^U6_P#SVC_[Z%*+B$])
M4/\ P(5Y%N;U/YTH=U.0Q'XU/]G+^8K^U7_+^)Z_O7&=P_.C>O\ >'YUY$UQ
M.\90S2;3Z,:YK4=.U2)C+9:A=%>NWSFR/UJ7ESZ2*6:+K$^@Z*^=M(\1:G9W
MOEZAJ]['$!PI8\GWK=EU/4WC-Q:^(YQ'[R9%9O R3M<U690:O8]LHKP8>-/$
M=H^U-9$WU4&HYOB/XIVYCO5XX!,8YI/ 5$KW0+,J3=K,]]HKY^3XH^+8MI>1
M'!Z9BZUH6_QCUJ([;FT@;'7 (-9_5:AK]>I'N-%>*2?&6_V_N[2//HPHB^-.
MI XDTV!_HQ%+ZK4&L;1[GM=%>6Z/\5KK4KAXI--CCVKD8<YK;7QZP^]9#\&J
ME@ZS5TA?7Z%[7.WHKCE\?08^:RD_!A3AX^M>]G*/Q%+ZG7_E']>P_P#,=?17
M*)X\T\GYH)E_"IQXWTD]Y1_P"I>%K+[+*6+H/[2.DHKG/^$VT<#+22 #N4JH
M?B3X:5]K7C#'?8:3P]5;Q92Q-%[21UU%<L/B)X8(S_:2_P#?)I__  L#PSD?
M\3-.?8U/LI]F5[:G_,CIJ*Y^/QOX=D^[J<7XU9C\4Z'*,IJ=N?\ @=+V<^S'
M[6G_ #(UZ*S!XAT@]-1M_P#ONG?V]I)_YB%O_P!]BCV<^S#VM/\ F7WFC@>E
M-**>J@_A5-=9TUNE] ?^!BI5U"S;I=0G_@8I<LET*4XOJ3>3%_SS3_OFCR8L
M$>6F#U&T<TS[7;?\_$7_ 'V*/M5O_P _$7_?8HM(=T/\J/:%V+@=!BCRH_\
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M_OD4GVRV_P"?F'_OL4?;+;_GYA_[[%%F',A?LT'_ #QC_P"^11]F@_YXQ_\
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MJUA?1NY',;':P_ UN5RM-.S-D[[!1112 **** "BBB@ HHHH **** "BBB@
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M[UZ7I]W;ZC;1SPR*T;CD@]*\ZU[.EWLD4@+6MU\Z'^X_<4[P7JSV>H-;.?\
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M.I*;]YFRBEL%%%%0,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNA;S9Q'>W5W.3]*V**F5>K)6E)CCAZ4'>,4F%4-8UFQT+3WO=0G6*%/7JQ]
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M%W.*'@FXSS=Q_D:L+X)7;\UV<^RUUM%0\;7?4M8"@NARJ>"H0?GNG(]A4_\
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MH **** $Z?2EHI.GTH 6BBB@ HHHH **** "BBB@ HHHH **** "BD9@HRQ
M [FLJ\U-F/E6V23QN']*+&E.G*;LB34=2$"F*(YE(ZCM6--X=N-5ML/=&!'.
M6P,L16M8Z7M;SKGENH7T^M:M7&3@[Q-*LH*#I0Z[LXN+X<:>K9DO+AQZ  5=
MC\!Z)&V2D[^S2<?I73T5J\77>\F>='!T([01C+X4T-""-.BR/4D_UJVNC:8N
M-MA;C'3]V*O45FZM1[R?WFJHTUM%?<1+;0(,+#& .P45(%51@*!]!2T5%V79
M(****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDLI)H;>S@=>55D+<?G6-;_%/Q-/.3-> +V6*-0/Y5R5U=0".40R/(\O!+#
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M9_:K]68?NXOF;W/85U]5+L=^.FHJ-&/0****D\X**** "BBB@ HHHH ****
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M5/ \KZ5/"23&H! QWS4Q^)G<Y7A%LQG<EB >.U:]DL TV57D<;R"3MX!K,,
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M]E L-K!'#&O147 J:BBN8T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+ITKIY855)Y&2:3![&000!1GYA3Y&+RECC).>*LK;1;PC%O,(SP.!5!<JLX
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MLG/K4T"Y(/I7M,/P;T=6S/>7,OX@5H0_"CPU"0?+G?V:0UF\QH+N7]1K-6/
M[E?G)R.33H1D"OHE?ASX67&=,1B.Y8U=@\&>'K;_ %>E6X^JYK-YG3Z)E_V?
M4M9M'S7<+D CMQTH@BE(XC<_137T\/#VCKTTVV_[]BK*:;8Q#"6<"CVC%2\T
MCTB-9<[6<CYB:SNVC^2"9OHAIR:1J;J-NGW)S_TR-?4"VT"_=AC'T45)@ 8
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MT%+112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'C_QK_X^=)_W)/YBO*:]6^-?_'SI/^Y)_,5Y37T6!_@1/$Q?\9A3A2 $G &2
M>@KT[P+\-9+[R]2UJ,I;_>C@/!?Z^U;5:T*4>:1E3I2J.T3%\%^ ;SQ+,ES<
M!H--4_-)_$_LO^->[:9IEGI%C'9V,*Q0QC  [^Y]35B&&."%8H45(T&%51@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /(?C5_Q\:3_ +DG\Q7EUO;RW4Z001M)+(=JHHR2
M:]=^*VDWNLZOHMG8P-+*ZN,#H.1R:Z/P9X$L_#%NLTH6?4&'S2D<)[+7LTL5
M&AAHWW['EU</*K7=MC%\#_#6+31'J.LHLEYU2 \K']?4UZ2  , 8 HIDLJ0Q
MM)(P5%&23VKRZM6=67-(]"G3C3CRQ'UY5X_^*4>G^9I>A2+)=<K+<#E4]AZF
MM+7KCQ+XQWZ?H,36&EGY9;V;*M*/11UQ_.I/#WPET+2 LU\&U&Z'),O" ^R_
MXU<(PA[U3[@DY/2)XMI7AK7_ !3<M+:VDTY=LO._"Y]V->G^'_@M:PJDVMW1
MGDZF&+A1^/>O5H88K>)8H8UCC48"J, 4^JGBIRTCH*-)+<HZ;H^G:1 L-A:1
M0(!_ O/YU>HHKF;;W-0HHHI %%%% !1110 4444 %%%% !1110 A (P:@=2I
M]NQJQ2$!A@T#3L1I)_"QY]:EJLZ%.O(]:?'+_"WX&@IQZHFHHHH("BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHK'U/5Q%F&W.9.A<=%H2N:4Z<JDN6))JFJBU4PPD&
M8]?]FL*SLYM0N2!G&<NYIUG8S:A,<$A<_/(?\]:ZJWMHK6%8HEPH_6JV.^4X
M86/)#606]O';0K%&,*/UJ6BBI/-;;=V%%%% @HHHH **** "BBB@#C-2\!M)
MK,NJZ/J<NG7$W^L"#*L:>W@5;K1I[+4=2N+JXED$@N'ZHPZ8%=A2=ZW^LU;)
M7V.?ZK2NW;<XJ#P+=3WEI)K.LRW\%HP,,)4 <=,UKGPT/^$T7Q"+C&V#R?)V
M^V,YK?HI2Q%1]>EAQP]..RZW,'3?#8T_Q-J>L?:-_P!M4#R]OW<8[_A6#?>&
MO^$?\(^)&%P9OM8:7&W&WVKO*1E5U*LH93U!&0:<<1-.[\OPV"6'@XV7G^.Y
MY;H/@BZUCPQI^_69TTZ91+):XR,Y[>U=7X@\&P:OI]C;VT[6DECCR)%&<8KI
MU544*BA5'0 8 I:J>+J2GS)D0PE*,.5JYQFG^!9;7Q#9ZS<ZM-=W, ;>9!][
M*D#'H.:DU#P9<3>*&UJPU1[.24 3*JYW 8_GBNOHJ?K-6_-?I;Y%?5:7+RVZ
MW^9Q3^!KF/4;Z6QUB2VMKXDS1A 3SZ&K%OX(BB\&S^'Y+IG61RXE"\@YR.*Z
MVBAXFJTM>WX L+23>G?\3B#X%O)O#;:1=ZP\RB1&B8IQ&J]A5W6O!HU)K&ZM
M;U[2_LT").@SD#U%=511]9JWO?\ IA]5I6M;^D<MHGA!K#5Y-7U&_>_U!TV"
M1EP%'L*FT/PM_8YU4_:?,^WNS?=QMSG_ !KHZ*4J]25[O?\ 0J.'IQM9;?J<
M9%X B7PI<:))>,WF3&990N-I^E0MX$OKF;3Y;_6GG:Q=3&OE@*%';Z\"NYHJ
MOK57N1]4I::&!:>&_LOBV\US[1N^T1A/*V]/QK?HHK&4Y3U9O"$8*T0HHHJ2
M@K!\2VX>&.;'3Y3]#6]5'5XO-TR88Y4;A^%-;F^&GR58L^9-4M'M/$MU9XV@
M2DK]#S3KU<V^W+<>M;WCN$6WB"WNP,;XQD^XKFKZ]\R,,6! Z 5]?A)\U&,F
M?+YE0=/&2@MDS(M4VW!-='#D6997]L5S]CF2X)KJ[2V!M&4N!N.:*>SL<>,G
M:USFX[/S;WGN>M='/I%ND00ABV.6["LK<$O2!U#5NWURDMH&$H4  L.]*$48
M5ZE1RA;8Y:6V6"YQZ'%=1H[_ /$OD82G<H^Z*Y"ZOM]SNZ<UNZ+=1?9Y@\ZJ
M77 !J5:[2-<73DZ2;*$LP.KY;DDUU(F!TJ4K.0R(2$%<7.__ !-1M(;#=1WK
MK(%C^Q2&24*70KC'2LXKWC/$P24+G+LAEE9V8DDY)K<MK5H0( TQ+(&+*<!<
MUEG"RLBX;'0^M=#!<PW%J"9/+*(!( N2<5<'9LNM4:CH<9JEL]IJ,D;'<0W7
MUJ^OS:,["Y?>O/ECH*JZW<BYU)Y , GBIX!;KITFZ<AG&" OW:E?$SNNW"+9
MBY.^MBPNK:.!XGC<[\9(/>LA@!(<'(]:L01.S9"G K%-W-II.)9W[+O<O'/%
M=/J4Q7P_'+'<R2$MM;)X'%<J_P#K<=ZZ*5;<^'EC,TF-VX-LXSCI5+H<\DKJ
MYS-LP^TY9MHSUK1U@((+8QW$DJ.#DM60%S-CGKSBM;4!;C3[95>;<@.W<F W
M-(W:]ZXZPAC;?*SL!!&9/EZFKLT#/IQN"SJ0P_=NV>O>JNEW!BFYB9Q)&4(5
M<GZU:NI!#:/ !,6D8,SR+BCH8SO8L:-H]J=/:_NH9;EFF$4<,9QD^IIGC#1K
M;3H[.XM25CG!S&6SM(]ZVO!W]H7MG/IT-A>-&YW+/#']WUY-;VI_#77-9M;*
MS@B2VM[8'#W#Y8D^H%82JQC+WG8Z(PE*UD>>:';1O;S;IY5DVEE1>!]:RPDG
MVY1NW,S=37N6@?!^"PBSJ&H/-(5VD1+M'/UKH['X;^&+"02+IXED'1I6+5G/
M'4DK+4J&#K.3<M$SQX:7/=I)8P0S%0-K2 DY;'3%1>'O &O75WF33IHXQG#O
M\M?1D-I;6XQ#!&@Z_*H%35A/,I/X8ET<K48N,I;]CQN+X1:AJ"JU[=I;8;[@
M8OQ726'PGTFV4"XN9Y<?W?EKT"BN>>-KR>]CKC@:$5:U_4YRQ\">&[!@\>F1
M/(#G?+\Q_6MV&SMK<8AMXHQ_L(!4U%<\IRE\3N=,81CL@HHHJ"@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO"E'DH_>-AAC@B$<:A5'84^BBI.!MMW84444""BBB@ HHHH **** "BBB@#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "F21+(.>#ZT^B@$[%)XVC//3L13H[@KPW(]:MD9&#5>2V!Y0X/I3-5)/21
M,KJXRIS3JSSOB;NIJ9+O'$@_$46$Z;Z%JBFJZN,J0:=2,PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **CEFCA7=(X4>YK+N=: ^
M6W7/^T::5S2G2G4^%&K+-'"FZ1PH]ZQ;S6F;*6PVC^^>OX50)N;Z7^*1C^0K
M4M-$48>Y.3_<'2G9+<ZU2I4=:CNS+@M+B]D)4$Y/+M6_9:;#9C=C?)W<_P!*
MMHBQJ%10%'0"G4FS&MB95-%H@HHHI',%%%% !1110 4444 %%%% !1110 44
M44 >:R^!)M4^*&IZCJVF13Z+<6H1'=U.7^7^'.X'@\XKN-(T#2]"M&MM,LHK
M:%CEE1?O?7UJRNHV;W[V*W,1NT7<T(8;@/7%6>] '-3> /"L]\;V31;5IRVX
MG;P3ZXZ5N7%A:7=A)83P(]K(GEM$1\I7TQ5FB@#&A\)Z%!HTFD1:;"MA(<O#
MC@GUJ[INE6.D6"V-A;)!;+G$:#CGK5RB@#F)_AYX4N+MKJ31;8R,=S8& 3[C
MI6K=>']*O9;*6XLHG>RQ]F)'^KQTQ6E10 5A:CX,\/:MJ/V^^TN":ZXS(PY;
M'KZUNU6;4;);];!KJ(7;+N6$M\Q'KB@#-7PCH*Z9<::NF0"SN'\R6(+PS>M3
MW_AW2=4TR'3;VQBFLX2K1Q,.%(&!C\":U** ,K6/#6CZ_#'%JEA#<K%]S>.5
M^AIEAX5T/2[R.[L=-@MYXX_*5XUP0OI6Q10!1U;1]/URR-GJ5K'<P$[MCCH?
M7ZUD_P#"(:7I6AZC;:)IT4,US"R?+U<XX!)KI** /-/!?PTL(O#MLOB71+<Z
MC$['YF5SC/&2I(-=_=Z3I]_I_P!@NK2&6TP!Y3*"H Z<5<HH P-*\$^'-%O!
M=Z?I<,-POW9!DE?IGI2ZMX,\/:Y<_:=1TN":?_GIC#'ZD5O44 9MMX?TFSTE
MM*M["!+%L[H ORG/7(K+B^'WA2&)HH]$M0K,&/R]QTKIJ* $50B!5&% P!22
M'$3'V-.JMJ$GDV$S]PAQ05%7DD>*?$0[XK1<9S(QKCKN$#2ON\@UTWC^X_TV
MUA!^ZA;]:Y&^GSIQP2<]37U& 5L.CQ<\;ECW;I;\C#TT8NF&,BNFAC<VK@(>
M>E<OI;$W#5UL&PV;,-V\<9K;#_ >=C7:1R[*5U+IWKJ4B<Z;)A0-R\<US3?\
MA%A[UTOR-I4F%;>%ZTJ74C%-M0^1ST,I6=D)QS6[%J)N+9B\+MY(^\&P/QKF
M!G[5[9K7TX2-!=1Y<ILR!VS3IN]S2O3C:[,^[O7N-0\QSR3T]*ZRPP;&5FDB
M4/&5&6P<US-GX?U75;[R["QGG;/\*' _&O2M&^$.LWD:'4KF.SC[J/F:N6>(
MA3D^=FE3!RK1BJ:.)B4B1TW D<9!XKL-+L[C5HD6RB8N%"OA23Q7HNC?#/P_
MI(5GA:[E'\4YR/RZ5UT-O#;QB.")(T'144 5Q3S&*^!7-?['E4_B2MZ'DT/P
MUU?4KTW%T\-I$2,!CN8CZ"NUM_ NE(BBZ5K@@#.XX!Q["NHHKBJ8RK/K;T/1
MI9;AZ=O=OZE.TTG3[ ?Z+9P1>ZH :N445S-MZL[4DM$%%%%(84444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "
M%0PP1FJ\EH#RAQ[&K-% U)K8S61XFR00?44]+N1>OS"K_7K4#VL;\@;3[4[F
MJJ1?Q($NHVZG:?>I@01D'-47LY%^[AA4'[R(_P 2T6'[.,OA9K45FK>RKUPW
MUJ9;]?XT(^E%B72DBY14"WD)_CQ]:D$B-T=3^-(S<6MT/HHHH$%%%% !1110
M 444QI8U'S.H_&@+-CZ*K-J%LO\ RT!^E5I-7C _=HS'WXIV-(TIRV1I4A(4
M9) 'O6')JUPWW=J?09JJ6N+EL$O(3VZT6-XX27VG8VYM3MH?X][>B<UFSZQ,
M^1$HC'KU-)%I-Q)@OB,>]:$.D6T1RX,C?[72GHBK8>GYLQ%CN+R3Y5>1O4]*
MTK?1,$-</G_97_&M=5"C"@ #L!2TKD3Q<WI'1#(H8X5VQH%'M3Z**1S-M[A1
M110(**** "BBB@ HHHH **** "BBB@ HHHH **** //+&^T[_A<.IVR:8JWR
M6>]KO><L,#C'2LJ'XLZQ?V%U=:=X9>X6S=A<2"3"(HZ?4U;L+"\7XW:O=M:S
M"V>QPLI0[2<+QGI5'P#IE];_  _\303V<\<TL\NQ'C(9OE[#O0!TLGQ(L(O
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MQGZ5V5%>;4QM:=];+R/6AA*45JK^I%!;06J;+>%(E]$7%2T45R7N=.P4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)T/UI:* "BD]J6@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *S=5OQ;0F.,CS6_05-?7R6D
M9 .9#T%9NGV3WDWVJXY7.0#W--+J=-&FDO:5-E^)/HU@8E^U2C]XP^4'L*UZ
M.@P**3,JE1U)<S"BBB@S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BHIIUA7)Y/I65,U]?-MB)5/;@?G0!ISWEK;\33QH?1F
M&:J'7]+4X:]C'YUF_P#"."0GS[H*>I"C--?P992K_P ?,V3W&/\ "@#;M]4L
M+MMMO>02-_=609_+K5NN#OOAX[ M:7PW=A(N/U%84M]XM\'R@S;YK4=G.]"/
MKU% 'K-%<QX9\;Z=XB'DY^SW@ZPN>O\ NGO73T %%%% !1110 4444 %%%03
M744(^9LGT% TFW9$]9U[J:0@I%AG[GL*@ENKB\;RX5(4^G]:L6FF)"=\N'?L
M.PIV[G0J<:>M3[BI9Z?)<R>?=9VGD ]6K: "@ # '0"EHH;,JE651ZA1112,
MPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I":
M6DH @\@.VY^GI3KF9;2TEFP,1J6Q]*FK@/&?B.)+Q+-9)!#%N$V!P6QP*:5R
M9245=F+>>)FU.QOYFNS#G((0\H,\5H6'C1+*"VMWN?W31#9+)W/UK"TB\TZZ
MM&6".%D<%9@1DGZU;U'0-,UFRM;=866"(X8Q':5K2QQ<[3.\T;Q+;:E;H3(I
M8G;D'J:W)(XYHRDB*Z,,%6&0:\;LO#T=C=VT6DZL$AC?]\DAWOC/4>G%>QP!
M1 @1MRA1@YZU$E8Z:,W):GEWC7X?R6@;6/#^]'B/F/"AY7W7_"M?X>>/!XAA
M_L[4&"ZE$N0W3S5]?K7?=:\.^(^A7'@_Q';>)=('E0R2[B$Z))U(QZ&I-CW#
M.*3>M9GA[6(/$&@VFIPXQ,@+ ?PMW'YUI&-30-6%\Q/[U(9HQ_%33 I[FD^S
M)ZF@KW0:ZC7N3^%0/?8X1/SJ?[+%W!/XT]8HT^Z@'X4QIP70SV-W<< $*?PI
M\6FC.Z9L^PK0HHN-UI6M'0:D:1KM10H]J=112,@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7'_?% ';45Q7_"T-!]+C_OBC_A9^A?W;C_OB@#M:*XK_ (6?H7]VY_[XI?\
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M ,\V_.C^V(_^>;?G0!IT5F_VQ'_SR;\Z/[73_GDWYT :5%9W]K)_SS/YTO\
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M_P#0-'_?Q_\ &NCHH YS_A!/#?\ T#A_W\?_ !IZ^"/#J# TU#]68_UKH**
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MP?XC_M']*11V/A30H_#GANTTU -T:9D([N>IK7F:18)&B7=(%)13W..!3Z*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?Q%XHCETSP]>^'W@L(8BAN75@1@9'M7K=% 'EWB/Q_XM\/Z_>VB^&C=V8?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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7 HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>41
<FILENAME>rlay-20201231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Instance Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-25T16:08:59.0359913+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : b6984381c2ae479bb023a8d6e22330cc -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xbrli:xbrl xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:rlay="http://relaytx.com/20201231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="rlay-20201231.xsd" />
  <xbrli:unit id="U_iso4217USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_xbrlishares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD_xbrlishares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U_rlaySegment">
    <xbrli:measure>rlay:Segment</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_rlayAgreement">
    <xbrli:measure>rlay:Agreement</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_xbrlipure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_rlayTarget">
    <xbrli:measure>rlay:Target</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_utrsqft">
    <xbrli:measure>utr:sqft</xbrli:measure>
  </xbrli:unit>
  <xbrli:context id="C_0001812364_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_20200720">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_20210323">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-23</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementClassOfStockAxis_rlayUndesignatedpreferredstockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rlay:UndesignatedpreferredstockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementClassOfStockAxis_rlayUndesignatedpreferredstockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rlay:UndesignatedpreferredstockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210101_20210131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:GenentechIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_20200720_20200720">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-20</xbrli:startDate>
      <xbrli:endDate>2020-07-20</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_20200708">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_20200707">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-07</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_20200708_20200708">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-08</xbrli:startDate>
      <xbrli:endDate>2020-07-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapCreditFacilityAxis_us-gaapLetterOfCreditMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapCreditFacilityAxis_us-gaapLetterOfCreditMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:GenentechIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rlay:GenentechAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapPropertyPlantAndEquipmentByTypeAxis_rlayLaboratoryAndComputerEquipmentMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rlay:LaboratoryAndComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_20200701_20200731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-01</xbrli:startDate>
      <xbrli:endDate>2020-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapFairValueByAssetClassAxis_us-gaapInvestmentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapFairValueByAssetClassAxis_us-gaapInvestmentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapFairValueByAssetClassAxis_us-gaapInvestmentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapFairValueByAssetClassAxis_us-gaapInvestmentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapFairValueByAssetClassAxis_us-gaapInvestmentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapFairValueByAssetClassAxis_us-gaapInvestmentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapFairValueByAssetClassAxis_us-gaapInvestmentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapFairValueByAssetClassAxis_us-gaapInvestmentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapFairValueByAssetClassAxis_us-gaapInvestmentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapFairValueByAssetClassAxis_us-gaapInvestmentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapFairValueByAssetClassAxis_us-gaapInvestmentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapFairValueByAssetClassAxis_us-gaapInvestmentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneYearOrLessMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">rlay:InvestmentsWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneYearOrLessMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">rlay:InvestmentsWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneYearOrLessMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">rlay:InvestmentsWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneToTwoYearsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">rlay:InvestmentsWithMaturityOfOneToTwoYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneToTwoYearsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">rlay:InvestmentsWithMaturityOfOneToTwoYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneToTwoYearsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">rlay:InvestmentsWithMaturityOfOneToTwoYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneYearOrLessMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">rlay:InvestmentsWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneYearOrLessMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">rlay:InvestmentsWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneYearOrLessMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">rlay:InvestmentsWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rlay:GenentechAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:GenentechIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_us-gaapTypeOfArrangementAxis_rlayStandAloneSellingPricesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rlay:GenentechAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:GenentechIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rlay:StandAloneSellingPricesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_srtProductOrServiceAxis_rlayLicenseAndTransferAgreementMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_us-gaapTypeOfArrangementAxis_rlayStandAloneSellingPricesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rlay:GenentechAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:GenentechIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rlay:StandAloneSellingPricesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rlay:LicenseAndTransferAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_srtProductOrServiceAxis_rlayResearchAndDevelopmentServicesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_us-gaapTypeOfArrangementAxis_rlayStandAloneSellingPricesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rlay:GenentechAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:GenentechIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rlay:StandAloneSellingPricesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rlay:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_srtProductOrServiceAxis_rlayTransferOfActivePharmaceuticalIngredientsMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_us-gaapTypeOfArrangementAxis_rlayStandAloneSellingPricesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rlay:GenentechAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:GenentechIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rlay:StandAloneSellingPricesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rlay:TransferOfActivePharmaceuticalIngredientsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_srtProductOrServiceAxis_rlayLicenseAndTransferAgreementMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rlay:GenentechAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:GenentechIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rlay:LicenseAndTransferAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_srtProductOrServiceAxis_rlayResearchAndDevelopmentServicesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rlay:GenentechAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:GenentechIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rlay:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_srtProductOrServiceAxis_rlayTransferOfActivePharmaceuticalIngredientsMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rlay:GenentechAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:GenentechIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rlay:TransferOfActivePharmaceuticalIngredientsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_srtProductOrServiceAxis_rlayResearchAndDevelopmentServicesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rlay:GenentechAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:GenentechIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rlay:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_srtProductOrServiceAxis_rlayTransferOfActivePharmaceuticalIngredientsMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rlay:GenentechAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:GenentechIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rlay:TransferOfActivePharmaceuticalIngredientsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapPropertyPlantAndEquipmentByTypeAxis_rlayLaboratoryEquipmentMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rlay:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapPropertyPlantAndEquipmentByTypeAxis_rlayLaboratoryEquipmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rlay:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20200708_20200708">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-08</xbrli:startDate>
      <xbrli:endDate>2020-07-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtRangeAxis_srtMaximumMember_20200708">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200708">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapSubsidiarySaleOfStockAxis_rlayUnderwrittenPublicOfferingMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlay:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapSubsidiarySaleOfStockAxis_rlayUnderwrittenPublicOfferingMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rlay:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_rlayEmployeeStockPurchasePlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlay:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapPlanNameAxis_rlayEmployeeStockPurchasePlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlay:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapPlanNameAxis_rlayTwoThousandTwentyPlanMember_20200708">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlay:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapPlanNameAxis_rlayTwoThousandTwentyPlanMember_20200801">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlay:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapPlanNameAxis_rlayTwoThousandSixteenPlanMember_20200801">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlay:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapPlanNameAxis_rlayTwoThousandTwentyPlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlay:TwoThousandTwentyPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapPlanNameAxis_rlayTwoThousandSixteenPlanMember_20200101_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlay:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapPlanNameAxis_rlayTwoThousandSixteenPlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rlay:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapIncomeStatementLocationAxis_us-gaapOperatingIncomeLossMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingIncomeLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtRangeAxis_srtMaximumMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_rlayConvertiblePreferredStocksMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rlay:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:DEShawResearchMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:DEShawResearchMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:DEShawResearchMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:DEShawResearchMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20200615">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:DEShawResearchMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:DEShawResearchMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20200615_20200615">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:DEShawResearchMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-06-15</xbrli:startDate>
      <xbrli:endDate>2020-06-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:DEShawResearchMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayLeaseAgreementMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:DEShawResearchMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rlay:LeaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayLeaseAgreementMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:DEShawResearchMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">rlay:LeaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:DEShawResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:DEShawResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:DEShawResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:DEShawResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayOtherthirdPartiesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:OtherthirdPartiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayOtherthirdPartiesMember_srtRangeAxis_srtMinimumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:OtherthirdPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayOtherthirdPartiesMember_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:OtherthirdPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayOtherthirdPartiesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:OtherthirdPartiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayOtherthirdPartiesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:OtherthirdPartiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtCounterpartyNameAxis_rlayOtherthirdPartiesMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rlay:OtherthirdPartiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtStatementGeographicalAxis_rlayFirstStreetInCambridgeMassachusettsMember_20151101_20151130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rlay:FirstStreetInCambridgeMassachusettsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-11-01</xbrli:startDate>
      <xbrli:endDate>2015-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_20151101_20151130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-11-01</xbrli:startDate>
      <xbrli:endDate>2015-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtStatementGeographicalAxis_rlayBinneyStreetCambridgeMassachusettsMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rlay:BinneyStreetCambridgeMassachusettsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtStatementGeographicalAxis_rlayBinneyStreetCambridgeMassachusettsMember_20180131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rlay:BinneyStreetCambridgeMassachusettsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtStatementGeographicalAxis_rlayBinneyStreetCambridgeMassachusettsMember_20171201_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rlay:BinneyStreetCambridgeMassachusettsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-12-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtStatementGeographicalAxis_rlayBinneyStreetCambridgeMassachusettsMember_20200930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rlay:BinneyStreetCambridgeMassachusettsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_srtStatementGeographicalAxis_rlayBinneyStreetCambridgeMassachusettsMember_20200901_20200930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rlay:BinneyStreetCambridgeMassachusettsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-09-01</xbrli:startDate>
      <xbrli:endDate>2020-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapRelatedPartyTransactionAxis_rlayConsultingAndManagementServicesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_rlayThirdRockVentureMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rlay:ThirdRockVentureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rlay:ConsultingAndManagementServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapRelatedPartyTransactionAxis_rlayConsultingAndManagementServicesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_rlayThirdRockVentureMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rlay:ThirdRockVentureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rlay:ConsultingAndManagementServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapRelatedPartyTransactionAxis_rlayConsultingAndManagementServicesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_rlayThirdRockVentureMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rlay:ThirdRockVentureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rlay:ConsultingAndManagementServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001812364_us-gaapRelatedPartyTransactionAxis_rlayConsultingAndManagementServicesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_rlayThirdRockVentureMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812364</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">rlay:ThirdRockVentureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rlay:ConsultingAndManagementServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <dei:DocumentType id="F_000000" contextRef="C_0001812364_20200101_20201231">10-K</dei:DocumentType>
  <dei:AmendmentFlag id="F_000001" contextRef="C_0001812364_20200101_20201231">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate id="F_000002" contextRef="C_0001812364_20200101_20201231">2020-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalYearFocus id="F_000003" contextRef="C_0001812364_20200101_20201231">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="F_000004" contextRef="C_0001812364_20200101_20201231">FY</dei:DocumentFiscalPeriodFocus>
  <dei:EntityRegistrantName id="F_000005" contextRef="C_0001812364_20200101_20201231">RELAY THERAPEUTICS, INC.</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="F_000006" contextRef="C_0001812364_20200101_20201231">0001812364</dei:EntityCentralIndexKey>
  <dei:EntityCurrentReportingStatus id="F_000007" contextRef="C_0001812364_20200101_20201231">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityVoluntaryFilers id="F_000008" contextRef="C_0001812364_20200101_20201231">No</dei:EntityVoluntaryFilers>
  <dei:EntityInteractiveDataCurrent id="F_000009" contextRef="C_0001812364_20200101_20201231">Yes</dei:EntityInteractiveDataCurrent>
  <dei:CurrentFiscalYearEndDate id="F_000010" contextRef="C_0001812364_20200101_20201231">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityFilerCategory id="F_000011" contextRef="C_0001812364_20200101_20201231">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityWellKnownSeasonedIssuer id="F_000012" contextRef="C_0001812364_20200101_20201231">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityPublicFloat id="F_000013" contextRef="C_0001812364_20200720" decimals="0" unitRef="U_iso4217USD">2543277454</dei:EntityPublicFloat>
  <dei:IcfrAuditorAttestationFlag id="F_000014" contextRef="C_0001812364_20200101_20201231">false</dei:IcfrAuditorAttestationFlag>
  <dei:EntityCommonStockSharesOutstanding id="F_000015" contextRef="C_0001812364_20210323" decimals="INF" unitRef="U_xbrlishares">90399972</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityShellCompany id="F_000016" contextRef="C_0001812364_20200101_20201231">false</dei:EntityShellCompany>
  <dei:EntitySmallBusiness id="F_000017" contextRef="C_0001812364_20200101_20201231">true</dei:EntitySmallBusiness>
  <dei:EntityEmergingGrowthCompany id="F_000018" contextRef="C_0001812364_20200101_20201231">true</dei:EntityEmergingGrowthCompany>
  <dei:EntityExTransitionPeriod id="F_000019" contextRef="C_0001812364_20200101_20201231">false</dei:EntityExTransitionPeriod>
  <dei:Security12bTitle id="F_000020" contextRef="C_0001812364_20200101_20201231">Common Stock, par value $0.001 per share</dei:Security12bTitle>
  <dei:TradingSymbol id="F_000021" contextRef="C_0001812364_20200101_20201231">RLAY</dei:TradingSymbol>
  <dei:SecurityExchangeName id="F_000022" contextRef="C_0001812364_20200101_20201231">NASDAQ</dei:SecurityExchangeName>
  <dei:EntityFileNumber id="F_000023" contextRef="C_0001812364_20200101_20201231">001-39385</dei:EntityFileNumber>
  <dei:EntityIncorporationStateCountryCode id="F_000024" contextRef="C_0001812364_20200101_20201231">DE</dei:EntityIncorporationStateCountryCode>
  <dei:EntityTaxIdentificationNumber id="F_000025" contextRef="C_0001812364_20200101_20201231">47-3923475</dei:EntityTaxIdentificationNumber>
  <dei:EntityAddressAddressLine1 id="F_000026" contextRef="C_0001812364_20200101_20201231">399 Binney Street</dei:EntityAddressAddressLine1>
  <dei:EntityAddressAddressLine2 id="F_000027" contextRef="C_0001812364_20200101_20201231">2nd Floor</dei:EntityAddressAddressLine2>
  <dei:EntityAddressCityOrTown id="F_000028" contextRef="C_0001812364_20200101_20201231">Cambridge</dei:EntityAddressCityOrTown>
  <dei:EntityAddressStateOrProvince id="F_000029" contextRef="C_0001812364_20200101_20201231">MA</dei:EntityAddressStateOrProvince>
  <dei:EntityAddressPostalZipCode id="F_000030" contextRef="C_0001812364_20200101_20201231">02139</dei:EntityAddressPostalZipCode>
  <dei:CityAreaCode id="F_000031" contextRef="C_0001812364_20200101_20201231">617</dei:CityAreaCode>
  <dei:LocalPhoneNumber id="F_000032" contextRef="C_0001812364_20200101_20201231">370-8837</dei:LocalPhoneNumber>
  <dei:DocumentAnnualReport id="F_000033" contextRef="C_0001812364_20200101_20201231">true</dei:DocumentAnnualReport>
  <dei:DocumentTransitionReport id="F_000034" contextRef="C_0001812364_20200101_20201231">false</dei:DocumentTransitionReport>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000035" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">447646000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000036" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">41954000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:Investments id="F_000037" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">230415000</us-gaap:Investments>
  <us-gaap:Investments id="F_000038" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">313862000</us-gaap:Investments>
  <us-gaap:AccountsReceivableNetCurrent id="F_000039" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">75000000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:ContractWithCustomerAssetNet id="F_000040" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">7654000</us-gaap:ContractWithCustomerAssetNet>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000041" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">9385000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000042" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">4720000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000043" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">770100000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000044" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">360536000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000045" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">6250000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000046" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">8094000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:OperatingLeaseRightOfUseAsset id="F_000047" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">22579000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseRightOfUseAsset id="F_000048" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">23560000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:RestrictedCashNoncurrent id="F_000049" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">878000</us-gaap:RestrictedCashNoncurrent>
  <us-gaap:RestrictedCashNoncurrent id="F_000050" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">878000</us-gaap:RestrictedCashNoncurrent>
  <us-gaap:OtherAssets id="F_000051" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">22000</us-gaap:OtherAssets>
  <us-gaap:Assets id="F_000052" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">799829000</us-gaap:Assets>
  <us-gaap:Assets id="F_000053" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">393068000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="F_000054" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">6351000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="F_000055" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">6991000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000056" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">5760000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000057" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">3746000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent id="F_000058" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">1521000</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent id="F_000059" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">1249000</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000060" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">13632000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000061" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">11986000</us-gaap:LiabilitiesCurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent id="F_000062" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">22901000</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent id="F_000063" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">23583000</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <rlay:RestrictedStockLiability id="F_000064" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">3000</rlay:RestrictedStockLiability>
  <rlay:RestrictedStockLiability id="F_000065" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">156000</rlay:RestrictedStockLiability>
  <us-gaap:Liabilities id="F_000066" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">36536000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="F_000067" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">35725000</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies id="F_000068" xsi:nil="true" contextRef="C_0001812364_20201231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="F_000069" xsi:nil="true" contextRef="C_0001812364_20191231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000070" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">537781000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:CommonStockValueOutstanding id="F_000071" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">90000</us-gaap:CommonStockValueOutstanding>
  <us-gaap:CommonStockValueOutstanding id="F_000072" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">4000</us-gaap:CommonStockValueOutstanding>
  <us-gaap:AdditionalPaidInCapital id="F_000073" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">1167367000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital id="F_000074" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">8715000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="F_000075" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">64000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="F_000076" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">325000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000077" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">-404228000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000078" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">-189482000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="F_000079" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">763293000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000080" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">-180438000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000081" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">799829000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000082" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">393068000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000083" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000084" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000085" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000086" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">337272859</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="F_000087" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000088" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">212642857</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000089" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000090" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">212642857</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityLiquidationPreference id="F_000091" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">519825000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000092" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_rlayUndesignatedpreferredstockMember_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000093" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_rlayUndesignatedpreferredstockMember_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="F_000094" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_rlayUndesignatedpreferredstockMember_20201231" decimals="INF" unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="F_000095" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_rlayUndesignatedpreferredstockMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="F_000096" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_rlayUndesignatedpreferredstockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued id="F_000097" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_rlayUndesignatedpreferredstockMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="F_000098" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_rlayUndesignatedpreferredstockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="F_000099" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_rlayUndesignatedpreferredstockMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000100" contextRef="C_0001812364_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000101" contextRef="C_0001812364_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000102" contextRef="C_0001812364_20201231" decimals="INF" unitRef="U_xbrlishares">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000103" contextRef="C_0001812364_20191231" decimals="INF" unitRef="U_xbrlishares">260000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000104" contextRef="C_0001812364_20201231" decimals="INF" unitRef="U_xbrlishares">89991324</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000105" contextRef="C_0001812364_20191231" decimals="INF" unitRef="U_xbrlishares">4716634</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000106" contextRef="C_0001812364_20201231" decimals="INF" unitRef="U_xbrlishares">89906835</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000107" contextRef="C_0001812364_20191231" decimals="INF" unitRef="U_xbrlishares">4037476</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000108" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">82654000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList id="F_000109" contextRef="C_0001812364_20200101_20201231">rlay:LicenseRevenueMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
  <us-gaap:Revenues id="F_000110" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">82654000</us-gaap:Revenues>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000111" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">99862000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000112" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">70306000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000113" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">38588000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000114" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">13742000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="F_000115" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">138450000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000116" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">84048000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000117" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-55796000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000118" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-84048000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestIncomeOther id="F_000119" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3400000</us-gaap:InterestIncomeOther>
  <us-gaap:InterestIncomeOther id="F_000120" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">8801000</us-gaap:InterestIncomeOther>
  <us-gaap:OtherNonoperatingExpense id="F_000121" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">16000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingExpense id="F_000122" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">58000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000123" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3384000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000124" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">8743000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss id="F_000125" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-52412000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000126" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-75305000</us-gaap:NetIncomeLoss>
  <rlay:DeemedDividendResultingFromExtinguishmentOfPreferredStock id="F_000127" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-177789000</rlay:DeemedDividendResultingFromExtinguishmentOfPreferredStock>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000128" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-230201000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000129" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-75305000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000130" contextRef="C_0001812364_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-5.40</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000131" contextRef="C_0001812364_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-21.82</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000132" contextRef="C_0001812364_20200101_20201231" decimals="0" unitRef="U_xbrlishares">42619582</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000133" contextRef="C_0001812364_20190101_20191231" decimals="0" unitRef="U_xbrlishares">3450500</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax id="F_000134" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-261000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax id="F_000135" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">325000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax id="F_000136" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-261000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax id="F_000137" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">325000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000138" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-52673000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000139" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-74980000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:SharesOutstanding id="F_000140" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">210863764</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000141" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">532120000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="F_000142" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">2998017</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000143" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000144" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" unitRef="U_iso4217USD">3247000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000145" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" unitRef="U_iso4217USD">-114177000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000146" contextRef="C_0001812364_20181231" decimals="-3" unitRef="U_iso4217USD">-110927000</us-gaap:StockholdersEquity>
  <rlay:StockIssuedDuringPeriodSharesPreferredStockNetOfIssuanceCosts id="F_000147" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">1779093</rlay:StockIssuedDuringPeriodSharesPreferredStockNetOfIssuanceCosts>
  <rlay:StockIssuedDuringPeriodValuePreferredStockNetOfIssuanceCosts id="F_000148" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">5661000</rlay:StockIssuedDuringPeriodValuePreferredStockNetOfIssuanceCosts>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000149" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">178969</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000150" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">613000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000151" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">613000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <rlay:VestingOfRestrictedCommonStockShares id="F_000152" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">860490</rlay:VestingOfRestrictedCommonStockShares>
  <rlay:VestingOfRestrictedCommonStockValue id="F_000153" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1000</rlay:VestingOfRestrictedCommonStockValue>
  <rlay:VestingOfRestrictedCommonStockValue id="F_000154" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">399000</rlay:VestingOfRestrictedCommonStockValue>
  <rlay:VestingOfRestrictedCommonStockValue id="F_000155" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">400000</rlay:VestingOfRestrictedCommonStockValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000156" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4456000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000157" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4456000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax id="F_000158" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">325000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax id="F_000159" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">325000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax>
  <us-gaap:NetIncomeLoss id="F_000160" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-75305000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding id="F_000161" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">212642857</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000162" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">537781000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="F_000163" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">4037476</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000164" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">4000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000165" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" unitRef="U_iso4217USD">8715000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000166" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="-3" unitRef="U_iso4217USD">325000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000167" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" unitRef="U_iso4217USD">-189482000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued id="F_000168" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">177789000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
  <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued id="F_000169" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-15455000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
  <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued id="F_000170" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-162334000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
  <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued id="F_000171" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-177789000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000172" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">-212642857</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000173" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-715570000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000174" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">61992534</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000175" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">62000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000176" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">715508000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000177" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">715570000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000178" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">23000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000179" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">23000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000180" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">425270000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000181" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">425293000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000182" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">297000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000183" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1216000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000184" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1216000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <rlay:VestingOfRestrictedCommonStockShares id="F_000185" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">579825</rlay:VestingOfRestrictedCommonStockShares>
  <rlay:VestingOfRestrictedCommonStockValue id="F_000186" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1000</rlay:VestingOfRestrictedCommonStockValue>
  <rlay:VestingOfRestrictedCommonStockValue id="F_000187" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">153000</rlay:VestingOfRestrictedCommonStockValue>
  <rlay:VestingOfRestrictedCommonStockValue id="F_000188" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">154000</rlay:VestingOfRestrictedCommonStockValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000189" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">31960000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000190" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">31960000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax id="F_000191" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-261000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax id="F_000192" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-261000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax>
  <us-gaap:NetIncomeLoss id="F_000193" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-52412000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding id="F_000194" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">89906835</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000195" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" unitRef="U_iso4217USD">90000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000196" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" unitRef="U_iso4217USD">1167367000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000197" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="-3" unitRef="U_iso4217USD">64000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000198" contextRef="C_0001812364_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" unitRef="U_iso4217USD">-404228000</us-gaap:StockholdersEquity>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="F_000199" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">50000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts id="F_000200" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">34707000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts>
  <us-gaap:ShareBasedCompensation id="F_000201" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">31960000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000202" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4456000</us-gaap:ShareBasedCompensation>
  <us-gaap:Depreciation id="F_000203" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3549000</us-gaap:Depreciation>
  <us-gaap:Depreciation id="F_000204" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2845000</us-gaap:Depreciation>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments id="F_000205" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">416000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments id="F_000206" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2495000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:GainLossOnDispositionOfAssets id="F_000207" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-56000</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:IncreaseDecreaseInPrepaidExpense id="F_000208" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">4665000</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInPrepaidExpense id="F_000209" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2123000</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <rlay:IncreaseDecreaseInLeaseAssetsAndLiabilitiesNet id="F_000210" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-571000</rlay:IncreaseDecreaseInLeaseAssetsAndLiabilitiesNet>
  <rlay:IncreaseDecreaseInLeaseAssetsAndLiabilitiesNet id="F_000211" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-1233000</rlay:IncreaseDecreaseInLeaseAssetsAndLiabilitiesNet>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000212" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-410000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000213" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3000000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="F_000214" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2010000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="F_000215" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2200000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="F_000216" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">75000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInCommodityContractAssetsAndLiabilities id="F_000217" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">7654000</us-gaap:IncreaseDecreaseInCommodityContractAssetsAndLiabilities>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="F_000218" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">22000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000219" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-102489000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000220" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-66133000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000221" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1931000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000222" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">8002000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="F_000223" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">20000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquireInvestments id="F_000224" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">266455000</us-gaap:PaymentsToAcquireInvestments>
  <us-gaap:PaymentsToAcquireInvestments id="F_000225" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">553517000</us-gaap:PaymentsToAcquireInvestments>
  <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments id="F_000226" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">350058000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
  <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments id="F_000227" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">242475000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000228" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">81672000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000229" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-319024000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000230" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4993000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000231" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1216000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000232" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">613000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="F_000233" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">427800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:PaymentOfFinancingAndStockIssuanceCosts id="F_000234" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2507000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000235" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">426509000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000236" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">5606000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000237" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">405692000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000238" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-379551000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000239" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">42832000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000240" contextRef="C_0001812364_20181231" decimals="-3" unitRef="U_iso4217USD">422383000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000241" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">448524000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="F_000242" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">519000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="F_000243" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">745000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <rlay:ReclassificationOfRestrictedStockLiabilityToAdditionalPaidInCapital id="F_000244" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">153000</rlay:ReclassificationOfRestrictedStockLiabilityToAdditionalPaidInCapital>
  <rlay:ReclassificationOfRestrictedStockLiabilityToAdditionalPaidInCapital id="F_000245" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">400000</rlay:ReclassificationOfRestrictedStockLiabilityToAdditionalPaidInCapital>
  <rlay:LossOnExtinguishmentAndReissuanceOfPreferredStock id="F_000246" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-177789000</rlay:LossOnExtinguishmentAndReissuanceOfPreferredStock>
  <us-gaap:ConversionOfStockAmountConverted1 id="F_000247" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">715508000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability id="F_000248" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">819000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
  <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability id="F_000249" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">24936000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
  <us-gaap:RestrictedCash id="F_000250" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">878000</us-gaap:RestrictedCash>
  <us-gaap:RestrictedCash id="F_000251" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">878000</us-gaap:RestrictedCash>
  <dei:DocumentsIncorporatedByReferenceTextBlock id="F_000252" contextRef="C_0001812364_20200101_20201231">
&lt;p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/p&gt;
&lt;p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2021 Annual Meeting of Stockholders within 120 days of the end of the registrant&amp;#8217;s fiscal year ended December&amp;#160;31, 2020. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
  <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock id="F_000253" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1. Nature of Business and Basis of Presentation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Relay Therapeutics, Inc. (the &amp;#8220;Company&amp;#8221;) was incorporated in Delaware on May 4, 2015 and is headquartered in Cambridge, Massachusetts. The Company is a clinical-stage, precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The Company is built upon unparalleled insights into protein motion and how this dynamic behavior relates to protein function. The Company&amp;#8217;s Dynamo platform integrates an array of leading edge experimental and computational approaches, which allows the Company to apply the understanding of protein structure and motion to drug discovery. The Company is advancing its pipeline of medicines to address targets in precision oncology, including its lead product candidates, RLY-4008 and RLY-1971, as well as its PI3K&amp;#945; mutant selective program, known as the RLY-PI3K1047 program. The Company initiated a Phase 1 clinical trial for RLY-1971 in patients with advanced solid tumors in the first quarter of 2020 and a first-in-human clinical trial of RLY-4008 enriched for patients with advanced solid tumors having oncogenic FGFR2 alterations in the third quarter of 2020. &lt;font style="color:#231F20;"&gt;In December 2020, the Company entered into the Collaboration and License Agreement (the &amp;#8220;Genentech Agreement&amp;#8221;) with Genentech, Inc. (&amp;#8220;Genentech&amp;#8221;), a member of the Roche Group, for the development and commercialization of RLY-1971, as further discussed in Note 5.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive pre-clinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s product candidates are in development. There can be no assurance that the Company&amp;#8217;s research and development will be successfully completed, that adequate protection for the Company&amp;#8217;s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&amp;#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has devoted substantially all of its resources to developing its product candidates, including RLY-1971 and RLY-4008, and the RLY-PI3K1047 program by developing its innovative, experimental and computational approaches on protein motion, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has incurred net operating losses since inception and had an accumulated deficit of $404,228 as of December 31, 2020. The Company expects that its existing cash, cash equivalents and investments as of December 31, 2020, together with the upfront payment of $75,000 received in January 2021 from Genentech under the Genentech Agreement discussed in Note 5, will enable it to fund its planned operating expenses and capital expenditure requirements for at least one year from the date of the issuance of these consolidated financial statements. The future viability of the Company is dependent on its ability to generate cash from operating activities or to raise additional capital to finance its operations. The Company&amp;#8217;s failure to raise capital as and when needed could have a material adverse effect on its financial condition and ability to pursue its business strategies. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into license or collaboration arrangements or obtain government grants. The terms of any financing may adversely affect the holdings or the rights of the Company&amp;#8217;s stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. In the event the Company requires additional funding, there can be no assurance that it will be successful in obtaining sufficient funding on terms acceptable to the Company to fund its continuing operations, if at all. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Initial Public Offering &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July 20, 2020, the Company closed its initial public offering (&amp;#8220;IPO&amp;#8221;) and issued 23,000,000 shares of its common stock at a price of $20.00 per share for net proceeds of $425,293, after deducting underwriting discounts and commissions of $32,200 and expenses of $2,507. In connection with the IPO, all shares of Series A, Series B and Series C convertible preferred stock converted into 61,992,534 shares of common stock. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reverse Stock Split &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July 8, 2020, the Company&amp;#8217;s stockholders approved a decrease in the number of authorized shares of common stock from 260,000,000 to 150,000,000. The Company also effected a one-for-3.55092 reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company&amp;#8217;s preferred stock. Accordingly, all share and per share amounts for all periods presented in the accompanying financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse stock split and adjustment of the preferred stock conversion ratios.&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="F_000254" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2. Significant Accounting Policies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basis of presentation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) for reporting on Form 10-K. The Company&amp;#8217;s consolidated financial statements include the accounts of Relay Therapeutics, Inc. and its wholly-owned subsidiary, Relay Therapeutics Securities Corporation. All intercompany balances and transactions have been eliminated. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development and manufacturing expenses, the valuation of equity instruments, the determination of the transaction price and standalone selling price of performance obligations under &lt;font style="color:#000000;"&gt;Accounting Standards Codification Topic 606, &lt;/font&gt;&lt;font style="font-style:italic;color:#000000;"&gt;Revenue from Contracts with Customers&lt;/font&gt;, and the incremental borrowing rate for determining the operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&amp;#8217;s business, results of operations and financial condition, including expenses, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has made estimates of the impact of COVID-19 within its financial statements and there may be changes to those estimates in future periods. Actual results could differ from the Company&amp;#8217;s estimates. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Segment Information &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company&amp;#8217;s singular focus is on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets. The Company operates in the United States and all tangible assets are held in the United States.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash Equivalents &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all short-term, highly liquid investments with original maturities of 90&amp;#160;days or less at acquisition date to be cash equivalents. Cash equivalents, which consist of money market funds, are stated at fair value. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted Cash &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had restricted cash of $878 as of December&amp;#160;31, 2020 and 2019 to secure a letter of credit in connection with the lease of the Company&amp;#8217;s facilities (see Note 14). The Company classified the restricted cash as a noncurrent asset on its consolidated balance sheets. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments in marketable securities are classified as available-for-sale. Available-for-sale securities are measured and reported at fair value using quoted prices in active markets for similar securities. Unrealized gains and losses on available-for-sale securities are reported as a separate component of stockholders&amp;#8217; equity (deficit). Premiums or discounts from par value are amortized to investment income over the life of the underlying investment. All of the Company&amp;#8217;s available-for-sale securities are available to the Company for use in current operations. As a result, the Company classified all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) within the consolidated statements of operations and comprehensive loss. If any adjustment is required to reflect a decline in the value of the investment that the Company considers to be &amp;#8220;other than temporary&amp;#8221;, the Company recognizes a charge to the consolidated statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk and Significant Suppliers &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and investments. From time to time, the Company has maintained all of its cash, cash equivalents and investments at certain accredited financial institutions in amounts that exceed federally insured limits. The Company generally invests its excess capital in money market funds, U.S. treasury bonds, U.S. treasury bills and agency bonds are subject to minimal credit and market risk. Management has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. The investment portfolio is maintained in accordance with the Company&amp;#8217;s investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is dependent on third-party suppliers for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a small number of these suppliers, including D. E. Shaw Research, LLC as discussed in Note 13, to meet its requirements for its programs. These programs could be adversely affected by a significant interruption in pre-clinical and clinical testing and the supply of active pharmaceutical ingredients and formulated drugs. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.4%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.4%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Level 1&amp;#8212;Quoted prices in active markets for identical assets or liabilities. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.4%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.4%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Level 2&amp;#8212;Observable inputs (other than Level&amp;#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.4%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.4%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Level 3&amp;#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue Recognition &lt;/p&gt;
&lt;p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for revenue recognition in accordance with Accounting Standards Codification Topic (&amp;#8220;ASC&amp;#8221;) 606, &lt;font style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt; (&amp;#8220;ASC 606&amp;#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/p&gt;
&lt;p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract and determines those that are performance obligations. The Company then determines the transaction price and allocates it to the performance obligations using the relative selling price model. As part of the accounting for these arrangements, the Company must use significant judgment to determine: (a) the number of performance obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above, including the determination of whether milestones or other variable consideration should be included in the transaction price; and (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of the transaction price in step (iv) above. &lt;/p&gt;
&lt;p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company utilizes key assumptions and judgments to determine the stand-alone selling price for each performance obligation, which may include discounted cash flow models, evaluation of comparable transactions, pricing considered in negotiating the transaction and estimated costs,&lt;font style="Background-color:#FFFFFF;"&gt; to determine how the transaction price is allocated among the performance obligations&lt;/font&gt;. The Company uses judgment to determine whether milestones or other variable consideration should be included in the transaction price. For revenue-based royalties, including milestone payments based on the level of sales, the Company will include royalties in the transaction price at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty is allocated has been satisfied (or partially satisfied). As part of management&amp;#8217;s evaluation of the transaction price, the Company considers numerous factors, including whether the achievement of the milestones is outside of our control, contingent upon the efforts of others or subject to scientific risks of success. If the Company concludes it is probable that a significant revenue reversal would not occur, the associated milestone payment is included in the transaction price. Milestone payments that are not within our control, such as regulatory approvals, are generally not considered probable until those milestones are achieved. The Company re-evaluates the transaction price, including estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/p&gt;
&lt;p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Once the performance obligations are identified, the transaction price is allocated to each performance obligation based on the relative stand-alone selling price. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied, either at a point in time or over time. If the performance obligation is satisfied over time, the Company recognizes revenue based on the use of either an output or input method. &lt;/p&gt;
&lt;p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, the Company had one collaboration and license agreement with Genentech, which the Company entered into on December 11, 2020. &lt;font style="letter-spacing:-0.1pt;"&gt;For a discussion of the accounting related to the Genentech Agreement, see Note 5,&amp;#160;&lt;/font&gt;&lt;font style="font-style:italic;letter-spacing:-0.1pt;"&gt;Collaboration and License Arrangement with Genentech&lt;/font&gt;.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease Agreements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under ASC 842, &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt;, the Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does not recognize a right-of-use asset or lease liability. The Company&amp;#8217;s operating leases are recognized on its consolidated balance sheets as other noncurrent assets, other current liabilities and other noncurrent liabilities. The Company does not have any finance leases. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets represent the Company&amp;#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&amp;#8217;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&amp;#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Operating lease right-of-use assets also include the effect of any lease payments made prior to commencement and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has lease agreements with lease and non-lease components, which are accounted for as a combined element. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and Equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the useful life of the asset. Laboratory and computer equipment are depreciated over three years. Furniture and fixtures are depreciated over five years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the related asset. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured in an amount by which the book values of the assets exceed their fair value. The Company did not recognize any impairment losses for the years ended December&amp;#160;31, 2020 and 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Classification and Accretion of Convertible Preferred Stock &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s convertible preferred stock was classified outside of stockholders&amp;#8217; equity (deficit) on the consolidated balance sheet because the holders of such shares had liquidation rights in the event of a deemed liquidation that, in certain situations, were not solely within the control of the Company and would require the redemption of the then-outstanding convertible preferred stock. The convertible preferred stock was not currently redeemable, except in the event of a deemed liquidation (see Note 8). Because the occurrence of a deemed liquidation event was not probable, the carrying value of the convertible preferred stock was not accreted to their redemption values. Subsequent adjustments to the carrying values of the convertible preferred stock would have been made only when a deemed liquidation event became probable. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon the closing of the Company&amp;#8217;s IPO in July 2020, all outstanding convertible preferred stock automatically converted into 61,992,534 shares of common stock. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures stock options and other stock-based awards granted to employees, directors and non-employees based on their fair value on the date of grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company recognizes the impact of forfeitures on stock-based compensation expense as forfeitures occur. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company issued certain options with performance-based vesting conditions whereby the service inception date preceded the accounting grant date and therefore applied variable accounting for the awards until the fair value of the awards was known on the accounting grant date. The board of directors approved the commencement of vesting for all such awards in 2020, therefore the Company no longer applies variable accounting as of December 11, 2020.&lt;font style="font-size:12pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimates the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model, which uses as inputs the fair value of the Company&amp;#8217;s common stock and assumptions the Company makes for the volatility of its common stock, the expected term of the stock options, the risk-free interest rate for a period that approximates the expected term of the stock options and the expected dividend yield. &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the Company&amp;#8217;s IPO, the estimated fair value of its common stock was determined by the board of directors, or compensation committee thereof, as of the date of each option grant, with input from management, considering the most recently available third-party valuations of common stock and the board of directors&amp;#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. Historically, these independent third-party valuations of the Company&amp;#8217;s equity instruments were performed contemporaneously with identified value inflection points.&lt;/p&gt;
&lt;p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&amp;#8217; Accounting and Valuation Guide,&amp;#160;&lt;font style="font-style:italic;"&gt;Valuation of Privately-Held-Company Equity Securities Issued as Compensation &lt;/font&gt;(the &amp;#8220;Practice Aid&amp;#8221;). The Practice Aid identifies various available methods for allocating the enterprise value across classes of series of capital stock in determining the fair value of the Company&amp;#8217;s common stock at each valuation date.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Following the Company&amp;#8217;s IPO, in connection with the accounting for granted stock options and other awards the Company may grant, the fair value of the Company&amp;#8217;s common stock is determined based on the quoted market price of its common stock.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and Development Costs &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. Research and development expenses include salaries, stock-based compensation and benefits of employees, third-party license fees and other operational costs related to the Company&amp;#8217;s research and development activities, including allocated facility-related expenses and external costs of outside vendors engaged to conduct both pre-clinical studies and clinical trials. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and Manufacturing Contracts &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into various research and development contracts with research institutions and other companies whose costs are included in research and development expense in the accompanying consolidated statements of operations and comprehensive loss. These agreements are generally cancelable and related payments are recorded as research and development expenses as the underlying services are performed. When evaluating the adequacy of the expense recognized, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the expense recognized and the related prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&amp;#8217;s estimates. The Company&amp;#8217;s historical estimates have not been materially different from the actual costs. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Patent Costs &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company&amp;#8217;s financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&amp;#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. For the years ended December&amp;#160;31, 2020 and 2019, other comprehensive income (loss) consisted of changes in unrealized gains and losses from available-for-sale investments.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Loss Per Common Share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed using the sum of the weighted average number of common shares outstanding during the period and the effect of dilutive securities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company applies the two-class method to calculate its basic and diluted net loss per share as the Company has issued shares that meet the definition of participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. The Company&amp;#8217;s participating securities contractually entitle the holders of such shares to participate in dividends; but do not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additionally, in periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. &lt;font style="color:#000000;letter-spacing:-0.1pt;"&gt;For additional discussion of net loss per common share, please see Note 12, &lt;/font&gt;&lt;font style="font-style:italic;color:#000000;letter-spacing:-0.1pt;"&gt;Net Loss Per Share. &lt;/font&gt;&lt;font style="color:#000000;letter-spacing:-0.1pt;"&gt; &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company adopted Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No.&amp;#160;2018-13, &lt;font style="font-style:italic;"&gt;Fair Value Measurement (Topic 820): Disclosure Framework&amp;#8212;Changes to the Disclosure Requirements for Fair Value Measurement&lt;/font&gt; on January&amp;#160;1, 2020. This standard modifies certain disclosure requirements on fair value measurements. The adoption of this standard did not have a material impact on the Company&amp;#8217;s disclosures. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued ASU No. 2016-13,&lt;font style="font-style:italic;"&gt;&amp;#160;Financial Instruments&amp;#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/font&gt;. This standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and it establishes additional disclosure requirements related to credit risks. For available-for-sale securities with expected credit losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This guidance was originally effective for fiscal years beginning after December&amp;#160;15, 2019, including interim periods within those fiscal years, and early adoption was permitted. In November 2019, the FASB subsequently issued ASU 2019-10, &lt;font style="font-style:italic;"&gt;Financial Instruments&amp;#8212;Credit Losses (Topic 326), Derivatives and Hedging&lt;/font&gt; &lt;font style="font-style:italic;"&gt;(Topic 815), and Leases (Topic 842): Effective Dates &lt;/font&gt;(&amp;#8220;ASU 2019-10&amp;#8221;), whereby the effective date of this standard for smaller reporting companies was deferred to fiscal years beginning after December&amp;#160;15, 2022, including interim periods within those fiscal years, and early adoption is still permitted. The Company is assessing the impact of ASU 2019-10 on the consolidated financial statements and does not expect it to have a material impact.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2020, the FASB issued ASU No.&amp;#160;2020-06, &lt;font style="font-style:italic;"&gt;Debt &amp;#8211; Debt with Conversion and Other&lt;/font&gt; &lt;font style="font-style:italic;"&gt;Options&lt;/font&gt; (Subtopic 470-20) &lt;font style="font-style:italic;"&gt;and Derivatives and Hedging&amp;#8212;Contracts in Entity&amp;#8217;s Own Equity&lt;/font&gt; (Subtopic 815-40)&lt;font style="font-size:12pt;"&gt; &lt;/font&gt;(&amp;#8220;ASU 2020-06&amp;#8221;). This standard amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity&amp;#8217;s own equity and amends the related earnings per share (&amp;#8220;EPS&amp;#8221;) guidance. The ASU will be effective for smaller reporting companies for fiscal years beginning after December&amp;#160;15, 2023 and interim periods within those fiscal years. Early adoption is permitted in fiscal years beginning after December&amp;#160;15, 2020, including interim periods within those fiscal years. The Company is assessing the impact of&amp;#160;ASU 2020-06&amp;#160;on the consolidated financial statements and does not expect it to have a material impact. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued&amp;#160;ASU&amp;#160;2019-12,&lt;font style="font-style:italic;"&gt;&amp;#160;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/font&gt;&amp;#160;(&amp;#8220;ASU&amp;#160;2019-12&amp;#8221;), which is intended to simplify the accounting for income taxes.&amp;#160;ASU&amp;#160;2019-12&amp;#160;removes certain exceptions to the general principles in Topic 740 and also clarifies and amends certain aspects of the existing guidance to improve consistent application. The new standard will be effective for public business entities for fiscal years beginning after December&amp;#160;15, 2020. The Company is assessing the potential impact&amp;#160;ASU&amp;#160;2019-12&amp;#160;may have on its financial statements upon adoption. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &amp;#8220;emerging growth company&amp;#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected to use the extended transition period related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different effective dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time that the Company either (i)&amp;#160;irrevocably elects to &amp;#8220;opt out&amp;#8221; of such extended transition period or (ii)&amp;#160;no longer qualifies as an emerging growth company. &lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="F_000255" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;3. Fair Value of Financial Assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables present information about the Company&amp;#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2020:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;Assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;447,146&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;447,146&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US treasury bills&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,026&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,026&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;197,389&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;197,389&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total investments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230,415&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230,415&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;447,146&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230,415&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;677,561&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2019:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;Assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,658&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,658&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US treasury bills&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;232,604&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;232,604&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,258&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,258&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total investments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;313,862&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;313,862&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,658&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;313,862&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;355,520&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In determining the fair value of its investments at each date presented above, the Company relied on quoted prices for similar securities in active markets or using other inputs that are observable or can be corroborated by observable market data. The Company did not have any financial assets or liabilities during any of the periods presented in the accompanying consolidated financial statements that required Level&amp;#160;3 inputs. &lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:InvestmentTextBlock id="F_000256" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;4. Investments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of available-for-sale investments by type of security was as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:98.64%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S treasury bills&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,997&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,996&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,001&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total investments with a maturity of one year or less&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,993&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S treasury bills&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,008&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,008&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;176,350&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;176,388&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total investments with a maturity of one to two years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179,358&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179,396&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total investments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230,351&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230,415&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:93.84%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S treasury bills&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;232,336&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;268&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;232,604&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,201&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,258&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total investments with a maturity of one year or less&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;313,537&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;325&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;313,862&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:InvestmentTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock id="F_000257" contextRef="C_0001812364_20200101_20201231">
&lt;p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5. Collaboration and License Arrangement with Genentech&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December 11, 2020, the Company entered into the Genentech Agreement, which granted Genentech a license to develop and commercialize RLY-1971. RLY-1971 is currently being developed in a Phase 1a clinical trial for patients with advanced solid tumors (the &amp;#8220;Phase 1a Trial&amp;#8221;). Unless Genentech elects to exercise its option to conduct the remainder of the ongoing Phase 1a Trial, the Company is responsible for the completion of this trial. Genentech is responsible for conducting all subsequent clinical development of RLY-1971. The Company is also responsible for the one-time transfer of the active pharmaceutical ingredient (&amp;#8220;API&amp;#8221;) and other materials related to RLY-1971 to Genentech. &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Genentech Agreement, the Company is entitled to a non-refundable upfront payment of $75,000, which is due upon completion of certain technology transfer activities and is reflected as accounts receivable on the consolidated balance sheet at December 31, 2020. The Company collected this amount in full in January 2021. The Company is eligible to receive up to $25,000 in near-term milestone payments. The Company is also eligible to receive up to an aggregate of an additional $695,000 upon the achievement of specified development, commercialization and sales-based milestones for RLY-1971 worldwide as well as tiered royalties ranging from low-to-mid teens on annual worldwide net sales of RLY-1971, on a country-by-country basis, subject to reduction in certain circumstances. &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has the option, exercisable one time at the Company&amp;#8217;s sole discretion, to (a) fund half of the development costs of RLY-1971 in the U.S., (b) share half of the net profits or net loss of commercializing RLY-1971 in the U.S. (the &amp;#8220;Profit/Cost Share&amp;#8221;) and (c) be eligible to receive up to an aggregate of an additional $410,000 upon the achievement of specified commercialization and sales-based milestones for RLY-1971 outside of the U.S and tiered royalties ranging from low-to-mid teens on annual net sales of RLY-1971 outside of the U.S., on a country-by-country basis, subject to reduction in certain circumstances. The Company may elect to opt-out of further participation in the Profit/Cost Share at any time prior to the third anniversary of the first commercial sale of RLY-1971 in the U.S, in which case the financial terms would revert to the terms applicable as if Company had not opted into the Profit/Cost Share as of the effective opt-out date.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Genentech may terminate the Genentech Agreement for convenience and the Company may terminate the Genentech Agreement under certain limited circumstances. Unless otherwise terminated, the Genentech Agreement will remain in effect until the expiration of all Genentech&amp;#8217;s royalty payment obligations to the Company.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accounting Analysis &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Identification of the Contract &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company concluded that Genentech is a customer in this arrangement and as such, the arrangement falls within the scope of the revenue recognition guidance in ASC 606. &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Identification of Performance Obligations &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the commencement of the Genentech Agreement, the Company identified the following performance obligations in the agreement:&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.4%;white-space:nowrap"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;#8226;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License to develop and commercialize RLY-1971 and the related know-how; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.4%;white-space:nowrap"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;#8226;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development services to complete the Phase 1a Trial for RLY-1971; and&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.4%;white-space:nowrap"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;#8226;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Transfer of API and other materials related to RLY-1971 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined that the performance obligations outlined above are both capable of being distinct and distinct within the context of the contract given such rights and activities are independent of each other. The license can be used by &lt;font style="color:#000000;"&gt;Genentech without the research and development services or API outlined above,&lt;/font&gt; and similarly those services and inventory provide distinct benefit to Genentech within the context of the contract, separate from the license.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Determination of Transaction Price &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined the transaction price for the Genentech Agreement to be $85,867, which includes both fixed and variable consideration amounts. The total transaction price of $85,867 is comprised of (i) the $75,000 fixed, non-refundable upfront payment, (ii) a $5,000 non-refundable milestone payment due upon the transfer of the  &lt;font style="color:#000000;"&gt;Investigational New Drug (&amp;#8220;IND&amp;#8221;) application &lt;/font&gt;to Genentech, (iii) a $5,000 non-refundable milestone payment due upon completion of the Phase 1a Trial for RLY-1971 and (iv) $867 of estimated variable consideration related to reimbursements due from Genentech for research and development services. No additional development milestone payments and no regulatory milestone payments are included in the transaction price as all such payments are fully constrained. As part of management&amp;#8217;s evaluation of the constraint, the Company considered numerous factors, including the consideration that achievement of the milestones is outside of the Company&amp;#8217;s control, contingent upon Genentech&amp;#8217;s efforts and the receipt of regulatory approval and subject to scientific risks of success. &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Allocation of Transaction Price to Performance Obligations &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company allocated the transaction price of $85,867 based on the stand-alone selling prices (&amp;#8220;SSP&amp;#8221;) of each of the performance obligations as follows:&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.4%;white-space:nowrap"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;#8226;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$82,654 million for the transfer of the license&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.4%;white-space:nowrap"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;#8226;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$2,896 million for research and development services; and&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.4%;white-space:nowrap"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;#8226;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$317 million for the transfer of API.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The SSP for the license was determined using an approach that considered discounted, probability-weighted cash flows related to the license transferred. The Company also reviewed comparable market transactions in determining the SSP of the license. The SSP for the research and development services as well as the transfer of API were based on estimates of the associated effort and cost of these services and cost to manufacture API, adjusted for a reasonable profit margin that would be expected to be realized under similar contracts. The Company performed sensitivity analyses supporting reasonable changes to the SSPs noting no material impact on revenue recognized for the year ended December 31, 2020.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Recognition of Revenue &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is recognizing revenue for each of the three performance obligations as follows: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.4%;white-space:nowrap"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;#8226;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognized revenue related to the license at a point in time upon transfer of the license to Genentech. The Company recognized the full amount allocated to the license and related know-how in the fourth quarter of 2020 because the Company had transferred the license upon execution of the Genentech Agreement. Revenue recognized during the year ended December 31, 2020 related to the license amounted to $82,654.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.4%;white-space:nowrap"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;#8226;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company will satisfy the research and development performance obligation for RLY-1971&amp;#160;as the research and development services are performed.&amp;#160;The research and development services performance obligation consists of the Company completing the Phase 1a clinical trial initiated in the first quarter of 2020. The Company recognizes revenue related to the research and development services over time using a cost-based input method by calculating actual costs incurred to date at each period end relative to total estimated costs expected to be incurred to fulfill the performance obligation. There was no revenue recognized related to this performance obligation during the year ended December 31, 2020 as the services performed from contract inception to December 31, 2020 were immaterial.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.4%;white-space:nowrap"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:&apos;Times New Roman&apos;;font-size:10pt;"&gt;&amp;#8226;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company will recognize revenue related to the transfer of API at a point in time upon transfer to Genentech. There was no revenue recognized related to this performance obligation during the year ended December 31, 2020.&amp;nbsp;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December 31, 2020, the Company recognized an aggregate of $82,654 of revenue from the Genentech Agreement related entirely to the transfer of the license. At December 31, 2020, the Company recorded accounts receivable under the Genentech Agreement in the amount of $75,000 and a contract asset in the amount of $7,654, which is classified as a current asset, on the balance sheet. The contract asset relates to the amount of revenue recognized for which the right to payment is contingent upon conditions other than the passage of time, such as the completion of future milestone activities.&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="F_000258" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;6. Property and Equipment, Net &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,534&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,003&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;886&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;860&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;888&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;827&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;895&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;895&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in process&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;577&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;490&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,780&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,075&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,530&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,981&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,094&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded $3,549 and $2,845 of depreciation expense for the years ended December&amp;#160;31, 2020 and 2019, respectively. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock id="F_000259" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;7. Accrued Expenses and Other Current Liabilities &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses and other current liabilities consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;External research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,099&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,077&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;464&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;336&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;197&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;333&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued expenses and other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,760&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,746&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
  <rlay:ConvertiblePreferredStockTextBlock id="F_000260" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;8. Convertible Preferred Stock &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company issued Series A, Series B and Series C convertible preferred stock (collectively, &amp;#8220;Convertible Preferred Stock&amp;#8221;). Upon issuance of each class of Convertible Preferred Stock, the Company assessed the embedded conversion and liquidity features of the shares and determined that such features did not require the Company to separately account for these features. The Company also concluded that no beneficial conversion feature existed on the issuance date of each class of Convertible Preferred Stock. The Company&amp;#8217;s Convertible Preferred Stock was classified outside of stockholders&amp;#8217; equity (deficit) on the consolidated balance sheet prior to the Company&amp;#8217;s IPO because the holders of such shares had liquidation rights in the event of a deemed liquidation that, in certain situations, were not solely within the control of the Company and would require the redemption of the then-outstanding Convertible Preferred Stock. The Convertible Preferred Stock was not currently redeemable. Because the occurrence of a deemed liquidation event was not probable, the carrying values of the Convertible Preferred Stock were not accreted to their redemption values. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July 8, 2020, the Company&amp;#8217;s board of directors and its Series C preferred stockholders approved a reduction in the conversion price of the Series C preferred stock from $3.21 to $3.027603 and the Series C preferred stockholders relinquished their protective right with respect to the approval of an automatic conversion of preferred stock in a firm commitment underwritten public offering if the per share price is less than $22.80. As a result of the change in the conversion price, the outstanding shares of Series C preferred stock were convertible into 37,206,604 shares of common stock. The changes to the conversion feature were considered to be a significant change to the substantive contractual terms of the Series C preferred stock and, therefore, the Company accounted for the changes as an extinguishment and reissuance of the Series C preferred stock, which required the difference between the fair value of the modified Series C preferred stock and its carrying amount to be treated in a manner similar to the treatment of dividends paid on preferred stock.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon the closing of the Company&amp;#8217;s IPO in July 2020, all outstanding Convertible Preferred Stock automatically converted into 61,992,534 shares of common stock. No Convertible Preferred Stock was outstanding as of December 31, 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to January&amp;#160;1, 2019, the Company issued a total of 56,824,740 shares of Series A convertible preferred stock (&amp;#8220;Series A preferred stock&amp;#8221;), 31,188,115 shares of Series B convertible preferred stock (&amp;#8220;Series B preferred stock&amp;#8221;) and 122,850,909 shares of Series C convertible preferred stock (&amp;#8220;Series C preferred stock&amp;#8221;) in exchange for net proceeds of $56,692, $62,876 and $393,587, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December&amp;#160;31, 2019, the Company issued an additional 1,779,093 shares of Series C preferred stock at a per share price of $3.21 for proceeds of $5,661, net of issuance costs. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible Preferred Stock consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Authorized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;and&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Carrying&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liquidation&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preference&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Conversion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,824,740&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,824,740&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75,657&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,825&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,002,820&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series B preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,188,115&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,188,115&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62,876&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;63,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,783,102&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series C preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;249,260,004&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;124,630,002&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;399,248&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;400,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,097,955&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;337,272,859&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;212,642,857&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;537,781&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;519,825&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,883,877&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There were no shares of Convertible Preferred Stock outstanding at December 31, 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The holders of the Convertible Preferred Stock had the following rights and preferences: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Voting &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The holders of the Convertible Preferred Stock had voting rights equivalent to the number of shares of common stock into which their shares of preferred stock would convert. So long as any of the Convertible Preferred Stock was outstanding, a requisite vote of the Convertible Preferred Stockholders, which was defined as a majority of the Convertible Preferred Stockholders, was required to affirm certain corporate actions, which included, but was not limited to, the disposal of assets, the acquisition of assets or a business and the authorization of additional shares of the Company&amp;#8217;s capital. In addition, such actions required a requisite vote of the Series C preferred stockholders and a majority vote of the Series B preferred stockholders, if any of the respective preferred stock was outstanding. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Dividends &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The holders of the Convertible Preferred Stock were entitled to receive noncumulative dividends when and if declared by the Company&amp;#8217;s board of directors. If the Company declared, paid or set aside, on the same date, a dividend on shares of more than one class or series of capital stock of the Company, the holders of the Convertible Preferred Stock were entitled to the same dividend based on the number of common shares the Convertible Preferred Stock would convert into. No dividends were declared or paid during the years ended December&amp;#160;31, 2020 or 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Liquidation Rights &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the event of any voluntary or involuntary liquidation, dissolution or winding up of the corporation, holders of the Series C preferred stock then outstanding were entitled to be paid out of the assets of the Company available for distribution to its stockholders before any payment was made to the holders of Series A and B preferred stock or common stock by reason of their ownership thereof, an amount per share equal to the greater of (i)&amp;#160;the Series C preferred stock original issue price ($3.21), plus any accrued but unpaid dividends declared, and (ii)&amp;#160;an amount per share if the Series C preferred stock had been converted prior to the liquidation event. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Next, the holders of the Series A preferred stock then outstanding together with holders of Series B preferred stock were entitled to be paid out of the assets of the Company available for distribution to its stockholders before any payment would be made to the common stockholders by reason of their ownership thereof, an amount per share equal to the greater of (i)&amp;#160;their original issue price, which was $1.00 and $2.02 for Series A and B preferred stock, respectively, plus any accrued but unpaid dividends declared, and (ii)&amp;#160;an amount per share if the Series A and B preferred stock, respectively, had been converted prior to the liquidation event. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Conversion &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Convertible Preferred Stock was convertible into common stock at any time at the option of the holder, and was subject to automatic conversion upon the closing of a firm commitment underwritten public offering with either a price per share of at least $22.80 and proceeds of at least $100,000 or approval by a specified vote of the Convertible Preferred Stockholders. As of December 31, 2019, the Convertible Preferred Stock was convertible into 59,382,845 shares of common stock. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July 8, 2020, the required Convertible Preferred Stockholders authorized the automatic conversion of all shares of Convertible Preferred Stock in an IPO, regardless of the price per share or total proceeds raised, as long as the IPO was completed on or before September 30, 2020.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Protective Rights &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For as long as any of the Series C preferred stock was outstanding, a requisite vote of the Convertible Preferred Stockholders was required to affirm a liquidation, dissolution, a merger or consolidation or any other deemed liquidation event if the per share proceeds to the holders of the Series C preferred stock would be equal to or greater than $22.80 per share. In addition, both a requisite vote of the Convertible Preferred Stockholders and a majority of the Series C preferred stockholders was required to affirm a liquidation, dissolution, a merger or consolidation or any other deemed liquidation event if the per share proceeds to the holders of the Series C preferred stock was less than $22.80 per share. &lt;/p&gt;</rlay:ConvertiblePreferredStockTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="F_000261" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;9. Common Stock &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&amp;#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Company&amp;#8217;s board of directors, however, holders of convertible preferred stock were entitled to any dividend received by the common stockholders if each preferred share had been converted into common stock. As of December&amp;#160;31, 2020 and 2019, no dividends had been declared. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company issued restricted shares of common stock to its founders and non-employees. In addition, the Company issued restricted shares of common stock upon the early exercise of stock options under the Company&amp;#8217;s 2016 Stock Option and Grant Plan (the &amp;#8220;2016 Stock Plan&amp;#8221;). The restrictions on the common shares generally lapse over four years. The Company included the proceeds from the sale of the restricted shares of common stock as a restricted stock liability on the accompanying consolidated balance sheets. Amounts are reclassified to additional paid-in capital as the restrictions lapse. The Company has the right to repurchase any unvested shares of restricted common stock at the original cost in the event of termination. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the restricted stock activity for the year ended December&amp;#160;31, 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchase&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;679,158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(579,825&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14,844&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.03&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;84,489&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.04&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of shares that vested during the year ended December&amp;#160;31, 2020 was $9,619. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has reserved the following shares of common stock: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Conversion of Series A preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,002,820&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Conversion of Series B preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,783,102&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Conversion of Series C preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,097,955&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares reserved under the compensation plan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,026,772&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,407,169&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total shares of common stock reserved for&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; issuance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,026,772&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,291,046&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee Stock Purchase Plan &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July&amp;#160;8, 2020, the Company&amp;#8217;s stockholders approved the 2020 Employee Stock Purchase Plan (the &amp;#8220;ESPP&amp;#8221;). The ESPP became effective on the date immediately prior to the effectiveness of Company&amp;#8217;s registration statement on Form S-1 for its IPO. As of December 31, 2020, the ESPP provides for the issuance of up to 1,092,532 of share-based awards. As of December&amp;#160;31, 2020, no shares have been issued under the ESPP. &lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="F_000262" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;10. Share-Based Payments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2016, the Company adopted the 2016 Stock Plan. On July&amp;#160;8, 2020, the Company&amp;#8217;s stockholders approved the 2020 Stock Option and Incentive Plan (the &amp;#8220;2020 Stock Plan&amp;#8221;), which became effective on the date immediately prior to the effectiveness of the Company&amp;#8217;s registration statement on Form S-1 for its IPO. The 2020 Stock Plan provides for the issuance of up to 8,376,080 of share-based awards. Subsequent to July&amp;#160;20, 2020, no further awards will be made under the 2016 Stock Plan and all future equity-based awards will be granted under the 2020 Stock Plan. To the extent outstanding options granted under the 2016 Plan are cancelled, forfeited or otherwise terminated without being exercised and would otherwise have been returned to the share reserve under the 2016 Plan, the number of shares underlying such awards will be available for future grant under the 2020 Stock Plan. All of the Company&amp;#8217;s employees, officers, directors and consultants are eligible to be granted options, restricted stock units and other stock-based awards under the terms of the 2020 Stock Plan. There were 8,026,772 share-based awards available for grant at December&amp;#160;31, 2020. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the stock option activity under the 2016 Stock Plan and the 2020 Stock Plan for the year ended December&amp;#160;31, 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:89.88%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,306,176&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.62&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.99&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,214&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,898,663&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.90&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(297,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.09&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(210,781&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.91&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,697,058&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.99&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.50&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;266,050&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,148,119&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.49&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.90&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79,625&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-vested at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,548,939&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.96&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.74&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186,425&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the first quarter of 2020, the Company&amp;#8217;s board of directors approved the issuance of options with performance-based vesting conditions to purchase 1,960,547 shares of common stock. The commencement of vesting was based on the achievement of certain scientific and operational milestones during a two-year period, for which the achievement was discretionary and subject to the approval of the Company&amp;#8217;s board of directors. Accordingly, the Company applied variable accounting for these awards until the board of directors approved the commencement of vesting for the options. The service inception date preceded the grant date for these awards as the awards were authorized prior to the grant date, the recipients were providing service prior to the grant date and there were performance conditions that, if not met by the accounting grant date, would have resulted in the forfeiture of the award. The stock-based compensation expense for the options was determined based on the fair value of the awards on the accounting grant date. The Company&amp;#8217;s board of directors, in its discretion, determined that a portion of the performance conditions were achieved during the second quarter of 2020 and that the remaining portion of the performance conditions were achieved during the fourth quarter of 2020. The grant dates for all performance-based awards was therefore known as of December 31, 2020, and all performance conditions have been resolved. The Company recognized stock-based compensation expense associated with the awards with performance-based vesting conditions in the amount of $25,527 in the statement of operations for the year ended December 31, 2020. Expense for these awards is recognized using an accelerated attribution model, over the four-year vesting term, commencing upon grant date. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimated the fair value of its stock options using the following assumptions: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.32%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.4 - 1.8%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.5 &amp;#8211; 2.5%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;73.5 - 77.6%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72.8 &amp;#8211; 73.47%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted average grant date fair value of stock options granted during the years ended December&amp;#160;31, 2020 and 2019 was $30.14 per share and $3.34 per share, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense included in the Company&amp;#8217;s consolidated statements of operations and comprehensive loss is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,691&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,687&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,269&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,769&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,960&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,456&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020, total unrecognized compensation cost related to the unvested stock-based awards was $69,948, which is expected to be recognized over a weighted average period of 2.61 years. &lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="F_000263" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;11. Income Taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December&amp;#160;31, 2020 and 2019, the Company recorded no income tax benefits due to the losses incurred due to the uncertainty of future taxable income. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the expected income tax (benefit) computed using the federal statutory income tax rate to the Company&amp;#8217;s effective income tax rate is as follows for the year ended December&amp;#160;31, 2020 and 2019: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax computed at federal statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(31.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;R&amp;amp;D credit carryovers&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s deferred tax assets at December&amp;#160;31, 2020 and 2019, consist of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,832&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,647&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credit carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,270&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,309&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,430&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,542&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangibles&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,498&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,496&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;534&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;188&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total gross deferred tax asset&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71,741&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,731&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(65,813&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(51,537&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax asset&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,928&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,194&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,928&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,194&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,928&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,194&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has incurred net operating losses (&amp;#8220;NOL&amp;#8221;) since inception. As of December&amp;#160;31, 2020, the Company had federal NOL carryforwards of $174,028 available to reduce taxable income, of which $43,127 expire beginning in 2035 and $130,901 do not expire. The Company has state NOL carryforwards of $192,346 as of December&amp;#160;31, 2020 available to reduce future state taxable income, which expire at various dates beginning in 2035. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020, the Company also had available federal research and development tax credit carryforwards of $8,139 available to reduce future tax liabilities, which begin to expire beginning in 2035. The Company also has state research and development tax credit carryforwards of $2,699 available to reduce future state tax liabilities, which expire at various dates beginning in 2030.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Utilization of the NOL carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section&amp;#160;382 of the Internal Revenue Code of 1986 (&amp;#8220;Section 382&amp;#8221;) due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section&amp;#160;382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section&amp;#160;382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section&amp;#160;382, which is determined by first multiplying the value of the Company&amp;#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed and any limitation is known, no amounts are being presented as an uncertain tax position. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded a valuation allowance against its deferred tax assets for the years ended December&amp;#160;31, 2020 and 2019 because the Company&amp;#8217;s management believes that it is more likely than not that these assets will not be realized. The valuation allowance increased by approximately $14,276 and $23,307 for the years ended December&amp;#160;31, 2020 and 2019, respectively, primarily as a result of operating losses generated with no corresponding financial statement benefit. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had no unrecognized tax benefits as of December&amp;#160;31, 2020 and 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company&amp;#8217;s tax years are still open under statute from inception to the present. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law in March 2020. The CARES Act lifts certain deduction limitations originally imposed by the Tax Cuts and Jobs Act of 2017 (&amp;#8220;2017 Tax Act&amp;#8221;). Corporate taxpayers may carryback NOLs originating during 2018 through 2020 for up to five years, which was not previously allowed under the 2017 Tax Act. The CARES Act also eliminates the 80% of taxable income limitations by allowing corporate entities to fully utilize NOL carryforwards to offset taxable income in 2018, 2019 or 2020. Taxpayers may generally deduct interest up to the sum of 50% of adjusted taxable income plus business interest income (30% limit under the 2017 Tax Act) for tax years beginning January&amp;#160;1, 2019 and 2020. The CARES Act allows taxpayers with alternative minimum tax credits to claim a refund in 2020 for the entire amount of the credits instead of recovering the credits through refunds over a period of years, as originally enacted by the 2017 Tax Act. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition, the CARES Act raises the corporate charitable deduction limit to 25% of taxable income and makes qualified improvement property generally eligible for 15-year cost-recovery and 100% bonus depreciation. The enactment of the CARES Act did not result in any adjustments to the Company&amp;#8217;s income tax provision for the year ended December&amp;#160;31, 2020, or to the Company&amp;#8217;s net deferred tax assets as of December&amp;#160;31, 2020, since the Company has not recorded any U.S. federal or state income tax benefits for the net losses incurred in any year due to the uncertainty of realizing a benefit from those items. &lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:EarningsPerShareTextBlock id="F_000264" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;12. Net Loss Per Share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the computation of basic and diluted net loss per share of the Company: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(52,412&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(75,305&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deemed dividend resulting from extinguishment upon modification of Series&amp;#160;C preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(177,789&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(230,201&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(75,305&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders per share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5.40&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21.82&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average shares of common stock, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,619,582&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,450,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As discussed in Note 8, on July&amp;#160;8, 2020, the Company&amp;#8217;s board of directors and its Series C preferred stockholders approved an amendment to the conversion preferences and rights of the Series C preferred stock which, among other changes, resulted in a reduction in the conversion price of the Series C preferred stock from $3.21 to $3.027603. The changes to the conversion feature were considered to be a significant change to the substantive contractual terms of the Series C preferred stock and, therefore, the Company accounted for the changes as an extinguishment and reissuance of the Series C preferred stock. In accordance with SEC staff guidance codified in ASC 260-10-S99-2, when equity classified preferred shares are extinguished, the difference between (1)&amp;#160;the fair value of the consideration transferred to the holders of the preferred shares and (2)&amp;#160;the carrying amount of the preferred shares, net of issuance costs, is subtracted from (or added back to) net income to arrive at income available to common stockholders in the calculation of earnings per share. This difference between the fair value of consideration transferred and carrying amount of the preferred shares, also referred to as a &amp;#8220;deemed dividend&amp;#8221;, was therefore added back to net loss above to derive net loss attributable to common stockholders. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s potentially dilutive securities, which include Convertible Preferred Stock (prior to the IPO), options to purchase common stock and unvested restricted stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,883,877&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,697,058&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,306,176&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;84,489&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;679,158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.5%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,781,547&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65,869,211&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:CommitmentsDisclosureTextBlock id="F_000265" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;13. Commitments and Contingencies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Intellectual Property License &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has a Collaboration and License Agreement with D. E. Shaw Research, LLC (&amp;#8220;D. E. Shaw Research&amp;#8221;), which held 9,999,999 shares of Series A preferred stock and 1,557,875 shares of Series C preferred stock at December 31, 2019. Upon the IPO these shares were converted into 3,281,253 shares of common stock, which are outstanding at December 31, 2020. The agreement provides that the parties will jointly conduct research efforts with the goal of identifying and developing product candidates. The original term of the agreement was three years and required the Company to pay an annual fee of $1,000. On June 15, 2020, the Company and D. E. Shaw Research agreed to amend the Collaboration and License Agreement (the &amp;#8220;Amended and Restated Collaboration and License Agreement&amp;#8221;). The Amended and Restated Collaboration and License Agreement extended the term of the agreement to August 16, 2025 and increased the annual fee from $1,000 to $7,900. The Amended and Restated Collaboration and License Agreement automatically renews for successive one year periods unless either party provides at least one year notice of non-renewal, and the annual fee during each of the one year renewal terms is subject to the mutual agreement of the Company and D. E. Shaw Research. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is obligated to pay potential development milestone payments under the terms of the agreement up to $7,300 per target, plus sales milestones and royalties, upon the achievement of certain specified contingent events. Such payments for achievement of development and regulatory milestones total up to $7,250 in the aggregate for each of the first three products the Company develops, and up to $6,250 in the aggregate for each product the Company develops after the first three. The Company assessed the milestone and royalty events through December 31, 2020 and concluded $1,500 was due to D.E. Shaw related to the execution of the Genentech Agreement in December 2020. The Company concluded no such payments were due as of December 31, 2019. The Company recorded research and development expense of $6,376 and $1,500 under this agreement for the years ended December 31, 2020 and 2019, respectively. At December 31, 2020 and December 31, 2019, the Company had an accrued expense balance to D. E. Shaw Research of approximately $1,500 and $372, respectively, on its balance sheets. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Other Research Arrangements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has certain other research and license arrangements with third-parties, which provide the Company with research services with the goal of identifying and developing product candidates. The Company is obligated to pay development milestone payments for up to four targets, each in the range of $4,000 to $7,000 upon the achievement of certain specified contingent events. The Company assessed the milestones at December&amp;#160;31, 2020 and 2019 and concluded no such milestone payments were due. The Company incurred approximately $2,704 and $3,493 of research and development expense under these agreements in the years ended December&amp;#160;31, 2020 and 2019, respectively. &lt;/p&gt;</us-gaap:CommitmentsDisclosureTextBlock>
  <us-gaap:LeasesOfLesseeDisclosureTextBlock id="F_000266" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;14. Leases &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;215 First Street &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company leased office and laboratory space at 215 First Street in Cambridge, Massachusetts (&amp;#8220;First Lease&amp;#8221;) under an operating lease, which commenced in November 2015 and was originally set to expire in December 2020. As discussed below, the Company executed a lease at 399 Binney Street (&amp;#8220;Binney Lease&amp;#8221;) whereby the Company vacated the 215 First Street lease in January 2019 and the future lease commitments terminated at no cost once the Binney Lease commenced. The lease included certain tenant improvement allowances, which the Company amortized through January 2019, the termination of the lease. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;399 Binney Street &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2017, the Company entered into a facility lease agreement for approximately 44,336 square feet of office and laboratory space at 399 Binney Street, Cambridge, Massachusetts, which was increased to 44,807 square feet in January 2018. The Company gained control of the leased space in January 2019 and recorded a right of use asset and a lease liability, accordingly. The lease expires in April 2029, subject to certain renewal options, which have not been included in the Company&amp;#8217;s right of use asset and liability, as the Company is not reasonably certain to exercise those options. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2020, the Company entered into an amendment to its facility lease agreement to expand the leased area by approximately 1,824 square feet of office space at 399 Binney Street, Cambridge, Massachusetts. The amended lease expires in April 2029, subject to certain renewal options. The amendment to the lease agreement met the criteria to be accounted for as a separate lease. The Company gained control of the leased space in October 2020 and recorded a right of use asset and a lease liability, accordingly. The right of use asset and lease liability recorded in connection with this amendment were not material.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As discussed in Note 2, the Company provided a letter of credit in the amount of $878 with a financial institution, which expires September&amp;#160;30, 2028. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the presentation of the Company&amp;#8217;s operating leases on its consolidated balance sheets: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.66%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance sheet location&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.8%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,579&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,560&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current operating lease&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,521&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,249&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-current operating lease&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities, net of current portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,901&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,583&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.8%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,422&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,832&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the effect of lease costs in the Company&amp;#8217;s consolidated statements of operations and comprehensive loss for the years ended December&amp;#160;31, 2020 and 2019: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Statement of operations location&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,273&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,216&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;748&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;581&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.8%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,797&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company made cash payments of $4,878 and $2,602 under the lease agreements during the years ended December&amp;#160;31, 2020 and 2019, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The minimum lease payments as of December&amp;#160;31, 2020 for the next five years and thereafter is expected to be as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,985&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,134&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,254&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,377&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,503&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,959&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,212&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: interest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12,790&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,422&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted average remaining lease term and weighted average discount rate of the operating leases were 8.3 years and 10.4%, respectively, at December&amp;#160;31, 2020. The weighted average remaining lease term and weighted average discount rate of the operating leases were 9.3 years and 10.4%, respectively, at December&amp;#160;31, 2019.&lt;/p&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock id="F_000267" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;15. Employee Benefits &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2016, the Company established a defined-contribution plan under Section&amp;#160;401(k) of the Internal Revenue Code (the &amp;#8220;401(k) Plan&amp;#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. The Company made matching contributions to the 401(k) Plan of $590 for the year ended December&amp;#160;31, 2020. The Company was not required to make and did not make any matching contributions to the 401(k) Plan for the year ended December&amp;#160;31, 2019.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="F_000268" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;16. Related Party Transactions &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From inception to December&amp;#160;31, 2020, the Company received consulting and management services from Third Rock Ventures LLP (&amp;#8220;TRV&amp;#8221;), an entity affiliated with certain of the Company&amp;#8217;s investors. The Company did not incur expenses for such services during the year ended December 31, 2020&lt;font style="font-size:12pt;"&gt;. &lt;/font&gt;The Company incurred approximately $200 for these services during the year ended December&amp;#160;31, 2019. No amounts were due to TRV at December&amp;#160;31, 2020. At December&amp;#160;31, 2019, $80 was due to TRV for these services.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:SubsequentEventsTextBlock id="F_000269" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;17. Subsequent Events &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In preparing the consolidated financial statements as of December&amp;#160;31, 2020, the Company evaluated subsequent events for recognition and measurement purposes through the filing date of this Annual Report on Form 10-K. The Company concluded that no events or transactions have occurred that require disclosure in the accompanying consolidated financial statements.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
  <rlay:BasisOfPresentationPolicyTextBlock id="F_000270" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basis of presentation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) for reporting on Form 10-K. The Company&amp;#8217;s consolidated financial statements include the accounts of Relay Therapeutics, Inc. and its wholly-owned subsidiary, Relay Therapeutics Securities Corporation. All intercompany balances and transactions have been eliminated. &lt;/p&gt;</rlay:BasisOfPresentationPolicyTextBlock>
  <us-gaap:UseOfEstimates id="F_000271" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development and manufacturing expenses, the valuation of equity instruments, the determination of the transaction price and standalone selling price of performance obligations under &lt;font style="color:#000000;"&gt;Accounting Standards Codification Topic 606, &lt;/font&gt;&lt;font style="font-style:italic;color:#000000;"&gt;Revenue from Contracts with Customers&lt;/font&gt;, and the incremental borrowing rate for determining the operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&amp;#8217;s business, results of operations and financial condition, including expenses, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has made estimates of the impact of COVID-19 within its financial statements and there may be changes to those estimates in future periods. Actual results could differ from the Company&amp;#8217;s estimates. &lt;/p&gt;</us-gaap:UseOfEstimates>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock id="F_000272" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Segment Information &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company&amp;#8217;s singular focus is on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets. The Company operates in the United States and all tangible assets are held in the United States.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock id="F_000273" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash Equivalents &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all short-term, highly liquid investments with original maturities of 90&amp;#160;days or less at acquisition date to be cash equivalents. Cash equivalents, which consist of money market funds, are stated at fair value. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy id="F_000274" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted Cash &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had restricted cash of $878 as of December&amp;#160;31, 2020 and 2019 to secure a letter of credit in connection with the lease of the Company&amp;#8217;s facilities (see Note 14). The Company classified the restricted cash as a noncurrent asset on its consolidated balance sheets. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:InvestmentPolicyTextBlock id="F_000275" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments in marketable securities are classified as available-for-sale. Available-for-sale securities are measured and reported at fair value using quoted prices in active markets for similar securities. Unrealized gains and losses on available-for-sale securities are reported as a separate component of stockholders&amp;#8217; equity (deficit). Premiums or discounts from par value are amortized to investment income over the life of the underlying investment. All of the Company&amp;#8217;s available-for-sale securities are available to the Company for use in current operations. As a result, the Company classified all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) within the consolidated statements of operations and comprehensive loss. If any adjustment is required to reflect a decline in the value of the investment that the Company considers to be &amp;#8220;other than temporary&amp;#8221;, the Company recognizes a charge to the consolidated statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented. &lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
  <rlay:ConcentrationOfCreditRiskAndSignificantSuppliersPolicyTextBlock id="F_000276" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk and Significant Suppliers &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and investments. From time to time, the Company has maintained all of its cash, cash equivalents and investments at certain accredited financial institutions in amounts that exceed federally insured limits. The Company generally invests its excess capital in money market funds, U.S. treasury bonds, U.S. treasury bills and agency bonds are subject to minimal credit and market risk. Management has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. The investment portfolio is maintained in accordance with the Company&amp;#8217;s investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is dependent on third-party suppliers for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a small number of these suppliers, including D. E. Shaw Research, LLC as discussed in Note 13, to meet its requirements for its programs. These programs could be adversely affected by a significant interruption in pre-clinical and clinical testing and the supply of active pharmaceutical ingredients and formulated drugs. &lt;/p&gt;</rlay:ConcentrationOfCreditRiskAndSignificantSuppliersPolicyTextBlock>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock id="F_000277" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.4%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.4%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Level 1&amp;#8212;Quoted prices in active markets for identical assets or liabilities. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.4%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.4%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Level 2&amp;#8212;Observable inputs (other than Level&amp;#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.4%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.4%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8226;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Level 3&amp;#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:RevenueRecognitionPolicyTextBlock id="F_000278" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue Recognition &lt;/p&gt;
&lt;p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for revenue recognition in accordance with Accounting Standards Codification Topic (&amp;#8220;ASC&amp;#8221;) 606, &lt;font style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt; (&amp;#8220;ASC 606&amp;#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/p&gt;
&lt;p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract and determines those that are performance obligations. The Company then determines the transaction price and allocates it to the performance obligations using the relative selling price model. As part of the accounting for these arrangements, the Company must use significant judgment to determine: (a) the number of performance obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above, including the determination of whether milestones or other variable consideration should be included in the transaction price; and (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of the transaction price in step (iv) above. &lt;/p&gt;
&lt;p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company utilizes key assumptions and judgments to determine the stand-alone selling price for each performance obligation, which may include discounted cash flow models, evaluation of comparable transactions, pricing considered in negotiating the transaction and estimated costs,&lt;font style="Background-color:#FFFFFF;"&gt; to determine how the transaction price is allocated among the performance obligations&lt;/font&gt;. The Company uses judgment to determine whether milestones or other variable consideration should be included in the transaction price. For revenue-based royalties, including milestone payments based on the level of sales, the Company will include royalties in the transaction price at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty is allocated has been satisfied (or partially satisfied). As part of management&amp;#8217;s evaluation of the transaction price, the Company considers numerous factors, including whether the achievement of the milestones is outside of our control, contingent upon the efforts of others or subject to scientific risks of success. If the Company concludes it is probable that a significant revenue reversal would not occur, the associated milestone payment is included in the transaction price. Milestone payments that are not within our control, such as regulatory approvals, are generally not considered probable until those milestones are achieved. The Company re-evaluates the transaction price, including estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/p&gt;
&lt;p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Once the performance obligations are identified, the transaction price is allocated to each performance obligation based on the relative stand-alone selling price. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied, either at a point in time or over time. If the performance obligation is satisfied over time, the Company recognizes revenue based on the use of either an output or input method. &lt;/p&gt;
&lt;p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, the Company had one collaboration and license agreement with Genentech, which the Company entered into on December 11, 2020. &lt;font style="letter-spacing:-0.1pt;"&gt;For a discussion of the accounting related to the Genentech Agreement, see Note 5,&amp;#160;&lt;/font&gt;&lt;font style="font-style:italic;letter-spacing:-0.1pt;"&gt;Collaboration and License Arrangement with Genentech&lt;/font&gt;.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:LesseeLeasesPolicyTextBlock id="F_000279" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease Agreements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under ASC 842, &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt;, the Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does not recognize a right-of-use asset or lease liability. The Company&amp;#8217;s operating leases are recognized on its consolidated balance sheets as other noncurrent assets, other current liabilities and other noncurrent liabilities. The Company does not have any finance leases. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets represent the Company&amp;#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&amp;#8217;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&amp;#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Operating lease right-of-use assets also include the effect of any lease payments made prior to commencement and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has lease agreements with lease and non-lease components, which are accounted for as a combined element. &lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="F_000280" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and Equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the useful life of the asset. Laboratory and computer equipment are depreciated over three years. Furniture and fixtures are depreciated over five years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the related asset. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock id="F_000281" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured in an amount by which the book values of the assets exceed their fair value. The Company did not recognize any impairment losses for the years ended December&amp;#160;31, 2020 and 2019.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy id="F_000282" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Classification and Accretion of Convertible Preferred Stock &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s convertible preferred stock was classified outside of stockholders&amp;#8217; equity (deficit) on the consolidated balance sheet because the holders of such shares had liquidation rights in the event of a deemed liquidation that, in certain situations, were not solely within the control of the Company and would require the redemption of the then-outstanding convertible preferred stock. The convertible preferred stock was not currently redeemable, except in the event of a deemed liquidation (see Note 8). Because the occurrence of a deemed liquidation event was not probable, the carrying value of the convertible preferred stock was not accreted to their redemption values. Subsequent adjustments to the carrying values of the convertible preferred stock would have been made only when a deemed liquidation event became probable. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon the closing of the Company&amp;#8217;s IPO in July 2020, all outstanding convertible preferred stock automatically converted into 61,992,534 shares of common stock. &lt;/p&gt;</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
  <us-gaap:CompensationRelatedCostsPolicyTextBlock id="F_000283" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures stock options and other stock-based awards granted to employees, directors and non-employees based on their fair value on the date of grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company recognizes the impact of forfeitures on stock-based compensation expense as forfeitures occur. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company issued certain options with performance-based vesting conditions whereby the service inception date preceded the accounting grant date and therefore applied variable accounting for the awards until the fair value of the awards was known on the accounting grant date. The board of directors approved the commencement of vesting for all such awards in 2020, therefore the Company no longer applies variable accounting as of December 11, 2020.&lt;font style="font-size:12pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimates the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model, which uses as inputs the fair value of the Company&amp;#8217;s common stock and assumptions the Company makes for the volatility of its common stock, the expected term of the stock options, the risk-free interest rate for a period that approximates the expected term of the stock options and the expected dividend yield. &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the Company&amp;#8217;s IPO, the estimated fair value of its common stock was determined by the board of directors, or compensation committee thereof, as of the date of each option grant, with input from management, considering the most recently available third-party valuations of common stock and the board of directors&amp;#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. Historically, these independent third-party valuations of the Company&amp;#8217;s equity instruments were performed contemporaneously with identified value inflection points.&lt;/p&gt;
&lt;p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&amp;#8217; Accounting and Valuation Guide,&amp;#160;&lt;font style="font-style:italic;"&gt;Valuation of Privately-Held-Company Equity Securities Issued as Compensation &lt;/font&gt;(the &amp;#8220;Practice Aid&amp;#8221;). The Practice Aid identifies various available methods for allocating the enterprise value across classes of series of capital stock in determining the fair value of the Company&amp;#8217;s common stock at each valuation date.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Following the Company&amp;#8217;s IPO, in connection with the accounting for granted stock options and other awards the Company may grant, the fair value of the Company&amp;#8217;s common stock is determined based on the quoted market price of its common stock.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy id="F_000284" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and Development Costs &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. Research and development expenses include salaries, stock-based compensation and benefits of employees, third-party license fees and other operational costs related to the Company&amp;#8217;s research and development activities, including allocated facility-related expenses and external costs of outside vendors engaged to conduct both pre-clinical studies and clinical trials. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <rlay:ResearchAndManufacturingContractsPolicyTextBlock id="F_000285" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and Manufacturing Contracts &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into various research and development contracts with research institutions and other companies whose costs are included in research and development expense in the accompanying consolidated statements of operations and comprehensive loss. These agreements are generally cancelable and related payments are recorded as research and development expenses as the underlying services are performed. When evaluating the adequacy of the expense recognized, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the expense recognized and the related prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&amp;#8217;s estimates. The Company&amp;#8217;s historical estimates have not been materially different from the actual costs. &lt;/p&gt;</rlay:ResearchAndManufacturingContractsPolicyTextBlock>
  <rlay:PatentCostsPolicyTextBlock id="F_000286" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Patent Costs &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. &lt;/p&gt;</rlay:PatentCostsPolicyTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock id="F_000287" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company&amp;#8217;s financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock id="F_000288" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&amp;#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. For the years ended December&amp;#160;31, 2020 and 2019, other comprehensive income (loss) consisted of changes in unrealized gains and losses from available-for-sale investments.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock id="F_000289" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Loss Per Common Share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed using the sum of the weighted average number of common shares outstanding during the period and the effect of dilutive securities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company applies the two-class method to calculate its basic and diluted net loss per share as the Company has issued shares that meet the definition of participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. The Company&amp;#8217;s participating securities contractually entitle the holders of such shares to participate in dividends; but do not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additionally, in periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. &lt;font style="color:#000000;letter-spacing:-0.1pt;"&gt;For additional discussion of net loss per common share, please see Note 12, &lt;/font&gt;&lt;font style="font-style:italic;color:#000000;letter-spacing:-0.1pt;"&gt;Net Loss Per Share. &lt;/font&gt;&lt;font style="color:#000000;letter-spacing:-0.1pt;"&gt; &lt;/font&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="F_000290" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company adopted Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No.&amp;#160;2018-13, &lt;font style="font-style:italic;"&gt;Fair Value Measurement (Topic 820): Disclosure Framework&amp;#8212;Changes to the Disclosure Requirements for Fair Value Measurement&lt;/font&gt; on January&amp;#160;1, 2020. This standard modifies certain disclosure requirements on fair value measurements. The adoption of this standard did not have a material impact on the Company&amp;#8217;s disclosures. &lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <rlay:DescriptionOfNewAccountingPronouncementsNotYetAdoptedPolicyTextBlock id="F_000291" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued ASU No. 2016-13,&lt;font style="font-style:italic;"&gt;&amp;#160;Financial Instruments&amp;#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/font&gt;. This standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and it establishes additional disclosure requirements related to credit risks. For available-for-sale securities with expected credit losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This guidance was originally effective for fiscal years beginning after December&amp;#160;15, 2019, including interim periods within those fiscal years, and early adoption was permitted. In November 2019, the FASB subsequently issued ASU 2019-10, &lt;font style="font-style:italic;"&gt;Financial Instruments&amp;#8212;Credit Losses (Topic 326), Derivatives and Hedging&lt;/font&gt; &lt;font style="font-style:italic;"&gt;(Topic 815), and Leases (Topic 842): Effective Dates &lt;/font&gt;(&amp;#8220;ASU 2019-10&amp;#8221;), whereby the effective date of this standard for smaller reporting companies was deferred to fiscal years beginning after December&amp;#160;15, 2022, including interim periods within those fiscal years, and early adoption is still permitted. The Company is assessing the impact of ASU 2019-10 on the consolidated financial statements and does not expect it to have a material impact.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2020, the FASB issued ASU No.&amp;#160;2020-06, &lt;font style="font-style:italic;"&gt;Debt &amp;#8211; Debt with Conversion and Other&lt;/font&gt; &lt;font style="font-style:italic;"&gt;Options&lt;/font&gt; (Subtopic 470-20) &lt;font style="font-style:italic;"&gt;and Derivatives and Hedging&amp;#8212;Contracts in Entity&amp;#8217;s Own Equity&lt;/font&gt; (Subtopic 815-40)&lt;font style="font-size:12pt;"&gt; &lt;/font&gt;(&amp;#8220;ASU 2020-06&amp;#8221;). This standard amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity&amp;#8217;s own equity and amends the related earnings per share (&amp;#8220;EPS&amp;#8221;) guidance. The ASU will be effective for smaller reporting companies for fiscal years beginning after December&amp;#160;15, 2023 and interim periods within those fiscal years. Early adoption is permitted in fiscal years beginning after December&amp;#160;15, 2020, including interim periods within those fiscal years. The Company is assessing the impact of&amp;#160;ASU 2020-06&amp;#160;on the consolidated financial statements and does not expect it to have a material impact. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued&amp;#160;ASU&amp;#160;2019-12,&lt;font style="font-style:italic;"&gt;&amp;#160;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/font&gt;&amp;#160;(&amp;#8220;ASU&amp;#160;2019-12&amp;#8221;), which is intended to simplify the accounting for income taxes.&amp;#160;ASU&amp;#160;2019-12&amp;#160;removes certain exceptions to the general principles in Topic 740 and also clarifies and amends certain aspects of the existing guidance to improve consistent application. The new standard will be effective for public business entities for fiscal years beginning after December&amp;#160;15, 2020. The Company is assessing the potential impact&amp;#160;ASU&amp;#160;2019-12&amp;#160;may have on its financial statements upon adoption. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &amp;#8220;emerging growth company&amp;#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected to use the extended transition period related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different effective dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time that the Company either (i)&amp;#160;irrevocably elects to &amp;#8220;opt out&amp;#8221; of such extended transition period or (ii)&amp;#160;no longer qualifies as an emerging growth company. &lt;/p&gt;</rlay:DescriptionOfNewAccountingPronouncementsNotYetAdoptedPolicyTextBlock>
  <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock id="F_000292" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables present information about the Company&amp;#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2020:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;Assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;447,146&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;447,146&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US treasury bills&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,026&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,026&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;197,389&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;197,389&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total investments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230,415&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230,415&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;447,146&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230,415&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;677,561&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2019:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;Assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,658&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,658&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US treasury bills&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;232,604&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;232,604&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;US agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,258&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,258&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total investments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;313,862&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;313,862&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,658&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;313,862&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;355,520&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
  <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock id="F_000293" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of available-for-sale investments by type of security was as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:98.64%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S treasury bills&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,997&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,996&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,001&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total investments with a maturity of one year or less&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,993&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S treasury bills&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,008&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,008&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;176,350&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;176,388&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total investments with a maturity of one to two years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179,358&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179,396&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total investments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230,351&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230,415&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:93.84%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S treasury bills&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;232,336&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;268&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;232,604&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,201&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,258&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total investments with a maturity of one year or less&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;313,537&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;325&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;313,862&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="F_000294" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,534&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,003&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;886&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;860&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;888&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;827&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;895&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;895&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in process&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;577&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;490&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,780&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,075&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,530&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,981&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,094&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock id="F_000295" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses and other current liabilities consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;External research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,099&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,077&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;464&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;336&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;197&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;333&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued expenses and other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,760&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,746&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfStockByClassTextBlock id="F_000296" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible Preferred Stock consisted of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Authorized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preferred&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;and&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Carrying&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liquidation&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preference&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Conversion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,824,740&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,824,740&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75,657&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,825&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,002,820&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series B preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,188,115&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,188,115&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62,876&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;63,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,783,102&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series C preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;249,260,004&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;124,630,002&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;399,248&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;400,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,097,955&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;337,272,859&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;212,642,857&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;537,781&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;519,825&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,883,877&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
  <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock id="F_000297" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the restricted stock activity for the year ended December&amp;#160;31, 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchase&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;679,158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(579,825&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14,844&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.03&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;84,489&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.04&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
  <rlay:ReservedSharesOfCommonStockForFutureIssuanceTableTableTextBlock id="F_000298" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has reserved the following shares of common stock: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Conversion of Series A preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,002,820&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Conversion of Series B preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,783,102&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Conversion of Series C preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,097,955&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares reserved under the compensation plan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,026,772&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,407,169&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total shares of common stock reserved for&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; issuance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,026,772&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,291,046&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</rlay:ReservedSharesOfCommonStockForFutureIssuanceTableTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="F_000299" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the stock option activity under the 2016 Stock Plan and the 2020 Stock Plan for the year ended December&amp;#160;31, 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:89.88%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,306,176&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.62&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.99&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,214&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,898,663&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.90&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(297,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.09&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(210,781&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.91&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,697,058&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.99&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.50&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;266,050&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,148,119&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.49&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.90&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;79,625&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-vested at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,548,939&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.96&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.74&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;186,425&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="F_000300" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimated the fair value of its stock options using the following assumptions: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.32%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.4 - 1.8%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.5 &amp;#8211; 2.5%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;73.5 - 77.6%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72.8 &amp;#8211; 73.47%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock id="F_000301" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense included in the Company&amp;#8217;s consolidated statements of operations and comprehensive loss is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,691&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,687&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,269&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,769&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,960&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,456&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock id="F_000302" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the expected income tax (benefit) computed using the federal statutory income tax rate to the Company&amp;#8217;s effective income tax rate is as follows for the year ended December&amp;#160;31, 2020 and 2019: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax computed at federal statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(31.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;R&amp;amp;D credit carryovers&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6.7&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock id="F_000303" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s deferred tax assets at December&amp;#160;31, 2020 and 2019, consist of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,832&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,647&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credit carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,270&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,309&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,430&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,542&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangibles&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,498&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,496&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;534&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;188&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total gross deferred tax asset&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71,741&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,731&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(65,813&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(51,537&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax asset&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,928&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,194&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,928&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,194&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,928&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,194&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="F_000304" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the computation of basic and diluted net loss per share of the Company: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(52,412&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(75,305&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deemed dividend resulting from extinguishment upon modification of Series&amp;#160;C preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(177,789&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(230,201&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(75,305&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders per share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5.40&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21.82&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average shares of common stock, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,619,582&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,450,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="F_000305" contextRef="C_0001812364_20200101_20201231">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,883,877&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,697,058&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,306,176&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested restricted stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;84,489&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;679,158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.5%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,781,547&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;65,869,211&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <rlay:ScheduleOfOperatingLeasePresentationInConsolidatedBalanceSheetTableTextBlock id="F_000306" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the presentation of the Company&amp;#8217;s operating leases on its consolidated balance sheets: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.66%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance sheet location&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.8%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,579&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,560&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current operating lease&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,521&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,249&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-current operating lease&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities, net of current portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,901&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,583&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.8%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,422&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,832&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</rlay:ScheduleOfOperatingLeasePresentationInConsolidatedBalanceSheetTableTextBlock>
  <rlay:SummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossTableTextBlock id="F_000307" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the effect of lease costs in the Company&amp;#8217;s consolidated statements of operations and comprehensive loss for the years ended December&amp;#160;31, 2020 and 2019: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Statement of operations location&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,273&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,216&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;748&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;581&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.8%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,797&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</rlay:SummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossTableTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock id="F_000308" contextRef="C_0001812364_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The minimum lease payments as of December&amp;#160;31, 2020 for the next five years and thereafter is expected to be as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,985&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,134&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,254&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,377&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,503&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,959&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,212&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: interest&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12,790&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,422&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="F_000309" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210101_20210131" decimals="-3" unitRef="U_iso4217USD">75000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="F_000310" contextRef="C_0001812364_20200720_20200720" decimals="INF" unitRef="U_xbrlishares">23000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockPricePerShare id="F_000311" contextRef="C_0001812364_20200720" decimals="INF" unitRef="U_iso4217USD_xbrlishares">20.00</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000312" contextRef="C_0001812364_20200720_20200720" decimals="-3" unitRef="U_iso4217USD">425293000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <rlay:UnderwritingDiscountsAndCommissions id="F_000313" contextRef="C_0001812364_20200720_20200720" decimals="-3" unitRef="U_iso4217USD">32200000</rlay:UnderwritingDiscountsAndCommissions>
  <us-gaap:PaymentOfFinancingAndStockIssuanceCosts id="F_000314" contextRef="C_0001812364_20200720_20200720" decimals="-3" unitRef="U_iso4217USD">2507000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
  <us-gaap:ConversionOfStockSharesConverted1 id="F_000315" contextRef="C_0001812364_20200720_20200720" decimals="INF" unitRef="U_xbrlishares">61992534</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:CommonStockSharesAuthorized id="F_000316" contextRef="C_0001812364_20200708" decimals="INF" unitRef="U_xbrlishares">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000317" contextRef="C_0001812364_20200707" decimals="INF" unitRef="U_xbrlishares">260000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:StockholdersEquityReverseStockSplit id="F_000318" contextRef="C_0001812364_20200708_20200708">one-for-3.55092</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:NumberOfOperatingSegments id="F_000319" contextRef="C_0001812364_20200101_20201231" decimals="INF" unitRef="U_rlaySegment">1</us-gaap:NumberOfOperatingSegments>
  <rlay:CashAndCashEquivalentsMaturityDateDescription id="F_000320" contextRef="C_0001812364_20200101_20201231">The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition date to be cash equivalents.</rlay:CashAndCashEquivalentsMaturityDateDescription>
  <us-gaap:RestrictedCashNoncurrent id="F_000321" contextRef="C_0001812364_us-gaapCreditFacilityAxis_us-gaapLetterOfCreditMember_20201231" decimals="-3" unitRef="U_iso4217USD">878000</us-gaap:RestrictedCashNoncurrent>
  <us-gaap:RestrictedCashNoncurrent id="F_000322" contextRef="C_0001812364_us-gaapCreditFacilityAxis_us-gaapLetterOfCreditMember_20191231" decimals="-3" unitRef="U_iso4217USD">878000</us-gaap:RestrictedCashNoncurrent>
  <rlay:NumberOfCollaborationAndLicenseAgreement id="F_000323" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_20200101_20201231" decimals="INF" unitRef="U_rlayAgreement">1</rlay:NumberOfCollaborationAndLicenseAgreement>
  <rlay:CollaborationAndLicenseAgreementEnteredDate id="F_000324" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_20200101_20201231">2020-12-11</rlay:CollaborationAndLicenseAgreementEnteredDate>
  <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend id="F_000325" contextRef="C_0001812364_20200101_20201231">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
  <us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate id="F_000326" contextRef="C_0001812364_20200101_20201231">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000327" contextRef="C_0001812364_us-gaapPropertyPlantAndEquipmentByTypeAxis_rlayLaboratoryAndComputerEquipmentMember_20200101_20201231">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000328" contextRef="C_0001812364_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse id="F_000329" contextRef="C_0001812364_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse id="F_000330" contextRef="C_0001812364_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000331" contextRef="C_0001812364_20200701_20200731" decimals="INF" unitRef="U_xbrlishares">61992534</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement id="F_000332" contextRef="C_0001812364_20200101_20201231">greater than 50%</us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000333" contextRef="C_0001812364_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20201231" decimals="-3" unitRef="U_iso4217USD">447146000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000334" contextRef="C_0001812364_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20201231" decimals="-3" unitRef="U_iso4217USD">447146000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:InvestmentsFairValueDisclosure id="F_000335" contextRef="C_0001812364_us-gaapFairValueByAssetClassAxis_us-gaapInvestmentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">33026000</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:InvestmentsFairValueDisclosure id="F_000336" contextRef="C_0001812364_us-gaapFairValueByAssetClassAxis_us-gaapInvestmentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">33026000</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:InvestmentsFairValueDisclosure id="F_000337" contextRef="C_0001812364_us-gaapFairValueByAssetClassAxis_us-gaapInvestmentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">197389000</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:InvestmentsFairValueDisclosure id="F_000338" contextRef="C_0001812364_us-gaapFairValueByAssetClassAxis_us-gaapInvestmentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231" decimals="-3" unitRef="U_iso4217USD">197389000</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:InvestmentsFairValueDisclosure id="F_000339" contextRef="C_0001812364_us-gaapFairValueByAssetClassAxis_us-gaapInvestmentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">230415000</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:InvestmentsFairValueDisclosure id="F_000340" contextRef="C_0001812364_us-gaapFairValueByAssetClassAxis_us-gaapInvestmentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">230415000</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000341" contextRef="C_0001812364_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">447146000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000342" contextRef="C_0001812364_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">230415000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000343" contextRef="C_0001812364_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">677561000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000344" contextRef="C_0001812364_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20191231" decimals="-3" unitRef="U_iso4217USD">41658000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000345" contextRef="C_0001812364_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20191231" decimals="-3" unitRef="U_iso4217USD">41658000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:InvestmentsFairValueDisclosure id="F_000346" contextRef="C_0001812364_us-gaapFairValueByAssetClassAxis_us-gaapInvestmentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">232604000</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:InvestmentsFairValueDisclosure id="F_000347" contextRef="C_0001812364_us-gaapFairValueByAssetClassAxis_us-gaapInvestmentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">232604000</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:InvestmentsFairValueDisclosure id="F_000348" contextRef="C_0001812364_us-gaapFairValueByAssetClassAxis_us-gaapInvestmentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">81258000</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:InvestmentsFairValueDisclosure id="F_000349" contextRef="C_0001812364_us-gaapFairValueByAssetClassAxis_us-gaapInvestmentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20191231" decimals="-3" unitRef="U_iso4217USD">81258000</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:InvestmentsFairValueDisclosure id="F_000350" contextRef="C_0001812364_us-gaapFairValueByAssetClassAxis_us-gaapInvestmentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">313862000</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:InvestmentsFairValueDisclosure id="F_000351" contextRef="C_0001812364_us-gaapFairValueByAssetClassAxis_us-gaapInvestmentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">313862000</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000352" contextRef="C_0001812364_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">41658000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000353" contextRef="C_0001812364_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">313862000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000354" contextRef="C_0001812364_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">355520000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000355" contextRef="C_0001812364_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneYearOrLessMember_20201231" decimals="-3" unitRef="U_iso4217USD">29997000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000356" contextRef="C_0001812364_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneYearOrLessMember_20201231" decimals="-3" unitRef="U_iso4217USD">20996000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000357" contextRef="C_0001812364_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneYearOrLessMember_20201231" decimals="-3" unitRef="U_iso4217USD">50993000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000358" contextRef="C_0001812364_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneToTwoYearsMember_20201231" decimals="-3" unitRef="U_iso4217USD">3008000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000359" contextRef="C_0001812364_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneToTwoYearsMember_20201231" decimals="-3" unitRef="U_iso4217USD">176350000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000360" contextRef="C_0001812364_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneToTwoYearsMember_20201231" decimals="-3" unitRef="U_iso4217USD">179358000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000361" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">230351000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000362" contextRef="C_0001812364_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneYearOrLessMember_20201231" decimals="-3" unitRef="U_iso4217USD">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000363" contextRef="C_0001812364_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneYearOrLessMember_20201231" decimals="-3" unitRef="U_iso4217USD">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000364" contextRef="C_0001812364_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneYearOrLessMember_20201231" decimals="-3" unitRef="U_iso4217USD">26000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000365" contextRef="C_0001812364_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneToTwoYearsMember_20201231" decimals="-3" unitRef="U_iso4217USD">38000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000366" contextRef="C_0001812364_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneToTwoYearsMember_20201231" decimals="-3" unitRef="U_iso4217USD">38000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000367" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">64000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000368" contextRef="C_0001812364_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneYearOrLessMember_20201231" decimals="-3" unitRef="U_iso4217USD">30018000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000369" contextRef="C_0001812364_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneYearOrLessMember_20201231" decimals="-3" unitRef="U_iso4217USD">21001000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000370" contextRef="C_0001812364_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneYearOrLessMember_20201231" decimals="-3" unitRef="U_iso4217USD">51019000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000371" contextRef="C_0001812364_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneToTwoYearsMember_20201231" decimals="-3" unitRef="U_iso4217USD">3008000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000372" contextRef="C_0001812364_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneToTwoYearsMember_20201231" decimals="-3" unitRef="U_iso4217USD">176388000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000373" contextRef="C_0001812364_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneToTwoYearsMember_20201231" decimals="-3" unitRef="U_iso4217USD">179396000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000374" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">230415000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000375" contextRef="C_0001812364_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneYearOrLessMember_20191231" decimals="-3" unitRef="U_iso4217USD">232336000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000376" contextRef="C_0001812364_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneYearOrLessMember_20191231" decimals="-3" unitRef="U_iso4217USD">81201000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000377" contextRef="C_0001812364_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneYearOrLessMember_20191231" decimals="-3" unitRef="U_iso4217USD">313537000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000378" contextRef="C_0001812364_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneYearOrLessMember_20191231" decimals="-3" unitRef="U_iso4217USD">268000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000379" contextRef="C_0001812364_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneYearOrLessMember_20191231" decimals="-3" unitRef="U_iso4217USD">57000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000380" contextRef="C_0001812364_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneYearOrLessMember_20191231" decimals="-3" unitRef="U_iso4217USD">325000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000381" contextRef="C_0001812364_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneYearOrLessMember_20191231" decimals="-3" unitRef="U_iso4217USD">232604000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000382" contextRef="C_0001812364_us-gaapFinancialInstrumentAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneYearOrLessMember_20191231" decimals="-3" unitRef="U_iso4217USD">81258000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000383" contextRef="C_0001812364_us-gaapInvestmentSecondaryCategorizationAxis_rlayInvestmentsWithMaturityOfOneYearOrLessMember_20191231" decimals="-3" unitRef="U_iso4217USD">313862000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:CollaborativeArrangementNatureAndPurpose id="F_000384" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_20200101_20201231">On December 11, 2020, the Company entered into the Genentech Agreement, which granted Genentech a license to develop and commercialize RLY-1971.</us-gaap:CollaborativeArrangementNatureAndPurpose>
  <us-gaap:CollaborativeArrangementRightsAndObligations id="F_000385" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_20200101_20201231">Unless Genentech elects to exercise its option to conduct the remainder of the ongoing Phase 1a Trial, the Company is responsible for the completion of this trial. Genentech is responsible for conducting all subsequent clinical development of RLY-1971. The Company is also responsible for the one-time transfer of the active pharmaceutical ingredient (&#8220;API&#8221;) and other materials related to RLY-1971 to Genentech</us-gaap:CollaborativeArrangementRightsAndObligations>
  <rlay:NonRefundableUpfrontPayment id="F_000386" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">75000000</rlay:NonRefundableUpfrontPayment>
  <rlay:MilestonePaymentReceivable id="F_000387" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">25000000</rlay:MilestonePaymentReceivable>
  <rlay:MaximumAdditionalAmountReceivedUponMilestoneAchievement id="F_000388" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">695000000</rlay:MaximumAdditionalAmountReceivedUponMilestoneAchievement>
  <rlay:MaximumAdditionalAmountReceivedUponMilestoneAchievement id="F_000389" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">410000000</rlay:MaximumAdditionalAmountReceivedUponMilestoneAchievement>
  <rlay:CollaborationAgreementTransactionPrice id="F_000390" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">85867000</rlay:CollaborationAgreementTransactionPrice>
  <rlay:NonRefundableMilestoneTransferAmount id="F_000391" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5000000</rlay:NonRefundableMilestoneTransferAmount>
  <rlay:NonRefundableMilestoneForCompletionAmount id="F_000392" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5000000</rlay:NonRefundableMilestoneForCompletionAmount>
  <rlay:VariableConsiderationRelatedToReimbursementsDueForResearchAndDevelopmentServices id="F_000393" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">867000</rlay:VariableConsiderationRelatedToReimbursementsDueForResearchAndDevelopmentServices>
  <rlay:DevelopmentBasedMilestonePaymentsUnderAgreement id="F_000394" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</rlay:DevelopmentBasedMilestonePaymentsUnderAgreement>
  <rlay:RegulatoryBasedMilestonePaymentsUnderAgreement id="F_000395" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</rlay:RegulatoryBasedMilestonePaymentsUnderAgreement>
  <rlay:CollaborationAgreementTransactionPrice id="F_000396" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_us-gaapTypeOfArrangementAxis_rlayStandAloneSellingPricesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">85867000</rlay:CollaborationAgreementTransactionPrice>
  <us-gaap:RevenueRemainingPerformanceObligation id="F_000397" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_srtProductOrServiceAxis_rlayLicenseAndTransferAgreementMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_us-gaapTypeOfArrangementAxis_rlayStandAloneSellingPricesMember_20201231" decimals="-6" unitRef="U_iso4217USD">82654000000</us-gaap:RevenueRemainingPerformanceObligation>
  <us-gaap:RevenueRemainingPerformanceObligation id="F_000398" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_srtProductOrServiceAxis_rlayResearchAndDevelopmentServicesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_us-gaapTypeOfArrangementAxis_rlayStandAloneSellingPricesMember_20201231" decimals="-6" unitRef="U_iso4217USD">2896000000</us-gaap:RevenueRemainingPerformanceObligation>
  <us-gaap:RevenueRemainingPerformanceObligation id="F_000399" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_srtProductOrServiceAxis_rlayTransferOfActivePharmaceuticalIngredientsMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_us-gaapTypeOfArrangementAxis_rlayStandAloneSellingPricesMember_20201231" decimals="-6" unitRef="U_iso4217USD">317000000</us-gaap:RevenueRemainingPerformanceObligation>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000400" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_srtProductOrServiceAxis_rlayLicenseAndTransferAgreementMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">82654000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000401" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_srtProductOrServiceAxis_rlayResearchAndDevelopmentServicesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000402" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_srtProductOrServiceAxis_rlayTransferOfActivePharmaceuticalIngredientsMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:AccountsReceivableNet id="F_000403" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_srtProductOrServiceAxis_rlayResearchAndDevelopmentServicesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_20201231" decimals="-3" unitRef="U_iso4217USD">75000000</us-gaap:AccountsReceivableNet>
  <us-gaap:ContractWithCustomerAssetNet id="F_000404" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayGenentechIncMember_srtProductOrServiceAxis_rlayTransferOfActivePharmaceuticalIngredientsMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayGenentechAgreementMember_20201231" decimals="-3" unitRef="U_iso4217USD">7654000</us-gaap:ContractWithCustomerAssetNet>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000405" contextRef="C_0001812364_us-gaapPropertyPlantAndEquipmentByTypeAxis_rlayLaboratoryEquipmentMember_20201231" decimals="-3" unitRef="U_iso4217USD">13534000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000406" contextRef="C_0001812364_us-gaapPropertyPlantAndEquipmentByTypeAxis_rlayLaboratoryEquipmentMember_20191231" decimals="-3" unitRef="U_iso4217USD">12003000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000407" contextRef="C_0001812364_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" unitRef="U_iso4217USD">886000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000408" contextRef="C_0001812364_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231" decimals="-3" unitRef="U_iso4217USD">860000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000409" contextRef="C_0001812364_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231" decimals="-3" unitRef="U_iso4217USD">888000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000410" contextRef="C_0001812364_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231" decimals="-3" unitRef="U_iso4217USD">827000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000411" contextRef="C_0001812364_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231" decimals="-3" unitRef="U_iso4217USD">895000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000412" contextRef="C_0001812364_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231" decimals="-3" unitRef="U_iso4217USD">895000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000413" contextRef="C_0001812364_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231" decimals="-3" unitRef="U_iso4217USD">577000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000414" contextRef="C_0001812364_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231" decimals="-3" unitRef="U_iso4217USD">490000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000415" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">16780000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000416" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">15075000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000417" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">10530000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000418" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">6981000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <rlay:AccruedExternalResearchAndDevelopmentExpenseCurrent id="F_000419" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">5099000</rlay:AccruedExternalResearchAndDevelopmentExpenseCurrent>
  <rlay:AccruedExternalResearchAndDevelopmentExpenseCurrent id="F_000420" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">3077000</rlay:AccruedExternalResearchAndDevelopmentExpenseCurrent>
  <rlay:AccruedProfessionalServicesCurrent id="F_000421" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">464000</rlay:AccruedProfessionalServicesCurrent>
  <rlay:AccruedProfessionalServicesCurrent id="F_000422" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">336000</rlay:AccruedProfessionalServicesCurrent>
  <rlay:AccruedOtherExpensesCurrent id="F_000423" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">197000</rlay:AccruedOtherExpensesCurrent>
  <rlay:AccruedOtherExpensesCurrent id="F_000424" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">333000</rlay:AccruedOtherExpensesCurrent>
  <rlay:PreferredStockConvertibleConversionPrice id="F_000425" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20200708_20200708" decimals="INF" unitRef="U_iso4217USD_xbrlishares">3.027603</rlay:PreferredStockConvertibleConversionPrice>
  <rlay:PreferredStockConvertibleConversionPrice id="F_000426" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">3.21</rlay:PreferredStockConvertibleConversionPrice>
  <us-gaap:SaleOfStockPricePerShare id="F_000427" contextRef="C_0001812364_srtRangeAxis_srtMaximumMember_20200708" decimals="INF" unitRef="U_iso4217USD_xbrlishares">22.80</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000428" contextRef="C_0001812364_20200708" decimals="INF" unitRef="U_xbrlishares">37206604</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000429" contextRef="C_0001812364_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200708" decimals="INF" unitRef="U_xbrlishares">61992534</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000430" contextRef="C_0001812364_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000431" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">56824740</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000432" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">31188115</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000433" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">122850909</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="F_000434" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">56692000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="F_000435" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">62876000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="F_000436" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">393587000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000437" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">1779093</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharesIssuedPricePerShare id="F_000438" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">3.21</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity id="F_000439" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">5661000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:PreferredStockSharesAuthorized id="F_000440" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">56824740</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="F_000441" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">31188115</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="F_000442" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">249260004</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="F_000443" contextRef="C_0001812364_20191231" decimals="INF" unitRef="U_xbrlishares">337272859</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="F_000444" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">56824740</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued id="F_000445" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">31188115</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued id="F_000446" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">124630002</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued id="F_000447" contextRef="C_0001812364_20191231" decimals="INF" unitRef="U_xbrlishares">212642857</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="F_000448" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">56824740</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="F_000449" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">31188115</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="F_000450" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">124630002</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="F_000451" contextRef="C_0001812364_20191231" decimals="INF" unitRef="U_xbrlishares">212642857</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue id="F_000452" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">75657000</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue id="F_000453" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">62876000</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue id="F_000454" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">399248000</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue id="F_000455" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">537781000</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockLiquidationPreferenceValue id="F_000456" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">56825000</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:PreferredStockLiquidationPreferenceValue id="F_000457" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">63000000</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:PreferredStockLiquidationPreferenceValue id="F_000458" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">400000000</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:PreferredStockLiquidationPreferenceValue id="F_000459" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">519825000</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000460" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">16002820</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000461" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">8783102</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000462" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">35097955</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000463" contextRef="C_0001812364_20191231" decimals="INF" unitRef="U_xbrlishares">59883877</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:PreferredStockSharesOutstanding id="F_000464" contextRef="C_0001812364_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockVotingRights id="F_000465" contextRef="C_0001812364_20200101_20201231">The holders of the Convertible Preferred Stock had voting rights equivalent to the number of shares of common stock into which their shares of preferred stock would convert. So long as any of the Convertible Preferred Stock was outstanding, a requisite vote of the Convertible Preferred Stockholders, which was defined as a majority of the Convertible Preferred Stockholders, was required to affirm certain corporate actions, which included, but was not limited to, the disposal of assets, the acquisition of assets or a business and the authorization of additional shares of the Company&#8217;s capital. In addition, such actions required a requisite vote of the Series C preferred stockholders and a majority vote of the Series B preferred stockholders, if any of the respective preferred stock was outstanding.</us-gaap:PreferredStockVotingRights>
  <us-gaap:DividendsPreferredStock id="F_000466" contextRef="C_0001812364_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:DividendsPreferredStock>
  <us-gaap:DividendsPreferredStock id="F_000467" contextRef="C_0001812364_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:DividendsPreferredStock>
  <us-gaap:PreferredStockLiquidationPreference id="F_000468" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">3.21</us-gaap:PreferredStockLiquidationPreference>
  <us-gaap:PreferredStockLiquidationPreference id="F_000469" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.00</us-gaap:PreferredStockLiquidationPreference>
  <us-gaap:PreferredStockLiquidationPreference id="F_000470" contextRef="C_0001812364_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">2.02</us-gaap:PreferredStockLiquidationPreference>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="F_000471" contextRef="C_0001812364_us-gaapSubsidiarySaleOfStockAxis_rlayUnderwrittenPublicOfferingMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">100000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <rlay:PreferredStockConvertibleConversionPrice id="F_000472" contextRef="C_0001812364_us-gaapSubsidiarySaleOfStockAxis_rlayUnderwrittenPublicOfferingMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">22.80</rlay:PreferredStockConvertibleConversionPrice>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000473" contextRef="C_0001812364_us-gaapSubsidiarySaleOfStockAxis_rlayUnderwrittenPublicOfferingMember_20191231" decimals="INF" unitRef="U_xbrlishares">59382845</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:PreferredStockLiquidationPreference id="F_000474" contextRef="C_0001812364_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">22.80</us-gaap:PreferredStockLiquidationPreference>
  <us-gaap:PreferredStockLiquidationPreference id="F_000475" contextRef="C_0001812364_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">22.80</us-gaap:PreferredStockLiquidationPreference>
  <us-gaap:CommonStockVotingRights id="F_000476" contextRef="C_0001812364_20200101_20201231">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders.</us-gaap:CommonStockVotingRights>
  <us-gaap:DividendsCommonStock id="F_000477" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DividendsCommonStock>
  <us-gaap:DividendsCommonStock id="F_000478" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DividendsCommonStock>
  <rlay:CommonStockRestrictionPeriod id="F_000479" contextRef="C_0001812364_20200101_20201231">P4Y</rlay:CommonStockRestrictionPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_000480" contextRef="C_0001812364_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">679158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="F_000481" contextRef="C_0001812364_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">579825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares id="F_000482" contextRef="C_0001812364_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">14844</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_000483" contextRef="C_0001812364_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">84489</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased id="F_000484" contextRef="C_0001812364_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
  <rlay:ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAveragePriceOfSharesPurchased id="F_000485" contextRef="C_0001812364_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.26</rlay:ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAveragePriceOfSharesPurchased>
  <rlay:ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAveragePriceOfSharesPurchased id="F_000486" contextRef="C_0001812364_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.03</rlay:ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAveragePriceOfSharesPurchased>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased id="F_000487" contextRef="C_0001812364_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue id="F_000488" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">9619000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
  <rlay:CommonStockCapitalSharesReservedUnderCompensationPlan id="F_000489" contextRef="C_0001812364_20201231" decimals="INF" unitRef="U_xbrlishares">8026772</rlay:CommonStockCapitalSharesReservedUnderCompensationPlan>
  <rlay:CommonStockCapitalSharesReservedUnderCompensationPlan id="F_000490" contextRef="C_0001812364_20191231" decimals="INF" unitRef="U_xbrlishares">8407169</rlay:CommonStockCapitalSharesReservedUnderCompensationPlan>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000491" contextRef="C_0001812364_20201231" decimals="INF" unitRef="U_xbrlishares">8026772</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000492" contextRef="C_0001812364_20191231" decimals="INF" unitRef="U_xbrlishares">68291046</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_000493" contextRef="C_0001812364_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_rlayEmployeeStockPurchasePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">1092532</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_000494" contextRef="C_0001812364_us-gaapPlanNameAxis_rlayEmployeeStockPurchasePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_000495" contextRef="C_0001812364_us-gaapPlanNameAxis_rlayTwoThousandTwentyPlanMember_20200708" decimals="INF" unitRef="U_xbrlishares">8376080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_000496" contextRef="C_0001812364_us-gaapPlanNameAxis_rlayTwoThousandTwentyPlanMember_20200801" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_000497" contextRef="C_0001812364_us-gaapPlanNameAxis_rlayTwoThousandSixteenPlanMember_20200801" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_000498" contextRef="C_0001812364_us-gaapPlanNameAxis_rlayTwoThousandTwentyPlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">8026772</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000499" contextRef="C_0001812364_20191231" decimals="INF" unitRef="U_xbrlishares">5306176</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000500" contextRef="C_0001812364_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">2898663</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000501" contextRef="C_0001812364_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">297000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000502" contextRef="C_0001812364_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">210781</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000503" contextRef="C_0001812364_20201231" decimals="INF" unitRef="U_xbrlishares">7697058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="F_000504" contextRef="C_0001812364_20201231" decimals="INF" unitRef="U_xbrlishares">2148119</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares id="F_000505" contextRef="C_0001812364_20201231" decimals="INF" unitRef="U_xbrlishares">5548939</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000506" contextRef="C_0001812364_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">4.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000507" contextRef="C_0001812364_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">10.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000508" contextRef="C_0001812364_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">4.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000509" contextRef="C_0001812364_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">4.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000510" contextRef="C_0001812364_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">6.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000511" contextRef="C_0001812364_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">4.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="F_000512" contextRef="C_0001812364_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">7.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000513" contextRef="C_0001812364_20190101_20191231">P8Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000514" contextRef="C_0001812364_20200101_20201231">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="F_000515" contextRef="C_0001812364_20200101_20201231">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <rlay:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm id="F_000516" contextRef="C_0001812364_20200101_20201231">P8Y8M26D</rlay:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000517" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">3214000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000518" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">266050000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="F_000519" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">79625000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="F_000520" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">186425000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward id="F_000521" contextRef="C_0001812364_us-gaapPlanNameAxis_rlayTwoThousandSixteenPlanMember_20200101_20200331" decimals="INF" unitRef="U_xbrlishares">1960547</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights id="F_000522" contextRef="C_0001812364_us-gaapPlanNameAxis_rlayTwoThousandSixteenPlanMember_20200101_20201231">The commencement of vesting was based on the achievement of certain scientific and operational milestones during a two-year period, for which the achievement was discretionary and subject to the approval of the Company&#8217;s board of directors.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000523" contextRef="C_0001812364_us-gaapIncomeStatementLocationAxis_us-gaapOperatingIncomeLossMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">25527000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000524" contextRef="C_0001812364_20200101_20201231">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="F_000525" contextRef="C_0001812364_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="F_000526" contextRef="C_0001812364_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="F_000527" contextRef="C_0001812364_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="F_000528" contextRef="C_0001812364_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000529" contextRef="C_0001812364_20200101_20201231">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000530" contextRef="C_0001812364_20190101_20191231">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="F_000531" contextRef="C_0001812364_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.735</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="F_000532" contextRef="C_0001812364_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.728</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="F_000533" contextRef="C_0001812364_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.776</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="F_000534" contextRef="C_0001812364_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.7347</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000535" contextRef="C_0001812364_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000536" contextRef="C_0001812364_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000537" contextRef="C_0001812364_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">30.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000538" contextRef="C_0001812364_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">3.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000539" contextRef="C_0001812364_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">14691000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000540" contextRef="C_0001812364_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2687000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000541" contextRef="C_0001812364_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">17269000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000542" contextRef="C_0001812364_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1769000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000543" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">31960000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000544" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4456000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="F_000545" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">69948000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000546" contextRef="C_0001812364_20200101_20201231">P2Y7M9D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000547" contextRef="C_0001812364_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000548" contextRef="C_0001812364_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000549" contextRef="C_0001812364_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000550" contextRef="C_0001812364_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="F_000551" contextRef="C_0001812364_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.057</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="F_000552" contextRef="C_0001812364_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.070</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000553" contextRef="C_0001812364_20200101_20201231" decimals="3" unitRef="U_xbrlipure">-0.273</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000554" contextRef="C_0001812364_20190101_20191231" decimals="3" unitRef="U_xbrlipure">-0.310</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch id="F_000555" contextRef="C_0001812364_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.076</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch id="F_000556" contextRef="C_0001812364_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.041</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent id="F_000557" contextRef="C_0001812364_20200101_20201231" decimals="3" unitRef="U_xbrlipure">-0.067</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
  <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent id="F_000558" contextRef="C_0001812364_20190101_20191231" decimals="3" unitRef="U_xbrlipure">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
  <rlay:EffectiveIncomeTaxRateReconciliationPermanentDifferences id="F_000559" contextRef="C_0001812364_20200101_20201231" decimals="3" unitRef="U_xbrlipure">-0.003</rlay:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
  <rlay:EffectiveIncomeTaxRateReconciliationPermanentDifferences id="F_000560" contextRef="C_0001812364_20190101_20191231" decimals="3" unitRef="U_xbrlipure">-0.002</rlay:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="F_000561" contextRef="C_0001812364_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="F_000562" contextRef="C_0001812364_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000563" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">48832000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000564" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">42647000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards id="F_000565" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">10270000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards id="F_000566" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">6309000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <rlay:DeferredTaxAssetsLeaseLiability id="F_000567" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">6430000</rlay:DeferredTaxAssetsLeaseLiability>
  <rlay:DeferredTaxAssetsLeaseLiability id="F_000568" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">6542000</rlay:DeferredTaxAssetsLeaseLiability>
  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets id="F_000569" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">1469000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets id="F_000570" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">1498000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="F_000571" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">4496000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="F_000572" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">534000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <rlay:DeferredTaxAssetsDepreciationAndAmortization id="F_000573" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">230000</rlay:DeferredTaxAssetsDepreciationAndAmortization>
  <rlay:DeferredTaxAssetsDepreciationAndAmortization id="F_000574" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">188000</rlay:DeferredTaxAssetsDepreciationAndAmortization>
  <us-gaap:DeferredTaxAssetsOther id="F_000575" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">14000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOther id="F_000576" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">13000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsGross id="F_000577" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">71741000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross id="F_000578" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">57731000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000579" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">65813000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000580" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">51537000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsNet id="F_000581" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">5928000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsNet id="F_000582" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">6194000</us-gaap:DeferredTaxAssetsNet>
  <rlay:DeferredTaxLiabilitiesOperatingLeaseAssets id="F_000583" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">5928000</rlay:DeferredTaxLiabilitiesOperatingLeaseAssets>
  <rlay:DeferredTaxLiabilitiesOperatingLeaseAssets id="F_000584" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">6194000</rlay:DeferredTaxLiabilitiesOperatingLeaseAssets>
  <us-gaap:DeferredIncomeTaxLiabilities id="F_000585" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">5928000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredIncomeTaxLiabilities id="F_000586" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">6194000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic id="F_000587" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">174028000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration id="F_000588" contextRef="C_0001812364_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-3" unitRef="U_iso4217USD">43127000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration id="F_000589" contextRef="C_0001812364_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-3" unitRef="U_iso4217USD">130901000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
  <rlay:DeferredTaxAssetsOperatingLossCarryforwardsBeginningToExpireYear id="F_000590" contextRef="C_0001812364_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">2035</rlay:DeferredTaxAssetsOperatingLossCarryforwardsBeginningToExpireYear>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal id="F_000591" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">192346000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
  <rlay:DeferredTaxAssetsOperatingLossCarryforwardsBeginningToExpireYear id="F_000592" contextRef="C_0001812364_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">2035</rlay:DeferredTaxAssetsOperatingLossCarryforwardsBeginningToExpireYear>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000593" contextRef="C_0001812364_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-3" unitRef="U_iso4217USD">8139000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <rlay:DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear id="F_000594" contextRef="C_0001812364_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">2035</rlay:DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000595" contextRef="C_0001812364_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231" decimals="-3" unitRef="U_iso4217USD">2699000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <rlay:DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear id="F_000596" contextRef="C_0001812364_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">2030</rlay:DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear>
  <rlay:IncreaseInDeferredTaxAssetsValuationAllowance id="F_000597" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">14276000</rlay:IncreaseInDeferredTaxAssetsValuationAllowance>
  <rlay:IncreaseInDeferredTaxAssetsValuationAllowance id="F_000598" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">23307000</rlay:IncreaseInDeferredTaxAssetsValuationAllowance>
  <us-gaap:UnrecognizedTaxBenefits id="F_000599" contextRef="C_0001812364_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits id="F_000600" contextRef="C_0001812364_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:IncomeTaxExaminationDescription id="F_000601" contextRef="C_0001812364_20200101_20201231">There are currently no pending tax examinations.</us-gaap:IncomeTaxExaminationDescription>
  <rlay:TaxCutsAndJobsActOf2017DescriptionOfCorporateTaxPayers id="F_000602" contextRef="C_0001812364_20200101_20201231">Corporate taxpayers may carryback NOLs originating during 2018 through 2020 for up to five years, which was not previously allowed under the 2017 Tax Act. The CARES Act also eliminates the 80% of taxable income limitations by allowing corporate entities to fully utilize NOL carryforwards to offset taxable income in 2018, 2019 or 2020. Taxpayers may generally deduct interest up to the sum of 50% of adjusted taxable income plus business interest income (30% limit under the 2017 Tax Act) for tax years beginning January 1, 2019 and 2020. The CARES Act allows taxpayers with alternative minimum tax credits to claim a refund in 2020 for the entire amount of the credits instead of recovering the credits through refunds over a period of years, as originally enacted by the 2017 Tax Act.</rlay:TaxCutsAndJobsActOf2017DescriptionOfCorporateTaxPayers>
  <rlay:TaxCutsAndJobsActOf2017NetOperatingLossCarrybackPeriod id="F_000603" contextRef="C_0001812364_srtRangeAxis_srtMaximumMember_20200101_20201231">P5Y</rlay:TaxCutsAndJobsActOf2017NetOperatingLossCarrybackPeriod>
  <rlay:CARESActPercentageOfEliminatesOfTaxableIncome id="F_000604" contextRef="C_0001812364_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.80</rlay:CARESActPercentageOfEliminatesOfTaxableIncome>
  <rlay:TaxCutsAndJobsActOf2017MaximumPercentageOfInterestDeductedByTaxPayers id="F_000605" contextRef="C_0001812364_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.50</rlay:TaxCutsAndJobsActOf2017MaximumPercentageOfInterestDeductedByTaxPayers>
  <rlay:CARESActPercentageOfInterestDeductedByTaxPayers id="F_000606" contextRef="C_0001812364_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.30</rlay:CARESActPercentageOfInterestDeductedByTaxPayers>
  <rlay:CARESActPercentageOfCorporateCharitableDeductionLimit id="F_000607" contextRef="C_0001812364_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.25</rlay:CARESActPercentageOfCorporateCharitableDeductionLimit>
  <rlay:CARESActPeriodOfQualifiedImprovementPropertyForCostRecovery id="F_000608" contextRef="C_0001812364_20200101_20201231">P15Y</rlay:CARESActPeriodOfQualifiedImprovementPropertyForCostRecovery>
  <rlay:CARESActPercentageOfBonusDepreciation id="F_000609" contextRef="C_0001812364_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</rlay:CARESActPercentageOfBonusDepreciation>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000610" contextRef="C_0001812364_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000611" contextRef="C_0001812364_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:PreferredStockDividendsAndOtherAdjustments id="F_000612" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">177789000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
  <us-gaap:IncomeLossFromContinuingOperations id="F_000613" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-230201000</us-gaap:IncomeLossFromContinuingOperations>
  <us-gaap:IncomeLossFromContinuingOperations id="F_000614" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-75305000</us-gaap:IncomeLossFromContinuingOperations>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000615" contextRef="C_0001812364_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_rlayConvertiblePreferredStocksMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">59883877</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000616" contextRef="C_0001812364_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">7697058</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000617" contextRef="C_0001812364_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">5306176</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000618" contextRef="C_0001812364_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">84489</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000619" contextRef="C_0001812364_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">679158</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000620" contextRef="C_0001812364_20200101_20201231" decimals="0" unitRef="U_xbrlishares">7781547</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000621" contextRef="C_0001812364_20190101_20191231" decimals="0" unitRef="U_xbrlishares">65869211</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:InvestmentsInAndAdvancesToAffiliatesBalanceShares id="F_000622" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">9999999</us-gaap:InvestmentsInAndAdvancesToAffiliatesBalanceShares>
  <us-gaap:InvestmentsInAndAdvancesToAffiliatesBalanceShares id="F_000623" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesCPreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">1557875</us-gaap:InvestmentsInAndAdvancesToAffiliatesBalanceShares>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000624" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20201231" decimals="INF" unitRef="U_xbrlishares">3281253</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <rlay:ResearchAndDevelopmentArrangementAnnualFee id="F_000625" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191231" decimals="-3" unitRef="U_iso4217USD">1000000</rlay:ResearchAndDevelopmentArrangementAnnualFee>
  <rlay:ResearchAndDevelopmentArrangementAnnualFee id="F_000626" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20200615" decimals="-3" unitRef="U_iso4217USD">7900000</rlay:ResearchAndDevelopmentArrangementAnnualFee>
  <rlay:ResearchAndDevelopmentArrangementTermOfContract id="F_000627" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20200101_20201231">P3Y</rlay:ResearchAndDevelopmentArrangementTermOfContract>
  <rlay:ResearchAndDevelopmentArrangementExpirationDate id="F_000628" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20200615_20200615">2025-08-16</rlay:ResearchAndDevelopmentArrangementExpirationDate>
  <rlay:ResearchAndDevelopmentArrangementContractToPerformForOthersRenewalPeriod id="F_000629" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20200101_20201231">P1Y</rlay:ResearchAndDevelopmentArrangementContractToPerformForOthersRenewalPeriod>
  <rlay:PotentialDevelopmentMilestonePayments id="F_000630" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">7300000</rlay:PotentialDevelopmentMilestonePayments>
  <rlay:MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement id="F_000631" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20201231" decimals="-3" unitRef="U_iso4217USD">7250000</rlay:MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement>
  <rlay:MaximumAdditionalAmountReceivedUponMilestoneAchievement id="F_000632" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">6250000</rlay:MaximumAdditionalAmountReceivedUponMilestoneAchievement>
  <rlay:MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement id="F_000633" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayLeaseAgreementMember_20201231" decimals="-3" unitRef="U_iso4217USD">1500000</rlay:MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement>
  <rlay:MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement id="F_000634" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_rlayLeaseAgreementMember_20191231" decimals="INF" unitRef="U_iso4217USD">0</rlay:MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000635" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">6376000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000636" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1500000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000637" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_20201231" decimals="-3" unitRef="U_iso4217USD">1500000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000638" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayDEShawResearchMember_20191231" decimals="-3" unitRef="U_iso4217USD">372000</us-gaap:AccruedLiabilitiesCurrent>
  <rlay:NumberOfMilestoneTargets id="F_000639" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayOtherthirdPartiesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20201231" decimals="INF" unitRef="U_rlayTarget">4</rlay:NumberOfMilestoneTargets>
  <rlay:PotentialDevelopmentMilestonePayments id="F_000640" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayOtherthirdPartiesMember_srtRangeAxis_srtMinimumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">4000000</rlay:PotentialDevelopmentMilestonePayments>
  <rlay:PotentialDevelopmentMilestonePayments id="F_000641" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayOtherthirdPartiesMember_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">7000000</rlay:PotentialDevelopmentMilestonePayments>
  <rlay:MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement id="F_000642" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayOtherthirdPartiesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20201231" decimals="INF" unitRef="U_iso4217USD">0</rlay:MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement>
  <rlay:MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement id="F_000643" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayOtherthirdPartiesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20191231" decimals="INF" unitRef="U_iso4217USD">0</rlay:MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000644" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayOtherthirdPartiesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2704000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000645" contextRef="C_0001812364_srtCounterpartyNameAxis_rlayOtherthirdPartiesMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3493000</us-gaap:ResearchAndDevelopmentExpense>
  <rlay:LeaseExpirationMonthAndYear id="F_000646" contextRef="C_0001812364_srtStatementGeographicalAxis_rlayFirstStreetInCambridgeMassachusettsMember_20151101_20151130">2020-12</rlay:LeaseExpirationMonthAndYear>
  <us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate id="F_000647" contextRef="C_0001812364_20151101_20151130">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate>
  <us-gaap:LandSubjectToGroundLeases id="F_000648" contextRef="C_0001812364_srtStatementGeographicalAxis_rlayBinneyStreetCambridgeMassachusettsMember_20171231" decimals="0" unitRef="U_utrsqft">44336</us-gaap:LandSubjectToGroundLeases>
  <us-gaap:LandSubjectToGroundLeases id="F_000649" contextRef="C_0001812364_srtStatementGeographicalAxis_rlayBinneyStreetCambridgeMassachusettsMember_20180131" decimals="0" unitRef="U_utrsqft">44807</us-gaap:LandSubjectToGroundLeases>
  <rlay:LeaseExpirationMonthAndYear id="F_000650" contextRef="C_0001812364_srtStatementGeographicalAxis_rlayBinneyStreetCambridgeMassachusettsMember_20171201_20171231">2029-04</rlay:LeaseExpirationMonthAndYear>
  <us-gaap:LandSubjectToGroundLeases id="F_000651" contextRef="C_0001812364_srtStatementGeographicalAxis_rlayBinneyStreetCambridgeMassachusettsMember_20200930" decimals="0" unitRef="U_utrsqft">1824</us-gaap:LandSubjectToGroundLeases>
  <rlay:LeaseExpirationMonthAndYear id="F_000652" contextRef="C_0001812364_srtStatementGeographicalAxis_rlayBinneyStreetCambridgeMassachusettsMember_20200901_20200930">2029-04</rlay:LeaseExpirationMonthAndYear>
  <us-gaap:LettersOfCreditOutstandingAmount id="F_000653" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">878000</us-gaap:LettersOfCreditOutstandingAmount>
  <us-gaap:DebtInstrumentMaturityDate id="F_000654" contextRef="C_0001812364_20200101_20201231">2028-09-30</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList id="F_000655" contextRef="C_0001812364_20201231">rlay:OperatingLeaseAssetsMember</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
  <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList id="F_000656" contextRef="C_0001812364_20191231">rlay:OperatingLeaseAssetsMember</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
  <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList id="F_000657" contextRef="C_0001812364_20201231">rlay:OperatingLeaseLiabilitiesMember</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
  <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList id="F_000658" contextRef="C_0001812364_20191231">rlay:OperatingLeaseLiabilitiesMember</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
  <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList id="F_000659" contextRef="C_0001812364_20201231">rlay:OperatingLeaseLiabilitiesNetOfCurrentPortionMember</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
  <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList id="F_000660" contextRef="C_0001812364_20191231">rlay:OperatingLeaseLiabilitiesNetOfCurrentPortionMember</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
  <us-gaap:OperatingLeaseLiability id="F_000661" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">24422000</us-gaap:OperatingLeaseLiability>
  <us-gaap:OperatingLeaseLiability id="F_000662" contextRef="C_0001812364_20191231" decimals="-3" unitRef="U_iso4217USD">24832000</us-gaap:OperatingLeaseLiability>
  <us-gaap:OperatingLeaseCost id="F_000663" contextRef="C_0001812364_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3273000</us-gaap:OperatingLeaseCost>
  <us-gaap:OperatingLeaseCost id="F_000664" contextRef="C_0001812364_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3216000</us-gaap:OperatingLeaseCost>
  <us-gaap:OperatingLeaseCost id="F_000665" contextRef="C_0001812364_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">748000</us-gaap:OperatingLeaseCost>
  <us-gaap:OperatingLeaseCost id="F_000666" contextRef="C_0001812364_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">581000</us-gaap:OperatingLeaseCost>
  <us-gaap:OperatingLeaseCost id="F_000667" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">4021000</us-gaap:OperatingLeaseCost>
  <us-gaap:OperatingLeaseCost id="F_000668" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3797000</us-gaap:OperatingLeaseCost>
  <us-gaap:OperatingLeasePayments id="F_000669" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">4878000</us-gaap:OperatingLeasePayments>
  <us-gaap:OperatingLeasePayments id="F_000670" contextRef="C_0001812364_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2602000</us-gaap:OperatingLeasePayments>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths id="F_000671" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">3985000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo id="F_000672" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">4134000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree id="F_000673" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">4254000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour id="F_000674" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">4377000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive id="F_000675" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">4503000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive id="F_000676" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">15959000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue id="F_000677" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">37212000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
  <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount id="F_000678" contextRef="C_0001812364_20201231" decimals="-3" unitRef="U_iso4217USD">12790000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
  <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 id="F_000679" contextRef="C_0001812364_20201231">P8Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 id="F_000680" contextRef="C_0001812364_20191231">P9Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent id="F_000681" contextRef="C_0001812364_20201231" decimals="3" unitRef="U_xbrlipure">0.104</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent id="F_000682" contextRef="C_0001812364_20191231" decimals="3" unitRef="U_xbrlipure">0.104</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount id="F_000683" contextRef="C_0001812364_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">590000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty id="F_000684" contextRef="C_0001812364_us-gaapRelatedPartyTransactionAxis_rlayConsultingAndManagementServicesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_rlayThirdRockVentureMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty id="F_000685" contextRef="C_0001812364_us-gaapRelatedPartyTransactionAxis_rlayConsultingAndManagementServicesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_rlayThirdRockVentureMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">200000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent id="F_000686" contextRef="C_0001812364_us-gaapRelatedPartyTransactionAxis_rlayConsultingAndManagementServicesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_rlayThirdRockVentureMember_20201231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent id="F_000687" contextRef="C_0001812364_us-gaapRelatedPartyTransactionAxis_rlayConsultingAndManagementServicesMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_rlayThirdRockVentureMember_20191231" decimals="-3" unitRef="U_iso4217USD">80000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>42
<FILENAME>rlay-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-25T16:08:59.0369926+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : b6984381c2ae479bb023a8d6e22330cc -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:rlay="http://relaytx.com/20201231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://relaytx.com/20201231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://relaytx.com/20201231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rlay-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rlay-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rlay-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rlay-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit" id="Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit">
        <link:definition>100040 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders&apos; Deficit</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitParenthetical" id="Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitParenthetical">
        <link:definition>100050 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders&apos; Deficit (parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" id="Role_StatementConsolidatedStatementsOfCashFlowsParenthetical">
        <link:definition>100070 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentation">
        <link:definition>100080 - Disclosure - Nature of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureSignificantAccountingPolicies" id="Role_DisclosureSignificantAccountingPolicies">
        <link:definition>100090 - Disclosure - Significant  Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssets" id="Role_DisclosureFairValueOfFinancialAssets">
        <link:definition>100100 - Disclosure - Fair Value of Financial Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureInvestments" id="Role_DisclosureInvestments">
        <link:definition>100110 - Disclosure - Investments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseArrangementWithGenentech" id="Role_DisclosureCollaborationAndLicenseArrangementWithGenentech">
        <link:definition>100120 - Disclosure - Collaboration and License Arrangement with Genentech</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>100130 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>100140 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock" id="Role_DisclosureConvertiblePreferredStock">
        <link:definition>100150 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStock" id="Role_DisclosureCommonStock">
        <link:definition>100160 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPayments" id="Role_DisclosureShareBasedPayments">
        <link:definition>100170 - Disclosure - Share-Based Payments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100180 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100190 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100200 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100210 - Disclosure -  Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureEmployeeBenefits" id="Role_DisclosureEmployeeBenefits">
        <link:definition>100220 - Disclosure - Employee Benefits</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100230 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100240 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" id="Role_DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>100250 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsTables" id="Role_DisclosureFairValueOfFinancialAssetsTables">
        <link:definition>100260 - Disclosure - Fair Value of Financial Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureInvestmentsTables" id="Role_DisclosureInvestmentsTables">
        <link:definition>100270 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100280 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>100290 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockTables" id="Role_DisclosureConvertiblePreferredStockTables">
        <link:definition>100300 - Disclosure - Convertible Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStockTables" id="Role_DisclosureCommonStockTables">
        <link:definition>100310 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPaymentsTables" id="Role_DisclosureShareBasedPaymentsTables">
        <link:definition>100320 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100330 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100340 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100350 - Disclosure -  Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail">
        <link:definition>100360 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100370 - Disclosure - Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" id="Role_DisclosureFairValueOfFinancialAssetsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail">
        <link:definition>100380 - Disclosure - Fair Value of Financial Assets - Summary of Financial Assets Measured at Fair Value on a Recurring Basis and Level of the Fair Value Hierarchy (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail" id="Role_DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail">
        <link:definition>100390 - Disclosure - Investments - Summary of Fair Value of Available-for-Sale Investments by Type of Security (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseArrangementWithGenentechAdditionalInformationDetail" id="Role_DisclosureCollaborationAndLicenseArrangementWithGenentechAdditionalInformationDetail">
        <link:definition>100400 - Disclosure - Collaboration and License Arrangement with Genentech - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" id="Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail">
        <link:definition>100410 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail">
        <link:definition>100420 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail">
        <link:definition>100430 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetail" id="Role_DisclosureConvertiblePreferredStockAdditionalInformationDetail">
        <link:definition>100440 - Disclosure - Convertible Preferred Stock - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetail" id="Role_DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetail">
        <link:definition>100450 - Disclosure - Convertible Preferred Stock - Summary of Convertible Preferred Stock (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" id="Role_DisclosureCommonStockAdditionalInformationDetail">
        <link:definition>100460 - Disclosure - Common Stock - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfTheRestrictedStockActivityDetail" id="Role_DisclosureCommonStockSummaryOfTheRestrictedStockActivityDetail">
        <link:definition>100470 - Disclosure - Common Stock - Summary Of The Restricted Stock Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetail" id="Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetail">
        <link:definition>100480 - Disclosure - Common Stock - Summary of Reserved Shares of Common Stock (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPaymentsAdditionalInformationDetail" id="Role_DisclosureShareBasedPaymentsAdditionalInformationDetail">
        <link:definition>100490 - Disclosure - Share-Based Payments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfStockOptionActivityDetail" id="Role_DisclosureShareBasedPaymentsScheduleOfStockOptionActivityDetail">
        <link:definition>100500 - Disclosure - Share-Based Payments - Schedule of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfEstimatedFairValueOfStockOptionsDetail" id="Role_DisclosureShareBasedPaymentsScheduleOfEstimatedFairValueOfStockOptionsDetail">
        <link:definition>100510 - Disclosure - Share-Based Payments - Schedule of Estimated Fair Value of Stock Options (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfStockBasedCompensationExpenseIncludedInTheCompanySConsolidatedStatementsOfOperationsAndComprehensiveLossDetail" id="Role_DisclosureShareBasedPaymentsScheduleOfStockBasedCompensationExpenseIncludedInTheCompanySConsolidatedStatementsOfOperationsAndComprehensiveLossDetail">
        <link:definition>100520 - Disclosure - Share-Based Payments - Schedule of Stock-Based Compensation Expense Included In The Company&apos;s Consolidated Statements of Operations And Comprehensive Loss (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100530 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfExpectedIncomeTaxBenefitComputedUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail" id="Role_DisclosureIncomeTaxesSummaryOfReconciliationOfExpectedIncomeTaxBenefitComputedUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail">
        <link:definition>100540 - Disclosure - Income Taxes - Summary of Reconciliation of Expected Income Tax (Benefit) Computed Using Federal Statutory Income Tax Rate to Effective Income Tax Rate (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetail" id="Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetail">
        <link:definition>100550 - Disclosure - Income Taxes - Summary of Deferred Tax Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail" id="Role_DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail">
        <link:definition>100560 - Disclosure - Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" id="Role_DisclosureNetLossPerShareAdditionalInformationDetail">
        <link:definition>100570 - Disclosure - Net Loss Per Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" id="Role_DisclosureNetLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail">
        <link:definition>100580 - Disclosure - Net Loss Per Share - Summary of Antidilutive Securities Excluded From Computation of Earnings Per Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>100590 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="Role_DisclosureLeasesAdditionalInformationDetails">
        <link:definition>100600 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeasesPresentationInConsolidatedBalanceSheetsDetails" id="Role_DisclosureLeasesScheduleOfOperatingLeasesPresentationInConsolidatedBalanceSheetsDetails">
        <link:definition>100610 - Disclosure - Leases - Schedule of Operating Leases Presentation in Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" id="Role_DisclosureLeasesSummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails">
        <link:definition>100620 - Disclosure - Leases - Summary of Operating Lease Presentation in Consolidated Statements of Operations and Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails" id="Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails">
        <link:definition>100630 - Disclosure - Leases - Summary of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails2" id="Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails2">
        <link:definition>100640 - Disclosure - Leases - Summary of Future Minimum Lease Payments (Details)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails" id="Role_DisclosureEmployeeBenefitsAdditionalInformationDetails">
        <link:definition>100650 - Disclosure - Employee Benefits - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail">
        <link:definition>100660 - Disclosure - Related Party Transactions - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="rlay_RestrictedStockLiability" name="RestrictedStockLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="rlay_UndesignatedpreferredstockMember" name="UndesignatedpreferredstockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_DeemedDividendResultingFromExtinguishmentOfPreferredStock" name="DeemedDividendResultingFromExtinguishmentOfPreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="rlay_OperationsAndComprehensiveLossStatementAbstract" name="OperationsAndComprehensiveLossStatementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_StockIssuedDuringPeriodSharesPreferredStockNetOfIssuanceCosts" name="StockIssuedDuringPeriodSharesPreferredStockNetOfIssuanceCosts" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_StockIssuedDuringPeriodValuePreferredStockNetOfIssuanceCosts" name="StockIssuedDuringPeriodValuePreferredStockNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="rlay_VestingOfRestrictedCommonStockShares" name="VestingOfRestrictedCommonStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_VestingOfRestrictedCommonStockValue" name="VestingOfRestrictedCommonStockValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="rlay_IncreaseDecreaseInLeaseAssetsAndLiabilitiesNet" name="IncreaseDecreaseInLeaseAssetsAndLiabilitiesNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="rlay_ReclassificationOfRestrictedStockLiabilityToAdditionalPaidInCapital" name="ReclassificationOfRestrictedStockLiabilityToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="rlay_LossOnExtinguishmentAndReissuanceOfPreferredStock" name="LossOnExtinguishmentAndReissuanceOfPreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="rlay_RestrictedCashAndCashEquivalentsAtCarryingValueAbstract" name="RestrictedCashAndCashEquivalentsAtCarryingValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_ConvertiblePreferredStockTextBlock" name="ConvertiblePreferredStockTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_BasisOfPresentationPolicyTextBlock" name="BasisOfPresentationPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_ConcentrationOfCreditRiskAndSignificantSuppliersPolicyTextBlock" name="ConcentrationOfCreditRiskAndSignificantSuppliersPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_ResearchAndManufacturingContractsPolicyTextBlock" name="ResearchAndManufacturingContractsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_PatentCostsPolicyTextBlock" name="PatentCostsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_DescriptionOfNewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" name="DescriptionOfNewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_ReservedSharesOfCommonStockForFutureIssuanceTableTableTextBlock" name="ReservedSharesOfCommonStockForFutureIssuanceTableTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_ScheduleOfOperatingLeasePresentationInConsolidatedBalanceSheetTableTextBlock" name="ScheduleOfOperatingLeasePresentationInConsolidatedBalanceSheetTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_SummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossTableTextBlock" name="SummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" name="NatureOfBusinessAndBasisOfPresentationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_NatureOfBusinessAndBasisOfPresentationTable" name="NatureOfBusinessAndBasisOfPresentationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_GenentechIncMember" name="GenentechIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_UnderwritingDiscountsAndCommissions" name="UnderwritingDiscountsAndCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="rlay_SignificantAccountingPoliciesLineItems" name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_SignificantAccountingPoliciesTable" name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_GenentechAgreementMember" name="GenentechAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_LaboratoryAndComputerEquipmentMember" name="LaboratoryAndComputerEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_CashAndCashEquivalentsMaturityDateDescription" name="CashAndCashEquivalentsMaturityDateDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_NumberOfCollaborationAndLicenseAgreement" name="NumberOfCollaborationAndLicenseAgreement" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_CollaborationAndLicenseAgreementEnteredDate" name="CollaborationAndLicenseAgreementEnteredDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_CashAndCashEquivalentsFairValueDisclosureAbstract" name="CashAndCashEquivalentsFairValueDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_InvestmentsWithMaturityOfOneYearOrLessMember" name="InvestmentsWithMaturityOfOneYearOrLessMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_InvestmentsWithMaturityOfOneToTwoYearsMember" name="InvestmentsWithMaturityOfOneToTwoYearsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_CollaborationAndLicenseArrangementAbstract" name="CollaborationAndLicenseArrangementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_CollaborationAndLicenseArrangementLineItems" name="CollaborationAndLicenseArrangementLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_CollaborationAndLicenseArrangementTable" name="CollaborationAndLicenseArrangementTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_StandAloneSellingPricesMember" name="StandAloneSellingPricesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_LicenseAndTransferAgreementMember" name="LicenseAndTransferAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_ResearchAndDevelopmentServicesMember" name="ResearchAndDevelopmentServicesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_TransferOfActivePharmaceuticalIngredientsMember" name="TransferOfActivePharmaceuticalIngredientsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_NonRefundableUpfrontPayment" name="NonRefundableUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement" name="MaximumAdditionalAmountReceivedUponMilestoneAchievement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="rlay_MilestonePaymentReceivable" name="MilestonePaymentReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="rlay_CollaborationAgreementTransactionPrice" name="CollaborationAgreementTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="rlay_NonRefundableMilestoneTransferAmount" name="NonRefundableMilestoneTransferAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="rlay_NonRefundableMilestoneForCompletionAmount" name="NonRefundableMilestoneForCompletionAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="rlay_VariableConsiderationRelatedToReimbursementsDueForResearchAndDevelopmentServices" name="VariableConsiderationRelatedToReimbursementsDueForResearchAndDevelopmentServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="rlay_DevelopmentBasedMilestonePaymentsUnderAgreement" name="DevelopmentBasedMilestonePaymentsUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="rlay_RegulatoryBasedMilestonePaymentsUnderAgreement" name="RegulatoryBasedMilestonePaymentsUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="rlay_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_AccruedExternalResearchAndDevelopmentExpenseCurrent" name="AccruedExternalResearchAndDevelopmentExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="rlay_AccruedProfessionalServicesCurrent" name="AccruedProfessionalServicesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="rlay_AccruedOtherExpensesCurrent" name="AccruedOtherExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="rlay_PreferredStockConvertibleConversionPrice" name="PreferredStockConvertibleConversionPrice" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_CommonStockRestrictionPeriod" name="CommonStockRestrictionPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAveragePriceOfSharesPurchased" name="ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAveragePriceOfSharesPurchased" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAveragePriceOfSharesPurchased" name="ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAveragePriceOfSharesPurchased" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_CommonStockCapitalSharesReservedUnderCompensationPlan" name="CommonStockCapitalSharesReservedUnderCompensationPlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="rlay_TwoThousandTwentyPlanMember" name="TwoThousandTwentyPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_TwoThousandSixteenPlanMember" name="TwoThousandSixteenPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_EffectiveIncomeTaxRateReconciliationPermanentDifferences" name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="rlay_DeferredTaxAssetsDepreciationAndAmortization" name="DeferredTaxAssetsDepreciationAndAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="rlay_DeferredTaxLiabilitiesOperatingLeaseAssets" name="DeferredTaxLiabilitiesOperatingLeaseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="rlay_DeferredTaxAssetsOperatingLossCarryforwardsBeginningToExpireYear" name="DeferredTaxAssetsOperatingLossCarryforwardsBeginningToExpireYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_IncreaseInDeferredTaxAssetsValuationAllowance" name="IncreaseInDeferredTaxAssetsValuationAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="rlay_TaxCutsAndJobsActOf2017DescriptionOfCorporateTaxPayers" name="TaxCutsAndJobsActOf2017DescriptionOfCorporateTaxPayers" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_TaxCutsAndJobsActOf2017NetOperatingLossCarrybackPeriod" name="TaxCutsAndJobsActOf2017NetOperatingLossCarrybackPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_TaxCutsAndJobsActOf2017MaximumPercentageOfInterestDeductedByTaxPayers" name="TaxCutsAndJobsActOf2017MaximumPercentageOfInterestDeductedByTaxPayers" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_CARESActPercentageOfInterestDeductedByTaxPayers" name="CARESActPercentageOfInterestDeductedByTaxPayers" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_CARESActPercentageOfEliminatesOfTaxableIncome" name="CARESActPercentageOfEliminatesOfTaxableIncome" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_CARESActPercentageOfCorporateCharitableDeductionLimit" name="CARESActPercentageOfCorporateCharitableDeductionLimit" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_CARESActPeriodOfQualifiedImprovementPropertyForCostRecovery" name="CARESActPeriodOfQualifiedImprovementPropertyForCostRecovery" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_CARESActPercentageOfBonusDepreciation" name="CARESActPercentageOfBonusDepreciation" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_ConvertiblePreferredStocksMember" name="ConvertiblePreferredStocksMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_ResearchAndDevelopmentArrangementAnnualFee" name="ResearchAndDevelopmentArrangementAnnualFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="rlay_ResearchAndDevelopmentArrangementContractToPerformForOthersRenewalPeriod" name="ResearchAndDevelopmentArrangementContractToPerformForOthersRenewalPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_ResearchAndDevelopmentArrangementExpirationDate" name="ResearchAndDevelopmentArrangementExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_ResearchAndDevelopmentArrangementTermOfContract" name="ResearchAndDevelopmentArrangementTermOfContract" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_CommitmentsAndContingenciesDisclosureLineItems" name="CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_CommitmentsAndContingenciesDisclosureTable" name="CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_DEShawResearchMember" name="DEShawResearchMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_LeaseAgreementMember" name="LeaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_OtherthirdPartiesMember" name="OtherthirdPartiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_PotentialDevelopmentMilestonePayments" name="PotentialDevelopmentMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="rlay_MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement" name="MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="rlay_NumberOfMilestoneTargets" name="NumberOfMilestoneTargets" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="rlay_LeaseExpirationMonthAndYear" name="LeaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rlay_FirstStreetInCambridgeMassachusettsMember" name="FirstStreetInCambridgeMassachusettsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_BinneyStreetCambridgeMassachusettsMember" name="BinneyStreetCambridgeMassachusettsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_ThirdRockVentureMember" name="ThirdRockVentureMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rlay_ConsultingAndManagementServicesMember" name="ConsultingAndManagementServicesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>43
<FILENAME>rlay-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-25T16:08:59.0369926+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : b6984381c2ae479bb023a8d6e22330cc -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="rlay-20201231.xsd#TemplateLink" roleURI="http://relaytx.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="rlay-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments" xlink:type="locator" xlink:label="us-gaap_Investments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets" xlink:type="locator" xlink:label="us-gaap_OtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_RestrictedStockLiability" xlink:type="locator" xlink:label="rlay_RestrictedStockLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockValueOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValueOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockValueOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValueOutstanding" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValueOutstanding" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="rlay_RestrictedStockLiability" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssets" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_Investments" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10250.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="rlay-20201231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther" xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_DeemedDividendResultingFromExtinguishmentOfPreferredStock" xlink:type="locator" xlink:label="rlay_DeemedDividendResultingFromExtinguishmentOfPreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="rlay_DeemedDividendResultingFromExtinguishmentOfPreferredStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeOther" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingExpense" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10140.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="rlay-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_IncreaseDecreaseInLeaseAssetsAndLiabilitiesNet" xlink:type="locator" xlink:label="rlay_IncreaseDecreaseInLeaseAssetsAndLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10150.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="10160.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="10170.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="rlay_IncreaseDecreaseInLeaseAssetsAndLiabilitiesNet" order="10180.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10210.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities" order="10220.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10230.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="rlay-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCash" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureFairValueOfFinancialAssetsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" xlink:href="rlay-20201231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail">
    <link:loc xlink:href="rlay-20201231.xsd#rlay_AccruedOtherExpensesCurrent" xlink:type="locator" xlink:label="rlay_AccruedOtherExpensesCurrent" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_AccruedProfessionalServicesCurrent" xlink:type="locator" xlink:label="rlay_AccruedProfessionalServicesCurrent" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_AccruedExternalResearchAndDevelopmentExpenseCurrent" xlink:type="locator" xlink:label="rlay_AccruedExternalResearchAndDevelopmentExpenseCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="rlay_AccruedExternalResearchAndDevelopmentExpenseCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="rlay_AccruedProfessionalServicesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="rlay_AccruedOtherExpensesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetail">
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CommonStockCapitalSharesReservedUnderCompensationPlan" xlink:type="locator" xlink:label="rlay_CommonStockCapitalSharesReservedUnderCompensationPlan" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="rlay_CommonStockCapitalSharesReservedUnderCompensationPlan" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfExpectedIncomeTaxBenefitComputedUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfReconciliationOfExpectedIncomeTaxBenefitComputedUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfExpectedIncomeTaxBenefitComputedUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail">
    <link:loc xlink:href="rlay-20201231.xsd#rlay_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="locator" xlink:label="rlay_EffectiveIncomeTaxRateReconciliationPermanentDifferences" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="rlay_EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_DeferredTaxAssetsDepreciationAndAmortization" xlink:type="locator" xlink:label="rlay_DeferredTaxAssetsDepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_DeferredTaxAssetsLeaseLiability" xlink:type="locator" xlink:label="rlay_DeferredTaxAssetsLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:type="locator" xlink:label="rlay_DeferredTaxLiabilitiesOperatingLeaseAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="rlay_DeferredTaxLiabilitiesOperatingLeaseAssets" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="rlay_DeferredTaxAssetsLeaseLiability" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="rlay_DeferredTaxAssetsDepreciationAndAmortization" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10120.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeasesPresentationInConsolidatedBalanceSheetsDetails" xlink:href="rlay-20201231.xsd#Role_DisclosureLeasesScheduleOfOperatingLeasesPresentationInConsolidatedBalanceSheetsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeasesPresentationInConsolidatedBalanceSheetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails" xlink:href="rlay-20201231.xsd#Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails2" xlink:href="rlay-20201231.xsd#Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails2">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>44
<FILENAME>rlay-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-25T16:08:59.0369926+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : b6984381c2ae479bb023a8d6e22330cc -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="rlay-20201231.xsd#TemplateLink" roleURI="http://relaytx.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="rlay-20201231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_UndesignatedpreferredstockMember" xlink:type="locator" xlink:label="rlay_UndesignatedpreferredstockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlay_UndesignatedpreferredstockMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10760.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit" xlink:href="rlay-20201231.xsd#Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_VestingOfRestrictedCommonStockShares" xlink:type="locator" xlink:label="rlay_VestingOfRestrictedCommonStockShares" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_VestingOfRestrictedCommonStockValue" xlink:type="locator" xlink:label="rlay_VestingOfRestrictedCommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_StockIssuedDuringPeriodSharesPreferredStockNetOfIssuanceCosts" xlink:type="locator" xlink:label="rlay_StockIssuedDuringPeriodSharesPreferredStockNetOfIssuanceCosts" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_StockIssuedDuringPeriodValuePreferredStockNetOfIssuanceCosts" xlink:type="locator" xlink:label="rlay_StockIssuedDuringPeriodValuePreferredStockNetOfIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rlay_StockIssuedDuringPeriodValuePreferredStockNetOfIssuanceCosts" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rlay_StockIssuedDuringPeriodSharesPreferredStockNetOfIssuanceCosts" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rlay_VestingOfRestrictedCommonStockValue" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rlay_VestingOfRestrictedCommonStockShares" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11900.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitParenthetical" xlink:href="rlay-20201231.xsd#Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_UnderwritingDiscountsAndCommissions" xlink:type="locator" xlink:label="rlay_UnderwritingDiscountsAndCommissions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_GenentechIncMember" xlink:type="locator" xlink:label="rlay_GenentechIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_NatureOfBusinessAndBasisOfPresentationTable" xlink:type="locator" xlink:label="rlay_NatureOfBusinessAndBasisOfPresentationTable" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:type="locator" xlink:label="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="rlay_NatureOfBusinessAndBasisOfPresentationTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rlay_GenentechIncMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="rlay_UnderwritingDiscountsAndCommissions" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10660.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CollaborationAndLicenseAgreementEnteredDate" xlink:type="locator" xlink:label="rlay_CollaborationAndLicenseAgreementEnteredDate" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_NumberOfCollaborationAndLicenseAgreement" xlink:type="locator" xlink:label="rlay_NumberOfCollaborationAndLicenseAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CashAndCashEquivalentsMaturityDateDescription" xlink:type="locator" xlink:label="rlay_CashAndCashEquivalentsMaturityDateDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_LaboratoryAndComputerEquipmentMember" xlink:type="locator" xlink:label="rlay_LaboratoryAndComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_GenentechAgreementMember" xlink:type="locator" xlink:label="rlay_GenentechAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_GenentechIncMember" xlink:type="locator" xlink:label="rlay_GenentechIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:type="locator" xlink:label="us-gaap_LetterOfCreditMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_SignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="rlay_SignificantAccountingPoliciesTable" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_SignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="rlay_SignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rlay_SignificantAccountingPoliciesLineItems" xlink:to="rlay_SignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rlay_SignificantAccountingPoliciesTable" xlink:to="us-gaap_CreditFacilityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rlay_SignificantAccountingPoliciesTable" xlink:to="srt_CounterpartyNameAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rlay_GenentechIncMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rlay_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="rlay_GenentechAgreementMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rlay_SignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="rlay_LaboratoryAndComputerEquipmentMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_SignificantAccountingPoliciesLineItems" xlink:to="rlay_CashAndCashEquivalentsMaturityDateDescription" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_SignificantAccountingPoliciesLineItems" xlink:to="rlay_NumberOfCollaborationAndLicenseAgreement" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_SignificantAccountingPoliciesLineItems" xlink:to="rlay_CollaborationAndLicenseAgreementEnteredDate" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" order="10860.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureFairValueOfFinancialAssetsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsFairValueDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CashAndCashEquivalentsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="rlay_CashAndCashEquivalentsFairValueDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsMember" xlink:type="locator" xlink:label="us-gaap_InvestmentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashEquivalentsMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_InvestmentsMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="rlay_CashAndCashEquivalentsFairValueDisclosureAbstract" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CashAndCashEquivalentsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosureAbstract" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentsFairValueDisclosureAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="11680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="11920.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_InvestmentsWithMaturityOfOneToTwoYearsMember" xlink:type="locator" xlink:label="rlay_InvestmentsWithMaturityOfOneToTwoYearsMember" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_InvestmentsWithMaturityOfOneYearOrLessMember" xlink:type="locator" xlink:label="rlay_InvestmentsWithMaturityOfOneYearOrLessMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsBySecondaryCategorizationDomain" xlink:type="locator" xlink:label="us-gaap_InvestmentsBySecondaryCategorizationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsBySecondaryCategorizationDomain" xlink:type="locator" xlink:label="us-gaap_InvestmentsBySecondaryCategorizationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentSecondaryCategorizationAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentSecondaryCategorizationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentSecondaryCategorizationAxis" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentSecondaryCategorizationAxis" xlink:to="us-gaap_InvestmentsBySecondaryCategorizationDomain_2" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentSecondaryCategorizationAxis" xlink:to="us-gaap_InvestmentsBySecondaryCategorizationDomain" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentsBySecondaryCategorizationDomain" xlink:to="rlay_InvestmentsWithMaturityOfOneYearOrLessMember" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentsBySecondaryCategorizationDomain" xlink:to="rlay_InvestmentsWithMaturityOfOneToTwoYearsMember" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="11150.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseArrangementWithGenentechAdditionalInformationDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureCollaborationAndLicenseArrangementWithGenentechAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseArrangementWithGenentechAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_RegulatoryBasedMilestonePaymentsUnderAgreement" xlink:type="locator" xlink:label="rlay_RegulatoryBasedMilestonePaymentsUnderAgreement" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_DevelopmentBasedMilestonePaymentsUnderAgreement" xlink:type="locator" xlink:label="rlay_DevelopmentBasedMilestonePaymentsUnderAgreement" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_VariableConsiderationRelatedToReimbursementsDueForResearchAndDevelopmentServices" xlink:type="locator" xlink:label="rlay_VariableConsiderationRelatedToReimbursementsDueForResearchAndDevelopmentServices" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_NonRefundableMilestoneForCompletionAmount" xlink:type="locator" xlink:label="rlay_NonRefundableMilestoneForCompletionAmount" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_NonRefundableMilestoneTransferAmount" xlink:type="locator" xlink:label="rlay_NonRefundableMilestoneTransferAmount" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CollaborationAgreementTransactionPrice" xlink:type="locator" xlink:label="rlay_CollaborationAgreementTransactionPrice" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement" xlink:type="locator" xlink:label="rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_MilestonePaymentReceivable" xlink:type="locator" xlink:label="rlay_MilestonePaymentReceivable" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_NonRefundableUpfrontPayment" xlink:type="locator" xlink:label="rlay_NonRefundableUpfrontPayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementRightsAndObligations" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementRightsAndObligations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementNatureAndPurpose" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementNatureAndPurpose" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_TransferOfActivePharmaceuticalIngredientsMember" xlink:type="locator" xlink:label="rlay_TransferOfActivePharmaceuticalIngredientsMember" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ResearchAndDevelopmentServicesMember" xlink:type="locator" xlink:label="rlay_ResearchAndDevelopmentServicesMember" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_LicenseAndTransferAgreementMember" xlink:type="locator" xlink:label="rlay_LicenseAndTransferAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_StandAloneSellingPricesMember" xlink:type="locator" xlink:label="rlay_StandAloneSellingPricesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:type="locator" xlink:label="us-gaap_ForeignCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_GenentechAgreementMember" xlink:type="locator" xlink:label="rlay_GenentechAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_GenentechIncMember" xlink:type="locator" xlink:label="rlay_GenentechIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CollaborationAndLicenseArrangementTable" xlink:type="locator" xlink:label="rlay_CollaborationAndLicenseArrangementTable" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CollaborationAndLicenseArrangementLineItems" xlink:type="locator" xlink:label="rlay_CollaborationAndLicenseArrangementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="rlay_CollaborationAndLicenseArrangementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rlay_CollaborationAndLicenseArrangementTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rlay_GenentechIncMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rlay_CollaborationAndLicenseArrangementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="rlay_GenentechAgreementMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rlay_CollaborationAndLicenseArrangementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rlay_CollaborationAndLicenseArrangementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rlay_StandAloneSellingPricesMember" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rlay_CollaborationAndLicenseArrangementTable" xlink:to="srt_ProductOrServiceAxis" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_2" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rlay_LicenseAndTransferAgreementMember" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rlay_ResearchAndDevelopmentServicesMember" order="11370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rlay_TransferOfActivePharmaceuticalIngredientsMember" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="us-gaap_CollaborativeArrangementNatureAndPurpose" order="12020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="us-gaap_CollaborativeArrangementRightsAndObligations" order="12040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="rlay_NonRefundableUpfrontPayment" order="12090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="rlay_MilestonePaymentReceivable" order="12110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement" order="12130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="rlay_CollaborationAgreementTransactionPrice" order="12230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="rlay_NonRefundableMilestoneTransferAmount" order="12270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="rlay_NonRefundableMilestoneForCompletionAmount" order="12290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="rlay_VariableConsiderationRelatedToReimbursementsDueForResearchAndDevelopmentServices" order="12310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="rlay_DevelopmentBasedMilestonePaymentsUnderAgreement" order="12330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="rlay_RegulatoryBasedMilestonePaymentsUnderAgreement" order="12350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="12420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="12510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="12620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="12640.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" xlink:href="rlay-20201231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="rlay_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="rlay_LaboratoryEquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockVotingRights" xlink:type="locator" xlink:label="us-gaap_PreferredStockVotingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_PreferredStockConvertibleConversionPrice" xlink:type="locator" xlink:label="rlay_PreferredStockConvertibleConversionPrice" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="rlay_UnderwrittenPublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rlay_UnderwrittenPublicOfferingMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rlay_PreferredStockConvertibleConversionPrice" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockVotingRights" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DividendsPreferredStock" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreference" order="11390.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockValue" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10760.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureCommonStockAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CommonStockRestrictionPeriod" xlink:type="locator" xlink:label="rlay_CommonStockRestrictionPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStock" xlink:type="locator" xlink:label="us-gaap_DividendsCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="rlay_EmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rlay_EmployeeStockPurchasePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DividendsCommonStock" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rlay_CommonStockRestrictionPeriod" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10410.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfTheRestrictedStockActivityDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureCommonStockSummaryOfTheRestrictedStockActivityDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfTheRestrictedStockActivityDetail">
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAveragePriceOfSharesPurchased" xlink:type="locator" xlink:label="rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAveragePriceOfSharesPurchased" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAveragePriceOfSharesPurchased" xlink:type="locator" xlink:label="rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAveragePriceOfSharesPurchased" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAveragePriceOfSharesPurchased" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAveragePriceOfSharesPurchased" order="10450.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CommonStockCapitalSharesReservedUnderCompensationPlan" xlink:type="locator" xlink:label="rlay_CommonStockCapitalSharesReservedUnderCompensationPlan" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rlay_CommonStockCapitalSharesReservedUnderCompensationPlan" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10360.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPaymentsAdditionalInformationDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureShareBasedPaymentsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPaymentsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLossMember" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLossMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_TwoThousandSixteenPlanMember" xlink:type="locator" xlink:label="rlay_TwoThousandSixteenPlanMember" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_TwoThousandTwentyPlanMember" xlink:type="locator" xlink:label="rlay_TwoThousandTwentyPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rlay_TwoThousandTwentyPlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rlay_TwoThousandSixteenPlanMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingIncomeLossMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10890.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfStockBasedCompensationExpenseIncludedInTheCompanySConsolidatedStatementsOfOperationsAndComprehensiveLossDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureShareBasedPaymentsScheduleOfStockBasedCompensationExpenseIncludedInTheCompanySConsolidatedStatementsOfOperationsAndComprehensiveLossDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfStockBasedCompensationExpenseIncludedInTheCompanySConsolidatedStatementsOfOperationsAndComprehensiveLossDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CARESActPercentageOfBonusDepreciation" xlink:type="locator" xlink:label="rlay_CARESActPercentageOfBonusDepreciation" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CARESActPeriodOfQualifiedImprovementPropertyForCostRecovery" xlink:type="locator" xlink:label="rlay_CARESActPeriodOfQualifiedImprovementPropertyForCostRecovery" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CARESActPercentageOfCorporateCharitableDeductionLimit" xlink:type="locator" xlink:label="rlay_CARESActPercentageOfCorporateCharitableDeductionLimit" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CARESActPercentageOfInterestDeductedByTaxPayers" xlink:type="locator" xlink:label="rlay_CARESActPercentageOfInterestDeductedByTaxPayers" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_TaxCutsAndJobsActOf2017MaximumPercentageOfInterestDeductedByTaxPayers" xlink:type="locator" xlink:label="rlay_TaxCutsAndJobsActOf2017MaximumPercentageOfInterestDeductedByTaxPayers" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CARESActPercentageOfEliminatesOfTaxableIncome" xlink:type="locator" xlink:label="rlay_CARESActPercentageOfEliminatesOfTaxableIncome" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_TaxCutsAndJobsActOf2017NetOperatingLossCarrybackPeriod" xlink:type="locator" xlink:label="rlay_TaxCutsAndJobsActOf2017NetOperatingLossCarrybackPeriod" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_TaxCutsAndJobsActOf2017DescriptionOfCorporateTaxPayers" xlink:type="locator" xlink:label="rlay_TaxCutsAndJobsActOf2017DescriptionOfCorporateTaxPayers" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_IncreaseInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="rlay_IncreaseInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" xlink:type="locator" xlink:label="rlay_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_DeferredTaxAssetsOperatingLossCarryforwardsBeginningToExpireYear" xlink:type="locator" xlink:label="rlay_DeferredTaxAssetsOperatingLossCarryforwardsBeginningToExpireYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="rlay_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="rlay_IncomeTaxDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="rlay_IncomeTaxDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rlay_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rlay_IncomeTaxDisclosureTable" xlink:to="srt_RangeAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="rlay_DeferredTaxAssetsOperatingLossCarryforwardsBeginningToExpireYear" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="rlay_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="rlay_IncreaseInDeferredTaxAssetsValuationAllowance" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationDescription" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="rlay_TaxCutsAndJobsActOf2017DescriptionOfCorporateTaxPayers" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="rlay_TaxCutsAndJobsActOf2017NetOperatingLossCarrybackPeriod" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="rlay_CARESActPercentageOfEliminatesOfTaxableIncome" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="rlay_TaxCutsAndJobsActOf2017MaximumPercentageOfInterestDeductedByTaxPayers" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="rlay_CARESActPercentageOfInterestDeductedByTaxPayers" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="rlay_CARESActPercentageOfCorporateCharitableDeductionLimit" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="rlay_CARESActPeriodOfQualifiedImprovementPropertyForCostRecovery" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="rlay_CARESActPercentageOfBonusDepreciation" order="11150.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureNetLossPerShareAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail">
    <link:loc xlink:href="rlay-20201231.xsd#rlay_PreferredStockConvertibleConversionPrice" xlink:type="locator" xlink:label="rlay_PreferredStockConvertibleConversionPrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="rlay_PreferredStockConvertibleConversionPrice" order="10120.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureNetLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ConvertiblePreferredStocksMember" xlink:type="locator" xlink:label="rlay_ConvertiblePreferredStocksMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rlay_ConvertiblePreferredStocksMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="rlay-20201231.xsd#rlay_NumberOfMilestoneTargets" xlink:type="locator" xlink:label="rlay_NumberOfMilestoneTargets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement" xlink:type="locator" xlink:label="rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement" xlink:type="locator" xlink:label="rlay_MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_PotentialDevelopmentMilestonePayments" xlink:type="locator" xlink:label="rlay_PotentialDevelopmentMilestonePayments" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ResearchAndDevelopmentArrangementContractToPerformForOthersRenewalPeriod" xlink:type="locator" xlink:label="rlay_ResearchAndDevelopmentArrangementContractToPerformForOthersRenewalPeriod" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ResearchAndDevelopmentArrangementExpirationDate" xlink:type="locator" xlink:label="rlay_ResearchAndDevelopmentArrangementExpirationDate" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ResearchAndDevelopmentArrangementTermOfContract" xlink:type="locator" xlink:label="rlay_ResearchAndDevelopmentArrangementTermOfContract" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ResearchAndDevelopmentArrangementAnnualFee" xlink:type="locator" xlink:label="rlay_ResearchAndDevelopmentArrangementAnnualFee" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" xlink:type="locator" xlink:label="us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_OtherthirdPartiesMember" xlink:type="locator" xlink:label="rlay_OtherthirdPartiesMember" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_LeaseAgreementMember" xlink:type="locator" xlink:label="rlay_LeaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:type="locator" xlink:label="us-gaap_LicenseAgreementTermsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_DEShawResearchMember" xlink:type="locator" xlink:label="rlay_DEShawResearchMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CommitmentsAndContingenciesDisclosureTable" xlink:type="locator" xlink:label="rlay_CommitmentsAndContingenciesDisclosureTable" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="locator" xlink:label="rlay_CommitmentsAndContingenciesDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rlay_CommitmentsAndContingenciesDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rlay_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rlay_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_RangeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rlay_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_CounterpartyNameAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rlay_DEShawResearchMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rlay_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="rlay_LeaseAgreementMember" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rlay_OtherthirdPartiesMember" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rlay_ResearchAndDevelopmentArrangementAnnualFee" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rlay_ResearchAndDevelopmentArrangementTermOfContract" order="11620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rlay_ResearchAndDevelopmentArrangementExpirationDate" order="11680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rlay_ResearchAndDevelopmentArrangementContractToPerformForOthersRenewalPeriod" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rlay_PotentialDevelopmentMilestonePayments" order="11830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rlay_MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement" order="11870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement" order="11910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="12030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rlay_NumberOfMilestoneTargets" order="12100.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="rlay-20201231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:type="locator" xlink:label="us-gaap_LettersOfCreditOutstandingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:type="locator" xlink:label="us-gaap_LandSubjectToGroundLeases" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_LeaseExpirationMonthAndYear" xlink:type="locator" xlink:label="rlay_LeaseExpirationMonthAndYear" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_BinneyStreetCambridgeMassachusettsMember" xlink:type="locator" xlink:label="rlay_BinneyStreetCambridgeMassachusettsMember" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_FirstStreetInCambridgeMassachusettsMember" xlink:type="locator" xlink:label="rlay_FirstStreetInCambridgeMassachusettsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="rlay_FirstStreetInCambridgeMassachusettsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="rlay_BinneyStreetCambridgeMassachusettsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="rlay_LeaseExpirationMonthAndYear" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LandSubjectToGroundLeases" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10710.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" xlink:href="rlay-20201231.xsd#Role_DisclosureLeasesSummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ConsultingAndManagementServicesMember" xlink:type="locator" xlink:label="rlay_ConsultingAndManagementServicesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ThirdRockVentureMember" xlink:type="locator" xlink:label="rlay_ThirdRockVentureMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="rlay_ThirdRockVentureMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="rlay_ConsultingAndManagementServicesMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" order="10260.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>45
<FILENAME>rlay-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-25T16:08:59.0369926+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : b6984381c2ae479bb023a8d6e22330cc -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_RestrictedStockLiability" xlink:type="locator" xlink:label="rlay_RestrictedStockLiability" />
    <link:label xml:lang="en-US" xlink:label="rlay_RestrictedStockLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_RestrictedStockLiability" xlink:to="rlay_RestrictedStockLiability_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments" xlink:type="locator" xlink:label="us-gaap_Investments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Investments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Investments" xlink:to="us-gaap_Investments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Investments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNet" xlink:to="us-gaap_ContractWithCustomerAssetNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets" xlink:type="locator" xlink:label="us-gaap_OtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, Convertible Preferred Stock, and Stockholders&#8217; Equity (Deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_RestrictedStockLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock liability</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_RestrictedStockLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 13)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock (Series A, B and C), $0.001 par value; no shares authorized as of December 31, 2020 and 337,272,859 shares authorized as of December 31, 2019; no shares issued and outstanding as of December 31, 2020 and 212,642,857 shares issued and outstanding (aggregate liquidation preference of $519,825) as of December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity (deficit):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValueOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockValueOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValueOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Undesignated preferred stock, $0.001 par value, 10,000,000 shares authorized as of December 31, 2020 and no shares authorized as of December 31, 2019; no shares issued and outstanding at December 31, 2020 and December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValueOutstanding" xlink:to="us-gaap_PreferredStockValueOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValueOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockValueOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValueOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 150,000,000 and 260,000,000 shares authorized at December 31, 2020 and December 31, 2019, respectively; 89,991,324 and 4,716,634 shares issued at December 31, 2020 and December 31, 2019, respectively; 89,906,835 and 4,037,476 shares outstanding at December 31, 2020 and December 31, 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValueOutstanding" xlink:to="us-gaap_CommonStockValueOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValueOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, convertible preferred stock, and stockholders&#8217; equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_UndesignatedpreferredstockMember" xlink:type="locator" xlink:label="rlay_UndesignatedpreferredstockMember" />
    <link:label xml:lang="en-US" xlink:label="rlay_UndesignatedpreferredstockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Undesignated preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_UndesignatedpreferredstockMember" xlink:to="rlay_UndesignatedpreferredstockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_UndesignatedpreferredstockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Undesignated Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_UndesignatedpreferredstockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Undesignatedpreferredstock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity liquidation preference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Liquidation Preference</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_DeemedDividendResultingFromExtinguishmentOfPreferredStock" xlink:type="locator" xlink:label="rlay_DeemedDividendResultingFromExtinguishmentOfPreferredStock" />
    <link:label xml:lang="en-US" xlink:label="rlay_DeemedDividendResultingFromExtinguishmentOfPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deemed dividend resulting from extinguishment of preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_DeemedDividendResultingFromExtinguishmentOfPreferredStock" xlink:to="rlay_DeemedDividendResultingFromExtinguishmentOfPreferredStock_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_OperationsAndComprehensiveLossStatementAbstract" xlink:type="locator" xlink:label="rlay_OperationsAndComprehensiveLossStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="rlay_OperationsAndComprehensiveLossStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operations and Comprehensive Loss Statement [Abstract].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_OperationsAndComprehensiveLossStatementAbstract" xlink:to="rlay_OperationsAndComprehensiveLossStatementAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_OperationsAndComprehensiveLossStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operations And Comprehensive Loss Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from contract with customer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from Contract with Customer, Product and Service [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Product And Service Extensible List</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Income And Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther" xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_DeemedDividendResultingFromExtinguishmentOfPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deemed dividend resulting from extinguishment upon modification of Series C preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_DeemedDividendResultingFromExtinguishmentOfPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deemed Dividend Resulting From Extinguishment Of Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to common stockholders per share, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares of common stock, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized holding gain (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other comprehensive income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_StockIssuedDuringPeriodSharesPreferredStockNetOfIssuanceCosts" xlink:type="locator" xlink:label="rlay_StockIssuedDuringPeriodSharesPreferredStockNetOfIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="rlay_StockIssuedDuringPeriodSharesPreferredStockNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares preferred stock net of issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_StockIssuedDuringPeriodSharesPreferredStockNetOfIssuanceCosts" xlink:to="rlay_StockIssuedDuringPeriodSharesPreferredStockNetOfIssuanceCosts_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_StockIssuedDuringPeriodValuePreferredStockNetOfIssuanceCosts" xlink:type="locator" xlink:label="rlay_StockIssuedDuringPeriodValuePreferredStockNetOfIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="rlay_StockIssuedDuringPeriodValuePreferredStockNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value preferred stock net of issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_StockIssuedDuringPeriodValuePreferredStockNetOfIssuanceCosts" xlink:to="rlay_StockIssuedDuringPeriodValuePreferredStockNetOfIssuanceCosts_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_VestingOfRestrictedCommonStockShares" xlink:type="locator" xlink:label="rlay_VestingOfRestrictedCommonStockShares" />
    <link:label xml:lang="en-US" xlink:label="rlay_VestingOfRestrictedCommonStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting of restricted common stock shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_VestingOfRestrictedCommonStockShares" xlink:to="rlay_VestingOfRestrictedCommonStockShares_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_VestingOfRestrictedCommonStockValue" xlink:type="locator" xlink:label="rlay_VestingOfRestrictedCommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="rlay_VestingOfRestrictedCommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting of restricted common stock value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_VestingOfRestrictedCommonStockValue" xlink:to="rlay_VestingOfRestrictedCommonStockValue_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extinguishment upon modification of Series C preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:to="us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Treasury Stock Reissued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock upon initial public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock upon initial public offering, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in public offering, net of discounts and issuance costs of $34,707</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in public offering, net of discounts and issuance costs of $34,707, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_StockIssuedDuringPeriodValuePreferredStockNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series C convertible preferred stock, net of issuance costs of $50</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_StockIssuedDuringPeriodValuePreferredStockNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Preferred Stock Net Of Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_StockIssuedDuringPeriodSharesPreferredStockNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series C convertible preferred stock, net of issuance costs of $50, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_StockIssuedDuringPeriodSharesPreferredStockNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Preferred Stock Net Of Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_VestingOfRestrictedCommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_VestingOfRestrictedCommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Of Restricted Common Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_VestingOfRestrictedCommonStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock ,shares</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_VestingOfRestrictedCommonStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Of Restricted Common Stock Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Stock Issued Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net of discounts and issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_IncreaseDecreaseInLeaseAssetsAndLiabilitiesNet" xlink:type="locator" xlink:label="rlay_IncreaseDecreaseInLeaseAssetsAndLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="rlay_IncreaseDecreaseInLeaseAssetsAndLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in lease assets and liabilities net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_IncreaseDecreaseInLeaseAssetsAndLiabilitiesNet" xlink:to="rlay_IncreaseDecreaseInLeaseAssetsAndLiabilitiesNet_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ReclassificationOfRestrictedStockLiabilityToAdditionalPaidInCapital" xlink:type="locator" xlink:label="rlay_ReclassificationOfRestrictedStockLiabilityToAdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="rlay_ReclassificationOfRestrictedStockLiabilityToAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of restricted stock liability to additional paid in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_ReclassificationOfRestrictedStockLiabilityToAdditionalPaidInCapital" xlink:to="rlay_ReclassificationOfRestrictedStockLiabilityToAdditionalPaidInCapital_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_LossOnExtinguishmentAndReissuanceOfPreferredStock" xlink:type="locator" xlink:label="rlay_LossOnExtinguishmentAndReissuanceOfPreferredStock" />
    <link:label xml:lang="en-US" xlink:label="rlay_LossOnExtinguishmentAndReissuanceOfPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Loss on extinguishment and reissuance of preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_LossOnExtinguishmentAndReissuanceOfPreferredStock" xlink:to="rlay_LossOnExtinguishmentAndReissuanceOfPreferredStock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net amortization of premiums and discounts on investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Amortization Of Discounts And Premiums Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on sale of equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Disposition Of Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_IncreaseDecreaseInLeaseAssetsAndLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Lease assets and liabilities, net</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_IncreaseDecreaseInLeaseAssetsAndLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Lease Assets And Liabilities Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Contract asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities" xlink:to="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Commodity Contract Assets And Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale And Maturity Of Other Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible preferred stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock upon exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock upon initial public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Offering costs paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Financing And Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment additions included in accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_ReclassificationOfRestrictedStockLiabilityToAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of restricted stock liability to additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_ReclassificationOfRestrictedStockLiabilityToAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Restricted Stock Liability To Additional Paid In Capital</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_LossOnExtinguishmentAndReissuanceOfPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extinguishment upon modification of Series C preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_LossOnExtinguishmentAndReissuanceOfPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss On Extinguishment And Reissuance Of Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock into common stock upon initial public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Amount Converted1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of use asset obtained in exchange for lease obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Finance Lease Liability</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_RestrictedCashAndCashEquivalentsAtCarryingValueAbstract" xlink:type="locator" xlink:label="rlay_RestrictedCashAndCashEquivalentsAtCarryingValueAbstract" />
    <link:label xml:lang="en-US" xlink:label="rlay_RestrictedCashAndCashEquivalentsAtCarryingValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash and cash equivalents at carrying value abstract.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_RestrictedCashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="rlay_RestrictedCashAndCashEquivalentsAtCarryingValueAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_RestrictedCashAndCashEquivalentsAtCarryingValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents At Carrying Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash as shown on consolidated statements of cash flows</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TextBlockAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Text Block [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business and Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Description And Basis Of Presentation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInvestmentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Investments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfInvestmentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTextBlock" xlink:to="us-gaap_InvestmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Arrangement with Genentech</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ConvertiblePreferredStockTextBlock" xlink:type="locator" xlink:label="rlay_ConvertiblePreferredStockTextBlock" />
    <link:label xml:lang="en-US" xlink:label="rlay_ConvertiblePreferredStockTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible Preferred Stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_ConvertiblePreferredStockTextBlock" xlink:to="rlay_ConvertiblePreferredStockTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_ConvertiblePreferredStockTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_ConvertiblePreferredStockTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases Of Lessee Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:type="locator" xlink:label="us-gaap_PostemploymentBenefitsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PostemploymentBenefitsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Postemployment Benefits [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitsAbstract" xlink:to="us-gaap_PostemploymentBenefitsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pension And Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_BasisOfPresentationPolicyTextBlock" xlink:type="locator" xlink:label="rlay_BasisOfPresentationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="rlay_BasisOfPresentationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_BasisOfPresentationPolicyTextBlock" xlink:to="rlay_BasisOfPresentationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_BasisOfPresentationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of presentation</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_BasisOfPresentationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Policy [Text Block]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ConcentrationOfCreditRiskAndSignificantSuppliersPolicyTextBlock" xlink:type="locator" xlink:label="rlay_ConcentrationOfCreditRiskAndSignificantSuppliersPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="rlay_ConcentrationOfCreditRiskAndSignificantSuppliersPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentration of credit risk and significant suppliers.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_ConcentrationOfCreditRiskAndSignificantSuppliersPolicyTextBlock" xlink:to="rlay_ConcentrationOfCreditRiskAndSignificantSuppliersPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_ConcentrationOfCreditRiskAndSignificantSuppliersPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk and Significant Suppliers</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_ConcentrationOfCreditRiskAndSignificantSuppliersPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Of Credit Risk And Significant Suppliers Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classification and Accretion of Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Redeemable Preferred Stock Issue Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ResearchAndManufacturingContractsPolicyTextBlock" xlink:type="locator" xlink:label="rlay_ResearchAndManufacturingContractsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="rlay_ResearchAndManufacturingContractsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and manufacturing contracts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_ResearchAndManufacturingContractsPolicyTextBlock" xlink:to="rlay_ResearchAndManufacturingContractsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_ResearchAndManufacturingContractsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Manufacturing Contracts</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_ResearchAndManufacturingContractsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Manufacturing Contracts Policy [Text Block]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_PatentCostsPolicyTextBlock" xlink:type="locator" xlink:label="rlay_PatentCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="rlay_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_PatentCostsPolicyTextBlock" xlink:to="rlay_PatentCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Patent Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_DescriptionOfNewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:type="locator" xlink:label="rlay_DescriptionOfNewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="rlay_DescriptionOfNewAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of new accounting pronouncements not yet adopted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_DescriptionOfNewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="rlay_DescriptionOfNewAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_DescriptionOfNewAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_DescriptionOfNewAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of New Accounting Pronouncements Not Yet Adopted Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Assets Measured at Fair Value on a Recurring Basis and Level of the Fair Value Hierarchy</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value of Available-for-Sale Investments by Type of Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of The Restricted Stock Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Share Based Compensation Arrangements By Share Based Payment Award [Text Block]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ReservedSharesOfCommonStockForFutureIssuanceTableTableTextBlock" xlink:type="locator" xlink:label="rlay_ReservedSharesOfCommonStockForFutureIssuanceTableTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="rlay_ReservedSharesOfCommonStockForFutureIssuanceTableTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of reserved shares of common stock for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_ReservedSharesOfCommonStockForFutureIssuanceTableTableTextBlock" xlink:to="rlay_ReservedSharesOfCommonStockForFutureIssuanceTableTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_ReservedSharesOfCommonStockForFutureIssuanceTableTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reserved Shares of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_ReservedSharesOfCommonStockForFutureIssuanceTableTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reserved Shares Of Common Stock For Future Issuance Table Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Fair Value of Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-Based Compensation Expense Included In The Company&apos;s Consolidated Statements of Operations And Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciliation of Expected Income Tax (Benefit) Computed Using Federal Statutory Income Tax Rate to Effective Income Tax Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Deferred Tax Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Computation of Basic and Diluted Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Antidilutive Securities Excluded From Computation of Earnings Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ScheduleOfOperatingLeasePresentationInConsolidatedBalanceSheetTableTextBlock" xlink:type="locator" xlink:label="rlay_ScheduleOfOperatingLeasePresentationInConsolidatedBalanceSheetTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="rlay_ScheduleOfOperatingLeasePresentationInConsolidatedBalanceSheetTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of operating lease presentation in consolidated balance sheet.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_ScheduleOfOperatingLeasePresentationInConsolidatedBalanceSheetTableTextBlock" xlink:to="rlay_ScheduleOfOperatingLeasePresentationInConsolidatedBalanceSheetTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_ScheduleOfOperatingLeasePresentationInConsolidatedBalanceSheetTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Operating Leases Presentation in Consolidated Balance Sheets</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_ScheduleOfOperatingLeasePresentationInConsolidatedBalanceSheetTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Operating Lease Presentation In Consolidated Balance Sheet Table [Text Block]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_SummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossTableTextBlock" xlink:type="locator" xlink:label="rlay_SummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="rlay_SummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of operating lease presentation in consolidated statements of operations and comprehensive loss.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_SummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossTableTextBlock" xlink:to="rlay_SummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_SummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Operating Lease Presentation in Consolidated Statements of Operations and Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_SummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Operating Lease Presentation In Consolidated Statements Of Operations And Comprehensive Loss Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Lease Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:type="locator" xlink:label="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" />
    <link:label xml:lang="en-US" xlink:label="rlay_NatureOfBusinessAndBasisOfPresentationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of business and basis of presentation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="rlay_NatureOfBusinessAndBasisOfPresentationLineItems_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_NatureOfBusinessAndBasisOfPresentationTable" xlink:type="locator" xlink:label="rlay_NatureOfBusinessAndBasisOfPresentationTable" />
    <link:label xml:lang="en-US" xlink:label="rlay_NatureOfBusinessAndBasisOfPresentationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nature of business and basis of presentation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="rlay_NatureOfBusinessAndBasisOfPresentationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_NatureOfBusinessAndBasisOfPresentationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature Of Business And Basis Of Presentation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_NatureOfBusinessAndBasisOfPresentationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Business And Basis Of Presentation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_GenentechIncMember" xlink:type="locator" xlink:label="rlay_GenentechIncMember" />
    <link:label xml:lang="en-US" xlink:label="rlay_GenentechIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Genentech Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_GenentechIncMember" xlink:to="rlay_GenentechIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_GenentechIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Genentech [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_GenentechIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Genentech Inc [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_NatureOfBusinessAndBasisOfPresentationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business and Basis of Presentation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_NatureOfBusinessAndBasisOfPresentationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Business And Basis Of Presentation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Including Assessed Tax</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_UnderwritingDiscountsAndCommissions" xlink:type="locator" xlink:label="rlay_UnderwritingDiscountsAndCommissions" />
    <link:label xml:lang="en-US" xlink:label="rlay_UnderwritingDiscountsAndCommissions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts and commissions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_UnderwritingDiscountsAndCommissions" xlink:to="rlay_UnderwritingDiscountsAndCommissions_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued in transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Number Of Shares Issued In Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale price of stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Issuance of common stock in public offering</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_UnderwritingDiscountsAndCommissions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_UnderwritingDiscountsAndCommissions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Discounts And Commissions</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expense on initial public offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of stock shares converted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Shares Converted1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; Equity, Reverse Stock Split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Reverse Stock Split</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_SignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="rlay_SignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="rlay_SignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_SignificantAccountingPoliciesLineItems" xlink:to="rlay_SignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_SignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="rlay_SignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="rlay_SignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_SignificantAccountingPoliciesTable" xlink:to="rlay_SignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_SignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_SignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:type="locator" xlink:label="us-gaap_LetterOfCreditMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of Credit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Letter Of Credit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Type [Domain]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_GenentechAgreementMember" xlink:type="locator" xlink:label="rlay_GenentechAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="rlay_GenentechAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Genentech agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_GenentechAgreementMember" xlink:to="rlay_GenentechAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_GenentechAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Genentech Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_GenentechAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Genentech Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_LaboratoryAndComputerEquipmentMember" xlink:type="locator" xlink:label="rlay_LaboratoryAndComputerEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="rlay_LaboratoryAndComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory and computer equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_LaboratoryAndComputerEquipmentMember" xlink:to="rlay_LaboratoryAndComputerEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_LaboratoryAndComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory and Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_LaboratoryAndComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory And Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_SignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_SignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CashAndCashEquivalentsMaturityDateDescription" xlink:type="locator" xlink:label="rlay_CashAndCashEquivalentsMaturityDateDescription" />
    <link:label xml:lang="en-US" xlink:label="rlay_CashAndCashEquivalentsMaturityDateDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents maturity date description.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_CashAndCashEquivalentsMaturityDateDescription" xlink:to="rlay_CashAndCashEquivalentsMaturityDateDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_CashAndCashEquivalentsMaturityDateDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity days for highly liquid investments</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_CashAndCashEquivalentsMaturityDateDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Maturity Date Description</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_NumberOfCollaborationAndLicenseAgreement" xlink:type="locator" xlink:label="rlay_NumberOfCollaborationAndLicenseAgreement" />
    <link:label xml:lang="en-US" xlink:label="rlay_NumberOfCollaborationAndLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of collaboration and license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_NumberOfCollaborationAndLicenseAgreement" xlink:to="rlay_NumberOfCollaborationAndLicenseAgreement_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CollaborationAndLicenseAgreementEnteredDate" xlink:type="locator" xlink:label="rlay_CollaborationAndLicenseAgreementEnteredDate" />
    <link:label xml:lang="en-US" xlink:label="rlay_CollaborationAndLicenseAgreementEnteredDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreement entered date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_CollaborationAndLicenseAgreementEnteredDate" xlink:to="rlay_CollaborationAndLicenseAgreementEnteredDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_NumberOfCollaborationAndLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of collaboration and license agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_NumberOfCollaborationAndLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Collaboration And License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_CollaborationAndLicenseAgreementEnteredDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and license agreement entered date</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_CollaborationAndLicenseAgreementEnteredDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreement Entered Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease option to extent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Existence Of Option To Extend</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease option to terminate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Existence Of Option To Terminate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment loss of long lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Long Lived Assets Held For Use</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Income tax benefit, likelihood of realized upon ultimate settlement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination Likelihood Of Unfavorable Settlement</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CashAndCashEquivalentsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="rlay_CashAndCashEquivalentsFairValueDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="rlay_CashAndCashEquivalentsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents fair value disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_CashAndCashEquivalentsFairValueDisclosureAbstract" xlink:to="rlay_CashAndCashEquivalentsFairValueDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value on a recurring basis [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsMember" xlink:type="locator" xlink:label="us-gaap_InvestmentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsMember" xlink:to="us-gaap_InvestmentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US treasury bills [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US agency securities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_CashAndCashEquivalentsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents:</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_CashAndCashEquivalentsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets, fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsFairValueDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosureAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Fair Value To Amortized Cost Basis [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">U.S treasury bills [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">U.S agency securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentSecondaryCategorizationAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentSecondaryCategorizationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentSecondaryCategorizationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Secondary Categorization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentSecondaryCategorizationAxis" xlink:to="us-gaap_InvestmentSecondaryCategorizationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentSecondaryCategorizationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Secondary Categorization [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsBySecondaryCategorizationDomain" xlink:type="locator" xlink:label="us-gaap_InvestmentsBySecondaryCategorizationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsBySecondaryCategorizationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments by Secondary Categorization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsBySecondaryCategorizationDomain" xlink:to="us-gaap_InvestmentsBySecondaryCategorizationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsBySecondaryCategorizationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments By Secondary Categorization [Domain]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_InvestmentsWithMaturityOfOneYearOrLessMember" xlink:type="locator" xlink:label="rlay_InvestmentsWithMaturityOfOneYearOrLessMember" />
    <link:label xml:lang="en-US" xlink:label="rlay_InvestmentsWithMaturityOfOneYearOrLessMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Investments with maturity of one year or less.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_InvestmentsWithMaturityOfOneYearOrLessMember" xlink:to="rlay_InvestmentsWithMaturityOfOneYearOrLessMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_InvestmentsWithMaturityOfOneYearOrLessMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments with a maturity of one year or less [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_InvestmentsWithMaturityOfOneYearOrLessMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments With Maturity Of One Year Or Less [Member]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_InvestmentsWithMaturityOfOneToTwoYearsMember" xlink:type="locator" xlink:label="rlay_InvestmentsWithMaturityOfOneToTwoYearsMember" />
    <link:label xml:lang="en-US" xlink:label="rlay_InvestmentsWithMaturityOfOneToTwoYearsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Investments with maturity of one to two years.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_InvestmentsWithMaturityOfOneToTwoYearsMember" xlink:to="rlay_InvestmentsWithMaturityOfOneToTwoYearsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_InvestmentsWithMaturityOfOneToTwoYearsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments with a maturity of one to two years [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_InvestmentsWithMaturityOfOneToTwoYearsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments With Maturity Of One To Two Years [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Held To Maturity Securities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Held To Maturity Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CollaborationAndLicenseArrangementAbstract" xlink:type="locator" xlink:label="rlay_CollaborationAndLicenseArrangementAbstract" />
    <link:label xml:lang="en-US" xlink:label="rlay_CollaborationAndLicenseArrangementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_CollaborationAndLicenseArrangementAbstract" xlink:to="rlay_CollaborationAndLicenseArrangementAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_CollaborationAndLicenseArrangementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Arrangement [Abstract]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CollaborationAndLicenseArrangementLineItems" xlink:type="locator" xlink:label="rlay_CollaborationAndLicenseArrangementLineItems" />
    <link:label xml:lang="en-US" xlink:label="rlay_CollaborationAndLicenseArrangementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="rlay_CollaborationAndLicenseArrangementLineItems_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CollaborationAndLicenseArrangementTable" xlink:type="locator" xlink:label="rlay_CollaborationAndLicenseArrangementTable" />
    <link:label xml:lang="en-US" xlink:label="rlay_CollaborationAndLicenseArrangementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_CollaborationAndLicenseArrangementTable" xlink:to="rlay_CollaborationAndLicenseArrangementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_CollaborationAndLicenseArrangementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration And License Arrangement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_CollaborationAndLicenseArrangementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Arrangement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:type="locator" xlink:label="us-gaap_ForeignCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outside US [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Country [Member]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_StandAloneSellingPricesMember" xlink:type="locator" xlink:label="rlay_StandAloneSellingPricesMember" />
    <link:label xml:lang="en-US" xlink:label="rlay_StandAloneSellingPricesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stand-alone selling prices.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_StandAloneSellingPricesMember" xlink:to="rlay_StandAloneSellingPricesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_StandAloneSellingPricesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stand-alone Selling Prices (&#8220;SSP&#8221;) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_StandAloneSellingPricesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stand Alone Selling Prices [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_LicenseAndTransferAgreementMember" xlink:type="locator" xlink:label="rlay_LicenseAndTransferAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="rlay_LicenseAndTransferAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License and transfer agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_LicenseAndTransferAgreementMember" xlink:to="rlay_LicenseAndTransferAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_LicenseAndTransferAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfer of License [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_LicenseAndTransferAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License And Transfer Agreement [Member]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ResearchAndDevelopmentServicesMember" xlink:type="locator" xlink:label="rlay_ResearchAndDevelopmentServicesMember" />
    <link:label xml:lang="en-US" xlink:label="rlay_ResearchAndDevelopmentServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development services.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_ResearchAndDevelopmentServicesMember" xlink:to="rlay_ResearchAndDevelopmentServicesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_ResearchAndDevelopmentServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Services [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_ResearchAndDevelopmentServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Services [Member]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_TransferOfActivePharmaceuticalIngredientsMember" xlink:type="locator" xlink:label="rlay_TransferOfActivePharmaceuticalIngredientsMember" />
    <link:label xml:lang="en-US" xlink:label="rlay_TransferOfActivePharmaceuticalIngredientsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Transfer of active pharmaceutical ingredients.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_TransferOfActivePharmaceuticalIngredientsMember" xlink:to="rlay_TransferOfActivePharmaceuticalIngredientsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_TransferOfActivePharmaceuticalIngredientsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfer of Active Pharmaceutical Ingredients [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_TransferOfActivePharmaceuticalIngredientsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfer Of Active Pharmaceutical Ingredients [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_CollaborationAndLicenseArrangementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration And License Arrangement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_CollaborationAndLicenseArrangementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Arrangement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementNatureAndPurpose" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementNatureAndPurpose" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementNatureAndPurpose_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative arrangement, purpose</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementNatureAndPurpose" xlink:to="us-gaap_CollaborativeArrangementNatureAndPurpose_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementNatureAndPurpose_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Nature And Purpose</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementRightsAndObligations" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementRightsAndObligations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementRightsAndObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative arrangement, rights and obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementRightsAndObligations" xlink:to="us-gaap_CollaborativeArrangementRightsAndObligations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementRightsAndObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Rights And Obligations</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_NonRefundableUpfrontPayment" xlink:type="locator" xlink:label="rlay_NonRefundableUpfrontPayment" />
    <link:label xml:lang="en-US" xlink:label="rlay_NonRefundableUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-refundable upfront payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_NonRefundableUpfrontPayment" xlink:to="rlay_NonRefundableUpfrontPayment_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement" xlink:type="locator" xlink:label="rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement" />
    <link:label xml:lang="en-US" xlink:label="rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum additional amount received upon milestone achievement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement" xlink:to="rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_MilestonePaymentReceivable" xlink:type="locator" xlink:label="rlay_MilestonePaymentReceivable" />
    <link:label xml:lang="en-US" xlink:label="rlay_MilestonePaymentReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_MilestonePaymentReceivable" xlink:to="rlay_MilestonePaymentReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_NonRefundableUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_NonRefundableUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_MilestonePaymentReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_MilestonePaymentReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum additional amount received upon milestone achievement</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Additional Amount Received Upon Milestone Achievement</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CollaborationAgreementTransactionPrice" xlink:type="locator" xlink:label="rlay_CollaborationAgreementTransactionPrice" />
    <link:label xml:lang="en-US" xlink:label="rlay_CollaborationAgreementTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement transaction price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_CollaborationAgreementTransactionPrice" xlink:to="rlay_CollaborationAgreementTransactionPrice_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_NonRefundableMilestoneTransferAmount" xlink:type="locator" xlink:label="rlay_NonRefundableMilestoneTransferAmount" />
    <link:label xml:lang="en-US" xlink:label="rlay_NonRefundableMilestoneTransferAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-refundable milestone transfer amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_NonRefundableMilestoneTransferAmount" xlink:to="rlay_NonRefundableMilestoneTransferAmount_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_NonRefundableMilestoneForCompletionAmount" xlink:type="locator" xlink:label="rlay_NonRefundableMilestoneForCompletionAmount" />
    <link:label xml:lang="en-US" xlink:label="rlay_NonRefundableMilestoneForCompletionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-refundable milestone for completion amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_NonRefundableMilestoneForCompletionAmount" xlink:to="rlay_NonRefundableMilestoneForCompletionAmount_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_VariableConsiderationRelatedToReimbursementsDueForResearchAndDevelopmentServices" xlink:type="locator" xlink:label="rlay_VariableConsiderationRelatedToReimbursementsDueForResearchAndDevelopmentServices" />
    <link:label xml:lang="en-US" xlink:label="rlay_VariableConsiderationRelatedToReimbursementsDueForResearchAndDevelopmentServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Variable consideration related to reimbursements due for research and development services.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_VariableConsiderationRelatedToReimbursementsDueForResearchAndDevelopmentServices" xlink:to="rlay_VariableConsiderationRelatedToReimbursementsDueForResearchAndDevelopmentServices_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_DevelopmentBasedMilestonePaymentsUnderAgreement" xlink:type="locator" xlink:label="rlay_DevelopmentBasedMilestonePaymentsUnderAgreement" />
    <link:label xml:lang="en-US" xlink:label="rlay_DevelopmentBasedMilestonePaymentsUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate potential clinical development milestone payments available to be earned under a collaboration arrangement for each available target selected by the collaborator.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_DevelopmentBasedMilestonePaymentsUnderAgreement" xlink:to="rlay_DevelopmentBasedMilestonePaymentsUnderAgreement_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_RegulatoryBasedMilestonePaymentsUnderAgreement" xlink:type="locator" xlink:label="rlay_RegulatoryBasedMilestonePaymentsUnderAgreement" />
    <link:label xml:lang="en-US" xlink:label="rlay_RegulatoryBasedMilestonePaymentsUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate potential regulatory milestone payments available to be earned under a collaboration arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_RegulatoryBasedMilestonePaymentsUnderAgreement" xlink:to="rlay_RegulatoryBasedMilestonePaymentsUnderAgreement_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_CollaborationAgreementTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement transaction price</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_CollaborationAgreementTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Transaction Price</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_NonRefundableMilestoneTransferAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable milestone payment transfer amount</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_NonRefundableMilestoneTransferAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Milestone Transfer Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_NonRefundableMilestoneForCompletionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable milestone payment for completion amount</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_NonRefundableMilestoneForCompletionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Milestone For Completion Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_VariableConsiderationRelatedToReimbursementsDueForResearchAndDevelopmentServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable consideration related to reimbursements due for research and development services</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_VariableConsiderationRelatedToReimbursementsDueForResearchAndDevelopmentServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Consideration Related To Reimbursements Due For Research And Development Services</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_DevelopmentBasedMilestonePaymentsUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development based milestone payments under agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_DevelopmentBasedMilestonePaymentsUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development Based Milestone Payments Under Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_RegulatoryBasedMilestonePaymentsUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory based milestone payments under agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_RegulatoryBasedMilestonePaymentsUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Based Milestone Payments Under Agreement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining performance obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Collaboration revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="rlay_LaboratoryEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="rlay_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_LaboratoryEquipmentMember" xlink:to="rlay_LaboratoryEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Process [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant and Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_AccruedExternalResearchAndDevelopmentExpenseCurrent" xlink:type="locator" xlink:label="rlay_AccruedExternalResearchAndDevelopmentExpenseCurrent" />
    <link:label xml:lang="en-US" xlink:label="rlay_AccruedExternalResearchAndDevelopmentExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued external research and development expense current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_AccruedExternalResearchAndDevelopmentExpenseCurrent" xlink:to="rlay_AccruedExternalResearchAndDevelopmentExpenseCurrent_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_AccruedProfessionalServicesCurrent" xlink:type="locator" xlink:label="rlay_AccruedProfessionalServicesCurrent" />
    <link:label xml:lang="en-US" xlink:label="rlay_AccruedProfessionalServicesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued professional services current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_AccruedProfessionalServicesCurrent" xlink:to="rlay_AccruedProfessionalServicesCurrent_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_AccruedOtherExpensesCurrent" xlink:type="locator" xlink:label="rlay_AccruedOtherExpensesCurrent" />
    <link:label xml:lang="en-US" xlink:label="rlay_AccruedOtherExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued other expenses current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_AccruedOtherExpensesCurrent" xlink:to="rlay_AccruedOtherExpensesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_AccruedExternalResearchAndDevelopmentExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">External research and development</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_AccruedExternalResearchAndDevelopmentExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued External Research And Development Expense Current</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_AccruedProfessionalServicesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional services</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_AccruedProfessionalServicesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Services Current</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_AccruedOtherExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_AccruedOtherExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Other Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_PreferredStockConvertibleConversionPrice" xlink:type="locator" xlink:label="rlay_PreferredStockConvertibleConversionPrice" />
    <link:label xml:lang="en-US" xlink:label="rlay_PreferredStockConvertibleConversionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock convertible conversion price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_PreferredStockConvertibleConversionPrice" xlink:to="rlay_PreferredStockConvertibleConversionPrice_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="rlay_UnderwrittenPublicOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="rlay_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwritten public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_UnderwrittenPublicOfferingMember" xlink:to="rlay_UnderwrittenPublicOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwritten Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Underwritten Public Offering [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_PreferredStockConvertibleConversionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock convertible conversion price</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_PreferredStockConvertibleConversionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Convertible Conversion Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding convertible preferred stock converted into common shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Shares Issued Upon Conversion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from exchange of stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Preferred Stock And Preference Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares price, per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Or Sale Of Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidation preference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Liquidation Preference Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock issuable upon conversion</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible preferred stock outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockVotingRights" xlink:type="locator" xlink:label="us-gaap_PreferredStockVotingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock voting rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockVotingRights" xlink:to="us-gaap_PreferredStockVotingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Voting Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DividendsPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends declared</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DividendsPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidation preference per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Liquidation Preference</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="rlay_EmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="rlay_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_EmployeeStockPurchasePlanMember" xlink:to="rlay_EmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Voting Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Voting Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStock" xlink:type="locator" xlink:label="us-gaap_DividendsCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends declared</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Common Stock</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CommonStockRestrictionPeriod" xlink:type="locator" xlink:label="rlay_CommonStockRestrictionPeriod" />
    <link:label xml:lang="en-US" xlink:label="rlay_CommonStockRestrictionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock, restriction period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_CommonStockRestrictionPeriod" xlink:to="rlay_CommonStockRestrictionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_CommonStockRestrictionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Restriction Period</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_CommonStockRestrictionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Restriction Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares - Beginning</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares - Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares - Cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares - Ending</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAveragePriceOfSharesPurchased" xlink:type="locator" xlink:label="rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAveragePriceOfSharesPurchased" />
    <link:label xml:lang="en-US" xlink:label="rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAveragePriceOfSharesPurchased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation By Share Based Arrangement Equity Instruments Other Than Options Vested In Period Weighted Average Price Of Shares Purchased.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAveragePriceOfSharesPurchased" xlink:to="rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAveragePriceOfSharesPurchased_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAveragePriceOfSharesPurchased" xlink:type="locator" xlink:label="rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAveragePriceOfSharesPurchased" />
    <link:label xml:lang="en-US" xlink:label="rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAveragePriceOfSharesPurchased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation By Share Based Arrangement Equity Instruments Other Than Options Cancelled In Period Weighted Average Price Of Shares Purchased.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAveragePriceOfSharesPurchased" xlink:to="rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAveragePriceOfSharesPurchased_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted- Average Purchase Price - Beginning</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAveragePriceOfSharesPurchased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Purchase Price - Vested</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAveragePriceOfSharesPurchased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation By Share Based Arrangement Equity Instruments Other Than Options Vested In Period Weighted Average Price Of Shares Purchased</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAveragePriceOfSharesPurchased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Purchase Price - Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAveragePriceOfSharesPurchased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation By Share Based Arrangement Equity Instruments Other Than Options Cancelled In Period Weighted Average Price Of Shares Purchased</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted- Average Purchase Price - Ending</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of shares, vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CommonStockCapitalSharesReservedUnderCompensationPlan" xlink:type="locator" xlink:label="rlay_CommonStockCapitalSharesReservedUnderCompensationPlan" />
    <link:label xml:lang="en-US" xlink:label="rlay_CommonStockCapitalSharesReservedUnderCompensationPlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate number of common shares reserved under the compensation plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_CommonStockCapitalSharesReservedUnderCompensationPlan" xlink:to="rlay_CommonStockCapitalSharesReservedUnderCompensationPlan_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_CommonStockCapitalSharesReservedUnderCompensationPlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares reserved under the compensation plan</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_CommonStockCapitalSharesReservedUnderCompensationPlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved Under Compensation Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total shares of common stock reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based awards, authorized for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_TwoThousandTwentyPlanMember" xlink:type="locator" xlink:label="rlay_TwoThousandTwentyPlanMember" />
    <link:label xml:lang="en-US" xlink:label="rlay_TwoThousandTwentyPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2020 Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_TwoThousandTwentyPlanMember" xlink:to="rlay_TwoThousandTwentyPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_TwoThousandTwentyPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_TwoThousandTwentyPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Plan [Member]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_TwoThousandSixteenPlanMember" xlink:type="locator" xlink:label="rlay_TwoThousandSixteenPlanMember" />
    <link:label xml:lang="en-US" xlink:label="rlay_TwoThousandSixteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2016 Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_TwoThousandSixteenPlanMember" xlink:to="rlay_TwoThousandSixteenPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_TwoThousandSixteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2016 Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_TwoThousandSixteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Sixteen Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLossMember" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLossMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLossMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Income (Loss) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLossMember" xlink:to="us-gaap_OperatingIncomeLossMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLossMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel">Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options and Warrants Outstanding, Number of Shares Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, Number of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised, Number of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancelled, Number of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options and Warrants Outstanding, Number of Shares Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares, Non-vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price Per Share, Outstanding Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price Per Share, Outstanding Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Non-vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm" xlink:type="locator" xlink:label="rlay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm" />
    <link:label xml:lang="en-US" xlink:label="rlay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options non vested weighted average remaining contractual term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm" xlink:to="rlay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Life, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Life, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Life, Non-vested</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Non-vested Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Award, Award Vesting Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total share-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement by share-based payment award, vesting term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility rate minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility rate maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value of stock options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expenses [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized compensation cost related to the unvested stock-based awards, Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized compensation cost related to the unvested stock-based awards, Weighted average period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="rlay_IncomeTaxDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="rlay_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="rlay_IncomeTaxDisclosureLineItems_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="rlay_IncomeTaxDisclosureTable" />
    <link:label xml:lang="en-US" xlink:label="rlay_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_IncomeTaxDisclosureTable" xlink:to="rlay_IncomeTaxDisclosureTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="locator" xlink:label="rlay_EffectiveIncomeTaxRateReconciliationPermanentDifferences" />
    <link:label xml:lang="en-US" xlink:label="rlay_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation permanent differences.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="rlay_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax computed at federal statutory rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes, net of federal benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">R&amp;D credit carryovers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Permanent Differences</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_DeferredTaxAssetsLeaseLiability" xlink:type="locator" xlink:label="rlay_DeferredTaxAssetsLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="rlay_DeferredTaxAssetsLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_DeferredTaxAssetsLeaseLiability" xlink:to="rlay_DeferredTaxAssetsLeaseLiability_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_DeferredTaxAssetsDepreciationAndAmortization" xlink:type="locator" xlink:label="rlay_DeferredTaxAssetsDepreciationAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="rlay_DeferredTaxAssetsDepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets depreciation and amortization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_DeferredTaxAssetsDepreciationAndAmortization" xlink:to="rlay_DeferredTaxAssetsDepreciationAndAmortization_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:type="locator" xlink:label="rlay_DeferredTaxLiabilitiesOperatingLeaseAssets" />
    <link:label xml:lang="en-US" xlink:label="rlay_DeferredTaxLiabilitiesOperatingLeaseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities operating lease assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:to="rlay_DeferredTaxLiabilitiesOperatingLeaseAssets_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_DeferredTaxAssetsLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_DeferredTaxAssetsLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangibles</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Goodwill And Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_DeferredTaxAssetsDepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_DeferredTaxAssetsDepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Depreciation And Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total gross deferred tax asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_DeferredTaxLiabilitiesOperatingLeaseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease assets</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_DeferredTaxLiabilitiesOperatingLeaseAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Operating Lease Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_DeferredTaxAssetsOperatingLossCarryforwardsBeginningToExpireYear" xlink:type="locator" xlink:label="rlay_DeferredTaxAssetsOperatingLossCarryforwardsBeginningToExpireYear" />
    <link:label xml:lang="en-US" xlink:label="rlay_DeferredTaxAssetsOperatingLossCarryforwardsBeginningToExpireYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating loss carryforwards beginning to expire year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_DeferredTaxAssetsOperatingLossCarryforwardsBeginningToExpireYear" xlink:to="rlay_DeferredTaxAssetsOperatingLossCarryforwardsBeginningToExpireYear_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, subject to expiration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, not subject to expiration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_DeferredTaxAssetsOperatingLossCarryforwardsBeginningToExpireYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, beginning to expiring year</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_DeferredTaxAssetsOperatingLossCarryforwardsBeginningToExpireYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Beginning To Expire Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, state</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards State And Local</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" xlink:type="locator" xlink:label="rlay_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="rlay_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets tax credit carryforwards research expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" xlink:to="rlay_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit carryforwards, expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research Expiration Year</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_IncreaseInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="rlay_IncreaseInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="rlay_IncreaseInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in deferred tax assets valuation allowance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_IncreaseInDeferredTaxAssetsValuationAllowance" xlink:to="rlay_IncreaseInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_IncreaseInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_IncreaseInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of income tax examinations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationDescription" xlink:to="us-gaap_IncomeTaxExaminationDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination Description</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_TaxCutsAndJobsActOf2017DescriptionOfCorporateTaxPayers" xlink:type="locator" xlink:label="rlay_TaxCutsAndJobsActOf2017DescriptionOfCorporateTaxPayers" />
    <link:label xml:lang="en-US" xlink:label="rlay_TaxCutsAndJobsActOf2017DescriptionOfCorporateTaxPayers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax Cuts and Jobs Act of 2017, description of corporate tax payers.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_TaxCutsAndJobsActOf2017DescriptionOfCorporateTaxPayers" xlink:to="rlay_TaxCutsAndJobsActOf2017DescriptionOfCorporateTaxPayers_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_TaxCutsAndJobsActOf2017NetOperatingLossCarrybackPeriod" xlink:type="locator" xlink:label="rlay_TaxCutsAndJobsActOf2017NetOperatingLossCarrybackPeriod" />
    <link:label xml:lang="en-US" xlink:label="rlay_TaxCutsAndJobsActOf2017NetOperatingLossCarrybackPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax Cuts and Jobs Act of 2017, net operating loss carryback period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_TaxCutsAndJobsActOf2017NetOperatingLossCarrybackPeriod" xlink:to="rlay_TaxCutsAndJobsActOf2017NetOperatingLossCarrybackPeriod_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_TaxCutsAndJobsActOf2017MaximumPercentageOfInterestDeductedByTaxPayers" xlink:type="locator" xlink:label="rlay_TaxCutsAndJobsActOf2017MaximumPercentageOfInterestDeductedByTaxPayers" />
    <link:label xml:lang="en-US" xlink:label="rlay_TaxCutsAndJobsActOf2017MaximumPercentageOfInterestDeductedByTaxPayers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax Cuts and Jobs Act of 2017, maximum percentage of interest deducted by tax payers.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_TaxCutsAndJobsActOf2017MaximumPercentageOfInterestDeductedByTaxPayers" xlink:to="rlay_TaxCutsAndJobsActOf2017MaximumPercentageOfInterestDeductedByTaxPayers_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CARESActPercentageOfInterestDeductedByTaxPayers" xlink:type="locator" xlink:label="rlay_CARESActPercentageOfInterestDeductedByTaxPayers" />
    <link:label xml:lang="en-US" xlink:label="rlay_CARESActPercentageOfInterestDeductedByTaxPayers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">CARES Act, percentage of interest deducted by tax payers.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_CARESActPercentageOfInterestDeductedByTaxPayers" xlink:to="rlay_CARESActPercentageOfInterestDeductedByTaxPayers_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CARESActPercentageOfEliminatesOfTaxableIncome" xlink:type="locator" xlink:label="rlay_CARESActPercentageOfEliminatesOfTaxableIncome" />
    <link:label xml:lang="en-US" xlink:label="rlay_CARESActPercentageOfEliminatesOfTaxableIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">CARES Act, percentage of eliminates of taxable income.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_CARESActPercentageOfEliminatesOfTaxableIncome" xlink:to="rlay_CARESActPercentageOfEliminatesOfTaxableIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_TaxCutsAndJobsActOf2017DescriptionOfCorporateTaxPayers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Cuts and Jobs Act of 2017, description of corporate tax payers</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_TaxCutsAndJobsActOf2017DescriptionOfCorporateTaxPayers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Cuts And Jobs Act Of2017 Description Of Corporate Tax Payers</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_TaxCutsAndJobsActOf2017NetOperatingLossCarrybackPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryback period</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_TaxCutsAndJobsActOf2017NetOperatingLossCarrybackPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Cuts And Jobs Act Of2017 Net Operating Loss Carryback Period</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_CARESActPercentageOfEliminatesOfTaxableIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CARES Act, percentage of eliminates of taxable income</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_CARESActPercentageOfEliminatesOfTaxableIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">C A R E S Act Percentage Of Eliminates Of Taxable Income</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_TaxCutsAndJobsActOf2017MaximumPercentageOfInterestDeductedByTaxPayers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Cuts and Jobs Act of 2017, maximum percentage of interest deducted by tax payers</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_TaxCutsAndJobsActOf2017MaximumPercentageOfInterestDeductedByTaxPayers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Cuts And Jobs Act Of2017 Maximum Percentage Of Interest Deducted By Tax Payers</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_CARESActPercentageOfInterestDeductedByTaxPayers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CARES Act, percentage of interest deducted by tax payers</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_CARESActPercentageOfInterestDeductedByTaxPayers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">C A R E S Act Percentage Of Interest Deducted By Tax Payers</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CARESActPercentageOfCorporateCharitableDeductionLimit" xlink:type="locator" xlink:label="rlay_CARESActPercentageOfCorporateCharitableDeductionLimit" />
    <link:label xml:lang="en-US" xlink:label="rlay_CARESActPercentageOfCorporateCharitableDeductionLimit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">CARES Act, percentage of corporate charitable deduction limit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_CARESActPercentageOfCorporateCharitableDeductionLimit" xlink:to="rlay_CARESActPercentageOfCorporateCharitableDeductionLimit_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CARESActPeriodOfQualifiedImprovementPropertyForCostRecovery" xlink:type="locator" xlink:label="rlay_CARESActPeriodOfQualifiedImprovementPropertyForCostRecovery" />
    <link:label xml:lang="en-US" xlink:label="rlay_CARESActPeriodOfQualifiedImprovementPropertyForCostRecovery_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">CARES Act, Period of qualified improvement property for cost-recovery.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_CARESActPeriodOfQualifiedImprovementPropertyForCostRecovery" xlink:to="rlay_CARESActPeriodOfQualifiedImprovementPropertyForCostRecovery_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CARESActPercentageOfBonusDepreciation" xlink:type="locator" xlink:label="rlay_CARESActPercentageOfBonusDepreciation" />
    <link:label xml:lang="en-US" xlink:label="rlay_CARESActPercentageOfBonusDepreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">CARES Act, percentage of bonus depreciation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_CARESActPercentageOfBonusDepreciation" xlink:to="rlay_CARESActPercentageOfBonusDepreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_CARESActPercentageOfCorporateCharitableDeductionLimit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CARES Act, percentage of corporate charitable deduction limit</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_CARESActPercentageOfCorporateCharitableDeductionLimit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">C A R E S Act Percentage Of Corporate Charitable Deduction Limit</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_CARESActPeriodOfQualifiedImprovementPropertyForCostRecovery_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CARES Act, period of qualified improvement property for cost-recovery</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_CARESActPeriodOfQualifiedImprovementPropertyForCostRecovery_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">C A R E S Act Period Of Qualified Improvement Property For Cost Recovery</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_CARESActPercentageOfBonusDepreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CARES Act, percentage of bonus depreciation</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_CARESActPercentageOfBonusDepreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">C A R E S Act Percentage Of Bonus Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deemed dividend resulting from extinguishment upon modification of Series C preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Dividends And Other Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Earnings Per Share Basic By Common Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic By Common Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings Per Share Basic [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ConvertiblePreferredStocksMember" xlink:type="locator" xlink:label="rlay_ConvertiblePreferredStocksMember" />
    <link:label xml:lang="en-US" xlink:label="rlay_ConvertiblePreferredStocksMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stocks.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_ConvertiblePreferredStocksMember" xlink:to="rlay_ConvertiblePreferredStocksMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_ConvertiblePreferredStocksMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible preferred stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_ConvertiblePreferredStocksMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stocks [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to purchase common stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unvested restricted stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ResearchAndDevelopmentArrangementAnnualFee" xlink:type="locator" xlink:label="rlay_ResearchAndDevelopmentArrangementAnnualFee" />
    <link:label xml:lang="en-US" xlink:label="rlay_ResearchAndDevelopmentArrangementAnnualFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development arrangement, annual fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_ResearchAndDevelopmentArrangementAnnualFee" xlink:to="rlay_ResearchAndDevelopmentArrangementAnnualFee_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ResearchAndDevelopmentArrangementContractToPerformForOthersRenewalPeriod" xlink:type="locator" xlink:label="rlay_ResearchAndDevelopmentArrangementContractToPerformForOthersRenewalPeriod" />
    <link:label xml:lang="en-US" xlink:label="rlay_ResearchAndDevelopmentArrangementContractToPerformForOthersRenewalPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development arrangement contract to perform for others renewal period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_ResearchAndDevelopmentArrangementContractToPerformForOthersRenewalPeriod" xlink:to="rlay_ResearchAndDevelopmentArrangementContractToPerformForOthersRenewalPeriod_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ResearchAndDevelopmentArrangementExpirationDate" xlink:type="locator" xlink:label="rlay_ResearchAndDevelopmentArrangementExpirationDate" />
    <link:label xml:lang="en-US" xlink:label="rlay_ResearchAndDevelopmentArrangementExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development arrangement, expiration date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_ResearchAndDevelopmentArrangementExpirationDate" xlink:to="rlay_ResearchAndDevelopmentArrangementExpirationDate_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ResearchAndDevelopmentArrangementTermOfContract" xlink:type="locator" xlink:label="rlay_ResearchAndDevelopmentArrangementTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="rlay_ResearchAndDevelopmentArrangementTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development arrangement, term of contract.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_ResearchAndDevelopmentArrangementTermOfContract" xlink:to="rlay_ResearchAndDevelopmentArrangementTermOfContract_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="locator" xlink:label="rlay_CommitmentsAndContingenciesDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="rlay_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rlay_CommitmentsAndContingenciesDisclosureLineItems_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CommitmentsAndContingenciesDisclosureTable" xlink:type="locator" xlink:label="rlay_CommitmentsAndContingenciesDisclosureTable" />
    <link:label xml:lang="en-US" xlink:label="rlay_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_CommitmentsAndContingenciesDisclosureTable" xlink:to="rlay_CommitmentsAndContingenciesDisclosureTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_DEShawResearchMember" xlink:type="locator" xlink:label="rlay_DEShawResearchMember" />
    <link:label xml:lang="en-US" xlink:label="rlay_DEShawResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">DE shaw research.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_DEShawResearchMember" xlink:to="rlay_DEShawResearchMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_DEShawResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">DE Shaw Research [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_DEShawResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">D E Shaw Research [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:type="locator" xlink:label="us-gaap_LicenseAgreementTermsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement Terms [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Terms [Member]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_LeaseAgreementMember" xlink:type="locator" xlink:label="rlay_LeaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="rlay_LeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_LeaseAgreementMember" xlink:to="rlay_LeaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_LeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_LeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Agreement [Member]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_OtherthirdPartiesMember" xlink:type="locator" xlink:label="rlay_OtherthirdPartiesMember" />
    <link:label xml:lang="en-US" xlink:label="rlay_OtherthirdPartiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other third parties [member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_OtherthirdPartiesMember" xlink:to="rlay_OtherthirdPartiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_OtherthirdPartiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Third Parties [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_OtherthirdPartiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Otherthird Parties [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" xlink:type="locator" xlink:label="us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares held</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" xlink:to="us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments In And Advances To Affiliates Balance Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_ResearchAndDevelopmentArrangementAnnualFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development arrangement, annual fee</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_ResearchAndDevelopmentArrangementAnnualFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Annual Fee</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_ResearchAndDevelopmentArrangementTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development arrangement, term of contract</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_ResearchAndDevelopmentArrangementTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Term Of Contract</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_ResearchAndDevelopmentArrangementExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development arrangement, expiration date</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_ResearchAndDevelopmentArrangementExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_ResearchAndDevelopmentArrangementContractToPerformForOthersRenewalPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement renewal period</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_ResearchAndDevelopmentArrangementContractToPerformForOthersRenewalPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Renewal Period</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_PotentialDevelopmentMilestonePayments" xlink:type="locator" xlink:label="rlay_PotentialDevelopmentMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="rlay_PotentialDevelopmentMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential development milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_PotentialDevelopmentMilestonePayments" xlink:to="rlay_PotentialDevelopmentMilestonePayments_lbl" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement" xlink:type="locator" xlink:label="rlay_MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement" />
    <link:label xml:lang="en-US" xlink:label="rlay_MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment due upon specified regulatory milestone achievement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement" xlink:to="rlay_MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_PotentialDevelopmentMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential development milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_PotentialDevelopmentMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Potential Development Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment Due</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Due Upon Specified Regulatory Milestone Achievement</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued expenses</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_NumberOfMilestoneTargets" xlink:type="locator" xlink:label="rlay_NumberOfMilestoneTargets" />
    <link:label xml:lang="en-US" xlink:label="rlay_NumberOfMilestoneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of milestone targets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_NumberOfMilestoneTargets" xlink:to="rlay_NumberOfMilestoneTargets_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_NumberOfMilestoneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of milestone targets</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_NumberOfMilestoneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Milestone Targets</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_LeaseExpirationMonthAndYear" xlink:type="locator" xlink:label="rlay_LeaseExpirationMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="rlay_LeaseExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_LeaseExpirationMonthAndYear" xlink:to="rlay_LeaseExpirationMonthAndYear_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Operating Leased Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_FirstStreetInCambridgeMassachusettsMember" xlink:type="locator" xlink:label="rlay_FirstStreetInCambridgeMassachusettsMember" />
    <link:label xml:lang="en-US" xlink:label="rlay_FirstStreetInCambridgeMassachusettsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">215 First Street in Cambridge, Massachusetts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_FirstStreetInCambridgeMassachusettsMember" xlink:to="rlay_FirstStreetInCambridgeMassachusettsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_FirstStreetInCambridgeMassachusettsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">215 First Street [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_FirstStreetInCambridgeMassachusettsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">First Street In Cambridge Massachusetts [Member]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_BinneyStreetCambridgeMassachusettsMember" xlink:type="locator" xlink:label="rlay_BinneyStreetCambridgeMassachusettsMember" />
    <link:label xml:lang="en-US" xlink:label="rlay_BinneyStreetCambridgeMassachusettsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">399 Binney Street, Cambridge, Massachusetts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_BinneyStreetCambridgeMassachusettsMember" xlink:to="rlay_BinneyStreetCambridgeMassachusettsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_BinneyStreetCambridgeMassachusettsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">399 Binney Street [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_BinneyStreetCambridgeMassachusettsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Binney Street Cambridge Massachusetts [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leased Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasedAssetsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leased Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_LeaseExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease agreement expiration date</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_LeaseExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Month And Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:type="locator" xlink:label="us-gaap_LandSubjectToGroundLeases" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LandSubjectToGroundLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Land subject to ground leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandSubjectToGroundLeases" xlink:to="us-gaap_LandSubjectToGroundLeases_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LandSubjectToGroundLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Land Subject To Ground Leases</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:type="locator" xlink:label="us-gaap_LettersOfCreditOutstandingAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Letters Of Credit Outstanding Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit expiry date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current operating lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current Statement Of Financial Position Extensible List</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-current operating lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Present value of operating lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer matching contribution</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ThirdRockVentureMember" xlink:type="locator" xlink:label="rlay_ThirdRockVentureMember" />
    <link:label xml:lang="en-US" xlink:label="rlay_ThirdRockVentureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Third Rock Venture [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_ThirdRockVentureMember" xlink:to="rlay_ThirdRockVentureMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_ThirdRockVentureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third Rock Venture [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_ThirdRockVentureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Third Rock Venture [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ConsultingAndManagementServicesMember" xlink:type="locator" xlink:label="rlay_ConsultingAndManagementServicesMember" />
    <link:label xml:lang="en-US" xlink:label="rlay_ConsultingAndManagementServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Consulting And Management Services [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rlay_ConsultingAndManagementServicesMember" xlink:to="rlay_ConsultingAndManagementServicesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rlay_ConsultingAndManagementServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting And Management Services [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rlay_ConsultingAndManagementServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consulting And Management Services [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Expenses From Transactions With Related Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due To Related Parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due To Related Parties Current And Noncurrent</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>46
<FILENAME>rlay-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-25T16:08:59.0369926+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : b6984381c2ae479bb023a8d6e22330cc -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://relaytx.com/20201231/role/TemplateLink" xlink:href="rlay-20201231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="rlay-20201231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="rlay-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockValueOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValueOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockValueOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_RestrictedStockLiability" xlink:type="locator" xlink:label="rlay_RestrictedStockLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets" xlink:type="locator" xlink:label="us-gaap_OtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments" xlink:type="locator" xlink:label="us-gaap_Investments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Investments" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssets" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="rlay_RestrictedStockLiability" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValueOutstanding" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValueOutstanding" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="rlay-20201231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_UndesignatedpreferredstockMember" xlink:type="locator" xlink:label="rlay_UndesignatedpreferredstockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="rlay_UndesignatedpreferredstockMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="rlay-20201231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_DeemedDividendResultingFromExtinguishmentOfPreferredStock" xlink:type="locator" xlink:label="rlay_DeemedDividendResultingFromExtinguishmentOfPreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther" xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_OperationsAndComprehensiveLossStatementAbstract" xlink:type="locator" xlink:label="rlay_OperationsAndComprehensiveLossStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_OperationsAndComprehensiveLossStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_OperationsAndComprehensiveLossStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_OperationsAndComprehensiveLossStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_OperationsAndComprehensiveLossStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestIncomeOther" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="rlay_DeemedDividendResultingFromExtinguishmentOfPreferredStock" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_OperationsAndComprehensiveLossStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_OperationsAndComprehensiveLossStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_OperationsAndComprehensiveLossStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_OperationsAndComprehensiveLossStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit" xlink:href="rlay-20201231.xsd#Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_VestingOfRestrictedCommonStockShares" xlink:type="locator" xlink:label="rlay_VestingOfRestrictedCommonStockShares" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_VestingOfRestrictedCommonStockValue" xlink:type="locator" xlink:label="rlay_VestingOfRestrictedCommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_StockIssuedDuringPeriodSharesPreferredStockNetOfIssuanceCosts" xlink:type="locator" xlink:label="rlay_StockIssuedDuringPeriodSharesPreferredStockNetOfIssuanceCosts" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_StockIssuedDuringPeriodValuePreferredStockNetOfIssuanceCosts" xlink:type="locator" xlink:label="rlay_StockIssuedDuringPeriodValuePreferredStockNetOfIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rlay_StockIssuedDuringPeriodValuePreferredStockNetOfIssuanceCosts" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rlay_StockIssuedDuringPeriodSharesPreferredStockNetOfIssuanceCosts" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rlay_VestingOfRestrictedCommonStockValue" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rlay_VestingOfRestrictedCommonStockShares" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="12070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="12090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitParenthetical" xlink:href="rlay-20201231.xsd#Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="rlay-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_LossOnExtinguishmentAndReissuanceOfPreferredStock" xlink:type="locator" xlink:label="rlay_LossOnExtinguishmentAndReissuanceOfPreferredStock" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ReclassificationOfRestrictedStockLiabilityToAdditionalPaidInCapital" xlink:type="locator" xlink:label="rlay_ReclassificationOfRestrictedStockLiabilityToAdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_IncreaseDecreaseInLeaseAssetsAndLiabilitiesNet" xlink:type="locator" xlink:label="rlay_IncreaseDecreaseInLeaseAssetsAndLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="rlay_IncreaseDecreaseInLeaseAssetsAndLiabilitiesNet" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="rlay_ReclassificationOfRestrictedStockLiabilityToAdditionalPaidInCapital" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="rlay_LossOnExtinguishmentAndReissuanceOfPreferredStock" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="11920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="rlay-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_RestrictedCashAndCashEquivalentsAtCarryingValueAbstract" xlink:type="locator" xlink:label="rlay_RestrictedCashAndCashEquivalentsAtCarryingValueAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_RestrictedCashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_RestrictedCashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="us-gaap_RestrictedCash" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_RestrictedCashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:href="rlay-20201231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_TextBlockAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureSignificantAccountingPolicies" xlink:href="rlay-20201231.xsd#Role_DisclosureSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssets" xlink:href="rlay-20201231.xsd#Role_DisclosureFairValueOfFinancialAssets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureInvestments" xlink:href="rlay-20201231.xsd#Role_DisclosureInvestments" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureInvestments">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="us-gaap_InvestmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseArrangementWithGenentech" xlink:href="rlay-20201231.xsd#Role_DisclosureCollaborationAndLicenseArrangementWithGenentech" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseArrangementWithGenentech">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet" xlink:href="rlay-20201231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="rlay-20201231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock" xlink:href="rlay-20201231.xsd#Role_DisclosureConvertiblePreferredStock" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock">
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ConvertiblePreferredStockTextBlock" xlink:type="locator" xlink:label="rlay_ConvertiblePreferredStockTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="rlay_ConvertiblePreferredStockTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStock" xlink:href="rlay-20201231.xsd#Role_DisclosureCommonStock" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStock">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPayments" xlink:href="rlay-20201231.xsd#Role_DisclosureShareBasedPayments" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPayments">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="rlay-20201231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShare" xlink:href="rlay-20201231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShare">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="rlay-20201231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureLeases" xlink:href="rlay-20201231.xsd#Role_DisclosureLeases" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureLeases">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureEmployeeBenefits" xlink:href="rlay-20201231.xsd#Role_DisclosureEmployeeBenefits" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureEmployeeBenefits">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:type="locator" xlink:label="us-gaap_PostemploymentBenefitsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PostemploymentBenefitsAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:href="rlay-20201231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="rlay-20201231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureSubsequentEvents">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:href="rlay-20201231.xsd#Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="rlay-20201231.xsd#rlay_DescriptionOfNewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:type="locator" xlink:label="rlay_DescriptionOfNewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_PatentCostsPolicyTextBlock" xlink:type="locator" xlink:label="rlay_PatentCostsPolicyTextBlock" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ResearchAndManufacturingContractsPolicyTextBlock" xlink:type="locator" xlink:label="rlay_ResearchAndManufacturingContractsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ConcentrationOfCreditRiskAndSignificantSuppliersPolicyTextBlock" xlink:type="locator" xlink:label="rlay_ConcentrationOfCreditRiskAndSignificantSuppliersPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_BasisOfPresentationPolicyTextBlock" xlink:type="locator" xlink:label="rlay_BasisOfPresentationPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rlay_BasisOfPresentationPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rlay_ConcentrationOfCreditRiskAndSignificantSuppliersPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rlay_ResearchAndManufacturingContractsPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rlay_PatentCostsPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rlay_DescriptionOfNewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsTables" xlink:href="rlay-20201231.xsd#Role_DisclosureFairValueOfFinancialAssetsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureInvestmentsTables" xlink:href="rlay-20201231.xsd#Role_DisclosureInvestmentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureInvestmentsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:href="rlay-20201231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="rlay-20201231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockTables" xlink:href="rlay-20201231.xsd#Role_DisclosureConvertiblePreferredStockTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStockTables" xlink:href="rlay-20201231.xsd#Role_DisclosureCommonStockTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStockTables">
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ReservedSharesOfCommonStockForFutureIssuanceTableTableTextBlock" xlink:type="locator" xlink:label="rlay_ReservedSharesOfCommonStockForFutureIssuanceTableTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="rlay_ReservedSharesOfCommonStockForFutureIssuanceTableTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPaymentsTables" xlink:href="rlay-20201231.xsd#Role_DisclosureShareBasedPaymentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPaymentsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="rlay-20201231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="rlay-20201231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesTables" xlink:href="rlay-20201231.xsd#Role_DisclosureLeasesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_SummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossTableTextBlock" xlink:type="locator" xlink:label="rlay_SummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossTableTextBlock" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ScheduleOfOperatingLeasePresentationInConsolidatedBalanceSheetTableTextBlock" xlink:type="locator" xlink:label="rlay_ScheduleOfOperatingLeasePresentationInConsolidatedBalanceSheetTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="rlay_ScheduleOfOperatingLeasePresentationInConsolidatedBalanceSheetTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="rlay_SummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_UnderwritingDiscountsAndCommissions" xlink:type="locator" xlink:label="rlay_UnderwritingDiscountsAndCommissions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:type="locator" xlink:label="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_GenentechIncMember" xlink:type="locator" xlink:label="rlay_GenentechIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_NatureOfBusinessAndBasisOfPresentationTable" xlink:type="locator" xlink:label="rlay_NatureOfBusinessAndBasisOfPresentationTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="rlay_NatureOfBusinessAndBasisOfPresentationTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rlay_GenentechIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="rlay_UnderwritingDiscountsAndCommissions" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CollaborationAndLicenseAgreementEnteredDate" xlink:type="locator" xlink:label="rlay_CollaborationAndLicenseAgreementEnteredDate" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_NumberOfCollaborationAndLicenseAgreement" xlink:type="locator" xlink:label="rlay_NumberOfCollaborationAndLicenseAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CashAndCashEquivalentsMaturityDateDescription" xlink:type="locator" xlink:label="rlay_CashAndCashEquivalentsMaturityDateDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_SignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="rlay_SignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_LaboratoryAndComputerEquipmentMember" xlink:type="locator" xlink:label="rlay_LaboratoryAndComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_GenentechAgreementMember" xlink:type="locator" xlink:label="rlay_GenentechAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_GenentechIncMember" xlink:type="locator" xlink:label="rlay_GenentechIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:type="locator" xlink:label="us-gaap_LetterOfCreditMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_SignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="rlay_SignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rlay_SignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_SignificantAccountingPoliciesTable" xlink:to="us-gaap_CreditFacilityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_SignificantAccountingPoliciesTable" xlink:to="srt_CounterpartyNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rlay_GenentechIncMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="rlay_GenentechAgreementMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_SignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="rlay_LaboratoryAndComputerEquipmentMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_SignificantAccountingPoliciesTable" xlink:to="rlay_SignificantAccountingPoliciesLineItems" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_SignificantAccountingPoliciesLineItems" xlink:to="rlay_CashAndCashEquivalentsMaturityDateDescription" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_SignificantAccountingPoliciesLineItems" xlink:to="rlay_NumberOfCollaborationAndLicenseAgreement" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_SignificantAccountingPoliciesLineItems" xlink:to="rlay_CollaborationAndLicenseAgreementEnteredDate" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureFairValueOfFinancialAssetsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsFairValueDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CashAndCashEquivalentsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="rlay_CashAndCashEquivalentsFairValueDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsMember" xlink:type="locator" xlink:label="us-gaap_InvestmentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10050.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashEquivalentsMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10050.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10050.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_InvestmentsMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10050.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10050.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="rlay_CashAndCashEquivalentsFairValueDisclosureAbstract" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CashAndCashEquivalentsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosureAbstract" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsFairValueDisclosureAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_InvestmentsWithMaturityOfOneToTwoYearsMember" xlink:type="locator" xlink:label="rlay_InvestmentsWithMaturityOfOneToTwoYearsMember" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_InvestmentsWithMaturityOfOneYearOrLessMember" xlink:type="locator" xlink:label="rlay_InvestmentsWithMaturityOfOneYearOrLessMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsBySecondaryCategorizationDomain" xlink:type="locator" xlink:label="us-gaap_InvestmentsBySecondaryCategorizationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentSecondaryCategorizationAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentSecondaryCategorizationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentSecondaryCategorizationAxis" order="10060.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentSecondaryCategorizationAxis" xlink:to="us-gaap_InvestmentsBySecondaryCategorizationDomain" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsBySecondaryCategorizationDomain" xlink:to="rlay_InvestmentsWithMaturityOfOneYearOrLessMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsBySecondaryCategorizationDomain" xlink:to="rlay_InvestmentsWithMaturityOfOneToTwoYearsMember" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseArrangementWithGenentechAdditionalInformationDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureCollaborationAndLicenseArrangementWithGenentechAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseArrangementWithGenentechAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_RegulatoryBasedMilestonePaymentsUnderAgreement" xlink:type="locator" xlink:label="rlay_RegulatoryBasedMilestonePaymentsUnderAgreement" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_DevelopmentBasedMilestonePaymentsUnderAgreement" xlink:type="locator" xlink:label="rlay_DevelopmentBasedMilestonePaymentsUnderAgreement" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_VariableConsiderationRelatedToReimbursementsDueForResearchAndDevelopmentServices" xlink:type="locator" xlink:label="rlay_VariableConsiderationRelatedToReimbursementsDueForResearchAndDevelopmentServices" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_NonRefundableMilestoneForCompletionAmount" xlink:type="locator" xlink:label="rlay_NonRefundableMilestoneForCompletionAmount" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_NonRefundableMilestoneTransferAmount" xlink:type="locator" xlink:label="rlay_NonRefundableMilestoneTransferAmount" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CollaborationAgreementTransactionPrice" xlink:type="locator" xlink:label="rlay_CollaborationAgreementTransactionPrice" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement" xlink:type="locator" xlink:label="rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_MilestonePaymentReceivable" xlink:type="locator" xlink:label="rlay_MilestonePaymentReceivable" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_NonRefundableUpfrontPayment" xlink:type="locator" xlink:label="rlay_NonRefundableUpfrontPayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementRightsAndObligations" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementRightsAndObligations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementNatureAndPurpose" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementNatureAndPurpose" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CollaborationAndLicenseArrangementLineItems" xlink:type="locator" xlink:label="rlay_CollaborationAndLicenseArrangementLineItems" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_TransferOfActivePharmaceuticalIngredientsMember" xlink:type="locator" xlink:label="rlay_TransferOfActivePharmaceuticalIngredientsMember" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ResearchAndDevelopmentServicesMember" xlink:type="locator" xlink:label="rlay_ResearchAndDevelopmentServicesMember" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_LicenseAndTransferAgreementMember" xlink:type="locator" xlink:label="rlay_LicenseAndTransferAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_StandAloneSellingPricesMember" xlink:type="locator" xlink:label="rlay_StandAloneSellingPricesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:type="locator" xlink:label="us-gaap_ForeignCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_GenentechAgreementMember" xlink:type="locator" xlink:label="rlay_GenentechAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_GenentechIncMember" xlink:type="locator" xlink:label="rlay_GenentechIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CollaborationAndLicenseArrangementTable" xlink:type="locator" xlink:label="rlay_CollaborationAndLicenseArrangementTable" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CollaborationAndLicenseArrangementAbstract" xlink:type="locator" xlink:label="rlay_CollaborationAndLicenseArrangementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CollaborationAndLicenseArrangementAbstract" xlink:to="rlay_CollaborationAndLicenseArrangementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CollaborationAndLicenseArrangementTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rlay_GenentechIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CollaborationAndLicenseArrangementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="rlay_GenentechAgreementMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CollaborationAndLicenseArrangementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CollaborationAndLicenseArrangementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rlay_StandAloneSellingPricesMember" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CollaborationAndLicenseArrangementTable" xlink:to="srt_ProductOrServiceAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rlay_LicenseAndTransferAgreementMember" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rlay_ResearchAndDevelopmentServicesMember" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="rlay_TransferOfActivePharmaceuticalIngredientsMember" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CollaborationAndLicenseArrangementTable" xlink:to="rlay_CollaborationAndLicenseArrangementLineItems" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="us-gaap_CollaborativeArrangementNatureAndPurpose" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="us-gaap_CollaborativeArrangementRightsAndObligations" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="rlay_NonRefundableUpfrontPayment" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="rlay_MilestonePaymentReceivable" order="12100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="rlay_CollaborationAgreementTransactionPrice" order="12220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="rlay_NonRefundableMilestoneTransferAmount" order="12260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="rlay_NonRefundableMilestoneForCompletionAmount" order="12280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="rlay_VariableConsiderationRelatedToReimbursementsDueForResearchAndDevelopmentServices" order="12300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="rlay_DevelopmentBasedMilestonePaymentsUnderAgreement" order="12320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="rlay_RegulatoryBasedMilestonePaymentsUnderAgreement" order="12340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="12410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="12500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="12610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CollaborationAndLicenseArrangementLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="12630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" xlink:href="rlay-20201231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="rlay_LaboratoryEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="rlay_LaboratoryEquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" xlink:href="rlay-20201231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_AccruedOtherExpensesCurrent" xlink:type="locator" xlink:label="rlay_AccruedOtherExpensesCurrent" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_AccruedProfessionalServicesCurrent" xlink:type="locator" xlink:label="rlay_AccruedProfessionalServicesCurrent" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_AccruedExternalResearchAndDevelopmentExpenseCurrent" xlink:type="locator" xlink:label="rlay_AccruedExternalResearchAndDevelopmentExpenseCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="rlay_AccruedExternalResearchAndDevelopmentExpenseCurrent" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="rlay_AccruedProfessionalServicesCurrent" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="rlay_AccruedOtherExpensesCurrent" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockVotingRights" xlink:type="locator" xlink:label="us-gaap_PreferredStockVotingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_PreferredStockConvertibleConversionPrice" xlink:type="locator" xlink:label="rlay_PreferredStockConvertibleConversionPrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="rlay_UnderwrittenPublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rlay_UnderwrittenPublicOfferingMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rlay_PreferredStockConvertibleConversionPrice" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockVotingRights" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DividendsPreferredStock" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreference" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockValue" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureCommonStockAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CommonStockRestrictionPeriod" xlink:type="locator" xlink:label="rlay_CommonStockRestrictionPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStock" xlink:type="locator" xlink:label="us-gaap_DividendsCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="rlay_EmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rlay_EmployeeStockPurchasePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DividendsCommonStock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rlay_CommonStockRestrictionPeriod" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfTheRestrictedStockActivityDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureCommonStockSummaryOfTheRestrictedStockActivityDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfTheRestrictedStockActivityDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_li0l2" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAveragePriceOfSharesPurchased" xlink:type="locator" xlink:label="rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAveragePriceOfSharesPurchased" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAveragePriceOfSharesPurchased" xlink:type="locator" xlink:label="rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAveragePriceOfSharesPurchased" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAveragePriceOfSharesPurchased" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAveragePriceOfSharesPurchased" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_li0l2" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CommonStockCapitalSharesReservedUnderCompensationPlan" xlink:type="locator" xlink:label="rlay_CommonStockCapitalSharesReservedUnderCompensationPlan" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rlay_CommonStockCapitalSharesReservedUnderCompensationPlan" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPaymentsAdditionalInformationDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureShareBasedPaymentsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPaymentsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLossMember" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLossMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_TwoThousandSixteenPlanMember" xlink:type="locator" xlink:label="rlay_TwoThousandSixteenPlanMember" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_TwoThousandTwentyPlanMember" xlink:type="locator" xlink:label="rlay_TwoThousandTwentyPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rlay_TwoThousandTwentyPlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rlay_TwoThousandSixteenPlanMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingIncomeLossMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfStockOptionActivityDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureShareBasedPaymentsScheduleOfStockOptionActivityDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfStockOptionActivityDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm" xlink:type="locator" xlink:label="rlay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="rlay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfEstimatedFairValueOfStockOptionsDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureShareBasedPaymentsScheduleOfEstimatedFairValueOfStockOptionsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfEstimatedFairValueOfStockOptionsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfStockBasedCompensationExpenseIncludedInTheCompanySConsolidatedStatementsOfOperationsAndComprehensiveLossDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureShareBasedPaymentsScheduleOfStockBasedCompensationExpenseIncludedInTheCompanySConsolidatedStatementsOfOperationsAndComprehensiveLossDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfStockBasedCompensationExpenseIncludedInTheCompanySConsolidatedStatementsOfOperationsAndComprehensiveLossDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CARESActPercentageOfBonusDepreciation" xlink:type="locator" xlink:label="rlay_CARESActPercentageOfBonusDepreciation" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CARESActPeriodOfQualifiedImprovementPropertyForCostRecovery" xlink:type="locator" xlink:label="rlay_CARESActPeriodOfQualifiedImprovementPropertyForCostRecovery" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CARESActPercentageOfCorporateCharitableDeductionLimit" xlink:type="locator" xlink:label="rlay_CARESActPercentageOfCorporateCharitableDeductionLimit" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CARESActPercentageOfInterestDeductedByTaxPayers" xlink:type="locator" xlink:label="rlay_CARESActPercentageOfInterestDeductedByTaxPayers" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_TaxCutsAndJobsActOf2017MaximumPercentageOfInterestDeductedByTaxPayers" xlink:type="locator" xlink:label="rlay_TaxCutsAndJobsActOf2017MaximumPercentageOfInterestDeductedByTaxPayers" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CARESActPercentageOfEliminatesOfTaxableIncome" xlink:type="locator" xlink:label="rlay_CARESActPercentageOfEliminatesOfTaxableIncome" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_TaxCutsAndJobsActOf2017NetOperatingLossCarrybackPeriod" xlink:type="locator" xlink:label="rlay_TaxCutsAndJobsActOf2017NetOperatingLossCarrybackPeriod" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_TaxCutsAndJobsActOf2017DescriptionOfCorporateTaxPayers" xlink:type="locator" xlink:label="rlay_TaxCutsAndJobsActOf2017DescriptionOfCorporateTaxPayers" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_IncreaseInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="rlay_IncreaseInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" xlink:type="locator" xlink:label="rlay_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_DeferredTaxAssetsOperatingLossCarryforwardsBeginningToExpireYear" xlink:type="locator" xlink:label="rlay_DeferredTaxAssetsOperatingLossCarryforwardsBeginningToExpireYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="rlay_IncomeTaxDisclosureLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="rlay_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rlay_IncomeTaxDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_IncomeTaxDisclosureTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_IncomeTaxDisclosureTable" xlink:to="rlay_IncomeTaxDisclosureLineItems" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="rlay_DeferredTaxAssetsOperatingLossCarryforwardsBeginningToExpireYear" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="rlay_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="rlay_IncreaseInDeferredTaxAssetsValuationAllowance" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationDescription" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="rlay_TaxCutsAndJobsActOf2017DescriptionOfCorporateTaxPayers" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="rlay_TaxCutsAndJobsActOf2017NetOperatingLossCarrybackPeriod" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="rlay_CARESActPercentageOfEliminatesOfTaxableIncome" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="rlay_TaxCutsAndJobsActOf2017MaximumPercentageOfInterestDeductedByTaxPayers" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="rlay_CARESActPercentageOfInterestDeductedByTaxPayers" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="rlay_CARESActPercentageOfCorporateCharitableDeductionLimit" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="rlay_CARESActPeriodOfQualifiedImprovementPropertyForCostRecovery" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_IncomeTaxDisclosureLineItems" xlink:to="rlay_CARESActPercentageOfBonusDepreciation" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfExpectedIncomeTaxBenefitComputedUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfReconciliationOfExpectedIncomeTaxBenefitComputedUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfExpectedIncomeTaxBenefitComputedUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="locator" xlink:label="rlay_EffectiveIncomeTaxRateReconciliationPermanentDifferences" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rlay_EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_DeferredTaxLiabilitiesOperatingLeaseAssets" xlink:type="locator" xlink:label="rlay_DeferredTaxLiabilitiesOperatingLeaseAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_DeferredTaxAssetsDepreciationAndAmortization" xlink:type="locator" xlink:label="rlay_DeferredTaxAssetsDepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_DeferredTaxAssetsLeaseLiability" xlink:type="locator" xlink:label="rlay_DeferredTaxAssetsLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="rlay_DeferredTaxAssetsLeaseLiability" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="rlay_DeferredTaxAssetsDepreciationAndAmortization" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="rlay_DeferredTaxLiabilitiesOperatingLeaseAssets" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperations" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureNetLossPerShareAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail">
    <link:loc xlink:href="rlay-20201231.xsd#rlay_PreferredStockConvertibleConversionPrice" xlink:type="locator" xlink:label="rlay_PreferredStockConvertibleConversionPrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_EarningsPerShareBasicLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="rlay_PreferredStockConvertibleConversionPrice" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureNetLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ConvertiblePreferredStocksMember" xlink:type="locator" xlink:label="rlay_ConvertiblePreferredStocksMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rlay_ConvertiblePreferredStocksMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="rlay-20201231.xsd#rlay_NumberOfMilestoneTargets" xlink:type="locator" xlink:label="rlay_NumberOfMilestoneTargets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement" xlink:type="locator" xlink:label="rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement" xlink:type="locator" xlink:label="rlay_MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_PotentialDevelopmentMilestonePayments" xlink:type="locator" xlink:label="rlay_PotentialDevelopmentMilestonePayments" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ResearchAndDevelopmentArrangementContractToPerformForOthersRenewalPeriod" xlink:type="locator" xlink:label="rlay_ResearchAndDevelopmentArrangementContractToPerformForOthersRenewalPeriod" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ResearchAndDevelopmentArrangementExpirationDate" xlink:type="locator" xlink:label="rlay_ResearchAndDevelopmentArrangementExpirationDate" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ResearchAndDevelopmentArrangementTermOfContract" xlink:type="locator" xlink:label="rlay_ResearchAndDevelopmentArrangementTermOfContract" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ResearchAndDevelopmentArrangementAnnualFee" xlink:type="locator" xlink:label="rlay_ResearchAndDevelopmentArrangementAnnualFee" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" xlink:type="locator" xlink:label="us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="locator" xlink:label="rlay_CommitmentsAndContingenciesDisclosureLineItems" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_OtherthirdPartiesMember" xlink:type="locator" xlink:label="rlay_OtherthirdPartiesMember" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_LeaseAgreementMember" xlink:type="locator" xlink:label="rlay_LeaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:type="locator" xlink:label="us-gaap_LicenseAgreementTermsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_DEShawResearchMember" xlink:type="locator" xlink:label="rlay_DEShawResearchMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_CommitmentsAndContingenciesDisclosureTable" xlink:type="locator" xlink:label="rlay_CommitmentsAndContingenciesDisclosureTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="rlay_CommitmentsAndContingenciesDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_CounterpartyNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rlay_DEShawResearchMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="rlay_LeaseAgreementMember" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rlay_OtherthirdPartiesMember" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CommitmentsAndContingenciesDisclosureTable" xlink:to="rlay_CommitmentsAndContingenciesDisclosureLineItems" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rlay_ResearchAndDevelopmentArrangementAnnualFee" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rlay_ResearchAndDevelopmentArrangementTermOfContract" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rlay_ResearchAndDevelopmentArrangementExpirationDate" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rlay_ResearchAndDevelopmentArrangementContractToPerformForOthersRenewalPeriod" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rlay_PotentialDevelopmentMilestonePayments" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rlay_MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rlay_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="rlay_NumberOfMilestoneTargets" order="12090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="rlay-20201231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:type="locator" xlink:label="us-gaap_LettersOfCreditOutstandingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:type="locator" xlink:label="us-gaap_LandSubjectToGroundLeases" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_LeaseExpirationMonthAndYear" xlink:type="locator" xlink:label="rlay_LeaseExpirationMonthAndYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_BinneyStreetCambridgeMassachusettsMember" xlink:type="locator" xlink:label="rlay_BinneyStreetCambridgeMassachusettsMember" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_FirstStreetInCambridgeMassachusettsMember" xlink:type="locator" xlink:label="rlay_FirstStreetInCambridgeMassachusettsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="rlay_FirstStreetInCambridgeMassachusettsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="rlay_BinneyStreetCambridgeMassachusettsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_OperatingLeasedAssetsLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="rlay_LeaseExpirationMonthAndYear" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LandSubjectToGroundLeases" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeasesPresentationInConsolidatedBalanceSheetsDetails" xlink:href="rlay-20201231.xsd#Role_DisclosureLeasesScheduleOfOperatingLeasesPresentationInConsolidatedBalanceSheetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeasesPresentationInConsolidatedBalanceSheetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" xlink:href="rlay-20201231.xsd#Role_DisclosureLeasesSummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_OperatingLeasedAssetsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails" xlink:href="rlay-20201231.xsd#Role_DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails" xlink:href="rlay-20201231.xsd#Role_DisclosureEmployeeBenefitsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://relaytx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:href="rlay-20201231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://relaytx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ConsultingAndManagementServicesMember" xlink:type="locator" xlink:label="rlay_ConsultingAndManagementServicesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="rlay-20201231.xsd#rlay_ThirdRockVentureMember" xlink:type="locator" xlink:label="rlay_ThirdRockVentureMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="rlay_ThirdRockVentureMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="rlay_ConsultingAndManagementServicesMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464758390952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 23, 2021</div></th>
<th class="th"><div>Jul. 20, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">RELAY THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001812364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,543,277,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,399,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RLAY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3923475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">399 Binney Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">2nd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">370-8837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2021 Annual Meeting of Stockholders within 120 days of the end of the registrant&#8217;s fiscal year ended December&#160;31, 2020. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464756267880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 447,646<span></span>
</td>
<td class="nump">$ 41,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="nump">230,415<span></span>
</td>
<td class="nump">313,862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract asset</a></td>
<td class="nump">7,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">9,385<span></span>
</td>
<td class="nump">4,720<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">770,100<span></span>
</td>
<td class="nump">360,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">6,250<span></span>
</td>
<td class="nump">8,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">22,579<span></span>
</td>
<td class="nump">23,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">878<span></span>
</td>
<td class="nump">878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">799,829<span></span>
</td>
<td class="nump">393,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,351<span></span>
</td>
<td class="nump">6,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">5,760<span></span>
</td>
<td class="nump">3,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">1,521<span></span>
</td>
<td class="nump">1,249<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">13,632<span></span>
</td>
<td class="nump">11,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">22,901<span></span>
</td>
<td class="nump">23,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_RestrictedStockLiability', window );">Restricted stock liability</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">36,536<span></span>
</td>
<td class="nump">35,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock (Series A, B and C), $0.001 par value; no shares authorized as of December 31, 2020 and 337,272,859 shares authorized as of December 31, 2019; no shares issued and outstanding as of December 31, 2020 and 212,642,857 shares issued and outstanding (aggregate liquidation preference of $519,825) as of December 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">537,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.001 par value; 150,000,000 and 260,000,000 shares authorized at December 31, 2020 and December 31, 2019, respectively; 89,991,324 and 4,716,634 shares issued at December 31, 2020 and December 31, 2019, respectively; 89,906,835 and 4,037,476 shares outstanding at December 31, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,167,367<span></span>
</td>
<td class="nump">8,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(404,228)<span></span>
</td>
<td class="num">(189,482)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">763,293<span></span>
</td>
<td class="num">(180,438)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock, and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">$ 799,829<span></span>
</td>
<td class="nump">$ 393,068<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_RestrictedStockLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted stock liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_RestrictedStockLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464752006728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337,272,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,642,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">212,642,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">260,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">89,991,324<span></span>
</td>
<td class="nump">4,716,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="nump">89,906,835<span></span>
</td>
<td class="nump">4,037,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">337,272,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">212,642,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">212,642,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Temporary equity liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 519,825<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=rlay_UndesignatedpreferredstockMember', window );">Undesignated Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=rlay_UndesignatedpreferredstockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=rlay_UndesignatedpreferredstockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464752034376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 82,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service [Extensible List]</a></td>
<td class="text">rlay:LicenseRevenueMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 82,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">99,862<span></span>
</td>
<td class="nump">$ 70,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">38,588<span></span>
</td>
<td class="nump">13,742<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">138,450<span></span>
</td>
<td class="nump">84,048<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(55,796)<span></span>
</td>
<td class="num">(84,048)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">3,400<span></span>
</td>
<td class="nump">8,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">3,384<span></span>
</td>
<td class="nump">8,743<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(52,412)<span></span>
</td>
<td class="num">(75,305)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_DeemedDividendResultingFromExtinguishmentOfPreferredStock', window );">Deemed dividend resulting from extinguishment upon modification of Series C preferred stock</a></td>
<td class="num">(177,789)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (230,201)<span></span>
</td>
<td class="num">$ (75,305)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss attributable to common stockholders per share, basic and diluted</a></td>
<td class="num">$ (5.40)<span></span>
</td>
<td class="num">$ (21.82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares of common stock, basic and diluted</a></td>
<td class="nump">42,619,582<span></span>
</td>
<td class="nump">3,450,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized holding gain (loss)</a></td>
<td class="num">$ (261)<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income (loss)</a></td>
<td class="num">(261)<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (52,673)<span></span>
</td>
<td class="num">$ (74,980)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_DeemedDividendResultingFromExtinguishmentOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend resulting from extinguishment of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_DeemedDividendResultingFromExtinguishmentOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121551570&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464754148328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="num">$ (110,927)<span></span>
</td>
<td class="nump">$ 532,120<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 3,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (114,177)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,863,764<span></span>
</td>
<td class="nump">2,998,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_StockIssuedDuringPeriodValuePreferredStockNetOfIssuanceCosts', window );">Issuance of Series C convertible preferred stock, net of issuance costs of $50</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_StockIssuedDuringPeriodSharesPreferredStockNetOfIssuanceCosts', window );">Issuance of Series C convertible preferred stock, net of issuance costs of $50, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,779,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_VestingOfRestrictedCommonStockValue', window );">Vesting of restricted common stock</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_VestingOfRestrictedCommonStockShares', window );">Vesting of restricted common stock ,shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">860,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">4,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(75,305)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,305)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="num">(180,438)<span></span>
</td>
<td class="nump">$ 537,781<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">8,715<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="num">(189,482)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,642,857<span></span>
</td>
<td class="nump">4,037,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Extinguishment upon modification of Series C preferred stock</a></td>
<td class="num">(177,789)<span></span>
</td>
<td class="nump">$ 177,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,455)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(162,334)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock upon initial public offering</a></td>
<td class="nump">715,570<span></span>
</td>
<td class="num">$ (715,570)<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">715,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock upon initial public offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(212,642,857)<span></span>
</td>
<td class="nump">61,992,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in public offering, net of discounts and issuance costs of $34,707</a></td>
<td class="nump">425,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">425,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in public offering, net of discounts and issuance costs of $34,707, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 1,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="nump">297,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_VestingOfRestrictedCommonStockValue', window );">Vesting of restricted common stock</a></td>
<td class="nump">$ 154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_VestingOfRestrictedCommonStockShares', window );">Vesting of restricted common stock ,shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">579,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">31,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(52,412)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,412)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 763,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">$ 1,167,367<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="num">$ (404,228)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,906,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_StockIssuedDuringPeriodSharesPreferredStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares preferred stock net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_StockIssuedDuringPeriodSharesPreferredStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_StockIssuedDuringPeriodValuePreferredStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value preferred stock net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_StockIssuedDuringPeriodValuePreferredStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_VestingOfRestrictedCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting of restricted common stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_VestingOfRestrictedCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_VestingOfRestrictedCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting of restricted common stock value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_VestingOfRestrictedCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558989&amp;loc=d3e80720-113993<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464765193768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit (parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts', window );">Net of discounts and issuance costs</a></td>
<td class="nump">$ 34,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from issuance costs from a share-lending arrangement entered into, in contemplation of a convertible debt offering or other financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 20A<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=SL6757427-112606<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464754190552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (52,412)<span></span>
</td>
<td class="num">$ (75,305)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">31,960<span></span>
</td>
<td class="nump">4,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">3,549<span></span>
</td>
<td class="nump">2,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization of premiums and discounts on investments</a></td>
<td class="num">(416)<span></span>
</td>
<td class="num">(2,495)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on sale of equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(4,665)<span></span>
</td>
<td class="num">(2,123)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_IncreaseDecreaseInLeaseAssetsAndLiabilitiesNet', window );">Lease assets and liabilities, net</a></td>
<td class="nump">571<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(410)<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">2,010<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(75,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities', window );">Contract asset</a></td>
<td class="num">(7,654)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(102,489)<span></span>
</td>
<td class="num">(66,133)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,931)<span></span>
</td>
<td class="num">(8,002)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(266,455)<span></span>
</td>
<td class="num">(553,517)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from maturities of investments</a></td>
<td class="nump">350,058<span></span>
</td>
<td class="nump">242,475<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">81,672<span></span>
</td>
<td class="num">(319,024)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="nump">1,216<span></span>
</td>
<td class="nump">613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock upon initial public offering</a></td>
<td class="nump">427,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Offering costs paid</a></td>
<td class="num">(2,507)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">426,509<span></span>
</td>
<td class="nump">5,606<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">405,692<span></span>
</td>
<td class="num">(379,551)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">42,832<span></span>
</td>
<td class="nump">422,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">448,524<span></span>
</td>
<td class="nump">42,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment additions included in accounts payable and accrued expenses</a></td>
<td class="nump">519<span></span>
</td>
<td class="nump">745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_ReclassificationOfRestrictedStockLiabilityToAdditionalPaidInCapital', window );">Reclassification of restricted stock liability to additional paid-in capital</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_LossOnExtinguishmentAndReissuanceOfPreferredStock', window );">Extinguishment upon modification of Series C preferred stock</a></td>
<td class="num">(177,789)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of preferred stock into common stock upon initial public offering</a></td>
<td class="nump">715,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right of use asset obtained in exchange for lease obligation</a></td>
<td class="nump">$ 819<span></span>
</td>
<td class="nump">$ 24,936<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_IncreaseDecreaseInLeaseAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in lease assets and liabilities net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_IncreaseDecreaseInLeaseAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_LossOnExtinguishmentAndReissuanceOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss on extinguishment and reissuance of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_LossOnExtinguishmentAndReissuanceOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_ReclassificationOfRestrictedStockLiabilityToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of restricted stock liability to additional paid in capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_ReclassificationOfRestrictedStockLiabilityToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the assets (liabilities) created through trading commodity-based derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInCommodityContractAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464757579528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_RestrictedCashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Restricted Cash And Cash Equivalents At Carrying Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 447,646<span></span>
</td>
<td class="nump">$ 41,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">878<span></span>
</td>
<td class="nump">878<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash as shown on consolidated statements of cash flows</a></td>
<td class="nump">$ 448,524<span></span>
</td>
<td class="nump">$ 42,832<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_RestrictedCashAndCashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted cash and cash equivalents at carrying value abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_RestrictedCashAndCashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464839376152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of Business and Basis of Presentation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Business and Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Relay Therapeutics, Inc. (the &#8220;Company&#8221;) was incorporated in Delaware on May 4, 2015 and is headquartered in Cambridge, Massachusetts. The Company is a clinical-stage, precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The Company is built upon unparalleled insights into protein motion and how this dynamic behavior relates to protein function. The Company&#8217;s Dynamo platform integrates an array of leading edge experimental and computational approaches, which allows the Company to apply the understanding of protein structure and motion to drug discovery. The Company is advancing its pipeline of medicines to address targets in precision oncology, including its lead product candidates, RLY-4008 and RLY-1971, as well as its PI3K&#945; mutant selective program, known as the RLY-PI3K1047 program. The Company initiated a Phase 1 clinical trial for RLY-1971 in patients with advanced solid tumors in the first quarter of 2020 and a first-in-human clinical trial of RLY-4008 enriched for patients with advanced solid tumors having oncogenic FGFR2 alterations in the third quarter of 2020. <font style="color:#231F20;">In December 2020, the Company entered into the Collaboration and License Agreement (the &#8220;Genentech Agreement&#8221;) with Genentech, Inc. (&#8220;Genentech&#8221;), a member of the Roche Group, for the development and commercialization of RLY-1971, as further discussed in Note 5.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive pre-clinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s product candidates are in development. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has devoted substantially all of its resources to developing its product candidates, including RLY-1971 and RLY-4008, and the RLY-PI3K1047 program by developing its innovative, experimental and computational approaches on protein motion, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred net operating losses since inception and had an accumulated deficit of $404,228 as of December 31, 2020. The Company expects that its existing cash, cash equivalents and investments as of December 31, 2020, together with the upfront payment of $75,000 received in January 2021 from Genentech under the Genentech Agreement discussed in Note 5, will enable it to fund its planned operating expenses and capital expenditure requirements for at least one year from the date of the issuance of these consolidated financial statements. The future viability of the Company is dependent on its ability to generate cash from operating activities or to raise additional capital to finance its operations. The Company&#8217;s failure to raise capital as and when needed could have a material adverse effect on its financial condition and ability to pursue its business strategies. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into license or collaboration arrangements or obtain government grants. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. In the event the Company requires additional funding, there can be no assurance that it will be successful in obtaining sufficient funding on terms acceptable to the Company to fund its continuing operations, if at all. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Initial Public Offering </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 20, 2020, the Company closed its initial public offering (&#8220;IPO&#8221;) and issued 23,000,000 shares of its common stock at a price of $20.00 per share for net proceeds of $425,293, after deducting underwriting discounts and commissions of $32,200 and expenses of $2,507. In connection with the IPO, all shares of Series A, Series B and Series C convertible preferred stock converted into 61,992,534 shares of common stock. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reverse Stock Split </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 8, 2020, the Company&#8217;s stockholders approved a decrease in the number of authorized shares of common stock from 260,000,000 to 150,000,000. The Company also effected a one-for-3.55092 reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company&#8217;s preferred stock. Accordingly, all share and per share amounts for all periods presented in the accompanying financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse stock split and adjustment of the preferred stock conversion ratios.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464758357064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant  Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. Significant Accounting Policies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis of presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) for reporting on Form 10-K. The Company&#8217;s consolidated financial statements include the accounts of Relay Therapeutics, Inc. and its wholly-owned subsidiary, Relay Therapeutics Securities Corporation. All intercompany balances and transactions have been eliminated. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development and manufacturing expenses, the valuation of equity instruments, the determination of the transaction price and standalone selling price of performance obligations under <font style="color:#000000;">Accounting Standards Codification Topic 606, </font><font style="font-style:italic;color:#000000;">Revenue from Contracts with Customers</font>, and the incremental borrowing rate for determining the operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has made estimates of the impact of COVID-19 within its financial statements and there may be changes to those estimates in future periods. Actual results could differ from the Company&#8217;s estimates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Segment Information </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company&#8217;s singular focus is on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets. The Company operates in the United States and all tangible assets are held in the United States.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash Equivalents </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all short-term, highly liquid investments with original maturities of 90&#160;days or less at acquisition date to be cash equivalents. Cash equivalents, which consist of money market funds, are stated at fair value. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Restricted Cash </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had restricted cash of $878 as of December&#160;31, 2020 and 2019 to secure a letter of credit in connection with the lease of the Company&#8217;s facilities (see Note 14). The Company classified the restricted cash as a noncurrent asset on its consolidated balance sheets. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Investments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments in marketable securities are classified as available-for-sale. Available-for-sale securities are measured and reported at fair value using quoted prices in active markets for similar securities. Unrealized gains and losses on available-for-sale securities are reported as a separate component of stockholders&#8217; equity (deficit). Premiums or discounts from par value are amortized to investment income over the life of the underlying investment. All of the Company&#8217;s available-for-sale securities are available to the Company for use in current operations. As a result, the Company classified all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) within the consolidated statements of operations and comprehensive loss. If any adjustment is required to reflect a decline in the value of the investment that the Company considers to be &#8220;other than temporary&#8221;, the Company recognizes a charge to the consolidated statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Significant Suppliers </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and investments. From time to time, the Company has maintained all of its cash, cash equivalents and investments at certain accredited financial institutions in amounts that exceed federally insured limits. The Company generally invests its excess capital in money market funds, U.S. treasury bonds, U.S. treasury bills and agency bonds are subject to minimal credit and market risk. Management has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. The investment portfolio is maintained in accordance with the Company&#8217;s investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is dependent on third-party suppliers for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a small number of these suppliers, including D. E. Shaw Research, LLC as discussed in Note 13, to meet its requirements for its programs. These programs could be adversely affected by a significant interruption in pre-clinical and clinical testing and the supply of active pharmaceutical ingredients and formulated drugs. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Level 2&#8212;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for revenue recognition in accordance with Accounting Standards Codification Topic (&#8220;ASC&#8221;) 606, <font style="font-style:italic;">Revenue from Contracts with Customers</font> (&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. </p>
<p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract and determines those that are performance obligations. The Company then determines the transaction price and allocates it to the performance obligations using the relative selling price model. As part of the accounting for these arrangements, the Company must use significant judgment to determine: (a) the number of performance obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above, including the determination of whether milestones or other variable consideration should be included in the transaction price; and (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of the transaction price in step (iv) above. </p>
<p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilizes key assumptions and judgments to determine the stand-alone selling price for each performance obligation, which may include discounted cash flow models, evaluation of comparable transactions, pricing considered in negotiating the transaction and estimated costs,<font style="Background-color:#FFFFFF;"> to determine how the transaction price is allocated among the performance obligations</font>. The Company uses judgment to determine whether milestones or other variable consideration should be included in the transaction price. For revenue-based royalties, including milestone payments based on the level of sales, the Company will include royalties in the transaction price at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty is allocated has been satisfied (or partially satisfied). As part of management&#8217;s evaluation of the transaction price, the Company considers numerous factors, including whether the achievement of the milestones is outside of our control, contingent upon the efforts of others or subject to scientific risks of success. If the Company concludes it is probable that a significant revenue reversal would not occur, the associated milestone payment is included in the transaction price. Milestone payments that are not within our control, such as regulatory approvals, are generally not considered probable until those milestones are achieved. The Company re-evaluates the transaction price, including estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</p>
<p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once the performance obligations are identified, the transaction price is allocated to each performance obligation based on the relative stand-alone selling price. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied, either at a point in time or over time. If the performance obligation is satisfied over time, the Company recognizes revenue based on the use of either an output or input method. </p>
<p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had one collaboration and license agreement with Genentech, which the Company entered into on December 11, 2020. <font style="letter-spacing:-0.1pt;">For a discussion of the accounting related to the Genentech Agreement, see Note 5,&#160;</font><font style="font-style:italic;letter-spacing:-0.1pt;">Collaboration and License Arrangement with Genentech</font>.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 842, <font style="font-style:italic;">Leases</font>, the Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does not recognize a right-of-use asset or lease liability. The Company&#8217;s operating leases are recognized on its consolidated balance sheets as other noncurrent assets, other current liabilities and other noncurrent liabilities. The Company does not have any finance leases. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Operating lease right-of-use assets also include the effect of any lease payments made prior to commencement and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has lease agreements with lease and non-lease components, which are accounted for as a combined element. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the useful life of the asset. Laboratory and computer equipment are depreciated over three years. Furniture and fixtures are depreciated over five years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the related asset. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured in an amount by which the book values of the assets exceed their fair value. The Company did not recognize any impairment losses for the years ended December&#160;31, 2020 and 2019.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Classification and Accretion of Convertible Preferred Stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s convertible preferred stock was classified outside of stockholders&#8217; equity (deficit) on the consolidated balance sheet because the holders of such shares had liquidation rights in the event of a deemed liquidation that, in certain situations, were not solely within the control of the Company and would require the redemption of the then-outstanding convertible preferred stock. The convertible preferred stock was not currently redeemable, except in the event of a deemed liquidation (see Note 8). Because the occurrence of a deemed liquidation event was not probable, the carrying value of the convertible preferred stock was not accreted to their redemption values. Subsequent adjustments to the carrying values of the convertible preferred stock would have been made only when a deemed liquidation event became probable. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the closing of the Company&#8217;s IPO in July 2020, all outstanding convertible preferred stock automatically converted into 61,992,534 shares of common stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures stock options and other stock-based awards granted to employees, directors and non-employees based on their fair value on the date of grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company recognizes the impact of forfeitures on stock-based compensation expense as forfeitures occur. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company issued certain options with performance-based vesting conditions whereby the service inception date preceded the accounting grant date and therefore applied variable accounting for the awards until the fair value of the awards was known on the accounting grant date. The board of directors approved the commencement of vesting for all such awards in 2020, therefore the Company no longer applies variable accounting as of December 11, 2020.<font style="font-size:12pt;">&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model, which uses as inputs the fair value of the Company&#8217;s common stock and assumptions the Company makes for the volatility of its common stock, the expected term of the stock options, the risk-free interest rate for a period that approximates the expected term of the stock options and the expected dividend yield. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Company&#8217;s IPO, the estimated fair value of its common stock was determined by the board of directors, or compensation committee thereof, as of the date of each option grant, with input from management, considering the most recently available third-party valuations of common stock and the board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. Historically, these independent third-party valuations of the Company&#8217;s equity instruments were performed contemporaneously with identified value inflection points.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide,&#160;<font style="font-style:italic;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation </font>(the &#8220;Practice Aid&#8221;). The Practice Aid identifies various available methods for allocating the enterprise value across classes of series of capital stock in determining the fair value of the Company&#8217;s common stock at each valuation date.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following the Company&#8217;s IPO, in connection with the accounting for granted stock options and other awards the Company may grant, the fair value of the Company&#8217;s common stock is determined based on the quoted market price of its common stock.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Costs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development expenses include salaries, stock-based compensation and benefits of employees, third-party license fees and other operational costs related to the Company&#8217;s research and development activities, including allocated facility-related expenses and external costs of outside vendors engaged to conduct both pre-clinical studies and clinical trials. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Research and Manufacturing Contracts </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development contracts with research institutions and other companies whose costs are included in research and development expense in the accompanying consolidated statements of operations and comprehensive loss. These agreements are generally cancelable and related payments are recorded as research and development expenses as the underlying services are performed. When evaluating the adequacy of the expense recognized, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the expense recognized and the related prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical estimates have not been materially different from the actual costs. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Patent Costs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company&#8217;s financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive Loss </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. For the years ended December&#160;31, 2020 and 2019, other comprehensive income (loss) consisted of changes in unrealized gains and losses from available-for-sale investments.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Loss Per Common Share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed using the sum of the weighted average number of common shares outstanding during the period and the effect of dilutive securities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies the two-class method to calculate its basic and diluted net loss per share as the Company has issued shares that meet the definition of participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. The Company&#8217;s participating securities contractually entitle the holders of such shares to participate in dividends; but do not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, in periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. <font style="color:#000000;letter-spacing:-0.1pt;">For additional discussion of net loss per common share, please see Note 12, </font><font style="font-style:italic;color:#000000;letter-spacing:-0.1pt;">Net Loss Per Share. </font><font style="color:#000000;letter-spacing:-0.1pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2018-13, <font style="font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement</font> on January&#160;1, 2020. This standard modifies certain disclosure requirements on fair value measurements. The adoption of this standard did not have a material impact on the Company&#8217;s disclosures. </p>
<p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements Not Yet Adopted </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-13,<font style="font-style:italic;">&#160;Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</font>. This standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and it establishes additional disclosure requirements related to credit risks. For available-for-sale securities with expected credit losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This guidance was originally effective for fiscal years beginning after December&#160;15, 2019, including interim periods within those fiscal years, and early adoption was permitted. In November 2019, the FASB subsequently issued ASU 2019-10, <font style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging</font> <font style="font-style:italic;">(Topic 815), and Leases (Topic 842): Effective Dates </font>(&#8220;ASU 2019-10&#8221;), whereby the effective date of this standard for smaller reporting companies was deferred to fiscal years beginning after December&#160;15, 2022, including interim periods within those fiscal years, and early adoption is still permitted. The Company is assessing the impact of ASU 2019-10 on the consolidated financial statements and does not expect it to have a material impact.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the FASB issued ASU No.&#160;2020-06, <font style="font-style:italic;">Debt &#8211; Debt with Conversion and Other</font> <font style="font-style:italic;">Options</font> (Subtopic 470-20) <font style="font-style:italic;">and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity</font> (Subtopic 815-40)<font style="font-size:12pt;"> </font>(&#8220;ASU 2020-06&#8221;). This standard amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity&#8217;s own equity and amends the related earnings per share (&#8220;EPS&#8221;) guidance. The ASU will be effective for smaller reporting companies for fiscal years beginning after December&#160;15, 2023 and interim periods within those fiscal years. Early adoption is permitted in fiscal years beginning after December&#160;15, 2020, including interim periods within those fiscal years. The Company is assessing the impact of&#160;ASU 2020-06&#160;on the consolidated financial statements and does not expect it to have a material impact. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued&#160;ASU&#160;2019-12,<font style="font-style:italic;">&#160;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</font>&#160;(&#8220;ASU&#160;2019-12&#8221;), which is intended to simplify the accounting for income taxes.&#160;ASU&#160;2019-12&#160;removes certain exceptions to the general principles in Topic 740 and also clarifies and amends certain aspects of the existing guidance to improve consistent application. The new standard will be effective for public business entities for fiscal years beginning after December&#160;15, 2020. The Company is assessing the potential impact&#160;ASU&#160;2019-12&#160;may have on its financial statements upon adoption. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected to use the extended transition period related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different effective dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time that the Company either (i)&#160;irrevocably elects to &#8220;opt out&#8221; of such extended transition period or (ii)&#160;no longer qualifies as an emerging growth company. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464757776680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3. Fair Value of Financial Assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Assets</font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">447,146</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">447,146</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US treasury bills</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,026</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,026</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US agency securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197,389</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197,389</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,415</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,415</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">447,146</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,415</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">677,561</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Assets</font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,658</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,658</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US treasury bills</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,604</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,604</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US agency securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,258</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,258</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313,862</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313,862</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,658</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313,862</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">355,520</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In determining the fair value of its investments at each date presented above, the Company relied on quoted prices for similar securities in active markets or using other inputs that are observable or can be corroborated by observable market data. The Company did not have any financial assets or liabilities during any of the periods presented in the accompanying consolidated financial statements that required Level&#160;3 inputs. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464757846536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsAbstract', window );"><strong>Schedule Of Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">Investments</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4. Investments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of available-for-sale investments by type of security was as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:98.64%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S treasury bills</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,997</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S agency securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,996</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,001</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments with a maturity of one year or less</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,993</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S treasury bills</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,008</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,008</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S agency securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176,350</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176,388</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments with a maturity of one to two years</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179,358</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179,396</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,351</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,415</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:93.84%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S treasury bills</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,336</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">268</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,604</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S agency securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,201</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,258</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments with a maturity of one year or less</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313,537</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313,862</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -URI http://asc.fasb.org/topic&amp;trid=75115024<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -URI http://asc.fasb.org/topic&amp;trid=2197064<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464757878024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Arrangement with Genentech<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Arrangement with Genentech</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. Collaboration and License Arrangement with Genentech</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 11, 2020, the Company entered into the Genentech Agreement, which granted Genentech a license to develop and commercialize RLY-1971. RLY-1971 is currently being developed in a Phase 1a clinical trial for patients with advanced solid tumors (the &#8220;Phase 1a Trial&#8221;). Unless Genentech elects to exercise its option to conduct the remainder of the ongoing Phase 1a Trial, the Company is responsible for the completion of this trial. Genentech is responsible for conducting all subsequent clinical development of RLY-1971. The Company is also responsible for the one-time transfer of the active pharmaceutical ingredient (&#8220;API&#8221;) and other materials related to RLY-1971 to Genentech. </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Genentech Agreement, the Company is entitled to a non-refundable upfront payment of $75,000, which is due upon completion of certain technology transfer activities and is reflected as accounts receivable on the consolidated balance sheet at December 31, 2020. The Company collected this amount in full in January 2021. The Company is eligible to receive up to $25,000 in near-term milestone payments. The Company is also eligible to receive up to an aggregate of an additional $695,000 upon the achievement of specified development, commercialization and sales-based milestones for RLY-1971 worldwide as well as tiered royalties ranging from low-to-mid teens on annual worldwide net sales of RLY-1971, on a country-by-country basis, subject to reduction in certain circumstances. </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has the option, exercisable one time at the Company&#8217;s sole discretion, to (a) fund half of the development costs of RLY-1971 in the U.S., (b) share half of the net profits or net loss of commercializing RLY-1971 in the U.S. (the &#8220;Profit/Cost Share&#8221;) and (c) be eligible to receive up to an aggregate of an additional $410,000 upon the achievement of specified commercialization and sales-based milestones for RLY-1971 outside of the U.S and tiered royalties ranging from low-to-mid teens on annual net sales of RLY-1971 outside of the U.S., on a country-by-country basis, subject to reduction in certain circumstances. The Company may elect to opt-out of further participation in the Profit/Cost Share at any time prior to the third anniversary of the first commercial sale of RLY-1971 in the U.S, in which case the financial terms would revert to the terms applicable as if Company had not opted into the Profit/Cost Share as of the effective opt-out date.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genentech may terminate the Genentech Agreement for convenience and the Company may terminate the Genentech Agreement under certain limited circumstances. Unless otherwise terminated, the Genentech Agreement will remain in effect until the expiration of all Genentech&#8217;s royalty payment obligations to the Company.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting Analysis </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Identification of the Contract </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company concluded that Genentech is a customer in this arrangement and as such, the arrangement falls within the scope of the revenue recognition guidance in ASC 606. </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Identification of Performance Obligations </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the commencement of the Genentech Agreement, the Company identified the following performance obligations in the agreement:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.4%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;">&#8226;</p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License to develop and commercialize RLY-1971 and the related know-how; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.4%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;">&#8226;</p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development services to complete the Phase 1a Trial for RLY-1971; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.4%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;">&#8226;</p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transfer of API and other materials related to RLY-1971 </p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the performance obligations outlined above are both capable of being distinct and distinct within the context of the contract given such rights and activities are independent of each other. The license can be used by <font style="color:#000000;">Genentech without the research and development services or API outlined above,</font> and similarly those services and inventory provide distinct benefit to Genentech within the context of the contract, separate from the license.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Determination of Transaction Price </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined the transaction price for the Genentech Agreement to be $85,867, which includes both fixed and variable consideration amounts. The total transaction price of $85,867 is comprised of (i) the $75,000 fixed, non-refundable upfront payment, (ii) a $5,000 non-refundable milestone payment due upon the transfer of the  <font style="color:#000000;">Investigational New Drug (&#8220;IND&#8221;) application </font>to Genentech, (iii) a $5,000 non-refundable milestone payment due upon completion of the Phase 1a Trial for RLY-1971 and (iv) $867 of estimated variable consideration related to reimbursements due from Genentech for research and development services. No additional development milestone payments and no regulatory milestone payments are included in the transaction price as all such payments are fully constrained. As part of management&#8217;s evaluation of the constraint, the Company considered numerous factors, including the consideration that achievement of the milestones is outside of the Company&#8217;s control, contingent upon Genentech&#8217;s efforts and the receipt of regulatory approval and subject to scientific risks of success. </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Allocation of Transaction Price to Performance Obligations </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company allocated the transaction price of $85,867 based on the stand-alone selling prices (&#8220;SSP&#8221;) of each of the performance obligations as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.4%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;">&#8226;</p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$82,654 million for the transfer of the license</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.4%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;">&#8226;</p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2,896 million for research and development services; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.4%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;">&#8226;</p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$317 million for the transfer of API.</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SSP for the license was determined using an approach that considered discounted, probability-weighted cash flows related to the license transferred. The Company also reviewed comparable market transactions in determining the SSP of the license. The SSP for the research and development services as well as the transfer of API were based on estimates of the associated effort and cost of these services and cost to manufacture API, adjusted for a reasonable profit margin that would be expected to be realized under similar contracts. The Company performed sensitivity analyses supporting reasonable changes to the SSPs noting no material impact on revenue recognized for the year ended December 31, 2020.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Recognition of Revenue </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is recognizing revenue for each of the three performance obligations as follows: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.4%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;">&#8226;</p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized revenue related to the license at a point in time upon transfer of the license to Genentech. The Company recognized the full amount allocated to the license and related know-how in the fourth quarter of 2020 because the Company had transferred the license upon execution of the Genentech Agreement. Revenue recognized during the year ended December 31, 2020 related to the license amounted to $82,654.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.4%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;">&#8226;</p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will satisfy the research and development performance obligation for RLY-1971&#160;as the research and development services are performed.&#160;The research and development services performance obligation consists of the Company completing the Phase 1a clinical trial initiated in the first quarter of 2020. The Company recognizes revenue related to the research and development services over time using a cost-based input method by calculating actual costs incurred to date at each period end relative to total estimated costs expected to be incurred to fulfill the performance obligation. There was no revenue recognized related to this performance obligation during the year ended December 31, 2020 as the services performed from contract inception to December 31, 2020 were immaterial.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.4%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;">&#8226;</p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will recognize revenue related to the transfer of API at a point in time upon transfer to Genentech. There was no revenue recognized related to this performance obligation during the year ended December 31, 2020.&nbsp;&nbsp;</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, the Company recognized an aggregate of $82,654 of revenue from the Genentech Agreement related entirely to the transfer of the license. At December 31, 2020, the Company recorded accounts receivable under the Genentech Agreement in the amount of $75,000 and a contract asset in the amount of $7,654, which is classified as a current asset, on the balance sheet. The contract asset relates to the amount of revenue recognized for which the right to payment is contingent upon conditions other than the passage of time, such as the completion of future milestone activities.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464757871976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6. Property and Equipment, Net </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,534</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,003</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">886</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">860</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">888</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">827</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">895</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">895</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in process</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">577</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">490</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,780</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,075</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,530</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,981</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,250</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,094</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded $3,549 and $2,845 of depreciation expense for the years ended December&#160;31, 2020 and 2019, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464757657864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7. Accrued Expenses and Other Current Liabilities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">External research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,099</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,077</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional services</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">464</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">336</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other current liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,760</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,746</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464757862248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_ConvertiblePreferredStockTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8. Convertible Preferred Stock </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company issued Series A, Series B and Series C convertible preferred stock (collectively, &#8220;Convertible Preferred Stock&#8221;). Upon issuance of each class of Convertible Preferred Stock, the Company assessed the embedded conversion and liquidity features of the shares and determined that such features did not require the Company to separately account for these features. The Company also concluded that no beneficial conversion feature existed on the issuance date of each class of Convertible Preferred Stock. The Company&#8217;s Convertible Preferred Stock was classified outside of stockholders&#8217; equity (deficit) on the consolidated balance sheet prior to the Company&#8217;s IPO because the holders of such shares had liquidation rights in the event of a deemed liquidation that, in certain situations, were not solely within the control of the Company and would require the redemption of the then-outstanding Convertible Preferred Stock. The Convertible Preferred Stock was not currently redeemable. Because the occurrence of a deemed liquidation event was not probable, the carrying values of the Convertible Preferred Stock were not accreted to their redemption values. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 8, 2020, the Company&#8217;s board of directors and its Series C preferred stockholders approved a reduction in the conversion price of the Series C preferred stock from $3.21 to $3.027603 and the Series C preferred stockholders relinquished their protective right with respect to the approval of an automatic conversion of preferred stock in a firm commitment underwritten public offering if the per share price is less than $22.80. As a result of the change in the conversion price, the outstanding shares of Series C preferred stock were convertible into 37,206,604 shares of common stock. The changes to the conversion feature were considered to be a significant change to the substantive contractual terms of the Series C preferred stock and, therefore, the Company accounted for the changes as an extinguishment and reissuance of the Series C preferred stock, which required the difference between the fair value of the modified Series C preferred stock and its carrying amount to be treated in a manner similar to the treatment of dividends paid on preferred stock.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the closing of the Company&#8217;s IPO in July 2020, all outstanding Convertible Preferred Stock automatically converted into 61,992,534 shares of common stock. No Convertible Preferred Stock was outstanding as of December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to January&#160;1, 2019, the Company issued a total of 56,824,740 shares of Series A convertible preferred stock (&#8220;Series A preferred stock&#8221;), 31,188,115 shares of Series B convertible preferred stock (&#8220;Series B preferred stock&#8221;) and 122,850,909 shares of Series C convertible preferred stock (&#8220;Series C preferred stock&#8221;) in exchange for net proceeds of $56,692, $62,876 and $393,587, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2019, the Company issued an additional 1,779,093 shares of Series C preferred stock at a per share price of $3.21 for proceeds of $5,661, net of issuance costs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible Preferred Stock consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Authorized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issued</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preference</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issuable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Upon</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Conversion</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,824,740</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,824,740</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,657</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,825</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,002,820</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B preferred stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,188,115</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,188,115</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,876</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,783,102</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249,260,004</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124,630,002</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">399,248</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">400,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,097,955</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">337,272,859</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212,642,857</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">537,781</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">519,825</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,883,877</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no shares of Convertible Preferred Stock outstanding at December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of the Convertible Preferred Stock had the following rights and preferences: </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Voting </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of the Convertible Preferred Stock had voting rights equivalent to the number of shares of common stock into which their shares of preferred stock would convert. So long as any of the Convertible Preferred Stock was outstanding, a requisite vote of the Convertible Preferred Stockholders, which was defined as a majority of the Convertible Preferred Stockholders, was required to affirm certain corporate actions, which included, but was not limited to, the disposal of assets, the acquisition of assets or a business and the authorization of additional shares of the Company&#8217;s capital. In addition, such actions required a requisite vote of the Series C preferred stockholders and a majority vote of the Series B preferred stockholders, if any of the respective preferred stock was outstanding. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Dividends </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of the Convertible Preferred Stock were entitled to receive noncumulative dividends when and if declared by the Company&#8217;s board of directors. If the Company declared, paid or set aside, on the same date, a dividend on shares of more than one class or series of capital stock of the Company, the holders of the Convertible Preferred Stock were entitled to the same dividend based on the number of common shares the Convertible Preferred Stock would convert into. No dividends were declared or paid during the years ended December&#160;31, 2020 or 2019.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidation Rights </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the corporation, holders of the Series C preferred stock then outstanding were entitled to be paid out of the assets of the Company available for distribution to its stockholders before any payment was made to the holders of Series A and B preferred stock or common stock by reason of their ownership thereof, an amount per share equal to the greater of (i)&#160;the Series C preferred stock original issue price ($3.21), plus any accrued but unpaid dividends declared, and (ii)&#160;an amount per share if the Series C preferred stock had been converted prior to the liquidation event. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Next, the holders of the Series A preferred stock then outstanding together with holders of Series B preferred stock were entitled to be paid out of the assets of the Company available for distribution to its stockholders before any payment would be made to the common stockholders by reason of their ownership thereof, an amount per share equal to the greater of (i)&#160;their original issue price, which was $1.00 and $2.02 for Series A and B preferred stock, respectively, plus any accrued but unpaid dividends declared, and (ii)&#160;an amount per share if the Series A and B preferred stock, respectively, had been converted prior to the liquidation event. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Conversion </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Convertible Preferred Stock was convertible into common stock at any time at the option of the holder, and was subject to automatic conversion upon the closing of a firm commitment underwritten public offering with either a price per share of at least $22.80 and proceeds of at least $100,000 or approval by a specified vote of the Convertible Preferred Stockholders. As of December 31, 2019, the Convertible Preferred Stock was convertible into 59,382,845 shares of common stock. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 8, 2020, the required Convertible Preferred Stockholders authorized the automatic conversion of all shares of Convertible Preferred Stock in an IPO, regardless of the price per share or total proceeds raised, as long as the IPO was completed on or before September 30, 2020.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Protective Rights </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For as long as any of the Series C preferred stock was outstanding, a requisite vote of the Convertible Preferred Stockholders was required to affirm a liquidation, dissolution, a merger or consolidation or any other deemed liquidation event if the per share proceeds to the holders of the Series C preferred stock would be equal to or greater than $22.80 per share. In addition, both a requisite vote of the Convertible Preferred Stockholders and a majority of the Series C preferred stockholders was required to affirm a liquidation, dissolution, a merger or consolidation or any other deemed liquidation event if the per share proceeds to the holders of the Series C preferred stock was less than $22.80 per share. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_ConvertiblePreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_ConvertiblePreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464772443784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9. Common Stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Company&#8217;s board of directors, however, holders of convertible preferred stock were entitled to any dividend received by the common stockholders if each preferred share had been converted into common stock. As of December&#160;31, 2020 and 2019, no dividends had been declared. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company issued restricted shares of common stock to its founders and non-employees. In addition, the Company issued restricted shares of common stock upon the early exercise of stock options under the Company&#8217;s 2016 Stock Option and Grant Plan (the &#8220;2016 Stock Plan&#8221;). The restrictions on the common shares generally lapse over four years. The Company included the proceeds from the sale of the restricted shares of common stock as a restricted stock liability on the accompanying consolidated balance sheets. Amounts are reclassified to additional paid-in capital as the restrictions lapse. The Company has the right to repurchase any unvested shares of restricted common stock at the original cost in the event of termination. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the restricted stock activity for the year ended December&#160;31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchase</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">679,158</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.21</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(579,825</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.26</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,844</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.03</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,489</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.04</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of shares that vested during the year ended December&#160;31, 2020 was $9,619. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has reserved the following shares of common stock: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Series A preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,002,820</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Series B preferred stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,783,102</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Series C preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,097,955</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved under the compensation plan</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,026,772</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,407,169</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total shares of common stock reserved for</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issuance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,026,772</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,291,046</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July&#160;8, 2020, the Company&#8217;s stockholders approved the 2020 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP became effective on the date immediately prior to the effectiveness of Company&#8217;s registration statement on Form S-1 for its IPO. As of December 31, 2020, the ESPP provides for the issuance of up to 1,092,532 of share-based awards. As of December&#160;31, 2020, no shares have been issued under the ESPP. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464757643704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payments</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. Share-Based Payments </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2016, the Company adopted the 2016 Stock Plan. On July&#160;8, 2020, the Company&#8217;s stockholders approved the 2020 Stock Option and Incentive Plan (the &#8220;2020 Stock Plan&#8221;), which became effective on the date immediately prior to the effectiveness of the Company&#8217;s registration statement on Form S-1 for its IPO. The 2020 Stock Plan provides for the issuance of up to 8,376,080 of share-based awards. Subsequent to July&#160;20, 2020, no further awards will be made under the 2016 Stock Plan and all future equity-based awards will be granted under the 2020 Stock Plan. To the extent outstanding options granted under the 2016 Plan are cancelled, forfeited or otherwise terminated without being exercised and would otherwise have been returned to the share reserve under the 2016 Plan, the number of shares underlying such awards will be available for future grant under the 2020 Stock Plan. All of the Company&#8217;s employees, officers, directors and consultants are eligible to be granted options, restricted stock units and other stock-based awards under the terms of the 2020 Stock Plan. There were 8,026,772 share-based awards available for grant at December&#160;31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the stock option activity under the 2016 Stock Plan and the 2020 Stock Plan for the year ended December&#160;31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:89.88%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,306,176</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.62</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.99</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,214</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,898,663</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.90</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(297,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.09</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(210,781</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.91</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,697,058</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.99</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.50</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">266,050</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,148,119</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.49</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.90</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,625</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-vested at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,548,939</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.96</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.74</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,425</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the first quarter of 2020, the Company&#8217;s board of directors approved the issuance of options with performance-based vesting conditions to purchase 1,960,547 shares of common stock. The commencement of vesting was based on the achievement of certain scientific and operational milestones during a two-year period, for which the achievement was discretionary and subject to the approval of the Company&#8217;s board of directors. Accordingly, the Company applied variable accounting for these awards until the board of directors approved the commencement of vesting for the options. The service inception date preceded the grant date for these awards as the awards were authorized prior to the grant date, the recipients were providing service prior to the grant date and there were performance conditions that, if not met by the accounting grant date, would have resulted in the forfeiture of the award. The stock-based compensation expense for the options was determined based on the fair value of the awards on the accounting grant date. The Company&#8217;s board of directors, in its discretion, determined that a portion of the performance conditions were achieved during the second quarter of 2020 and that the remaining portion of the performance conditions were achieved during the fourth quarter of 2020. The grant dates for all performance-based awards was therefore known as of December 31, 2020, and all performance conditions have been resolved. The Company recognized stock-based compensation expense associated with the awards with performance-based vesting conditions in the amount of $25,527 in the statement of operations for the year ended December 31, 2020. Expense for these awards is recognized using an accelerated attribution model, over the four-year vesting term, commencing upon grant date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimated the fair value of its stock options using the following assumptions: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.4 - 1.8%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5 &#8211; 2.5%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73.5 - 77.6%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.8 &#8211; 73.47%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average grant date fair value of stock options granted during the years ended December&#160;31, 2020 and 2019 was $30.14 per share and $3.34 per share, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense included in the Company&#8217;s consolidated statements of operations and comprehensive loss is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,691</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,687</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,269</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,769</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,960</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,456</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, total unrecognized compensation cost related to the unvested stock-based awards was $69,948, which is expected to be recognized over a weighted average period of 2.61 years. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464757803080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11. Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2020 and 2019, the Company recorded no income tax benefits due to the losses incurred due to the uncertainty of future taxable income. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the expected income tax (benefit) computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows for the year ended December&#160;31, 2020 and 2019: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax computed at federal statutory rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes, net of federal benefit</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27.3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D credit carryovers</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.6</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6.7</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.9</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s deferred tax assets at December&#160;31, 2020 and 2019, consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,832</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,647</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credit carryforwards</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,270</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,309</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,430</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,542</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangibles</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,469</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,498</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,496</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">534</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross deferred tax asset</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,741</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,731</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,813</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,537</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax asset</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,928</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,194</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,928</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,194</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,928</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,194</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred net operating losses (&#8220;NOL&#8221;) since inception. As of December&#160;31, 2020, the Company had federal NOL carryforwards of $174,028 available to reduce taxable income, of which $43,127 expire beginning in 2035 and $130,901 do not expire. The Company has state NOL carryforwards of $192,346 as of December&#160;31, 2020 available to reduce future state taxable income, which expire at various dates beginning in 2035. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company also had available federal research and development tax credit carryforwards of $8,139 available to reduce future tax liabilities, which begin to expire beginning in 2035. The Company also has state research and development tax credit carryforwards of $2,699 available to reduce future state tax liabilities, which expire at various dates beginning in 2030.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilization of the NOL carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section&#160;382 of the Internal Revenue Code of 1986 (&#8220;Section 382&#8221;) due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section&#160;382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section&#160;382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section&#160;382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed and any limitation is known, no amounts are being presented as an uncertain tax position. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded a valuation allowance against its deferred tax assets for the years ended December&#160;31, 2020 and 2019 because the Company&#8217;s management believes that it is more likely than not that these assets will not be realized. The valuation allowance increased by approximately $14,276 and $23,307 for the years ended December&#160;31, 2020 and 2019, respectively, primarily as a result of operating losses generated with no corresponding financial statement benefit. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had no unrecognized tax benefits as of December&#160;31, 2020 and 2019.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company&#8217;s tax years are still open under statute from inception to the present. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law in March 2020. The CARES Act lifts certain deduction limitations originally imposed by the Tax Cuts and Jobs Act of 2017 (&#8220;2017 Tax Act&#8221;). Corporate taxpayers may carryback NOLs originating during 2018 through 2020 for up to five years, which was not previously allowed under the 2017 Tax Act. The CARES Act also eliminates the 80% of taxable income limitations by allowing corporate entities to fully utilize NOL carryforwards to offset taxable income in 2018, 2019 or 2020. Taxpayers may generally deduct interest up to the sum of 50% of adjusted taxable income plus business interest income (30% limit under the 2017 Tax Act) for tax years beginning January&#160;1, 2019 and 2020. The CARES Act allows taxpayers with alternative minimum tax credits to claim a refund in 2020 for the entire amount of the credits instead of recovering the credits through refunds over a period of years, as originally enacted by the 2017 Tax Act. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the CARES Act raises the corporate charitable deduction limit to 25% of taxable income and makes qualified improvement property generally eligible for 15-year cost-recovery and 100% bonus depreciation. The enactment of the CARES Act did not result in any adjustments to the Company&#8217;s income tax provision for the year ended December&#160;31, 2020, or to the Company&#8217;s net deferred tax assets as of December&#160;31, 2020, since the Company has not recorded any U.S. federal or state income tax benefits for the net losses incurred in any year due to the uncertainty of realizing a benefit from those items. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464757632936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12. Net Loss Per Share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the computation of basic and diluted net loss per share of the Company: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,412</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,305</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deemed dividend resulting from extinguishment upon modification of Series&#160;C preferred stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(177,789</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(230,201</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,305</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders per share, basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5.40</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21.82</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares of common stock, basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,619,582</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,450,500</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As discussed in Note 8, on July&#160;8, 2020, the Company&#8217;s board of directors and its Series C preferred stockholders approved an amendment to the conversion preferences and rights of the Series C preferred stock which, among other changes, resulted in a reduction in the conversion price of the Series C preferred stock from $3.21 to $3.027603. The changes to the conversion feature were considered to be a significant change to the substantive contractual terms of the Series C preferred stock and, therefore, the Company accounted for the changes as an extinguishment and reissuance of the Series C preferred stock. In accordance with SEC staff guidance codified in ASC 260-10-S99-2, when equity classified preferred shares are extinguished, the difference between (1)&#160;the fair value of the consideration transferred to the holders of the preferred shares and (2)&#160;the carrying amount of the preferred shares, net of issuance costs, is subtracted from (or added back to) net income to arrive at income available to common stockholders in the calculation of earnings per share. This difference between the fair value of consideration transferred and carrying amount of the preferred shares, also referred to as a &#8220;deemed dividend&#8221;, was therefore added back to net loss above to derive net loss attributable to common stockholders. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s potentially dilutive securities, which include Convertible Preferred Stock (prior to the IPO), options to purchase common stock and unvested restricted stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,883,877</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,697,058</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,306,176</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,489</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">679,158</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,781,547</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,869,211</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464757827800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13. Commitments and Contingencies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intellectual Property License </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a Collaboration and License Agreement with D. E. Shaw Research, LLC (&#8220;D. E. Shaw Research&#8221;), which held 9,999,999 shares of Series A preferred stock and 1,557,875 shares of Series C preferred stock at December 31, 2019. Upon the IPO these shares were converted into 3,281,253 shares of common stock, which are outstanding at December 31, 2020. The agreement provides that the parties will jointly conduct research efforts with the goal of identifying and developing product candidates. The original term of the agreement was three years and required the Company to pay an annual fee of $1,000. On June 15, 2020, the Company and D. E. Shaw Research agreed to amend the Collaboration and License Agreement (the &#8220;Amended and Restated Collaboration and License Agreement&#8221;). The Amended and Restated Collaboration and License Agreement extended the term of the agreement to August 16, 2025 and increased the annual fee from $1,000 to $7,900. The Amended and Restated Collaboration and License Agreement automatically renews for successive one year periods unless either party provides at least one year notice of non-renewal, and the annual fee during each of the one year renewal terms is subject to the mutual agreement of the Company and D. E. Shaw Research. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is obligated to pay potential development milestone payments under the terms of the agreement up to $7,300 per target, plus sales milestones and royalties, upon the achievement of certain specified contingent events. Such payments for achievement of development and regulatory milestones total up to $7,250 in the aggregate for each of the first three products the Company develops, and up to $6,250 in the aggregate for each product the Company develops after the first three. The Company assessed the milestone and royalty events through December 31, 2020 and concluded $1,500 was due to D.E. Shaw related to the execution of the Genentech Agreement in December 2020. The Company concluded no such payments were due as of December 31, 2019. The Company recorded research and development expense of $6,376 and $1,500 under this agreement for the years ended December 31, 2020 and 2019, respectively. At December 31, 2020 and December 31, 2019, the Company had an accrued expense balance to D. E. Shaw Research of approximately $1,500 and $372, respectively, on its balance sheets. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Research Arrangements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has certain other research and license arrangements with third-parties, which provide the Company with research services with the goal of identifying and developing product candidates. The Company is obligated to pay development milestone payments for up to four targets, each in the range of $4,000 to $7,000 upon the achievement of certain specified contingent events. The Company assessed the milestones at December&#160;31, 2020 and 2019 and concluded no such milestone payments were due. The Company incurred approximately $2,704 and $3,493 of research and development expense under these agreements in the years ended December&#160;31, 2020 and 2019, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464757613208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14. Leases </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">215 First Street </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leased office and laboratory space at 215 First Street in Cambridge, Massachusetts (&#8220;First Lease&#8221;) under an operating lease, which commenced in November 2015 and was originally set to expire in December 2020. As discussed below, the Company executed a lease at 399 Binney Street (&#8220;Binney Lease&#8221;) whereby the Company vacated the 215 First Street lease in January 2019 and the future lease commitments terminated at no cost once the Binney Lease commenced. The lease included certain tenant improvement allowances, which the Company amortized through January 2019, the termination of the lease. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">399 Binney Street </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2017, the Company entered into a facility lease agreement for approximately 44,336 square feet of office and laboratory space at 399 Binney Street, Cambridge, Massachusetts, which was increased to 44,807 square feet in January 2018. The Company gained control of the leased space in January 2019 and recorded a right of use asset and a lease liability, accordingly. The lease expires in April 2029, subject to certain renewal options, which have not been included in the Company&#8217;s right of use asset and liability, as the Company is not reasonably certain to exercise those options. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2020, the Company entered into an amendment to its facility lease agreement to expand the leased area by approximately 1,824 square feet of office space at 399 Binney Street, Cambridge, Massachusetts. The amended lease expires in April 2029, subject to certain renewal options. The amendment to the lease agreement met the criteria to be accounted for as a separate lease. The Company gained control of the leased space in October 2020 and recorded a right of use asset and a lease liability, accordingly. The right of use asset and lease liability recorded in connection with this amendment were not material.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As discussed in Note 2, the Company provided a letter of credit in the amount of $878 with a financial institution, which expires September&#160;30, 2028. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the presentation of the Company&#8217;s operating leases on its consolidated balance sheets: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance sheet location</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,579</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,560</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current operating lease</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,521</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,249</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current operating lease</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, net of current portion</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,901</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,583</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,422</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,832</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the effect of lease costs in the Company&#8217;s consolidated statements of operations and comprehensive loss for the years ended December&#160;31, 2020 and 2019: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Statement of operations location</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease costs</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,273</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,216</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">748</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">581</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease cost</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,797</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company made cash payments of $4,878 and $2,602 under the lease agreements during the years ended December&#160;31, 2020 and 2019, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The minimum lease payments as of December&#160;31, 2020 for the next five years and thereafter is expected to be as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,985</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,134</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,254</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,377</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,503</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,959</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,212</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: interest</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,790</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of operating lease liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,422</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average remaining lease term and weighted average discount rate of the operating leases were 8.3 years and 10.4%, respectively, at December&#160;31, 2020. The weighted average remaining lease term and weighted average discount rate of the operating leases were 9.3 years and 10.4%, respectively, at December&#160;31, 2019.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464757653064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Benefits</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15. Employee Benefits </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2016, the Company established a defined-contribution plan under Section&#160;401(k) of the Internal Revenue Code (the &#8220;401(k) Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. The Company made matching contributions to the 401(k) Plan of $590 for the year ended December&#160;31, 2020. The Company was not required to make and did not make any matching contributions to the 401(k) Plan for the year ended December&#160;31, 2019.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464757622120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16. Related Party Transactions </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From inception to December&#160;31, 2020, the Company received consulting and management services from Third Rock Ventures LLP (&#8220;TRV&#8221;), an entity affiliated with certain of the Company&#8217;s investors. The Company did not incur expenses for such services during the year ended December 31, 2020<font style="font-size:12pt;">. </font>The Company incurred approximately $200 for these services during the year ended December&#160;31, 2019. No amounts were due to TRV at December&#160;31, 2020. At December&#160;31, 2019, $80 was due to TRV for these services.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464765206584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17. Subsequent Events </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In preparing the consolidated financial statements as of December&#160;31, 2020, the Company evaluated subsequent events for recognition and measurement purposes through the filing date of this Annual Report on Form 10-K. The Company concluded that no events or transactions have occurred that require disclosure in the accompanying consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464756234680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_BasisOfPresentationPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis of presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) for reporting on Form 10-K. The Company&#8217;s consolidated financial statements include the accounts of Relay Therapeutics, Inc. and its wholly-owned subsidiary, Relay Therapeutics Securities Corporation. All intercompany balances and transactions have been eliminated. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development and manufacturing expenses, the valuation of equity instruments, the determination of the transaction price and standalone selling price of performance obligations under <font style="color:#000000;">Accounting Standards Codification Topic 606, </font><font style="font-style:italic;color:#000000;">Revenue from Contracts with Customers</font>, and the incremental borrowing rate for determining the operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has made estimates of the impact of COVID-19 within its financial statements and there may be changes to those estimates in future periods. Actual results could differ from the Company&#8217;s estimates. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Segment Information </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company&#8217;s singular focus is on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets. The Company operates in the United States and all tangible assets are held in the United States.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash Equivalents </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all short-term, highly liquid investments with original maturities of 90&#160;days or less at acquisition date to be cash equivalents. Cash equivalents, which consist of money market funds, are stated at fair value. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Restricted Cash </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had restricted cash of $878 as of December&#160;31, 2020 and 2019 to secure a letter of credit in connection with the lease of the Company&#8217;s facilities (see Note 14). The Company classified the restricted cash as a noncurrent asset on its consolidated balance sheets. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Investments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments in marketable securities are classified as available-for-sale. Available-for-sale securities are measured and reported at fair value using quoted prices in active markets for similar securities. Unrealized gains and losses on available-for-sale securities are reported as a separate component of stockholders&#8217; equity (deficit). Premiums or discounts from par value are amortized to investment income over the life of the underlying investment. All of the Company&#8217;s available-for-sale securities are available to the Company for use in current operations. As a result, the Company classified all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cost of securities sold is determined on a specific identification basis, and realized gains and losses are included in other income (expense) within the consolidated statements of operations and comprehensive loss. If any adjustment is required to reflect a decline in the value of the investment that the Company considers to be &#8220;other than temporary&#8221;, the Company recognizes a charge to the consolidated statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_ConcentrationOfCreditRiskAndSignificantSuppliersPolicyTextBlock', window );">Concentration of Credit Risk and Significant Suppliers</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Significant Suppliers </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and investments. From time to time, the Company has maintained all of its cash, cash equivalents and investments at certain accredited financial institutions in amounts that exceed federally insured limits. The Company generally invests its excess capital in money market funds, U.S. treasury bonds, U.S. treasury bills and agency bonds are subject to minimal credit and market risk. Management has established guidelines relative to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. The investment portfolio is maintained in accordance with the Company&#8217;s investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is dependent on third-party suppliers for research and development activities of its programs, including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a small number of these suppliers, including D. E. Shaw Research, LLC as discussed in Note 13, to meet its requirements for its programs. These programs could be adversely affected by a significant interruption in pre-clinical and clinical testing and the supply of active pharmaceutical ingredients and formulated drugs. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Level 2&#8212;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.4%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for revenue recognition in accordance with Accounting Standards Codification Topic (&#8220;ASC&#8221;) 606, <font style="font-style:italic;">Revenue from Contracts with Customers</font> (&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. </p>
<p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract and determines those that are performance obligations. The Company then determines the transaction price and allocates it to the performance obligations using the relative selling price model. As part of the accounting for these arrangements, the Company must use significant judgment to determine: (a) the number of performance obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above, including the determination of whether milestones or other variable consideration should be included in the transaction price; and (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of the transaction price in step (iv) above. </p>
<p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilizes key assumptions and judgments to determine the stand-alone selling price for each performance obligation, which may include discounted cash flow models, evaluation of comparable transactions, pricing considered in negotiating the transaction and estimated costs,<font style="Background-color:#FFFFFF;"> to determine how the transaction price is allocated among the performance obligations</font>. The Company uses judgment to determine whether milestones or other variable consideration should be included in the transaction price. For revenue-based royalties, including milestone payments based on the level of sales, the Company will include royalties in the transaction price at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty is allocated has been satisfied (or partially satisfied). As part of management&#8217;s evaluation of the transaction price, the Company considers numerous factors, including whether the achievement of the milestones is outside of our control, contingent upon the efforts of others or subject to scientific risks of success. If the Company concludes it is probable that a significant revenue reversal would not occur, the associated milestone payment is included in the transaction price. Milestone payments that are not within our control, such as regulatory approvals, are generally not considered probable until those milestones are achieved. The Company re-evaluates the transaction price, including estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</p>
<p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once the performance obligations are identified, the transaction price is allocated to each performance obligation based on the relative stand-alone selling price. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied, either at a point in time or over time. If the performance obligation is satisfied over time, the Company recognizes revenue based on the use of either an output or input method. </p>
<p style="margin-top:15pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had one collaboration and license agreement with Genentech, which the Company entered into on December 11, 2020. <font style="letter-spacing:-0.1pt;">For a discussion of the accounting related to the Genentech Agreement, see Note 5,&#160;</font><font style="font-style:italic;letter-spacing:-0.1pt;">Collaboration and License Arrangement with Genentech</font>.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lease Agreements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 842, <font style="font-style:italic;">Leases</font>, the Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does not recognize a right-of-use asset or lease liability. The Company&#8217;s operating leases are recognized on its consolidated balance sheets as other noncurrent assets, other current liabilities and other noncurrent liabilities. The Company does not have any finance leases. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Operating lease right-of-use assets also include the effect of any lease payments made prior to commencement and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has lease agreements with lease and non-lease components, which are accounted for as a combined element. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the useful life of the asset. Laboratory and computer equipment are depreciated over three years. Furniture and fixtures are depreciated over five years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the related asset. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company continually evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparing the book values of the assets to the expected future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured in an amount by which the book values of the assets exceed their fair value. The Company did not recognize any impairment losses for the years ended December&#160;31, 2020 and 2019.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Classification and Accretion of Convertible Preferred Stock</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Classification and Accretion of Convertible Preferred Stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s convertible preferred stock was classified outside of stockholders&#8217; equity (deficit) on the consolidated balance sheet because the holders of such shares had liquidation rights in the event of a deemed liquidation that, in certain situations, were not solely within the control of the Company and would require the redemption of the then-outstanding convertible preferred stock. The convertible preferred stock was not currently redeemable, except in the event of a deemed liquidation (see Note 8). Because the occurrence of a deemed liquidation event was not probable, the carrying value of the convertible preferred stock was not accreted to their redemption values. Subsequent adjustments to the carrying values of the convertible preferred stock would have been made only when a deemed liquidation event became probable. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the closing of the Company&#8217;s IPO in July 2020, all outstanding convertible preferred stock automatically converted into 61,992,534 shares of common stock. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures stock options and other stock-based awards granted to employees, directors and non-employees based on their fair value on the date of grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company recognizes the impact of forfeitures on stock-based compensation expense as forfeitures occur. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company issued certain options with performance-based vesting conditions whereby the service inception date preceded the accounting grant date and therefore applied variable accounting for the awards until the fair value of the awards was known on the accounting grant date. The board of directors approved the commencement of vesting for all such awards in 2020, therefore the Company no longer applies variable accounting as of December 11, 2020.<font style="font-size:12pt;">&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model, which uses as inputs the fair value of the Company&#8217;s common stock and assumptions the Company makes for the volatility of its common stock, the expected term of the stock options, the risk-free interest rate for a period that approximates the expected term of the stock options and the expected dividend yield. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Company&#8217;s IPO, the estimated fair value of its common stock was determined by the board of directors, or compensation committee thereof, as of the date of each option grant, with input from management, considering the most recently available third-party valuations of common stock and the board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. Historically, these independent third-party valuations of the Company&#8217;s equity instruments were performed contemporaneously with identified value inflection points.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide,&#160;<font style="font-style:italic;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation </font>(the &#8220;Practice Aid&#8221;). The Practice Aid identifies various available methods for allocating the enterprise value across classes of series of capital stock in determining the fair value of the Company&#8217;s common stock at each valuation date.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following the Company&#8217;s IPO, in connection with the accounting for granted stock options and other awards the Company may grant, the fair value of the Company&#8217;s common stock is determined based on the quoted market price of its common stock.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Costs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development expenses include salaries, stock-based compensation and benefits of employees, third-party license fees and other operational costs related to the Company&#8217;s research and development activities, including allocated facility-related expenses and external costs of outside vendors engaged to conduct both pre-clinical studies and clinical trials. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_ResearchAndManufacturingContractsPolicyTextBlock', window );">Research and Manufacturing Contracts</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Research and Manufacturing Contracts </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development contracts with research institutions and other companies whose costs are included in research and development expense in the accompanying consolidated statements of operations and comprehensive loss. These agreements are generally cancelable and related payments are recorded as research and development expenses as the underlying services are performed. When evaluating the adequacy of the expense recognized, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the expense recognized and the related prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical estimates have not been materially different from the actual costs. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Patent Costs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company&#8217;s financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive Loss </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. For the years ended December&#160;31, 2020 and 2019, other comprehensive income (loss) consisted of changes in unrealized gains and losses from available-for-sale investments.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Loss Per Common Share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed using the sum of the weighted average number of common shares outstanding during the period and the effect of dilutive securities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies the two-class method to calculate its basic and diluted net loss per share as the Company has issued shares that meet the definition of participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. The Company&#8217;s participating securities contractually entitle the holders of such shares to participate in dividends; but do not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, in periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. <font style="color:#000000;letter-spacing:-0.1pt;">For additional discussion of net loss per common share, please see Note 12, </font><font style="font-style:italic;color:#000000;letter-spacing:-0.1pt;">Net Loss Per Share. </font><font style="color:#000000;letter-spacing:-0.1pt;"> </font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2018-13, <font style="font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement</font> on January&#160;1, 2020. This standard modifies certain disclosure requirements on fair value measurements. The adoption of this standard did not have a material impact on the Company&#8217;s disclosures. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_DescriptionOfNewAccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Recently Issued Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements Not Yet Adopted </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-13,<font style="font-style:italic;">&#160;Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</font>. This standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and it establishes additional disclosure requirements related to credit risks. For available-for-sale securities with expected credit losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This guidance was originally effective for fiscal years beginning after December&#160;15, 2019, including interim periods within those fiscal years, and early adoption was permitted. In November 2019, the FASB subsequently issued ASU 2019-10, <font style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging</font> <font style="font-style:italic;">(Topic 815), and Leases (Topic 842): Effective Dates </font>(&#8220;ASU 2019-10&#8221;), whereby the effective date of this standard for smaller reporting companies was deferred to fiscal years beginning after December&#160;15, 2022, including interim periods within those fiscal years, and early adoption is still permitted. The Company is assessing the impact of ASU 2019-10 on the consolidated financial statements and does not expect it to have a material impact.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the FASB issued ASU No.&#160;2020-06, <font style="font-style:italic;">Debt &#8211; Debt with Conversion and Other</font> <font style="font-style:italic;">Options</font> (Subtopic 470-20) <font style="font-style:italic;">and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity</font> (Subtopic 815-40)<font style="font-size:12pt;"> </font>(&#8220;ASU 2020-06&#8221;). This standard amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity&#8217;s own equity and amends the related earnings per share (&#8220;EPS&#8221;) guidance. The ASU will be effective for smaller reporting companies for fiscal years beginning after December&#160;15, 2023 and interim periods within those fiscal years. Early adoption is permitted in fiscal years beginning after December&#160;15, 2020, including interim periods within those fiscal years. The Company is assessing the impact of&#160;ASU 2020-06&#160;on the consolidated financial statements and does not expect it to have a material impact. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued&#160;ASU&#160;2019-12,<font style="font-style:italic;">&#160;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</font>&#160;(&#8220;ASU&#160;2019-12&#8221;), which is intended to simplify the accounting for income taxes.&#160;ASU&#160;2019-12&#160;removes certain exceptions to the general principles in Topic 740 and also clarifies and amends certain aspects of the existing guidance to improve consistent application. The new standard will be effective for public business entities for fiscal years beginning after December&#160;15, 2020. The Company is assessing the potential impact&#160;ASU&#160;2019-12&#160;may have on its financial statements upon adoption. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected to use the extended transition period related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different effective dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time that the Company either (i)&#160;irrevocably elects to &#8220;opt out&#8221; of such extended transition period or (ii)&#160;no longer qualifies as an emerging growth company. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_BasisOfPresentationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_BasisOfPresentationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_ConcentrationOfCreditRiskAndSignificantSuppliersPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration of credit risk and significant suppliers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_ConcentrationOfCreditRiskAndSignificantSuppliersPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_DescriptionOfNewAccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of new accounting pronouncements not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_DescriptionOfNewAccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patent costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_ResearchAndManufacturingContractsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and manufacturing contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_ResearchAndManufacturingContractsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116854557&amp;loc=d3e20905-112640<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464765192040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Financial Assets Measured at Fair Value on a Recurring Basis and Level of the Fair Value Hierarchy</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Assets</font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">447,146</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">447,146</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US treasury bills</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,026</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,026</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US agency securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197,389</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197,389</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,415</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,415</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">447,146</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,415</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">677,561</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Assets</font></p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,658</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,658</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US treasury bills</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,604</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,604</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US agency securities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,258</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,258</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313,862</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313,862</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,658</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313,862</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">355,520</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464757814792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsAbstract', window );"><strong>Schedule Of Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Fair Value of Available-for-Sale Investments by Type of Security</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of available-for-sale investments by type of security was as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:98.64%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S treasury bills</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,997</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S agency securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,996</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,001</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments with a maturity of one year or less</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,993</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S treasury bills</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,008</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,008</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S agency securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176,350</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176,388</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments with a maturity of one to two years</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179,358</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179,396</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,351</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,415</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:93.84%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S treasury bills</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,336</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">268</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,604</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S agency securities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,201</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,258</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total investments with a maturity of one year or less</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313,537</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313,862</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464765177256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,534</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,003</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">886</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">860</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">888</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">827</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">895</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">895</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in process</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">577</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">490</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,780</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,075</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,530</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,981</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,250</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,094</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464765182920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">External research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,099</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,077</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional services</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">464</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">336</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">197</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other current liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,760</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,746</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464757602904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Summary of Convertible Preferred Stock</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible Preferred Stock consisted of the following: </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Authorized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issued</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Carrying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preference</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issuable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Upon</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Conversion</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,824,740</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,824,740</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,657</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,825</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,002,820</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B preferred stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,188,115</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,188,115</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,876</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,783,102</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249,260,004</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124,630,002</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">399,248</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">400,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,097,955</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">337,272,859</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212,642,857</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">537,781</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">519,825</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,883,877</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464757786232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Summary Of The Restricted Stock Activity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the restricted stock activity for the year ended December&#160;31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchase</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">679,158</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.21</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(579,825</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.26</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,844</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.03</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,489</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.04</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_ReservedSharesOfCommonStockForFutureIssuanceTableTableTextBlock', window );">Summary of Reserved Shares of Common Stock</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has reserved the following shares of common stock: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Series A preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,002,820</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Series B preferred stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,783,102</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of Series C preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,097,955</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved under the compensation plan</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,026,772</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,407,169</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total shares of common stock reserved for</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issuance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,026,772</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,291,046</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_ReservedSharesOfCommonStockForFutureIssuanceTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of reserved shares of common stock for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_ReservedSharesOfCommonStockForFutureIssuanceTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464754995816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the stock option activity under the 2016 Stock Plan and the 2020 Stock Plan for the year ended December&#160;31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:89.88%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,306,176</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.62</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.99</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,214</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,898,663</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.90</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(297,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.09</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(210,781</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.91</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,697,058</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.99</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.50</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">266,050</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,148,119</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.49</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.90</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,625</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-vested at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,548,939</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.96</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.74</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186,425</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Estimated Fair Value of Stock Options</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimated the fair value of its stock options using the following assumptions: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.4 - 1.8%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5 &#8211; 2.5%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73.5 - 77.6%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.8 &#8211; 73.47%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation Expense Included In The Company's Consolidated Statements of Operations And Comprehensive Loss</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense included in the Company&#8217;s consolidated statements of operations and comprehensive loss is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,691</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,687</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,269</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,769</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,960</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,456</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464682581480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Reconciliation of Expected Income Tax (Benefit) Computed Using Federal Statutory Income Tax Rate to Effective Income Tax Rate</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the expected income tax (benefit) computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows for the year ended December&#160;31, 2020 and 2019: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax computed at federal statutory rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes, net of federal benefit</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27.3</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D credit carryovers</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.6</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6.7</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.9</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Deferred Tax Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s deferred tax assets at December&#160;31, 2020 and 2019, consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,832</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,647</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credit carryforwards</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,270</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,309</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,430</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,542</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangibles</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,469</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,498</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,496</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">534</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross deferred tax asset</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,741</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,731</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,813</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,537</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax asset</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,928</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,194</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,928</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,194</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,928</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,194</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464857341864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Computation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the computation of basic and diluted net loss per share of the Company: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,412</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,305</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deemed dividend resulting from extinguishment upon modification of Series&#160;C preferred stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(177,789</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(230,201</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,305</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders per share, basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5.40</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21.82</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares of common stock, basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,619,582</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,450,500</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Antidilutive Securities Excluded From Computation of Earnings Per Share</a></td>
<td class="text">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,883,877</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,697,058</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,306,176</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,489</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">679,158</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,781,547</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,869,211</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464765166136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_ScheduleOfOperatingLeasePresentationInConsolidatedBalanceSheetTableTextBlock', window );">Schedule of Operating Leases Presentation in Consolidated Balance Sheets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the presentation of the Company&#8217;s operating leases on its consolidated balance sheets: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance sheet location</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,579</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,560</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current operating lease</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,521</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,249</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current operating lease</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, net of current portion</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,901</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,583</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,422</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,832</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_SummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossTableTextBlock', window );">Summary of Operating Lease Presentation in Consolidated Statements of Operations and Comprehensive Loss</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the effect of lease costs in the Company&#8217;s consolidated statements of operations and comprehensive loss for the years ended December&#160;31, 2020 and 2019: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Statement of operations location</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease costs</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.8%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,273</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,216</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">748</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">581</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:29.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease cost</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,797</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Summary of Future Minimum Lease Payments</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The minimum lease payments as of December&#160;31, 2020 for the next five years and thereafter is expected to be as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,985</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,134</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,254</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,377</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,503</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,959</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,212</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: interest</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,790</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of operating lease liabilities</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,422</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_ScheduleOfOperatingLeasePresentationInConsolidatedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of operating lease presentation in consolidated balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_ScheduleOfOperatingLeasePresentationInConsolidatedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_SummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of operating lease presentation in consolidated statements of operations and comprehensive loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_SummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464758125080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 20, 2020</div></th>
<th class="th"><div>Jul. 08, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 07, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_NatureOfBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature of Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (404,228)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (189,482)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction</a></td>
<td class="nump">23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale price of stock</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in public offering</a></td>
<td class="nump">$ 425,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">425,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_UnderwritingDiscountsAndCommissions', window );">Underwriting discounts and commissions</a></td>
<td class="nump">32,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Expense on initial public offering</a></td>
<td class="nump">$ 2,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock shares converted</a></td>
<td class="nump">61,992,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">260,000,000<span></span>
</td>
<td class="nump">260,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-3.55092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rlay_GenentechIncMember', window );">Genentech [Member] | Subsequent Event [Member] | Collaboration and License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_NatureOfBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature of Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_NatureOfBusinessAndBasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nature of business and basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_NatureOfBusinessAndBasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_UnderwritingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriting discounts and commissions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_UnderwritingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rlay_GenentechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rlay_GenentechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464682343864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th"><div>Nov. 30, 2015</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>Agreement</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CashAndCashEquivalentsMaturityDateDescription', window );">Maturity days for highly liquid investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition date to be cash equivalents.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 878,000<span></span>
</td>
<td class="nump">$ 878,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Operating lease option to extent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate', window );">Operating lease option to terminate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment loss of long lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock upon initial public offering, shares | shares</a></td>
<td class="nump">61,992,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement', window );">Description of Income tax benefit, likelihood of realized upon ultimate settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">greater than 50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rlay_LaboratoryAndComputerEquipmentMember', window );">Laboratory and Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rlay_GenentechIncMember', window );">Genentech [Member] | Genentech Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_NumberOfCollaborationAndLicenseAgreement', window );">Number of collaboration and license agreement | Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CollaborationAndLicenseAgreementEnteredDate', window );">Collaboration and license agreement entered date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 11,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 878,000<span></span>
</td>
<td class="nump">$ 878,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_CashAndCashEquivalentsMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents maturity date description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_CashAndCashEquivalentsMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_CollaborationAndLicenseAgreementEnteredDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreement entered date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_CollaborationAndLicenseAgreementEnteredDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_NumberOfCollaborationAndLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of collaboration and license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_NumberOfCollaborationAndLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 15<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877542&amp;loc=d3e27249-109313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to terminate operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rlay_LaboratoryAndComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=rlay_LaboratoryAndComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rlay_GenentechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rlay_GenentechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rlay_GenentechAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rlay_GenentechAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464682384040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Assets - Summary of Financial Assets Measured at Fair Value on a Recurring Basis and Level of the Fair Value Hierarchy (Detail) - Fair value on a recurring basis [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosureAbstract', window );"><strong>Investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 677,561<span></span>
</td>
<td class="nump">$ 355,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosureAbstract', window );"><strong>Investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">230,415<span></span>
</td>
<td class="nump">313,862<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Investments [Member] | US treasury bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosureAbstract', window );"><strong>Investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">33,026<span></span>
</td>
<td class="nump">232,604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Investments [Member] | US agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosureAbstract', window );"><strong>Investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">197,389<span></span>
</td>
<td class="nump">81,258<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosureAbstract', window );"><strong>Investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">447,146<span></span>
</td>
<td class="nump">41,658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosureAbstract', window );"><strong>Investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">230,415<span></span>
</td>
<td class="nump">313,862<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 [Member] | Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosureAbstract', window );"><strong>Investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">230,415<span></span>
</td>
<td class="nump">313,862<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 [Member] | Investments [Member] | US treasury bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosureAbstract', window );"><strong>Investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">33,026<span></span>
</td>
<td class="nump">232,604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 [Member] | Investments [Member] | US agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosureAbstract', window );"><strong>Investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
<td class="nump">197,389<span></span>
</td>
<td class="nump">81,258<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash equivalents [Member] | Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CashAndCashEquivalentsFairValueDisclosureAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">447,146<span></span>
</td>
<td class="nump">41,658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash equivalents [Member] | Level 1 [Member] | Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CashAndCashEquivalentsFairValueDisclosureAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">$ 447,146<span></span>
</td>
<td class="nump">$ 41,658<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_CashAndCashEquivalentsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_CashAndCashEquivalentsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464758109608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Summary of Fair Value of Available-for-Sale Investments by Type of Security (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 230,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">230,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentSecondaryCategorizationAxis=rlay_InvestmentsWithMaturityOfOneYearOrLessMember', window );">Investments with a maturity of one year or less [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">50,993<span></span>
</td>
<td class="nump">$ 313,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">51,019<span></span>
</td>
<td class="nump">313,862<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentSecondaryCategorizationAxis=rlay_InvestmentsWithMaturityOfOneToTwoYearsMember', window );">Investments with a maturity of one to two years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">179,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">179,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S treasury bills [Member] | Investments with a maturity of one year or less [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">29,997<span></span>
</td>
<td class="nump">232,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">30,018<span></span>
</td>
<td class="nump">232,604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S treasury bills [Member] | Investments with a maturity of one to two years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">3,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">3,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S agency securities [Member] | Investments with a maturity of one year or less [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">20,996<span></span>
</td>
<td class="nump">81,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">21,001<span></span>
</td>
<td class="nump">$ 81,258<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S agency securities [Member] | Investments with a maturity of one to two years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">176,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 176,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentSecondaryCategorizationAxis=rlay_InvestmentsWithMaturityOfOneYearOrLessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentSecondaryCategorizationAxis=rlay_InvestmentsWithMaturityOfOneYearOrLessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentSecondaryCategorizationAxis=rlay_InvestmentsWithMaturityOfOneToTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentSecondaryCategorizationAxis=rlay_InvestmentsWithMaturityOfOneToTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464682127448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Arrangement with Genentech - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CollaborationAndLicenseArrangementLineItems', window );"><strong>Collaboration And License Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 82,654,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract asset</a></td>
<td class="nump">$ 7,654,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rlay_GenentechIncMember', window );">Genentech [Member] | Genentech Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CollaborationAndLicenseArrangementLineItems', window );"><strong>Collaboration And License Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementNatureAndPurpose', window );">Collaborative arrangement, purpose</a></td>
<td class="text">On December 11, 2020, the Company entered into the Genentech Agreement, which granted Genentech a license to develop and commercialize RLY-1971.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementRightsAndObligations', window );">Collaborative arrangement, rights and obligations</a></td>
<td class="text">Unless Genentech elects to exercise its option to conduct the remainder of the ongoing Phase 1a Trial, the Company is responsible for the completion of this trial. Genentech is responsible for conducting all subsequent clinical development of RLY-1971. The Company is also responsible for the one-time transfer of the active pharmaceutical ingredient (&#8220;API&#8221;) and other materials related to RLY-1971 to Genentech<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_NonRefundableUpfrontPayment', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement', window );">Maximum additional amount received upon milestone achievement</a></td>
<td class="nump">695,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CollaborationAgreementTransactionPrice', window );">Collaboration agreement transaction price</a></td>
<td class="nump">85,867,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_NonRefundableMilestoneTransferAmount', window );">Non-refundable milestone payment transfer amount</a></td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_NonRefundableMilestoneForCompletionAmount', window );">Non-refundable milestone payment for completion amount</a></td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_VariableConsiderationRelatedToReimbursementsDueForResearchAndDevelopmentServices', window );">Variable consideration related to reimbursements due for research and development services</a></td>
<td class="nump">867,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_DevelopmentBasedMilestonePaymentsUnderAgreement', window );">Development based milestone payments under agreement</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_RegulatoryBasedMilestonePaymentsUnderAgreement', window );">Regulatory based milestone payments under agreement</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rlay_GenentechIncMember', window );">Genentech [Member] | Genentech Agreement [Member] | Transfer of License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CollaborationAndLicenseArrangementLineItems', window );"><strong>Collaboration And License Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">82,654,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rlay_GenentechIncMember', window );">Genentech [Member] | Genentech Agreement [Member] | Research and Development Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CollaborationAndLicenseArrangementLineItems', window );"><strong>Collaboration And License Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rlay_GenentechIncMember', window );">Genentech [Member] | Genentech Agreement [Member] | Transfer of Active Pharmaceutical Ingredients [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CollaborationAndLicenseArrangementLineItems', window );"><strong>Collaboration And License Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract asset</a></td>
<td class="nump">7,654,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rlay_GenentechIncMember', window );">Genentech [Member] | Genentech Agreement [Member] | Stand-alone Selling Prices (&#8220;SSP&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CollaborationAndLicenseArrangementLineItems', window );"><strong>Collaboration And License Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CollaborationAgreementTransactionPrice', window );">Collaboration agreement transaction price</a></td>
<td class="nump">85,867,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rlay_GenentechIncMember', window );">Genentech [Member] | Genentech Agreement [Member] | Stand-alone Selling Prices (&#8220;SSP&#8221;) [Member] | Transfer of License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CollaborationAndLicenseArrangementLineItems', window );"><strong>Collaboration And License Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligations</a></td>
<td class="nump">82,654,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rlay_GenentechIncMember', window );">Genentech [Member] | Genentech Agreement [Member] | Stand-alone Selling Prices (&#8220;SSP&#8221;) [Member] | Research and Development Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CollaborationAndLicenseArrangementLineItems', window );"><strong>Collaboration And License Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligations</a></td>
<td class="nump">2,896,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rlay_GenentechIncMember', window );">Genentech [Member] | Genentech Agreement [Member] | Stand-alone Selling Prices (&#8220;SSP&#8221;) [Member] | Transfer of Active Pharmaceutical Ingredients [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CollaborationAndLicenseArrangementLineItems', window );"><strong>Collaboration And License Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligations</a></td>
<td class="nump">317,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rlay_GenentechIncMember', window );">Genentech [Member] | Genentech Agreement [Member] | Outside US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CollaborationAndLicenseArrangementLineItems', window );"><strong>Collaboration And License Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement', window );">Maximum additional amount received upon milestone achievement</a></td>
<td class="nump">$ 410,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_CollaborationAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_CollaborationAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_CollaborationAndLicenseArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_CollaborationAndLicenseArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_DevelopmentBasedMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential clinical development milestone payments available to be earned under a collaboration arrangement for each available target selected by the collaborator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_DevelopmentBasedMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum additional amount received upon milestone achievement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_MilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_MilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_NonRefundableMilestoneForCompletionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-refundable milestone for completion amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_NonRefundableMilestoneForCompletionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_NonRefundableMilestoneTransferAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-refundable milestone transfer amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_NonRefundableMilestoneTransferAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_NonRefundableUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-refundable upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_NonRefundableUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_RegulatoryBasedMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential regulatory milestone payments available to be earned under a collaboration arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_RegulatoryBasedMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_VariableConsiderationRelatedToReimbursementsDueForResearchAndDevelopmentServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable consideration related to reimbursements due for research and development services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_VariableConsiderationRelatedToReimbursementsDueForResearchAndDevelopmentServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementNatureAndPurpose">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of nature and purpose of collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementNatureAndPurpose</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementRightsAndObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of rights and obligations under the collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementRightsAndObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rlay_GenentechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rlay_GenentechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rlay_GenentechAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rlay_GenentechAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rlay_LicenseAndTransferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rlay_LicenseAndTransferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rlay_ResearchAndDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rlay_ResearchAndDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rlay_TransferOfActivePharmaceuticalIngredientsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rlay_TransferOfActivePharmaceuticalIngredientsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rlay_StandAloneSellingPricesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rlay_StandAloneSellingPricesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464754158824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 16,780<span></span>
</td>
<td class="nump">$ 15,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(10,530)<span></span>
</td>
<td class="num">(6,981)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">6,250<span></span>
</td>
<td class="nump">8,094<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rlay_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">13,534<span></span>
</td>
<td class="nump">12,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">886<span></span>
</td>
<td class="nump">860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">888<span></span>
</td>
<td class="nump">827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">895<span></span>
</td>
<td class="nump">895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Process [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 577<span></span>
</td>
<td class="nump">$ 490<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rlay_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=rlay_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464757819944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 3,549<span></span>
</td>
<td class="nump">$ 2,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464755971848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_AccruedExternalResearchAndDevelopmentExpenseCurrent', window );">External research and development</a></td>
<td class="nump">$ 5,099<span></span>
</td>
<td class="nump">$ 3,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_AccruedProfessionalServicesCurrent', window );">Professional services</a></td>
<td class="nump">464<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_AccruedOtherExpensesCurrent', window );">Other</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">333<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 5,760<span></span>
</td>
<td class="nump">$ 3,746<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_AccruedExternalResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued external research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_AccruedExternalResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_AccruedOtherExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued other expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_AccruedOtherExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_AccruedProfessionalServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued professional services current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_AccruedProfessionalServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464681313176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 08, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jul. 20, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale price of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Outstanding convertible preferred stock converted into common shares</a></td>
<td class="nump">37,206,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,883,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">212,642,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The holders of the Convertible Preferred Stock had voting rights equivalent to the number of shares of common stock into which their shares of preferred stock would convert. So long as any of the Convertible Preferred Stock was outstanding, a requisite vote of the Convertible Preferred Stockholders, which was defined as a majority of the Convertible Preferred Stockholders, was required to affirm certain corporate actions, which included, but was not limited to, the disposal of assets, the acquisition of assets or a business and the authorization of additional shares of the Company&#8217;s capital. In addition, such actions required a requisite vote of the Series C preferred stockholders and a majority vote of the Series B preferred stockholders, if any of the respective preferred stock was outstanding.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Outstanding convertible preferred stock converted into common shares</a></td>
<td class="nump">61,992,534<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rlay_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_PreferredStockConvertibleConversionPrice', window );">Preferred stock convertible conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Outstanding convertible preferred stock converted into common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,382,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Net proceeds from exchange of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale price of stock</a></td>
<td class="nump">$ 22.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_PreferredStockConvertibleConversionPrice', window );">Preferred stock convertible conversion price</a></td>
<td class="nump">$ 3.027603<span></span>
</td>
<td class="nump">$ 3.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Outstanding convertible preferred stock converted into common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,097,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in public offering, net of discounts and issuance costs of $34,707, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,779,093<span></span>
</td>
<td class="nump">122,850,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Net proceeds from exchange of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 393,587,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares price, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,661,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,630,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Liquidation preference per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Liquidation preference per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Liquidation preference per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Outstanding convertible preferred stock converted into common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,002,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in public offering, net of discounts and issuance costs of $34,707, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,824,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Net proceeds from exchange of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,692,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,824,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Liquidation preference per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Outstanding convertible preferred stock converted into common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,783,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in public offering, net of discounts and issuance costs of $34,707, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,188,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Net proceeds from exchange of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,876,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,188,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Liquidation preference per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock convertible conversion price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21484-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rlay_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rlay_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464682353432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock - Summary of Convertible Preferred Stock (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 08, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337,272,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,642,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,642,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 537,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 519,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common stock issuable upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,206,604<span></span>
</td>
<td class="nump">59,883,877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,824,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,824,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,824,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common stock issuable upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,002,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,188,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,188,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,188,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common stock issuable upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,783,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249,260,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,630,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,630,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 399,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common stock issuable upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,097,955<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464758278888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common Stock, Voting Rights</a></td>
<td class="text">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends declared</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CommonStockRestrictionPeriod', window );">Common Stock Restriction Period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of shares, vested</a></td>
<td class="nump">$ 9,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rlay_EmployeeStockPurchasePlanMember', window );">ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based awards, authorized for issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rlay_EmployeeStockPurchasePlanMember', window );">ESPP [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based awards, authorized for issuance</a></td>
<td class="nump">1,092,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_CommonStockRestrictionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock, restriction period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_CommonStockRestrictionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rlay_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rlay_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464773712968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Summary Of The Restricted Stock Activity (Detail) - Restricted Stock [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares - Beginning | shares</a></td>
<td class="nump">679,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares - Vested | shares</a></td>
<td class="num">(579,825)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Shares - Cancelled | shares</a></td>
<td class="num">(14,844)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares - Ending | shares</a></td>
<td class="nump">84,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased', window );">Weighted- Average Purchase Price - Beginning | $ / shares</a></td>
<td class="nump">$ 0.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAveragePriceOfSharesPurchased', window );">Weighted- Average Purchase Price - Vested | $ / shares</a></td>
<td class="nump">0.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAveragePriceOfSharesPurchased', window );">Weighted- Average Purchase Price - Cancelled | $ / shares</a></td>
<td class="nump">0.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased', window );">Weighted- Average Purchase Price - Ending | $ / shares</a></td>
<td class="nump">$ 0.04<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAveragePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation By Share Based Arrangement Equity Instruments Other Than Options Cancelled In Period Weighted Average Price Of Shares Purchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAveragePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAveragePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation By Share Based Arrangement Equity Instruments Other Than Options Vested In Period Weighted Average Price Of Shares Purchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_ShareBasedCompensationByShareBasedArrangementEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAveragePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464682306824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Summary of Reserved Shares of Common Stock (Detail) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 08, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Outstanding convertible preferred stock converted into common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,206,604<span></span>
</td>
<td class="nump">59,883,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CommonStockCapitalSharesReservedUnderCompensationPlan', window );">Shares reserved under the compensation plan</a></td>
<td class="nump">8,026,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,407,169<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for issuance</a></td>
<td class="nump">8,026,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,291,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Outstanding convertible preferred stock converted into common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,002,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Outstanding convertible preferred stock converted into common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,783,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Outstanding convertible preferred stock converted into common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,097,955<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_CommonStockCapitalSharesReservedUnderCompensationPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved under the compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_CommonStockCapitalSharesReservedUnderCompensationPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464758134632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 01, 2020</div></th>
<th class="th"><div>Jul. 08, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,960<span></span>
</td>
<td class="nump">$ 4,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based compensation arrangement by share-based payment award, vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.14<span></span>
</td>
<td class="nump">$ 3.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to the unvested stock-based awards, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Total unrecognized compensation cost related to the unvested stock-based awards, Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingIncomeLossMember', window );">Operating Income (Loss) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rlay_TwoThousandTwentyPlanMember', window );">2020 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,026,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,376,080<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rlay_TwoThousandSixteenPlanMember', window );">2016 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award</a></td>
<td class="nump">1,960,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Share-based Payment Award, Award Vesting Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The commencement of vesting was based on the achievement of certain scientific and operational milestones during a two-year period, for which the achievement was discretionary and subject to the approval of the Company&#8217;s board of directors.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingIncomeLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingIncomeLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rlay_TwoThousandTwentyPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rlay_TwoThousandTwentyPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rlay_TwoThousandSixteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rlay_TwoThousandSixteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464758143464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Schedule of Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options and Warrants Outstanding, Number of Shares Beginning Balance</a></td>
<td class="nump">5,306,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, Number of Shares</a></td>
<td class="nump">2,898,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, Number of Shares</a></td>
<td class="num">(297,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled, Number of Shares</a></td>
<td class="num">(210,781)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options and Warrants Outstanding, Number of Shares Ending Balance</a></td>
<td class="nump">7,697,058<span></span>
</td>
<td class="nump">5,306,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, Vested</a></td>
<td class="nump">2,148,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Shares, Non-vested</a></td>
<td class="nump">5,548,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Outstanding Beginning Balance</a></td>
<td class="nump">$ 4.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Granted</a></td>
<td class="nump">10.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Exercised</a></td>
<td class="nump">4.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Cancelled</a></td>
<td class="nump">4.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Outstanding Ending Balance</a></td>
<td class="nump">6.99<span></span>
</td>
<td class="nump">$ 4.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Vested</a></td>
<td class="nump">4.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Per Share, Non-vested</a></td>
<td class="nump">$ 7.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Outstanding</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">8 years 11 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Vested</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Life, Non-vested</a></td>
<td class="text">8 years 8 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Value</a></td>
<td class="nump">$ 266,050<span></span>
</td>
<td class="nump">$ 3,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Vested Value</a></td>
<td class="nump">79,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Aggregate Intrinsic Value, Non-vested Value</a></td>
<td class="nump">$ 186,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options non vested weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464756162392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Schedule of Estimated Fair Value of Stock Options (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate minimum</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate maximum</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility rate minimum</a></td>
<td class="nump">73.50%<span></span>
</td>
<td class="nump">72.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility rate maximum</a></td>
<td class="nump">77.60%<span></span>
</td>
<td class="nump">73.47%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464754034072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Schedule of Stock-Based Compensation Expense Included In The Company's Consolidated Statements of Operations And Comprehensive Loss (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 31,960<span></span>
</td>
<td class="nump">$ 4,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">14,691<span></span>
</td>
<td class="nump">2,687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 17,269<span></span>
</td>
<td class="nump">$ 1,769<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464759436200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Net operating loss carryforwards, federal</a></td>
<td class="nump">174,028,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Net operating loss carryforwards, state</a></td>
<td class="nump">192,346,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_IncreaseInDeferredTaxAssetsValuationAllowance', window );">Increase in valuation allowance</a></td>
<td class="nump">14,276,000<span></span>
</td>
<td class="nump">23,307,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Description of income tax examinations</a></td>
<td class="text">There are currently no pending tax examinations.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_TaxCutsAndJobsActOf2017DescriptionOfCorporateTaxPayers', window );">Tax Cuts and Jobs Act of 2017, description of corporate tax payers</a></td>
<td class="text">Corporate taxpayers may carryback NOLs originating during 2018 through 2020 for up to five years, which was not previously allowed under the 2017 Tax Act. The CARES Act also eliminates the 80% of taxable income limitations by allowing corporate entities to fully utilize NOL carryforwards to offset taxable income in 2018, 2019 or 2020. Taxpayers may generally deduct interest up to the sum of 50% of adjusted taxable income plus business interest income (30% limit under the 2017 Tax Act) for tax years beginning January 1, 2019 and 2020. The CARES Act allows taxpayers with alternative minimum tax credits to claim a refund in 2020 for the entire amount of the credits instead of recovering the credits through refunds over a period of years, as originally enacted by the 2017 Tax Act.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CARESActPercentageOfEliminatesOfTaxableIncome', window );">CARES Act, percentage of eliminates of taxable income</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_TaxCutsAndJobsActOf2017MaximumPercentageOfInterestDeductedByTaxPayers', window );">Tax Cuts and Jobs Act of 2017, maximum percentage of interest deducted by tax payers</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CARESActPercentageOfInterestDeductedByTaxPayers', window );">CARES Act, percentage of interest deducted by tax payers</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CARESActPercentageOfCorporateCharitableDeductionLimit', window );">CARES Act, percentage of corporate charitable deduction limit</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CARESActPeriodOfQualifiedImprovementPropertyForCostRecovery', window );">CARES Act, period of qualified improvement property for cost-recovery</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CARESActPercentageOfBonusDepreciation', window );">CARES Act, percentage of bonus depreciation</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_TaxCutsAndJobsActOf2017NetOperatingLossCarrybackPeriod', window );">Net operating loss carryback period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards, subject to expiration</a></td>
<td class="nump">43,127,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating loss carryforwards, not subject to expiration</a></td>
<td class="nump">$ 130,901,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_DeferredTaxAssetsOperatingLossCarryforwardsBeginningToExpireYear', window );">Net operating loss carryforwards, beginning to expiring year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">$ 8,139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear', window );">Research and development tax credit carryforwards, expiration year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_DeferredTaxAssetsOperatingLossCarryforwardsBeginningToExpireYear', window );">Net operating loss carryforwards, beginning to expiring year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">$ 2,699,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear', window );">Research and development tax credit carryforwards, expiration year</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_CARESActPercentageOfBonusDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act, percentage of bonus depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_CARESActPercentageOfBonusDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_CARESActPercentageOfCorporateCharitableDeductionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act, percentage of corporate charitable deduction limit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_CARESActPercentageOfCorporateCharitableDeductionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_CARESActPercentageOfEliminatesOfTaxableIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act, percentage of eliminates of taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_CARESActPercentageOfEliminatesOfTaxableIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_CARESActPercentageOfInterestDeductedByTaxPayers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act, percentage of interest deducted by tax payers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_CARESActPercentageOfInterestDeductedByTaxPayers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_CARESActPeriodOfQualifiedImprovementPropertyForCostRecovery">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act, Period of qualified improvement property for cost-recovery.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_CARESActPeriodOfQualifiedImprovementPropertyForCostRecovery</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_DeferredTaxAssetsOperatingLossCarryforwardsBeginningToExpireYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating loss carryforwards beginning to expire year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_DeferredTaxAssetsOperatingLossCarryforwardsBeginningToExpireYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax credit carryforwards research expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_IncreaseInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in deferred tax assets valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_IncreaseInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_TaxCutsAndJobsActOf2017DescriptionOfCorporateTaxPayers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts and Jobs Act of 2017, description of corporate tax payers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_TaxCutsAndJobsActOf2017DescriptionOfCorporateTaxPayers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_TaxCutsAndJobsActOf2017MaximumPercentageOfInterestDeductedByTaxPayers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts and Jobs Act of 2017, maximum percentage of interest deducted by tax payers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_TaxCutsAndJobsActOf2017MaximumPercentageOfInterestDeductedByTaxPayers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_TaxCutsAndJobsActOf2017NetOperatingLossCarrybackPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts and Jobs Act of 2017, net operating loss carryback period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_TaxCutsAndJobsActOf2017NetOperatingLossCarrybackPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464755912152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Reconciliation of Expected Income Tax (Benefit) Computed Using Federal Statutory Income Tax Rate to Effective Income Tax Rate (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax computed at federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">5.70%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(27.30%)<span></span>
</td>
<td class="num">(31.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">R&amp;D credit carryovers</a></td>
<td class="nump">7.60%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Stock-based compensation</a></td>
<td class="num">(6.70%)<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation permanent differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120384911&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464681981432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Deferred Tax Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 48,832<span></span>
</td>
<td class="nump">$ 42,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">10,270<span></span>
</td>
<td class="nump">6,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">6,430<span></span>
</td>
<td class="nump">6,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">1,469<span></span>
</td>
<td class="nump">1,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">4,496<span></span>
</td>
<td class="nump">534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_DeferredTaxAssetsDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax asset</a></td>
<td class="nump">71,741<span></span>
</td>
<td class="nump">57,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(65,813)<span></span>
</td>
<td class="num">(51,537)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="nump">5,928<span></span>
</td>
<td class="nump">6,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_DeferredTaxLiabilitiesOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="num">(5,928)<span></span>
</td>
<td class="num">(6,194)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liability</a></td>
<td class="num">$ (5,928)<span></span>
</td>
<td class="num">$ (6,194)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_DeferredTaxAssetsDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_DeferredTaxAssetsDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_DeferredTaxLiabilitiesOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities operating lease assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_DeferredTaxLiabilitiesOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464682524632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (52,412)<span></span>
</td>
<td class="num">$ (75,305)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Deemed dividend resulting from extinguishment upon modification of Series C preferred stock</a></td>
<td class="nump">177,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (230,201)<span></span>
</td>
<td class="num">$ (75,305)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss attributable to common stockholders per share, basic and diluted</a></td>
<td class="num">$ (5.40)<span></span>
</td>
<td class="num">$ (21.82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares of common stock, basic and diluted</a></td>
<td class="nump">42,619,582<span></span>
</td>
<td class="nump">3,450,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464756396936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Additional Information (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 08, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_PreferredStockConvertibleConversionPrice', window );">Preferred stock convertible conversion price</a></td>
<td class="nump">$ 3.027603<span></span>
</td>
<td class="nump">$ 3.21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock convertible conversion price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464682382904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Antidilutive Securities Excluded From Computation of Earnings Per Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive effect</a></td>
<td class="nump">7,781,547<span></span>
</td>
<td class="nump">65,869,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rlay_ConvertiblePreferredStocksMember', window );">Convertible preferred stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,883,877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive effect</a></td>
<td class="nump">7,697,058<span></span>
</td>
<td class="nump">5,306,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive effect</a></td>
<td class="nump">84,489<span></span>
</td>
<td class="nump">679,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rlay_ConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rlay_ConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464680918536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 15, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Target </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 08, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Outstanding convertible preferred stock converted into common shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,883,877<span></span>
</td>
<td class="nump">37,206,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,862,000<span></span>
</td>
<td class="nump">$ 70,306,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,760,000<span></span>
</td>
<td class="nump">3,746,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rlay_DEShawResearchMember', window );">DE Shaw Research [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,376,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">372,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rlay_DEShawResearchMember', window );">DE Shaw Research [Member] | License Agreement Terms [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Outstanding convertible preferred stock converted into common shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,281,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_ResearchAndDevelopmentArrangementAnnualFee', window );">Research and development arrangement, annual fee</a></td>
<td class="nump">$ 7,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_ResearchAndDevelopmentArrangementTermOfContract', window );">Research and development arrangement, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_ResearchAndDevelopmentArrangementExpirationDate', window );">Research and development arrangement, expiration date</a></td>
<td class="text">Aug. 16,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement', window );">Milestone payment Due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement', window );">Maximum additional amount received upon milestone achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rlay_DEShawResearchMember', window );">DE Shaw Research [Member] | Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement', window );">Milestone payment Due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rlay_OtherthirdPartiesMember', window );">Other Third Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,704,000<span></span>
</td>
<td class="nump">3,493,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rlay_OtherthirdPartiesMember', window );">Other Third Parties [Member] | License Agreement Terms [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement', window );">Milestone payment Due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_NumberOfMilestoneTargets', window );">Number of milestone targets | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | DE Shaw Research [Member] | License Agreement Terms [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_ResearchAndDevelopmentArrangementContractToPerformForOthersRenewalPeriod', window );">Agreement renewal period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_PotentialDevelopmentMilestonePayments', window );">Potential development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Other Third Parties [Member] | License Agreement Terms [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_PotentialDevelopmentMilestonePayments', window );">Potential development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Other Third Parties [Member] | License Agreement Terms [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_PotentialDevelopmentMilestonePayments', window );">Potential development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Outstanding convertible preferred stock converted into common shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,002,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | DE Shaw Research [Member] | License Agreement Terms [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares', window );">Shares held | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,999,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Outstanding convertible preferred stock converted into common shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,097,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member] | DE Shaw Research [Member] | License Agreement Terms [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares', window );">Shares held | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,557,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum additional amount received upon milestone achievement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_MaximumAdditionalAmountReceivedUponMilestoneAchievement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment due upon specified regulatory milestone achievement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_MilestonePaymentDueUponSpecifiedRegulatoryMilestoneAchievement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_NumberOfMilestoneTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of milestone targets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_NumberOfMilestoneTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_PotentialDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential development milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_PotentialDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_ResearchAndDevelopmentArrangementAnnualFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development arrangement, annual fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_ResearchAndDevelopmentArrangementAnnualFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_ResearchAndDevelopmentArrangementContractToPerformForOthersRenewalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development arrangement contract to perform for others renewal period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_ResearchAndDevelopmentArrangementContractToPerformForOthersRenewalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_ResearchAndDevelopmentArrangementExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development arrangement, expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_ResearchAndDevelopmentArrangementExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_ResearchAndDevelopmentArrangementTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development arrangement, term of contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_ResearchAndDevelopmentArrangementTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of affiliates held for management investment companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611322-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rlay_DEShawResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rlay_DEShawResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rlay_LeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rlay_LeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rlay_OtherthirdPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rlay_OtherthirdPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464680883512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Nov. 30, 2015</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate', window );">Operating lease option to terminate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Letter of credit expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,878<span></span>
</td>
<td class="nump">$ 2,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.40%<span></span>
</td>
<td class="nump">10.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=rlay_FirstStreetInCambridgeMassachusettsMember', window );">215 First Street [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_LeaseExpirationMonthAndYear', window );">Operating lease agreement expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2020-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=rlay_BinneyStreetCambridgeMassachusettsMember', window );">399 Binney Street [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rlay_LeaseExpirationMonthAndYear', window );">Operating lease agreement expiration date</a></td>
<td class="text">2029-04<span></span>
</td>
<td class="text">2029-04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Land subject to ground leases | ft&#178;</a></td>
<td class="nump">1,824<span></span>
</td>
<td class="nump">44,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,807<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rlay_LeaseExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rlay_LeaseExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rlay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to terminate operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=rlay_FirstStreetInCambridgeMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=rlay_FirstStreetInCambridgeMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=rlay_BinneyStreetCambridgeMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=rlay_BinneyStreetCambridgeMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464764802456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Operating Leases Presentation in Consolidated Balance Sheets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 22,579<span></span>
</td>
<td class="nump">$ 23,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">rlay:OperatingLeaseAssetsMember<span></span>
</td>
<td class="text">rlay:OperatingLeaseAssetsMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">$ 1,521<span></span>
</td>
<td class="nump">$ 1,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">rlay:OperatingLeaseLiabilitiesMember<span></span>
</td>
<td class="text">rlay:OperatingLeaseLiabilitiesMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">$ 22,901<span></span>
</td>
<td class="nump">$ 23,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">rlay:OperatingLeaseLiabilitiesNetOfCurrentPortionMember<span></span>
</td>
<td class="text">rlay:OperatingLeaseLiabilitiesNetOfCurrentPortionMember<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 24,422<span></span>
</td>
<td class="nump">$ 24,832<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464754068344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Operating Lease Presentation in Consolidated Statements of Operations and Comprehensive Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 4,021<span></span>
</td>
<td class="nump">$ 3,797<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">3,273<span></span>
</td>
<td class="nump">3,216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 748<span></span>
</td>
<td class="nump">$ 581<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464682331880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Future Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 3,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">4,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">4,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">4,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">4,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">15,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">37,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="num">(12,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 24,422<span></span>
</td>
<td class="nump">$ 24,832<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464765226552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer matching contribution</a></td>
<td class="nump">$ 590<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140464764764344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Detail) - Third Rock Venture [Member] - Consulting And Management Services [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related Party Expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due To Related Parties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rlay_ThirdRockVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rlay_ThirdRockVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rlay_ConsultingAndManagementServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rlay_ConsultingAndManagementServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>113
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MJ^?)2&=_R2$_M]_O$"_51L9%,!#$89+_YV]%(DX"ALZ9 %H$T&\"W'-78$4
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M_EI^@QIG7UYZU>GY!ZQ';M]'-(G$%D*=RP'8D,J_">4[1NZSKR0;:8R,L\U
M<!@+>P(<WTIICCOV N67N;O_ 5!+ P04    " #;@WE2^U:L[#$&   U&
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M0M/=47<O6N[;:]X[J;6LVL<=9Q"&$8#O-Q(:F..+N3GN_U.P^@=02P,$%
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M4*+YPM \*+XSA_1'KN#49&YS1D%GM '\O^%<O3[H";KO/*O_ %!+ P04
M" #;@WE2&EY% #L&  #Q&P  &    'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;+U976_;-A3]*X118"T0UR3U73@&&CMQ^] M:)KN8=B#(M$V44GT1#K)]NM'
MRHIED12=I>WR$$OVN9?G7I+W'DK3!U9_XQM"!'@LBXJ?CS9";-]-)CS;D#+E
M;]F65/*7%:O+5,C;>CWAVYJD>6-4%A,,83@I4UJ-9M/FN^MZ-F4[4="*7->
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M3VI![PH"KN4"(77=8%CV#:15>[5A14YJ_@M8D!7-J !C<'NS *]?O0&O *W
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MQLZ/%Y@I8?PO;+O8*("L,595'9@45%RV7_;<Y6$/,+@Z H@[0/P:,#H"&':
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M$YR\+JY C5P\3(8V&8<V2Z;#UBL(#DL(')&, E5J<]&[]%@+YEF:Q!,K]VJ
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MZ+:.A0G0YSGGZG-A.D?WH4C^ E!+ P04    " #;@WE2]C789(H+  #1'
M&    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;+59;7/CMA'^*Q@GDVEG:%N2
M[7O)O<R<[Y+TVESBN4O;Z73Z 2)7$F(24/ BG?+K^^P")"59ODD_](LMDL!B
ML?OLLP_(EUOG[\.***K/76O#J[-5C.MO+R]#O:).APNW)HLG"^<['7'IEY=A
M[4DW,JEK+V>3R9/+3AM[]OJEW+OSKU^Z%%MCZ<ZKD+I.^]TMM6[[ZFQZUM_X
M:):KR#<N7[]<ZR5]HOCW]9W'U>5@I3$=V6"<59X6K\[>3+^]O>;Q,N ?AK9A
M[[?BG<R=N^>+]\VKLPD[1"W5D2UH_-O06VI;-@0W?BLVSX8E>>+^[][Z][)W
M[&6N [UU[3]-$U>OSIZ=J886.K7QH]O^A<I^;MA>[=H@?]4VC[V^.5-U"M%U
M93(\Z(S-__7G$H>]"<\FCTR8E0DS\3LO)%Z^TU&_?NG=5GD>#6O\0[8JL^&<
ML9R43]'CJ<&\^/HG'9,GY1;J-@4\"T%IVZA;'4S@NW>> MFH.80O+R-6Y'F7
M=;%^FZW/'K$^G:D/SL954-_9AII# Y=P=?!WUOM[._NBQ7=47ZBK::5FD]GD
M"_:NAOU?B;VK1^S]0I^CNFU=?:_^_68>H@=,_O,%N]>#W6NQ>_U_BNN7K4\O
MU/^R@/I(K=ZI7U;D]9I2-'6HU'N+2/XIKDA]\]6SV6SRXJWKUMKNY&KZXL]J
MJX,RMG9^[;R.U.!"O8.AK>9UK?H D]><B.F-+(UU5Z"%WY+VD7P>_U9W<V^:
M)548'H*N5RE0!(VP,ZJLR#.UJK%)4^OV/$3-X\$QM9':[Z@Q-6]1U64"TF0#
M,Y*Q2\5;:'Q:JL:$VFW([S#7U1R1K8DK^ 9/3#2Z50N'DF+?R:ZTK7EVZ'3;
MJLZ!)E)+;*R/T9X]["1JOR2.@D-(6K?</=C"/)DVJK2&^637VL,NR(?#$)@:
M.)C1L6N18*]SF940N!6@%5>PT.RL[K#PG%9Z8YP'Z[6(?%![\Q;)"I\=+,\Y
MFSY]$=0[MH#!F,;AX25IZ<4&PJ"]1\X CA9YXLT3,J/H\YH\$VU$A-@?CG+*
MR.$[:RR-Q!$PLUV9&@%M0>5!XMYO'PYB7+N3FPFU[I%%*VM@N=YWE%>J!;:\
M3(D IAYF[R$VFDU)ED$4UV9-7 ]L>$0&.] TGI.>,\7AWL-0G[6*(=VFIK?&
MD6#_&CBF:G:YX6A5ZN./_SJ_GDR>B:M\,7W^%+2#FMBBA?!_GG[W_NIOWWSU
M_/KFA>H0,AM5:3@;8JL(?5>I>^NVEF=P<-@4SYI.KI_V0XYV+&!EJ&EUMT+'
M4=.A.(#\C&,_^"3[1+*0OQ[P$B_,#ZXUC8JI<U["P>LO#%*C2I%R#)E(99,Z
M/SLW]GR5.L#E:%&,'8)"U@,)6((]^2.K,Z 9#$C#DF!5??_#]Q]G@!*\$*0-
M#J(2?'/LX 7H"N134S?'3;Y3'> /RQ?* 1#R@[;5<Y=MR_9^-#6T!*DW2T_$
M:#\@OQ_(L@V@>W@^$B%O:QC0,^?QQ'XX, )<BI]P7E+N$"KU@W=I74G A+%H
M T6T%D=*T77D:P3:_)Z=+O$><+=(GME)"B6%D GV)U26NGE0,B'-?P4,N2R\
M"??"G%TNMLRAAH: SXUC_ZW4!VXV4!W">:5.*C!;5-9%U9K.,"ZCJY2%X!JF
M"4J,M6Z3<UGEDJ_[?>!J[0VA,G?C)-1B0Q"7#0$N3,KW!.8&<SAKJ:W$T=8P
MEG(&ELP.5@+F:9G: AL.'F_#DGBFW#Q"BS(;F,)@"V,S?UR@*QY7.D26][ )
M[A+>.DC,UJ#4/?V6##@++&[- EOEC(W6N<]JS[0(1_8GTP*YCF&?<2 V6,\*
M.=#Y4%^2_Z'8*$0>RS?+/AW")C2\T2V'EEM#SN0A9 0&@'A9^;3GG4M<J\C*
MWB9JO3:1C>L&<Q"7,1%P?^'U(76/^QB3=.X)0D%<AS4]-RV,4SC=IQXRKF)5
M@;SM15"FXBX&H24"@:B"D+P@(JYTW&> P?*CZ9!<PDQ(-6N#16J1<G&?VWJ5
M+8[;'_';5^SQ2MQ;6R;[A  RPLG'W;!,AN%HV.[Z38?>+>!51A?$6F*_N$0>
M(GT? 4K\*3;S36I&X[T#(SJPSXW1\Y8NU'<;@AI:G-Q/GY,3&);DC($#I".S
M#*0(]LR^;U=D*S:,N?Z0FL4?<#[S_"$4/0;;A);D73>L'G1[!!K%D16(<%FS
M=ML8[W)X@&+(-;29&GIN*0#:XS*& )B0I8C(/\XV19.S*HNN-$YVM<B]4H>'
M;#B0I32@OF .-\C"K?!8D7_\-)#?H.-(H;%2( #-[8A"87L;<&Z$7T=[1;_G
M!#BFV3W7D4*6J<46,.Z2K[/L*>D:Y-$)+3,2T" :>E7#W;P:./24.%'SW?$:
M/=-O(-/_L'IDAC\4OY5(YF:T>JJ>F%,64!*.1Y>##N2MM=*9O(:\RXQC>@>X
M((Q8S:C+=W6#PX+A YZ(LY#6;+DO;I!F1AFWE(<900"Y2S2HT=@/A/W6H0VC
MV1IF)/ZS'C4]9"4K[KI.'1<P,1D!]T8P^_7UY+J:S9YQ6\?E(&SZ@^VA!QQB
MKFPI>L'29Q,*T0;H$?ZKF.I!#J+#Y#1F-V@D7;X^O0I@##$FFD(:K&CW-0H#
M.%[K75]@7S^]J2:3"5!7D]EDV?%7;1,S%<Q,<RF- BJW439V0E2=4B]5Y@BR
MS%%,+4 UCCE-QC/GFH]=0]0Y'#;TA502+S=1G=RA2MO+>^<$(VS0^9"]#L>&
M'=I#=EED&)-2T6D&W46:2[X.)&7**E;R5V0$%D-5QFP^)VJ19%TF6>YZN][@
M288 0'A?_5#L=2!'2:2X-NY67EM))U6YZS/DZ43OEJB)BR0+/(+G@>X7VK3L
M]6!RJ*$<6:9T$57$-9U:QC0*!^(6KLJ! $H?(D'D!FO-LK$Q3(A>=C(7X+CA
M=?(A92^'FI;*I.6Q8L!J.]&>Z&@"CU'A#;).R=L]KKX\@GP'TLMY!VN.]/8%
MFW* R,>'MAP48* ^/$7@^(PFDW&%I\6/O6X-OAQ (6Z(S,**HZ^\=@D<DWH.
M'3NW<D*%.<VX]OFE@3O=K$-T]3U/@2'TI@=X2_8X6LEF,;\_,.<584"5U%D^
M-_RJ",1*Z"(2 V+5;QF>I?6<EE>E6V3I+QUH8&XN3IU?XTI,CP\Z@U#.KQ>R
M4P]B=( 6K!&$%*4O\Y982QPHPIX&PL%18"\*7U*6YI1>9,;*T9071VG!?,ZK
M%JN,PYSU?32Z Z?VJ0WU@1)/,G,H5E%1&;B\M_S>ZB[-@4KU,R+A>?C/8.#4
M,OU6)P[#-?H2-:6G9@/K;,#U!OK3Z_N[GX=C;GZ'A\)LU.R*&5]8/T BC2JF
M'",%?>(EGT8R8WZ-MH7QV$B>(\S+_5)>QE$3<N.;W52SYU>HR464PQ9#A3V2
MKK'U1B[D75#J6QDO"L?DM,<VKF;5;#(I!Y'2"\2!ZF;R5 !1\\DEJ_>ALV&K
ME8BH<4>?$ S\>E/UOV[%:+EXRV8 PF@XCSBP(7:L ?+FR[/^G<.3:?7\.1RX
MNMZSOQ^M"_61,EU^DOF?<&R*0R*?G<CCR5H?!;]&\&I/_'ZH'.1MZM\ZZ!17
MSIO?V=N3WN0N,WLR&?*,/4QOALM##M9M<(7E96&TT7-D]_SJXN9F\GPF0IYW
MEDT'V5D!3 $4A]6E.+P4?,2K_!J*M1^?)+. ;'Y-6<?TI32J'TE!_CS$Q9.;
M/4%MLOHV]"AY'N7R0KVI:^?9L7:WAY&L)@<\]R=G4108P[K7-6*-W[1G1</+
MH?KS@NSD*=4@AM& *&0>PL:DM\Z);-DP\>$_LG1FN<IN;86Q^"TKSBI 9"6=
MFQ9M;B FG$Q#EKY#"$M 3H-Y+Y(7ISZ!7.Y]9@*%+^5C&G,"PI*_. UWA^]U
M;_)GJG%X_MCW0?NEL?SZ=8&IDXNG-V>YX?47T:WEH]7<Q>@Z^<D?%\CS #Q?
M.(2O7/ "PU?,U_\%4$L#!!0    ( -N#>5(_ IH&I!X  (%=   9    >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;*U<;7/;1I+^?K\"Y7LIJXJD)=EQG#A)
ME2P[&^\YL2]:9^OJZCZ P)"<-8AA,(!DYM=?/]T]+R!!6;M[7VR1',ST]/3+
MTR^#[^Y<]\EOC.F+S]NF]=\_VO3][MLG3WRU,=O2+]S.M/3+RG7;LJ>/W?J)
MWW6FK/FA;?/D\OS\^9-M:=M'/WS'WWWH?OC.#7UC6_.A*_RPW9;=_I5IW-WW
MCRX>A2]^M>M-CR^>_/#=KER;&]-_W'WHZ-.3.$MMMZ;UUK5%9U;?/[JZ^/;5
M,XSG ;]9<^>SOPOL9.G<)WQX6W__Z!P$F<94/68HZ;];<VV:!A,1&;_KG(_B
MDG@P_SO,_B/OG?:R++VY=LU?;=UOOG_TXE%1FU4Y-/VO[NXGH_OY"O-5KO'\
M;W$G8Y\^?514@^_=5A\F"K:VE?_+S\J'[($7YR<>N-0'+IEN68BI?%WVY0_?
M=>ZNZ#":9L,?O%5^FHBS+0[EIN_H5TO/]3_<V'5K5[8JV[XHKJK*#6UOVW7Q
MP36VLL9_]Z2G53#V2:4SOI(9+T_,>'%9_.S:?N.+-VUMZO$$3XB\2.-EH/'5
MY;TSOC;5HGAZ,2LNSR_/[YGO:=SS4Y[OZ8GY)K99_,_5TO<=R<C_WK/ L[C
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M#\K(-4_TT8I-]+JFRY)7DM#C[^<2)Y1WG,M>4]09$B@4C;B],9R%1Q.Y4[P
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M"GU[XD*1QFCL)\/I+?*S4%T6 ;[ J&F0$#U.4,&H(1:-Y#[AXG1;;*Y3>*.
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M1?':-D,0EP<M[(>8W?S_H2&E16._50VBI$D^O?%@Y XT.\Y6B8PWHZ/0<(/
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M:Q'&DXS<8SU=/DP>D+9*I7$4Z!76(YMX\ZLT+++<5?[<-X4G)%KC6J%]2P[
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M0-,"O-\H6#C<T 'MET)7_P%02P,$%     @ VX-Y4ME&-?K+!0   PX  !D
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MK>!P'\,-L%XH9?L?>,#PN?GZ_U!+ P04    " #;@WE2",0F3T(+  "*'0
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M.6%U0Q9;@[U>&5T)NN9VHVR!/>U$LX:WE<[52F6=ZQ=D%((Z$Q"8%1D#..R
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M&PW2A/U'(TYGTW@T\#NM7?6!R%8D78.-LT%XW&]1Y R*F4N"8U9=UKZ6P4M
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MJG276X%6U;0!S]<*X[V](0.'KUFW_P-02P,$%     @ VX-Y4D8OWNSY @
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MO"(H=X(R^>X3)9>7S+/%S)HMV!A-M#A(I28UF1,Z?I1[;VE7D,XO[L/:X6-
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MC:>.3\.6KEBT,8#V:V/\?A(3#)?VXB=02P,$%     @ VX-Y4LRY>#I3(
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M&C7Q433Z9<<=9V;)/LP>P \9F=J)",0,X^2+X88)7W-P%"JWW!<VB=0PQHH
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M+S/G[QU^"-C:HSUSF:RU?G+&EV(6QBX@D)"C8^"T/,,-2.F(*(P_>\ZPEW3
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M>8^?08"-71'G"-JC @]-K-3.K2T,20<96F;._FK)Q,(F19]8M6Z*RVPJ3.1
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MRJ?8;K-DP4,TH>8+>3Q-O%G,Y[,%C\+P)3'Z>W.J KUUT]@@$2Q0-[*&I\/
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M?2?67Z%:4&3LQ2)3]I>L*UVW1^)2:9%78&20,[[YI\]5(!H 7&@[P*\ _EM
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MLR&K$^!HU:L65;_?JGI]E.IN.!KGO]?=$TP<4I%AD:O?R.5CR?3+9W(')FM
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M&X:$,*VA/75&SQS_-#1&SY*](RIHV'3'T$MV*C&]E-L5(<_8O1D^%T!P6[8
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M@0<6A50\JY-U"S*65]_D=PVBE0##$PFH3D!]$W"=4)+SJY:5W;HEBDS'@N^
M,-%:S5R4;,ILW1N6FS(^*:&?,IVGIG>$"?"=I 4%? 7N6$[R!2,I^"0E51+\
M!9ZJ^G8^O:=$%H(N 5&@+:2K Q[IHA""Y6MP0R23@.1+\#?=TM0HJ82V$SXS
M*HA8)'OP_I8JPM(/^L7E\ZT5%(W@O!3\<4^S.14_=>BWIUOP_MT'\ ZP''Q-
M>"'UV^385QJ0Z::_J&'<5##0"1BW='$%,/P(4(""CO19[W0X^G^ZK\O2U 8U
MM4&E'CZA]R7?4JGTF%'RVB&'&SE<RH4GY+YR1=(N*%5:5*:98;^=QH-!%,.Q
MOVUW_C@,1U%D0&T[6A4VK0J=K6IULBFIH[-1(QM=@EW<R,5_9J?_78UH%\=*
M(FX!0C@(873 \3@,0SR,43?'0=/"P:LY@G_UT !*E,-T#^8L37M!'C;O'%X"
M\JB1&[T=\NB8'@Y0?,#X. IA% =A-V,86+<,SJ2LY[Q\L0?2N!13C/8"#5LV
M#2^!&EIO@>CML&N--D<X&N#AZ !W1]P0HFAX K=U+.BVK&K"@+U06L.!X450
M6JN!T7G&6N>UL83A (:'_]:N.!B?Q&=-"[I=J\*'>N&S/@,'%\%G300.S\0W
M[&>H'7$N1X76CZ#;D [YZ9'^RND*66=!P26P(NL8"+Y]@-<:?T3<$>="C%I+
M'+<-]41\[DR&K-4@?!'^UF:0>V'3CW_8:SKK"'/-9\A:%W);UZOPGS7%(>M6
M*+Y(!:Q3(?>2J%\%!OVFN(XXQQ2'K/LAM_O-B$P _54PO=4Y9'[/<[K7NSWQ
MK/?SJT+O:7H1M_Z&1D[BA^]V[C*LDV'W&JG:''X$JV8#U[GI"/K-C5UQI^=&
M;.T1N^W1Q?UPV7%V*;#U0>S>Z[VJ%*T=GWO]U+,4QSN[[E)TQ'64PF^=1IBC
MH'LBUBR7(*4KG1=<#;2 J$Y7JAO%-^4!Q9PKQ;/R,J%D284)T,]7G*N7&W/F
MT9QQ3?\#4$L#!!0    ( -N#>5*"I-*T2P0  !(5   9    >&PO=V]R:W-H
M965T<R]S:&5E=#0P+GAM;+V8;V^;.!S'WXJ%]F"3K@7;@<"41.I2[5;IJJN6
M=O?@= ^<X#1H@'.VDRRG>_%G \4T&):)6YXDD/CW_\M'QI,#XU_%AE()OF5I
M+J;.1LKM>]<5JPW-B+AF6YJK?]:,9T2J6_[LBBVG)"Z,LM1%GA>X&4ER9S8I
M?GO@LPG;R33)Z0,'8I=EA!\_T)0=I@YT7G[XG#QOI/[!G4VVY)DNJ'S:/G!U
MY]9>XB2CN4A8#CA=3YT;^'Z.1]J@6/$EH0?1N :ZE"5C7_7-73QU/)T13>E*
M:A=$?>WIG*:I]J3R^+MRZM0QM6'S^L7[QZ)X5<R2"#IGZ1])+#=3)W1 3-=D
ME\K/[/")5@7YVM^*I:+X!(=JK>> U4Y(EE7&*H,LR<MO\JUJ1,, CCH,4&6
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M!W#EC63;X@QKR:1D67&YH22F7"]0_Z\9DR\W^EBL/@:=_0=02P,$%     @
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MZ)IG:B71KUE,X^<3],&IVC.\]NP".V>\I-$)"OPCA#WLW<TNT:N?7SNF#>J
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M:0+P_DH(_30Q[73S^33["U!+ P04    " #;@WE2;N4L=TP"   S!0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6R-5-]/VS 0_E>LB >0&$F3E#'4
M1NH/IO' 5,'8'J8]N,FUL7#L8%]H^>\Y.VG6,<KVDOCL^[[[[GSGT4:;!UL"
M(-M64MEQ4"+6EV%H\Q(J;L]T#8I.5MI4',DTZ]#6!GCA094,XR@Z#RLN5)"-
M_-["9"/=H!0*%H;9IJJX>9Z"U)MQ, AV&[=B7:+;"+-1S==P!WA?+PQ98<]2
MB J4%5HQ ZMQ,!E<SE+G[QV^"]C8O35SF2RU?G#&=3$.(B<().3H&#C]GF &
M4CHBDO'8<09]2 ?<7^_8/_O<*9<EMS#3\H<HL!P'%P$K8,4;B;=Z\P6Z?(:.
M+]?2^B_;=+Y1P/+&HJXZ,"FHA&K_?-O580\P.#\ B#M _!J0'@ D'2#QB;;*
M?%ISCCP;&;UAQGD3FUOXVG@T92.4N\4[-'0J"(?9PE!#&'QF7!7LZK$1-5T1
MGK*OU$ ?V*0HA*LVE^Q:M2WC:G\\!^1"GI#'_=V<'1^=L",F%/M6ZL82D1V%
M2-I<A##O=$Q;'?$!'8.8W6B%I657JH#B3X*0DNHSBW>93>-W&>>0G[%D<,KB
M*([>$#3[;_C@TSMRDK[0B>=+_E7HA>0*V62_W.SG9&G14$O_>B=2VD=*?:3T
MH'*:YURT5P5;FG<+;UU(RS+T+&[8G[)DF%*J3_M%^MLIODB'O5,K,-SKOPK,
MVH^E9;EN%+87UN_VDS_Q#?]J?THO0CO OVG:Y^2&F[50EDE8$65T]I$DF79$
M6P-U[;M\J9%FQB]+>M7 . <Z7VF-.\,%Z-_)[ 502P,$%     @ VX-Y4I>A
M*<V= @  O 8  !D   !X;"]W;W)K<VAE971S+W-H965T-#0N>&ULE55=;YLP
M%/TK%MI#*VV%0$+6*D%*DTZ;M&E1TVX/TQX<N 2K!C/;).F_W[6AC"8DZE[
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MRPH2<K?'<Z% $5HDY+O.0))Y)244FGQE=,TXTPQW/Y 5GJ.DXD!$2OX3?+$
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MLR,3*KY/&+C3)6="L U8*;Y^ +^"U7DV +X%?0W?+IFB<?).1WQ=+<';-^_
M&Q!GX*\]SR7--G+J*.VUR.BLC:_;LR_<X6O)UC> H%\ AABVA"_ZP__(DQL
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MXFEYN6=TPT310+_?<JX>;XJSF^IP;_X_4$L#!!0    ( -N#>5([QX9Q;@,
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M1+\?*/0$^K[D7!TZVD'Y0S/Z#U!+ P04    " #;@WE2$]].]C@#  #1"P
M&0   'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6S-5EMOVC 4_BM6GC9I:YP+
MN52 5$#3-JT:*KL\5'LPR0&L)C:S#;3_?K83 I2 4*6I?8'8/M\YWSF??>SN
MAHL'N0!0Z+$LF.PY"Z66UZXKLP641%[Q)3"],N.B)$H/Q=R52P$DMZ"R<'V,
M([<DE#G]KIT;BWZ7KU1!&8P%DJNR).)I  7?]!S/V4[<T?E"F0FWWUV2.4Q
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MT*D F<8Q$=MK&O'-5<-N[#:^L&6H]$9[-%R1)9U1];2:"ERU"RD!BVDB&4]
MT,558VQ?WMD##3 GGAG=R-(S:%/FG+_HQ7UPU; T(QI17VD1!/^MZ81&D9:$
M/+[G0AN%3@TL/^^DWQGCT9@YD73"HZ\L4.%5H]^ @"Y(&JDO?/,SS0WJ:GD^
MCZ3Y"YO\K-4 /Y6*QSD8&<0LR?Z3U]P1)0#*J08X.< Y !S5T,D!G4,-[A&
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MZ<X^;O0 CH4QT-]7G*O7A1GQNI%^]@]02P,$%     @ VX-Y4CL>!/@U P
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MX=BI;<CUW]=V0II*@/J2^&-F=F>]=E)+M=<%HH'7D@L]#0ICJCM"=%9@2?5
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M+1S<W@2@FFO63(RL?*=NI+%][X>%?9E0.8#=WTII3A/7_-U;E_X!4$L#!!0
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M,+5!?I]2*C8O2D ]^O:^ E!+ P04    " #;@WE2;5^--AH#  "4"@  &0
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M^&0E9$DU3N7:5QL)=&E%)?>C(.CY)665-QK8>U,Y&HA:<U;!5!)5ER65KS?
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M^/K9,&W@@<6!2'^6:[S:>(>\W =835_J$&RG>"=B.\5S#8@_;^"1)/YJ8W'
M ZL"UCL0WQ\'>LKO$T5054P;]@3C2))@"/2BOT?C&,E.#!]_?;"G)(J2Q(\
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
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M>#ZW7"]_67[MG-SC%YS3;45]_@M02P,$%     @ VX-Y4J5_#G'N 0  D"8
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MJ_E/6>^=6_]Q_/@L.]OT;_EL_"/:X@502P$"% ,4    " #;@WE2!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( -N#>5*0"B'Q[P   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( -N#>5*97)PC$ 8  )PG   3
M          "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
MVX-Y4J'9KTKM!@  I1L  !@              ("!#@@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( -N#>5+[5JSL,08  #48   8
M          " @3$/  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    " #;@WE2BB#RB:,#  #8#@  &               @(&8%0  >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ VX-Y4I\_I!@4!0  \Q$
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M965T."YX;6Q02P$"% ,4    " #;@WE2]C789(H+  #1'   &
M    @('2,0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
MVX-Y4C\"F@:D'@  @5T  !D              ("!DCT  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    " #;@WE21/O(GQ4$   %"@  &0
M            @(%M7   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( -N#>5*6B&F3*P,  *P'   9              " @;E@  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ VX-Y4IT<XA1I"P
M+B(  !D              ("!&V0  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    " #;@WE2'DIU!0X#  ")!@  &0              @(&[
M;P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( -N#>5(]
MII48?0(  +0%   9              " @0!S  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ VX-Y4FTVRN L"P  -20  !D
M     ("!M'4  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -N#>5+>"FW$/ 8  -@0   9              "
M@?NA  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ VX-Y
M4B*NQ7L-!P  V1(  !D              ("!;J@  'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    " #;@WE21B_>[/D"  "7!@  &0
M        @(&RKP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( -N#>5)J_#)RG0(  ,$%   9              " @>*R  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ VX-Y4AIOW:^/ @  P 4
M !D              ("!MK4  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    " #;@WE2S+EX.E,@  "*:@  &0              @(%\N
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( -N#>5(AZ',C
M8@,  '@(   9              " @0;9  !X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ VX-Y4O@& 31& P  Y@<  !D
M ("!G]P  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #;
M@WE2E])4M\L"  #L!0  &0              @($<X   >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( -N#>5*T5;X@C (  )<%   9
M          " @1[C  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#
M%     @ VX-Y4M (U_@$ P  @P8  !D              ("!X>4  'AL+W=O
M<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #;@WE2,, !X$T#  "<
M!P  &0              @($<Z0  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM
M;%!+ 0(4 Q0    ( -N#>5*VOM1UQ 0  -<*   9              " @:#L
M  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ VX-Y4E[$
MME4O!   OPD  !D              ("!F_$  'AL+W=O<FMS:&5E=',O<VAE
M970S-"YX;6Q02P$"% ,4    " #;@WE2%CV<"?8#   2"0  &0
M    @($!]@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (
M -N#>5+O67@/+@0  ,,*   9              " @2[Z  !X;"]W;W)K<VAE
M971S+W-H965T,S8N>&UL4$L! A0#%     @ VX-Y4G%Z,AHD!   A T  !D
M             ("!D_X  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"
M% ,4    " #;@WE2#[UQ7# %  "T$@  &0              @('N @$ >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( -N#>5*>M+';$@0
M .\2   9              " @54( 0!X;"]W;W)K<VAE971S+W-H965T,SDN
M>&UL4$L! A0#%     @ VX-Y4H*DTK1+!   $A4  !D              ("!
MG@P! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #;@WE2
M(0.LZ5$&  #X'0  &0              @($@$0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;%!+ 0(4 Q0    ( -N#>5(6QMH=8 ,  $H-   9
M      " @:@7 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%
M  @ VX-Y4F[E+'=, @  ,P4  !D              ("!/QL! 'AL+W=O<FMS
M:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " #;@WE2EZ$IS9T"  "\!@
M&0              @('"'0$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+
M 0(4 Q0    ( -N#>5)-OR<Y# <  &4C   9              " @98@ 0!X
M;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ VX-Y4@J&7W9$
M!   Z!,  !D              ("!V2<! 'AL+W=O<FMS:&5E=',O<VAE970T
M-BYX;6Q02P$"% ,4    " #;@WE2.\>&<6X#  !Z"@  &0
M@(%4+ $ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( -N#
M>5)]5\%X^@(  -P(   9              " @?DO 0!X;"]W;W)K<VAE971S
M+W-H965T-#@N>&UL4$L! A0#%     @ VX-Y4A/?3O8X P  T0L  !D
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M=#4S+GAM;%!+ 0(4 Q0    ( -N#>5)2+>V3B08  ,H9   9
M  " @0Y' 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @
MVX-Y4J"F(& ] P  >0H  !D              ("!SDT! 'AL+W=O<FMS:&5E
M=',O<VAE970U-2YX;6Q02P$"% ,4    " #;@WE2B F\F74#  #>"P  &0
M            @(%"40$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4
M Q0    ( -N#>5(['@3X-0,  'X(   9              " @>Y4 0!X;"]W
M;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ VX-Y4G-G<X$Z @
M]P0  !D              ("!6E@! 'AL+W=O<FMS:&5E=',O<VAE970U."YX
M;6Q02P$"% ,4    " #;@WE2:NK'LQ4#  !?"@  &0              @('+
M6@$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( -N#>5)%
M26ERWP4  +\?   9              " @1=> 0!X;"]W;W)K<VAE971S+W-H
M965T-C N>&UL4$L! A0#%     @ VX-Y4O] A"D&!   !@\  !D
M     ("!+60! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -N#>5(RIS'L@P(  !@&   9              "
M@3=T 0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ VX-Y
M4@,M:-D> P  .!(   T              ( !\78! 'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " #;@WE2EXJ[',     3 @  "P              @ $Z>@$
M7W)E;',O+G)E;'-02P$"% ,4    " #;@WE2W^>Z&"@%  ##*P  #P
M        @ $C>P$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ VX-Y4A[?
MF5X< @  /2<  !H              ( !>( ! 'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ VX-Y4J5_#G'N 0  D"8  !,
M     ( !S((! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $H 2@ ]%
&ZX0!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>171</ContextCount>
  <ElementCount>422</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>59</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficit</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit (parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit (parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Nature of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Significant  Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>Significant  Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Fair Value of Financial Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssets</Role>
      <ShortName>Fair Value of Financial Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureInvestments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Collaboration and License Arrangement with Genentech</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseArrangementWithGenentech</Role>
      <ShortName>Collaboration and License Arrangement with Genentech</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Share-Based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPayments</Role>
      <ShortName>Share-Based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure -  Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureEmployeeBenefits</Role>
      <ShortName>Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://relaytx.com/20201231/taxonomy/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Fair Value of Financial Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsTables</Role>
      <ShortName>Fair Value of Financial Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://relaytx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssets</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureInvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://relaytx.com/20201231/taxonomy/role/DisclosureInvestments</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://relaytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://relaytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Convertible Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockTables</Role>
      <ShortName>Convertible Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://relaytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStock</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPayments</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure -  Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://relaytx.com/20201231/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetail</Role>
      <ShortName>Nature of Business and Basis of Presentation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Fair Value of Financial Assets - Summary of Financial Assets Measured at Fair Value on a Recurring Basis and Level of the Fair Value Hierarchy (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialAssetsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisAndLevelOfFairValueHierarchyDetail</Role>
      <ShortName>Fair Value of Financial Assets - Summary of Financial Assets Measured at Fair Value on a Recurring Basis and Level of the Fair Value Hierarchy (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Investments - Summary of Fair Value of Available-for-Sale Investments by Type of Security (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureInvestmentsSummaryOfFairValueOfAvailableForSaleInvestmentsByTypeOfSecurityDetail</Role>
      <ShortName>Investments - Summary of Fair Value of Available-for-Sale Investments by Type of Security (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Collaboration and License Arrangement with Genentech - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseArrangementWithGenentechAdditionalInformationDetail</Role>
      <ShortName>Collaboration and License Arrangement with Genentech - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Convertible Preferred Stock - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetail</Role>
      <ShortName>Convertible Preferred Stock - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Convertible Preferred Stock - Summary of Convertible Preferred Stock (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockSummaryOfConvertiblePreferredStockDetail</Role>
      <ShortName>Convertible Preferred Stock - Summary of Convertible Preferred Stock (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Common Stock - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail</Role>
      <ShortName>Common Stock - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Common Stock - Summary Of The Restricted Stock Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfTheRestrictedStockActivityDetail</Role>
      <ShortName>Common Stock - Summary Of The Restricted Stock Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Common Stock - Summary of Reserved Shares of Common Stock (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockDetail</Role>
      <ShortName>Common Stock - Summary of Reserved Shares of Common Stock (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Share-Based Payments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPaymentsAdditionalInformationDetail</Role>
      <ShortName>Share-Based Payments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Share-Based Payments - Schedule of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfStockOptionActivityDetail</Role>
      <ShortName>Share-Based Payments - Schedule of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Share-Based Payments - Schedule of Estimated Fair Value of Stock Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfEstimatedFairValueOfStockOptionsDetail</Role>
      <ShortName>Share-Based Payments - Schedule of Estimated Fair Value of Stock Options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Share-Based Payments - Schedule of Stock-Based Compensation Expense Included In The Company's Consolidated Statements of Operations And Comprehensive Loss (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureShareBasedPaymentsScheduleOfStockBasedCompensationExpenseIncludedInTheCompanySConsolidatedStatementsOfOperationsAndComprehensiveLossDetail</Role>
      <ShortName>Share-Based Payments - Schedule of Stock-Based Compensation Expense Included In The Company's Consolidated Statements of Operations And Comprehensive Loss (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Income Taxes - Summary of Reconciliation of Expected Income Tax (Benefit) Computed Using Federal Statutory Income Tax Rate to Effective Income Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfExpectedIncomeTaxBenefitComputedUsingFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail</Role>
      <ShortName>Income Taxes - Summary of Reconciliation of Expected Income Tax (Benefit) Computed Using Federal Statutory Income Tax Rate to Effective Income Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Income Taxes - Summary of Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsDetail</Role>
      <ShortName>Income Taxes - Summary of Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfComputationOfBasicAndDilutedNetLossPerShareDetail</Role>
      <ShortName>Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Net Loss Per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail</Role>
      <ShortName>Net Loss Per Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Net Loss Per Share - Summary of Antidilutive Securities Excluded From Computation of Earnings Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetail</Role>
      <ShortName>Net Loss Per Share - Summary of Antidilutive Securities Excluded From Computation of Earnings Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Leases - Schedule of Operating Leases Presentation in Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeasesPresentationInConsolidatedBalanceSheetsDetails</Role>
      <ShortName>Leases - Schedule of Operating Leases Presentation in Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Leases - Summary of Operating Lease Presentation in Consolidated Statements of Operations and Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfOperatingLeasePresentationInConsolidatedStatementsOfOperationsAndComprehensiveLossDetails</Role>
      <ShortName>Leases - Summary of Operating Lease Presentation in Consolidated Statements of Operations and Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Leases - Summary of Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Summary of Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Employee Benefits - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails</Role>
      <ShortName>Employee Benefits - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="rlay-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Related Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://relaytx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>rlay-20201231.xml</File>
    <File>rlay-20201231.xsd</File>
    <File>rlay-20201231_cal.xml</File>
    <File>rlay-20201231_def.xml</File>
    <File>rlay-20201231_lab.xml</File>
    <File>rlay-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>118
<FILENAME>0001564590-21-015518-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-015518-xbrl.zip
M4$L#!!0    ( -N#>5*@)X4/6&,!  86'0 1    <FQA>2TR,#(P,3(S,2YX
M;6SLO6MSVTB2*/I](_8_X.K,;+3C4C(?HDC*W7U"ENT>[;I;.I(\>^9^F8#
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MC<66&K;#XBUU-N=-8*JBS?EA\9,21R--8*4JN[;#8C'EMF]-8[UB+78 G*5
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MLNNSZ>1/#'[W7#;_W?2_L_!+Y(Z#K$?VQ;3]OYM.Q#[.DS__!KA#)V#^%5V
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MS1]78D?*;[%?Q$E%S_)T "CI]DX'&:0LF2</SL5X#)HQ$/]\!9W1D4&IJ/]
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M,#HK!C*%HA*8Z_(B-D'E\0I<+@.3NF2Q(.2_4RJ+#&8U>U92!9SF?.<"&*H
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M3CKGX:N#-S!S;(J'([Y<_YQE>Y]?]_LO1I7*3[AOB26J& <E4?"'QWL2I#C
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ML@9JBY5>$2P9<V'>T]A5P7+C'9=8]N?T$J\XFV-FVKY4%LS<^((NJ=4:;X'
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M0Z%U2ZKX+'+MC'&4]-])*FHQ(_4!/!DA))2'E=43/!\2.%]<.9,,MWAYGM"
M/+0[1L$,Z#:>YP2@IK#E%;\'[-[\P9K"EDL.&,?Q$7UH_EA6D1('ZO.I=_@*
M&EK*S[!X8$(D%)+3FO$:D]PX=ZD.+;R0'.>&>7P&4[I!W)8,=A>!"*:T2JV!
MYR4O[HYC-8O@QY<NT/Y[$98TVR2^GBFV/CCO@QDLY/'E@4A/8YC++2,M+;X!
M6I24" SQ?#U;[G<F YO/9>3-#U"0I0 .OV2(+M46MU07X4JDEY.[8D]:V= !
MY\)D84DDB]')!S42X/X^G@PZ]G=&!]^P*4"C1FQ0T#VC" K:XB3IH_S>OD8>
M5F<:"LJ:VG;C"PA#4CR+4E,H(0_444+4ON$U$,?4P CL"%WZM="T1RK"1[[E
MV_>%)-83XPM>*]%*&'SFB0NDJ<_5 TNRCL>+4Q ?V$]>?-AFISO8 -[F_2&H
M;TBR[V8_S*3GE#CW@5EI31&(>7Q1JBC$SP!$@2]*VD(F/.9,>(Q,>$Q,Z&7F
M+5B13>ZW&S<_*UA0BC,)7VGF[0KR<'\PV_@@&0-Q(Z[\S*8/$Q*Q[ "K!Z2V
MB$]4(01..W6[(3GKM_\JXYM Y.7FXNY+PC.6!U 1'LA:&-<5(614RQ?$G0XS
M_&?'+5A(8Y%R"E+7.:XXX-H9MPZB577D2FN16(R"0J);BI1<30>Q,]^F! H\
MH'"<>#\4^T^8XYV<YY*/!/K3R5\G4&-_XS*S"?V*8?]F>!V7"[OKE*N0JO2-
M1/6%3B^E$XY%UU#D2K%CDAJ#\4TF,)TWM:VDZ"$-8/%D+_+$Y0EYY7IJC$LG
MS[>D"$>Z_/AV65STN_C"2E[F(ZTX6G$5-"VLX"9D^3++1@C$'\ ;) 8W@,5+
M?D1QAVFA#9&+CV8 C)A(P R3(6EY=A"7X\F%?GQR5)981_,H]XV,SV]$SJR4
MBKMPF>Z)\<EVHEBAEIHXB))4F.W D.;0)/738P2*]^1,+T1OHM\G$N3(_0 O
MC3;7<=4FGBJ8CD6%@70N]T <PN\-6THT,WN&B-Z!2(44M. >!I9;"+?;%FV-
ML>-H?*E<R ..*?+OBR"T>3&_Z;O\"M:TEZ:XB)%/AE?%AM2<MVAX["Z)^T)R
M4'@U![6C$H/RVG-4G2]X#I[/U<_<\"X?7";Z>EGL;=E:DRBE**3#'L/.RIH4
MF#D=C(<I11)8\,%XB,*X1T)V8+EHI/3 0NEGSW]/*(O"1^G"%!O;36[*SFP5
MTZW^C'KRF0G[B)9TTCWH5(PA=]RB!Y:S1T-D\R+)K=H4D2LD4_CP 5:,F+$T
M+S[7PGMZ+9;JP*PJ3:B#B92<-JDT"$FWB3UL/PD?H)R&]G$\Y&(;JVS:Q;JF
M5FD&6K:[568Q,M@M8\;KM).2HX[H1E2AB55I&#.> KD()ZOG*CWRXC"U=ZMN
MX^3%B[$W0\Z5,K)N?'"/(Y$5WI3]1\;^+JXYO9SAVXRR&;.W(GS+7,CPAW>2
MNOS@Y0^/\5KEDJEJQ;?Z&C_Q>R"&W?:[<_#.Z()0#*U^\4%QO'C^=^F.E4NQ
M1Q Q?NGIV_QUSL6S92^  '']3].-3'\N79$5=[Z[Q_AJ?.4XIH>+.\E%@<4X
MG3MSE30Z ]+]LM+UQ2(,,O:D:DEYBKB:F7>[2@["DN*7Y5'C%):-35-O)=N^
M/=?F6O]574_I6V/>6.F(Q,OE.@>,A?$/T.>Q=FJ&#KK"@DF786! 7+:0WBQ<
MJ(L^4H*XK(J^7-Q]S.@B8?M!1:%:HJ%1&Y541BE_I9!<I0G6LL[!&]>Y@04T
M"6W5ZYZ!MI+5&.8 9YX$>2T>.M_57-8!0I6(;8#%!Q1^*D5(Q2U2?'MJNNGY
MAWB(RE@RF4F([>1$,_-4W&HV+:W&W*H6[;A@6A;@Y4UV\(1>6-8%*E)\4N*:
M@)LZ7/, 4D' 1MJ!4-0I64EFU:V<DG2]EQ1)R=E.(,7N^1D.X)N9%%>"T2(K
MR1-)^NM05QJQKTAC1X(>2?(W5F-XL$NS7;XY(O\ROK]P I@ A/# V .#ARA/
MPYQ@8'HQ1-;IMT1D+$TMH9"N/4W\[J0*'X-Q\OB<*O"7,T]-"$(WPQ ].'#C
M$V RD(1G7E_&)R)) \'!6@E10^[,9<G!QXX[[?(V?%-A:0%"*#L=>[S16O[&
MQH"QQZQ%+@E&[#-T^N\X8G@'S\27..V"='Y.B/6)CA>SV>U9+R=&A*QA6IF2
MR)3T:<V'S)AT028H/(?Y4E*-E-]ERB?-WF;,T^UNCWD(>#R1DCA(]A5Q$T6'
M0;'LI$6X$L(*NUP4GM%1'"?NZ,F%7=Q;4^SP;!C%56Z/#5)Y$3WB@6':SIED
M,FO 9+^ZVSZN<//9)_80)H4:G<X'@[[@%Y]1@X$@SE.^1JNPD<!=SQ9OY#!^
MNHL>0A*XTT'[&/SWLJ/QK/1B=2#IDB25$ICZ,UU]E?%ZKU]<4=JR#"S0#\>G
M[7=E2FS7:0<B2;[L199_V*RXHIXA+1UR,\T@Y *N. 8\EM# KZ7B+4WBTTA+
M1D)RY5JV-RO@09P%45I2"DB2YAT'%]/@C+S"SS=W&<\JAI_K UQ_?'*=M7^K
MU-W&]K';X_Y'6=UV8GQ>T&N)1J,\\8V@:&^D:,MJT'2Z!>["+W>G4YL2N+R2
MFM7G7!VN5C,8SL0LP&IUJ^\2,NEPPLT8G&+(XH[Z_T[F,9$OLG50\HO9:%HR
M=F'$18(V[Y2(+AO4K'$LPM4"B*)*+#FAX60U7M(O>,/%--R1:*4D^!*G0LY\
MF,">.?SH-L&,N \E\#"#TN>Q$TD]Q>.:P2S.J>#Y=3;OPY#H4)A-=,E,CHNS
MZ:!<YES@MD07%ZNK&2_,?,"]$V8%D2I]G:YJKQ'X;-=!*RR+_:0\671B+Q1^
M2FJ)U5YC)/L+)2[@]2/(9W2'"-)6XNE9-F+"CQK(E1*N.JF!Y,Z<A"LP[0??
M?_#&-I,Z(V:"HX%4,X^LR3-_L\Y_ENA_1J O.'O3\: DS  A8AJ[DW@OX(Y9
MV=@=R+/!=P5R??%_1M,9P.R'QG7D&Q]C;KW#KZ)9@/GY""#P3)<$BFI4G"0)
M,NYIQMMCXW>(>7[B*<Z?Y9TZ5C.0ZB)_$3'-KS>C&RXEI,=83#HW3YGIQI59
MO&M8@F@[.8*5Q^)!!80VS>O/XC60Q51T.1*?$L<B=]N7*22 OLU!G[IF_&=B
MJH(ARXR Q1PPUQ@TK2=:U= )(6?4/">)&VQ^LM^E(FW#QN_9LZ@-.7/BRWHE
M9D$8O"B4F2,^'EU!2W&16SI/VHTFSYA+N%'6'#^_CX+C1].<G4N%*JE!N_&P
MT3T+[@&@CXYG??_UW__-,'Z.W\&0.T7<T[A\^JAACW\Y^O+/=KO=[?>/>,>"
M'^$MF_QR=(G?=H:=;N_L])^H5=N==H?^@*\Z1[_6^+2I=R(?1  ]I;AGT]KR
MIE<XTZ7O07+K0.86@Z048W7Z>]Q/-^XA"Q*6;6MF8K O\BFWAO?<Y]L&J5-O
M<L5BKIK\R0;'Q;>>DDL_<]FN)'/I\\'Y9D1:=@:1[CQ5.5,9V\_)WT0[O)0"
M=J:_'+5!4IGCB+/AY/,,X\'B,_4_^.7(HCK)HQ@S?(!CNJ=J%K#S^(\/8&C&
MX=/Y"+!QE$[JIW]2KQ(:$I!X9#P\TFGU+T>B7U R@X#AV&&3D' =?T&WJ9RW
M3P9]Z<M[) C_B@/0;Y_TNG_](%8:DY#V6P9_D&O;F8F62H*U//'%QP3 +#?@
M%^M5SR[;7N::B<V2,_YP7$0.OM#=4:1STMT[052Z$*XD>0!DP G0IW-Z] :T
MBK_ZF&*9D^]T<')ZNII^,5X+:">U4N&:9'4GE0KB)5O^9=U6ACMV XJ3$<1>
MHT1WF0:B9'D*^?F>M=%2#N^4XV[8'X6,TJD0-2^^.=NE]5"!EF4TU7O9QA^H
MN:^A=='&7VGR),:_NU?;WVF?=(8I^1#EA:I1.P>%5['B-K53 ZOW*KIJLZB4
MBEU*2TT4K5B;06JN6+M:L1ZH#&O%JB!1M&*M/ZFY8NUIQ7J@,JP5JX)$T8JU
M_J2^]T+3T6KU$"6X<GS\\LN7]I?+'=);A,P/(-::2P:FM\=82D8Y*^>\)[$-
M8_"F"92:LJ0ROI+([IR$W( >  5?Z[?LGA(EE.>;*49-NBJD&Y5S:,I13_)?
MJ/G/-MP734XMB8=!.FW.5*&$%J*ZDDZ;LT:14TMB?4FGS9DJE-!"5%?2:7/6
M*')J2:POZ;0Y4X426HCJ2CIMSAI%3BV)=2P9TD>BEV;P1$W% --8J:AN39YV
M.E2AQ%^U)E.3,MRGT"Y#/:BEY4A9RFA;HPHEM(PH2AEM:^I$+2U'RE)&VQI5
M**%E1%'*:%M3)VII.5*6,MK6J$()+2.*4D;;FCI12\O1%D_5ZE)HV.F=#)2G
MT._P\]P L+^ST)A$[CA0]NA:>P6J4.) M=E?5"6(=@92(IV>#EJ=TS-5276H
MLE,#K:;MBRJ4.% 9T?:E!D1*[H?I:OE1D31J:S9M8U2AQ('*B+8Q-2"2MC%J
MDT9MS:9MC"J4.% 9T3:F!D32<3(ER:+KT)0FSY7[S()PJDO0%*"%/O;7E-&>
MP"%02\N1LI31MD852F@9490RVM;4B5I:CI2EC+8UJE!"RXBBE-&VID[4TG*D
M+&6TK5&%$EI&%*6,MC5UHI:6HRT>J.D2M"U2Z-N=$?K,#")_;CS8CJ,KT&H@
M,CH[0%-&.P4ZC;/.I%%:D+2Q48826D84I8PV-BFU>KU6NZO3.16CBOHRI.V,
M,I30,J(H9;2=T9N:NI!&:4'2QD892F@9490RVMCH38W:5%&Z1BUS?A;?=2<P
MG[GNCI8[,WU \<&<LYF/S+7F1L"LR+=#FVUZU+9=8G&OX*UHU0SYVGLRP2IR
MZ9LDE:9>]D[7UQ.PZ5[(Z[>\6B#W33X5!%);.Z7)HX6KD=33UJX:13NC0:LW
M'*E*3BV,-1!&;>F4)H\6KD923ULZO:_3 JFMG2:/%J[F4T];.[VOT\*X^8'K
MMH[']W+@JC[-[KW0= P[[1>ZYRP&[:34,QU(THN(XD*EJ!5G;<F;]6+>@,)-
M=W/JD9^L1;KV(JT-JM+DT=)WF.35!G7+)._VVJW33E]5>FMQ;H(X:V.J-'FT
M]!TF>;4QU;M3+=)U%&EM4)4FCY:^PR2O-JAZ=ZK%N>EUQF,O>G"8T3TY/ M+
MQ][JYN,=,&74S^C:0%EFZ'G0RG+32[??.$_O#0C;=)?G=3=W:RE6F;;**&EM
M0Y4FCY8^;4.U#=U7V$!+L<JT549):QNJ-'FT]&D;JFWHH91/:TFNK:+6=E1I
M\FCITW94V]'-*7TV&+3Z9QU5Z=T$*>;TB\FWBM+[/<%^'YJ N VPDD'"7^5%
M=]>L>BF<!,'8?D[9$&$3E/[EJ'UD6,QQD)[ -LEGP4;T6?"L!4 Q/^%0P2I
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M:/5]*N<5N^2]M_+N^GES_,&@+E.0R_[^>^IAV^72V+<HK"]!C2Q!F'X#^^2
MR]W 0@^CP'N<%"A&GY?.*^X%T"[@&YRQL092P0^S0+LHH-QJ;CRHX@P,!%!<
M1D?A5Y70%0H1T!@J\V>&LZL_3H%)30#$JC?EQXM"VZ/ZBC+\UX^O(VW=L.L,
MO"P43G##Y><K-F@/OH45[?8N_2@2O%'3Y4-%F)W7AKU,\^C3'-57;NSN%G*P
M-!5&XTW!)8]O41(N*J2MZ@F[7WD^W.L56@?RAMD#'3S$*,] =.S?GJ3\^*S]
M##0E\,""^_"TXF][4J/_MIC9LQ<,%O"%$J_S#V^8/8MMMZN%K.]XT\X.:&[K
MMS:6^-UP9K/+IAELW#,N;9(''JJO$ZS7ZFTL5'U0BE5I]/_P1:S>K%#*?+G=
MV$5O<K#[$D\5[5\?$MDO[-T\=/LG(/MJ%M^^81L)63G6N^=4CX2!F]N#A,$Y
M"8-/0@F>X(E?5 L^,R62&Q 4RIR)Z=,"X][6S[YJ\:\W. J)A9/<*"06SDDL
M?*F<!%]^?+_S8>XCF?_$G;%J]" 0)KJ7AP]0M&[SJ^(L#?65?!+?8+  Y6"*
MD>Z%.1J:YID64J4R\DV H?BC$DJPR46Y"^CG49QK>2,B'8]@.M?0'/96SWX3
MC"X$8B$T97$ P>%JO2G,>4&>,>+S" ]J,CPHF2SUED"2Y-#6 5F)R>)4,61N
M+,[[5!.H'MR<=?)X>E?A$W%H<W0C 7">A$L8-X89%@/H$VV,[:9QLL3SK!L\
M5RD(-X%Y365:2U'8@9H>/&#!$XP'ZP.>M"3.MXJ=.A*5>2OR$+8-RFBYPLWI
MT\<$:')FX9BM$L FWUC2+#1I\OR<36%_V)+ 8\]'%]YH,"PR/$Q 4AGI,)5?
MD2<BU%@P%104F)(!.SQ/K--)%?:T+]7E;]8G@7DDYBDZM0OFGDCD;/C^A7RI
MYV?S3,P#O7L24SRX#>[C[+FY:>7JM52,,F>E(%(E0VD7Z6)R-:TPA34BWF^3
M[+J6O?3^M[?U$V=S(J@)41,H55F@U[+?8E;3P>ZTJ\WYM[QY"5  #BA[84%S
MK7VW8%M1SHF0\TF6*&&J&N$4M%@JMQ4^ZUYIVV*_Q=4#]>HUZPDT>I@('WZ=
MP4Q0O&ZZ2&L5&T67T18^P#0CG?L&LZO=BKE .@ZOX"9DI!:[5/H\&FD$',U-
M2+UVT"7 ?LMJ9QG% "OQSYRB,+<HFPL01HI-869QHCP[;52Z^1 E\;5"7TDO
MP*LJ:0-2K1[C;\KGT!HE#CW] 9ZECQ)Q^VP^PQ-30-+2WFA07\B%?GP%!]C:
MH.@ 0:T:R[P Y4L;0P<;0/VI#[2!Y@#]-\G)<4EO789A[-^AM(!:=+RPJL^X
M(=I6=5;1)":+QLIT//\.7O$0)8,"'UZ?,"3:/JM*Z,^?/]8D=&&!3N^TG;FR
M!Q>*3B.:X7M2I.&<(@W/1UUO<-%'W1BBK,B-WE5+SSI0%%T\R5U /']6/-_U
M1N-!C>7O=3_H;.%T]P-Q_UEQ?Z\SO%/=7WY\WWHDIY^!VP7^4$&]//1^"]Y.
M):R8*?W>8&1<?G26=&2B$M? =T4P"(AQ.[ADPB<RE.G23A=3E+F:L2FZ3]60
M4O69.7()AE_J_J!^W_!&BEOS4@7&Q'58C"=_BK3J(>K4L7SB>4P%%U@W_LSX
MU87??T90??]I?9_!;WB8DKNC>5BM2.;G2L6^U,LVP16;*J/RF,[J:8+^"2@$
M^R##6%$&P\-S/,:#_V0*Q\&I<Y@X5W&DR6%>HV%F QJ$S)L*$YV];=^"T_%>
MN NS<P*;3V[/-8J#AY47-ZQ+C._/ O6D/LL!6'0:L\#LT\4"5H3DKLS&GV$B
M:I'S#<16^ 8$7A7%Q>D?D_ (/V4ZTEA+2/VO72+>K"NEXX%1L.%UO_.**'VJ
MI.OB&RR6:.<;+=(ODIH=8W:@(0ANG6I8)YTE8J?@SBHIR=9S4_N3K7=.MEZ5
MXRL*HM09&TT*/#UABUB:-[[U&X/F!'!S3&BEA,"69^H4=GQYW+Y+7@E7KSP]
M"M:R7?/#J6F,+SVROS*>I&8>J,M -?L\LV\=5E\=K-A&M4?HU8BOPL^JYU ;
MSGE;A::HK"3(DMQ&NDO#;J7NW%A\^G5X$WU[K+E-PM9-]B-A>Z["5K\6JL!,
M4M/EW9[29MNJEG]@B-P9M-]8+VH'MRL1I?_1*@?XLM/=6^:D'5=;K*!^4&^2
M*:Q0W%9@2*+]S=,RU<"\8+XBS+<H$+5-:>V0IG:#15ZT%C,.N?82;2D!&2TR
M</Y$.HMUNAQ,U\>3>GTA^(\P;U.@04:ZKI)^+KY1CEI26\I + GWBEQMX:OG
M.#>=T%,FBIA15AS*ZJ"@'*>X:[:?IFK2)";,H',[UE13C39R*Y"[:C"[W5;W
M!;J8F,%2I"_",D11P6E]&.WDRWGNO)*V.TWY1]KNK+5=(8:V2>K5V-^];L::
M7_$-95^KLIOOWM<4%<^SC7>C;#W)KP+@:@&A/#5!I\_9\%2>S[TI)S?? )A%
M!Y^7F_9=+9I]N:$,VOKL$ES%ICIKV5W5XXJ7L8VW6Y:#,YG]I>[D2HF-5^/:
M*[7C_!"N-&^#<U/@0%=Y-/=[>3)7K<Z;,:56GF2H5 28RR=N"22;"6A+"S<+
MWI=GTTJUEAB)]1*E?6M"OZ^2SKB9V0(>SZ]-NB5L3<_DDUH+HYZ..\UTW+Y,
M6"U?A*C8#F4UV <4>ZU7B?V8Q" ETN5'(%IZ&07O_LKD8H<RL:/'E(F]LWJ/
MK@^[6S66.BO?R?7[\_2@Q7(BZ8U;4,B#AVRO/G+G&@?;C@IV7]%A!5=MA:)<
M(9;_LCZ/R;BOE6%8"WE_BSK)3V6V:>=P/82_OVEM+2!?U\'=V=(>[FIH/U6_
MA\&@-5YO^%"K//[T#1\:9<8_?0>.0??8@+AD9>T(#TP9: +X#)X=LXI_K]WJ
MW<-/M9>%MK9@,(+D$#T8UM3IMJK]HR?6K57;\\BLMKV;RF[8?;,."\Z ]]#^
M"N>JRQHH.DFS.0U/H=FZ1]5LG5YKM$>+7%)]N%;TC1N@\AX%*NE$I^3K5BP)
M%)*JIP%UM]T9DU0]1P9^L*=Q]<LO[5^NGA!OZWR<OM6Z.7C\>D\^?')<C%(\
M?5@>;8L\/1([2,2S;$'; .BZNUDIU&BV(7@2*S86.M)GKB!!3-18Z$B?G1:>
MQ(H-/+5[:E^ZTVL-G4?H5Y/(AX42"V?:V9@6V1ZN(+'IM8$S0.:YLX 8BX(,
M!EQMI^==]/K.0G6FO-, J4;ZQ14DSI1'2+\T :5.UVNW>\Y"=::\<];GMLWP
M-0578A:' 9932V+3+$ Y&]0A:\ 5)$BBN8H,F04E7*/1P%F<B(-<18:TC"M(
M$(^XB@QIF8J6&>S[)@=Q4),\3SKE/"!"6%\FPZ)W=,;I""(4@R9DR!XXB-<Y
M<A8GXB!7D2$MXPH2Q".N(D-:IJ)END-G<2(.HO-.)Q'Z)4LBJ4MKXKNJ4_D5
M/]-Y9P/XAN)HA S9!/?9!.,+9W$B#G(5&=(RKB!!/.(J,J1E2,LX#(G3YYU'
MJ<7:"'?T*HY4FF2Z S4VP%@DL2_4OOXHU68]-HL=/>SF5/TX0F\/$^-P")ZZ
M&7(Q=#D 3ISH.B>2FG,:'F*NTT2/U-S#(.V/FU GGCB1SH(;YGPW(.I(D7E7
MD*!R<HV%CBH[/J20QL ;CEQ^G8G8L*%L2+K,%22(B1H+'>FRA^BR"Z\]=/FH
MFMB0SK)/QIW^52CUFG'?S^99R+%=?" 6B? EQ]-MBO4["%D#HL4486PR>A3K
M?QBD+SIM[Z)'\?X&0O>2-)R#J#1 1A)/-1D]TG /U' #;SSJ. LG,>,^"NYH
MY]AW>>-!G$U"P;JM\]-Z7^*4AYA,OJ$MK\<BL6^IK</"MM%6.6/4&A!^?G@'
M\QJ>9RT_]VTDX<RAPN&0/74C9^!U+QI]ADY,[+J,)A7J-#S$?:1"284^YAUS
MKSW>MU\@,?$.R!KT<O#NPOFXI_O?IQP(5UP5R)L]*%0CR'=5 G3OH<#6.1]L
M!NUOC\&7F6!8?YM'2Y8('S=JP)[WO(O^6 <+GG>]4?^"Q=/:$3X37Q<B4H+!
M(U@*0RP%3Q03$=[]5OAB/A&))M4_.H/VFU['8]UVMZU'[+8[8P^>I1;"3^6-
M")<M5M+RA^\S]>J:\\7KCS9F\3&$25]&P;L\;/%6*C^,59:(+[#4G\/8__.G
MO_^-L1_R.R]]/\ZB5'WD2]PP\&>2B>!7R2<RE*D4"D;[ +-.*E^5@UYE"9I(
MQ=A,!C\^^^4/X);NQ?@9\X&4\-,G,?WQV15^VQEUNKU!_P]<8+O3[N@/\%7G
MV4\/V!B=T9:=8>&>Q&'PX*WRB'TQ;#%+-_;.8*TT>IINS-*(50C(]N*'@6O\
MD"]:5!<=ZT7[=M%A9=&P&Y14F.$"'(*,,(W#,+X%5?%Z/X(\I8BJ"DPM2JUB
M^O%9&_:U"$-4/S#UXF^K]?3?5L7Z,"F1% K5:C90*B%?*/$Z__"&&?4X;%<3
M?8^4GM4_]C%HPSTA.I=V !Z8,M $\!D\.^:Q6*_=NH>=<JK>[:D8.7((5V5-
M2VZS<$=/K#)SNX>!N4.GF@T#KR&9QD=790V4G*38G(:G4&S=HRJV3F^ON!VI
M/EPKNKP-4'F/ I5THE/R=2N6! I)U=. &B.E)%7/D8'=K ;4/X>7]M]]!3$2
M\1!/* 1/_)F.  ?B1H3Q8WJ34E4%5[P^)\Z$*6G#*<2HF,)#JNUZ[?&^A@DQ
M'\E-TF#.(T%,1!KLA#58SVOO73&>F,]EN7FT,SKRG#\F\50H)6/TGI5(;J2_
M=S_5IX]?D:WA"A+4I\M59*C370E7?[#O.PC$0>?+0:1E7$&">,159$C+5!S3
MWL!9G(B#W#NOI<S0C9CIMY2.'-^AI-#&Q[Z=2%PA]!X1!W\\@J=N<73&30B$
M$R>ZRHFDYIR&AYCK--$C-?=0Q[KG+);$B<T\\KW+^3[CRFNFY"Q_4"&-(P>]
MJ(1>0V/')U!]JW&Y;-^ZDCZ5T'LTU!?><'!*+^@2$SLGHTF%.@T/<1^I4%*A
MCTH9'_9=/IMO/!-3%=JBQ./6>97540];X]343TU"OGQ]%4<W(DDE#/HQ$5,!
M%P:?4[AF4T'40?O)"J)NJPQZI'JHHQ:K4(85I&&:-O?5^LP7M+YBIXJ?5HL!
M2Z4P?/-9)%CG]-++/_VL SGVCRM$OR#*HB"*TD1Y@=5 \R*_'C/U@$?=;OO-
M':0LKNJ\>=EB_U[$D9X*CWR!-58%]V?,#[E2^-<=XWBZ'&N^&KA>P/\"_256
MZ0NP4K&9/+ZQH!<5RK\R&<ATR::"I\ F*J_JJF8\L2&L0*0BF<M(C\53IC*8
M4'%] '(WBE.68).E1-3FD,9,";!\>0KDP/@8,G!>01EK*=M!6JR* P]5C!/U
MPRS(GQG%;"(B,96^Y&%U%78()K[:HK21GD%!P ">_2 JUN:20],9OE%W<L,M
M5V9T.94XBRQ5,M /UAMC!KP+$ZX,IWM2 =U?!'I1Z<M\YEA?%Y69;B(]X:%>
MA9H)D<)NDTBZN$KCV@S??_P 9/)YI@P.]K%Z&@B:!77&<^1-:6MMO2@FS03$
M#48JX18.R(NYJ%^+:'AXJ0^DX/"ODFFF?U(>NQ6 !&X&6 $B?BO3F2R6E29Q
MF&^O FO87[=Q%@:U_0-T%?.%?IZ]'OX?O4*JIG '& 2[('@W6CA-&Y8-E_J)
M8HYZI<5^KE P]LTUAA4W4L30*Q]RD<03',8PH\^39(G3!4LI*YGKSKGE-,1P
MLL!-8 "7294L9KS6B4CA#Q'[5P8HC$S1=&_K!I_$/-&%IP/8*GX:)T9"2=B]
MA7Q>D<DY#_ %0',#WW*D8^9K,I:;,Y<GP&,&:_Q^VYALFL1S]KS7ZG80'?C0
M[@X'[9Z>S%TWYI-)1"@CV$+ UX$%%V:7&LUA^%$S3UXT/F=ZLPBNV8B#",\
M3MB%?G4%\-/J=&&9G$UE,H?KYG.98E$7E@'XR6TBTU3 LL$TAF'B*=R'^U4:
M BQ$8H2&I8M4+ 2M@E(@8L^[X'*U6^Q2:9JJ+$QSPOGP^[781EZ#;Y6;K6""
MN[>27/-%5??*"(C2&WK=]L ;M/N5,7"1\"Q5"@,S'Y63<8/^R(='L9T8IIL
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M$ON,66(LSE*5\@@9@O&4O16^F$]$PGH=CW7;W7;KH*0IE_^4 *P0^=LQ 0#
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M8&KJXUT3N%N8XSP]B:V[%L <6)'SP7AT.-M_ GU2]C$$5? "[\QOZ;;?5&[
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M& LP-:)$%9;EU8??W[]]!<(:*!>(N?1S7!,P)6YD H[KI0P\<)- 0$\UA._
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M#"GF>#:8+"OGGFMI8YA4\5^D$D:?,!IG.6HS#78DP6^Q2=XJ:6"SG<!V 1\
MIE0]#K$1K?Q@?O4@\EY%7\E]N,)0(KKE.+\/TRMM-WV2ZD^P)2I'+)^SQ2*4
M0+\[3(;!V9@,-:+I"*8Q-Y%N&N+JX51!NA.Q+GXI(K.5HRK#<8L8 _Y2GXB
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M%?](-O]HROH>V[SAF92;]C(M/SU?:9[<VLI%\1&FZ+_YP7<_/=9KER .TD/
M>C/2[TM\PU/WDM47 BGT8RE!IDFJJ+A]BO=2<F8)+<G&9%/.#_@UGV7^\.U&
M:[=;'!>0)ZIL*=;-9IM+I<W%(N>7M;2-.<_YF*R79X*GP,D2-8%_K;3+O<EO
M/9L*B[L)5>],%/!O7A:*7E,9)N*-45ZJN^Y4KK\%Y0;&FKF7\LRE;Y(OX#E@
MJ7I>TF!<Y SD#]*+CI8TX4$XR"6U(C['TG,OI\R1S7LD4CKF8P7M5 B+U%?&
M$#\D*N]^1=8H*_LH;X/. HA+EWA;4MPVYN'OJ]S7I+Z=,2J2Q&6W&+CZBAN_
M>)!6L>9"3BH!2P3R2W&FBV092>6QQ[AQ3(B04\%43X2.S!.<=62FT86*$'F*
MW'>>9[3KF=,M92'>QH]I 7YYE%KV2TU1L\SW%R9W=GI>;D>^_(LZME0RLTX8
MR5BO@*>C<Y/!=]+L=-XQ1&3*)SFH[&KE\<QJ<3$/B4>>4\,GKUWA=S;A9I5"
M#_*46&FWTB!4>2"]_&E.SH[V/R[=:R@N)1Q['I;/6\AN)M6F0_1R[*K85Z+6
MN>GC)XWA?=9;,?% R&5523M(GU?F\J1=EC$;E9P]P%7%#M4!B2_O.=4W4'J%
M=ANZ+;,.T2)6MHB]M"TS^T,R_=S7/B;=M/D!8(T[!:4_+Q[H'2\M(V<M*>6S
M+567L].8]Z3\%^M(O9(X6B+E[D^YS(2*HV=Z(+WEY?]067R9ZAIQCY4GC'\4
MQJ(=K;E_I3;%*[99J=#\,RO'8T;AM>L4J\V9VI;_FI\[80JQ6I9<5(@H;I1:
M6KRH+Y$N/*V7*N0H'9M@3T(6TN.^0W&#C]@H6B%8DB[C0K*L2=:IHK%C(2!S
M9M\ZH(,?2MZIY(JYDMSI<KLV \XU'Z1.FUO4V8:)52NF?7J+W73Q36SKHDVT
M3'521?R*Y=.%%+"D U7:,3:=.;VJ?]>&64IZ<U;[D(A^V=>^\R[O!?Y>W$M?
MQE!:-38N;Y,ND4;C-&V($^C+UK',6>33CX08SI,M-GXQ&SJ?YO!%MF>'O'AS
MHQ>$/>.!^&3J)H/K<W^2K!S3$HPI*>069TD4?#)U%$>K91!KLVEW-\$OC)7.
MJH62@7;+R_0EV89%GB.?XYPNA)<TBBC2,[6K AY)?;23+!;FU5A,J!D8,.>'
MW!D^BNEKDT>N3--F$VY\>KVG-Q1Q=V?-JB=2)B:7:KRK K<^T[8*HH,VRWM\
M(**==#[7N<Q$@,)1R,I:LYY/65UJ;K'0=62?$PO*PP]9!V^*7-;I+R^6S4LF
M69QBO0N\A."2IO-(G_[=]A?,$N=3@+).-EM<WNV9X%?@Z@*=I)8_S9!\JVFM
MA5JMU!S<,K6^T  I^UQA=$TNHGBRBL_8Z#MW5N?25<X+V_BV+/\P]R?RA:=M
M"*H/#!,W$"F9MU@M/&&BQ<M:CZ<B3ZH"$ DLH2/TPZX=1&E[?ZEX(9-0MGS?
MZ6C_%HE&PL1-C#TJ#/Z[L"?+U-)*"9,GT:RTFJ&B>/E_))GFP3(^4V]1\M+5
MQB3S)S[/5"#F9?D2(M^)??@YX&O-Y)<@K#@,:7.'3F%J5=[;0NX#D8Q\9%'8
M-7>"E_O*?!(9!CQIDDM9%E%>Y(D&45HQP//EITEB8K$NND-O>#&;"B@R%M.I
M)HX[95,3,B_#VFM^NH/-!4=/F6]!VB\7_B+/B\>?Z8Y%QP+Q4G9*I,1*OKB$
MFK+TKR3,)3WPV68Y;;N"G.T9P";HT2B;EHWXG/-M93::D+>I];KN:CAUO=39
M064%FPLIN$60AT=,)E(]_#JC6',667>RK-\ 2T5_H#9@PKL\H[$HOD0B-&7(
M9,I9]KB7<V43P2P\]@Z3%Q&?YO.<+6@=MVP^\JO3C-E8RGO[QQ;&:,\ 'T$-
MC9*#-(4Q-D2NG31=);9_;"K12R- JVFT["O, N&Y2A/A\4J2@_F%HV#Q9WFN
M_D;ED@\!E$V9D+\G)/25?I2VC:0WPRCQTNFE]B!*(EZZ75+]PY:?3NSACIV7
M:\DSK]*9A*E:9N]]L*,7.;FKB\C#?,07)@/?FN@RYZ<U=@F%1.ZM*_>CE!>[
MFI<LFM,P42)Y!L5D/79#M/EXVG@MK9+*%F['N5.]Z),2IS#;6.8B)3RDQAN]
MB+L:"SE[[C?",RKHA8YI>WX,UG0W6K<*?CW-4L'%4-U&9D$4&K[*NL+UT^G
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M+[THIA8<J]?($@6XE4;EI[<ZBT:>V+S>F'F9_YA=B<57=LTP'-71BUL-$ZA
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METCB*7VN'<W3M!B1(NF*'BV9#*5O2WHL9^'U8DZQX#F?GK9,%J\75W-1M/W
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M4L!> I'1!P9+1=+YSJ[N%=0NJ/Q!PY,I?^NLNM\TZLM^;YUQ\(D\$T]KDI<
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MV)0"#%4<:&R@]*4S.EWL2U>YT#>YAFVZ_#1[^W=/E*&C=N[]>A$_!2%]DZ.
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MWZ@K'0?0>#=(F"5)'3? 6J[ F?<&"2SXJ8K01E\B>M4330\'L.F6B-4;Z];
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MJ"P3HB:#@@0R$5[%&JS NKIE]L!"B<RGX)"#8P<TE>@&^"_ZP9@X8%,%T,"
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M)^1"R%S8V&;4\.%Y)U^><?0N$%04</UB<PFHR&![%J7@0D:"B@PJ&RA(((]
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M+1SB? B#V4T^*>?E.[/GRY.&^OM-&KK/9^IH)'DQ'[23C_"9!S'%UK6]S ?
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M_B4L5H7(;XEM'42'^CR<FTS>JG0P.WO>!PZA0YG)IP?:M57I8'4VNSQ+T>'
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M,JSNAW&'8O0:KG:VEIG%8:3I9N]%'T/?-H7[MB"7E'INDQS.,(0KZH77=37
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M*2JW9HY2ACS78"TQ_:+VA>R:Q:C^R7F!OF%1[U_1Z@41K[H%1N-B;@=^.P6
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MB5<?EVU)_)IZ)E__4-Z,S>DO_P)02P,$%     @ VX-Y4M&_Z(S_$   [OH
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M(7;<DA@J4YL]BO$""NC)MA>BS0/D!6SUC0!H,#R,A\TW\=>_W5"TL+%[_KI
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MOF:\YW-J,^S(])(T:6WS*&>C[L&GR/;PG\C]&7B";OED8Y\S?NW?(2>D43X
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M7PY$*PV,LQ&+Z+Q7:*NO F.*CI-VZ#@Q3<=Q.W0<&Z%CO:NWHS<\4*BN-,0
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M5U/;OH$+O4@6XKNAX*'.<$O;:"1QVWZHLPE^M&12#K.M1^S$J\MIT6P9F:&
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M4QLO_ZZ=HXNTW%MJR064; *IC>]% 0]I*#2-(S-ENRTZ^;3?/N@>T(O?LRV
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M?Y:&*X<8/'N#]I__\.ZGDS^^_\.W7>*&$:C,705;6^GLW*((=17W\NB\ZF7
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M.)TC(W5[L>_%>AW3M5&$;J)X?96<1;LXCY"^K0\0,L>@E[!['ZC9 <KO39R
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M-!>.^]2B'XAR\  ?XR2A%D,+PAFQ5Q 4G<>X24-6>!'(R1OQ >BD_9Z\GN]
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M-WMT'6^TG%>)G(<2E)J\>Q>MZE!HBEC5.YR />-)DL9-("ZJ@Z5*Z5!;J3/
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MYMN@3N>!G'0+3@HA8QS./EQVK!HW.W(]A!VO/+L8?=4^J07QT/Y!OX9G!>?
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M!VR>5'YTU#S=N5J<1,3E(G259'G*;D=IIZ]=)"S"G9RDAVWYDA&H.85A[T/
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M[Z,7AYZLRM";4:@)X*%%2L4(4$Z!5*2Y-0_U4*"#PJLP!8V@48L%F%R@93J
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MIL_ Z:'QP;*S*!,RU+)F5P8GK7MV@NFK,2XTC5WYB5@PI>E",Y3JU]WTDK$
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M_CIE%J*O**#9Z4!#&IT+<AVN)H(H;(T->. <3@/:[^+R$QXV:+9XIL<#>WH
ML%(X #"&E8]2.);R,[CNDRY<LYXV;< Y$>$V?GS*-1\WZ*;B;$83J/H_9']F
MW$#*V(48+J50=6<81\H+%Y:N?(,C<CN B!<O.8^?XS5,UEES[#HNTDG"'(@.
MDNZ=HV($UG"%2*Q<A^$10[!@15T%"@%J:[_E$N$EWX[S;L^)VUC9=FB'9SI
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ML$=B]U:2$*78_5#S/6,W4:N<[XW;[G40,+<"*4'WCE^S";+%7C\N6$E=06*
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M@ AC!#*/+5@9NJR;M<%50A:H\(Y8.4L*KJD;TT1&LS=7+QGS+*N'K'O#XLQ
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M$/.OR#PU N_ 2YR=!V2O+/R6TH<7@34EF]#*M22=- Y7IZ&O)!*;6:_+8&R
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M2AAQ/CK#21XG^SAY7.Y@RJ1UL%$FI^HZ%,BX.#)@6I]=&#"KU0YY'NB%<##
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M0./RQ?43=ME@Q2CI_WK &[ 2>9/K5&6+'7ZK9+E7N[$RAQ>$0S6ZG7F(&\%
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MG(20I+UYM%'YU?8AE+Y]2O4S[/2>6<:A2KQ7*360QI$F9>;)?+FB-X]PS4R
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M,;#7TI&FLQL41:BIFU:"F G]D;*AHB#VO^Q< Y2(0D"8V[C++^G>)&N$SE"
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M6H"$ZTV.<T)U5G:H D-EY8AU:G6HA5-+D>M4KK.U2I"U%+EF =?9D:(:=GU
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MV+:"XONA)-N:/H_V'^!VCR![JQ'4/V26NT TOMF*Y3R0 ZJME_?"NT!!BOY
M3K!6M$99N,FNSOAL+[HU(3OYEMY:XY%L[R;8:O18;E:JHN,$QG:KB/8QEHVJ
M;+&E8Z\0;U4I5P7F[NCE$WL!E@AQ+BUE 0W9MKV^@-8 ^ASJ9<D  D^[CS8S
M]SD]Z27;.3D9WVP4TH%R\R*1]B2PMK,@1.M8J^;09<"?_FPE\ VS%FM-C,+4
MR@S4#W86E3"F.63S=3/ /]JM/H 9T=)(YA#\9*<>Z/ZPRV'\1?\J);'C=U&V
M([>N1 4(421B\NQ@G]EK5R1\</S\GZ?U;J>SS8U8K1Y'6\-W7FA#NV F<N7W
MF!*^CEW/!R2*5)ZFD6H >]SL\C!QW629^ Z]+7X-211]IWK#\?%?= _3_SI#
M,Q*R6C]-Q%<<L,_8?'5P8!2;O0%[@,V2A#'C[)Q$,3]A-,)00-N$Q _N GF)
M3_40J[;V2+859P5GAZ>HA+ @LDH53G*:]'<<+[8#3&?3 #V2QQ_D#^2$@%PH
M!:+:^6;4IR$KTZB1[T.BAO.MS]BLD\"C9^-N=!\\\09"U:R4)<RHIWY5$AQK
M6(PU+%I](1MK6!0+W6D-BSV+8<^> .>[29'KPNH23&4WJ4=R:" I5?9J.E3G
MCA%=8!'@0AA*BA9DD\&BC2Q_,>P\VNC8SJ+OO8HVTO_L1\W!)S(DE,'Q1B?:
M'Z=ZAKFBRI6\*^TJX"%D'LK<18N?G&HOU2*W9C />++N"Z+DBQ& VOT$W1*@
MATXY :C=YH"BT@0Y9D6TF]V+4\4)3IIX]ML,RSQX8;866-F7(]$[QNX@V([0
MWGO#S-#^,J(-0+O\P5S$7!H U% X2EF3/-'VFQWUHHNWY^%4PNN M0!/S065
M0!3] W<>@J)1)!/%*C?MW!E/YTD4DR4*>2S6+0)Y<JOI&'%;ISVD6!$AA'D.
M*%"$$@)F&@X\HR!!5U2C%0%Y^>+ZB<?"ZBBB]'\]8,B'$GF#<M\C=M-(VZ3Q
M/< :(#[Y>,XW@X*D=0250@7NT9P=N"1<4[,1>=^P3^]!)$!WSIK?AKY3_1'F
MNK)*!@M R2KQ?L'*(!#>#%$K\V"Z2MS_YH28[4>Z>"/LH52UWB-N_3R2>X27
M3PD].5-?7\*.\'NJZEFA"*I_<RRF'D2Y2+J6!E:2_Y8-.DOH'9WRDD%,1SLG
M[)CC!\V2Z2YIP0 4-7*\]>9J87:?F%ICIIW#>KM,.6FJ).G/[D(Z;]*<RI)3
MXO6;\X*7R5(8#*GDZ7&%O.\K$F3@3*BE3)<?:"\KTU>39D]3B%-7GN$*$LU7
M[?<5O6 $\8:VVF+=IV&D_+A8@\]YJ_,>SQ<\<E\<A+ F/B"Z74IZRZY^B')T
MEX0K$L$ZP4G3U*!OBBX'A[=4F-*IH:G$]5;53F<3E^%RMW"H3>6B),8NN[=0
M1>?A@@S>.L[!=!7MMJHC&<BR'#$E/K?S%GC9T;8]08!,2E!2V)]1&.?V)OVO
M_7U)?\1Z<'N)&XOW6@2(9:LAT#+/TW SH&P46OFW2O/_$#N!-_'I>?: ?)]=
M7D*%!5I#Q<A-7&B>*$T$<\1/<L:00G0GF+21D$^>.)1C#1K&6$+ 2! F"1&>
M!^?,T@O7"DTE"K\W$^R]:0(^2>(%=\"J!+"7T>A& GA\>C$%)?TC7)**QTXY
M 4--.PM.YMRFVKJ^'LG&*T37[C1>H)"'#L$7CZ8!>XY-FA<)79B:!FRVCNGN
M4%W!N4_;LCKNT2JA"#G43MMN%ZY%4;ARPGA]ZRP!:Q)(L"V9]L>#6%+%W[9T
MRY*.SH?1:XE;>%=P ,F.:XS A2?061$AAW96_55:\Z1JUPG$[(PTJM55!*Q2
M;4\L4#NR2,7!:GN''-5MJ=F&VMW+]@9<Z[5Q]<Q#WLX7"01V!V+IO8<=*)"#
MNZ7 U4[%VU2-E/D(=O6"O>UB:KPLE4@=[%W+Z[;6^M1(G>?/]HJL37=CB:MW
M=S/:VSBCVE5.&CCZ145.N\O.JCZN$+GW(0'C>%?>OPT6O_7M;EW[^E?4OI"2
MVH?;;%%9VG9)[N&;R+_."\#LM#=@@,G%7 C,[+0\8)B!0VL$?*,W1L'5?'.8
MIDD9&S*2-U7I5O)A=@)-.U/<VT2S.#13(&JG<[\)HO4AO *]0>O)<O2JHK(S
M\"SM#=(</-48?(&LG29V8V1E4S,R((=] 9;4CJ79. )&.ZWQEF LS, 26(Y'
M3B&6^M/T,L@M;;?=&')PXJ= =-2KA8A"\X %H';ZB'1<C"33P3,H/XQWS!HH
M834$,F#U-VGM2=%$'="6%)[(P/LTKLIRST=5V1&!H %/AZ%2/7<A6:$P7E.L
M6#\]?@)3847YHY(_4"K/HV>PSDOR-!3#0(+&EH$[WPGB/2X@>1?5= R5X=D6
M)KM ='Y=O*EHM+W4!-ZF!)^3WKI+&(9(K6],$PB5#L\+N6F9[0VE3J4YU-M-
M)+J136'75A:+58_FCJ%KMF"HW0UI R1'QTB"9Q(&>/.H<H5?V+\IR%%%Q<Q\
M+%<)/7.S]: R%24D3/!_@^B=;D%\[WJY"DGJM%68ADHR:D4'4N.+WCH5H*VC
MT*G^44OJE"+7J5QJ"9E2Y,QVN"N'&MHZ1YYFIS.GTB%'@ECG(8GR A=6OJZ;
M,Q%@9Z>C2WEG$.#V'DK/((CJE,&P,(O'TN=_E6.5U%L"(DG'SO<41=BD[#J!
MG9TO)PVQ*[7KAY)PIXA;U97.]IRZQDNNZE8OP+/[B&C%7KDI:'=B>48/P(,F
M@^#&]S>4UE!JZ.GS&&<X?]!G5'])<0[0G#'XNI&N?I$0Z.EO#W70>:?;%SI]
M33/4!^CK2US'33#R*@#BG-G];O0M]<6WM#LOXLINX"0TI&/H^14FR+M\6;%H
M"9[BP2IHG"=AR!6R\X1]WJ](&&G2GRCI)',,=:[##(AJYIV>L90;>\,-\.&]
MC(C2:]2&'@=G"Q: K7H:3;BBJFA&KWE<46PCA169JR35A,=+NLI#2K0XOGD#
MAR+3,-I&3D-GS2Z8;#]Q'AT_4CH'J\AT?P)*"$F:S-10WE<4@*S<IX-Y"H#C
M5JQ\!^/(E@-,XA!MTP_;U?7XG 3/U*+'%*&[+<</,7'_U-E54GV(SLU+)>:-
M7#WSS-Q@>A'S-LXQ]@L4R/7) I$S841<X&?LT;F+=CD"^0'*2)AQ">3'_(W$
M.)BGB?_JT[%+Q;P4#PNJ9*-I$D>L6A5E15V4 E*&'#4N0E[$\F6NHRCA*4>\
ML_!TQGP8\1KHJ:FE9B1XBX/).&"V$;6&[E#(?P:*UBHGTMG,S/94;> )-016
M!ZHC&)E!-E2*_442IBEQF'CIG-RB'_Q7(,TA2]%0V';QV9E?<ZR(0OJ'$=#?
MJT3>R*QR3<!94=^6I324'!*[ .60$]C >FO*$S2F"7FB+HL_H?><S04C2UL[
M6XL_V:3P3GXXH7?X6":K,AN.IC2+/.GX![UQ4.OV+GGRL3N=T5F@NQP8)5Y/
MR,BLT1%1=+:[E.!A^)5DS,DQT2-'"1DC';#NIG"N<Q\9UJVLP<%TEJL9 \\O
MD*%F1*KD*<(>=L)UCB-H4D$%D;8Z#'W# 2N0)+]J"CYJC;>T>!.0M]V/6NLV
MQ4X*&&<[G[3*%Z1-5.X#<YKV7(^F+2%CQ#+VG2C:[%"XUBKZVLQMQ8G3GA$Y
M!L!:JIR(V82G6BLN*C/C&F1$-1[4C ]NZ_V<SO)L;FHXG9,HCCB33SDFE=[Z
MFH[4^>.")J@*,[$:KQ7;.ZVUMZ>)E+ZRO2^;O-XGU8>3[=W8)(YU(FE]#.49
MNY4]NV>1VMYKK=AB)P7W!=O?^LON5*3P5F=[*EH=&KOW[Z%DE[5K)93[7H;2
MV:W>AT5@CK>A9)P!7)JDT.\J@+)3NZN85R5N= &5W>85!*J2EY,,*DN++JMM
M/\GGLZ&TJ&SW4-7PSII-Q,^63X2^%W "?N(7(-M=RD8OR/6A'@)7_?FX]N.J
M%!^40?[9<I]>.TM9,OHL0_G+SR/*8)15(QJSIH*V^ZO;6=OE@;(9L)8ZE#I8
MSGOAU )ARYU4+2%<$X,O^DQK3\KO26<(DP#OYFL(;,>E"T>V-)E'=,BUNZ*2
MB05;DN]EM EQU_F.#\ERZ81K%L91\A=ZDQ^AX_4W$U):DC'EI#6Y)?;S;XZ?
MZ,X)W=#L(+&RF3"=\6U#*F79NF\JRI9*5U),DGA!C[>_FDN2IV0ZG/CPV =&
M%-^8[>UB2TCWF,S4KV2F,<2^!R'V;."S-6>C2=#\(1ECR=FL##PUY%(_U"V)
MD4J8>QVE[B^9<J(6AZD?SLX  \]+5_H82CZ&DG<<ZV1Y*+G.6"?+&Z+H3%"P
M-)1<4;>7W*!L#S67NX'6/$7EK\L",+M#B1H!MO64B&A6N\,H&H%5^-!Y_-[N
MB"I%Q#9^41&]:O?;FB)*5:[P##H33>Y? W3-HO#T!Y06Q2,8>WM<+DF@O;HJ
MA&@/7A&EV.USS;#;A%G"FXAWQ5>#%@;O=9VUU*ETS1NU\60 7I/Z<>$$4[Z/
MH]]0%"/O.D@#1A]9.>0K!X?@=[ZN.%2JYY;;#/>4>HAYTDDZ@(S0$D2,UNS-
ML0*9L^+O#36RWPZH6JJWE$2O]^/AD=V+NH=C);*Q$EG;E<A*=/$E-8G(&J6Q
M\G=)Z"[H*F9]KH"E-6OI& EOH..Q9$;XP^?^ER:YA;YS[GXW5@\;JX>-U</&
MZF&]2F'>55%#>>4M5.@%J SM4;?D6":RIL-07G3'XF!C<; 6D!B+@XW%P5Y]
M'9,3[:I_$!F:I6XZ :S=+\(MIV?NN&Y%7(+==FX+17>JO?F#J<G57@6'#MZ&
MQ*S9'=/4LUDK?RK-)N2#@6UD/K@@2\A]7*"M$MF6A:'JY)D*VC34 #Q$GP(/
MY)GO\Q/>MOS,[XA9,LB;4#O.F2->FF:[Z+=.!#.Q"2"._N[C8_]4\;&FF,4\
M7SEV:[7W.:LXX_M"@6N#M$?,]@#GW5.RSR K<=KK!_]7KBUZCF[M@KIEP8UL
M3:5&23\BFO:8DM/(&I%^JA?J:5^H?=8W_WU%PAG"F2C;]0/&V01+KWLE[ZK&
M?BSD?9Y>-\*O05?T'./#"V5_P]O J.Q=6>"U&4H(]&)&2[WKJ8N=2L<JFRJ'
M-[4SO@GDQ/C **F]#\<PJ3%,:@R3&L.D>O5"NJ>CAA(G5:S3(;YOI>-J*.%6
MK1H;I-:>&J.U^A8[H;_ITR!B)PS>*L54:8_&6*6M*&(GC,?ITN-G$0_;^NH$
M?$EG*T!S9ML-8*9,N!S%1.DSJ 8W429]\"V&C*1Z\#(8ITS+NU2+L236GUA]
M>;D5<VCY';[OLZ<:W" FT,Z@?1M4Y<'1]D&[]Z'X:.LP .^>#AD^HTT#/.Z]
MW/Z-M@@\Z3%Z&8)7S[W9,B#GS@K'CI^RLV6.VM5724PEV+8G@[C?%8@W+293
M. YO6IS?X,RQ)1U?I4C=3!&78?9\&5_'QWX2DG*,_23&?A(V]),8HPG&:(*!
M1!-8_C3;ZINA3)\-NRMFZ^NS,79$J+,^;*^?H0)5;9\-N_UT6OMLC"=!/Z)'
M]%?>Z-=$M.);;E;^?:S) 7V/4?33M1')83_B#5R\;=:$8.4GNG@!.4 NTM?F
M0(EVYR\>,*X-^ FR$H-T76(7%6^'+":%K_R(ES/)_YY=D6])_ >*[Y%+Y@$K
MJI$^U]*%OOD1^[L3B%_!-&<FO#*MR=0+8'O^RK$)*?A*_S".2N()^"\OZ%79
M;*\)5=9ZC3?_?RS\!@?S5"+0_M<[KI&,/)]+M'F[/F#]\H7]*VA!R5)\->L
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MP_[?DQ.A?_O_4$L! A0#%     @ VX-Y4J GA0]88P$ !A8= !$
M     ( !     ')L87DM,C R,#$R,S$N>&UL4$L! A0#%     @ VX-Y4L.R
M")P %P  *P(! !$              ( !AV,! ')L87DM,C R,#$R,S$N>'-D
M4$L! A0#%     @ VX-Y4M&_Z(S_$   [OH  !4              ( !MGH!
M ')L87DM,C R,#$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( -N#>5)3.=656BT
M ",N P 5              "  >B+ 0!R;&%Y+3(P,C Q,C,Q7V1E9BYX;6Q0
M2P$"% ,4    " #;@WE2RV[?=D*$  !0&P@ %0              @ %UN0$
M<FQA>2TR,#(P,3(S,5]L86(N>&UL4$L! A0#%     @ VX-Y4OE_A:>G3P
MEB4& !4              ( !ZCT" ')L87DM,C R,#$R,S%?<')E+GAM;%!+
4!08     !@ & (H!  #$C0(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
